,PMCID,sentence_id,CONSORT_Item,labels,section,text,metamap_concepts,metamap_concepts_text,metamap_semantictypes
0,PMC3002766,S45,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"this double-blind, randomised, parallel-group, placebo-controlled study consisted of a ≤2-week screening period, a 24-week treatment period and an 8-week post-treatment follow-up period.","['C0205173', 'C0456909', 'C1710032', 'C3274571', 'C0439230', 'C3538994', 'C0687676', 'C1533734', 'C1257890', 'C0087111', 'C1704687', 'C0441833', 'C0589120', 'C3887704', 'C1705169', 'C1705765', 'C0039798', 'C2348164', 'C0150108', 'C1698960', 'C0599724', 'C0525065', 'C1705764', 'C1705428', 'C0439531', 'C1519504', 'C0220908', 'C1705429', 'C3469826', 'C1522577', 'C1710031', 'C4554418', 'C2826345', 'C1522326', 'C1080058', 'C0220909', 'C1704685', 'C2348042', 'C0687744', 'C1515981', 'C1710477', 'C1948053']","['Duplicate', 'Group Object', 'Aspects of disease screening', 'Screening procedure', 'And', 'Post', 'Follow-up status', 'Period (temporal qualifier)', 'Trial Screening', 'Treatment Epoch', 'SLC35G1 gene', 'Double Value Type', 'Screening', 'Biomaterial Treatment', 'Administration procedure', 'User Group', 'Parallel Study', 'Groups', 'Screening Study', 'Population Group', 'Clinical Study Follow-up', 'Social group', 'Visually Impaired Persons', 'Disease Screening', 'Blinded', 'Doubling', 'placebo controlled study', 'follow-up', 'research subject screening', 'Post Device', 'treatment - ActInformationManagementReason', 'Follow-Up Report', 'Parallel Lesion', 'Treating', 'therapeutic aspects', 'week', 'per period (qualifier value)', 'Parallel', 'This (eukaryote)', 'Stage Grouping', 'Blindness', 'Therapeutic procedure']","['tmco', 'mnob', 'acty', 'fndg', 'gngm', 'hlca', 'topp', 'idcn', 'inpr', 'qlco', 'euka', 'resa', 'podg', 'ftcn', 'diap', 'popg', ' inpr', 'cnce']"
1,PMC3002766,S46,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,the study was approved by local ethics committees and conducted in accordance with the amended declaration of helsinki.,"['C1515981', 'C0086902', 'C2603343', 'C1691222']","['Regional Ethics Committees', 'And', 'Study', 'Amended']","['qlco', 'idcn', 'prog', 'resa']"
2,PMC3002766,S47,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,all patients gave written informed consent.,"['C0444868', 'C0030705', 'C0021430']","['Informed Consent', 'Patients', 'All']","['rnlw', 'podg', 'qnco']"
3,PMC3002766,S49,['4b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Settings and participants,the study was conducted from october 2003 to may 2005 at 41 centres in europe and north america.,"['C2603343', 'C0015176', 'C3828732', 'C1515981', 'C0028405', 'C0205099', 'C3812381']","['October', 'And', 'North America', 'Month of May', 'Study', 'Europe', 'Central']","['tmco', 'idcn', 'geoa', 'spco', 'resa']"
4,PMC3002766,S50,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Settings and participants,"recruited patients were ≥18 years old, with ssc as defined by the preliminary classification criteria of the american college of rheumatology (acr)17 and at least one active du (onset between 1 week and 3 months prior to randomisation) that was selected by the investigator and termed the ‘cardinal ulcer’ (painful area, ≥2 mm in diameter with visible depth and loss of dermis, amenable to healing and in a location judged compatible with a vascular aetiology, specified by protocol as volar surface of the digit distal to the proximal interphalangeal digital crease).","['C1515974', 'C0443349', 'C0332290', 'C0017446', 'C0205447', 'C0205107', 'C1565156', 'C4284931', 'C2348563', 'C1801960', 'C0243161', 'C0582802', 'C0332152', 'C0205177', 'C3888249', 'C0043240', 'C0205103', 'C3715209', 'C4282383', 'C1515941', 'C0206132', 'C0596070', 'C0439234', 'C0030705', 'C0015127', 'C1522729', 'C0332162', 'C0008902', 'C1412134', 'C0205125', 'C0030193', 'C2599718', 'C0005847', 'C0205108', 'C0450429', 'C0332287', 'C1883674', 'C0035452', 'C0011646', 'C0008903', 'C4522154', 'C4489236', 'C1421478', 'C0043194', 'C0439611', 'C1524057', 'C3897657', 'C1558950', 'C1301886', 'C0205148', 'C0442711', 'C0035173', 'C4284930', 'C1442461', 'C1707391', 'C0557806', 'C1517945', 'C1507394', 'C0205379', 'C1442452', 'C0205146', 'C1515981', 'C3241971', 'C0580836', 'C0678229', 'C3900053', 'C3853793', 'C0205369']","['Etiology aspects', 'Active License', 'Deep (qualifier value)', 'Compatible', 'year', 'In addition to', 'Proximal', 'And', 'Volar', 'active (HL7 RoleLink)', 'Classification of information', 'Anatomic Site', 'Blood Vessel', 'Digit - number character', 'American College of Radiology', 'Loss', 'Location of Pharyngeal Residue Following Swallowing', 'Clinical trial protocol', 'Proximal Resection Margin', 'Digital', 'Specific qualifier value', '3 Months', 'Location', 'Onset of (contextual qualifier)', 'Distal Resection Margin', 'Protocols documentation', 'Age of Onset', 'Diameter (qualifier value)', 'REMS Protocol', 'Rheumatology specialty', 'Before', 'Dermis', 'Americas Ethnicity', 'Wound Healing', 'Geographic Locations', 'Active', 'Wiskott-Aldrich Syndrome', 'college', 'Adverse Event Associated with Vascular', 'Library Protocol', 'Old', 'Vascular', 'WAS gene', 'Patients', 'Digit structure', 'Consistent with', 'One', 'Intermediate', 'Choose (action)', 'Pain', 'visible', 'Taxonomic', 'Sample Size Calculation', 'Distal (qualifier value)', 'Clinical trial protocol document', 'WAS protein, human', 'surface', 'Area', 'Research Personnel', 'Study Protocol', 'criteria', 'Protocol - answer to question', '1 Week', 'Location of Oral Residue Following Swallowing', 'preliminary', 'ACR gene', 'Amenable', 'Classification']","['pros', 'qnco', 'podg', ' aapp', 'clna', 'blor', 'fndg', 'clas', 'idcn', 'inpr', 'sosy', 'qlco', 'bacs', 'ftcn', 'mnob', 'popg', 'bpoc', 'tmco', 'ocac', 'prog', 'tisu', 'spco', 'acty', 'gngm', 'geoa', 'bmod', 'dsyn', 'orgf']"
5,PMC3002766,S51,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Settings and participants,"patients were excluded if they had received intravenous prostanoids within the previous 3 months, had used phosphodiesterase inhibitors other than for intermittent treatment of male erectile dysfunction, or had received inhaled or oral prostanoids or injected botulinum toxin in an affected finger within 1 month.","['C0205156', 'C1706428', 'C0444735', 'C1442451', 'C0030705', 'C1656262', 'C0392760', 'C0442027', 'C0242350', 'C0006055', 'C1706180', 'C1442461', 'C0004048', 'C1961100', 'C3539996', 'C1552607', 'C0086582', 'C0016129', 'C0033554', 'C0348016', 'C0031638', 'C1706429']","['Intravenous', 'Male Phenotype', '3 Months', 'Male, Self-Reported', 'Inspiration function', 'Affecting', 'Males', '1 Month', 'Male Gender, Self Report', 'Phosphodiesterase Inhibitors [MoA]', 'Botulinum Toxins', 'Phosphodiesterase Inhibitors', 'Erectile dysfunction', 'Patients', 'Act Relationship Subset - previous', 'Oral', 'Intermittent Treatment', 'Phosphodiesterase inhibitors, cardiac stimulant', 'Erectile Dysfunction, CTCAE', 'Fingers', 'Prostaglandins', 'Previous']","['tmco', 'spco', 'fndg', ' orch', 'topp', 'qlco', 'orga', 'hops', 'dsyn', ' phsu', 'podg', ' aapp', 'ftcn', 'horm', 'orgf', 'moft', 'bpoc', 'phsu']"
6,PMC3002766,S52,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Settings and participants,patients were also excluded if they received systemic antibiotics to treat infected dus within 2 weeks prior to randomisation.,"['C1442457', 'C0205373', 'C3540709', 'C0332152', 'C0332285', 'C0003237', 'C0003232', 'C3540706', 'C3540704', 'C3540710', 'C3540705', 'C0030705', 'C2826257', 'C3540708', 'C0013261', 'C3540707']","['2 Weeks', 'Systemic', 'Within', 'Antibiotics, Gynecological', 'Antifungal Antibiotics, Topical', 'Prior Medication Usage', 'Duane Retraction Syndrome', 'Antibiotics, Antitubercular', 'Patients', 'Before', 'Antibiotics, ophthalmologic', 'Antibiotic throat preparations', 'antibiotics, intestinal', 'Antibiotics', 'Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE', 'Antibiotics for systemic use']","['tmco', 'antb', 'dsyn', 'spco', 'podg', 'ftcn', 'evnt']"
7,PMC3002766,S53,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Settings and participants,"also excluded were patients with body weight <40 kg, severe pah (who class iii/iv), moderate to severe hepatic impairment or serum aminotransferase levels >3 times the upper limit of the normal range (uln).","['C4284467', 'C1305866', 'C0441889', 'C0205082', 'C3272598', 'C2698969', 'C0229671', 'C0030705', 'C0441887', 'C4035626', 'C1519815', 'C0948807', 'C3203102', 'C0439801', 'C0005910', 'C0002594', 'C4050466', 'C2349209', 'C0086715', 'C1550100', 'C1549649', 'C1282910', 'C0030123', 'C1546774', 'C1299393', 'C4050465']","['Canadian Cardiovascular Society Grading Scale Class III', 'Borg Category-Ratio 10 Perceived Exertion Score 5', 'Weighing patient', 'Idiopathic pulmonary arterial hypertension', 'Hepatic impairment', 'Body Weight', 'Para-Aminohippurate Sodium Measurement', 'Normal Range', 'Bound (value)', '4-Aminohippuric Acid', 'Limit - Amount class', 'Limited (extensiveness)', '3 times', 'Severe Extremity Pain', 'moderate to severe', 'Patients', 'Levels (qualifier value)', 'Class 3', 'Serum', 'Specimen Source Codes - Serum', 'Severe (severity modifier)', 'WHO Temperature/Humidity Storage Condition', 'Upper', 'Upper Limit of Normal', 'Transaminases', 'Specimen Type - Serum']","['fndg', ' orch', 'hlca', 'irda', 'idcn', 'enzy', 'inpr', ' aapp', 'qlco', 'qnco', 'orga', 'dsyn', 'lbpr', 'spco', 'podg', 'ftcn', ' phsu', 'cnce', 'bdsu']"
8,PMC3002766,S54,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Settings and participants,contraceptive measures and monthly pregnancy testing were required during and for 3 months after the end of study treatment.,"['C0032976', 'C1521826', 'C0009871', 'C0079809', 'C2746065', 'C0009886', 'C0332177', 'C1515981', 'C0444930', 'C1442461']","['Contraceptive Devices', 'Contraceptive Agents', 'Stop (qualifier value)', 'And', 'Protocol Agent', 'End', 'Monthly (qualifier value)', 'Measures', 'Pregnancy Tests', '3 Months']","['tmco', 'medd', 'idcn', 'inpr', 'qnco', 'spco', 'diap', 'phsu']"
9,PMC3002766,S56,"['8a', '8b']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0]",Randomisation and interventions,"after screening, patients were randomised to bosentan or placebo (1:1 ratio) by sequential allocation of randomisation numbers distributed to each centre in blocks of four.","['C1706778', 'C1548958', 'C4553402', 'C0237753', 'C0028778', 'C1457900', 'C0449788', 'C1547037', 'C0030705', 'C3811660', 'C0205450', 'C0456603', 'C1705294', 'C1533157', 'C0332206', 'C0205099']","['Block Specimens', 'data type - ratio', 'Sequential', 'Four', 'Each (qualifier value)', 'Count of entities', 'Obstruction', 'Ratio', 'Patients', 'Sequential - Sequence/Results Flag', 'Central', 'Blocking', 'Block Unit of Distance', 'Allocation', 'Group Sequential Design', 'Numbers']","['idcn', 'inpr', 'qnco', 'qlco', 'spco', 'resa', 'podg', 'ftcn', 'acty', 'patf', 'bdsu']"
10,PMC3002766,S57,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Randomisation and interventions,patients received bosentan 62.5 mg twice daily for 4 weeks and then 125 mg twice daily for the remainder of the treatment period or matching placebo.,"['C0439531', 'C0087111', 'C1522326', 'C0032042', 'C1708943', 'C3887704', 'C1442465', 'C1705169', 'C0039798', 'C3538994', 'C0030705', 'C1706408', 'C1515981', 'C0150103', 'C1696465', 'C1883708', 'C0585361', 'C1533734', 'C1948053']","['Period (temporal qualifier)', 'placebo', 'Placebo Control', 'treatment - ActInformationManagementReason', 'Treating', '4 Weeks', 'Treatment Epoch', 'And', 'Match', 'Placebos', 'therapeutic aspects', 'Patients', 'Then', 'Twice a day', 'per period (qualifier value)', 'Biomaterial Treatment', 'MATCHING', 'Administration procedure', 'Therapeutic procedure']","['tmco', 'bodm', 'topp', 'idcn', 'hlca', 'qlco', 'resa', 'podg', 'ftcn', 'cnce']"
11,PMC3002766,S58,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Randomisation and interventions,"the dose could remain at or be decreased to the starting dose due to intolerance, with possible subsequent increase to the target dose.","['C2986546', 'C0332282', 'C0332287', 'C0332149', 'C1705910', 'C2355652', 'C0178602', 'C0231199', 'C1744706', 'C0678226', 'C1521840', 'C0442805']","['Increase', 'intolerance to substance', 'In addition to', 'Following', 'Intolerance - biological effect of chemicals', 'Target', 'Due to', 'Possibly Related to Intervention', 'Dosage', 'intolerance function', 'Target Lesion Identification', 'Possible']","['tmco', 'fndg', 'qnco', 'qlco', 'orga', 'orgf', 'ftcn', 'diap']"
12,PMC3002766,S59,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Randomisation and interventions,"concomitant use of systemic antibiotics, analgaesics and topical treatments for wound care were allowed, and randomised treatment was administered in addition to the usual, stable (over the previous month) treatment for raynaud's phenomenon.","['C0521115', 'C0205373', 'C3540709', 'C0205156', 'C3538994', 'C3540710', 'C1883712', 'C0886052', 'C0205136', 'C3540707', 'C1533734', 'C0087111', 'C3887704', 'C1882365', 'C1705169', 'C1272654', 'C0039798', 'C3540706', 'C0332177', 'C0042153', 'C0332237', 'C0332287', 'C1547311', 'C0003237', 'C0003232', 'C0347984', 'C3540705', 'C3540708', 'C0457083', 'C1522326', 'C0439231', 'C1552607', 'C3540704', 'C0205360', 'C1515981', 'C3538928']","['In addition to', 'Systemic', 'Antibiotics, Gynecological', 'Antifungal Antibiotics, Topical', 'And', 'utilization qualifier', 'Stable status', 'antibiotics, intestinal', 'Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE', 'Simultaneous', 'month', 'Patient Condition Code - Stable', 'Topical surface', 'Treatment Epoch', 'Antibiotics, Antitubercular', 'Antibiotics, ophthalmologic', 'Biomaterial Treatment', 'Administration procedure', 'Antibiotics for systemic use', 'Phenomenon', 'wound care', 'Monthly (qualifier value)', 'During', 'Antibiotic throat preparations', 'Act Relationship Subset - previous', 'Antibiotics', 'Wound care management', 'treatment - ActInformationManagementReason', 'Treating', 'Over (spatial)', 'Usage', 'therapeutic aspects', 'Usual', 'Add - instruction imperative', 'Previous', 'Therapeutic procedure']","['tmco', 'antb', 'topp', 'hlca', 'idcn', 'inpr', 'qlco', 'phpr', 'spco', 'resa', 'ftcn', 'cnce']"
13,PMC3002766,S60,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Randomisation and interventions,"patients who required parenteral, oral or inhaled prostanoid treatment during the study were first discontinued from study treatment.","['C0087111', 'C3272598', 'C1521826', 'C2603343', 'C0205435', 'C1522326', 'C1444662', 'C3887704', 'C0442027', 'C1705169', 'C1279901', 'C0039798', 'C3538994', 'C0030705', 'C0033554', 'C1517320', 'C1533734', 'C0004048', 'C0030547']","['Inspiration function', 'Firstly', 'Parenteral Nutrition', 'treatment - ActInformationManagementReason', 'First (number)', 'Treating', 'WHO Temperature/Humidity Storage Condition', 'Treatment Epoch', 'Protocol Agent', 'therapeutic aspects', 'Patients', 'Discontinued', 'From', 'Prostaglandins', 'Biomaterial Treatment', 'Oral', 'Study', 'Administration procedure', 'Therapeutic procedure']","['fndg', 'resa', ' orch', 'topp', 'hlca', 'inpr', 'qlco', 'qnco', 'orgf', 'spco', 'podg', 'ftcn', 'horm', ' phsu', 'cnce']"
14,PMC3002766,S61,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Randomisation and interventions,"use of glibenclamide, fluconazole, calcineurin inhibitors or ciclosporin a was not allowed due to potential drug interactions.","['C0687133', 'C1518422', 'C0017628', 'C3146286', 'C0678226', 'C3245505', 'C0042153', 'C2757068', 'C0457083', 'C0010592', 'C1562036']","['Calcineurin inhibitor', 'Glyburide', 'Drug Interactions', 'potential', 'Usage', 'Due', 'Due to', 'Calcineurin Inhibitors [MoA]', 'utilization qualifier', 'Cyclosporine', 'Negation']","['idcn', 'orch', 'qlco', 'aapp', 'ftcn', ' phsu', 'moft', 'patf', 'phsu']"
15,PMC3002766,S63,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,the two primary end points were (1) the mean number of new dus per patient assessed by the investigator up to week 24 and (2) the time to healing of the cardinal ulcer up to week 24 in patients with cardinal ulcer healing maintained for 12 or more weeks.,"['C0237753', 'C0205225', 'C0439230', 'C0043240', 'C0333293', 'C0449788', 'C4281991', 'C0030705', 'C0205448', 'C0205172', 'C0205314', 'C1516048', 'C2700598', 'C0332287', 'C2348143', 'C3887532', 'C0547043', 'C0444930', 'C0444504', 'C0013261', 'C0035173', 'C0326926', 'C0041582', 'C2746065', 'C0040223', 'C1515981', 'C2347634', 'C3887962']","['Cardinalis cardinalis', 'In addition to', 'Per (qualifier)', 'And', 'Sample Mean', 'Time', 'Count of entities', 'Population Mean', 'Assessed', 'Follow', 'Wound Healing', 'Ulceration', 'Up', 'Two', 'More', 'Argynnis pandora', 'End', 'Patients', 'Statistical mean', 'Numbers', 'Primary', 'Ulcer', 'Research Personnel', 'Healing ulcer', 'New', 'Stop (qualifier value)', 'week', 'Duane Retraction Syndrome']","['tmco', 'prog', 'idcn', 'qnco', 'qlco', 'dsyn', 'euka', 'spco', 'podg', 'ftcn', 'orgf', 'bird', 'acab', 'patf', 'acty']"
16,PMC3002766,S64,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"healing was defined as complete epithelialisation, regardless of residual pain.","['C3641650', 'C0043240', 'C4085210', 'C1317977', 'C3853530', 'C0205197', 'C0518090', 'C4283785', 'C4553004', 'C1609982', 'C4554132', 'C0030193', 'C2984058', 'C4085211', 'C0334029', 'C4085212']","['Pain', 'How Much Distress Pain', 'Feel Pain', 'Have Pain', 'Usual Severity Pain', 'Regardless', 'Residual', 'Data operation - complete', 'Frequency of Pain Question', 'Epithelialization', 'Epithelial metaplasia', 'Pain Distress Question', 'Pain, CTCAE', 'Complete Pharyngeal Contraction', 'Wound Healing', 'Complete']","['fndg', 'ortf', 'inpr', 'sosy', 'qlco', 'orgf', 'ftcn', 'comd']"
17,PMC3002766,S65,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,maintenance of cardinal ulcer healing required no recurrence at or contiguous to the original location at week 24 (if healing occurred before or at week 12) or during 12 weeks of observation with permissible extension of the treatment period (if healing occurred after week 12).,"['C1515974', 'C0439230', 'C3538994', 'C0700325', 'C4284931', 'C0687676', 'C0205283', 'C0332152', 'C1533734', 'C0043240', 'C0087111', 'C0302523', 'C0333293', 'C3887704', 'C1705169', 'C0039798', 'C1458156', 'C0024501', 'C0439531', 'C0450429', 'C1880641', 'C2700598', 'C0332287', 'C0231448', 'C0347984', 'C2825055', 'C0326926', 'C4284930', 'C2347409', 'C0231290', 'C1522326', 'C1964257', 'C3889687', 'C0205313', 'C1709305', 'C1948053', 'C0034897']","['Cardinalis cardinalis', 'In addition to', 'Observation in research', 'Anatomic Site', 'Location of Pharyngeal Residue Following Swallowing', 'Recurrence', 'Post', 'Recurrent Malignant Neoplasm', 'Location', 'Period (temporal qualifier)', 'Treatment Epoch', 'contiguous', 'Before', 'Biomaterial Treatment', 'Clinical Observation', 'Wound Healing', 'Administration procedure', 'Recurrence (disease attribute)', 'Status post', 'Maintenance', 'Occur (action)', 'Argynnis pandora', 'Patient observation', 'During', 'Original Regulatory Submission', 'Original', 'treatment - ActInformationManagementReason', 'Observation - diagnostic procedure', 'Treating', 'Healing ulcer', 'therapeutic aspects', 'week', 'Location of Oral Residue Following Swallowing', 'per period (qualifier value)', 'Telephone Extension Number', 'Extension', 'Therapeutic procedure']","['tmco', 'blor', 'cnce', 'fndg', 'ocac', 'hlca', 'topp', 'qlco', 'phpr', 'acab', 'orgf', 'resa', 'euka', 'neop', 'diap', 'bird', 'ftcn', 'spco', 'patf', 'acty']"
18,PMC3002766,S66,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"to verify that the effect of treatment would not vary substantially across relevant baseline subgroups, the number of new dus up to week 24 was additionally analysed in subgroups based on predefined baseline factors associated with disease severity.","['C0237753', 'C0168634', 'C3538994', 'C0439230', 'C1533734', 'C0087111', 'C2348382', 'C1518681', 'C3887704', 'C1705169', 'C0449788', 'C1280500', 'C2347946', 'C0039798', 'C0521117', 'C0205314', 'C1079230', 'C0013261', 'C2828360', 'C1518422', 'C1442488', 'C1522326']","['Effect, Appearance', 'Relevance', 'Count of entities', 'Treatment Epoch', 'Biomaterial Treatment', 'Baseline', 'Administration procedure', 'Traverse', 'Outcome of Therapy', 'Effect', 'Severity of illness', 'Negation', 'Numbers', 'BaseLine dental cement', 'treatment - ActInformationManagementReason', 'Treating', 'New', 'therapeutic aspects', 'Subgroup A Nepoviruses', 'week', 'Duane Retraction Syndrome', 'Therapeutic procedure']","['tmco', 'fndg', 'resa', 'virs', 'topp', 'hlca', 'qnco', 'qlco', 'dsyn', 'ftcn', 'bodm', 'cnce']"
19,PMC3002766,S67,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"secondary and exploratory end points included: (1) reduction of new dus and overall du number (proportions of patients with no new dus and with each number of new dus up to week 24, time to onset of each number of new dus up to week 24 and change from baseline to week 24 in total number of all dus), (2) healing (time to healing of all baseline dus and of all new dus through week 24, and proportions of patients with healing of all dus by the end of week 24) and (3) pain and disability parameters (changes from baseline to week 24: in pain of the cardinal ulcer and overall hand pain assessed on visual analogue scales; hand disability index (an averaged score from the three health assessment questionnaire (haq) domains of dressing/grooming, grip and hygiene); and haq disability index18 19).","['C4085210', 'C1561607', 'C2986546', 'C1705241', 'C4318763', 'C0237753', 'C0042815', 'C0205449', 'C1882141', 'C0439230', 'C1830398', 'C0168634', 'C0392756', 'C0392747', 'C0102923', 'C4085212', 'C0231170', 'C0043240', 'C0020405', 'C0443172', 'C0282416', 'C0600653', 'C1293152', 'C0918012', 'C0518090', 'C0449788', 'C0021400', 'C0205436', 'C0030705', 'C0206132', 'C1457900', 'C0449820', 'C4554132', 'C0030193', 'C0205314', 'C4050231', 'C2700598', 'C0332287', 'C0018249', 'C3887532', 'C0451208', 'C0175668', 'C0547043', 'C0018563', 'C1550549', 'C4553004', 'C4551656', 'C4288115', 'C0332273', 'C0444930', 'C4319952', 'C2984058', 'C0444868', 'C0013261', 'C1517320', 'C0518461', 'C1552914', 'C0027627', 'C0326926', 'C0301630', 'C0041582', 'C1442488', 'C2746065', 'C0040223', 'C1515981', 'C1552854', 'C0332162', 'C4085211', 'C0220843', 'C4321404']","['Usually Need Help from Another Person for Hygiene', 'Usual Severity Pain', 'disability', 'Have Pain', 'Overall', 'Grooming Ability', 'In addition to', 'Cardinalis cardinalis', 'Through', 'hand - unit of measure', 'Hand', 'Html Link Type - index', 'And', 'Pain Distress Question', 'Each (qualifier value)', 'Surgical reduction', 'From', 'Grooming:-:Point in time:^Patient:-', 'Onset of (contextual qualifier)', 'Age of Onset', 'Grooming', 'Index', 'Influenza', 'Time', 'Count of entities', 'second (number)', 'Health assessment questionnaire', 'Reduction (chemical)', 'Changed status', 'Score', 'grasp', 'Baseline', 'Wound Healing', 'Ulceration', 'Hygiene', 'Up', 'Feel Pain', 'Neoplasm Metastasis', 'Changing', 'All', 'Reduced', 'Reduction procedure', 'Argynnis pandora', 'End', 'Patients', 'Change -- procedure', 'Overall Publication Type', 'Numbers', 'Pain', 'How Much Distress Pain', 'BaseLine dental cement', 'Grooming self-care', 'Ulcer', 'Frequency of Pain Question', 'Visual Analog Pain Scale', 'Secondary to', 'Stop (qualifier value)', 'New', 'Indexes', 'Pain, CTCAE', 'ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated', 'week', 'Act Relationship Checkpoint - through', 'Of Each', 'ametantrone', 'Delta (difference)', 'Total Number', 'Duane Retraction Syndrome', 'Three', 'Target Lesion Identification']","['topp', 'qnco', 'podg', 'bodm', 'patf', 'clna', 'fndg', 'npop', 'idcn', 'inpr', 'sosy', 'qlco', 'ftcn', 'bird', 'bpoc', 'tmco', 'inbe', 'orch', 'spco', 'euka', 'neop', 'bmod', 'dsyn', 'orgf', 'diap', ' phsu']"
20,PMC3002766,S68,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"post hoc analyses included: (1) the number of new dus up to week 12 in the overall patient population and in subgroups defined by randomisation month (october–february or autumn–winter and march–september or spring–summer) and (2) number of new dus, time to each successive new du and total number of dus through week 24 in subgroups defined by the number of dus at baseline (<4 and ≥4).","['C1561607', 'C0237753', 'C0439230', 'C0168634', 'C0687676', 'C1257890', 'C0032659', 'C0282416', 'C1457900', 'C0449788', 'C0030705', 'C0332177', 'C0205314', 'C1704788', 'C1550549', 'C0547043', 'C1079230', 'C3469826', 'C4288115', 'C0332273', 'C0013261', 'C1442488', 'C0439231', 'C0040223', 'C1515981', 'C1704687']","['Overall', 'Through', 'Each (qualifier value)', 'And', 'geographic population', 'Definition', 'Post', 'month', 'Count of entities', 'Time', 'SLC35G1 gene', 'Baseline', 'Population Group', 'Up', 'Monthly (qualifier value)', 'Patients', 'Overall Publication Type', 'Numbers', 'BaseLine dental cement', 'Post Device', 'New', 'Act Relationship Checkpoint - through', 'Subgroup A Nepoviruses', 'week', 'Total Number', 'Duane Retraction Syndrome']","['tmco', 'virs', 'gngm', 'idcn', 'inpr', 'qlco', 'qnco', 'dsyn', 'spco', 'ftcn', 'podg', 'bodm', 'mnob', 'popg']"
21,PMC3002766,S69,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Outcomes,"patients were evaluated at randomisation/baseline and every 4 weeks during treatment (or premature withdrawal, week 24 and, if applicable, 12 weeks after healing of the cardinal ulcer), with dus assessed at each study visit.","['C1275555', 'C3812880', 'C0439230', 'C0168634', 'C3538994', 'C0687676', 'C0205252', 'C1512346', 'C1533734', 'C0043240', 'C0087111', 'C2349954', 'C3887704', 'C1705169', 'C1457900', 'C0039798', 'C0030705', 'C0545082', 'C1710677', 'C4049634', 'C1706839', 'C2700598', 'C3887532', 'C1272460', 'C0151526', 'C2826704', 'C0326926', 'C0231290', 'C2603343', 'C0041582', 'C1442488', 'C1522326', 'C1515981', 'C2825032', 'C4018905']","['Patient Visit', 'Cardinalis cardinalis', 'Withdrawal by Subject', 'Each (qualifier value)', 'And', 'Study', 'Every Four Weeks', 'Visit', 'Post', 'Withdrawal (dysfunction)', 'Treatment Epoch', 'Biomaterial Treatment', 'Baseline', 'Wound Healing', 'Ulceration', 'Administration procedure', 'Status post', 'Premature Birth', 'Applicable', 'Visit Name', 'Withdrawal - birth control', 'Withdrawal Scale (BASC-2)', 'Argynnis pandora', 'Patients', 'Withdraw (activity)', 'Not Applicable', 'BaseLine dental cement', 'treatment - ActInformationManagementReason', 'Ulcer', 'Too early', 'Treating', 'therapeutic aspects', 'week', 'Immature', 'Therapeutic procedure']","['tmco', 'acty', 'fndg', 'idcn', 'topp', 'hlca', 'inpr', 'qlco', 'qnco', 'mobd', 'bhvr', 'euka', 'resa', 'podg', 'bodm', 'ftcn', 'bird', 'orgf', 'patf', 'cnce']"
22,PMC3002766,S70,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Outcomes,safety was continually monitored.,"['C0036043', 'C1705187']","['Safety', 'Safety Study']","['resa', 'hcpp']"
23,PMC3002766,S72,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"efficacy analyses were performed on all treated patients using sas software (sas institute, cary, north carolina, usa).","['C0021622', 'C0041703', 'C1522326', 'C0028407', 'C1823519', 'C0030705', 'C1707887', 'C0605290', 'C1426104', 'C0444868', 'C0037585', 'C1272753', 'C1280519']","['Institution (social concept)', 'Effectiveness', 'All', 'TSPAN31 gene', 'Treating', 'North Carolina', 'Computer software', 'Institutes', 'United States', 'Efficacy Study', 'Patients', 'SAS', 'NANS gene']","['gngm', ' mnob', 'orgt', 'idcn', 'inpr', 'orch', 'geoa', 'qlco', 'qnco', 'resa', 'podg', 'ftcn']"
24,PMC3002766,S73,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,means±ses are presented for numerical variables and kaplan–meier estimates for time-to-event variables.,"['C0237753', 'C0040223', 'C0439828', 'C0750572', 'C1515981', 'C4019010', 'C0441471']","['National reporting jurisdiction:Loc:Pt:^Event:Nom', 'Estimated', 'Variable (uniformity)', 'Time', 'And', 'Event', 'Numbers']","['tmco', 'idcn', 'qlco', 'qnco', 'evnt', 'clna']"
25,PMC3002766,S74,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,treatment effects for the primary end points were evaluated using the pitman permutation (new dus) and log-rank test with asymptotic approximation (time to healing of the cardinal ulcer).,"['C0667477', 'C1515976', 'C0022885', 'C4318744', 'C0205225', 'C3538994', 'C2986775', 'C1533734', 'C0043240', 'C0087111', 'C0699794', 'C3887704', 'C1705169', 'C1280500', 'C0039798', 'C0392366', 'C0205314', 'C1882348', 'C2700598', 'C0220825', 'C1708728', 'C0332287', 'C3887532', 'C0456984', 'C0444930', 'C0013261', 'C0326926', 'C0041582', 'C1522326', 'C0039593', 'C2746065', 'C0040223', 'C1515981', 'C3831328']","['TNFRSF11A protein, human', 'Logarithm', 'Cardinalis cardinalis', 'In addition to', 'Rank', 'And', 'Test - temporal region', 'Time', 'Treatment Epoch', 'Tests (qualifier value)', 'Biomaterial Treatment', 'Laboratory Procedures', 'Wound Healing', 'Ulceration', 'Administration procedure', 'Event Log', 'Test Result', 'Testing', 'Argynnis pandora', 'End', 'Effect', 'Primary', 'Ulcer', 'treatment - ActInformationManagementReason', 'Treating', 'Anatomic Structure, System, or Substance', 'Stop (qualifier value)', 'New', 'therapeutic aspects', 'Blood Products Laboratory Testing', 'Duane Retraction Syndrome', 'Evaluation', 'Permutation', 'Therapeutic procedure']","['topp', 'qnco', ' aapp', 'patf', 'blor', 'clas', 'idcn', 'hlca', 'inpr', 'qlco', 'bacs', 'lbpr', 'resa', 'ftcn', 'bird', 'tmco', 'lbtr', 'euka', 'spco', 'cnce', 'dsyn', 'orgf']"
26,PMC3002766,S75,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"missing data on new dus were imputed using extrapolation, with the incidence rate of new dus at the last assessment corrected for the missing time period.","['C1517741', 'C3272743', 'C3245479', 'C1708485', 'C1948053', 'C0521125', 'C1705492', 'C1261322', 'C0205202', 'C3714741', 'C1511726', 'C0013261', 'C0205314', 'C1516048', 'C1551393', 'C4321252']","['Incidence Rate', 'Data call receiving device', 'Period (temporal qualifier)', 'Container status - Missing', 'Last', 'Data (eukaryote)', 'Missing', 'New', 'Missing Study Animal', 'WWOX wt Allele', 'Assessed', 'Evaluation procedure', 'Corrected', 'Duane Retraction Syndrome', 'Preposition For', 'Data']","['tmco', 'fndg', 'medd', 'idcn', 'hlca', 'gngm', 'qlco', 'qnco', 'dsyn', 'euka', 'acty']"
27,PMC3002766,S76,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,the worst of either the calculated number or observed values at week 24 was used for patients who prematurely discontinued study treatment.,"['C1441672', 'C3272598', 'C1441506', 'C1521826', 'C1522166', 'C1444662', 'C0237753', 'C0444686', 'C0449788', 'C0439230', 'C0030705', 'C0042295']","['Observed', 'Calculated', 'WHO Temperature/Humidity Storage Condition', 'Count of entities', 'Protocol Agent', 'Worst', 'Patients', 'Calculation', 'Discontinued', 'week', 'Values', 'Numbers']","['tmco', 'fndg', 'inpr', 'qlco', 'qnco', 'podg', 'ftcn', 'acty']"
28,PMC3002766,S77,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"patients with no valid assessment post baseline (three patients on bosentan, one on placebo) were excluded from the main analysis.","['C2349099', 'C0252643', 'C0205447', 'C1442488', 'C0032042', 'C0205449', 'C0205225', 'C0168634', 'C0030705', 'C1542147', 'C1706408', 'C0687676', 'C3469826', 'C1696465', 'C1261322', 'C1704687', 'C1524024', 'C1516048', 'C0936012']","['BaseLine dental cement', 'Post Device', 'Main', 'Placebo Control', 'Primary', 'Valid', 'placebo', 'Analysis', 'SLC35G1 gene', 'Placebos', 'analysis aspect', 'Assessed', 'Patients', 'Evaluation procedure', 'Three', 'Baseline', 'One', 'bosentan', 'Post']","['tmco', 'bodm', 'gngm', 'hlca', 'topp', 'orch', 'qnco', 'qlco', 'resa', 'podg', 'ftcn', 'mnob', ' phsu', 'acty']"
29,PMC3002766,S78,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,treatment effects for new dus in predefined subgroups were presented as point estimates and 95% two-sided cis.,"['C0087111', 'C1504308', 'C1742862', 'C1552961', 'C1522326', 'C3887704', 'C1705169', 'C1280500', 'C1079230', 'C3538994', 'C0750572', 'C0039798', 'C1515981', 'C2347617', 'C3714763', 'C0205448', 'C0013261', 'C0205314', 'C1533734']","['point - UnitsOfMeasure', 'Point', 'Genus Cis', 'Estimated', 'Two', 'treatment - ActInformationManagementReason', 'Treating', 'Point Name', 'Treatment Epoch', 'And', 'New', 'therapeutic aspects', 'Subgroup A Nepoviruses', 'Effect', 'Biomaterial Treatment', 'Duane Retraction Syndrome', 'Administration procedure', 'CISH protein, human', 'Therapeutic procedure']","['resa', 'virs', 'topp', 'idcn', 'hlca', 'qlco', 'bacs', 'qnco', 'dsyn', 'euka', 'spco', 'ftcn', ' aapp', 'cnce']"
30,PMC3002766,S79,"['12a', '12b']","[0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"for exploratory purposes, statistical tests of treatment difference were provided for planned secondary/exploratory and unplanned post hoc efficacy analyses and included the pitman permutation (for changes from baseline), the fisher exact test (for proportions) and the log-rank test (for times to event), each performed without correction for multiple testing.","['C0667477', 'C1705241', 'C1947976', 'C1515976', 'C0022885', 'C4318744', 'C0168634', 'C3538994', 'C0521125', 'C2986775', 'C0392747', 'C1533734', 'C4321252', 'C0443172', 'C0087111', 'C0699794', 'C2828393', 'C3887704', 'C1285529', 'C1705169', 'C1457900', 'C1301732', 'C0205436', 'C0039798', 'C0392366', 'C1632851', 'C1882348', 'C1708728', 'C0175668', 'C0456984', 'C1705565', 'C1705242', 'C1517320', 'C0237913', 'C0441471', 'C0027627', 'C1522326', 'C1442488', 'C0039593', 'C0040223', 'C4050514', 'C1515981', 'C3831328', 'C0439064', 'C4019010']","['TNFRSF11A protein, human', 'Logarithm', 'National reporting jurisdiction:Loc:Pt:^Event:Nom', 'Rank', 'Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome Questionnaire', 'Each (qualifier value)', 'And', 'Test - temporal region', 'Event', 'From', 'second (number)', 'Time', 'Treatment Epoch', 'Tests (qualifier value)', 'Changed status', 'Laboratory Procedures', 'Baseline', 'Biomaterial Treatment', 'Planned', 'Administration procedure', 'Times', 'Neoplasm Metastasis', 'Changing', 'Event Log', 'Test Result', 'WWOX wt Allele', 'Correction (change)', 'Testing', 'Purpose', 'Therapeutic procedure', 'Preposition For', 'Numerous', 'Different', 'BaseLine dental cement', 'treatment - ActInformationManagementReason', 'Anatomic Structure, System, or Substance', 'Statistical Test', 'Treating', 'Secondary to', 'therapeutic aspects', 'Blood Products Laboratory Testing', 'Delta (difference)', 'Exact (qualifier)', 'Permutation', 'Correction Report']","['topp', 'qnco', 'bodm', ' aapp', 'clna', 'blor', 'clas', 'idcn', 'hlca', 'inpr', 'qlco', 'bacs', 'lbpr', 'resa', 'ftcn', 'tmco', 'lbtr', 'neop', 'cnce', 'gngm', 'evnt']"
31,PMC3002766,S80,"['12a', '12b']","[0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"placebo-corrected changes from baseline, rr and hrs from cox modelling were each reported with 95% cis where appropriate.","['C0443172', 'C1504308', 'C1742862', 'C1442488', 'C1457900', 'C0168634', 'C1565830', 'C1515981', 'C0392747', 'C0205202', 'C1568891', 'C1548787']","['BaseLine dental cement', 'Changing', 'Genus Cis', 'Each (qualifier value)', 'And', 'Appropriate', 'PTGS1 protein, human', 'Changed status', 'Corrected', 'Baseline', 'HGS protein, human', 'CISH protein, human']","['idcn', 'enzy', 'qlco', 'bacs', 'qnco', 'euka', 'ftcn', 'bodm', ' aapp']"
32,PMC3002766,S81,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"safety and baseline data were summarised descriptively, with no statistical testing planned or given.","['C1442488', 'C3245479', 'C0038215', 'C0036043', 'C0039593', 'C0168634', 'C1515981', 'C0392366', 'C3714741', 'C1511726', 'C1705187']","['Data call receiving device', 'BaseLine dental cement', 'Data (eukaryote)', 'And', 'Testing', 'Tests (qualifier value)', 'Safety', 'Safety Study', 'Baseline', 'Science of Statistics', 'Data']","['medd', 'idcn', 'hcpp', 'ocdi', 'inpr', 'qnco', 'euka', 'resa', 'ftcn', 'bodm']"
33,PMC3002834,S49,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study subjects,"we studied a subgroup of crs patients from the epocares trial (clinicaltrials.gov, nct00356733), and healthy controls of comparable age and gender.",,,
34,PMC3002834,S50,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study subjects,a detailed description with inclusion and exclusion criteria of the study has previously been published.14,"['C2603343', 'C0678257', 'C1522508', 'C0680252', 'C0680251']","['inclusion and exclusion', 'Exclusion Criteria', 'Details', 'Description', 'Study']","['qlco', 'ftcn', 'inpr', 'resa']"
35,PMC3002834,S51,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study subjects,the protocol was approved by the medical ethics committee and all patients gave informed consent.,"['C3715209', 'C4282383', 'C0085546', 'C1507394', 'C0030705', 'C0021430', 'C1522729', 'C1515981', 'C2348563', 'C0015004', 'C0444868', 'C2599718', 'C0442711']","['Ethics, Medical', 'Protocols documentation', 'All', 'REMS Protocol', 'Clinical trial protocol document', 'Library Protocol', 'Study Protocol', 'And', 'Informed Consent', 'Ethics Committees', 'Patients', 'Protocol - answer to question', 'Clinical trial protocol']","['fndg', 'prog', 'rnlw', 'idcn', 'inpr', 'qnco', 'podg']"
36,PMC3002834,S52,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study subjects,procedures were in accordance with the helsinki declaration.,"['C2700391', 'C0025664', 'C3538935', 'C0184661', 'C0018898']","['Procedure (set of actions)', 'Helsinki Declaration', 'Procedure Domain', 'Interventional procedure', 'Methods aspects']","['rnlw', 'topp', 'inpr', 'ftcn']"
37,PMC3002834,S53,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study subjects,"patients with mild anaemia (women: 6.4–7.4 mmol/l; men: 6.4–7.8 mmol/l), moderate ckd (estimated creatinine clearance 20–70 ml/min, cockcroft–gault formula) and chf (functional nyha class ii–iv, based on symptoms, signs and objective abnormality on echocardiography,15 reduced ejection fraction (<50%) or left ventricular end-diastolic volume index <97 ml/m2 with evidence of diastolic left ventricular dysfunction16) were included.","['C0025266', 'C2986546', 'C1561643', 'C0220913', 'C0018802', 'C0489482', 'C0600653', 'C0043210', 'C0002871', 'C1704258', 'C0030705', 'C0750572', 'C0042509', 'C4321335', 'C0812399', 'C3887511', 'C4049706', 'C1881878', 'C4049705', 'C0489829', 'C0332287', 'C1705501', 'C0220912', 'C0225897', 'C0018017', 'C2945599', 'C1571702', 'C4552789', 'C0311392', 'C2700378', 'C0013516', 'C0683368', 'C4085643', 'C0205081', 'C1515981', 'C0012000', 'C1552854', 'C1457887', 'C0012164', 'C0918012']","['Left ventricular structure', 'Estimated', 'In addition to', 'Borg Category-Ratio 10 Perceived Exertion Score 3', 'Evidence', 'Moderate Level', 'Html Link Type - index', 'Symptoms', 'And', 'Echocardiography', 'Clinical Trial Objective', 'Abnormality', 'Congestive heart failure', 'Moderate (severity modifier)', 'Mathematical formula', 'Ventricular End-Diastolic Volume', 'Creatinine clearance', 'Index', 'Chemical Formula', 'Anemia', 'Woman', 'Objective observation', 'Moderate Extremity Pain', 'Formula - diet', 'Mild (qualifier value)', 'Physical findings', 'Male population group', 'Aspects of signs', 'Moderation', 'Symptoms aspect', 'Diastole', 'Patients', 'Chronic Kidney Diseases', 'Ejection fraction (procedure)', 'objective (goal)', 'Moderate Response', 'Indexes', 'Ejection fraction (finding)', 'Manufactured sign', 'Target Lesion Identification']","['mnob', 'fndg', 'biof', 'idcn', 'topp', 'inpr', 'sosy', 'qnco', 'qlco', 'dsyn', 'podg', 'ftcn', 'diap', 'popg', 'bpoc', 'clna']"
38,PMC3002834,S55,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study design,epc levels and function were compared between 45 crs patients at baseline and 20 healthy controls.,"['C3850017', 'C3898900', 'C1442488', 'C0542341', 'C1705273', 'C0168634', 'C0030705', 'C0010278', 'C0169014', 'C1515981', 'C0031843', 'C0441889']","['BaseLine dental cement', 'Mathematical Operator', 'erucylphosphocholine', 'Endothelial Progenitor Cells', 'physiological aspects', 'And', 'Patients', 'Function (attribute)', 'Craniosynostosis', 'Baseline', 'Levels (qualifier value)', 'Healthy']","['idcn', 'phsf', 'inpr', 'orch', 'qnco', 'qlco', 'cell', 'dsyn', 'ftcn', 'podg', 'bodm', ' phsu']"
39,PMC3002834,S56,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"the effects of epo treatment were evaluated in an open-label, randomised design.","['C0087111', 'C2827499', 'C2976467', 'C0175566', 'C1522326', 'C3887704', 'C1705169', 'C1280500', 'C4551445', 'C3538994', 'C0039798', 'C2983265', 'C1707689', 'C0181496', 'C4522130', 'C1533734']","['Label (document)', 'EPO protein, human', 'Human Cells, Tissues, and Cellular and Tissue-Based Products Labeling', 'Open', 'Design', 'treatment - ActInformationManagementReason', 'Treating', 'Labels (device)', 'Treatment Epoch', 'therapeutic aspects', 'CDISC SEND Study Design Terminology', 'Effect', 'Biomaterial Treatment', 'Labeling Activity', 'Administration procedure', 'Therapeutic procedure']","['topp', 'hlca', 'inpr', 'qlco', 'bacs', 'spco', 'resa', 'ftcn', ' aapp', 'mnob', 'cnce', 'acty']"
40,PMC3002834,S57,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,"patients received epo treatment (50 iu/kg/week; neorecormon, roche pharmaceuticals, woerden, netherlands) or standard treatment without epo for one year.","['C0027778', 'C4684780', 'C2976467', 'C0087111', 'C0205447', 'C1522326', 'C0376540', 'C1135440', 'C1705169', 'C3887704', 'C0039798', 'C0439230', 'C0030705', 'C3538994', 'C0439234', 'C0331965', 'C1254351', 'C1533734', 'C0013227']","['Netherlands', 'EPO protein, human', 'year', 'treatment - ActInformationManagementReason', 'Standard Treatment', 'Treating', 'roche', 'Treatment Epoch', 'therapeutic aspects', 'Patients', 'week', 'Procedures involving the use of pharmaceuticals', 'Biomaterial Treatment', 'One', 'Administration procedure', 'Pharmaceutical Preparations', 'Pharmacologic Substance', 'Recormon', 'Therapeutic procedure']","['tmco', 'resa', 'topp', 'hlca', 'geoa', 'hcro', 'qnco', 'bacs', 'phsu', 'ftcn', 'aapp', 'podg', ' phsu', ' aapp', 'cnce']"
41,PMC3002834,S58,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study design,"short-term effects of epo (n =30) versus no epo (n =15) were evaluated after 18 days (3 days after third epo injection), when epo treatment was not yet expected to result in a haematopoietic response.","['C1515273', 'C4049935', 'C0871261', 'C1282927', 'C2826302', 'C0687676', 'C3538994', 'C1272883', 'C1533734', 'C0087111', 'C1533685', 'C3887704', 'C1705169', 'C1280500', 'C0039798', 'C1948054', 'C0220825', 'C0233324', 'C0018957', 'C0231290', 'C2976467', 'C1518422', 'C1706817', 'C1522326', 'C2350002', 'C2911692', 'C0205437', 'C1806781', 'C1705313', 'C1704632', 'C0021485', 'C1828121']","['Short Value', 'Reported Term', 'Response (communication)', 'Term (lexical)', 'Response process', 'Injection of therapeutic agent', 'Disease Response', 'Post', 'Treatment Epoch', 'Biomaterial Treatment', 'Shortened', 'Administration procedure', 'Hematopoietic System', 'EPO protein, human', 'Injection', 'Short', 'When (temporal qualifier)', 'Status post', 'Injection Dosing Unit', 'Effect', 'Response (statement)', 'Negation', 'treatment - ActInformationManagementReason', 'Injection procedure', 'Treating', 'Third', 'Term (temporal)', 'therapeutic aspects', 'Injection Route of Drug Administration', 'Term Birth', 'Evaluation', 'Therapeutic procedure']","['tmco', 'fndg', 'resa', 'topp', 'hlca', 'bdsy', 'idcn', 'inpr', 'qnco', 'bacs', 'qlco', 'orga', 'orgf', 'ftcn', 'bodm', 'menp', ' aapp', 'cnce']"
42,PMC3002834,S59,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study design,"long-term (52 week) effects of epo were assessed in a subgroup of epo-treated patients, who were allowed to increase haemoglobin (hb) levels up to 8.5 mmol/l for men and 8.3 mmol/l for women (n =13), and a non epo-treated group (n =13).","['C0025266', 'C1515273', 'C0521125', 'C2826302', 'C0441889', 'C4321252', 'C1257890', 'C3272598', 'C0043210', 'C0441833', 'C1515021', 'C1280500', 'C0030705', 'C1706317', 'C1705428', 'C0442805', 'C1516048', 'C0205166', 'C1519504', 'C0547043', 'C1079230', 'C1705429', 'C0233324', 'C2976467', 'C1522326', 'C1518422', 'C0683607', 'C1705313', 'C0687744', 'C1515981', 'C0019046']","['Group Object', 'Reported Term', 'And', 'Term (lexical)', 'Hemoglobin', 'Subgroup', 'Assessed', 'Woman', 'allowing', 'User Group', 'Increase', 'EPO protein, human', 'Male population group', 'Groups', 'Population Group', 'Up', 'Social group', 'WWOX wt Allele', 'Patients', 'Effect', 'Preposition For', 'Levels (qualifier value)', 'Negation', 'Long', 'Treating', 'WHO Temperature/Humidity Storage Condition', 'Term (temporal)', 'Subgroup A Nepoviruses', 'Stage Grouping', 'Term Birth', 'Long Variable']","['tmco', 'virs', 'gngm', 'idcn', 'clas', 'inpr', 'qlco', 'bacs', 'orgf', 'ftcn', 'podg', ' aapp', 'spco', 'popg', 'socb', 'cnce', 'acty']"
43,PMC3002834,S61,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Plasma measurements,"serum epo levels were measured by sandwich chemiluminescent immunoassay (immulite 2000 platform, siemens healthcare diagnostics, breda, netherlands).","['C2697666', 'C0027778', 'C0020980', 'C1550100', 'C2657734', 'C2976467', 'C1710360', 'C0229671', 'C0441889', 'C1546774', 'C0086388', 'C3829562', 'C1551054']","['Netherlands', 'Serum', 'EPO protein, human', 'Immunoenzyme Procedure', 'Specimen Type - Serum', 'Units Of Measure - Siemens', 'Technology Platform', 'Immunoassay method', 'Health Care', 'Breda (invertebrate)', 'Immulite', 'Levels (qualifier value)', 'Specimen Source Codes - Serum']","['hlca', 'inpr', 'geoa', 'resd', 'qlco', 'bacs', 'qnco', 'lbpr', 'euka', ' aapp', 'mnob', 'bdsu']"
44,PMC3002834,S62,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Plasma measurements,"endothelial dysfunction, epc mobilising factors and inflammation markers were measured using elisa (e-selectin, vascular cell adhesion molecule-1 (vcam-1), interleukin (il)-6, vegf, sdf-1α (r&d systems, minneapolis, minnesota, usa) and thrombomodulin (diaclone, stamford, connecticut, usa)) or multiplex immunoassay17 (intercellular adhesion molecule-1 (icam-1) and monocyte chemotactic protein-1 (mcp-1) (bio-rad laboratories,hercules, california, usa)).","['C0128897', 'C0856169', 'C0009778', 'C1449159', 'C0021368', 'C3891450', 'C0115305', 'C3850017', 'C0041703', 'C1527200', 'C0406775', 'C0014441', 'C1522558', 'C0078056', 'C2744539', 'C1505125', 'C2742136', 'C3146274', 'C0145779', 'C0006754', 'C0169014', 'C0022877', 'C1256770', 'C1420720', 'C0063695', 'C0021764', 'C1515981', 'C1337114', 'C0026183', 'C3811628']","['endothelial dysfunction', 'E-Selectin', 'Connecticut', 'CCL2 protein, human', 'Minnesota', 'Laboratory', 'Enzyme-Linked Immunosorbent Assay', 'And', 'Recombinant Monocyte Chemoattractant Protein-1', 'THBD protein, human', 'California', 'Recombinant Interleukins', 'Radiography Study File', 'Intercellular adhesion molecule 1', 'Thrombomodulin', 'Symmetrical dyschromatosis of extremities', 'Inflammation', 'THBD gene', 'ribosome-associated ubiquitin-dependent protein catabolic process', 'Vascular Cell Adhesion Molecule-1', 'California (plant)', 'Vascular Endothelial Growth Factors', 'erucylphosphocholine', 'Endothelial Progenitor Cells', 'RRAD protein, human', 'United States', 'SELE gene', 'SELE protein, human', 'Monocyte Chemoattractant Protein-1', 'Interleukins']","['imft', ' imft', 'celf', 'cgab', 'gngm', ' hcro', 'idcn', 'plnt', 'inpr', 'geoa', 'orch', 'bacs', 'lbpr', 'cell', 'dsyn', 'rcpt', ' aapp', 'mnob', ' phsu', 'patf']"
45,PMC3002834,S63,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Plasma measurements,"high sensitivity c reactive protein (hscrp) was determined by particle-enhanced immunonephelometry (standard cardio-phase hscrp for bnii, dade behring holding, liederbach, germany).","['C0046889', 'C0006560', 'C0205390', 'C2349975', 'C1442989', 'C1710475', 'C0017480', 'C1441604', 'C4505179', 'C2828392']","['Phase', 'High sensitivity', 'Immunonephelometry', 'C-reactive protein', 'Enhance (action)', 'Standard (qualifier)', 'Trial Phase', 'Germany', 'Standard (document)', ""3,3'-diallyldiethylstilbestrol""]","['tmco', 'imft', 'clas', 'inpr', 'orch', 'geoa', 'qlco', 'lbpr', ' aapp', 'acty']"
46,PMC3002834,S64,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Plasma measurements,"n-terminal prohormone of brain natriuretic peptide (nt-probnp) was measured using electrochemiluminescense immunoassay (cobas ca6000, roche, mannheim, germany).","['C2697666', 'C0020980', 'C0205088', 'C0301817', 'C0054015', 'C3541902', 'C1421478', 'C1565156', 'C0043194', 'C1705315', 'C1705314', 'C0444706', 'C0017480', 'C0331965', 'C0754710']","['Measured', 'Immunoenzyme Procedure', 'Nesiritide', 'End-stage', 'WAS protein, human', 'roche', 'WAS gene', 'Immunoassay method', 'Terminal (end postition)', 'Measured Tumor Identification', 'Prohormone (substance)', 'Terminal Device', 'Amino-terminal pro-brain natriuretic peptide', 'Germany', 'Wiskott-Aldrich Syndrome']","['mnob', 'gngm', 'geoa', 'hcro', 'qlco', 'bacs', 'lbpr', 'dsyn', 'spco', ' phsu', ' aapp', 'diap', 'horm']"
47,PMC3002834,S65,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Plasma measurements,samples were measured in duplicate and averaged for analysis.,"['C1524024', 'C1515981', 'C0205173', 'C0936012']","['Duplicate', 'analysis aspect', 'Analysis', 'And']","['ftcn', 'idcn', 'resa']"
48,PMC3002834,S67,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Circulating EPC levels,"circulating epc were defined as cells positive for haematopoietic stem cell marker cd34 and endothelial marker kinase insert domain receptor (kdr; ie, vegf receptor-2).","['C3850017', 'C0018957', 'C0007584', 'C0378796', 'C0148199', 'C0007634', 'C3538723', 'C1446409', 'C1514241', 'C0005516', 'C3849882', 'C1334306', 'C0169014', 'C0038250', 'C1515981', 'C0014257', 'C3812269', 'C2825490']","['KDR gene', 'Hematopoietic System', 'Vascular Endothelial Growth Factor Receptor 2, human', 'Positive Finding', 'erucylphosphocholine', 'Cells', 'Endothelial Progenitor Cells', 'Stem cells', 'Vascular Endothelial Growth Factor Receptor-2', 'CD34 Measurement', 'Vascular Endothelial Growth Factor Receptor', 'Biological Markers', 'Endothelium', 'And', 'Cell Count', 'Positive Charge', 'Positive', 'Positive Number']","['fndg', 'gngm', 'idcn', 'bdsy', ' enzy', 'orch', 'tisu', 'qlco', 'cell', 'lbpr', 'rcpt', ' aapp', ' phsu', 'cnce', 'clna']"
49,PMC3002834,S68,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Circulating EPC levels,this cd34+kdr+-epc has previously shown clinical importance by predicting cardiovascular events and death in cardiovascular risk populations.18 19,"['C3850017', 'C0032659', 'C1080058', 'C3887460', 'C0035647', 'C0011065', 'C3538723', 'C1306577', 'C0169014', 'C1515981', 'C3849882', 'C1320716', 'C0205210', 'C0007226', 'C4552904']","['Death (finding)', 'Clinical', 'Vascular Endothelial Growth Factor Receptor 2, human', 'Cardiovascular', 'erucylphosphocholine', 'Endothelial Progenitor Cells', 'CD34 Measurement', 'Subject Risk', 'And', 'cardiovascular event', 'This (eukaryote)', 'geographic population', 'Cessation of life', 'Cardiovascular system', 'Risk']","['blor', 'fndg', 'idcn', 'bdsy', ' enzy', 'orch', 'rcpt', 'qnco', 'qlco', 'cell', 'lbpr', 'orgf', 'euka', ' aapp', ' phsu', 'cnce']"
50,PMC3002834,S69,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Circulating EPC levels,"blood (100 μl) was incubated with anti-cd34-fitc (bd pharmingen, california, usa), anti-kdr-pe (r&d systems) and anti-cd45-pe-cy7 (bd pharmingen) antibodies for 45 min. erythrocytes were lysed and analysed by flow cytometry (beckman coulter, california, usa).","['C0085216', 'C0005767', 'C0005768', 'C0041703', 'C0332287', 'C1439852', 'C1328195', 'C3146274', 'C3538723', 'C0016263', 'C0014792', 'C0006754', 'C0229664', 'C1421478', 'C1515981', 'C3849882', 'C1565156', 'C0043194', 'C0003241', 'C0014772']","['Flow Cytometry', 'Erythrocytes', 'Vascular Endothelial Growth Factor Receptor 2, human', 'monoclonal antibody BC8', 'In addition to', 'CD34 Measurement', 'WAS protein, human', 'Fluorescein-5-isothiocyanate', 'peripheral blood', 'United States', 'And', 'Antibodies', 'WAS gene', 'California (plant)', 'In Blood', 'incubated', 'California', 'Blood', 'Red Blood Cell Count measurement', 'Wiskott-Aldrich Syndrome']","['imft', ' orch', 'irda', 'idcn', 'gngm', 'plnt', ' enzy', 'geoa', 'rcpt', 'bacs', 'lbpr', 'cell', 'dsyn', 'ftcn', ' aapp', ' phsu', 'bdsu']"
51,PMC3002834,S70,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Circulating EPC levels,circulating hsc and epc were identified as cd34+ and cd34+kdr+ cells in the lymphocyte region of the forward/sideward scatter plot.,"['C3850017', 'C1523748', 'C0007584', 'C0017446', 'C0439742', 'C0024264', 'C0007634', 'C0439780', 'C1515981', 'C0169014', 'C0205147', 'C0175630', 'C0018956', 'C1705576']","['Hematopoietic stem cells', 'Allogeneic Hematopoietic Stem Cell Transplantation', 'Circulating', 'Hedgehog signaling complex location', 'erucylphosphocholine', 'Lymphocyte', 'Endothelial Progenitor Cells', 'Cells', 'regional', 'And', 'Cell Count', 'scattered', 'Geographic Locations', 'Forward']","['idcn', 'topp', 'orch', 'geoa', 'celc', 'cell', 'lbpr', 'spco', 'ftcn', ' phsu']"
52,PMC3002834,S71,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Circulating EPC levels,"cell numbers were quantified relative to 105 granulocytes, identified as cd45+ cells with a typical granulocyte distribution.","['C0007584', 'C4521391', 'C0018183', 'C1704711', 'C0237753', 'C0007634', 'C0449788', 'C1413336', 'C1948049', 'C1704653', 'C0857490', 'C0520511', 'C0205345', 'C0080103', 'C1870006', 'C3538928']","['Cell Device', 'Distributing', 'Cells', 'Cell (compartment)', 'Count of entities', 'Relative', 'Cell Count', 'Relative (related person)', 'Usual', 'Distribution', 'CEL gene', 'Granulocyte count', 'PTPRC protein, human', 'Granulocytes Product', 'granulocyte', 'Numbers']","['medd', 'gngm', 'idcn', 'enzy', 'famg', 'qnco', 'qlco', 'lbpr', 'cell', 'spco', 'ftcn', ' aapp', 'phsu']"
53,PMC3002834,S72,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Circulating EPC levels,measurements were performed in duplicate and results were averaged.,"['C0205173', 'C1515981', 'C0242485']","['Duplicate', 'And', 'Measurement']","['idcn', 'ftcn']"
54,PMC3002834,S73,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Circulating EPC levels,isotype-stained samples served as negative controls.,"['C2986582', 'C3853545', 'C1513916', 'C2825491', 'C0205160', 'C2825415']","['Negative Charge', 'Negative', 'Negative Number', 'Negative - answer', 'Stained Appearance', 'Negative Finding']","['qlco', 'fndg', 'cnce']"
55,PMC3002834,S75,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outgrowth of EPC in culture,epc outgrowth from mononuclear cells (mnc) was assessed as described previously.3,"['C3850017', 'C0169014', 'C0806987', 'C1552738']","['mononuclear cells', 'described', 'erucylphosphocholine', 'Endothelial Progenitor Cells']","['idcn', ' phsu', 'cell', 'orch']"
56,PMC3002834,S76,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outgrowth of EPC in culture,"in brief, mnc were isolated from blood using ficoll density gradient separation (histopaque 1077, sigma, st louis, missouri, usa).","['C0005767', 'C0005768', 'C0164836', 'C0041703', 'C0178587', 'C0036679', 'C0812409', 'C1881713', 'C1282927', 'C0229664', 'C1879313', 'C4050216', 'C0237868', 'C0016071', 'C0026222']","['Gradient', 'Diastasis', 'Missouri', 'Shortened', 'histopaque', 'peripheral blood', 'United States', 'Behavior Rating Inventory of Executive Function', 'density', 'In Blood', 'Brief', 'Marital separation', 'Blood', 'Ficoll', 'Medical Device Material Separation']","['tmco', 'fndg', ' orch', 'irda', 'inpr', 'geoa', 'qnco', 'qlco', 'socb', 'patf', 'bdsu']"
57,PMC3002834,S77,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outgrowth of EPC in culture,"to evaluate epc outgrowth in culture, 107 mnc/well were seeded on a human fibronectin (sigma) coated 6-well plate in egm-2 (cambrex, baltimore, maryland, usa), supplemented with accompanying aliquots, 20% fetal calf serum (invitrogen, carlsbad, california, usa), 100 ng/ml recombinant vegf-165 (r&d systems) and antibiotics.","['C1514798', 'C3540709', 'C1570610', 'C3540710', 'C0430400', 'C0086418', 'C3540707', 'C2242979', 'C1999501', 'C0205170', 'C3850017', 'C0376854', 'C0041703', 'C3812213', 'C3540706', 'C3146287', 'C0010453', 'C0024858', 'C0016055', 'C4283957', 'C1139930', 'C0332287', 'C3537155', 'C3146274', 'C0003237', 'C0003232', 'C0006754', 'C3540705', 'C0169014', 'C3540708', 'C0220814', 'C0004716', 'C3540704', 'C1515981', 'C1522408']","['In addition to', 'Antibiotics, Gynecological', 'Antifungal Antibiotics, Topical', 'FN1 protein, human', 'And', 'vascular endothelial growth factor-165', 'Recombinants', 'Baltimore', 'California', 'Homo sapiens', 'Fetal Bovine Serum', 'antibiotics, intestinal', 'Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE', 'Microplate Well', 'Antibiotics, Antitubercular', 'Well', 'Antibiotics, ophthalmologic', 'Coating (film)', 'Antibiotics for systemic use', 'Device Plate', 'California (plant)', 'Microbial culture (procedure)', 'Plate Device Component', 'Antibiotic throat preparations', 'Anthropological Culture', 'Antibiotics', 'Maryland (geographic location)', 'Laboratory culture', 'erucylphosphocholine', 'Fibronectins', 'Endothelial Progenitor Cells', 'United States', 'Good', 'VEGF165 protein, human', 'Cultural aspects']","['orgm', 'antb', 'medd', 'idcn', 'irda', 'plnt', 'geoa', 'orch', 'qlco', 'bacs', 'lbpr', 'cell', 'spco', 'ftcn', ' aapp', 'mnob', ' phsu', 'humn']"
58,PMC3002834,S78,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outgrowth of EPC in culture,medium was changed after 4 days to wash non-adherent cells away.,"['C0007584', 'C1518422', 'C1705217', 'C0009458', 'C0007634', 'C4522282', 'C4085196', 'C0334154', 'C0439536', 'C4522283', 'C3244283']","['adherent', 'Cells', 'Medium', 'A Medium Amount of Time', 'A Medium Amount', 'Communications Media', 'Cell Count', 'medium exposure', 'Medium Growth Rate', 'Negation', 'Medium (Substance)']","['fndg', 'inpr', 'qnco', 'sbst', 'qlco', 'lbpr', 'cell', 'ftcn', 'cnce']"
59,PMC3002834,S79,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outgrowth of EPC in culture,"after 7 days, cultured epc in selected wells were placed on serum free medium (ebm-2 with hegf, hydrocortisone, ga-1000, r3-igf-1, ascorbic acid, heparin and antibiotics) overnight.","['C0439583', 'C1996904', 'C3540709', 'C1705217', 'C3540710', 'C3540707', 'C3850017', 'C0009458', 'C4085196', 'C3540706', 'C0439536', 'C4522283', 'C0332287', 'C4522282', 'C0003968', 'C0021665', 'C3712803', 'C0003232', 'C0003237', 'C1880497', 'C3540705', 'C0169014', 'C0904505', 'C0332296', 'C3540708', 'C3179044', 'C1707391', 'C1414235', 'C0795974', 'C0020268', 'C0019134', 'C3540704', 'C1515981', 'C3244283', 'C0770546']","['In addition to', 'Medium', 'Antibiotics, Gynecological', 'Antifungal Antibiotics, Topical', 'And', 'Communications Media', 'Hereditary macular epidermolysis bullosa', 'Free of (attribute)', 'antibiotics, intestinal', 'IGF1 protein, human', 'Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE', 'overnight', 'Ascorbic Acid', 'Antibiotics, Antitubercular', 'Antibiotics, ophthalmologic', 'heparin', 'medium exposure', 'Free (available (qualifier))', 'Antibiotics for systemic use', 'A Medium Amount of Time', 'Empty (qualifier)', 'mecasermin', 'Antibiotic throat preparations', 'heparin, porcine', 'Antibiotics', 'Choose (action)', 'EBM gene', 'Water Wells', 'erucylphosphocholine', 'Endothelial Progenitor Cells', 'A Medium Amount', 'Hydrocortisone', 'Insulin-Like Growth Factor I', 'Medium Growth Rate', 'Medium (Substance)']","['antb', 'qnco', 'cell', ' aapp', 'horm', 'fndg', ' orch', 'idcn', 'inpr', 'qlco', 'bacs', 'sbst', 'ftcn', 'mnob', 'tmco', 'orch', 'vita', 'cnce', 'acty', 'gngm', 'dsyn', ' phsu']"
60,PMC3002834,S80,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outgrowth of EPC in culture,"conditioned medium was stored for functional experiments and cultured epc were detached by trypsin and cell scraping, and automatically counted using a haemocytometer.","['C0184933', 'C1705217', 'C1413336', 'C3850017', 'C0009458', 'C0542341', 'C4085196', 'C2700217', 'C0681814', 'C0439536', 'C4522283', 'C1704653', 'C3842331', 'C0205245', 'C4522282', 'C0169014', 'C1948049', 'C0041236', 'C0007634', 'C0009647', 'C1515981', 'C3244283']","['Scraping', 'Cell (compartment)', 'Medium', 'And', 'Communications Media', 'Function (attribute)', 'Functional', 'Cells', 'medium exposure', 'A Medium Amount of Time', 'Functional Relationship', 'Cell Device', 'erucylphosphocholine', 'Automatically', 'Endothelial Progenitor Cells', 'A Medium Amount', 'TRYPSIN', 'research study', 'Conditioning (Psychology)', 'CEL gene', 'Medium Growth Rate', 'Medium (Substance)']","['fndg', 'resa', 'gngm', 'idcn', 'medd', 'topp', 'enzy', 'inpr', 'orch', 'qnco', 'sbst', 'qlco', 'cell', 'spco', 'ftcn', ' aapp', ' phsu', 'menp', 'cnce']"
61,PMC3002834,S82,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",In vitro scratch wound assay,the potential of epc outgrowth to excrete paracrine factors that stimulate endothelial cell migration was assessed by in vitro scratch wound assay.20,"['C3850017', 'C0243073', 'C1624612', 'C1510438', 'C0005507', 'C0597170', 'C0169014', 'C0043250', 'C3263723', 'C3245505', 'C0221102', 'C2987480']","['erucylphosphocholine', 'Excretory function', 'Endothelial Progenitor Cells', 'Assay', 'Traumatic injury', 'paracrine', 'potential', 'Injury wounds', 'Scratch -action', 'endothelial cell migration', 'Biological Assay', 'assay qualifier']","['celf', 'phsf', 'orch', 'qlco', 'inpo', 'lbpr', 'cell', ' phsu', 'acty']"
62,PMC3002834,S83,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",In vitro scratch wound assay,"in brief, epc outgrowth medium was placed on a mechanically scratched confluent human microvascular endothelial cell layer.","['C3850017', 'C0205200', 'C1705217', 'C0009458', 'C4522282', 'C4085196', 'C0443258', 'C0439536', 'C1879313', 'C1282927', 'C4522283', 'C0169014', 'C4050216', 'C0225336', 'C0934502', 'C3244283', 'C3669471', 'C0086418', 'C1882981', 'C1522408']","['erucylphosphocholine', 'Chicken laying egg for human food', 'A Medium Amount', 'Endothelial Progenitor Cells', 'A Medium Amount of Time', 'Medium', 'Medium Growth Rate', 'Scratched Medical Device Material', 'anatomical layer', 'Communications Media', 'microvascular', 'Behavior Rating Inventory of Executive Function', 'Endothelial Cells', 'Homo sapiens', 'confluent', 'Brief', 'medium exposure', 'Shortened', 'Coating (film)', 'Medium (Substance)']","['tmco', 'fndg', 'bird', 'inpr', 'orch', 'qlco', 'qnco', 'sbst', 'cell', 'ftcn', ' phsu', 'humn', 'bpoc', 'cnce']"
63,PMC3002834,S84,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",In vitro scratch wound assay,"after 6 h, the extent of scratch closure relative to the starting width was compared between study groups using light photography.","['C4050248', 'C0441833', 'C2603343', 'C0487742', 'C1570446', 'C1521802', 'C1881376', 'C1552839', 'C3842678', 'C4521367', 'C0687744', 'C0023693', 'C0031749', 'C0439792', 'C0205345', 'C2987480', 'C0080103']","['Borg Scale Rating of Perceived Exertion Score 11', 'Groups', 'Extent', 'Social group', 'Light', 'TNFSF14 protein, human', 'TNFSF14 wt Allele', 'Relative', 'Light - subjective measurement', 'Relative (related person)', 'Scratch -action', 'width', 'Study', 'Photography', 'Light (qualifier)', 'Closure', 'Table Rules - groups']","['fndg', 'ocac', 'npop', 'gngm', 'idcn', 'inpr', 'famg', 'qlco', 'bacs', 'qnco', 'spco', 'resa', ' aapp', 'popg', 'acty']"
64,PMC3002834,S85,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",In vitro scratch wound assay,each sample was measured in two separate wells and two picture fields per well were examined.,"['C2347026', 'C0441469', 'C0441468', 'C1457900', 'C0443299', 'C3146287', 'C1515981', 'C3179044', 'C0205448', 'C4283957', 'C0370003', 'C0205170']","['Microplate Well', 'Separate', 'Two', 'Each (qualifier value)', 'And', 'Specimen', 'Good', 'Biospecimen', 'Well', 'Picture', 'Water Wells', 'photograph']","['idcn', 'qnco', 'qlco', 'sbst', 'spco', 'mnob', 'cnce']"
65,PMC3002834,S86,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",In vitro scratch wound assay,results were averaged for data analysis.,['C0010992'],['Data Analysis'],['ocac']
66,PMC3002834,S88,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,data analysis was performed using spss v.15.0 for windows.,"['C0557702', 'C0010992']","['Data Analysis', 'Window (physical object)']","['mnob', 'ocac']"
67,PMC3002834,S89,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,data distribution was tested by the kolmogorov–smirnov test.,"['C1704711', 'C3245479', 'C1515976', 'C0022885', 'C4318744', 'C0039593', 'C0456984', 'C0392366', 'C0520511', 'C3831328', 'C3714741', 'C1511726']","['Data call receiving device', 'Anatomic Structure, System, or Substance', 'Test Result', 'Data (eukaryote)', 'Testing', 'Blood Products Laboratory Testing', 'Tests (qualifier value)', 'Test - temporal region', 'Distribution', 'Laboratory Procedures', 'Distributing', 'Data']","['blor', 'lbtr', 'medd', 'idcn', 'clas', 'inpr', 'lbpr', 'euka', 'ftcn']"
68,PMC3002834,S90,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,data are expressed as mean ± sd for parametric data and as median (iqr) for non-parametric data.,"['C0876920', 'C0549183', 'C1518422', 'C3245479', 'C4321252', 'C0521125', 'C2348144', 'C1515981', 'C2347635', 'C3714741', 'C1511726', 'C2939193']","['Data call receiving device', 'Population Median', 'Median Statistical Measurement', 'Data (eukaryote)', 'Midline (qualifier value)', 'And', 'Median (qualifier value)', 'Sample Median', 'WWOX wt Allele', 'Preposition For', 'Negation', 'Data']","['medd', 'idcn', 'gngm', 'qnco', 'qlco', 'spco', 'euka', 'ftcn']"
69,PMC3002834,S91,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,differences between groups were analysed using student's t test or the mann–whitney test.,"['C0441833', 'C0022885', 'C1515976', 'C0039593', 'C1552839', 'C4318744', 'C0456984', 'C0687744', 'C0392366', 'C3831328', 'C0871472', 'C0038492']","['Groups', 't test', 'student', 'Social group', 'Anatomic Structure, System, or Substance', 'Test Result', 'Testing', 'Blood Products Laboratory Testing', 'Tests (qualifier value)', 'Test - temporal region', 'Laboratory Procedures', 'Table Rules - groups']","['blor', 'lbtr', 'idcn', 'clas', 'inpr', 'lbpr', 'ftcn', 'popg']"
70,PMC3002834,S92,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,fisher's exact test was used to analyse whether proportions of categories varied by group.,"['C0683312', 'C1257890', 'C2828393', 'C0441833', 'C1515976', 'C0022885', 'C1519504', 'C4318744', 'C0039593', 'C0456984', 'C1705429', 'C4050514', 'C0687744', 'C0392366', 'C3831328', 'C1705428']","['Groups', 'Population Group', 'Group Object', 'Social group', 'Anatomic Structure, System, or Substance', 'Categories', 'Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome Questionnaire', 'Test Result', 'Testing', 'Blood Products Laboratory Testing', 'Tests (qualifier value)', 'Test - temporal region', 'Stage Grouping', 'Laboratory Procedures', 'Exact (qualifier)', 'User Group']","['blor', 'lbtr', 'clas', 'idcn', 'inpr', 'qlco', 'lbpr', 'ftcn', 'popg', 'cnce']"
71,PMC3002834,S93,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,multiple group comparisons were performed using anova with lsd post-hoc testing for which non-parametric data were log-transformed.,"['C1257890', 'C1414110', 'C1704687', 'C0441833', 'C1518422', 'C0024334', 'C3245479', 'C1519504', 'C0039593', 'C1705429', 'C3469826', 'C0687676', 'C0687744', 'C0392366', 'C3714741', 'C0753802', 'C0439064', 'C1511726', 'C0202406', 'C1705428']","['Data call receiving device', 'Groups', 'Group Object', 'Neuro-Oncological Ventral Antigen 2, Human', 'DNASE1L3 gene', 'Population Group', 'Lysergic acid diethylamide measurement', 'Post Device', 'Social group', 'Data (eukaryote)', 'Lysergic Acid Diethylamide', 'SLC35G1 gene', 'Testing', 'Tests (qualifier value)', 'Negation', 'Stage Grouping', 'Numerous', 'User Group', 'Post', 'Data']","['tmco', 'imft', 'gngm', ' orch', 'idcn', 'medd', 'inpr', 'qnco', 'lbpr', 'hops', 'euka', 'ftcn', ' aapp', 'mnob', 'popg', 'cnce']"
72,PMC3002834,S94,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,correlations were measured by pearson's or spearman's correlation coefficient where appropriate.,"['C1548787', 'C1707520', 'C1707429']","['Coefficient', 'Correlation', 'Appropriate']","['qlco', 'qnco']"
73,PMC3002834,S95,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,multivariate determinants of log-transformed progenitor cell counts were identified by stepwise multiple linear regression analysis.,"['C0007584', 'C1708728', 'C2346679', 'C0023733', 'C2986775', 'C0038250', 'C0439064', 'C0034980']","['Logarithm', 'Event Log', 'Stem cells', 'Cell Count', 'Regression Analysis', 'Linear Regression Body Surface Area Formula for Infants and Children', 'Linear Regression', 'Numerous']","['qnco', 'cell', 'lbpr', 'inpr']"
74,PMC3002834,S96,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,a value of p <0.05 was considered statistically significant.,"['C0237881', 'C1522609']","['Numerical value', 'Statistical Significance']",['qnco']
75,PMC3016167,S100,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study treatments,"mesobuthus tamulus is not the only venomous scorpion in the state of western maharashtra, but it may be the only dangerously venomous scorpion in the mahad area.24 25","['C0205171', 'C0017446', 'C0205146', 'C1301808', 'C3812381', 'C3148680', 'C1442792', 'C1705493', 'C1005220', 'C0233535', 'C0036451', 'C0885762', 'C1518422']","['State', 'Month of May', 'Area', 'Scorpions', 'Geographic Locations', 'Geographic state', 'Singular', 'West (direction)', 'butting', 'Mesobuthus tamulus', 'Scorpio europaeus homeopathic preparations', 'US State', 'Negation']","['geoa', 'ftcn', 'spco', 'tmco', 'euka', 'mobd', 'qnco', 'phsu']"
76,PMC3016167,S101,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study treatments,haffkine biopharma (mumbai) has been manufacturing monovalent anti-scorpion venom serum f(ab)2 against mesobuthus tamulus since 1997 and it has been available for clinical use in a rural setting since 2002.,"['C0240919', 'C0042479', 'C0542559', 'C1515981', 'C0229671', 'C4281677', 'C1546774', 'C0205210', 'C0457083', 'C0036451', 'C0470187', 'C0885762', 'C1550100', 'C0042153', 'C1005220', 'C1552652']","['Venoms', 'Clinical', 'Parameterized Data Type - Set', 'Rural', 'availability of', 'utilization qualifier', 'Application Context', 'Scorpions', 'Specimen Type - Serum', 'And', 'Serum', 'Mesobuthus tamulus', 'contextual factors', 'Scorpio europaeus homeopathic preparations', 'Specimen Source Codes - Serum', 'Usage']","['inpr', 'idcn', 'hops', 'fndg', 'ftcn', 'bdsu', 'euka', 'qlco', 'menp', ' aapp', 'phsu']"
77,PMC3016167,S102,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study treatments,studies conducted at different times show that the antivenom is potent; 1 ml of reconstituted anti-scorpion venom serum neutralised 1.2 mg of indian red scorpion venom by intravenous route in an in vivo study in mice.35,"['C0042479', 'C0885164', 'C0013153', 'C0036450', 'C1550100', 'C0003450', 'C0026809', 'C2603343', 'C0036451', 'C1705242', 'C4697669', 'C0060240', 'C0229671', 'C1546774', 'C0885762', 'C0025914', 'C0025929', 'C0040223', 'C1879941', 'C0449444', 'C0947630', 'C1632851', 'C0348016']","['Venoms', 'House mice', 'Mus', 'Route', 'Serum', 'Time', 'Times', 'Buthus australis, scorpion venom', 'Intravenous', 'Drug Administration Routes', 'Reconstituted', 'Scorpion Venoms', 'Laboratory mice', 'Specimen Type - Serum', 'CDISC SDTM Route of Administration Terminology', 'Study', 'Antivenin', 'Scorpions', 'ferric oxide', 'Scientific Study', 'Different', 'Scorpio europaeus homeopathic preparations', 'Specimen Source Codes - Serum']","['bacs', 'inpr', ' hops', 'lbpr', 'inch', 'phsu', 'hops', 'ftcn', 'spco', 'bdsu', 'euka', 'imft', 'qlco', 'fndg', ' phsu', 'resa', ' aapp', 'tmco', 'qnco', 'mamm']"
78,PMC3016167,S103,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study treatments,"the maximum volume of venom injected in one sting by the indian red scorpion is 1.5 mg, and each ml of antivenom is capable of neutralising 1.2 to 1.5 mg of venom.36","['C1552615', 'C0042479', 'C2826546', 'C1457900', 'C1705102', 'C0060240', 'C0205447', 'C0806909', 'C1515981', 'C0449468', 'C0038340', 'C1823437', 'C2700258', 'C0036451', 'C0885762', 'C3538738', 'C0003450']","['Volume Measurement', 'Venoms', 'Act Relationship Subset - maximum', 'Antivenin', 'Scorpions', 'Sting Injury', 'And', 'Maximum', 'Volume (publication)', 'ferric oxide', 'Volume', 'TMEM173 gene', 'Each (qualifier value)', 'Scorpio europaeus homeopathic preparations', 'One', 'Maximum Value Derivation Technique', 'TMEM173 wt Allele']","['inpr', 'idcn', 'inch', 'lbpr', 'gngm', 'inpo', 'hops', 'euka', 'imft', ' phsu', ' aapp', 'qnco', 'phsu']"
79,PMC3016167,S104,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study treatments,"a single 30 ml dose of haffkine biopharma monovalent antivenom (batch no ss811001, manufacturing date november 2008, expiry date april 2013) was added to 100 ml of normal saline, which was infused intravenously over 30 minutes irrespective of patient’s age.","['C1706374', 'C0445115', 'C1550176', 'C0870840', 'C3828767', 'C0456693', 'C3811652', 'C1565156', 'C0347984', 'C0003450', 'C1442458', 'C0043194', 'C0011008', 'C3641829', 'C0178602', 'C0205136', 'C1948031', 'C3715025', 'C3715024', 'C0205171', 'C0087136', 'C2348077', 'C1421478', 'C1524062', 'C0001779']","['Date in time', 'per 30 minutes', '30 Minutes', 'April', 'Unmarried', 'WAS protein, human', 'Additional', 'WAS gene', 'Age', 'November', 'Dosage', 'manufacture', 'Singular', 'Normal saline', 'Batch (Response Modality)', 'TNFSF13 wt Allele', 'During', 'Antivenin', 'Batch (group)', 'Tumor Necrosis Factor Ligand Superfamily Member 13', 'Wiskott-Aldrich Syndrome', 'A Proliferation-Inducing Ligand Measurement', 'Date Fruit', 'Batch Number', 'Over (spatial)']","['bacs', 'inpr', 'inch', 'lbpr', 'gngm', 'ocac', 'ftcn', 'spco', 'fndg', 'tmco', 'food', 'imft', ' phsu', ' aapp', 'qnco', 'orga', 'dsyn']"
80,PMC3016167,S105,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study treatments,"during infusion the patient was closely observed for reaction to the serum in the form of sudden onset of vomiting, urticaria, hypotension, tachycardia, bronchospasm, angioneurotic oedema, or anaphylaxis.","['C4553015', 'C0039231', 'C0030705', 'C1272517', 'C4084766', 'C0574032', 'C4321252', 'C1565156', 'C1550100', 'C0002792', 'C3827868', 'C3898969', 'C0443286', 'C0348078', 'C0043194', 'C3163620', 'C1441672', 'C4255237', 'C1276802', 'C4084769', 'C0229671', 'C4316895', 'C1546774', 'C0002994', 'C0020649', 'C1827465', 'C0376315', 'C0521125', 'C4084767', 'C4552901', 'C0006266', 'C1421478', 'C4084768', 'C1963281', 'C1522492', 'C0042963']","['Hypotension, CTCAE', 'Sudden onset (attribute)', 'Reaction', 'Bronchospasm, CTCAE', 'Patients', 'Serum', 'Vomiting, CTCAE', 'Preposition For', 'Sudden onset (contextual qualifier) (qualifier value)', 'WWOX wt Allele', 'Anaphylaxis, CTCAE', 'Tachycardia', 'WAS protein, human', 'Anaphylactic shock', 'Bronchospasm', 'WAS gene', 'Infusion procedures', 'anaphylaxis', 'Infusion route', 'How Often Vomiting', 'Observed', 'Bothered by Vomiting', 'Hypotension', 'Specimen Type - Serum', 'Formation', 'Usual Severity Vomiting', 'Angioedema', 'Specimen Source Codes - Serum', 'Tachycardia by ECG Finding', 'Form:Finding:Point in time:{Setting}:Document:{Role}', 'Have Been Vomiting', 'How Much Distress Vomiting', 'Wiskott-Aldrich Syndrome', 'Manufactured form', 'Qualitative form', 'Vomiting']","['sosy', 'bacs', 'inpr', 'clna', 'gngm', 'topp', 'ftcn', 'fndg', 'patf', 'bdsu', 'mnob', 'podg', 'qlco', 'dsyn', ' aapp']"
81,PMC3016167,S106,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study treatments,"oral prazosin (batch no ml.nh 138 batch no gk 60372 manufactured 04/2006, expiry 03/2011, and ml.nh 138 batch no gk 80282 manufactured 02/2008, expiry 01/2013) was given at a dose of 250 µg in children up age 18 years and 500 µg in adults.","['C0008059', 'C0001675', 'C0178602', 'C3816747', 'C1550176', 'C0032912', 'C0001779', 'C0870840', 'C1515981', 'C1948031', 'C3641829', 'C0680063', 'C0442027', 'C0439234']","['Batch (group)', 'Oral', 'And', 'Adult', 'Age', '500', 'Prazosin', 'Batch Number', 'Offspring', 'Dosage', 'year', 'Batch (Response Modality)', 'manufacture', 'Child']","['inpr', 'idcn', 'aggp', 'famg', 'ocac', 'spco', 'orch', 'tmco', ' phsu', 'qnco', 'orga']"
82,PMC3016167,S107,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study treatments,the same dose was repeated at intervals of 3 hours until the extremities were cold.,"['C0009443', 'C0178602', 'C0278454', 'C0445247', 'C0041912', 'C0009264', 'C1442460', 'C1272706', 'C0015385', 'C0234192']","['Common Cold', 'Upper Respiratory Infections', 'Cold Temperature', 'Limb structure', 'All extremities', 'Interval', 'Same', '3 Hours', 'Dosage', 'Cold Sensation']","['bpoc', 'phsf', 'tmco', 'qlco', 'dsyn', 'npop', 'qnco']"
83,PMC3016167,S108,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study treatments,similar doses were administered in both randomisation groups.,"['C2348205', 'C0178602', 'C1706086', 'C1552839', 'C0441833', 'C0687744']","['Groups', 'Both', 'Similarity', 'Table Rules - groups', 'Social group', 'Dosage']","['inpr', 'idcn', 'popg', 'qlco', 'qnco']"
84,PMC3016167,S109,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study treatments,dehydration owing to vomiting and sweating was corrected by intravenous crystalloid solution.,"['C3898969', 'C4084769', 'C0037633', 'C4084766', 'C4284399', 'C0042963', 'C0038990', 'C1515981', 'C2752561', 'C0525069', 'C0011175', 'C4084768', 'C1963281', 'C0056562', 'C0348016', 'C4084767']","['Dehydration procedure', 'Sweating', 'Dehydration', 'Have Been Vomiting', 'Solutions', 'Bothered by Vomiting', 'How Much Distress Vomiting', 'And', 'crystalloid', 'Usual Severity Vomiting', 'crystalloid solutions', 'Intravenous', 'Vomiting, CTCAE', 'Pharmaceutical Solutions', 'Vomiting', 'How Often Vomiting']","['sosy', 'inpr', 'idcn', 'lbpr', 'fndg', 'celc', 'spco', 'dsyn', 'sbst', 'bodm', 'phsu']"
85,PMC3016167,S110,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study treatments,the prazosin treated group required longer duration and larger volumes of intravenous crystalloid solution than the antivenom plus prazosin group.,"['C0032912', 'C0441833', 'C0687744', 'C1515981', 'C0056562', 'C0003450', 'C0549177', 'C1705429', 'C0525069', 'C2752561', 'C1514873', 'C0449468', 'C1519504', 'C1704243', 'C1257890', 'C0449238', 'C1522326', 'C1705428', 'C2926735', 'C0037633', 'C0348016']","['Solutions', 'And', 'Stage Grouping', 'Duration', 'Requirement', 'User Group', 'Intravenous', 'Volume', 'Pharmaceutical Solutions', 'Group Object', 'Social group', 'Duration (temporal concept)', 'crystalloid', 'crystalloid solutions', 'Prazosin', 'Antivenin', 'Groups', 'Treating', 'Population Group', 'Greater', 'Large']","['idcn', 'bodm', 'popg', 'ftcn', 'cnce', 'celc', 'orch', 'imft', 'tmco', 'spco', ' phsu', 'sbst', ' aapp', 'qnco', 'phsu']"
86,PMC3016167,S111,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study treatments,patients who developed grade 3 and 4 symptoms were transferred to the intensive care unit.,"['C0475271', 'C1549475', 'C0021708', 'C0030705', 'C0683368', 'C4283821', 'C4283822', 'C0450094', 'C1515981', 'C1457887', 'C0687697', 'C3889290', 'C3272598', 'C4283820']","['West Haven Hepatic Encephalopathy Grade 3', 'Bayer Corneal Epitheliopathy Grade 3', 'Tumor grade G3', 'WHO Temperature/Humidity Storage Condition', 'And', 'Patients', 'Room type - Intensive care unit', 'intensive care unit', 'Grade three rank', 'Symptoms aspect', 'Third grade in elementary school', 'Simpson Grade 3', 'Symptoms', 'Bayer Visual Acuity Changes Grade 3']","['sosy', 'inpr', 'idcn', 'clas', 'ftcn', 'mnob', 'fndg', 'qlco', 'podg', 'dsyn', ' hcro']"
87,PMC3016167,S112,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study treatments,before discharge all participants were immunised for tetanus.,"['C0444868', 'C0679646', 'C0305062', 'C0039614']","['tetanus toxoid vaccine, inactivated', 'All', 'Tetanus', 'Participant']","['popg', 'imft', ' phsu', 'dsyn', ' aapp', 'qnco']"
88,PMC3016167,S114,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,the primary end point was the proportion of patients achieving resolution of the grade 2 clinical syndrome at the end of 10 hours after administration of the study drugs and prevention of deterioration to grade 3 and 4.18 21 37,"['C0030705', 'C4283821', 'C3687832', 'C1515981', 'C1709707', 'C1442445', 'C0475270', 'C4284295', 'C2349179', 'C2700409', 'C0868945', 'C4283822', 'C0450094', 'C1514893', 'C2603343', 'C4284294', 'C0444930', 'C0687696', 'C0475271', 'C2699488', 'C0221444', 'C0205225', 'C0687697', 'C1522446', 'C3889290', 'C0013227', 'C1706463', 'C4283820', 'C0001758', 'C3889824', 'C1706420', 'C0199176', 'C4284293', 'C2746065']","['Resolution Property', 'Aftercare', 'Second grade in elementary school', 'clinical syndromes', 'And', 'Patients', 'physiologic resolution', 'Drugs - dental services', 'End', 'Proportion', 'prevention aspects', 'Simpson Grade 2', 'West Haven Hepatic Encephalopathy Grade 3', 'Bayer Corneal Epitheliopathy Grade 3', 'deterioration', 'Bayer Visual Acuity Changes Grade 3', 'Stop (qualifier value)', 'End Point', 'Resolution', 'Bayer Visual Acuity Changes Grade 2', 'Tumor grade G3', 'Prophylactic treatment', 'G2 stage (tumor staging)', 'Study', 'Bayer Corneal Epitheliopathy Grade 2', 'West Haven Hepatic Encephalopathy Grade 2', 'Disease Grade 2', 'Pharmaceutical Preparations', 'Prevention Study', 'Third grade in elementary school', 'Simpson Grade 3', '10 Hours', 'Grade three rank', 'Primary']","['inpr', 'phpr', 'idcn', 'clas', 'topp', 'spco', 'cnce', 'podg', 'qlco', 'tmco', 'resa', 'patf', 'hlca', 'fndg', 'qnco', 'phsu', 'dsyn']"
89,PMC3016167,S115,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"secondary end points were time required for complete resolution of clinical syndrome, prevention of deterioration to higher grade, doses of prazosin required within 10 hours and overall, and adverse events.","['C1561607', 'C0205436', 'C0032912', 'C0205250', 'C0205197', 'C1515981', 'C3853530', 'C0027627', 'C0919553', 'C1442445', 'C0441800', 'C2700409', 'C0868945', 'C0877248', 'C1514893', 'C0444930', 'C4283785', 'C0178602', 'C2699488', 'C0221444', 'C1705413', 'C0282416', 'C1706463', 'C3244287', 'C1706420', 'C0040223', 'C0199176', 'C2746065', 'C0175668']","['Resolution Property', 'clinical syndromes', 'And', 'Complete Pharyngeal Contraction', 'physiologic resolution', 'End', 'Time', 'Grade', 'Secondary to', 'prevention aspects', 'Adverse event', 'Dosage', 'deterioration', 'Stop (qualifier value)', 'Complete', 'Adverse Event Domain', 'Resolution', 'Prophylactic treatment', 'Prazosin', 'Neoplasm Metastasis', 'High', 'Overall', 'Prevention Study', 'second (number)', 'School Grade', '10 Hours', 'Data operation - complete', 'Histopathologic Grade', 'Overall Publication Type']","['inpr', 'phpr', 'idcn', 'clas', 'topp', 'neop', 'ftcn', 'fndg', 'patf', 'qlco', 'orch', 'tmco', 'spco', 'resa', ' phsu', 'cnce', 'qnco']"
90,PMC3016167,S46,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Trial design,this study and trial were done without the help of any funding agency.,,,
91,PMC3016167,S47,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Trial design,anti-scorpion antivenom was purchased from haffkine biopharma mumbai and given to participants in this trial.,"['C0679646', 'C0008976', 'C1515981', 'C0305050', 'C1080058']","['Clinical Trials', 'And', 'Scorpion Antivenoms', 'This (eukaryote)', 'Participant']","['idcn', 'popg', 'imft', 'euka', 'resa', ' phsu', ' aapp']"
92,PMC3016167,S48,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Trial design,"we proposed to include people admitted with scorpion sting over one year, between march 2009 and february 2010.","['C1856053', 'C3829202', 'C3830166', 'C0205136', 'C0347984', 'C0205447', 'C1515981', 'C0038340', 'C1823437', 'C3538738', 'C0027361', 'C0439234']","['During', 'March (month)', 'Over (spatial)', 'And', 'Sting Injury', 'February', 'Persons', 'TMEM173 gene', 'One', 'year', 'Hydranencephaly with Renal Aplasia-Dysplasia', 'TMEM173 wt Allele']","['idcn', 'gngm', 'inpo', 'popg', 'spco', 'qlco', 'tmco', 'dsyn', 'qnco']"
93,PMC3016167,S49,"['3a', '4b']","[0, 0, 0, 0, 0, 0, 1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Trial design,"this was a randomised (1:1 allocation ratio), parallel group, open label, controlled trial conducted at bawaskar hospital in mahad, a region of india with a population of 20 000, situated 180 km south of mumbai on the mumbai-goa highway.","['C0441833', 'C0687744', 'C1425957', 'C0205147', 'C0456603', 'C4554418', 'C0017446', 'C1080058', 'C0009933', 'C1709323', 'C0032659', 'C0332287', 'C0019994', 'C1547037', 'C2700456', 'C1705429', 'C2348042', 'C0936233', 'C2826345', 'C1706778', 'C1519504', 'C0021201', 'C1257890', 'C1705428', 'C1710133']","['India', 'This (eukaryote)', 'geographic population', 'TRIM47 gene', 'Stage Grouping', 'Controlled Clinical Trial [Publication Type]', 'Open Label Study', 'User Group', 'Ratio', 'Group Object', 'data type - ratio', 'Social group', 'regional', 'Parallel Study', 'Allocation', 'In addition to', 'Parallel', 'Groups', 'India - zebrafish', 'Geographic Locations', 'Population Group', 'South', 'Controlled Clinical Trials as Topic', 'Hospitals', 'Parallel Lesion']","['inpr', 'fish', 'geoa', 'idcn', 'acty', 'gngm', 'popg', 'ftcn', 'mnob', 'cnce', 'fndg', 'euka', 'qlco', 'resa', 'spco', ' hcro', 'qnco']"
94,PMC3016167,S50,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Trial design,an independent data and safety monitoring board monitored the trial and had access to the all data.,"['C0085862', 'C1511726', 'C3539897', 'C3245479', 'C0949757', 'C1515981', 'C0008976', 'C1290940', 'C1415458', 'C1554204', 'C0444454', 'C0444868', 'C0062074', 'C3714741', 'C1299583']","['Independently able', 'Role Class - access', 'Have', 'All', 'Clinical Trials', 'And', 'Data call receiving device', 'Independence', 'HAC protocol', 'Independent for Transfer', 'Data (eukaryote)', 'Data', 'Clinical Trials Data Monitoring Committees', 'Access', 'HADH gene']","['idcn', 'gngm', 'prog', 'topp', 'medd', 'ftcn', 'spco', 'fndg', 'qlco', 'euka', 'resa', 'qnco']"
95,PMC3016167,S51,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Trial design,statistical analysis was done by a statistician in collaboration with the investigators.,"['C0282116', 'C0035173', 'C0334957', 'C0871424']","['Research Personnel', 'statistical analysis', 'collaboration', 'statistician']","['prog', 'resa', 'socb']"
96,PMC3016167,S52,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Trial design,the study design was approved by the independent ethics committee of byl medical college mumbai (iec/08/39) and all participants provided written informed consent.,"['C2983265', 'C0679646', 'C0021430', 'C4554082', 'C2986888', 'C0557806', 'C0199168', 'C1515981', 'C0035171', 'C0444868', 'C0086911', 'C0205476']","['Independent Ethics Committee', 'All', 'And', 'college', 'Informed Consent', 'Medical service', 'Medical', 'Research Design', 'Ethics Committees, Research', 'CDISC SEND Study Design Terminology', 'Nonclinical Study Design', 'Participant']","['inpr', 'rnlw', 'idcn', 'prog', 'popg', 'ftcn', 'mnob', 'resa', 'hlca', 'qnco']"
97,PMC3016167,S54,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Sample size,the primary efficacy variable was the time required for recovery after venomous scorpion sting.,"['C1280519', 'C0237820', 'C0040223', 'C0439828', 'C0205225', 'C1555688', 'C4553760', 'C0238417', 'C1707887', 'C2004454']","['recovery - adjustment', 'Efficacy Study', 'Effectiveness', 'Recovery - action', 'Recovery - healing process', 'Variable (uniformity)', 'Time', 'Study Variable', 'Scorpion sting', 'Primary']","['inpr', 'acty', 'inpo', 'qlco', 'tmco', 'resa', 'orgf', 'qnco']"
98,PMC3016167,S55,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size,"we estimated that 35 patients in each group would be required to achieve 80% power; α=0.05 to detect a mean difference of four hours in the recovery time between the groups, assuming a mean recovery time of 10 hours (sd 2.5 hours) in the antivenom plus prazosin group and 14 (sd 3) hours for the prazosin alone group.","['C1705428', 'C0237820', 'C1442467', 'C0030705', 'C0032912', 'C0441833', 'C0687744', 'C0032863', 'C1515981', 'C1442445', 'C4321252', 'C2004454', 'C0003450', 'C3891454', 'C0444504', 'C2347634', 'C2826346', 'C1705242', 'C1552839', 'C1457900', 'C1705429', 'C0205450', 'C0521125', 'C1519504', 'C0040223', 'C1257890', 'C2348143', 'C3854080', 'C1555688', 'C0205103', 'C0442726', 'C1705241', 'C0439227']","['Hour', 'And', 'Detected (finding)', 'Recovery - action', 'Recovery - healing process', 'Patients', 'Power', 'Time', 'Preposition For', 'Stage Grouping', 'WWOX wt Allele', 'Sample Mean', 'Delta (difference)', 'Four', 'recovery - adjustment', '5 Hours', 'User Group', 'Population Mean', 'Group Object', 'Each (qualifier value)', 'Social group', 'Intermediate', 'Prazosin', 'Dosing Days to Detection', 'Antivenin', 'Statistical mean', 'Groups', 'Power (Psychology)', 'Table Rules - groups', 'Population Group', '10 Hours', 'Different', 'Single Group Study']","['hcpp', 'inpr', 'idcn', 'acty', 'gngm', 'popg', 'ftcn', 'cnce', 'fndg', 'orch', 'tmco', 'podg', 'imft', 'qlco', ' phsu', 'spco', ' aapp', 'resa', 'orgf', 'qnco']"
99,PMC3016167,S57,"['8a', '8b']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0]",Randomisation,a statistician generated the sequentially numbered randomisation list with random block sizes of 4 4 2 4 4 6 2 4 6 6 6 8 4 8 2 using www.randomisation.com.,"['C0282111', 'C1706084', 'C0439605', 'C2828370', 'C0332206', 'C0034656', 'C3272378', 'C0334957', 'C0028778', 'C0449788', 'C0745732', 'C1533157']","['Count of entities', 'Obstruction', 'Randomization', 'statistician', 'Random', 'Block (unit of measure)', 'Block Specimens', 'Sequence Data Type', 'List', 'Blocking', 'Internet', '(City) Block']","['inpr', 'geoa', 'prog', 'ftcn', 'mnob', 'patf', 'bdsu', 'qlco', 'resa', 'qnco']"
100,PMC3016167,S58,['8a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0]",Randomisation,this process can be reproduced by using seed 22491 (6 march 2009).,"['C1856053', 'C3829202', 'C1705192', 'C2346495', 'C1522240', 'C1184743', 'C0036563', 'C1080058', 'C4521541']","['Human Cells, Tissues, and Cellular and Tissue-Based Products Processing', 'March (month)', 'This (eukaryote)', 'bony process', 'Seeding', 'Process', 'Seed entity', 'Hydranencephaly with Renal Aplasia-Dysplasia', 'Plant seeds']","['bpoc', 'phpr', 'lbpr', 'plnt', 'cnce', 'tmco', 'euka', 'hlca', 'dsyn']"
101,PMC3016167,S59,['9'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1]",Randomisation,"this randomisation sequence was concealed by using sequentially numbered, opaque, sealed, and stapled envelopes.","['C1882150', 'C1261286', 'C1519249', 'C3853789', 'C0004793', 'C0029053', 'C1080058', 'C0162327', 'C0162326']","['Sequence - TransmissionRelationshipTypeCode', 'Base Sequence', 'Opaque', 'DNA Sequence', 'RNA Sequence', 'Decreased translucency', 'Opacification of Medical Device Material', 'Sequence', 'This (eukaryote)']","['inpr', 'nusq', 'ftcn', 'fndg', 'qlco', 'euka']"
102,PMC3016167,S60,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation,envelopes were opened alternately by hsb or phb after an eligible patient consented to take part in the trial and patients were allocated according to the randomisation label inside the envelope.,"['C0030705', 'C0205102', 'C2827499', 'C0084178', 'C1709471', 'C0008976', 'C1515981', 'C0449719', 'C1134548', 'C0304340', 'C1548635', 'C0680240', 'C4551445', 'C1622204', 'C1335208', 'C4522130', 'C0181496']","['Eligible', 'Labels (device)', 'Human Cells, Tissues, and Cellular and Tissue-Based Products Labeling', 'Internal', 'Hydroxystilbamidine isethionate', 'Clinical Trials', 'And', 'Agreement', 'Patients', 'herba scutellaria barbatae preparation', 'Part', 'Labeling Activity', 'Part Dosing Unit', 'prohibitin', 'PHB gene', 'envelope', 'Label (document)']","['inpr', 'idcn', 'acty', 'gngm', 'spco', 'mnob', 'podg', 'qlco', 'celc', 'resa', 'socb', ' phsu', 'aapp', 'orch', 'qnco', 'phsu']"
103,PMC3016167,S62,"['12a', '12b']","[0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,demographic factors and clinical characteristics were summarised as counts (percentages) for categorical variables and as mean (standard deviation; sd) for normally distributed continuous variables.,"['C0444504', 'C1704711', 'C0439828', 'C1515981', 'C2348143', 'C0871420', 'C0549178', 'C4321252', 'C0011292', 'C0683325', 'C2347634', 'C0521125', 'C0439157', 'C0011298']","['Statistical mean', 'Demographic Factors', 'Distribution', 'Standard deviation', 'clinical aspects', 'And', 'Continuous', 'Variable (uniformity)', 'counts', 'Population Mean', 'Preposition For', 'WWOX wt Allele', 'Demography', 'Sample Mean']","['clna', 'idcn', 'gngm', 'ocdi', 'ftcn', 'qlco', 'qnco']"
104,PMC3016167,S63,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,all patients who had been randomly assigned to a treatment group were included in the intention-to-treat analyses.,,,
105,PMC3016167,S64,"['12a', '12b']","[0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"the groups were compared using χ2 test or fisher’s exact test for categorical variables, unpaired t test for normally distributed continuous variables, and mann-whitney u test for other continuous variables.","['C0441833', 'C0687744', 'C0439828', 'C1515981', 'C4321252', 'C4318744', 'C0871472', 'C2828393', 'C1515976', 'C1552839', 'C1704711', 'C4050514', 'C3831328', 'C0521125', 'C0022885', 'C2700112', 'C0242927', 'C0456984', 'C0549178', 'C0392366', 'C0039593']","['Laboratory Procedures', 'And', 'Preposition For', 'Test - temporal region', 'WWOX wt Allele', 'Mann-Whitney U Test', 't test', 'Tests (qualifier value)', 'Testing', 'Variable (uniformity)', 'Unpaired', 'Test Result', 'Social group', 'Distribution', 'Anatomic Structure, System, or Substance', 'Blood Products Laboratory Testing', 'Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome Questionnaire', 'Groups', 'Table Rules - groups', 'Continuous', 'Exact (qualifier)']","['inpr', 'idcn', 'lbpr', 'gngm', 'clas', 'lbtr', 'popg', 'ftcn', 'blor', 'qlco', 'qnco']"
106,PMC3016167,S65,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,we analysed results with spss 17 software.,['C0037585'],['Computer software'],"[' mnob', 'inpr']"
107,PMC3016167,S66,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"blood pressure and pulse rate were measured at different time points and were repeated factors, and treatment group was included as a between-participant measure.","['C0079809', 'C0679646', 'C0441833', 'C1705169', 'C0687744', 'C3887704', 'C0242485', 'C1515981', 'C1271104', 'C2698741', 'C1705242', 'C0039798', 'C3538994', 'C0005823', 'C4554048', 'C0232117', 'C1705429', 'C1519504', 'C1272641', 'C0040223', 'C1257890', 'C0087111', 'C0205103', 'C1533734', 'C1705428', 'C1522326', 'C0205341']","['Study Participant', 'Biomaterial Treatment', 'And', 'Blood Pressure', 'Time', 'Systemic arterial pressure', 'Stage Grouping', 'Therapeutic procedure', 'Repeat', 'User Group', 'Administration procedure', 'Pulse Rate', 'Group Object', 'Social group', 'Measurement', 'Intermediate', 'Treatment Epoch', 'Blood pressure finding', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Groups', 'Treating', 'Population Group', 'Measures', 'Participant Object', 'Different', 'Participant']","['clna', 'idcn', 'clas', 'topp', 'popg', 'ftcn', 'fndg', 'cnce', 'tmco', 'qlco', 'spco', 'resa', 'hlca', 'orgf', 'qnco']"
108,PMC3016167,S67,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,α was set at 0.05.,,,
109,PMC3016167,S68,"['12a', '12b']","[0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,we used the greenhouse-geisser p value.,['C1522609'],['Numerical value'],['qnco']
110,PMC3016167,S70,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,between march 2009 and february 2010 we recruited patients who reported to bawaskar hospital and mahad research centre after being stung by mesobuthus tamulus (fig 1).2 4 6 31,"['C1856053', 'C3829202', 'C0019994', 'C0242481', 'C3830166', 'C0030705', 'C1515981', 'C1005220', 'C0035168', 'C1337208', 'C0349966', 'C3272598', 'C0205099']","['Fig Flavor', 'March (month)', 'WHO Temperature/Humidity Storage Condition', 'Figs - dietary', 'And', 'February', 'Research Activities', 'Patients', 'Central', 'Mesobuthus tamulus', 'research', 'Hospitals', 'Hydranencephaly with Renal Aplasia-Dysplasia']","['idcn', 'mnob', 'spco', 'qlco', 'food', 'podg', 'resa', 'tmco', 'dsyn', 'euka', ' hcro']"
111,PMC3016167,S71,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,fig 1 indian red scorpion (mesobuthus tamulus),"['C0885762', 'C1005220', 'C0060240', 'C0036451']","['Scorpions', 'Mesobuthus tamulus', 'Scorpio europaeus homeopathic preparations', 'ferric oxide']","['inch', 'euka', ' phsu', 'phsu']"
112,PMC3016167,S73,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Inclusion and exclusion criteria,"patients were eligible for enrolment if they reported to hospital with mesobuthus tamulus sting of clinical grade 2 severity, with an interval of less than six hours between sting and hospital admission, and were older than six months.","['C0439231', 'C0030705', 'C1515981', 'C0475270', 'C1005220', 'C1548635', 'C4284295', 'C0205210', 'C1552654', 'C0332287', 'C4284294', 'C0687696', 'C0019994', 'C1552713', 'C0038340', 'C1522446', 'C1272706', 'C0184666', 'C0522510', 'C0205452', 'C0439793', 'C3538738', 'C3889824', 'C1823437', 'C0205103', 'C4284293', 'C0439092', 'C0439227']","['Parameterized Data Type - Interval', 'Second grade in elementary school', 'Hour', 'And', 'Patients', 'With intensity', 'month', 'Simpson Grade 2', 'TMEM173 wt Allele', 'Clinical', 'Intermediate', 'Hospital admission', 'Less Than', 'Bayer Visual Acuity Changes Grade 2', 'Mesobuthus tamulus', 'G2 stage (tumor staging)', 'Data Type Interval', 'Interval', 'Bayer Corneal Epitheliopathy Grade 2', 'Six', 'In addition to', 'West Haven Hepatic Encephalopathy Grade 2', 'Disease Grade 2', 'Eligible', 'Severities', 'Sting Injury', 'TMEM173 gene', 'Hospitals']","['inpr', 'idcn', 'gngm', 'inpo', 'clas', 'ftcn', 'mnob', 'spco', 'podg', 'qlco', 'tmco', 'euka', 'hlca', ' hcro', 'qnco']"
113,PMC3016167,S74,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Inclusion and exclusion criteria,"mesobuthus tamulus sting was confirmed if the victim or bystander had seen a red scorpion, had brought in the killed specimen, or recognised the hospital’s preserved specimen.","['C1005220', 'C3539897', 'C4049926', 'C0680681', 'C4521763', 'C0332302', 'C4697784', 'C1415458', 'C0162388', 'C0038340', 'C1823437', 'C0062074', 'C0036451', 'C0885762', 'C0033085', 'C3538738', 'C1260956', 'C0205397', 'C0370003', 'C2347026']","['HADH gene', 'Bystander', 'Biologic Preservation', 'Biospecimen', 'Have', 'Killing', 'victim', 'Scorpions', 'Sting Injury', 'Red color', 'Mesobuthus tamulus', 'HAC protocol', 'Radiological Exposure Device', 'brought on by', 'seen', 'Specimen', 'TMEM173 gene', 'Killed', 'Scorpio europaeus homeopathic preparations', 'TMEM173 wt Allele']","['lbpr', 'gngm', 'inpo', 'topp', 'popg', 'ftcn', 'cnce', 'fndg', 'qlco', 'euka', 'mnob', 'socb', 'sbst', 'phsu']"
114,PMC3016167,S75,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Inclusion and exclusion criteria,"in this way we made sure that mesobuthus tamulus was not confused with palamneus gravimanus, a larger scorpion that is less lethal and causes only severe local pain without systemic involvement or transient reversible cardiovascular effects.1 32","['C4554132', 'C0030193', 'C0205373', 'C1005220', 'C1314939', 'C1080058', 'C4050466', 'C3151529', 'C1518422', 'C4050465', 'C4085210', 'C0007226', 'C4085211', 'C0205082', 'C0036451', 'C0549177', 'C0205343', 'C3887460', 'C4553004', 'C0205276', 'C1280500', 'C0885762', 'C0205423', 'C2984058', 'C1704243', 'C0205171', 'C0040704', 'C0518090', 'C4085212', 'C0205374']","['Involvement with', 'This (eukaryote)', 'Borg Category-Ratio 10 Perceived Exertion Score 5', 'Usual Severity Pain', 'Systemic', 'Cardiovascular system', 'Severe (severity modifier)', 'Cardiovascular', 'Lethal', 'Feel Pain', 'Negation', 'How Much Distress Pain', 'Have Pain', 'Transient Population Group', 'Local', 'Mesobuthus tamulus', 'Singular', 'Certain (qualifier value)', 'Pain Distress Question', 'Pain', 'Effect', 'Frequency of Pain Question', 'Pain, CTCAE', 'Severe Extremity Pain', 'Scorpions', 'reversible', 'Transitory', 'Greater', 'Scorpio europaeus homeopathic preparations', 'Large']","['sosy', 'inpr', 'popg', 'ftcn', 'fndg', 'blor', 'tmco', 'euka', 'qlco', 'spco', 'bdsy', 'qnco', 'phsu']"
115,PMC3016167,S76,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Inclusion and exclusion criteria,"major exclusion criteria were: patient reporting six hours after sting, pregnant women, history of taking prazosin or antivenom, history of bronchial asthma, history of allergic reaction to foreign serum, and refusal to give consent.","['C2923685', 'C0020517', 'C0262926', 'C0030705', 'C0032912', 'C1515981', 'C0019665', 'C1527304', 'C0376327', 'C1550100', 'C4552863', 'C0003450', 'C0680251', 'C0004096', 'C0262512', 'C0033011', 'C0205164', 'C1517294', 'C0229671', 'C0019664', 'C1546774', 'C0038340', 'C1511481', 'C1554192', 'C2004062', 'C0205452', 'C1705255', 'C4318856', 'C1823437', 'C3538738', 'C0439227']","['Medical History', 'Major', 'Asthma', 'Hour', 'And', 'Patients', 'Consent:Finding:Point in time:{Setting}:Document:Patient', 'History', 'Exclusion Criteria', 'Serum', 'ActClass - consent', 'TMEM173 wt Allele', 'foreign', 'Pregnant Women', 'Hypersensitivity', 'Specimen Type - Serum', 'Allergic Reaction, CTCAE', 'Major <insect>', 'International Aspects', 'Concept History', 'Prazosin', 'History of present illness', 'Six', 'Antivenin', 'Consent', 'Historical aspects qualifier', 'Sting Injury', 'Allergic Reaction', 'TMEM173 gene', 'History of previous events', 'Specimen Source Codes - Serum']","['clna', 'fndg', 'bdsu', 'qlco', ' phsu', 'inpr', 'idcn', 'gngm', 'inpo', 'patf', 'imft', ' aapp', 'popg', 'ftcn', 'orch', 'podg', 'tmco', 'dsyn', 'ocdi', 'cnce', 'euka', 'qnco']"
116,PMC3016167,S77,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Inclusion and exclusion criteria,written informed consent was obtained in the local language.,"['C0023008', 'C0205276', 'C0021430']","['Local', 'Informed Consent', 'Languages']","['lang', 'spco', 'rnlw']"
117,PMC3016167,S78,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Inclusion and exclusion criteria,"for illiterate adults, a literate relative of the patient read the statement out loud to them and consent was obtained by thumb impression witnessed by the relative.","['C2923685', 'C1710187', 'C0030705', 'C0439787', 'C0205345', 'C1515981', 'C1565156', 'C1301820', 'C0001675', 'C0023864', 'C0178733', 'C0043194', 'C0034754', 'C1705179', 'C0020899', 'C0080103', 'C0682356', 'C1511481', 'C1554192', 'C4049863', 'C0682193', 'C0040067', 'C0596764', 'C1421478', 'C1998467', 'C0849355']","['Reading (activity)', 'Obtain', 'Out (direction)', 'And', 'Relative', 'Patients', 'Consent:Finding:Point in time:{Setting}:Document:Patient', 'ActClass - consent', 'Removed', 'Illiteracy', 'WAS protein, human', 'WAS gene', 'Adult', 'impression (attitude)', 'Thumb structure', 'Impression', 'literate', 'Literacy', 'Statement', 'Radiologic Impression', 'Consent', 'Reading (datum presentation)', 'Wiskott-Aldrich Syndrome', 'Witnesses', 'Relative (related person)', 'Loudness']","['bacs', 'bpoc', 'clna', 'idcn', 'aggp', 'dora', 'famg', 'gngm', 'popg', 'ftcn', 'fndg', 'spco', 'qlco', 'podg', 'cnce', 'dsyn', 'menp', ' aapp']"
118,PMC3016167,S79,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Inclusion and exclusion criteria,parent’s consent was obtained for minor children.,"['C0008059', 'C2923685', 'C0205165', 'C0680063', 'C1511481', 'C1554192', 'C0026193']","['Consent', 'Consent:Finding:Point in time:{Setting}:Document:Patient', 'Minor (person)', 'ActClass - consent', 'Offspring', 'Minor (value)', 'Child']","['clna', 'idcn', 'aggp', 'famg', 'popg', 'ftcn', 'qlco']"
119,PMC3016167,S80,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Inclusion and exclusion criteria,"the study protocol was approved by the independent ethics committee of mumbai (registration number 1433/1999g.b.b.s.d, iec/08/39).","['C4554082', 'C1514821', 'C1553384', 'C2599718', 'C0449788', 'C1507394', 'C0086911', 'C2697663', 'C2348563', 'C0237753']","['Registration', 'Count of entities', 'Image Registration', 'Clinical trial protocol', 'Clinical trial protocol document', 'Numbers', 'Study Protocol', 'registration - ActClass', 'Ethics Committees, Research', 'Independent Ethics Committee']","['inpr', 'prog', 'hlca', 'qnco', 'mcha']"
120,PMC3016167,S81,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Inclusion and exclusion criteria,all people admitted with scorpion sting between march 2009 to february 2010 were insured by the oriental insurance company limited clinical trial liability cover policy no 111600/48/2009/227.,"['C1856053', 'C1548605', 'C3829202', 'C0180153', 'C3830166', 'C1549448', 'C0008976', 'C0242456', 'C4050251', 'C2674459', 'C1096775', 'C0444868', 'C0439801', 'C0699027', 'C0027361', 'C0078988', 'C1999244']","['Policy', 'Insurance company', 'Covers (device)', 'Insured', 'March (month)', 'All', 'Asians', 'Clinical Trials', 'Limited (extensiveness)', 'February', 'Limited Lifting Ability', 'Limited Walking Ability', 'Clinical Trial [Publication Type]', 'Persons', 'Cover - action', 'Oriental Herbs and Botanicals', 'Hydranencephaly with Renal Aplasia-Dysplasia']","['inpr', 'idcn', 'plnt', 'popg', 'ftcn', 'mnob', 'fndg', 'qlco', 'tmco', 'resa', 'dsyn', 'qnco']"
121,PMC3016167,S83,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Evaluation of clinical grade,cases are graded according to severity of clinical manifestations on arrival at hospital (box).,"['C1555577', 'C0019994', 'C1280464', 'C0439793', 'C1706079', 'C0205210', 'C0205319', 'C0868928', 'C0522510', 'C0179400']","['Clinical', 'Case (situation)', 'Severities', 'Manifestation of', 'arrival - ActRelationshipType', 'Arrival - action', 'With intensity', 'Manifest', 'Box', 'Hospitals']","['acty', 'ftcn', 'mnob', 'qlco', ' hcro']"
122,PMC3016167,S84,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Evaluation of clinical grade,"severity of clinical manifestations, morbidity, and mortality depend on the time lapsed between sting and hospital admission, as well as the grade of a case on arrival.5 9 18 33 34","['C1555577', 'C1280464', 'C1515981', 'C0919553', 'C0441800', 'C1706255', 'C0205210', 'C0205319', 'C3146287', 'C0868928', 'C0026566', 'C1706079', 'C0220880', 'C0026538', 'C0038340', 'C1706256', 'C0184666', 'C0522510', 'C3244287', 'C0026565', 'C0439793', 'C0040223', 'C1823437', 'C0205103', 'C0205170', 'C3538738', 'C4283957']","['morbidity aspects', 'Case (situation)', 'Aspects of mortality statistics', 'And', 'With intensity', 'Time', 'Grade', 'Mortality Vital Statistics', 'Well', 'Morbidity - disease rate', 'TMEM173 wt Allele', 'arrival - ActRelationshipType', 'Arrival - action', 'Packaging Case', 'Clinical', 'Intermediate', 'Hospital admission', 'Manifestation of', 'Good', 'Manifest', 'Microplate Well', 'Severities', 'Sting Injury', 'School Grade', 'TMEM173 gene', 'Clinical Study Case', 'Histopathologic Grade']","['inpr', 'idcn', 'acty', 'gngm', 'inpo', 'clas', 'medd', 'ftcn', 'cnce', 'spco', 'tmco', 'qlco', 'fndg', 'mnob', 'hlca', 'qnco']"
123,PMC3016167,S86,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Evaluation of clinical grade,"grade 1: severe, excruciating local pain at the sting site radiating along with corresponding dermatomes, mild local oedema with sweating at the sting site, without systemic involvement","['C0392338', 'C4554132', 'C0030193', 'C0205373', 'C2945599', 'C0038990', 'C1314939', 'C4050466', 'C4050465', 'C4085210', 'C0687695', 'C0013604', 'C4085211', 'C0205082', 'C0332301', 'C0332287', 'C1515974', 'C4284292', 'C4553004', 'C0547053', 'C0205276', 'C0038340', 'C0205145', 'C2825164', 'C4284291', 'C4055051', 'C0475269', 'C2984058', 'C0180383', 'C0518090', 'C1823437', 'C4085212', 'C3538738', 'C4284290', 'C3889292']","['Involvement with', 'Borg Category-Ratio 10 Perceived Exertion Score 5', 'Anatomic Site', 'Edema', 'Site', 'Usual Severity Pain', 'Excruciating', 'Simpson Grade 1', 'TMEM173 wt Allele', 'Mild (qualifier value)', 'West Haven Hepatic Encephalopathy Grade 1', 'Sweating', 'Systemic', 'Severe (severity modifier)', 'Feel Pain', 'Tumor grade G1', 'Bayer Corneal Epitheliopathy Grade 1', 'How Much Distress Pain', 'Grade one rank', 'Have Pain', 'Local', 'First grade in elementary school', 'Dermatome device', 'Pain Distress Question', 'In addition to', 'Pain', 'Frequency of Pain Question', 'radiating to', 'Pain, CTCAE', 'Cutaneous Receptive Fields', 'Severe Extremity Pain', 'Sting Injury', 'Bayer Visual Acuity Changes Grade 1', 'TMEM173 gene', 'Study Site']","['sosy', 'inpr', 'gngm', 'inpo', 'clas', 'medd', 'ftcn', 'fndg', 'blor', 'spco', 'qlco']"
124,PMC3016167,S87,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Evaluation of clinical grade,"grade 2: signs and symptoms of autonomic storm characterised by acetylcholine excess or parasympathetic stimulation (vomiting, profuse sweating from all over body, ropey salivation, bradycardia, premature ventricular contraction, hypotension, priapism in men) and sympathetic stimulation (hypertension with blood pressure >140/90, tachycardia with heart rate >120 per minute, cold extremities, transient systolic murmur).","['C0039231', 'C0428977', 'C4084766', 'C0460148', 'C1515981', 'C0475270', 'C0702093', 'C4284295', 'C0232257', 'C3812171', 'C3827868', 'C3898969', 'C1271104', 'C0242821', 'C0001041', 'C4082212', 'C0018810', 'C3163620', 'C1292856', 'C0037088', 'C0332287', 'C4284294', 'C0020538', 'C0687696', 'C0005823', 'C0037036', 'C4084769', 'C0277925', 'C0036104', 'C1963138', 'C0205374', 'C1979886', 'C0020649', 'C0025266', 'C1522446', 'C0700590', 'C0151636', 'C4084767', 'C1948023', 'C3889824', 'C1272641', 'C0040704', 'C0004388', 'C4284293', 'C0444868', 'C4084768', 'C1268086', 'C1963281', 'C0033117', 'C0042963']","['Hypotension, CTCAE', 'Per Minute', 'Second grade in elementary school', 'And', 'heart rate', 'Blood Pressure', 'Autonomic nervous system', 'Increased sweating', 'Systemic arterial pressure', 'Priapism', 'Simpson Grade 2', 'Tachycardia', 'Sialorrhea', 'Bradycardia by ECG Finding', 'Vomiting', 'Excess', 'Stimulation procedure', 'Hypertensive disease', 'Human body', 'How Often Vomiting', 'Signs and Symptoms', 'Premature ventricular contractions', 'Transient Population Group', 'Acetylcholine', 'Bayer Visual Acuity Changes Grade 2', 'Stimulation (motivation)', 'Bothered by Vomiting', 'Hypotension', 'All', 'G2 stage (tumor staging)', 'Usual Severity Vomiting', 'Body structure', 'Blood pressure finding', 'Tachycardia by ECG Finding', 'Hypertension, CTCAE', 'Bayer Corneal Epitheliopathy Grade 2', 'West Haven Hepatic Encephalopathy Grade 2', 'In addition to', 'Bradycardia', 'Male population group', 'cold extremities', 'Disease Grade 2', 'Human body structure', 'Have Been Vomiting', 'How Much Distress Vomiting', 'Transitory', 'Adult human body', 'secretion of saliva', 'Vomiting, CTCAE', 'Systolic Murmurs']","['ortf', 'clna', 'bacs', ' orch', 'topp', 'fndg', 'qlco', 'bdsy', ' phsu', 'inpr', 'idcn', 'clas', 'npop', 'orgf', 'sosy', 'popg', 'ftcn', 'humn', 'tmco', 'dsyn', 'anst', 'qnco']"
125,PMC3016167,S88,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Evaluation of clinical grade,"grade 3: cold extremities, tachycardia, hypotension or hypertension with pulmonary oedema (respiratory rate >24 per minute, basal rales or crackles in lungs).","['C4283821', 'C0700321', 'C0034063', 'C4283822', 'C0450094', 'C3163620', 'C0020538', 'C2347166', 'C0240859', 'C0475271', 'C0277925', 'C1963138', 'C0020649', 'C0024109', 'C0034642', 'C0687697', 'C3889290', 'C4283820', 'C0489258', 'C0231832', 'C0439232', 'C1282918']","['Hypotension, CTCAE', 'Rales', 'Respiratory rate', 'Pulmonary Edema', 'Minute Unit of Plane Angle', 'Bayer Corneal Epitheliopathy Grade 3', 'West Haven Hepatic Encephalopathy Grade 3', 'Small', 'Lung', 'Hypertensive disease', 'Minute (diminutive)', 'Minute of time', 'Bayer Visual Acuity Changes Grade 3', 'Tumor grade G3', 'Hypotension', 'Hypertension, CTCAE', 'cold extremities', 'Breaths:Number = Count/Time:Point in time:Respiratory system:Quantitative', 'Basilar Rales', 'Third grade in elementary school', 'Simpson Grade 3', 'Grade three rank']","['clna', 'bpoc', 'inpr', 'clas', 'fndg', 'tmco', 'dsyn', 'qnco']"
126,PMC3016167,S89,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Evaluation of clinical grade,"grade 4: tachycardia, hypotension with or without pulmonary oedema with warm extremities (warm shock).","['C0036974', 'C0687712', 'C0278454', 'C4284298', 'C3537125', 'C0547054', 'C0582051', 'C4284296', 'C4284297', 'C3889293', 'C0020649', 'C3163620', 'C0684258', 'C0015385', 'C0039231', 'C3827868']","['Hypotension, CTCAE', 'Bayer Corneal Epitheliopathy Grade 4', 'Tachycardia', 'Shock', 'warming process', 'Hypotension', 'Life Threatening or Disabling Adverse Event', 'Grade four rank', 'Limb structure', 'All extremities', 'Tachycardia by ECG Finding', 'Simpson Grade 4', 'Fourth grade in elementary school', 'West Haven Hepatic Encephalopathy Grade 4', 'Feels warm', 'Bayer Visual Acuity Changes Grade 4']","['bpoc', 'inpr', 'clas', 'fndg', 'patf', 'npop']"
127,PMC3016167,S90,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Evaluation of clinical grade,patients with grade 2 signs and symptoms were included in the present study.,"['C3889824', 'C0150312', 'C0030705', 'C0449450', 'C4284293', 'C0475270', 'C2603343', 'C4284295', 'C1522446', 'C0037088', 'C4284294', 'C0687696']","['Disease Grade 2', 'Second grade in elementary school', 'Presentation', 'Bayer Visual Acuity Changes Grade 2', 'Present', 'G2 stage (tumor staging)', 'Patients', 'Study', 'Bayer Corneal Epitheliopathy Grade 2', 'West Haven Hepatic Encephalopathy Grade 2', 'Simpson Grade 2', 'Signs and Symptoms']","['sosy', 'inpr', 'idcn', 'clas', 'fndg', 'podg', 'resa']"
128,PMC3016167,S91,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Evaluation of clinical grade,"after giving written consent, all eligible patients were examined by one of the two authors and baseline data were recorded on a standard form.","['C2923685', 'C1511726', 'C0030705', 'C1515981', 'C1548635', 'C3714741', 'C0205447', 'C0348078', 'C1442488', 'C4255237', 'C1442989', 'C1511481', 'C0205448', 'C1554192', 'C0376315', 'C0168634', 'C3812881', 'C3245479', 'C2828392', 'C0444868', 'C1522492']","['Baseline', 'Standard (document)', 'And', 'Data call receiving device', 'Patients', 'Consent:Finding:Point in time:{Setting}:Document:Patient', 'ActClass - consent', 'Standard (qualifier)', 'BaseLine dental cement', 'All', 'Formation', 'Two', 'Data', 'One', 'author', 'Eligible', 'Form:Finding:Point in time:{Setting}:Document:{Role}', 'Consent', 'Manufactured form', 'Qualitative form', 'Data (eukaryote)']","['clna', 'inpr', 'idcn', 'bodm', 'prog', 'medd', 'ftcn', 'mnob', 'qlco', 'podg', 'euka', 'qnco']"
129,PMC3016167,S92,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Evaluation of clinical grade,"data included age, sex, time between sting and hospital admission, and history of any medication before admission, vomiting soon after sting, or paraesthesia (tingling and numbness in the perioral region, or sometimes reported by the patient to be felt all over the body).","['C1998882', 'C1511726', 'C0030554', 'C0262926', 'C0030705', 'C4084766', 'C0460148', 'C0205147', 'C1515981', 'C0020580', 'C0019665', 'C4318061', 'C0017446', 'C3714741', 'C0347984', 'C1709908', 'C3898969', 'C4284232', 'C0009253', 'C0804628', 'C3272371', 'C0242821', 'C0262512', 'C0457008', 'C0028643', 'C4082212', 'C1552551', 'C4084769', 'C3244316', 'C2242996', 'C0205136', 'C0019664', 'C0079399', 'C0038340', 'C0036864', 'C0013227', 'C0184666', 'C2004062', 'C0332152', 'C4084767', 'C0809949', 'C3538738', 'C1705255', 'C3245479', 'C0040223', 'C1823437', 'C1522384', 'C0444868', 'C4084768', 'C1268086', 'C0205103', 'C1963281', 'C0001779', 'C0042963']","['Gender', 'Medical History', 'Reported By', 'medication - HL7 publishing domain', 'And', 'Data call receiving device', 'Patients', 'History', 'Has tingling sensation', 'Time', 'Gender:Type:Point in time:^Patient:Nominal', 'TMEM173 wt Allele', 'Numbness', 'Vomiting', 'Any Data Type', 'Sex Behavior', 'Medications', 'Admission activity', 'Hypesthesia', 'Coitus', 'Age', 'sex', 'After Sting', 'Before', 'Human body', 'regional', 'How Often Vomiting', 'Data (eukaryote)', 'Any', 'Intermediate', 'Hospital admission', 'Sometimes', 'All', 'Bothered by Vomiting', 'Usual Severity Vomiting', 'Body structure', 'Concept History', 'History of present illness', 'Data', 'During', 'Human body structure', 'Pharmaceutical Preparations', 'Have Been Vomiting', 'Historical aspects qualifier', 'How Much Distress Vomiting', 'Geographic Locations', 'Sting Injury', 'Paresthesia', 'TMEM173 gene', 'Adult human body', 'History of previous events', 'Vomiting, CTCAE', 'Over (spatial)', 'around mouth']","['clna', 'medd', 'fndg', 'qlco', 'hlca', ' phsu', 'phsu', 'inpr', 'idcn', 'geoa', 'gngm', 'inpo', 'orgf', 'sosy', 'ftcn', 'humn', 'podg', 'tmco', 'orch', 'dsyn', 'anst', 'grup', 'ocdi', 'cnce', 'spco', 'euka', 'bhvr', 'qnco', 'orga']"
130,PMC3016167,S93,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Evaluation of clinical grade,"one of the authors sat by the side of the patients and closely clinically examined them for signs and symptoms of systemic manifestations: presence of profuse sweating all over the body, ropey salivation, priapism in men, heart murmur, coolness of the extremities.","['C1280464', 'C0030705', 'C0460148', 'C0205373', 'C1515981', 'C0332128', 'C0441987', 'C4321252', 'C0347984', 'C0150312', 'C0242821', 'C0205447', 'C4082212', 'C0205319', 'C0037088', 'C2744672', 'C0037036', 'C0036104', 'C0205136', 'C0392148', 'C0018808', 'C1705827', 'C0025266', 'C0015385', 'C0700590', 'C0521125', 'C3812881', 'C0278454', 'C0444868', 'C1268086', 'C0033117']","['And', 'Present', 'Limb structure', 'Patients', 'Providing presence (regime/therapy)', 'Side', 'Increased sweating', 'Preposition For', 'Priapism', 'WWOX wt Allele', 'Sialorrhea', 'Systemic', 'Heart murmur', 'All extremities', 'Human body', 'Signs and Symptoms', 'Manifestation of', 'Examined', 'All', 'SAT1 protein, human', 'SAT1 wt Allele', 'Manifest', 'Body structure', 'One', 'During', 'Male population group', 'author', 'Human body structure', 'Adult human body', 'secretion of saliva', 'Over (spatial)']","['sosy', 'ortf', 'bpoc', 'idcn', 'gngm', 'prog', 'topp', 'popg', 'enzy', 'ftcn', 'fndg', 'humn', 'podg', 'tmco', 'qlco', 'spco', 'dsyn', 'anst', ' aapp', 'qnco']"
131,PMC3016167,S94,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Evaluation of clinical grade,"blood pressure, heart rate, cardiac arrhythmias, respiratory rate, and oxygen saturation were monitored on a multipara monitor.","['C0005823', 'C0483415', 'C0489258', 'C0003811', 'C1272641', 'C0231832', 'C0030695', 'C1271104', 'C0150369', 'C1515981', 'C1521743', 'C0018810', 'C0596972', 'C0181904']","['Preventive monitoring', 'Monitoring Device', 'Respiratory rate', 'Monitor Device', 'Breaths:Number = Count/Time:Point in time:Respiratory system:Quantitative', 'Cardiac Arrhythmia', 'Oxygen saturation test result', 'And', 'heart rate', 'Blood Pressure', 'Blood pressure finding', 'Systemic arterial pressure', 'Patient Monitoring', 'Monitor, occupation']","['clna', 'idcn', 'prog', 'medd', 'fndg', 'dsyn', 'hlca', 'orgf', 'orga']"
132,PMC3016167,S95,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Evaluation of clinical grade,"these findings were noted on admission at 00.00, at 30 minutes, and at 1, 2, 4, 6, 8, 10, 14, 18, and 24 hours.","['C0809949', 'C2926606', 'C0039828', 'C1442770', 'C0439584', 'C1515981', 'C0456693', 'C2607943', 'C0184666', 'C1442458', 'C3539655']","['Theses', '24 Hours', 'Procedure findings:Finding:Point in time:^Patient:Narrative', 'Hospital admission', 'per 30 minutes', 'Admission activity', '24 hour time frame', 'And', '30 Minutes', 'findings aspects', 'CDISC Findings Class']","['inpr', 'clna', 'idcn', 'ftcn', 'tmco', 'hlca']"
133,PMC3016167,S96,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Evaluation of clinical grade,subsequent improvement or deteriorations to grade 3 or 4 were closely followed by the author who examined the patient on arrival.,"['C0332282', 'C1555577', 'C3812881', 'C0475271', 'C4283822', 'C0030705', 'C4283821', 'C0450094', 'C1706079', 'C0332128', 'C2986411', 'C0687697', 'C3889290', 'C3272598', 'C4283820']","['author', 'West Haven Hepatic Encephalopathy Grade 3', 'Bayer Corneal Epitheliopathy Grade 3', 'Improvement', 'Examined', 'WHO Temperature/Humidity Storage Condition', 'arrival - ActRelationshipType', 'Tumor grade G3', 'Arrival - action', 'Patients', 'Third grade in elementary school', 'Simpson Grade 3', 'Following', 'Grade three rank', 'Bayer Visual Acuity Changes Grade 3']","['inpr', 'acty', 'prog', 'clas', 'ftcn', 'fndg', 'cnce', 'qlco', 'podg', 'tmco', 'dsyn']"
134,PMC3016167,S97,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Evaluation of clinical grade,"blood was collected from all participants on admission for measurement of haemoglobin, white cell count, and creatine kinase-mb.","['C0809949', 'C0679646', 'C0019046', 'C0005767', 'C0427512', 'C0229664', 'C0242485', 'C1515981', 'C0444868', 'C0005768', 'C0184666', 'C0010287', 'C0023508']","['White Blood Cell Count procedure', 'White blood cell count laboratory result', 'Hospital admission', 'In Blood', 'Blood', 'Admission activity', 'All', 'And', 'Creatine Kinase', 'Measurement', 'Hemoglobin', 'peripheral blood', 'Participant']","['bacs', 'idcn', 'lbpr', 'enzy', 'popg', 'lbtr', 'ftcn', 'bdsu', 'hlca', ' aapp', 'qnco']"
135,PMC3016167,S98,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Evaluation of clinical grade,"a 12 lead electrocardiogram (ecg) was done on arrival, after six hours, and before discharge.","['C0205452', 'C0023175', 'C1555577', 'C0012621', 'C2926602', 'C1706079', 'C0181586', 'C1442948', 'C0013798', 'C3275067', 'C1515981', 'C0030685', 'C0620347', 'C1623258', 'C1522538', 'C2348269', 'C0439227']","['Electrocardiogram', 'Lead', 'Discharge, body substance', 'arrival - ActRelationshipType', 'Hour', 'And', 'Arrival - action', 'Plumbum metallicum, homeopathic preparation', 'Electrocardiography', 'Leading', 'Body Fluid Discharge', 'Patient Discharge', 'Leads (device)', 'compound A 12', 'Six', 'Cardiac Lead Procedure', 'Dietary Lead']","['sosy', 'idcn', ' hops', 'inch', 'acty', 'elii', 'topp', 'ftcn', 'mnob', 'bdsu', 'tmco', 'orch', ' phsu', 'hlca', 'diap', 'qnco']"
136,PMC3018567,S100,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analysis,"on the basis of our preliminary study,32 the planned cohort size of 2500 was expected to accrue 1860 person-years of follow-up in infancy and 1594 infants were expected to be seen at age 1 year.","['C0231330', 'C0599755', 'C0021270', 'C1515981', 'C0332283', 'C2603343', 'C0439611', 'C0456389', 'C1527178', 'C0009247', 'C1874451', 'C2347489', 'C0027361', 'C0001779', 'C1301732', 'C4281991', 'C0439234']","['Cohort', 'Basis - conceptual entity', 'Follow', 'Person Observer', 'Followed by', 'Infant', 'Planned', 'And', 'Age', 'Study', 'preliminary', 'Persons', 'size', 'Cohort Studies', 'Basis', 'year', 'Infancy']","['grup', 'idcn', 'aggp', 'orga', 'popg', 'ftcn', 'spco', 'tmco', 'resa', 'qnco', 'phsu']"
137,PMC3018567,S101,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analysis,"for either maternal treatment, assuming no interaction between treatments, this number would give 80% power to detect rate ratios of 0·82 for malaria, 0·91 for diarrhoea, and 0·76 for pneumonia, with p values of less than 0·05, assuming frequency of disease in the placebo groups to be 50 per 100 person-years for malaria,33 190 per 100 person-years for diarrhoea,34 and 25 per 100 person-years for pneumonia.35","['C0441833', 'C1705169', 'C0687744', 'C0032863', 'C3887704', 'C1515981', 'C0456603', 'C0012634', 'C4321252', 'C1521828', 'C1080058', 'C2347489', 'C3891454', 'C0237753', 'C0024530', 'C0376249', 'C1561548', 'C0871396', 'C1696465', 'C0332287', 'C0027361', 'C0039798', 'C3538994', 'C3541306', 'C3898838', 'C1552839', 'C1705502', 'C0042295', 'C3844638', 'C4321352', 'C0449788', 'C0521125', 'C0871208', 'C1704675', 'C4281991', 'C0439234', 'C0439603', 'C0032042', 'C2984572', 'C1706408', 'C3887962', 'C0087111', 'C0032285', 'C3854080', 'C1947971', 'C1522326', 'C1533734', 'C0442726', 'C2347083', 'C0439092', 'C0011991']","['Plasmodium Measurement', 'Rating (action)', 'Biomaterial Treatment', 'And', 'Detected (finding)', 'Persons', 'Power', 'Preposition For', 'placebo', 'WWOX wt Allele', 'Therapeutic procedure', 'Malaria Pathway', 'Pneumonia', 'Either', 'Give - dosing instruction imperative', 'Placebos', 'Ratio', 'Administration procedure', 'Frequencies (time pattern)', 'Interaction', 'Kind of quantity - Frequency', 'Per (qualifier)', 'Social group', 'Maternal Relative', 'Person Observer', 'Treatment Epoch', 'Statistical Frequency', 'Less Than', 'Malaria', 'Numbers', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Frequency', 'Dosing Days to Detection', 'year', 'In addition to', 'Placebo Control', 'Follow', 'Count of entities', 'Groups', 'Spatial Frequency', 'Rate', 'Power (Psychology)', 'Table Rules - groups', 'Treating', 'With frequency', 'Values', 'Diarrhea', 'Disease', 'How Often', 'This (eukaryote)']","['hcpp', 'famg', 'topp', 'fndg', 'qlco', 'hlca', 'inpr', 'idcn', 'lbpr', 'gngm', 'resa', 'bodm', 'sosy', 'popg', 'ftcn', 'tmco', 'dsyn', 'grup', 'acty', 'cnce', 'euka', 'qnco']"
138,PMC3018567,S102,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"incidence of both tuberculosis and measles was expected to be low,18 therefore only very large differences in incidence would be detected.","['C0041296', 'C0021149', 'C1706086', 'C4321351', 'C0205171', 'C0450093', 'C0025007', 'C1515981', 'C0205251', 'C3890211', 'C1550472', 'C4048187', 'C0220856', 'C4522223']","['Tuberculosis', 'incidence of cases', 'low', 'Low Level', 'Incidence', 'Both', 'And', 'Low Mitosis-Karyorrhexis Index', 'low confidentiality', 'Singular', 'very large', 'low exposure', 'IPSS Risk Category Low', 'Measles']","['inpr', 'idcn', 'ftcn', 'fndg', 'qlco', 'dsyn', 'qnco']"
139,PMC3018567,S103,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"samples from 1594 infants assessed at 1 year would detect differences in infant cytokine responses of 0·11 log10 between intervention groups.18,32","['C0079189', 'C0886296', 'C0184661', 'C0439234', 'C1552839', 'C0021270', 'C0441833', 'C0687744', 'C1690986', 'C0871261']","['Response process', 'Social group', 'year', 'Groups', 'Infant', 'log10', 'Nursing interventions', 'Table Rules - groups', 'Interventional procedure', 'cytokine']","['inpr', 'idcn', 'aggp', 'topp', 'popg', 'tmco', 'imft', 'hlca', ' aapp', 'qnco', 'orga']"
140,PMC3018567,S104,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,the patients that were included in analysis for each of the primary outcomes differed because data for each outcome was obtained at different times.,"['C1511726', 'C1274040', 'C0030705', 'C3245479', 'C1457900', 'C0936012', 'C0040223', 'C0205225', 'C1524024', 'C4321252', 'C1632851', 'C3714741', 'C0521125', 'C1705242']","['Data call receiving device', 'Patients', 'Analysis', 'Time', 'Preposition For', 'Data (eukaryote)', 'Data', 'Times', 'Each (qualifier value)', 'Different', 'Result', 'WWOX wt Allele', 'Primary', 'analysis aspect']","['idcn', 'gngm', 'medd', 'ftcn', 'podg', 'euka', 'qlco', 'resa', 'tmco', 'qnco']"
141,PMC3018567,S105,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"for immune response at age 1 year, analysis included all children who provided a blood sample at 1 year and who had received full bcg (for ccfp analysis) or tetanus (for tetanus toxoid analysis) immunisation at entebbe hospital; second-born twins were excluded.","['C0178913', 'C0205436', 'C1515981', 'C1705190', 'C1524024', 'C0457385', 'C0039614', 'C0041427', 'C0936012', 'C0020971', 'C0042196', 'C0443225', 'C0680063', 'C1999230', 'C0019994', 'C1561503', 'C0040555', 'C0301872', 'C0332257', 'C0439234', 'C0305062', 'C0008059', 'C0444868', 'C1148523', 'C3272598', 'C0001779']","['Vaccination', 'And', 'Providing (action)', 'Toxoids', 'Immunization', 'Age', 'Offspring', 'full', 'Immune response', 'WHO Temperature/Humidity Storage Condition', 'All', 'Second Suffix', 'Twin sibling (person)', 'year', 'seconds', 'Child', 'analysis aspect', 'Precision - second', 'Tetanus', 'tetanus toxoid vaccine, inactivated', 'second (number)', 'Including (qualifier)', 'Analysis', 'Blood specimen', 'Childbirth', 'Hospitals']","['ortf', 'idcn', 'aggp', 'acty', 'famg', 'topp', 'ftcn', 'mnob', 'qlco', 'imft', ' phsu', 'resa', 'tmco', 'dsyn', 'bdsu', ' aapp', ' hcro', 'orgf', 'qnco', 'orga']"
142,PMC3018567,S106,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"for incidence of infectious diseases during infancy, analysis included all liveborn children, excluding second-born twins.","['C0008059', 'C0231330', 'C0021149', 'C0205436', 'C1561503', 'C0041427', 'C0936012', 'C0810062', 'C1705190', 'C1524024', 'C0680063', 'C0444868', 'C0457385', 'C0220856', 'C0009450']","['Precision - second', 'incidence of cases', 'Communicable Diseases', 'second (number)', 'Incidence', 'All', 'Second Suffix', 'Analysis', 'seconds', 'Offspring', 'Twin sibling (person)', 'analysis aspect', 'Infancy', 'Liveborn', 'Child']","['idcn', 'aggp', 'famg', 'ftcn', 'fndg', 'tmco', 'qlco', 'resa', 'dsyn', 'qnco']"
143,PMC3018567,S107,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"for vertical hiv transmission, analysis included all children whose mothers were not receiving highly-active antiretroviral therapy, and from whom blood samples at age 6 weeks were available; second-born twins were excluded.","['C0178913', 'C0205436', 'C3853793', 'C0205250', 'C1515981', 'C1705190', 'C1524024', 'C1521797', 'C0470187', 'C0457385', 'C1518422', 'C0041427', 'C0936012', 'C0439230', 'C0026591', 'C0205177', 'C0680063', 'C3888249', 'C1963724', 'C1561503', 'C0242781', 'C0040722', 'C0205128', 'C0008059', 'C0019682', 'C0444868', 'C1148523', 'C0001779']","['Active License', 'HIV', 'active (HL7 RoleLink)', 'And', 'transmission process', 'disease transmission qualifier', 'Vertical', 'Age', 'Offspring', 'Negation', 'Active', 'Antiretroviral therapy', 'availability of', 'All', 'week', 'Second Suffix', 'Twin sibling (person)', 'Mother (person)', 'seconds', 'analysis aspect', 'Child', 'Precision - second', 'High', 'second (number)', 'disease transmission', 'Analysis', 'Blood specimen', 'Childbirth']","['idcn', 'aggp', 'famg', 'topp', 'ftcn', 'spco', 'patf', 'qlco', 'virs', 'bdsu', 'resa', 'orgf', 'tmco', 'npop', 'qnco', 'orga']"
144,PMC3018567,S108,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"cytokine and antibody responses showed skewed distributions, with disproportionate numbers of zero values.","['C3665580', 'C4284144', 'C0079189', 'C0919414', 'C0003241', 'C0042295', 'C1515981', 'C0037775', 'C1167408', 'C0021027', 'C0449788', 'C0237753', 'C0871261']","['Response process', 'Count of entities', 'Zero Activity Time', 'And', 'Immunoglobulins', 'Numbers', 'Arabic numeral 0', 'Values', 'Antibodies', 'immunoglobulin complex location', 'Spatial Distribution', 'cytokine', 'Immunoglobulin complex location, circulating']","['idcn', 'spco', 'celc', 'qlco', 'imft', 'fndg', ' phsu', ' aapp', 'qnco', 'orga']"
145,PMC3018567,S109,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,results were transformed to log10(concentration+1) and analysed by linear regression with bootstrapping to estimate bias-corrected accelerated confidence intervals.36,"['C0086045', 'C1504315', 'C0009667', 'C2346679', 'C1446561', 'C3827302', 'C1515981', 'C0005346', 'C0242568', 'C1690986', 'C0023733']","['Linear Regression Body Surface Area Formula for Infants and Children', 'Concentration measurement', 'log10', 'Linear Regression', 'Mental concentration', 'And', 'Biases', 'Confidence Intervals', 'Bias genus', 'Bias (Epidemiology)', 'Able to Concentrate Question']","['inpr', 'idcn', 'bird', 'menp', 'qnco']"
146,PMC3018567,S110,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,regression coefficients were back-transformed to give geometric mean ratios.,"['C2986759', 'C0205095', 'C0684321', 'C0456603', 'C0684320', 'C1836830', 'C0460009', 'C0004600']","['Back', 'Ratio', 'Disease regression', 'Geometric Mean', 'Dorsal', 'Regression - mental defense mechanism', 'Developmental regression', 'Back structure, including back of neck']","['blor', 'patf', 'spco', 'dsyn', 'menp', 'qnco']"
147,PMC3018567,S111,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,interactions were examined with wald tests.,"['C0022885', 'C0392366']","['Laboratory Procedures', 'Tests (qualifier value)']","['lbpr', 'inpr']"
148,PMC3018567,S112,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"for doctor-diagnosed disease incidence, time at risk began at birth and was censored at loss to follow-up, death, or age 1 year.","['C0439234', 'C0005615', 'C1550722', 'C0040223', 'C1306577', 'C1515981', 'C0035647', 'C0011900', 'C0026538', 'C0031831', 'C1148523', 'C1517945', 'C4552904', 'C3245487', 'C0001779', 'C0011065', 'C2348314']","['Subject Risk', 'Cessation of life', 'Loss', 'Risk', 'Morbidity - disease rate', 'And', 'Name Given at Birth', 'Death (finding)', 'Age', 'Diagnosis', 'Physicians', 'Time', 'Doctor - Title', 'Childbirth', 'year', 'Entity Name Part Qualifier - birth', 'Birth']","['inpr', 'idcn', 'prog', 'cnce', 'fndg', 'tmco', 'diap', 'orgf', 'qnco', 'orga']"
149,PMC3018567,S113,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"all children with known date of birth were included in the analysis until censoring, irrespective of whether they had made a clinic visit for illness.","['C0008059', 'C0221423', 'C0205309', 'C0442592', 'C0005615', 'C1550722', 'C0936012', 'C1512346', 'C0545082', 'C2826704', 'C1524024', 'C2348077', 'C0680063', 'C0444868', 'C1148523', 'C0011008', 'C3245487', 'C0002424']","['Date in time', 'Clinic', 'Visit', 'All', 'analysis aspect', 'Patient Visit', 'Name Given at Birth', 'Child', 'Date Fruit', 'Known', 'Analysis', 'Illness (finding)', 'Visit Name', 'Offspring', 'Childbirth', 'Ambulatory Care Facilities', 'Entity Name Part Qualifier - birth', 'Birth']","['sosy', 'inpr', 'aggp', 'famg', 'ftcn', 'mnob', 'tmco', 'food', 'qlco', 'resa', 'bhvr', 'hlca', ' hcro', 'orgf', 'qnco']"
150,PMC3018567,S114,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"for each disease, we calculated incidence rates for all events.","['C3541888', 'C0021149', 'C1457900', 'C0441471', 'C0012634', 'C0444868', 'C0220856']","['incidence of cases', 'CDISC Events Class', 'All', 'Incidence', 'Disease', 'Each (qualifier value)', 'Event']","['clas', 'ftcn', 'dsyn', 'qnco', 'evnt']"
151,PMC3018567,S115,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"disease episodes within 14 days of an initial presentation with the same disease were regarded as part of the same episode and excluded from the analysis; time at risk was adjusted accordingly, excluding these 14-day periods from the total person-time denominator.","['C0332189', 'C0039828', 'C1554077', 'C2825218', 'C0439810', 'C1515981', 'C0012634', 'C1524024', 'C2347489', 'C2828389', 'C0936012', 'C1555582', 'C1292711', 'C0027361', 'C0449450', 'C0332173', 'C0332196', 'C0439228', 'C0205265', 'C4552904', 'C1517320', 'C0445247', 'C0040223', 'C1279901', 'C1705685', 'C0035647']","['Initial (abbreviation)', 'Theses', 'Exclusion', 'day', 'Firstly', 'And', 'Persons', 'From', 'Time', 'Initially', 'Denominator', 'part of', 'Excluded - Conformance Inclusion', 'Total', 'Subject Risk', 'Initial Usage', 'Person Observer', 'Risk', 'Daily', 'Same', 'Exclude', 'Episode of', 'analysis aspect', 'Presentation', 'Analysis', 'Disease']","['grup', 'inpr', 'idcn', 'acty', 'popg', 'ftcn', 'cnce', 'spco', 'tmco', 'qlco', 'resa', 'dsyn', 'qnco']"
152,PMC3018567,S116,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"hazard ratios (hrs) for effects of treatment were calculated with cox regression, with robust ses to allow for within-child clustering.","['C0008059', 'C1568891', 'C0598697', 'C3538994', 'C1705169', 'C3887704', 'C0684321', 'C2986815', 'C0456603', 'C0087111', 'C0684320', 'C1280500', 'C0009085', 'C1836830', 'C0680063', 'C1533734', 'C1522326', 'C0332285', 'C0039798', 'C1565830']","['Effect', 'Therapeutic procedure', 'Treatment Epoch', 'HGS protein, human', 'Biomaterial Treatment', 'Robust', 'Ratio', 'Administration procedure', 'Treating', 'Disease regression', 'Within', 'hazard', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Offspring', 'Regression - mental defense mechanism', 'PTGS1 protein, human', 'Developmental regression', 'statistical cluster', 'Child']","['bacs', 'aggp', 'famg', 'topp', 'enzy', 'ftcn', 'cnce', 'patf', 'qlco', 'spco', 'hlca', 'resa', 'dsyn', 'menp', ' aapp', 'qnco']"
153,PMC3018567,S117,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"for community-reported illness data, a generalised-estimating-equation approach with exchangeable correlation structure was used to model effects of treatment on repeated binary outcomes.","['C1511726', 'C0684224', 'C0678594', 'C0449445', 'C3887704', 'C1705169', 'C1706942', 'C3714741', 'C0750572', 'C0039798', 'C3538994', 'C0221423', 'C0205246', 'C0552449', 'C1280500', 'C0009462', 'C0700287', 'C3245479', 'C0087111', 'C1707520', 'C1522326', 'C1533734', 'C4319718', 'C0205341']","['Reporting', 'Generalized', 'Biomaterial Treatment', 'Data call receiving device', 'Therapeutic procedure', 'Reported', 'Repeat', 'equation', 'Administration procedure', 'Community', 'Estimated', 'Treatment Epoch', 'Approach', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Correlation', 'Data', 'Effect', 'Report (document)', 'structure', 'Treating', 'Illness (finding)', 'Data (eukaryote)', 'Binary']","['sosy', 'grup', 'inpr', 'idcn', 'topp', 'medd', 'ftcn', 'spco', 'cnce', 'qlco', 'euka', 'resa', 'hlca', 'qnco']"
154,PMC3018567,S118,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,odds ratios (ors) for the effects of treatment on vertical hiv transmission were calculated with logistic regression.,"['C0205128', 'C0028873', 'C0019682', 'C3887704', 'C0069590', 'C0242781', 'C1705169', 'C0087111', 'C1963718', 'C0040722', 'C1280500', 'C1521797', 'C0206031', 'C1522326', 'C1533734', 'C0039798', 'C3538994']","['Vertical', 'Effect', 'Treatment Epoch', 'HIV', 'Logistic Regression', 'ORALIT', 'Biomaterial Treatment', 'disease transmission', 'Treating', 'Administration procedure', 'transmission process', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Oculorespiratory syndrome', 'disease transmission qualifier', 'Odds Ratio', 'Therapeutic procedure']","['idcn', 'inch', 'topp', 'ftcn', 'cnce', 'patf', 'qlco', 'virs', 'spco', 'resa', ' phsu', 'hlca', 'npop', 'qnco', 'dsyn']"
155,PMC3018567,S119,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,the prevalence of asymptomatic malaria at 1 year was compared between treatment groups with logistic regression.,"['C3541306', 'C0439234', 'C2984572', 'C1552839', 'C0033105', 'C0441833', 'C1705169', 'C0687744', 'C3538994', 'C0087111', 'C0231221', 'C3887704', 'C0039798', 'C0206031', 'C1522326', 'C1533734', 'C0220900', 'C0024530']","['Prevalence aspects', 'year', 'Plasmodium Measurement', 'Treatment Epoch', 'Groups', 'Malaria', 'Logistic Regression', 'Statistical Prevalence', 'Biomaterial Treatment', 'Table Rules - groups', 'Administration procedure', 'Treating', 'therapeutic aspects', 'symptomless', 'treatment - ActInformationManagementReason', 'Therapeutic procedure', 'Malaria Pathway', 'Social group']","['inpr', 'idcn', 'lbpr', 'topp', 'popg', 'ftcn', 'cnce', 'fndg', 'tmco', 'resa', 'dsyn', 'hlca', 'qnco']"
156,PMC3018567,S120,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"infant mortality per 1000 livebirths was estimated from kaplan-meier survival probabilities to age 1 year, and effects of maternal anthelmintic treatment were assessed by cox regression.","['C3887704', 'C1705169', 'C1515981', 'C0684320', 'C0038952', 'C1836830', 'C0220921', 'C0003158', 'C0684321', 'C0021278', 'C0039798', 'C3538994', 'C1565830', 'C0033204', 'C3536838', 'C1280500', 'C0439234', 'C0087111', 'C1522326', 'C1533734', 'C2347083', 'C0001779']","['Antihelminthic [EPC]', 'Anthelmintics', 'Probability', 'And', 'Biomaterial Treatment', 'Continuance of life', 'PTGS1 protein, human', 'Therapeutic procedure', 'Age', 'Administration procedure', 'Infant Mortality', 'Developmental regression', 'Maternal Relative', 'Treatment Epoch', 'survival aspects', 'Disease regression', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Regression - mental defense mechanism', 'year', 'Effect', 'Treating']","['idcn', 'acty', 'famg', 'topp', 'enzy', 'phsu', 'ftcn', 'cnce', 'patf', 'qlco', 'hlca', 'tmco', 'resa', 'dsyn', 'menp', ' aapp', 'qnco', 'orga']"
157,PMC3018567,S121,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"weight-for-age, height-for-age, and weight-for-height z scores at 1 year were derived from who growth standard reference scales, with igrowup macros.","['C0220844', 'C0489786', 'C0175659', 'C1515981', 'C1514811', 'C4321252', 'C0005910', 'C1706462', 'C1621966', 'C0043100', 'C1442989', 'C0521125', 'C0439234', 'C1305866', 'C2911660', 'C2828392', 'C1705104', 'C0018270', 'C0222045', 'C0871421', 'C3272598', 'C0001779']","['Standard (document)', 'growth aspects', 'And', 'Weight', 'Preposition For', 'WWOX wt Allele', 'Tissue Growth', 'Age', 'Bibliographic Reference', 'Reference Object', 'Standard (qualifier)', 'WHO Temperature/Humidity Storage Condition', 'z-score', 'Growth', 'year', 'Importance Weight', 'Weight measurement scales', 'Growth action', 'Body Weight', 'Height', 'Weighing patient', 'Integumentary scale']","['ortf', 'bpoc', 'phpr', 'inpr', 'idcn', 'phsf', 'gngm', 'medd', 'cnce', 'qlco', 'tmco', 'hlca', 'orgf', 'qnco', 'orga']"
158,PMC3018567,S122,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,we examined effects of maternal treatment on z scores and on haemoglobin at 1 year by linear regression.,"['C0439234', 'C0019046', 'C3887704', 'C1705169', 'C2346679', 'C0087111', 'C1515981', 'C0039798', 'C1280500', 'C1522326', 'C1533734', 'C2347083', 'C0871421', 'C0023733', 'C3538994']","['Linear Regression Body Surface Area Formula for Infants and Children', 'Maternal Relative', 'Effect', 'year', 'Treatment Epoch', 'Linear Regression', 'Biomaterial Treatment', 'And', 'z-score', 'Treating', 'Administration procedure', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Therapeutic procedure', 'Hemoglobin']","['bacs', 'inpr', 'idcn', 'famg', 'topp', 'ftcn', 'cnce', 'qlco', 'tmco', 'resa', 'hlca', ' aapp', 'qnco']"
159,PMC3018567,S123,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"we did two prespecified subgroup analyses, examining effects of albendazole treatment in children of mothers with a hookworm infection, and effects of praziquantel treatment in children of mothers with schistosomiasis.","['C0008059', 'C0036323', 'C0001911', 'C3887704', 'C1705169', 'C0087111', 'C0019911', 'C0032911', 'C0026591', 'C1515981', 'C1280500', 'C1515021', 'C1079230', 'C0680063', 'C1533734', 'C1522326', 'C0205448', 'C0039798', 'C3538994']","['Effect', 'Treatment Epoch', 'Hookworm Infections', 'Biomaterial Treatment', 'And', 'Treating', 'Administration procedure', 'Schistosomiasis', 'Albendazole', 'Subgroup', 'Two', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Subgroup A Nepoviruses', 'Offspring', 'Therapeutic procedure', 'Mother (person)', 'Praziquantel', 'Child']","['idcn', 'aggp', 'famg', 'clas', 'topp', 'ftcn', 'cnce', 'orch', 'qlco', 'virs', 'resa', ' phsu', 'hlca', 'qnco', 'dsyn']"
160,PMC3018567,S124,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,differences between subgroups were examined by fitting interaction terms in regression models.,"['C0684321', 'C0684320', 'C1079230', 'C1836830', 'C1704675', 'C3161035']","['Model', 'Disease regression', 'Interaction', 'Subgroup A Nepoviruses', 'Regression - mental defense mechanism', 'Developmental regression']","['inpr', 'ftcn', 'patf', 'virs', 'dsyn', 'menp']"
161,PMC3018567,S125,"['12a', '12b']","[0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,all p values were two-sided with no adjustment made for multiple comparisons.,"['C0439064', 'C0042295', 'C0376209', 'C0683269', 'C0444868', 'C0205448', 'C0456081']","['Adjustment Action', 'All', 'Two', 'Numerous', 'Individual Adjustment', 'Values', 'Psychological adjustment']","['ftcn', 'qlco', 'qnco', 'inbe']"
162,PMC3018567,S126,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,analyses were done with stata 10.1.,,,
163,PMC3018567,S128,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Role of the funding source,"the sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.","['C1511726', 'C0010995', 'C0684224', 'C0043266', 'C2584304', 'C4255046', 'C3714741', 'C3273238', 'C2983265', 'C2986888', 'C0010992', 'C2603343', 'C4283917', 'C2347796', 'C3173575', 'C1711305', 'C3887707', 'C0035171', 'C4050126', 'C0062074', 'C1705810', 'C0700287', 'C0035820', 'C3539897', 'C3245479', 'C1415458', 'C0459471', 'C3871154']","['Writing (function)', 'Reporting', 'Interpretation:Impression/interpretation of study:Point in time:^Patient:Nominal', 'Sponsor (person)', 'Role', 'Data call receiving device', 'Ability to Write question', 'Have', 'Research Design', 'Writing Ability', 'Regulatory Report', 'HADH gene', 'Nonclinical Study Design', 'Data Collection', 'Data Collection Methods', 'Social Role', 'Clinical Study Sponsor', 'Study', 'Data', 'Data Analysis', 'Report (document)', 'Report:Finding:Point in time:{Setting}:Document:{Role}', 'Interpretation Process', 'HAC protocol', 'Generic Role', 'Data (eukaryote)', 'CDISC SEND Study Design Terminology', 'Writing (occupation or discipline)']","['inpr', 'clna', 'idcn', 'gngm', 'ocdi', 'ocac', 'topp', 'medd', 'popg', 'qlco', 'euka', 'resa', 'socb', 'hlca', 'menp', 'qnco', 'orgt']"
164,PMC3018567,S129,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Role of the funding source,ame had full access to all the data in the study and had final responsibility for the decision to submit for publication.,"['C1511726', 'C1515981', 'C4321252', 'C3887949', 'C3714741', 'C3853528', 'C0678341', 'C0443225', 'C2603343', 'C1546485', 'C1704324', 'C0034037', 'C0679006', 'C0444454', 'C0062074', 'C0521125', 'C3539897', 'C3245479', 'C0034036', 'C1415458', 'C0444868', 'C1554204', 'C0205088']","['Role Class - access', 'And', 'Data call receiving device', 'Preposition For', 'Have', 'WWOX wt Allele', 'HADH gene', 'Final', 'responsibility', 'Diagnosis Type - Final', 'Publishing', 'Data (eukaryote)', 'full', 'All', 'Apparent mineralocorticoid excess', 'Study', 'Publications', 'Data', 'End-stage', 'HAC protocol', 'Decision', 'Scientific Publication', 'Access']","['inpr', 'inbe', 'idcn', ' mnob', 'gngm', 'ocac', 'topp', 'medd', 'ftcn', 'spco', 'qlco', 'euka', 'tmco', 'resa', 'dsyn', 'menp', 'qnco']"
165,PMC3018567,S46,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,the study is described in detail elsewhere.18,"['C2603343', 'C1561567', 'C1522508']","['Study', 'detail - Response Level', 'Details']","['ftcn', 'qlco', 'resa']"
166,PMC3018567,S47,['4b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,"briefly, the study area was entebbe municipality and katabi subcounty, beside lake victoria, uganda.","['C1550712', 'C0205146', 'C0997115', 'C0337049', 'C1515981', 'C0041573', 'C2603343', 'C0017446', 'C0600182', 'C0042645']","['Address Part Type- municipality', 'Lake (environment)', 'municipality', 'Area', 'And', 'Geographic Locations', 'Study', 'Uganda', 'Victoria Genus', 'Victoria Austrailia']","['idcn', 'geoa', 'plnt', 'spco', 'resa']"
167,PMC3018567,S48,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,"the area is occupied by urban, rural, and fishing communities.","['C0240919', 'C0205146', 'C1515981', 'C0009462', 'C0442529', 'C0017446', 'C2700386']","['Rural', 'Urban environment', 'Geographic Locations', 'Area', 'And', 'Urban - qualifier', 'Community']","['grup', 'geoa', 'idcn', 'spco', 'fndg', 'qlco']"
168,PMC3018567,S49,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,"helminth infection is highly prevalent in the area,19 and malaria, diarrhoea, and pneumonia are common in young children.20","['C0008059', 'C3541306', 'C0205214', 'C2984572', 'C0332239', 'C0205146', 'C0205250', 'C0018889', 'C1515981', 'C0032285', 'C0680063', 'C0017446', 'C1522138', 'C3245511', 'C0011991', 'C0024530']","['young', 'Plasmodium Measurement', 'Common Specifications in HL7 V3 Publishing', 'High', 'Malaria', 'shared attribute', 'Area', 'And', 'Geographic Locations', 'Helminthiasis', 'Diarrhea', 'Offspring', 'Common (qualifier value)', 'Malaria Pathway', 'Pneumonia', 'Child']","['sosy', 'inpr', 'idcn', 'geoa', 'aggp', 'lbpr', 'famg', 'ftcn', 'spco', 'qlco', 'tmco', 'dsyn', 'qnco']"
169,PMC3018567,S50,['4b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,"the study population consisted of pregnant women who presented at the government-funded antenatal clinic at entebbe general hospital between april 9, 2003, and nov 24, 2005, where roughly 70% of pregnant women from the study area received antenatal care.21","['C1706374', 'C0205146', 'C0016820', 'C0018104', 'C1515981', 'C3811652', 'C0017446', 'C0020008', 'C1274027', 'C0033011', 'C2603343', 'C1514756', 'C0949920', 'C3854060', 'C3715025', 'C2348561', 'C3715024', 'C1517320', 'C1121443', 'C0033052', 'C0205103', 'C3272598']","['Hospitals, General', 'Area', 'And', 'antenatal clinic', 'From', 'Study Population (group)', 'April', 'Receive', 'Prenatal care', 'government - ActInformationManagementReason', 'Pregnant Women', 'Funds', 'Intermediate', 'WHO Temperature/Humidity Storage Condition', 'Study', 'Government', 'Norovirus', 'TNFSF13 wt Allele', 'NOV protein, human', 'Geographic Locations', 'Tumor Necrosis Factor Ligand Superfamily Member 13', 'A Proliferation-Inducing Ligand Measurement']","['bacs', 'idcn', 'geoa', 'lbpr', 'gngm', 'ocac', 'popg', 'mnob', 'spco', 'qlco', 'tmco', 'virs', 'resa', 'hlca', ' aapp', ' hcro', 'qnco', 'orgt']"
170,PMC3018567,S51,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,"women were included if resident in the study area, planning to deliver in the hospital, willing to know their hiv status, and in the second or third trimester of pregnancy.","['C2709249', 'C0205436', 'C3835651', 'C0205146', 'C1874964', 'C1515981', 'C0032961', 'C1705190', 'C0600109', 'C0017446', 'C0032981', 'C0457385', 'C1549439', 'C0043210', 'C2603343', 'C1301732', 'C0019994', 'C1561503', 'C2347958', 'C1320928', 'C0308779', 'C0458074', 'C1705822', 'C0032074']","['Woman', 'Area', 'And', 'Resident (person)', 'Resident - answer to question', 'DELIVER (Dietary Supplement)', 'human immunodeficiency virus status:History:Point in time:^Patient:Nominal', 'Pregnancy', 'DELIVER (veterinary product)', 'Cognitive function: planning', 'Planned', 'Second Suffix', 'Study', 'Human immunodeficiency virus (HIV) status', 'seconds', 'Pregnancy Trimester, Third', 'willing', 'Precision - second', 'Transfer Technique', 'Resident - Procedure Practitioner Identifier Code Type', 'second (number)', 'Geographic Locations', 'Resident (physician)', 'Hospitals']","['inpr', 'clna', 'idcn', 'geoa', 'prog', 'popg', 'ftcn', 'mnob', 'spco', 'tmco', 'orch', 'fndg', 'qlco', 'resa', ' phsu', 'menp', ' hcro', 'orgf', 'qnco', 'phsu']"
171,PMC3018567,S52,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,"they were excluded if they had possible helminth-induced pathological changes (haemoglobin <80 g/l, clinically apparent severe liver disease, or diarrhoea with blood in stool), a history of an adverse reaction to anthelmintics, already been enrolled in the trial during an earlier pregnancy, or if the pregnancy was deemed abnormal by a midwife.","['C0262926', 'C1521733', 'C1279919', 'C0030664', 'C0750489', 'C0032961', 'C0008976', 'C4684790', 'C0019665', 'C1565156', 'C4050466', 'C0347984', 'C4050465', 'C1705910', 'C0015733', 'C0003158', 'C0262512', 'C0043194', 'C0205082', 'C0229664', 'C0018893', 'C0443172', 'C0019664', 'C0023895', 'C0205161', 'C2004062', 'C2699333', 'C0205263', 'C0332149', 'C0392747', 'C0456615', 'C0026083', 'C1705255', 'C0005767', 'C0439294', 'C1421478', 'C0005768', 'C0559546', 'C0011991']","['Feces', 'Medical History', 'In Blood', 'Anthelmintics', 'Borg Category-Ratio 10 Perceived Exertion Score 5', 'Possibly Related to Intervention', 'History', 'Possible', 'Pathologic', 'WAS protein, human', 'Blood', 'Clinical Trials', 'WAS gene', 'Changed status', 'Study Subject Enrolled', 'Severe (severity modifier)', 'Pregnancy', 'Midwife', 'Changing', 'apparent', 'Billion per Liter', 'Kilogram per Cubic Meter', 'Early', 'Concept History', 'History of present illness', 'Abnormal', 'During', 'Abnormal Reference Range', 'Liver diseases', 'Pathology', 'Historical aspects qualifier', 'Severe Extremity Pain', 'Wiskott-Aldrich Syndrome', 'Diarrhea', 'Induce (action)', 'Adverse reactions', 'Helminths', 'History of previous events', 'peripheral blood']","['bacs', 'fndg', 'bdsu', 'qlco', 'phsu', 'bmod', 'inpr', 'idcn', 'gngm', 'prog', 'patf', 'resa', ' aapp', 'orgf', 'sosy', 'ftcn', 'tmco', 'dsyn', 'ocdi', 'cnce', 'euka', 'qnco']"
172,PMC3018567,S53,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,"all participants gave written, informed consent.","['C0679646', 'C0021430', 'C0444868']","['All', 'Informed Consent', 'Participant']","['popg', 'qnco', 'rnlw']"
173,PMC3018567,S54,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,"ethics approval was given by the uganda virus research institute, uganda national council for science and technology, and london school of hygiene and tropical medicine.","['C0020405', 'C1527243', 'C0035172', 'C0023973', 'C4321404', 'C0319157', 'C1551807', 'C3245503', 'C0015000', 'C0036375', 'C0041573', 'C1515981', 'C0205540', 'C0041186', 'C0036397', 'C0042776', 'C2346845', 'C2697909']","['London', 'Council Eskimos', 'Usually Need Help from Another Person for Hygiene', 'Virus', 'Hygiene', 'Research Institutes', 'And', 'Tropical Medicine', 'Ethics', 'Science', 'Approved', 'Letter of Authorization', 'National citizen', 'Uganda', 'Approval (document)', 'School', 'ethics qualifier', 'AS virus']","['bmod', 'inpr', 'rnlw', 'idcn', 'geoa', ' mnob', 'ocdi', 'popg', 'ftcn', 'qlco', 'virs', 'orgt']"
174,PMC3018567,S56,"['8b', '5', '3a']","[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1, 0]",Randomisation and masking,"we used a two-by-two factorial design to randomly assign patients in a 1:1:1:1 ratio to receive simultaneously either single-dose albendazole (440 mg) and single-dose praziquantel (40 mg/kg), albendazole and a praziquantel-matching placebo, an albendazole-matching placebo and praziquantel, or an albendazole-matching placebo and a praziquantel-matching placebo (albendazole and matching placebo, glaxosmithkline, brentford, uk; praziquantel and matching placebo, medochemie ltd, limassal, cyprus).","['C0030705', 'C1515981', 'C0456603', 'C1708943', 'C1516050', 'C0681865', 'C1696465', 'C0521115', 'C0032911', 'C1552903', 'C1136140', 'C0010622', 'C0439272', 'C0150103', 'C1547037', 'C0178602', 'C3844638', 'C0205448', 'C0032042', 'C1706408', 'C0001911', 'C0205171', 'C0087136']","['And', 'Patients', 'placebo', 'Unmarried', 'Either', 'Match', 'Simultaneous', 'Placebos', 'Ratio', 'SmithKline Beecham', 'data type - ratio', 'Dosage', 'factorial design', 'Assignment - action', 'Singular', 'Albendazole', 'Two', 'mg/kg', 'Praziquantel', 'Cyprus', 'Placebo Control', 'Long-Term Synaptic Depression', 'MATCHING']","['ortf', 'inpr', 'geoa', 'idcn', 'qnco', 'topp', 'ftcn', 'fndg', 'orch', 'qlco', 'podg', 'resa', 'tmco', ' phsu', 'hcro', 'bodm']"
175,PMC3018567,S57,"['8a', '8b']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0]",Randomisation and masking,"the randomisation code was generated by the trial statistician with a computer-generated random number sequence, with block size 100.","['C3889831', 'C0009622', 'C1706084', 'C0439605', 'C2828370', 'C1519249', 'C0009219', 'C0332206', 'C0034656', 'C0004793', 'C0162327', 'C3853789', 'C0028778', 'C0449788', 'C0805701', 'C1533157', 'C0456389', 'C0237753', 'C4684804', 'C0162326']","['Sequence - TransmissionRelationshipTypeCode', 'Base Sequence', 'Count of entities', 'Obstruction', 'Randomization', 'Trial Statistician', 'Computers', 'DNA Sequence', 'Random', 'Block (unit of measure)', 'Block Specimens', 'Numbers', 'RNA Sequence', 'Coding', 'Blocking', 'size', 'Code', '(City) Block', 'Sequence', 'eTMF Content Model Code']","['inpr', 'nusq', 'geoa', 'prog', 'ocac', 'ftcn', 'mnob', 'patf', 'bdsu', 'qlco', 'spco', 'resa', 'qnco']"
176,PMC3018567,S58,['9'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1]",Randomisation and masking,treatments were packed in sealed envelopes and labelled with an allocation number by colleagues at the medical research council unit in entebbe who did not otherwise contribute to the trial.,"['C2828361', 'C1706778', 'C1707660', 'C1704753', 'C3853603', 'C0439148', 'C0087111', 'C0079816', 'C1515981', 'C0008976', 'C1880177', 'C1880519', 'C0439453', 'C0449788', 'C1509845', 'C1519795', 'C1551807', 'C3272598', 'C1518422', 'C0237753']","['Council Eskimos', 'Count of entities', 'Negation', 'Medical Research activity', 'Unit - NCI Thesaurus Property', 'Unit device', 'WHO Temperature/Humidity Storage Condition', 'Clinical Trials', 'And', 'Contribution', 'Do (activity)', 'Numbers', 'Unit', 'Deidentification', 'Allocation', 'Unit of Measure', 'International Unit', 'Therapeutic procedure', 'Storage Unit', 'Enzyme Unit']","['idcn', 'acty', 'topp', 'popg', 'medd', 'ftcn', 'mnob', 'qlco', 'resa', 'qnco', 'mcha']"
177,PMC3018567,S59,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,treatments were allocated in numerical order by trained interviewer-counsellors who observed the patients taking the treatment correctly on enrolment to the study.,"['C0021821', 'C0030705', 'C1705175', 'C1705169', 'C3887704', 'C0087111', 'C1705178', 'C1705177', 'C1705176', 'C2603343', 'C1522326', 'C1533734', 'C3889825', 'C1882348', 'C3272598', 'C0237753', 'C0039798', 'C3538994']","['Order (action)', 'Sequence of Planned Assessment Schedule', 'Order (document)', 'Treatment Epoch', 'WHO Temperature/Humidity Storage Condition', 'Biomaterial Treatment', 'Numbers', 'Treating', 'Patients', 'Administration procedure', 'Study', 'therapeutic aspects', 'Interviewers', 'treatment - ActInformationManagementReason', 'Therapeutic procedure', 'Order (arrangement)', 'Permutation', 'Order (taxonomic)']","['inpr', 'acty', 'prog', 'clas', 'topp', 'ftcn', 'cnce', 'qlco', 'podg', 'resa', 'hlca', 'qnco']"
178,PMC3018567,S60,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,treatment allocation was masked from all participants and staff during the study.,"['C1706778', 'C0679646', 'C3887704', 'C1705169', 'C0087111', 'C1515981', 'C0851286', 'C2603343', 'C1522326', 'C0444868', 'C1533734', 'C1947908', 'C0039798', 'C3538994']","['Treatment Epoch', 'All', 'Biomaterial Treatment', 'And', 'Treating', 'Administration procedure', 'Study', 'Staff', 'Allocation', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'On Staff', 'Therapeutic procedure', 'Participant']","['idcn', 'acty', 'prog', 'topp', 'popg', 'ftcn', 'cnce', 'resa', 'hlca', 'qnco']"
179,PMC3018567,S62,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,"demographic and clinical details, and blood samples were obtained at screening; stool samples were obtained before enrolment.","['C0015733', 'C0178913', 'C0011298', 'C1515981']","['Demography', 'Feces', 'And', 'Blood specimen']","['bdsu', 'ocdi', 'idcn']"
180,PMC3018567,S63,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Procedures,"after enrolment, women continued to receive standard antenatal care, including haematinics, tetanus immunisation, and intermittent presumptive treatment for malaria twice after their first trimester of pregnancy; women with hiv were offered intrapartum and neonatal single-dose nevirapine for prevention of mother-to-child (vertical) hiv transmission.22","['C3887704', 'C1705169', 'C1948050', 'C0032961', 'C1515981', 'C1521797', 'C2939425', 'C2700409', 'C0039614', 'C0024530', 'C0205267', 'C0043210', 'C0020971', 'C0042196', 'C0026591', 'C0018928', 'C0680063', 'C0039798', 'C3538994', 'C3541306', 'C0178602', 'C0242781', 'C3640893', 'C1442989', 'C0040722', 'C0332257', 'C0305062', 'C0205128', 'C0008059', 'C0019682', 'C2984572', 'C1706420', 'C0205171', 'C2828392', 'C0087136', 'C0087111', 'C0032979', 'C0033052', 'C0199176', 'C1522326', 'C1533734', 'C0021289']","['Woman', 'Vaccination', 'Plasmodium Measurement', 'HIV', 'Biomaterial Treatment', 'And', 'Standard (document)', 'transmission process', 'disease transmission qualifier', 'Immunization', 'prevention aspects', 'Malaria Pathway', 'Infant, Newborn', 'Therapeutic procedure', 'Unmarried', 'Prenatal care', 'Vertical', 'Presumptive', 'Hematinics', 'Administration procedure', 'Pregnancy', 'Intermittent', 'Offspring', 'Pregnancy Trimester, First', 'Dosage', 'Standard (qualifier)', 'Treatment Epoch', 'Malaria', 'Prophylactic treatment', 'Singular', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Twice (Numerical Qualifier)', 'Mother (person)', 'Child', 'Tetanus', 'Prevention Study', 'tetanus toxoid vaccine, inactivated', 'Including (qualifier)', 'disease transmission', 'Treating', 'Neonatal (qualifier value)']","['famg', 'topp', 'fndg', 'qlco', 'virs', ' phsu', 'hlca', 'phsu', 'inpr', 'idcn', 'aggp', 'lbpr', 'patf', 'imft', 'resa', ' aapp', 'npop', 'orgf', 'popg', 'ftcn', 'tmco', 'dsyn', 'cnce', 'spco', 'qnco']"
181,PMC3018567,S64,"['5', '6a']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0]",Procedures,"stool samples were obtained after delivery to assess effectiveness of anthelmintic treatment; thereafter, all mothers received praziquantel and albendazole.","['C1280519', 'C0015733', 'C0003158', 'C1705169', 'C3536838', 'C0011209', 'C0087111', 'C0026591', 'C1148523', 'C3538994', 'C3887704', 'C4553491', 'C1522326', 'C1533734', 'C0444868', 'C0039798', 'C1705822']","['Obstetric Delivery', 'Antihelminthic [EPC]', 'Feces', 'Effectiveness', 'Transfer Technique', 'Treatment Epoch', 'Anthelmintics', 'All', 'Biomaterial Treatment', 'Treating', 'Administration procedure', 'Effectiveness (finding)', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Therapeutic procedure', 'Childbirth', 'Mother (person)']","['famg', 'topp', 'ftcn', 'cnce', 'fndg', 'bdsu', 'qlco', 'resa', 'hlca', 'orgf', 'qnco', 'phsu']"
182,PMC3018567,S65,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Procedures,"infants received bcg and polio immunisation at birth; diphtheria, pertussis, tetanus, haemophilus influenzae, hepatitis b, and polio immunisation at 6, 10, and 14 weeks; and measles immunisation at 9 months.","['C0439231', 'C0005615', 'C0018483', 'C1550722', 'C0021270', 'C0439230', 'C0012546', 'C0020971', 'C1515981', 'C0042196', 'C4552978', 'C1148523', 'C0019163', 'C3245487', 'C0199809']","['Vaccination', 'Poliomyelitis vaccination', 'Infant', 'Diphtheria', 'week', 'And', 'Name Given at Birth', 'month', 'Childbirth', 'Immunization', 'Haemophilus influenzae', 'Hepatitis B', 'Haemophilus influenzae Measurement', 'Entity Name Part Qualifier - birth', 'Birth']","['inpr', 'idcn', 'lbpr', 'aggp', 'topp', 'tmco', 'bact', 'dsyn', 'orgf']"
183,PMC3018567,S66,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,"children also attended the study clinic when unwell; doctors diagnosed, treated, and recorded their illnesses.","['C0008059', 'C0221423', 'C0442592', 'C0011900', 'C2603343', 'C0680063', 'C0031831', 'C0002424']","['Clinic', 'Diagnosis', 'Study', 'Illness (finding)', 'Physicians', 'Offspring', 'Ambulatory Care Facilities', 'Child']","['sosy', 'aggp', 'famg', 'prog', 'mnob', 'diap', 'resa', ' hcro']"
184,PMC3018567,S67,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"community fieldworkers visited each participant's home twice a month, measured the child's temperature, and recorded symptoms reported by the child's carer.","['C0008059', 'C4554048', 'C0679646', 'C0683368', 'C0439231', 'C1457900', 'C1709908', 'C0332177', 'C1948050', 'C2698741', 'C1515981', 'C1457887', 'C0680063', 'C0009462', 'C0005903', 'C0039476', 'C0442519']","['Twice (Numerical Qualifier)', 'Reported By', 'Study Participant', 'Body Temperature', 'Home environment', 'And', 'Temperature', 'month', 'Participant', 'Monthly (qualifier value)', 'Offspring', 'Participant Object', 'Symptoms aspect', 'Each (qualifier value)', 'Symptoms', 'Community', 'Child']","['sosy', 'grup', 'idcn', 'aggp', 'famg', 'clas', 'popg', 'ftcn', 'spco', 'tmco', 'qnco', 'orga']"
185,PMC3018567,S68,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"at age 12 months, blood and stool samples were obtained from the children and growth outcomes were measured.","['C0008059', 'C0220844', 'C2911660', 'C0015733', 'C0439231', 'C0005767', 'C0001779', 'C0229664', 'C1515981', 'C0018270', 'C0680063', 'C0005768', 'C1621966']","['Feces', 'In Blood', 'Blood', 'Tissue Growth', 'growth aspects', 'And', 'Age', 'month', 'Growth', 'Growth action', 'Offspring', 'peripheral blood', 'Child']","['ortf', 'phpr', 'idcn', 'aggp', 'phsf', 'famg', 'bdsu', 'tmco', 'orgf', 'orga']"
186,PMC3018567,S69,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,children who were unwell at their 12-month visit were given appropriate treatment and asked to return to complete the visit procedures when well.,"['C0008059', 'C3538935', 'C0184661', 'C0439231', 'C2826704', 'C1512346', 'C0545082', 'C3640049', 'C0332177', 'C1515981', 'C2700391', 'C0025664', 'C0680063', 'C0205170', 'C3146287', 'C3272598', 'C4283957']","['Procedure (set of actions)', 'Appropriate Treatment', 'Microplate Well', 'Visit', 'WHO Temperature/Humidity Storage Condition', 'Patient Visit', 'And', 'Visit Name', 'Methods aspects', 'Good', 'month', 'Monthly (qualifier value)', 'Offspring', 'Well', 'Interventional procedure', 'Procedure Domain', 'Child']","['inpr', 'clna', 'idcn', 'aggp', 'famg', 'topp', 'ftcn', 'spco', 'mnob', 'qlco', 'tmco', 'bhvr', 'hlca']"
187,PMC3018567,S70,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"the primary outcomes were immune response at age 1 year to bcg, tetanus, and measles immunisation; incidence of malaria, diarrhoea, pneumonia, measles, and tuberculosis during infancy as diagnosed by doctors at the study clinic; and vertical hiv transmission.18","['C0025007', 'C1515981', 'C1521797', 'C0024530', 'C0039614', 'C0231330', 'C0041296', 'C0020971', 'C0042196', 'C2603343', 'C0031831', 'C0002424', 'C3541306', 'C0442592', 'C0242781', 'C0040722', 'C0301872', 'C0205225', 'C0305062', 'C0205128', 'C0439234', 'C0019682', 'C0021149', 'C2984572', 'C0032285', 'C0220856', 'C0001779']","['Vaccination', 'Plasmodium Measurement', 'HIV', 'And', 'transmission process', 'disease transmission qualifier', 'Immunization', 'Malaria Pathway', 'Pneumonia', 'Vertical', 'Clinic', 'Incidence', 'Age', 'Tuberculosis', 'Immune response', 'Malaria', 'Study', 'Infancy', 'year', 'Ambulatory Care Facilities', 'Measles', 'incidence of cases', 'Tetanus', 'tetanus toxoid vaccine, inactivated', 'disease transmission', 'Physicians', 'Primary']","['ortf', 'topp', 'mnob', 'qlco', 'virs', ' phsu', ' hcro', 'idcn', 'lbpr', 'prog', 'patf', 'imft', 'resa', ' aapp', 'npop', 'ftcn', 'tmco', 'dsyn', 'spco', 'qnco', 'orga']"
188,PMC3018567,S71,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,planned secondary outcomes were growth and anaemia at age 1 year.,"['C0175668', 'C0220844', 'C2911660', 'C0205436', 'C0001779', 'C1515981', 'C0027627', 'C0018270', 'C1301732', 'C0002871', 'C1621966', 'C0439234']","['Neoplasm Metastasis', 'second (number)', 'Tissue Growth', 'Planned', 'growth aspects', 'And', 'Age', 'Growth', 'Secondary to', 'year', 'Anemia', 'Growth action']","['ortf', 'phpr', 'idcn', 'phsf', 'neop', 'ftcn', 'qlco', 'tmco', 'dsyn', 'orgf', 'qnco', 'orga']"
189,PMC3018567,S72,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,community-reported data for illness events were included as a secondary outcome for comparison with doctor-diagnosed illness events from clinic visits.,"['C3541888', 'C1511726', 'C1274040', 'C0205436', 'C0221423', 'C3245479', 'C0441471', 'C0008952', 'C0027627', 'C0011900', 'C0009462', 'C1707455', 'C3714741', 'C0031831', 'C0175668', 'C2348314']","['Neoplasm Metastasis', 'Data (eukaryote)', 'CDISC Events Class', 'Clinic Visits', 'second (number)', 'Data call receiving device', 'Diagnosis', 'Comparison', 'Illness (finding)', 'Physicians', 'Doctor - Title', 'Secondary to', 'Data', 'Result', 'Community', 'Event']","['sosy', 'grup', 'idcn', 'acty', 'clas', 'prog', 'neop', 'medd', 'ftcn', 'cnce', 'qlco', 'euka', 'hlca', 'diap', 'qnco', 'evnt']"
190,PMC3018567,S73,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,we also considered two additional unplanned secondary outcomes: infant mortality and asymptomatic malaria (presence of malaria parasitaemia) at 1 year of age.,"['C3541306', 'C0439234', 'C2984572', 'C0205436', 'C0150312', 'C4698437', 'C0001779', 'C0392148', 'C0231221', 'C1515981', 'C0027627', 'C0021278', 'C0205448', 'C1524062', 'C0175668', 'C0024530']","['year', 'Neoplasm Metastasis', 'Plasmodium Measurement', 'second (number)', 'Malaria', 'Additional', 'And', 'Present', 'Age', 'Providing presence (regime/therapy)', 'Unplanned', 'Two', 'Malaria Pathway', 'Infant Mortality', 'symptomless', 'Secondary to']","['idcn', 'lbpr', 'topp', 'neop', 'ftcn', 'fndg', 'qlco', 'tmco', 'dsyn', 'qnco', 'orga']"
191,PMC3018567,S74,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,cytokine responses at 1 year of age to crude culture filtrate proteins of mycobacterium tuberculosis (ccfp) were measured as an indicator of response to bcg immunisation.,"['C0026926', 'C1704632', 'C0199804', 'C0079189', 'C0439234', 'C0430400', 'C4317078', 'C2242979', 'C0001779', 'C1235732', 'C1706817', 'C1522602', 'C0021212', 'C0220814', 'C2911692', 'C0010453', 'C0033684', 'C0871261']","['Response process', 'Microbial culture (procedure)', 'Disease Response', 'Mycobacterium tuberculosis', 'Proteins', 'Anthropological Culture', 'Response (communication)', 'Age', 'Indicators', 'Response (statement)', 'Cultural aspects', 'Indicator', 'Mycobacterium Tuberculosis Measurement', 'Vaccination against tuberculosis', 'year', 'Indicator bird', 'cytokine', 'Laboratory culture']","['bacs', 'inpr', 'idcn', 'bird', 'lbpr', 'topp', 'irda', 'ftcn', 'fndg', 'tmco', 'bact', 'imft', 'menp', ' aapp', 'orga']"
192,PMC3018567,S75,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,cytokine responses at age 1 year to tetanus toxoid were measured as an indicator of response to tetanus immunisation.,"['C1704632', 'C0079189', 'C0439234', 'C0305062', 'C3541902', 'C1235732', 'C0020971', 'C0042196', 'C0039614', 'C1706817', 'C1522602', 'C0021212', 'C2911692', 'C0001779', 'C0444706', 'C0871261']","['Response process', 'Measured', 'Vaccination', 'Tetanus', 'Disease Response', 'tetanus toxoid vaccine, inactivated', 'Measured Tumor Identification', 'Response (communication)', 'Age', 'Indicators', 'Response (statement)', 'Indicator', 'Immunization', 'year', 'Indicator bird', 'cytokine']","['inpr', 'bird', 'topp', 'irda', 'ftcn', 'fndg', 'qlco', 'imft', 'tmco', ' phsu', 'menp', ' aapp', 'diap', 'orga', 'dsyn']"
193,PMC3018567,S76,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"we examined stimulated interferon-γ (type 1), interleukin-5 (type 2), interleukin-13 (type 2), and interleukin-10 (regulatory) responses in a whole-blood assay, as previously described.23","['C0441729', 'C0021759', 'C1699802', 'C1515981', 'C0243073', 'C0220905', 'C1702088', 'C4085652', 'C0229664', 'C0441730', 'C1704735', 'C0214743', 'C0444667', 'C0005767', 'C1522550', 'C0085295', 'C1510438', 'C0005768', 'C2983956', 'C4085651', 'C0005507', 'C1334121', 'C0871261']","['Assay', 'assay qualifier', 'In Blood', 'And', 'IL5 gene', 'Whole', 'Type 1', 'IL10 protein, human', 'Blood', 'Interleukin-10', 'Regulator', 'Bristol Stool Type 2', 'Recombinant Interleukin-10', 'Biological Assay', 'Interleukin-5', 'Type 2', 'Interleukin-13', 'regulatory', 'IL5 protein, human', 'Response process', 'Human Interleukin-10 (Nonglycosylated)', 'Bristol Stool Type 1', 'peripheral blood']","['bacs', 'rnlw', 'idcn', 'lbpr', 'gngm', 'clas', 'fndg', 'cnce', 'bdsu', 'imft', 'qlco', ' phsu', ' aapp', 'qnco', 'orga']"
194,PMC3018567,S77,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"total serum igg, igg4, and ige responses to tetanus toxoid were measured by elisa (webappendix p 1).","['C2828357', 'C0439810', 'C1515981', 'C0229671', 'C4049862', 'C0020860', 'C1546774', 'C0871261', 'C0014441', 'C1550100', 'C0305062']","['Response process', 'Enzyme-Linked Immunosorbent Assay', 'tetanus toxoid vaccine, inactivated', 'And', 'Specimen Type - Serum', 'IgG4 immunoglobulin complex', 'Serum', 'Total', 'Immunoglobulin IgG4', 'Specimen Source Codes - Serum', 'Immunoglobulin G Subclass 4 Measurement']","['inpr', 'idcn', 'lbpr', 'celc', 'bdsu', 'imft', 'qlco', ' phsu', ' aapp', 'orga']"
195,PMC3018567,S78,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"total serum measles-specific igg was measured by elisa (dade behring/siemens, eschborn, germany) according to the manufacturer's protocol.","['C3715209', 'C0947322', 'C0205369', 'C0017480', 'C4282383', 'C0025007', 'C0439810', 'C0229671', 'C0046889', 'C1546774', 'C2599718', 'C1522729', 'C1507394', 'C0442711', 'C0014441', 'C1550100', 'C2348563', 'C1551054', 'C1552740']","['Manufacturer Name', 'Protocol - answer to question', 'Entity Determiner - specific', 'Enzyme-Linked Immunosorbent Assay', 'Clinical trial protocol', 'REMS Protocol', 'Specific qualifier value', 'Specimen Type - Serum', 'Clinical trial protocol document', 'Units Of Measure - Siemens', ""3,3'-diallyldiethylstilbestrol"", 'Serum', 'Protocols documentation', 'Study Protocol', 'Germany', 'Total', 'Library Protocol', 'Specimen Source Codes - Serum', 'Measles']","['inpr', 'geoa', 'lbpr', 'fndg', 'bdsu', 'orch', 'qlco', 'dsyn', 'qnco']"
196,PMC3018567,S79,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"immunological assays were done after all samples had been obtained, in a randomised sequence (by use of a computer-generated random number sequence), to avoid confounding of secular trends with variations in assay performance.","['C0243073', 'C0009622', 'C0439605', 'C0205419', 'C0237753', 'C0681685', 'C1519249', 'C0034656', 'C3853789', 'C0004793', 'C1510438', 'C0042153', 'C0457083', 'C0449788', 'C0444868', 'C0597198', 'C0162327', 'C1882330', 'C0005507', 'C0162326']","['Sequence - TransmissionRelationshipTypeCode', 'Assay', 'Base Sequence', 'Count of entities', 'Biological Assay', 'Randomization', 'assay qualifier', 'secular trend', 'Computers', 'DNA Sequence', 'All', 'Random', 'Numbers', 'utilization qualifier', 'RNA Sequence', 'performance - action', 'Performance', 'Sequence', 'Usage', 'Variant']","['inpr', 'nusq', 'inbe', 'lbpr', 'acty', 'ftcn', 'mnob', 'qlco', 'tmco', 'resa', 'qnco']"
197,PMC3018567,S80,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"for the primary outcome, doctor-diagnosed illness events, clinical malaria was fever (temperature ≥37·5°c) with parasitaemia; diarrhoea was an infant's carer's definition, with stool frequency recorded;24 pneumonia was cough with difficulty in breathing, and age-specific fast breathing;25 measles was defined by standard clinical criteria and confirmed by measurement of specific antibody;26 and children with suspected tuberculosis were investigated as clinically indicated.27","['C0424755', 'C1160636', 'C0242485', 'C0025007', 'C1515981', 'C0005903', 'C1704788', 'C4084725', 'C0024530', 'C0376249', 'C1274040', 'C1561548', 'C0041296', 'C0015733', 'C0871396', 'C0021270', 'C0441471', 'C0035203', 'C0205210', 'C0010200', 'C0231835', 'C0680063', 'C3888054', 'C0031831', 'C0015967', 'C0004048', 'C1552740', 'C4084726', 'C3541306', 'C3541888', 'C0221423', 'C3898838', 'C0205369', 'C1705502', 'C0243161', 'C0443640', 'C1442989', 'C0205225', 'C4084727', 'C0011900', 'C4321352', 'C4084858', 'C0439603', 'C0008059', 'C1299586', 'C0750491', 'C2984572', 'C2828392', 'C1550452', 'C3274924', 'C0032285', 'C4552740', 'C0039476', 'C1961131', 'C0001779', 'C0011991', 'C2348314']","['Feces', 'Plasmodium Measurement', 'specific antibody', 'Body Temperature', 'Infant', 'CDISC Events Class', 'Specific qualifier value', 'Usual Severity Cough', 'And', 'Standard (document)', 'Cough, CTCAE', 'Malaria Pathway', 'Result', 'Pneumonia', 'Fever, CTCAE', 'Fever symptoms (finding)', 'respiratory gaseous exchange in organisms', 'Diagnosis', 'Tachypnea', 'Age', 'Frequencies (time pattern)', 'Kind of quantity - Frequency', 'Offspring', 'criteria', 'Breathing Distress Question', 'Standard (qualifier)', 'Measurement', 'Event', 'Tuberculosis', 'Clinical', 'DEFINITION - NCI Thesaurus Property', 'Entity Determiner - specific', 'Statistical Frequency', 'Malaria', 'Have Been Coughing', 'Doctor - Title', 'Frequency', 'Inspiration function', 'How Much Distress Cough', 'Suspected qualifier', 'Measles', 'Child', 'Fever', 'Respiration', 'Spatial Frequency', 'Definition', 'Temperature', 'Illness (finding)', 'With frequency', 'Diarrhea', 'Coughing', 'Has difficulty doing (qualifier value)', 'Physicians', 'definition - ActMoodCompletionTrack', 'How Often', 'Primary', 'Cough Frequency']","['famg', 'biof', 'fndg', 'qlco', 'bdsu', 'diap', 'inpr', 'idcn', 'aggp', 'lbpr', 'clas', 'prog', 'imft', ' aapp', 'orgf', 'sosy', 'phsf', 'ftcn', 'tmco', 'dsyn', 'cnce', 'qnco', 'orga', 'evnt']"
198,PMC3018567,S81,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"for the secondary outcome, community-reported illnesses, febrile illness was defined as measured by fieldworkers (temperature ≥37·5°c) or as reported by the child's carer; diarrhoea as reported by the carer, with stool frequency recorded; presumptive pneumonia was cough with difficulty in breathing, or age-specific fast breathing as measured by fieldworkers.","['C0684224', 'C0205436', 'C1160636', 'C4319718', 'C0027627', 'C1565156', 'C0005903', 'C1704788', 'C1709908', 'C4084725', 'C0376249', 'C1274040', 'C1561548', 'C0015733', 'C0871396', 'C0035203', 'C0085537', 'C0010200', 'C0231835', 'C0680063', 'C0043194', 'C0004048', 'C1552740', 'C0444706', 'C4084726', 'C0221423', 'C3898838', 'C3541902', 'C0205369', 'C1705502', 'C3640893', 'C4084727', 'C4321352', 'C0009462', 'C4084858', 'C0700287', 'C0439603', 'C0008059', 'C1299586', 'C0001779', 'C3274924', 'C1305660', 'C0032285', 'C1421478', 'C0743841', 'C0039476', 'C1961131', 'C0175668', 'C0011991']","['Feces', 'Reported By', 'Body Temperature', 'Measured Tumor Identification', 'Reporting', 'Specific qualifier value', 'Usual Severity Cough', 'Cough, CTCAE', 'Secondary to', 'Reported', 'Pneumonia', 'Result', 'Presumptive', 'WAS protein, human', 'respiratory gaseous exchange in organisms', 'Carer (occupation)', 'WAS gene', 'Age', 'Tachypnea', 'Frequencies (time pattern)', 'Kind of quantity - Frequency', 'Offspring', 'Breathing Distress Question', 'Community', 'Entity Determiner - specific', 'Statistical Frequency', 'Have Been Coughing', 'Frequency', 'Inspiration function', 'How Much Distress Cough', 'Child', 'Measured', 'Neoplasm Metastasis', 'Report (document)', 'Respiration', 'second (number)', 'Spatial Frequency', 'Caregiver', 'Wiskott-Aldrich Syndrome', 'Definition', 'Temperature', 'Illness (finding)', 'With frequency', 'Diarrhea', 'Coughing', 'Febrile illness', 'Has difficulty doing (qualifier value)', 'How Often', 'Cough Frequency']","['bacs', 'famg', 'biof', 'neop', 'fndg', 'qlco', 'bdsu', 'hlca', 'diap', 'inpr', 'aggp', 'gngm', 'prog', ' aapp', 'orgf', 'sosy', 'phsf', 'ftcn', 'tmco', 'dsyn', 'grup', 'qnco', 'orga']"
199,PMC3018567,S82,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"stool samples were examined for helminth ova with the kato-katz method28 and by charcoal culture for strongyloides sterocoralis infection;29 two kato-katz slides were prepared from each sample and examined for hookworm ova within 30 mins of preparation, or examined the next day for other species.","['C0430400', 'C0007955', 'C0444330', 'C1515981', 'C0002830', 'C1265425', 'C1551914', 'C0010453', 'C0015733', 'C2242979', 'C1521827', 'C1883708', 'C1705920', 'C0721226', 'C0038461', 'C1457900', 'C0332173', 'C0220814', 'C0205448', 'C0439228', 'C0332282', 'C3812761', 'C3714514', 'C0205117', 'C0029974', 'C0370003', 'C2347026']","['Feces', 'Biospecimen', 'day', 'Anthropological Culture', 'And', 'Adjacent', 'Species', 'Charcoal', 'Prepared Material', 'Laboratory culture', 'Ancylostomatoidea', 'Then', 'Following', 'Each (qualifier value)', 'Slide (glass microscope)', 'Daily', 'Preparation', 'Cultural aspects', 'Two', 'Specimen', 'Cahto language', 'Ovum', 'Hookworms', 'Microbial culture (procedure)', 'Strongyloides', 'Kato', 'Infection']","['sbst', 'idcn', 'inch', 'lbpr', 'acty', 'elii', 'clas', 'ftcn', 'spco', 'patf', 'bdsu', 'euka', 'cnce', 'tmco', 'resd', ' phsu', 'lang', 'cell', 'qnco']"
200,PMC3018567,S83,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"hookworm and schistosoma mansoni infections were classified into low, medium, and high intensities according to who guidelines.30","['C4522209', 'C1299351', 'C0205250', 'C1515981', 'C0002830', 'C1265425', 'C3890211', 'C1550472', 'C4522223', 'C3889660', 'C0009458', 'C0162791', 'C4321237', 'C3887512', 'C1705217', 'C0439536', 'C0220845', 'C4085196', 'C4049786', 'C3244283', 'C4522282', 'C4048187', 'C4321351', 'C0282423', 'C0522510', 'C4522283', 'C0205251', 'C2700149', 'C3714514', 'C3272598', 'C0036319']","['A Medium Amount', 'And', 'Abnormally high', 'With intensity', 'Medium Growth Rate', 'High Level', 'IPSS Risk Category Low', 'high - ActExposureLevelCode', 'Low Mitosis-Karyorrhexis Index', 'low confidentiality', 'Ancylostomatoidea', 'Communications Media', 'guiding characteristics', 'High Mitosis-Karyorrhexis Index', 'low', 'Medium', 'WHO Temperature/Humidity Storage Condition', 'Value Above Reference Range', 'IPSS Risk Category High', 'A Medium Amount of Time', 'low exposure', 'Medium (Substance)', 'medium exposure', 'Hookworms', 'Guideline [Publication Type]', 'Schistosoma mansoni', 'High', 'Low Level', 'Guidelines', 'Infection', 'Intensities']","['inpr', 'idcn', 'clas', 'fndg', 'patf', 'qlco', 'euka', 'cnce', 'sbst', 'qnco']"
201,PMC3018567,S84,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,blood samples were examined by a modified knott's method for mansonella perstans31 and by thick film for malaria parasites.,"['C3541306', 'C0871511', 'C0178913', 'C2984572', 'C0392747', 'C0030498', 'C0521066', 'C4050301', 'C0449851', 'C0024756', 'C1441758', 'C1515981', 'C3889737', 'C0025663', 'C0024530']","['Data Change Date', 'Test Method', 'parasitic', 'Plasmodium Measurement', 'Changing', 'Malaria', 'Thick film procedure', 'Methods', 'Techniques', 'And', 'Mansonella', 'Parasites', 'Parasite Present', 'Blood specimen', 'Malaria Pathway']","['inpr', 'idcn', 'lbpr', 'ftcn', 'fndg', 'bdsu', 'euka', 'tmco', 'dsyn']"
202,PMC3018567,S85,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"haemoglobin was estimated by coulter analyser (beckman coulter, nyon, switzerland).","['C0179038', 'C0019046', 'C0039021']","['Analyzer, device', 'Switzerland', 'Hemoglobin']","[' aapp', 'mnob', 'bacs', 'geoa']"
203,PMC3018567,S86,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"quality control for kato-katz analyses was provided by the vector control programme of the ministry of health, uganda, and for haematology and malaria parasitology through the uk national external quality assessment schemes.","['C1261322', 'C0332306', 'C0018684', 'C1515981', 'C4321252', 'C1551914', 'C1561524', 'C1550549', 'C0024530', 'C0721226', 'C3245503', 'C0041573', 'C3541306', 'C0205101', 'C0521125', 'C0332273', 'C2984572', 'C0031249', 'C0034378', 'C2239174', 'C1610034', 'C1516048', 'C0030504']","['Extrinsic', 'Plasmodium Measurement', 'Evaluation procedure', 'And', 'Through', 'Preposition For', 'National citizen', 'Uganda', 'WWOX wt Allele', 'Malaria Pathway', 'Pest Control', 'Specimen Source Codes - Quality Control', 'Parasitology - branch of biology', 'parasitology', 'Quality Control Specimen', 'Malaria', 'with quality', 'quality control', 'Act Relationship Checkpoint - through', 'Cahto language', 'Kato', 'Health', 'Assessed']","['inpr', 'geoa', 'idcn', 'lbpr', 'acty', 'ocdi', 'inch', 'ocac', 'popg', 'gngm', 'ftcn', 'spco', 'qlco', 'hlca', ' phsu', 'dsyn', 'lang']"
204,PMC3018567,S87,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,mothers' hiv serology was done by rapid test algorithm.30,"['C0019682', 'C0036745', 'C1553907', 'C0026591', 'C0002045', 'C0699835', 'C0086890', 'C0220911']","['Quick Test of Performance Intelligence', 'HIV', 'Serological aspects', 'algorithm', 'Observation Method - algorithm', 'Study of serum', 'Quick Test for Liver Function', 'Mother (person)']","['bmod', 'inpr', ' diap', 'lbpr', 'famg', 'ftcn', 'virs']"
205,PMC3018567,S88,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,blood was obtained from cord and at 6 weeks of age from infants of mothers with hiv for assessment of vertical hiv transmission.,"['C0205128', 'C0019682', 'C1261322', 'C0005767', 'C0021270', 'C1516048', 'C0242781', 'C0229664', 'C1550235', 'C0026591', 'C1706500', 'C0439230', 'C0040722', 'C1521797', 'C0005768', 'C3489532', 'C0001779']","['Vertical', 'Assessed', 'Infant', 'HIV', 'Blood', 'In Blood', 'Cone-Rod Dystrophy 2', 'Evaluation procedure', 'disease transmission', 'Age', 'week', 'transmission process', 'disease transmission qualifier', 'Mother (person)', 'peripheral blood', 'Device Cord', 'Cord - Body Parts']","['bpoc', 'idcn', 'aggp', 'acty', 'famg', 'mnob', 'patf', 'bdsu', 'virs', 'spco', 'tmco', 'dsyn', 'hlca', 'npop', 'orga']"
206,PMC3018567,S89,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,plasma and whole blood cell pellet were separated by centrifugation and stored at −80°c until assays were done.,"['C0370231', 'C3831156', 'C4521445', 'C0005773', 'C0007703', 'C0229664', 'C1515981', 'C1608383', 'C0032105']","['Centrifugation', 'Plasma Product', 'And', 'Plasma', 'Blood Cells', 'whole blood', 'whole blood specimen', 'peripheral blood', 'Cell Pellet']","['idcn', 'lbpr', 'bdsu', 'cell', 'phsu']"
207,PMC3018567,S90,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"for detection of hiv-1 proviral dna in infants at 6 weeks, dna was extracted from stored whole blood cell pellets and amplified by nested pcr of three conserved viral regions, tat, gp41, and nef (webappendix p 1).","['C0370231', 'C0019682', 'C0993610', 'C0012854', 'C0021270', 'C0439230', 'C0205449', 'C0005773', 'C0229664', 'C1515981', 'C3273837', 'C3897364', 'C1511790', 'C4521340', 'C0242574', 'C3820394', 'C0521026', 'C1698986', 'C1608383']","['Storage', 'DNA', 'Deoxyribonucleic Acid Measurement', 'HIV', 'Infant', 'Nested Polymerase Chain Reaction', 'Detection', 'And', 'Oral Pellet', 'S100B wt Allele', 'Thermoacoustic Computed Tomography', 'Viral', 'week', 'whole blood', 'Blood Cells', 'Three', 'Thrombin to Antithrombin Ratio Measurement', 'whole blood specimen', 'peripheral blood']","['bacs', 'idcn', 'lbpr', 'aggp', 'gngm', 'qnco', ' nnon', 'topp', 'mbrt', 'ftcn', 'bdsu', 'virs', 'tmco', 'cell', 'diap', 'bodm']"
208,PMC3018567,S91,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"for both cord and 6-week samples, plasma hiv load was measured with bayer versant branched dna assay version 3.0 (bayer, leverkusen, germany) or roche amplicor hiv-1 rna monitor test version 1.5 (roche, nj, usa).","['C0041703', 'C0035668', 'C0017480', 'C0150369', 'C1515981', 'C0331965', 'C4318744', 'C0032105', 'C0243073', 'C0012854', 'C0439230', 'C4521445', 'C1550235', 'C4319105', 'C1521743', 'C4521340', 'C0596972', 'C0019704', 'C1708715', 'C0181904', 'C3489532', 'C1515976', 'C1704782', 'C0333052', 'C1550025', 'C3831328', 'C0022885', 'C0019682', 'C1706086', 'C0030695', 'C1706500', 'C1510438', 'C0456984', 'C0392366', 'C0039593', 'C0005507']","['Assay', 'assay qualifier', 'DNA', 'Load - Remote control command', 'Preventive monitoring', 'Monitor Device', 'Deoxyribonucleic Acid Measurement', 'HIV', 'Laboratory Procedures', 'Both', 'Plasma Product', 'And', 'Cone-Rod Dystrophy 2', 'HIV-1', 'roche', 'Germany', 'Monitoring Device', 'Test - temporal region', 'Device Cord', 'Cord - Body Parts', 'Ribonucleic Acid Measurement', 'Monitor, occupation', 'Tests (qualifier value)', 'Testing', 'Test Result', 'Biological Assay', 'week', 'Anatomic Structure, System, or Substance', 'Blood Products Laboratory Testing', 'Load Component of Device', 'Plasma', 'United States', 'Version', 'Patient Monitoring', 'Loading Technique', 'RNA']","['bacs', 'medd', 'mnob', 'bdsu', 'virs', 'qlco', 'hlca', 'phsu', 'inpr', 'bpoc', 'geoa', 'idcn', 'lbpr', 'clas', 'prog', 'lbtr', ' nnon', 'ftcn', 'blor', 'tmco', 'dsyn', 'hcro', 'nnon', 'acty']"
209,PMC3018567,S92,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"infants were regarded as being hiv positive if the 6-week sample had a positive dna pcr for any of the viral regions and a viral load of 1000 copies per ml or more; for four infants, only viral load data were available, so they were used to establish hiv status.","['C3812269', 'C1511726', 'C2709249', 'C1515981', 'C1948062', 'C4321252', 'C0470187', 'C4050242', 'C1261478', 'C3714741', 'C0012854', 'C0021270', 'C3272371', 'C0439230', 'C4521340', 'C1552551', 'C0205172', 'C0062074', 'C0521026', 'C0032520', 'C0205450', 'C0376705', 'C0521125', 'C1514241', 'C3539897', 'C3245479', 'C2825490', 'C0205171', 'C1415458', 'C0458074', 'C1446409', 'C0370003', 'C2347026']","['DNA', 'Positive', 'Biospecimen', 'Infant', 'Viral load measurement', 'Deoxyribonucleic Acid Measurement', 'Viral', 'And', 'Data call receiving device', 'Preposition For', 'Have', 'WWOX wt Allele', 'Four', 'HADH gene', 'Pathologic Complete Response', 'Any Data Type', 'Positive Charge', 'human immunodeficiency virus status:History:Point in time:^Patient:Nominal', 'Positive Number', 'Any', 'Positive Finding', 'availability of', 'week', 'Singular', 'Human immunodeficiency virus (HIV) status', 'Copy (object)', 'Data', 'Polymerase Chain Reaction', 'Viral Load result', 'Specimen', 'More', 'HAC protocol', 'Data (eukaryote)']","['bacs', 'inpr', 'clna', 'idcn', 'lbpr', 'aggp', 'gngm', ' nnon', 'medd', 'topp', 'mbrt', 'fndg', 'cnce', 'qlco', 'mnob', 'euka', 'ftcn', 'tmco', 'sbst', 'qnco']"
210,PMC3018567,S93,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,"viral load and dna-pcr results were concordant apart from one infant (viral load 6699 copies per ml, pcr negative) who was seronegative by rapid test algorithm at age 18 months and was classified as hiv negative.","['C2825491', 'C0439231', 'C1553907', 'C1513916', 'C1515981', 'C1948062', 'C0699835', 'C4050242', 'C1261478', 'C0012854', 'C0021270', 'C4553529', 'C0205447', 'C2825415', 'C4521340', 'C0086890', 'C0205160', 'C0032520', 'C0376705', 'C1517320', 'C3853545', 'C0439526', 'C0481430', 'C0002045', 'C3272598', 'C0001779']","['DNA', 'Deoxyribonucleic Acid Measurement', 'Viral load measurement', 'Infant', 'And', 'month', 'Negative Finding', 'From', 'Negative - answer', 'Negative Number', 'Negative', 'Quick Test for Liver Function', 'Quick Test of Performance Intelligence', 'Pathologic Complete Response', 'Age', 'Observation Method - algorithm', 'WHO Temperature/Humidity Storage Condition', 'algorithm', 'Copy (object)', 'Polymerase Chain Reaction', 'Viral Load result', 'One', 'per milliliter', 'Concordance', 'HIV negative finding', 'Negative Charge']","['bacs', 'inpr', ' diap', 'idcn', 'lbpr', 'aggp', ' nnon', 'mbrt', 'fndg', 'ftcn', 'qlco', 'mnob', 'cnce', 'tmco', 'qnco', 'orga']"
211,PMC3018567,S94,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"in infants with hiv infection, transmission was regarded as likely to have been intrauterine if the viral load in cord blood was 1000 copies per ml or more.","['C0332148', 'C0205172', 'C0021270', 'C0242781', 'C1948062', 'C1546555', 'C0162371', 'C0040722', 'C1521797', 'C0750492', 'C1261478', 'C0376705', 'C0019693']","['HIV Infections', 'Infant', 'Viral load measurement', 'Umbilical Cord Blood', 'More', 'disease transmission', 'transmission process', 'Probably', 'Copy (object)', 'disease transmission qualifier', 'Viral Load result', 'Probable diagnosis', 'Specimen Source Codes - Cord blood']","['inpr', 'idcn', 'lbpr', 'aggp', 'fndg', 'patf', 'bdsu', 'mnob', 'dsyn', 'npop', 'qnco']"
212,PMC3018567,S96,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,analysis was done after all children were older than 15 months.,"['C0008059', 'C0439231', 'C0936012', 'C1524024', 'C0680063', 'C0444868']","['All', 'month', 'Analysis', 'Offspring', 'analysis aspect', 'Child']","['aggp', 'famg', 'ftcn', 'tmco', 'resa', 'qnco']"
213,PMC3018567,S97,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"data for samples and measurements obtained at routine, 1-year visits were included if the child attended within 2 months after their first birthday.","['C0008059', 'C1511726', 'C0439234', 'C1442456', 'C3245479', 'C1512346', 'C0545082', 'C0242485', 'C1515981', 'C1279901', 'C0680063', 'C3714741', 'C0205435', 'C0205547']","['2 Months', 'Firstly', 'Routine', 'Visit', 'Patient Visit', 'And', 'Data call receiving device', 'First (number)', 'Offspring', 'Data (eukaryote)', 'Data', 'year', 'Measurement', 'Child']","['idcn', 'aggp', 'famg', 'medd', 'ftcn', 'qlco', 'euka', 'tmco', 'bhvr', 'hlca', 'qnco']"
214,PMC3018567,S98,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,data for illness events and mortality were censored strictly at 1 year.,"['C1511726', 'C3541888', 'C0026565', 'C0026566', 'C0221423', 'C3245479', 'C0441471', 'C1515981', 'C3714741', 'C0439234']","['CDISC Events Class', 'Aspects of mortality statistics', 'And', 'Data call receiving device', 'Illness (finding)', 'Data (eukaryote)', 'Data', 'Mortality Vital Statistics', 'year', 'Event']","['sosy', 'idcn', 'clas', 'medd', 'tmco', 'euka', 'qnco', 'evnt']"
215,PMC3018567,S99,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,results for younger twins were excluded from all analyses.,"['C0041427', 'C0444868']","['Twin sibling (person)', 'All']","['famg', 'qnco']"
216,PMC3028347,S100,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis.,"bmi z change (or change in each secondary outcome variable) was the dependent variable; metformin treatment was the independent variable; and age, sex, and race/ethnicity were covariates.","['C1705241', 'C0036864', 'C0871711', 'C0013675', 'C0439828', 'C0009253', 'C4553760', 'C3538994', 'C1706779', 'C0243103', 'C0392747', 'C1533734', 'C0443172', 'C0087111', 'C0034510', 'C3887704', 'C1522384', 'C1705169', 'C1457900', 'C0039798', 'C0205436', 'C0085862', 'C0804628', 'C0025598', 'C0175668', 'C4319952', 'C0027627', 'C0079399', 'C1522326', 'C0015031', 'C0578022', 'C1515981', 'C1290940', 'C3853635', 'C1299583', 'C0001779', 'C1274040']","['Age', 'Dependent Variable', 'Each (qualifier value)', 'And', 'Independent for Transfer', 'Metformin', 'Gender:Type:Point in time:^Patient:Nominal', 'Independence', 'Ethnicity aspects', 'sex', 'Race', 'Sex Behavior', 'Racial group', 'Variable (uniformity)', 'second (number)', 'Treatment Epoch', 'Changed status', 'Biomaterial Treatment', 'Administration procedure', 'Result', 'Coitus', 'Neoplasm Metastasis', 'Changing', 'Finding of body mass index', 'Ethnic group', 'Independently able', 'AMACR wt Allele', 'Change -- procedure', 'Study Variable', 'Gender', 'treatment - ActInformationManagementReason', 'Treating', 'Secondary to', 'Effect Modifier, Epidemiologic', 'therapeutic aspects', 'Delta (difference)', 'Therapeutic procedure']","['fndg', 'resa', 'gngm', 'topp', 'idcn', 'hlca', 'inpr', 'orch', 'qlco', 'qnco', 'orga', 'bhvr', 'orgf', ' phsu', 'ftcn', 'neop', 'popg', 'cnce', 'clna']"
217,PMC3028347,S101,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis.,we then combined the coefficients from analyses of the 20 imputed datasets into a single set of estimates according to rubin’s rules for scalar estimands.,"['C1710017', 'C1705195', 'C0036849', 'C0087136', 'C0750572', 'C2699638', 'C1883708', 'C0870077', 'C1442518', 'C1517320', 'C0205171']","['Scalar', 'set (group)', 'Set (Psychology)', 'Estimated', 'Rule (guideline)', 'Singular', 'Statistical Imputation', 'From', 'Then', 'Set scale', 'Unmarried']","['tmco', 'fndg', 'inpr', 'qnco', 'qlco', 'ftcn', 'menp', 'cnce']"
218,PMC3028347,S102,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis.,"to assess sensitivity of the results to the missing-at-random assumption, we conducted three additional analyses: assuming that all participants who withdrew from the study had major weight gain (≥2.27 kg [≥5 lb]); that those who received metformin had no weight gain, whereas those who received placebo had major weight gain; and that those who received placebo had no weight gain, whereas those who received metformin had major weight gain.","['C0205449', 'C0043094', 'C1705492', 'C1524062', 'C3889988', 'C0205164', 'C3272598', 'C0439605', 'C0034656', 'C1706408', 'C2911647', 'C4318856', 'C1551393', 'C2346484', 'C4084773', 'C1511883', 'C0036667', 'C0025598', 'C0679646', 'C0444868', 'C2349185', 'C1517320', 'C3272743', 'C2603343', 'C0032042', 'C0020517', 'C1522640', 'C1696465']","['Weight Gain', 'placebo', 'Diagnostic Sensitivity', 'Bothered by Weight Gain', 'Weight Gain, CTCAE', 'Signal Sensitivity', 'Metformin', 'From', 'Study', 'Major <insect>', 'Missing Study Animal', 'Have Gained Weight', 'Participant', 'Placebos', 'Random', 'Hypersensitivity', 'Missing', 'Container status - Missing', 'Placebo Control', 'All', 'stimulus sensitivity', 'Additional', 'WHO Temperature/Humidity Storage Condition', 'Statistical sensitivity', 'Three', 'Randomization', 'Increased Sensitivy', 'Major']","['fndg', 'popg', 'topp', 'inpr', 'orch', 'qnco', 'phpr', 'qlco', 'euka', 'resa', 'ftcn', 'bodm', ' phsu', 'patf']"
219,PMC3028347,S103,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis.,we used multiple imputations to impute the missing 6-month weight measurements by using the same imputation model used for the main analysis.,"['C3274659', 'C0205225', 'C1705104', 'C0521125', 'C1305866', 'C1705492', 'C0242485', 'C4321252', 'C0936012', 'C1542147', 'C0332177', 'C3714583', 'C1551393', 'C0445247', 'C0005910', 'C2699638', 'C0043100', 'C3272743', 'C0439231', 'C3853906', 'C3161035', 'C1273517', 'C0439064', 'C1524024']","['Weighing patient', 'Statistical Imputation', 'Measurement', 'used by', 'month', 'Missing Study Animal', 'Same', 'Body Weight', 'Main', 'Digital Model Attachment', 'Model Number', 'analysis aspect', 'Weight', 'Model - style/design', 'Missing', 'Container status - Missing', 'Model', 'WWOX wt Allele', 'Monthly (qualifier value)', 'Preposition For', 'Numerous', 'Primary', 'Analysis', 'Importance Weight']","['tmco', 'fndg', 'gngm', 'hlca', 'inpr', 'qlco', 'qnco', 'orga', 'resa', 'ftcn', 'cnce']"
220,PMC3028347,S104,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis.,"for the three scenarios, we added fixed amounts to the imputed values, reanalyzed the results by using ancova, and combined them by using the rubin rules for scalar estimands.","['C0683579', 'C1265611', 'C1710017', 'C0443218', 'C0870077', 'C0205449', 'C0814908', 'C2699638', 'C1515981', 'C3714578', 'C1524062', 'C0205195', 'C2827483', 'C0042295']","['Scalar', 'ancova', 'Fixed Specimen', 'Rule (guideline)', 'Fix', 'Fixed behavior', 'Additional', 'And', 'scenario', 'Statistical Imputation', 'Three', 'Combined', 'Quantity', 'Values']","['idcn', 'inpr', 'qlco', 'phpr', 'qnco', 'ftcn', 'bdsu']"
221,PMC3028347,S105,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis.,an additional confirmatory analysis used the last-observation-carried-forward method for individuals who did not complete the study.,"['C0521125', 'C0700325', 'C1524062', 'C0936012', 'C4321252', 'C3272598', 'C0302523', 'C0699809', 'C0025663', 'C0871511', 'C2828361', 'C3853530', 'C0439780', 'C0750484', 'C0449851', 'C1517741', 'C1707660', 'C2603343', 'C1518422', 'C0206243', 'C0205197', 'C1964257', 'C4283785', 'C3889687', 'C1524024']","['Observation in research', 'Confirmation', 'Complete Pharyngeal Contraction', 'Study', 'Forward', 'Techniques', 'analysis aspect', 'Clinical Observation', 'Carrying', 'Does carry', 'Test Method', 'Do (activity)', 'WWOX wt Allele', 'Patient observation', 'Preposition For', 'Deidentification', 'Negation', 'Methods', 'Observation - diagnostic procedure', 'Data operation - complete', 'Last', 'Analysis', 'Additional', 'WHO Temperature/Humidity Storage Condition', 'Complete']","['fndg', 'mcha', 'gngm', 'hlca', 'inpr', 'qlco', 'lbpr', 'spco', 'resa', 'ftcn', 'diap', 'acty']"
222,PMC3028347,S106,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis.,unadjusted analyses were also run both for the imputation and the last-observation-carried-forward models.,"['C1517741', 'C0302523', 'C1439367', 'C0206243', 'C0699809', 'C1964257', 'C0439780', 'C3889687', 'C3161035', 'C0700325', 'C1515981', 'C2699638', 'C1706086']","['Carrying', 'Does carry', 'Observation - diagnostic procedure', 'Model', 'Observation in research', 'Last', 'unadjusted', 'And', 'Statistical Imputation', 'Patient observation', 'Clinical Observation', 'Forward', 'Both']","['fndg', 'hlca', 'idcn', 'inpr', 'qlco', 'spco', 'resa', 'ftcn', 'diap', 'acty']"
223,PMC3028347,S107,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis.,"because all of these models yielded similar results, only the primary efficacy model is presented.","['C2348205', 'C3274659', 'C0039828', 'C0205225', 'C3853906', 'C3161035', 'C0444868', 'C1707887', 'C3714583', 'C0205171', 'C1280519']","['Effectiveness', 'Model Number', 'Digital Model Attachment', 'All', 'Model', 'Primary', 'Similarity', 'Singular', 'Efficacy Study', 'Model - style/design', 'Theses']","['inpr', 'qnco', 'qlco', 'resa', 'cnce']"
224,PMC3028347,S108,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis.,"we examined baseline characteristics by simple t tests or, in the case of categorical data, with exact tests.","['C2828393', 'C0868928', 'C0022885', 'C1706256', 'C1706255', 'C4050514', 'C0871472', 'C0392366', 'C4684582', 'C4684572', 'C0205352']","['Case (situation)', 't test', 'Categorical Data', 'Simple', 'Packaging Case', 'Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome Questionnaire', 'Tests (qualifier value)', 'Laboratory Procedures', 'Clinical Study Case', 'Exact (qualifier)', 'Baseline Characteristics']","['medd', 'inpr', 'qlco', 'lbpr', 'ftcn', 'cnce']"
225,PMC3028347,S109,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis.,reports of adverse events were also examined by exact tests.,"['C2828393', 'C0022885', 'C0684224', 'C3889645', 'C4050514', 'C0392366', 'C1705413', 'C0700287', 'C0877248']","['Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome Questionnaire', 'Reporting', 'Adverse Event Domain', 'Tests (qualifier value)', 'Report (document)', 'Laboratory Procedures', 'Exact (qualifier)', 'Clinical Trial Final Report', 'Adverse event']","['hlca', 'inpr', 'qlco', 'lbpr', 'patf']"
226,PMC3028347,S111,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Funding and role of the sponsor.,"the intramural research programs of nichd and national institute of diabetes and digestive and kidney diseases (niddk), nih, and the national center on minority health and health disparities (ncmhd), nih, which funded the study, had no role in study design, data accrual, data analysis, or manuscript preparation.","['C1513843', 'C0010992', 'C0011849', 'C0012240', 'C3245503', 'C3539897', 'C0016820', 'C2986888', 'C1513896', 'C1521827', 'C0035171', 'C2983265', 'C1513898', 'C1415458', 'C3812761', 'C0011847', 'C3245479', 'C0600659', 'C0027468', 'C0022658', 'C0062074', 'C0376691', 'C0012238', 'C1512959', 'C3484370', 'C0021622', 'C2603343', 'C1705810', 'C0035820', 'C2826334', 'C1510756', 'C1515981', 'C3714741', 'C1511726', 'C3871154', 'C1272753']","['Intramural Research', 'Generic Role', 'Kidney Diseases', 'Diabetes', 'Data (eukaryote)', 'Institutes', 'And', 'Diabetes Mellitus', 'HAC protocol', 'Study', 'National Center on Minority Health and Health Disparities', 'Gastrointestinal system', 'HADH gene', 'Prepared Material', 'National citizen', 'Social Role', 'Institution (social concept)', 'Data Analysis', 'Preparation', 'National Institute of Child Health and Human Development (U.S.)', 'Programs - Publication Format', 'Funds', 'Nonclinical Study Design', 'Accrual', 'Data call receiving device', 'Programs', 'United States National Institutes of Health', 'CDISC SEND Study Design Terminology', 'Manuscripts', 'Digestion', 'Research Design', 'National Institute of Diabetes and Digestive and Kidney Diseases (U.S.)', 'Have', 'NIH Mouse', 'Role', 'Data']","['topp', 'qnco', 'idcn', 'inpr', 'hcro', 'qlco', 'socb', 'resa', 'ftcn', 'popg', 'ocac', ' mnob', 'bdsy', 'euka', 'acty', 'medd', 'gngm', 'orgt', 'mamm', 'dsyn', 'orgf']"
227,PMC3028347,S112,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Funding and role of the sponsor.,"the authors designed the study, wrote and made the decision to submit the manuscript for publication, and affirmed the completeness, accuracy, and integrity of the data and data analyses.","['C0034037', 'C0439812', 'C2603343', 'C3245479', 'C0600659', 'C1515023', 'C0443131', 'C0205266', 'C0010992', 'C0872403', 'C1704324', 'C1515981', 'C0521125', 'C3812881', 'C3714741', 'C0679006', 'C1511726', 'C1947912', 'C0034036', 'C4321252']","['Submitted', 'Data call receiving device', 'Integrity', 'Data Analysis', 'Publishing', 'Accurate (qualifier)', 'Decision', 'Scientific Publication', 'Data (eukaryote)', 'Intact', 'And', 'Personal Integrity', 'WWOX wt Allele', 'author', 'completeness', 'Study', 'Manuscripts', 'Preposition For', 'Publications', 'Data']","['ocac', 'prog', 'medd', ' mnob', 'idcn', 'inbe', 'gngm', 'inpr', 'qlco', 'euka', 'resa', 'ftcn', 'menp']"
228,PMC3028347,S113,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Funding and role of the sponsor.,"monitoring of the study, measurement and adjudication of study end points, and statistical analyses were performed by the authors without sponsor involvement.","['C1283169', 'C2603343', 'C1711305', 'C0038215', 'C2746065', 'C0680730', 'C2347796', 'C0150369', 'C1515981', 'C3812881', 'C0444930', 'C1314939', 'C1550369', 'C0242485']","['Monitoring - action', 'Preventive monitoring', 'Adjudication', 'Performed By', 'Sponsor (person)', 'Stop (qualifier value)', 'And', 'author', 'End', 'Involvement with', 'Study', 'Measurement', 'Clinical Study Sponsor', 'Science of Statistics']","['tmco', 'gora', 'prog', 'idcn', 'hlca', 'orgt', 'ocdi', 'qlco', 'spco', 'resa', 'ftcn', 'popg']"
229,PMC3028347,S114,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Funding and role of the sponsor.,the manuscript was drafted by the principal investigator and revised by the coauthors.,"['C1515981', 'C1527075', 'C1521895', 'C0600659']","['Revision procedure', 'And', 'Principal Investigator', 'Manuscripts']","['prog', ' mnob', 'idcn', 'topp', 'inpr']"
230,PMC3028347,S36,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study sample.,"obese children, aged 6–12 years, recruited through newspaper advertisements and letters to physicians, were eligible if they had bmi ≥95th percentile according to the centers for disease control and prevention 2000 growth charts for the united states; were prepubertal or early pubertal (defined as breast tanner stage i–iii for girls; testes <8 ml for boys); and had fasting hyperinsulinemia, defined as fasting insulin ≥15 μu/ml, the 99th percentile for fasting insulin among 224 nonobese 6- to 12-year-old children studied as outpatients at the national institutes of health (nih) with the same insulin assay (unpublished data).","['C1513843', 'C3846009', 'C0439340', 'C1864954', 'C0870604', 'C1880521', 'C2718056', 'C1579433', 'C0021641', 'C0870221', 'C0521125', 'C4321252', 'C1264641', 'C0041703', 'C0043210', 'C0007670', 'C1510438', 'C0439234', 'C2826146', 'C0027989', 'C3714501', 'C0243073', 'C1704788', 'C0332287', 'C0680063', 'C3245479', 'C1550549', 'C0027468', 'C0021358', 'C0445247', 'C2945590', 'C0005507', 'C0015663', 'C0332273', 'C1548635', 'C0029921', 'C0006141', 'C1533581', 'C0008059', 'C0949214', 'C1279919', 'C0039597', 'C0282413', 'C0578022', 'C0233888', 'C1515981', 'C4698461', 'C3714741', 'C0580836', 'C1511726', 'C0028754']","['year', 'In addition to', 'Through', 'Prepuberty', 'Data (eukaryote)', 'Insulin', 'Inferior Colliculus', 'percentile', 'Offspring', 'And', 'Testis', 'Definition', 'Insulin [EPC]', 'Fasting hyperinsulinemia', 'Eligible', 'Tanner stage', 'Same', '99th', 'Growth Charts', 'Boys', 'Assay', 'Advertisements', 'Woman', 'Centers for Disease Control and Prevention (U.S.)', 'Biological Assay', 'Newspapers', 'Female child', 'Data call receiving device', 'To doctor', 'Early', 'Finding of body mass index', 'United States National Institutes of Health', 'Fasting', 'WWOX wt Allele', 'Old', 'Outpatients', 'Enzyme Unit per Milliliter', 'Kilounit per Liter', 'Breast', 'Preposition For', 'Recombinant Insulin', 'Insulin Drug Class', 'Child', 'United States', 'Act Relationship Checkpoint - through', 'NIH Mouse', 'Obesity', 'Unit per Milliliter', 'assay qualifier', 'Correspondence as Topic', 'Data']","['qnco', 'podg', ' aapp', 'horm', 'fndg', 'idcn', 'inpr', 'hcro', 'qlco', 'lbpr', 'ftcn', 'popg', 'bpoc', 'phsu', 'tmco', ' mnob', 'euka', 'gngm', 'medd', 'famg', 'geoa', 'mamm', 'orga', 'dsyn', ' phsu', 'aggp']"
231,PMC3028347,S37,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study sample.,this cut point is also consistent with some prior adult data (41).,"['C1552961', 'C0332290', 'C3245479', 'C1080058', 'C0000925', 'C1706450', 'C2826257', 'C0205392', 'C0001675', 'C2347617', 'C3714741', 'C1511726', 'C0332152', 'C3714763']","['point - UnitsOfMeasure', 'Data call receiving device', 'Incised wound', 'Point', 'Point Name', 'Data (eukaryote)', 'Adult', 'Legal Adult', 'Prior Medication Usage', 'Some (qualifier value)', 'Before', 'This (eukaryote)', 'Consistent with', 'Data']","['tmco', 'evnt', 'medd', 'idcn', 'qnco', 'inpo', 'euka', 'spco', 'popg', 'aggp']"
232,PMC3028347,S38,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study sample.,"children were excluded if they had impaired fasting glucose, were diabetic, or reported a diagnosed renal, cardiac, endocrine, pulmonary, or hepatic disease that might alter body weight.","['C0011900', 'C0008059', 'C0680063', 'C1522601', 'C0521425', 'C0005910', 'C0014136', 'C0022646', 'C1305866', 'C0024109', 'C2707265', 'C0015663', 'C0017725', 'C0018787', 'C0023895', 'C2709248']","['Body Weight', 'Diagnosis', 'Kidney', 'Liver diseases', 'Pulmonary (qualifier value)', 'Child', 'Heart', 'Endocrine system', 'Fasting', 'Weighing patient', 'Endocrine', 'Pulmonary:-:Point in time:^Patient:-', 'Offspring', 'Cardiac - anatomy qualifier', 'Lung', 'Glucose']","['fndg', ' orch', 'hlca', 'bdsy', 'famg', 'qlco', 'bacs', 'orga', 'dsyn', 'ftcn', 'diap', ' phsu', 'aggp', 'bpoc', 'clna']"
233,PMC3028347,S39,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study sample.,subjects were excluded for baseline creatinine >1 mg/dl and for alanine aminotransferase (alt) or aspartate aminotransferase (ast) that exceeded 1.5 times the upper limit of the laboratory normal range.,"['C0168634', 'C0521125', 'C3891303', 'C4321252', 'C1561535', 'C3244292', 'C0439269', 'C4283904', 'C1632851', 'C4553172', 'C1266129', 'C0439801', 'C2349209', 'C0022877', 'C0086715', 'C0010294', 'C0004002', 'C1415274', 'C0001899', 'C1442488', 'C1549649', 'C0040223', 'C1282910', 'C1415181', 'C1515981', 'C3887708']","['Laboratory', 'Alanine Aminotransferase 1, human', 'And', 'Alanine Transaminase', 'Atypical Lipoma', 'Laboratory observation', 'Aspartate Transaminase', 'Atlantic Standard Time', 'Creatinine, CTCAE', 'Normal Range', 'Time', 'Times', 'Baseline', 'mg/dl', 'Bound (value)', 'Limit - Amount class', 'Limited (extensiveness)', 'GOT1 gene', 'WWOX wt Allele', 'Preposition For', 'Antibiotic Lock Therapy', 'Creatinine', 'BaseLine dental cement', 'Laboratory domain', 'Upper', 'GPT gene']","['tmco', 'fndg', 'bodm', 'lbtr', 'gngm', ' orch', ' hcro', 'idcn', 'enzy', 'topp', 'qnco', 'bacs', 'qlco', 'spco', 'ftcn', 'neop', ' aapp', 'mnob', 'cnce']"
234,PMC3028347,S40,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study sample.,"the study was approved by the institutional review boards of the eunice kennedy shriver national institute of child health and human development (nichd), nih, and the phoenix area indian health service.","['C1513843', 'C1513896', 'C0972401', 'C0331993', 'C0017446', 'C2603343', 'C3826809', 'C0027468', 'C1080696', 'C0205146', 'C1029979', 'C1515981', 'C0282443', 'C1552617', 'C0085141']","['United States Indian Health Service', 'Phoenix Pharmaceuticals', 'Genus Phoenix', 'Area', 'United States National Institutes of Health', 'And', 'National Institute of Child Health and Human Development (U.S.)', 'NIH Mouse', 'Act Class - review', 'Study', 'Geographic Locations', 'Eunice', 'Review [Publication Type]', 'Boards (medical device)', 'National Institute of Child Health and Human Development Terminology']","['resa', 'medd', 'idcn', 'plnt', 'inpr', 'geoa', 'hcro', 'mamm', 'spco', 'euka']"
235,PMC3028347,S41,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study sample.,written assent and consent were obtained from children and their parents.,"['C1879749', 'C1511481', 'C1883385', 'C0008059', 'C0680063', 'C2923685', 'C1515981', 'C1554192', 'C0030551']","['Consent:Finding:Point in time:{Setting}:Document:Patient', 'Child', 'Treatment Assent', 'parent', 'And', 'Offspring', 'Consent', 'Assent', 'ActClass - consent']","['clna', 'idcn', 'famg', 'ftcn', 'aggp', 'cnce']"
236,PMC3028347,S42,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study sample.,the study was overseen by a data and safety monitoring board convened by nichd.,"['C1513896', 'C2603343', 'C3245479', 'C1515981', 'C0949757', 'C3714741', 'C1511726']","['Data call receiving device', 'Data (eukaryote)', 'And', 'National Institute of Child Health and Human Development (U.S.)', 'Study', 'Clinical Trials Data Monitoring Committees', 'Data']","['prog', 'medd', 'idcn', 'hcro', 'euka', 'resa']"
237,PMC3028347,S44,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Design overview.,we conducted a single-center trial from september 2000 to august 2008.,,,
238,PMC3028347,S45,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Design overview.,"after an outpatient screening visit, participants were admitted as inpatients to the nih clinical research center (crc) for assessment and then entered a 6-month randomized placebo-controlled double-blind treatment period and were then readmitted for reassessment.","['C1513843', 'C0008972', 'C4050364', 'C0456909', 'C0205173', 'C1710032', 'C3538994', 'C1883708', 'C1512346', 'C1533734', 'C1549405', 'C0087111', 'C3887704', 'C1705169', 'C1705765', 'C0039798', 'C2348164', 'C0150108', 'C1698960', 'C0332177', 'C0545082', 'C0525065', 'C1705764', 'C1548439', 'C0009402', 'C1516048', 'C0439531', 'C0027468', 'C0679646', 'C0220908', 'C2826704', 'C0021562', 'C1710031', 'C0029921', 'C1522326', 'C0220909', 'C0439231', 'C1515981', 'C1527249', 'C0683939', 'C1261322', 'C1710477', 'C1948053']","['Duplicate', 'Aspects of disease screening', 'Screening procedure', 'Patient Visit', 'And', 'Evaluation procedure', 'Visit', 'month', 'Period (temporal qualifier)', 'Trial Screening', 'Participant', 'Treatment Epoch', 'Double Value Type', 'Assessed', 'Screening', 'Cytogenetic Complete Response', 'Biomaterial Treatment', 'Administration procedure', 'Clinical Research', 'research center', 'Referral category - Outpatient', 'Screening Study', 'inpatient', 'Colorectal Cancer', 'Visit Name', 'Visually Impaired Persons', 'United States National Institutes of Health', 'Disease Screening', 'Outpatients', 'Monthly (qualifier value)', 'Blinded', 'Doubling', 'research subject screening', 'treatment - ActInformationManagementReason', 'Treating', 'therapeutic aspects', 'NIH Mouse', 'Then', 'per period (qualifier value)', 'Blindness', 'Patient Class - Outpatient', 'Colorectal Carcinoma', 'Therapeutic procedure']","['topp', 'bhvr', 'podg', 'fndg', 'hlca', 'clas', 'idcn', 'inpr', 'hcro', 'qlco', 'resa', 'ftcn', 'popg', 'tmco', ' mnob', 'neop', 'cnce', 'acty', 'orgt', 'mamm', 'diap']"
239,PMC3028347,S46,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Design overview.,participants who completed the randomized phase were offered an additional 6 months of open-label metformin.,"['C3815594', 'C2827499', 'C3272598', 'C0175566', 'C0025598', 'C0679646', 'C0205390', 'C0439231', 'C4551445', 'C0034656', 'C1710475', 'C0181496', 'C1524062', 'C4522130']","['Label (document)', 'Human Cells, Tissues, and Cellular and Tissue-Based Products Labeling', 'Open', 'Participant', 'month', 'Subject is Randomized', 'Additional', 'Labels (device)', 'WHO Temperature/Humidity Storage Condition', 'Metformin', 'Trial Phase', 'Randomization', 'Labeling Activity', 'Phase']","['tmco', 'fndg', 'popg', 'clas', 'inpr', 'orch', 'qlco', 'spco', 'resa', 'ftcn', 'mnob', ' phsu', 'acty']"
240,PMC3028347,S48,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Randomization and interventions.,"we randomly assigned participants in a 1:1 randomization ratio to receive metformin hydrochloride or placebo, twice daily with meals.","['C0032042', 'C0679646', 'C0770893', 'C1998602', 'C1706408', 'C1696465', 'C2985098', 'C0585361']","['Metformin hydrochloride', 'placebo', 'Placebo Control', 'Participant', 'Randomization Ratio', 'Placebos', 'Twice a day', 'Meal (occasion for eating)']","['tmco', 'topp', 'dora', 'orch', 'qnco', 'resa', 'bodm', 'popg', ' phsu']"
241,PMC3028347,S49,['8a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0]",Randomization and interventions.,"investigators assigned consecutive code numbers to participants from prespecified lists stratified by race/ethnicity, sex, and degree of pubertal development.","['C1527148', 'C0036864', 'C0237753', 'C0009253', 'C1706779', 'C0243103', 'C0441889', 'C0678723', 'C0243107', 'C3889831', 'C0034510', 'C1522384', 'C0449788', 'C0804628', 'C2348088', 'C1707491', 'C0679646', 'C0009219', 'C0542560', 'C0035173', 'C0079399', 'C0015031', 'C0805701', 'C1515981', 'C3853635', 'C0449286']","['And', 'Gender:Type:Point in time:^Patient:Nominal', 'Code', 'Ethnicity aspects', 'sex', 'Participant', 'Race', 'Sex Behavior', 'Racial group', 'Academic degree', 'Count of entities', 'development aspects', 'Coding', 'Coitus', 'Development', 'Biologic Development', 'Ethnic group', 'AMACR wt Allele', 'Degree or extent', 'Levels (qualifier value)', 'Numbers', 'Degree Unit of Plane Angle', 'eTMF Content Model Code', 'Gender', 'Consecutive', 'Research Personnel']","['ocac', 'prog', 'gngm', 'idcn', 'phsf', 'inpr', 'qlco', 'qnco', 'orga', 'bhvr', 'orgf', 'ftcn', 'popg', 'clna']"
242,PMC3028347,S50,"['8b', '11b', '8a']","[0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0]",Randomization and interventions.,the crc pharmaceutical development section used permuted blocks with stratification to generate allocations that translated code numbers into study group assignments by using a pseudo-random number program and prepared identically appearing placebo and metformin (u.s.p.,"['C4050364', 'C0237753', 'C0040710', 'C1705191', 'C3714523', 'C3889831', 'C1709697', 'C1257890', 'C0441833', 'C0439605', 'C1521827', 'C0028778', 'C0449788', 'C0034656', 'C0872152', 'C3811660', 'C0009402', 'C1705428', 'C1552923', 'C1519504', 'C1705429', 'C0009219', 'C1514983', 'C1533157', 'C0376691', 'C2728259', 'C4082130', 'C3484370', 'C2603343', 'C0205237', 'C0805701', 'C0687744', 'C1515981', 'C1527249', 'C1522472', 'C0332206', 'C0700320']","['Group Object', 'And', 'Translating', 'Drug Development', 'Study', 'Code', 'Blocking', 'Preparation', 'Count of entities', 'Section - Geographic Area', 'False', 'Square Mile', 'Programs - Publication Format', 'Random', 'Cytogenetic Complete Response', 'Program', 'User Group', 'Block Specimens', 'Coding', 'Groups', 'Population Group', 'Programs', 'Colorectal Cancer', 'Social group', 'Stratification', 'Numbers', 'eTMF Content Model Code', 'Program - framework of goals', 'Prepared', 'Obstruction', 'Section (object)', 'Stage Grouping', 'Randomization', 'Block Unit of Distance', 'Sectioning technique', 'section sample', 'Colorectal Carcinoma']","['qnco', 'phob', 'patf', 'fndg', 'idcn', 'inpr', 'qlco', 'sbst', 'lbpr', 'resa', 'ftcn', 'popg', 'bdsu', 'ocac', 'orch', 'neop', 'acty', 'cnce', 'geoa', 'bmod', ' phsu']"
243,PMC3028347,S51,"['11b', '8b', '8a']","[0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0]",Randomization and interventions.,"grade; sst corporation, clifton, nj) capsules (250 mg/capsule).","['C3244287', 'C0919553', 'C2347138', 'C0006935', 'C1553430', 'C0441800', 'C3890731', 'C0683758']","['Grade', 'School Grade', 'Milligram per Capsule', 'Samoa Standard Time', 'capsule (pharmacologic)', 'Serum Separator Tube', 'corporation', 'Histopathologic Grade']","['tmco', 'fndg', 'medd', 'clas', 'orgt', 'qnco', 'bodm']"
244,PMC3028347,S52,['9'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1]",Randomization and interventions.,pharmacy personnel not involved with the conduct of the study dispensed study capsules in containers that differed only by participant code number.,"['C2603343', 'C0180098', 'C1518422', 'C0031321', 'C0237753', 'C0679646', 'C0006935', 'C0004927', 'C0805701', 'C0449788', 'C0031336', 'C0009219', 'C1527117', 'C0031322', 'C0700103', 'C2698741', 'C3889831', 'C4554048', 'C3244303', 'C0205171']","['Coding', 'eTMF Content Model Code', 'Pharmaceutical Services', 'Study Participant', 'Participant', 'Singular', 'capsule (pharmacologic)', 'Pharmacy domain', 'Count of entities', 'Human Resources', 'Participant Object', 'Numbers', 'Study', 'Behavior', 'Code', 'Personnel', 'Pharmacy (field)', 'Negation', 'Containers', 'Pharmacy facility']","['ocac', ' hcro', 'hlca', 'clas', 'inpr', 'qnco', 'bmod', 'bhvr', 'ftcn', 'resa', 'bodm', 'mnob', 'popg']"
245,PMC3028347,S53,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomization and interventions.,"no participant, investigator, or other medical or nursing staff interacting with participants was aware of study group assignments during the trial.","['C1257890', 'C2603343', 'C0441833', 'C0205476', 'C1519504', 'C0679646', 'C0004448', 'C1705429', 'C0028698', 'C0199168', 'C0687744', 'C0008976', 'C2698741', 'C1705428', 'C4554048', 'C0035173']","['Groups', 'Population Group', 'Group Object', 'Study Participant', 'Participant', 'Social group', 'Clinical Trials', 'Medical', 'Research Personnel', 'Awareness', 'Participant Object', 'Nursing Staff', 'Stage Grouping', 'Study', 'Medical service', 'User Group']","['prog', 'idcn', 'hlca', 'clas', 'resa', 'ftcn', 'popg', 'menp', 'cnce']"
246,PMC3028347,S54,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Randomization and interventions.,"once baseline assessments were completed, subject’s study medication dose was progressively increased according to a prespecified algorithm over a 3-week period, starting with 500 mg twice daily and increasing to a maximum dose of 1,000 mg twice daily.","['C0801821', 'C1948045', 'C0002045', 'C0168634', 'C0178602', 'C0439230', 'C3816747', 'C0205136', 'C3174092', 'C0585361', 'C2826546', 'C0439531', 'C0332287', 'C0347984', 'C0806909', 'C2603343', 'C1442488', 'C1553907', 'C1552615', 'C0442808', 'C1515981', 'C1261322', 'C1948053']","['Maximum Value Derivation Technique', '500', 'Observation Method - algorithm', 'In addition to', 'And', 'Evaluation procedure', 'Study', 'Twice a day', 'Maximum', 'Period (temporal qualifier)', 'increasing', 'Medication dose', 'Baseline', 'Act Relationship Subset - maximum', 'Medication XXX:Dosage:Point in time:^Patient:Quantitative', 'Once (schedule frequency)', 'algorithm', 'Dosage', 'During', 'BaseLine dental cement', 'Over (spatial)', 'week', 'per period (qualifier value)']","['tmco', 'bodm', 'idcn', 'hlca', 'inpr', 'qnco', 'spco', 'resa', 'ftcn', 'clna']"
247,PMC3028347,S55,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Randomization and interventions.,the typical adult maximum dose was selected as the goal because the weight of the severely obese participants to be enrolled (table 1) was anticipated to be similar to that of adults.,"['C2348205', 'C1706450', 'C0679646', 'C3538928', 'C1552615', 'C0005910', 'C0039224', 'C1705104', 'C0001675', 'C0018017', 'C0178602', 'C1706074', 'C1305866', 'C0806909', 'C1571704', 'C0043100', 'C2826546', 'C0028754', 'C0205082']","['Body Weight', 'Maximum', 'Maximum Value Derivation Technique', 'Participant', 'Data Table', 'Severe (severity modifier)', 'Weighing patient', 'Adult', 'Legal Adult', 'Importance Weight', 'Act Mood - Goal', 'Dosage', 'Usual', 'Weight', 'Obesity', 'Table - furniture', 'Act Relationship Subset - maximum', 'Similarity', 'objective (goal)']","['fndg', 'idcn', 'hlca', 'inpr', 'qnco', 'qlco', 'orga', 'dsyn', 'mnob', 'popg', 'aggp']"
248,PMC3028347,S56,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Randomization and interventions.,we decreased the dose by 250 mg/dose for 1 week when participants reported difficulty tolerating study medication and then attempted to increase it.,"['C2603343', 'C0679646', 'C1442452', 'C4284232', 'C1299586', 'C0178602', 'C1515981', 'C3244316', 'C1883708', 'C0013227']","['Medications', 'Participant', '1 Week', 'And', 'Dosage', 'Then', 'Study', 'Pharmaceutical Preparations', 'Has difficulty doing (qualifier value)', 'medication - HL7 publishing domain']","['tmco', 'fndg', 'idcn', 'inpr', 'qnco', 'resa', 'popg', 'phsu']"
249,PMC3028347,S57,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Randomization and interventions.,study medication dose was progressively lowered by 250 mg/day if a prescribed dosage could not be tolerated after a 7-day trial.,"['C0231290', 'C2603343', 'C0278329', 'C1518422', 'C0332173', 'C0801821', 'C0178602', 'C0687676', 'C2986497', 'C0008976', 'C3174092', 'C0439228', 'C0163299']","['day', 'Cumulative Dose', 'Clinical Trials', 'Post', 'Status post', 'A 7', 'prescribed', 'Dosage', 'Medication dose', 'Study', 'Daily', 'Medication XXX:Dosage:Point in time:^Patient:Quantitative', 'Negation']","['tmco', 'clna', 'hlca', 'orch', 'qnco', 'resa', 'ftcn', ' phsu', 'cnce']"
250,PMC3028347,S58,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Randomization and interventions.,"once a tolerated dose was found, attempts were made to increase the dosage prescribed.","['C0178602', 'C2986497', 'C1948045']","['Cumulative Dose', 'Dosage', 'Once (schedule frequency)']","['qnco', 'cnce', 'tmco']"
251,PMC3028347,S59,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Randomization and interventions.,study medication was discontinued if 250 mg/day was not tolerated.,"['C2603343', 'C1518422', 'C0332173', 'C4284232', 'C3244316', 'C0439228', 'C0013227']","['Medications', 'day', 'Study', 'Daily', 'Pharmaceutical Preparations', 'Negation', 'medication - HL7 publishing domain']","['tmco', 'inpr', 'resa', 'ftcn', 'phsu']"
252,PMC3028347,S60,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Randomization and interventions.,a daily chewable multivitamin (flintstones complete) containing 6 μg cyanocobalamin was also prescribed.,"['C0042845', 'C0332173', 'C3853530', 'C0205197', 'C3714801', 'C4283785', 'C0301532', 'C0303753']","['Vitamin B 12', 'Cyanocobalamin Drug Class', 'Data operation - complete', 'Complete Pharyngeal Contraction', 'Multivitamin preparation', 'Flint substance', 'Daily', 'Complete']","['tmco', 'fndg', ' orch', 'inch', 'qlco', 'vita', 'ftcn', ' phsu']"
253,PMC3028347,S61,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Randomization and interventions.,"after conclusion of the randomized phase, participants were prescribed increasing doses of commercially available metformin in two divided doses with a maximum dose of 2,000 mg/day plus a daily multivitamin for an additional 6 months.","['C3815594', 'C0025598', 'C0679646', 'C0205390', 'C0439231', 'C1552615', 'C0439422', 'C1707478', 'C0034656', 'C0178602', 'C1710475', 'C0719642', 'C0470187', 'C1524062', 'C0205448', 'C0806909', 'C2826546', 'C0332849']","['Daily MULTIVITAMINS', 'Maximum', 'Maximum Value Derivation Technique', 'Two', 'availability of', 'Participant', 'month', 'divided', 'Subject is Randomized', 'Additional', 'Dosage', 'Metformin', 'Trial Phase', 'Randomization', 'milligram/day', 'Act Relationship Subset - maximum', 'Conclusion', 'Phase']","['tmco', 'fndg', 'popg', ' orch', 'idcn', 'clas', 'orch', 'qnco', 'vita', 'resa', 'ftcn', ' phsu']"
254,PMC3028347,S62,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Randomization and interventions.,"table 1 baseline participant characteristics          during both study phases, each participant and a parent/guardian met monthly with a dietitian who administered a weight-reduction lifestyle modification program that promoted a reduced-energy diet, increased physical activity, and decreased inactivity.","['C1521801', 'C0039224', 'C0168634', 'C1705104', 'C1305866', 'C0392756', 'C1706086', 'C1442080', 'C4554048', 'C1709697', 'C1519433', 'C3272598', 'C1550543', 'C1293152', 'C1457900', 'C1521970', 'C0542479', 'C0332177', 'C1706074', 'C0030551', 'C4317104', 'C4330907', 'C0332287', 'C0679646', 'C0012159', 'C0870811', 'C0005910', 'C0424589', 'C4551656', 'C0012155', 'C0428210', 'C0585064', 'C2960841', 'C0043100', 'C0376691', 'C2728259', 'C3890554', 'C0301630', 'C3484370', 'C0023226', 'C2603343', 'C1442488', 'C0474395', 'C1274041', 'C3536818', 'C2699423', 'C1515981', 'C2698741', 'C2983588']","['Dietitian', 'Data Table', 'In addition to', 'Diet therapy', 'parent', 'Each (qualifier value)', 'Surgical reduction', 'And', 'Guardian', 'Weighing patient', 'Participant Object', 'Lifestyle changes', 'Study', 'Characteristics', 'Behavior showing increased motor activity', 'Numerical phases', 'Body Weight', 'Study Participant', 'Conceptual Parent', 'Participant', 'Energy, Physics', 'Reduction (chemical)', 'Vitality', 'Metabolic Equivalent of Task Unit', 'Programs - Publication Format', 'Weight', 'Baseline', 'Program', 'Energy', 'Programs', 'Reduced', 'Reduction procedure', 'Having administered', 'Physical Inactivity', 'Monthly (qualifier value)', 'Legal Guardians', 'Basal Diet', 'Table - furniture', 'Overall Energy Level', 'Fulfill', 'BaseLine dental cement', 'Program - framework of goals', 'Lifestyle change therapy', 'Special Diet Therapy', 'WHO Temperature/Humidity Storage Condition', 'Importance Weight', 'Diet', 'Methionine measurement', 'Both']","['topp', 'qnco', 'phpr', 'bodm', 'fndg', 'npop', 'hlca', 'idcn', 'clas', 'inpr', 'qlco', 'lbpr', 'socb', 'resa', 'ftcn', 'mnob', 'popg', 'tmco', 'food', 'prog', 'orch', 'cnce', 'dora', 'famg', 'orga', ' phsu']"
255,PMC3028347,S63,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Randomization and interventions.,participants were trained to complete a baseline 7-day food diary that was reviewed by a registered dietitian.,"['C0439228', 'C1442488', 'C0332173', 'C0679646', 'C1553101', 'C1421478', 'C1709940', 'C0168634', 'C1565156', 'C0043194', 'C0282443', 'C0012157']","['BaseLine dental cement', 'Reviewed', 'day', 'Participant', 'WAS protein, human', 'WAS gene', 'Dietitian, Registered', 'Daily', 'Baseline', 'Review [Publication Type]', 'Diet Records', 'Wiskott-Aldrich Syndrome']","['tmco', 'prog', 'gngm', 'inpr', 'qnco', 'qlco', 'bacs', 'dsyn', 'bodm', 'popg', ' aapp']"
256,PMC3028347,S64,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Randomization and interventions.,these data were used to offer individualized prescriptions for a “traffic light” style (42) 500 kcal/day–deficit diet that reduced fat and energy intake.,"['C1519433', 'C0424612', 'C0033080', 'C3245479', 'C2741652', 'C0012159', 'C1708004', 'C3887682', 'C3816747', 'C0012155', 'C0006777', 'C1515981', 'C0030234', 'C3714741', 'C0439259', 'C0489654', 'C1511726', 'C2983588', 'C0039828']","['Theses', 'Data call receiving device', 'Palmitic Acid', 'kilocalorie', 'FAT1 wt Allele', '500', 'Diet therapy', 'style', 'Special Diet Therapy', 'Data (eukaryote)', 'And', 'Diet', 'Energy Intake', 'Obese build', 'Platelet Glycoprotein 4, human', 'Basal Diet', 'Prescriptions:Finding:Point in time:^Patient:Narrative', 'Prescription procedure', 'Data']","['food', 'medd', 'hlca', 'topp', 'idcn', 'gngm', ' orch', 'inpr', 'qnco', 'bacs', 'qlco', 'orga', 'euka', 'rcpt', ' aapp', 'clna']"
257,PMC3028347,S65,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Randomization and interventions.,the exercise prescription consisted of encouraging 30 min of aerobic exercise every day and inclusion of lifestyle exercise whenever possible and was monitored by pedometer readings recorded by parents.,"['C0456693', 'C1512693', 'C0332149', 'C0332173', 'C1705910', 'C1442458', 'C0007637', 'C1522704', 'C0023676', 'C1515981', 'C0001701', 'C2709220', 'C0588464', 'C0015259', 'C0030551']","['Pedometer', 'Life Style', 'Exercise', 'per 30 minutes', '30 Minutes', 'parent', 'Exercise Pain Management', 'Inclusion', 'And', 'Possibly Related to Intervention', 'Inclusion Bodies', 'Daily', 'exercise on prescription', 'Possible', 'Exercise, Aerobic']","['tmco', 'fndg', 'medd', 'idcn', 'topp', 'dora', 'famg', 'celc', 'qlco', 'socb']"
258,PMC3028347,S66,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Randomization and interventions.,"adherence was gauged through self-monitoring of medication taken, food eaten, activity performed, amount of inactive time, and pedometer readings recorded in a progress book that was reviewed monthly.","['C4284232', 'C4049938', 'C0441655', 'C0205177', 'C3834263', 'C1265611', 'C0332177', 'C3244316', 'C0588436', 'C1510802', 'C0006002', 'C1272688', 'C1280477', 'C3540798', 'C0016452', 'C3890554', 'C0013227', 'C0040223', 'C2709220', 'C1515981', 'C4049939']","['Physical Activity Measurement', 'Self Monitoring', 'Inactive - answer to question', 'And', 'Quantity', 'Food', 'Time', 'FDA Establishment Activity Terminology', 'Food allergenic extracts', 'Active', 'Pedometer', 'Books', 'Physical Inactivity', 'Monthly (qualifier value)', 'Adherence (attribute)', 'Pharmaceutical Preparations', 'medication - HL7 publishing domain', 'Medications', 'Activities', 'Progress', 'status - In progress']","['tmco', 'food', 'imft', 'fndg', 'medd', 'idcn', 'topp', 'dora', 'inpr', 'qlco', 'phsu', 'qnco', 'lbpr', 'ftcn', ' phsu', 'acty']"
259,PMC3028347,S68,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Initial assessment.,"subjects who met inclusion criteria were admitted as inpatients to the crc for the following measurements: weight in a hospital gown using a calibrated digital scale (life measurement instruments, concord, ca); height in triplicate using a stadiometer (holtain, crymych, u.k.) calibrated before each measurement; abdominal and hip circumferences (assessed in triplicate) and triceps skinfold thickness (lange calipers; cambridge scientific industries, cambridge, md) by trained research dietitians (c.g.s. and n.g.s.); blood pressure using an automated sphygmomanometer (dinamap-plus; critikon, tampa, fl) measured in the seated position after at least 5 min rest; a hand roentgenogram for determination of skeletal age; whole-body fat mass by dual-energy x-ray absorptiometry (dexa) (4500a; hologic, bedford, ma; software version 11.2) and by air displacement plethysmography; and intra-abdominal and subcutaneous abdominal adipose tissue by magnetic resonance imaging at l2–l3 and l4–l5 (t1-weighted spin-echo images, 0.5 t, relaxation time 400 ms, time of excitation 10 ms, number of repetitions of excitations 10).","['C1655045', 'C3827995', 'C3536832', 'C0019552', 'C0037253', 'C1305866', 'C1705104', 'C0183427', 'C1442080', 'C1622890', 'C0021267', 'C3272598', 'C0035168', 'C0349674', 'C0019994', 'C1457900', 'C0005823', 'C3538851', 'C1510486', 'C4330907', 'C0205341', 'C1823107', 'C0005910', 'C0424589', 'C0021562', 'C2314876', 'C1552914', 'C0242821', 'C3887682', 'C1527249', 'C4082212', 'C4050364', 'C0332282', 'C1512693', 'C0086894', 'C0521125', 'C1415347', 'C1272641', 'C0012727', 'C0542479', 'C0001527', 'C0009402', 'C1306372', 'C0460148', 'C0036397', 'C0521324', 'C1554184', 'C0001861', 'C1306645', 'C2347509', 'C0205174', 'C0030234', 'C1268086', 'C1947916', 'C0001779', 'C1148554', 'C0205173', 'C0851346', 'C0242485', 'C0035028', 'C1505163', 'C0022122', 'C1883674', 'C0018563', 'C0035253', 'C0043100', 'C0175659', 'C4283905', 'C1708004', 'C3536818', 'C0443315', 'C0012725', 'C0024485', 'C0000726', 'C0205554', 'C0237753', 'C0242481', 'C4284725', 'C0518022', 'C0489786', 'C4321252', 'C0449788', 'C0332520', 'C0376558', 'C4551823', 'C0032221', 'C0521095', 'C0233651', 'C0577573', 'C0175720', 'C0577559', 'C1271104', 'C0549255', 'C0181064', 'C2584297', 'C0424612', 'C0444667', 'C0040223', 'C1515981', 'C0058928', 'C3152252']","['Duplicate', 'subcutaneous', 'Air (substance)', 'Systemic arterial pressure', 'Dipturus trachyderma', 'CALIPER', 'Body Weight', 'Automated (qualifier value)', 'Scaling', 'Time', 'site-specific telomere resolvase activity', 'Spatial Displacement', 'Weight', 'Rest', 'HHIP protein, human', 'Rajiformes', 'Bone structure of ischium', 'Plain x-ray', 'Preposition For', 'Overall Energy Level', 'Morphology, Attenuation, Size, and Structure Criteria', 'Human body structure', 'Dual-Energy X-Ray Absorptiometry', 'research', 'WHO Temperature/Humidity Storage Condition', 'Body structure', 'Molecular Mass', 'FAT1 wt Allele', 'Dietitian', 'GTF2I gene', 'Hand', 'Sitting Function', 'And', 'Platelet Glycoprotein 4, human', 'Adipose tissue', 'Blood Pressure', 'Determined by', 'REG3A wt Allele', 'Physical Shift', 'Mass of body region', 'Intellectual scale', 'instruments', 'inpatient', 'Palmitic Acid', 'Repeat', 'Colorectal Cancer', 'Obese build', 'Blood pressure finding', 'Numbers', 'Hip structure', 'Height', 'Whole', 'Echo (insect)', 'hand - unit of measure', 'Each (qualifier value)', 'Air', 'Magnetic Resonance Imaging', 'HHIP wt Allele', 'Vitality', 'Hospitals', 'Radiation', 'Dual', 'Software Version', 'Skeletal system', 'Plethysmography', 'Inclusion', 'Perseveration', 'WWOX wt Allele', 'Determination Aspects', 'Industry', 'Mass, a measure of quantity of matter', 'Importance Weight', 'Triceps skin fold thickness (observable entity)', 'Weight measurement scales', 'Colorectal Carcinoma', 'Excitation', 'Age', 'Relaxation', 'Mass of body structure', 'Weighing patient', 'Adult human body', 'Measurement', 'Digital', 'Triplicate', 'Following', 'Energy, Physics', 'Count of entities', 'Circumference', 'Cytogenetic Complete Response', 'Skeletal', 'Energy', 'Psychologic Displacement', 'Human body', 'Science', 'SPIN1 gene', 'Abdomen', 'Life', 'Research Activities', 'ECHO protocol', 'GOWN', 'Sphygmomanometers']","[' hcro', 'topp', 'qnco', 'phpr', 'podg', ' aapp', 'menp', 'clna', 'blor', 'fndg', 'npop', ' orch', 'idcn', 'hlca', 'phsf', 'anst', 'inpr', 'sosy', 'qlco', 'sbst', 'bacs', 'lbpr', 'resa', 'ftcn', 'mnob', 'moft', 'bpoc', 'humn', 'tmco', 'ocac', 'prog', 'bdsy', 'ocdi', 'tisu', 'mobd', 'spco', 'euka', 'neop', 'fish', 'acty', 'gngm', 'medd', 'dora', 'inch', 'orga', 'orgf', 'rcpt', 'diap', ' phsu']"
260,PMC3028347,S69,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Initial assessment.,a 2-h hyperglycemic (200 mg/dl) clamp was also performed at baseline and follow-up admissions to estimate insulin sensitivity and first-phase insulin secretion as previously described (43).,"['C4049919', 'C1256369', 'C0920563', 'C3810601', 'C1442488', 'C0205435', 'C1552738', 'C0205390', 'C1279901', 'C0175721', 'C0168634', 'C1710475', 'C1515981', 'C1883710', 'C0184666']","['Firstly', 'BaseLine dental cement', 'Clamping Activity', 'First (number)', 'PDZK1 wt Allele', 'Insulin Secretion', 'And', 'Insulin Sensitivity', 'Insulin Sensitivity Measurement', 'Hospital admission', 'Clamp (device)', 'Trial Phase', 'Baseline', 'described', 'Phase']","['tmco', 'celf', 'gngm', 'idcn', 'hlca', 'clas', 'qnco', 'qlco', 'lbpr', 'ftcn', 'bodm', 'mnob', 'patf']"
261,PMC3028347,S70,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Initial assessment.,first-phase insulin was calculated as the mean of measurements obtained during the first 15 min.,"['C1533581', 'C1301820', 'C0205435', 'C2348143', 'C0205390', 'C1279901', 'C1579433', 'C0021641', 'C0347984', 'C1710475', 'C2347634', 'C0444504', 'C0242485', 'C3714501']","['Phase', 'Insulin Drug Class', 'Firstly', 'Sample Mean', 'First (number)', 'Insulin', 'Population Mean', 'Statistical mean', 'During', 'Trial Phase', 'Measurement', 'Obtain', 'Insulin [EPC]', 'Recombinant Insulin']","['tmco', 'clas', 'qlco', 'qnco', 'ftcn', ' phsu', ' aapp', 'horm', 'phsu']"
262,PMC3028347,S71,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Initial assessment.,"whole-body glucose uptake (metabolic rate: m) was defined as the infusion rate of exogenous glucose administered, corrected for urinary glucose losses and the glucose space correction.","['C1159527', 'C0870882', 'C1947976', 'C0205228', 'C0444667', 'C1524119', 'C1521801', 'C0460148', 'C0242821', 'C1883067', 'C2964135', 'C0521125', 'C0205101', 'C1515981', 'C1268086', 'C0017725', 'C1705565', 'C4082212', 'C0205202', 'C4321252']","['Human body structure', 'Extrinsic', 'Human body', 'Infusion Rate', 'Having administered', 'Body structure', 'And', 'Adult human body', 'Correction (change)', 'Exogenous', 'WWOX wt Allele', 'metabolic rates', 'Space - property', 'Corrected', 'glucose uptake', 'Preposition For', 'Whole', 'urinary', 'Glucose', 'Correction Report']","['tmco', 'celf', ' orch', 'idcn', 'gngm', 'phsf', 'anst', 'inpr', 'qnco', 'bacs', 'qlco', 'spco', 'ftcn', ' phsu', 'humn']"
263,PMC3028347,S72,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Initial assessment.,as a measure of insulin sensitivity (siclamp) the ratio of metabolic rate to steady-state insulin (m/i) was calculated.,"['C4049919', 'C0870882', 'C0920563', 'C1533581', 'C0079809', 'C3148680', 'C1579433', 'C0021641', 'C1547037', 'C0456603', 'C0205361', 'C1301808', 'C1442792', 'C0242485', 'C3714501']","['data type - ratio', 'Insulin Drug Class', 'Ratio', 'Insulin', 'metabolic rates', 'Insulin Sensitivity', 'Insulin Sensitivity Measurement', 'Measures', 'US State', 'Measurement', 'Geographic state', 'Insulin [EPC]', 'State', 'steady', 'Recombinant Insulin']","['phsf', 'inpr', 'geoa', 'qnco', 'qlco', 'lbpr', 'ftcn', ' phsu', ' aapp', 'horm', 'patf', 'phsu']"
264,PMC3028347,S73,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Initial assessment.,"at baseline and follow-up, samples obtained in the fasted state were collected for measurement of alt, ast, total and hdl cholesterol, direct ldl cholesterol, and triglycerides (synchron lx20; beckman coulter, fullerton, ca).","['C1266129', 'C0392885', 'C1442488', 'C1947931', 'C0242485', 'C0168634', 'C1415181', 'C0023824', 'C1515981', 'C0015663', 'C3891303', 'C0439851', 'C0439810', 'C0202117', 'C0041004', 'C0023822', 'C4553172']","['BaseLine dental cement', 'LDL Cholesterol Lipoproteins', 'Atlantic Standard Time', 'GOT1 gene', 'Triglycerides', 'Fasting', 'Total', 'And', 'High density lipoprotein measurement', 'Direct type of relationship', 'Measurement', 'Low density lipoprotein cholesterol measurement', 'High Density Lipoprotein Cholesterol', 'Atypical Lipoma', 'Baseline', 'Direct (qualifier)', 'Antibiotic Lock Therapy']","['tmco', 'fndg', 'bodm', ' orch', 'idcn', 'topp', 'gngm', 'qnco', 'bacs', 'qlco', 'lbpr', 'ftcn', 'neop']"
265,PMC3028347,S74,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Initial assessment.,"plasma for glucose was collected in tubes containing powdered sodium fluoride and measured by the nih crc clinical laboratory using a roche diagnostics (indianapolis, in) analyzer.","['C1513843', 'C3658216', 'C4050364', 'C0179038', 'C0027468', 'C3828314', 'C0032105', 'C1171560', 'C4684595', 'C0037508', 'C1515981', 'C1527249', 'C0017725', 'C1547937', 'C0175730', 'C0009402', 'C4521445']","['Plasma', 'Roche Diagnostics', 'Sodium Fluoride', 'Analyzer, device', 'Colorectal Cancer', 'United States National Institutes of Health', 'Clinical Laboratory Services', 'And', 'NIH Mouse', 'Colorectal Carcinoma', 'Cytogenetic Complete Response', 'Specimen Source Codes - Tube', 'Plasma Product', 'Natrium fluoratum, sodium fluoride, Homeopathic preparation', 'biomedical tube device', 'Glucose', 'Clinical Laboratory']","['fndg', ' orch', 'idcn', ' hcro', 'hlca', 'orgt', 'bdsu', 'inpr', 'hcro', 'medd', 'phsu', 'mamm', 'bacs', 'neop', 'bodm', 'mnob', ' phsu', ' inch']"
266,PMC3028347,S75,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Initial assessment.,c-reactive protein was measured by a high-sensitivity assay (immage immunochemistry systems; beckman coulter) with sensitivity of 0.020 mg/dl.,"['C1511883', 'C2700149', 'C0243073', 'C0020986', 'C0033684', 'C0036667', 'C3887512', 'C4321237', 'C0020517', 'C1510438', 'C1522640', 'C1299351', 'C0005507', 'C0205332', 'C4522209', 'C0205250', 'C3889660', 'C2349185', 'C2346484']","['Immunochemistry', 'High Level', 'Assay', 'Value Above Reference Range', 'Diagnostic Sensitivity', 'Reactive', 'Statistical sensitivity', 'high - ActExposureLevelCode', 'Abnormally high', 'Signal Sensitivity', 'High Mitosis-Karyorrhexis Index', 'stimulus sensitivity', 'High', 'Increased Sensitivy', 'Hypersensitivity', 'Biological Assay', 'Proteins', 'assay qualifier', 'IPSS Risk Category High']","['fndg', 'idcn', 'inpr', 'qnco', 'phpr', 'bmod', 'qlco', 'lbpr', 'bacs', ' aapp', 'patf']"
267,PMC3028347,S76,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Initial assessment.,"vitamin b12 and insulin were measured by chemiluminescent immunoassays using siemens healthcare diagnostics (los angeles, ca) immulite instruments.","['C0042845', 'C0020980', 'C1533581', 'C0024015', 'C2936883', 'C1579433', 'C0021641', 'C1515981', 'C1551054', 'C4551823', 'C0086388', 'C3829562', 'C3714501']","['Insulin Drug Class', 'Vitamin B 12', 'instruments', 'Los Angeles', 'Units Of Measure - Siemens', 'Vitamin B12 [EPC]', 'Insulin', 'And', 'Immunoassay method', 'Immulite', 'Health Care', 'Insulin [EPC]', 'Recombinant Insulin']","[' orch', 'hlca', 'idcn', 'geoa', 'horm', 'qnco', 'vita', 'lbpr', 'ftcn', ' aapp', 'mnob', ' phsu', 'phsu']"
268,PMC3028347,S77,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Initial assessment.,fasting samples were used to estimate insulin resistance by the homeostasis model assessment–insulin resistance (homa-ir) index = insulin (μu/ml) × [glucose (mmol/l)/22.5].,"['C3274659', 'C2986546', 'C0439340', 'C1880521', 'C1579433', 'C0021641', 'C1514892', 'C0600653', 'C0021655', 'C4049994', 'C0017725', 'C3714583', 'C3714501', 'C2945590', 'C0015663', 'C0019868', 'C1533581', 'C3853906', 'C4281815', 'C3161035', 'C0237834', 'C1552854', 'C0918012']","['Html Link Type - index', 'Insulin', 'Insulin [EPC]', 'Resistance', 'Model Number', 'Digital Model Attachment', 'Index', 'Model - style/design', 'Model', 'Insulin Resistance', 'Fasting', 'Resistance Process', 'Enzyme Unit per Milliliter', 'Kilounit per Liter', 'Insulin Resistance Measurement', 'Recombinant Insulin', 'Insulin Drug Class', 'Homeostasis', 'Indexes', 'Unit per Milliliter', 'Target Lesion Identification', 'Resistance (Psychotherapeutic)', 'Glucose']","['cnce', 'fndg', 'biof', ' orch', 'idcn', 'phsf', 'inpr', 'qnco', 'bacs', 'lbpr', 'ftcn', ' phsu', ' aapp', 'diap', 'horm', 'menp', 'patf', 'phsu']"
269,PMC3028347,S78,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Initial assessment.,"diagnosis of pediatric metabolic syndrome was made when three or more components were present from among the following: waist circumference, blood pressure, and triglycerides ≥90th percentile for age and sex; hdl cholesterol ≤10th percentile for age and sex; and fasting glucose ≥100 mg/dl (44).","['C0392885', 'C0332282', 'C0036864', 'C0449450', 'C0205449', 'C1521725', 'C0009253', 'C1272641', 'C0023822', 'C1264641', 'C0449432', 'C1704656', 'C1522384', 'C0005823', 'C0439269', 'C0524620', 'C0205172', 'C0804628', 'C0041004', 'C1948054', 'C1704338', 'C1271104', 'C0455829', 'C0150312', 'C0011900', 'C0079399', 'C1515981', 'C0001779']","['Age', 'Metabolic Syndrome X', 'Triglycerides', 'diagnosis aspect', 'And', 'percentile', 'Gender:Type:Point in time:^Patient:Nominal', 'Systemic arterial pressure', 'sex', 'Diagnosis', 'Blood Pressure', 'Presentation', 'Following', 'Sex Behavior', 'mg/dl', 'Coitus', 'When (temporal qualifier)', 'More', 'High density lipoprotein measurement', 'Pediatric', 'Blood pressure finding', 'Waist Circumference', 'Component object', 'Gender', 'Three', 'Diagnosis Study', 'High Density Lipoprotein Cholesterol', 'Present']","['mnob', 'tmco', 'fndg', ' orch', 'idcn', 'qlco', 'bacs', 'qnco', 'lbpr', 'dsyn', 'orgf', 'resa', 'orga', 'bhvr', 'diap', 'clna']"
270,PMC3028347,S79,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Initial assessment.,subjects and parents were also interviewed by a clinical pharmacist who used a structured questionnaire containing a comprehensive list of symptoms designed to identify potential adverse drug reactions (45).,"['C1880156', 'C3272598', 'C3272378', 'C0034394', 'C1457887', 'C0683368', 'C0031323', 'C2700400', 'C1515981', 'C3245505', 'C0205210', 'C1273517', 'C0332256', 'C0745732', 'C0041755', 'C0030551']","['Clinical', 'Contain (action)', 'Symptoms aspect', 'Questionnaires', 'Pharmacist', 'parent', 'potential', 'WHO Temperature/Humidity Storage Condition', 'And', 'List', 'Symptoms', 'Containing (qualifier)', 'used by', 'Adverse reaction to drug', 'Sequence Data Type', 'Comprehensive']","['fndg', 'prog', 'idcn', 'inpr', 'famg', 'sosy', 'qlco', 'ftcn', 'patf', 'acty']"
271,PMC3028347,S81,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes and follow-up measures.,"the prespecified primary study end point was change in bmi sd score (bmi z), as determined at the end of the 6-month randomized treatment phase.","['C3815594', 'C1705241', 'C0205225', 'C3538994', 'C1710475', 'C0392747', 'C1533734', 'C0443172', 'C0087111', 'C3887704', 'C1705169', 'C0039798', 'C0034656', 'C0332177', 'C0205390', 'C2349179', 'C0444930', 'C4319952', 'C2603343', 'C1522326', 'C2746065', 'C0439231', 'C0578022']","['Study', 'month', 'Treatment Epoch', 'Changed status', 'Biomaterial Treatment', 'Administration procedure', 'Changing', 'Subject is Randomized', 'Finding of body mass index', 'End', 'Monthly (qualifier value)', 'Change -- procedure', 'Trial Phase', 'Phase', 'Primary', 'treatment - ActInformationManagementReason', 'Treating', 'Stop (qualifier value)', 'therapeutic aspects', 'Delta (difference)', 'Randomization', 'End Point', 'Therapeutic procedure']","['tmco', 'fndg', 'topp', 'clas', 'hlca', 'qnco', 'qlco', 'spco', 'resa', 'ftcn', 'cnce']"
272,PMC3028347,S82,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes and follow-up measures.,"secondary outcomes were changes in bmi, body weight, and fat mass at the conclusion of the randomized phase.","['C3815594', 'C1305866', 'C1710475', 'C0392747', 'C0443172', 'C0205436', 'C1707478', 'C0034656', 'C1306372', 'C0577573', 'C0205390', 'C0175668', 'C0005910', 'C0577559', 'C0027627', 'C0424612', 'C4283905', 'C3887682', 'C1708004', 'C0578022', 'C1515981', 'C0030234', 'C3152252']","['FAT1 wt Allele', 'Mass of body structure', 'Weighing patient', 'And', 'Platelet Glycoprotein 4, human', 'Body Weight', 'second (number)', 'Changed status', 'Mass of body region', 'Palmitic Acid', 'Neoplasm Metastasis', 'Changing', 'Subject is Randomized', 'Finding of body mass index', 'Obese build', 'Trial Phase', 'Conclusion', 'Phase', 'Morphology, Attenuation, Size, and Structure Criteria', 'Secondary to', 'Mass, a measure of quantity of matter', 'Randomization', 'Molecular Mass']","['tmco', 'fndg', 'resa', 'gngm', 'hlca', 'idcn', ' orch', 'clas', 'inpr', 'sosy', 'qlco', 'qnco', 'bacs', 'rcpt', 'orga', 'ftcn', 'neop', ' aapp']"
273,PMC3028347,S83,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes and follow-up measures.,"tertiary outcomes included changes in skinfold thickness, body circumferences, visceral adipose tissue, insulin resistance, and laboratory components of the metabolic syndrome.","['C0443172', 'C0449432', 'C0205372', 'C0442045', 'C0021655', 'C0037302', 'C3244292', 'C0001527', 'C0524620', 'C4049994', 'C4283904', 'C1515981', 'C0022877', 'C0392747', 'C0332257']","['Skinfold Thickness', 'Laboratory', 'Visceral', 'Changing', 'Component object', 'Laboratory domain', 'Metabolic Syndrome X', 'Insulin Resistance', 'tertiary', 'And', 'Changed status', 'Adipose tissue', 'Including (qualifier)', 'Insulin Resistance Measurement', 'Laboratory observation']","['patf', 'lbtr', ' hcro', 'idcn', 'tisu', 'qnco', 'lbpr', 'dsyn', 'spco', 'ftcn', 'mnob', 'diap']"
274,PMC3028347,S84,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Outcomes and follow-up measures.,participants were seen monthly and exchanged their unused study medication for a new supply at each visit.,"['C1875802', 'C2603343', 'C0679646', 'C1457900', 'C4284232', 'C1999230', 'C0445107', 'C2826704', 'C0332177', 'C1561604', 'C0545082', 'C3244316', 'C0243163', 'C0699914', 'C1512346', 'C0205314', 'C0013227']","['Healthcare supplies', 'Providing (action)', 'supply aspects', 'Medications', 'Participant', 'Patient Visit', 'Visit Name', 'Economic supply', 'Each (qualifier value)', 'New', 'not used', 'Monthly (qualifier value)', 'Study', 'Pharmaceutical Preparations', 'Visit', 'medication - HL7 publishing domain', 'Supply (process)']","['tmco', 'medd', 'hlca', 'idcn', 'inpr', 'qnco', 'qlco', 'bhvr', 'resa', 'ftcn', 'acty', 'popg', 'phsu']"
275,PMC3028347,S85,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Outcomes and follow-up measures.,we used the tally of returned capsules to assess adherence.,"['C3714905', 'C0006935', 'C1510802', 'C0332156']","['Quantity Final Containers Returned', 'Return to (contextual qualifier) (qualifier value)', 'Adherence (attribute)', 'capsule (pharmacologic)']","['qnco', 'bodm', 'qlco', 'ftcn']"
276,PMC3028347,S86,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes and follow-up measures.,"measurements of bmi, blood pressure, liver function, plasma lactate, and serum vitamin b12 were obtained at each visit, along with an interim history obtained using a structured list of queries.","['C1301820', 'C3272378', 'C0376261', 'C0019664', 'C0032105', 'C1272641', 'C1512346', 'C0242485', 'C1457900', 'C0005823', 'C0545082', 'C0262926', 'C0022924', 'C0019665', 'C1271104', 'C2826704', 'C2004062', 'C1705255', 'C0745732', 'C0262512', 'C4521445', 'C0578022', 'C2827738', 'C1515981', 'C0427408', 'C0232741']","['Patient Visit', 'Each (qualifier value)', 'And', 'Lactates', 'Systemic arterial pressure', 'History', 'Measurement', 'Obtain', 'List', 'Serum vitamin B12 measurement', 'Visit', 'Blood Pressure', 'Medical History', 'History of previous events', 'Concept History', 'liver function', 'Visit Name', 'History of present illness', 'Finding of body mass index', 'Blood pressure finding', 'Sequence Data Type', 'Interim', 'Lactate', 'Plasma Product', 'Plasma', 'Historical aspects qualifier']","['tmco', 'fndg', 'ortf', 'idcn', 'hlca', 'bdsu', 'ocdi', 'orch', 'qnco', 'inpr', 'lbpr', 'bhvr', 'orgf', 'ftcn', ' phsu', 'cnce', 'phsu']"
277,PMC3028347,S87,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Outcomes and follow-up measures.,"after 6 months of treatment, subjects were re-evaluated and then offered open-label metformin for a second 6-month treatment period with continued monthly visits.","['C1561503', 'C3538994', 'C0521125', 'C0181496', 'C1883708', 'C1512346', 'C1533734', 'C4321252', 'C0087111', 'C3887704', 'C1705169', 'C0039798', 'C0205436', 'C0332177', 'C0545082', 'C0457385', 'C4522130', 'C1705190', 'C0439531', 'C2827499', 'C0220825', 'C0025598', 'C4551445', 'C0175566', 'C1522326', 'C0549178', 'C0439231', 'C1515981', 'C1948053']","['Patient Visit', 'And', 'Metformin', 'Visit', 'month', 'Label (document)', 'Period (temporal qualifier)', 'Human Cells, Tissues, and Cellular and Tissue-Based Products Labeling', 'Treatment Epoch', 'second (number)', 'Biomaterial Treatment', 'Precision - second', 'Administration procedure', 'Continuous', 'Open', 'Labels (device)', 'WWOX wt Allele', 'Monthly (qualifier value)', 'Labeling Activity', 'Preposition For', 'Second Suffix', 'seconds', 'treatment - ActInformationManagementReason', 'Treating', 'therapeutic aspects', 'Then', 'per period (qualifier value)', 'Evaluation', 'Therapeutic procedure']","['tmco', 'mnob', 'gngm', 'topp', 'hlca', 'idcn', 'inpr', 'orch', 'qlco', 'qnco', 'bhvr', 'spco', 'resa', 'ftcn', 'acty', ' phsu', 'cnce']"
278,PMC3028347,S89,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analysis.,power was based on prior data we collected examining bmi change over 6 months in obese 6- to 11-year-old children with hyperinsulinemia.,"['C0443172', 'C1705241', 'C0032863', 'C0008059', 'C0680063', 'C3245479', 'C0439231', 'C0020459', 'C0852795', 'C2826257', 'C0439234', 'C3854080', 'C0578022', 'C0580836', 'C0392747', 'C4319952', 'C3714741', 'C1511726', 'C0332152', 'C0028754']","['Data call receiving device', 'year', 'Changing', 'Child', 'Power (Psychology)', 'Finding of body mass index', 'Increased insulin level', 'Data (eukaryote)', 'Old', 'Prior Medication Usage', 'Hyperinsulinism', 'Power', 'Offspring', 'Changed status', 'Change -- procedure', 'Obesity', 'Before', 'Delta (difference)', 'month', 'Data']","['tmco', 'evnt', 'fndg', 'medd', 'topp', 'idcn', 'famg', 'qnco', 'dsyn', 'euka', 'hcpp', 'ftcn', 'aggp']"
279,PMC3028347,S90,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analysis.,"we calculated that among severely obese children, a total sample size of 60 participants would detect a between-group difference of 0.09 bmi sd score units (approximately equivalent to a 2 kg/m2 difference) with 80% power.","['C1705241', 'C3853603', 'C0439185', 'C0442726', 'C0205082', 'C1257890', 'C0205103', 'C0441833', 'C0449820', 'C0439810', 'C0242618', 'C1705428', 'C0439148', 'C0332232', 'C4050231', 'C0032863', 'C0332287', 'C0680063', 'C1519504', 'C0679646', 'C1705429', 'C3854080', 'C1705242', 'C0008059', 'C0578022', 'C0687744', 'C0205163', 'C3891454', 'C1519795', 'C0028754']","['Group Object', 'In addition to', 'Unit - NCI Thesaurus Property', 'Power', 'Offspring', 'Detected (finding)', 'Unit of Measure', 'Equal', 'Participant', 'Unit', 'Score', 'Dosing Days to Detection', 'approximately', 'User Group', 'Groups', 'Population Group', 'Social group', 'Finding of body mass index', 'Total', 'Equivalent Weight', 'Intermediate', 'Different', 'Sample Size', 'Child', 'Power (Psychology)', 'Severe (severity modifier)', 'ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated', 'Obesity', 'Delta (difference)', 'Stage Grouping']","['tmco', 'fndg', 'idcn', 'famg', 'qnco', 'qlco', 'dsyn', 'spco', 'hcpp', 'ftcn', 'popg', 'aggp', 'cnce', 'clna']"
280,PMC3028347,S91,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analysis.,participant accrual was set at 100 participants to allow as much as 40% loss to follow-up (46).,"['C1510756', 'C0679646', 'C4281574', 'C1517945', 'C2698741', 'C4554048']","['Accrual', 'Study Participant', 'Much', 'Participant', 'Participant Object', 'Loss']","['fndg', 'clas', 'qnco', 'ftcn', 'popg']"
281,PMC3028347,S92,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis.,"the reported primary data analyses were prespecified and analyzed using spss for windows, version 14.0 (spss, chicago, il).","['C0333052', 'C2827398', 'C0684224', 'C0557702', 'C0010992', 'C0008044', 'C0700287', 'C4319718']","['Chicago', 'Data Analysis', 'Version', 'Window (physical object)', 'Reported', 'Reporting', 'Report (document)', 'Primary Data']","['ocac', 'idcn', 'hlca', 'inpr', 'geoa', 'ftcn', 'mnob']"
282,PMC3028347,S93,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis.,interim analyses for efficacy were performed by the data safety monitoring board when 40 and 70 subjects had been enrolled for 6 months of randomized phase treatment.,"['C3815594', 'C0087111', 'C1522326', 'C0439231', 'C0205390', 'C3887704', 'C1705169', 'C0039798', 'C0034656', 'C3538994', 'C2827738', 'C1515981', 'C1710475', 'C3889145', 'C1707887', 'C1533734', 'C1280519']","['Effectiveness', 'month', 'treatment - ActInformationManagementReason', 'Subject is Randomized', 'Treating', 'Treatment Epoch', 'And', 'Interim', 'Clinical Trial Oversight Committee Information', 'Efficacy Study', 'therapeutic aspects', 'Trial Phase', 'Biomaterial Treatment', 'Randomization', 'Administration procedure', 'Phase', 'Therapeutic procedure']","['tmco', 'fndg', 'topp', 'idcn', 'clas', 'hlca', 'inpr', 'qlco', 'resa', 'ftcn', 'cnce']"
283,PMC3028347,S94,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis.,"using the lan-demets implementation of the o’brien-fleming method, the critical two-tailed α values were defined for each look, such that a p value of 0.04515 was considered significant at the end of the study.","['C1704926', 'C0039259', 'C1565156', 'C0521125', 'C0750502', 'C4321252', 'C1708476', 'C1457900', 'C1511545', 'C0205448', 'C0042295', 'C1704788', 'C1421478', 'C0043194', 'C1522609', 'C0444930', 'C0233426', 'C0750591', 'C2603343', 'C2746065', 'C1517210', 'C1546944', 'C0237881']","['Personal appearance', 'Numerical value', 'Tail', 'Each (qualifier value)', 'ABCB6 wt Allele', 'Study', 'Definition', 'Critical', 'Fleming Method Relaxation', 'Values', 'Wiskott-Aldrich Syndrome', 'Implementation', 'Two', 'WAS gene', 'Statistical Significance', 'WWOX wt Allele', 'consider', 'End', 'Preposition For', 'Event Seriousness - Significant', 'Significant', 'WAS protein, human', 'Stop (qualifier value)']","['tmco', 'gngm', 'topp', 'idcn', 'inpr', 'qnco', 'qlco', 'bacs', 'orga', 'dsyn', 'spco', 'resa', ' aapp', 'bpoc', 'acty']"
284,PMC3028347,S95,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis.,we assessed efficacy in the intention-to-treat sample of all randomly assigned participants using a multiple imputation model for missing data under a missing-at-random assumption.,"['C3274659', 'C1516050', 'C0521125', 'C1705492', 'C4321252', 'C0439605', 'C0034656', 'C1707887', 'C3714583', 'C1551393', 'C1280519', 'C2347026', 'C3245479', 'C0679646', 'C1283828', 'C0162425', 'C2699638', 'C0444868', 'C0370003', 'C3272743', 'C3853906', 'C3161035', 'C1552601', 'C3714741', 'C0439064', 'C1511726']","['Data (eukaryote)', 'Statistical Imputation', 'Missing Study Animal', 'intent', 'Effectiveness', 'Model Number', 'Digital Model Attachment', 'Participant', 'Intention - mental process', 'Random', 'Model - style/design', 'Missing', 'Assignment - action', 'Data call receiving device', 'Container status - Missing', 'All', 'Model', 'WWOX wt Allele', 'Preposition For', 'Numerous', 'Efficacy Study', 'Specimen', 'Biospecimen', 'Randomization', 'PersonNameUse - assigned', 'Data']","['fndg', 'medd', 'idcn', 'gngm', 'inpr', 'qlco', 'qnco', 'sbst', 'euka', 'resa', 'ftcn', 'popg', 'menp', 'cnce']"
285,PMC3028347,S96,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis.,"by using norm, version 2.03 (pennsylvania state university, state university park, pa), we included all available baseline and follow-up measures in an imputation model.","['C3274659', 'C0333052', 'C1442488', 'C0079809', 'C0030853', 'C3853906', 'C3148680', 'C0562547', 'C0168634', 'C0470187', 'C3161035', 'C2699638', 'C1515981', 'C3160718', 'C0444868', 'C0041740', 'C1301808', 'C1442792', 'C3714583']","['availability of', 'BaseLine dental cement', 'Model Number', 'All', 'Digital Model Attachment', 'Model', 'Version', 'Park (environment)', 'And', 'Statistical Imputation', 'PARKINSON DISEASE, LATE-ONSET', 'Measures', 'US State', 'Baseline', 'Geographic state', 'Universities', 'State', 'Model - style/design', 'Pennsylvania']","['bodm', ' mnob', 'orgt', 'idcn', 'inpr', 'geoa', 'qnco', 'dsyn', 'ftcn', 'cnce']"
286,PMC3028347,S97,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis.,"the imputation datasets were obtained using a sequential chain of 1,200 iterations using initial parameter estimates supplied by running the expectation-maximization (em) algorithm.","['C2350001', 'C1555582', 'C4553402', 'C0205265', 'C0679138', 'C1704769', 'C1548958', 'C1553907', 'C1279901', 'C0549193', 'C0002045', 'C0750572', 'C2699638', 'C0337112', 'C1705685', 'C4319934', 'C1854293', 'C1705294', 'C1524075']","['imaging chain', 'Firstly', 'Estimated', 'Observation Method - algorithm', 'Initially', 'algorithm', 'Sequential', 'chain of objects', 'Initial (abbreviation)', 'Initial Usage', 'Expectations', 'Iterations', 'Programming Parameter', 'Population Parameter', 'Sequential - Sequence/Results Flag', 'Parameter Value', 'Statistical Imputation', 'Group Sequential Design', 'Chain device']","['tmco', 'fndg', 'medd', 'idcn', 'inpr', 'qnco', 'qlco', 'resa', 'ftcn', 'mnob', 'cnce']"
287,PMC3028347,S98,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis.,"starting after the first 200 iterations, data were sampled with 50 iterations between successive imputations.","['C3245479', 'C0205435', 'C1279901', 'C3714741', 'C1511726', 'C1854293']","['Data call receiving device', 'Firstly', 'First (number)', 'Data (eukaryote)', 'Iterations', 'Data']","['fndg', 'medd', 'idcn', 'qnco', 'qlco', 'euka']"
288,PMC3028347,S99,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis.,"each of the imputation-completed datasets was then analyzed separately using the prespecified ancova model with spss for windows, version 14.0.","['C3854010', 'C3274659', 'C0333052', 'C0205197', 'C1457900', 'C3853906', 'C1421478', 'C1565156', 'C0557702', 'C3161035', 'C2699638', 'C0043194', 'C0814908', 'C1883708', 'C3714583', 'C0936012']","['ancova', 'completed - RoleLinkStatus', 'Model Number', 'Digital Model Attachment', 'Version', 'Model', 'WAS protein, human', 'Analysis', 'Window (physical object)', 'Each (qualifier value)', 'WAS gene', 'Statistical Imputation', 'Then', 'Complete', 'Model - style/design', 'Wiskott-Aldrich Syndrome']","['tmco', 'gngm', 'idcn', 'inpr', 'qnco', 'qlco', 'bacs', 'dsyn', 'resa', 'ftcn', 'mnob', ' aapp', 'cnce']"
289,PMC3036630,S43,['4b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"thirty-two patients with mild to moderately severe copd were included from two respiratory clinics in amsterdam, the netherlands.","['C4050465', 'C1517320', 'C0030705', 'C0442592', 'C4321491', 'C1412502', 'C2945599', 'C1881878', 'C0027778', 'C0332287', 'C4085643', 'C3816446', 'C0205448', 'C0205082', 'C4050466', 'C0521346', 'C0332257', 'C1546767']","['Mild (qualifier value)', 'respiratory', 'Clinic', 'Netherlands', 'Borg Category-Ratio 10 Perceived Exertion Score 5', 'Specimen Source Codes - Respiratory', 'Severe Extremity Pain', 'Including (qualifier)', 'Severe (severity modifier)', 'Patients', 'Two', 'ARCN1 gene', 'Thirty', 'From', 'Moderate Response', 'In addition to', 'Moderately Able', 'Moderation']","['inpr', 'geoa', 'gngm', 'ftcn', 'mnob', 'fndg', 'podg', 'qlco', ' hcro', 'qnco']"
290,PMC3036630,S44,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,the definition of copd was based on gold[1].,"['C1304897', 'C0018026', 'C1412502', 'C3888054', 'C1704788', 'C1550452']","['DEFINITION - NCI Thesaurus Property', 'Definition', 'ARCN1 gene', 'definition - ActMoodCompletionTrack', 'Gold color', 'Gold']","['inpr', 'idcn', 'gngm', 'elii', 'cnce', 'qlco', ' phsu']"
291,PMC3036630,S45,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"inclusion criteria were symptoms of dyspnea, chronic cough or sputum production, current or ex-smoker with at least 20 packyears of smoking history, postbronchodilator fev1 >1.5 liter and >50% of predicted value, fev1/fvc <0.70 and clinically stable for ≥ 4 weeks prior to recruitment.","['C0262926', 'C0683368', 'C1515981', 'C4321252', 'C0019665', 'C0521116', 'C0010201', 'C0262512', 'C0013404', 'C0242104', 'C0337664', 'C1547311', 'C2949735', 'C0205360', 'C0019664', 'C1457887', 'C0681842', 'C0521125', 'C0475211', 'C0332152', 'C2004062', 'C1963100', 'C1705970', 'C1522609', 'C1705255', 'C1442465', 'C3714541', 'C1512693']","['Electrical Current', 'Medical History', 'And', 'History', 'liter', 'Preposition For', 'WWOX wt Allele', 'Forced Vital Capacity', 'Patient Condition Code - Stable', 'Current (present time)', 'Before', 'Stable status', 'Dyspnea, CTCAE', 'Symptoms', 'Inclusion', 'Concept History', 'Symptoms aspect', 'Dyspnea', 'History of present illness', 'Recruitment', '4 Weeks', 'Smoker', 'Numerical value', 'Historical aspects qualifier', 'prediction', 'Chronic cough', 'Sputum production', 'History of previous events']","['sosy', 'ortf', 'inpr', 'idcn', 'acty', 'gngm', 'ocdi', 'lbtr', 'ftcn', 'fndg', 'cnce', 'qlco', 'tmco', 'npop', 'qnco']"
292,PMC3036630,S46,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"exclusion criteria were (inhaled) steroid therapy or antibiotic treatment or exacerbation or chest infection ≤ 4 weeks prior to recruitment, treatment with β-blockers, respiratory disease other than copd including known asthma or allergic rhinitis and contra-indications for challenge testing according to international guidelines[15].","['C3887704', 'C1705169', 'C1412502', 'C1515981', 'C4552864', 'C0680251', 'C1334103', 'C0199779', 'C0004096', 'C0162791', 'C0238990', 'C0332287', 'C2607914', 'C0004048', 'C0039798', 'C3538994', 'C0220845', 'C2949735', 'C0282423', 'C1315011', 'C0332152', 'C0332257', 'C0035204', 'C2984299', 'C0392360', 'C0035242', 'C0149783', 'C0205309', 'C1442465', 'C0087111', 'C1522326', 'C1533734', 'C1512888', 'C4086268', 'C0149725']","['Allergic rhinitis (disorder)', 'Asthma', 'Biomaterial Treatment', 'And', 'Exclusion Criteria', 'Administration of antibiotic', 'International', 'Steroid therapy', 'Challenge tests', 'Therapeutic procedure', 'Administration procedure', 'ARCN1 gene', 'Before', 'Asthma Pathway', 'guiding characteristics', 'IL13 gene', 'Treatment Epoch', 'Known', 'Indication of (contextual qualifier)', 'Lower respiratory tract infection', 'therapeutic aspects', 'Acute lower respiratory tract infection', 'treatment - ActInformationManagementReason', '4 Weeks', 'Inspiration function', 'Recruitment', 'Respiration Disorders', 'In addition to', 'Allergic Rhinitis, CTCAE', 'Guideline [Publication Type]', 'Including (qualifier)', 'Treating', 'Exacerbation', 'Respiratory Tract Diseases', 'Guidelines']","['inpr', 'idcn', 'lbpr', 'gngm', 'acty', 'topp', 'ftcn', 'fndg', 'cnce', 'tmco', 'qlco', 'resa', 'dsyn', 'hlca', 'orgf']"
293,PMC3036630,S47,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,patients were asked to withhold strenuous exercise and smoking for 6 hrs and eating for 2 hrs; caffeine and short-acting bronchodilators for 8 hrs; long-acting bronchodilators for 48 hrs; short-acting anti-cholinergics for 24 hrs; long-acting anti-cholinergics and anti-histamines for 72 hrs; and leukotriene antagonists for 4 days prior to the mannitol challenge.,"['C0030705', 'C0024730', 'C1515981', 'C0805586', 'C0205166', 'C0037369', 'C0006644', 'C0595726', 'C1706317', 'C3274764', 'C1514989', 'C1442765', 'C0019588', 'C2350002', 'C0798503', 'C0242893', 'C0006280', 'C1282927', 'C1806781', 'C1881674', 'C0332152', 'C1568891', 'C2826257', 'C0453996']","['Strenuous Exercise', 'HGS protein, human', 'Mannitol', 'And', 'Histamine', 'Patients', 'Cholinergic Agents', 'Short', 'Long', 'Proficiency Testing Challenge', 'Shortened', 'Before', 'Leukotriene Antagonists', 'Long Variable', 'Tobacco smoking behavior', 'Prior Medication Usage', 'Challenge:Type:Point in time:^Patient:Nominal', 'Caffeine', '4 Days', 'Short Value', 'Challenge', 'Bronchodilator Agents', 'Smoking', 'Medical Device Emits Smoke']","['bacs', 'clna', ' orch', 'inbe', 'idcn', 'dora', 'fndg', 'cnce', 'orch', 'podg', 'qlco', 'tmco', ' phsu', 'hlca', ' aapp', 'qnco', 'phsu', 'evnt']"
294,PMC3036630,S48,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,the study was approved by the hospital medical ethics committee and all patients gave their written informed consent.,"['C0015004', 'C0019994', 'C0021430', 'C0030705', 'C0085546', 'C1515981', 'C2603343', 'C0444868']","['Ethics Committees', 'All', 'And', 'Ethics, Medical', 'Patients', 'Study', 'Informed Consent', 'Hospitals']","['rnlw', 'idcn', 'prog', 'mnob', 'podg', 'resa', ' hcro', 'qnco']"
295,PMC3036630,S49,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"the study was registered in the netherlands trial register under ntr 1283, was designed, performed and analysed by the authors, and was not sponsored by others than the academic medical centre, amsterdam, the netherlands itself.",,,
296,PMC3036630,S51,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,the study had a cross-sectional design with two studies days comprising randomized challenges with hypertonic saline and mannitol (figure 1).,"['C0036085', 'C2983265', 'C1707689', 'C0024730', 'C0034656', 'C1515981', 'C2828360', 'C0947630', 'C2603343', 'C0205155', 'C0205448', 'C0805586', 'C0439228', 'C3815594']","['Traverse', 'Randomization', 'day', 'Sectional Distribution', 'Subject is Randomized', 'Mannitol', 'And', 'Study', 'Two', 'Challenge', 'Scientific Study', 'Design', 'CDISC SEND Study Design Terminology', 'Saline Solution, Hypertonic']","['inpr', 'idcn', 'inch', 'acty', 'lbpr', 'spco', 'fndg', 'orch', 'cnce', 'tmco', 'resa', ' phsu', 'hlca', 'qnco']"
297,PMC3036630,S52,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"at a separate screening visit, inclusion and exclusion criteria were examined, postbronchodilator (400 μg salbutamol) spirometry was performed and diffusion capacity was measured.","['C0443299', 'C2348164', 'C0805915', 'C1698960', 'C1512346', 'C0037981', 'C0545082', 'C1710031', 'C2826704', 'C0220909', 'C0680252', 'C0001927', 'C1710032', 'C1710477', 'C0220908', 'C0680251']","['Albuterol', 'Spirometry', 'research subject screening', 'Visit', 'Screening Study', 'Aspects of disease screening', 'Patient Visit', 'Visit Name', 'Exclusion Criteria', 'Screening procedure', 'inclusion and exclusion', 'Screening', 'diffusion capacity', 'Trial Screening', 'Separate', 'Disease Screening']","['inpr', 'clna', 'ftcn', 'orch', 'qlco', ' phsu', 'resa', 'bhvr', 'hlca', 'diap']"
298,PMC3036630,S53,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,figure 1 study design.,,,
299,PMC3036630,S54,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,the sequence of the two study visits was randomized [interval (median (range)):7(7-15) days].,"['C2939193', 'C3853789', 'C0004793', 'C1519249', 'C0034656', 'C2603343', 'C1552654', 'C2348147', 'C0545082', 'C1552713', 'C2348144', 'C0205448', 'C1272706', 'C0439228', 'C1514721', 'C0162326', 'C0549183', 'C1512346', 'C0876920', 'C0162327', 'C3815594', 'C2347635']","['Base Sequence', 'Parameterized Data Type - Interval', 'Randomization', 'day', 'Visit', 'RNA Sequence', 'Median Statistical Measurement', 'Sequence', 'Sequence - TransmissionRelationshipTypeCode', 'Sample Range', 'DNA Sequence', 'Midline (qualifier value)', 'Population Median', 'Range', 'Patient Visit', 'Data Type Interval', 'Interval', 'Study', 'Two', 'Median (qualifier value)', 'Subject is Randomized', 'Sample Median']","['inpr', 'nusq', 'ftcn', 'spco', 'fndg', 'tmco', 'resa', 'bhvr', 'hlca', 'qnco']"
300,PMC3036630,S55,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,on one day sputum was induced by hypertonic saline and a venous blood sample was obtained.,"['C0036085', 'C3844320', 'C0444255', 'C1515981', 'C0038056']","['venous blood sample', 'Sputum', 'One day', 'And', 'Saline Solution, Hypertonic']","['idcn', 'inch', 'bdsu', 'tmco', ' phsu']"
301,PMC3036630,S56,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,"on the other day exhaled nitric oxide was measured first, followed by assessment of atopy and mannitol challenge testing.","['C0028128', 'C1261322', 'C1279901', 'C0332173', 'C3810607', 'C0439228', 'C0205435', 'C1516048', 'C1315011']","['Nitric Oxide Measurement', 'Firstly', 'day', 'Evaluation procedure', 'Daily', 'First (number)', 'Challenge tests', 'Nitric Oxide', 'Assessed']","['bacs', 'lbpr', 'acty', 'tmco', 'qlco', ' phsu', 'hlca', 'qnco', ' inch']"
302,PMC3036630,S59,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Measurements,"spirometry (masterscreenpneumo; jaeger; würzburg, germany) was performed by a trained respiratory technician according to the latest recommendations[16].","['C0325865', 'C0034866', 'C0017480', 'C1556020', 'C0521346', 'C1546767']","['Recommendation', 'respiratory', 'Specimen Source Codes - Respiratory', 'jaeger', 'Technician', 'Germany']","['inpr', 'idcn', 'bird', 'geoa', 'prog', 'ftcn']"
303,PMC3036630,S60,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Measurements,"diffusion capacity of the lung for carbon monoxide (dl, co) was measured according to the recommendations using the single breath method and was corrected for haemoglobin[17].","['C0871511', 'C0521125', 'C0034866', 'C3541902', 'C0449851', 'C0805915', 'C1515981', 'C0007018', 'C1979974', 'C4321252', 'C1565156', 'C0024109', 'C0680240', 'C1421478', 'C0043194', 'C0025663', 'C4520712', 'C0444706']","['Recommendation', 'Carbon Monoxide', 'Measured', 'Measured Tumor Identification', 'WAS protein, human', 'WAS gene', 'Techniques', 'Methods', 'And', 'Agreement', 'Wiskott-Aldrich Syndrome', 'Lung', 'Preposition For', 'WWOX wt Allele', 'diffusion capacity', 'Test Method', 'Carbon Monoxide Measurement', 'Single breath']","['bacs', 'bpoc', 'inpr', 'clna', 'idcn', 'lbpr', 'gngm', 'hops', 'ftcn', 'qlco', 'socb', 'dsyn', ' aapp', 'diap', ' inch']"
304,PMC3036630,S62,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Measurements,"mannitol challenge was performed using a commercially available kit (pharmaxis ltd; sydney, australia) as described by anderson et al[8].","['C1150635', 'C3274764', 'C0024730', 'C3853650', 'C0004340', 'C1705213', 'C0812225', 'C0470187', 'C1136140', 'C0805586', 'C0798503', 'C3273202']","['Proficiency Testing Challenge', 'Drug Kit', 'Kit device', 'Promotional Kit', 'Challenge:Type:Point in time:^Patient:Nominal', 'availability of', 'Long-Term Synaptic Depression', 'Mannitol', 'stem cell factor receptor activity', 'Challenge', 'Mast/Stem Cell Growth Factor Receptor Kit, human', 'Australia']","['ortf', 'clna', 'moft', 'geoa', 'rcpt', 'medd', ' imft', 'ftcn', 'cnce', 'mnob', 'orch', ' phsu', 'hlca', ' aapp']"
305,PMC3036630,S63,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Measurements,"patients inhaled sequential doses of 5, 10, 20, 40, 80, 160, 160 and 160 mg of mannitol via the inhaler.","['C1705294', 'C4553402', 'C0178602', 'C0030705', 'C1548958', 'C0024730', 'C0021461', 'C1515981', 'C1881212', 'C0004048']","['Sequential', 'Inhaler Dosing Unit', 'Mannitol', 'And', 'Patients', 'Inhaler', 'Sequential - Sequence/Results Flag', 'Inspiration function', 'Dosage', 'Group Sequential Design']","['idcn', 'medd', 'podg', 'orch', 'qlco', 'resa', ' phsu', 'orgf', 'qnco']"
306,PMC3036630,S64,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Measurements,the test stopped when 15% fall in fev1 was achieved or the cumulative dose of 635 mg had been administered.,"['C0022885', 'C0238715', 'C1515976', 'C0085639', 'C4553726', 'C2986497', 'C0456984', 'C0392366', 'C3831328', 'C4318744', 'C0039593']","['Test Result', 'Laboratory Procedures', 'Tests (qualifier value)', 'Testing', 'Autumn', 'Anatomic Structure, System, or Substance', 'Cumulative Dose', 'Test - temporal region', 'Blood Products Laboratory Testing', 'Fall, CTCAE', 'Falls']","['inpr', 'lbpr', 'clas', 'lbtr', 'ftcn', 'fndg', 'cnce', 'tmco', 'blor']"
307,PMC3036630,S65,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Measurements,"response-dose-ratio (rdr) was calculated as the%fall in fev1 at the last dose, divided by the total cumulative dose mannitol (%fall.mg) in milligrams administered[18].","['C1549885', 'C3889386', 'C1547037', 'C1441506', 'C0178602', 'C0238715', 'C0085639', 'C0024730', 'C0332849', 'C1517741', 'C4553726', 'C2986497', 'C0439810', 'C0444686', 'C0456603', 'C0439210', 'C0043194', 'C1565156', 'C1421478']","['Calculation', 'RDR - Message structure', 'WAS protein, human', 'milligram', 'Calculated', 'Mannitol', 'WAS gene', 'Ratio', 'Autumn', 'Wiskott-Aldrich Syndrome', 'Cumulative Dose', 'divided', 'Total', 'SLC1A5 wt Allele', 'data type - ratio', 'Dosage', 'Last', 'Fall, CTCAE', 'Falls']","['bacs', 'inpr', 'acty', 'gngm', 'ftcn', 'fndg', 'cnce', 'orch', 'tmco', 'qlco', ' phsu', ' aapp', 'qnco', 'dsyn']"
308,PMC3036630,S66,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Measurements,"if a patient had to cough spontaneously during the mannitol challenge, he or she was asked to expectorate.","['C3274764', 'C0030705', 'C0024730', 'C0805586', 'C1822717', 'C0798503']","['Proficiency Testing Challenge', 'Challenge:Type:Point in time:^Patient:Nominal', 'Mannitol', 'Patients', 'Challenge', 'SHE gene']","['clna', 'gngm', 'cnce', 'orch', 'podg', ' phsu', 'hlca']"
309,PMC3036630,S67,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Measurements,this sputum was labeled as mannitol-induced sputum.,"['C1708632', 'C0024730', 'C0038056', 'C0043194', 'C1565156', 'C1421478', 'C1080058', 'C0205263']","['Labeled (qualifier)', 'WAS protein, human', 'Sputum', 'WAS gene', 'Mannitol', 'Wiskott-Aldrich Syndrome', 'Induce (action)', 'This (eukaryote)']","['bacs', 'gngm', 'ftcn', 'orch', 'qlco', 'bdsu', 'euka', ' phsu', ' aapp', 'dsyn']"
310,PMC3036630,S69,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Measurements,"prior to sputum induction, patients inhaled 200 μg salbutamol.","['C0030705', 'C0332152', 'C0001927', 'C2826257', 'C0857127', 'C0205263']","['Albuterol', 'Prior Medication Usage', 'Induction procedure', 'Patients', 'Induce (action)', 'Before']","['topp', 'ftcn', 'orch', 'podg', 'tmco', ' phsu', 'evnt']"
311,PMC3036630,S70,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Measurements,sputum was induced by inhalation of nacl 4.5% during 3 × 5 min intervals[19].,"['C0037494', 'C0038056', 'C1272706', 'C0205535', 'C1705211', 'C0004048']","['Sodium Chloride', 'Sputum', 'Inhalation Route of Drug Administration', 'Interval', 'Inhalation Dosing Unit', 'Inspiration function']","['bacs', 'ftcn', 'bdsu', 'tmco', ' phsu', 'orgf', 'qnco', ' inch']"
312,PMC3036630,S71,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Measurements,this sputum was labeled as induced sputum.,"['C1080058', 'C0038056', 'C0205263']","['Sputum', 'Induce (action)', 'This (eukaryote)']","['ftcn', 'bdsu', 'euka']"
313,PMC3036630,S72,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Measurements,whole sputum samples were processed according to a protocol that has been validated in our laboratory[20].,"['C3715209', 'C0444667', 'C4283904', 'C4282383', 'C3244292', 'C0442711', 'C2599718', 'C0038056', 'C1522729', 'C1507394', 'C0022877', 'C2348563']","['Library Protocol', 'Protocol - answer to question', 'REMS Protocol', 'Clinical trial protocol', 'Sputum', 'Clinical trial protocol document', 'Whole', 'Protocols documentation', 'Study Protocol', 'Laboratory', 'Laboratory observation', 'Laboratory domain']","['inpr', 'lbtr', 'ftcn', 'mnob', 'fndg', 'bdsu', ' hcro', 'qnco']"
314,PMC3036630,S73,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Measurements,differential cell counts were expressed as the percentage of non-squamous cells.,"['C1561533', 'C1549488', 'C0439165', 'C0221910', 'C4554467', 'C0007584', 'C0443199', 'C1518422', 'C1705242']","['Money or percentage indicator - Percentage', 'Squamous Epithelial Cells', 'Differential - view', 'Percent (qualifier value)', 'Cell Count', 'Differential quality', 'Different', 'Negation', 'Amount type - Percentage']","['idcn', 'lbpr', 'ftcn', 'spco', 'qlco', 'cell', 'qnco']"
315,PMC3036630,S74,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Measurements,absolute cell numbers were calculated as (% cell × total cell count)/sputum weight.,"['C1305866', 'C0043100', 'C0007634', 'C1704653', 'C0205344', 'C0439810', 'C1413336', 'C0007584', 'C0038056', 'C1705104', 'C0449788', 'C1948049', 'C0005910', 'C0237753']","['Count of entities', 'Importance Weight', 'Body Weight', 'Sputum', 'Cells', 'Numbers', 'Weight', 'absolute', 'Weighing patient', 'Cell Device', 'Total', 'Cell Count', 'CEL gene', 'Cell (compartment)']","['lbpr', 'gngm', 'medd', 'spco', 'bdsu', 'qlco', 'hlca', 'cell', 'qnco', 'orga']"
316,PMC3036630,S75,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Measurements,sputum samples containing >80% non-squamous cells were excluded from analysis.,"['C0936012', 'C0221910', 'C0038056', 'C1524024', 'C1518422']","['Squamous Epithelial Cells', 'Sputum', 'Analysis', 'Negation', 'analysis aspect']","['ftcn', 'cell', 'bdsu', 'resa']"
317,PMC3036630,S76,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Measurements,all sputum cell counts were performed by one experienced and qualified technician blinded to the clinical details.,"['C0205447', 'C0205210', 'C0007584', 'C0038056', 'C1522508', 'C0444868']","['Clinical', 'Sputum', 'All', 'One', 'Cell Count', 'Details']","['lbpr', 'bdsu', 'qlco', 'qnco']"
318,PMC3036630,S77,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Measurements,as an extra control 10% of the samples were analyzed by a second technician.,"['C4553389', 'C1550141', 'C0205436', 'C1561503', 'C1705190', 'C1883702', 'C1556020', 'C0243148', 'C0457385', 'C3274648', 'C1882979', 'C2587213']","['Precision - second', 'True Control Status', 'Study Control', 'Supernumerary', 'second (number)', 'Second Suffix', 'control aspects', 'Control function', 'Technician', 'control substance', 'seconds', 'Scientific Control']","['idcn', 'prog', 'ftcn', 'cnce', 'qlco', 'tmco', 'sbst', 'qnco']"
319,PMC3036630,S79,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Measurements,"levels of eosinophil cationic protein (ecp; detection limit >60 pg/ml), myeloperoxidase (mpo; detection limit >1.5 ng/ml), interleukin-8 (il-8; detection limit >19.1 pg/ml) and alpha-2-macroglobulin (α2m; detection limit >2.1 mg/ml) were measured by enzyme-linked immunosorbent assays (elisa)[21,22].","['C1698756', 'C2003941', 'C0021075', 'C0441889', 'C0021764', 'C1527200', 'C1515981', 'C0439095', 'C0014441', 'C3889675', 'C0033684', 'C2718050', 'C0024420', 'C2350010']","['Alpha Value', 'Interleukins', 'Greek letter alpha (qualifier value)', 'Edit Check Program', 'Immunosorbents', 'Enzyme-Linked Immunosorbent Assay', 'Proteins', 'Macroglobulins', 'And', 'Levels (qualifier value)', 'Limit of Detection', 'Alpha', 'Recombinant Interleukins', 'CXCL8 protein, human']","['bacs', 'inpr', 'idcn', 'lbpr', 'irda', 'qlco', 'imft', ' phsu', ' aapp', 'qnco']"
320,PMC3036630,S81,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Measurements,"feno was measured with a portable rapid-response chemoluminescent analyser (flow rate 50 ml/s; niox system, aerocrine, sweden) according to recent guidelines[23].","['C1704632', 'C0220845', 'C3888058', 'C1553451', 'C2826285', 'C0332185', 'C1706817', 'C0162791', 'C0871261', 'C4299032', 'C0456962', 'C0449913', 'C2911692', 'C0282423', 'C0439390', 'C0038995']","['Response process', 'Guideline [Publication Type]', 'Flow Rate', 'Disease Response', 'System - kit', 'Response (communication)', 'Device system', 'Sweden', 'Portable', 'guiding characteristics', 'Guidelines', 'Rapid', 'System', 'Milliliter per Second', 'Response (statement)', 'Recent']","['inpr', 'geoa', 'ftcn', 'mnob', 'fndg', 'spco', 'qlco', 'tmco', 'menp', 'qnco', 'orga']"
321,PMC3036630,S83,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Measurements,the relationship between ahr to mannitol (rdr) and the markers of airway inflammation were analyzed using pearson's correlation coefficient (rp).,"['C1707429', 'C1549885', 'C3889386', 'C3540605', 'C1706279', 'C0439849', 'C1515981', 'C1705630', 'C1707520', 'C0458827', 'C0021368', 'C0178987']","['RDR - Message structure', 'Concept Relationship', 'Inflammation', 'Airway structure', 'Artificial Airways', 'And', 'CDISC Relationship Class', 'Correlation', 'Object Relationship', 'SLC1A5 wt Allele', 'Coefficient', 'Relationships']","['inpr', 'bpoc', 'idcn', 'gngm', 'medd', 'patf', 'qlco', 'qnco']"
322,PMC3036630,S84,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Measurements,non-normally distributed data were log-transformed for further analysis.,"['C1511726', 'C3245479', 'C0936012', 'C1704711', 'C1517331', 'C1524024', 'C3714741']","['Further', 'Distribution', 'Data call receiving device', 'Analysis', 'Data (eukaryote)', 'Data', 'analysis aspect']","['idcn', 'medd', 'ftcn', 'spco', 'euka', 'resa']"
323,PMC3036630,S85,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Measurements,"if no cells were counted, a value of 0.1 was taken before log-transformation.","['C1705163', 'C1522609', 'C0007634', 'C1510411', 'C0007584', 'C0040682']","['Numerical value', 'Data Transformation', 'cell transformation', 'Cells', 'metaplastic cell transformation', 'Cell Count']","['celf', 'lbpr', 'patf', 'resa', 'cell', 'qnco']"
324,PMC3036630,S86,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Measurements,"receiver operating characteristic (roc) curves were constructed, using rdr against eosinophilic vs non eosinophilic copd (threshold 2.5% sputum eosinophils).","['C1549885', 'C3889386', 'C1521970', 'C0521124', 'C0333930', 'C0449864', 'C0200638', 'C1412502', 'C0683187', 'C1518422', 'C0038056', 'C0014467', 'C1527113']","['against', 'Eosinophil count procedure', 'RDR - Message structure', 'Receiver Operator Characteristics', 'Sputum', 'threshold', 'ARCN1 gene', 'eosinophilic', 'eosinophil', 'Characteristics', 'SLC1A5 wt Allele', 'receptor operated channel', 'Negation']","['bacs', 'inpr', ' aapp', 'lbpr', 'gngm', 'ftcn', 'bdsu', 'qlco', 'cell', 'qnco']"
325,PMC3036630,S87,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Measurements,wilcoxon signed rank test and bland-altman analysis was used to compare cell counts of the two sputum samples.,"['C0022885', 'C0699794', 'C1515976', 'C0936012', 'C0667477', 'C1515981', 'C0007584', 'C0038056', 'C1524024', 'C0456984', 'C0205448', 'C0392366', 'C3831328', 'C4318744', 'C0039593']","['Test Result', 'TNFRSF11A protein, human', 'Laboratory Procedures', 'Sputum', 'Tests (qualifier value)', 'And', 'Testing', 'Anatomic Structure, System, or Substance', 'Analysis', 'Rank', 'Two', 'Test - temporal region', 'Blood Products Laboratory Testing', 'Cell Count', 'analysis aspect']","['bacs', 'inpr', 'idcn', 'lbpr', 'clas', 'lbtr', 'ftcn', 'blor', 'bdsu', 'resa', ' aapp', 'qnco']"
326,PMC3036630,S88,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Measurements,a sample size estimation showed that the detectable value of the correlation (r) under the alternative hypothesis with a sample of 23 patients (n) is between 1-0.55 (power = 0.808; alpha = 0.05).,"['C0680844', 'C0542339', 'C2003941', 'C0030705', 'C0750572', 'C1522609', 'C0032863', 'C1512571', 'C2347026', 'C0439095', 'C3854080', 'C1707520', 'C0681916', 'C3830527', 'C0242618', 'C0370003', 'C1523987', 'C2350010']","['Alpha Value', 'Estimated', 'Greek letter alpha (qualifier value)', 'Numerical value', 'Biospecimen', 'Detectable', 'Inferior', 'Alternative', 'Sample Size', 'Power (Psychology)', 'Hypothesis', 'Patients', 'estimation <subjective>', 'Alpha', 'Power', 'Correlation', 'Specimen', 'Statistical Estimation']","['hcpp', 'inpr', 'clna', 'idcn', 'cnce', 'spco', 'podg', 'qlco', 'menp', 'sbst', 'qnco']"
327,PMC3036630,S89,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Measurements,"therefore, thirty-two patients were recruited taking into account an expected 10% drop-out rate and a 20% probability of missing or non-valid data.","['C1511726', 'C3272743', 'C0033204', 'C0030705', 'C1551393', 'C3245479', 'C0439787', 'C0849355', 'C2981730', 'C1705492', 'C0871208', 'C3816446', 'C0205448', 'C2349099', 'C3714741', 'C1521828', 'C1517001', 'C1518422']","['Negation', 'Missing', 'Rate', 'Out (direction)', 'Probability', 'Data call receiving device', 'Rating (action)', 'Container status - Missing', 'Patients', 'Two', 'Thirty', 'Financial Account', 'Data (eukaryote)', 'Data', 'Expected', 'Valid', 'Removed', 'Missing Study Animal']","['inpr', 'idcn', 'acty', 'medd', 'ftcn', 'fndg', 'spco', 'podg', 'euka', 'qlco', 'qnco']"
328,PMC3070271,S34,['4b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,this was a multicentre trial including six centres.,"['C0008976', 'C0205099', 'C1080058', 'C0205452']","['Central', 'Clinical Trials', 'Six', 'This (eukaryote)']","['qnco', 'spco', 'euka', 'resa']"
329,PMC3070271,S35,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"inclusion criteria were age 2–20 years, a diagnosis of sjia,1 more than 6 months' disease duration, active systemic disease (disease-related fever and/or c-reactive protein (crp) >20 mg/l and/or first hour erythrocyte sedimentation rate (esr) >20) and significant overall disease activity at day 1 (d1) (at least three of the following criteria: (1) physician global assessment of disease activity ≥20/100; (2) parent/patient assessment of disease effect on overall wellbeing ≥20/100; (3) childhood health assessment questionnaire score ≥0.375/3; (4) ≥2 joints with active arthritis; (5) ≥2 joints with non-irreversible limited range of motion and (6) esr ≥30) despite oral prednisone or prednisolone ≥0.3 mg/kg or 10 mg/day (whichever was lower).","['C3811131', 'C3890735', 'C1561607', 'C3853793', 'C1512693', 'C0332282', 'C0205449', 'C0439268', 'C0442893', 'C1279901', 'C1565156', 'C4553855', 'C0012634', 'C0872146', 'C1518422', 'C0243161', 'C0750502', 'C1706528', 'C0026597', 'C0205177', 'C0439422', 'C3888249', 'C2732494', 'C0804815', 'C1292728', 'C0282416', 'C0031831', 'C2348382', 'C0205435', 'C4552845', 'C1704656', 'C1546944', 'C2003888', 'C1518681', 'C1280500', 'C2348147', 'C0439234', 'C0439272', 'C0439227', 'C1384600', 'C0205172', 'C4552740', 'C0030551', 'C0441994', 'C0679830', 'C1704338', 'C0003864', 'C0439801', 'C0442027', 'C1421478', 'C0032950', 'C0043194', 'C0439849', 'C4048285', 'C0022417', 'C2674459', 'C1413716', 'C1176468', 'C0011900', 'C0006560', 'C0032952', 'C1548802', 'C4050251', 'C1514721', 'C0281858', 'C0439231', 'C1442449', 'C2699423', 'C3813622', 'C1515981', 'C0392905', 'C1619634', 'C0001779', 'C0424755', 'C0015967', 'C0237881']","['Joints', 'C-Reactive Protein, human', 'Active License', 'Age', 'Overall', 'prednisolone', 'Effect, Appearance', 'Articular system', 'Overall Well Being', 'year', 'parent', 'diagnosis aspect', 'And', 'active (HL7 RoleLink)', 'global assessment', 'mg/kg', 'Systemic onset juvenile chronic arthritis', 'Systemic disease', 'Prednisone', 'Body Site Modifier - Lower', 'Motion', 'month', 'disease length', 'Diagnosis', 'Firstly', 'Range', 'Arthritis', 'Erythrocyte sedimentation rate measurement', 'Conceptual Parent', 'First (number)', 'Following', 'And/Or', 'Fever', 'Complete Response with Incomplete Platelet Recovery', 'Lower (action)', 'Childhood Health Assessment Questionnaire', 'Physicians', 'Physician:Identifier:Point in time:^Patient:Nominal', 'Active', 'Wiskott-Aldrich Syndrome', 'Limited Walking Ability', '1 Day', 'Limited (extensiveness)', 'Relationships', 'Sample Range', 'Inclusion', 'More', 'erythrocyte sedimentation rate result', 'Outcome of Therapy', 'Statistical Significance', 'WAS gene', 'Disease activity', 'Effect', 'Overall Publication Type', 'CRP gene', 'Event Seriousness - Significant', 'Fever, CTCAE', 'Negation', 'Significant', 'Fever symptoms (finding)', 'Well Being Visual Analogue Scale', 'WAS protein, human', 'Estrogen Receptor Measurement', 'criteria', 'patient assessment', 'C-reactive protein', 'Arthritis, CTCAE', 'Disease', 'Limited Lifting Ability', 'Microgram per Milliliter', 'Three', 'Diagnosis Study', 'Oral', 'milligram/day', 'Lower - spatial qualifier', 'Hour']","['qnco', ' aapp', 'horm', 'clna', 'blor', 'fndg', 'npop', ' orch', 'idcn', 'hlca', 'inpr', 'sosy', 'qlco', 'bacs', 'lbpr', 'resa', 'ftcn', 'tmco', 'prog', 'lbtr', 'bdsy', 'orch', 'spco', 'bsoj', 'cnce', 'acty', 'imft', 'gngm', 'famg', 'orga', 'dsyn', 'diap', ' phsu']"
330,PMC3070271,S36,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"female subjects entering the study were prepubescent, sexually inactive or required to use effective contraception.","['C1514873', 'C3834263', 'C2603343', 'C0043210', 'C0036864', 'C1705498', 'C1704419', 'C0086287', 'C3890554', 'C0700589', 'C1705497', 'C1280519']","['Effectiveness', 'Inactive - answer to question', 'Sex Behavior', 'Contraceptive methods', 'Requirement', 'Female Phenotype', 'Physical Inactivity', 'Woman', 'Female, Self-Report', 'Study', 'Females', 'Effective']","['fndg', 'topp', 'dora', 'qlco', 'orga', 'bhvr', 'resa', 'ftcn', 'popg']"
331,PMC3070271,S37,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,exclusion criteria included previous treatment with an il-1 inhibitor or any condition contraindicating immunosuppressive treatment.,"['C3272371', 'C0087111', 'C3864998', 'C1522326', 'C0348080', 'C3887704', 'C0021081', 'C1705169', 'C1552607', 'C0039798', 'C3538994', 'C0012634', 'C1999216', 'C1552551', 'C1705253', 'C0205156', 'C0680251', 'C1533734']","['Condition:Find:Pt:^Patient:Nom', 'treatment - ActInformationManagementReason', 'Immunosuppressive Agents', 'Logical Condition', 'Treating', 'Exclusion Criteria', 'Previous', 'Treatment Epoch', 'therapeutic aspects', 'Any', 'Any Data Type', 'Disease', 'Act Relationship Subset - previous', 'Biomaterial Treatment', 'Condition', 'Administration procedure', 'Inhibitor', 'Therapeutic procedure']","['tmco', 'clna', 'imft', 'topp', 'hlca', 'inpr', 'qlco', 'dsyn', 'resa', 'ftcn', ' phsu', 'cnce']"
332,PMC3070271,S38,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"intravenous or intra-articular steroids, immunosuppressive drugs and disease-modifying antirheumatic drugs (dmards) had to be stopped at least 1 month before study onset or for longer periods of time depending on their half-life.","['C0038317', 'C2603343', 'C1442451', 'C0040223', 'C0206132', 'C2359945', 'C0012634', 'C0003191', 'C1515981', 'C0521339', 'C0348016', 'C0332162', 'C0242708', 'C0347985', 'C0018517', 'C0022417']","['Joints', 'Antirheumatic Agents', 'Steroids', 'Intravenous', 'Age of Onset', 'Onset of (contextual qualifier)', 'Half-Life', 'Articular', 'Time', 'And', 'Disease', 'Study', '1 Month', 'Antirheumatic Drugs, Disease-Modifying', 'Immunosuppressive drugs attachment:Find:Pt:^Patient:Doc', 'intra']","['tmco', 'clna', 'resa', 'idcn', 'orch', 'qnco', 'qlco', 'dsyn', 'spco', 'bsoj', 'ftcn', ' phsu', 'phsu']"
333,PMC3070271,S39,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"all patients entering the study, and their parents for patients aged <18, gave written informed consent.","['C2603343', 'C0021430', 'C0030705', 'C1515981', 'C0001792', 'C0444868', 'C0001779', 'C0030551', 'C1999167']","['Age', 'All', 'Elderly (population group)', 'parent', 'And', 'Old age', 'Informed Consent', 'Patients', 'Study']","['rnlw', 'idcn', 'famg', 'qnco', 'orga', 'resa', 'podg', 'popg']"
334,PMC3070271,S41,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,the study was approved by the local independent ethics committee and consisted of two parts (figure 1).,"['C2603343', 'C0205276', 'C0449719', 'C1515981', 'C1709471', 'C0205448', 'C0086911', 'C4554082']","['Part Dosing Unit', 'Two', 'Part', 'And', 'Ethics Committees, Research', 'Study', 'Independent Ethics Committee', 'Local']","['prog', 'idcn', 'qnco', 'spco', 'resa']"
335,PMC3070271,S42,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"part 1 was a randomised, double-blind, placebo-controlled phase.","['C0205173', 'C0449719', 'C0205390', 'C1705765', 'C1710475', 'C1709471', 'C1705764']","['Duplicate', 'Part Dosing Unit', 'Part', 'Double Value Type', 'Doubling', 'Trial Phase', 'Phase']","['tmco', 'clas', 'qnco', 'qlco', 'spco', 'ftcn', 'acty']"
336,PMC3070271,S43,"['8a', '5']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0]",Study design,"at d1, eligible patients were randomised to receive either anakinra or placebo (1:1) from d1 to month 1 (m1) using a computer-generated random list.","['C3844638', 'C0439605', 'C0032042', 'C3272378', 'C0439231', 'C0034656', 'C0030705', 'C0009622', 'C0332177', 'C1706408', 'C0245109', 'C1696465', 'C1548635', 'C0745732']","['placebo', 'Placebo Control', 'Either', 'anakinra', 'Placebos', 'Monthly (qualifier value)', 'Patients', 'Random', 'Randomization', 'Computers', 'List', 'Sequence Data Type', 'month', 'Eligible']","['tmco', 'fndg', 'bodm', 'topp', 'inpr', 'qlco', 'resa', 'aapp', 'podg', 'mnob', ' phsu']"
337,PMC3070271,S44,['8b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0]",Study design,patients were stratified by centres and randomisation was balanced across treatments and centres.,"['C0087111', 'C1515981', 'C0205099', 'C0030705']","['Central', 'Patients', 'And', 'Therapeutic procedure']","['podg', 'idcn', 'topp', 'spco']"
338,PMC3070271,S45,['8b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0]",Study design,"the randomisation information included the randomisation number, the centre, the assigned treatment and the date of randomisation.","['C0087111', 'C1522326', 'C1516050', 'C0237753', 'C3887704', 'C1705169', 'C0449788', 'C1533716', 'C3538994', 'C0011008', 'C0039798', 'C1515981', 'C2348077', 'C0332257', 'C1552601', 'C1533734', 'C0205099']","['Assignment - action', 'Date Fruit', 'Information', 'treatment - ActInformationManagementReason', 'Treating', 'Count of entities', 'And', 'Treatment Epoch', 'therapeutic aspects', 'Therapeutic procedure', 'Including (qualifier)', 'Biomaterial Treatment', 'Central', 'Administration procedure', 'Date in time', 'PersonNameUse - assigned', 'Numbers']","['tmco', 'food', 'topp', 'idcn', 'hlca', 'inpr', 'qnco', 'spco', 'resa', 'ftcn', 'cnce']"
339,PMC3070271,S46,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"investigators, other caregivers, the patients and their parents remained blinded to the assigned treatment.","['C0087111', 'C1522326', 'C1516050', 'C3887704', 'C1705169', 'C0039798', 'C3538994', 'C0030705', 'C0150108', 'C1515981', 'C1552601', 'C0085537', 'C1533734', 'C0030551', 'C0035173']","['Assignment - action', 'Caregiver', 'treatment - ActInformationManagementReason', 'Treating', 'parent', 'Research Personnel', 'Treatment Epoch', 'And', 'therapeutic aspects', 'Patients', 'Blinded', 'Biomaterial Treatment', 'Administration procedure', 'PersonNameUse - assigned', 'Therapeutic procedure']","['prog', 'idcn', 'topp', 'hlca', 'inpr', 'famg', 'resa', 'podg', 'ftcn', 'cnce']"
340,PMC3070271,S47,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study design,the primary objective was to demonstrate a higher proportion of responders in group 1 than group 2.,"['C0441865', 'C1709707', 'C4050003', 'C4050004', 'C0441861', 'C2827976', 'C0205250']","['Group 2', 'Trial Primary Objective', 'Arm or Leg Response Group 2', 'Arm or Leg Response Group 1', 'High', 'Group 1', 'Proportion']","['qlco', 'qnco', 'inpr', 'ftcn']"
341,PMC3070271,S48,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,no immunosuppressive drugs or dmards were allowed during the trial.,"['C0242708', 'C2359945', 'C0008976']","['Clinical Trials', 'Immunosuppressive drugs attachment:Find:Pt:^Patient:Doc', 'Antirheumatic Drugs, Disease-Modifying']","['clna', 'resa', 'phsu']"
342,PMC3070271,S49,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,non-steroidal anti-inflammatory drugs and corticosteroids had to be taken at stable dosage for 1 month before d1 and until m1.,"['C1442451', 'C0001617', 'C1547311', 'C3540726', 'C3540727', 'C0178602', 'C0205360', 'C3540725', 'C1515981', 'C2986497', 'C0333348', 'C3539185', 'C3687832', 'C0013227']","['Corticosteroid otologicals', 'Patient Condition Code - Stable', 'Corticosteroids, topical for treatment of hemorrhoids and anal fissures', 'Cumulative Dose', 'Corticosteroid nasal preparations for topical use', 'Drugs - dental services', 'Adrenal Cortex Hormones', 'Corticosteroid ophthalmologic and otologic preparations', 'And', 'Dosage', '1 Month', 'Stable status', 'Pharmaceutical Preparations', 'inflammatory']","['tmco', ' orch', 'idcn', 'topp', 'inpr', 'orch', 'qnco', 'phsu', 'qlco', ' phsu', 'ftcn', 'horm', 'cnce']"
343,PMC3070271,S50,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,figure 1 study design.,"['C2983265', 'C2986888', 'C0035171']","['CDISC SEND Study Design Terminology', 'Nonclinical Study Design', 'Research Design']","['inpr', 'resa']"
344,PMC3070271,S51,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"*measurement of serum amyloid a and ferritin levels, assessment of the percentage of glycosylated ferritin, gene expression profiling analysis and cytokine measurements.","['C1561533', 'C0079189', 'C4282142', 'C1549488', 'C4521390', 'C1515981', 'C0017262', 'C1261322', 'C0002723', 'C1524024', 'C0439165', 'C0427405', 'C1516048', 'C0242485', 'C0936012']","['Gene Expression', 'cytokine', 'Percent (qualifier value)', 'Analysis', 'And', 'Ferritin level', 'analysis aspect', 'Amyloid A Measurement', 'Assessed', 'Evaluation procedure', 'Money or percentage indicator - Percentage', 'Measurement', 'Serum amyloid A protein', 'Gene Expression Level Analysis', 'Amount type - Percentage']","['imft', 'resa', 'lbtr', 'idcn', 'hlca', 'genf', 'qnco', 'lbpr', 'ftcn', ' aapp', 'acty']"
345,PMC3070271,S52,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,†measurement of the concentration of anakinra in plasma (pharmacokinetic analyses).,"['C0201734', 'C3827302', 'C0032105', 'C0086045', 'C0245109', 'C1446561', 'C4521445']","['Pharmacokinetic study', 'anakinra', 'Mental concentration', 'Plasma Product', 'Plasma', 'Concentration measurement', 'Able to Concentrate Question']","['inpr', 'bdsu', 'qnco', 'resa', 'aapp', ' phsu', 'menp', 'phsu']"
346,PMC3070271,S53,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,‡measurement of serum anti-pneumococcal antibodies.,"['C1550100', 'C0229671', 'C0305065', 'C0038410', 'C1546774', 'C0003241']","['Serum', 'Specimen Type - Serum', 'Streptococcus pneumoniae', 'Antibodies', 'Specimen Source Codes - Serum', 'Polyvalent pneumococcal vaccine']","['imft', 'bact', 'inpr', ' aapp', ' phsu', 'bdsu']"
347,PMC3070271,S54,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"d, day; m, month.","['C0332177', 'C0439228', 'C0439231', 'C0332173']","['Monthly (qualifier value)', 'month', 'day', 'Daily']",['tmco']
348,PMC3070271,S55,"['3a', '5']","[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,part 2 was an open-label treatment period: all patients received anakinra after m1.,"['C0439531', 'C0087111', 'C2827499', 'C0175566', 'C1522326', 'C0449719', 'C3887704', 'C1705169', 'C4551445', 'C3538994', 'C0030705', 'C0039798', 'C0245109', 'C0181496', 'C1709471', 'C0444868', 'C4522130', 'C1533734', 'C1948053']","['Label (document)', 'Part Dosing Unit', 'Period (temporal qualifier)', 'Human Cells, Tissues, and Cellular and Tissue-Based Products Labeling', 'Open', 'All', 'treatment - ActInformationManagementReason', 'Treating', 'anakinra', 'Part', 'Labels (device)', 'Treatment Epoch', 'therapeutic aspects', 'Patients', 'per period (qualifier value)', 'Biomaterial Treatment', 'Labeling Activity', 'Administration procedure', 'Therapeutic procedure']","['mnob', 'tmco', 'topp', 'hlca', 'inpr', 'qnco', 'spco', 'resa', 'aapp', 'podg', 'acty', ' phsu', 'ftcn', 'cnce']"
349,PMC3070271,S56,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,"tapering the dose of corticosteroids was allowed after the m1 visit (reduction of 0.4–0.5 mg/kg monthly for daily doses of ≥1.5 mg/kg, 0.3–0.4 mg/kg for doses between 1 and 1.5 mg/kg, 0.2–0.3 mg/kg between 0.6 and 1 mg/kg, 0.1–0.2 mg/kg between 0.3 and 0.6 mg/kg, ≤0.10 mg/kg for doses <0.3 mg/kg).","['C0001617', 'C1565156', 'C3540727', 'C0521125', 'C0178602', 'C0687676', 'C0392756', 'C3539185', 'C4321252', 'C0205103', 'C1293152', 'C0332173', 'C0332177', 'C1421478', 'C0043194', 'C4551656', 'C0301630', 'C0231290', 'C0683607', 'C3540726', 'C1515981', 'C3540725', 'C0439272']","['Surgical reduction', 'And', 'mg/kg', 'Post', 'Corticosteroid otologicals', 'Corticosteroids, topical for treatment of hemorrhoids and anal fissures', 'Reduction (chemical)', 'Adrenal Cortex Hormones', 'Corticosteroid ophthalmologic and otologic preparations', 'allowing', 'Wiskott-Aldrich Syndrome', 'Reduced', 'Reduction procedure', 'Corticosteroid nasal preparations for topical use', 'Status post', 'WAS gene', 'WWOX wt Allele', 'Dosage', 'Monthly (qualifier value)', 'Daily', 'Preposition For', 'Intermediate', 'WAS protein, human']","['tmco', 'npop', 'gngm', 'idcn', ' orch', 'topp', 'orch', 'qnco', 'qlco', 'bacs', 'dsyn', 'spco', ' phsu', 'socb', ' aapp', 'horm']"
350,PMC3070271,S57,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study design,"measurement of serum amyloid a (saa) and ferritin levels and the percentage of glycosylated ferritin were performed at d1, m1 and m6.","['C1561533', 'C1419799', 'C4282142', 'C1549488', 'C1515981', 'C0002723', 'C0439165', 'C1419798', 'C0427405', 'C0242485', 'C1883018']","['SAA@ gene cluster', 'Percent (qualifier value)', 'And', 'Ferritin level', 'Amyloid A Measurement', 'Severe Aplastic Anemia', 'Money or percentage indicator - Percentage', 'SAA1 gene', 'Measurement', 'Serum amyloid A protein', 'Amount type - Percentage']","['imft', 'lbtr', 'gngm', 'idcn', 'qnco', 'lbpr', 'dsyn', 'ftcn', ' aapp']"
351,PMC3070271,S58,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study design,"total ferritin concentration was measured on a dimension rxl hm according to the guidelines of the manufacturer (dade behring, paris, france).","['C0220845', 'C0046889', 'C3827302', 'C0439534', 'C0015879', 'C0947322', 'C0086045', 'C0282423', 'C0331677', 'C0439810', 'C0162791', 'C0016674', 'C1446561', 'C1824032', 'C0030561']","['Guidelines', 'guiding characteristics', 'Genus Paris', 'ZNF746 gene', 'Dimensions', 'Guideline [Publication Type]', 'Total', 'France', 'Paris, France', 'Mental concentration', 'Ferritin', 'Manufacturer Name', 'Concentration measurement', 'Able to Concentrate Question', ""3,3'-diallyldiethylstilbestrol""]","['gngm', 'plnt', 'inpr', 'geoa', 'orch', 'qnco', 'bacs', 'qlco', ' aapp', ' phsu', 'menp']"
352,PMC3070271,S59,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study design,"glycosylated ferritin was determined according to the method of worwood et al,11 with minor modifications as previously described.12","['C0205165', 'C0025663', 'C0119873', 'C0871511', 'C0449851', 'C0026193']","['Methods', 'glycosylated ferritin', 'Test Method', 'Minor (value)', 'Techniques', 'Minor (person)']","['inpr', 'qlco', 'lbpr', 'aapp', 'ftcn', 'popg']"
353,PMC3070271,S60,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study design,pharmacokinetic (pk) analyses were performed on blood taken at m2 and m6.,"['C0201734', 'C0005767', 'C0005768', 'C0229664', 'C1515981']","['Pharmacokinetic study', 'peripheral blood', 'And', 'In Blood', 'Blood']","['idcn', 'resa', 'bdsu']"
354,PMC3070271,S61,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study design,"concentrations of anakinra in plasma samples were determined using the antibody (ab) elisa purchased from r&d systems (minneapolis, minnesota, usa).","['C0041703', 'C0021027', 'C0032105', 'C0014441', 'C0086045', 'C3665580', 'C0245109', 'C0003241', 'C0026183', 'C4521445', 'C1167408']","['Immunoglobulins', 'Minnesota', 'Enzyme-Linked Immunosorbent Assay', 'anakinra', 'United States', 'Antibodies', 'Mental concentration', 'Plasma Product', 'Plasma', 'immunoglobulin complex location', 'Immunoglobulin complex location, circulating']","['imft', 'geoa', 'celc', 'phsu', 'lbpr', 'aapp', ' aapp', ' phsu', 'menp', 'bdsu']"
355,PMC3070271,S62,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study design,patients who were naive from anti-pneumococcal immunisation received pneumo23 immunisation at d1 in order to assess at m1 and m12 the effect of anakinra treatment on anti-pneumococcal ab response to five capsular polysaccharides.13,"['C1549809', 'C0305065', 'C0871261', 'C3538994', 'C1533734', 'C1705176', 'C0087111', 'C3272598', 'C2348382', 'C1518681', 'C3887704', 'C1705169', 'C1280500', 'C0039798', 'C0205451', 'C0030705', 'C0245109', 'C1514756', 'C1516048', 'C0042196', 'C1882348', 'C0038410', 'C0020971', 'C1705177', 'C1705175', 'C3889825', 'C1705178', 'C1706817', 'C1522326', 'C2911692', 'C0205151', 'C0032594', 'C1515981', 'C1704632']","['Effect, Appearance', 'And', 'Response (communication)', 'Polysaccharides', 'Vaccination', 'Response process', 'Disease Response', 'M12', 'anakinra', 'Treatment Epoch', 'Assessed', 'Biomaterial Treatment', 'Administration procedure', 'Order (action)', 'Outcome of Therapy', 'Patients', 'Effect', 'Therapeutic procedure', 'Response (statement)', 'Order (document)', 'Order (taxonomic)', 'Receive', 'Polyvalent pneumococcal vaccine', 'treatment - ActInformationManagementReason', 'Streptococcus pneumoniae', 'Treating', 'WHO Temperature/Humidity Storage Condition', 'Immunization', 'therapeutic aspects', 'Five', 'Sequence of Planned Assessment Schedule', 'Permutation', 'capsular', 'Order (arrangement)']","['bact', 'topp', 'qnco', 'podg', 'menp', 'fndg', 'idcn', 'clas', 'hlca', 'inpr', 'qlco', 'resa', 'aapp', 'ftcn', 'orch', 'spco', 'cnce', 'acty', 'imft', 'orga', ' phsu']"
356,PMC3070271,S64,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Gene expression profiling and cytokine measurements,"blood samples were collected in tempus tubes (abi, foster city, california, usa) from the patients at d1, m1 and m6 and from age and gender-matched healthy controls.","['C0175730', 'C3898900', 'C0041703', 'C3262831', 'C0344349', 'C3146274', 'C1328319', 'C0030705', 'C0006754', 'C0008848', 'C1515981', 'C0178913', 'C3888326', 'C1547937', 'C0242298', 'C0001779', 'C1517320']","['Fostering', 'Age', 'Ankle brachial pressure index (observable entity)', 'Cities', 'Fostered', 'Intravascular systolic.tibial artery/Brachial artery:PresRto:Pt:Arterial system:Qn', 'And', 'United States', 'California (plant)', 'Patients', 'City:Location:Point in time:^Patient:Nominal', 'California', 'From', 'Specimen Source Codes - Tube', 'biomedical tube device', 'Healthy', 'Blood specimen']","['medd', 'idcn', 'dora', 'plnt', 'bdsu', 'geoa', 'famg', 'qlco', 'inpr', 'orga', 'podg', 'clna']"
357,PMC3070271,S66,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Transcriptional module-based analysis,this mining strategy has been described in detail elsewhere.14,"['C1080058', 'C0679199', 'C1522508', 'C1561567', 'C0026175']","['strategy', 'detail - Response Level', 'Details', 'Mining', 'This (eukaryote)']","['ocac', 'qlco', 'euka', 'ftcn', 'menp']"
358,PMC3070271,S67,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Transcriptional module-based analysis,"in this study, refseq ids were used to match probes between the affymetrix u133 platform, which was used to generate the original set of modules using pbmc expression data,14 and illumina hu6 platform, which was used to hybridise whole blood samples from patients enrolled in this study and healthy controls.","['C3898900', 'C4684790', 'C1565156', 'C0036849', 'C1608383', 'C0205103', 'C0030705', 'C4085938', 'C1710360', 'C3245479', 'C1708943', 'C1705195', 'C1421478', 'C0043194', 'C0185117', 'C1709876', 'C1517320', 'C0182400', 'C2347409', 'C2603343', 'C1080058', 'C0205313', 'C1515981', 'C0150103', 'C1321301', 'C3714741', 'C1273517', 'C1511726', 'C1442518']","['set (group)', 'Set (Psychology)', 'RefSeq', 'Data (eukaryote)', 'And', 'Match', 'From', 'Study', 'used by', 'Healthy', 'Expression procedure', 'Peripheral blood mononuclear cell (cell)', 'Wiskott-Aldrich Syndrome', 'Data call receiving device', 'WAS gene', 'Probes', 'Affymetrix', 'Patients', 'Intermediate', 'Original Regulatory Submission', 'Study Subject Enrolled', 'Original', 'WAS protein, human', 'Technology Platform', 'Set scale', 'whole blood specimen', 'This (eukaryote)', 'MATCHING', 'Data']","['topp', 'cell', 'podg', ' aapp', 'menp', 'fndg', 'idcn', 'inpr', 'hcro', 'qlco', 'bacs', 'resa', 'ftcn', 'bdsu', 'ocac', 'euka', 'spco', 'cnce', 'gngm', 'medd', 'resd', 'dsyn']"
359,PMC3070271,S68,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Transcriptional module-based analysis,unambiguous matches in illumina were found for 2109 out of the 5348 affymetrix probe sets.,"['C0336766', 'C4085938', 'C1704681', 'C2347609', 'C0182400']","['Chemical Probe', 'matches', 'Probes', 'Affymetrix', 'probe gene fragment']","['chvf', 'medd', 'gngm', 'hcro', 'mnob']"
360,PMC3070271,S69,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Transcriptional module-based analysis,illumina modules containing <10 genes were not included in the analysis.,"['C1524024', 'C0017337', 'C1518422', 'C0936012']","['Genes', 'Analysis', 'Negation', 'analysis aspect']","['gngm', 'ftcn', 'resa']"
361,PMC3070271,S71,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Cytokine multiplex analysis,"serum samples were analysed using the cytokine assay kit (bio-rad, hercules, california, usa) according to the manufacturer's protocol.","['C2348563', 'C3891450', 'C3715209', 'C4282383', 'C0041703', 'C3853650', 'C0229671', 'C1705213', 'C0406775', 'C1522729', 'C1505125', 'C0947322', 'C2599718', 'C0680240', 'C1150635', 'C3146274', 'C0006754', 'C0442711', 'C3273202', 'C1550100', 'C0201576', 'C1507394', 'C1546774', 'C0812225', 'C3811628']","['cytokine assay', 'California', 'Radiography Study File', 'Clinical trial protocol', 'Protocols documentation', 'REMS Protocol', 'stem cell factor receptor activity', 'Kit device', 'Manufacturer Name', 'Symmetrical dyschromatosis of extremities', 'Library Protocol', 'ribosome-associated ubiquitin-dependent protein catabolic process', 'California (plant)', 'Agreement', 'Serum', 'Specimen Source Codes - Serum', 'RRAD protein, human', 'Clinical trial protocol document', 'Study Protocol', 'United States', 'Promotional Kit', 'Drug Kit', 'Protocol - answer to question', 'Mast/Stem Cell Growth Factor Receptor Kit, human', 'Specimen Type - Serum']","['celf', ' imft', 'fndg', 'cgab', 'medd', 'plnt', 'inpr', 'geoa', 'bacs', 'lbpr', 'socb', 'rcpt', ' aapp', 'mnob', 'moft', 'bdsu']"
362,PMC3070271,S73,"['5', '6a']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0]","Assessment, outcome and safety measures","the primary objective was to compare the efficacy after 1 month's treatment with anakinra (2 mg/kg subcutaneously daily, maximum 100 mg) or placebo in the two groups of patients.","['C3538994', 'C0687676', 'C2827976', 'C1533734', 'C0087111', 'C0441833', 'C0332173', 'C1442451', 'C3887704', 'C1705169', 'C0039798', 'C0030705', 'C1706408', 'C0245109', 'C0205448', 'C1707887', 'C2826546', 'C1280519', 'C0332287', 'C1552839', 'C0806909', 'C0231290', 'C1522326', 'C0032042', 'C1552615', 'C0687744', 'C1696465', 'C0439272']","['Maximum Value Derivation Technique', 'placebo', 'In addition to', 'mg/kg', 'Post', 'Table Rules - groups', 'Maximum', 'Effectiveness', 'anakinra', 'Treatment Epoch', 'Placebos', '1 Month', 'Biomaterial Treatment', 'Act Relationship Subset - maximum', 'Administration procedure', 'Groups', 'Two', 'Placebo Control', 'Social group', 'Status post', 'Patients', 'Daily', 'treatment - ActInformationManagementReason', 'Treating', 'Trial Primary Objective', 'therapeutic aspects', 'Efficacy Study', 'Therapeutic procedure']","['tmco', 'popg', 'bodm', 'topp', 'idcn', 'hlca', 'inpr', 'qnco', 'qlco', 'ftcn', 'resa', 'aapp', 'podg', ' phsu', 'cnce']"
363,PMC3070271,S74,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]","Assessment, outcome and safety measures","to be responders to a modified american college of rheumatology pediatric (acrpedi) 30 score built for the purpose of the trial, patients had to fulfil the three following conditions: (1) acrpedi 30 response15; (2) absence of disease-related fever (body temperature <38°c over the past 8 days) and (3) 50% decrease compared with d1 or normalisation of both crp and esr values.","['C3811131', 'C3890735', 'C0547047', 'C0332282', 'C0205449', 'C0005903', 'C1521725', 'C0012634', 'C0521125', 'C0392756', 'C0392747', 'C1706086', 'C3539897', 'C4321252', 'C3889737', 'C1285529', 'C0596070', 'C0449820', 'C0030705', 'C4552740', 'C0439228', 'C0042295', 'C1415458', 'C0332197', 'C4050231', 'C0035452', 'C0062074', 'C0439849', 'C4048285', 'C1444637', 'C0557806', 'C1515981', 'C0008976', 'C0424755', 'C0015967', 'C4284302']","['C-Reactive Protein, human', 'Clinical Trials', 'And', 'Data Change Date', 'HAC protocol', 'Body Temperature', 'HADH gene', 'Following', 'Fever', 'Decrease', 'Complete Response with Incomplete Platelet Recovery', 'Score', 'Rheumatology specialty', 'Americas Ethnicity', 'Values', 'college', 'Changing', 'Relationships', 'EHD1 wt Allele', 'Reduced', 'WWOX wt Allele', 'Patients', 'Pediatric', 'Purpose', 'Preposition For', 'Fever, CTCAE', 'Absent', 'Fever symptoms (finding)', 'day', 'Estrogen Receptor Measurement', 'Have', 'ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated', 'Disease', 'Three', 'In the past', 'Both']","['tmco', 'imft', 'fndg', 'gngm', 'idcn', 'topp', 'sosy', 'qlco', 'qnco', 'bmod', 'orga', 'dsyn', 'lbpr', 'resa', 'podg', 'ftcn', 'mnob', 'popg', ' aapp', 'clna']"
364,PMC3070271,S75,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]","Assessment, outcome and safety measures","modified acrpedi 30, 50, 70 and 100 responses, assessed throughout the study, included an improvement of 30%, 50%, 70% or more and 100% respectively, in at least three of the six core criteria for juvenile rheumatoid arthritis and a worsening of 30 or more in no more than one of the criteria.","['C0205447', 'C0205449', 'C0871261', 'C0521125', 'C0243161', 'C0392747', 'C1546960', 'C0332271', 'C4321252', 'C3889737', 'C2986411', 'C3714757', 'C0205172', 'C1516048', 'C0444669', 'C0332257', 'C1167518', 'C3274653', 'C0205452', 'C2603343', 'C3495559', 'C1515981', 'C1706352', 'C1882467']","['viral nucleocapsid location', 'And', 'Data Change Date', 'Including (qualifier)', 'Core Specimen', 'Study', 'Response process', 'Worsening pattern', 'Core', 'Juvenile arthritis', 'Assessed', 'Juvenile rheumatoid arthritis', 'Changing', 'More', 'WWOX wt Allele', 'Core Device', 'Improvement', 'One', 'Preposition For', 'Six', 'Patient Outcome - Worsening', 'Processor Core', 'criteria', 'Three']","['tmco', 'medd', 'idcn', 'gngm', 'bdsu', 'celc', 'qnco', 'qlco', 'orga', 'dsyn', 'spco', 'resa', 'ftcn', 'mnob', 'cnce', 'acty']"
365,PMC3070271,S76,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]","Assessment, outcome and safety measures","the criteria were the physician's global assessment of disease activity and the patient's or the parents' global assessment of overall wellbeing, the number of joints with active arthritis, the number of joints with limited range of motion, the childhood health assessment questionnaire and esr.15","['C3811131', 'C1561607', 'C4553855', 'C0243161', 'C0205177', 'C3888249', 'C2732494', 'C0282416', 'C0449813', 'C4050369', 'C4552845', 'C0030705', 'C0030551', 'C0332287', 'C0080078', 'C0003864', 'C0439801', 'C0150220', 'C4050251', 'C0281858', 'C3813622', 'C1515981', 'C2674459', 'C3853793']","['Active License', 'Overall', 'In addition to', 'Overall Well Being', 'parent', 'global assessment', 'And', 'active (HL7 RoleLink)', 'Arthritis', 'Range of motion exercise', 'Childhood Health Assessment Questionnaire', 'Active', 'Limited Walking Ability', 'number of joints', 'Limited (extensiveness)', 'Patients', 'Overall Publication Type', 'Well Being Visual Analogue Scale', 'Estrogen Receptor Measurement', 'criteria', 'Range of Motion, Articular', 'Arthritis, CTCAE', 'Limited Lifting Ability', 'Physician Global Assessment of Disease Activity']","['fndg', 'topp', 'idcn', 'inpr', 'famg', 'qlco', 'qnco', 'lbpr', 'dsyn', 'resa', 'podg', 'ftcn', 'clna']"
366,PMC3070271,S77,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]","Assessment, outcome and safety measures","a disease flare was defined as either (1) a reoccurrence of disease-related fever or any systemic symptom, or (2) an increase by twofold of either the esr or crp value, or (3) a worsening of ≥30% in at least three of the six acrpedi core criteria and an improvement of ≥30% in no more than one of the criteria.","['C3811131', 'C3890735', 'C0205373', 'C0205447', 'C0205449', 'C1565156', 'C0012634', 'C0243161', 'C1546960', 'C0332271', 'C3844638', 'C1517205', 'C2986411', 'C0205172', 'C4552740', 'C0442805', 'C1704788', 'C3540542', 'C1421478', 'C0444669', 'C0043194', 'C1522609', 'C1552551', 'C3854129', 'C1167518', 'C0439849', 'C3274653', 'C0205452', 'C4048285', 'C3272371', 'C1515981', 'C1457887', 'C0424755', 'C0015967', 'C1706352', 'C1882467']","['C-Reactive Protein, human', 'viral nucleocapsid location', 'Numerical value', 'Systemic', 'Symptoms', 'And', 'Core Specimen', 'Definition', 'Worsening pattern', 'Fever', 'Complete Response with Incomplete Platelet Recovery', 'Core', 'Any Data Type', 'Flare', 'Wiskott-Aldrich Syndrome', 'Increase', 'Relationships', 'More', 'WAS gene', 'Any', 'Core Device', 'Improvement', 'One', 'Six', 'Fever, CTCAE', 'Exacerbation of cGVHD', 'Patient Outcome - Worsening', 'Fever symptoms (finding)', 'Processor Core', 'Either', 'WAS protein, human', 'Estrogen Receptor Measurement', 'criteria', 'Disease', 'Three', 'Symptom:Find:Pt:^Patient:Nom']","['clna', 'imft', 'fndg', 'medd', 'idcn', 'gngm', 'inpr', 'celc', 'sosy', 'qlco', 'qnco', 'bacs', 'lbpr', 'dsyn', 'spco', 'ftcn', ' aapp', 'mnob', 'cnce', 'bdsu']"
367,PMC3070271,S78,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]","Assessment, outcome and safety measures","if the number of joints with active arthritis was used as a criterion of flare and the patient initially had no active joints or only one active joint, an increase in the number of joints with active arthritis to at least two was required.","['C0205265', 'C0205447', 'C1565156', 'C0243161', 'C0205177', 'C0205171', 'C3888249', 'C0449813', 'C1517205', 'C4552845', 'C0030705', 'C0205448', 'C0442805', 'C0332287', 'C3540542', 'C0003864', 'C1421478', 'C0043194', 'C0022417', 'C1706309', 'C1515981', 'C0392905', 'C1273517', 'C3853793']","['Joints', 'Active License', 'In addition to', 'Singular', 'Articular system', 'And', 'active (HL7 RoleLink)', 'used by', 'Arthritis', 'Flare', 'Active', 'Wiskott-Aldrich Syndrome', 'Increase', 'number of joints', 'Two', 'Initially', 'WAS gene', 'Patients', 'One', 'Exacerbation of cGVHD', 'WAS protein, human', 'criteria', 'Arthritis, CTCAE', 'Joint Device']","['tmco', 'fndg', 'gngm', 'idcn', 'bdsy', 'sosy', 'qlco', 'qnco', 'bacs', 'dsyn', 'podg', 'ftcn', 'mnob', ' aapp', 'bsoj']"
368,PMC3070271,S79,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]","Assessment, outcome and safety measures","we also aimed to assess the number of patients who reached m6 with inactive disease, as defined by wallace et al16 under a daily dose of predniso(lo)ne <0.3 mg/kg or 10 mg, whichever was lower.","['C3272598', 'C2003888', 'C0237753', 'C1548802', 'C0449788', 'C0030705', 'C2348070', 'C0544452', 'C0331925', 'C0441994']","['Lower - spatial qualifier', 'Daily Dose', 'WHO Temperature/Humidity Storage Condition', 'Count of entities', 'Disease remission', 'Lower (action)', 'Patients', 'wallace', 'Body Site Modifier - Lower', 'Numbers']","['blor', 'fndg', 'hcro', 'qlco', 'qnco', 'spco', 'podg', 'acty']"
369,PMC3070271,S80,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]","Assessment, outcome and safety measures",adverse events (aes) were recorded throughout the study.,"['C2603343', 'C2699274', 'C1705413', 'C1412268', 'C0877248']","['Scanning Auger Spectrometer (device)', 'AES gene', 'Adverse Event Domain', 'Study', 'Adverse event']","['gngm', 'inpr', 'resd', 'resa', 'patf']"
370,PMC3070271,S81,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]","Assessment, outcome and safety measures",specific procedures were set up for serious aes (saes).,"['C2700391', 'C2699274', 'C0025664', 'C0521125', 'C3538935', 'C1412268', 'C0205404', 'C0184661', 'C0205369', 'C1552740', 'C4321252']","['Procedure (set of actions)', 'Entity Determiner - specific', 'Scanning Auger Spectrometer (device)', 'Procedure Domain', 'AES gene', 'WWOX wt Allele', 'Interventional procedure', 'Methods aspects', 'Preposition For', 'Specific qualifier value', 'Serious']","['gngm', 'topp', 'inpr', 'resd', 'qlco', 'ftcn']"
371,PMC3070271,S82,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]","Assessment, outcome and safety measures",this trial was registered at http://www.clinicaltrials.gov (registration number: nct00339157).,,,
372,PMC3070271,S84,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Data analysis,"we expected at least 60% difference in the percentage of patients obtaining improvement in the anakinra-treated group (group 1) compared with the control group (group 2), with no more than 10% patients improving in group 2.","['C1705241', 'C1707455', 'C0439165', 'C1257890', 'C0441833', 'C2986411', 'C0030705', 'C1549488', 'C0245109', 'C0205172', 'C1561533', 'C1705428', 'C1272745', 'C0332287', 'C1519504', 'C4050004', 'C1705429', 'C1705242', 'C0441865', 'C0009932', 'C1522326', 'C4050003', 'C0441861', 'C0687744']","['Group Object', 'In addition to', 'Arm or Leg Response Group 2', 'Arm or Leg Response Group 1', 'Money or percentage indicator - Percentage', 'anakinra', 'Comparison', 'Control Groups', 'User Group', 'Amount type - Percentage', 'Groups', 'Population Group', 'Group 2', 'Percent (qualifier value)', 'Social group', 'More', 'Patients', 'Improvement', 'Group 1', 'Different', 'Treating', 'Stage Grouping', 'Delta (difference)', 'Improving (qualifier value)']","['popg', 'idcn', 'inpr', 'qnco', 'qlco', 'grup', 'ftcn', 'aapp', 'podg', ' phsu', 'cnce', 'acty']"
373,PMC3070271,S85,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Data analysis,"given a 5% type i error, a 20% type ii error and a two-sided fisher exact test, 12 patients per group were required.","['C1257890', 'C2828393', 'C0441833', 'C1515976', 'C0022885', 'C1519504', 'C4318744', 'C0039593', 'C0205557', 'C0456984', 'C4050514', 'C0030705', 'C0687744', 'C1515981', 'C1705429', 'C0392366', 'C3831328', 'C0205448', 'C1705428', 'C0205558']","['Groups', 'False Negative', 'Group Object', 'Population Group', 'Two', 'Social group', 'Anatomic Structure, System, or Substance', 'Test Result', 'Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome Questionnaire', 'And', 'False Positive', 'Blood Products Laboratory Testing', 'Testing', 'Patients', 'Test - temporal region', 'Stage Grouping', 'Tests (qualifier value)', 'Laboratory Procedures', 'Exact (qualifier)', 'User Group']","['blor', 'fndg', 'lbtr', 'clas', 'idcn', 'inpr', 'qlco', 'qnco', 'lbpr', 'podg', 'ftcn', 'popg', 'cnce']"
374,PMC3070271,S86,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data analysis,an intention-to-treat analysis was retained.,"['C0087111', 'C1292734', 'C1522326', 'C1283828', 'C0162425', 'C1524024', 'C0936012']","['Intention - mental process', 'Analysis', 'Treating', 'analysis aspect', 'Treatment intent', 'intent', 'Therapeutic procedure']","['topp', 'qlco', 'resa', 'ftcn', 'menp']"
375,PMC3070271,S87,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data analysis,"to explore whether each variable from the acrpedi score, crp, saa and/or parent/patient assessment of pain were associated with response to treatment, the ratio (value at inclusion − value at m1)/value at inclusion, was compared in both groups.","['C4085210', 'C3890735', 'C1512693', 'C0439828', 'C0332281', 'C4553760', 'C1706528', 'C1706086', 'C1419798', 'C4085212', 'C0441833', 'C0518090', 'C1457900', 'C0449820', 'C4554132', 'C0030193', 'C0456603', 'C0030551', 'C4050231', 'C0679830', 'C1552839', 'C0007637', 'C0521982', 'C1547037', 'C4553004', 'C1522609', 'C2984058', 'C0002723', 'C4048285', 'C1419799', 'C2699423', 'C0687744', 'C4085211', 'C1883018']","['Usual Severity Pain', 'C-Reactive Protein, human', 'Have Pain', 'Numerical value', 'parent', 'Each (qualifier value)', 'Pain Distress Question', 'Severe Aplastic Anemia', 'Table Rules - groups', 'Conceptual Parent', 'And/Or', 'Variable (uniformity)', 'Score', 'Complete Response with Incomplete Platelet Recovery', 'Ratio', 'Inclusion Bodies', 'Groups', 'Feel Pain', 'Social group', 'Inclusion', 'SAA1 gene', 'Study Variable', 'Serum amyloid A protein', 'Pain', 'data type - ratio', 'How Much Distress Pain', 'SAA@ gene cluster', 'Associated with', 'Frequency of Pain Question', 'Response to treatment', 'patient assessment', 'ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated', 'Pain, CTCAE', 'Both']","['clna', 'imft', 'fndg', 'gngm', 'idcn', 'hlca', 'inpr', 'famg', 'sosy', 'qnco', 'qlco', 'celc', 'dsyn', ' aapp', 'popg', 'cnce']"
376,PMC3070271,S88,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data analysis,"qualitative and quantitative data were compared using wilcoxon test and fisher exact test, respectively.","['C2828393', 'C1515976', 'C3245479', 'C0022885', 'C4318744', 'C0039593', 'C0205556', 'C0456984', 'C4050514', 'C1515981', 'C0392366', 'C0871608', 'C3714741', 'C3831328', 'C0392762', 'C1511726']","['Data call receiving device', 'qualitative', 'Anatomic Structure, System, or Substance', 'Test Result', 'Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome Questionnaire', 'Data (eukaryote)', 'And', 'Testing', 'Blood Products Laboratory Testing', 'Tests (qualifier value)', 'Test - temporal region', 'Laboratory Procedures', 'Wilcoxon Signed Rank Test', 'Exact (qualifier)', 'quantitative', 'Data']","['blor', 'lbtr', 'medd', 'idcn', 'clas', 'inpr', 'qlco', 'qnco', 'lbpr', 'euka', 'ftcn']"
377,PMC3070271,S89,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data analysis,the r statistical software was used for statistical analysis.,"['C0871424', 'C0038215', 'C1421478', 'C1565156', 'C0043194', 'C0521125', 'C1273517', 'C0037585', 'C4321252']","['WAS protein, human', 'statistical analysis', 'Computer software', 'WAS gene', 'WWOX wt Allele', 'used by', 'Preposition For', 'Wiskott-Aldrich Syndrome', 'Science of Statistics']","['fndg', 'gngm', ' mnob', 'ocdi', 'inpr', 'qlco', 'bacs', 'dsyn', 'resa', ' aapp']"
378,PMC3076731,S34,['4b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,members of the british society for paediatric endocrinology and diabetes recruited patients from participating paediatric endocrinology departments in uk hospitals.,"['C0019994', 'C0596227', 'C0680022', 'C0030705', 'C0011847', 'C1515981', 'C0037455', 'C0014137', 'C0011849', 'C0030755']","['Endocrinology', 'Societies', 'british', 'member', 'And', 'Diabetes', 'Patients', 'Pediatrics', 'Diabetes Mellitus', 'Hospitals']","['bmod', 'idcn', 'popg', 'mnob', 'podg', 'dsyn', ' hcro', 'orgt']"
379,PMC3076731,S35,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,"inclusion criteria for participation of patients were karyotype confirmed turner’s syndrome (all karyotypes were eligible, including mosaic), age 7-13 years, no previous growth hormone treatment or previous treatment in the range 8.3-11.7 mg/m2/week in five to seven injections a week, no previous oxandrolone and oestrogen therapy, and open epiphyses.","['C0750484', 'C0030705', 'C0439750', 'C1261273', 'C3887704', 'C1705169', 'C0039082', 'C1515981', 'C1548635', 'C2987512', 'C0022526', 'C0014570', 'C0279494', 'C0439230', 'C0205453', 'C0175566', 'C4520819', 'C2348147', 'C0021485', 'C0039798', 'C1533685', 'C3538994', 'C0029995', 'C0205156', 'C1514721', 'C0700058', 'C0439234', 'C0521093', 'C0087111', 'C2981713', 'C1512693', 'C1552607', 'C0744483', 'C1522326', 'C1533734', 'C1828121', 'C0444868', 'C0679823', 'C0205451', 'C0001779']","['Biomaterial Treatment', 'And', 'Estrogen Therapy', 'Patients', 'Act Relationship Subset - previous', 'Karyotype result', 'Therapeutic procedure', 'Five', 'Syndrome', 'Sample Range', 'Mosaic Organism', 'Injection Route of Drug Administration', 'Epiphysis of bone', 'Age', 'Administration procedure', 'Injection of therapeutic agent', 'Karyotype determination procedure', 'Range', 'Injection procedure', 'Mosaic - computer software', 'Treatment Epoch', 'growth hormone treatment', 'Oxandrolone', 'Inclusion', 'All', 'week', 'Spatial Mosaic', 'Milligram per Square Meter per Week', 'therapeutic aspects', 'Confirmation', 'Confirmed by', 'treatment - ActInformationManagementReason', 'Seven', 'participation', 'year', 'Karyotype (cell structure)', 'Eligible', 'Open', 'Previous', 'Treating']","[' orch', 'topp', 'fndg', 'qlco', ' phsu', 'hlca', 'bpoc', 'inpr', 'idcn', 'orgm', 'lbtr', 'horm', 'resa', 'ftcn', 'tmco', 'podg', 'dsyn', 'mbrt', 'cnce', 'celc', 'spco', 'qnco', 'orga']"
380,PMC3076731,S36,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,exclusion criteria were major systemic illness that might affect growth and social or psychological difficulties likely to seriously impair concordance.,"['C0220844', 'C1299586', 'C0205164', 'C0332148', 'C2911660', 'C0442893', 'C4553529', 'C1515981', 'C4318856', 'C0750492', 'C0728831', 'C0018270', 'C0680240', 'C1306597', 'C0205486', 'C1621966', 'C0680251']","['Major', 'Concordance', 'Systemic disease', 'social', 'Psychiatric problem', 'Tissue Growth', 'growth aspects', 'And', 'Exclusion Criteria', 'Agreement', 'Major <insect>', 'Has difficulty doing (qualifier value)', 'Growth', 'Probably', 'Psychologic', 'Probable diagnosis', 'Growth action']","['ortf', 'phpr', 'idcn', 'phsf', 'ftcn', 'fndg', 'qlco', 'euka', 'socb', 'dsyn', 'mobd', 'orgf']"
381,PMC3076731,S38,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"we devised a double blind, placebo controlled, randomised controlled trial, including two randomisations in a two by two factorial design.","['C0032042', 'C1706408', 'C1696465', 'C0013072', 'C2911690', 'C0205448', 'C0936233', 'C0009933', 'C0681865', 'C0332257', 'C2587213']","['Placebo Control', 'factorial design', 'Controlled Clinical Trial [Publication Type]', 'Double-Blind Method', 'Including (qualifier)', 'Placebos', 'Two', 'Disease Controlled', 'Controlled Clinical Trials as Topic', 'Control function', 'placebo']","['inpr', 'bodm', 'topp', 'ftcn', 'fndg', 'resa', 'qnco']"
382,PMC3076731,S39,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,figure 1 shows the flow chart of the design and participants.,"['C2983265', 'C0679646', 'C1707689', 'C1515981', 'C0016262']","['And', 'Design', 'CDISC SEND Study Design Terminology', 'Flowcharts (Computer)', 'Participant']","['acty', 'inpr', 'popg', 'idcn']"
383,PMC3076731,S40,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"a steering committee (british society for paediatric endocrinology and diabetes clinical trials/audit group) supervised the study, and an independent data and safety monitoring group was established.","['C0085862', 'C1511726', 'C0036043', 'C0596227', 'C3853835', 'C3889431', 'C0441833', 'C0687744', 'C1704774', 'C0150369', 'C1515981', 'C0008976', 'C0014137', 'C3714741', 'C0030755', 'C2348534', 'C2603343', 'C1299583', 'C1283169', 'C0011847', 'C1705429', 'C1290940', 'C0037455', 'C0011849', 'C1704775', 'C1519504', 'C3245479', 'C1257890', 'C1096775', 'C1705428', 'C1705187']","['Endocrinology', 'Preventive monitoring', 'And', 'Data call receiving device', 'Audit', 'Independent for Transfer', 'Safety', 'Stage Grouping', 'Monitoring - action', 'Audit Object', 'Societies', 'british', 'Clinical Trials', 'User Group', 'Diabetes', 'Group Object', 'Social group', 'Independently able', 'Alcohol Use Disorder Identification Test Self-Report Version Questionnaire', 'Pediatrics', 'Study', 'Data', 'Groups', 'Safety Study', 'Population Group', 'Audit (administrative)', 'Independence', 'Clinical Trial [Publication Type]', 'Steering Committee', 'Data (eukaryote)', 'Diabetes Mellitus']","['hcpp', 'bmod', 'inpr', 'idcn', 'popg', 'medd', 'ftcn', 'cnce', 'fndg', 'euka', 'resa', 'dsyn', 'hlca', 'orgt']"
384,PMC3076731,S41,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,all participants’ parents gave written informed consent.,"['C0030551', 'C0021430', 'C0444868']","['All', 'Informed Consent', 'parent']","['famg', 'qnco', 'rnlw']"
385,PMC3076731,S42,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"fig 1 flow chart of participation in uk turner study according to treatment groups, completions, and withdrawals.","['C1552839', 'C0441833', 'C1705169', 'C0687744', 'C0007963', 'C0087111', 'C3887704', 'C1515981', 'C0684240', 'C0679823', 'C2603343', 'C1522326', 'C1533734', 'C0039798', 'C3538994']","['Charts (publication)', 'Treatment Epoch', 'Groups', 'Charts (device)', 'Biomaterial Treatment', 'And', 'Table Rules - groups', 'Administration procedure', 'Study', 'Treating', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'participation', 'Therapeutic procedure', 'Social group']","['inpr', 'idcn', 'topp', 'medd', 'popg', 'ftcn', 'cnce', 'resa', 'hlca']"
386,PMC3076731,S43,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"*withdrawn before 12 years of age (that is, randomised only at randomisation 1 to oxandrolone or placebo).","['C0029995', 'C0032042', 'C0439234', 'C1706408', 'C0205171', 'C0424092', 'C1696465', 'C2349954', 'C2825032', 'C0001779', 'C0332152', 'C3853865']","['Placebo Control', 'Oxandrolone', 'Withdrawn - HL7ApprovalStatus', 'Withdraw (activity)', 'Placebos', 'Age', 'Singular', 'Withdrawal (dysfunction)', 'Before', 'placebo', 'year', 'Withdrawn']","[' orch', 'inpr', 'bodm', 'acty', 'topp', 'fndg', 'tmco', 'horm', 'resa', ' phsu', 'mobd', 'qnco', 'orga']"
387,PMC3076731,S44,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,†aged ≥12.25 years at recruitment; oestrogen treatment started at 14 years with no randomisation.,"['C1999167', 'C2949735', 'C3538994', 'C1705169', 'C0014939', 'C3887704', 'C0087111', 'C0039798', 'C1522326', 'C1533734', 'C0001779', 'C0001792', 'C0439234']","['Old age', 'Treatment Epoch', 'Biomaterial Treatment', 'Age', 'Administration procedure', 'Treating', 'Elderly (population group)', 'Estrogens', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Recruitment', 'Therapeutic procedure', 'year']","[' orch', 'acty', 'topp', 'popg', 'ftcn', 'cnce', 'tmco', 'horm', 'resa', ' phsu', 'hlca', 'orga']"
388,PMC3076731,S45,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"‡withdrawn after 12 years of age (that is, randomised at randomisation 1 to oxandrolone or placebo and at randomisation 2 if oestrogen treatment needed)","['C0029995', 'C0032042', 'C0439234', 'C1706408', 'C1696465', 'C3538994', 'C1705169', 'C0014939', 'C3887704', 'C0087111', 'C1515981', 'C1522326', 'C1533734', 'C0687676', 'C0001779', 'C0039798', 'C0231290']","['Placebo Control', 'Post', 'Status post', 'Treatment Epoch', 'Oxandrolone', 'Biomaterial Treatment', 'And', 'Placebos', 'Age', 'Administration procedure', 'Treating', 'Estrogens', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'placebo', 'Therapeutic procedure', 'year']","[' orch', 'idcn', 'topp', 'ftcn', 'cnce', 'tmco', 'horm', 'resa', ' phsu', 'hlca', 'bodm', 'orga']"
389,PMC3076731,S47,['8b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0]",Randomisation and masking,"the british society for paediatric endocrinology and diabetes clinical trials unit (cambridge, uk) used minimisation by weighted randomisation for the study’s two randomisations.20","['C1305866', 'C0596227', 'C0043100', 'C3853603', 'C0439148', 'C0011847', 'C0008976', 'C1515981', 'C1880519', 'C0439453', 'C0037455', 'C0014137', 'C1096775', 'C0205448', 'C1509845', 'C0005910', 'C0011849', 'C1519795', 'C1704753', 'C0030755']","['Endocrinology', 'Societies', 'Body Weight', 'Unit - NCI Thesaurus Property', 'Unit device', 'Clinical Trials', 'british', 'And', 'Unit', 'Diabetes', 'Weight', 'Pediatrics', 'Two', 'Clinical Trial [Publication Type]', 'Unit of Measure', 'Weighing patient', 'International Unit', 'Diabetes Mellitus', 'Storage Unit', 'Enzyme Unit']","['bmod', 'inpr', 'idcn', 'medd', 'popg', 'mnob', 'resa', 'dsyn', 'hlca', 'qnco', 'orga', 'orgt']"
390,PMC3076731,S48,"['10', '5']","[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,"randomisation 1, to oxandrolone or placebo, took place at age 9 years (or at enrolment, if older) and was balanced for enrolling centre, quarter of mid-parental height, and previous exposure to growth hormone treatment.","['C0444598', 'C2825406', 'C0489786', 'C1515981', 'C4321252', 'C1565156', 'C0205099', 'C1696465', 'C0332157', 'C0043194', 'C0442504', 'C0029995', 'C0205156', 'C0521125', 'C0439234', 'C0032042', 'C1882509', 'C1706408', 'C0205415', 'C2986716', 'C1552607', 'C0744483', 'C1421478', 'C0030551', 'C0001779', 'C1533810']","['And', 'Quarter of the Udder', 'Act Relationship Subset - previous', 'Preposition For', 'placebo', 'WWOX wt Allele', 'WAS protein, human', 'Balanced - adjective', 'put - instruction imperative', 'WAS gene', 'Placebos', 'Age', 'Central', 'Quarter', 'Placement action', 'parent', 'growth hormone treatment', 'Oxandrolone', 'Middle', 'Exposure to', 'year', 'Placebo Control', 'Height', 'Previous', 'Wiskott-Aldrich Syndrome', 'Place']","['bacs', ' orch', 'famg', 'topp', 'qlco', ' phsu', 'hlca', 'bpoc', 'idcn', 'gngm', 'horm', 'resa', ' aapp', 'bodm', 'ftcn', 'tmco', 'dsyn', 'acty', 'spco', 'qnco', 'orga']"
391,PMC3076731,S49,"['10', '5']","[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,"randomisation 2 took place at age 12 years in girls with ovarian failure (basal serum follicle stimulating hormone concentration >10 u/l), with additional minimisation for randomisation 1, to begin oral ethinylestradiol or placebo at 12 years; the placebo group subsequently started ethinylestradiol at 14 years.","['C0747102', 'C0086045', 'C1705428', 'C0018120', 'C0441833', 'C0687744', 'C1550100', 'C1696465', 'C0043210', 'C0439339', 'C1446561', 'C3827302', 'C0442504', 'C1705429', 'C0229671', 'C1546774', 'C0019932', 'C0205112', 'C0442027', 'C0439234', 'C0032042', 'C1571705', 'C1948023', 'C1882509', 'C1519504', 'C1706408', 'C1257890', 'C0870604', 'C0015011', 'C1524062', 'C0001779', 'C1533810']","['Woman', 'Serum', 'placebo', 'Stage Grouping', 'Concentration measurement', 'Additional', 'put - instruction imperative', 'User Group', 'Placebos', 'Age', 'Ethinyl Estradiol', 'Ovarian failure', 'Placement action', 'Group Object', 'Social group', 'Basal', 'Oral', 'Stimulation (motivation)', 'Mental concentration', 'Specimen Type - Serum', 'Unit per Liter', 'year', 'Follicle', 'Placebo Control', 'Female child', 'Groups', 'Population Group', 'Ovarian Follicle', 'Place', 'Able to Concentrate Question', 'Hormones', 'Specimen Source Codes - Serum']","[' orch', 'topp', 'bdsu', 'hlca', ' phsu', 'inpr', 'bpoc', 'idcn', 'aggp', 'horm', 'resa', 'npop', 'bodm', 'popg', 'ftcn', 'tmco', 'dsyn', 'menp', 'acty', 'spco', 'cnce', 'qnco', 'orga']"
392,PMC3076731,S50,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,"girls with a follicle stimulating hormone concentration below 10u/l and a karyotype associated with preservation of ovarian function (45,x/46,xx and 45,x/47,xxx21) (the spontaneous puberty group) were not randomised at randomisation 2.","['C0086045', 'C1261273', 'C0441833', 'C0687744', 'C1515981', 'C1514402', 'C0034011', 'C0022526', 'C1518422', 'C0043210', 'C1446561', 'C3827302', 'C0205359', 'C0033085', 'C4520819', 'C1705429', 'C0733758', 'C0678879', 'C1519504', 'C1552829', 'C1257890', 'C0870604', 'C1705428', 'C0542339']","['Woman', 'Inferior', 'Able to Concentrate Question', 'And', 'Table Frame - below', 'Karyotype result', 'Stage Grouping', 'Concentration measurement', 'User Group', 'Preservation Technique', 'Karyotype determination procedure', 'spontaneous', 'Group Object', 'Social group', 'Negation', 'Biologic Preservation', 'Follicle Stimulating Hormone', 'Mental concentration', 'Karyotype (cell structure)', 'Female child', 'ovarian function', 'Groups', 'Population Group', 'Puberty']","['ortf', 'inpr', 'idcn', 'phsf', 'aggp', 'lbpr', 'lbtr', 'popg', 'mbrt', 'cnce', 'celc', 'spco', 'ftcn', 'horm', ' phsu', 'menp', ' aapp', 'qnco']"
393,PMC3076731,S51,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,girls with other karyotypes were tested for concentrations of gonadotrophin releasing hormone and were randomised at randomisation 2 if the peak follicle stimulating hormone concentration was above 30 u/l.,"['C0444505', 'C0086045', 'C1261273', 'C0043210', 'C0023610', 'C1552828', 'C1282910', 'C1446561', 'C0439339', 'C3827302', 'C1515981', 'C0870604', 'C4520819', 'C0022526', 'C0733758']","['Woman', 'Concentration measurement', 'Female child', 'Follicle Stimulating Hormone', 'Mental concentration', 'And', 'Unit per Liter', 'Table Frame - above', 'Gonadorelin', 'Karyotype determination procedure', 'Peak level', 'Karyotype result', 'Able to Concentrate Question', 'Upper', 'Karyotype (cell structure)']","['inpr', 'idcn', 'aggp', 'lbtr', 'popg', 'mbrt', 'spco', 'celc', 'qlco', 'horm', ' phsu', 'menp', ' aapp', 'qnco']"
394,PMC3076731,S52,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,participants enrolled after the age of 12.25 years and without spontaneous puberty (the late group) started ethinylestradiol at 14 years.,"['C1705428', 'C1519504', 'C0441833', 'C0205087', 'C0687744', 'C1257890', 'C1705429', 'C1515981', 'C0332288', 'C0034011', 'C0205359', 'C0015011', 'C0001779', 'C0439234']","['Social group', 'Puberty', 'Without', 'Groups', 'And', 'Ethinyl Estradiol', 'Age', 'Population Group', 'User Group', 'spontaneous', 'Stage Grouping', 'Group Object', 'year', 'Late']","[' orch', 'idcn', 'phsf', 'popg', 'ftcn', 'cnce', 'tmco', 'qlco', 'horm', ' phsu', 'orga']"
395,PMC3076731,S54,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Treatment,all participants received the growth hormone preparation of their choice at 10 mg/m2/week in daily subcutaneous injections.,"['C1707391', 'C0679646', 'C3714500', 'C0037663', 'C0021499', 'C1521827', 'C0439230', 'C3812761', 'C0332173', 'C0444868', 'C0008300', 'C0169964']","['Subcutaneous Injections', 'All', 'week', 'Daily', 'Preparation', 'Choose (action)', 'Somatropin', 'Human Growth Hormone', 'Growth Hormone', 'Choice Behavior', 'Prepared Material', 'Participant']","['inbe', 'acty', 'popg', 'ftcn', 'tmco', 'horm', ' phsu', ' aapp', 'qnco']"
396,PMC3076731,S55,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Treatment,"oral oxandrolone (spa, milan, italy) was given at 0.05 mg/kg/day, with a maximum daily dose of 2.5 mg.","['C0029995', 'C1552615', 'C1420002', 'C2348070', 'C0022277', 'C0806909', 'C0332173', 'C0439228', 'C2826546', 'C0442027']","['Daily Dose', 'Act Relationship Subset - maximum', 'Oral', 'day', 'SFTPA1 gene', 'Oxandrolone', 'Daily', 'Maximum', 'Italy', 'Maximum Value Derivation Technique']","[' orch', 'geoa', 'gngm', 'spco', 'tmco', 'horm', ' phsu', 'qnco']"
397,PMC3076731,S56,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Treatment,"oral ethinylestradiol (ucb pharma, slough, uk) was given daily as follows, regardless of the age at starting: year 1, 2 μg; year 2, 4 μg; year 3, four months each of 6, 8, and 10 μg.","['C1550718', 'C3641650', 'C0439231', 'C0027544', 'C1457900', 'C0442027', 'C1515981', 'C0332173', 'C1947971', 'C0332283', 'C1442162', 'C1565156', 'C1421478', 'C0043194', 'C0015011', 'C3244317', 'C0205450', 'C0001779', 'C0439234']","['GIVEN', 'Give - dosing instruction imperative', 'Regardless', 'Oral', 'Followed by', 'WAS protein, human', 'WAS gene', 'Daily', 'And', 'Age', 'Entity Name Part Type - given', 'Ethinyl Estradiol', 'Wiskott-Aldrich Syndrome', 'month', 'Necrotic debris', 'Each (qualifier value)', 'year', 'Given name', 'Four']","['bacs', ' orch', 'inpr', 'idcn', 'gngm', 'ftcn', 'spco', 'patf', 'tmco', 'qlco', 'horm', ' phsu', ' aapp', 'qnco', 'orga', 'dsyn']"
398,PMC3076731,S57,"['5', '10']","[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Treatment,"the code for randomisation 2 was broken at 15 years to allow introduction of progesterone therapy: oral norethisterone (cp pharmaceuticals, wrexham, uk) 5 mg daily for five days each month.","['C3889831', 'C1254351', 'C0439231', 'C4282183', 'C0279495', 'C1457900', 'C0009219', 'C0332177', 'C1135440', 'C0332173', 'C0205451', 'C0439228', 'C0805701', 'C0013227', 'C0028356', 'C0442027', 'C0439234']","['[AA000] INTRODUCTION', 'Norethindrone', 'Oral', 'Pharmaceutical Preparations', 'day', 'Five', 'Pharmacologic Substance', 'Daily', 'progestin therapy', 'month', 'Coding', 'Monthly (qualifier value)', 'Code', 'Each (qualifier value)', 'year', 'eTMF Content Model Code', 'Procedures involving the use of pharmaceuticals']","['inpr', ' orch', 'ocac', 'topp', 'spco', 'tmco', 'horm', ' phsu', 'qnco', 'phsu']"
399,PMC3076731,S58,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Treatment,treatment with growth hormone and oxandrolone continued until final height was reached.,"['C0029995', 'C3714500', 'C0037663', 'C3538994', 'C1705169', 'C3887704', 'C0087111', 'C0489786', 'C1515981', 'C0039798', 'C0549178', 'C1546485', 'C1522326', 'C1533734', 'C3853528', 'C0169964', 'C0205088']","['Final', 'Treatment Epoch', 'Oxandrolone', 'Diagnosis Type - Final', 'Biomaterial Treatment', 'And', 'Height', 'Treating', 'Administration procedure', 'Continuous', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Somatropin', 'Human Growth Hormone', 'End-stage', 'Therapeutic procedure', 'Growth Hormone']","[' orch', 'idcn', 'topp', 'ftcn', 'cnce', 'qlco', 'tmco', 'horm', 'resa', ' phsu', 'hlca', ' aapp', 'orga']"
400,PMC3076731,S59,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Treatment,oestrogen/progesterone therapy continued at an adult replacement dose once pubertal induction was completed.,"['C0001675', 'C1948045', 'C0178602', 'C0559956', 'C1555302', 'C0279495', 'C0014939', 'C0035139', 'C1706450', 'C4553149', 'C0857127', 'C0205263']","['Replacement', 'Surgical Replantation', 'Legal Adult', 'Induction procedure', 'Trial Subject Replacement', 'Adult', 'progestin therapy', 'Estrogens', 'Replacement - supply', 'Induce (action)', 'Once (schedule frequency)', 'Dosage']","[' orch', 'aggp', 'topp', 'popg', 'ftcn', 'tmco', 'horm', 'resa', ' phsu', 'hlca', 'qnco']"
401,PMC3076731,S60,['11b'],"[0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Treatment,"white, uncoated, flat bevelled edge placebo tablets (7 and 5 mm in diameter) (essential nutrition, brough, uk) were specially manufactured to match the size, weight, and appearance of oxandrolone 2.5 mg and ethinylestradiol 2 µg tablets respectively.","['C0007457', 'C0039225', 'C0870840', 'C0205154', 'C0220938', 'C1515981', 'C0988297', 'C1708943', 'C0005910', 'C0043157', 'C0392209', 'C0028707', 'C1442959', 'C1696465', 'C0205224', 'C1519767', 'C0150103', 'C0233426', 'C0043100', 'C0700364', 'C0456389', 'C3840882', 'C0205324', 'C0032042', 'C1305866', 'C1706408', 'C2697523', 'C1301886', 'C1705104', 'C0518896', 'C4084721', 'C0015011']","['White color', 'And', 'Diameter (qualifier value)', 'Weight', 'Graph Edge', 'placebo', 'Uncoated', 'Match', 'Caucasians', 'Ethinyl Estradiol', 'Placebos', 'Nutrition function', '5 mm', 'Nutritional status', 'manufacture', 'Oxandrolone 2.5 MG', 'Caucasoid Race', 'Appearance Distress Question', 'Personal appearance', 'Along edge (qualifier value)', 'Importance Weight', 'Nutrition outcomes', 'Flat shape', 'Placebo Control', 'Body Weight', 'Appearance', 'Science of nutrition', 'Weighing patient', 'size', 'Tablet Dosage Form', 'MATCHING', 'essential']","['bmod', 'inpr', ' orch', 'idcn', 'qnco', 'ocac', 'topp', 'popg', 'spco', 'cnce', 'qlco', 'fndg', 'horm', 'resa', 'clnd', ' phsu', 'hlca', 'orgf', 'bodm', 'orga']"
402,PMC3076731,S61,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Treatment,"the study’s central pharmacy (royal hospital for sick children, glasgow, uk) supplied all tablets in a double blind, placebo controlled fashion; only staff at the british society for paediatric endocrinology and diabetes clinical trials unit and the central distributing pharmacy were not blinded to treatment allocations.","['C0596227', 'C0039225', 'C3887704', 'C1705169', 'C1515981', 'C0008976', 'C2911690', 'C4321252', 'C0014137', 'C0031336', 'C0031321', 'C2587213', 'C0205099', 'C1518422', 'C0030755', 'C3853603', 'C1696465', 'C0439148', 'C0013072', 'C0851286', 'C1509845', 'C1947908', 'C1999230', 'C3244303', 'C0260101', 'C1704753', 'C0039798', 'C3538994', 'C0019994', 'C0011847', 'C0037455', 'C0011849', 'C0031322', 'C0521125', 'C1519795', 'C0032042', 'C1706408', 'C0205171', 'C0087111', 'C1880519', 'C0439453', 'C1096775', 'C1522326', 'C1533734', 'C0444868', 'C0520511']","['Endocrinology', 'Double-Blind Method', 'Biomaterial Treatment', 'And', 'Unit', 'Providing (action)', 'Pharmaceutical Services', 'Pharmacy facility', 'Unit of Measure', 'Preposition For', 'placebo', 'WWOX wt Allele', 'Therapeutic procedure', 'Enzyme Unit', 'Societies', 'british', 'Clinical Trials', 'Placebos', 'Diabetes', 'Administration procedure', 'Central', 'On Staff', 'Negation', 'Treatment Epoch', 'All', 'Storage Unit', 'Singular', 'Pediatrics', 'Staff', 'Disease Controlled', 'Control function', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'International Unit', 'Placebo Control', 'Unit - NCI Thesaurus Property', 'Unit device', 'Pharmacy domain', 'Treating', 'sick child', 'Pharmacy (field)', 'Clinical Trial [Publication Type]', 'Tablet Dosage Form', 'Diabetes Mellitus', 'Distributing', 'Hospitals']","['topp', 'medd', 'mnob', 'fndg', 'qlco', 'hlca', ' hcro', 'bmod', 'inpr', 'idcn', 'gngm', 'prog', 'resa', 'bodm', 'popg', 'ftcn', 'podg', 'dsyn', 'acty', 'spco', 'cnce', 'qnco', 'orgt']"
403,PMC3076731,S63,['3b'],"[0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Oxandrolone supplies,"in 2004 and 2008, the sole european manufacturer of oxandrolone 2.5 mg ceased production, resulting in 34 participants in 2004 and 11 in 2008 temporarily suspending active oxandrolone treatment (mean duration: 2004, 52 days; 2008, 163 days).","['C1535514', 'C0679646', 'C3853793', 'C3887704', 'C1705169', 'C0678226', 'C1515981', 'C0988297', 'C0239307', 'C0947322', 'C0444504', 'C0205177', 'C0230463', 'C2347634', 'C0039798', 'C3538994', 'C0029995', 'C3888249', 'C0439228', 'C0033268', 'C0038959', 'C0087111', 'C1705537', 'C2348143', 'C0449238', 'C1522326', 'C1533734', 'C2926735']","['Active License', 'day', 'active (HL7 RoleLink)', 'Biomaterial Treatment', 'And', 'Sole of Foot', 'Due to', 'Therapeutic procedure', 'Duration', 'Sample Mean', 'Manufacturer Name', 'Administration procedure', 'Suspending Agents', 'European race', 'Population Mean', 'Oxandrolone 2.5 MG', 'Duration (temporal concept)', 'Active', 'Treatment Epoch', 'Oxandrolone', 'production', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Statistical mean', 'Treating', 'ethnic european', 'Suspension (action)', 'Participant']","[' orch', 'inpr', 'idcn', 'bodm', 'ocac', 'topp', 'popg', 'ftcn', 'cnce', 'blor', 'tmco', 'qlco', 'horm', 'orch', 'resa', ' phsu', 'hlca', 'clnd', 'qnco']"
404,PMC3076731,S64,['3b'],"[0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Oxandrolone supplies,"in 2008, the decision was taken to terminate the treatment arm forthwith, resulting in eight participants stopping oxandrolone treatment prematurely.","['C0029995', 'C1522541', 'C0679646', 'C1883727', 'C3887704', 'C1705169', 'C0205454', 'C0087111', 'C0679006', 'C0043194', 'C1565156', 'C1522326', 'C1533734', 'C1421478', 'C0039798', 'C3538994']","['Protocol Treatment Arm', 'Treatment Epoch', 'Oxandrolone', 'WAS protein, human', 'Biomaterial Treatment', 'Taken', 'WAS gene', 'Treating', 'Administration procedure', 'Wiskott-Aldrich Syndrome', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Decision', 'Eight', 'Therapeutic procedure', 'Participant']","['bacs', ' orch', 'gngm', 'topp', 'popg', 'ftcn', 'cnce', 'hlca', 'horm', 'resa', ' phsu', 'menp', ' aapp', 'qnco', 'dsyn']"
405,PMC3076731,S66,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study procedures,"at clinic visits every four to six months, height was measured with a harpenden stadiometer to the last completed 1 mm and converted to an sd score by using the british 1990 reference.22","['C0205452', 'C0596227', 'C0439231', 'C1948061', 'C4050231', 'C1517741', 'C0205197', 'C3854010', 'C0489786', 'C1515981', 'C1514811', 'C0008952', 'C1706462', 'C3842090', 'C0205450', 'C0449820']","['Complete', 'Reference Object', 'Clinic Visits', 'british', 'Height', 'And', 'month', '1 mm', 'ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated', 'completed - RoleLinkStatus', 'Bibliographic Reference', 'Score', 'Six', 'Every (qualifier)', 'Last', 'Four']","['inpr', 'clna', 'idcn', 'popg', 'cnce', 'fndg', 'qlco', 'tmco', 'hlca', 'qnco', 'orga']"
406,PMC3076731,S67,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study procedures,"radiographs of the left wrist were obtained annually, and a single observer (wfp) analysed them for bone age estimation according to the tanner whitehouse ii method.23","['C1301820', 'C0429620', 'C0871511', 'C1306645', 'C0521125', 'C0680844', 'C0750572', 'C0205171', 'C0449851', 'C0087136', 'C1515981', 'C0681916', 'C0230366', 'C4321252', 'C0335730', 'C0680240', 'C0025663', 'C0332181', 'C0870992']","['Estimated', 'WWOX wt Allele', 'observers', 'Techniques', 'Methods', 'And', 'Agreement', 'Plain x-ray', 'Singular', 'estimation <subjective>', 'tanner', 'Statistical Estimation', 'Preposition For', 'bone age', 'Annual', 'Test Method', 'Unmarried', 'Obtain', 'Structure of left wrist']","['inpr', 'bpoc', 'grup', 'idcn', 'lbpr', 'gngm', 'prog', 'ftcn', 'fndg', 'tmco', 'qlco', 'socb', 'menp', 'diap', 'qnco']"
407,PMC3076731,S68,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study procedures,"biochemical analyses followed local protocols, and the results were reported centrally.","['C0442711', 'C0205474', 'C0205276', 'C1515981']","['Local', 'Protocols documentation', 'And', 'Biochemical']","['ftcn', 'spco', 'inpr', 'idcn']"
408,PMC3076731,S69,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study procedures,"standardised pharmacovigilance procedures were followed, with recording of adverse events or reactions at each visit and subsequent review by the data and safety monitoring group.","['C1511726', 'C0036043', 'C0441833', 'C0687744', 'C0150369', 'C1515981', 'C2700391', 'C3714741', 'C0877248', 'C2826704', 'C3178990', 'C3538935', 'C1283169', 'C0184661', 'C1457900', 'C0545082', 'C1705429', 'C1705413', 'C0282443', 'C1552617', 'C0332282', 'C1519504', 'C3245479', 'C1512346', 'C1257890', 'C0025664', 'C1705428', 'C1705187']","['Preventive monitoring', 'Visit', 'And', 'Data call receiving device', 'Methods aspects', 'Safety', 'Stage Grouping', 'Procedure Domain', 'Monitoring - action', 'User Group', 'Visit Name', 'Adverse event', 'Act Class - review', 'Group Object', 'Following', 'Each (qualifier value)', 'Social group', 'Pharmacovigilance', 'Adverse Event Domain', 'Patient Visit', 'Data', 'Procedure (set of actions)', 'Review [Publication Type]', 'Groups', 'Safety Study', 'Population Group', 'Data (eukaryote)', 'Interventional procedure']","['hcpp', 'inpr', 'idcn', 'topp', 'medd', 'popg', 'ftcn', 'cnce', 'patf', 'tmco', 'euka', 'resa', 'bhvr', 'hlca', 'qnco']"
409,PMC3076731,S70,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study procedures,"data collection ceased if participants withdrew consent, although we included previously collected data in the analysis.","['C2923685', 'C0010995', 'C1511726', 'C0679646', 'C1516695', 'C3245479', 'C3887707', 'C0936012', 'C1524024', 'C1516698', 'C1511481', 'C1554192', 'C3714741']","['Consent', 'Data Collection', 'Data Collection Methods', 'Data call receiving device', 'Consent:Finding:Point in time:{Setting}:Document:Patient', 'Analysis', 'Collected', 'ActClass - consent', 'Participant', 'Data (eukaryote)', 'Data', 'Collection (action)', 'analysis aspect']","['clna', 'idcn', 'medd', 'popg', 'ftcn', 'euka', 'resa', 'qnco']"
410,PMC3076731,S72,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical methods,"the primary outcome was final height, defined as height velocity less than 1 cm/year and bone age at least 15.5 years.","['C1274040', 'C0429620', 'C0489786', 'C1515981', 'C0205225', 'C0205088', 'C1546485', 'C3853528', 'C1704788', 'C0439092', 'C0439830', 'C0547044', 'C0439234']","['Smaller', 'Final', 'Diagnosis Type - Final', 'Less Than', 'Height', 'And', 'Definition', 'Velocity', 'bone age', 'Result', 'End-stage', 'year', 'Primary']","['inpr', 'idcn', 'ftcn', 'fndg', 'tmco', 'qlco', 'qnco', 'orga']"
411,PMC3076731,S73,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical methods,"secondary outcomes were maximum height (that is, the most recently available height), age of attaining final height, and the three summary growth parameters from the sitar analysis described below.","['C0220844', 'C0205436', 'C0489786', 'C1515981', 'C0027627', 'C1524024', 'C0470187', 'C2826546', 'C3853528', 'C0175668', 'C1552615', 'C0936012', 'C1546485', 'C1706244', 'C1552616', 'C0205449', 'C0806909', 'C1517320', 'C2911660', 'C0001779', 'C1552829', 'C0205393', 'C0018270', 'C0205088', 'C1621966', 'C0542339']","['Inferior', 'growth aspects', 'And', 'Table Frame - below', 'From', 'Secondary to', 'Final', 'Most', 'Diagnosis Type - Final', 'Tissue Growth', 'Summary (document)', 'Age', 'Act Relationship Subset - maximum', 'availability of', 'summary - ActRelationshipSubset', 'Growth', 'End-stage', 'analysis aspect', 'Growth action', 'Neoplasm Metastasis', 'second (number)', 'Height', 'Three', 'Maximum', 'Analysis', 'Maximum Value Derivation Technique']","['ortf', 'inpr', 'phpr', 'idcn', 'phsf', 'neop', 'ftcn', 'spco', 'qlco', 'tmco', 'resa', 'orgf', 'qnco', 'orga']"
412,PMC3076731,S74,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical methods,"assuming a standard deviation of 5 cm, we needed 50 girls in each group to detect a difference between groups in mean final height of 2.8 cm with 80% power at 5% significance—a total of 100 patients.","['C0030705', 'C0441833', 'C0687744', 'C0032863', 'C0489786', 'C0439810', 'C3891454', 'C3853528', 'C0043210', 'C0444504', 'C1705241', 'C0871420', 'C1546485', 'C0332287', 'C2347634', 'C1705242', 'C1552839', 'C1457900', 'C1705429', 'C0686904', 'C1519504', 'C1257890', 'C2348143', 'C3854080', 'C0870604', 'C0205103', 'C0442726', 'C1705428', 'C0205088']","['Woman', 'Detected (finding)', 'Patients', 'Power', 'Stage Grouping', 'Standard deviation', 'Sample Mean', 'Delta (difference)', 'Final', 'Diagnosis Type - Final', 'User Group', 'Population Mean', 'Total', 'Group Object', 'Each (qualifier value)', 'Social group', 'Intermediate', 'End-stage', 'Dosing Days to Detection', 'In addition to', 'Statistical mean', 'Female child', 'Groups', 'Height', 'Power (Psychology)', 'Table Rules - groups', 'Population Group', 'Different', 'Patient need for (contextual qualifier)']","['hcpp', 'inpr', 'idcn', 'aggp', 'popg', 'ftcn', 'fndg', 'cnce', 'podg', 'qlco', 'tmco', 'spco', 'qnco', 'orga']"
413,PMC3076731,S75,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,the study was not formally powered to detect a significant interaction between the two randomisations.,"['C0237881', 'C1546944', 'C2603343', 'C0205448', 'C1518422', 'C1704675', 'C0750502']","['Event Seriousness - Significant', 'Statistical Significance', 'Significant', 'Study', 'Two', 'Interaction', 'Negation']","['idcn', 'ftcn', 'qlco', 'resa', 'qnco']"
414,PMC3076731,S76,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"in the event, more than 100 patients were recruited, but fewer than 100 were followed up to final height.","['C0205172', 'C0030705', 'C0441471', 'C0489786', 'C0205088', 'C1546485', 'C4019010', 'C3853528']","['Final', 'Diagnosis Type - Final', 'More', 'Height', 'Patients', 'National reporting jurisdiction:Loc:Pt:^Event:Nom', 'End-stage', 'Event']","['clna', 'idcn', 'podg', 'qlco', 'tmco', 'qnco', 'orga', 'evnt']"
415,PMC3076731,S77,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,we estimated the effects of the two randomisations separately by using multiple regression.,"['C1280500', 'C0681923', 'C0205448']","['Two', 'Effect', 'multiple regression']","['qlco', 'qnco']"
416,PMC3076731,S78,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,we also adjusted randomisation 2 (timing of pubertal induction) for randomisation 1 (oxandrolone) and tested for an interaction.,"['C0205263', 'C0029995', 'C1515981', 'C1704250', 'C4321252', 'C0857127', 'C0449243', 'C0521125', 'C1704675']","['Timing', 'Oxandrolone', 'Induction procedure', 'Timing, LOINC Axis 3', 'And', 'Interaction', 'Induce (action)', 'Preposition For', 'WWOX wt Allele']","[' orch', 'idcn', 'gngm', 'topp', 'ftcn', 'cnce', 'qlco', 'tmco', 'horm', ' phsu']"
417,PMC3076731,S79,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"in addition, we applied sitar (superimposition by translation and rotation), a novel method of growth curve analysis, to the data.24","['C0220844', 'C0871511', 'C1511726', 'C1515981', 'C1524024', 'C3714741', 'C0025663', 'C0677597', 'C0936012', 'C0040712', 'C0332287', 'C1883712', 'C0205134', 'C0449851', 'C0035868', 'C1519614', 'C2911660', 'C3245479', 'C0205314', 'C0679622', 'C0597295', 'C0018270', 'C1621966']","['growth aspects', 'Methods', 'And', 'Rotation', 'Data call receiving device', 'Language Translations', 'Protein Biosynthesis', 'Tissue Growth', 'literary novel', 'New', 'Musculoskeletal rotation', 'Growth', 'Data', 'In addition to', 'analysis aspect', 'Growth action', 'Curved', 'Genetic Translation Process', 'Techniques', 'Analysis', 'Data (eukaryote)', 'Test Method', 'Add - instruction imperative']","['ortf', 'inpr', 'phpr', 'idcn', 'genf', 'phsf', 'lbpr', 'medd', 'ftcn', 'spco', 'qlco', 'euka', 'resa', 'moft', 'orgf']"
418,PMC3076731,S80,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"sitar transforms individual growth curves so that they become essentially the same as each other and, when superimposed, define the average summary curve.","['C0220844', 'C0027361', 'C2911660', 'C0205134', 'C0445247', 'C0237401', 'C1510992', 'C1457900', 'C2825518', 'C1515981', 'C1948054', 'C0018270', 'C1706244', 'C4684637', 'C1621966', 'C1552616']","['Each (qualifier value)', 'Average', 'Curved', 'Tissue Growth', 'Summary (document)', 'growth aspects', 'And', 'Same', 'When (temporal qualifier)', 'Persons', 'summary - ActRelationshipSubset', 'Growth', 'Define.xml', 'Individual', 'Average of Value Derivation Technique', 'Growth action']","['ortf', 'inpr', 'phpr', 'idcn', 'phsf', 'popg', 'spco', 'qlco', 'tmco', 'orgf', 'qnco']"
419,PMC3076731,S81,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"to achieve this, each individual curve is suitably altered in three distinct ways: the curve is shifted up/down (a measure of the child’s size in cm) and left/right (a measure of growth tempo in years), and the age axis is stretched/squashed (a measure of percentage velocity).","['C0220844', 'C0079809', 'C1561533', 'C0205090', 'C1522496', 'C0242485', 'C1515981', 'C1080058', 'C0027361', 'C0443246', 'C1621966', 'C0333051', 'C0205134', 'C0205449', 'C0999597', 'C1457900', 'C0444532', 'C0004457', 'C1552822', 'C0439830', 'C0456389', 'C0439234', 'C0205104', 'C2911660', 'C1549488', 'C0237401', 'C0439165', 'C0018270', 'C0876945', 'C0001779', 'C0205091']","['Genus Axis', 'Right', 'growth aspects', 'And', 'Downward', 'Persons', 'Money or percentage indicator - Percentage', 'shift displacement', 'Tissue Growth', 'Age', 'Axis vertebra', 'Tempo (rate)', 'Each (qualifier value)', 'Measurement', 'Left sided', 'Left', 'Table Cell Horizontal Align - left', 'Growth', 'Individual', 'Axis', 'year', 'Amount type - Percentage', 'Growth action', 'Curved', 'Percent (qualifier value)', 'Velocity', 'Three', 'Measures', 'Right sided', 'size', 'This (eukaryote)']","['ortf', 'bpoc', 'phpr', 'mamm', 'idcn', 'phsf', 'popg', 'ftcn', 'spco', 'tmco', 'euka', 'orgf', 'qnco', 'orga']"
420,PMC3076731,S82,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"size, tempo, and velocity are thus participant specific random effects summarising how each girl’s curve differs from the average curve.","['C4554048', 'C0679646', 'C0439605', 'C0205134', 'C0205369', 'C1510992', 'C1457900', 'C0034656', 'C2825518', 'C1515981', 'C1280500', 'C0456389', 'C0876945', 'C2698741', 'C0439830', 'C1552740']","['Each (qualifier value)', 'Effect', 'Study Participant', 'Randomization', 'Average', 'Entity Determiner - specific', 'Curved', 'Specific qualifier value', 'Random', 'And', 'Velocity', 'Tempo (rate)', 'Participant Object', 'size', 'Average of Value Derivation Technique', 'Participant']","['inpr', 'idcn', 'clas', 'popg', 'spco', 'tmco', 'qlco', 'resa', 'qnco']"
421,PMC3076731,S83,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,the effects of the randomisations can be explored by comparing the values of the random effects by trial arm.,"['C3715044', 'C0439605', 'C1704712', 'C0034656', 'C0446516', 'C0042295', 'C0008976', 'C4553528', 'C1280500']","['Effect', 'Randomization', 'AKR1A1 wt Allele', 'Upper arm', 'Clinical Trials', 'Random', 'Can - object', 'Sequence Arm', 'Values']","['inpr', 'gngm', 'blor', 'mnob', 'qlco', 'resa']"
422,PMC3076731,S84,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"equally, separate summary curves can be constructed for each trial arm.","['C3715044', 'C0443299', 'C1457900', 'C0446516', 'C0008976', 'C4553528', 'C1706244', 'C1552616']","['AKR1A1 wt Allele', 'Upper arm', 'Clinical Trials', 'Summary (document)', 'Sequence Arm', 'summary - ActRelationshipSubset', 'Each (qualifier value)', 'Separate']","['inpr', 'gngm', 'blor', 'qlco', 'resa', 'qnco']"
423,PMC3103669,S39,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"this was a 24-week, dose-ranging, multicentre, double-blind, double-dummy, active-controlled study and was approved by all responsible independent ethics committees.","['C0205173', 'C0456909', 'C0439230', 'C0178602', 'C0205177', 'C3888249', 'C0085546', 'C1705765', 'C0085862', 'C0150108', 'C1273518', 'C0525065', 'C1705764', 'C0444868', 'C1080058', 'C0681867', 'C1515981', 'C1290940', 'C4684647', 'C1299583', 'C3853793']","['Duplicate', 'Active License', 'responsible', 'Double-Dummy', 'And', 'active (HL7 RoleLink)', 'Independent for Transfer', 'Independence', 'Double Value Type', 'Active', 'Controlled Study', 'All', 'Visually Impaired Persons', 'Independently able', 'Dosage', 'Blinded', 'Doubling', 'week', 'Ethics Committees', 'This (eukaryote)', 'Blindness']","['tmco', 'fndg', 'prog', 'idcn', 'qlco', 'qnco', 'euka', 'resa', 'podg', 'ftcn', 'acty']"
424,PMC3103669,S40,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"the study was performed in accordance with the international conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ich) harmonised tripartite guidelines for good clinical practice and the ethical principles laid down in the declaration of helsinki, and all patients provided written informed consent.","['C0220845', 'C4055445', 'C1553384', 'C0205104', 'C0521125', 'C3272597', 'C2986419', 'C0162791', 'C1135440', 'C4321252', 'C0030705', 'C0021430', 'C2697663', 'C1254351', 'C3281105', 'C0026528', 'C0444868', 'C0086047', 'C0449851', 'C0013227', 'C1514821', 'C2603343', 'C1512888', 'C1515981', 'C0282423']","['Registration', 'Guideline [Publication Type]', 'And', 'Image Registration', 'Procedures involving the use of pharmaceuticals', 'Study', 'Moral Obligations', 'ICH Temperature/Humidity Storage Condition', 'International', 'Conferences', 'Techniques', 'Approved for Human Use Product', 'Pharmacologic Substance', 'HEMORRHAGE, INTRACEREBRAL, SUSCEPTIBILITY TO', 'All', 'WWOX wt Allele', 'Informed Consent', 'Patients', 'Preposition For', 'Pharmaceutical Preparations', 'Guidelines', 'guiding characteristics', 'Downward', 'Good Clinical Practice', 'registration - ActClass']","['fndg', 'mcha', 'resa', 'rnlw', 'idcn', 'gngm', 'topp', 'hlca', 'inpr', 'qlco', 'qnco', 'spco', 'hcpp', 'podg', 'ftcn', 'phsu']"
425,PMC3103669,S41,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,the trial was registered with http://www.clinicaltrials.gov (registration number: nct00819585).,,,
426,PMC3103669,S42,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study design,"at screening, patients indicated which of their joints was most affected by previous gouty arthritis flares.","['C0003868', 'C0220909', 'C1710032', 'C1552607', 'C0205156', 'C0220908', 'C2348164', 'C1698960', 'C0030705', 'C0392905', 'C1710477', 'C1710031', 'C0022417']","['Joints', 'Screening Study', 'research subject screening', 'Aspects of disease screening', 'Screening procedure', 'Trial Screening', 'Articular system', 'Disease Screening', 'Patients', 'Screening', 'Previous', 'Act Relationship Subset - previous', 'Arthritis, Gouty']","['tmco', 'hlca', 'bdsy', 'dsyn', 'resa', 'podg', 'ftcn', 'diap', 'bsoj']"
427,PMC3103669,S43,"['5', '8b']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1, 0]",Study design,"eligible patients were subsequently randomised 1:1:1:1:1:1:2 to receive a single dose of canakinumab, 25 mg, 50 mg, 100 mg, 200 mg, or 300 mg on day 1, or four canakinumab doses administered at 4-weekly intervals (50 mg on day 1 and at week 4, and 25 mg at weeks 8 and 12), or daily oral doses of colchicine 0.5 mg given for 16 weeks.","['C0332174', 'C0332173', 'C1521801', 'C0442027', 'C0087136', 'C1442449', 'C0439230', 'C0178602', 'C0030705', 'C1515981', 'C0985105', 'C0205450', 'C1272706', 'C1548635', 'C2718773', 'C0205171']","['1 Day', 'canakinumab', 'Singular', 'Colchicine 0.5 MG', 'Having administered', 'Four', 'And', 'Dosage', 'week', 'Patients', 'Interval', 'Unmarried', 'Daily', 'Oral', 'Weekly', 'Eligible']","['tmco', 'clnd', 'imft', 'fndg', 'idcn', 'qnco', 'qlco', 'spco', 'ftcn', 'podg', ' aapp', ' phsu']"
428,PMC3103669,S44,"['11a', '11b']","[0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"in order to achieve blinding for patients and investigators, all patients received subcutaneous injections of canakinumab or canakinumab placebo on day 1, and at weeks 4, 8 and 12, and took capsules of colchicine or colchicine placebo daily for 16 weeks (see supplementary material for details).","['C0439230', 'C1705176', 'C0332173', 'C0030705', 'C1522508', 'C1706408', 'C0009262', 'C1882348', 'C0021499', 'C0444868', 'C1705177', 'C2718773', 'C0035173', 'C1705175', 'C3889825', 'C1705178', 'C0032042', 'C0006935', 'C1442449', 'C2936424', 'C1515981', 'C1696465']","['placebo', 'Subcutaneous Injections', 'Details', 'And', 'Placebos', '1 Day', 'canakinumab', 'Placebo Control', 'All', 'Order (action)', 'capsule (pharmacologic)', 'Patients', 'Daily', 'Order (document)', 'Order (taxonomic)', 'Colchicine', 'Research Personnel', 'week', 'Sequence of Planned Assessment Schedule', 'Permutation', 'Electronic Supplementary Materials', 'Order (arrangement)']","['tmco', 'imft', 'resa', 'prog', 'bodm', 'idcn', 'topp', 'clas', 'inpr', 'orch', 'qnco', 'qlco', 'ftcn', 'podg', ' aapp', ' phsu', 'acty']"
429,PMC3103669,S45,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,patients were followed for 24 weeks.,,,
430,PMC3103669,S46,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,allopurinol treatment (100–300 mg) was initiated at baseline or within 1 month before baseline and was administered to all randomised patients once daily for 24 weeks (see supplementary material for details).,"['C0087111', 'C0556983', 'C1522326', 'C1442488', 'C1442451', 'C0332285', 'C3887704', 'C1705169', 'C0039798', 'C0168634', 'C0030705', 'C1522508', 'C2936424', 'C1515981', 'C3538994', 'C0439230', 'C0444868', 'C0332152', 'C1533734', 'C0002144']","['BaseLine dental cement', 'All', 'treatment - ActInformationManagementReason', 'Allopurinol', 'Treating', 'Within', 'Details', 'Treatment Epoch', 'And', 'therapeutic aspects', 'Patients', 'week', 'Before', 'Biomaterial Treatment', 'Baseline', '1 Month', 'Administration procedure', 'Electronic Supplementary Materials', 'Once daily', 'Therapeutic procedure']","['tmco', 'resa', 'topp', 'idcn', 'hlca', 'inpr', 'orch', 'qnco', 'qlco', 'spco', 'ftcn', 'podg', 'bodm', ' phsu', 'cnce']"
431,PMC3103669,S47,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,patients could receive rescue medication as needed (see supplementary material for details).,"['C4284232', 'C1522508', 'C0030705', 'C2936424', 'C3244316', 'C0013227']","['Medications', 'Details', 'Patients', 'Pharmaceutical Preparations', 'Electronic Supplementary Materials', 'medication - HL7 publishing domain']","['podg', 'inpr', 'qlco', 'phsu']"
432,PMC3103669,S49,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"inclusion criteria were: age 18–80 years, diagnosis of gouty arthritis as defined by the american college of rheumatology 1977 preliminary criteria,29 having had at least two gouty arthritis flares in the previous year, body mass index (bmi) of ≤40 kg/m2 and willingness to initiate allopurinol treatment or having initiated allopurinol treatment within 1 month of screening.","['C0003868', 'C1512693', 'C1710032', 'C0205156', 'C3538994', 'C1305855', 'C0243161', 'C3539897', 'C1533734', 'C0087111', 'C1442451', 'C1704656', 'C3887704', 'C1705169', 'C0005893', 'C0439234', 'C2348164', 'C0596070', 'C1698960', 'C0039798', 'C0205448', 'C0002144', 'C1415458', 'C1704338', 'C0035452', 'C0439611', 'C0220908', 'C0062074', 'C1710031', 'C0011900', 'C1522326', 'C0557806', 'C0220909', 'C1552607', 'C0578022', 'C1515981', 'C1710477', 'C0001779']","['year', 'Aspects of disease screening', 'Screening procedure', 'Age', 'Allopurinol', 'diagnosis aspect', 'And', 'HAC protocol', 'HADH gene', 'Diagnosis', 'Trial Screening', 'Treatment Epoch', 'Rheumatology specialty', 'Screening', '1 Month', 'Biomaterial Treatment', 'Americas Ethnicity', 'Administration procedure', 'college', 'Screening Study', 'Two', 'Finding of body mass index', 'Inclusion', 'Disease Screening', 'Body mass index', 'Act Relationship Subset - previous', 'Arthritis, Gouty', 'Body mass index procedure', 'research subject screening', 'treatment - ActInformationManagementReason', 'Treating', 'Have', 'criteria', 'therapeutic aspects', 'Diagnosis Study', 'preliminary', 'Previous', 'Therapeutic procedure']","['tmco', 'mnob', 'fndg', 'popg', 'gngm', 'hlca', 'topp', 'idcn', 'orch', 'qlco', 'qnco', 'bmod', 'orga', 'dsyn', 'resa', 'ftcn', 'diap', ' phsu', 'cnce', 'clna']"
433,PMC3103669,S50,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"key exclusion criteria were: having a gouty arthritis flare within 2 weeks of screening, present at screening, or having pain associated with a flare at screening; history of allergy, contraindication, or intolerance to allopurinol or colchicine (see supplementary material for further details).","['C0003868', 'C4085210', 'C0449450', 'C0002111', 'C3714732', 'C1710032', 'C0019664', 'C0522473', 'C0680251', 'C4085212', 'C1517205', 'C0518090', 'C2348164', 'C1522508', 'C1698960', 'C0231199', 'C4554132', 'C0030193', 'C1527304', 'C0262926', 'C3540542', 'C0332285', 'C0019665', 'C0220908', 'C4553004', 'C1744706', 'C2004062', 'C1314973', 'C1705255', 'C2984058', 'C0262512', 'C1710031', 'C0150312', 'C1442457', 'C0220909', 'C0020517', 'C1301624', 'C2355652', 'C2936424', 'C1710477', 'C1517331', 'C4085211']","['Usual Severity Pain', 'Aspects of disease screening', 'Screening procedure', 'Have Pain', 'Details', 'Pain Distress Question', 'History', 'Further', '2 Weeks', 'Medical History', 'Presentation', 'Trial Screening', 'Allergic Reaction', 'Within', 'Screening', 'History of previous events', 'Contraindication:Find:Pt:^Patient:Nom', 'Hypersensitivity', 'Allergy Specialty', 'Flare', 'Concept History', 'intolerance function', 'Response to antigens', 'Screening Study', 'Feel Pain', 'intolerance to substance', 'Exclusion Criteria', 'History of present illness', 'Medical contraindication', 'Disease Screening', 'Arthritis, Gouty', 'Exacerbation of cGVHD', 'Pain', 'How Much Distress Pain', 'research subject screening', 'Intolerance - biological effect of chemicals', 'Frequency of Pain Question', 'Electronic Supplementary Materials', 'Contraindication', 'Pain, CTCAE', 'Present', 'Historical aspects qualifier']","['clna', 'tmco', 'fndg', 'hlca', 'idcn', 'phsf', 'inpr', 'ocdi', 'sosy', 'qlco', 'bmod', 'orga', 'dsyn', 'spco', 'resa', 'orgf', 'ftcn', 'diap', 'patf', 'cnce']"
434,PMC3103669,S52,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,flares were patient reported.,['C0030705'],['Patients'],['podg']
435,PMC3103669,S53,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,"for each flare, patients recorded in a diary the start date, the most affected joint on that day and the severity of pain (see supplementary material for further details).","['C4085210', 'C0439793', 'C4085212', 'C1517205', 'C0332173', 'C0518090', 'C1457900', 'C0376660', 'C0030705', 'C1522508', 'C4554132', 'C0030193', 'C0522510', 'C0439228', 'C0392760', 'C3540542', 'C4553004', 'C2984058', 'C0808070', 'C0022417', 'C1706309', 'C0205393', 'C2936424', 'C1515981', 'C0392905', 'C1517331', 'C4085211']","['Joints', 'Usual Severity Pain', 'With intensity', 'Have Pain', 'Articular system', 'Details', 'Each (qualifier value)', 'And', 'Pain Distress Question', 'Further', 'Diary', 'Affecting', 'Severities', 'Flare', 'Feel Pain', 'Patients', 'Daily', 'Exacerbation of cGVHD', 'Pain', 'How Much Distress Pain', 'day', 'Frequency of Pain Question', 'Pain, CTCAE', 'Joint Device', 'Most', 'Start Date', 'Electronic Supplementary Materials']","['tmco', 'fndg', 'idcn', 'bdsy', 'inpr', 'sosy', 'qlco', 'qnco', 'spco', 'podg', 'ftcn', 'mnob', 'bsoj']"
436,PMC3103669,S54,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,patients also recorded rescue medication use and pain for at least 7 days after the onset of the flare or longer if the flares persisted for more than 7 days.,"['C4085210', 'C1517205', 'C3540542', 'C0518090', 'C0206132', 'C4553004', 'C0030705', 'C1515981', 'C0240320', 'C4554132', 'C0030193', 'C0205172', 'C2984058', 'C0332162', 'C4085211', 'C1547085', 'C4085212']","['Pain', 'Onset of (contextual qualifier)', 'How Much Distress Pain', 'Feel Pain', 'Have Pain', 'Usual Severity Pain', 'Age of Onset', 'medication use', 'Frequency of Pain Question', 'More', 'And', 'Pain Distress Question', 'Pain, CTCAE', 'Patients', '7 days', 'Flare', 'Exacerbation of cGVHD']","['tmco', 'fndg', 'idcn', 'inpr', 'sosy', 'qnco', 'qlco', 'podg']"
437,PMC3103669,S55,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,"safety assessments were performed at scheduled visits (2, 4, 8, 12, 16, 20 and 24 weeks) and included collection of blood samples for assessment of the inflammatory marker, c reactive protein (crp), haematology and immunogenicity (at baseline and weeks 8, 16 and 24) and doctor's assessments of local tolerability at sites of subcutaneous injections.","['C3890735', 'C3274448', 'C0205145', 'C1516698', 'C1704814', 'C0168634', 'C0439230', 'C0086960', 'C1512346', 'C1705187', 'C0031831', 'C0005516', 'C2348314', 'C0178913', 'C0545082', 'C1516048', 'C0205276', 'C0036043', 'C0021499', 'C0333348', 'C4048285', 'C0205539', 'C1442488', 'C0006560', 'C4054739', 'C4554585', 'C1515981', 'C1261322', 'C0600644']","['C-Reactive Protein, human', 'Patient Visit', 'Subcutaneous Injections', 'Biological Markers', 'And', 'Schedule (document type)', 'Evaluation procedure', 'Safety', 'Visit', 'Complete Response with Incomplete Platelet Recovery', 'Assessed', 'Immunogenicity (package insert)', 'Safety Study', 'Baseline', 'Physicians', 'Tolerability Study', 'Scheduled - procedure status', 'Collections (publication)', 'Site', 'inflammatory', 'Blood specimen', 'BaseLine dental cement', 'Doctor - Title', 'C-reactive protein', 'Item Collection', 'week', 'Collection (action)', 'Immunogenicity Study', 'Local']","['clna', 'tmco', 'imft', 'fndg', 'bodm', 'prog', 'idcn', 'hcpp', 'hlca', 'inpr', 'bdsu', 'qnco', 'qlco', 'bhvr', 'ftcn', 'resa', 'spco', ' aapp', 'cnce', 'acty']"
438,PMC3103669,S56,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,adverse events (aes) were reported throughout the study.,"['C2603343', 'C2699274', 'C1705413', 'C1412268', 'C0877248']","['Scanning Auger Spectrometer (device)', 'AES gene', 'Adverse Event Domain', 'Study', 'Adverse event']","['gngm', 'inpr', 'resd', 'resa', 'patf']"
439,PMC3103669,S57,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,"the primary outcome was determination of the canakinumab dose producing equivalent efficacy to that achieved with colchicine 0.5 mg, with respect to the mean number of flares per patient occurring within 16 weeks post randomisation (ie, the target dose).","['C0332287', 'C2348143', 'C0237753', 'C0439185', 'C0679133', 'C0449788', 'C0205225', 'C0439230', 'C0030705', 'C0178602', 'C0444504', 'C0205163', 'C0985105', 'C1148554', 'C2347634', 'C0521095', 'C1707887', 'C2718773', 'C1274040', 'C1280519']","['Effectiveness', 'Sample Mean', 'canakinumab', 'In addition to', 'Equal', 'Primary', 'Colchicine 0.5 MG', 'Count of entities', 'Determined by', 'Population Mean', 'Efficacy Study', 'Dosage', 'Patients', 'Statistical mean', 'week', 'Determination Aspects', 'Equivalent Weight', 'Respect', 'Result', 'Numbers']","['tmco', 'clnd', 'imft', 'resa', 'qnco', 'qlco', 'lbpr', 'socb', 'ftcn', 'podg', ' aapp', ' phsu']"
440,PMC3103669,S58,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,"secondary efficacy outcomes included: mean number of flares per patient, proportion of patients with at least one flare, time to first flare, average duration of flares and crp levels (see supplementary material for further details).","['C3890735', 'C1517331', 'C2825518', 'C0205447', 'C0237753', 'C1279901', 'C0441889', 'C1517205', 'C0205435', 'C0449788', 'C4281991', 'C0205436', 'C0030705', 'C1522508', 'C1707887', 'C1280519', 'C0449238', 'C1709707', 'C0332287', 'C3540542', 'C0175668', 'C1510992', 'C4048285', 'C0027627', 'C0040223', 'C2936424', 'C1515981', 'C2926735', 'C3887962']","['C-Reactive Protein, human', 'In addition to', 'Details', 'Per (qualifier)', 'And', 'Further', 'Firstly', 'Effectiveness', 'First (number)', 'Complete Response with Incomplete Platelet Recovery', 'second (number)', 'Time', 'Count of entities', 'Follow', 'Flare', 'Duration', 'Neoplasm Metastasis', 'Duration (temporal concept)', 'Average', 'Patients', 'One', 'Levels (qualifier value)', 'Exacerbation of cGVHD', 'Numbers', 'Secondary to', 'Efficacy Study', 'Average of Value Derivation Technique', 'Electronic Supplementary Materials', 'Proportion']","['tmco', 'imft', 'fndg', 'idcn', 'inpr', 'orch', 'sosy', 'qlco', 'qnco', 'ftcn', 'resa', 'podg', 'neop', 'spco', ' phsu', ' aapp']"
441,PMC3103669,S59,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,"safety variables included the incidence of aes, serious aes (saes) and infectious aes, the incidence and severity of injection-site reactions, and immunogenicity.","['C1515974', 'C0439793', 'C4049935', 'C0205145', 'C0439828', 'C1272883', 'C0205404', 'C0021149', 'C1705187', 'C1533685', 'C2699274', 'C0036043', 'C0220856', 'C2825164', 'C4054739', 'C4554585', 'C1515981', 'C1412268', 'C0021485', 'C0522510', 'C1828121']","['With intensity', 'And', 'Anatomic Site', 'Safety', 'Study Site', 'Injection of therapeutic agent', 'Incidence', 'Variable (uniformity)', 'Severities', 'Immunogenicity (package insert)', 'Safety Study', 'Injection', 'incidence of cases', 'Injection Dosing Unit', 'Site', 'Injection procedure', 'Scanning Auger Spectrometer (device)', 'AES gene', 'Injection Route of Drug Administration', 'Immunogenicity Study', 'Serious']","['blor', 'bodm', 'gngm', 'hcpp', 'topp', 'idcn', 'inpr', 'resd', 'qnco', 'qlco', 'spco', 'resa', 'ftcn']"
442,PMC3103669,S61,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size determination and statistical analysis,a sample size of 350 patients (50 patients in each of the 5 canakinumab single-dose groups and 100 patients in the colchicine group) was considered sufficient to give a 95% confidence interval (ci) of the target dose with reasonable precision.,"['C1257890', 'C0009262', 'C0009667', 'C0441833', 'C1519504', 'C1552839', 'C1457900', 'C0205410', 'C0087136', 'C1547902', 'C0030705', 'C0687744', 'C0178602', 'C1515981', 'C1706245', 'C1705429', 'C0242618', 'C2718773', 'C1705428', 'C0205171']","['Groups', 'Population Group', 'Colchicine', 'Group Object', 'canakinumab', 'Confidence Intervals', 'Sample Size', 'Social group', 'Precision - characteristic', 'Singular', 'Each (qualifier value)', 'And', 'Dosage', 'Patients', 'Stage Grouping', 'Sufficient', 'User Group', 'Precision - temporal', 'Unmarried', 'Table Rules - groups']","['tmco', 'imft', 'fndg', 'popg', 'idcn', 'inpr', 'orch', 'qnco', 'qlco', 'ftcn', 'podg', ' aapp', ' phsu', 'cnce']"
443,PMC3103669,S62,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size determination and statistical analysis,in order to increase the precision of the analysis the planned total sample size of 400 was increased to approximately 440 patients (see supplementary material for more details).,"['C1705176', 'C1705175', 'C3889825', 'C1705178', 'C1882348', 'C1301732', 'C1547902', 'C0030705', 'C1522508', 'C2936424', 'C1706245', 'C0439810', 'C0205172', 'C1524024', 'C1705177', 'C0242618', 'C0332232', 'C0936012']","['Order (taxonomic)', 'Sample Size', 'Order (action)', 'Precision - characteristic', 'Precision - temporal', 'Analysis', 'Details', 'More', 'Total', 'analysis aspect', 'Patients', 'Sequence of Planned Assessment Schedule', 'Planned', 'approximately', 'Order (document)', 'Permutation', 'Electronic Supplementary Materials', 'Order (arrangement)']","['tmco', 'clas', 'inpr', 'qnco', 'qlco', 'resa', 'podg', 'ftcn', 'acty']"
444,PMC3103669,S63,"['6a', '7b']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 1, 0, 0, 0]",Sample size determination and statistical analysis,a preplanned interim analysis was performed when 200 patients had completed 16 weeks.,"['C4684691', 'C0439230', 'C0030705']","['Patients', 'Interim Analysis', 'week']","['podg', 'qnco', 'tmco']"
445,PMC3103669,S64,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Sample size determination and statistical analysis,efficacy and safety analyses were then performed when all patients had completed the study (24 weeks).,"['C2603343', 'C0036043', 'C0439230', 'C0030705', 'C1515981', 'C1707887', 'C1883708', 'C0444868', 'C1705187', 'C1280519']","['Effectiveness', 'All', 'And', 'Efficacy Study', 'Patients', 'Then', 'Study', 'Safety', 'Safety Study', 'week']","['tmco', 'hcpp', 'idcn', 'qnco', 'qlco', 'resa', 'podg']"
446,PMC3103669,S65,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size determination and statistical analysis,"for determination of the primary outcome, the number of flares per patient during 16 weeks was modelled using a negative binomial distribution and a common overdispersion (variance divided by expectation minus 1) for all treatment arms (see supplementary material for more details).","['C0332288', 'C0237753', 'C0205225', 'C1522138', 'C0446516', 'C3538994', 'C0439230', 'C1533734', 'C0087111', 'C0679138', 'C3887704', 'C1705169', 'C0449788', 'C0039798', 'C0030705', 'C1522508', 'C2681631', 'C0205214', 'C0205172', 'C0521095', 'C3245511', 'C2348152', 'C0206655', 'C0444868', 'C0027558', 'C1522326', 'C1711260', 'C2936424', 'C1515981', 'C1148554', 'C1274040']","['KIDINS220 gene', 'Details', 'Negative Binomial Distribution', 'And', 'Common Specifications in HL7 V3 Publishing', 'Alveolar rhabdomyosarcoma', 'Count of entities', 'Determined by', 'Treatment Epoch', 'Expectations', 'Upper arm', 'Biomaterial Treatment', 'Administration procedure', 'Result', 'Without', 'All', 'Variance', 'More', 'shared attribute', 'Sample Variance', 'Patients', 'Determination Aspects', 'Common (qualifier value)', 'Numbers', 'Primary', 'treatment - ActInformationManagementReason', 'Treating', 'therapeutic aspects', 'week', 'Electronic Supplementary Materials', 'Therapeutic procedure']","['tmco', 'blor', 'resa', 'gngm', 'idcn', 'topp', 'hlca', 'inpr', 'qnco', 'qlco', 'lbpr', 'ftcn', 'podg', 'neop', 'cnce']"
447,PMC3103669,S66,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Sample size determination and statistical analysis,the main secondary outcome was the mean number of flares per patient at 16 weeks.,"['C0027627', 'C2348143', 'C0237753', 'C0205225', 'C0175668', 'C0449788', 'C0205436', 'C0030705', 'C1542147', 'C0439230', 'C2347634', 'C0444504', 'C1274040']","['Neoplasm Metastasis', 'Main', 'Primary', 'Sample Mean', 'Secondary to', 'second (number)', 'Count of entities', 'Population Mean', 'Statistical mean', 'Patients', 'week', 'Result', 'Numbers']","['tmco', 'qlco', 'qnco', 'ftcn', 'podg', 'neop']"
448,PMC3103669,S67,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size determination and statistical analysis,"data were analysed according to an analysis of covariance (ancova) with treatment group, allopurinol dose at baseline and bmi at baseline as covariates.","['C0168634', 'C3538994', 'C0178602', 'C1524024', 'C1533734', 'C0936012', 'C1257890', 'C0087111', 'C0441833', 'C3887704', 'C0814908', 'C1705169', 'C0039798', 'C1705428', 'C0002144', 'C3245479', 'C1519504', 'C1705429', 'C1522326', 'C1442488', 'C0578022', 'C0687744', 'C1515981', 'C3714741', 'C1511726']","['Group Object', 'Allopurinol', 'Data (eukaryote)', 'And', 'Data', 'Treatment Epoch', 'analysis aspect', 'Biomaterial Treatment', 'Baseline', 'Administration procedure', 'User Group', 'Data call receiving device', 'Groups', 'Population Group', 'ancova', 'Social group', 'Finding of body mass index', 'Dosage', 'BaseLine dental cement', 'treatment - ActInformationManagementReason', 'Treating', 'Analysis', 'therapeutic aspects', 'Stage Grouping', 'Therapeutic procedure']","['fndg', 'popg', 'bodm', 'medd', 'idcn', 'topp', 'hlca', 'orch', 'qnco', 'euka', 'resa', 'ftcn', ' phsu', 'cnce']"
449,PMC3103669,S68,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size determination and statistical analysis,"however, as the distribution of flares per patient was observed to be skewed, the preplanned ancova was considered inappropriate for these data.","['C1441672', 'C3537135', 'C1704711', 'C3245479', 'C1548788', 'C0814908', 'C4281991', 'C1421478', 'C1565156', 'C0030705', 'C0043194', 'C0520511', 'C3714741', 'C1511726', 'C3887962', 'C0039828']","['Observed', 'Data call receiving device', 'Theses', 'ancova', 'WAS protein, human', 'Data (eukaryote)', 'Per (qualifier)', 'Inappropriate Specimen', 'WAS gene', 'Patients', 'Distribution', 'Follow', 'Inappropriate', 'Distributing', 'Wiskott-Aldrich Syndrome', 'Data']","['medd', 'idcn', 'gngm', 'inpr', 'qlco', 'bacs', 'qnco', 'dsyn', 'euka', 'podg', 'ftcn', ' aapp']"
450,PMC3103669,S69,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size determination and statistical analysis,"therefore a post hoc analysis using a negative binomial model with treatment group, allopurinol dose at baseline and bmi at baseline as covariates and log (time on study) as an offset was performed with an adjustment made for multiplicity (see supplementary material for further details of analyses for secondary outcomes).","['C3274659', 'C1565156', 'C0376209', 'C0168634', 'C0178602', 'C0687676', 'C3538994', 'C1533734', 'C0936012', 'C2825415', 'C1257890', 'C0087111', 'C0441833', 'C3887704', 'C1705169', 'C0039798', 'C0205436', 'C1522508', 'C3714583', 'C1705428', 'C0002144', 'C0456081', 'C0332287', 'C1519504', 'C0175668', 'C1421478', 'C0043194', 'C1705429', 'C3469826', 'C0884358', 'C2825491', 'C0205160', 'C1711330', 'C0027627', 'C2603343', 'C1522326', 'C1442488', 'C3853545', 'C1513916', 'C0040223', 'C3853906', 'C0578022', 'C0683269', 'C2936424', 'C1515981', 'C3161035', 'C0687744', 'C1704687', 'C1517331', 'C1524024', 'C0449822']","['Group Object', 'Negative Charge', 'In addition to', 'Allopurinol', 'Details', 'Performed', 'And', 'Study', 'Further', 'Post', 'Adjustment Action', 'Digital Model Attachment', 'Model Number', 'second (number)', 'Time', 'Psychological adjustment', 'Offset', 'analysis aspect', 'SLC35G1 gene', 'Treatment Epoch', 'Biomaterial Treatment', 'Baseline', 'Individual Adjustment', 'Administration procedure', 'User Group', 'Model - style/design', 'Negative Finding', 'Wiskott-Aldrich Syndrome', 'Groups', 'Population Group', 'Neoplasm Metastasis', 'Model', 'Social group', 'Finding of body mass index', 'WAS gene', 'Negative', 'Dosage', 'Negative - answer', 'BaseLine dental cement', 'Post Device', 'treatment - ActInformationManagementReason', 'Treating', 'Analysis', 'WAS protein, human', 'Secondary to', 'therapeutic aspects', 'Stage Grouping', 'Negative Number', 'multiplicity', 'Electronic Supplementary Materials', 'Therapeutic procedure']","['topp', 'qnco', 'bodm', ' aapp', 'fndg', 'idcn', 'hlca', 'inpr', 'qlco', 'bacs', 'resa', 'ftcn', 'mnob', 'popg', 'tmco', 'inbe', 'orch', 'spco', 'neop', 'cnce', 'gngm', 'dsyn', ' phsu']"
451,PMC3109952,S38,"['3a', '4b']","[0, 0, 0, 0, 0, 0, 1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Methods,"this multicentre, two arm, randomised, controlled, open trial was carried out in 13 centres in the united kingdom and one in the republic of ireland.","['C3715044', 'C0041700', 'C0446516', 'C0205447', 'C1515981', 'C0008976', 'C4553528', 'C0022067', 'C2911690', 'C0205448', 'C0175566', 'C1080058', 'C0205099', 'C2587213']","['Open', 'Ireland', 'AKR1A1 wt Allele', 'Upper arm', 'And', 'Clinical Trials', 'Sequence Arm', 'Two', 'Disease Controlled', 'Control function', 'Central', 'United Kingdom', 'One', 'This (eukaryote)']","['inpr', 'geoa', 'idcn', 'gngm', 'ftcn', 'blor', 'spco', 'fndg', 'euka', 'resa', 'qnco']"
452,PMC3109952,S40,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population,"participants were eligible for the study if they were aged 12 years or over and had a plantar wart (verruca) that, in the opinion of a healthcare professional, was suitable for treatment with both salicylic acid and cryotherapy.","['C0871010', 'C0679646', 'C3887704', 'C1705169', 'C1515981', 'C1548635', 'C0347984', 'C3900053', 'C1999167', 'C0036079', 'C0043037', 'C4551716', 'C2603343', 'C0042548', 'C0039798', 'C3538994', 'C0205136', 'C0062074', 'C0439234', 'C3539897', 'C1025954', 'C1706086', 'C3665596', 'C0087111', 'C1415458', 'C1522326', 'C1533734', 'C0001779', 'C0001792']","['Old age', 'Cryotherapy', 'Both', 'Biomaterial Treatment', 'And', 'Elderly (population group)', 'Have', 'Therapeutic procedure', 'HADH gene', 'Verruca <invertebrate>', 'Age', 'Administration procedure', 'Opinions', 'Treatment Epoch', 'Study', 'Warts', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Salicylic Acid', 'year', 'Amenable', 'During', 'Plantar wart', 'Common wart', 'Eligible', 'Treating', 'HAC protocol', 'Over (spatial)', 'Participant']","['idcn', 'gngm', 'topp', 'neop', 'popg', 'ftcn', 'cnce', 'spco', 'orch', 'euka', 'qlco', 'tmco', 'resa', ' phsu', 'hlca', 'orga', 'dsyn']"
453,PMC3109952,S41,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population,"participants were excluded from the study if they had impaired healing (such as from diabetes or peripheral vascular disease); were immunosuppressed (such as agammaglobulinaemia) or were taking immunosuppressant drugs (such as oral corticosteroids); had neuropathy; were receiving renal dialysis; had cold intolerance (such as raynaud’s syndrome or cold urticaria); had any of the following conditions (blood dyscrasias of unknown origin, cryoglobulinaemia, cryofibrinogenaemia, collagen or autoimmune disease); were unable to give informed consent; or were currently in a trial evaluating other treatments for their plantar wart.","['C0009325', 'C0679646', 'C4321405', 'C0039082', 'C0010403', 'C0008976', 'C3687832', 'C0009269', 'C0521116', 'C0001617', 'C0021081', 'C3540727', 'C0021430', 'C3272371', 'C0001768', 'C1299582', 'C0004364', 'C3540726', 'C2603343', 'C3539185', 'C0042548', 'C1552551', 'C4551529', 'C4048706', 'C3540725', 'C0221207', 'C0013227', 'C0442027', 'C0272263', 'C0442874', 'C0332282', 'C0332240', 'C0087111', 'C0042373', 'C0566415', 'C0019004', 'C0018939']","['Unable to Do', 'Unable to Use Stairs', 'Drugs - dental services', 'Unknown (origin) (qualifier value)', 'Unable to feed self', 'Therapeutic procedure', 'Corticosteroid ophthalmologic and otologic preparations', 'Renal Dialysis', 'Syndrome', 'Any Data Type', 'Autoimmune Diseases', 'Clinical Trials', 'Current (present time)', 'Informed Consent', 'Vascular Diseases', 'Participant', 'Cold urticaria', 'Following', 'Corticosteroid otologicals', 'Immunosuppressive Agents', 'Neuropathy', 'Cold intolerance', 'Any', 'Collagen', 'Adrenal Cortex Hormones', 'Oral', 'Cryofibrinogenemia', 'Corticosteroid nasal preparations for topical use', 'Study', 'Hemodialysis', 'Plantar wart', 'Pharmaceutical Preparations', 'Unable', 'Agammaglobulinemia', 'Corticosteroids, topical for treatment of hemorrhoids and anal fissures', 'Cryoglobulinemia', 'Hematological Disease']","[' orch', 'inpr', 'rnlw', 'topp', 'popg', 'ftcn', 'fndg', 'spco', 'orch', 'qlco', 'horm', 'resa', 'tmco', ' phsu', 'aapp', 'imft', 'phsu', 'dsyn']"
454,PMC3109952,S43,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Recruitment and randomisation of participants,"participants were recruited between november 2006 and january 2010 (end of extended recruitment period) from university podiatry school clinics, nhs podiatry clinics, and primary care.","['C3829466', 'C0679646', 'C0032331', 'C0442592', 'C0439792', 'C0231449', 'C1417725', 'C4684754', 'C3828767', 'C1515981', 'C0036375', 'C0041740', 'C0796085', 'C0231448', 'C2746065', 'C0444930', 'C0033137']","['Stop (qualifier value)', 'Universities', 'Primary Health Care', 'Nance-Horan syndrome', 'Clinic', 'Recruitment Period', 'November', 'And', 'Extension', 'Extent', 'End', 'NHS gene', 'January', 'Extended', 'School', 'Podiatry (discipline)', 'Participant']","['bmod', 'idcn', ' mnob', 'gngm', 'dsyn', 'popg', 'ftcn', 'mnob', 'spco', 'qlco', 'tmco', 'resa', 'hlca', ' hcro', 'orgt']"
455,PMC3109952,S44,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Recruitment and randomisation of participants,eligible participants gave written informed consent.,"['C0679646', 'C0021430', 'C1548635']","['Informed Consent', 'Eligible', 'Participant']","['qlco', 'popg', 'rnlw']"
456,PMC3109952,S45,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Recruitment and randomisation of participants,they were then randomised equally to receive cryotherapy with liquid nitrogen or daily self treatment with an over the counter 50% salicylic acid treatment.,"['C0036079', 'C0036588', 'C1551994', 'C0260055', 'C3887704', 'C1705169', 'C0677601', 'C1883708', 'C0087111', 'C4551716', 'C0332173', 'C1522326', 'C1533734', 'C1550121', 'C0039798', 'C3538994']","['Liquid nitrogen - Special Handling Code', 'Treatment Epoch', 'Cryotherapy', 'Self', 'Biomaterial Treatment', 'Daily', 'Treating', 'Administration procedure', 'Liquid nitrogen', 'subscriber - self', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Then', 'Salicylic Acid', 'Therapeutic procedure', 'Counter device']","['inpr', 'idcn', 'elii', 'topp', 'ftcn', 'cnce', 'mnob', 'orch', 'tmco', 'resa', ' phsu', 'hlca']"
457,PMC3109952,S46,"['9', '10']","[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1]",Recruitment and randomisation of participants,"randomisation was performed by a member of the research team either telephoning an independent, secure, remote, telephone randomisation service (york trials unit) or accessing a secure online web randomisation programme, thereby concealing treatment allocation until the moment of randomisation.","['C0085862', 'C0282111', 'C0680022', 'C3887704', 'C1705169', 'C0871489', 'C0205157', 'C1550013', 'C3146231', 'C0443203', 'C3853603', 'C0439148', 'C0039457', 'C1509845', 'C1299583', 'C1704753', 'C0039798', 'C3538994', 'C1519222', 'C0659450', 'C1705541', 'C3844638', 'C1290940', 'C0035168', 'C0444454', 'C0557854', 'C3245478', 'C2825316', 'C1720302', 'C1519795', 'C0443189', 'C0242481', 'C1706778', 'C2698041', 'C0087111', 'C1880519', 'C1515258', 'C0439453', 'C1522326', 'C1533734']","['teams', 'member', 'Biomaterial Treatment', 'Telephone Device', 'Unit', 'Independent for Transfer', 'Unit of Measure', 'Internet', 'Until', 'location - remote', 'Therapeutic procedure', 'Enzyme Unit', 'Either', 'Member Organization', 'Remote', 'Secure - resin cement', 'Administration procedure', 'concealed', 'Security - service', 'Secure feeling', 'Independently able', 'Services', 'Treatment Epoch', 'Telephone', 'Allocation', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'International Unit', 'Distant', 'research', 'Software Service', 'Unit - NCI Thesaurus Property', 'Unit device', 'ActInformationPrivacyReason <service>', 'Treating', 'Research Activities', 'Independence', 'Telephone Number', 'Access', 'Storage Unit']","['inpr', 'grup', 'idcn', 'acty', 'qnco', 'prog', 'ocac', 'topp', 'medd', 'popg', 'ftcn', 'mnob', 'cnce', 'spco', 'fndg', 'qlco', 'resa', 'hlca', 'menp', 'bodm']"
458,PMC3109952,S47,"['8b', '8a']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0]",Recruitment and randomisation of participants,"randomisation was simple (that is, it was not restricted in any way such as by stratification or blocked allocation with the allocation sequence being computer generated).","['C0009622', 'C1706778', 'C1514983', 'C3272371', 'C1519249', 'C1518422', 'C0004793', 'C3853789', 'C0205352', 'C0162327', 'C1552551', 'C0162326']","['Sequence - TransmissionRelationshipTypeCode', 'Any', 'Base Sequence', 'Any Data Type', 'Computers', 'DNA Sequence', 'RNA Sequence', 'Allocation', 'Simple', 'Stratification', 'Sequence', 'Negation']","['inpr', 'nusq', 'acty', 'ftcn', 'mnob', 'qlco', 'resa']"
459,PMC3109952,S50,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Intervention,participants randomised to cryotherapy with liquid nitrogen received a maximum of four treatments given two to three weeks apart by a healthcare professional.,"['C1552615', 'C1550718', 'C0260055', 'C0679646', 'C0205449', 'C0439230', 'C0205450', 'C4551716', 'C1550121', 'C0806909', 'C0087111', 'C1947971', 'C1442162', 'C1704312', 'C0205448', 'C3244317', 'C0018724', 'C2826546']","['GIVEN', 'Give - dosing instruction imperative', 'Act Relationship Subset - maximum', 'Four', 'Cryotherapy', 'Health Personnel', 'week', 'Three', 'Maximum', 'Entity Name Part Type - given', 'Liquid nitrogen', 'Two', 'Therapeutic procedure', 'Health Professional', 'Liquid nitrogen - Special Handling Code', 'Given name', 'Maximum Value Derivation Technique', 'Participant']","['inpr', 'idcn', 'prog', 'elii', 'topp', 'popg', 'ftcn', 'tmco', 'qnco']"
460,PMC3109952,S51,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Intervention,the liquid nitrogen was applied with a spray (method of choice if available) or a probe.,"['C0871511', 'C2347609', 'C1707391', 'C0260055', 'C2003858', 'C0449851', 'C0182400', 'C1704681', 'C0470187', 'C1550121', 'C0025663', 'C0008300']","['Liquid nitrogen - Special Handling Code', 'Probes', 'availability of', 'Chemical Probe', 'Techniques', 'Methods', 'Liquid nitrogen', 'Choose (action)', 'Spray (action)', 'probe gene fragment', 'Test Method', 'Choice Behavior']","['inpr', 'inbe', 'lbpr', 'acty', 'elii', 'gngm', 'medd', 'ftcn', 'chvf']"
461,PMC3109952,S52,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Intervention,"the treatment was delivered according to the site’s usual practice (such as debridement before treatment, masking of the surrounding area, and padding after treatment).","['C3887704', 'C0205146', 'C1705169', 'C1515981', 'C1565156', 'C0017446', 'C0150112', 'C3245512', 'C1514463', 'C3538928', 'C0043194', 'C0039798', 'C3538994', 'C1282914', 'C0011079', 'C1705822', 'C0237607', 'C0001758', 'C0087111', 'C0150108', 'C0441601', 'C3245462', 'C1522326', 'C1533734', 'C0680240', 'C1421478']","['Aftercare', 'Usual', 'Prior Therapy', 'Area', 'And', 'Biomaterial Treatment', 'Blinded', 'Therapeutic procedure', 'psychological masking', 'WAS protein, human', 'WAS gene', 'HL7PublishingSubSection <practice>', 'Administration procedure', 'Debridement', 'Debridement by Maggots', 'Treatment Epoch', 'Surrounding (qualifier value)', 'Agreement', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'padding', 'Practice Experience', 'Transfer Technique', 'Geographic Locations', 'Wiskott-Aldrich Syndrome', 'Treating']","['bacs', 'inpr', 'clna', 'idcn', 'geoa', 'gngm', 'topp', 'ftcn', 'spco', 'cnce', 'qlco', 'resa', 'socb', 'hlca', 'menp', ' aapp', 'dsyn']"
462,PMC3109952,S53,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Intervention,"on advice from the trial steering committee, sites were advised that the first treatment should be a “gentle freeze” in order to ensure the participant could tolerate the treatment.","['C0679646', 'C3887704', 'C1705169', 'C0008976', 'C2348534', 'C1705175', 'C1705178', 'C1705177', 'C2698741', 'C0039798', 'C3538994', 'C4554048', 'C0218063', 'C3889825', 'C0205145', 'C0150600', 'C0087111', 'C1279901', 'C1705176', 'C1522326', 'C1533734', 'C1882348', 'C0205435']","['Study Participant', 'Firstly', 'Order (document)', 'Biomaterial Treatment', 'First (number)', 'Site', 'Therapeutic procedure', 'Permutation', 'Order (taxonomic)', 'Advice', 'Ensure (product)', 'Clinical Trials', 'Administration procedure', 'Treatment Epoch', 'Order (action)', 'Sequence of Planned Assessment Schedule', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Order (arrangement)', 'Treating', 'Steering Committee', 'Participant Object', 'Participant']","['inpr', 'acty', 'clas', 'topp', 'popg', 'ftcn', 'cnce', 'spco', 'qlco', 'food', 'resa', 'hlca', 'qnco']"
463,PMC3109952,S55,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Intervention,"participants randomised to self treatment with 50% salicylic acid (verrugon, william ransom and son) were instructed how to apply the treatment according to the manufacturer’s instructions by the treating healthcare professional.","['C1442085', 'C0036079', 'C0036588', 'C1551994', 'C0679646', 'C3887704', 'C1705169', 'C0302828', 'C0087111', 'C1515981', 'C0037683', 'C3263700', 'C1522326', 'C1533734', 'C0680240', 'C1704312', 'C0018724', 'C0039798', 'C3538994']","['Health Professional', 'Treatment Epoch', 'Self', 'Health Personnel', 'Biomaterial Treatment', 'And', 'Treating', 'Administration procedure', 'Son (person)', 'Agreement', 'Instruction [Publication Type]', 'subscriber - self', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Instructions', 'Instructions:Text:Point in time:^Patient:Narrative', 'Salicylic Acid', 'Therapeutic procedure', 'Participant']","['inpr', 'clna', 'idcn', 'famg', 'prog', 'topp', 'popg', 'ftcn', 'cnce', 'orch', 'resa', 'socb', ' phsu', 'hlca']"
464,PMC3109952,S56,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Intervention,patients were directed to fix the adhesive ring with the hole over the verruca and to squeeze a little ointment into the hole and directly on to the verruca.,"['C0544726', 'C2984078', 'C3889124', 'C0028912', 'C1025954', 'C0030705', 'C0043037', 'C0205136', 'C3665596', 'C1260969', 'C1515981', 'C0332286', 'C0413258', 'C0521164', 'C1823381', 'C0332287', 'C0347984', 'C0001516', 'C1947931']","['Verruca <invertebrate>', 'Common wart', 'Direct (qualifier)', 'Ring (shape)', 'squeeze', 'A little bit', 'TMEM121 gene', 'And', 'Ring device', 'into', 'Patients', 'Adhesives', 'Warts', 'Ointments', 'Only a Little', 'Hole Finding', 'In addition to', 'Over (spatial)', 'During']","['idcn', 'gngm', 'inpo', 'neop', 'medd', 'ftcn', 'mnob', 'fndg', 'podg', 'euka', 'qlco', 'tmco', 'spco', 'dsyn', 'bodm']"
465,PMC3109952,S57,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Intervention,the backing paper from the plaster was then removed and the plaster applied to cover the ring completely.,"['C0180153', 'C1883708', 'C1547566', 'C0460977', 'C0205197', 'C1515981', 'C1260969', 'C4319730', 'C0521164', 'C4319731', 'C1421478', 'C4048755', 'C1565156', 'C0030351', 'C0043194', 'C0849355', 'C1999244']","['Ring (shape)', 'Complete', 'Apply', 'Covers (device)', 'WAS protein, human', 'Completely Able', 'And', 'Ring device', 'WAS gene', 'Wiskott-Aldrich Syndrome', 'Paper', 'Cover - action', 'Then', 'Plaster', 'Complete Agreement', 'Removed', 'Paper Authorization']","['bacs', 'inpr', 'idcn', 'gngm', 'medd', 'ftcn', 'mnob', 'fndg', 'qlco', 'spco', 'tmco', 'dsyn', ' aapp', 'bodm']"
466,PMC3109952,S58,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Intervention,the plaster was then sealed into position.,"['C1883708', 'C4019252', 'C0460977', 'C0733755']","['Plaster', 'Position of phenotypic abnormality', 'Then', 'Positioning Attribute']","['spco', 'tmco', 'bodm']"
467,PMC3109952,S59,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Intervention,the treatment was repeated daily after gently pumicing or filing off the dead part of the verruca for a maximum of eight weeks.,"['C1638411', 'C1552615', 'C1025954', 'C0043037', 'C3887704', 'C1705169', 'C3665596', 'C0439230', 'C0087111', 'C0806909', 'C0205454', 'C0332173', 'C0039798', 'C1522326', 'C1533734', 'C2826546', 'C1292711', 'C0011065', 'C3538994']","['Verruca <invertebrate>', 'Common wart', 'Act Relationship Subset - maximum', 'Cessation of life', 'Treatment Epoch', 'week', 'Biomaterial Treatment', 'Daily', 'Maximum', 'Treating', 'Administration procedure', 'part of', 'Warts', 'Gently', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Therapeutic procedure', 'Maximum Value Derivation Technique', 'Eight']","['topp', 'neop', 'ftcn', 'cnce', 'spco', 'tmco', 'euka', 'qlco', 'resa', 'dsyn', 'hlca', 'orgf', 'qnco']"
468,PMC3109952,S62,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcome measurements,the primary outcome was complete clearance of all plantar warts at 12 weeks after randomisation.,"['C4554548', 'C1274040', 'C0449297', 'C0439230', 'C0205197', 'C1382187', 'C3853530', 'C0205225', 'C0444868', 'C0042548', 'C2825073', 'C4283785']","['Clearance [PK]', 'Complete', 'Clearance procedure', 'All', 'week', 'Complete Pharyngeal Contraction', 'Clearance of substance', 'Result', 'Data operation - complete', 'Clearance', 'Primary', 'Plantar wart']","['clna', 'topp', 'ftcn', 'fndg', 'qlco', 'tmco', 'dsyn', 'npop', 'qnco']"
469,PMC3109952,S63,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcome measurements,clearance of plantar wart was defined as the restoration of normal skin on close inspection.,"['C4554548', 'C0449982', 'C0449297', 'C0587267', 'C1382187', 'C3810854', 'C4553631', 'C0558145', 'C0042548', 'C0199219', 'C2825073']","['Clearance [PK]', 'Clinical Trial Inspection', 'Clearance procedure', 'Closed', 'Inspection (procedure)', 'Close', 'type of restoration', 'Skin appearance normal (finding)', 'Clearance of substance', 'Clearance', 'Plantar wart']","['clna', 'inpr', 'topp', 'ftcn', 'fndg', 'qlco', 'npop', 'dsyn', 'diap', 'gora']"
470,PMC3109952,S64,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcome measurements,digital photographs of the plantar wart(s) were taken at baseline and at the outcome assessment.,"['C0168634', 'C1883727', 'C1548899', 'C1515981', 'C0085565', 'C1442488', 'C1883674', 'C0042548', 'C0441468']","['BaseLine dental cement', 'Baseline', 'And', 'Taken', 'Digital', 'photograph', 'Outcome Assessment (Health Care)', 'Consent Type - Photographs', 'Plantar wart']","['idcn', 'qnco', 'ocac', 'mnob', 'cnce', 'qlco', 'hlca', 'bodm', 'dsyn']"
471,PMC3109952,S65,"['6a', '11a']","[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcome measurements,the photographs were assessed by two assessors who were blind to treatment allocation.,"['C1706778', 'C1548899', 'C3887704', 'C1705169', 'C0456909', 'C0087111', 'C0039798', 'C0150108', 'C1522326', 'C1533734', 'C0205448', 'C3272598', 'C0441468', 'C0525065', 'C3538994']","['Treatment Epoch', 'WHO Temperature/Humidity Storage Condition', 'Biomaterial Treatment', 'Blindness', 'Administration procedure', 'Treating', 'Blinded', 'Two', 'Allocation', 'photograph', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Therapeutic procedure', 'Visually Impaired Persons', 'Consent Type - Photographs']","['acty', 'topp', 'ftcn', 'mnob', 'cnce', 'qlco', 'fndg', 'podg', 'resa', 'hlca', 'qnco']"
472,PMC3109952,S66,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcome measurements,they independently assessed the photographs for each participant to determine whether the plantar wart had cleared.,"['C4554048', 'C0679646', 'C1548899', 'C1457900', 'C4321252', 'C2698741', 'C0042548', 'C0521125', 'C0521095', 'C0441468']","['Study Participant', 'Determined by', 'Plantar wart', 'photograph', 'Participant Object', 'Preposition For', 'WWOX wt Allele', 'Each (qualifier value)', 'Consent Type - Photographs', 'Participant']","['gngm', 'clas', 'popg', 'mnob', 'qlco', 'hlca', 'qnco', 'dsyn']"
473,PMC3109952,S67,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcome measurements,any discrepancies were referred to a third assessor.,"['C1290905', 'C0205437', 'C3272371', 'C1707957', 'C2646699', 'C1552551']","['Any', 'Discrepancy (finding)', 'Any Data Type', 'Assessor (genus)', 'Third', 'Evaluator - personnel']","['inpr', 'fish', 'prog', 'fndg', 'qlco', 'qnco']"
474,PMC3109952,S68,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcome measurements,"if no photographs were available for a participant, however, then the blinded outcome assessment undertaken at the site was used.","['C4554048', 'C0679646', 'C1548899', 'C2825164', 'C1883708', 'C0085565', 'C0150108', 'C0470187', 'C0205145', 'C2698741', 'C0441468', 'C1515974']","['Study Participant', 'availability of', 'Anatomic Site', 'Site', 'Blinded', 'photograph', 'Participant Object', 'Then', 'Study Site', 'Outcome Assessment (Health Care)', 'Consent Type - Photographs', 'Participant']","['clas', 'ocac', 'popg', 'ftcn', 'mnob', 'blor', 'spco', 'tmco', 'resa', 'hlca']"
475,PMC3109952,S69,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcome measurements,"if neither of these were available for a participant, the patient’s self reported outcome recorded in the week 12 patient questionnaire or on the “verrucae gone form” was used.","['C1274040', 'C4554048', 'C0679646', 'C0039828', 'C0030705', 'C3274651', 'C0034394', 'C0439230', 'C0470187', 'C2698741', 'C0681906', 'C4284892']","['Theses', 'Study Participant', 'availability of', 'week', 'Patient Self-Report', 'Questionnaires', 'Patients', 'Neither', 'Participant Object', 'Result', 'Neither Case or Control Status', 'Participant']","['inpr', 'clas', 'popg', 'ftcn', 'qlco', 'podg', 'tmco', 'resa']"
476,PMC3109952,S71,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcome measurements,"secondary outcomes included (a) complete clearance of all plantar warts at 12 weeks after controlling for age, whether the plantar wart had been treated previously, and type of wart and (b) a second model to explore the effect of patient preferences, (c) with clearance of plantar wart at six months, (d) number of warts at 12 weeks, (e) time to clearance of wart, (f) patient satisfaction with the treatment, and (g) adverse events.","['C0687676', 'C3853906', 'C0205436', 'C0439231', 'C3887704', 'C1705169', 'C0205197', 'C1515981', 'C1705190', 'C0347390', 'C0027627', 'C3853530', 'C4321252', 'C0457385', 'C0237753', 'C3161035', 'C3274659', 'C0877248', 'C0043037', 'C0449297', 'C0439230', 'C0231290', 'C1547970', 'C0332287', 'C0042548', 'C2825073', 'C0030702', 'C4283785', 'C3538994', 'C4554548', 'C0039798', 'C1561503', 'C1367460', 'C1705413', 'C1382187', 'C2239193', 'C1280500', 'C0449788', 'C1518681', 'C0062074', 'C1705714', 'C2348382', 'C0521125', 'C0205452', 'C3539897', 'C0001779', 'C0040223', 'C3665596', 'C0332307', 'C0376409', 'C0087111', 'C1415458', 'C1522326', 'C1533734', 'C0444868', 'C3714583', 'C0175668', 'C2587213']","['Model Number', 'Status post', 'Biomaterial Treatment', 'And', 'Complete Pharyngeal Contraction', 'Model', 'month', 'Effect, Appearance', 'LATS1 wt Allele', 'Time', 'Preposition For', 'Secondary to', 'Have', 'WWOX wt Allele', 'Therapeutic procedure', 'Controlling (action)', 'HADH gene', 'Outcome of Therapy', 'Specimen Source Codes - Wart', 'Patient Preference', 'Age', 'Administration procedure', 'Adverse event', 'Clearance of substance', 'Type - attribute', 'Complete', 'Treatment Epoch', 'Client satisfaction', 'Adverse Event Domain', 'week', 'All', 'Numbers', 'Second Suffix', 'Skin Papilloma', 'Warts', 'therapeutic aspects', 'Control function', 'treatment - ActInformationManagementReason', 'Six', 'In addition to', 'seconds', 'Plantar wart', 'Common wart', 'Clearance [PK]', 'Neoplasm Metastasis', 'Count of entities', 'Clearance procedure', 'Effect', 'Post', 'second (number)', 'Precision - second', 'LATS1 gene', 'Treating', 'Model - style/design', 'Digital Model Attachment', 'HAC protocol', 'Data operation - complete', 'Clearance']","['inpr', 'clna', 'phpr', 'idcn', 'gngm', 'topp', 'neop', 'ftcn', 'cnce', 'patf', 'qlco', 'tmco', 'fndg', 'resa', 'dsyn', 'hlca', 'npop', 'qnco', 'orga']"
477,PMC3109952,S72,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcome measurements,"questionnaires were administered by post or were completed on line at one, three, and 12 weeks and six months.","['C0205452', 'C0439231', 'C1550648', 'C0205449', 'C0034394', 'C1552960', 'C3469826', 'C0439230', 'C0205447', 'C1704687', 'C1515981', 'C1706422', 'C0205132', 'C0687676', 'C0700221']","['Post', 'Post Device', 'SLC35G1 gene', 'week', 'And', 'Questionnaires', 'Three', 'month', 'Linear', 'Six', 'Intravascular line', 'Questionnaire Domain', 'Line Specimen', 'One', 'Line Unit of Length']","['inpr', 'idcn', 'gngm', 'medd', 'spco', 'mnob', 'tmco', 'sbst', 'qnco']"
478,PMC3109952,S74,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size,"the cochrane systematic review found only one small trial directly comparing the effectiveness of a chemical treatment, salicylic acid, with cryotherapy in patients with warts on their feet alone.6","['C0030705', 'C3887704', 'C1705169', 'C0008976', 'C0700321', 'C0036079', 'C0439044', 'C4551716', 'C0205447', 'C4553491', 'C0679994', 'C0039798', 'C3538994', 'C1280519', 'C0016504', 'C3272558', 'C1367460', 'C0347981', 'C1705714', 'C1955832', 'C0205171', 'C3665596', 'C0087111', 'C0220806', 'C1522326', 'C1533734', 'C1947931']","['Effectiveness', 'Cryotherapy', 'Biomaterial Treatment', 'Patients', 'alone - group size', 'LATS1 wt Allele', 'Therapeutic procedure', 'Small', 'Clinical Trials', 'Administration procedure', 'Foot', 'Chemical or Textual Reference to Actual Test or Parameter', 'Treatment Epoch', 'Feet, unit of measurement', 'Systematic Review', 'Chemicals', 'Singular', 'Warts', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Salicylic Acid', 'One', 'Living Alone', 'Direct (qualifier)', 'LATS1 gene', 'Treating', 'Effectiveness (finding)']","['chem', 'bpoc', 'inpr', 'grpa', 'gngm', 'topp', 'neop', 'ftcn', 'cnce', 'fndg', 'orch', 'podg', 'qlco', 'resa', ' phsu', 'hlca', 'qnco']"
479,PMC3109952,S75,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size,"this poor quality study found a 58% cure rate among the patients allocated to cryotherapy, compared with 41% among those treated with salicylic acid.","['C2700379', 'C0036079', 'C0332306', 'C0030705', 'C4551716', 'C2603343', 'C0032854', 'C1880198', 'C1080058', 'C1521828', 'C0871208']","['Cryotherapy', 'Poor - qualifier', 'Rate', 'This (eukaryote)', 'Rating (action)', 'with quality', 'Patients', 'Study', 'Salicylic Acid', 'Cure (remedy)', 'Poverty']","['grpa', 'acty', 'topp', 'cnce', 'orch', 'podg', 'qlco', 'resa', 'euka', ' phsu', 'qnco']"
480,PMC3109952,S76,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size,this difference of 17% was not statistically significant.,"['C0237881', 'C1705241', 'C1080058', 'C1518422', 'C1705242']","['This (eukaryote)', 'Statistical Significance', 'Different', 'Delta (difference)', 'Negation']","['ftcn', 'qlco', 'euka', 'qnco']"
481,PMC3109952,S77,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size,"the overall cure rates from this study are smaller than those observed in two placebo controlled trials of salicylic acid, both of which reported cure rates of 85% for active treatment, possibly because more resistant verrucae were included in the study comparing cryotherapy with salicylic acid.","['C0684224', 'C1561607', 'C1704532', 'C4321252', 'C0700321', 'C1080058', 'C0036079', 'C0043037', 'C2827757', 'C1696465', 'C0332325', 'C4551716', 'C2603343', 'C0332287', 'C1550464', 'C0547044', 'C0205172', 'C0205448', 'C1880198', 'C0282416', 'C1514892', 'C0521125', 'C0700287', 'C0332257', 'C0032042', 'C1706086', 'C1706408', 'C3665596', 'C4319718']","['Cryotherapy', 'Reporting', 'Both', 'Preposition For', 'placebo', 'WWOX wt Allele', 'Resistant (qualifier value)', 'Reported', 'Active Method', 'Small', 'Placebos', 'Cure (remedy)', 'Smaller', 'Study', 'Two', 'Warts', 'Resistance Process', 'resistant - Observation Interpretation Susceptibility', 'Salicylic Acid', 'In addition to', 'Common wart', 'Placebo Control', 'Overall', 'Report (document)', 'More', 'Including (qualifier)', 'Antimicrobial Resistance Result', 'This (eukaryote)', 'Overall Publication Type']","['inpr', 'bodm', 'idcn', 'phsf', 'gngm', 'topp', 'lbtr', 'neop', 'ftcn', 'cnce', 'orch', 'qlco', 'euka', 'resa', ' phsu', 'hlca', 'qnco', 'dsyn']"
482,PMC3109952,S78,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size,this trial was a superiority study of cryotherapy compared with salicylic acid and was powered to show a 15% difference in effectiveness.,"['C1280519', 'C0036079', 'C1547282', 'C0032863', 'C4551716', 'C0008976', 'C1515981', 'C1705241', 'C4553491', 'C2603343', 'C1421478', 'C1565156', 'C1707455', 'C1080058', 'C0332287', 'C0043194', 'C1705242', 'C0680218']","['Effectiveness', 'Cryotherapy', 'WAS protein, human', 'Clinical Trials', 'Show', 'And', 'Power (Psychology)', 'WAS gene', 'Comparison', 'Study', 'Wiskott-Aldrich Syndrome', 'Effectiveness (finding)', 'In addition to', 'superiority', 'Salicylic Acid', 'Different', 'Delta (difference)', 'This (eukaryote)']","['hcpp', 'bacs', 'idcn', 'acty', 'gngm', 'topp', 'anim', 'ftcn', 'fndg', 'orch', 'qlco', 'euka', 'resa', 'socb', ' phsu', ' aapp', 'qnco', 'dsyn']"
483,PMC3109952,S79,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size,"in order to give 80% power (5% two sided significance) to show a difference in cure rates of 70% for salicylic acid versus 85% for cryotherapy at 12 weeks, a sample size of 120 patients in each treatment group was required, or 133 patients in each group after allowing for 10% attrition (266 patients in total).","['C1705428', 'C0004277', 'C0030705', 'C0441833', 'C0687744', 'C1705169', 'C3887704', 'C0439810', 'C0683607', 'C4321252', 'C1565156', 'C0242618', 'C0237881', 'C0036079', 'C1705175', 'C0439230', 'C4551716', 'C1705178', 'C1705177', 'C0043194', 'C1705242', 'C0039798', 'C3538994', 'C1457900', 'C1705429', 'C1514873', 'C3889825', 'C0205448', 'C1880198', 'C0521125', 'C0750502', 'C1519504', 'C1257890', 'C0087111', 'C1705176', 'C1522326', 'C1533734', 'C1705241', 'C1882348', 'C0687676', 'C1421478', 'C0231290']","['Status post', 'Cryotherapy', 'Order (document)', 'Statistical Significance', 'allowing', 'Biomaterial Treatment', 'Sample Size', 'Patients', 'Preposition For', 'Stage Grouping', 'WWOX wt Allele', 'Therapeutic procedure', 'Delta (difference)', 'Order (taxonomic)', 'Permutation', 'Tooth Attrition', 'WAS protein, human', 'Requirement', 'User Group', 'WAS gene', 'Administration procedure', 'Significant', 'Total', 'Group Object', 'Cure (remedy)', 'Each (qualifier value)', 'Social group', 'Order (action)', 'Sequence of Planned Assessment Schedule', 'Treatment Epoch', 'week', 'Two', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Salicylic Acid', 'Order (arrangement)', 'Post', 'Groups', 'Wiskott-Aldrich Syndrome', 'Treating', 'Population Group', 'Different']","['bacs', 'topp', 'qlco', 'socb', ' phsu', 'hlca', 'inpr', 'idcn', 'gngm', 'clas', 'acab', 'resa', ' aapp', 'popg', 'ftcn', 'orch', 'podg', 'tmco', 'dsyn', 'acty', 'cnce', 'qnco']"
484,PMC3109952,S81,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"all analyses were conducted on an intention to treat basis, including all patients in the groups to which they were randomised.","['C1283828', 'C0030705', 'C1552839', 'C0162425', 'C0441833', 'C0687744', 'C0444868', 'C1527178', 'C1874451']","['Basis - conceptual entity', 'Groups', 'intent', 'All', 'Table Rules - groups', 'Patients', 'Basis', 'Social group', 'Intention - mental process']","['inpr', 'idcn', 'popg', 'ftcn', 'qlco', 'podg', 'menp', 'qnco', 'phsu']"
485,PMC3109952,S82,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"analyses were conducted in sas version 9.2 (sas institute, nc, usa) and spss version 17.0.2 (spss) using two sided significance tests at the 5% significance level for the primary outcome measure and 1% significance level for secondary outcome measures.","['C0041703', 'C1272753', 'C0205436', 'C1515981', 'C0027627', 'C4321252', 'C0021622', 'C0237881', 'C3274433', 'C0814896', 'C1426104', 'C0333052', 'C0205448', 'C0086749', 'C0521125', 'C1823519', 'C0750502', 'C0022885', 'C0392366', 'C0605290', 'C0175668']","['significance level', 'Laboratory Procedures', 'Statistical Significance', 'And', 'TSPAN31 gene', 'Preposition For', 'Secondary to', 'WWOX wt Allele', 'SAS', 'Primary Outcome Measure', 'Tests (qualifier value)', 'Significant', 'Outcome Measures', 'Institutes', 'Two', 'NANS gene', 'Neoplasm Metastasis', 'second (number)', 'Institution (social concept)', 'United States', 'Version']","['inpr', 'idcn', 'geoa', 'lbpr', 'gngm', 'neop', 'orch', 'qlco', 'resa', 'qnco', 'orgt']"
486,PMC3109952,S84,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,the primary analysis compared the clearance rate of all plantar warts at 12 weeks between the two randomised groups using a χ2 test.,"['C0022885', 'C1515976', 'C1552839', 'C0441833', 'C0936012', 'C0687744', 'C0439230', 'C0392366', 'C0205225', 'C0456984', 'C1524024', 'C0205103', 'C0444868', 'C0025515', 'C0205448', 'C3831328', 'C0042548', 'C4318744', 'C0039593']","['Test Result', 'Intermediate', 'Groups', 'Laboratory Procedures', 'All', 'Tests (qualifier value)', 'week', 'Testing', 'Plantar wart', 'Anatomic Structure, System, or Substance', 'Metabolic Clearance Rate', 'Analysis', 'Table Rules - groups', 'Two', 'Test - temporal region', 'Blood Products Laboratory Testing', 'Social group', 'Primary', 'analysis aspect']","['clna', 'inpr', 'idcn', 'lbpr', 'clas', 'popg', 'lbtr', 'ftcn', 'spco', 'blor', 'qlco', 'tmco', 'resa', 'dsyn', 'qnco']"
487,PMC3109952,S85,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,cohen’s κ measure of inter-rater agreement was used to assess agreement between the two assessors of the photographs for clearance.,"['C4554548', 'C0079809', 'C4255433', 'C1548610', 'C4331219', 'C1548899', 'C0449297', 'C0242485', 'C1382187', 'C0680240', 'C0205448', 'C4255373', 'C2825073', 'C0441468']","['Agreement:Finding:Point in time:{Setting}:Document:{Role}', 'Clearance [PK]', 'Clearance procedure', 'Inter', 'Agreement <document>', 'Rater', 'Agreement', 'Two', 'Clearance of substance', 'Measures', 'photograph', 'Clearance', 'Measurement', 'Consent Type - Photographs']","['inpr', 'clna', 'prog', 'topp', 'ftcn', 'mnob', 'qlco', 'tmco', 'socb', 'hlca', 'npop', 'qnco']"
488,PMC3109952,S87,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"a logistic regression model was used to adjust the primary analysis for important prognostic variables (age, whether the plantar wart had been previously treated, and type of wart).","['C3853906', 'C0439828', 'C1515981', 'C0347390', 'C1524024', 'C4321252', 'C3161035', 'C0220901', 'C3274659', 'C0043037', 'C0936012', 'C1547970', 'C0206031', 'C0042548', 'C4084912', 'C3898777', 'C0205225', 'C0062074', 'C0521125', 'C3539897', 'C3665596', 'C0332307', 'C1415458', 'C1522326', 'C3714583', 'C0001779']","['Model Number', 'And', 'Model', 'Preposition For', 'Have', 'WWOX wt Allele', 'HADH gene', 'Specimen Source Codes - Wart', 'Age', 'Variable (uniformity)', 'Type - attribute', 'Importance Rating Score 0', 'Logistic Regression', 'Skin Papilloma', 'Warts', 'Important', 'Plantar wart', 'analysis aspect', 'Common wart', 'prognostic', 'Treating', 'Model - style/design', 'Analysis', 'Digital Model Attachment', 'HAC protocol', 'Primary']","['inpr', 'idcn', 'gngm', 'topp', 'neop', 'ftcn', 'cnce', 'qlco', 'resa', 'dsyn', 'orga']"
489,PMC3109952,S88,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,we also extended the primary outcome model to explore the effect of patient preferences by including preference and an interaction term between preferred treatment and randomised treatment.,"['C3853906', 'C3887704', 'C1705169', 'C0558295', 'C1549513', 'C1515981', 'C1548789', 'C3161035', 'C1274040', 'C3274659', 'C1705313', 'C0039798', 'C3538994', 'C2826302', 'C0233324', 'C1280500', 'C0205225', 'C1518681', 'C1515273', 'C1704675', 'C0332257', 'C0087111', 'C0376409', 'C1522326', 'C1533734', 'C3714583', 'C2348382']","['Model Number', 'Biomaterial Treatment', 'And', 'Term (temporal)', 'Model', 'Effect, Appearance', 'Therapeutic procedure', 'Term (lexical)', 'Outcome of Therapy', 'Patient Preference', 'Administration procedure', 'Interaction', 'Term Birth', 'Diet Code Specification Type - Preference', 'Treatment Epoch', 'Preferred - Specimen Appropriateness', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'preference', 'Effect', 'Reported Term', 'Including (qualifier)', 'Treating', 'Model - style/design', 'Digital Model Attachment', 'Result', 'Primary']","['inpr', 'idcn', 'topp', 'ftcn', 'cnce', 'fndg', 'qlco', 'tmco', 'resa', 'hlca', 'orgf']"
490,PMC3109952,S89,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,the complete clearance of all plantar warts at six months was analysed in the same way as the primary outcome with adjustments for the same covariates.,"['C4554548', 'C1274040', 'C0205452', 'C0445247', 'C0439231', 'C0449297', 'C0205197', 'C0376209', 'C1382187', 'C2945673', 'C3853530', 'C0205225', 'C4321252', 'C0444868', 'C0332287', 'C0042548', 'C0521125', 'C2825073', 'C4283785']","['Clearance [PK]', 'Complete', 'Clearance procedure', 'All', 'Complete Pharyngeal Contraction', 'Same', 'month', 'Six', 'Individual Adjustment', 'Clearance of substance', 'Preposition For', 'Clinical adjustment', 'Result', 'Data operation - complete', 'In addition to', 'Clearance', 'WWOX wt Allele', 'Primary', 'Plantar wart']","['clna', 'inbe', 'gngm', 'topp', 'ftcn', 'fndg', 'qlco', 'tmco', 'dsyn', 'npop', 'qnco']"
491,PMC3109952,S90,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,we used negative binomial regression to compare the number of plantar warts at 12 weeks between the two treatment groups with adjustment for the number of plantar warts at baseline.,"['C2825491', 'C0441833', 'C1705169', 'C0687744', 'C1513916', 'C3887704', 'C0376209', 'C0684320', 'C0683269', 'C1836830', 'C0456081', 'C0237753', 'C0439230', 'C0684321', 'C2825415', 'C1442488', 'C0042548', 'C0039798', 'C0205160', 'C3538994', 'C1552839', 'C0449788', 'C0205448', 'C0168634', 'C3853545', 'C0087111', 'C0205103', 'C1533734', 'C1522326']","['Adjustment Action', 'Baseline', 'Biomaterial Treatment', 'Negative Finding', 'Negative - answer', 'Negative Number', 'Negative', 'Therapeutic procedure', 'Psychological adjustment', 'Administration procedure', 'Individual Adjustment', 'Social group', 'Developmental regression', 'BaseLine dental cement', 'Intermediate', 'Treatment Epoch', 'week', 'Numbers', 'Disease regression', 'Two', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Regression - mental defense mechanism', 'Plantar wart', 'Count of entities', 'Groups', 'Table Rules - groups', 'Treating', 'Negative Charge']","['inpr', 'inbe', 'idcn', 'qnco', 'topp', 'popg', 'ftcn', 'cnce', 'patf', 'spco', 'fndg', 'qlco', 'resa', 'hlca', 'dsyn', 'menp', 'tmco', 'bodm']"
492,PMC3109952,S91,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,these models are used to estimate the number of occurrences of an event when the event has poisson variation with over-dispersion.,"['C0039828', 'C0205136', 'C0441471', 'C0449788', 'C0205419', 'C0332624', 'C4019010', 'C0347984', 'C2745955', 'C0237753', 'C3161035']","['Theses', 'During', 'Count of entities', 'Variant', 'Numbers', 'Model', 'dispersion', 'National reporting jurisdiction:Loc:Pt:^Event:Nom', 'Occurrence', 'Over (spatial)', 'Event']","['inpr', 'clna', 'spco', 'tmco', 'qlco', 'qnco', 'evnt']"
493,PMC3109952,S92,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical analysis,"the time to clearance of plantar warts was derived as the number of days from randomisation until the date of clearance, as detailed from the participant’s self reported questionnaire.","['C1551994', 'C1565156', 'C0237753', 'C0449297', 'C0043194', 'C0011008', 'C0042548', 'C2825073', 'C4554548', 'C0034394', 'C1441547', 'C1382187', 'C0449788', 'C1720302', 'C0439228', 'C0036588', 'C1517320', 'C3245521', 'C0040223', 'C2348077', 'C1522508', 'C1421478']","['Date in time', 'day', 'Questionnaires', 'Derived value', 'From', 'Time', 'Until', 'WAS protein, human', 'WAS gene', 'subscriber - self', 'Clearance of substance', 'Derivation', 'Self', 'Numbers', 'Plantar wart', 'Clearance [PK]', 'Count of entities', 'Clearance procedure', 'Wiskott-Aldrich Syndrome', 'Date Fruit', 'Clearance', 'Details']","['bacs', 'clna', 'inpr', 'idcn', 'gngm', 'topp', 'qlco', 'tmco', 'food', 'dsyn', ' aapp', 'npop', 'qnco']"
494,PMC3109952,S93,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"participants whose plantar warts had not cleared were treated as censored, and we calculated their duration in the trial from their date of trial exit, date of last available assessment, or the 183 days to trial cessation, as appropriate.","['C0679646', 'C1261322', 'C1548787', 'C1515981', 'C0008976', 'C0470187', 'C1518422', 'C1880019', 'C1550550', 'C0011008', 'C0042548', 'C0439228', 'C0337094', 'C3889990', 'C1517320', 'C1517741', 'C0449238', 'C3889994', 'C2348077', 'C2926735', 'C1516048']","['Date in time', 'day', 'Appropriate', 'Evaluation procedure', 'And', 'From', 'Act Relationship Checkpoint - exit', 'Duration', 'Last', 'Clinical Trials', 'Cessation', 'Negation', 'Duration (temporal concept)', 'Clinical Trial Censoring', 'availability of', 'Exit', 'Plantar wart', 'Censor', 'Date Fruit', 'Assessed', 'Participant']","['idcn', 'acty', 'popg', 'ftcn', 'spco', 'tmco', 'food', 'qlco', 'resa', 'orch', ' phsu', 'hlca', 'dsyn']"
495,PMC3109952,S94,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,a cox proportional hazards model was used to compare the time to clearance of plantar warts between the two groups adjusting for the same covariates as for the primary outcome.,"['C4554548', 'C1274040', 'C0445247', 'C1552839', 'C0449297', 'C0033489', 'C0040223', 'C0441833', 'C0687744', 'C1382187', 'C0205225', 'C4321252', 'C0205103', 'C0205448', 'C0042548', 'C0521125', 'C2825073', 'C1565830']","['Clearance [PK]', 'Intermediate', 'Clearance procedure', 'Groups', 'Table Rules - groups', 'Same', 'Two', 'Clearance of substance', 'Time', 'Preposition For', 'Primary', 'WWOX wt Allele', 'PTGS1 protein, human', 'Social group', 'Clearance', 'Result', 'Proportional Hazards Models', 'Plantar wart']","['clna', 'inpr', 'idcn', 'gngm', 'topp', 'enzy', 'popg', 'ftcn', 'spco', 'qlco', 'tmco', 'dsyn', ' aapp', 'npop', 'qnco']"
496,PMC3109952,S95,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,the cox proportional hazard assumption was tested globally by the correlation of schoenfeld residuals and survival time (or ranked survival time) and separately for each covariate through the correlation of schoenfeld scaled residuals and survival time (or ranked survival time).,"['C0521125', 'C0332273', 'C0598697', 'C0205351', 'C0040223', 'C1457900', 'C1515981', 'C1707520', 'C4321252', 'C0038952', 'C0699794', 'C1609982', 'C0220921', 'C1550549', 'C1565830']","['Residual', 'survival aspects', 'PTGS1 protein, human', 'And', 'hazard', 'Rank', 'Through', 'proportional', 'Continuance of life', 'Time', 'Correlation', 'Act Relationship Checkpoint - through', 'Preposition For', 'Each (qualifier value)', 'WWOX wt Allele']","['inpr', 'idcn', 'acty', 'gngm', 'enzy', 'ftcn', 'tmco', 'qlco', ' aapp', 'qnco']"
497,PMC3109952,S96,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,non-significant correlation indicates that there is not enough evidence that the proportional hazard assumption has been violated.,"['C0237881', 'C0598697', 'C0205351', 'C3887511', 'C1546944', 'C1707520', 'C1518422', 'C0750502']","['Evidence', 'Event Seriousness - Significant', 'Statistical Significance', 'hazard', 'Significant', 'proportional', 'Correlation', 'Negation']","['ftcn', 'qlco', 'qnco', 'idcn']"
498,PMC3109952,S97,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,data on patient satisfaction with the treatment and adverse events were summarised by treatment group but no statistical analyses were performed.,"['C1511726', 'C3887704', 'C1705169', 'C0441833', 'C0687744', 'C1515981', 'C0233535', 'C3714741', 'C0038215', 'C0877248', 'C0030702', 'C0039798', 'C3538994', 'C1705429', 'C1705413', 'C1519504', 'C3245479', 'C0087111', 'C1257890', 'C1522326', 'C1533734', 'C1705428']","['Biomaterial Treatment', 'And', 'Data call receiving device', 'butting', 'Stage Grouping', 'Therapeutic procedure', 'User Group', 'Administration procedure', 'Adverse event', 'Group Object', 'Social group', 'Treatment Epoch', 'Client satisfaction', 'Adverse Event Domain', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Data', 'Groups', 'Treating', 'Population Group', 'Science of Statistics', 'Data (eukaryote)']","['inpr', 'idcn', 'ocdi', 'topp', 'medd', 'popg', 'ftcn', 'cnce', 'patf', 'qlco', 'euka', 'resa', 'hlca', 'mobd']"
499,PMC3128457,S101,['11b'],"[0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Blinding,tranexamic acid and placebo ampoules were indistinguishable.,"['C0032042', 'C1706408', 'C1515981', 'C1696465', 'C0040613']","['placebo', 'Placebo Control', 'And', 'Placebos', 'Tranexamic Acid']","['idcn', 'topp', 'orch', 'resa', 'bodm', ' phsu']"
500,PMC3128457,S102,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Blinding,"tranexamic acid was manufactured by pharmacia (pfizer, sandwich, uk) and placebo by st mary’s pharmaceutical unit, cardiff, uk.","['C0032042', 'C0331888', 'C0331955', 'C0031336', 'C0439453', 'C1515981', 'C1706408', 'C0439148', 'C3853603', 'C1880519', 'C1509845', 'C1519795', 'C0040613', 'C1696465', 'C1704753', 'C1135440']","['International Unit', 'Unit of Measure', 'Placebo Control', 'placebo', 'Unit', 'Unit - NCI Thesaurus Property', 'And', 'Placebos', 'Procedures involving the use of pharmaceuticals', 'Enzyme Unit', 'Storage Unit', 'pfizer', 'Pharmacy (field)', 'pharmacia', 'Tranexamic Acid', 'Unit device']","['medd', 'idcn', 'topp', 'orch', 'hcro', 'qnco', 'bmod', 'resa', 'bodm', 'mnob', ' phsu']"
501,PMC3128457,S103,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Blinding,"the treatment packs were prepared by an independent clinical trial supply company (bilcare, crickhowell, uk).","['C0087111', 'C1875802', 'C0683757', 'C1522326', 'C1968515', 'C3887704', 'C1705169', 'C1999230', 'C0085862', 'C2825051', 'C1561604', 'C3538994', 'C0039798', 'C1290940', 'C0008976', 'C1299583', 'C0699914', 'C1533734', 'C0243163', 'C1096775']","['Healthcare supplies', 'Providing (action)', 'supply aspects', 'Pack (physical object)', 'treatment - ActInformationManagementReason', 'Clinical Trials', 'Economic supply', 'Treating', 'Company (organization)', 'Treatment Epoch', 'Independently able', 'therapeutic aspects', 'Clinical Trial [Publication Type]', 'Independent for Transfer', 'Pack unit', 'Therapeutic procedure', 'Biomaterial Treatment', 'Independence', 'Administration procedure', 'Supply (process)']","['fndg', 'medd', 'topp', 'orgt', ' mnob', 'idcn', 'inpr', 'hlca', 'qnco', 'drdd', 'resa', 'ftcn', 'acty', 'cnce']"
502,PMC3128457,S104,['11b'],"[0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Blinding,correct blinding and coding of ampoules was assured by independent random testing of each batch by high performance liquid chromatography to confirm the contents.,"['C1579831', 'C1948031', 'C0439605', 'C0456205', 'C1457900', 'C0085862', 'C0150108', 'C0034656', 'C2700640', 'C0392366', 'C3641829', 'C1552853', 'C1550176', 'C0009219', 'C4050310', 'C0039593', 'C2349182', 'C0008562', 'C1515981', 'C1290940', 'C4050311', 'C1299583']","['contents - HtmlLinkType', 'Encode (action)', 'Batch (group)', 'Each (qualifier value)', 'And', 'Independent for Transfer', 'Independence', 'Coding Subtest (WAIS-IV)', 'Coding Subtest (WISC-V)', 'Correct (qualifier)', 'Tests (qualifier value)', 'Random', 'Coding', 'Batch Number', 'Observation Method - High performance liquid chromatography', 'Independently able', 'Testing', 'Blinded', 'Contents', 'Batch (Response Modality)', 'High pressure liquid chromatography procedure', 'Randomization']","['ocac', 'fndg', 'idcn', 'inpr', 'qlco', 'qnco', 'lbpr', 'resa', 'ftcn', 'cnce', 'acty']"
503,PMC3128457,S106,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,we assessed the intra-observer reliability of haemorrhage measurements using the intra-class correlation coefficient.,"['C0456387', 'C0019080', 'C0870992', 'C1707429', 'C1707520', 'C2347947', 'C1705943', 'C1518526', 'C0242485', 'C0347985']","['Class', 'Coefficient', 'observers', 'Correlation', 'Reliability (characteristic)', 'Measurement', 'Class (taxonomic)', 'Hemorrhage', 'Object Class', 'intra']","['tmco', 'clas', 'inpr', 'qnco', 'qlco', 'grup', 'ftcn', 'patf', 'cnce']"
504,PMC3128457,S107,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,we assessed the reliability of binary measurements with the κ statistic.,"['C0332287', 'C1706942', 'C2828391', 'C2347947', 'C2348149', 'C0242485']","['Sample Statistic', 'In addition to', 'Reliability (characteristic)', 'Binary', 'Statistic (data)', 'Measurement']","['qnco', 'ftcn', 'qlco']"
505,PMC3128457,S108,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"for continuous variables measuring the haemorrhage, we used the average measurement of the two independent readings in all analyses.","['C0549178', 'C0019080', 'C2825518', 'C0439828', 'C1510992', 'C0085862', 'C1273517', 'C1290940', 'C1299583', 'C0205448', 'C0444868', 'C0242485']","['Continuous', 'Two', 'All', 'Variable (uniformity)', 'Average', 'Independently able', 'Independent for Transfer', 'Measurement', 'Hemorrhage', 'Average of Value Derivation Technique', 'Independence', 'used by']","['fndg', 'idcn', 'qnco', 'qlco', 'ftcn', 'patf']"
506,PMC3128457,S109,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"for binary variables, we considered an intracranial finding to be present only if it was reported as present on both readings of a particular patient’s brain scan.","['C0037088', 'C0524466', 'C0449450', 'C0596217', 'C0439828', 'C0243095', 'C0205171', 'C1706942', 'C1706086', 'C2825141', 'C0150312']","['Finding', 'Presentation', 'Singular', 'Binary', 'Experimental Finding', 'Intracranial', 'Signs and Symptoms', 'Present', 'Variable (uniformity)', 'Both', 'Brain scan']","['blor', 'fndg', 'idcn', 'sosy', 'qlco', 'qnco', 'diap']"
507,PMC3128457,S110,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,we used generalised linear models adjusted for baseline variables.,"['C1442488', 'C0439828', 'C0168634', 'C0023732']","['Linear Models', 'Variable (uniformity)', 'BaseLine dental cement', 'Baseline']","['qnco', 'bodm', 'qlco']"
508,PMC3128457,S111,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,covariates included in the adjustment were glasgow coma scale and age.,"['C1369880', 'C0456081', 'C0376209', 'C0017594', 'C0683269', 'C1515981', 'C0001779']","['Age', 'Adjustment Action', 'Glasgow coma score:-:Point in time:^Patient:-', 'And', 'Psychological adjustment', 'Individual Adjustment', 'Glasgow coma scale']","['inbe', 'idcn', 'inpr', 'orga', 'ftcn', 'clna']"
509,PMC3128457,S112,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"for computed tomography outcomes, we also adjusted for time from injury to first and second scan and for initial haemorrhage volume.","['C1555582', 'C0205265', 'C0019080', 'C0205435', 'C1561503', 'C0040405', 'C0040223', 'C1279901', 'C2700258', 'C1705102', 'C0205436', 'C0441633', 'C0449468', 'C1515981', 'C1705685', 'C0034606', 'C2826292', 'C0457385', 'C3263723', 'C1705190']","['Firstly', 'seconds', 'Initially', 'First (number)', 'Volume', 'Traumatic injury', 'Radionuclide Imaging', 'Time', 'And', 'Initial (abbreviation)', 'Initial Usage', 'Scanning', 'Volume Measurement', 'second (number)', 'Hemorrhage', 'Related to Cancer', 'Volume (publication)', 'Precision - second', 'Second Suffix', 'X-Ray Computed Tomography']","['tmco', 'fndg', 'idcn', 'inpr', 'qlco', 'qnco', 'inpo', 'lbpr', 'ftcn', 'diap', 'patf']"
510,PMC3128457,S113,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,in our analysis of mass effect we adjusted for initial mass effect.,"['C1555582', 'C0205265', 'C4086564', 'C1279901', 'C1705685', 'C1524024', 'C0936012']","['Firstly', 'Initially', 'Mass Effect', 'Analysis', 'Initial (abbreviation)', 'Initial Usage', 'analysis aspect']","['tmco', 'fndg', 'idcn', 'qlco', 'resa', 'ftcn']"
511,PMC3128457,S114,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"adjusted effects are considered in the primary analysis, but both adjusted and unadjusted effect measures are reported.","['C0456081', 'C2348382', 'C1439367', 'C0079809', 'C1518681', 'C0205225', 'C1280500', 'C1515981', 'C0233535', 'C1706086', 'C1524024', 'C0936012']","['Effect, Appearance', 'Adjustment Action', 'Primary', 'butting', 'unadjusted', 'Analysis', 'And', 'Outcome of Therapy', 'analysis aspect', 'Effect', 'Measures', 'Both']","['fndg', 'idcn', 'qlco', 'qnco', 'mobd', 'resa', 'ftcn']"
512,PMC3128457,S115,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,we reported 95% confidence intervals for all the effects estimated and p values for the adjusted analyses.,"['C0456081', 'C0009667', 'C1280500', 'C0750572', 'C0521125', 'C1515981', 'C0444868', 'C0042295', 'C4321252']","['Confidence Intervals', 'All', 'Adjustment Action', 'Estimated', 'WWOX wt Allele', 'And', 'Effect', 'Preposition For', 'Values']","['gngm', 'idcn', 'qnco', 'qlco', 'ftcn']"
513,PMC3128457,S116,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"haemorrhage growth was analysed using multiple linear regression (analysis of covariance), the main factor being the treatment group.","['C1621966', 'C2346679', 'C0205225', 'C0023733', 'C3538994', 'C0018270', 'C1533734', 'C0936012', 'C1257890', 'C0087111', 'C2911660', 'C0441833', 'C0019080', 'C3887704', 'C1705169', 'C0039798', 'C1542147', 'C1705428', 'C1519504', 'C1705429', 'C1521761', 'C0220844', 'C2987476', 'C2827422', 'C1522326', 'C0687744', 'C0439064', 'C1524024']","['Group Object', 'growth aspects', 'Exist', 'Tissue Growth', 'Main', 'Treatment Epoch', 'Growth', 'analysis aspect', 'Mathematical Factor', 'Biomaterial Treatment', 'Administration procedure', 'User Group', 'Groups', 'Population Group', 'Social group', 'Growth action', 'Linear Regression Body Surface Area Formula for Infants and Children', 'Factor', 'Linear Regression', 'Numerous', 'Primary', 'treatment - ActInformationManagementReason', 'Treating', 'Analysis', 'therapeutic aspects', 'Hemorrhage', 'Stage Grouping', 'Therapeutic procedure']","['ortf', 'topp', 'idcn', 'phsf', 'hlca', 'inpr', 'qnco', 'phpr', 'qlco', 'orgf', 'resa', 'ftcn', 'popg', 'patf', 'cnce']"
514,PMC3128457,S117,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,outcomes are reported combined and separately for patients who did or did not undergo neurosurgical evacuation between the first and second computed tomography scan.,"['C3272598', 'C1518422', 'C0205435', 'C1561503', 'C0040405', 'C1279901', 'C0205436', 'C0030705', 'C0441633', 'C1515981', 'C0034606', 'C2826292', 'C0457385', 'C1282573', 'C1705190']","['Firstly', 'seconds', 'First (number)', 'X-Ray Computed Tomography', 'evacuation', 'Radionuclide Imaging', 'WHO Temperature/Humidity Storage Condition', 'And', 'second (number)', 'Scanning', 'Patients', 'Related to Cancer', 'Precision - second', 'Second Suffix', 'Negation']","['tmco', 'fndg', 'idcn', 'topp', 'qlco', 'qnco', 'podg', 'ftcn', 'diap']"
515,PMC3128457,S118,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,binary outcomes were analysed using logistic regression.,"['C1706942', 'C0206031']","['Binary', 'Logistic Regression']","['qlco', 'resa']"
516,PMC3128457,S119,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,subarachnoid haemorrhage scale was compared in the two groups using a non-parametric rank test (kruskal-wallis).,"['C0175659', 'C0349674', 'C0699794', 'C0441833', 'C0667477', 'C0022885', 'C1515976', 'C0039593', 'C1552839', 'C4318744', 'C1518422', 'C0456984', 'C0687744', 'C1947916', 'C0392366', 'C3831328', 'C0038525', 'C0205448']","['Subarachnoid Hemorrhage', 'Groups', 'Scaling', 'TNFRSF11A protein, human', 'Two', 'Rank', 'Anatomic Structure, System, or Substance', 'Social group', 'Test Result', 'Testing', 'Blood Products Laboratory Testing', 'Tests (qualifier value)', 'Test - temporal region', 'Laboratory Procedures', 'Weight measurement scales', 'Intellectual scale', 'Negation', 'Table Rules - groups']","['blor', 'lbtr', 'medd', 'clas', 'idcn', 'inpr', 'qnco', 'bacs', 'lbpr', 'dsyn', 'ftcn', ' aapp', 'popg', 'acty']"
517,PMC3128457,S120,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,all analyses were undertaken on an intention to treat basis.,"['C1283828', 'C0162425', 'C1527178', 'C1874451', 'C0444868']","['Basis - conceptual entity', 'All', 'Intention - mental process', 'Basis', 'intent']","['qlco', 'qnco', 'ftcn', 'menp', 'phsu']"
518,PMC3128457,S121,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"to evaluate the clinical relevance of the primary surrogate outcome selected in this study, we also analysed the clinical effect of haemorrhage growth.","['C1707391', 'C2911660', 'C2603343', 'C2348382', 'C0019080', 'C1621966', 'C1080058', 'C1518681', 'C0205225', 'C1280500', 'C2347946', 'C4053457', 'C0018270', 'C0205210', 'C0220844', 'C1274040']","['Tissue Growth', 'Clinical', 'Surrogate', 'Effect, Appearance', 'Primary', 'Relevance', 'growth aspects', 'Growth action', 'Growth', 'Outcome of Therapy', 'Effect', 'Hemorrhage', 'Study', 'This (eukaryote)', 'Result', 'Choose (action)']","['ortf', 'fndg', 'phsf', 'famg', 'qlco', 'phpr', 'orgf', 'resa', 'euka', 'ftcn', 'patf', 'acty']"
519,PMC3128457,S122,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,"we conducted a logistic regression analysis with dependency (as defined by the modified oxford handicap scale) as the outcome and haemorrhage growth as the main exposure variable, with adjustment by the potential confounders of initial haemorrhage volume, glasgow coma scale, age, time from injury to computed tomography, and treatment.","['C0205265', 'C1621966', 'C0205225', 'C1279901', 'C0439828', 'C0376209', 'C4553760', 'C3538994', 'C0018270', 'C0392747', 'C1533734', 'C1369880', 'C0087111', 'C2911660', 'C1555582', 'C0349674', 'C0019080', 'C3889737', 'C0040405', 'C2700258', 'C1705169', 'C0681925', 'C1705102', 'C0039798', 'C1542147', 'C0231172', 'C3887704', 'C3263723', 'C0456081', 'C0332287', 'C1705685', 'C0011546', 'C0220844', 'C1517320', 'C0175659', 'C1522326', 'C0040223', 'C0017594', 'C0683269', 'C1515981', 'C0332157', 'C1947916', 'C0449468', 'C3245505', 'C1546937', 'C0001779', 'C1274040']","['Age', 'In addition to', 'Exposure to', 'Volume', 'growth aspects', 'And', 'Data Change Date', 'From', 'Volume (publication)', 'Tissue Growth', 'Event Qualification - Dependency', 'Firstly', 'Scaling', 'Adjustment Action', 'Main', 'Variable (uniformity)', 'Time', 'Growth', 'Psychological adjustment', 'Treatment Epoch', 'Volume Measurement', 'Biomaterial Treatment', 'Individual Adjustment', 'Intellectual scale', 'Administration procedure', 'Result', 'Changing', 'Initially', 'handicapping condition', 'Traumatic injury', 'logistic regression analysis', 'Growth action', 'Initial (abbreviation)', 'Initial Usage', 'emotional dependency', 'Study Variable', 'X-Ray Computed Tomography', 'Primary', 'treatment - ActInformationManagementReason', 'Glasgow coma score:-:Point in time:^Patient:-', 'Treating', 'potential', 'therapeutic aspects', 'Hemorrhage', 'Weight measurement scales', 'Glasgow coma scale', 'Therapeutic procedure']","['topp', 'qnco', 'phpr', 'menp', 'patf', 'clna', 'ortf', 'fndg', 'idcn', 'hlca', 'phsf', 'inpr', 'qlco', 'lbpr', 'resa', 'ftcn', 'tmco', 'inbe', 'cnce', 'acty', 'medd', 'inpo', 'orga', 'orgf', 'diap']"
520,PMC3128457,S123,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical methods,we used the statistical software package stata (version se/11·0) from statacorp.,"['C0038215', 'C0333052', 'C1704709']","['Computer program package', 'Version', 'Science of Statistics']","['ocdi', 'inpr']"
521,PMC3128457,S125,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Role of the funding source,"the funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.","['C0010995', 'C2584304', 'C0684224', 'C0010992', 'C0043266', 'C3273238', 'C0700287', 'C3539897', 'C2986888', 'C0035171', 'C2983265', 'C3887707', 'C1415458', 'C4255046', 'C3245479', 'C3173575', 'C0062074', 'C4050126', 'C2603343', 'C1705810', 'C0035820', 'C3714741', 'C0459471', 'C1511726', 'C4283917', 'C3871154']","['Generic Role', 'Data (eukaryote)', 'Reporting', 'HAC protocol', 'Study', 'Writing (function)', 'HADH gene', 'Social Role', 'Data Analysis', 'Data Collection Methods', 'Report:Finding:Point in time:{Setting}:Document:{Role}', 'Report (document)', 'Nonclinical Study Design', 'Interpretation:Impression/interpretation of study:Point in time:^Patient:Nominal', 'Data call receiving device', 'Ability to Write question', 'Data Collection', 'CDISC SEND Study Design Terminology', 'Writing (occupation or discipline)', 'Research Design', 'Regulatory Report', 'Have', 'Role', 'Interpretation Process', 'Writing Ability', 'Data']","['ocac', 'medd', 'hlca', 'idcn', 'topp', 'gngm', 'inpr', 'ocdi', 'qnco', 'qlco', 'socb', 'resa', 'euka', 'menp', 'clna']"
522,PMC3128457,S126,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Role of the funding source,the writing committee had full access to all data in the study and had final responsibility for the decision to submit for publication.,"['C2584304', 'C0521125', 'C1554204', 'C0444454', 'C0043266', 'C3539897', 'C4321252', 'C0205088', 'C3853528', 'C2699414', 'C1546485', 'C1415458', 'C0034037', 'C3245479', 'C0062074', 'C1704324', 'C0679006', 'C0444868', 'C4050126', 'C0443225', 'C2603343', 'C1515981', 'C3714741', 'C1511726', 'C4283917', 'C0678341', 'C0034036']","['Publishing', 'End-stage', 'Scientific Publication', 'Data (eukaryote)', 'And', 'HAC protocol', 'Study', 'full', 'Writing (function)', 'HADH gene', 'Publications', 'Diagnosis Type - Final', 'responsibility', 'Committee', 'Access', 'Data call receiving device', 'All', 'Decision', 'Ability to Write question', 'WWOX wt Allele', 'Role Class - access', 'Writing (occupation or discipline)', 'Preposition For', 'Have', 'Final', 'Writing Ability', 'Data']","['tmco', 'ocac', 'resa', 'medd', ' mnob', 'idcn', 'topp', 'gngm', 'ocdi', 'inpr', 'inbe', 'qnco', 'qlco', 'grup', 'spco', 'euka', 'ftcn', 'menp']"
523,PMC3128457,S39,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Methods,"trial design—this double blind, randomised, placebo controlled trial was nested in a cohort of crash-2 trial participants.","['C0936233', 'C0013072', 'C0679646', 'C0009247', 'C0599755', 'C0008976', 'C0009933']","['Cohort Studies', 'Double-Blind Method', 'Participant', 'Clinical Trials', 'Controlled Clinical Trials as Topic', 'Cohort', 'Controlled Clinical Trial [Publication Type]']","['qnco', 'popg', 'inpr', 'resa']"
524,PMC3128457,S40,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Methods,"the aims, methods, and results of the crash-2 trial are presented in detail elsewhere.2","['C3540473', 'C0025663', 'C1947946', 'C0025664', 'C1522508', 'C1515981', 'C0008976', 'C0449851', 'C1561567']","['Methods', 'Aim (idea)', 'Clinical Trials', 'Abnormal Involuntary Movement Scale Questionnaire', 'Details', 'detail - Response Level', 'Techniques', 'And', 'Methods aspects']","['idcn', 'inpr', 'qlco', 'resa', 'ftcn']"
525,PMC3128457,S41,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Methods,participants—the trial was conducted in a cohort of crash-2 trial participants.,"['C0679646', 'C0009247', 'C0599755', 'C0008976']","['Cohort', 'Clinical Trials', 'Cohort Studies', 'Participant']","['qnco', 'popg', 'resa']"
526,PMC3128457,S42,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Methods,"patients eligible for inclusion in the intracranial bleeding study fulfilled the inclusion criteria for the crash-2 trial—adult trauma patients with significant haemorrhage (systolic blood pressure <90 mm hg or heart rate >110 beats per min, or both) or who were considered to be at risk of significant haemorrhage, and who were within 8 hours of injury (study entry governed by the uncertainty principle)11—but they also had traumatic brain injury (glasgow coma scale ≤14 and a brain computed tomography compatible with traumatic brain injury).","['C1512693', 'C0332290', 'C0087130', 'C0488055', 'C0521125', 'C0750502', 'C4049136', 'C1706086', 'C0876926', 'C4321252', 'C1369880', 'C3272598', 'C0019080', 'C1306620', 'C4281991', 'C0030705', 'C0151699', 'C3263723', 'C0871470', 'C0332287', 'C0332285', 'C0007637', 'C0018810', 'C1524057', 'C1548635', 'C1444641', 'C1705654', 'C1510467', 'C0750591', 'C2603343', 'C0043251', 'C0412585', 'C0017594', 'C1515981', 'C1292429', 'C1546944', 'C3714660', 'C3887962', 'C0237881']","['Compatible', 'In addition to', 'Trauma, nursing specialty', 'Per (qualifier)', 'And', 'Systolic blood pressure measurement', 'Study', 'Eligible', 'trauma qualifier', 'Within', 'Follow', 'Inclusion Bodies', '8 Hours', 'Traumatic Brain Injury', 'Intracranial Hemorrhage', 'Uncertainty', 'At risk', 'Traumatic injury', 'Inclusion', 'Statistical Significance', 'WWOX wt Allele', 'consider', 'Patients', 'Consistent with', 'Event Seriousness - Significant', 'Glasgow coma scale', 'Preposition For', 'Wounds and Injuries', 'Trauma', 'Significant', 'Entry (data)', 'Glasgow coma score:-:Point in time:^Patient:-', 'CAT scan of brain', 'WHO Temperature/Humidity Storage Condition', 'Hemorrhage', 'Systolic Pressure', 'Intravascular systolic:Pressure:Point in time:Arterial system:Quantitative', 'Both', 'heart rate']","['tmco', 'fndg', 'gngm', 'idcn', 'inpr', 'celc', 'qlco', 'qnco', 'bmod', 'inpo', 'spco', 'resa', 'podg', 'ftcn', 'diap', 'patf', 'clna']"
527,PMC3128457,S43,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Methods,pregnant women and patients for whom a second brain scan was not possible were excluded.,"['C1518422', 'C0332149', 'C1705910', 'C1561503', 'C0596217', 'C0205436', 'C0030705', 'C0033011', 'C1515981', 'C0457385', 'C1705190']","['seconds', 'second (number)', 'And', 'Possibly Related to Intervention', 'Patients', 'Pregnant Women', 'Precision - second', 'Second Suffix', 'Possible', 'Negation', 'Brain scan']","['tmco', 'fndg', 'idcn', 'qlco', 'qnco', 'podg', 'ftcn', 'diap', 'popg']"
528,PMC3128457,S44,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Methods,consent procedures at participating hospitals were established by local regulation and the appropriate ethics committees.,"['C2700391', 'C1511481', 'C0851285', 'C0085546', 'C0205276', 'C2923685', 'C0019994', 'C1327622', 'C0025664', 'C3538935', 'C1515981', 'C1554192', 'C1548787', 'C0184661']","['Consent:Finding:Point in time:{Setting}:Document:Patient', 'Procedure (set of actions)', 'Procedure Domain', 'And', 'Regulation of biological process', 'Appropriate', 'Hospitals', 'Consent', 'Ethics Committees', 'Interventional procedure', 'Methods aspects', 'ActClass - consent', 'Regulation', 'Local']","['gora', 'biof', 'prog', ' hcro', 'topp', 'idcn', 'inpr', 'qlco', 'spco', 'ftcn', 'mnob', 'clna']"
529,PMC3128457,S45,['4b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Methods,study settings—patients were recruited from 10 hospitals in india and colombia.,"['C2603343', 'C2700456', 'C0019994', 'C1515981', 'C0021201', 'C3245499']","['And', 'Hospitals', 'Study', 'India', 'Colombia', 'India - zebrafish']","[' hcro', 'idcn', 'geoa', 'resa', 'mnob', 'fish']"
530,PMC3128457,S46,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Methods,"the sites were selected according to their interest in the topic, adequate facilities for conducting computed tomography, and expected recruitment rate.","['C1522168', 'C0205145', 'C0040405', 'C0205410', 'C1521828', 'C0205411', 'C1515981', 'C1555712', 'C2949735', 'C0871208', 'C0543488']","['Sufficient', 'Topical Route of Drug Administration', 'X-Ray Computed Tomography', 'interest', 'Rate', 'And', 'Site', 'Rating (action)', 'topic - ActClassContainer', 'Adequate', 'Recruitment']","['idcn', 'inpr', 'qlco', 'qnco', 'spco', 'ftcn', 'diap', 'menp', 'acty']"
531,PMC3128457,S48,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Interventions,"participants were randomly allocated to receive a loading dose of 1 g tranexamic acid infused over 10 minutes, followed by an intravenous infusion of 1 g over eight hours, or matching placebo (sodium chloride 0.9%).","['C0205454', 'C0021440', 'C1442446', 'C1708715', 'C0032042', 'C1272892', 'C0679646', 'C0037494', 'C0178602', 'C0439227', 'C1706408', 'C1696465', 'C1621368', 'C0040613']","['Intravenous Drip Route of Administration', 'Intravenous infusion procedures', 'placebo', 'Participant', 'Placebo Control', 'Loading Technique', 'Dosage', 'Placebos', 'Intravenous infusion (product)', 'Eight', '10 Minutes', 'Sodium Chloride', 'Tranexamic Acid', 'Hour']","['tmco', 'popg', 'bodm', 'topp', 'orch', 'qnco', 'bacs', 'resa', 'ftcn', 'acty', ' phsu', ' inch']"
532,PMC3128457,S50,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"we obtained two brain computed tomograms for each participant, the first before randomisation and the second 24–48 hours later.","['C1561503', 'C0205435', 'C0006104', 'C0205087', 'C0679646', 'C1457900', 'C1279901', 'C0040395', 'C0205436', 'C0439227', 'C1515981', 'C0457385', 'C0205448', 'C2698741', 'C0332152', 'C4554048', 'C1705190']","['Firstly', 'Late', 'Study Participant', 'Two', 'seconds', 'Participant', 'First (number)', 'Each (qualifier value)', 'second (number)', 'And', 'Brain', 'Participant Object', 'Before', 'tomography', 'Precision - second', 'Second Suffix', 'Hour']","['tmco', 'idcn', 'clas', 'qlco', 'qnco', 'diap', 'popg', 'bpoc']"
533,PMC3128457,S51,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,a neuroradiologist (zoe morris) who was blind to treatment allocation and clinical findings evaluated the first and second scans.,"['C0456909', 'C1561503', 'C2985415', 'C1279901', 'C3538994', 'C0441633', 'C1533734', 'C0037088', 'C0087111', 'C1706778', 'C3272598', 'C0205435', 'C3887704', 'C1705169', 'C0039798', 'C0205436', 'C0150108', 'C0457385', 'C0525065', 'C1705190', 'C1522326', 'C1515981']","['And', 'Neuroradiologist', 'Firstly', 'First (number)', 'Treatment Epoch', 'second (number)', 'Biomaterial Treatment', 'Precision - second', 'Administration procedure', 'Signs and Symptoms', 'Visually Impaired Persons', 'Blinded', 'Second Suffix', 'seconds', 'treatment - ActInformationManagementReason', 'Treating', 'WHO Temperature/Humidity Storage Condition', 'therapeutic aspects', 'Scanning', 'Blindness', 'Allocation', 'Therapeutic procedure']","['tmco', 'fndg', 'prog', 'idcn', 'topp', 'hlca', 'sosy', 'qlco', 'qnco', 'resa', 'podg', 'ftcn', 'acty', 'diap', 'cnce']"
534,PMC3128457,S52,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"readings of the two scans were done twice (with the second reading blind to the results of the first reading) by central reading of the electronic dicom image files in digital jacket software (desacc, chicago il, usa).","['C0034754', 'C0456909', 'C1561503', 'C1279901', 'C0441633', 'C1547561', 'C0037585', 'C2348045', 'C1704922', 'C0041703', 'C0205435', 'C1948050', 'C0205436', 'C0150108', 'C0457385', 'C0205448', 'C4284139', 'C0525065', 'C0453944', 'C1705190', 'C1699030', 'C1272695', 'C0332287', 'C1883674', 'C0008044', 'C0013850', 'C0205099', 'C4281784', 'C1704254', 'C1705179']","['Authorization Mode - Electronic', 'In addition to', 'DICOM Terminology', 'Computer software', 'jacket', 'Digital', 'Reading Ability question', 'Firstly', 'Chicago', 'First (number)', 'Reading (datum presentation)', 'second (number)', 'Electronics discipline', 'Twice (Numerical Qualifier)', 'Digital Imaging and Communications in Medicine (DICOM)', 'Precision - second', 'Medical Image', 'Two', 'Visually Impaired Persons', 'Blinded', 'Central', 'Second Suffix', 'Reading (activity)', 'Electronic', 'seconds', 'United States', 'Scanning', 'Image', 'Done (qualifier value)', 'Blindness']","['mnob', 'tmco', 'fndg', 'idcn', ' mnob', 'dora', 'inpr', 'geoa', 'ocdi', 'qlco', 'qnco', 'spco', 'resa', 'podg', 'ftcn', 'diap', 'cnce']"
535,PMC3128457,S53,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"the size of intra-parenchymal haemorrhages, haemorrhagic contusions, subdural epidural haematomas, subarachnoid haemorrhage, ischaemic lesions; mass effect; and the overall amount of tissue damage were assessed with validated rating scales based on previous work (see box).12 13 14 15 16","['C0456389', 'C0475224', 'C0282416', 'C1561607', 'C0238154', 'C0019080', 'C4086564', 'C1265611', 'C0010957', 'C1552607', 'C0333275', 'C0205156', 'C0009938', 'C0038541', 'C0681889', 'C0179400', 'C0043227', 'C0038525', 'C0221198', 'C0347985']","['Subarachnoid Hemorrhage', 'Hemorrhagic', 'Subdural space', 'rating scale', 'intra', 'Overall', 'Ischemic', 'Mass Effect', 'Box', 'Contusions', 'Quantity', 'Lesion', 'Hematoma, Epidural, Cranial', 'Hemorrhage', 'Overall Publication Type', 'Previous', 'size', 'Act Relationship Subset - previous', 'Work', 'Tissue damage']","['tmco', ' qnco', 'fndg', 'ocac', 'inpr', 'qlco', 'qnco', 'inpo', 'dsyn', 'spco', 'ftcn', 'mnob', 'patf', 'bsoj']"
536,PMC3128457,S54,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,the individual ratings and measurements were recorded on a rating form developed for the purposes of this study (shown in appendix on bmj.com).,"['C0348078', 'C0237401', 'C4255237', 'C2603343', 'C0206008', 'C1080058', 'C1285529', 'C0376315', 'C1522492', 'C1515981', 'C0871208', 'C0027361', 'C0242485', 'C0003617']","['Individual', 'Formation', 'Rating (action)', 'Qualitative form', 'Persons', '2-Mercaptoethanesulfonic Acid', 'And', 'Purpose', 'Study', 'Form:Finding:Point in time:{Setting}:Document:{Role}', 'Measurement', 'This (eukaryote)', 'Manufactured form', 'Appendix']","['acty', 'popg', 'idcn', 'orch', 'qlco', 'euka', 'resa', 'ftcn', 'mnob', ' phsu', 'bpoc', 'clna']"
537,PMC3128457,S57,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,measurement—a representative slice at the centre of the haematoma was selected.,"['C0018944', 'C1882932', 'C0205099', 'C1519355']","['Representation (action)', 'Slice', 'Hematoma', 'Central']","['sbst', 'patf', 'spco', 'acty']"
538,PMC3128457,S58,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,the maximum linear length (a) in cm was multiplied by the maximum width perpendicular to a (b) and the maximum depth (c) in cm.,"['C0487742', 'C1552615', 'C1421478', 'C1565156', 'C1706316', 'C0205132', 'C1295725', 'C1515981', 'C0043194', 'C0205125', 'C1444754', 'C0806909', 'C3272860', 'C2826546']","['Deep (qualifier value)', 'Maximum', 'Maximum Value Derivation Technique', 'Perpendicular axis', 'WAS protein, human', 'WAS gene', 'And', 'Perpendicular', 'width', 'Length of Trial', 'Linear', 'Act Relationship Subset - maximum', 'Length', 'Wiskott-Aldrich Syndrome']","['gngm', 'idcn', 'qnco', 'bacs', 'dsyn', 'spco', 'resa', ' aapp', 'cnce']"
539,PMC3128457,S59,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,the depth (c) was determined by multiplying the number of slices on which haematoma is visible by the slice interval thickness listed on the ct scan.,"['C3889666', 'C1519355', 'C1552654', 'C0040405', 'C1280412', 'C1552713', 'C0205379', 'C0018944', 'C0205125', 'C1272706']","['Deep (qualifier value)', 'visible', 'Data Type Interval', 'Slice', 'Thick', 'Number of Slices', 'Interval', 'Hematoma', 'Parameterized Data Type - Interval', 'X-Ray Computed Tomography']","['tmco', 'inpr', 'qnco', 'sbst', 'qlco', 'spco', 'diap', 'patf']"
540,PMC3128457,S60,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,to obtain the volume in cm3 the final product (a.b.c) was divided by 2,"['C1514468', 'C0205088', 'C0439242', 'C2700258', 'C3853528', 'C1705102', 'C0449468', 'C1546485', 'C1704444']","['product', 'Volume', 'End-stage', 'Volume Measurement', 'milliliter', 'Volume (publication)', 'Multiplicative Product', 'Final', 'Diagnosis Type - Final']","['tmco', 'idcn', 'inpr', 'qlco', 'qnco', 'lbpr', 'enty']"
541,PMC3128457,S62,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,measurement—a representative slice near the centre of the haematoma was selected.,"['C0018944', 'C1882932', 'C0205099', 'C1519355']","['Representation (action)', 'Slice', 'Hematoma', 'Central']","['sbst', 'patf', 'spco', 'acty']"
542,PMC3128457,S63,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,the linear distance in cm between each corner of the subdural crescent was used to determine the length (a).,"['C0444628', 'C1457900', 'C0012751', 'C1421478', 'C1565156', 'C0043194', 'C0205132', 'C0038541', 'C1273517', 'C1444754', 'C1706316', 'C0521095']","['Subdural space', 'WAS protein, human', 'Each (qualifier value)', 'Distance', 'Determined by', 'WAS gene', 'Length of Trial', 'Linear', 'crescents', 'used by', 'Length', 'Wiskott-Aldrich Syndrome']","['fndg', 'gngm', 'qlco', 'qnco', 'bacs', 'dsyn', 'spco', 'resa', ' aapp', 'bsoj']"
543,PMC3128457,S64,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,the width (b) was measured as the maximum thickness in cm of haematoma from the inner table of the skull perpendicular to the length.,"['C0487742', 'C2951888', 'C0039224', 'C4054567', 'C0018944', 'C1706074', 'C1444754', 'C3272860', 'C1706316', 'C1517320', 'C0037303', 'C1295725', 'C0205102']","['Bone structure of cranium', 'Skull', 'Data Table', 'Perpendicular', 'width', 'Length of Trial', 'From', 'Hematoma', 'Maximum Thickness', 'Table - furniture', 'Internal', 'Perpendicular axis', 'Length']","['inpr', 'qlco', 'qnco', 'spco', 'resa', 'bpoc', 'mnob', 'patf', 'cnce']"
544,PMC3128457,S65,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,the depth (c) was determined by multiplying the number of slices on which haematoma is visible by the slice interval thickness listed on the ct scan.,"['C3889666', 'C1519355', 'C1552654', 'C0040405', 'C1280412', 'C1552713', 'C0205379', 'C0018944', 'C0205125', 'C1272706']","['Deep (qualifier value)', 'visible', 'Data Type Interval', 'Slice', 'Thick', 'Number of Slices', 'Interval', 'Hematoma', 'Parameterized Data Type - Interval', 'X-Ray Computed Tomography']","['tmco', 'inpr', 'qnco', 'sbst', 'qlco', 'spco', 'diap', 'patf']"
545,PMC3128457,S66,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,to obtain the volume in cm3 the final product (a.b.c) was divided by 2.,"['C1514468', 'C0205088', 'C0439242', 'C2700258', 'C3853528', 'C1705102', 'C0449468', 'C1546485', 'C1704444']","['product', 'Volume', 'End-stage', 'Volume Measurement', 'milliliter', 'Volume (publication)', 'Multiplicative Product', 'Final', 'Diagnosis Type - Final']","['tmco', 'idcn', 'inpr', 'qlco', 'qnco', 'lbpr', 'enty']"
546,PMC3128457,S68,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,measurement—a representative slice near the centre of the haematoma was selected.,"['C0018944', 'C1882932', 'C0205099', 'C1519355']","['Representation (action)', 'Slice', 'Hematoma', 'Central']","['sbst', 'patf', 'spco', 'acty']"
547,PMC3128457,S69,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,the linear distance in cm between each corner of the epidural lens shape was used to determine the length (a).,"['C0348078', 'C0332479', 'C1457900', 'C0012751', 'C1421478', 'C1565156', 'C0023317', 'C0205132', 'C3273461', 'C0043194', 'C1273517', 'C0996842', 'C1444754', 'C0522512', 'C1706316', 'C0228134', 'C0521095', 'C0812144', 'C0023318']","['Remetinostat', 'With shape', 'Qualitative form', 'WAS protein, human', 'Shapes', 'Spinal epidural space', 'Each (qualifier value)', 'Distance', 'Determined by', 'WAS gene', 'Length of Trial', 'Medication administration: epidural', 'Genus Lens', 'Linear', 'used by', 'Lens (device)', 'Length', 'Lens, Crystalline', 'Wiskott-Aldrich Syndrome']","['fndg', 'gngm', 'topp', 'plnt', 'qlco', 'qnco', 'bacs', 'dsyn', 'spco', 'resa', 'bsoj', ' aapp', 'mnob', 'bpoc', 'phsu']"
548,PMC3128457,S70,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,the width (b) was measured as the maximum thickness in cm of haematoma (b) from the inner table of the skull perpendicular to the length.,"['C0487742', 'C2951888', 'C0039224', 'C4054567', 'C0018944', 'C1706074', 'C1444754', 'C3272860', 'C1706316', 'C1517320', 'C0037303', 'C1295725', 'C0205102']","['Bone structure of cranium', 'Skull', 'Data Table', 'Perpendicular', 'width', 'Length of Trial', 'From', 'Hematoma', 'Maximum Thickness', 'Table - furniture', 'Internal', 'Perpendicular axis', 'Length']","['inpr', 'qlco', 'qnco', 'spco', 'resa', 'bpoc', 'mnob', 'patf', 'cnce']"
549,PMC3128457,S71,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,the depth (c) was determined by multiplying the number of slices on which haematoma is visible by the slice interval listed on the ct scan.,"['C3889666', 'C1519355', 'C1552654', 'C0040405', 'C1552713', 'C0205379', 'C0018944', 'C0205125', 'C1272706']","['Deep (qualifier value)', 'visible', 'Data Type Interval', 'Slice', 'Number of Slices', 'Interval', 'Hematoma', 'Parameterized Data Type - Interval', 'X-Ray Computed Tomography']","['tmco', 'inpr', 'qnco', 'sbst', 'qlco', 'spco', 'diap', 'patf']"
550,PMC3128457,S72,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"to obtain the volume in cm3, the final product (a.b.c) was divided by 2","['C1514468', 'C0205088', 'C0439242', 'C2700258', 'C3853528', 'C1705102', 'C0449468', 'C1546485', 'C1704444']","['product', 'Volume', 'End-stage', 'Volume Measurement', 'milliliter', 'Volume (publication)', 'Multiplicative Product', 'Final', 'Diagnosis Type - Final']","['tmco', 'idcn', 'inpr', 'qlco', 'qnco', 'lbpr', 'enty']"
551,PMC3128457,S74,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,measurement—blood within subarachnoid spaces between pia and arachnoid membranes.,"['C0025255', 'C3539746', 'C1836945', 'C0038527', 'C1515981', 'C3273239', 'C0003707', 'C0063264']","['Cisplatin/Doxorubicin/Ifosfamide protocol', 'And', 'RICTOR wt Allele', 'RICTOR gene', 'Subarachnoid Space', 'Proliferative Inflammatory Atrophy', 'Tissue membrane', 'Arachnoid mater']","['gngm', 'idcn', 'topp', 'tisu', 'dsyn', 'bpoc', 'bsoj']"
552,PMC3128457,S75,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,haemorrhage thickness was categorised as ≤5 mm or >5 mm.,"['C1280412', 'C3840882', 'C0019080']","['Thick', 'Hemorrhage', '5 mm']","['qlco', 'fndg', 'patf']"
553,PMC3128457,S76,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,the thickness was rated within a representative sulcus,"['C1184482', 'C1882932', 'C3893558', 'C1280412']","['Thick', 'dinoflagellate sulcus', 'Groove', 'Representation (action)']","['qlco', 'acty', 'celc', 'bsoj']"
554,PMC3128457,S78,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,measurement—focal low attenuation in distribution indicating arterial ischaemic cause rather than traumatic contusional injury rated according to validated scale for ischaemic stroke,"['C0475224', 'C4698491', 'C0521125', 'C0871208', 'C1524003', 'C4321252', 'C0349674', 'C1704711', 'C0332663', 'C0599946', 'C0015127', 'C0680240', 'C3263723', 'C4321351', 'C3890211', 'C4522223', 'C4048187', 'C0175659', 'C0205251', 'C1947916', 'C0520511', 'C0003842', 'C1550472', 'C0221464']","['Etiology aspects', 'low confidentiality', 'Ischemic', 'low exposure', 'Low Mitosis-Karyorrhexis Index', 'Arterial', 'Science of Etiology', 'Rating (action)', 'Distributing', 'traumatic', 'Scaling', 'Arteries', 'IPSS Risk Category Low', 'Intellectual scale', 'Traumatic injury', 'WWOX wt Allele', 'Preposition For', 'Agreement', 'Rather', 'Low Level', 'low', 'Attenuation', 'Distribution', 'Weight measurement scales']","['cnce', 'fndg', 'gngm', 'idcn', 'medd', 'inpr', 'qnco', 'qlco', 'inpo', 'spco', 'socb', 'ftcn', 'bpoc', 'acty']"
555,PMC3128457,S80,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"measurement—(1) sulcal effacement, (2) ventricular effacement, (3) uncal herniation, (4) cisterns compressed, (5) cisterns absent, (6) midline shift (in mm)","['C0552443', 'C0332197', 'C1660780', 'C0549183', 'C1185718', 'C1522565', 'C4285062', 'C0018827', 'C0393985', 'C0332260']","['Absent', 'Pharyngeal Stripping Wave Absent', 'Compressing (action)', 'Cistern', 'Heart Ventricle', 'Midline (qualifier value)', 'midline cell component', 'uncal herniation', 'Ventricular', 'effacement']","['fndg', 'celc', 'spco', 'bsoj', 'ftcn', 'acab', 'bpoc', 'clna']"
556,PMC3128457,S81,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"the primary outcome was total haemorrhage growth, defined as the difference in the combined volume (ml) of all intracranial haemorrhagic lesions (intra-parenchymal haematoma + haemorrhagic contusion + subdural haematoma + epidural haematoma) from the first to the second scan.","['C1561503', 'C1621966', 'C0205225', 'C1279901', 'C0333275', 'C0441633', 'C0018270', 'C0018944', 'C2826292', 'C0205195', 'C0524466', 'C2911660', 'C0205435', 'C2700258', 'C1705102', 'C0205436', 'C0009938', 'C0457385', 'C1705190', 'C0347985', 'C0220844', 'C0444868', 'C1517320', 'C0238154', 'C0232100', 'C0449468', 'C0018946', 'C0034606', 'C0221198', 'C0025320', 'C1274040']","['Volume', 'growth aspects', 'Hematoma, Subdural', 'Lesion', 'From', 'Volume (publication)', 'intra', 'Tissue Growth', 'Firstly', 'First (number)', 'Contusions', 'Volume Measurement', 'Growth', 'second (number)', 'Precision - second', 'Result', 'Exsanguination', 'Hemorrhagic', 'All', 'Menopause', 'Radionuclide Imaging', 'Growth action', 'Second Suffix', 'seconds', 'Primary', 'Intracranial', 'Scanning', 'Combined', 'Hematoma', 'Hematoma, Epidural, Cranial', 'Related to Cancer']","['tmco', 'blor', 'ortf', 'fndg', 'idcn', 'phsf', 'inpr', 'qlco', 'phpr', 'qnco', 'inpo', 'lbpr', 'orgf', 'ftcn', 'diap', 'patf']"
557,PMC3128457,S82,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"secondary outcomes were (a) significant haemorrhage growth defined as an increase by ≥25% of total haemorrhage in relation to its initial volume, (b) new intracranial haemorrhage (apparent on the second scan but not apparent on the first), (c) change in subarachnoid haemorrhage grade, (d) mass effect, and (e) new focal cerebral ischaemic lesions (apparent on the second scan but not the first).","['C0475224', 'C1705241', 'C1561503', 'C1621966', 'C1279901', 'C0205234', 'C0441633', 'C0018270', 'C0750502', 'C0392747', 'C2826292', 'C0038525', 'C0443172', 'C0869014', 'C2911660', 'C0205435', 'C0019080', 'C0919553', 'C0205436', 'C0151699', 'C0457385', 'C0205314', 'C0442805', 'C1705190', 'C1704788', 'C1551352', 'C0175668', 'C0750489', 'C4319952', 'C0220844', 'C0027627', 'C3244287', 'C1518422', 'C4086564', 'C0232100', 'C1515981', 'C0233535', 'C0034606', 'C0441800', 'C1546944', 'C0221198', 'C0080103', 'C0237881']","['Ischemic', 'apparent', 'Mass Effect', 'growth aspects', 'And', 'Lesion', 'Initial Volume', 'Definition', 'Histopathologic Grade', 'Tissue Growth', 'Firstly', 'School Grade', 'First (number)', 'second (number)', 'Growth', 'Changed status', 'Precision - second', 'butting', 'Exsanguination', 'Increase', 'Intracranial Hemorrhage', 'Subarachnoid Hemorrhage', 'Neoplasm Metastasis', 'Changing', 'Radionuclide Imaging', 'Growth action', 'Statistical Significance', 'Relative (related person)', 'Change -- procedure', 'Event Seriousness - Significant', 'Second Suffix', 'Negation', 'Significant', 'seconds', 'Grade', 'Focal', 'Relations', 'Secondary to', 'New', 'Scanning', 'Hemorrhage', 'Related to Cancer', 'Delta (difference)']","['topp', 'qnco', 'phpr', 'patf', 'ortf', 'fndg', 'idcn', 'clas', 'phsf', 'inpr', 'qlco', 'socb', 'ftcn', 'tmco', 'mobd', 'spco', 'neop', 'famg', 'dsyn', 'orgf', 'diap']"
558,PMC3128457,S83,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"the clinical outcomes were death from any cause, dependency, and the need for neurosurgical intervention.","['C3272371', 'C0027552', 'C0011065', 'C0686904', 'C1306577', 'C1552551', 'C1515981', 'C0011546', 'C0015127', 'C0205210', 'C0524850', 'C1546937', 'C1524003']","['Death (finding)', 'Event Qualification - Dependency', 'Clinical', 'Etiology aspects', 'Needs', 'Neurosurgical Procedures', 'Patient need for (contextual qualifier)', 'And', 'Any', 'Any Data Type', 'emotional dependency', 'Science of Etiology', 'Cessation of life']","['fndg', 'idcn', 'topp', 'inpr', 'qlco', 'orgf', 'ftcn', 'menp', 'cnce']"
559,PMC3128457,S84,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"clinical outcomes were recorded at hospital discharge, at 28 days after randomisation, or death, whichever occurred first.","['C0205435', 'C0011065', 'C1279901', 'C0586003', 'C1306577', 'C0205210', 'C0439228']","['Death (finding)', 'Clinical', 'Firstly', 'day', 'First (number)', 'Cessation of life', 'Discharge from hospital']","['tmco', 'fndg', 'hlca', 'qlco', 'qnco', 'orgf']"
560,PMC3128457,S85,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,dependency was measured using the five point modified oxford handicap scale (mohs).17,"['C0175659', 'C0349674', 'C1552961', 'C0205451', 'C0231172', 'C0011546', 'C2347617', 'C1947916', 'C1546937', 'C3714763']","['point - UnitsOfMeasure', 'Event Qualification - Dependency', 'Scaling', 'Point', 'handicapping condition', 'Point Name', 'Five', 'emotional dependency', 'Weight measurement scales', 'Intellectual scale']","['fndg', 'medd', 'idcn', 'inpr', 'qnco', 'spco', 'menp', 'acty']"
561,PMC3128457,S86,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"we dichotomised the scale into “dependent” (fully dependent requiring attention day and night, or dependent but not requiring constant attention) or “independent” (some restriction in lifestyle but independent, minor symptoms, or no symptoms).","['C0240526', 'C0026193', 'C0349674', 'C0205165', 'C0443288', 'C0332173', 'C0085862', 'C0231221', 'C0851827', 'C0439228', 'C0004268', 'C0023676', 'C4281780', 'C0175659', 'C1518422', 'C0429986', 'C1457887', 'C1948059', 'C4321395', 'C3244310', 'C0205392', 'C1515981', 'C0683368', 'C0233535', 'C1701901', 'C1290940', 'C1299583', 'C1947916', 'C0429964']","['Restricted', 'Symptoms', 'And', 'Independent for Transfer', 'Independence', 'Attention', 'Scaling', 'Life Style', 'Minor (value)', 'Conditional', 'dependent', 'Intellectual scale', 'butting', 'Minor (person)', 'Dependent for dressing', 'Symptoms aspect', 'Independently able', 'Daily', 'Some (qualifier value)', 'symptomless', 'Negation', 'Dependent for bathing', 'Dependent for Toilet Use', 'Attention G-code', 'day', 'Constant (qualifier)', 'Weight measurement scales', 'Dependent - ability', 'Night time']","['tmco', 'fndg', 'medd', 'idcn', 'inpr', 'sosy', 'qlco', 'qnco', 'mobd', 'socb', 'ftcn', 'popg', 'menp', 'acty']"
562,PMC3128457,S87,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"we also reported a “composite poor outcome” defined as a patient who developed one or more of the following during the follow-up period—significant haemorrhage growth, new intracranial haemorrhage, new focal cerebral ischaemic lesions, the need for neurosurgery, or death.","['C0475224', 'C0332282', 'C0205447', 'C1621966', 'C0011065', 'C3274571', 'C1306577', 'C0205234', 'C0018270', 'C0032854', 'C0521125', 'C0524850', 'C4321252', 'C2911660', 'C3272598', 'C0589120', 'C0019080', 'C0027926', 'C0686904', 'C0030705', 'C0151699', 'C0205172', 'C0205314', 'C1704788', 'C0347984', 'C1522577', 'C0220844', 'C0027552', 'C1704685', 'C2700379', 'C0221198']","['Science of neurosurgery', 'Neurosurgical Procedures', 'Ischemic', 'growth aspects', 'Lesion', 'Definition', 'Follow-up status', 'Tissue Growth', 'Following', 'Patient need for (contextual qualifier)', 'Poor - qualifier', 'Growth', 'Cessation of life', 'Clinical Study Follow-up', 'Intracranial Hemorrhage', 'Needs', 'More', 'Growth action', 'WWOX wt Allele', 'Patients', 'During', 'One', 'Preposition For', 'follow-up', 'Death (finding)', 'Focal', 'Follow-Up Report', 'Poverty', 'WHO Temperature/Humidity Storage Condition', 'New', 'Hemorrhage']","['tmco', 'fndg', 'ortf', 'gngm', 'topp', 'hlca', 'phsf', 'inpr', 'qlco', 'phpr', 'bmod', 'qnco', 'grpa', 'orgf', 'spco', 'podg', 'ftcn', 'patf']"
563,PMC3128457,S88,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"adverse events that were serious, unexpected, and suspected to be related to the study treatment were reported separately.","['C4055646', 'C1521826', 'C1705413', 'C0205404', 'C0877248']","['Adverse event', 'Protocol Agent', 'Adverse Event Domain', 'Unexpected', 'Serious']","['qlco', 'inpr', 'patf']"
564,PMC3128457,S90,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size,"assuming an initial intracranial haemorrhage volume of 20 ml, an average haemorrhage growth of 7 ml in the control group and a correlation of 0.6 between initial and follow-up volumes, we estimated that a trial with 300 patients would have 80% power (α=0.05) to detect a 35% reduction in haemorrhage growth.","['C0205265', 'C2825518', 'C1621966', 'C1279901', 'C3274571', 'C0018270', 'C0392756', 'C3539897', 'C0442726', 'C3154893', 'C2911660', 'C1555582', 'C0205103', 'C1293152', 'C0019080', 'C0589120', 'C2700258', 'C1705102', 'C0030705', 'C0750572', 'C0151699', 'C0032863', 'C0332287', 'C1510992', 'C3854080', 'C4551656', 'C1705685', 'C1707520', 'C1522577', 'C0220844', 'C0301630', 'C0009932', 'C1704685', 'C0449468', 'C1515981', 'C3891454', 'C0008976']","['Estimated', 'In addition to', 'Volume', 'Clinical Trials', 'growth aspects', 'Surgical reduction', 'And', 'Power', 'Detected (finding)', 'Volume (publication)', 'Follow-up status', 'Tissue Growth', 'Firstly', 'Reduction (chemical)', 'Volume Measurement', 'Growth', 'Dosing Days to Detection', 'Control Groups', 'Possess', 'Clinical Study Follow-up', 'Intracranial Hemorrhage', 'Initially', 'Correlation', 'Reduced', 'Reduction procedure', 'Average', 'Growth action', 'Initial (abbreviation)', 'Initial Usage', 'Patients', 'Intermediate', 'follow-up', 'Power (Psychology)', 'Follow-Up Report', 'Have', 'Hemorrhage', 'Average of Value Derivation Technique']","['topp', 'qnco', 'phpr', 'podg', 'patf', 'ortf', 'fndg', 'npop', 'idcn', 'hlca', 'phsf', 'inpr', 'qlco', 'lbpr', 'resa', 'hcpp', 'ftcn', 'tmco', 'spco', 'grup', 'orgf']"
565,PMC3128457,S91,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size,"we pre-specified in the protocol that, as this study was nested within the main crash-2 trial, even if the planned sample size of 300 patients was not achieved, recruitment would stop at the same time as the main crash-2 trial.","['C0205225', 'C1565156', 'C2348563', 'C2949735', 'C0332152', 'C3715209', 'C4282383', 'C1542147', 'C0030705', 'C1522729', 'C2599718', 'C0332285', 'C0445247', 'C1421478', 'C0043194', 'C0740175', 'C2257086', 'C0442711', 'C4528313', 'C2603343', 'C1518422', 'C1080058', 'C0040223', 'C1507394', 'C1947925', 'C0008976']","['Clinical Trials', 'Study', 'photoreactivating enzyme activity', 'Clinical trial protocol', 'Recruitment', 'Same', 'Protocols documentation', 'Main', 'REMS Protocol', 'Within', 'Time', 'Before', 'Wiskott-Aldrich Syndrome', 'Library Protocol', 'WAS gene', 'Patients', 'Negation', 'Primary', 'Clinical trial protocol document', 'WAS protein, human', 'Target Sample Size', 'Study Protocol', 'Before values', 'This (eukaryote)', 'Protocol - answer to question', 'Stop (Instruction Imperative)']","['tmco', 'fndg', 'gngm', 'inpr', 'genf', 'qlco', 'bacs', 'qnco', 'dsyn', 'ftcn', 'resa', 'podg', ' aapp', 'euka', 'spco', 'acty']"
566,PMC3128457,S93,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation,"after eligibility had been confirmed and the locally approved consent procedures had been completed, patients were randomly assigned.","['C2700391', 'C1511481', 'C2923685', 'C0030705', 'C0025664', 'C0205540', 'C3538935', 'C0013893', 'C1517927', 'C1554192', 'C1548635', 'C0184661']","['Consent:Finding:Point in time:{Setting}:Document:Patient', 'Eligibility Determination', 'Procedure (set of actions)', 'Approved', 'Procedure Domain', 'Consent', 'Patients', 'Interventional procedure', 'Methods aspects', 'ActClass - consent', 'Locally', 'Eligible']","['topp', 'idcn', 'hlca', 'inpr', 'qlco', 'spco', 'podg', 'ftcn', 'clna']"
567,PMC3128457,S94,['8b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0]",Randomisation,"randomisation was balanced by centre, with an allocation sequence based on a block size of eight.","['C0456389', 'C0205454', 'C1706778', 'C2828370', 'C0162326', 'C3853789', 'C0028778', 'C0004793', 'C1519249', 'C0162327', 'C1706084', 'C1533157', 'C0332206', 'C0205099']","['Block Specimens', 'DNA Sequence', 'Sequence - TransmissionRelationshipTypeCode', 'Sequence', 'Obstruction', 'Block (unit of measure)', 'Eight', 'RNA Sequence', 'Base Sequence', 'size', 'Central', 'Blocking', 'Allocation', '(City) Block']","['nusq', 'inpr', 'geoa', 'qnco', 'spco', 'ftcn', 'acty', 'patf', 'bdsu']"
568,PMC3128457,S95,['8a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0]",Randomisation,we used a local pack system that selected the lowest numbered treatment pack from a box containing eight numbered packs.,"['C0205454', 'C1707391', 'C0087111', 'C3888058', 'C1968515', 'C0205276', 'C0449913', 'C2828395', 'C1522326', 'C1705169', 'C0449788', 'C0039798', 'C2825051', 'C3538994', 'C1708760', 'C1553451', 'C3887704', 'C0179400', 'C1517320', 'C1533734']","['System - kit', 'System', 'Pack (physical object)', 'treatment - ActInformationManagementReason', 'Device system', 'Treating', 'Box', 'Count of entities', 'Treatment Epoch', 'therapeutic aspects', 'Local', 'From', 'Pack unit', 'Packing (action)', 'Eight', 'Biomaterial Treatment', 'Administration procedure', 'Choose (action)', 'Lowest', 'Therapeutic procedure']","['mnob', 'medd', 'topp', 'hlca', 'drdd', 'qnco', 'qlco', 'spco', 'resa', 'ftcn', 'acty', 'cnce']"
569,PMC3128457,S96,['9'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1]",Randomisation,"apart from the pack number, the treatment packs were identical.","['C0087111', 'C1522326', 'C1968515', 'C0237753', 'C2828395', 'C3887704', 'C1705169', 'C0449788', 'C0205280', 'C2825051', 'C3538994', 'C0039798', 'C1533734']","['identical', 'Pack (physical object)', 'treatment - ActInformationManagementReason', 'Treating', 'Count of entities', 'Treatment Epoch', 'therapeutic aspects', 'Pack unit', 'Packing (action)', 'Therapeutic procedure', 'Biomaterial Treatment', 'Administration procedure', 'Numbers']","['medd', 'topp', 'hlca', 'qnco', 'drdd', 'qlco', 'resa', 'ftcn', 'acty', 'cnce']"
570,PMC3128457,S97,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation,"the pack number was recorded on the entry form, which was sent to the international trial coordinating centre in london, uk.","['C0348078', 'C4255237', 'C1512888', 'C1968515', 'C0237753', 'C0700114', 'C2828395', 'C0449788', 'C1421478', 'C0023973', 'C0376315', 'C2825051', 'C1522492', 'C1565156', 'C1519246', 'C0043194', 'C0008976', 'C0427184', 'C0205099', 'C1705654']","['Formation', 'Entry (data)', 'Pack (physical object)', 'Send (transmission)', 'Qualitative form', 'Clinical Trials', 'WAS protein, human', 'No incoordination', 'WAS gene', 'Count of entities', 'Coordinated', 'Pack unit', 'Packing (action)', 'Form:Finding:Point in time:{Setting}:Document:{Role}', 'Central', 'Wiskott-Aldrich Syndrome', 'Manufactured form', 'International', 'London', 'Numbers']","['acty', 'fndg', 'medd', 'idcn', 'gngm', 'inpr', 'geoa', 'qlco', 'qnco', 'drdd', 'bacs', 'dsyn', 'spco', 'resa', 'ftcn', 'mnob', ' aapp', 'clna']"
571,PMC3128457,S98,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation,"once the treatment pack number was recorded, the patient was included in the trial whether or not the treatment pack was opened or the allocated treatment started.","['C0087111', 'C1518422', 'C1968515', 'C1522326', 'C0237753', 'C2828395', 'C3887704', 'C1705169', 'C1948045', 'C0043194', 'C1421478', 'C1565156', 'C0030705', 'C0449788', 'C2825051', 'C0332257', 'C3538994', 'C0039798', 'C0008976', 'C1533734']","['Once (schedule frequency)', 'Pack (physical object)', 'treatment - ActInformationManagementReason', 'WAS protein, human', 'Clinical Trials', 'Treating', 'WAS gene', 'Count of entities', 'Treatment Epoch', 'therapeutic aspects', 'Patients', 'Numbers', 'Including (qualifier)', 'Pack unit', 'Biomaterial Treatment', 'Packing (action)', 'Therapeutic procedure', 'Administration procedure', 'Negation', 'Wiskott-Aldrich Syndrome']","['tmco', 'gngm', 'topp', 'medd', 'hlca', 'qnco', 'bacs', 'drdd', 'dsyn', 'ftcn', 'resa', 'podg', ' aapp', 'acty', 'cnce']"
572,PMC3128457,S99,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation,all site investigators and trial coordinating centre staff were masked to treatment allocation.,"['C0851286', 'C1515974', 'C1706778', 'C1947908', 'C2825164', 'C0087111', 'C1522326', 'C0205145', 'C0700114', 'C3887704', 'C1705169', 'C0205099', 'C3538994', 'C0039798', 'C1515981', 'C0008976', 'C0427184', 'C0444868', 'C1533734', 'C0035173']","['Allocation', 'All', 'treatment - ActInformationManagementReason', 'Clinical Trials', 'Treating', 'No incoordination', 'Research Personnel', 'Treatment Epoch', 'And', 'therapeutic aspects', 'Staff', 'Coordinated', 'Anatomic Site', 'Biomaterial Treatment', 'Central', 'Site', 'Study Site', 'Administration procedure', 'On Staff', 'Therapeutic procedure']","['blor', 'fndg', 'prog', 'topp', 'idcn', 'hlca', 'qnco', 'spco', 'resa', 'ftcn', 'cnce', 'acty']"
573,PMC3242163,S32,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients and randomisation,details of hps have been reported previously.1–3,"['C1522508', 'C0242994']","['Hantavirus Infections', 'Details']","['dsyn', 'qlco']"
574,PMC3242163,S33,"['4a', '5', '3a']","[0, 0, 0, 0, 0, 0, 1, 0, 1, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Patients and randomisation,"briefly, between july, 1994, and may, 1997, 20 536 men and women aged about 40–80 years, who were at increased risk of vascular events, were randomly allocated to receive 40 mg simvastatin daily or matching placebo.","['C1801960', 'C1515981', 'C0332232', 'C1708943', 'C0005847', 'C0074554', 'C1558950', 'C1999167', 'C0043210', 'C1696465', 'C0441471', 'C3829447', 'C0150103', 'C3541888', 'C0332173', 'C0025266', 'C0439234', 'C0032042', 'C1706408', 'C3812381', 'C4699158', 'C3272598', 'C0001779', 'C0001792']","['Woman', 'Old age', 'CDISC Events Class', 'And', 'Elderly (population group)', 'placebo', 'Adverse Event Associated with Vascular', 'Simvastatin', 'Match', 'Placebos', 'Age', 'July', 'Event', 'Blood Vessel', 'Month of May', 'WHO Temperature/Humidity Storage Condition', 'Daily', 'Increased risk', 'year', 'Vascular', 'Male population group', 'Placebo Control', 'approximately', 'MATCHING']","['bpoc', 'idcn', 'clas', 'topp', 'popg', 'fndg', 'orch', 'qlco', 'tmco', 'resa', ' phsu', 'bodm', 'orga', 'evnt']"
575,PMC3242163,S34,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Patients and randomisation,"at the final follow-up (may–october, 2001), participants were encouraged to continue their allocated study treatment (unless it was contraindicated) until the study results were sent to them and their family doctors on nov 11, 2001.","['C0679646', 'C1515981', 'C1522577', 'C1565156', 'C1704685', 'C1444657', 'C3853528', 'C3274571', 'C0043194', 'C1546485', 'C0949920', 'C0683954', 'C1720302', 'C0589120', 'C1521826', 'C1121443', 'C1519246', 'C1704221', 'C0549178', 'C1421478', 'C0205088']","['And', 'Physicians, Family', 'Until', 'Follow-up status', 'Clinical Study Follow-up', 'Send (transmission)', 'Final', 'Diagnosis Type - Final', 'WAS protein, human', 'WAS gene', 'research results', 'follow-up', 'Norovirus', 'End-stage', 'Contraindicated', 'NOV protein, human', 'Wiskott-Aldrich Syndrome', 'Continuous', 'Follow-Up Report', 'Protocol Agent', 'Participant']","['bacs', 'inpr', 'idcn', 'gngm', 'prog', 'popg', 'ftcn', 'fndg', 'qlco', 'tmco', 'virs', 'dsyn', 'hlca', ' aapp']"
576,PMC3242163,S35,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Patients and randomisation,"participants were advised to discuss with their doctors, in light of those results, whether non-trial statin treatment should be prescribed (and study treatment stopped).","['C1521826', 'C0679646', 'C4050248', 'C1881376', 'C3842678', 'C1705169', 'C3887704', 'C0087111', 'C0008976', 'C0039798', 'C0360714', 'C1570446', 'C0031831', 'C1522326', 'C1533734', 'C4521367', 'C1518422', 'C0023693', 'C3538994']","['TNFSF14 protein, human', 'Light', 'Treatment Epoch', 'Clinical Trials', 'Biomaterial Treatment', 'Protocol Agent', 'Treating', 'Administration procedure', 'Light (qualifier)', 'TNFSF14 wt Allele', 'Physicians', 'Borg Scale Rating of Perceived Exertion Score 11', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Light - subjective measurement', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors', 'Therapeutic procedure', 'Negation', 'Participant']","['bacs', 'inpr', 'gngm', 'prog', 'topp', 'popg', 'ftcn', 'fndg', 'cnce', 'qlco', 'orch', 'resa', ' phsu', 'hlca', ' aapp', 'npop']"
577,PMC3242163,S36,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients and randomisation,"to allow unbiased assessment of subsequent long-term effects, participants and their doctors were not made aware of their previously allocated study treatment unless there was a particular request to do so, and only 15% of participants were unblinded (18% simvastatin-allocated vs 13% placebo-allocated).","['C4553913', 'C0679646', 'C1261322', 'C1272683', 'C1515981', 'C0074554', 'C0205166', 'C1518422', 'C1706317', 'C1696465', 'C0031831', 'C0004448', 'C1705313', 'C1522634', 'C2826302', 'C0233324', 'C1280500', 'C1515273', 'C0332282', 'C0032042', 'C1521826', 'C1706408', 'C0205171', 'C1516048']","['Evaluation procedure', 'And', 'Term (temporal)', 'placebo', 'Request - action', 'Term (lexical)', 'Simvastatin', 'Long', 'Placebos', 'Term Birth', 'Following', 'Long Variable', 'Negation', 'Singular', 'Question (inquiry)', 'Placebo Control', 'Effect', 'Reported Term', 'Awareness', 'Physicians', 'Protocol Agent', 'Unblinding', 'Assessed', 'Participant']","['inpr', 'idcn', 'bodm', 'acty', 'prog', 'topp', 'popg', 'ftcn', 'orch', 'qlco', 'hlca', 'tmco', 'resa', ' phsu', 'menp', 'orgf', 'qnco']"
578,PMC3242163,S38,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures and follow-up,"during the in-trial treatment period, routine follow-up in study clinics was at 4, 8, and 12 months and then every 6 months.","['C0439231', 'C0442592', 'C1883708', 'C1705169', 'C1948053', 'C3538994', 'C0087111', 'C0439531', 'C0008976', 'C1515981', 'C3887704', 'C2603343', 'C1522326', 'C1533734', 'C0585339', 'C0039798', 'C0205547']","['Clinic', 'Routine', 'Treatment Epoch', 'Clinical Trials', 'Biomaterial Treatment', 'And', 'Every Six Months', 'Treating', 'Administration procedure', 'Study', 'month', 'per period (qualifier value)', 'therapeutic aspects', 'Period (temporal qualifier)', 'treatment - ActInformationManagementReason', 'Then', 'Therapeutic procedure']","['idcn', 'topp', 'ftcn', 'cnce', 'mnob', 'tmco', 'qlco', 'resa', 'hlca', ' hcro']"
579,PMC3242163,S39,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures and follow-up,"information was sought about any suspected heart attacks, strokes, vascular procedures, cancers, or other serious adverse events.","['C3538935', 'C0006826', 'C0750491', 'C0184661', 'C0027051', 'C0877248', 'C3272371', 'C0038454', 'C1801960', 'C1705413', 'C2700391', 'C0005847', 'C0025664', 'C1533716', 'C0205404', 'C1558950', 'C1552551']","['Procedure (set of actions)', 'Any', 'Myocardial Infarction', 'Any Data Type', 'Blood Vessel', 'Malignant Neoplasms', 'Adverse Event Domain', 'Cerebrovascular accident', 'Methods aspects', 'Adverse event', 'Suspected qualifier', 'Adverse Event Associated with Vascular', 'Information', 'Interventional procedure', 'Procedure Domain', 'Vascular', 'Serious']","['inpr', 'bpoc', 'idcn', 'topp', 'neop', 'ftcn', 'fndg', 'patf', 'qlco', 'dsyn']"
580,PMC3242163,S40,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures and follow-up,"participants unable or unwilling to attend were contacted by telephone, or follow-up was sought from their family doctors.","['C4048706', 'C0679646', 'C4321405', 'C1705541', 'C0039457', 'C1299582', 'C1704221', 'C1515258', 'C0566415']","['Unable to Do', 'Unable', 'Telephone', 'Telephone Device', 'Unable to Use Stairs', 'Physicians, Family', 'Telephone Number', 'Unable to feed self', 'Participant']","['inpr', 'prog', 'popg', 'mnob', 'fndg']"
581,PMC3242163,S41,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures and follow-up,"post-trial follow-up of serious adverse events was conducted by mailing questionnaires to all surviving participants in late november, 2001, and then annually until november, 2006, with a reminder mailed about 2 months later.","['C1442456', 'C0679646', 'C0877248', 'C0034394', 'C0205087', 'C3469826', 'C1883708', 'C1704687', 'C3828767', 'C1705413', 'C1706422', 'C1515981', 'C0008976', 'C0444868', 'C1709896', 'C0687676', 'C0205404', 'C0332181']","['2 Months', 'Post', 'Reminder', 'Serious', 'Post Device', 'Adverse Event Domain', 'All', 'Clinical Trials', 'And', 'Questionnaires', 'November', 'SLC35G1 gene', 'Adverse event', 'Then', 'Annual', 'Participant', 'Questionnaire Domain', 'Late']","['inpr', 'idcn', 'gngm', 'popg', 'mnob', 'patf', 'tmco', 'cnce', 'qlco', 'resa', 'qnco']"
582,PMC3242163,S42,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures and follow-up,follow-up of participants who did not complete questionnaires was sought from their family doctors.,"['C0679646', 'C0205197', 'C1704221', 'C3853530', 'C3272598', 'C1518422', 'C4283785']","['Complete', 'WHO Temperature/Humidity Storage Condition', 'Complete Pharyngeal Contraction', 'Physicians, Family', 'Data operation - complete', 'Negation', 'Participant']","['prog', 'popg', 'ftcn', 'fndg', 'qlco']"
583,PMC3242163,S43,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures and follow-up,"during both the in-trial and post-trial periods, information about the sites of registered cancers and certified causes of deaths was requested from uk national registries for all randomised patients.","['C0006826', 'C0030705', 'C1706086', 'C1514821', 'C0034975', 'C0007836', 'C3469826', 'C1314792', 'C3245503', 'C0008976', 'C1515981', 'C1704687', 'C0332232', 'C1533716', 'C0444868', 'C3245515', 'C0687676', 'C0015127', 'C0205145', 'C0011065']","['Registration', 'Post', 'Malignant Neoplasms', 'Cessation of life', 'approximately', 'Post Device', 'Clinical Trials', 'All', 'And', 'Both', 'Etiology aspects', 'Patients', 'Etiology', 'SLC35G1 gene', 'Site', 'National citizen', 'Registries domain', 'Information', 'Certification', 'Registries']","['inpr', 'idcn', 'gngm', 'neop', 'popg', 'ftcn', 'mnob', 'orgf', 'podg', 'qlco', 'tmco', 'resa', 'spco', 'hlca', 'gora', 'qnco']"
584,PMC3242163,S44,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures and follow-up,"further details were sought from the participants' family doctors (plus, if necessary, hospital records) about all reports that might relate to major vascular events or deaths.","['C3541888', 'C0684224', 'C0205164', 'C0679646', 'C0441471', 'C1801960', 'C1704221', 'C4318856', 'C0019980', 'C3889645', 'C0005847', 'C1522508', 'C0444868', 'C1517331', 'C1558950', 'C0700287', 'C0011065']","['Further', 'Blood Vessel', 'Report (document)', 'CDISC Events Class', 'Cessation of life', 'Reporting', 'Major', 'All', 'Hospital Records', 'Major <insect>', 'Physicians, Family', 'Participant', 'Adverse Event Associated with Vascular', 'Clinical Trial Final Report', 'Details', 'Vascular', 'Event']","['inpr', 'bpoc', ' mnob', 'clas', 'prog', 'popg', 'fndg', 'spco', 'qlco', 'euka', 'hlca', 'orgf', 'qnco', 'evnt']"
585,PMC3242163,S45,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures and follow-up,"in view of the high confirmation rate (>95%) in central adjudication of cancers reported during the in-trial period, further information was not routinely sought about non-fatal cancers reported during the post-trial period.","['C0006826', 'C0684224', 'C0750484', 'C4522209', 'C1299351', 'C0205250', 'C1704687', 'C3469826', 'C0332232', 'C1533716', 'C1565156', 'C1705232', 'C0347984', 'C0205099', 'C1518422', 'C3889660', 'C0449911', 'C4321237', 'C1517331', 'C0043194', 'C3887512', 'C1302234', 'C0871208', 'C0700287', 'C0680730', 'C0521091', 'C2347804', 'C2700149', 'C4319718', 'C1421478', 'C0687676', 'C1521828']","['Malignant Neoplasms', 'Reporting', 'Post Device', 'Rating (action)', 'Abnormally high', 'High Level', 'Reported', 'high - ActExposureLevelCode', 'approximately', 'Fatal', 'WAS protein, human', 'WAS gene', 'Adjudication', 'Central', 'SLC35G1 gene', 'Negation', 'High Mitosis-Karyorrhexis Index', 'Value Above Reference Range', 'Clinical Trial Period', 'Death Related to Adverse Event', 'IPSS Risk Category High', 'Confirmation', 'During', 'Further', 'Post', 'High', 'Report (document)', 'Rate', 'view', 'Wiskott-Aldrich Syndrome', 'Confirmation of', 'Information']","['bacs', 'inpr', 'idcn', 'acty', 'gngm', 'neop', 'ftcn', 'spco', 'fndg', 'tmco', 'qlco', 'mnob', 'resa', 'hlca', ' aapp', 'gora', 'qnco', 'dsyn']"
586,PMC3242163,S46,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures and follow-up,"events were coded according to prespecified criteria1 by clinical staff in the coordinating centre, who were unaware of the study treatment allocation.","['C1521826', 'C3541888', 'C1706778', 'C0427184', 'C0441471', 'C0205210', 'C0851286', 'C1947908', 'C0150114', 'C3272598', 'C0205099', 'C0700114']","['Clinical', 'CDISC Events Class', 'WHO Temperature/Humidity Storage Condition', 'Coordinated', 'Protocol Agent', 'No incoordination', 'unaware', 'Staff', 'Allocation', 'Central', 'On Staff', 'Event']","['inpr', 'acty', 'clas', 'prog', 'ftcn', 'spco', 'fndg', 'qlco', 'resa', 'evnt']"
587,PMC3242163,S47,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures and follow-up,"during the in-trial period, compliance with study treatment was assessed at each follow-up by questioning the participant and reviewing their remaining calendar-packed tablets.","['C0679646', 'C0039225', 'C0009563', 'C1515981', 'C3714738', 'C1522577', 'C1565156', 'C0876928', 'C3244300', 'C1704685', 'C1527428', 'C1516147', 'C0184967', 'C3274571', 'C0043194', 'C1704362', 'C2698741', 'C0332287', 'C4554048', 'C1457900', 'C0282443', 'C0589120', 'C1521826', 'C1321605', 'C2825051', 'C2347804', 'C1421478', 'C1516048']","['Compliance', 'Study Participant', 'Reviewing', 'And', 'Compliance behavior', 'Follow-up status', 'Clinical Study Follow-up', 'WAS protein, human', 'Operational Compliance', 'WAS gene', 'Each (qualifier value)', 'Biomechanical compliance', 'Remaining', 'follow-up', 'Clinical Trial Period', 'questioning', 'Insertion of pack (procedure)', 'Pack unit', 'In addition to', 'Calendar', 'Review [Publication Type]', 'Wiskott-Aldrich Syndrome', 'Follow-Up Report', 'Participant Object', 'Tablet Dosage Form', 'Protocol Agent', 'Assessed', 'Participant']","['bacs', 'inbe', 'topp', 'fndg', 'qlco', 'hlca', 'drdd', 'inpr', 'idcn', 'gngm', 'clas', 'resa', ' aapp', 'bodm', 'popg', 'ftcn', 'tmco', 'dsyn', 'menp', 'acty', 'qnco']"
588,PMC3242163,S48,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures and follow-up,"the effects of treatment allocation on cholesterol concentrations were assessed by assaying blood obtained at study clinics from a sample of about 5% of participants scheduled for follow-up at about the same time each year, and from all participants attending follow-up between august, 2000, and february, 2001.2","['C0086045', 'C0679646', 'C0008377', 'C3887704', 'C1705169', 'C1515981', 'C0332232', 'C0332283', 'C2603343', 'C0039798', 'C3538994', 'C0442592', 'C1457900', 'C0229664', 'C1280500', 'C3831448', 'C4281991', 'C0439234', 'C1706778', 'C3830166', 'C0445247', 'C0005767', 'C0040223', 'C0087111', 'C1522326', 'C1533734', 'C0005768', 'C0444868', 'C0370003', 'C2347026']","['Biospecimen', 'August', 'Followed by', 'In Blood', 'Biomaterial Treatment', 'And', 'Time', 'Therapeutic procedure', 'Clinic', 'Blood', 'Administration procedure', 'Each (qualifier value)', 'Treatment Epoch', 'All', 'Mental concentration', 'Same', 'Study', 'Allocation', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'year', 'Cholesterol', 'Specimen', 'Effect', 'Follow', 'February', 'Treating', 'approximately', 'peripheral blood', 'Participant']","['bacs', ' orch', 'sbst', 'idcn', 'acty', 'topp', 'popg', 'ftcn', 'cnce', 'mnob', 'bdsu', 'tmco', 'qlco', 'resa', 'hlca', 'menp', ' hcro', 'qnco']"
589,PMC3242163,S49,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures and follow-up,"during the post-trial period, participants were asked each year about their current statin use, and post-trial lipid profile assays were sought from 1500 randomly selected surviving participants between may, 2004, and august, 2004 (ie, about 3 years after the scheduled treatment period).","['C0679646', 'C1979963', 'C0086960', 'C3887704', 'C1705169', 'C3469826', 'C1948053', 'C1704687', 'C1515981', 'C0332232', 'C0008976', 'C0042153', 'C0023779', 'C0521116', 'C2003903', 'C0439531', 'C0360714', 'C0205539', 'C0039798', 'C3538994', 'C1707391', 'C1457900', 'C3831448', 'C0439234', 'C1705970', 'C1517320', 'C3812381', 'C0087111', 'C0457083', 'C2347804', 'C1533734', 'C0205103', 'C1522326', 'C0687676', 'C0231290']","['Electrical Current', 'Status post', 'August', 'Post Device', 'Biomaterial Treatment', 'And', 'From', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors', 'Therapeutic procedure', 'Usage', 'Lipids', 'Clinical Trials', 'Administration procedure', 'Choose (action)', 'Current (present time)', 'SLC35G1 gene', 'Each (qualifier value)', 'Intermediate', 'Profile (lab procedure)', 'Treatment Epoch', 'Month of May', 'Clinical Trial Period', 'per period (qualifier value)', 'therapeutic aspects', 'Period (temporal qualifier)', 'treatment - ActInformationManagementReason', 'Profiling (action)', 'year', 'Scheduled - procedure status', 'Post', 'Schedule (document type)', 'utilization qualifier', 'Treating', 'approximately', 'Participant']","['inpr', 'idcn', 'acty', 'gngm', 'lbpr', 'topp', 'popg', 'ftcn', 'mnob', 'cnce', 'tmco', 'qlco', 'orch', 'resa', 'spco', ' phsu', 'hlca', 'npop', 'qnco']"
590,PMC3242163,S50,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures and follow-up,about 1100 blood samples were obtained by participants' family doctors and were mailed to a central laboratory for assay using previously validated methods.15,"['C0178913', 'C0679646', 'C0243073', 'C0449851', 'C1880016', 'C1510438', 'C1515981', 'C1704221', 'C0332232', 'C0025664', 'C0025663', 'C0005507']","['Assay', 'Central Laboratory', 'assay qualifier', 'Biological Assay', 'Techniques', 'Methods', 'And', 'Methods aspects', 'Blood specimen', 'Physicians, Family', 'approximately', 'Participant']","['inpr', 'idcn', 'lbpr', 'prog', 'popg', 'ftcn', 'bdsu', 'qlco', 'orgt']"
591,PMC3242163,S52,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Endpoints and statistical analysis,"the main comparisons entail log-rank analyses of the first post-randomisation occurrence of particular events during the in-trial period (defined as events occurring up to nov 11, 2001) and during the post-trial period (defined as events occurring from nov 11, 2001, until march 31, 2007) among all those originally allocated 40 mg simvastatin daily versus all those allocated matching placebo tablets (ie, intention-to-treat analyses).","['C3829202', 'C0039225', 'C1292734', 'C3469826', 'C1704687', 'C1542147', 'C1515981', 'C0243132', 'C1708943', 'C0074554', 'C1704788', 'C1554210', 'C0347984', 'C2745955', 'C0699794', 'C1856053', 'C0162425', 'C1696465', 'C0441471', 'C0150103', 'C0949920', 'C3541888', 'C1283828', 'C0667477', 'C0332173', 'C0205225', 'C1720302', 'C0032042', 'C1517320', 'C1121443', 'C1706408', 'C2986775', 'C0087111', 'C1279901', 'C0547043', 'C2347804', 'C0444868', 'C1522326', 'C0687676', 'C1708728', 'C0205435']","['TNFRSF11A protein, human', 'CDISC Events Class', 'Firstly', 'Post Device', 'Event Log', 'And', 'First (number)', 'From', 'placebo', 'Until', 'Therapeutic procedure', 'Main', 'Simvastatin', 'March (month)', 'Match', 'Placebos', 'Rank', 'Logarithm', 'SLC35G1 gene', 'Treatment intent', 'Occurrence', 'Hydranencephaly with Renal Aplasia-Dysplasia', 'Intention - mental process', 'Event', 'Up', 'intent', 'All', 'Clinical Trial Period', 'Daily', 'occurrence characteristics', 'Primary', 'Norovirus', 'During', 'Placebo Control', 'Post', 'Act Relationship Type - occurrence', 'NOV protein, human', 'Definition', 'Treating', 'Tablet Dosage Form', 'MATCHING']","['bacs', 'topp', 'mnob', 'qlco', 'virs', ' phsu', 'inpr', 'idcn', 'gngm', 'clas', 'resa', ' aapp', 'bodm', 'ftcn', 'orch', 'tmco', 'dsyn', 'menp', 'spco', 'qnco', 'evnt']"
592,PMC3242163,S53,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Endpoints and statistical analysis,"the results of these in-trial analyses differ slightly from previously published findings2,3 because of the inclusion of events taking place between the participants' final follow-up visit and nov 11, 2001 (mean extra follow-up of 3·5 months [sd 1·4]).","['C0679646', 'C0039828', 'C0439231', 'C4321403', 'C0008976', 'C1515981', 'C0589121', 'C3853528', 'C0444504', 'C0441471', 'C0332283', 'C1883702', 'C1546485', 'C0750482', 'C1704324', 'C2347634', 'C0442504', 'C0949920', 'C3843225', 'C3541888', 'C0034037', 'C2937276', 'C4281991', 'C1882509', 'C1121443', 'C2348143', 'C1512693', 'C0007637', 'C0205103', 'C1533810', 'C0205088']","['Slightly Agree', 'Theses', 'CDISC Events Class', 'Followed by', 'Supernumerary', 'And', 'month', 'Sample Mean', 'Final', 'Diagnosis Type - Final', 'Clinical Trials', 'put - instruction imperative', 'follow-up visit', 'Slight (qualifier value)', 'Population Mean', 'Publishing', 'Placement action', 'Slightly Able', 'Event', 'Inclusion Bodies', 'Intermediate', 'Inclusion', 'Norovirus', 'End-stage', 'Follow', 'Slightly (qualifier value)', 'Statistical mean', 'NOV protein, human', 'Place', 'Scientific Publication', 'Participant']","['bacs', 'inpr', 'idcn', 'acty', 'clas', 'ocac', 'popg', 'ftcn', 'spco', 'celc', 'qlco', 'tmco', 'virs', 'resa', 'fndg', 'hlca', ' aapp', 'qnco', 'evnt']"
593,PMC3242163,S54,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Endpoints and statistical analysis,"the primary outcome for analyses of prolonged follow-up was prespecified to be the first post-randomisation major vascular event (defined as non-fatal myocardial infarction or coronary death, fatal or non-fatal stroke, coronary or non-coronary revascularisation).","['C0439590', 'C0687676', 'C0877341', 'C0376297', 'C3469826', 'C1801960', 'C1704687', 'C0005847', 'C4554100', 'C1705232', 'C1558950', 'C4019010', 'C1518422', 'C1274040', 'C0441471', 'C0018787', 'C0332283', 'C3810814', 'C4552959', 'C0205164', 'C0027051', 'C0038454', 'C1302234', 'C0205225', 'C4281991', 'C2926063', 'C1279901', 'C4318856', 'C0428953', 'C0205435']","['Myocardial Infarction ECG Assessment', 'Major', 'Myocardial Infarction', 'Stroke, CTCAE', 'Firstly', 'Followed by', 'Post Device', 'coronary revascularization', 'First (number)', 'Electrocardiogram: myocardial infarction (finding)', 'Adverse Event Associated with Vascular', 'Fatal', 'Cardiac Death', 'Heart', 'Cerebrovascular accident', 'SLC35G1 gene', 'Myocardial infarction:Finding:Point in time:^Patient:Ordinal', 'Myocardial Infarction, CTCAE', 'Negation', 'Event', 'Blood Vessel', 'Death Related to Adverse Event', 'Major <insect>', 'Vascular', 'Follow', 'Post', 'National reporting jurisdiction:Loc:Pt:^Event:Nom', 'Result', 'Prolonged', 'Primary']","['clna', 'bpoc', 'gngm', 'topp', 'lbtr', 'ftcn', 'fndg', 'patf', 'qlco', 'tmco', 'euka', 'mnob', 'dsyn', 'diap', 'qnco', 'evnt']"
594,PMC3242163,S55,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Endpoints and statistical analysis,"secondary outcomes were: major vascular events during each year of follow-up and in various subcategories of patients; major coronary events (ie, non-fatal myocardial infarction or coronary death), strokes, and revascularisations separately; deaths from vascular and non-vascular causes separately; and cancers at all sites (excluding non-melanoma skin cancer).","['C3540769', 'C0006826', 'C0205436', 'C0030705', 'C0376297', 'C1801960', 'C1515981', 'C0027627', 'C0005847', 'C1705232', 'C1558950', 'C0015127', 'C1518422', 'C3540765', 'C3540766', 'C0441471', 'C0007114', 'C0332283', 'C3540763', 'C3810814', 'C4552959', 'C0205164', 'C3541888', 'C0027051', 'C0038454', 'C1457900', 'C1302234', 'C1314792', 'C3540762', 'C2984289', 'C0011065', 'C4281991', 'C0439234', 'C3540761', 'C3540008', 'C0025202', 'C2926063', 'C1510853', 'C0741923', 'C4318856', 'C3539018', 'C0428953', 'C0175668']","['Myocardial Infarction ECG Assessment', 'Myocardial Infarction', 'Major', 'CDISC Events Class', 'Followed by', 'Malignant Neoplasms', 'various antiseptic throat preparations', 'And', 'various allergen extracts', 'Patients', 'Electrocardiogram: myocardial infarction (finding)', 'cardiac event', 'Secondary to', 'Malignant neoplasm of skin', 'Adverse Event Associated with Vascular', 'melanoma', 'NCI CTEP SDC Melanoma Sub-Category Terminology', 'Cardiac Death', 'Fatal', 'Cerebrovascular accident', 'various antiinfectives and antiseptics for local oral treatment', 'various other agents for local oral treatment in ATC', 'Etiology', 'Melanoma Pathway', 'Myocardial infarction:Finding:Point in time:^Patient:Ordinal', 'Each (qualifier value)', 'Myocardial Infarction, CTCAE', 'Negation', 'Event', 'VARIOUS DRUG CLASSES IN ATC', 'Blood Vessel', 'Cessation of life', 'Etiology aspects', 'Death Related to Adverse Event', 'Major <insect>', 'year', 'All Sites', 'Vascular', 'Follow', 'Neoplasm Metastasis', 'various other nasal preparations in ATC', 'second (number)', 'various other intestinal adsorbents in ATC']","['clna', 'neop', 'fndg', 'qlco', ' phsu', 'diap', 'phsu', 'inpr', 'bpoc', 'idcn', 'clas', 'lbtr', 'patf', 'imft', 'orgf', 'ftcn', 'podg', 'tmco', 'dsyn', 'spco', 'euka', 'qnco', 'evnt']"
595,PMC3242163,S56,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Endpoints and statistical analysis,"analyses are presented of other outcomes, some of which (eg, site-specific cancer, cerebral haemorrhage) were prespecified for the in-trial period whereas some were not (eg, cancer incidence each year).","['C0006826', 'C0521125', 'C0439234', 'C0021149', 'C0205392', 'C0205369', 'C1457900', 'C1518422', 'C0998265', 'C4321252', 'C2347804', 'C0205145', 'C2825164', 'C0220856', 'C1552740', 'C2937358', 'C1515974']","['Some (qualifier value)', 'incidence of cases', 'Malignant Neoplasms', 'Cancer Genus', 'Entity Determiner - specific', 'Specific qualifier value', 'Incidence', 'Anatomic Site', 'Clinical Trial Period', 'Site', 'Preposition For', 'Cerebral Hemorrhage', 'WWOX wt Allele', 'Study Site', 'Each (qualifier value)', 'year', 'Negation']","['inpr', 'gngm', 'neop', 'ftcn', 'blor', 'patf', 'qlco', 'euka', 'spco', 'resa', 'tmco', 'qnco']"
596,PMC3242163,S57,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Endpoints and statistical analysis,allowances for multiple comparisons and for the post-hoc nature of such analyses were made in their interpretation.,"['C0439064', 'C3469826', 'C1704687', 'C0556660', 'C0459471', 'C1262865', 'C0687676', 'C3173575', 'C0349590']","['Allowance', 'Post', 'Interpretation:Impression/interpretation of study:Point in time:^Patient:Nominal', 'Post Device', 'SLC35G1 gene', 'Interpretation Process', 'Natures', 'Numerous', 'Nature']","['inpr', 'clna', 'idcn', 'gngm', 'ftcn', 'mnob', 'tmco', 'qnco']"
597,PMC3242163,S59,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Role of the funding source,"the trial was designed, conducted, analysed, and interpreted by the investigators, independently of all funding sources.","['C0243098', 'C0008976', 'C0444868', 'C0376244', 'C0449416', 'C0035173']","['Funding', 'All', 'Clinical Trials', 'funding aspects', 'Research Personnel', 'Source']","['fndg', 'prog', 'qnco', 'resa']"
598,PMC3242163,S60,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Role of the funding source,the writing committee had full access to the study data and had final responsibility for the decision to submit for publication.,"['C0043266', 'C2584304', 'C1515981', 'C4321252', 'C3853528', 'C0681873', 'C0678341', 'C0443225', 'C1546485', 'C2699414', 'C4283917', 'C1704324', 'C0034037', 'C0679006', 'C4050126', 'C0444454', 'C0062074', 'C0521125', 'C3539897', 'C0034036', 'C1415458', 'C1554204', 'C0205088']","['Role Class - access', 'Writing (function)', 'And', 'Ability to Write question', 'Have', 'Preposition For', 'WWOX wt Allele', 'Writing Ability', 'HADH gene', 'Final', 'responsibility', 'Diagnosis Type - Final', 'Publishing', 'Committee', 'full', 'research data', 'Publications', 'End-stage', 'HAC protocol', 'Decision', 'Scientific Publication', 'Access', 'Writing (occupation or discipline)']","['inpr', 'grup', 'inbe', 'idcn', ' mnob', 'gngm', 'ocdi', 'ocac', 'topp', 'ftcn', 'spco', 'qlco', 'tmco', 'resa', 'menp']"
599,PMC3266479,S37,"['4b', '3a']","[0, 0, 0, 0, 0, 0, 1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and participants,"we undertook a multicentre, pragmatic, double-blind, placebo-controlled, parallel-group, randomised trial at 46 uk intensive-care units between december, 2006, and march, 2010.","['C3829202', 'C1705764', 'C0441833', 'C0687744', 'C0008976', 'C1515981', 'C4554418', 'C0525065', 'C1856053', 'C3853603', 'C1705765', 'C0439148', 'C3830550', 'C0456909', 'C0871858', 'C0205173', 'C1705429', 'C2348042', 'C2826345', 'C1519795', 'C1519504', 'C1706408', 'C1257890', 'C1947933', 'C0150108', 'C0205103', 'C1705428']","['And', 'Unit', 'Blinded', 'Unit of Measure', 'Stage Grouping', 'Visually Impaired Persons', 'Doubling', 'Duplicate', 'March (month)', 'Clinical Trials', 'User Group', 'Blindness', 'Group Object', 'Social group', 'Hydranencephaly with Renal Aplasia-Dysplasia', 'Parallel Study', 'Intermediate', 'December', 'pragmatics', 'Placebo Control', 'Parallel', 'Groups', 'Unit - NCI Thesaurus Property', 'Population Group', 'care activity', 'Double Value Type', 'Parallel Lesion']","['socb', 'idcn', 'acty', 'popg', 'ftcn', 'fndg', 'cnce', 'qlco', 'spco', 'tmco', 'resa', 'podg', 'dsyn', 'qnco']"
600,PMC3266479,S38,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and participants,eligible participants were intubated and mechanically ventilated adults aged 16 years and older within 72 h of ards onset.,"['C0001675', 'C0679646', 'C0332162', 'C1515981', 'C1548635', 'C0035222', 'C0206132', 'C0439234']","['Age of Onset', 'Respiratory Distress Syndrome, Adult', 'Eligible', 'Onset of (contextual qualifier)', 'And', 'Adult', 'year', 'Participant']","['idcn', 'aggp', 'popg', 'qlco', 'tmco', 'dsyn', 'qnco']"
601,PMC3266479,S39,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and participants,patients were identified and recruited by local investigators at each site.,"['C0030705', 'C1457900', 'C0205276', 'C0205145', 'C2825164', 'C0035173', 'C1515974']","['Local', 'Anatomic Site', 'Patients', 'Site', 'Research Personnel', 'Study Site', 'Each (qualifier value)']","['prog', 'blor', 'spco', 'podg', 'qnco']"
602,PMC3266479,S40,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and participants,"we defined ards in accordance with the american european consensus criteria:14 a pressure of arterial oxygen to fractional inspired oxygen concentration (pao2/fio2) ratio of 200 mm hg or less, bilateral pulmonary infiltrates consistent with oedema, and the absence of clinically evident left atrial hypertension.","['C1535514', 'C0033095', 'C1515981', 'C0456603', 'C0460139', 'C0332290', 'C0225860', 'C3897988', 'C0239307', 'C0003842', 'C0235896', 'C0013604', 'C0332197', 'C0428648', 'C0020538', 'C0547044', 'C1547037', 'C0030054', 'C0225861', 'C1963138', 'C0243161', 'C0376298', 'C0596070', 'C0221464', 'C0238767', 'C0439092']","['Arterial', 'Inspired oxygen concentration', 'Left auricular appendage', 'And', 'Edema', 'Consensus', 'Ratio', 'Hypertensive disease', 'Pressure- physical agent', 'European race', 'Left atrial structure', 'criteria', 'data type - ratio', 'Americas Ethnicity', 'Pressure (finding)', 'Smaller', 'Less Than', 'Absent', 'Hypertension, CTCAE', 'Bilateral', 'Arteries', 'Consistent with', 'Partial Pressure Arterial Oxygen to Fraction Inspired Oxygen Ratio Measurement', 'Oxygen', 'ethnic european', 'Pulmonary Infiltrate']","['sosy', 'bacs', 'bpoc', 'phpr', 'inpr', 'idcn', ' elii', 'lbpr', 'popg', 'ftcn', 'fndg', 'spco', 'qlco', 'socb', ' phsu', 'qnco', 'dsyn']"
603,PMC3266479,S41,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and participants,"exclusion criteria were pregnancy; current treatment with intravenous β-2 agonist or need for continuous, regular, aerolised β-2 agonists; current treatment with β-adrenergic antagonists; imminent withdrawal of medical treatment; chronic liver disease, defined as child-pugh grade c; and enrolment in another clinical trial of an investigational medicinal product within the previous 28 days.","['C1710677', 'C3812880', 'C2827774', 'C0032961', 'C0008976', 'C0919553', 'C0243192', 'C4321252', 'C4050412', 'C0441800', 'C0205272', 'C0680251', 'C0341439', 'C2757018', 'C0013230', 'C0686904', 'C2987634', 'C0679624', 'C0439228', 'C0205156', 'C0521125', 'C3244287', 'C2349954', 'C1552607', 'C1096775', 'C0549178', 'C0027552', 'C2825032', 'C4049634', 'C0242889', 'C0348016']","['day', 'Withdrawal - birth control', 'Exclusion Criteria', 'Act Relationship Subset - previous', 'Grade', 'Preposition For', 'WWOX wt Allele', 'Withdrawal Scale (BASC-2)', 'Clinical Trials', 'Intravenous', 'Withdrawal (dysfunction)', 'Withdrawal by Subject', 'chronic liver disease', 'Pregnancy', 'Current Therapy', 'Child-Pugh Clinical Classification', 'Needs', 'Adrenergic Antagonists [MoA]', 'medical treatment method', 'Investigational New Drugs', 'agonists', 'Agonist', 'Withdraw (activity)', 'Previous', 'Continuous', 'School Grade', 'Clinical Trial [Publication Type]', 'Adrenergic Antagonists', 'Regular', 'Histopathologic Grade', 'Patient need for (contextual qualifier)']","['inpr', 'idcn', 'acty', 'gngm', 'clas', 'topp', 'ftcn', 'spco', 'fndg', 'tmco', 'qlco', 'resa', 'dsyn', 'moft', 'mobd', 'orgf', 'phsu']"
604,PMC3266479,S42,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and participants,"sedated patients did not have capacity to give consent; therefore, consistent with requirements of the eu clinical trial directive,15 we obtained written informed consent from a personal or professional legal representative before randomisation.","['C2923685', 'C1882932', 'C1516240', 'C0021430', 'C0030705', 'C1519021', 'C0679924', 'C2698884', 'C1550438', 'C0008976', 'C3871158', 'C1550727', 'C1096775', 'C0235195', 'C1511481', 'C0332290', 'C1554192', 'C1518422', 'C1301860']","['Sedated state', 'Consistent with', 'Organization Name Type - Legal', 'Professional Occupation', 'professional occupation status', 'Representation (action)', 'Consent', 'Directive', 'Clinical Trials', 'Patients', 'Consent:Finding:Point in time:{Setting}:Document:Patient', 'Capacity', 'Informed Consent', 'Clinical Trial [Publication Type]', 'Entity Name Use - Legal', 'ActClass - consent', 'Personal Attribute', 'Legal', 'Negation']","['inpr', 'clna', 'rnlw', 'idcn', 'acty', 'ocdi', 'prog', 'ftcn', 'cnce', 'fndg', 'podg', 'resa', 'qnco', 'orga']"
605,PMC3266479,S43,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and participants,all surviving patients were informed about the trial at the earliest opportunity after regaining competence and consent to continue in the trial was sought.,"['C2923685', 'C0030705', 'C0086035', 'C1515981', 'C0008976', 'C0444868', 'C1511481', 'C1554192']","['Consent', 'All', 'Clinical Trials', 'And', 'Patients', 'Consent:Finding:Point in time:{Setting}:Document:Patient', 'Competence', 'ActClass - consent']","['clna', 'idcn', 'ftcn', 'qlco', 'podg', 'resa', 'qnco']"
606,PMC3266479,S44,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and participants,the study protocol16 was approved for all centres by the oxfordshire research ethics committee a.,,,
607,PMC3266479,S45,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and participants,site specific approval was obtained at each site.,"['C1457900', 'C0449604', 'C0205540', 'C0205145', 'C2825164', 'C2346845', 'C2697909', 'C1515974']","['Study Site', 'Approved', 'Anatomic Site', 'Site', 'specific site', 'Approval (document)', 'Each (qualifier value)', 'Letter of Authorization']","['inpr', 'rnlw', 'blor', 'spco', 'qlco', 'qnco']"
608,PMC3266479,S46,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and participants,the trial was monitored for safety by an independent data monitoring and ethics committee.,"['C0085862', 'C1511726', 'C0036043', 'C1283169', 'C3245479', 'C0085546', 'C0150369', 'C0008976', 'C1515981', 'C1290940', 'C3714741', 'C1705187', 'C1299583']","['Independently able', 'Monitoring - action', 'Preventive monitoring', 'Ethics Committees', 'Safety Study', 'And', 'Clinical Trials', 'Data call receiving device', 'Independence', 'Independent for Transfer', 'Safety', 'Data', 'Data (eukaryote)']","['hcpp', 'idcn', 'prog', 'medd', 'fndg', 'euka', 'resa', 'hlca']"
609,PMC3266479,S48,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,"study drug packs were prepared by bilcare global clinical supplies (europe; powys, uk).","['C0205246', 'C0038848', 'C2825051', 'C0205210', 'C0013175', 'C0015176', 'C2348867', 'C1968515']","['Clinical', 'Pack (physical object)', 'Drug Evaluation', 'Europe', 'Generalized', 'Pack unit', 'Manufactured Supplies', 'Global']","['geoa', 'medd', 'spco', 'mnob', 'qlco', 'resa', 'drdd']"
610,PMC3266479,S49,"['9', '5']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1]",Randomisation and masking,"the active and placebo drug components of the infusions were packaged identically into numbered treatment packs, each containing 5 ml of either salbutamol sulphate bp (1 mg/ml in a sterile isotonic solution, glaxosmithkline, middlesex, uk) or placebo (0·9% sterile sodium chloride).","['C3853793', 'C3887704', 'C0543495', 'C1705169', 'C1515981', 'C0574032', 'C0022260', 'C0037494', 'C1696465', 'C0332256', 'C0205177', 'C1552903', 'C1968515', 'C0039798', 'C3538994', 'C0449432', 'C3888249', 'C0232920', 'C1457900', 'C3844638', 'C0449788', 'C0013227', 'C0032042', 'C1254351', 'C1706408', 'C0439294', 'C2825051', 'C0087111', 'C0021359', 'C1522326', 'C1533734', 'C2700400']","['Active License', 'active (HL7 RoleLink)', 'Albuterol Sulfate', 'And', 'Biomaterial Treatment', 'Isotonic Solutions', 'placebo', 'Therapeutic procedure', 'Either', 'Placebos', 'Administration procedure', 'Infusion procedures', 'Contain (action)', 'SmithKline Beecham', 'Each (qualifier value)', 'Containing (qualifier)', 'Active', 'Treatment Epoch', 'Sodium Chloride', 'Kilogram per Cubic Meter', 'Pack unit', 'therapeutic aspects', 'Sterile (qualifier value)', 'treatment - ActInformationManagementReason', 'Placebo Control', 'Pack (physical object)', 'Component object', 'Count of entities', 'Pharmaceutical Preparations', 'Pharmacologic Substance', 'Treating', 'Infertility']","['bacs', 'topp', 'medd', 'mnob', 'fndg', 'qlco', ' phsu', 'hlca', 'drdd', 'phsu', 'idcn', 'patf', 'resa', 'bodm', 'ftcn', 'orch', 'hcro', ' inch', 'acty', 'cnce', 'qnco']"
611,PMC3266479,S50,"['8b', '8a']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0]",Randomisation and masking,we used a computer-generated randomisation sequence with a block size of eight.,"['C0009622', 'C1706084', 'C2828370', 'C1519249', 'C0205454', 'C0332206', 'C3853789', 'C0004793', 'C0162327', 'C0028778', 'C3146294', 'C0332287', 'C1533157', 'C0456389', 'C0162326']","['Sequence - TransmissionRelationshipTypeCode', 'Base Sequence', 'Obstruction', 'Computers', 'DNA Sequence', 'Generation (action)', 'Block (unit of measure)', 'Block Specimens', 'RNA Sequence', 'Blocking', 'size', '(City) Block', 'In addition to', 'Sequence', 'Eight']","['inpr', 'nusq', 'geoa', 'acty', 'ftcn', 'mnob', 'patf', 'bdsu', 'spco', 'qnco']"
612,PMC3266479,S51,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,"patients were randomly assigned in a 1:1 ratio by a centralised 24 h telephone or web-based randomisation service (university of aberdeen, uk).","['C0282111', 'C1547037', 'C0030705', 'C1705541', 'C0039457', 'C0456603', 'C1515258', 'C0041740', 'C0557854', 'C3245478', 'C2825316']","['Services', 'ActInformationPrivacyReason <service>', 'Telephone', 'Telephone Device', 'Ratio', 'Patients', 'Software Service', 'Telephone Number', 'Internet', 'data type - ratio', 'Universities']","['inpr', 'idcn', ' mnob', 'ocac', 'mnob', 'podg', 'qnco', 'orgt']"
613,PMC3266479,S52,['8b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0]",Randomisation and masking,"randomisation was minimised by centre, pao2/fio2 ratio (≤50, 51–99, or ≥100 mm hg), and age (<64, 65–84, ≥85 years).","['C1547037', 'C0456603', 'C1515981', 'C0428167', 'C0001779', 'C0439234']","['And', 'Ratio', 'Age', 'data type - ratio', 'year', 'Inspired fraction of oxygen']","['inpr', 'idcn', 'fndg', 'tmco', 'qnco', 'orga']"
614,PMC3266479,S53,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,"participants, care providers, and investigators were masked to group assignment.","['C0679646', 'C1138603', 'C1515981', 'C1516050', 'C1947933', 'C0035173']","['Provider', 'And', 'Assignment - action', 'Research Personnel', 'care activity', 'Participant']","['idcn', 'acty', 'prog', 'popg', 'ftcn']"
615,PMC3266479,S55,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"we obtained acute physiology and chronic health evaluation ii (apache ii) scores from intensive care national audit and research centre (icnarc) for sites (n=36) that participate in the icnarc's case mix programme or, for non-participating sites (ten), we obtained data necessary for calculation of the scores.","['C1511726', 'C3853835', 'C1548354', 'C0243028', 'C3889431', 'C1704774', 'C1515981', 'C4321252', 'C0205456', 'C3714741', 'C0205099', 'C1518422', 'C1301820', 'C0205191', 'C1441506', 'C3245503', 'C0007319', 'C0205178', 'C0014518', 'C0085559', 'C0035168', 'C0205145', 'C0521125', 'C1704775', 'C0449820', 'C0030858', 'C0242481', 'C1517320', 'C3245479', 'C0031842', 'C0031843', 'C0679823', 'C0175637']","['And', 'Data call receiving device', 'Site', 'APACHE II', 'Audit', 'From', 'intensive care', 'Preposition For', 'WWOX wt Allele', 'National citizen', 'Audit Object', 'physiological aspects', 'Pentaerythritol Tetranitrate', 'Physiology', 'Specialty Type - Intensive care', 'Central', 'Case Mix', 'Negation', 'Calculation', 'Alcohol Use Disorder Identification Test Self-Report Version Questionnaire', 'Ten', 'Health evaluation', 'chronic', 'Data', 'participation', 'research', 'Research Activities', 'Audit (administrative)', 'acute', 'Data (eukaryote)', 'Score', 'Toxic Epidermal Necrolysis', 'Obtain']","['bmod', 'inpr', 'idcn', 'phsf', 'gngm', 'acty', 'medd', 'popg', 'ftcn', 'spco', 'cnce', 'qlco', 'euka', 'orch', 'resa', ' phsu', 'hlca', 'tmco', 'qnco', 'dsyn']"
616,PMC3266479,S56,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"we used the apache ii score to calculate the mortality risk, which we used for subgroup analysis.","['C0026565', 'C0026566', 'C1441506', 'C0936012', 'C0035647', 'C1524024', 'C4552904', 'C0488478', 'C0489438']","['Subject Risk', 'Calculation', 'Aspects of mortality statistics', 'Risk', 'APACHE II score', 'Analysis', 'Apache II score:Function:Point in time:^Patient:Ordinal', 'Mortality Vital Statistics', 'analysis aspect']","['clna', 'idcn', 'acty', 'ftcn', 'cnce', 'resa', 'diap', 'qnco']"
617,PMC3266479,S57,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"the most likely cause of ards was identified by the treating clinician and categorised as direct lung injury (smoke or toxin inhalation, aspiration of gastric content, near drowning, thoracic trauma, pneumonia, or other) or indirect lung injury (sepsis, cardiopulmonary bypass, pancreatitis, non-thoracic trauma, other).","['C0439994', 'C0037366', 'C0243026', 'C1515981', 'C0030305', 'C0871685', 'C2827071', 'C0700198', 'C0015127', 'C1518422', 'C0273115', 'C0750501', 'C0036690', 'C0439852', 'C1524003', 'C0040549', 'C0439851', 'C0205535', 'C1705211', 'C0349707', 'C0007202', 'C0004048', 'C0220787', 'C2712334', 'C1881674', 'C0035222', 'C1963198', 'C1090821', 'C0039980', 'C4552837', 'C0032285', 'C1522326', 'C4554179', 'C0027516', 'C0038352', 'C1947931']","['Pulmonary aspiration', 'Respiratory Distress Syndrome, Adult', 'Endotracheal aspiration', 'And', 'Pancreatitis, CTCAE 5.0', 'Pancreatitis, CTCAE 3.0', 'Unintentional Material Aspiration', 'Direct type of relationship', 'Near Drowning', 'Pneumonia', 'Sepsis', 'most likely', 'Lung Injury', 'Inhalation Route of Drug Administration', 'Sepsis, CTCAE', 'Tobacco smoke', 'Sepsis (Invertebrate)', 'Thoracic Injuries', 'Negation', 'Actual Aspiration', 'Cardiopulmonary Bypass', 'Aspiration-action', 'Clinician', 'Etiology aspects', 'Septicemia', 'Inspiration function', 'Pancreatitis', 'Smoke', 'Direct (qualifier)', 'Gastric Content', 'Toxin', 'indirect', 'Treating', 'Science of Etiology', 'Inhalation Dosing Unit', 'Medical Device Emits Smoke']","['bacs', 'idcn', ' hops', 'inpo', 'prog', 'topp', 'ftcn', 'fndg', 'hops', 'qlco', 'euka', 'bdsu', 'patf', 'cnce', 'dsyn', 'hlca', 'orgf', 'qnco']"
618,PMC3266479,S58,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,"the protocol recommended use of a lung protective ventilation strategy on the basis of ideal bodyweight,17 fluid restriction,18 and appropriate high positive end-expiratory pressure.19","['C3812269', 'C4522209', 'C0033095', 'C1548787', 'C1299351', 'C0205250', 'C4282383', 'C1515981', 'C0460139', 'C2348563', 'C0231800', 'C3889660', 'C3715209', 'C0034866', 'C1512612', 'C0035203', 'C0442711', 'C2599718', 'C4321237', 'C1522729', 'C3887512', 'C1507394', 'C1527178', 'C1874451', 'C0444930', 'C0679199', 'C0024109', 'C1514241', 'C2825490', 'C0204700', 'C0457083', 'C2700149', 'C1446409', 'C2746065', 'C0042491', 'C0042153']","['Positive', 'REMS Protocol', 'Appropriate', 'And', 'Abnormally high', 'End', 'Study Protocol', 'High Level', 'Usage', 'high - ActExposureLevelCode', 'Positive Charge', 'Protocol - answer to question', 'Clinical trial protocol', 'Environmental air flow', 'Clinical trial protocol document', 'Basis', 'Lung', 'Pressure- physical agent', 'Protocols documentation', 'Positive Number', 'Expiration, function', 'Stop (qualifier value)', 'Pressure (finding)', 'High Mitosis-Karyorrhexis Index', 'strategy', 'Positive Finding', 'Value Above Reference Range', 'IPSS Risk Category High', 'Recommendation', 'Basis - conceptual entity', 'High', 'Respiration', 'utilization qualifier', 'fluid restriction', 'Library Protocol', 'Ideal']","['bpoc', 'phpr', 'inpr', 'idcn', 'phsf', 'topp', 'ftcn', 'fndg', 'spco', 'qlco', 'cnce', 'tmco', 'menp', 'orgf', 'qnco', 'phsu']"
619,PMC3266479,S59,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,compliance with recommendations for protective ventilation were assessed at baseline only (tidal volumes per kg ideal bodyweight).,"['C0040210', 'C0168634', 'C0034866', 'C1321605', 'C0205171', 'C0009563', 'C1512612', 'C0035203', 'C3714738', 'C1442488', 'C3244300', 'C0042491']","['Recommendation', 'Compliance', 'BaseLine dental cement', 'Baseline', 'Respiration', 'Environmental air flow', 'Operational Compliance', 'Singular', 'Tidal Volume', 'Ideal', 'Compliance behavior', 'Biomechanical compliance']","['clna', 'phpr', 'inbe', 'idcn', 'bodm', 'phsf', 'fndg', 'qlco', 'qnco']"
620,PMC3266479,S60,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,all other treatments were delivered in accordance with local clinical practice.,"['C3245512', 'C0205276', 'C0087111', 'C0205210', 'C0444868', 'C0237607']","['Clinical', 'Local', 'All', 'HL7PublishingSubSection <practice>', 'Practice Experience', 'Therapeutic procedure']","['inpr', 'topp', 'spco', 'qlco', 'menp', 'qnco']"
621,PMC3266479,S61,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"before the start of recruitment, the intensive-care unit nurse was trained to monitor side-effects of the treatment and to inform the research team as necessary.","['C1552002', 'C1705169', 'C0871489', 'C3887704', 'C0150369', 'C1515981', 'C0439659', 'C0441987', 'C1565156', 'C3853603', 'C0439148', 'C1509845', 'C1521743', 'C0043194', 'C0596972', 'C0181904', 'C1704753', 'C0537670', 'C3538994', 'C0039798', 'C2949735', 'C0028661', 'C1280500', 'C0035168', 'C1519795', 'C0700287', 'C0242481', 'C0030695', 'C0087111', 'C1880519', 'C0439453', 'C1947933', 'C1522326', 'C1533734', 'C1421478', 'C1879745']","['Preventive monitoring', 'Monitor Device', 'Reporting', 'teams', 'Biomaterial Treatment', 'And', 'Unit', 'Side', 'Unit of Measure', 'Monitoring Device', 'Therapeutic procedure', 'Enzyme Unit', 'Oprelvekin', 'WAS protein, human', 'WAS gene', 'Administration procedure', 'Treatment Epoch', 'inform', 'Beginning', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'International Unit', 'Recruitment', 'research', 'Effect', 'PRN (schedule frequency)', 'Unit - NCI Thesaurus Property', 'Unit device', 'Wiskott-Aldrich Syndrome', 'Treating', 'Research Activities', 'care activity', 'Nurses', 'Patient Monitoring', 'Storage Unit', 'Monitor, occupation']","['bacs', 'topp', 'medd', 'mnob', 'qlco', ' phsu', 'hlca', 'idcn', 'gngm', 'prog', 'imft', 'resa', ' aapp', 'ocac', 'ftcn', 'tmco', 'dsyn', 'grup', 'acty', 'cnce', 'spco', 'qnco']"
622,PMC3266479,S62,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,infusion syringes were prepared immediately before use by the nurse and contained two ampoules of the blinded solutions (salbutamol or placebo) diluted with 40 ml of saline in a 50 ml syringe.,"['C0032042', 'C0205548', 'C1706408', 'C0039142', 'C1696465', 'C0332256', 'C0028661', 'C1515981', 'C0574032', 'C1827465', 'C0150108', 'C0001927', 'C0036082', 'C0457083', 'C0205448', 'C2700400', 'C0037633', 'C0042153']","['Placebo Control', 'Albuterol', 'utilization qualifier', 'Solutions', 'And', 'Placebos', 'Saline Solution', 'placebo', 'Blinded', 'Contain (action)', 'Infusion procedures', 'Two', 'Infusion route', 'Nurses', 'Syringes', 'Stat (do immediately)', 'Containing (qualifier)', 'Usage']","['idcn', 'bodm', 'acty', 'prog', 'topp', 'medd', 'ftcn', 'orch', 'tmco', 'resa', ' phsu', 'sbst', 'qnco']"
623,PMC3266479,S63,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,salbutamol and placebo were administered through a dedicated intravenous line at a rate of 0·075 ml/kg ideal bodyweight per h (equivalent to 15 μg salbutamol per kg ideal bodyweight per h).,"['C0032042', 'C4524529', 'C1550648', 'C1706408', 'C1696465', 'C1552960', 'C1512612', 'C3887962', 'C1515981', 'C0439185', 'C0001927', 'C1521828', 'C0205132', 'C0205163', 'C0348016', 'C0871208', 'C4281991', 'C0700221']","['Equivalent Weight', 'Albuterol', 'Follow', 'Placebo Control', 'Rate', 'Rating (action)', 'Line Unit of Length', 'And', 'Dedicated Blood Product Donation', 'Equal', 'Intravenous', 'Placebos', 'Linear', 'placebo', 'Intravascular line', 'Per (qualifier)', 'Line Specimen', 'Ideal']","['idcn', 'bodm', 'acty', 'topp', 'medd', 'ftcn', 'spco', 'orch', 'qlco', 'resa', ' phsu', 'sbst', 'qnco', 'phsu']"
624,PMC3266479,S64,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"the patient was measured from heel to vertex with a soft tape measure, and the ideal bodyweight and infusion rate obtained from the conversion table.17","['C2964135', 'C1301820', 'C1517320', 'C0018870', 'C0039224', 'C0030705', 'C1512612', 'C0205358', 'C0336570', 'C3542022', 'C1515981', 'C0439836', 'C1706074', 'C2697524', 'C0230003']","['conversion', 'Data Table', 'Obtain', 'SHORT STATURE, ONYCHODYSPLASIA, FACIAL DYSMORPHISM, AND HYPOTRICHOSIS SYNDROME', 'Vertex', 'Heel', 'And', 'Soft', 'Patients', 'Infusion Rate', 'Ideal', 'From', 'Measuring Tape', 'Table - furniture', 'Graph Node']","['inpr', 'bpoc', 'idcn', 'medd', 'ftcn', 'mnob', 'cnce', 'podg', 'qlco', 'tmco', 'blor', 'dsyn']"
625,PMC3266479,S65,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"if any patient developed a tachycardia (heat rate >140 beats per min), new arrhythmia, or lactic acidosis, we adjusted the infusion rate according to a prespecified dose-adjustment schedule.15","['C2964135', 'C0018837', 'C0003811', 'C0178602', 'C0086960', 'C0030705', 'C4281991', 'C3272371', 'C0205314', 'C3887962', 'C0376209', 'C0683269', 'C0001125', 'C0680240', 'C0456081', 'C1521828', 'C0039231', 'C0871208', 'C1552551', 'C3827868']","['Adjustment Action', 'Tachycardia', 'Any', 'Schedule (document type)', 'Any Data Type', 'Follow', 'New', 'Cardiac Arrhythmia', 'Rate', 'Rating (action)', 'Acidosis, Lactic', 'Patients', 'Agreement', 'Infusion Rate', 'Tachycardia by ECG Finding', 'Individual Adjustment', 'Heat (physical force)', 'Per (qualifier)', 'Dosage', 'Psychological adjustment']","['inpr', 'inbe', 'acty', 'ftcn', 'fndg', 'podg', 'qlco', 'tmco', 'socb', 'dsyn', 'npop', 'qnco']"
626,PMC3266479,S66,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"infusion of the study drug was stopped at 7 days, or earlier if clinically indicated.","['C1279919', 'C0574032', 'C1547085', 'C1827465', 'C0013175']","['Drug Evaluation', 'Infusion procedures', 'Early', '7 days', 'Infusion route']","['ftcn', 'tmco', 'topp', 'resa']"
627,PMC3266479,S68,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study outcomes,"the primary outcome was 28-day mortality, defined as death up to the end of calendar day 28 after randomisation.","['C1274040', 'C0026565', 'C0026566', 'C1516147', 'C0332173', 'C0205225', 'C0439228', 'C2746065', 'C1306577', 'C0444930', 'C0011065']","['Stop (qualifier value)', 'Cessation of life', 'day', 'Aspects of mortality statistics', 'Daily', 'Death (finding)', 'End', 'Primary', 'Result', 'Mortality Vital Statistics', 'Calendar']","['ftcn', 'fndg', 'spco', 'tmco', 'qlco', 'orgf', 'qnco']"
628,PMC3266479,S69,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study outcomes,"secondary outcomes were mortality in the intensive-care unit or hospital before first discharge; ventilator-free and organ failure-free days from randomisation to day 28; length of stay in intensive-care unit and hospital; and tachycardia, new arrhythmia, or other side-effects sufficient to stop treatment with trial drug.","['C1880497', 'C0205436', 'C0012621', 'C3887704', 'C1705169', 'C1515981', 'C0008976', 'C0441987', 'C0027627', 'C1444754', 'C0349410', 'C1706316', 'C1547127', 'C3853603', 'C0439148', 'C1509845', 'C1996904', 'C0332296', 'C0205410', 'C1704753', 'C0039798', 'C3538994', 'C0019994', 'C0026566', 'C0003811', 'C2926602', 'C0332173', 'C1280500', 'C0439228', 'C0013227', 'C1519795', 'C0026565', 'C1254351', 'C0205314', 'C0087111', 'C1880519', 'C0439453', 'C0030685', 'C0087153', 'C1279901', 'C1522326', 'C1533734', 'C1947933', 'C0205435', 'C0175668']","['day', 'Firstly', 'Aspects of mortality statistics', 'Biomaterial Treatment', 'And', 'Unit', 'First (number)', 'Side', 'Unit of Measure', 'Body Fluid Discharge', 'Secondary to', 'Mortality Vital Statistics', 'Therapeutic procedure', 'Sufficient', 'Free (available (qualifier))', 'Enzyme Unit', 'Cardiac Arrhythmia', 'Discharge, body substance', 'Clinical Trials', 'Administration procedure', 'Free of (attribute)', 'Location Equipment - Ventilator', 'Patient Discharge', 'organ failure', 'New', 'Treatment Epoch', 'Daily', 'Length', 'Hospitals', 'Ventilator - respiratory equipment', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'International Unit', 'Effect', 'Neoplasm Metastasis', 'Pharmaceutical Preparations', 'second (number)', 'Unit - NCI Thesaurus Property', 'Empty (qualifier)', 'Unit device', 'Pharmacologic Substance', 'Treating', 'care activity', 'Storage Unit', 'Length of Trial']","['sosy', 'idcn', 'acty', 'topp', 'neop', 'medd', 'ftcn', 'mnob', 'spco', 'qlco', 'tmco', 'bdsu', 'cnce', 'resa', 'dsyn', 'hlca', ' hcro', 'qnco', 'phsu']"
629,PMC3266479,S70,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study outcomes,we defined ventilator-free days as the number of calendar days after patients started unassisted breathing until day 28 after randomisation for patients who survived at least 48 consecutive hours after start of unassisted breathing.20,"['C1880497', 'C1160636', 'C0030705', 'C0439659', 'C4321252', 'C0237753', 'C1707491', 'C1516147', 'C0231290', 'C0035203', 'C1996904', 'C0332296', 'C0004048', 'C0332173', 'C0449788', 'C0439228', 'C1720302', 'C4084858', 'C0521125', 'C0687676', 'C3272598', 'C0439227']","['Status post', 'day', 'Hour', 'Patients', 'Preposition For', 'Until', 'WWOX wt Allele', 'Free (available (qualifier))', 'respiratory gaseous exchange in organisms', 'Consecutive', 'Free of (attribute)', 'Breathing Distress Question', 'WHO Temperature/Humidity Storage Condition', 'Daily', 'Numbers', 'Beginning', 'Inspiration function', 'Calendar', 'Post', 'Count of entities', 'Respiration', 'Empty (qualifier)']","['inpr', 'phsf', 'gngm', 'biof', 'ftcn', 'qlco', 'podg', 'tmco', 'orgf', 'qnco']"
630,PMC3266479,S71,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study outcomes,the number of ventilator-free days was zero for patients who died without start of unassisted breathing or before 48 consecutive hours of unassisted breathing.20,"['C1547127', 'C4284144', 'C1880497', 'C1160636', 'C0030705', 'C1707491', 'C0919414', 'C0237753', 'C0332296', 'C0035203', 'C0439659', 'C1996904', 'C0087153', 'C0449788', 'C0439228', 'C4084858', 'C3272598', 'C0004048', 'C0332152', 'C0439227']","['Count of entities', 'day', 'Respiration', 'Zero Activity Time', 'WHO Temperature/Humidity Storage Condition', 'respiratory gaseous exchange in organisms', 'Empty (qualifier)', 'Hour', 'Numbers', 'Patients', 'Arabic numeral 0', 'Ventilator - respiratory equipment', 'Beginning', 'Location Equipment - Ventilator', 'Consecutive', 'Before', 'Free of (attribute)', 'Inspiration function', 'Breathing Distress Question', 'Free (available (qualifier))']","['inpr', 'phsf', 'biof', 'medd', 'ftcn', 'spco', 'fndg', 'qlco', 'podg', 'tmco', 'orgf', 'qnco']"
631,PMC3266479,S72,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study outcomes,"we defined organ failure-free days as the number of days in the first 28 days after randomisation that the patient received no cardiovascular, renal, liver, or neurological support as defined by the critical care minimum dataset.21","['C1880497', 'C0030705', 'C1552614', 'C1521721', 'C1704788', 'C0349410', 'C0237753', 'C2826545', 'C2346688', 'C1524031', 'C0007226', 'C0023884', 'C0010337', 'C1996904', 'C0332296', 'C1514756', 'C0205494', 'C3887460', 'C2707261', 'C0449788', 'C0439228', 'C1706233', 'C0022646', 'C1279901', 'C0687676', 'C0205435', 'C3486713', 'C0150098', 'C0231290']","['Status post', 'day', 'Firstly', 'First (number)', 'Patients', 'Kidney', 'Receive', 'Data Set', 'Free (available (qualifier))', 'Silo (dataset)', 'Mammal liver preparation', 'Minimum Value Derivation Technique', 'Cardiovascular system', 'ActRelationshipSubset - minimum', 'Cardiovascular', 'Free of (attribute)', 'Liver', 'Care of intensive care unit patient', 'Neurological:-:Point in time:^Patient:-', 'Neurologic (qualifier value)', 'Minimum', 'organ failure', 'Liver Flavor', 'Numbers', 'Count of entities', 'Post', 'Empty (qualifier)', 'Definition', 'Supportive assistance']","['sosy', 'inpr', 'bpoc', 'clna', 'idcn', 'ftcn', 'blor', 'cnce', 'tmco', 'food', ' phsu', 'podg', 'bdsy', 'hlca', 'aapp', 'qlco', 'qnco']"
632,PMC3266479,S73,['6b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0]",Study outcomes,"we did not plan to collect data for cause of death in the original trial protocol; however, after early termination of the trial because of the increased 28-day mortality in the salbutamol group, the data for the main cause of death were ascertained for all participants dying within 28 days of randomisation.","['C0270724', 'C1511726', 'C0679646', 'C0441833', 'C1279919', 'C0687744', 'C1542147', 'C0008976', 'C0007465', 'C2347409', 'C4321252', 'C0332285', 'C3714741', 'C0015127', 'C1692758', 'C1518422', 'C0205217', 'C1549081', 'C1524003', 'C1507394', 'C1301732', 'C0026566', 'C1705429', 'C0332173', 'C0205225', 'C0439228', 'C0205313', 'C1306577', 'C0521125', 'C0011065', 'C4050444', 'C0184532', 'C0026565', 'C0599880', 'C1519504', 'C3245479', 'C1257890', 'C0001927', 'C0444868', 'C1705428', 'C0442805']","['day', 'Aspects of mortality statistics', 'Increased', 'Data call receiving device', 'Preposition For', 'WWOX wt Allele', 'Mortality Vital Statistics', 'Stage Grouping', 'Main', 'termination - ActReason', 'Infantile Neuroaxonal Dystrophy', 'Clinical Trials', 'User Group', 'Death (finding)', 'Clinical trial protocol document', 'Within', 'Cause of Death', 'Group Object', 'Social group', 'Original', 'Original Regulatory Submission', 'Negation', 'Termination - Inactive Reason Code', 'Albuterol', 'Cessation of life', 'Increase', 'All', 'Planned', 'Daily', 'Cause of death:Find:Pt:^Patient:Nom', 'Etiology aspects', 'Early', 'Treatment Plan', 'Data', 'Groups', 'Population Group', 'Science of Etiology', 'Dying Process', 'Data (eukaryote)', 'Primary', 'Participant']","['clna', 'inpr', 'idcn', 'gngm', 'ocac', 'medd', 'popg', 'ftcn', 'fndg', 'cnce', 'orch', 'euka', 'qlco', 'tmco', 'resa', ' phsu', 'spco', 'orgf', 'qnco', 'dsyn']"
633,PMC3266479,S74,['6b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0]",Study outcomes,we requested causes of death as recorded on the death certificate for the disorder directly leading to death.,"['C0521125', 'C0011066', 'C1947931', 'C3853629', 'C1314792', 'C0012634', 'C4321252', 'C1522538', 'C1306577', 'C0015127', 'C0332152', 'C0011065']","['Direct (qualifier)', 'Cessation of life', 'Death Certificates', 'Etiology aspects', 'Death (finding)', 'Etiology', 'Leading', 'Before', 'Disease', 'Preposition For', 'WWOX wt Allele', 'Death certificate:Find:Pt:{Setting}:Doc:{Author Type}']","['inpr', 'clna', 'gngm', 'ftcn', 'fndg', 'tmco', 'qlco', 'dsyn', 'orgf']"
634,PMC3266479,S75,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study outcomes,"patients who remained alive and in critical care after randomisation were monitored daily until discharged to a ward, or until day 28.","['C2355574', 'C0030705', 'C4551704', 'C1305702', 'C0010337', 'C0332173', 'C2584946', 'C0030685', 'C0439228', 'C3272598']","['Ward (person)', 'day', 'Alive', 'WHO Temperature/Humidity Storage Condition', 'Daily', 'Patients', 'Alive (finding)', 'Patient Discharge', 'Care of intensive care unit patient', 'Ward (environment)']","['popg', 'cnce', 'fndg', 'qlco', 'podg', 'tmco', 'mnob', 'hlca', ' hcro']"
635,PMC3266479,S77,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analysis,we based the sample-size calculation on our balti trial13 and on 2005 data from the intensive care national audit and research centre.,"['C1511726', 'C0242481', 'C3853835', 'C1548354', 'C1441506', 'C3245479', 'C3889431', 'C1517320', 'C1704774', 'C3245503', 'C1515981', 'C0205099', 'C0456389', 'C0035168', 'C3714741', 'C1704775', 'C0085559', 'C0370003', 'C2347026']","['National citizen', 'Audit Object', 'Biospecimen', 'Calculation', 'And', 'Alcohol Use Disorder Identification Test Self-Report Version Questionnaire', 'Data call receiving device', 'Research Activities', 'Audit (administrative)', 'Specialty Type - Intensive care', 'Audit', 'From', 'intensive care', 'Central', 'Data', 'Specimen', 'size', 'research', 'Data (eukaryote)']","['bmod', 'inpr', 'idcn', 'acty', 'medd', 'popg', 'ftcn', 'cnce', 'spco', 'qlco', 'euka', 'resa', 'hlca', 'sbst']"
636,PMC3266479,S78,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analysis,"the target sample size of 1334 gave 90% power at p<0·05 to detect a risk ratio (rr) of 0·8 for 28-day mortality between the salbutamol and placebo groups with a 3% loss of patients for the primary outcome, with the assumption that the 28-day mortality in the placebo group was 44%.","['C0030705', 'C0441833', 'C0687744', 'C0032863', 'C1515981', 'C4321252', 'C1274040', 'C1696465', 'C1517945', 'C0332287', 'C0026566', 'C1552839', 'C1705429', 'C0332173', 'C0205225', 'C0439228', 'C0242492', 'C4528313', 'C0521125', 'C0028873', 'C0032042', 'C0026565', 'C1519504', 'C1706408', 'C1257890', 'C3854080', 'C0001927', 'C0205103', 'C1705428']","['day', 'Target Sample Size', 'Aspects of mortality statistics', 'And', 'Patients', 'Power', 'Preposition For', 'placebo', 'WWOX wt Allele', 'Mortality Vital Statistics', 'Stage Grouping', 'User Group', 'Placebos', 'Odds Ratio', 'Group Object', 'Social group', 'Albuterol', 'Intermediate', 'Loss', 'Daily', 'In addition to', 'Placebo Control', 'Groups', 'Power (Psychology)', 'Table Rules - groups', 'Population Group', 'Result', 'Relative Risk', 'Primary']","['hcpp', 'inpr', 'idcn', 'bodm', 'gngm', 'topp', 'popg', 'ftcn', 'cnce', 'spco', 'orch', 'tmco', 'qlco', 'resa', 'podg', ' phsu', 'qnco']"
637,PMC3266479,S79,['7b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0]",Statistical analysis,"we planned interim analyses every 12 months, or more frequently if requested by the data monitoring and ethics committee.","['C1511726', 'C1283169', 'C0439231', 'C3245479', 'C1948061', 'C0085546', 'C0150369', 'C1515981', 'C2827738', 'C0332183', 'C3714741']","['Monitoring - action', 'Preventive monitoring', 'Ethics Committees', 'And', 'Data call receiving device', 'Frequently', 'month', 'Data (eukaryote)', 'Data', 'Interim', 'Every (qualifier)']","['idcn', 'prog', 'medd', 'qlco', 'euka', 'tmco', 'hlca']"
638,PMC3266479,S80,['7b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0]",Statistical analysis,the committee used the haybittle-peto22 stopping guideline: a difference of three standard errors would be needed before considering recommending trial cessation for benefit at an interim analysis.,"['C0743559', 'C4684691', 'C2828392', 'C0723457', 'C0205449', 'C0008976', 'C0162791', 'C1442989', 'C0814225', 'C2699414', 'C1705241', 'C0282423', 'C1880019', 'C1705242']","['Stop brand of fluoride', 'Guideline [Publication Type]', 'benefit', 'Clinical Trials', 'Standard (document)', 'Three', 'Interim Analysis', 'Cessation', 'error', 'Guidelines', 'Committee', 'Different', 'Standard (qualifier)', 'Delta (difference)']","['inpr', 'grup', 'inch', 'acty', 'qlco', 'resa', ' phsu', 'qnco']"
639,PMC3266479,S81,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,all analyses were based on intention-to-treat analyses.,"['C1283828', 'C0162425', 'C1292734', 'C0087111', 'C1522326', 'C0444868']","['intent', 'All', 'Treating', 'Treatment intent', 'Therapeutic procedure', 'Intention - mental process']","['topp', 'ftcn', 'qlco', 'menp', 'qnco']"
640,PMC3266479,S82,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,we compared the primary outcome and other dichotomous outcomes using rrs and 95% cis.,"['C1274040', 'C4049798', 'C1515981', 'C0205225', 'C1849334', 'C1504308', 'C2827654', 'C1742862']","['Dichotomous Response Format', 'CISH protein, human', 'And', 'Genus Cis', 'Result', 'Total Respiratory System Resistance', 'Primary', 'Robinow syndrome, autosomal recessive']","['bacs', 'idcn', 'ftcn', 'qlco', 'euka', 'dsyn', ' aapp', 'diap']"
641,PMC3266479,S83,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,we compared continuous outcomes with mean differences and their 95% cis.,"['C0444504', 'C1515981', 'C2348143', 'C0549178', 'C1504308', 'C2347634', 'C1742862']","['Statistical mean', 'CISH protein, human', 'And', 'Genus Cis', 'Continuous', 'Population Mean', 'Sample Mean']","['bacs', 'idcn', 'euka', ' aapp', 'qnco']"
642,PMC3266479,S84,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"we analysed 28-day mortality with survival analysis, and by comparison of the two groups with hazard ratios and 95% cis and the kaplan–meier curve.","['C0026565', 'C0026566', 'C0598697', 'C0205134', 'C1552839', 'C0441833', 'C0687744', 'C1515981', 'C0332173', 'C0456603', 'C0332287', 'C0205448', 'C1707455', 'C1504308', 'C0038953', 'C0439228', 'C1742862']","['Social group', 'day', 'Groups', 'CISH protein, human', 'Aspects of mortality statistics', 'Curved', 'And', 'Daily', 'Ratio', 'Comparison', 'Genus Cis', 'Table Rules - groups', 'Two', 'Survival Analysis', 'hazard', 'Mortality Vital Statistics', 'In addition to']","['bacs', 'inpr', 'idcn', 'acty', 'popg', 'ftcn', 'spco', 'tmco', 'euka', 'qlco', 'resa', ' aapp', 'qnco']"
643,PMC3266479,S85,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,all reported p values are two-sided and were not adjusted for multiple comparisons.,"['C0684224', 'C0439064', 'C0042295', 'C1515981', 'C0444868', 'C4319718', 'C0205448', 'C1518422', 'C0700287']","['Report (document)', 'Reporting', 'All', 'And', 'Two', 'Numerous', 'Values', 'Reported', 'Negation']","['inpr', 'idcn', 'ftcn', 'qlco', 'hlca', 'qnco']"
644,PMC3266479,S86,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"we used prespecified subgroup analyses to investigate the effects of age, severity of hypoxaemia at study entry, cause (direct vs indirect causes of ards), and the apache ii mortality risk, on the effect of salbutamol.","['C0243028', 'C1515981', 'C0015127', 'C0439852', 'C1524003', 'C2603343', 'C0439851', 'C0026566', 'C1314792', 'C1280500', 'C1518681', 'C4552904', 'C0522510', 'C0035222', 'C0026565', 'C0700292', 'C0439793', 'C1705654', 'C0035647', 'C0001927', 'C0001779', 'C1947931', 'C2348382']","['Respiratory Distress Syndrome, Adult', 'Aspects of mortality statistics', 'And', 'With intensity', 'APACHE II', 'Effect, Appearance', 'Direct type of relationship', 'Hypoxemia', 'Mortality Vital Statistics', 'Outcome of Therapy', 'Entry (data)', 'Age', 'Etiology', 'Albuterol', 'Subject Risk', 'Risk', 'Etiology aspects', 'Study', 'Effect', 'Direct (qualifier)', 'Severities', 'indirect', 'Science of Etiology']","['inpr', 'idcn', 'ftcn', 'cnce', 'fndg', 'orch', 'qlco', 'resa', ' phsu', 'qnco', 'orga', 'dsyn']"
645,PMC3266479,S87,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"all subgroup analyses used interaction tests; we either calculated the ratio of rrs between the subgroups, or used interaction terms in logistic regression models.","['C4049798', 'C0022885', 'C1547037', 'C1273517', 'C1515021', 'C3844638', 'C0456603', 'C0392366', 'C1079230', 'C0206031', 'C0444868', 'C0205103', 'C1849334', 'C1704675', 'C3161035']","['Robinow syndrome, autosomal recessive', 'Intermediate', 'Laboratory Procedures', 'Logistic Regression', 'All', 'Tests (qualifier value)', 'used by', 'Model', 'Ratio', 'Subgroup', 'Interaction', 'Subgroup A Nepoviruses', 'data type - ratio', 'Total Respiratory System Resistance', 'Either']","['inpr', 'lbpr', 'clas', 'ftcn', 'fndg', 'spco', 'virs', 'resa', 'dsyn', 'diap', 'qnco']"
646,PMC3266479,S88,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,we did a post-hoc analysis for the main causes of death as recorded on the death certificates of participants who died within 28 days of randomisation.,"['C0679646', 'C0011066', 'C0936012', 'C3469826', 'C1542147', 'C1704687', 'C0007465', 'C0205225', 'C1524024', 'C0439228', 'C0687676', 'C3272598']","['Post', 'day', 'Post Device', 'WHO Temperature/Humidity Storage Condition', 'Death Certificates', 'SLC35G1 gene', 'Analysis', 'Participant', 'Cause of Death', 'Main', 'Primary', 'analysis aspect']","['inpr', 'gngm', 'popg', 'ftcn', 'fndg', 'mnob', 'qlco', 'tmco', 'resa']"
647,PMC3266479,S89,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"this trial is registered, isrctn38366450 and eudract number 2006-002647-86.",,,
648,PMC3266479,S91,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Role of the funding source,"the sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.","['C1511726', 'C0010995', 'C0684224', 'C0043266', 'C2584304', 'C4255046', 'C3714741', 'C3273238', 'C2983265', 'C2986888', 'C0010992', 'C2603343', 'C4283917', 'C2347796', 'C3173575', 'C1711305', 'C3887707', 'C0035171', 'C4050126', 'C0062074', 'C1705810', 'C0700287', 'C0035820', 'C3539897', 'C3245479', 'C1415458', 'C0459471', 'C3871154']","['Writing (function)', 'Reporting', 'Interpretation:Impression/interpretation of study:Point in time:^Patient:Nominal', 'Sponsor (person)', 'Role', 'Data call receiving device', 'Ability to Write question', 'Have', 'Research Design', 'Writing Ability', 'Regulatory Report', 'HADH gene', 'Nonclinical Study Design', 'Data Collection', 'Data Collection Methods', 'Social Role', 'Clinical Study Sponsor', 'Study', 'Data', 'Data Analysis', 'Report (document)', 'Report:Finding:Point in time:{Setting}:Document:{Role}', 'Interpretation Process', 'HAC protocol', 'Generic Role', 'Data (eukaryote)', 'CDISC SEND Study Design Terminology', 'Writing (occupation or discipline)']","['inpr', 'clna', 'idcn', 'gngm', 'ocdi', 'ocac', 'topp', 'medd', 'popg', 'qlco', 'euka', 'resa', 'socb', 'hlca', 'menp', 'qnco', 'orgt']"
649,PMC3266479,S92,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Role of the funding source,"fgs, sg, gdp, and sel had full access to all the data in the study, and the corresponding author had final responsibility for the decision to submit for publication.","['C1511726', 'C4554068', 'C1515981', 'C4321252', 'C3714741', 'C3853528', 'C0678341', 'C0443225', 'C2603343', 'C1546485', 'C1704324', 'C0220769', 'C0034037', 'C0679006', 'C0062074', 'C0444454', 'C0521125', 'C3812881', 'C3539897', 'C3245479', 'C0018340', 'C0034036', 'C1415458', 'C0444868', 'C1554204', 'C0205088']","['Role Class - access', 'FG syndrome', 'And', 'Data call receiving device', 'Preposition For', 'Have', 'WWOX wt Allele', 'HADH gene', 'Final', 'responsibility', 'GDP Regimen', 'Diagnosis Type - Final', 'Publishing', 'Data (eukaryote)', 'full', 'All', 'Study', 'Publications', 'Guanosine Diphosphate', 'Data', 'End-stage', 'author', 'HAC protocol', 'Decision', 'Scientific Publication', 'Access']","['bacs', 'inpr', 'inbe', 'idcn', ' mnob', 'gngm', 'prog', 'ocac', ' nnon', 'topp', 'medd', 'ftcn', 'spco', 'qlco', 'euka', 'tmco', 'resa', 'dsyn', 'menp', 'qnco']"
650,PMC3321505,S32,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,male and female patients aged 40–80 years expected to require daily nsaid therapy for at least 6 months for pain and/or inflammatory conditions were eligible.,"['C3536840', 'C4085210', 'C0150905', 'C1706528', 'C1363945', 'C1706428', 'C4085212', 'C0087111', 'C0332173', 'C0518090', 'C0039798', 'C0439234', 'C4554132', 'C0030193', 'C4553004', 'C0333348', 'C1706180', 'C2984058', 'C1548635', 'C0439231', 'C0086582', 'C1515981', 'C4085211', 'C0003211', 'C1706429']","['Usual Severity Pain', 'year', 'Have Pain', 'Male Phenotype', 'And', 'Pain Distress Question', 'month', 'Eligible', 'Male, Self-Reported', 'And/Or', 'Anti-Inflammatory Agents, Non-Steroidal', 'Males', 'Therapy Object (animal model)', 'Male Gender, Self Report', 'Feel Pain', 'Nonsteroidal Anti-inflammatory Drug [EPC]', 'Daily', 'inflammatory', 'Pain', 'How Much Distress Pain', 'Frequency of Pain Question', 'patient is female', 'therapeutic aspects', 'Pain, CTCAE', 'Therapeutic procedure']","['tmco', 'fndg', 'topp', 'idcn', 'inpr', 'sosy', 'qlco', 'orga', 'ftcn', 'cnce', 'phsu']"
651,PMC3321505,S33,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"exclusion criteria included history of erosive esophagitis; history of gi complications (bleeding, perforated ulcer, gastric outlet obstruction due to an ulcer); history of nsaid-associated asthma exacerbations, acute renal failure, interstitial nephritis, or hepatitis; history of gi malignancy; history of myocardial infarction, unstable cardiac arrhythmias, or stroke within 6 months of study entry; coronary artery bypass graft surgery within 14 days of study entry; uncontrolled congestive heart failure or hypertension at entry; acid-suppressive therapy or misoprostol within 14 days before study entry or investigational drug or nsaids (including aspirin >325 mg daily) within 30 days before study entry; ulcer or >5 erosions on screening upper gi tract endoscopy; or one of the following abnormalities on baseline laboratory testing: creatinine clearance <45 ml/min; aminotransferase >2.5 times upper limit of normal; fasting blood sugar >200 mg/dl; serum pregnancy test positive; serologic tests positive for human immunodeficiency virus, hepatitis b, or hepatitis c; or stool antigen for h. pylori positive.","['C0430064', 'C0079304', 'C0168634', 'C0013230', 'C0085174', 'C0685938', 'C1709362', 'C0205307', 'C2825073', 'C1171258', 'C0349790', 'C0009566', 'C0443343', 'C0240802', 'C0038351', 'C2825162', 'C3887532', 'C1446409', 'C0010055', 'C1705255', 'C0332257', 'C0027051', 'C0262512', 'C0010294', 'C0003811', 'C1442488', 'C1282910', 'C3810814', 'C0041349', 'C0202406', 'C0332282', 'C0022885', 'C1382187', 'C0019664', 'C0015733', 'C1883468', 'C0018802', 'C3812269', 'C0680251', 'C2825490', 'C1561535', 'C0205367', 'C0039798', 'C0019158', 'C4552959', 'C1998466', 'C0019665', 'C0267055', 'C0003320', 'C1705654', 'C2603343', 'C0019159', 'C0079488', 'C0036743', 'C0003211', 'C0019163', 'C0332281', 'C0428953', 'C0678226', 'C0019682', 'C4554548', 'C0231683', 'C0332173', 'C4028326', 'C1632851', 'C0333307', 'C0262926', 'C1704242', 'C0333292', 'C1514241', 'C0439801', 'C2004062', 'C0022660', 'C2349209', 'C0220847', 'C1261430', 'C0038454', 'C3536840', 'C0205447', 'C4553972', 'C0449297', 'C0027707', 'C1363945', 'C0087111', 'C0019196', 'C0019080', 'C0000768', 'C2926063', 'C3146286', 'C0439228', 'C0000769', 'C0020538', 'C0002594', 'C1959609', 'C0041582', 'C1963138', 'C1549649', 'C0439231', 'C0040223', 'C0205318', 'C0001128', 'C4554100']","['Positive Finding', 'HIV', 'Cerebrovascular accident', 'Outlet Device', 'Stroke, CTCAE', 'Anti-Inflammatory Agents, Non-Steroidal', 'Time', 'Myocardial Infarction', 'History of previous events', 'Laboratory Procedures', 'Times', 'Therapy Object (animal model)', 'Concept History', 'Hepatitis C virus', 'Nonsteroidal Anti-inflammatory Drug [EPC]', 'Clearance [PK]', 'perforated ulcer', 'Cardiac Arrhythmia', 'BaseLine dental cement', 'Ulcer', 'Lysergic acid diethylamide measurement', 'How Often Felt Normal question', 'Upper', 'Transaminases', 'suppressive', 'Misoprostol', 'Gastric (qualifier value)', 'Study', 'month', 'Gait normal', 'Feces', 'Baseline', 'Ulceration', 'Hepatitis', 'Fasting Blood Sugar Measurement', 'Limit - Amount class', 'Clearance procedure', 'Investigational New Drugs', 'Clearance of substance', 'History of present illness', 'Myocardial Infarction, CTCAE', 'teratologic', 'Coronary Artery Bypass Surgery', 'Complication Aspects', 'Daily', 'Hypertensive disease', 'Helicobacter pylori', 'Entry (data)', 'day', 'Associated with', 'Antigens', 'Hepatitis B', 'therapeutic aspects', 'Hemorrhage', 'Congenital Abnormality', 'Therapeutic procedure', 'Hypertension, CTCAE', 'Positive Charge', 'Erosion lesion', 'Including (qualifier)', 'Medical History', 'Creatinine, CTCAE', 'Hepatitis C', 'Erosive esophagitis', 'Due', 'Fasting blood sugar result', 'Serologic tests', 'Unstable Medical Device Problem', 'Stomach', 'Limited (extensiveness)', 'Acids', 'Clearance', 'One', 'Positive Number', 'Creatinine', 'positive pregnancy test', 'serum pregnancy test (non-specific)', 'Kidney Failure, Acute', 'Historical aspects qualifier', 'Outlet (position)', 'Unstable status', 'Positive', 'Esophagogastroduodenoscopy', 'History', 'Congestive heart failure', 'Normal', 'Following', 'Myocardial infarction:Finding:Point in time:^Patient:Ordinal', 'Due to', 'Electrocardiogram: myocardial infarction (finding)', 'Nephritis, Interstitial', 'Bound (value)', '30 days', 'Exclusion Criteria', 'Malignant neoplasm of gastrointestinal tract', 'Myocardial Infarction ECG Assessment', 'Hepatitis A', 'Exacerbation of asthma', 'uncontrolled', 'Superficial ulcer', 'Nephritis, Tubulointerstitial', 'Complication']","['bact', 'chem', 'virs', 'topp', 'qnco', 'bodm', ' aapp', 'patf', 'clna', 'fndg', 'npop', 'cgab', ' orch', 'idcn', 'inpr', 'qlco', 'bacs', 'lbpr', 'resa', 'ftcn', 'mnob', 'acab', 'bpoc', 'phsu', 'tmco', 'bdsu', 'lbtr', 'enzy', 'ocdi', 'orch', 'spco', 'neop', 'cnce', 'imft', 'dsyn', 'diap', ' phsu']"
652,PMC3321505,S35,"['8a', '9', '11b', '3a', '10']","[0, 1, 0, 1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 1]",Study design,"patients were randomly assigned, using a computer-generated randomization schedule, from a central location utilizing an interactive voice response system with blinded medication kit number allocation in a 2:1 ratio to identical-appearing tablets of hzt-501 (800 mg ibuprofen and 26.6 mg famotidine) or ibuprofen (800 mg) thrice daily for 24 weeks.","['C3898461', 'C3146294', 'C0205280', 'C0871261', 'C0439230', 'C2981406', 'C0039225', 'C1706778', 'C0042939', 'C0332173', 'C0449913', 'C0030705', 'C0020740', 'C0015620', 'C0456603', 'C3888058', 'C4281800', 'C0332287', 'C1547037', 'C0009622', 'C1517320', 'C0205099', 'C1706817', 'C2911692', 'C1553451', 'C4684578', 'C1515981', 'C1704632', 'C1704675', 'C3244282']","['Ibuprofen', 'System - kit', 'In addition to', 'Device system', 'And', 'Voice', 'From', 'Response (communication)', 'Response process', 'Disease Response', 'Master Randomization List', 'Ratio', 'Kit Number', 'Famotidine', 'Computers', 'Interaction', 'System', 'identical', 'Blinded Medication', 'Generation (action)', 'Patients', 'Central', 'Daily', 'Response (statement)', 'TelecommunicationCapabilities <voice>', 'data type - ratio', 'Voice G-code', 'week', 'Allocation', 'Tablet Dosage Form']","['tmco', 'fndg', 'idcn', 'inpr', 'orch', 'qlco', 'phsu', 'qnco', 'orga', 'menp', 'orgf', 'spco', 'podg', 'bodm', 'mnob', ' phsu', 'ftcn', 'acty']"
653,PMC3321505,S36,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"patients, care providers, and all study personnel were blinded to the treatment.","['C0087111', 'C1947933', 'C1522326', 'C3887704', 'C1705169', 'C2985653', 'C3538994', 'C0030705', 'C0039798', 'C1515981', 'C0444868', 'C1533734', 'C1138603']","['Study Personnel', 'All', 'treatment - ActInformationManagementReason', 'Provider', 'Treating', 'care activity', 'Treatment Epoch', 'And', 'therapeutic aspects', 'Patients', 'Biomaterial Treatment', 'Administration procedure', 'Therapeutic procedure']","['prog', 'topp', 'idcn', 'hlca', 'qnco', 'resa', 'podg', 'ftcn', 'acty', 'cnce']"
654,PMC3321505,S37,"['3a', '8b']","[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0]",Study design,patients were stratified for two risk factors for ulcer development: concomitant use of low-dose aspirin (≤325 mg daily) and/or anticoagulant medication and history of gastric or duodenal ulcer.,"['C0521115', 'C1527148', 'C0019664', 'C0178602', 'C1706528', 'C0243107', 'C0678723', 'C4551944', 'C0003280', 'C0332173', 'C0030705', 'C0205448', 'C0042153', 'C0038351', 'C0262926', 'C4321351', 'C1704242', 'C1553898', 'C3887532', 'C3890211', 'C0019665', 'C0013295', 'C2004062', 'C1705255', 'C4522223', 'C0262512', 'C4048187', 'C0457083', 'C0205363', 'C0041582', 'C0205251', 'C0035648', 'C1515981', 'C1550472']","['low confidentiality', 'And', 'low exposure', 'Gastric (qualifier value)', 'Low Mitosis-Karyorrhexis Index', 'risk factors - observation list', 'utilization qualifier', 'History', 'Simultaneous', 'Medical History', 'And/Or', 'stratified', 'IPSS Risk Category Low', 'History of previous events', 'development aspects', 'Ulceration', 'Concept History', 'Development', 'Stomach', 'Two', 'Duodenal Ulcer', 'Biologic Development', 'Duodenal Ulcer, CTCAE 5', 'History of present illness', 'Anticoagulants', 'Dosage', 'Patients', 'Daily', 'Low Level', 'Ulcer', 'low', 'Usage', 'risk factors', 'Historical aspects qualifier']","['tmco', 'fndg', 'idcn', 'phsf', 'inpr', 'ocdi', 'bpoc', 'qnco', 'phsu', 'qlco', 'dsyn', 'orgf', 'podg', 'ftcn', 'patf', 'cnce']"
655,PMC3321505,S38,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study design,"in addition to the screening upper endoscopy at baseline, patients had endoscopy at weeks 8, 16, and 24 (or earlier if premature study termination) of study therapy.","['C0017195', 'C1710032', 'C1883712', 'C0168634', 'C0439230', 'C1363945', 'C0205252', 'C1549081', 'C0087111', 'C0039798', 'C2348164', 'C0030705', 'C1698960', 'C0332287', 'C1692758', 'C0151526', 'C0220908', 'C1710031', 'C2603343', 'C1442488', 'C0220909', 'C1279919', 'C1515981', 'C1710477', 'C4018905']","['Endoscopy of stomach', 'Aspects of disease screening', 'Screening procedure', 'In addition to', 'Termination - Inactive Reason Code', 'And', 'Study', 'termination - ActReason', 'Trial Screening', 'Screening', 'Baseline', 'Therapy Object (animal model)', 'Screening Study', 'Premature Birth', 'Early', 'Disease Screening', 'Patients', 'research subject screening', 'BaseLine dental cement', 'Too early', 'therapeutic aspects', 'Add - instruction imperative', 'week', 'Immature', 'Therapeutic procedure']","['tmco', 'fndg', 'bodm', 'hlca', 'topp', 'idcn', 'inpr', 'qnco', 'qlco', 'resa', 'podg', 'ftcn', 'diap', 'patf']"
656,PMC3321505,S39,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,"the following medications were proscribed during the study: medications that may reduce ulcers (e.g., misoprostol, proton-pump inhibitors, and non-study h2ras), non-study nsaids other than low-dose aspirin taken for cardiovascular prophylaxis.","['C0332282', 'C0199176', 'C4284232', 'C0178602', 'C0085174', 'C3853787', 'C0243077', 'C0802604', 'C2598133', 'C3812381', 'C0182537', 'C4321351', 'C3887460', 'C3890211', 'C0033107', 'C4522223', 'C0007226', 'C4048187', 'C0013227', 'C0033727', 'C2603343', 'C0041582', 'C1518422', 'C0205251', 'C1515981', 'C1550472', 'C0004057', 'C0003211']","['low confidentiality', 'Medications:Presence or Identity:Duration of the study:^Patient:Nominal', 'Prophylactic treatment', 'Misoprostol', 'And', 'Low Mitosis-Karyorrhexis Index', 'low exposure', 'Month of May', 'Study', 'prophylaxis - ActNonObservationIndicationCode', 'Medications:-:Point in time:^Patient:-', 'Cardiovascular', 'Following', 'Aspirin', 'Anti-Inflammatory Agents, Non-Steroidal', 'Protons', 'IPSS Risk Category Low', 'inhibitors', 'Dosage', 'Pharmaceutical Preparations', 'Negation', 'Low Level', 'Medications', 'Ulcer', 'pump (device)', 'low', 'prevention & control', 'Cardiovascular system']","['clna', 'blor', 'tmco', 'chvf', 'elii', 'medd', 'idcn', 'bdsy', 'topp', 'inpr', 'orch', 'qnco', 'qlco', 'resa', 'ftcn', ' phsu', 'patf', 'phsu']"
657,PMC3321505,S40,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,"in addition, antacids could not be taken for >3 days in any 2-week period; patients requiring further antacid therapy were to be discontinued from the trial.","['C3272371', 'C0439531', 'C1517331', 'C0332287', 'C1518422', 'C1442459', 'C1883712', 'C0030705', 'C0439230', 'C1552551', 'C1096697', 'C0008976', 'C0003138', 'C1948053']","['Period (temporal qualifier)', 'Antacids', 'In addition to', 'Clinical Trials', 'antacid therapy', 'Any', 'Add - instruction imperative', 'Patients', 'Any Data Type', 'per period (qualifier value)', 'week', 'Further', 'Negation', '3 Days']","['tmco', 'topp', 'inpr', 'qlco', 'spco', 'resa', 'podg', 'ftcn', 'phsu']"
658,PMC3321505,S41,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,"the study medication was dispensed in an 8-week supply at 0, 8, and 16 weeks.","['C1875802', 'C2603343', 'C4284232', 'C1999230', 'C0439230', 'C1561604', 'C1515981', 'C3244316', 'C0699914', 'C0243163', 'C0013227']","['Healthcare supplies', 'Providing (action)', 'supply aspects', 'Medications', 'Economic supply', 'And', 'week', 'Study', 'Pharmaceutical Preparations', 'medication - HL7 publishing domain', 'Supply (process)']","['tmco', 'medd', 'idcn', 'inpr', 'qnco', 'resa', 'ftcn', 'acty', 'phsu']"
659,PMC3321505,S42,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,compliance was determined by pill count of returned bottles of study medication.,"['C0009563', 'C3244300', 'C2603343', 'C0009905', 'C0750480', 'C4284232', 'C4050367', 'C3714738', 'C1321605', 'C0013227', 'C0994475', 'C3244316', 'C1705566', 'C0179376']","['Compliance behavior', 'Count Dosing Unit', 'Compliance', 'Bottle, device', 'Medications', 'Pharmaceutical Preparations', 'Biomechanical compliance', 'Pills', 'Pill Dosing Unit', 'Study', 'Count', 'Operational Compliance', 'Contraceptives, Oral', 'medication - HL7 publishing domain']","['fndg', 'inbe', 'idcn', 'inpr', 'qnco', 'resa', 'bodm', 'mnob', 'phsu']"
660,PMC3321505,S43,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"serum chemistries, complete blood count, and prothrombin time were performed at screening, week 8, week 16, and the final study visit (week 24 or earlier if early termination).","['C0005767', 'C1710032', 'C0439230', 'C1512346', 'C1549081', 'C0205088', 'C0482694', 'C0229671', 'C3853528', 'C2348164', 'C1698960', 'C0545082', 'C1546485', 'C4554271', 'C0005768', 'C1692758', 'C3853530', 'C0220908', 'C2826704', 'C1710031', 'C2603343', 'C1550100', 'C1279919', 'C0220909', 'C0205197', 'C4283785', 'C1546774', 'C0229664', 'C1515981', 'C1710477']","['Aspects of disease screening', 'Screening procedure', 'Patient Visit', 'Termination - Inactive Reason Code', 'End-stage', 'And', 'Coagulation tissue factor induced:Time:Pt:PPP:Qn:Coag', 'Complete Pharyngeal Contraction', 'Study', 'In Blood', 'Blood', 'termination - ActReason', 'Visit', 'Diagnosis Type - Final', 'PROTHROMBIN TIME', 'Trial Screening', 'peripheral blood', 'Screening', 'Final', 'Screening Study', 'Visit Name', 'Early', 'Disease Screening', 'Specimen Source Codes - Serum', 'Serum', 'research subject screening', 'Data operation - complete', 'week', 'Complete', 'Specimen Type - Serum']","['tmco', 'fndg', 'hlca', 'irda', 'idcn', 'bdsu', 'inpr', 'qlco', 'bhvr', 'resa', 'ftcn', 'diap', 'clna']"
661,PMC3321505,S44,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,urinalysis was done at baseline and final visit.,"['C0042014', 'C0205088', 'C1442488', 'C3853528', 'C0168634', 'C2826704', 'C1515981', 'C0545082', 'C1546485', 'C1512346']","['BaseLine dental cement', 'Patient Visit', 'End-stage', 'Visit Name', 'Urinalysis', 'And', 'Visit', 'Baseline', 'Final', 'Diagnosis Type - Final']","['tmco', 'idcn', 'hlca', 'inpr', 'qnco', 'qlco', 'lbpr', 'bhvr', 'bodm']"
662,PMC3321505,S46,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",End points and analysis,"the primary end point for reduce-1 was gastric ulcers identified at endoscopy during the 24-week study period, with three secondary end points: upper gi ulcers (gastric and duodenal), duodenal ulcers, and gi complications (bleeding, ulcer perforation, and gastric outlet obstruction due to ulcer).","['C0162651', 'C0205449', 'C0205225', 'C0034194', 'C0439230', 'C0678226', 'C0205396', 'C1171258', 'C0009566', 'C0019080', 'C0013303', 'C0038358', 'C0205436', 'C0038351', 'C0439531', 'C1704242', 'C0549099', 'C1550043', 'C0332287', 'C3887532', 'C0175668', 'C2349179', 'C0013295', 'C0347984', 'C0444930', 'C0027627', 'C2603343', 'C0041582', 'C2746065', 'C0014245', 'C1881710', 'C0203057', 'C1515981', 'C1948053']","['In addition to', 'And', 'Gastric (qualifier value)', 'Study', 'Duodenum', 'upper gi series', 'Endoscopy (procedure)', 'Period (temporal qualifier)', 'Container status - Identified', 'second (number)', 'Due to', 'Gastric ulcer', 'Ulceration', 'Stomach', 'Neoplasm Metastasis', 'Duodenal Ulcer', 'Identified', 'End', 'Complication Aspects', 'During', 'Pyloric Stenosis', 'Gastric outlet obstruction', 'Medical Device Material Perforation', 'Primary', 'Ulcer', 'Secondary to', 'Stop (qualifier value)', 'Complication', 'Three', 'week', 'Hemorrhage', 'per period (qualifier value)', 'End Point', 'Perforation (observation)']","['tmco', 'fndg', 'idcn', 'bpoc', 'qlco', 'qnco', 'dsyn', 'spco', 'resa', 'neop', 'ftcn', 'diap', 'patf']"
663,PMC3321505,S47,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",End points and analysis,"the primary end point for reduce-2 was upper gi (gastric or duodenal) ulcers identified at endoscopy during the 24-week study period, with three secondary end points: gastric ulcers, duodenal ulcers, and gi complications.","['C0205449', 'C0205225', 'C0439230', 'C0205396', 'C1171258', 'C0009566', 'C0013303', 'C0038358', 'C0205436', 'C0038351', 'C0439531', 'C1704242', 'C1550043', 'C0332287', 'C0175668', 'C2349179', 'C0013295', 'C0347984', 'C0444930', 'C0027627', 'C2603343', 'C0041582', 'C2746065', 'C0014245', 'C0203057', 'C1515981', 'C1948053']","['In addition to', 'And', 'Gastric (qualifier value)', 'Study', 'Duodenum', 'upper gi series', 'Endoscopy (procedure)', 'Period (temporal qualifier)', 'Container status - Identified', 'second (number)', 'Gastric ulcer', 'Stomach', 'Neoplasm Metastasis', 'Duodenal Ulcer', 'Identified', 'End', 'Complication Aspects', 'During', 'Primary', 'Ulcer', 'Secondary to', 'Stop (qualifier value)', 'Complication', 'Three', 'week', 'per period (qualifier value)', 'End Point']","['tmco', 'fndg', 'resa', 'idcn', 'qlco', 'qnco', 'dsyn', 'spco', 'ftcn', 'bpoc', 'neop', 'diap', 'patf']"
664,PMC3321505,S48,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",End points and analysis,an endoscopic diagnosis of ulcer required unequivocal depth and diameter of ≥3 mm.,"['C1514873', 'C0011900', 'C0041582', 'C1704656', 'C3887532', 'C1704338', 'C0014245', 'C0442418', 'C4053896', 'C1515981', 'C0205125', 'C1301886']","['Diagnosis', 'Deep (qualifier value)', 'Endoscopy (procedure)', 'Diameter (qualifier value)', 'Ulcer', 'Unequivocal', 'Requirement', 'diagnosis aspect', 'And', 'Endoscopic approach - access', 'Diagnosis Study', 'Ulceration']","['idcn', 'qlco', 'qnco', 'spco', 'resa', 'ftcn', 'diap', 'patf']"
665,PMC3321505,S49,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",End points and analysis,"the predefined primary population for analysis included all patients who were randomized, received a dose of study medication, and had at least one study-mandated follow-up endoscopy.","['C3272598', 'C2603343', 'C0205447', 'C0014245', 'C4284232', 'C0030705', 'C0178602', 'C1515981', 'C3244316', 'C0680395', 'C0444868', 'C1524024', 'C0013227', 'C0936012']","['primary group', 'Endoscopy (procedure)', 'Medications', 'All', 'Analysis', 'WHO Temperature/Humidity Storage Condition', 'And', 'analysis aspect', 'Patients', 'Dosage', 'Study', 'One', 'Pharmaceutical Preparations', 'medication - HL7 publishing domain']","['idcn', 'inpr', 'qlco', 'qnco', 'resa', 'podg', 'ftcn', 'diap', 'popg', 'phsu']"
666,PMC3321505,S50,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",End points and analysis,a sample size for reduce-1 of 875 was calculated based on a 90% power to detect a difference of 6% vs. 14% in the incidence of gastric ulcers with a two-sided α of 0.05 and assuming a 15% drop-out rate.,"['C0849355', 'C1705241', 'C0032863', 'C0332287', 'C0871208', 'C0038358', 'C0220856', 'C3854080', 'C1521828', 'C1515981', 'C0439787', 'C3891454', 'C0205448', 'C1705242', 'C0021149', 'C0242618', 'C0442726']","['Different', 'Rating (action)', 'Two', 'Sample Size', 'incidence of cases', 'Power (Psychology)', 'In addition to', 'Incidence', 'Removed', 'Rate', 'And', 'Power', 'Detected (finding)', 'Out (direction)', 'Delta (difference)', 'Gastric ulcer', 'Dosing Days to Detection']","['tmco', 'fndg', 'idcn', 'qnco', 'qlco', 'dsyn', 'spco', 'hcpp', 'ftcn', 'acty']"
667,PMC3321505,S51,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",End points and analysis,a sample size for reduce-2 of 600 was calculated based on a 90% power to detect a difference of 6% vs. 16% in the incidence of upper gi ulcers with a two-sided α of 0.05 and assuming a 15% drop-out rate.,"['C0849355', 'C1705241', 'C0032863', 'C0041582', 'C0332287', 'C0871208', 'C0203057', 'C0220856', 'C3854080', 'C1521828', 'C1515981', 'C0439787', 'C3891454', 'C0205448', 'C1705242', 'C0021149', 'C0242618', 'C0442726']","['Different', 'upper gi series', 'Two', 'Sample Size', 'Power (Psychology)', 'incidence of cases', 'Ulcer', 'Incidence', 'In addition to', 'Rate', 'Removed', 'And', 'Power', 'Detected (finding)', 'Out (direction)', 'Delta (difference)', 'Dosing Days to Detection', 'Rating (action)']","['tmco', 'fndg', 'idcn', 'qnco', 'qlco', 'spco', 'hcpp', 'ftcn', 'diap', 'patf', 'acty']"
668,PMC3321505,S52,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",End points and analysis,"statistical comparisons were predefined to be done with a fixed testing sequence (hierarchical) in the following order of primary followed by secondary end points: reduce-1: gastric ulcers, upper gi ulcers, duodenal ulcers, gi complications; reduce-2: upper gi ulcers, gastric ulcers, duodenal ulcers, gi complications.","['C0332282', 'C0038215', 'C0205225', 'C1171258', 'C0009566', 'C1705176', 'C0004793', 'C0038358', 'C0205436', 'C0392366', 'C1882348', 'C0162326', 'C3853789', 'C0443218', 'C0175668', 'C0013295', 'C1519249', 'C0444930', 'C1705177', 'C0027627', 'C1705175', 'C3889825', 'C1705178', 'C0039593', 'C0203057', 'C2746065', 'C0162327', 'C3714578', 'C2827483']","['RNA Sequence', 'Base Sequence', 'upper gi series', 'Fixed Specimen', 'Following', 'Sequence - TransmissionRelationshipTypeCode', 'Fix', 'second (number)', 'Tests (qualifier value)', 'Gastric ulcer', 'Neoplasm Metastasis', 'Duodenal Ulcer', 'Order (action)', 'Sequence', 'Testing', 'End', 'Complication Aspects', 'DNA Sequence', 'Order (document)', 'Order (taxonomic)', 'Science of Statistics', 'Primary', 'Fixed behavior', 'Secondary to', 'Stop (qualifier value)', 'Complication', 'Sequence of Planned Assessment Schedule', 'Permutation', 'Order (arrangement)']","['tmco', 'nusq', 'acty', 'clas', 'inpr', 'ocdi', 'qlco', 'qnco', 'phpr', 'dsyn', 'spco', 'ftcn', 'neop', 'diap', 'patf', 'bdsu']"
669,PMC3321505,S53,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",End points and analysis,"with this approach, the first null hypothesis that is accepted (i.e., p≥0.05) will cause immediate acceptance of all subsequent null hypotheses in the sequence (subsequent comparisons will be considered not significantly different and no statistical comparison will be performed).","['C0456148', 'C0332282', 'C0162326', 'C0205435', 'C1518422', 'C0038215', 'C3853789', 'C0205548', 'C1279901', 'C1080058', 'C0004793', 'C1519249', 'C0162327', 'C1707455', 'C0444868', 'C1705242', 'C0449445', 'C4684719', 'C0205253']","['Different', 'Firstly', 'Stat (do immediately)', 'Immediate', 'DNA Sequence', 'All', 'Following', 'First (number)', 'Null Hypothesis', 'Sequence', 'Comparison', 'Sequence - TransmissionRelationshipTypeCode', 'RNA Sequence', 'This (eukaryote)', 'Base Sequence', 'Approach', 'Negation', 'Null Value', 'Science of Statistics']","['tmco', 'nusq', 'ocdi', 'inpr', 'qnco', 'qlco', 'spco', 'euka', 'ftcn', 'acty']"
670,PMC3321505,S54,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",End points and analysis,this approach also requires no α adjustment for multiple comparisons (14).,"['C0456081', 'C1080058', 'C0376209', 'C0683269', 'C0439064', 'C0449445']","['Adjustment Action', 'Psychological adjustment', 'This (eukaryote)', 'Individual Adjustment', 'Approach', 'Numerous']","['inbe', 'qnco', 'euka', 'spco', 'ftcn']"
671,PMC3321505,S55,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",End points and analysis,the two different primary end points in the individual studies were chosen to address both the more clinically relevant end point of upper gi ulcers (gastric and/or duodenal) and the traditional us fda (food and drug administration) end point of gastric ulcers.,"['C0237401', 'C1442065', 'C0205225', 'C1706528', 'C1706086', 'C0041714', 'C0013303', 'C2347946', 'C0038358', 'C0205448', 'C0205172', 'C0027361', 'C0038351', 'C1704242', 'C2349179', 'C0443324', 'C0444930', 'C1705242', 'C1707391', 'C1548559', 'C0041582', 'C2746065', 'C0203057', 'C0376649', 'C1515981', 'C0947630']","['And', 'Traditional origin', 'Gastric (qualifier value)', 'Duodenum', 'Addresses (publication format)', 'upper gi series', 'United States Food and Drug Administration', 'Persons', 'Relevance', 'And/Or', 'Gastric ulcer', 'Dispense Method - Traditional', 'Address', 'Individual', 'Stomach', 'Two', 'More', 'End', 'Scientific Study', 'Choose (action)', 'Different', 'Primary', 'Ulcer', 'Stop (qualifier value)', 'End Point', 'Both']","['tmco', 'cnce', 'idcn', 'inpr', 'hcro', 'qlco', 'qnco', 'lbpr', 'dsyn', 'spco', 'bpoc', 'ftcn', 'diap', 'popg', 'patf', 'acty']"
672,PMC3321505,S56,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",End points and analysis,"in clinical practice, physicians and patients are concerned about preventing ulcers, whether they are gastric or duodenal, and many clinical trials use this primary end point.","['C3245512', 'C0031831', 'C1704242', 'C0041582', 'C0013303', 'C1080058', 'C1551058', 'C0205225', 'C2349179', 'C0030705', 'C1515981', 'C0237607', 'C0205210', 'C0008976', 'C0439064', 'C0038351', 'C0747726', 'C1096775']","['Clinical', 'Stomach', 'Practice Experience', 'POLY', 'Primary', 'Ulcer', 'Clinical Trials', 'HL7PublishingSubSection <practice>', 'And', 'Clinical Trial [Publication Type]', 'Gastric (qualifier value)', 'Patients', 'Physicians', 'This (eukaryote)', 'Duodenum', 'are unit of measure', 'End Point', 'Numerous']","['prog', 'idcn', 'inpr', 'bpoc', 'qlco', 'qnco', 'euka', 'resa', 'podg', 'menp', 'patf', 'cnce']"
673,PMC3321505,S57,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",End points and analysis,"however, the fda generally has approved antisecretory medications for prevention of gastric ulcers (e.g., lansoprazole and esomeprazole).","['C1706420', 'C0050940', 'C0199176', 'C0038358', 'C2700409', 'C1515981', 'C0682875', 'C0041714', 'C0937846']","['United States Food and Drug Administration', 'lansoprazole', 'Prophylactic treatment', 'And', 'Prevention Study', 'prevention aspects', 'Esomeprazole', 'Gastric ulcer', 'antisecretory drugs']","['idcn', 'topp', 'orch', 'hcro', 'qlco', 'dsyn', 'resa', ' phsu', 'phsu']"
674,PMC3321505,S58,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",End points and analysis,"these two trials were designed to be used for registration, and, in pretrial meetings, the fda agreed to the use of the different end points in the two trials.","['C1514821', 'C2746065', 'C1553384', 'C0556656', 'C0444930', 'C0205448', 'C2697663', 'C0041714', 'C0042153', 'C1705242', 'C0457083', 'C0039828']","['Different', 'United States Food and Drug Administration', 'Two', 'Registration', 'Stop (qualifier value)', 'Image Registration', 'Usage', 'meeting', 'End', 'registration - ActClass', 'utilization qualifier', 'Theses']","['tmco', 'mcha', 'hlca', 'inpr', 'hcro', 'qnco', 'qlco', 'spco', 'ftcn', 'acty']"
675,PMC3321505,S59,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",End points and analysis,"comparison between treatment arms of the crude proportions of patients with ulcers at 24 weeks with a cochran–mantel–haenszel test stratified by the two randomization risk factor strata (use of low-dose aspirin and other anticoagulants, prior ulcer history) was specified as the primary statistical analysis at the time of sample size calculation and study initiation.","['C0871424', 'C1515976', 'C0022885', 'C4318744', 'C0205225', 'C0446516', 'C0019664', 'C3538994', 'C1565156', 'C0439230', 'C1707455', 'C0332152', 'C1533734', 'C2608320', 'C0087111', 'C0003280', 'C1158830', 'C3887704', 'C1705169', 'C0039798', 'C0034656', 'C0030705', 'C1704686', 'C2681631', 'C0392366', 'C0205448', 'C0042153', 'C0262926', 'C0332287', 'C3887532', 'C0019665', 'C2826257', 'C0456984', 'C1421478', 'C0043194', 'C2004062', 'C1705255', 'C0206655', 'C3897657', 'C0262512', 'C0589507', 'C0457083', 'C2603343', 'C0205363', 'C0041582', 'C1522326', 'C0039593', 'C0040223', 'C0035648', 'C1515981', 'C3831328', 'C0205369']","['KIDINS220 gene', 'In addition to', 'Low-Dose Aspirin', 'And', 'Test - temporal region', 'Study', 'utilization qualifier', 'History', 'Specific qualifier value', 'Alveolar rhabdomyosarcoma', 'Medical History', 'stratified', 'Comparison', 'Time', 'Treatment Epoch', 'Tests (qualifier value)', 'Upper arm', 'History of previous events', 'Before', 'Biomaterial Treatment', 'Cognitive function: initiation', 'Laboratory Procedures', 'Ulceration', 'Administration procedure', 'Concept History', 'Wiskott-Aldrich Syndrome', 'Two', 'Transcription Initiation', 'History of present illness', 'Test Result', 'WAS gene', 'statistical analysis', 'Anticoagulants', 'Testing', 'Patients', 'Initiation', 'Sample Size Calculation', 'Primary', 'Ulcer', 'treatment - ActInformationManagementReason', 'Anatomic Structure, System, or Substance', 'Treating', 'Prior Medication Usage', 'WAS protein, human', 'Usage', 'therapeutic aspects', 'Blood Products Laboratory Testing', 'week', 'Randomization', 'risk factors', 'Historical aspects qualifier', 'Therapeutic procedure']","['topp', 'qnco', 'podg', ' aapp', 'menp', 'patf', 'blor', 'fndg', 'idcn', 'clas', 'hlca', 'inpr', 'genf', 'qlco', 'bacs', 'lbpr', 'resa', 'ftcn', 'phsu', 'tmco', 'lbtr', 'ocdi', 'orch', 'neop', 'acty', 'cnce', 'gngm', 'dsyn', ' phsu', 'evnt']"
676,PMC3321505,S60,['6b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0]",End points and analysis,"before study termination and unblinding, the primary analysis was changed to a comparison between treatment arms of the life table estimates of the proportion of patients with ulcers at 24 weeks employing a modified χ2 using the sum of squares from the life table in the error term, with the comparison of crude proportions using the cochran–mantel–haenszel test maintained as a secondary analysis.","['C1515273', 'C1515976', 'C0022885', 'C0743559', 'C4318744', 'C0205225', 'C0446516', 'C1565156', 'C3538994', 'C0439230', 'C2826302', 'C1707455', 'C0392747', 'C1549081', 'C1533734', 'C0936012', 'C0443172', 'C0087111', 'C0205103', 'C3889737', 'C3887704', 'C1705169', 'C1608199', 'C1314677', 'C0205436', 'C0023683', 'C0030705', 'C0039798', 'C2681631', 'C0557351', 'C0392366', 'C4553913', 'C1709707', 'C0332287', 'C1692758', 'C0175668', 'C1421478', 'C0456984', 'C0043194', 'C0206655', 'C0233324', 'C1517320', 'C0027627', 'C3897431', 'C2603343', 'C0041582', 'C1522326', 'C0039593', 'C0023680', 'C1515051', 'C1705313', 'C1515981', 'C3831328', 'C1524024']","['KIDINS220 gene', 'Termination - Inactive Reason Code', 'Life Tables', 'In addition to', 'Reported Term', 'And', 'Data Change Date', 'From', 'Test - temporal region', 'Study', 'Sum', 'Act Reason - Error', 'Term (lexical)', 'termination - ActReason', 'Alveolar rhabdomyosarcoma', 'error', 'Comparison', 'second (number)', 'Treatment Epoch', 'Tests (qualifier value)', 'analysis aspect', 'Upper arm', 'Changed status', 'Biomaterial Treatment', 'Laboratory Procedures', 'Subject Unblinding Event Record', 'Administration procedure', 'Unblinding', 'Wiskott-Aldrich Syndrome', 'Neoplasm Metastasis', 'Changing', 'Employed', 'Test Result', 'WAS gene', 'treatment - ActInformationManagementReason', 'Testing', 'Patients', 'Therapeutic procedure', 'Intermediate', 'Life Table Estimates', 'Ulcer', 'Primary', 'Anatomic Structure, System, or Substance', 'Analysis', 'Treating', 'Secondary to', 'WAS protein, human', 'Maintaining (action)', 'Term (temporal)', 'Blood Products Laboratory Testing', 'therapeutic aspects', 'week', 'Term Birth', 'Proportion']","['topp', 'qnco', 'podg', ' aapp', 'patf', ' qnco', 'blor', 'fndg', 'clas', 'idcn', 'hlca', 'inpr', 'qlco', 'bacs', 'lbpr', 'resa', 'ftcn', 'tmco', 'lbtr', 'spco', 'neop', 'cnce', 'acty', 'gngm', 'dsyn', 'orgf']"
677,PMC3321505,S61,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",End points and analysis,numbers-needed-to-treat (nnts) and absolute risk reductions were calculated using crude proportions.,"['C0087111', 'C0301630', 'C1519101', 'C1292734', 'C1522326', 'C4551656', 'C1515981']","['Treating', 'Reduction (chemical)', 'Surgical reduction', 'And', 'Treatment intent', 'Risk Estimate', 'Therapeutic procedure']","['npop', 'idcn', 'topp', 'qnco', 'ftcn']"
678,PMC3321505,S62,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",End points and analysis,"a pooled analysis of the patients in reduce-1 and -2 was prespecified, with the primary end point being upper gi ulcers, and the secondary end points being gastric ulcers and duodenal ulcers.","['C0205225', 'C1565156', 'C0936012', 'C1709595', 'C0038358', 'C0205436', 'C0030705', 'C0332287', 'C0175668', 'C2349179', 'C0013295', 'C2349200', 'C1421478', 'C0043194', 'C0444930', 'C2987476', 'C0027627', 'C4522255', 'C0041582', 'C2746065', 'C0203057', 'C1515981', 'C1524024']","['In addition to', 'And', 'Exist', 'upper gi series', 'second (number)', 'Pooled Blood Products', 'analysis aspect', 'Gastric ulcer', 'Wiskott-Aldrich Syndrome', 'Neoplasm Metastasis', 'Duodenal Ulcer', 'Pooled Sample', 'WAS gene', 'End', 'Patients', 'Pool (action)', 'Primary', 'Ulcer', 'WAS protein, human', 'Analysis', 'Secondary to', 'Stop (qualifier value)', 'End Point']","['tmco', 'resa', 'gngm', 'idcn', ' aapp', 'qlco', 'qnco', 'phsu', 'sbst', 'bacs', 'dsyn', 'spco', 'ftcn', 'podg', 'neop', 'diap', 'patf', 'cnce']"
679,PMC3321505,S63,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",End points and analysis,"the proportion of patients developing ulcers was also prespecified to be assessed in the following subgroups: use of low-dose aspirin and/or anticoagulants, prior ulcer history, age (≥65 vs. <65 years), gender, and race.","['C0332282', 'C0019664', 'C0178602', 'C1706528', 'C1706779', 'C0332152', 'C0003280', 'C0034510', 'C1522384', 'C0030705', 'C0042153', 'C0262926', 'C4321351', 'C1709707', 'C3887532', 'C3890211', 'C0019665', 'C2826257', 'C1079230', 'C2004062', 'C1705255', 'C4522223', 'C0262512', 'C4048187', 'C0457083', 'C0079399', 'C0041582', 'C0205251', 'C1515981', 'C0004057', 'C3853635', 'C0001779', 'C1550472']","['Age', 'low confidentiality', 'And', 'low exposure', 'Low Mitosis-Karyorrhexis Index', 'utilization qualifier', 'History', 'sex', 'Medical History', 'Following', 'Race', 'Aspirin', 'Racial group', 'And/Or', 'IPSS Risk Category Low', 'History of previous events', 'Before', 'Ulceration', 'Concept History', 'History of present illness', 'Anticoagulants', 'Dosage', 'Patients', 'AMACR wt Allele', 'Low Level', 'Gender', 'Ulcer', 'Prior Medication Usage', 'low', 'Usage', 'Subgroup A Nepoviruses', 'Historical aspects qualifier', 'Proportion']","['tmco', 'cnce', 'fndg', 'popg', 'virs', 'gngm', 'idcn', 'ocdi', 'orch', 'inpr', 'qnco', 'qlco', 'orga', 'podg', 'ftcn', ' phsu', 'evnt', 'patf', 'phsu']"
680,PMC3321505,S64,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",End points and analysis,"in addition, post hoc subgroup analysis included use of low-dose aspirin alone, and presence or absence of erosions at screening endoscopy.","['C1883712', 'C0178602', 'C0687676', 'C0205171', 'C0042153', 'C2986480', 'C0333307', 'C0332197', 'C4321351', 'C0332287', 'C3890211', 'C3469826', 'C1959609', 'C0332257', 'C0679994', 'C4522223', 'C4048187', 'C0457083', 'C0150312', 'C0439044', 'C0014245', 'C0392148', 'C0205251', 'C1704687', 'C1550472']","['low confidentiality', 'In addition to', 'Singular', 'alone - group size', 'low exposure', 'Low Mitosis-Karyorrhexis Index', 'Erosion lesion', 'Including (qualifier)', 'utilization qualifier', 'Post', 'Subset Analysis', 'Endoscopy (procedure)', 'SLC35G1 gene', 'IPSS Risk Category Low', 'Dosage', 'Low Level', 'Absent', 'Post Device', 'Superficial ulcer', 'low', 'Usage', 'Providing presence (regime/therapy)', 'Add - instruction imperative', 'Living Alone', 'Present']","['tmco', 'mnob', 'fndg', 'gngm', 'topp', 'inpr', 'qnco', 'qlco', 'grpa', 'resa', 'ftcn', 'diap', 'acab', 'patf']"
681,PMC3321505,S65,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",End points and analysis,"for comparison of subgroups with <100 patients across the combined treatment arms, a fisher's exact test was used.","['C2828393', 'C1515976', 'C0009429', 'C0022885', 'C4318744', 'C0039593', 'C0446516', 'C1079230', 'C1704537', 'C0030705', 'C4050514', 'C0456984', 'C2681631', 'C0206655', 'C1707455', 'C3831328', 'C0392366']","['Alveolar rhabdomyosarcoma', 'KIDINS220 gene', 'Anatomic Structure, System, or Substance', 'Test Result', 'Comparison', 'Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome Questionnaire', 'Testing', 'Blood Products Laboratory Testing', 'Upper arm', 'Patients', 'Subgroup A Nepoviruses', 'Test - temporal region', 'Tests (qualifier value)', 'Laboratory Procedures', 'Exact (qualifier)', 'Osteopathic Combined Method', 'Combined Modality Therapy']","['blor', 'virs', 'gngm', 'clas', 'topp', 'lbtr', 'inpr', 'qlco', 'lbpr', 'ftcn', 'podg', 'neop', 'acty']"
682,PMC3321505,S66,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",End points and analysis,"the independent variables prior ulcer history, gender, age, low-dose aspirin use, baseline erosions, and therapy also were included in a proportional hazards model to determine the effect on the dependent variable of development of upper gi ulcer.","['C1527148', 'C0871711', 'C0013675', 'C0019664', 'C0168634', 'C0439828', 'C1363945', 'C0243107', 'C0678723', 'C0332152', 'C2608320', 'C0087111', 'C2348382', 'C1518681', 'C1522384', 'C1280500', 'C0039798', 'C0085862', 'C0042153', 'C0333307', 'C0262926', 'C0033489', 'C3887532', 'C0019665', 'C2826257', 'C2004062', 'C1959609', 'C1705255', 'C0262512', 'C0457083', 'C0079399', 'C0041582', 'C1442488', 'C0203057', 'C1515981', 'C1290940', 'C1299583', 'C0001779']","['Age', 'Effect, Appearance', 'Dependent Variable', 'Low-Dose Aspirin', 'And', 'Independent for Transfer', 'Erosion lesion', 'utilization qualifier', 'History', 'Independence', 'sex', 'upper gi series', 'Medical History', 'Variable (uniformity)', 'development aspects', 'History of previous events', 'Before', 'Baseline', 'Ulceration', 'Therapy Object (animal model)', 'Concept History', 'Development', 'Biologic Development', 'History of present illness', 'Independently able', 'Outcome of Therapy', 'Effect', 'Proportional Hazards Models', 'BaseLine dental cement', 'Gender', 'Ulcer', 'Superficial ulcer', 'Prior Medication Usage', 'Effect Modifier, Epidemiologic', 'Usage', 'therapeutic aspects', 'Historical aspects qualifier', 'Therapeutic procedure']","['tmco', 'fndg', 'bodm', 'topp', 'idcn', 'phsf', 'ocdi', 'inpr', 'orch', 'qnco', 'qlco', 'acab', 'orga', 'orgf', 'ftcn', 'diap', ' phsu', 'evnt', 'patf', 'cnce']"
683,PMC3321505,S67,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",End points and analysis,treatment-by-subgroup interaction was also assessed among these subgroups in the model.,"['C0087111', 'C3274659', 'C1522326', 'C3714583', 'C3887704', 'C1705169', 'C3853906', 'C1079230', 'C3538994', 'C0039798', 'C3161035', 'C1704675', 'C1533734', 'C0039828']","['Theses', 'Model Number', 'Digital Model Attachment', 'treatment - ActInformationManagementReason', 'Model', 'Treating', 'Treatment Epoch', 'therapeutic aspects', 'Subgroup A Nepoviruses', 'Biomaterial Treatment', 'Interaction', 'Administration procedure', 'Model - style/design', 'Therapeutic procedure']","['virs', 'topp', 'hlca', 'inpr', 'resa', 'ftcn', 'cnce']"
684,PMC3321505,S68,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",End points and analysis,"a post hoc fixed effect meta-analysis of the results of the two studies for end points of upper gi, gastric, and duodenal ulcers was also performed (review manager 5.1, cochrane collaboration, copenhagen, denmark).","['C0687676', 'C1524024', 'C0282443', 'C0936012', 'C2348382', 'C1518681', 'C1280500', 'C0205448', 'C0011318', 'C0038351', 'C1704242', 'C0443218', 'C0013295', 'C1546507', 'C3469826', 'C0444930', 'C1552617', 'C0335141', 'C2746065', 'C0203057', 'C3714578', 'C1704687', 'C2827483', 'C1042496', 'C0947630', 'C0282116']","['Effect, Appearance', 'Gastric (qualifier value)', 'Relationship - Manager', 'Post', 'upper gi series', 'Fixed Specimen', 'Meta', 'Fix', 'SLC35G1 gene', 'analysis aspect', 'manager', 'Denmark', 'Stomach', 'Two', 'Duodenal Ulcer', 'Outcome of Therapy', 'End', 'Effect', 'Scientific Study', 'Post Device', 'Fixed behavior', 'Analysis', 'Stop (qualifier value)', 'collaboration', 'Act Class - review', 'Review [Publication Type]']","['qnco', 'phpr', 'fndg', 'idcn', 'inpr', 'qlco', 'lbpr', 'socb', 'resa', 'ftcn', 'mnob', 'bpoc', 'bdsu', 'tmco', 'prog', 'spco', 'euka', 'gngm', 'geoa', 'dsyn', 'diap']"
685,PMC3321505,S69,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",End points and analysis,statistical comparison between the study groups in the population of all patients randomized was also prespecified for common adverse events (occurring in >5% of patients) with a cochran–mantel–haenszel test.,"['C1515976', 'C0022885', 'C0038215', 'C4318744', 'C1522138', 'C1707455', 'C1705413', 'C1257890', 'C0032659', 'C0441833', 'C0030705', 'C0392366', 'C0205214', 'C1552839', 'C0456984', 'C3245511', 'C0444868', 'C2603343', 'C0039593', 'C0687744', 'C3831328', 'C0877248']","['Test - temporal region', 'Common Specifications in HL7 V3 Publishing', 'Study', 'geographic population', 'Table Rules - groups', 'Comparison', 'Tests (qualifier value)', 'Laboratory Procedures', 'Population Group', 'Groups', 'All', 'Social group', 'Test Result', 'shared attribute', 'Testing', 'Patients', 'Common (qualifier value)', 'Science of Statistics', 'Anatomic Structure, System, or Substance', 'Adverse Event Domain', 'Blood Products Laboratory Testing', 'Adverse event']","['blor', 'lbtr', 'clas', 'idcn', 'inpr', 'ocdi', 'qnco', 'lbpr', 'resa', 'podg', 'ftcn', 'popg', 'patf', 'acty']"
686,PMC3321505,S70,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",End points and analysis,"in addition, we prespecified comparison of the proportion of patients who reported any symptom consistent with dyspepsia (e.g., dyspepsia, upper abdominal pain or discomfort, epigastric pain or discomfort, stomach pain or discomfort; with and without nausea).","['C4084796', 'C0332290', 'C4554097', 'C1883712', 'C0221512', 'C0000737', 'C4085862', 'C1707455', 'C1963179', 'C3829611', 'C3272598', 'C0232492', 'C2364135', 'C0030705', 'C2984057', 'C0027497', 'C0232493', 'C4553767', 'C1709707', 'C0332287', 'C0013395', 'C4085661', 'C4552968', 'C1552551', 'C3854129', 'C4552888', 'C3272371', 'C4085222', 'C1963242', 'C4552889', 'C4255480', 'C1457887']","['Discomfort', 'Nausea', 'In addition to', 'How Much Distress Nausea', 'Abdominal Pain', 'Symptoms', 'Epigastric pain', 'upper abdominal pain', 'Bothered by Nausea', 'Nausea:Presence or Threshold:Point in time:^Patient:Ordinal', 'Stomach Pain, CTCAE 5.0', 'Dyspepsia', 'Comparison', 'Any Data Type', 'Have Nausea', 'Usual Severity Nausea', 'Nausea Visual Analogue Scale', 'Stomach Pain, CTCAE 3.0', 'How Much Nausea During This Period', 'Any', 'Patients', 'Stomach ache', 'Nausea, CTCAE 3.0', 'Consistent with', 'Nausea, CTCAE 5.0', 'Dyspepsia, CTCAE', 'How Often Nausea', 'Feel Nausea', 'WHO Temperature/Humidity Storage Condition', 'Add - instruction imperative', 'Symptom:Find:Pt:^Patient:Nom', 'Proportion']","['fndg', 'idcn', 'inpr', 'sosy', 'qlco', 'qnco', 'podg', 'ftcn', 'acty', 'clna']"
687,PMC3321505,S71,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",End points and analysis,all study patients provided written informed consent and the study was approved by institutional review boards for all participating centers.,"['C0972401', 'C2603343', 'C0021430', 'C0030705', 'C1515981', 'C0282443', 'C0679823', 'C0444868', 'C1552617', 'C0205099']","['All', 'And', 'Informed Consent', 'Patients', 'Act Class - review', 'Study', 'Central', 'participation', 'Review [Publication Type]', 'Boards (medical device)']","['rnlw', 'idcn', 'medd', 'inpr', 'qnco', 'spco', 'resa', 'podg', 'ftcn']"
688,PMC3348565,S100,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,for our intention-to-treat analysis we included all children randomly assigned to our study groups.,,,
689,PMC3348565,S101,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,for our per-protocol analysis we included children who in both groups received all doses with an interval between the doses of 60 and 120 days and had not violated the randomisation codes.,,,
690,PMC3348565,S102,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,we analysed the repeat episodes accounting for clustering within individuals.,"['C1705914', 'C0332189', 'C1547730', 'C0009085', 'C0205341']","['Repeat Object', 'Repeat Pattern', 'Episode of', 'statistical cluster', 'Repeat']","['ftcn', 'tmco', 'resa']"
691,PMC3348565,S103,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,we made initial comparisons of time-to-an-episode between the two groups with log-rank tests and kaplan–meier plots.,"['C0022885', 'C0332189', 'C1552839', 'C0441833', 'C0040223', 'C2986775', 'C0687744', 'C1555582', 'C0667477', 'C1279901', 'C1515981', 'C1705685', 'C0205265', 'C0205448', 'C0392366', 'C0699794', 'C1708728']","['Initial (abbreviation)', 'Initial Usage', 'TNFRSF11A protein, human', 'Firstly', 'Groups', 'Laboratory Procedures', 'Event Log', 'Tests (qualifier value)', 'And', 'Table Rules - groups', 'Rank', 'Two', 'Time', 'Logarithm', 'Episode of', 'Social group', 'Initially']","['bacs', 'inpr', 'idcn', 'lbpr', 'popg', 'ftcn', 'tmco', 'qlco', ' aapp', 'qnco']"
692,PMC3348565,S104,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,we estimated the incidence rate ratio (rr) for the episodes of pneumonia with cox proportional hazard models.,"['C0332189', 'C1547037', 'C0598697', 'C0205351', 'C0456603', 'C0032285', 'C3161035', 'C4321252', 'C1708485', 'C0521125', 'C1565830']","['WWOX wt Allele', 'data type - ratio', 'Model', 'Ratio', 'hazard', 'proportional', 'Incidence Rate', 'Preposition For', 'Episode of', 'PTGS1 protein, human', 'Pneumonia']","['inpr', 'gngm', 'enzy', 'tmco', 'qlco', 'dsyn', ' aapp', 'qnco']"
693,PMC3348565,S105,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,we assessed violation of the proportionality assumption with schoenfeld residuals.,['C1609982'],['Residual'],['qlco']
694,PMC3348565,S106,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"this study is registered with clinicaltrials.gov, number nct00548379.",,,
695,PMC3348565,S108,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Role of the funding source,"the sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.","['C1511726', 'C0010995', 'C0684224', 'C0043266', 'C2584304', 'C4255046', 'C3714741', 'C3273238', 'C2983265', 'C2986888', 'C0010992', 'C2603343', 'C4283917', 'C2347796', 'C3173575', 'C1711305', 'C3887707', 'C0035171', 'C4050126', 'C0062074', 'C1705810', 'C0700287', 'C0035820', 'C3539897', 'C3245479', 'C1415458', 'C0459471', 'C3871154']","['Writing (function)', 'Reporting', 'Interpretation:Impression/interpretation of study:Point in time:^Patient:Nominal', 'Sponsor (person)', 'Role', 'Data call receiving device', 'Ability to Write question', 'Have', 'Research Design', 'Writing Ability', 'Regulatory Report', 'HADH gene', 'Nonclinical Study Design', 'Data Collection', 'Data Collection Methods', 'Social Role', 'Clinical Study Sponsor', 'Study', 'Data', 'Data Analysis', 'Report (document)', 'Report:Finding:Point in time:{Setting}:Document:{Role}', 'Interpretation Process', 'HAC protocol', 'Generic Role', 'Data (eukaryote)', 'CDISC SEND Study Design Terminology', 'Writing (occupation or discipline)']","['inpr', 'clna', 'idcn', 'gngm', 'ocdi', 'ocac', 'topp', 'medd', 'popg', 'qlco', 'euka', 'resa', 'socb', 'hlca', 'menp', 'qnco', 'orgt']"
696,PMC3348565,S109,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Role of the funding source,the corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.,"['C1511726', 'C1515981', 'C4321252', 'C3714741', 'C3853528', 'C0678341', 'C0443225', 'C2603343', 'C1546485', 'C1704324', 'C0034037', 'C0679006', 'C0444454', 'C0062074', 'C0521125', 'C3812881', 'C3539897', 'C3245479', 'C0034036', 'C1415458', 'C0444868', 'C1554204', 'C0205088']","['Role Class - access', 'And', 'Data call receiving device', 'Preposition For', 'Have', 'WWOX wt Allele', 'HADH gene', 'Final', 'responsibility', 'Diagnosis Type - Final', 'Publishing', 'Data (eukaryote)', 'full', 'All', 'Study', 'Publications', 'Data', 'End-stage', 'author', 'HAC protocol', 'Decision', 'Scientific Publication', 'Access']","['inpr', 'inbe', 'idcn', ' mnob', 'gngm', 'prog', 'ocac', 'topp', 'medd', 'ftcn', 'spco', 'qlco', 'euka', 'tmco', 'resa', 'menp', 'qnco']"
697,PMC3348565,S49,"['3a', '4b']","[0, 0, 0, 0, 0, 0, 1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,"between nov 4 and dec 4, 2008, we did a community based randomised placebo-controlled superiority trial in kabul, afghanistan, within the catchment area of the maiwand teaching hospital, which serves an inner-city population.","['C4505129', 'C1515981', 'C2911690', 'C1705310', 'C0332285', 'C4521283', 'C0008848', 'C0000872', 'C0032659', 'C0205102', 'C1696465', 'C0001732', 'C0949920', 'C0020027', 'C0007403', 'C0009462', 'C0032042', 'C1121443', 'C1706408', 'C1257890', 'C3262831', 'C2587213']","['Academic Medical Centers', 'geographic population', 'And', 'Cities', 'placebo', 'Superiority Trial', 'Placebos', 'Dose Expansion Cohort', 'Within', 'Catchment Area (Health)', 'Afghanistan', 'Community', 'Teaching Hospitals', 'Disease Controlled', 'Control function', 'Norovirus', 'PTEN wt Allele', 'Placebo Control', 'Internal', 'NOV protein, human', 'Population Group', 'City:Location:Point in time:^Patient:Nominal']","['bacs', 'grup', 'clna', 'geoa', 'idcn', 'bodm', 'gngm', 'topp', 'popg', 'ftcn', 'mnob', 'fndg', 'spco', 'virs', 'resa', ' aapp', ' hcro', 'qnco']"
698,PMC3348565,S50,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,"follow up ended in may, 2009.",,,
699,PMC3348565,S51,['4b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,the children we enrolled into our study largely came from five of the 18 socioeconomically deprived inner-city districts.,"['C0008059', 'C0008848', 'C0205102', 'C3262831', 'C2603343', 'C0205451', 'C0680063']","['Internal', 'Cities', 'City:Location:Point in time:^Patient:Nominal', 'Study', 'Offspring', 'Five', 'Child']","['clna', 'geoa', 'aggp', 'famg', 'spco', 'resa', 'qnco']"
700,PMC3348565,S52,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,"we identified households with young children with detailed maps and advice from staff of the agha khan trust for culture, a non-governmental organisation working in the region.","['C0026045', 'C0430400', 'C0205147', 'C1515981', 'C4321252', 'C0017446', 'C0010453', 'C1518422', 'C3245466', 'C2242979', 'C0851286', 'C0043227', 'C0680063', 'C1947908', 'C0237935', 'C0024779', 'C0220814', 'C0150600', 'C0521125', 'C0332239', 'C0008059', 'C0020052', 'C1522508']","['Anthropological Culture', 'And', 'Households', 'Preposition For', 'WWOX wt Allele', 'Work', 'Microtubule-Associated Proteins', 'Laboratory culture', 'Advice', 'young', 'Map', 'Offspring', 'regional', 'Negation', 'Trust (Social Behavior)', 'Cultural aspects', 'Staff', 'Child', 'Microbial culture (procedure)', 'Geographic Locations', 'ObservationValue - trust', 'On Staff', 'Details']","['bacs', 'idcn', 'geoa', 'lbpr', 'aggp', 'famg', 'prog', 'gngm', 'ocac', 'ftcn', 'mnob', 'spco', 'qlco', 'tmco', 'socb', 'hlca', ' aapp']"
701,PMC3348565,S53,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,"furthermore, the study field-supervisors mapped the region independently to verify the accuracy of the maps of the agha khan trust for culture, and during recruitment they visited every house in the mapped region to identify families with young children.","['C0026045', 'C0430400', 'C3858752', 'C0205147', 'C1515981', 'C0017446', 'C0010453', 'C3245466', 'C2242979', 'C1711411', 'C2603343', 'C0680063', 'C0237935', 'C2003847', 'C0442519', 'C0015576', 'C3539073', 'C2949735', 'C2349184', 'C0024779', 'C0220814', 'C0443131', 'C0332239', 'C2346620', 'C1521738', 'C0008059', 'C1948061']","['Field', 'Anthropological Culture', 'House (environment)', 'And', 'Every (qualifier)', 'Microtubule-Associated Proteins', 'Laboratory culture', 'young', 'Accurate (qualifier)', 'Map', 'Force Field', 'Offspring', 'regional', 'Family', 'Trust (Social Behavior)', 'Data Mapping', 'Cultural aspects', 'Study', 'Recruitment', 'In the Field', 'Child', 'Microbial culture (procedure)', 'Verification', 'Geographic Locations', 'Home environment', 'ObservationValue - trust', 'Knowledge Field']","['bacs', 'inpr', 'idcn', 'geoa', 'lbpr', 'aggp', 'famg', 'acty', 'ftcn', 'mnob', 'spco', 'qlco', 'cnce', 'tmco', 'resa', 'socb', ' aapp']"
702,PMC3348565,S54,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,20 pairs of female fieldworkers visited every home starting from streets closest to the hospital and radiating out until we reached our required sample size.,"['C0442658', 'C0019994', 'C0086287', 'C0043210', 'C1948061', 'C1515981', 'C1522666', 'C1705498', 'C1514873', 'C1705497', 'C0242618', 'C0442519']","['Woman', 'Closest', 'Female Phenotype', 'Home environment', 'Sample Size', 'Female, Self-Report', 'Females', 'And', 'Requirement', 'Every (qualifier)', 'Street (environment)', 'Hospitals']","['idcn', 'geoa', 'popg', 'ftcn', 'mnob', 'spco', 'qlco', ' hcro', 'qnco', 'orga']"
703,PMC3348565,S55,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,those homes where the carer or infant was absent were revisited again within 4 weeks of the recruitment period.,"['C0021270', 'C4684754', 'C1442465', 'C1305660', 'C4285062', 'C0085537', 'C0043194', 'C0332197', 'C1421478', 'C1565156', 'C0332285']","['Recruitment Period', 'Infant', 'WAS protein, human', 'Caregiver', 'Carer (occupation)', 'WAS gene', 'Absent', 'Wiskott-Aldrich Syndrome', 'Within', '4 Weeks', 'Pharyngeal Stripping Wave Absent']","['bacs', 'aggp', 'gngm', 'prog', 'ftcn', 'fndg', 'spco', 'tmco', 'resa', 'dsyn', ' aapp']"
704,PMC3348565,S56,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,our inclusion criteria were infants aged 1–11 months and living in our study region.,"['C0595998', 'C0439231', 'C0021270', 'C4520849', 'C4551704', 'C0205147', 'C1515981', 'C1512693', 'C2603343', 'C0017446']","['Household composition', 'Living', 'Alive', 'Infant', 'Inclusion', 'Geographic Locations', 'And', 'Study', 'month', 'regional']","['geoa', 'idcn', 'aggp', 'fndg', 'cnce', 'qlco', 'tmco', 'spco', 'resa']"
705,PMC3348565,S57,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,"our exclusion criteria were families expecting to move to another town within 18 months, diagnosis of rickets or treatment with vitamin d in the previous 3 months, and clinical diagnosis of kwashiorkor or marasmus.","['C0439231', 'C3887704', 'C1705169', 'C1515981', 'C0035579', 'C0680251', 'C0042866', 'C1704656', 'C3714503', 'C0022806', 'C2936842', 'C0039798', 'C1704338', 'C3538994', 'C0015576', 'C0332140', 'C0086588', 'C0011900', 'C0557750', 'C0205156', 'C3537249', 'C1442461', 'C0087111', 'C1552607', 'C1522326', 'C1533734', 'C0014695']","['Biomaterial Treatment', 'And', 'Exclusion Criteria', 'month', 'Act Relationship Subset - previous', 'Therapeutic procedure', 'Diagnosis', 'Administration procedure', 'Vitamin D Drug Class', 'Vitamin D [EPC]', 'Family', 'Diagnosis Study', 'Treatment Epoch', 'Diagnosis, clinical', 'diagnosis aspect', 'D Vitamin', 'Rickets', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Vitamin D', 'Marasmus', 'Ergocalciferol', '3 Months', 'Kwashiorkor', 'Towns', 'Previous', 'Treating']","[' orch', 'idcn', 'geoa', 'famg', 'topp', 'ftcn', 'cnce', 'qlco', 'vita', ' phsu', 'resa', 'tmco', 'dsyn', 'hlca', 'diap', 'phsu']"
706,PMC3348565,S58,"['5', '10']","[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Participants,"the fieldworkers obtained written informed consent from the mother, father, or another senior family member before recruitment; allocated the unique identification number (sequentially); and gave the first dose of vitamin d3 or placebo.","['C3265062', 'C0086282', 'C0032042', 'C0021430', 'C2949735', 'C0178602', 'C1706408', 'C1300638', 'C1696465', 'C0026591', 'C1279901', 'C0015671', 'C1705825', 'C1710548', 'C0008318', 'C0205435']","['Placebo Control', 'Father (person)', 'Firstly', 'identification number', 'First (number)', 'Family member', 'Placebos', 'Unique', 'placebo', 'Cholecalciferol', 'Informed Consent', 'Senior - Suffix', 'Recruitment', 'Mother (person)', 'Dosage', 'vitamin D3']","[' orch', 'inpr', 'rnlw', 'idcn', 'bodm', 'acty', 'famg', 'topp', 'orch', 'vita', 'qlco', 'resa', ' phsu', 'qnco']"
707,PMC3348565,S59,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,children with vomiting were excluded temporarily and enrolled 2 weeks later after recovery.,"['C0008059', 'C3898969', 'C4084769', 'C0237820', 'C0205087', 'C4084766', 'C0042963', 'C1555688', 'C0680063', 'C4084768', 'C1442457', 'C1963281', 'C2004454', 'C4084767']","['recovery - adjustment', 'Have Been Vomiting', 'How Much Distress Vomiting', 'Bothered by Vomiting', 'Recovery - action', 'Usual Severity Vomiting', 'Recovery - healing process', 'Late', 'Vomiting, CTCAE', 'Offspring', '2 Weeks', 'Vomiting', 'How Often Vomiting', 'Child']","['sosy', 'inpr', 'aggp', 'acty', 'famg', 'fndg', 'tmco', 'orgf', 'qnco']"
708,PMC3348565,S60,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,thumbprint or signature consent was obtained from the child's parents (mother and father if in kabul or another family member responsible for the child) at home if the child met our study criteria and after either the parent read the dari consent form or it was explained to him or her by the fieldworker.,"['C0009797', 'C2923685', 'C4534363', 'C1515981', 'C0030551', 'C4321252', 'C1565156', 'C1550543', 'C2699423', 'C0260096', 'C0026591', 'C2603343', 'C0043194', 'C0680063', 'C1705179', 'C1273518', 'C1705596', 'C0243161', 'C3844638', 'C1511481', 'C1554192', 'C1519316', 'C0521125', 'C0428210', 'C0086282', 'C0008059', 'C1514562', 'C0015671', 'C1421478', 'C4317104', 'C0687676', 'C0034754', 'C0231290']","['Status post', 'Reading (activity)', 'And', 'Family member', 'Consent:Finding:Point in time:{Setting}:Document:Patient', 'ActClass - consent', 'Preposition For', 'WWOX wt Allele', 'Routine Signature', 'responsible', 'Either', 'Father (person)', 'WAS protein, human', 'Protein Domain', 'WAS gene', 'Methionine measurement', 'Fulfill', 'Offspring', 'parent', 'criteria', 'Signature', 'Consent Forms', 'Conceptual Parent', 'Study', 'parent and child', 'Mother (person)', 'Child', 'Post', 'Consent', 'Reading (datum presentation)', 'Wiskott-Aldrich Syndrome', 'At home', 'Metabolic Equivalent of Task Unit']","['bacs', 'inpr', 'clna', 'phpr', 'idcn', 'aggp', 'lbpr', 'famg', 'amas', 'dora', 'gngm', 'ftcn', 'cnce', 'fndg', 'tmco', 'qlco', 'resa', 'dsyn', ' aapp', 'qnco']"
709,PMC3348565,S61,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,"our study was approved by the ethics and review board of the ministry of public health of afghanistan (reference 422328; issued may 12, 2007) and the ethics committee of the london school of hygiene and tropical medicine (application number 5117; issued may 29, 2008).","['C0972401', 'C0036375', 'C1515981', 'C1514811', 'C0041186', 'C0034019', 'C0237753', 'C0699943', 'C0085546', 'C3539080', 'C0001732', 'C1706462', 'C2603343', 'C4048755', 'C0023973', 'C1948070', 'C1947919', 'C0015000', 'C0282443', 'C0185125', 'C0449788', 'C1552617', 'C0020405', 'C1527243', 'C4321404', 'C3812381', 'C2347934', 'C3244304']","['Apply', 'Ethics Committees', 'And', 'Tropical Medicine', 'Ethics', 'School', 'London', 'Board (committee)', 'Usually Need Help from Another Person for Hygiene', 'Public health service', 'Act Class - review', 'Afghanistan', 'Bibliographic Reference', 'Boards (medical device)', 'Reference Object', 'Month of May', 'Numbers', 'public health medicine (field)', 'Study', 'Application Dosing Unit', 'Public health domain', 'ethics qualifier', 'Regulatory Application', 'Review [Publication Type]', 'Application procedure', 'Count of entities', 'Application (Document)', 'Hygiene']","['bmod', 'inpr', 'geoa', 'idcn', ' mnob', 'prog', 'medd', 'ftcn', 'cnce', 'tmco', 'resa', 'hlca', 'qnco', 'orgt']"
710,PMC3348565,S63,"['8a', '8b', '10']","[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0]",Randomisation and masking,"an independent statistician (shabbar jaffar, london school of hygiene and tropical medicine, london, uk) randomised unique identification numbers individually in fixed blocks of 20 to the vitamin d3 or placebo group by use of a random number generator with the sas routine.","['C3265062', 'C0085862', 'C0439605', 'C1300638', 'C0441833', 'C0687744', 'C0036375', 'C1515981', 'C0041186', 'C0237753', 'C0205547', 'C1696465', 'C0034656', 'C3714578', 'C0237638', 'C0008318', 'C1533157', 'C0332287', 'C1299583', 'C0023973', 'C1426104', 'C1705429', 'C1290940', 'C0334957', 'C0449788', 'C0443218', 'C1823519', 'C2827483', 'C0032042', 'C0020405', 'C1710548', 'C1519504', 'C4321404', 'C1706408', 'C0332206', 'C1257890', 'C0028778', 'C0457083', 'C1705428', 'C0605290', 'C3811660', 'C0042153']","['Randomization', 'Routine', 'identification number', 'Random', 'And', 'Fixed Specimen', 'Tropical Medicine', 'TSPAN31 gene', 'Block Specimens', 'Unique', 'Blocking', 'Independent for Transfer', 'placebo', 'Stage Grouping', 'statistician', 'School', 'SAS', 'Usage', 'London', 'Usually Need Help from Another Person for Hygiene', 'User Group', 'Placebos', 'Group Object', 'Social group', 'Fixed behavior', 'vitamin D3', 'Independently able', 'Generators (Apparatus)', 'Numbers', 'In addition to', 'Block Unit of Distance', 'Placebo Control', 'NANS gene', 'Count of entities', 'Obstruction', 'Groups', 'utilization qualifier', 'Hygiene', 'Fix', 'Population Group', 'Cholecalciferol', 'Independence']","[' orch', 'topp', 'mnob', 'fndg', 'bdsu', 'qlco', ' phsu', 'bmod', 'inpr', 'phpr', 'geoa', ' mnob', 'idcn', 'gngm', 'prog', 'patf', 'vita', 'resa', 'bodm', 'popg', 'ftcn', 'orch', 'cnce', 'qnco', 'orgt']"
711,PMC3348565,S64,['9'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1]",Randomisation and masking,"by use of the randomisation list, a pharmacist in the department of pharmacy, aga khan university hospital, karachi prepared 100 000 iu (2·5 mg) of vitamin d3 (cholecalciferol) in olive oil (sinochem ningbo laboratory, china) or placebo (olive oil) in sealed 2 ml plastic syringes labelled with the unique identification numbers.","['C3265062', 'C1300638', 'C1704729', 'C4082130', 'C0745732', 'C0031336', 'C0031321', 'C1521827', 'C4283904', 'C1696465', 'C0032167', 'C0022877', 'C3244303', 'C0008115', 'C0332287', 'C0008318', 'C0020028', 'C0031322', 'C0032042', 'C0031323', 'C0039142', 'C1706408', 'C3244292', 'C0069449', 'C3272378', 'C0457083', 'C1710548', 'C0042153']","['identification number', 'Unique', 'Pharmaceutical Services', 'Pharmacy facility', 'placebo', 'Laboratory domain', 'Usage', 'Placebos', 'Sequence Data Type', 'Laboratory', 'vitamin D3', 'Department', 'Preparation', 'Plastics', 'China', 'List', 'In addition to', 'Prepared', 'Placebo Control', 'Hospitals, University', 'utilization qualifier', 'olive oil', 'Pharmacy domain', 'Pharmacist', 'Cholecalciferol', 'Pharmacy (field)', 'Syringes', 'Laboratory observation']","[' orch', 'topp', 'medd', 'mnob', 'fndg', 'qlco', 'hlca', ' phsu', 'sbst', ' hcro', 'bmod', 'inpr', 'geoa', 'prog', 'lbtr', 'vita', 'resa', 'bodm', ' food', 'ftcn', 'orch', 'acty', 'orgt']"
712,PMC3348565,S65,"['11a', '11b']","[0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,"the vitamin d3 and the placebo were the same colour (pale yellow), taste, and quantity (0·5 ml) and therefore the study staff and the families did not know to which group the children were assigned.","['C3265062', 'C0441833', 'C1554108', 'C4699304', 'C0687744', 'C1515981', 'C1707660', 'C1518422', 'C1696465', 'C0039336', 'C0851286', 'C2603343', 'C0680063', 'C1947908', 'C1547046', 'C0008318', 'C1265611', 'C0015576', 'C1705429', 'C0008059', 'C2828361', 'C0032042', 'C0445247', 'C1519504', 'C1706408', 'C1561573', 'C1257890', 'C1705428']","['Pale yellow', 'And', 'placebo', 'Stage Grouping', 'User Group', 'Placebos', 'Offspring', 'Data Type - Quantity', 'Group Object', 'MDF Attribute Type - Quantity', 'Social group', 'Family', 'Negation', 'vitamin D3', 'Taste Perception', 'Do (activity)', 'Same', 'Study', 'Staff', 'Quantity', 'Child', 'Placebo Control', 'Groups', 'Population Group', 'Cholecalciferol', 'Deidentification', 'Kind of quantity - Taste', 'On Staff']","['ortf', ' orch', 'famg', 'topp', 'fndg', 'qlco', ' phsu', 'inpr', 'idcn', 'aggp', 'prog', 'vita', 'resa', 'bodm', 'mcha', 'popg', 'ftcn', 'orch', 'acty', 'cnce', 'qnco']"
713,PMC3348565,S66,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,fieldworkers allocated children to randomisation groups during recruitment and gave vitamin d or placebo.,"['C0042866', 'C0008059', 'C0032042', 'C3714503', 'C2949735', 'C1706408', 'C1552839', 'C0441833', 'C2936842', 'C0687744', 'C1696465', 'C1515981', 'C0680063', 'C0014695', 'C3537249']","['Placebo Control', 'Groups', 'And', 'Placebos', 'D Vitamin', 'Table Rules - groups', 'placebo', 'Vitamin D [EPC]', 'Vitamin D Drug Class', 'Offspring', 'Recruitment', 'Vitamin D', 'Social group', 'Ergocalciferol', 'Child']","[' orch', 'inpr', 'idcn', 'aggp', 'acty', 'famg', 'topp', 'popg', 'vita', 'resa', ' phsu', 'bodm', 'phsu']"
714,PMC3348565,S68,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Procedures,"we chose a quarterly supplementation regimen because in routine programme conditions a quarterly regimen is likely to have better adherence than a daily regimen,13,14 and has been shown to be effective at maintaining the serum vitamin d concentration within normal ranges for 2–3 months in a french high-risk infant population.16","['C0086045', 'C0439231', 'C4522209', 'C1299351', 'C0040808', 'C0205250', 'C1515981', 'C0376246', 'C3640168', 'C4321252', 'C0332285', 'C4522046', 'C1556084', 'C3889660', 'C0042866', 'C0332179', 'C0332148', 'C3714503', 'C0086715', 'C0032659', 'C1704419', 'C0205547', 'C0021270', 'C2936842', 'C1446561', 'C0332272', 'C3827302', 'C4321237', 'C3887512', 'C2945654', 'C1280519', 'C3154893', 'C0242297', 'C0332173', 'C4552904', 'C0521125', 'C3537249', 'C3539897', 'C1257890', 'C1510802', 'C0750492', 'C0035647', 'C2700149', 'C0014695', 'C0428581']","['Effectiveness', 'Routine', 'Infant', 'Normal Range', 'French Catheter Gauge', 'geographic population', 'And', 'Abnormally high', 'month', 'Preposition For', 'Have', 'WWOX wt Allele', 'High Level', 'Concentration measurement', 'French language', 'high - ActExposureLevelCode', 'Dietary Supplementation', 'Serum vitamin A measurement', 'quarterly', 'Within', 'Vitamin D Drug Class', 'Vitamin D [EPC]', 'Adherence (attribute)', 'Treatment Protocols', 'Regimen - CHV concept', 'Better', 'Better than Others', 'High Mitosis-Karyorrhexis Index', 'Subject Risk', 'french race', 'Risk', 'Value Above Reference Range', 'Mental concentration', 'Daily', 'D Vitamin', 'IPSS Risk Category High', 'Probably', 'Vitamin D', 'Probable diagnosis', 'Ergocalciferol', 'High', 'Effective', 'Possess', 'Population Group', 'Able to Concentrate Question']","[' orch', 'inpr', 'idcn', 'aggp', 'lbpr', 'gngm', 'topp', 'popg', 'ftcn', 'cnce', 'fndg', 'qlco', 'vita', 'tmco', 'lang', 'spco', ' phsu', 'menp', 'qnco', 'phsu']"
715,PMC3348565,S69,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Procedures,the syringes containing vitamin d or placebo were stored in conditions recommended by the manufacturer—a dry cool environment—between 2 and 24 weeks before administration.,"['C0042866', 'C0032042', 'C3714503', 'C1512080', 'C1706408', 'C0039142', 'C1696465', 'C2936842', 'C0011682', 'C1548792', 'C0439230', 'C1515981', 'C1533734', 'C0205222', 'C0014695', 'C0001554', 'C0678568', 'C3537249']","['Placebo Control', 'Dryness (characteristic)', 'week', 'Administration occupational activities', 'And', 'Placebos', 'D Vitamin', 'Administration procedure', 'placebo', 'Vitamin D [EPC]', 'Vitamin D Drug Class', 'Desiccation', 'Syringes', 'Dry', 'Vitamin D', 'Cool - action', 'Specimen Condition - Cool', 'Ergocalciferol']","[' orch', 'idcn', 'ocac', 'topp', 'medd', 'qlco', 'vita', 'tmco', 'resa', ' phsu', 'npop', 'bodm', 'phsu']"
716,PMC3348565,S70,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,"we provided each child with an identification card, which included a photograph of the child, to enable easy access to outpatient and out-of-hours paediatric services at the study hospital.","['C1548439', 'C0439787', 'C0562342', 'C1515981', 'C0441468', 'C0030755', 'C0332219', 'C1171285', 'C0020792', 'C2603343', 'C0680063', 'C0029921', 'C0019994', 'C0441469', 'C1457900', 'C0444454', 'C0557854', 'C0008059', 'C3275277', 'C2930619', 'C1549405', 'C0205396', 'C1554204', 'C0849355', 'C0439227']","['Picture', 'Role Class - access', 'Sex Differentiation Disorders', 'Out (direction)', 'Hour', 'And', 'Removed', 'Empowered', 'Card (document)', 'Identified', 'Enabling', 'Outpatients', 'Offspring', 'Each (qualifier value)', 'Referral category - Outpatient', 'Services', 'Patient Class - Outpatient', 'Pediatrics', 'Hospitals', 'Study', 'Child', 'Easy', 'photograph', 'Access', 'Identification (Psychology)']","['bmod', 'inpr', 'idcn', 'aggp', 'famg', 'clas', 'ocac', 'ftcn', 'mnob', 'spco', 'qlco', 'podg', 'fndg', 'tmco', 'resa', 'dsyn', 'menp', ' hcro', 'qnco']"
717,PMC3348565,S71,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,we encouraged families to bring their children to the study hospital for any illness for which quality treatment was offered free of charge.,"['C0007961', 'C1880497', 'C0332306', 'C3887704', 'C1705169', 'C3272371', 'C1996904', 'C1706211', 'C2603343', 'C0680063', 'C0332296', 'C1552551', 'C0039798', 'C3538994', 'C0015576', 'C0019994', 'C0221423', 'C0008059', 'C0087111', 'C1522326', 'C1533734']","['Biomaterial Treatment', 'Therapeutic procedure', 'Free (available (qualifier))', 'Any Data Type', 'charge amounts', 'Charge (electrical)', 'Administration procedure', 'Free of (attribute)', 'Offspring', 'Family', 'Any', 'Treatment Epoch', 'with quality', 'Study', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Child', 'Empty (qualifier)', 'Treating', 'Illness (finding)', 'Hospitals']","['sosy', 'inpr', 'aggp', 'famg', 'topp', 'ftcn', 'mnob', 'cnce', 'qlco', 'resa', 'hlca', ' hcro', 'qnco', 'orga']"
718,PMC3348565,S72,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,"four experienced paediatricians and 30 female fieldworkers (medical students, nurses, midwives, or community health workers) were rigorously trained in our study protocols, the integrated management of childhood illnesses strategy, and the assessment of signs and symptoms required by our study.","['C1261322', 'C0009467', 'C0086287', 'C1515981', 'C0001554', 'C1705498', 'C3273539', 'C1705497', 'C0043210', 'C0038495', 'C0442711', 'C2603343', 'C0037088', 'C1273870', 'C0679199', 'C0221423', 'C0028661', 'C1514873', 'C0205450', 'C0376636', 'C0026083', 'C0231335', 'C1516048']","['Woman', 'Female Phenotype', 'Evaluation procedure', 'And', 'Females', 'Students, Medical', 'Four', 'Disease Management', 'Administration occupational activities', 'Requirement', 'Management procedure', 'Protocols documentation', 'Community Health Workers', 'Signs and Symptoms', 'strategy', 'Midwife', 'Study', 'Management Occupations', 'Childhood', 'Female, Self-Report', 'Illness (finding)', 'Nurses', 'Assessed']","['sosy', 'inpr', 'idcn', 'acty', 'prog', 'ocac', 'ocdi', 'popg', 'ftcn', 'qlco', 'tmco', 'resa', 'hlca', 'menp', 'qnco', 'orga']"
719,PMC3348565,S73,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,the quality of clinical assessment in the clinics and during home visits was monitored weekly by study supervisors.,"['C1261322', 'C0332306', 'C0442592', 'C1516634', 'C1515981', 'C0020043', 'C2603343', 'C0332174', 'C4534461']","['Clinic', 'Evaluation procedure', 'And', 'research clinical testing', 'with quality', 'Home visit (procedure)', 'Study', 'Clinical assessment', 'Weekly']","['idcn', 'mnob', 'tmco', 'qlco', 'resa', 'hlca', ' hcro']"
720,PMC3348565,S74,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,"the fieldworkers followed up the children every 2 weeks until june, 2009, to obtain background information, assess illness (symptom history and examination of chest in-drawing, body temperature [thermoval classic hartmann digital thermometer], signs of dehydration by skin pinching, respiratory rate count over 1 min with a stopwatch), and to refer to the study hospital if needed.","['C0262926', 'C4321286', 'C1705566', 'C1515981', 'C4321457', 'C0019665', 'C0005903', 'C0011175', 'C1533716', 'C0347984', 'C1301820', 'C4284399', 'C0262512', 'C3829443', 'C2603343', 'C0680063', 'C0439858', 'C0332287', 'C0220912', 'C4520765', 'C0728376', 'C0019994', 'C0221423', 'C0220913', 'C1123023', 'C0205136', 'C0418416', 'C3854129', 'C0686904', 'C0019664', 'C1457887', 'C1706907', 'C1720302', 'C0013113', 'C0817096', 'C0205543', 'C2004062', 'C0008059', 'C0444099', 'C0489258', 'C0311392', 'C0231832', 'C1705255', 'C0585332', 'C0439658', 'C1706701', 'C0750480', 'C1527391', 'C1516048']","['Skin', 'Medical History', 'Dehydration', 'Respiratory rate', 'Body Temperature', 'Anterior thoracic region', 'And', 'Manufactured sign', 'Background', 'History', 'Acquisition (action)', 'Until', 'Skin, Human', 'Dehydration procedure', 'Chest', 'Offspring', 'Symptoms', 'classic behavior', 'Skin Specimen', 'June', 'Count Dosing Unit', 'Patient need for (contextual qualifier)', 'Referring', 'classical example', 'Physical findings', 'Aspects of signs', 'Count', 'Study', 'Concept History', 'History of present illness', 'Examination', 'Symptom:Find:Pt:^Patient:Nom', 'Classic Histology', 'In addition to', 'Assessed', 'Over (spatial)', 'Child', 'During', 'Biweekly', 'Breaths:Number = Count/Time:Point in time:Respiratory system:Quantitative', 'Historical aspects qualifier', 'thermometer digital', 'Illness (finding)', 'Pinched', 'Information', 'History of previous events', 'Hospitals', 'Obtain', 'Drawings (art)']","['clna', 'famg', 'medd', 'fndg', 'mnob', 'bdsu', 'qlco', 'bdsy', ' hcro', 'inpr', 'idcn', 'lbpr', 'aggp', 'clas', 'inpo', 'resa', 'sosy', 'ftcn', 'blor', 'tmco', 'dsyn', 'acty', 'ocdi', 'cnce', 'spco', 'qnco', 'orga']"
721,PMC3348565,S75,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,respiratory rate and anthropomorphic data were collected twice and we used the mean values in our analysis.,"['C1511726', 'C0489258', 'C0231832', 'C3245479', 'C0444504', 'C0936012', 'C1948050', 'C0042295', 'C1515981', 'C2348143', 'C1524024', 'C2347634', 'C3714741']","['Statistical mean', 'Respiratory rate', 'Breaths:Number = Count/Time:Point in time:Respiratory system:Quantitative', 'And', 'Data call receiving device', 'Analysis', 'Values', 'Population Mean', 'Data (eukaryote)', 'Data', 'Twice (Numerical Qualifier)', 'Sample Mean', 'analysis aspect']","['clna', 'idcn', 'medd', 'ftcn', 'qlco', 'euka', 'resa', 'qnco']"
722,PMC3348565,S76,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,all children clinically diagnosed with pneumonia were offered free chest radiographs taken by radiographers trained by a who trainer.,"['C0008059', 'C1880497', 'C0402007', 'C0039985', 'C1546517', 'C0032285', 'C1996904', 'C0453962', 'C0680063', 'C0444868', 'C0332296', 'C3272598']","['Trainers', 'radiographer', 'All', 'WHO Temperature/Humidity Storage Condition', 'Empty (qualifier)', 'Trainer relationship', 'Free of (attribute)', 'Offspring', 'Free (available (qualifier))', 'Pneumonia', 'Plain chest X-ray', 'Child']","['idcn', 'aggp', 'famg', 'prog', 'ftcn', 'mnob', 'qlco', 'dsyn', 'diap', 'qnco']"
723,PMC3348565,S77,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"the masked radiographs were read by two independent paediatric radiologists (based at the acute respiratory infections unit of the pakistan institute of medical sciences), experienced in reading paediatric chest radiographs from who vaccine trials, with who proformas for standardised interpretation of paediatric chest radiographs for the diagnosis of pneumonia.17","['C0085862', 'C1306645', 'C1272753', 'C4284139', 'C4321252', 'C0260194', 'C0039985', 'C0021622', 'C0030755', 'C0150112', 'C1704656', 'C3853603', 'C0439148', 'C1509845', 'C1705938', 'C1527178', 'C0042210', 'C0030211', 'C0332287', 'C1705179', 'C1299583', 'C3173575', 'C1704753', 'C0339901', 'C1704338', 'C0025118', 'C1290940', 'C0011900', 'C0205448', 'C0521125', 'C1519795', 'C1555580', 'C1517320', 'C1880519', 'C0032285', 'C0150108', 'C0439453', 'C0459471', 'C0034754', 'C3272598']","['Reading (activity)', 'Interpretation:Impression/interpretation of study:Point in time:^Patient:Nominal', 'Unit', 'Blinded', 'Independent for Transfer', 'From', 'Medicine', 'Preposition For', 'Pakistan', 'WWOX wt Allele', 'Unit of Measure', 'Pneumonia', 'Enzyme Unit', 'Reading Ability question', 'acute respiratory infections', 'psychological masking', 'Diagnosis', 'Diagnosis Study', 'Plain chest X-ray', 'Independently able', 'masked - No information', 'WHO Temperature/Humidity Storage Condition', 'Institutes', 'diagnosis aspect', 'Vaccines', 'Pediatrics', 'Two', 'International Unit', 'In addition to', 'Base - General Qualifier', 'Basis - conceptual entity', 'radiologist', 'Unit - NCI Thesaurus Property', 'Unit device', 'Reading (datum presentation)', 'Interpretation Process', 'Institution (social concept)', 'Plain x-ray', 'Independence', 'Storage Unit']","['clna', 'medd', 'fndg', 'mnob', 'qlco', ' phsu', 'diap', 'bmod', 'inpr', 'geoa', 'idcn', 'gngm', 'prog', 'imft', 'resa', ' aapp', 'ftcn', 'dsyn', 'dora', 'cnce', 'qnco', 'orgt']"
724,PMC3348565,S78,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"in case of disagreement, radiographs were read by a third independent radiologist and most decisions were accepted.","['C0085862', 'C1306645', 'C0205437', 'C1549438', 'C1706255', 'C0679006', 'C1515981', 'C1290940', 'C1706256', 'C0260194', 'C0680238', 'C0868928', 'C1299583', 'C0205393']","['Procedure Practitioner Identifier Code Type - Radiologist', 'Independently able', 'radiologist', 'Case (situation)', 'Most', 'Discord', 'And', 'Plain x-ray', 'Independence', 'Independent for Transfer', 'Packaging Case', 'Decision', 'Third', 'Clinical Study Case']","['inpr', 'idcn', 'prog', 'medd', 'ftcn', 'cnce', 'fndg', 'socb', 'menp', 'diap', 'qnco']"
725,PMC3348565,S79,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"we ascertained causes of death through scrutiny of hospital notes, and verbal autopsy interviews with the who standard questionnaire and review of the interview data by two physicians independently.","['C1511726', 'C1515981', 'C3714741', 'C0015127', 'C0439824', 'C1317574', 'C0031831', 'C0019994', 'C0034394', 'C1314792', 'C1442989', 'C0282443', 'C0205448', 'C0935630', 'C1306577', 'C0011065', 'C1552617', 'C3245479', 'C0021822', 'C2828392', 'C3272598', 'C0004398']","['Standard (document)', 'And', 'Questionnaires', 'Data call receiving device', 'Verbal', 'Death (finding)', 'Autopsy', 'Etiology', 'Act Class - review', 'Standard (qualifier)', 'Cessation of life', 'Note (document)', 'WHO Temperature/Humidity Storage Condition', 'Etiology aspects', 'Published Interview', 'Two', 'Interview', 'Data', 'Review [Publication Type]', 'Physicians', 'Data (eukaryote)', 'Hospitals']","[' hcro', 'inpr', 'idcn', 'acty', 'prog', 'medd', 'ftcn', 'fndg', 'mnob', 'qlco', 'euka', 'diap', 'orgf', 'qnco']"
726,PMC3348565,S80,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"we defined clinical pneumonia as a history of cough plus increased respiratory rate for age, chest in-drawing, or any danger sign (ie, not drinking or breastfeeding, convulsion, vomiting, lethargic or unconscious, stridor in a calm child).","['C0038450', 'C0262926', 'C4084766', 'C4321252', 'C0019665', 'C4084725', 'C1518422', 'C0522165', 'C0023380', 'C3898969', 'C3272371', 'C1547188', 'C4552982', 'C0262512', 'C4048158', 'C0010200', 'C0231835', 'C0680063', 'C1552551', 'C4084726', 'C4084769', 'C0684271', 'C0036572', 'C0019664', 'C4084727', 'C0013113', 'C0817096', 'C1527391', 'C0521125', 'C2004062', 'C0543829', 'C0041657', 'C4084767', 'C0006147', 'C0008059', 'C0311392', 'C0001948', 'C1705255', 'C3274924', 'C4084768', 'C1963281', 'C1961131', 'C0001779', 'C0042963']","['Lethargy', 'Medical History', 'Convulsions', 'Anterior thoracic region', 'Stridor', 'Usual Severity Cough', 'History', 'Vomiting, CTCAE', 'Preposition For', 'Cough, CTCAE', 'Feeling calm', 'WWOX wt Allele', 'Cough Frequency', 'Chest', 'Any Data Type', 'Drinking function', 'Age', 'Tachypnea', 'Offspring', 'How Often Vomiting', 'Negation', 'Alcohol consumption', 'Any', 'Physical findings', 'Bothered by Vomiting', 'Have Been Coughing', 'Usual Severity Vomiting', 'pneumonia clinical', 'Concept History', 'History of present illness', 'How Much Distress Cough', 'Child', 'Stridor, CTCAE', 'Have Been Vomiting', 'Historical aspects qualifier', 'How Much Distress Vomiting', 'Breast Feeding', 'Unconscious State', 'Language Ability - Sign', 'Coughing', 'History of previous events', 'Vomiting', 'Seizures', 'Drawings (art)']","['sosy', 'inpr', 'inbe', 'idcn', 'aggp', 'gngm', 'ocdi', 'famg', 'ftcn', 'fndg', 'cnce', 'blor', 'qlco', 'dsyn', 'menp', 'orgf', 'orga']"
727,PMC3348565,S81,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,we defined severe pneumonia as cough plus chest in-drawing and very severe diseases as cough plus any danger signs.,"['C4050465', 'C4050466', 'C0311392', 'C0220913', 'C3641272', 'C3272371', 'C4050419', 'C3274924', 'C0032285', 'C1836348', 'C0010200', 'C4084727', 'C0220912', 'C0205082', 'C0817096', 'C4084725', 'C1527391', 'C1961131', 'C1552551', 'C4084726']","['Severe disorder', 'Very severe', 'Any', 'Chest', 'Any Data Type', 'Physical findings', 'Anterior thoracic region', 'Aspects of signs', 'Borg Category-Ratio 10 Perceived Exertion Score 5', 'Usual Severity Cough', 'Have Been Coughing', 'Manufactured sign', 'Severe (severity modifier)', 'Severe Extremity Pain', 'Coughing', 'Cough, CTCAE', 'How Much Distress Cough', 'Borg Category-Ratio 10 Perceived Exertion Score 7', 'Pneumonia', 'Cough Frequency']","['sosy', 'inpr', 'ftcn', 'fndg', 'blor', 'qlco', 'mnob', 'dsyn']"
728,PMC3348565,S82,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,our primary endpoint was the first episode of pneumonia from the time of enrolment confirmed by chest radiograph (consolidation or infiltrates).,"['C0332189', 'C3842377', 'C1517320', 'C0040223', 'C0032285', 'C0439615', 'C0702116', 'C2986535', 'C0521530']","['Lung consolidation', 'Primary Endpoint', 'Consolidation', 'From', 'Time', 'Chest radiograph', 'Episode of', 'first episode', 'Pneumonia']","['tmco', 'qlco', 'dsyn', 'irda', 'diap']"
729,PMC3348565,S83,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,we defined as a new episode of pneumonia an episode happening 15 days or longer after the first.,"['C0332189', 'C0205314', 'C1279901', 'C0439228', 'C0205435']","['day', 'New', 'Firstly', 'First (number)', 'Episode of']","['tmco', 'qlco', 'qnco']"
730,PMC3348565,S84,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,we judged an episode happening within 14 days to be continuation of the previous episode.,"['C0205156', 'C0332189', 'C0439228', 'C1552607']","['Episode of', 'Act Relationship Subset - previous', 'Previous', 'day']",['tmco']
731,PMC3348565,S85,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,we collected venous blood samples from randomly selected blocks of children on the basis of the assumption that each block had an equal number of children from the vitamin d3 and placebo groups.,"['C3265062', 'C1706084', 'C0441833', 'C0687744', 'C0444255', 'C1549782', 'C1515981', 'C0237753', 'C1696465', 'C0680063', 'C1527178', 'C1874451', 'C0008318', 'C1533157', 'C1707391', 'C1552839', 'C1457900', 'C0449788', 'C0062074', 'C0205163', 'C0008059', 'C0032042', 'C1517320', 'C3539897', 'C1706408', 'C2828370', 'C0332206', 'C1415458', 'C0028778', 'C3811660']","['venous blood sample', 'And', 'Block (unit of measure)', 'Block Specimens', 'Equal', 'Blocking', 'From', 'Relational Operator - Equal', 'Have', 'placebo', 'HADH gene', 'Placebos', 'Choose (action)', 'Offspring', 'Each (qualifier value)', '(City) Block', 'Social group', 'vitamin D3', 'Numbers', 'Block Unit of Distance', 'Child', 'Basis - conceptual entity', 'Placebo Control', 'Count of entities', 'Obstruction', 'Groups', 'Table Rules - groups', 'Cholecalciferol', 'HAC protocol', 'Basis']","[' orch', 'famg', 'topp', 'bdsu', 'qlco', ' phsu', 'phsu', 'inpr', 'geoa', 'idcn', 'aggp', 'gngm', 'patf', 'vita', 'resa', 'bodm', 'popg', 'ftcn', 'orch', 'acty', 'qnco']"
732,PMC3348565,S86,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,this was to ascertain calcifediol serum concentrations 1 week after giving the first dose in the placebo group (a baseline value for the whole population) as well as early concentrations after the first vitamin d supplementation in the intervention group (70 in placebo and 69 in intervention groups).,"['C0086045', 'C0441833', 'C0687744', 'C1279919', 'C1515981', 'C4321252', 'C1080058', 'C0042866', 'C3714503', 'C0886296', 'C0032659', 'C1696465', 'C2936842', 'C1442488', 'C3146287', 'C0014695', 'C0184661', 'C0178602', 'C1552839', 'C1705429', 'C0242297', 'C0521125', 'C1522609', 'C3537249', 'C2986530', 'C0032042', 'C0168634', 'C0444667', 'C1519504', 'C1706408', 'C1442452', 'C1257890', 'C1279901', 'C0205170', 'C1705428', 'C0687676', 'C0205435', 'C4283957', 'C0231290']","['Status post', 'Baseline', 'Firstly', 'First (number)', 'geographic population', 'And', 'Whole', 'Preposition For', 'placebo', 'Stage Grouping', 'WWOX wt Allele', 'Well', 'Dietary Supplementation', 'Nursing interventions', 'Placebos', 'User Group', 'Vitamin D Drug Class', 'Vitamin D [EPC]', 'Group Object', 'Social group', 'Dosage', 'BaseLine dental cement', 'Mental concentration', '1 Week', 'D Vitamin', 'Good', 'Early', 'Intervention Group', 'Vitamin D', 'Ergocalciferol', 'Numerical value', 'Placebo Control', 'Microplate Well', 'Post', 'Groups', 'Table Rules - groups', 'Population Group', 'Interventional procedure', 'This (eukaryote)']","[' orch', 'topp', 'mnob', 'qlco', ' phsu', 'hlca', 'phsu', 'inpr', 'idcn', 'gngm', 'vita', 'resa', 'bodm', 'popg', 'ftcn', 'tmco', 'menp', 'cnce', 'spco', 'euka', 'qnco']"
733,PMC3348565,S87,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,we also collected samples at other times (appendix) from a different set of randomly selected children to check fluctuations in serum concentrations.,"['C0086045', 'C0008059', 'C1707391', 'C0003617', 'C0040223', 'C0036849', 'C0229671', 'C1546774', 'C0231239', 'C1442518', 'C1705195', 'C0680063', 'C1550100', 'C1632851', 'C1705242']","['Set scale', 'Set (Psychology)', 'Mental concentration', 'Specimen Type - Serum', 'Fluctuation', 'Choose (action)', 'Serum', 'Appendix', 'Time', 'Offspring', 'Times', 'Different', 'set (group)', 'Specimen Source Codes - Serum', 'Child']","['sosy', 'inpr', 'bpoc', 'aggp', 'acty', 'famg', 'ftcn', 'cnce', 'bdsu', 'qlco', 'tmco', 'menp', 'qnco']"
734,PMC3348565,S88,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"we stored the serum samples at −20°c and analysed them at the end of our study with ids-isys multi-discipline automated chemiluminescent assay (immunodiagnostic systems ltd, tyne and wear, uk) at the manchester royal infirmary, manchester, uk (supra-regional vitamin d reference laboratories accredited to iso9001:2000 and iso13485:2003 and participating in the vitamin d quality assurance scheme).","['C1519193', 'C0439064', 'C0205147', 'C1515981', 'C1514811', 'C0221502', 'C1550100', 'C0237070', 'C1947913', 'C0042866', 'C0680883', 'C3714503', 'C0178932', 'C0205554', 'C1282910', 'C2936842', 'C1706462', 'C2603343', 'C1136140', 'C0022877', 'C0332287', 'C0444930', 'C0205276', 'C0229671', 'C1546774', 'C0201709', 'C3266262', 'C3537249', 'C0679823', 'C2746065', 'C0014695']","['Automated (qualifier value)', 'quality assurance', 'And', 'End', 'Serum', 'Local-Regional anatomy', 'Vitamin D Drug Class', 'Vitamin D [EPC]', 'Laboratory', 'Bibliographic Reference', 'Reference Object', 'regional', 'Multiple Chronic Conditions', 'Stop (qualifier value)', 'accredited', 'Local', 'Specimen Type - Serum', 'D Vitamin', 'infirmaries', 'Study', 'Numerous', 'participation', 'Vitamin D', 'In addition to', 'Ergocalciferol', 'Upper', 'Long-Term Synaptic Depression', 'Chemiluminescence assay', 'Scheme', 'Specimen Source Codes - Serum', 'discipline']","['ortf', ' orch', 'mnob', 'bdsu', ' phsu', 'hlca', ' hcro', 'phsu', 'inpr', 'idcn', 'lbpr', 'vita', 'resa', 'ocac', 'ftcn', 'tmco', 'dsyn', 'hcro', 'gora', 'spco', 'cnce', 'qnco']"
735,PMC3348565,S90,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analysis,"we assumed that the incidence of the first or the only episode of pneumonia (first episode) in our placebo group would be 0·0585 per child per year based on the report that the incidence of acute lower respiratory infections in developing countries was greater than 0·65 per child per year,18 that 12% of these episodes were pneumonia, and 75% were first episodes.","['C0684224', 'C0332189', 'C0039828', 'C0441833', 'C0687744', 'C4255046', 'C1515981', 'C1565156', 'C3273238', 'C0439508', 'C1696465', 'C0238990', 'C0043194', 'C0680063', 'C1705938', 'C1527178', 'C0205435', 'C0011750', 'C1705429', 'C0439615', 'C0700287', 'C4281991', 'C0008059', 'C0032042', 'C0021149', 'C1519504', 'C1704243', 'C1706408', 'C0205171', 'C3887962', 'C1257890', 'C1279901', 'C0032285', 'C1421478', 'C1705428', 'C0220856']","['Theses', 'Firstly', 'Reporting', 'First (number)', 'And', 'placebo', 'Stage Grouping', 'per year', 'first episode', 'Pneumonia', 'Regulatory Report', 'WAS protein, human', 'Incidence', 'WAS gene', 'User Group', 'Placebos', 'Per (qualifier)', 'Offspring', 'Group Object', 'Social group', 'Singular', 'Acute lower respiratory tract infection', 'Episode of', 'Base - General Qualifier', 'Child', 'Basis - conceptual entity', 'Follow', 'incidence of cases', 'Placebo Control', 'Report (document)', 'Groups', 'Wiskott-Aldrich Syndrome', 'Population Group', 'Greater', 'Report:Finding:Point in time:{Setting}:Document:{Role}', 'Developing Countries']","['bacs', 'inpr', 'clna', 'idcn', 'bodm', 'aggp', 'gngm', 'famg', 'topp', 'popg', 'ftcn', 'cnce', 'qlco', 'tmco', 'resa', 'dsyn', 'hlca', ' aapp', 'qnco']"
736,PMC3348565,S91,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analysis,"given that 73% of children had vitamin d deficiency in the study region in 2005,12 and that the incidence of pneumonia was ten-times higher in vitamin d deficient children than in children without a deficiency in case-control studies1,2 we postulated that there would be at least a 35% reduction in pneumonia incidence in the vitamin d compared with the placebo group.","['C0441833', 'C0687744', 'C0205250', 'C0205147', 'C0332288', 'C1515981', 'C0301630', 'C0205456', 'C1565156', 'C0017446', 'C0042870', 'C1882979', 'C0042866', 'C3714503', 'C1696465', 'C2936842', 'C1706255', 'C1623416', 'C2603343', 'C0680063', 'C0043194', 'C1707455', 'C0868928', 'C0332287', 'C0014518', 'C0011155', 'C1293152', 'C0014695', 'C4553389', 'C1550141', 'C4551656', 'C1705429', 'C0243148', 'C1706256', 'C0392756', 'C3537249', 'C0030858', 'C0008059', 'C0032042', 'C0021149', 'C1519504', 'C1706408', 'C0040223', 'C1257890', 'C0032285', 'C1632851', 'C1421478', 'C1705428', 'C3274648', 'C0220856', 'C2587213']","['Case (situation)', 'And', 'Surgical reduction', 'Reduced', 'Time', 'placebo', 'Stage Grouping', 'Times', 'Pneumonia', 'Reduction (chemical)', 'Without', 'WAS protein, human', 'Incidence', 'WAS gene', 'User Group', 'Placebos', 'Comparison', 'Pentaerythritol Tetranitrate', 'deficiency aspects', 'Vitamin D Drug Class', 'Vitamin D [EPC]', 'Offspring', 'Packaging Case', 'Group Object', 'Social group', 'regional', 'Study Control', 'Ten', 'D Vitamin', 'Study', 'Control function', 'control substance', 'Vitamin D', 'In addition to', 'Ergocalciferol', 'Scientific Control', 'Child', 'Placebo Control', 'True Control Status', 'incidence of cases', 'High', 'Groups', 'Geographic Locations', 'Wiskott-Aldrich Syndrome', 'Reduction procedure', 'Population Group', 'control aspects', 'Vitamin D Deficiency', 'Deficiency', 'Clinical Study Case', 'Toxic Epidermal Necrolysis']","['bacs', ' orch', 'famg', 'topp', 'medd', 'qlco', ' phsu', 'sbst', 'phsu', 'idcn', 'geoa', 'aggp', 'gngm', 'vita', 'resa', ' aapp', 'npop', 'bodm', 'popg', 'ftcn', 'orch', 'tmco', 'dsyn', 'acty', 'cnce', 'spco', 'qnco']"
737,PMC3348565,S92,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analysis,thus a study with 80% power and 95% significance needed 22 079 child-months per group (total of 2454 children for 18 months follow-up).,"['C0008059', 'C0237881', 'C0439231', 'C1519504', 'C0441833', 'C0687744', 'C0032863', 'C1257890', 'C0439810', 'C1515981', 'C1705429', 'C3854080', 'C2603343', 'C0680063', 'C1705428', 'C0750502']","['Groups', 'Statistical Significance', 'Power (Psychology)', 'And', 'User Group', 'Population Group', 'month', 'Significant', 'Study', 'Power', 'Total', 'Offspring', 'Stage Grouping', 'Group Object', 'Social group', 'Child']","['hcpp', 'idcn', 'aggp', 'famg', 'popg', 'ftcn', 'cnce', 'tmco', 'qlco', 'resa', 'qnco']"
738,PMC3348565,S93,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analysis,assuming a 20% loss to follow-up and allowing for protocol violations we intended to recruit 3050 children for 18 months follow-up.,"['C0008059', 'C3890888', 'C0439231', 'C0680063', 'C1517945']","['Subject Evaluability Criteria and Classification Document', 'Loss', 'month', 'Offspring', 'Child']","['inpr', 'aggp', 'famg', 'tmco', 'qnco']"
739,PMC3348565,S94,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,data were entered into a microsoft access database (version 2007) and data processing and analysis was done in stata (version 11.0).,"['C1511726', 'C0242356', 'C0868941', 'C0993637', 'C3245479', 'C0333052', 'C0936012', 'C1272695', 'C1515981', 'C1554204', 'C1524024', 'C1565156', 'C1421478', 'C0444454', 'C0043194', 'C3714741']","['Published Database', 'Data (eukaryote)', 'Role Class - access', 'WAS protein, human', 'Done (qualifier value)', 'WAS gene', 'And', 'Data call receiving device', 'Wiskott-Aldrich Syndrome', 'Data Processing', 'Analysis', 'Version', 'Data', 'Databases', 'Access', 'analysis aspect']","['bacs', 'inpr', 'idcn', 'gngm', 'medd', 'ftcn', 'spco', 'qlco', 'euka', 'resa', 'dsyn', ' aapp', 'mcha']"
740,PMC3348565,S95,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,we compared baseline characteristics and the distribution of our prestated confounders for intervention and placebo groups.,"['C0032042', 'C0886296', 'C0184661', 'C1552839', 'C1706408', 'C1696465', 'C0441833', 'C1704711', 'C0687744', 'C1515981', 'C4684572', 'C0520511']","['Placebo Control', 'Social group', 'Groups', 'Distribution', 'And', 'Nursing interventions', 'Placebos', 'Table Rules - groups', 'placebo', 'Distributing', 'Interventional procedure', 'Baseline Characteristics']","['inpr', 'idcn', 'topp', 'popg', 'ftcn', 'qlco', 'resa', 'hlca', 'bodm']"
741,PMC3348565,S96,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,to assess the potential problem of multicollinearity we used pearsons correlation coefficient or cramers v (for paired categorical variables).,"['C0439828', 'C3840940']","['Variable (uniformity)', 'Potential problem']","['fndg', 'qlco']"
742,PMC3348565,S97,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"if a child was not seen for more than 45 days, at the two weekly visits, or at the hospital, they were censored for that period of our study.","['C0008059', 'C0205172', 'C0019994', 'C1512346', 'C1948053', 'C0545082', 'C0439531', 'C2603343', 'C0680063', 'C0205448', 'C0332174', 'C0439228', 'C1518422']","['day', 'More', 'Visit', 'Patient Visit', 'Study', 'Two', 'Weekly', 'per period (qualifier value)', 'Period (temporal qualifier)', 'Offspring', 'Hospitals', 'Negation', 'Child']","['aggp', 'famg', 'ftcn', 'mnob', 'tmco', 'resa', 'bhvr', 'hlca', ' hcro', 'qnco']"
743,PMC3348565,S98,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,these children could re-enter the study when next seen.,"['C0332282', 'C0008059', 'C0039828', 'C1883708', 'C2603343', 'C0680063', 'C0205117']","['Theses', 'Adjacent', 'Then', 'Study', 'Offspring', 'Following', 'Child']","['inpr', 'aggp', 'famg', 'spco', 'tmco', 'resa']"
744,PMC3348565,S99,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"we calculated person-time at risk for each child up to the date a child reached our primary endpoint, was last seen at the end of our study, or when censored because they were lost to follow-up.","['C0008059', 'C1565156', 'C2746065', 'C0040223', 'C1457900', 'C1517741', 'C0043194', 'C0035647', 'C2348077', 'C0680063', 'C0011008', 'C2986535', 'C2603343', 'C4552904', 'C2347489', 'C0027361', 'C0444930', 'C1421478', 'C0205397']","['Stop (qualifier value)', 'Date in time', 'Subject Risk', 'Person Observer', 'Primary Endpoint', 'WAS protein, human', 'Risk', 'WAS gene', 'Wiskott-Aldrich Syndrome', 'Date Fruit', 'Study', 'End', 'Persons', 'seen', 'Time', 'Offspring', 'Each (qualifier value)', 'Last', 'Child']","['bacs', 'grup', 'idcn', ' aapp', 'aggp', 'gngm', 'famg', 'popg', 'cnce', 'spco', 'tmco', 'food', 'qlco', 'resa', 'dsyn', 'irda', 'qnco']"
745,PMC3386495,S100,['7b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0]",Randomisation and masking,"the independent data monitoring committee met at least annually to review the unmasked data on major outcome events in the trial, on the background stroke-unit care received by trial patients (to ensure it was equal in both treatment groups), relevant external data (including updates of the cochrane systematic review and reports from large-scale registries of rt-pa use) in strict confidence throughout the course of the trial.","['C0085862', 'C1511726', 'C0684224', 'C0030705', 'C0441833', 'C1705169', 'C0687744', 'C1549782', 'C3887704', 'C2347946', 'C0008976', 'C1515981', 'C0175659', 'C3889645', 'C4554100', 'C1565156', 'C3245515', 'C3714741', 'C1274040', 'C0750729', 'C3853603', 'C0441471', 'C0439148', 'C1947916', 'C1704726', 'C1509845', 'C0043194', 'C0237529', 'C2699414', 'C1709850', 'C1299583', 'C0549177', 'C1704753', 'C0039798', 'C3538994', 'C3541888', 'C0205164', 'C1552839', 'C0038454', 'C0218063', 'C1290940', 'C1706907', 'C1704725', 'C0205101', 'C0205163', 'C0332181', 'C0700287', 'C1955832', 'C0332257', 'C1519795', 'C1517320', 'C3245479', 'C1706086', 'C0032143', 'C0034975', 'C0087111', 'C1880519', 'C0439453', 'C4318856', 'C1947933', 'C0457083', 'C1522326', 'C1533734', 'C0349674', 'C1421478', 'C0042153']","['Extrinsic', 'Scaling', 'Major', 'CDISC Events Class', 'Stroke, CTCAE', 'Reporting', 'Both', 'Biomaterial Treatment', 'Data call receiving device', 'And', 'Equal', 'Patients', 'Background', 'Unit', 'Independent for Transfer', 'From', 'Relational Operator - Equal', 'Unit of Measure', 'Therapeutic procedure', 'Clinical Trial Final Report', 'Result', 'Enzyme Unit', 'Usage', 'Confidence', 'Received By', 'WAS protein, human', 'Ensure (product)', 'Cerebrovascular accident', 'Clinical Trials', 'WAS gene', 'Administration procedure', 'Course', 'Committee', 'Social group', 'Registries', 'Event', 'Independently able', 'Treatment Epoch', 'Systematic Review', 'Intellectual scale', 'Major <insect>', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Data', 'Annual', 'International Unit', 'Statistical Confidence', 'Weight measurement scales', 'Report (document)', 'Groups', 'Unit - NCI Thesaurus Property', 'Relevance', 'Unit device', 'utilization qualifier', 'Including (qualifier)', 'Self Confidence', 'Table Rules - groups', 'Treating', 'Wiskott-Aldrich Syndrome', 'Independence', 'alteplase', 'care activity', 'Data (eukaryote)', 'Registries domain', 'Storage Unit', 'Large']","['bacs', 'topp', 'medd', 'enzy', 'fndg', 'mnob', 'qlco', 'food', 'hlca', ' phsu', 'inpr', 'idcn', 'gngm', 'clas', 'resa', ' aapp', 'popg', 'ftcn', 'podg', 'tmco', 'dsyn', 'menp', 'grup', 'acty', 'cnce', 'spco', 'euka', 'qnco', 'evnt']"
746,PMC3386495,S101,['7b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0]",Randomisation and masking,the committee judged these data never met the protocol-specified criteria to recommend modification of the protocol or halt recruitment to the study.,"['C1511726', 'C0039828', 'C4282383', 'C3714741', 'C2003901', 'C3715209', 'C0034866', 'C0442711', 'C2599718', 'C1522729', 'C2603343', 'C1507394', 'C2699414', 'C2949735', 'C0205369', 'C0243161', 'C3840684', 'C3889737', 'C1554963', 'C0392747', 'C3245479', 'C2348563']","['Theses', 'REMS Protocol', 'Specific qualifier value', 'Data call receiving device', 'Study Protocol', 'Protocol - answer to question', 'Clinical trial protocol', 'Clinical trial protocol document', 'Protocols documentation', 'Committee', 'criteria', 'ResponseLevel - modification', 'Data Change Date', 'Changing', 'Never (frequency)', 'Study', 'Data', 'Recruitment', 'Recommendation', 'Modification', 'Data (eukaryote)', 'Library Protocol']","['inpr', 'grup', 'idcn', 'acty', 'medd', 'ftcn', 'fndg', 'tmco', 'euka', 'qlco', 'resa']"
747,PMC3386495,S102,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,the statistical analysis plan was published14 before unmasking of the authors to the data.,"['C1511726', 'C4553913', 'C3812881', 'C3245479', 'C3889277', 'C3714741']","['author', 'Statistical Analysis Plan', 'Data call receiving device', 'Data (eukaryote)', 'Data', 'Unblinding']","['inpr', 'idcn', 'prog', 'medd', 'ftcn', 'euka']"
748,PMC3386495,S103,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,all randomly assigned patients were included in the analysis.,,,
749,PMC3386495,S104,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,"masked analysis of the patients' baseline characteristics showed clear differences in key prognostic factors (age, stroke severity, degree of ischaemic change on baseline ct or mri) in patients randomly assigned at different times after stroke onset, which might complicate the estimation of the effect of treatment overall and in subgroups.11","['C1561607', 'C0030705', 'C3887704', 'C1705169', 'C1515981', 'C1516050', 'C4684572', 'C4554100', 'C1524024', 'C0449286', 'C1079230', 'C3890166', 'C0150112', 'C0024485', 'C0750572', 'C0936012', 'C0231290', 'C0542560', 'C0681916', 'C1442488', 'C1705242', 'C0039798', 'C3538994', 'C0680844', 'C2963144', 'C0441889', 'C1824234', 'C0038454', 'C4319952', 'C1514474', 'C0443172', 'C1280500', 'C0231242', 'C2348088', 'C1518681', 'C0282416', 'C1709157', 'C0522510', 'C1555580', 'C0168634', 'C0392747', 'C0439793', 'C0475224', 'C0332162', 'C0040223', 'C0087111', 'C1552601', 'C0150108', 'C1632851', 'C1533734', 'C1705241', 'C1522326', 'C0687676', 'C0001779', 'C0206132', 'C2348382']","['Age of Onset', 'Status post', 'Baseline', 'Stroke, CTCAE', 'Biomaterial Treatment', 'And', 'Patients', 'Negative Surgical Margin', 'Blinded', 'Degree or extent', 'Effect, Appearance', 'With intensity', 'Time', 'Degree Unit of Plane Angle', 'Times', 'Therapeutic procedure', 'Delta (difference)', 'Ischemic', 'Outcome of Therapy', 'PersonNameUse - assigned', 'psychological masking', 'Cerebrovascular accident', 'Changed status', 'Age', 'Administration procedure', 'Prognostic Factors', 'Magnetic Resonance Imaging Study File', 'Estimated', 'BaseLine dental cement', 'Treatment Epoch', 'Clear', 'masked - No information', 'Changing', 'estimation <subjective>', 'Academic degree', 'Assignment - action', 'Complicated', 'Change -- procedure', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'CYREN gene', 'Statistical Estimation', 'Baseline Characteristics', 'analysis aspect', 'Effect', 'Post', 'Overall', 'Onset of (contextual qualifier)', 'Severities', 'Levels (qualifier value)', 'Treating', 'Analysis', 'Magnetic Resonance Imaging', 'Subgroup A Nepoviruses', 'Different', 'Overall Publication Type']","['inpr', 'clna', 'idcn', 'bodm', 'gngm', 'topp', 'ftcn', 'fndg', 'cnce', 'qlco', 'podg', 'tmco', 'resa', 'virs', 'dsyn', 'menp', 'hlca', 'diap', 'qnco', 'orga']"
750,PMC3386495,S105,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,"therefore, the primary analysis of the effect of treatment on the primary outcome was adjusted by logistic regression for linear effects for the following covariates: age; national institutes of health stroke scale (nihss) score; time from onset of stroke symptoms to randomisation; and presence (vs absence) of ischaemic change on the prerandomisation brain scan according to expert assessment.","['C1261322', 'C0683368', 'C0018684', 'C3887704', 'C4050231', 'C1705169', 'C0175659', 'C1524024', 'C4554100', 'C4321252', 'C1565156', 'C0456081', 'C0021622', 'C1274040', 'C0150312', 'C0936012', 'C1947916', 'C3245503', 'C0349674', 'C0206031', 'C0332197', 'C1697238', 'C0043194', 'C0205132', 'C0039798', 'C3538994', 'C0038454', 'C0596217', 'C0392148', 'C4319952', 'C0443172', 'C1280500', 'C0205225', 'C1457887', 'C1518681', 'C0521125', 'C0449820', 'C0332282', 'C0392747', 'C0475224', 'C0001779', 'C0040223', 'C0332162', 'C0087111', 'C1522326', 'C1533734', 'C1705241', 'C1421478', 'C1516048', 'C0206132', 'C2348382']","['Age of Onset', 'Adjustment Action', 'Scaling', 'Stroke, CTCAE', 'Biomaterial Treatment', 'Evaluation procedure', 'Present', 'Providing presence (regime/therapy)', 'Effect, Appearance', 'Time', 'Preposition For', 'National citizen', 'WWOX wt Allele', 'Therapeutic procedure', 'Result', 'Delta (difference)', 'Ischemic', 'Outcome of Therapy', 'WAS protein, human', 'Cerebrovascular accident', 'WAS gene', 'Changed status', 'Age', 'Administration procedure', 'Following', 'Symptoms', 'NIH stroke scale', 'Treatment Epoch', 'Changing', 'Logistic Regression', 'Institutes', 'Absent', 'Intellectual scale', 'Linear', 'Change -- procedure', 'therapeutic aspects', 'Symptoms aspect', 'Brain scan', 'treatment - ActInformationManagementReason', 'analysis aspect', 'Weight measurement scales', 'Effect', 'Onset of (contextual qualifier)', 'Wiskott-Aldrich Syndrome', 'Treating', 'Analysis', 'ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated', 'Health', 'Score', 'Assessed', 'Primary']","['bacs', 'clna', 'topp', 'medd', 'fndg', 'qlco', 'hlca', 'diap', 'inpr', 'idcn', 'gngm', 'resa', ' aapp', 'sosy', 'popg', 'ftcn', 'tmco', 'dsyn', 'acty', 'cnce', 'spco', 'qnco', 'orga', 'orgt']"
751,PMC3386495,S106,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,an unadjusted analysis is also presented.,"['C0936012', 'C1524024', 'C1439367']","['Analysis', 'unadjusted', 'analysis aspect']","['ftcn', 'resa']"
752,PMC3386495,S107,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,"the trial did not meet its original target of 6000 patients, and so was no longer adequately powered to detect a 3% absolute difference in the primary outcome (with 80% power and α=0·05).","['C1274040', 'C1521840', 'C0030705', 'C2986546', 'C0032863', 'C1518422', 'C1515981', 'C0008976', 'C3854080', 'C2347409', 'C0205225', 'C0205313', 'C1549031']","['Clinical Trials', 'Power (Psychology)', 'And', 'Patients', 'Absolute Change', 'Power', 'Target', 'Primary', 'Result', 'Target Lesion Identification', 'Original', 'Original Regulatory Submission', 'Negation']","['hcpp', 'idcn', 'ocac', 'ftcn', 'podg', 'qlco', 'resa', 'diap', 'qnco']"
753,PMC3386495,S108,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,"the statistical-analysis-plan writing committee, which did not have access to the accumulating data, was therefore expanded to include an independent statistician (gordon murray, university of edinburgh, edinburgh, uk) to advise on the correct approach.","['C0085862', 'C1511726', 'C0270724', 'C0043266', 'C2584304', 'C0449445', 'C2349182', 'C0041740', 'C1565156', 'C3714741', 'C1518422', 'C0205229', 'C0038215', 'C0043194', 'C2699414', 'C4283917', 'C1301732', 'C2700399', 'C1299583', 'C1290940', 'C0334957', 'C4050126', 'C0444454', 'C0332257', 'C0599880', 'C3245479', 'C1552866', 'C1421478', 'C1554204']","['Role Class - access', 'Writing (function)', 'Data call receiving device', 'Independent for Transfer', 'Ability to Write question', 'statistician', 'Writing Ability', 'Infantile Neuroaxonal Dystrophy', 'WAS protein, human', 'WAS gene', 'Committee', 'Negation', 'Independently able', 'Approach', 'Planned', 'Include (action)', 'Correct (qualifier)', 'include - SetOperator', 'Treatment Plan', 'Data', 'Universities', 'expanding', 'Including (qualifier)', 'Wiskott-Aldrich Syndrome', 'Science of Statistics', 'Independence', 'Data (eukaryote)', 'Access', 'Writing (occupation or discipline)']","['bacs', 'inpr', 'grup', 'idcn', ' mnob', 'acty', 'gngm', 'ocdi', 'prog', 'medd', 'ftcn', 'spco', 'fndg', 'qlco', 'euka', 'dsyn', 'menp', ' aapp', 'orgt']"
754,PMC3386495,S109,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,the writing group was persuaded by the recent empirical evidence that the ordinal method was both statistically more efficient (effectively reducing the sample size required in stroke trials29) and robust against substantial deviations from the proportional assumption.30,"['C0871511', 'C0043266', 'C2584304', 'C3887511', 'C0441833', 'C0687744', 'C1515981', 'C0442799', 'C4554100', 'C1565156', 'C0025663', 'C0242618', 'C0038215', 'C0205351', 'C0043194', 'C4283917', 'C1880496', 'C0205172', 'C0521124', 'C0449851', 'C0038454', 'C1705429', 'C2986815', 'C0439080', 'C0392756', 'C1514873', 'C4050126', 'C1517320', 'C1519504', 'C1706086', 'C0332185', 'C1257890', 'C1421478', 'C1705428']","['Writing (function)', 'Stroke, CTCAE', 'Both', 'Sample Size', 'Methods', 'And', 'From', 'Reduced', 'Ability to Write question', 'Stage Grouping', 'Writing Ability', 'against', 'WAS protein, human', 'Cerebrovascular accident', 'Requirement', 'User Group', 'Robust', 'WAS gene', 'Ordinal Position', 'Group Object', 'Social group', 'Evidence', 'Writing (occupation or discipline)', 'Empiric', 'Groups', 'More', 'Techniques', 'Wiskott-Aldrich Syndrome', 'Science of Statistics', 'Population Group', 'proportional', 'efficient', 'Test Method', 'Recent']","['bacs', 'inpr', 'idcn', 'lbpr', 'gngm', 'ocdi', 'popg', 'ftcn', 'fndg', 'cnce', 'qlco', 'tmco', 'dsyn', 'menp', ' aapp', 'qnco']"
755,PMC3386495,S110,"['6b', '3b']","[0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0]",Randomisation and masking,"we therefore specified in the statistical analysis plan an ordinal logistic regression analysis, as a secondary outcome, in which the ohs as a dependent variable had 5 levels: levels 4, 5, and 6 were combined into a single level and levels 0, 1, 2, 3 were retained as distinct.","['C0205436', 'C1515981', 'C0332286', 'C0027627', 'C1274040', 'C0681925', 'C0013675', 'C0205195', 'C0871711', 'C0441889', 'C0439080', 'C1861455', 'C0062074', 'C2946261', 'C1547707', 'C3539897', 'C0205171', 'C0087136', 'C0456951', 'C1415458', 'C3889277', 'C0268353', 'C0175668']","['Level', 'And', 'Floor - story of building', 'into', 'STOMATOCYTOSIS I', 'Have', 'Secondary to', 'Unmarried', 'Dependent Variable', 'HADH gene', 'level 5', 'Cutis laxa, x-linked', 'logistic regression analysis', 'Ordinal Position', 'Statistical Analysis Plan', 'Singular', 'Combined', 'Neoplasm Metastasis', 'second (number)', 'Levels (qualifier value)', 'Effect Modifier, Epidemiologic', 'HAC protocol', 'Result']","['inpr', 'idcn', 'geoa', 'inch', 'gngm', 'topp', 'neop', 'ftcn', 'fndg', 'qlco', 'resa', 'cgab', ' phsu', 'qnco', 'dsyn']"
756,PMC3386495,S111,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,"in this model the treatment odds ratios between one level and the next were assumed to be constant, so a single parameter summarises the shift in outcome distribution between treatment and control groups.","['C3853906', 'C3887704', 'C0009932', 'C1705169', 'C1515981', 'C1080058', 'C3161035', 'C1274040', 'C3274659', 'C1883708', 'C0205447', 'C3242379', 'C0549193', 'C0039798', 'C3538994', 'C0333051', 'C0441889', 'C1704769', 'C1704711', 'C2350001', 'C2347509', 'C0332282', 'C0028873', 'C2946261', 'C1547707', 'C1948059', 'C0205171', 'C0087136', 'C0087111', 'C0205103', 'C1533734', 'C1522326', 'C3714583', 'C0205117', 'C0520511']","['Model Number', 'Biomaterial Treatment', 'And', 'Adjacent', 'Floor - story of building', 'Level', 'Model', 'Therapeutic procedure', 'Population Parameter', 'Unmarried', 'shift displacement', 'Administration procedure', 'Then', 'Odds Ratio', 'Following', 'Control Groups', 'Intermediate', 'Treatment Epoch', 'Distribution', 'Singular', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'One', 'Assumed', 'Constant (qualifier)', 'Levels (qualifier value)', 'Parameter Value', 'Treating', 'Model - style/design', 'Digital Model Attachment', 'Programming Parameter', 'Result', 'Distributing', 'This (eukaryote)', 'Physical Shift']","['grup', 'inpr', 'phpr', 'idcn', 'geoa', 'inch', 'topp', 'ftcn', 'cnce', 'spco', 'qlco', 'tmco', ' phsu', 'resa', 'euka', 'hlca', 'fndg', 'qnco']"
757,PMC3386495,S112,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Randomisation and masking,"for patients known to be alive at 6 months, but with an unknown ohs, we used the level of function recorded on the 7-day form (ie, measured at 7 days or before discharge from hospital) to impute 6-month functional status.14","['C0439231', 'C0030705', 'C0439673', 'C0233535', 'C3541433', 'C0935587', 'C0348078', 'C2584946', 'C4255237', 'C0332287', 'C0444706', 'C3541902', 'C4551704', 'C1273517', 'C4050014', 'C0332173', 'C1547085', 'C1861455', 'C0598463', 'C0439228', 'C0376315', 'C0586003', 'C0332177', 'C0268353', 'C1522492']","['day', 'Measured Tumor Identification', 'Patients', 'month', 'STOMATOCYTOSIS I', 'butting', '7 days', 'Cutis laxa, x-linked', 'unknown vaccine or immune globulin', 'level of functioning', 'Alive', 'Unknown GENC', 'Daily', 'Formation', 'Monthly (qualifier value)', 'In addition to', 'Measured', 'Form:Finding:Point in time:{Setting}:Document:{Role}', 'Manufactured form', 'used by', 'Qualitative form', 'Discharge from hospital', 'Unknown', 'Alive (finding)', 'Functional Status']","['clna', 'geoa', ' aapp', 'ftcn', 'mnob', 'cnce', 'tmco', 'podg', 'qlco', 'fndg', 'cgab', 'hlca', 'imft', 'mobd', 'diap', 'dsyn']"
758,PMC3386495,S113,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,we chose this simple form of imputation because it effectively classified 6-month outcomes in patients for whom both 7-day and 6-month data were known (data not shown).,"['C1511726', 'C0521125', 'C0439231', 'C0030705', 'C1706086', 'C3245479', 'C0332177', 'C1515981', 'C0332173', 'C0348078', 'C2699638', 'C4321252', 'C0376315', 'C0205352', 'C4255237', 'C3714741', 'C1080058', 'C1522492', 'C1518422', 'C0439228']","['Statistical Imputation', 'day', 'This (eukaryote)', 'Form:Finding:Point in time:{Setting}:Document:{Role}', 'Both', 'Simple', 'And', 'Daily', 'Formation', 'Manufactured form', 'month', 'Patients', 'Qualitative form', 'Data call receiving device', 'Monthly (qualifier value)', 'Data (eukaryote)', 'Data', 'Preposition For', 'WWOX wt Allele', 'Negation']","['clna', 'idcn', 'gngm', 'medd', 'ftcn', 'mnob', 'tmco', 'podg', 'qlco', 'euka']"
759,PMC3386495,S114,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,analyses were done with sas (version 9.2).,"['C0605290', 'C0333052', 'C1823519', 'C1426104']","['SAS', 'NANS gene', 'Version', 'TSPAN31 gene']","['inpr', 'gngm', 'orch']"
760,PMC3386495,S116,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,"the sponsors of the study had no role in design, data collection, data analysis, data interpretation, or writing of the report.","['C1511726', 'C0010995', 'C0684224', 'C0043266', 'C2584304', 'C4255046', 'C3714741', 'C3273238', 'C2983265', 'C0010992', 'C2603343', 'C4283917', 'C3173575', 'C1707689', 'C3887707', 'C4050126', 'C0062074', 'C1705810', 'C0700287', 'C0035820', 'C3539897', 'C3245479', 'C1415458', 'C0459471', 'C3871154']","['Writing (function)', 'Reporting', 'Interpretation:Impression/interpretation of study:Point in time:^Patient:Nominal', 'Role', 'Data call receiving device', 'Ability to Write question', 'Have', 'Writing Ability', 'Regulatory Report', 'HADH gene', 'Data Collection', 'Data Collection Methods', 'Social Role', 'Study', 'Design', 'Data', 'Data Analysis', 'Report (document)', 'Report:Finding:Point in time:{Setting}:Document:{Role}', 'Interpretation Process', 'HAC protocol', 'Generic Role', 'Data (eukaryote)', 'CDISC SEND Study Design Terminology', 'Writing (occupation or discipline)']","['inpr', 'clna', 'idcn', 'acty', 'gngm', 'ocdi', 'ocac', 'topp', 'medd', 'qlco', 'euka', 'resa', 'socb', 'hlca', 'menp', 'qnco']"
761,PMC3386495,S117,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,the corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.,"['C1511726', 'C1515981', 'C4321252', 'C3714741', 'C3853528', 'C0678341', 'C0443225', 'C2603343', 'C1546485', 'C1704324', 'C0034037', 'C0679006', 'C0444454', 'C0062074', 'C0521125', 'C3812881', 'C3539897', 'C3245479', 'C0034036', 'C1415458', 'C0444868', 'C1554204', 'C0205088']","['Role Class - access', 'And', 'Data call receiving device', 'Preposition For', 'Have', 'WWOX wt Allele', 'HADH gene', 'Final', 'responsibility', 'Diagnosis Type - Final', 'Publishing', 'Data (eukaryote)', 'full', 'All', 'Study', 'Publications', 'Data', 'End-stage', 'author', 'HAC protocol', 'Decision', 'Scientific Publication', 'Access']","['inpr', 'inbe', 'idcn', ' mnob', 'gngm', 'prog', 'ocac', 'topp', 'medd', 'ftcn', 'spco', 'qlco', 'euka', 'tmco', 'resa', 'menp', 'qnco']"
762,PMC3386495,S36,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,"ist-3 was a pragmatic10 international, multicentre, randomised-controlled, open-treatment trial.","['C3538994', 'C1705169', 'C3887704', 'C0087111', 'C0008976', 'C2911690', 'C1522326', 'C1533734', 'C0175566', 'C1512888', 'C0039798', 'C2587213']","['Open', 'Treatment Epoch', 'Clinical Trials', 'Biomaterial Treatment', 'Treating', 'Administration procedure', 'Disease Controlled', 'Control function', 'International', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Therapeutic procedure']","['idcn', 'topp', 'ftcn', 'cnce', 'fndg', 'spco', 'resa', 'hlca']"
763,PMC3386495,S37,"['11a', '3a']","[0, 0, 1, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,the initial pilot phase was double-blinded and placebo-controlled.,"['C0205390', 'C1705764', 'C0473169', 'C1705765', 'C0205173', 'C1555582', 'C1279901', 'C1705685', 'C1414316', 'C0205265', 'C3890606', 'C1710475']","['Initial (abbreviation)', 'EGR3 wt Allele', 'Doubling', 'Duplicate', 'Initial Usage', 'Firstly', 'EGR3 gene', 'Trial Phase', 'Phase', 'Pilot', 'Double Value Type', 'Initially']","['idcn', 'acty', 'gngm', 'prog', 'clas', 'ftcn', 'qlco', 'tmco']"
764,PMC3386495,S38,['3b'],"[0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,"at the end of the pilot phase, since the main phase compared treatment with open control, several additional measures were introduced to minimise bias in the assessment of early and late outcomes.11","['C0079809', 'C0205390', 'C1261322', 'C3887704', 'C1705169', 'C1279919', 'C0205087', 'C1542147', 'C0439064', 'C1515981', 'C0005346', 'C1882979', 'C0473169', 'C0443302', 'C0242568', 'C1707455', 'C1710475', 'C0332287', 'C0175566', 'C0444930', 'C0039798', 'C3538994', 'C4553389', 'C1550141', 'C0205225', 'C0243148', 'C3890606', 'C1711239', 'C1504315', 'C0087111', 'C1414316', 'C1522326', 'C1533734', 'C2746065', 'C3274648', 'C1524062', 'C1516048', 'C2587213']","['Biomaterial Treatment', 'And', 'Evaluation procedure', 'End', 'Therapeutic procedure', 'Main', 'Late', 'Trial Phase', 'Additional', 'Several', 'Pilot', 'Administration procedure', 'Comparison', 'Bias genus', 'Since', 'Stop (qualifier value)', 'Treatment Epoch', 'Study Control', 'EGR3 gene', 'Early', 'Biases', 'Numerous', 'Control function', 'therapeutic aspects', 'control substance', 'treatment - ActInformationManagementReason', 'Bias (Epidemiology)', 'In addition to', 'Scientific Control', 'EGR3 wt Allele', 'True Control Status', 'Open', 'Phase', 'Treating', 'control aspects', 'Measures', 'Assessed', 'Primary']","['idcn', 'bird', 'acty', 'gngm', 'prog', 'clas', 'topp', 'ftcn', 'cnce', 'spco', 'tmco', 'qlco', 'resa', 'hlca', 'sbst', 'qnco']"
765,PMC3386495,S39,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,"we have published reports of the rationale for the trial,12 the protocol,13 an update on recruitment, amendments to the protocol and the baseline characteristics of the patients recruited,11 and the statistical analysis plan.14",,,
766,PMC3386495,S40,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,the eligibility criteria can be summarised in terms of the uncertainty principle.15–17,"['C1512693', 'C0087130']","['Inclusion', 'Uncertainty']","['fndg', 'qlco']"
767,PMC3386495,S41,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,inclusion and exclusion criteria are listed in detail in the protocol.13,"['C3715209', 'C4282383', 'C0442711', 'C2599718', 'C1522729', 'C1561567', 'C1507394', 'C1522508', 'C2348563', 'C0680252', 'C0680251']","['detail - Response Level', 'Protocol - answer to question', 'REMS Protocol', 'Clinical trial protocol', 'Clinical trial protocol document', 'Exclusion Criteria', 'inclusion and exclusion', 'Protocols documentation', 'Study Protocol', 'Library Protocol', 'Details']","['ftcn', 'fndg', 'inpr', 'qlco']"
768,PMC3386495,S42,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,"briefly, patients were eligible according to the following criteria: they had symp-toms and signs of clinically definite acute stroke; the time of stroke onset was known; treatment could be started within 6 h of onset; and ct or mri had reliably excluded both intracranial haemorrhage and structural brain lesions, which could mimic stroke (eg, cerebral tumour).","['C0678594', 'C0030705', 'C3887704', 'C1705169', 'C1515981', 'C4554100', 'C0751956', 'C1548635', 'C3890166', 'C0024485', 'C0220912', 'C0039798', 'C3538994', 'C0220913', 'C0151699', 'C1824234', 'C0038454', 'C1704787', 'C0243161', 'C1263885', 'C0332282', 'C0311392', 'C1706086', 'C0332162', 'C0040223', 'C0087111', 'C1522326', 'C1533734', 'C0439544', 'C0221505', 'C0206132']","['Age of Onset', 'Stroke, CTCAE', 'Both', 'Biomaterial Treatment', 'And', 'Manufactured sign', 'Patients', 'Time', 'Definite', 'Cerebral Neoplasm', 'Therapeutic procedure', 'Acute Cerebrovascular Accidents', 'Cerebrovascular accident', 'Definitely Related to Intervention', 'Administration procedure', 'Following', 'criteria', 'Magnetic Resonance Imaging Study File', 'Treatment Epoch', 'Physical findings', 'Aspects of signs', 'brain lesion', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'CYREN gene', 'Eligible', 'Intracranial Hemorrhage', 'structure', 'Onset of (contextual qualifier)', 'Treating', 'Magnetic Resonance Imaging']","['inpr', 'idcn', 'gngm', 'topp', 'neop', 'ftcn', 'fndg', 'cnce', 'qlco', 'podg', 'tmco', 'patf', 'mnob', 'dsyn', 'resa', 'spco', 'diap', 'hlca', 'qnco']"
769,PMC3386495,S43,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,"additionally, if the patient had a clear indication for intravenous thrombolysis with rt-pa, they were to be treated in accordance with local guidelines.","['C2963144', 'C0220845', 'C0392360', 'C0030705', 'C3146298', 'C0205276', 'C0162791', 'C0520997', 'C1709157', 'C0282423', 'C0348016']","['Guideline [Publication Type]', 'Indication', 'Clear', 'Local', 'Intravenous', 'Patients', 'Negative Surgical Margin', 'Indication of (contextual qualifier)', 'Thrombolysis, function', 'Guidelines', 'guiding characteristics']","['inpr', 'clna', 'idcn', 'spco', 'fndg', 'podg', 'qlco']"
770,PMC3386495,S44,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,"equally, if the patient had a clear contraindication to treatment they were not to be entered in the trial.","['C2963144', 'C3539897', 'C0030705', 'C0522473', 'C3714732', 'C1705169', 'C3887704', 'C1518422', 'C0087111', 'C0008976', 'C1521975', 'C1415458', 'C1522326', 'C1533734', 'C0062074', 'C1709157', 'C1301624', 'C0039798', 'C3538994']","['Contraindication', 'Contraindication:Find:Pt:^Patient:Nom', 'Treatment Epoch', 'Clear', 'Clinical Trials', 'Biomaterial Treatment', 'Treating', 'Administration procedure', 'Patients', 'Medical contraindication', 'HAC protocol', 'Negative Surgical Margin', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Have', 'Entered', 'Therapeutic procedure', 'Negation', 'HADH gene']","['clna', 'gngm', 'topp', 'ftcn', 'fndg', 'cnce', 'qlco', 'podg', 'resa', 'hlca']"
771,PMC3386495,S45,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,"only if both the clinician and the patient (or a relevant proxy for the patient) felt that the treatment was promising but unproven, could the patient be included in the trial after appropriate informed consent from the patient or a valid proxy.","['C0030705', 'C1548787', 'C1705169', 'C3887704', 'C2347946', 'C1515981', 'C0008976', 'C0456370', 'C4321252', 'C0871685', 'C1565156', 'C0233535', 'C0021430', 'C0043194', 'C0039798', 'C3538994', 'C0600420', 'C3897813', 'C0521125', 'C0332257', 'C1517320', 'C1706086', 'C0205171', 'C0087111', 'C1522326', 'C1533734', 'C1421478', 'C2349099', 'C0687676', 'C0231290']","['Status post', 'Appropriate', 'Both', 'Biomaterial Treatment', 'And', 'Patients', 'butting', 'From', 'Preposition For', 'WWOX wt Allele', 'Therapeutic procedure', 'WAS protein, human', 'Clinical Trials', 'WAS gene', 'Administration procedure', 'Informed Consent', 'Treatment Epoch', 'Clinician', 'Singular', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Post', 'Advance Directive - Proxy', 'unproven', 'Relevance', 'Proxy', 'Including (qualifier)', 'Wiskott-Aldrich Syndrome', 'Treating', 'Valid']","['bacs', 'inpr', 'grup', 'rnlw', 'idcn', 'mobd', 'gngm', 'prog', 'topp', 'ftcn', 'cnce', 'podg', 'qlco', 'tmco', 'resa', 'dsyn', 'hlca', ' aapp', 'qnco']"
772,PMC3386495,S46,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,"the protocol was approved by the multi-centre research ethics committees, scotland (reference mrec/99/0/78), and by local ethical committees.","['C3715209', 'C0026531', 'C0439064', 'C4282383', 'C0205276', 'C1515981', 'C1514811', 'C2599718', 'C1522729', 'C0442711', 'C1706462', 'C3266262', 'C0036453', 'C0086911', 'C1507394', 'C2348563', 'C0205099']","['Morality', 'Scotland', 'Protocol - answer to question', 'REMS Protocol', 'Clinical trial protocol', 'Local', 'And', 'Clinical trial protocol document', 'Numerous', 'Protocols documentation', 'Study Protocol', 'Central', 'Bibliographic Reference', 'Ethics Committees, Research', 'Library Protocol', 'Reference Object', 'Multiple Chronic Conditions']","['inpr', 'idcn', 'geoa', 'prog', 'spco', 'fndg', 'cnce', 'dsyn', 'qnco']"
773,PMC3386495,S47,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,"this study is registered, isrctn25765518.",,,
774,PMC3386495,S49,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,table 1 baseline characteristics,,,
775,PMC3386495,S50,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,clinicians entered baseline data via a telephone voice-activated or a secure web-based randomisation system.,"['C1511726', 'C0168634', 'C3245479', 'C3888058', 'C1553451', 'C1705541', 'C0042939', 'C0039457', 'C1515258', 'C3244282', 'C1442488', 'C0871685', 'C3714741', 'C0449913', 'C1879547', 'C4281800']","['Voice G-code', 'BaseLine dental cement', 'Baseline', 'System - kit', 'TelecommunicationCapabilities <voice>', 'Activation action', 'Telephone', 'Telephone Device', 'Clinician', 'Data', 'Data call receiving device', 'Device system', 'Telephone Number', 'Data (eukaryote)', 'Voice', 'System']","['inpr', 'idcn', 'acty', 'qnco', 'prog', 'medd', 'ftcn', 'mnob', 'qlco', 'euka', 'orgf', 'bodm']"
776,PMC3386495,S51,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,"after the system had recorded and checked the data, patients were allocated either immediate thrombolysis with 0·9 mg/kg of intravenous rt-pa to a maximum of 90 mg (10% bolus with the remainder over 1 h) or control treatment.","['C1511726', 'C0205548', 'C0030705', 'C3888058', 'C3887704', 'C1705169', 'C1515981', 'C0449913', 'C3714741', 'C2826546', 'C1882979', 'C1552615', 'C3812160', 'C0332287', 'C0439272', 'C0039798', 'C3538994', 'C4553389', 'C1550141', 'C1283174', 'C1553451', 'C0806909', 'C3844638', 'C0243148', 'C0062074', 'C0520997', 'C1186706', 'C0700308', 'C3539897', 'C3245479', 'C0032143', 'C0087111', 'C0205253', 'C1511237', 'C1415458', 'C1522326', 'C1533734', 'C3274648', 'C0348016', 'C2587213']","['Radiotherapy Bolus', 'Biomaterial Treatment', 'And', 'Checking (action)', 'Data call receiving device', 'Patients', 'Thrombolysis, function', 'Have', 'System', 'Therapeutic procedure', 'HADH gene', 'Either', 'Intravenous', 'Administration procedure', 'Immediate', 'Data (eukaryote)', 'Act Relationship Subset - maximum', 'Treatment Epoch', 'Study Control', 'Device system', 'therapeutic aspects', 'Control function', 'treatment - ActInformationManagementReason', 'control substance', 'Data', 'mg/kg', 'In addition to', 'Scientific Control', 'Protium', 'True Control Status', 'System - kit', 'alteplase', 'Maximum', 'Treating', 'control aspects', 'HAC protocol', 'bolus infusion', 'Bolus of ingested food', 'Stat (do immediately)', 'Maximum Value Derivation Technique']","['clna', 'topp', 'medd', 'enzy', 'mnob', 'fndg', 'bdsu', 'qlco', 'hlca', 'sbst', ' phsu', 'idcn', 'gngm', 'resa', ' aapp', 'elii', 'ftcn', 'podg', 'tmco', 'acty', 'cnce', 'spco', 'euka', 'qnco']"
777,PMC3386495,S52,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,the system would not accept patients with blood pressure or glucose levels outside protocol-defined criteria (appendix pp 4–5) or other data inconsistencies.,"['C1511726', 'C0030705', 'C3888058', 'C4282383', 'C0449913', 'C3714741', 'C1518422', 'C3715209', 'C1271104', 'C0442711', 'C2599718', 'C1522729', 'C1507394', 'C0005823', 'C1553451', 'C0243161', 'C1272641', 'C3245479', 'C0003617', 'C0428548', 'C2348563']","['REMS Protocol', 'Data call receiving device', 'Patients', 'Blood Pressure', 'Appendix', 'Study Protocol', 'Systemic arterial pressure', 'System', 'Glucose level - finding', 'Protocol - answer to question', 'Clinical trial protocol', 'Clinical trial protocol document', 'Protocols documentation', 'criteria', 'Negation', 'Device system', 'Blood pressure finding', 'Data', 'System - kit', 'Data (eukaryote)', 'Library Protocol']","['bpoc', 'inpr', 'idcn', 'medd', 'lbtr', 'ftcn', 'fndg', 'mnob', 'podg', 'euka', 'orgf']"
778,PMC3386495,S53,"['10', '8b']","[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0]",Study design and patients,"the system used a minimisation algorithm to achieve optimum balance for key prognostic factors (table 1), and from january, 2006, minimisation was additionally stratified by world region and then minimised on all the other key factors within regions.","['C3829466', 'C2700280', 'C2698651', 'C0039224', 'C1553907', 'C3888058', 'C1553451', 'C0560184', 'C1883708', 'C0205147', 'C4319618', 'C1515981', 'C1514474', 'C0002045', 'C0449913', 'C0444868', 'C1706074', 'C0017446', 'C0014653']","['Balance (substance)', 'Data Table', 'Optimum', 'System - kit', 'algorithm', 'All', 'And', 'Geographic Locations', 'Ability to balance', 'Device system', 'Observation Method - algorithm', 'Prognostic Factors', 'Equilibrium', 'Then', 'January', 'System', 'regional', 'Table - furniture', 'World']","['inpr', 'clna', 'idcn', 'geoa', 'popg', 'ftcn', 'mnob', 'fndg', 'orch', 'qlco', 'tmco', 'spco', ' phsu', 'orgf', 'qnco']"
779,PMC3386495,S54,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,"to be eligible to join the trial, participating hospitals had to have an organised system of stroke care.","['C0019994', 'C3888058', 'C1553451', 'C0038454', 'C0008976', 'C4554100', 'C1548635', 'C1947933', 'C0449913']","['Eligible', 'Stroke, CTCAE', 'System - kit', 'Cerebrovascular accident', 'Clinical Trials', 'Device system', 'care activity', 'System', 'Hospitals']","['acty', 'ftcn', 'fndg', 'mnob', 'qlco', 'resa', 'dsyn', ' hcro']"
780,PMC3386495,S55,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,"acute-care protocols were not specified by the trial, but had to include the components of effective stroke-unit care,19 including, soon after admission, intravenous access, monitoring of physiological variables, correction of any abnormalities, and where clinically appropriate, intravenous-fluid therapy.","['C1548787', 'C0150369', 'C0439828', 'C1515981', 'C0008976', 'C0000769', 'C4554100', 'C0233535', 'C1947976', 'C1518422', 'C1704419', 'C3853603', 'C3272371', 'C0439148', 'C1509845', 'C2700399', 'C0000768', 'C1552551', 'C1704753', 'C0449432', 'C1280519', 'C1283169', 'C0038454', 'C0250336', 'C0016286', 'C1554204', 'C0444454', 'C0062074', 'C0184666', 'C1519795', 'C1705565', 'C0332257', 'C0809949', 'C3539897', 'C0205463', 'C1552866', 'C1880519', 'C0439453', 'C1415458', 'C1947933', 'C0687676', 'C0348016', 'C0231290']","['Role Class - access', 'Preventive monitoring', 'Effectiveness', 'Status post', 'Stroke, CTCAE', 'Appropriate', 'teratologic', 'And', 'Unit', 'butting', 'Unit of Measure', 'Have', 'Correction Report', 'Enzyme Unit', 'Congenital Abnormality', 'HADH gene', 'Monitoring - action', 'Any Data Type', 'Admission activity', 'Cerebrovascular accident', 'Clinical Trials', 'Intravenous', 'Variable (uniformity)', 'Negation', 'Any', 'Hospital admission', 'Include (action)', 'include - SetOperator', 'CARE protocol', 'International Unit', 'Component object', 'Post', 'Unit - NCI Thesaurus Property', 'Unit device', 'Correction (change)', 'Effective', 'Including (qualifier)', 'Physiological', 'HAC protocol', 'care activity', 'Fluid Therapy', 'Access', 'Storage Unit']","['inpr', 'idcn', 'acty', 'gngm', 'topp', 'medd', 'ftcn', 'fndg', 'spco', 'qlco', 'mnob', 'tmco', 'resa', 'cgab', 'dsyn', 'hlca', 'mobd', 'qnco']"
781,PMC3386495,S56,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,"all patients in the trial were to be treated within that organised system of stroke care, irrespective of treatment allocation.","['C1706778', 'C0030705', 'C3888058', 'C1553451', 'C3887704', 'C0038454', 'C1705169', 'C0087111', 'C0008976', 'C1947933', 'C4554100', 'C1522326', 'C0444868', 'C1533734', 'C0449913', 'C0039798', 'C3538994']","['Treatment Epoch', 'Stroke, CTCAE', 'System - kit', 'Cerebrovascular accident', 'All', 'Biomaterial Treatment', 'Clinical Trials', 'Device system', 'Administration procedure', 'Patients', 'Treating', 'care activity', 'Allocation', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Therapeutic procedure', 'System']","['acty', 'topp', 'ftcn', 'fndg', 'cnce', 'podg', 'mnob', 'resa', 'dsyn', 'hlca', 'qnco']"
782,PMC3386495,S57,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,patients allocated to the control group were to avoid treatment with rt-pa and received stroke care in the same clinical environment as those allocated to the rt-pa group.,"['C0030705', 'C0441833', 'C0009932', 'C1705169', 'C0687744', 'C3887704', 'C1515981', 'C4554100', 'C0014406', 'C0205210', 'C0332287', 'C1514756', 'C0039798', 'C3538994', 'C0038454', 'C1705429', 'C0445247', 'C0032143', 'C1519504', 'C1257890', 'C0087111', 'C1947933', 'C1522326', 'C1533734', 'C1705428']","['Stroke, CTCAE', 'Biomaterial Treatment', 'And', 'Patients', 'Stage Grouping', 'Receive', 'Therapeutic procedure', 'Cerebrovascular accident', 'User Group', 'Administration procedure', 'Group Object', 'Social group', 'Clinical', 'Control Groups', 'Treatment Epoch', 'Environment', 'Same', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'In addition to', 'Groups', 'alteplase', 'Treating', 'Population Group', 'care activity']","['grup', 'idcn', 'acty', 'enzy', 'topp', 'popg', 'ftcn', 'fndg', 'spco', 'podg', 'cnce', ' phsu', 'qlco', 'resa', 'dsyn', 'hlca', ' aapp']"
783,PMC3386495,S58,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,both treatment groups had blood pressure monitored closely over the first 24 h.,"['C0005823', 'C1272641', 'C1706086', 'C1552839', 'C1271104', 'C1705169', 'C0441833', 'C0687744', 'C0087111', 'C3887704', 'C1279901', 'C1522326', 'C1533734', 'C0205435', 'C0039798', 'C3538994']","['Treatment Epoch', 'Firstly', 'Groups', 'Both', 'Biomaterial Treatment', 'First (number)', 'Table Rules - groups', 'Administration procedure', 'Blood Pressure', 'Treating', 'Blood pressure finding', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Systemic arterial pressure', 'Therapeutic procedure', 'Social group']","['inpr', 'idcn', 'topp', 'popg', 'ftcn', 'fndg', 'cnce', 'qlco', 'resa', 'hlca', 'orgf', 'qnco']"
784,PMC3386495,S59,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,"in the double-blinded phase, both groups were to avoid antiplatelet or anticoagulant therapy for 24 h.","['C0205390', 'C1705764', 'C1706086', 'C1552839', 'C1705765', 'C0205173', 'C0441833', 'C0687744', 'C0150108', 'C1710475', 'C0150457']","['Doubling', 'Duplicate', 'Groups', 'Trial Phase', 'anticoagulant therapy', 'Both', 'Phase', 'Table Rules - groups', 'Blinded', 'Double Value Type', 'Social group']","['inpr', 'idcn', 'acty', 'clas', 'topp', 'popg', 'ftcn', 'qlco', 'tmco', 'resa']"
785,PMC3386495,S60,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,"in the open phase, patients allocated to the control group were to start aspirin immediately.","['C0205548', 'C0205390', 'C0030705', 'C0009932', 'C0175566', 'C1710475']","['Open', 'Control Groups', 'Trial Phase', 'Phase', 'Patients', 'Stat (do immediately)']","['grup', 'clas', 'spco', 'podg', 'tmco']"
786,PMC3386495,S61,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,"blood pressure was managed in the same way in both treatment groups, according to local protocol.","['C0441833', 'C1705169', 'C4282383', 'C0687744', 'C3887704', 'C3715209', 'C1271104', 'C0442711', 'C2599718', 'C1522729', 'C1507394', 'C0039798', 'C3538994', 'C0005823', 'C1552839', 'C0205276', 'C0445247', 'C1272641', 'C1706086', 'C0087111', 'C1522326', 'C1533734', 'C2348563']","['REMS Protocol', 'Both', 'Biomaterial Treatment', 'Blood Pressure', 'Study Protocol', 'Systemic arterial pressure', 'Therapeutic procedure', 'Protocol - answer to question', 'Clinical trial protocol', 'Clinical trial protocol document', 'Administration procedure', 'Protocols documentation', 'Social group', 'Treatment Epoch', 'Local', 'Same', 'Blood pressure finding', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Groups', 'Table Rules - groups', 'Treating', 'Library Protocol']","['inpr', 'idcn', 'topp', 'popg', 'ftcn', 'fndg', 'cnce', 'qlco', 'spco', 'resa', 'hlca', 'orgf']"
787,PMC3386495,S62,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,"additionally, all centres were asked for their pretrial experience of thrombolysis for treatment of stroke, and if the centre had, before joining the trial, a protocol for open-label use of rt-pa and had treated at least three people in the 12 months before joining the trial, the centre was classed as experienced.","['C0439231', 'C3887704', 'C1705169', 'C4282383', 'C1515981', 'C0008976', 'C4554100', 'C4321252', 'C0205099', 'C3715209', 'C0596545', 'C2827499', 'C0442711', 'C2599718', 'C1522729', 'C1507394', 'C0175566', 'C0027361', 'C0181496', 'C3538994', 'C0039798', 'C0205449', 'C0038454', 'C0062074', 'C4551445', 'C0520997', 'C0521125', 'C0332152', 'C0237607', 'C3539897', 'C0032143', 'C0087111', 'C1415458', 'C0457083', 'C1522326', 'C1533734', 'C0444868', 'C2348563', 'C4522130', 'C0042153']","['Labels (device)', 'Stroke, CTCAE', 'REMS Protocol', 'Biomaterial Treatment', 'And', 'Thrombolysis, function', 'month', 'Persons', 'Study Protocol', 'Preposition For', 'Have', 'WWOX wt Allele', 'Therapeutic procedure', 'Usage', 'HADH gene', 'Human Cells, Tissues, and Cellular and Tissue-Based Products Labeling', 'Protocol - answer to question', 'Clinical trial protocol', 'Experience', 'Cerebrovascular accident', 'Clinical Trials', 'Clinical trial protocol document', 'Administration procedure', 'Protocols documentation', 'Before', 'Central', 'Treatment Epoch', 'All', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Labeling Activity', 'Practice Experience', 'Open', 'utilization qualifier', 'Three', 'alteplase', 'Treating', 'HAC protocol', 'Library Protocol', 'Label (document)']","['clna', 'topp', 'enzy', 'fndg', 'mnob', 'qlco', 'hlca', ' phsu', 'inpr', 'idcn', 'gngm', 'resa', ' aapp', 'popg', 'ftcn', 'tmco', 'dsyn', 'menp', 'acty', 'spco', 'cnce', 'qnco']"
788,PMC3386495,S63,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study design and patients,all patients had a ct or mri brain scan before randomisation and a follow-up scan at 24–48 h.,"['C0412675', 'C0444868', 'C0030705', 'C1515981']","['All', 'And', 'MRI brain procedure', 'Patients']","['podg', 'diap', 'qnco', 'idcn']"
789,PMC3386495,S64,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study design and patients,a repeat brain scan was required if the patient deteriorated neurologically or intracranial haemorrhage was suspected for any reason.,"['C1705914', 'C0392360', 'C0030705', 'C0151699', 'C3272371', 'C0596217', 'C1547730', 'C1552551', 'C0205341']","['Any', 'Repeat Object', 'Any Data Type', 'Intracranial Hemorrhage', 'Repeat Pattern', 'Patients', 'Indication of (contextual qualifier)', 'Brain scan', 'Repeat']","['inpr', 'idcn', 'ftcn', 'patf', 'podg', 'qlco', 'tmco', 'diap']"
790,PMC3386495,S65,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study design and patients,"although ct scanning was preferred, mri was allowed.","['C1824234', 'C0040405', 'C0024485', 'C3890166']","['X-Ray Computed Tomography', 'CYREN gene', 'Magnetic Resonance Imaging', 'Magnetic Resonance Imaging Study File']","['inpr', 'gngm', 'diap']"
791,PMC3386495,S66,"['6a', '11a']","[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study design and patients,"all scans were sent to the trial centre in edinburgh for masked central rating of any signs of visible early ischaemia (presence and extent of hypo-attenuation, swelling, hyperattenuated artery), haemorrhage, and background brain changes (leukoaraiosis, atrophy, prior stroke lesions, non-stroke lesions) with validated rating methods.20–25","['C0599946', 'C1279919', 'C1515981', 'C0008976', 'C0038999', 'C4554100', 'C0025663', 'C0205099', 'C1518422', 'C0150112', 'C0003842', 'C0006104', 'C0150312', 'C0439792', 'C3272371', 'C0013604', 'C0332287', 'C0220912', 'C1552551', 'C0333641', 'C0205379', 'C0948163', 'C0220913', 'C0449851', 'C0038454', 'C0392148', 'C0443172', 'C0221198', 'C1706907', 'C0226004', 'C0871208', 'C0332152', 'C1555580', 'C0392747', 'C0311392', 'C0019080', 'C0022116', 'C0150108', 'C0025664', 'C0444868', 'C2826257', 'C0441633']","['Scanning', 'Stroke, CTCAE', 'Arterial system', 'Rating (action)', 'Methods', 'And', 'Edema', 'Background', 'Methods aspects', 'Blinded', 'Manufactured sign', 'Present', 'Providing presence (regime/therapy)', 'Atrophic', 'Any Data Type', 'Hemorrhage', 'psychological masking', 'Cerebrovascular accident', 'Clinical Trials', 'Changed status', 'Brain', 'Swelling', 'Before', 'Central', 'Negation', 'Any', 'Prior Medication Usage', 'visible', 'masked - No information', 'Physical findings', 'Leukoaraiosis', 'Aspects of signs', 'All', 'Changing', 'Early', 'In addition to', 'Lesion', 'Arteries', 'Techniques', 'Extent', 'Ischemia', 'Attenuation']","['sosy', 'inpr', 'bpoc', 'idcn', 'acty', 'topp', 'ftcn', 'fndg', 'patf', 'spco', 'qlco', 'cnce', 'tmco', 'bdsy', 'dsyn', 'resa', 'mnob', 'diap', 'qnco', 'evnt']"
792,PMC3386495,S67,"['11a', '6a']","[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study design and patients,"images were assessed with all original identifiers stripped from the record, and then viewed via a secure web-based image viewing system by an international panel of expert radiologists.","['C0282111', 'C3888058', 'C1704254', 'C0441833', 'C1515981', 'C2347409', 'C0260194', 'C0449913', 'C3146231', 'C1883708', 'C3853788', 'C1519222', 'C1553451', 'C0659450', 'C0205313', 'C1704922', 'C1706365', 'C0600091', 'C1999270', 'C0444868', 'C1512888', 'C0034869']","['And', 'International', 'Internet', 'Laboratory Order Panels', 'System', 'Identifier', 'Secure - resin cement', 'Security - service', 'Then', 'Secure feeling', 'Record - QueryRequestLimit', 'Original', 'Original Regulatory Submission', 'Image', 'All', 'Device system', 'Medical Image', 'Device Panel', 'Records', 'radiologist', 'Groups', 'System - kit']","['inpr', 'idcn', 'bodm', 'lbpr', 'prog', 'ocac', 'ftcn', 'mnob', 'cnce', 'qlco', 'tmco', 'menp', 'qnco']"
793,PMC3386495,S68,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,all assessments were made masked to all patient details and treatment allocation.,"['C1706778', 'C1261322', 'C0030705', 'C0150112', 'C3887704', 'C1705169', 'C0087111', 'C1515981', 'C0150108', 'C1522508', 'C1533734', 'C0444868', 'C1522326', 'C1555580', 'C0039798', 'C3538994']","['Treatment Epoch', 'masked - No information', 'psychological masking', 'All', 'Biomaterial Treatment', 'And', 'Evaluation procedure', 'Treating', 'Administration procedure', 'Patients', 'Blinded', 'Allocation', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Therapeutic procedure', 'Details']","['idcn', 'acty', 'topp', 'ftcn', 'cnce', 'podg', 'qlco', 'resa', 'hlca', 'qnco']"
794,PMC3386495,S69,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study design and patients,"the primary outcome specified in version 1·93 of the protocol and in the published statistical analysis plan14 was the proportion of patients alive and independent as measured by the oxford handicap score (ohs),26 a commonly used variant of the modified rankin score.27","['C0085862', 'C0030705', 'C0231172', 'C4050231', 'C4282383', 'C0871424', 'C1515981', 'C1709707', 'C1565156', 'C1274040', 'C3715209', 'C0442711', 'C2599718', 'C2584946', 'C1522729', 'C0043194', 'C1507394', 'C0205419', 'C1704324', 'C1299583', 'C0444706', 'C0034037', 'C3541902', 'C4551704', 'C0333052', 'C1273517', 'C1290940', 'C0205225', 'C1861455', 'C3889737', 'C0449820', 'C0392747', 'C0268353', 'C1421478', 'C2348563']","['statistical analysis', 'REMS Protocol', 'Measured Tumor Identification', 'And', 'Patients', 'Independent for Transfer', 'STOMATOCYTOSIS I', 'Study Protocol', 'Proportion', 'Cutis laxa, x-linked', 'Protocol - answer to question', 'Clinical trial protocol', 'WAS protein, human', 'WAS gene', 'Clinical trial protocol document', 'Protocols documentation', 'Publishing', 'Variant', 'Data Change Date', 'Independently able', 'Alive', 'Changing', 'Version', 'handicapping condition', 'Measured', 'Wiskott-Aldrich Syndrome', 'used by', 'Independence', 'ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated', 'Alive (finding)', 'Scientific Publication', 'Result', 'Score', 'Library Protocol', 'Primary']","['bacs', 'clna', 'inpr', 'idcn', 'gngm', 'ocac', 'ftcn', 'cnce', 'fndg', 'podg', 'tmco', 'qlco', 'resa', 'cgab', 'dsyn', ' aapp', 'diap', 'qnco']"
795,PMC3386495,S70,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study design and patients,"patients with an ohs of 0, 1, or 2 were classed as independent.","['C0085862', 'C0030705', 'C1290940', 'C1861455', 'C0268353', 'C1299583']","['Cutis laxa, x-linked', 'Independently able', 'Patients', 'Independence', 'Independent for Transfer', 'STOMATOCYTOSIS I']","['idcn', 'fndg', 'podg', 'cgab', 'dsyn']"
796,PMC3386495,S71,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,the statistical analysis plan specified an ordinal analysis of the ohs score at 6 months.,"['C0439231', 'C0936012', 'C4050231', 'C0439080', 'C1524024', 'C1861455', 'C0268353', 'C3889277', 'C0449820']","['Cutis laxa, x-linked', 'Statistical Analysis Plan', 'month', 'Analysis', 'STOMATOCYTOSIS I', 'ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated', 'Ordinal Position', 'Score', 'analysis aspect']","['inpr', 'clna', 'ftcn', 'tmco', 'resa', 'cgab', 'dsyn', 'qnco']"
797,PMC3386495,S72,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,additional secondary outcomes were to be reported separately.,"['C0027627', 'C1524062', 'C0175668', 'C0205436']","['second (number)', 'Additional', 'Neoplasm Metastasis', 'Secondary to']","['ftcn', 'qlco', 'qnco', 'neop']"
798,PMC3386495,S73,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study design and patients,"events occurring within 7 days of stroke were recorded by the local trial clinician on the 7-day form: deaths subdivided by cause (swelling of the initial infarct, intracranial haemorrhage, other deaths from the initial stroke, recurrent ischaemic stroke, recurrent stroke of unknown type, any other cause); symptomatic intracranial haemorrhage; recurrent ischaemic stroke; recurrent stroke of unknown type; neurological deterioration attributed to swelling of the initial ischaemic stroke; neurological deterioration not attributable to swelling of the initial ischaemic stroke or haemorrhage; and major extracranial haemorrhage (operational definitions of each of these events are provided in the published protocol13 and statistical analysis plan14).","['C0039828', 'C0439673', 'C2242682', 'C0871424', 'C1515981', 'C0008976', 'C0038999', 'C4554100', 'C0021308', 'C3541433', 'C0871685', 'C0015127', 'C1518422', 'C0868945', 'C3272371', 'C0441471', 'C1555582', 'C0013604', 'C1524003', 'C0348078', 'C4255237', 'C1704324', 'C0596130', 'C1552551', 'C0205494', 'C3541888', 'C2945760', 'C0205164', 'C0034037', 'C0151699', 'C0038454', 'C2707261', 'C1457900', 'C0205276', 'C4050014', 'C0332173', 'C1547085', 'C0205265', 'C0439228', 'C0376315', 'C1455761', 'C0011065', 'C0580586', 'C1517320', 'C0332307', 'C0019080', 'C1279901', 'C1705685', 'C4318856', 'C0231220', 'C1522492', 'C0948008']","['Initial (abbreviation)', 'Theses', 'statistical analysis', 'Major', 'CDISC Events Class', 'Stroke, CTCAE', 'Firstly', 'day', 'And', 'Edema', 'From', '7 days', 'Symptomatic', 'Initially', 'unknown vaccine or immune globulin', 'Any Data Type', 'Hemorrhage', 'Cerebrovascular accident', 'Infarction', 'Clinical Trials', 'Episodic', 'Swelling', 'Publishing', 'Each (qualifier value)', 'Neurological:-:Point in time:^Patient:-', 'deterioration', 'Negation', 'Neurologic (qualifier value)', 'Type - attribute', 'Event', 'Any', 'Initial Usage', 'Cessation of life', 'Recurrent', 'Unknown GENC', 'Clinician', 'Local', 'Etiology aspects', 'Daily', 'Formation', 'Major <insect>', 'Recurrent Cerebral Ischemia', 'attribution', 'Ischemic stroke', 'Intracranial Hemorrhage', 'Form:Finding:Point in time:{Setting}:Document:{Role}', 'extracranial', 'Manufactured form', 'Qualitative form', 'Science of Etiology', 'Unknown', 'Scientific Publication']","['clna', 'fndg', 'mnob', 'qlco', 'inpr', 'phpr', 'idcn', 'geoa', 'clas', 'prog', 'patf', 'imft', 'resa', ' aapp', 'orgf', 'sosy', 'ocac', 'ftcn', 'tmco', 'dsyn', 'menp', 'cnce', 'spco', 'euka', 'qnco', 'evnt']"
799,PMC3386495,S74,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study design and patients,other fatal and non-fatal non-cerebral events were also recorded and coded.,"['C3541888', 'C0441471', 'C1302234', 'C1515981', 'C1705232', 'C1518422']","['CDISC Events Class', 'Fatal', 'And', 'Death Related to Adverse Event', 'Negation', 'Event']","['idcn', 'clas', 'ftcn', 'fndg', 'qlco', 'evnt']"
800,PMC3386495,S75,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,data on potential reports of any of these events were extracted from the trial database and presented to the adjudication committee who were masked to treatment allocation.,"['C1511726', 'C0684224', 'C2700368', 'C0039828', 'C3887704', 'C1705169', 'C1515981', 'C3889645', 'C3714741', 'C3272371', 'C0441471', 'C1552551', 'C0039798', 'C3538994', 'C3541888', 'C0449450', 'C1516642', 'C0700287', 'C1706778', 'C3245479', 'C0087111', 'C3245505', 'C1522326', 'C1533734', 'C3272598']","['Theses', 'CDISC Events Class', 'Reporting', 'Biomaterial Treatment', 'And', 'Data call receiving device', 'Therapeutic procedure', 'Clinical Trial Final Report', 'Any Data Type', 'Clinical Trials Database', 'Administration procedure', 'Event', 'Any', 'Treatment Epoch', 'WHO Temperature/Humidity Storage Condition', 'Adjudication Committee', 'potential', 'Allocation', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Data', 'Report (document)', 'Presentation', 'Treating', 'Data (eukaryote)']","['inpr', 'idcn', 'acty', 'prog', 'clas', 'topp', 'medd', 'ftcn', 'cnce', 'qlco', 'euka', 'resa', 'hlca', 'evnt']"
801,PMC3386495,S77,['8a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0]",Randomisation and masking,"to avoid predictable alternation of treatment allocation, and thus potential loss of allocation concealment, patients were allocated with a probability of 0·80 to the treatment group that would minimise the difference between the groups on the key prognostic factors.","['C0030705', 'C0441833', 'C1705169', 'C0687744', 'C3887704', 'C1515981', 'C0025320', 'C1517945', 'C0039798', 'C3538994', 'C0033204', 'C1552839', 'C0919661', 'C1705429', 'C1514474', 'C1706778', 'C1519504', 'C0087111', 'C1257890', 'C3245505', 'C1522326', 'C1533734', 'C1705428', 'C0205103']","['Probability', 'Biomaterial Treatment', 'And', 'alternation', 'Patients', 'Stage Grouping', 'Therapeutic procedure', 'User Group', 'Administration procedure', 'Prognostic Factors', 'Group Object', 'Social group', 'Intermediate', 'Treatment Epoch', 'Loss', 'potential', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Allocation', 'Groups', 'Treating', 'Population Group', 'Table Rules - groups', 'Menopause']","['clna', 'inpr', 'idcn', 'acty', 'phsf', 'topp', 'popg', 'ftcn', 'cnce', 'spco', 'podg', 'patf', 'qlco', 'resa', 'hlca', 'qnco']"
802,PMC3386495,S78,['8a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0]",Randomisation and masking,additional details of the procedures used in the double-blinded phase of the study are reported elsewhere.11,"['C3538935', 'C0205390', 'C0184661', 'C1705764', 'C1705765', 'C0205173', 'C1273517', 'C0150108', 'C2700391', 'C2603343', 'C0025664', 'C1522508', 'C1710475', 'C1524062']","['Procedure (set of actions)', 'Doubling', 'Duplicate', 'Trial Phase', 'Additional', 'Phase', 'used by', 'Methods aspects', 'Blinded', 'Study', 'Double Value Type', 'Interventional procedure', 'Procedure Domain', 'Details']","['inpr', 'acty', 'clas', 'topp', 'ftcn', 'fndg', 'qlco', 'tmco', 'resa']"
803,PMC3386495,S79,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,"the randomisation system informed local clinicians of the patients' unique trial identification number, and the weight-adjusted dose of drug or placebo in the double-blinded phase, or of the weight-adjusted drug dose among those allocated thrombolysis in the open phase, to be given as a 10% bolus with the remainder by an infusion over 1 h.","['C0205390', 'C1705764', 'C0030705', 'C3888058', 'C1300638', 'C1515981', 'C0008976', 'C0574032', 'C0871685', 'C0005910', 'C0456081', 'C0449913', 'C1696465', 'C1705765', 'C1442162', 'C0175566', 'C1710475', 'C0332287', 'C3812160', 'C0678766', 'C1550718', 'C0178602', 'C0043100', 'C1553451', 'C0205173', 'C0205276', 'C1827465', 'C0520997', 'C3244317', 'C0013227', 'C1186706', 'C0032042', 'C1305866', 'C0700308', 'C1254351', 'C1706408', 'C1511237', 'C0150108', 'C1705104', 'C1947971', 'C1710548']","['Adjustment Action', 'Radiotherapy Bolus', 'identification number', 'And', 'Weight', 'Patients', 'Thrombolysis, function', 'Blinded', 'Unique', 'placebo', 'System', 'GIVEN', 'Doubling', 'Duplicate', 'Give - dosing instruction imperative', 'Trial Phase', 'Clinical Trials', 'Placebos', 'Infusion procedures', 'Infusion route', 'Dosage', 'Local', 'Clinician', 'Device system', 'Entity Name Part Type - given', 'drug dose', 'In addition to', 'Importance Weight', 'Given name', 'Placebo Control', 'Protium', 'Open', 'Pharmaceutical Preparations', 'Body Weight', 'Pharmacologic Substance', 'System - kit', 'Phase', 'bolus infusion', 'Weighing patient', 'Bolus of ingested food', 'Double Value Type']","['clna', 'topp', 'medd', 'mnob', 'qlco', 'bdsu', 'hlca', 'phsu', 'inpr', 'idcn', 'clas', 'prog', 'resa', 'bodm', 'elii', 'ftcn', 'tmco', 'podg', 'acty', 'spco', 'qnco', 'orga']"
804,PMC3386495,S80,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,"with the exception of the 276 patients treated in the double-blinded phase of the trial, treatment was given openly and neither the patient nor the treating clinicians were masked.","['C0205390', 'C1705764', 'C0030705', 'C3887704', 'C1705169', 'C0028423', 'C1515981', 'C0008976', 'C0871685', 'C1565156', 'C3274651', 'C1705765', 'C1442162', 'C0043194', 'C1710475', 'C0039798', 'C3538994', 'C1550718', 'C0028609', 'C0205173', 'C1513854', 'C3244317', 'C1705847', 'C1554961', 'C0045071', 'C0087111', 'C0150108', 'C1947971', 'C1522326', 'C1533734', 'C1421478', 'C4284892']","['Biomaterial Treatment', 'And', 'Patients', 'Blinded', 'exception - ResponseLevel', 'Therapeutic procedure', 'GIVEN', 'Doubling', 'Duplicate', 'Give - dosing instruction imperative', 'Norway', 'Trial Phase', 'WAS protein, human', 'Clinical Trials', 'WAS gene', 'NOR Mouse', 'Administration procedure', 'Neither', '19-norandrostenedione', 'Treatment Epoch', 'Nucleolus Organizer Region', 'Exception - Property or Attribute', 'Clinician', 'Entity Name Part Type - given', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Given name', 'Phase', 'Wiskott-Aldrich Syndrome', 'Treating', 'Double Value Type', 'Neither Case or Control Status']","['bacs', 'topp', 'qlco', 'hlca', 'inpr', 'idcn', 'geoa', 'gngm', 'prog', 'clas', 'resa', ' aapp', 'ftcn', 'podg', 'orch', 'tmco', 'dsyn', 'acty', 'cnce', 'celc', 'mamm']"
805,PMC3386495,S81,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Randomisation and masking,"hospital staff completed an early outcome form at 7 days, death, or hospital discharge, whichever occured first, recording details of events occurring in hospital within 7 days, details of background treatments given and functional status.","['C0031228', 'C1279919', 'C0332285', 'C1274040', 'C0441471', 'C0348078', 'C4255237', 'C0205435', 'C3541888', 'C0019994', 'C1547085', 'C1706907', 'C0598463', 'C1306577', 'C0376315', 'C0011065', 'C0586003', 'C0087111', 'C1279901', 'C1522508', 'C1522492']","['CDISC Events Class', 'Firstly', 'First (number)', 'Background', '7 days', 'Therapeutic procedure', 'Death (finding)', 'Within', 'Details', 'Event', 'Cessation of life', 'Formation', 'Early', 'Form:Finding:Point in time:{Setting}:Document:{Role}', 'Personnel, Hospital', 'Manufactured form', 'Qualitative form', 'Discharge from hospital', 'Result', 'Hospitals', 'Functional Status']","['clna', 'clas', 'prog', 'topp', 'ftcn', 'fndg', 'mnob', 'tmco', 'qlco', 'cnce', 'spco', 'hlca', ' hcro', 'orgf', 'qnco', 'evnt']"
806,PMC3386495,S82,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Randomisation and masking,"6 months after randomisation, general practitioners (or hospital coordinators) were contacted by the ist-3 trial office staff to check that the patient was alive and inform them that they might be approached for follow-up.","['C0019994', 'C0439231', 'C0030705', 'C1283174', 'C4551704', 'C0442603', 'C0008976', 'C0017319', 'C0851286', 'C2584946', 'C0332283', 'C1947908', 'C4321547', 'C4281991']","['Follow', 'Followed by', 'Alive', 'Office', 'Clinical Trials', 'General Practitioners', 'Checking (action)', 'Patients', 'month', 'Staff', 'On Staff', 'Alive (finding)', 'Check', 'Hospitals']","['acty', 'prog', 'ftcn', 'mnob', 'cnce', 'podg', 'fndg', 'tmco', 'resa', ' hcro']"
807,PMC3386495,S83,"['11a', '6a']","[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Randomisation and masking,"if appropriate, the ist-3 trial office masked staff then mailed a postal questionnaire to patients to assess outcome.","['C1274040', 'C0030705', 'C0034394', 'C1548787', 'C1883708', 'C0442603', 'C0008976', 'C0851286', 'C1947908', 'C1514253']","['Postal', 'Appropriate', 'Clinical Trials', 'Office', 'Questionnaires', 'Patients', 'Staff', 'Then', 'Result', 'On Staff']","['inpr', 'prog', 'ftcn', 'mnob', 'qlco', 'podg', 'tmco', 'resa']"
808,PMC3386495,S84,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Randomisation and masking,"non-responders were contacted by telephone, and follow-up data was obtained by telephone interview.","['C1301820', 'C1511726', 'C0589120', 'C3245479', 'C1705541', 'C0039457', 'C3274571', 'C1515981', 'C1515258', 'C1522577', 'C0043194', 'C1565156', 'C1421478', 'C0021823', 'C3714741', 'C1704685']","['WAS protein, human', 'follow-up', 'WAS gene', 'Telephone', 'Telephone Device', 'And', 'Data call receiving device', 'Wiskott-Aldrich Syndrome', 'Follow-Up Report', 'Telephone Number', 'Data (eukaryote)', 'Data', 'Follow-up status', 'Clinical Study Follow-up', 'Interviews, Telephone', 'Obtain']","['bacs', 'inpr', 'idcn', 'gngm', 'medd', 'ftcn', 'mnob', 'fndg', 'euka', 'resa', 'dsyn', 'hlca', ' aapp']"
809,PMC3386495,S85,"['6a', '11a']","[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Randomisation and masking,"in italy and austria, all follow-ups were done as telephone interviews by a clinician, who was masked to treatment allocation and was highly experienced in outcome assessment.","['C0004348', 'C1706778', 'C3887704', 'C0022277', 'C1705169', 'C0205250', 'C0334463', 'C0087111', 'C1515981', 'C0085565', 'C3542434', 'C0871685', 'C1522326', 'C0021823', 'C1533734', 'C0444868', 'C3272598', 'C0039798', 'C3538994']","['Austria', 'High', 'Malignant Fibrous Histiocytoma', 'Treatment Epoch', 'WHO Temperature/Humidity Storage Condition', 'All', 'And', 'Biomaterial Treatment', 'Clinician', 'Administration procedure', 'Treating', 'Italy', 'Allocation', 'Outcome Assessment (Health Care)', 'Urgency Perception Scale Questionnaire', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Therapeutic procedure', 'Interviews, Telephone']","['inpr', 'idcn', 'geoa', 'acty', 'prog', 'ocac', 'topp', 'neop', 'ftcn', 'cnce', 'qlco', 'resa', 'hlca', 'qnco']"
810,PMC3386495,S86,"['6a', '11a']","[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Randomisation and masking,"in portugal, patients were followed up in clinic by clinicians not involved in the patients' initial treatment, again, masked to treatment allocation as far as possible.","['C0030705', 'C3887704', 'C1705169', 'C0871685', 'C1518422', 'C0150112', 'C1705910', 'C1555582', 'C0039798', 'C0002424', 'C3538994', 'C0442592', 'C0205265', 'C0032729', 'C1555580', 'C0332149', 'C0205108', 'C1706778', 'C0087111', 'C1279901', 'C1705685', 'C0150108', 'C1522326', 'C1533734']","['Initial (abbreviation)', 'Firstly', 'Biomaterial Treatment', 'Possibly Related to Intervention', 'Patients', 'Blinded', 'Possible', 'Portugal', 'Therapeutic procedure', 'Initially', 'Clinic', 'psychological masking', 'Administration procedure', 'Negation', 'Initial Usage', 'Treatment Epoch', 'masked - No information', 'Clinician', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Allocation', 'Ambulatory Care Facilities', 'Distal (qualifier value)', 'Treating']","['geoa', 'idcn', 'acty', 'prog', 'topp', 'ftcn', 'cnce', 'mnob', 'podg', 'spco', 'qlco', 'resa', 'tmco', 'hlca', 'fndg', ' hcro']"
811,PMC3386495,S87,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Randomisation and masking,"to assess the durability of any treatment benefit beyond 6 months, patients recruited in the uk (and in other countries where appropriate funding had been obtained) were also followed up at 18 months.","['C4688489', 'C0243098', 'C0439231', 'C0030705', 'C0454664', 'C3272371', 'C1548787', 'C0376244', 'C1552551']","['Any', 'Funding', 'Any Data Type', 'Appropriate', 'Country', 'funding aspects', 'Patients', 'month', 'Treatment Benefit']","['inpr', 'geoa', 'idcn', 'tmco', 'qlco', 'podg', 'qnco']"
812,PMC3386495,S88,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Randomisation and masking,"all follow-up done by patient contact for these analyses ceased on march 31, 2012, but recording of deaths from national registries of deaths continues in uk, norway, and sweden.","['C1856053', 'C3829202', 'C0039828', 'C1705415', 'C0030705', 'C0034975', 'C3812666', 'C0028423', 'C1515981', 'C3245503', 'C0337611', 'C0332158', 'C0233535', 'C0444868', 'C3245515', 'C0011065', 'C0038995']","['Theses', 'Norway', 'Communication Contact', 'contact person', 'Cessation of life', 'Contact with', 'March (month)', 'All', 'And', 'Sweden', 'Patients', 'butting', 'Hydranencephaly with Renal Aplasia-Dysplasia', 'Personal Contact', 'National citizen', 'Registries domain', 'Registries']","['inpr', 'idcn', 'geoa', 'acty', 'popg', 'ftcn', 'podg', 'tmco', 'dsyn', 'mobd', 'orgf', 'qnco']"
813,PMC3386495,S90,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Randomisation and masking,"at the outset of the trial in 2000, we estimated that, among the type of patients likely to be recruited at the time, to detect both an absolute difference of 10% in the proportion of patients alive and independent at 6 months after treatment and to have sufficient power to permit reliable analyses of the prespecified subgroups, a sample of 6000 patients would be needed.","['C0085862', 'C0439231', 'C0030705', 'C3887704', 'C1705169', 'C0032863', 'C1515981', 'C0008976', 'C1709707', 'C1079230', 'C3891454', 'C0332148', 'C0750572', 'C2584946', 'C0205410', 'C1299583', 'C0039798', 'C3538994', 'C3858758', 'C4551704', 'C1290940', 'C1549031', 'C1706086', 'C0040223', 'C0332307', 'C0087111', 'C3854080', 'C0750492', 'C1522326', 'C1533734', 'C0442726', 'C0370003', 'C2347026']","['Biospecimen', 'Both', 'Biomaterial Treatment', 'And', 'Detected (finding)', 'Patients', 'month', 'Independent for Transfer', 'Power', 'Time', 'Proportion', 'Therapeutic procedure', 'Sufficient', 'Clinical Trials', 'Administration procedure', 'Estimated', 'Independently able', 'Type - attribute', 'Treatment Epoch', 'Alive', 'Absolute Change', 'Probably', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'reliable', 'Dosing Days to Detection', 'Probable diagnosis', 'Specimen', 'Power (Psychology)', 'Treating', 'Independence', 'Alive (finding)', 'Subgroup A Nepoviruses']","['hcpp', 'inpr', 'idcn', 'topp', 'ftcn', 'cnce', 'fndg', 'podg', 'tmco', 'qlco', 'resa', 'virs', 'hlca', 'sbst', 'qnco']"
814,PMC3386495,S91,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Randomisation and masking,"a trial of that size could detect a clinically worthwhile net benefit of as little as 3% absolute difference in the primary outcome (80% power, α=0·05).","['C1274040', 'C2700395', 'C3889124', 'C3853572', 'C0032863', 'C3887809', 'C0008976', 'C3854080', 'C0205225', 'C1456447', 'C0700321', 'C0814225', 'C0456389', 'C1549031', 'C3890893']","['SLC6A2 protein, human', 'Smallest', 'Small', 'benefit', 'Clinical Trials', 'Power (Psychology)', 'SLC6A2 wt Allele', 'Absolute Change', 'Power', 'Only a Little', 'size', 'Result', 'Ephrin Type-B Receptor 1, human', 'Net (qualifier)', 'Primary']","['hcpp', ' enzy', 'bacs', 'idcn', 'rcpt', 'gngm', 'ftcn', 'fndg', 'spco', 'qlco', 'resa', ' aapp', 'qnco']"
815,PMC3386495,S92,['3b'],"[0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,"however, it was clear by 2007 that obtaining a sample of 6000 was no longer feasible, and the steering committee agreed a revised recruitment target.11","['C2963144', 'C4684755', 'C2348534', 'C1515981', 'C0043194', 'C1565156', 'C1421478', 'C1527075', 'C1709157', 'C0370003', 'C2347026']","['Biospecimen', 'Clear', 'WAS protein, human', 'WAS gene', 'And', 'Wiskott-Aldrich Syndrome', 'Steering Committee', 'Negative Surgical Margin', 'Recruitment Target', 'Revision procedure', 'Specimen']","['bacs', 'idcn', 'gngm', 'topp', 'popg', 'cnce', 'fndg', 'qlco', 'dsyn', 'sbst', ' aapp', 'qnco']"
816,PMC3386495,S93,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Randomisation and masking,"the sample size, re-estimated in 2007 on the basis of event rates in both treatment groups combined, was 3100.","['C1706086', 'C1552839', 'C0441833', 'C1705169', 'C0441471', 'C0687744', 'C0087111', 'C3887704', 'C1522326', 'C1527178', 'C1533734', 'C1874451', 'C4019010', 'C0242618', 'C0039798', 'C3538994']","['Basis - conceptual entity', 'Treatment Epoch', 'Groups', 'Both', 'Biomaterial Treatment', 'Sample Size', 'Table Rules - groups', 'Administration procedure', 'Treating', 'therapeutic aspects', 'National reporting jurisdiction:Loc:Pt:^Event:Nom', 'treatment - ActInformationManagementReason', 'Therapeutic procedure', 'Basis', 'Social group', 'Event']","['clna', 'inpr', 'idcn', 'topp', 'popg', 'ftcn', 'cnce', 'qlco', 'resa', 'hlca', 'qnco', 'phsu', 'evnt']"
817,PMC3386495,S94,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Randomisation and masking,this sample size gave 80% power to detect an absolute difference of 4·7% in the primary outcome.11,"['C1274040', 'C0032863', 'C0205225', 'C3854080', 'C1080058', 'C0242618', 'C1549031']","['This (eukaryote)', 'Sample Size', 'Power (Psychology)', 'Absolute Change', 'Power', 'Result', 'Primary']","['hcpp', 'idcn', 'ftcn', 'qlco', 'euka', 'qnco']"
818,PMC3386495,S95,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,"we monitored the quality and integrity of the accumulating clinical data according to a protocol agreed with the study sponsors, which involved central statistical monitoring according to the principles described by buyse and colleagues,28 supplemented by onsite monitoring and detailed source data verification in a random sample of 10% of records in centres that had recruited more than 30 patients, or when patterns in the data at a centre seemed anomalous.","['C1511726', 'C0332306', 'C0030705', 'C0449774', 'C1516606', 'C4282383', 'C1552738', 'C0150369', 'C1515981', 'C1314939', 'C3714741', 'C2348563', 'C0205099', 'C0038215', 'C3715209', 'C1948054', 'C0442711', 'C2599718', 'C1522729', 'C4086865', 'C2603343', 'C1507394', 'C0332287', 'C4553565', 'C4553741', 'C1548330', 'C1283169', 'C0205172', 'C1553414', 'C0062074', 'C0150105', 'C3539897', 'C3245479', 'C0205266', 'C1947912', 'C1415458', 'C1522508', 'C0680240', 'C3277934', 'C0034869', 'C0872403']","['Query Quantity Unit - Records', 'Preventive monitoring', 'Involvement with', 'pattern', 'REMS Protocol', 'And', 'Data call receiving device', 'Patients', 'Study Protocol', 'Have', 'HADH gene', 'Monitoring - action', 'described', 'Protocol - answer to question', 'Clinical trial protocol', 'Random Sampling', 'Clinical trial protocol document', 'Source Data Verification', 'Quantity limited request - Records', 'Protocols documentation', 'Central', 'Random Sample Population', 'with quality', 'Source Data Verification Document', 'Agreement', 'Study', 'Data', 'In addition to', 'Records', 'Personal Integrity', 'More', 'Anomalous', 'Integrity', 'Science of Statistics', 'When (temporal qualifier)', 'HAC protocol', 'Clinical Data', 'Data (eukaryote)', 'Intact', 'Library Protocol', 'Details']","['inpr', 'inbe', 'idcn', 'gngm', 'ocdi', 'topp', 'medd', 'popg', 'ftcn', 'spco', 'fndg', 'qlco', 'podg', 'euka', 'resa', 'socb', 'hlca', 'tmco', 'qnco']"
819,PMC3386495,S96,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,"all ist-3 monitoring procedures were compliant with requirements of all study sponsors, the national ethics committees and regulatory agencies in the 12 participating countries, and they met all appropriate regulatory and good clinical practice requirements.","['C1548787', 'C0150369', 'C1515981', 'C2700391', 'C1550543', 'C0237463', 'C0220905', 'C0085546', 'C3245503', 'C2603343', 'C3538935', 'C1283169', 'C0184661', 'C0454664', 'C1704735', 'C0428210', 'C2986419', 'C0679823', 'C0025664', 'C0444868', 'C4317104']","['Preventive monitoring', 'Appropriate', 'Ethics Committees', 'And', 'Methods aspects', 'National citizen', 'Procedure Domain', 'Monitoring - action', 'Methionine measurement', 'Fulfill', 'Regulator', 'All', 'Country', 'Agencies', 'Study', 'regulatory', 'Good Clinical Practice', 'participation', 'Procedure (set of actions)', 'Interventional procedure', 'Metabolic Equivalent of Task Unit']","['inpr', 'phpr', 'rnlw', 'idcn', 'geoa', 'lbpr', 'prog', 'topp', 'popg', 'ftcn', 'cnce', 'qlco', 'resa', 'hlca', 'qnco', 'orgt']"
820,PMC3386495,S97,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,"all baseline data, 7-day, and 6-month outcome data were subject to verification checks built into the randomisation and data management system.","['C1511726', 'C3891561', 'C0439231', 'C3888058', 'C1706203', 'C1515981', 'C0332286', 'C0449913', 'C3714741', 'C1274040', 'C0681850', 'C1711411', 'C2697811', 'C1442488', 'C1553451', 'C0332173', 'C0439228', 'C0237944', 'C0596404', 'C0168634', 'C2349001', 'C3245479', 'C0332177', 'C0444868']","['Baseline', 'day', 'And', 'Data call receiving device', 'into', 'month', 'System', 'Investigative Subject', 'Data Management Oversight Documentation', 'Verification of Theories', 'Subject - topic', 'BaseLine dental cement', 'All', 'Daily', 'Device system', 'Monthly (qualifier value)', 'Data', 'Data Management', 'Human Study Subject', 'Verification', 'System - kit', 'Study Subject', 'Data (eukaryote)', 'Result']","['inpr', 'grup', 'idcn', 'qnco', 'medd', 'popg', 'ftcn', 'mnob', 'tmco', 'euka', 'resa', 'bodm']"
821,PMC3386495,S98,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,"we monitored all baseline and postrandomisation imaging, which provided additional cross-checks on recruited patients and centre performance.","['C0168634', 'C0030705', 'C1515981', 'C2828360', 'C1442488', 'C0444868', 'C0597198', 'C0011923', 'C1524062', 'C0205099', 'C1882330', 'C0079595']","['BaseLine dental cement', 'Traverse', 'Baseline', 'Imaging Techniques', 'All', 'Additional', 'And', 'Patients', 'performance - action', 'Central', 'Performance', 'Diagnostic Imaging']","['inbe', 'idcn', 'qnco', 'acty', 'ftcn', 'spco', 'cnce', 'podg', 'diap', 'bodm']"
822,PMC3386495,S99,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,"an expert radiologist checked all scans, masked to clinical details and treatment allocation, immediately on receipt at the trial office, for evidence of adverse events and protocol deviations.","['C0205548', 'C3887511', 'C3887704', 'C1705169', 'C0442603', 'C1515981', 'C0008976', 'C0260194', 'C1704645', 'C0877248', 'C0205210', 'C0039798', 'C3538994', 'C1705413', 'C1706778', 'C1549438', 'C0087111', 'C1522508', 'C1533734', 'C0444868', 'C1522326', 'C0441633', 'C3889412']","['Scanning', 'Clinical Trial Protocol Deviation Document', 'Office', 'Biomaterial Treatment', 'And', 'Therapeutic procedure', 'Clinical Trials', 'Administration procedure', 'Adverse event', 'Procedure Practitioner Identifier Code Type - Radiologist', 'Clinical', 'Evidence', 'Treatment Epoch', 'Adverse Event Domain', 'All', 'Allocation', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Protocol Deviations Domain', 'radiologist', 'Treating', 'Stat (do immediately)', 'Details']","['inpr', 'idcn', 'acty', 'prog', 'topp', 'ftcn', 'cnce', 'patf', 'qlco', 'mnob', 'tmco', 'resa', 'hlca', 'diap', 'qnco']"
823,PMC3391717,S39,"['3a', '4b']","[0, 0, 0, 0, 0, 0, 1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,"we did this phase 3 randomised, placebo-controlled trial at six dutch, one scottish, and one chilean centre.","['C0205452', 'C0032042', 'C0439561', 'C1706408', 'C1696465', 'C0013331', 'C0205447', 'C1515981', 'C0240966', 'C0282461', 'C0936233', 'C0239045', 'C0009933', 'C1080058', 'C0205099']","['Placebo Control', 'Chilean', 'Scottish race', 'Phase 3 Clinical Trials', 'Controlled Clinical Trial [Publication Type]', 'And', 'Placebos', 'placebo', 'Controlled Clinical Trials as Topic', 'Central', 'Dutch Population', 'One', 'Phase 3', 'Six', 'This (eukaryote)']","['inpr', 'idcn', 'bodm', 'topp', 'popg', 'spco', 'tmco', 'euka', 'resa', 'qnco']"
824,PMC3391717,S40,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,the trial protocol has been published.11,,,
825,PMC3391717,S41,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,patients were eligible for inclusion if they were admitted to the neurological or neurosurgical units of one of the participating hospitals within 4 days of haemorrhage.,"['C0019994', 'C0030705', 'C3853603', 'C2707261', 'C0439148', 'C0205447', 'C0019080', 'C1512693', 'C0679823', 'C1442765', 'C1548635', 'C0007637', 'C1519795', 'C0205494']","['Inclusion Bodies', 'Eligible', '4 Days', 'Hemorrhage', 'Unit - NCI Thesaurus Property', 'Inclusion', 'Unit', 'Patients', 'Unit of Measure', 'participation', 'One', 'Neurological:-:Point in time:^Patient:-', 'Hospitals', 'Neurologic (qualifier value)']","['clna', 'ftcn', 'mnob', 'patf', 'qlco', 'podg', 'celc', 'tmco', ' hcro', 'qnco']"
826,PMC3391717,S42,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,"investigators based the diagnosis of aneurysmal subarachnoid haemorrhage on the presence of extravasated blood in the basal cisterns by brain ct, or—if ct was negative—by xanthochromia of cerebrospinal fluid.","['C0007807', 'C1704656', 'C0412585', 'C0038525', 'C0150312', 'C0007806', 'C0005767', 'C0439651', 'C0392148', 'C0229664', 'C0011900', 'C0005768', 'C0035173', 'C0863146', 'C4553273', 'C1185718', 'C0205112', 'C1704338']","['Basal', 'Yellow color on exam', 'In Blood', 'Blood', 'Cistern', 'Xanthochromia Measurement', 'Diagnosis', 'diagnosis aspect', 'Present', 'Providing presence (regime/therapy)', 'Research Personnel', 'In Cerebrospinal Fluid', 'CAT scan of brain', 'Subarachnoid Hemorrhage', 'Diagnosis Study', 'aneurysmal', 'peripheral blood', 'Cerebrospinal Fluid']","['bsoj', 'lbpr', 'prog', 'topp', 'ftcn', 'spco', 'fndg', 'bdsu', 'qlco', 'resa', 'dsyn', 'diap']"
827,PMC3391717,S43,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,"for patients with a normal ct scan and xanthochromia of cerebrospinal fluid, proof of an aneurysm was a prerequisite for inclusion.","['C0007807', 'C0679209', 'C0030705', 'C0002940', 'C0007806', 'C0436480', 'C1515981', 'C1512693', 'C0043194', 'C1565156', 'C0007637', 'C1421478', 'C0556981', 'C4553273', 'C0863146']","['Yellow color on exam', 'ct normal', 'Inclusion Bodies', 'WAS protein, human', 'Inclusion', 'Aneurysm', 'WAS gene', 'And', 'Wiskott-Aldrich Syndrome', 'Patients', '% proof', 'In Cerebrospinal Fluid', 'prerequisite', 'Xanthochromia Measurement', 'Cerebrospinal Fluid']","['bacs', 'idcn', 'lbpr', 'gngm', 'ftcn', 'fndg', 'celc', 'bdsu', 'anab', 'podg', 'qlco', 'dsyn', ' aapp', 'qnco']"
828,PMC3391717,S44,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,we included patients with a perimesencephalic pattern of haemorrhage on ct only if they had an aneurysm of the posterior circulation.,"['C0030705', 'C0002940', 'C0205171', 'C0449774', 'C0205095', 'C0019080', 'C0005775', 'C1516559']","['Blood Circulation', 'Hemorrhage', 'Aneurysm', 'Circulatory Process', 'Patients', 'Singular', 'Dorsal', 'pattern']","['phsf', 'spco', 'patf', 'podg', 'anab', 'orgf', 'qnco']"
829,PMC3391717,S45,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,"exclusion criteria were age younger than 18 years, renal failure (defined as serum creatinine concentration of more than 150 μmol/l), bodyweight less than 50 kg, or imminent death.","['C0086045', 'C0439234', 'C1963154', 'C0205172', 'C0680251', 'C1446561', 'C0439092', 'C3827302', 'C0201976', 'C0600061', 'C1306577', 'C0001779', 'C0011065', 'C0035078']","['Concentration measurement', 'year', 'Cessation of life', 'Less Than', 'More', 'Serum creatinine level', 'Mental concentration', 'Death (finding)', 'Age', 'Exclusion Criteria', 'Creatinine measurement, serum (procedure)', 'Able to Concentrate Question', 'Kidney Failure', 'Renal Failure, CTCAE']","['inpr', 'lbpr', 'ftcn', 'fndg', 'tmco', 'dsyn', 'menp', 'orgf', 'qnco', 'orga']"
830,PMC3391717,S46,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,the study complies with the declaration of helsinki and good clinical practice guidelines.,"['C1515981', 'C2986419', 'C2603343', 'C4281991', 'C0282451']","['Follow', 'Clinical Practice Guideline', 'And', 'Study', 'Good Clinical Practice']","['ftcn', 'inpr', 'resa', 'idcn']"
831,PMC3391717,S47,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,we obtained ethics committee approval from every centre.,"['C2346845', 'C1948061', 'C0085546', 'C0205540', 'C0205099', 'C2697909']","['Ethics Committees', 'Approved', 'Letter of Authorization', 'Central', 'Approval (document)', 'Every (qualifier)']","['inpr', 'rnlw', 'prog', 'spco', 'qlco']"
832,PMC3391717,S48,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and patients,all patients provided written and oral informed consent.,"['C0444868', 'C0442027', 'C0021430', 'C0030705']","['All', 'Informed Consent', 'Oral', 'Patients']","['spco', 'podg', 'qnco', 'rnlw']"
833,PMC3391717,S50,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,the randomisation code was produced by the university medical center utrecht (the netherlands) pharmacy.,"['C3889831', 'C0000872', 'C0805701', 'C0009219', 'C0027778', 'C0043194', 'C1565156', 'C1421478', 'C0031336', 'C0031321', 'C3244303', 'C0031322']","['Netherlands', 'WAS protein, human', 'Academic Medical Centers', 'WAS gene', 'Wiskott-Aldrich Syndrome', 'Pharmacy domain', 'Pharmacy (field)', 'Pharmaceutical Services', 'Pharmacy facility', 'Coding', 'Code', 'eTMF Content Model Code']","['bmod', 'inpr', 'bacs', 'geoa', 'gngm', 'ocac', 'mnob', 'hlca', ' aapp', ' hcro', 'dsyn']"
834,PMC3391717,S51,"['8a', '8b']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0]",Randomisation and masking,"the pharmacy used computer-generated randomisation codes in blocks of four, and stratified by centre.","['C0205363', 'C0009622', 'C1533157', 'C0205450', 'C1273517', 'C0332206', 'C1515981', 'C0919279', 'C0028778', 'C0031336', 'C0031321', 'C3244303', 'C0031322', 'C0205099', 'C3811660']","['Obstruction', 'Computers', 'And', 'stratified', 'Pharmacy domain', 'Block Specimens', 'used by', 'Pharmacy (field)', 'Pharmaceutical Services', 'Pharmacy facility', 'Blocking', 'A Codes', 'Central', 'Block Unit of Distance', 'Four']","['bmod', 'inpr', 'idcn', 'clas', 'ftcn', 'mnob', 'spco', 'bdsu', 'patf', 'qlco', 'fndg', 'hlca', ' hcro', 'qnco']"
835,PMC3391717,S52,['9'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1]",Randomisation and masking,"the pharmacy produced identical, sequentially numbered, randomly assigned boxes of study medication, containing either magnesium sulphate or placebo.","['C3244316', 'C4284232', 'C0205280', 'C1552601', 'C1516050', 'C2603343', 'C0031336', 'C0031321', 'C3244303', 'C0013227', 'C0031322', 'C0179400']","['Pharmaceutical Preparations', 'Medications', 'medication - HL7 publishing domain', 'identical', 'Assignment - action', 'Pharmacy domain', 'Study', 'Pharmacy (field)', 'Pharmaceutical Services', 'Pharmacy facility', 'Box', 'PersonNameUse - assigned']","['bmod', 'inpr', 'ftcn', 'mnob', 'qlco', 'resa', 'hlca', ' hcro', 'phsu']"
836,PMC3391717,S53,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,local investigators assigned the participant to the box with the lowest study number.,"['C4554048', 'C0679646', 'C0205276', 'C0332287', 'C0449788', 'C1708760', 'C2603343', 'C2698741', 'C0035173', 'C0237753', 'C0179400']","['Count of entities', 'Study Participant', 'Local', 'Numbers', 'Study', 'Research Personnel', 'Box', 'Participant Object', 'In addition to', 'Lowest', 'Participant']","['prog', 'clas', 'popg', 'ftcn', 'mnob', 'spco', 'qlco', 'resa', 'qnco']"
837,PMC3391717,S54,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,the randomisation key was kept by the pharmacy of the university medical center utrecht.,"['C0000872', 'C0031336', 'C0031321', 'C3244303', 'C0031322']","['Academic Medical Centers', 'Pharmacy domain', 'Pharmacy (field)', 'Pharmaceutical Services', 'Pharmacy facility']","['bmod', 'inpr', 'mnob', 'hlca', ' hcro']"
838,PMC3391717,S55,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,"patients, treating physicians, and investigators assessing outcomes and analysing data were masked to the allocation.","['C1511726', 'C1706778', 'C0030705', 'C3245479', 'C1515981', 'C3714741', 'C0035173', 'C0031831']","['And', 'Data call receiving device', 'Patients', 'Research Personnel', 'Physicians', 'Allocation', 'Data (eukaryote)', 'Data']","['idcn', 'acty', 'prog', 'medd', 'podg', 'euka']"
839,PMC3391717,S57,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,"at admission to hospital, investigators recorded sex, age, and world federation of neurological surgeons subarachnoid haemorrhage grade12 for each patient.","['C0809949', 'C2700280', 'C0019994', 'C0184666', 'C0030705', 'C1515008', 'C0009253', 'C0804628', 'C1457900', 'C2707261', 'C0019080', 'C1515981', 'C0079399', 'C1522384', 'C0036864', 'C0035173', 'C0582175', 'C0001779', 'C0205494']","['Gender', 'Hemorrhage', 'Surgeon', 'Sex Behavior', 'Hospital admission', 'Admission activity', 'World', 'And', 'Coitus', 'Patients', 'Age', 'Research Personnel', 'sex', 'Subarachnoid Route of Drug Administration', 'Each (qualifier value)', 'Neurological:-:Point in time:^Patient:-', 'Hospitals', 'Gender:Type:Point in time:^Patient:Nominal', 'Neurologic (qualifier value)']","['clna', 'idcn', 'prog', 'popg', 'ftcn', 'mnob', 'patf', 'podg', 'qlco', 'bhvr', 'hlca', ' hcro', 'orgf', 'qnco', 'orga']"
840,PMC3391717,S58,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,"a score of 1–3 was deemed a good clinical condition, and a score of 4–5 was deemed a poor clinical condition.","['C2700379', 'C0348080', 'C0032854', 'C4050231', 'C1705253', 'C0205210', 'C1515981', 'C0012634', 'C0043194', 'C1565156', 'C1421478', 'C0449820', 'C0205170', 'C3864998']","['Clinical', 'Poor - qualifier', 'WAS protein, human', 'Condition:Find:Pt:^Patient:Nom', 'Logical Condition', 'And', 'WAS gene', 'Wiskott-Aldrich Syndrome', 'Condition', 'Good', 'Disease', 'ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated', 'Score', 'Poverty']","['bacs', 'clna', 'grpa', 'idcn', 'gngm', 'cnce', 'qlco', 'dsyn', ' aapp', 'qnco']"
841,PMC3391717,S59,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Procedures,"study medication consisted of vials containing 64 mmol magnesium sulphate or placebo (saline), produced by the pharmacy of the university medical center utrecht and distributed to the participating centres (except for the centre in chile, which produced its own study medication).","['C0439190', 'C1515981', 'C0031336', 'C0036082', 'C0031321', 'C0205099', 'C0332300', 'C0000872', 'C4284232', 'C1696465', 'C2603343', 'C0008107', 'C3244303', 'C0184301', 'C3244316', 'C1704711', 'C0013227', 'C0031322', 'C0032042', 'C1706408', 'C0679823', 'C0024480']","['medication - HL7 publishing domain', 'except for', 'Academic Medical Centers', 'And', 'Pharmaceutical Services', 'Pharmacy facility', 'placebo', 'Medications', 'Placebos', 'Central', 'Chile', 'Distribution', 'Saline Solution', 'Study', 'participation', 'Magnesium Sulfate', 'Placebo Control', 'Pharmaceutical Preparations', 'Vial device', 'Pharmacy domain', 'Pharmacy (field)', 'millimole']","['bmod', 'inpr', 'geoa', 'idcn', 'inch', 'bodm', 'topp', 'medd', 'ftcn', 'mnob', 'spco', ' phsu', 'resa', 'hlca', 'sbst', ' hcro', 'qnco', 'phsu']"
842,PMC3391717,S60,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,an intravenous magnesium dosing regimen of 64 mmol per day after aneurysmal subarachnoid haemorrhage is safe and maintains serum magnesium concentrations at between 1·0 and 2·0 mmol/l.13,"['C2945654', 'C2348270', 'C0086045', 'C0439190', 'C0040808', 'C1532563', 'C4684764', 'C0024467', 'C1515981', 'C0332173', 'C3540792', 'C0205103', 'C0439228', 'C3714621', 'C0348016', 'C0038525']","['SAFE-Biopharma Standard', 'Millimole per Liter', 'Dietary Magnesium', 'Intermediate', 'day', 'Mental concentration', 'And', 'Daily', 'Magnesium', 'Intravenous', 'Treatment Protocols', 'Subarachnoid Hemorrhage', 'millimole', 'Magnesium supplements, alimentary tract and metabolism', 'Regimen - CHV concept', 'Magnesium Drug Class']","['bacs', 'inpr', 'idcn', 'inch', ' elii', 'elii', 'topp', 'spco', 'tmco', ' phsu', 'menp', 'qnco', 'phsu', 'dsyn']"
843,PMC3391717,S61,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,"furthermore, symptomatic hypermagnesaemia does not occur in patients with normal renal function.14","['C0030705', 'C0232805', 'C0231220', 'C0151714', 'C1518422']","['normal renal function', 'Patients', 'Hypermagnesemia', 'Symptomatic', 'Negation']","['dsyn', 'fndg', 'podg', 'ftcn']"
844,PMC3391717,S62,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Procedures,"therefore, participants received a fixed daily dose of 64 mmol magnesium sulphate reconstituted in 0·9% saline, or placebo, as soon as possible after providing consent.","['C2827483', 'C2923685', 'C0032042', 'C0679646', 'C1705910', 'C1706408', 'C1696465', 'C2348070', 'C4697669', 'C0439190', 'C0036082', 'C3714578', 'C1511481', 'C0443218', 'C1554192', 'C0024480', 'C0332149']","['Daily Dose', 'Placebo Control', 'Consent', 'Possibly Related to Intervention', 'Fixed Specimen', 'Fix', 'Consent:Finding:Point in time:{Setting}:Document:Patient', 'Placebos', 'Saline Solution', 'Possible', 'ActClass - consent', 'Reconstituted', 'placebo', 'millimole', 'Magnesium Sulfate', 'Fixed behavior', 'Participant']","['clna', 'phpr', 'idcn', 'inch', 'bodm', 'topp', 'popg', 'ftcn', 'fndg', 'bdsu', 'qlco', 'resa', ' phsu', 'sbst', 'qnco']"
845,PMC3391717,S63,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Procedures,"investigators administered study medication continuously via intravenous infusion and continued for 20 days after haemorrhage onset, or until hospital discharge or death if it occurred sooner.","['C0206132', 'C3244316', 'C4284232', 'C1521801', 'C0586003', 'C0332162', 'C0019080', 'C1515981', 'C0013227', 'C1272892', 'C2603343', 'C0439228', 'C0021440', 'C0035173', 'C1306577', 'C1621368', 'C0011065']","['Age of Onset', 'Pharmaceutical Preparations', 'Medications', 'Cessation of life', 'Hemorrhage', 'Onset of (contextual qualifier)', 'day', 'medication - HL7 publishing domain', 'And', 'Death (finding)', 'Study', 'Research Personnel', 'Discharge from hospital', 'Intravenous Drip Route of Administration', 'Intravenous infusion (product)', 'Intravenous infusion procedures', 'Having administered']","['inpr', 'idcn', 'qnco', 'prog', 'topp', 'ftcn', 'fndg', 'patf', 'qlco', 'tmco', 'resa', 'hlca', 'orgf', 'bodm', 'phsu']"
846,PMC3391717,S64,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Procedures,investigators checked renal function at least once every 2 days to prevent symptomatic hypermagnesaemia.,"['C1948045', 'C1948061', 'C0232804', 'C0231220', 'C1442455', 'C0035173', 'C0151714']","['Every (qualifier)', 'Renal function', 'Symptomatic', 'Research Personnel', '2 Days', 'Hypermagnesemia', 'Once (schedule frequency)']","['ortf', 'prog', 'ftcn', 'qlco', 'tmco', 'dsyn']"
847,PMC3391717,S65,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,monitoring of magnesium concentration was not mandatory.,"['C2348270', 'C0086045', 'C1283169', 'C1446561', 'C0150369', 'C3827302', 'C0024467', 'C1554132', 'C1619643', 'C1514873', 'C3540792', 'C3714621', 'C1518422']","['Concentration measurement', 'Monitoring - action', 'Preventive monitoring', 'Dietary Magnesium', 'Mandatory - HL7DefinedRoseProperty', 'Mandatory - HL7ConformanceInclusion', 'Requirement', 'Mental concentration', 'Magnesium', 'Able to Concentrate Question', 'Magnesium supplements, alimentary tract and metabolism', 'Negation', 'Magnesium Drug Class']","['bacs', 'inpr', 'inch', ' elii', 'elii', 'ftcn', 'hlca', ' phsu', 'menp', 'qnco', 'phsu']"
848,PMC3391717,S66,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Procedures,"we discouraged, but permitted, investigators to treat hypomagnesaemia at admission with intravenous magnesium sulphate.","['C0809949', 'C0151723', 'C0024480', 'C0035173', 'C0184666', 'C0348016']","['Hypomagnesemia', 'Hospital admission', 'Admission activity', 'Intravenous', 'Research Personnel', 'Magnesium Sulfate']","['inch', 'prog', 'spco', ' phsu', 'hlca', 'dsyn']"
849,PMC3391717,S67,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Procedures,"investigators treated patients according to local protocols, which included oral nimodipine 360 mg/day, bed rest until aneurysm occlusion, and early aneurysm occlusion, and aimed at achievement of normovolaemia.","['C1110554', 'C0030705', 'C0002940', 'C0004910', 'C0028094', 'C1279919', 'C0442027', 'C0205276', 'C1515981', 'C0332173', 'C0442711', 'C0028778', 'C1947917', 'C1720302', 'C0277816', 'C0001072', 'C0035173', 'C0439228', 'C0011382']","['Occluded', 'Obstruction', 'Lying in bed', 'Oral', 'day', 'Local', 'Aneurysm', 'And', 'Nimodipine', 'Bed rest', 'Patients', 'Daily', 'Research Personnel', 'Early', 'Achievement', 'Protocols documentation', 'Until', 'Cardiovascular occlusion', 'Dental Occlusion']","['ortf', 'inpr', 'idcn', 'prog', 'topp', 'ftcn', 'spco', 'patf', 'orch', 'anab', 'podg', 'bhvr', 'tmco', ' phsu']"
850,PMC3391717,S68,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"the primary outcome was dependence15 (defined as a modified rankin scale score of 4 or 5) or death, 3 months after haemorrhage.","['C1274040', 'C1442461', 'C0019080', 'C0205225', 'C2984908', 'C3854213', 'C4049715', 'C1306577', 'C0011065']","['PedsQL-4 Scale Score', 'Hemorrhage', 'Cessation of life', 'Modified Rankin Scale', 'Death (finding)', 'Modified rankin scale:Score:Point in time:^Patient:Ordinal', 'Result', '3 Months', 'Primary']","['clna', 'inpr', 'ftcn', 'fndg', 'patf', 'qlco', 'tmco', 'orgf']"
851,PMC3391717,S69,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"the research nurse and study coordinator collected outcome data centrally, and assessed the rankin score by semi-structured telephone interview in the patient's own language.","['C1511726', 'C1274040', 'C0030705', 'C3245479', 'C4050231', 'C1515981', 'C0023008', 'C0021823', 'C1710220', 'C3714741', 'C0687693', 'C0449820']","['Clinical Coordinator', 'research nurse', 'Languages', 'And', 'Data call receiving device', 'Patients', 'ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated', 'Data (eukaryote)', 'Data', 'Score', 'Interviews, Telephone', 'Result']","['clna', 'idcn', 'prog', 'medd', 'ftcn', 'podg', 'euka', 'resa', 'lang', 'qnco']"
852,PMC3391717,S70,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"the interview was translated into dutch and spanish with the standard procedure16,17 for forward–backward translation.","['C0021822', 'C2828392', 'C0086409', 'C0013331', 'C0040712', 'C1519614', 'C1515981', 'C0597295', 'C1442989', 'C0935630', 'C3161473']","['Language Translations', 'Protein Biosynthesis', 'Spanish Person', 'Genetic Translation Process', 'Standard (document)', 'And', 'Published Interview', 'Interview', 'Dutch Population', 'Hispanics', 'Standard (qualifier)']","['inpr', 'idcn', 'genf', 'acty', 'popg', 'qlco', 'moft']"
853,PMC3391717,S71,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,secondary outcome measures were no symptoms (modified rankin scale score of 0) 3 months after haemorrhage and the difference between the distribution of all scores on the modified rankin scale.,"['C0205436', 'C1704711', 'C1442461', 'C0231221', 'C0019080', 'C1515981', 'C0027627', 'C2984908', 'C0025320', 'C0205103', 'C0444868', 'C3854213', 'C4049715', 'C0086749', 'C0449820', 'C0175668', 'C0520511']","['Outcome Measures', 'Neoplasm Metastasis', 'Hemorrhage', 'Intermediate', 'Menopause', 'second (number)', 'Distribution', 'All', 'Modified Rankin Scale', 'And', 'PedsQL-4 Scale Score', 'Modified rankin scale:Score:Point in time:^Patient:Ordinal', 'Secondary to', 'Score', 'Distributing', 'symptomless', '3 Months']","['inpr', 'clna', 'idcn', 'phsf', 'neop', 'ftcn', 'spco', 'patf', 'qlco', 'fndg', 'tmco', 'qnco']"
854,PMC3391717,S73,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"in our pilot study, 35% of patients in the untreated group had a poor outcome compared with 27% in the intervention group (rr 0·77).10","['C1519504', 'C0030705', 'C0441833', 'C0687744', 'C0332155', 'C1257890', 'C3806166', 'C1705429', 'C0031928', 'C1705428']","['Did not receive therapy or drug for', 'Groups', 'Pilot Projects', 'User Group', 'Patients', 'Population Group', 'Poor outcome', 'Stage Grouping', 'Group Object', 'Social group']","['idcn', 'popg', 'ftcn', 'fndg', 'cnce', 'podg', 'resa']"
855,PMC3391717,S74,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analysis,on the basis of these data we estimated that 1082 patients would be needed to confirm this effect with an α of 5% and 80% power.,"['C1511726', 'C0039828', 'C0030705', 'C3245479', 'C0032863', 'C1515981', 'C3854080', 'C1280500', 'C1518681', 'C1527178', 'C1874451', 'C3714741', 'C1080058', 'C2348382']","['Basis - conceptual entity', 'Effect', 'Theses', 'This (eukaryote)', 'Power (Psychology)', 'And', 'Data call receiving device', 'Patients', 'Effect, Appearance', 'Power', 'Data (eukaryote)', 'Data', 'Basis', 'Outcome of Therapy']","['hcpp', 'inpr', 'idcn', 'medd', 'ftcn', 'fndg', 'podg', 'euka', 'qlco', 'qnco', 'phsu']"
856,PMC3391717,S75,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analysis,to allow for reliable detection of a slightly smaller effect (risk ratio 0·78) we decided to enrol 1200 patients.,"['C0028873', 'C0030705', 'C4321403', 'C3858758', 'C2937276', 'C1280500', 'C1511790', 'C0700321', 'C1518681', 'C0750482', 'C0242492', 'C0547044', 'C3843225', 'C2348382']","['Slightly Agree', 'Smaller', 'Effect', 'Slightly (qualifier value)', 'Small', 'Detection', 'reliable', 'Patients', 'Effect, Appearance', 'Slight (qualifier value)', 'Odds Ratio', 'Relative Risk', 'Slightly Able', 'Outcome of Therapy']","['inpr', 'topp', 'fndg', 'podg', 'qlco', 'qnco']"
857,PMC3391717,S76,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,a research nurse entered all baseline and outcome data in the study database.,"['C1511726', 'C0242356', 'C0168634', 'C1274040', 'C0993637', 'C3245479', 'C1515981', 'C2603343', 'C1442488', 'C0444868', 'C3714741', 'C0687693']","['Published Database', 'BaseLine dental cement', 'Baseline', 'research nurse', 'All', 'And', 'Data call receiving device', 'Study', 'Data (eukaryote)', 'Data', 'Databases', 'Result']","['inpr', 'idcn', 'qnco', 'prog', 'medd', 'ftcn', 'euka', 'resa', 'bodm']"
858,PMC3391717,S77,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,the study coordinator analysed the data.,"['C1710220', 'C1511726', 'C3245479', 'C3714741']","['Data', 'Clinical Coordinator', 'Data call receiving device', 'Data (eukaryote)']","['prog', 'euka', 'medd', 'idcn']"
859,PMC3391717,S78,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,the data were checked and results discussed by the executive committee.,"['C1511726', 'C3245479', 'C2699414', 'C0871735', 'C3714741']","['executives', 'Committee', 'Data call receiving device', 'Data (eukaryote)', 'Data']","['grup', 'idcn', 'prog', 'medd', 'euka']"
860,PMC3391717,S79,['7b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0]",Statistical analysis,"the data monitoring committee did two interim analyses during the study, after 350 and 750 patients had completed 3-month follow-up, with reference to a pre-defined stopping rule, and recommended continuation of the trial on both occasions.","['C1511726', 'C0439231', 'C0030705', 'C0205197', 'C1515981', 'C1514811', 'C0008976', 'C1522577', 'C1704788', 'C3714741', 'C1704685', 'C0522637', 'C0034866', 'C0740175', 'C3274571', 'C1706462', 'C2603343', 'C2699414', 'C0723457', 'C0332287', 'C3854010', 'C2257086', 'C2827738', 'C0870077', 'C0062074', 'C0205448', 'C0589120', 'C0332152', 'C0805874', 'C3539897', 'C1706086', 'C3245479', 'C0332177', 'C1415458', 'C1446409', 'C0687676', 'C0231290']","['Status post', 'Positive', 'Both', 'And', 'Data call receiving device', 'Patients', 'month', 'Have', 'Follow-up status', 'Clinical Study Follow-up', 'HADH gene', 'Stop brand of fluoride', 'Clinical Trials', 'Before', 'Before values', 'Committee', 'Bibliographic Reference', 'Reference Object', 'Complete', 'follow-up', 'Study', 'Two', 'Monthly (qualifier value)', 'derivation calculation', 'Data', 'In addition to', 'Rule (guideline)', 'Recommendation', 'Post', 'photoreactivating enzyme activity', 'Definition', 'HAC protocol', 'Follow-Up Report', 'completed - RoleLinkStatus', 'Data (eukaryote)', 'Interim', 'Measuring ruler, device']","['inpr', 'grup', 'idcn', 'inch', 'genf', 'gngm', 'topp', 'medd', 'ftcn', 'mnob', 'fndg', 'podg', 'qlco', 'tmco', 'resa', 'euka', 'cnce', ' phsu', 'hlca', 'qnco']"
861,PMC3391717,S80,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,we analysed the results according to intention to treat by comparing poor outcome at 3 months in each group with a risk ratio and 95% ci.,"['C0028873', 'C1283828', 'C1705428', 'C1519504', 'C0162425', 'C0441833', 'C1457900', 'C0687744', 'C1442461', 'C1257890', 'C3806166', 'C1515981', 'C1705429', 'C0242492']","['Each (qualifier value)', 'Stage Grouping', 'Groups', 'intent', 'And', 'User Group', 'Population Group', 'Poor outcome', 'Odds Ratio', 'Group Object', 'Relative Risk', 'Social group', '3 Months', 'Intention - mental process']","['idcn', 'popg', 'ftcn', 'cnce', 'fndg', 'qlco', 'tmco', 'menp', 'qnco']"
862,PMC3391717,S81,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"we did planned sensitivity analyses by assigning patients lost to follow-up to either a good outcome or a poor outcome irrespective of treatment group, and assigning patients with unknown randomisation codes to either the magnesium group or the placebo group.","['C0020517', 'C0030705', 'C0441833', 'C0687744', 'C1705169', 'C0439673', 'C3887704', 'C3806166', 'C1515981', 'C1522577', 'C1511883', 'C3541433', 'C3714621', 'C1704685', 'C2349185', 'C1274040', 'C0036667', 'C1696465', 'C3274571', 'C1301732', 'C0039798', 'C3538994', 'C1705429', 'C0024467', 'C3844638', 'C4050014', 'C0589120', 'C2348270', 'C0032042', 'C1519504', 'C1706408', 'C2346484', 'C1257890', 'C0087111', 'C0547043', 'C0919279', 'C3540792', 'C1522326', 'C1533734', 'C1705428', 'C1522640', 'C0205170']","['Signal Sensitivity', 'Biomaterial Treatment', 'And', 'Magnesium', 'Patients', 'placebo', 'Stage Grouping', 'Follow-up status', 'Therapeutic procedure', 'Clinical Study Follow-up', 'Magnesium supplements, alimentary tract and metabolism', 'Either', 'unknown vaccine or immune globulin', 'User Group', 'Placebos', 'Administration procedure', 'Group Object', 'Social group', 'Hypersensitivity', 'Up', 'Treatment Epoch', 'follow-up', 'Unknown GENC', 'Planned', 'Statistical sensitivity', 'Good', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'A Codes', 'Poor outcome', 'Placebo Control', 'Dietary Magnesium', 'Diagnostic Sensitivity', 'Groups', 'Increased Sensitivy', 'Treating', 'Population Group', 'Unknown', 'Follow-Up Report', 'Result', 'stimulus sensitivity', 'Magnesium Drug Class']","['bacs', 'topp', 'fndg', 'qlco', ' phsu', 'hlca', 'phsu', 'inpr', 'phpr', 'idcn', 'inch', ' elii', 'geoa', 'clas', 'patf', 'imft', 'resa', ' aapp', 'bodm', 'elii', 'popg', 'ftcn', 'podg', 'cnce', 'spco', 'qnco']"
863,PMC3391717,S82,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"planned subgroup analyses were done according to age, sex, clinical condition at admission, method of treatment of aneurysm, and whether the centre treated hypomagnesaemia with intravenous magnesium supplementation.","['C0871511', 'C0002940', 'C3887704', 'C1705169', 'C1515021', 'C1515981', 'C0012634', 'C1079230', 'C0025663', 'C0205099', 'C1096534', 'C0151723', 'C0009253', 'C0804628', 'C0205210', 'C1301732', 'C0039798', 'C3538994', 'C0449851', 'C1705253', 'C0079399', 'C0036864', 'C0184666', 'C0809949', 'C0348080', 'C0087111', 'C1522384', 'C1522326', 'C1533734', 'C0001779', 'C0348016', 'C3864998']","['Gender', 'Biomaterial Treatment', 'Methods', 'And', 'Condition', 'Therapeutic procedure', 'Gender:Type:Point in time:^Patient:Nominal', 'Hypomagnesemia', 'Sex Behavior', 'Admission activity', 'Intravenous', 'Coitus', 'Administration procedure', 'Age', 'sex', 'Central', 'Clinical', 'magnesium supplementation', 'Hospital admission', 'Treatment Epoch', 'Aneurysm', 'Planned', 'Condition:Find:Pt:^Patient:Nom', 'Logical Condition', 'Subgroup', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Techniques', 'Treating', 'Disease', 'Subgroup A Nepoviruses', 'Test Method']","['clna', 'inpr', 'idcn', 'lbpr', 'clas', 'topp', 'ftcn', 'cnce', 'spco', 'qlco', 'anab', 'virs', 'bhvr', 'resa', 'hlca', 'orgf', 'orga', 'dsyn']"
864,PMC3391717,S83,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,we compared the distributions of the modified rankin scale scores with the non-parametric mann-whitney u test.,"['C0022885', 'C1515976', 'C0039593', 'C0456984', 'C0332287', 'C2984908', 'C3854213', 'C0392366', 'C3831328', 'C4318744', 'C1518422', 'C0037775', 'C0449820']","['Test Result', 'Laboratory Procedures', 'Modified Rankin Scale', 'Spatial Distribution', 'Tests (qualifier value)', 'Testing', 'Anatomic Structure, System, or Substance', 'Modified rankin scale:Score:Point in time:^Patient:Ordinal', 'Test - temporal region', 'Score', 'Blood Products Laboratory Testing', 'In addition to', 'Negation']","['clna', 'inpr', 'lbpr', 'clas', 'lbtr', 'ftcn', 'spco', 'blor', 'qnco']"
865,PMC3391717,S84,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,we updated our previous cochrane meta-analysis5 with results of mash 2 and eligible randomised trials that had been published since the start of mash 2 and the last update of the cochrane review.18–20,"['C1519814', 'C1517741', 'C0439659', 'C1515981', 'C0282443', 'C1042496', 'C1552607', 'C1548635', 'C0205156', 'C1552617']","['Review [Publication Type]', 'Eligible', 'And', 'Previous', 'Beginning', 'Act Relationship Subset - previous', 'Act Class - review', 'Meta', 'Update', 'Last']","['inpr', 'idcn', 'qlco', 'euka', 'tmco']"
866,PMC3391717,S85,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,we used cochrane review manager (version 5.1) software for the meta-analysis and spss (version 15.0) for all other analyses.,"['C0936012', 'C0333052', 'C1515981', 'C1042496', 'C0282443', 'C1524024', 'C1546507', 'C0335141', 'C0037585', 'C0444868', 'C1552617']","['Review [Publication Type]', 'Relationship - Manager', 'All', 'And', 'Computer software', 'Analysis', 'Act Class - review', 'Meta', 'Version', 'manager', 'analysis aspect']","['inpr', 'idcn', ' mnob', 'prog', 'ftcn', 'euka', 'resa', 'qnco']"
867,PMC3391717,S86,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,this study is registered with controlled-trials.com (isrctn 68742385) and the eu clinical trials register (eudract 2006-003523-36).,,,
868,PMC3391717,S88,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Role of the funding source,"the sponsor had no role in study design, data collection, data analysis, data interpretation, or writing of the report.","['C1511726', 'C0010995', 'C0684224', 'C0043266', 'C2584304', 'C4255046', 'C3714741', 'C3273238', 'C2983265', 'C2986888', 'C0010992', 'C4283917', 'C2347796', 'C3173575', 'C1711305', 'C3887707', 'C0035171', 'C4050126', 'C1705810', 'C0700287', 'C0035820', 'C3245479', 'C0459471', 'C3871154']","['Writing (function)', 'Reporting', 'Interpretation:Impression/interpretation of study:Point in time:^Patient:Nominal', 'Sponsor (person)', 'Role', 'Data call receiving device', 'Ability to Write question', 'Research Design', 'Writing Ability', 'Regulatory Report', 'Nonclinical Study Design', 'Data Collection', 'Data Collection Methods', 'Social Role', 'Clinical Study Sponsor', 'Data', 'Data Analysis', 'Report (document)', 'Report:Finding:Point in time:{Setting}:Document:{Role}', 'Interpretation Process', 'Generic Role', 'Data (eukaryote)', 'CDISC SEND Study Design Terminology', 'Writing (occupation or discipline)']","['inpr', 'clna', 'idcn', 'ocdi', 'ocac', 'medd', 'popg', 'qlco', 'euka', 'resa', 'socb', 'hlca', 'menp', 'qnco', 'orgt']"
869,PMC3391717,S89,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Role of the funding source,the corresponding author had full access to all data in the study and had final responsibility for the decision to submit for publication.,"['C1511726', 'C1515981', 'C4321252', 'C3714741', 'C3853528', 'C0678341', 'C0443225', 'C2603343', 'C1546485', 'C1704324', 'C0034037', 'C0679006', 'C0444454', 'C0062074', 'C0521125', 'C3812881', 'C3539897', 'C3245479', 'C0034036', 'C1415458', 'C0444868', 'C1554204', 'C0205088']","['Role Class - access', 'And', 'Data call receiving device', 'Preposition For', 'Have', 'WWOX wt Allele', 'HADH gene', 'Final', 'responsibility', 'Diagnosis Type - Final', 'Publishing', 'Data (eukaryote)', 'full', 'All', 'Study', 'Publications', 'Data', 'End-stage', 'author', 'HAC protocol', 'Decision', 'Scientific Publication', 'Access']","['inpr', 'inbe', 'idcn', ' mnob', 'gngm', 'prog', 'ocac', 'topp', 'medd', 'ftcn', 'spco', 'qlco', 'euka', 'tmco', 'resa', 'menp', 'qnco']"
870,PMC3489506,S33,"['3a', '4b']","[0, 0, 0, 0, 0, 0, 1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and oversight,"this randomised, parallel group, double masked, multicentre, placebo controlled, phase iii trial was undertaken at 19 sites in england and wales.","['C0032042', 'C1706408', 'C1696465', 'C0013072', 'C1515981', 'C2911690', 'C0282461', 'C0014282', 'C1080058', 'C0205145', 'C0043015', 'C1551837', 'C2587213']","['Placebo Control', 'Phase 3 Clinical Trials', 'Double-Blind Method', 'And', 'Placebos', 'Site', 'placebo', 'Wales Eskimo', 'Control function', 'England', 'Disease Controlled', 'Country of Wales', 'This (eukaryote)']","['idcn', 'geoa', 'topp', 'popg', 'ftcn', 'fndg', 'spco', 'euka', 'resa', 'bodm']"
871,PMC3489506,S34,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and oversight,the trial was independently overseen by an independent data safety monitoring committee and a trial steering committee.,"['C0085862', 'C1511726', 'C0036043', 'C1283169', 'C3245479', 'C2348534', 'C0150369', 'C1515981', 'C0008976', 'C1290940', 'C2699414', 'C3714741', 'C1705187', 'C1299583']","['Safety', 'Independently able', 'Monitoring - action', 'Preventive monitoring', 'Safety Study', 'Clinical Trials', 'And', 'Data call receiving device', 'Steering Committee', 'Independence', 'Independent for Transfer', 'Committee', 'Data', 'Data (eukaryote)']","['hcpp', 'grup', 'idcn', 'medd', 'popg', 'fndg', 'euka', 'resa', 'hlca']"
872,PMC3489506,S36,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population,"children were eligible to participate if they were aged between 3 years and 15 years 8 months at registration visit, had a neurodevelopmental disorder scoring 1.5 sd or more below the mean on the adaptive behaviour assessment system (abas),11 and had a sleep disorder reported by parents for at least the past five months characterised as failing to fall asleep within one hour of “lights off” in three nights out of five or achieving less than six hours of continuous sleep in three nights out of five, or both.","['C4284302', 'C1261322', 'C0439231', 'C3888058', 'C0439787', 'C1553384', 'C0424522', 'C1515981', 'C4288557', 'C4321252', 'C1548635', 'C2697663', 'C0332285', 'C1709908', 'C0449913', 'C0238715', 'C1514821', 'C0444504', 'C2826704', 'C4553726', 'C0231175', 'C0680063', 'C0240526', 'C0085880', 'C2347634', 'C0439092', 'C1535926', 'C0205172', 'C1553451', 'C0205449', 'C0545082', 'C1444637', 'C0062074', 'C0851578', 'C0521125', 'C0439234', 'C0205452', 'C0008059', 'C3539897', 'C1706086', 'C0085639', 'C1512346', 'C2348143', 'C1415458', 'C0037313', 'C0205451', 'C0549178', 'C0030551', 'C0849355', 'C1516048', 'C0439227']","['Reported By', 'In the past', 'Out (direction)', 'Both', 'And', 'Evaluation procedure', 'Hour', 'Visit', 'month', 'Preposition For', 'Have', 'WWOX wt Allele', 'registration - ActClass', 'System', 'Five', 'Sample Mean', 'Removed', 'HADH gene', 'Registration', 'Sleep Disorders', 'Neurodevelopmental Disorders', 'Sleep', 'One Activity Hour', 'Behavior, Adaptive', 'Visit Name', 'Within', 'Population Mean', 'parent', 'Offspring', 'Night time', 'EHD1 wt Allele', 'Less Than', 'Patient Visit', 'Device system', 'Autumn', 'Six', 'year', 'Asleep', 'Child', 'Falls', 'Eligible', 'Statistical mean', 'failed', 'More', 'System - kit', 'Three', 'Continuous', 'HAC protocol', 'Image Registration', 'Assessed', 'Fall, CTCAE']","['inbe', 'famg', 'topp', 'fndg', 'mnob', 'qlco', 'hlca', 'inpr', 'idcn', 'aggp', 'gngm', 'orgf', 'mcha', 'ftcn', 'tmco', 'grup', 'acty', 'spco', 'bhvr', 'mobd', 'qnco']"
873,PMC3489506,S37,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population,children were required to be free from drugs that could cause sleepiness and no have taken no melatonin within the preceding five months.,"['C0008059', 'C1880497', 'C0025219', 'C3154893', 'C3539897', 'C1883727', 'C0439231', 'C1527137', 'C0013144', 'C1515981', 'C3687832', 'C1996904', 'C0013227', 'C0205451', 'C0680063', 'C0332296', 'C0332152', 'C2830004']","['Melatonin', 'Pharmaceutical Preparations', 'Have', 'Empty (qualifier)', 'And', 'Somnolence', 'Possess', 'Taken', 'month', 'Free of (attribute)', 'Drugs - dental services', 'Drowsiness', 'Before', 'Recombinant melatonin', 'Offspring', 'Five', 'Free (available (qualifier))', 'Child']","[' orch', 'idcn', 'aggp', 'famg', 'topp', 'ftcn', 'fndg', 'cnce', 'tmco', 'qlco', 'horm', ' phsu', 'mobd', 'qnco', 'phsu']"
874,PMC3489506,S38,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population,"at registration, parents/carers were provided with a booklet of advice on previously trialled and standardised sleep behaviour treatment.12","['C0150600', 'C0004927', 'C1514821', 'C1553384', 'C1705169', 'C3887704', 'C0087111', 'C1305660', 'C1515981', 'C0085537', 'C0037313', 'C1522326', 'C0030258', 'C1533734', 'C2697663', 'C0030551', 'C0039798', 'C3538994']","['Registration', 'Advice', 'Sleep', 'parent', 'Treatment Epoch', 'Behavior', 'Caregiver', 'Carer (occupation)', 'And', 'Biomaterial Treatment', 'Administration procedure', 'Treating', 'registration - ActClass', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Pamphlets', 'Image Registration', 'Therapeutic procedure']","['inpr', 'idcn', ' mnob', 'famg', 'prog', 'topp', 'ftcn', 'cnce', 'bhvr', 'resa', 'hlca', 'orgf', 'mcha']"
875,PMC3489506,S39,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population,this was used as a run in to ensure that children who progressed to the randomisation phase did not include those whose sleep disorder could have been amenable to treatment with non-pharmacological intervention.,"['C0205390', 'C3887704', 'C1705169', 'C1080058', 'C1518422', 'C3900053', 'C0035953', 'C0886296', 'C0680063', 'C1710475', 'C0031330', 'C0600140', 'C0039798', 'C3538994', 'C0184661', 'C0851578', 'C0008059', 'C0205464', 'C1704688', 'C0087111', 'C1522326', 'C1533734', 'C3272598']","['Run action', 'Biomaterial Treatment', 'Therapeutic procedure', 'Does run (finding)', 'Sleep Disorders', 'Trial Phase', 'Nursing interventions', 'Administration procedure', 'Offspring', 'Negation', 'Treatment Epoch', 'WHO Temperature/Humidity Storage Condition', 'Running (physical activity)', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Amenable', 'pharmacological', 'Pharmacology', 'Child', 'Phase', 'Treating', 'Interventional procedure', 'This (eukaryote)']","['bmod', 'aggp', 'dora', 'famg', 'clas', 'topp', 'ftcn', 'cnce', 'fndg', 'qlco', 'euka', 'tmco', 'resa', 'hlca', 'mobd']"
876,PMC3489506,S40,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population,"sleep was monitored during the registration period by using sleep diaries completed by parents, and children were randomised if they continued to fulfil the eligibility criteria with the sleep disorder criteria evident from these sleep diaries.","['C0008059', 'C0039828', 'C1514821', 'C1553384', 'C1948053', 'C0205197', 'C3854010', 'C0439531', 'C1515981', 'C0376660', 'C0037313', 'C0549178', 'C0680063', 'C2697663', 'C1512693', 'C0030551']","['Registration', 'Theses', 'Complete', 'Sleep', 'parent', 'Inclusion', 'And', 'registration - ActClass', 'Continuous', 'per period (qualifier value)', 'Diary', 'Period (temporal qualifier)', 'completed - RoleLinkStatus', 'Offspring', 'Image Registration', 'Child']","['inpr', 'idcn', 'aggp', 'famg', 'qlco', 'tmco', 'hlca', 'orgf', 'mcha']"
877,PMC3489506,S42,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study intervention,the child’s age appropriate bedtime was established at the start of the registration period and the trial drug was administered 45 minutes before this time either orally or through a feeding tube if required.,"['C1442463', 'C1548787', 'C1948053', 'C1515981', 'C0439659', 'C0008976', 'C2697663', 'C1080058', 'C1514821', 'C2945625', 'C0439531', 'C3844638', 'C0521112', 'C1514873', 'C0013227', 'C0442027', 'C0332152', 'C1254351', 'C0040223', 'C0041281', 'C1553384', 'C0001779']","['Appropriate', 'And', 'Bedtime (qualifier value)', 'Time', 'registration - ActClass', 'Either', 'Registration', 'Feeding tube', 'Clinical Trials', 'Requirement', 'Age', 'Before', 'Oral', 'Tube feeding of patient', 'Beginning', 'per period (qualifier value)', 'Period (temporal qualifier)', 'Pharmaceutical Preparations', 'Pharmacologic Substance', 'Image Registration', '45 Minutes', 'This (eukaryote)']","['inpr', 'idcn', 'topp', 'medd', 'phsu', 'ftcn', 'fndg', 'spco', 'tmco', 'qlco', 'euka', 'resa', 'hlca', 'mcha', 'orga']"
878,PMC3489506,S43,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study intervention,"if the child was tube fed, the capsule was opened and the study treatment suspended in an appropriate medium.12","['C1548787', 'C0006935', 'C1515981', 'C1565156', 'C0175730', 'C1704730', 'C0009458', 'C0043194', 'C0680063', 'C0175566', 'C1325531', 'C1705217', 'C0439536', 'C0342895', 'C4085196', 'C3244283', 'C4522282', 'C1521826', 'C0008059', 'C1561954', 'C4522283', 'C1421478', 'C1704652']","['Capsule Shape', 'A Medium Amount', 'Appropriate', 'And', 'Medium Growth Rate', 'biomedical tube device', 'Microbial anatomical capsule structure', 'WAS protein, human', 'WAS gene', 'Offspring', 'Communications Media', 'Packaging Tube', 'Medium', 'capsule (pharmacologic)', 'A Medium Amount of Time', 'Fish-Eye Disease', 'Medium (Substance)', 'Child', 'medium exposure', 'Open', 'Wiskott-Aldrich Syndrome', 'tube', 'Protocol Agent']","['bacs', 'inpr', 'idcn', 'bodm', 'aggp', 'gngm', 'famg', 'medd', 'fndg', 'cnce', 'qlco', 'celc', 'spco', 'mnob', 'dsyn', 'sbst', ' aapp', 'qnco']"
879,PMC3489506,S44,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study intervention,"at randomisation, each child was given 0.5 mg.","['C0008059', 'C1457900', 'C0680063']","['Each (qualifier value)', 'Offspring', 'Child']","['aggp', 'famg', 'qnco']"
880,PMC3489506,S45,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study intervention,"at each of four weekly intervals, the child’s sleep pattern, as recorded on the sleep diary, was reviewed and the dose was increased to the next dose increment on the basis that the child fulfilled the sleep disorder eligibility criteria, had received at least five of the possible seven doses in the preceding week, and had not experienced any serious adverse events.","['C1515981', 'C1565156', 'C0332174', 'C1705117', 'C1518422', 'C0205217', 'C1705910', 'C0877248', 'C3272371', 'C1883708', 'C0439230', 'C0205453', 'C0043194', 'C0680063', 'C1527178', 'C1874451', 'C1514756', 'C1552551', 'C0178602', 'C0474396', 'C1457900', 'C1705413', 'C0282443', 'C0376660', 'C0062074', 'C0851578', 'C1272706', 'C0205450', 'C0332152', 'C0332149', 'C0332282', 'C0008059', 'C3539897', 'C1415458', 'C0037313', 'C1512693', 'C1421478', 'C0205451', 'C0205404', 'C0442805', 'C0205117', 'C1709940']","['Increased', 'And', 'Adjacent', 'Possibly Related to Intervention', 'Possible', 'Weekly', 'Have', 'Receive', 'Five', 'Four', 'HADH gene', 'Sleep Disorders', 'Sleep', 'Any Data Type', 'WAS protein, human', 'WAS gene', 'Adverse event', 'Diary', 'Before', 'Increment', 'Offspring', 'Then', 'Following', 'Each (qualifier value)', 'Dosage', 'Negation', 'Any', 'Adverse Event Domain', 'Inclusion', 'Increase', 'week', 'Interval', 'Seven', 'sleep pattern', 'Child', 'Basis - conceptual entity', 'Review [Publication Type]', 'Reviewed', 'Wiskott-Aldrich Syndrome', 'HAC protocol', 'Basis', 'Serious']","['bacs', 'inpr', 'idcn', ' aapp', 'aggp', 'gngm', 'famg', 'topp', 'ftcn', 'spco', 'patf', 'qlco', 'tmco', 'fndg', 'dsyn', 'mobd', 'orgf', 'qnco', 'phsu']"
881,PMC3489506,S46,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study intervention,"there was a maximum of three dose increments from 0.5 mg, 2 mg, 6 mg, and a maximum of 12 mg.","['C1552615', 'C0178602', 'C0205449', 'C0806909', 'C1515981', 'C2826546']","['Act Relationship Subset - maximum', 'And', 'Maximum', 'Three', 'Dosage', 'Maximum Value Derivation Technique']","['qnco', 'idcn']"
882,PMC3489506,S47,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study intervention,step down in dose was possible if adverse effects were experienced at a higher dose.,"['C0178602', 'C1705910', 'C0205250', 'C0879626', 'C0001688', 'C0332149']","['Adverse effects', 'High', 'aspects of adverse effects', 'Possibly Related to Intervention', 'Possible', 'Dosage']","['ftcn', 'fndg', 'patf', 'qlco', 'qnco']"
883,PMC3489506,S48,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study intervention,"participants were followed up for 12 weeks from randomisation with a combination of home visits, telephone calls, and clinic attendance.","['C0679646', 'C3811910', 'C0442592', 'C1947911', 'C1705541', 'C2827364', 'C0439230', 'C0039457', 'C1515981', 'C1515258', 'C0020043', 'C4321252', 'C0521125', 'C0002424']","['Clinic', 'Attendance', 'week', 'Telephone', 'Telephone Device', 'And', 'Home visit (procedure)', 'combination - answer to question', 'Telephone Number', 'Preposition For', 'WWOX wt Allele', 'combination of objects', 'Ambulatory Care Facilities', 'Participant']","['inpr', 'idcn', 'acty', 'gngm', 'phob', 'popg', 'mnob', 'fndg', 'qlco', 'tmco', 'hlca', ' hcro']"
884,PMC3489506,S50,"['8a', '8b', '10']","[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0]",Randomisation,"the trial statistician generated randomisation lists in stata (release 9, college station, tx) in a 1:1 ratio using block randomisation with random variable block lengths of two and four stratified by centre.","['C0205363', 'C1706084', 'C0439605', 'C1963578', 'C0439828', 'C1515981', 'C0456603', 'C1444754', 'C4553760', 'C0205099', 'C4684804', 'C0680255', 'C1283071', 'C0034656', 'C1533157', 'C1547037', 'C0557806', 'C0205448', 'C0205450', 'C1883167', 'C0391871', 'C2828370', 'C0332206', 'C0030685', 'C0028778']","['Randomization', 'Random', 'And', 'Block (unit of measure)', 'Block Specimens', 'stratified', 'Blocking', 'Four', 'Ratio', 'Variable (uniformity)', 'Patient Discharge', 'Central', 'college', '(City) Block', 'data type - ratio', 'Discharge (release)', 'Station', 'Trial Statistician', 'Length', 'Two', 'Study Variable', 'Obstruction', 'Release - action (qualifier value)', 'Released (action)', 'Release (procedure)']","['inpr', 'geoa', 'idcn', 'prog', 'topp', 'ftcn', 'spco', 'patf', 'bdsu', 'qlco', 'mnob', 'resa', 'hlca', 'qnco']"
885,PMC3489506,S51,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation,the statistician had no further access until determination of the analysis population.,"['C0032659', 'C0936012', 'C1257890', 'C0334957', 'C1517331', 'C1524024', 'C0444454', 'C1148554', 'C1554204', 'C0521095']","['Further', 'Role Class - access', 'Determination Aspects', 'Determined by', 'geographic population', 'Population Group', 'Analysis', 'statistician', 'Access', 'analysis aspect']","['lbpr', 'prog', 'popg', 'ftcn', 'spco', 'qlco', 'resa', 'qnco']"
886,PMC3489506,S52,['11b'],"[0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation,the placebo capsules and contents were identical in internal and external appearance.,"['C0032042', 'C0233426', 'C0456205', 'C1552853', 'C0205102', 'C1706408', 'C0006935', 'C0205280', 'C1696465', 'C1553872', 'C1515981', 'C0700364', 'C0205101', 'C4084721']","['Extrinsic', 'Placebo Control', 'Internal', 'contents - HtmlLinkType', 'identical', 'And', 'Contents', 'Placebos', 'Code System Type - Internal', 'Appearance', 'capsule (pharmacologic)', 'Appearance Distress Question', 'Personal appearance', 'placebo']","['inpr', 'idcn', 'topp', 'cnce', 'spco', 'qlco', 'resa', 'bodm', 'orga']"
887,PMC3489506,S53,['9'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1]",Randomisation,treatment packs were numbered sequentially and dispensed by the pharmacy of each site.,"['C2825164', 'C3538994', 'C1705169', 'C1457900', 'C2825051', 'C0087111', 'C0205145', 'C3887704', 'C1522326', 'C1533734', 'C0031336', 'C3244303', 'C0031322', 'C1968515', 'C0031321', 'C0039798', 'C1515974']","['Each (qualifier value)', 'Pack (physical object)', 'Treatment Epoch', 'Biomaterial Treatment', 'Anatomic Site', 'Pharmacy domain', 'Administration procedure', 'Treating', 'Pack unit', 'Pharmacy (field)', 'Pharmaceutical Services', 'Pharmacy facility', 'Site', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Study Site', 'Therapeutic procedure']","['bmod', 'inpr', 'drdd', 'topp', 'medd', 'ftcn', 'mnob', 'cnce', 'blor', 'spco', 'resa', 'hlca', ' hcro', 'qnco']"
888,PMC3489506,S54,['9'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1]",Randomisation,treatment packs held enough drugs for the 12 week period and allowed for potential dose escalation.,"['C3816728', 'C3887704', 'C1705169', 'C1948053', 'C0439531', 'C0087111', 'C0439230', 'C1515981', 'C3687832', 'C3245505', 'C1522326', 'C1533734', 'C2983683', 'C0013227', 'C0039798', 'C3538994']","['Pharmaceutical Preparations', 'Treatment Epoch', 'week', 'Biomaterial Treatment', 'And', 'potential', 'Treating', 'Administration procedure', 'Titration Study', 'per period (qualifier value)', 'Drugs - dental services', 'therapeutic aspects', 'Period (temporal qualifier)', 'treatment - ActInformationManagementReason', 'Dose Escalation', 'Therapeutic procedure']","['idcn', 'topp', 'ftcn', 'cnce', 'tmco', 'qlco', 'resa', 'hlca', 'phsu']"
889,PMC3489506,S55,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation,all trial staff and participants were blind to treatment allocation throughout the trial.,"['C0679646', 'C1706778', 'C3887704', 'C1705169', 'C0456909', 'C0087111', 'C0008976', 'C1515981', 'C0150108', 'C0851286', 'C1522326', 'C0444868', 'C1533734', 'C1947908', 'C0525065', 'C0039798', 'C3538994']","['Treatment Epoch', 'Clinical Trials', 'All', 'And', 'Biomaterial Treatment', 'Blindness', 'Administration procedure', 'Treating', 'Blinded', 'Staff', 'Allocation', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'On Staff', 'Therapeutic procedure', 'Visually Impaired Persons', 'Participant']","['idcn', 'acty', 'prog', 'topp', 'popg', 'ftcn', 'cnce', 'fndg', 'podg', 'resa', 'hlca', 'qnco']"
890,PMC3489506,S57,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Measuring sleep,"the trial design included both subjective (diary) and objective (actigraphy) measures of sleep, as recommended by sadeh.13","['C3641234', 'C0079809', 'C1171301', 'C1571702', 'C1706086', 'C1516636', 'C0439655', 'C1515981', 'C0376660', 'C0037313', 'C0018017', 'C2979880', 'C4552789']","['Objective observation', 'Subjective:Finding:Point in time:^Patient:Narrative', 'Sleep', 'objective (goal)', 'Both', 'Clinical Trial Objective', 'And', 'Clinical Trials Design', 'Diary', 'Measures', 'Actigraphy', 'CDISC Trial Design Class', 'Subjective observation (qualifier value)']","['inpr', 'clna', 'idcn', 'qlco', 'diap', 'orgf', 'qnco']"
891,PMC3489506,S58,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Measuring sleep,"there are benefits with each approach and reasons why the results might not be concordant4 7; for example, sleep diaries would not detect periods when the child was awake but not disturbing the household (a particular concern for determining sleep onset latency), and actigraphy could interpret restless sleep as being awake.","['C0449445', 'C1515981', 'C0234422', 'C4321252', 'C1565156', 'C0233535', 'C1518422', 'C3891454', 'C1707959', 'C1948054', 'C0043194', 'C0680063', 'C2699424', 'C0235160', 'C1171301', 'C1457900', 'C0376660', 'C0521125', 'C4505222', 'C0008059', 'C0392360', 'C0020052', 'C0814225', 'C0037313', 'C1421478', 'C0442726']","['restless sleep', 'And', 'Detected (finding)', 'butting', 'Households', 'Actigraphy', 'Preposition For', 'WWOX wt Allele', 'Sleep', 'WAS protein, human', 'benefit', 'WAS gene', 'Sleep Latency', 'Diary', 'Offspring', 'Each (qualifier value)', 'Negation', 'Approach', 'Concern', 'Indication of (contextual qualifier)', 'Dosing Days to Detection', 'Child', 'Example', 'Wiskott-Aldrich Syndrome', 'awake', 'When (temporal qualifier)']","['sosy', 'bacs', 'inpr', 'mobd', 'idcn', 'aggp', 'gngm', 'famg', 'ftcn', 'fndg', 'spco', 'tmco', 'cnce', 'qlco', 'dsyn', ' aapp', 'diap', 'orgf', 'qnco']"
892,PMC3489506,S59,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Measuring sleep,"between registration and study completion, parents were asked to complete weekly sleep diaries.","['C2348557', 'C1514821', 'C1553384', 'C1515981', 'C0376660', 'C0037313', 'C2697663', 'C0332174', 'C0030551']","['Registration', 'Sleep', 'Study Completed', 'And', 'registration - ActClass', 'Weekly', 'Diary', 'parent', 'Image Registration']","['inpr', 'idcn', 'famg', 'ftcn', 'tmco', 'hlca', 'orgf', 'mcha']"
893,PMC3489506,S60,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Measuring sleep,"the actigraph (micromini-motionlogger, ambulatory monitoring, new york), an accelerometer, is worn on the wrist and movement is monitored continuously and stored within the unit.","['C1322271', 'C0242882', 'C0178951', 'C3853603', 'C0439148', 'C0026649', 'C1515981', 'C4285610', 'C1880519', 'C0439453', 'C1509845', 'C0332285', 'C0043262', 'C0027976', 'C1698986', 'C1704753', 'C1519795', 'C1139952']","['accelerometers', 'Monitoring, Ambulatory', 'Storage', 'Wrist', 'Actigraph record', 'Unit - NCI Thesaurus Property', 'Wrist joint', 'Recorders, Physiologic, Physical Activity', 'Unit device', 'And', 'Unit', 'Within', 'Unit of Measure', 'International Unit', 'New York (geographic location)', 'Storage Unit', 'Enzyme Unit', 'Movement']","['bsoj', 'inpr', 'geoa', 'idcn', 'medd', 'ftcn', 'blor', 'mnob', 'spco', 'diap', 'orgf', 'qnco']"
894,PMC3489506,S61,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Measuring sleep,subsequent analysis of frequency and pattern of movement by means of validated algorithms permits detection of basic sleep-wake patterns.13,"['C0332282', 'C0376249', 'C1561548', 'C0449774', 'C3898838', 'C0871396', 'C1704970', 'C0936012', 'C0026649', 'C0585034', 'C1705502', 'C0442696', 'C1515981', 'C0002045', 'C1511790', 'C0037313', 'C1524024', 'C4321352', 'C1527178', 'C0439603']","['Movement', 'Basis - conceptual entity', 'Sleep', 'Statistical Frequency', 'Spatial Frequency', 'Waking', 'Detection', 'algorithm', 'And', 'Analysis', 'Frequencies (time pattern)', 'Kind of quantity - Frequency', 'Means', 'On waking-temporal period', 'Frequency', 'With frequency', 'pattern', 'Following', 'How Often', 'analysis aspect']","['inpr', 'idcn', 'phsf', 'topp', 'ftcn', 'spco', 'cnce', 'tmco', 'resa', 'orgf', 'qnco']"
895,PMC3489506,S62,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Measuring sleep,children wore the actigraph continuously between registration and randomisation and the 12th week after randomisation.,"['C0008059', 'C1514821', 'C1553384', 'C0439230', 'C1515981', 'C4285610', 'C0680063', 'C2697663', 'C0205103', 'C0687676', 'C1139952', 'C0231290']","['Registration', 'Post', 'Intermediate', 'Status post', 'Actigraph record', 'Recorders, Physiologic, Physical Activity', 'week', 'And', 'registration - ActClass', 'Offspring', 'Image Registration', 'Child']","['inpr', 'idcn', 'aggp', 'famg', 'medd', 'spco', 'tmco', 'hlca', 'mcha']"
896,PMC3489506,S64,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study outcomes,"the primary outcome was total sleep time, measured by diaries completed by parents.","['C1274040', 'C0040223', 'C0439810', 'C0205225', 'C0376660', 'C0037313', 'C0030551']","['Sleep', 'Diary', 'Time', 'parent', 'Result', 'Total', 'Primary']","['inpr', 'famg', 'ftcn', 'qlco', 'tmco', 'orgf']"
897,PMC3489506,S65,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study outcomes,each night the minutes between the times that the child went to sleep and woke up the next morning were calculated minus any night time awakenings.,"['C0332282', 'C0008059', 'C3272371', 'C1457900', 'C1883708', 'C0040223', 'C1515981', 'C0439232', 'C0037313', 'C0700321', 'C0680063', 'C0240526', 'C0205103', 'C1282918', 'C1632851', 'C0332170', 'C0205117', 'C1552551']","['Any', 'Sleep', 'Any Data Type', 'Intermediate', 'Small', 'Times', 'And', 'Adjacent', 'Minute of time', 'Then', 'Minute (diminutive)', 'Morning', 'Time', 'Offspring', 'Following', 'Each (qualifier value)', 'Night time', 'Child']","['inpr', 'idcn', 'aggp', 'famg', 'spco', 'tmco', 'qlco', 'orgf', 'qnco']"
898,PMC3489506,S66,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study outcomes,a minimum of five out of seven nights’ data at baseline (the week before randomisation) and during the final week were required and the weekly average calculated at each time point.,"['C1511726', 'C1510992', 'C1552614', 'C1515981', 'C0332174', 'C3714741', 'C0347984', 'C2826545', 'C3853528', 'C1524031', 'C2348792', 'C0439230', 'C1442488', 'C1546485', 'C1457900', 'C1514873', 'C0332152', 'C0168634', 'C3245479', 'C2825518', 'C0205451', 'C0205453', 'C0205088']","['Baseline', 'And', 'Data call receiving device', 'Weekly', 'Five', 'Average', 'Final', 'Diagnosis Type - Final', 'Minimum Value Derivation Technique', 'Requirement', 'ActRelationshipSubset - minimum', 'Before', 'Each (qualifier value)', 'Average of Value Derivation Technique', 'BaseLine dental cement', 'Minimum', 'week', 'Data', 'End-stage', 'Seven', 'During', 'Timepoint', 'Data (eukaryote)']","['idcn', 'qnco', 'medd', 'ftcn', 'tmco', 'euka', 'qlco', 'bodm']"
899,PMC3489506,S67,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study outcomes,secondary sleep outcomes included total sleep time measured by actigraphy; sleep onset latency measured by diaries and actigraphy; and sleep efficiency (the proportion of time spent in bed asleep) measured by actigraphy.,"['C0175668', 'C1171301', 'C0205436', 'C0040223', 'C0424522', 'C0439810', 'C1515981', 'C1709707', 'C0027627', 'C0037313', 'C0376660', 'C0013682', 'C4505222', 'C0004916']","['Neoplasm Metastasis', 'Sleep', 'Efficiency', 'second (number)', 'And', 'Sleep Latency', 'Beds', 'Diary', 'Actigraphy', 'Time', 'Secondary to', 'Proportion', 'Total', 'Asleep']","['inpr', 'idcn', 'neop', 'fndg', 'mnob', 'tmco', 'qlco', 'diap', 'orgf', 'qnco']"
900,PMC3489506,S68,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study outcomes,"sleep onset latency measured the time taken for a child to go to sleep from “snuggle down” time recorded on the sleep diary for both sleep diary and actigraphy measures, with onset of sleep determined by the respective methods.","['C0008059', 'C0521125', 'C0079809', 'C1171301', 'C0521095', 'C1706086', 'C1517320', 'C0449851', 'C1883727', 'C0040223', 'C0332162', 'C1515981', 'C0376660', 'C0037313', 'C0025664', 'C0680063', 'C4321252', 'C0025663', 'C4505222']","['Sleep', 'Onset of (contextual qualifier)', 'Determined by', 'Both', 'Methods', 'Techniques', 'And', 'Taken', 'Methods aspects', 'Sleep Latency', 'Diary', 'From', 'Actigraphy', 'Time', 'Offspring', 'Preposition For', 'Measures', 'WWOX wt Allele', 'Child']","['inpr', 'idcn', 'aggp', 'gngm', 'famg', 'ftcn', 'fndg', 'cnce', 'tmco', 'qlco', 'diap', 'orgf', 'qnco']"
901,PMC3489506,S69,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study outcomes,four questionnaires were completed at baseline and at the final visit: the composite sleep disturbance index (csdi; based on allocating scores according to the frequency and duration of sleep problems reported by parents in questionnaires)14 15 16; the aberrant behaviour checklist (abc) to assess behavioural problems17 18; the family impact module of the paediatric quality of life inventory (pedsql) to assess the quality of life of the care giver19; and the epworth sleepiness scale (ess) to assess the daytime sleepiness of the care giver.20,"['C0034380', 'C1515981', 'C1706422', 'C1546466', 'C0030755', 'C3853528', 'C0376249', 'C1561548', 'C0004927', 'C3890225', 'C1709061', 'C0871396', 'C2826704', 'C0206630', 'C1704727', 'C1707357', 'C0037317', 'C1442488', 'C1546485', 'C0700201', 'C4255434', 'C1552854', 'C0015576', 'C4552790', 'C0663655', 'C3898838', 'C2986546', 'C0034394', 'C0918012', 'C0031213', 'C3541276', 'C1705502', 'C0545082', 'C4084897', 'C4321352', 'C0851578', 'C2698752', 'C0205450', 'C0152244', 'C0205199', 'C0439603', 'C0449820', 'C1547335', 'C0168634', 'C4049986', 'C0021941', 'C1512346', 'C0518214', 'C0449238', 'C0037313', 'C0600653', 'C0443127', 'C0541854', 'C1947933', 'C0030551', 'C2926735', 'C1516048', 'C1825598', 'C0205088']","['Active Breathing Coordinator-Mediated Radiation Therapy', 'Baseline', 'Index', 'Visit', 'Composite', 'And', 'Questionnaires', 'Personality inventories', 'Questionnaire Domain', 'Duration', 'Family (taxonomic)', 'daytime sleepiness', 'Four', 'Sleep Disorders', 'Impact', 'Sleep', 'Final', 'Perceived quality of life', 'Behavior', 'Diagnosis Type - Final', 'Checklist:Finding:Point in time:{Setting}:Document:{Role}', 'Visit Name', 'Frequencies (time pattern)', 'Epworth Sleepiness Scale Questionnaire', 'Kind of quantity - Frequency', 'Sleep disturbances', 'parent', 'Equipment and supply inventories', 'Html Link Type - index', 'Family', 'Duration (temporal concept)', 'BaseLine dental cement', 'aberrant', 'Statistical Frequency', 'IMPACT gene', 'Checklist', 'Patient Visit', 'Pediatrics', 'Bone Cysts, Aneurysmal', 'Dyssomnias', 'Frequency', 'abacavir', 'Pediatric Quality of Life Inventory', 'End-stage', 'Target Lesion Identification', 'Module', 'Active Breathing Control', 'Problems - What subject filter', 'Spatial Frequency', 'Data types- Composite', 'Sleep Disturbance Subordinate Domain', 'Indexes', 'With frequency', 'care activity', 'How Often', 'Score', 'Endometrial Stromal Sarcoma', 'Quality of life', 'Assessed']","['clna', 'famg', 'topp', 'neop', 'mnob', 'fndg', 'qlco', ' phsu', 'hlca', 'diap', 'bmod', 'inpr', 'idcn', 'gngm', 'orgf', 'bodm', 'sosy', 'orch', 'tmco', 'dsyn', 'nnon', 'acty', 'cnce', 'bhvr', 'mobd', 'qnco']"
902,PMC3489506,S70,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study outcomes,we used a seven point likert scale to assess parental perception of child’s sleep quality.,"['C0332306', 'C1552961', 'C0451267', 'C3714763', 'C0030971', 'C2347617', 'C0205453', 'C0030551']","['Point', 'with quality', 'point - UnitsOfMeasure', 'Point Name', 'parent', 'Seven', 'Perception', 'likert scale']","['inpr', 'famg', 'spco', 'qlco', 'menp', 'qnco']"
903,PMC3489506,S71,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study outcomes,we measured salivary melatonin concentrations for each participant to calculate dim light melatonin onset (dlmo).,"['C0086045', 'C0206132', 'C0025219', 'C4050248', 'C1881376', 'C0163151', 'C0114346', 'C1527137', 'C3842678', 'C1457900', 'C0332162', 'C0679646', 'C1570446', 'C2698741', 'C4521367', 'C4554048', 'C0023693']","['TNFSF14 protein, human', 'Age of Onset', 'Light', 'Melatonin', 'Study Participant', 'Onset of (contextual qualifier)', 'Dimesna', 'Mental concentration', 'Light (qualifier)', 'TNFSF14 wt Allele', 'Borg Scale Rating of Perceived Exertion Score 11', 'Recombinant melatonin', 'Light - subjective measurement', 'Participant Object', 'Each (qualifier value)', ""3,3'-diindolylmethane"", 'Participant']","['bacs', 'inpr', ' orch', 'gngm', 'clas', 'popg', 'fndg', 'qlco', 'orch', 'horm', ' phsu', 'menp', ' aapp', 'npop', 'qnco']"
904,PMC3489506,S72,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study outcomes,melatonin is a hormone produced by the pineal gland in a circadian rhythm influenced by light levels.,"['C0025219', 'C4050248', 'C1881376', 'C0031939', 'C0441889', 'C1527137', 'C3842678', 'C1570446', 'C1522723', 'C0019932', 'C0008810', 'C4521367', 'C0023693']","['TNFSF14 protein, human', 'Light', 'Melatonin', 'Circadian Rhythm Pathway KEGG', 'Levels (qualifier value)', 'Light (qualifier)', 'TNFSF14 wt Allele', 'Circadian Rhythms', 'Borg Scale Rating of Perceived Exertion Score 11', 'Pineal gland', 'Recombinant melatonin', 'Light - subjective measurement', 'Hormones']","['bacs', 'inpr', 'bpoc', ' orch', 'gngm', 'biof', 'fndg', 'orgf', 'qlco', 'horm', ' phsu', ' aapp', 'npop']"
905,PMC3489506,S73,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study outcomes,"concentrations are usually low during the day, but as evening approaches they start to rise sharply peaking at around midnight.","['C0086045', 'C0332172', 'C0587117', 'C0750503', 'C3538928', 'C0205251', 'C0332173', 'C3888388', 'C3890211', 'C0233535', 'C0439228', 'C1550472', 'C4048187', 'C4321351', 'C4522223']","['day', 'Evening', 'Usual', 'Low Level', 'low', 'Low Mitosis-Karyorrhexis Index', 'low confidentiality', 'Daily', 'Mental concentration', 'Usually', 'midnight', 'butting', 'low exposure', 'around', 'IPSS Risk Category Low']","['inpr', 'idcn', 'fndg', 'tmco', 'qlco', 'menp', 'mobd', 'qnco']"
906,PMC3489506,S74,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study outcomes,the beginning of this rise is what is known as the dim light melatonin onset time.,"['C0025219', 'C4050248', 'C1881376', 'C0163151', 'C0114346', 'C1527137', 'C3842678', 'C0439659', 'C4321377', 'C1570446', 'C0449244', 'C1080058', 'C4521367', 'C0023693']","['TNFSF14 protein, human', 'Relational and Item-Specific Encoding Task', 'Light', 'Melatonin', 'Dimesna', 'Light (qualifier)', 'TNFSF14 wt Allele', 'Beginning', 'Borg Scale Rating of Perceived Exertion Score 11', 'Recombinant melatonin', 'Light - subjective measurement', ""3,3'-diindolylmethane"", 'time of onset', 'This (eukaryote)']","['bacs', 'inpr', ' orch', 'gngm', 'fndg', 'qlco', 'orch', 'horm', 'tmco', 'euka', ' phsu', ' aapp', 'npop']"
907,PMC3489506,S75,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study outcomes,salivary samples were collected at two time points on the night before the randomisation clinic visit and at the beginning of the 11th week with two nights of trial treatment omitted.,"['C3887704', 'C1705169', 'C1515981', 'C0439659', 'C0008976', 'C0442040', 'C2826704', 'C0439230', 'C0240526', 'C0332287', 'C0039798', 'C3538994', 'C0002424', 'C0442592', 'C0545082', 'C0205448', 'C0332152', 'C0040223', 'C1512346', 'C0087111', 'C1522326', 'C1533734']","['Visit', 'Biomaterial Treatment', 'And', 'Time', 'Therapeutic procedure', 'Clinic', 'Clinical Trials', 'Visit Name', 'Administration procedure', 'Before', 'Night time', 'Treatment Epoch', 'week', 'Patient Visit', 'Two', 'Beginning', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'In addition to', 'Ambulatory Care Facilities', 'salivary', 'Treating']","['inpr', 'idcn', 'topp', 'ftcn', 'mnob', 'cnce', 'tmco', 'spco', 'resa', 'bhvr', 'hlca', ' hcro', 'qnco']"
908,PMC3489506,S76,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study outcomes,saliva samples were collected hourly from 5 pm until the child’s usual bedtime.,"['C3538928', 'C0521112', 'C0036087', 'C0558292', 'C1608524', 'C1546769']","['Usual', 'Specimen Source Codes - Saliva', 'Hourly', 'saliva', 'Saliva - SpecimenType', 'Bedtime (qualifier value)']","['inpr', 'bdsu', 'qlco', 'tmco']"
909,PMC3489506,S77,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study outcomes,a minimum of 2 ml of saliva was obtained by asking the child to spit into a tube or by placing a saliva sponge in the buccal cavity of the child’s mouth.,"['C0008059', 'C0441126', 'C1524031', 'C0232515', 'C0183461', 'C1561954', 'C1552614', 'C2826545', 'C0032699', 'C0442504', 'C0332286', 'C0036087', 'C0175730', 'C0680063', 'C1608524', 'C1546769', 'C0230028', 'C1704730', 'C0226896']","['Packaging Tube', 'Minimum', 'Contraceptive Sponge - device', 'Sponges', 'Oral cavity', 'biomedical tube device', 'Specimen Source Codes - Saliva', 'Minimum Value Derivation Technique', 'saliva', 'Saliva - SpecimenType', 'ActRelationshipSubset - minimum', 'Spitting', 'into', 'tube', 'Porifera', 'Place', 'Offspring', 'Oral region', 'Child']","['bsoj', 'inpr', 'idcn', 'aggp', 'phsf', 'famg', 'medd', 'ftcn', 'blor', 'spco', 'bdsu', 'euka', 'qlco', 'mnob', 'qnco']"
910,PMC3489506,S78,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study outcomes,saliva samples were also taken for dna analysis to identify genetic polymorphisms associated with the sleep outcomes.,"['C0037313', 'C0036087', 'C0032529', 'C1608524', 'C1546769', 'C0200898']","['Sleep', 'Genetic Polymorphism', 'Specimen Source Codes - Saliva', 'saliva', 'Saliva - SpecimenType', 'dna analysis']","['inpr', 'genf', 'lbpr', 'bdsu', 'orgf']"
911,PMC3489506,S79,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study outcomes,dna analyses are ongoing.,"['C0549178', 'C4521340', 'C0012854']","['DNA', 'Continuous', 'Deoxyribonucleic Acid Measurement']","['lbpr', 'bacs', ' nnon', 'idcn']"
912,PMC3489506,S81,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Safety assessments,a paediatrician physically examined the children at the screening and final visits.,"['C0008059', 'C2348164', 'C1698960', 'C1512346', 'C0237433', 'C0545082', 'C1710031', 'C0220909', 'C1515981', 'C1710032', 'C0680063', 'C1546485', 'C3853528', 'C1710477', 'C0220908', 'C0205088']","['research subject screening', 'Final', 'Diagnosis Type - Final', 'Visit', 'Screening Study', 'Aspects of disease screening', 'And', 'Child', 'Patient Visit', 'Pediatrician (occupation)', 'Screening procedure', 'Offspring', 'Screening', 'End-stage', 'Trial Screening', 'Disease Screening']","['idcn', 'aggp', 'famg', 'prog', 'ftcn', 'qlco', 'tmco', 'resa', 'bhvr', 'hlca', 'diap']"
913,PMC3489506,S82,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Safety assessments,"the frequency and severity of spontaneously reported adverse events were recorded weekly along with prompted reports of adverse events of interest (treatment emergent signs and symptoms) covering somnolence, increased excitability, mood swings, rash, hypothermia, and cough.","['C0684224', 'C0235169', 'C0013144', 'C1705169', 'C4319718', 'C3887704', 'C1515981', 'C3889645', 'C0332174', 'C4084725', 'C2830004', 'C0376249', 'C0877248', 'C0871396', 'C0871157', 'C0010200', 'C0015230', 'C0037088', 'C0039798', 'C4084726', 'C3538994', 'C3898838', 'C0413252', 'C1705502', 'C1705413', 'C4084727', 'C4321352', 'C0085633', 'C0522510', 'C0700287', 'C0439603', 'C0750573', 'C0543488', 'C0439793', 'C3274924', 'C0087111', 'C1522326', 'C4553740', 'C1533734', 'C1961131', 'C0020672', 'C1561548']","['Reporting', 'Usual Severity Cough', 'And', 'Biomaterial Treatment', 'With intensity', 'Weekly', 'Hypothermia due to exposure', 'Somnolence, CTCAE', 'interest', 'Cough, CTCAE', 'Therapeutic procedure', 'Clinical Trial Final Report', 'Reported', 'Mood swings', 'Administration procedure', 'Adverse event', 'Frequencies (time pattern)', 'Kind of quantity - Frequency', 'Drowsiness', 'Signs and Symptoms', 'emergent', 'excitability', 'Treatment Epoch', 'Statistical Frequency', 'Adverse Event Domain', 'Hypothermia, natural', 'Have Been Coughing', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Frequency', 'How Much Distress Cough', 'Report (document)', 'Severities', 'Exanthema', 'Spatial Frequency', 'Somnolence', 'Prompting', 'Treating', 'With frequency', 'Coughing', 'How Often', 'Cough Frequency']","['sosy', 'inpr', 'idcn', 'inpo', 'topp', 'ftcn', 'fndg', 'patf', 'cnce', 'tmco', 'qlco', 'resa', 'hlca', 'menp', 'mobd', 'qnco']"
914,PMC3489506,S83,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Safety assessments,weekly seizure diaries recording the type and number of seizures were completed for those children with a pre-existing diagnosis of epilepsy.,"['C0008059', 'C1704656', 'C0740175', 'C0237753', 'C0332307', 'C1959629', 'C1515981', 'C2257086', 'C0036572', 'C0376660', 'C0011900', 'C0449788', 'C4553401', 'C0680063', 'C0332174', 'C0014544', 'C0332152', 'C1704338']","['Type - attribute', 'Count of entities', 'photoreactivating enzyme activity', 'Diagnosis', 'diagnosis aspect', 'Seizure, CTCAE 3.0', 'Child', 'And', 'Numbers', 'Weekly', 'Diary', 'Epilepsy', 'Before', 'Offspring', 'Before values', 'Diagnosis Study', 'Seizures', 'Seizure, CTCAE 5.0']","['sosy', 'inpr', 'idcn', 'genf', 'aggp', 'famg', 'fndg', 'qlco', 'tmco', 'resa', 'dsyn', 'diap', 'qnco']"
915,PMC3489506,S84,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Safety assessments,the investigator’s brochure was referred to in the assessment of causality and expectedness.,"['C1261322', 'C1314792', 'C1515981', 'C0030258', 'C0015127', 'C1516048']","['Evaluation procedure', 'Etiology aspects', 'And', 'Etiology', 'Pamphlets', 'Assessed']","['inpr', 'idcn', ' mnob', 'acty', 'ftcn', 'hlca']"
916,PMC3489506,S86,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Exploratory analyses,"interactions between treatment and autism, the type of sleep disorder (categorised as delayed sleep onset, poor sleep maintenance, or both), baseline measurements, and child’s age and weight were considered for the primary outcome and sleep onset latency as post hoc analyses.","['C3887704', 'C1705169', 'C3469826', 'C0242485', 'C1704687', 'C1515981', 'C4321252', 'C0004352', 'C0005910', 'C1274040', 'C0024501', 'C1442488', 'C0750591', 'C0039798', 'C3538994', 'C0043100', 'C0205225', 'C0851578', 'C0521125', 'C4505222', 'C1303139', 'C0168634', 'C1305866', 'C1706086', 'C0235162', 'C0332307', 'C0087111', 'C1705104', 'C1522326', 'C1533734', 'C0687676', 'C0001779']","['Baseline', 'Post Device', 'Both', 'Biomaterial Treatment', 'And', 'Weight', 'Preposition For', 'WWOX wt Allele', 'Therapeutic procedure', 'Sleep Disorders', 'Age', 'Administration procedure', 'Sleep Latency', 'Autistic Disorder', 'SLC35G1 gene', 'Measurement', 'consider', 'Type - attribute', 'BaseLine dental cement', 'Treatment Epoch', 'Difficulty sleeping', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Importance Weight', 'Post', 'Delayed onset of sleep', 'Body Weight', 'Treating', 'Weighing patient', 'Result', 'Primary', 'Maintenance']","['sosy', 'idcn', 'acty', 'qnco', 'gngm', 'topp', 'ftcn', 'fndg', 'cnce', 'qlco', 'tmco', 'mnob', 'resa', 'hlca', 'mobd', 'bodm', 'orga']"
917,PMC3489506,S87,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Exploratory analyses,additional analyses assessed whether there was a change in morning wake up time and number and duration of night awakenings to determine whether the observed increase in total sleep time was explained by reduced sleep onset latency.,"['C0392747', 'C0040223', 'C1170730', 'C4319952', 'C1515981', 'C0443172', 'C0449238', 'C0439810', 'C0037313', 'C0449788', 'C0392756', 'C0240526', 'C1705241', 'C0332170', 'C0442805', 'C2926735', 'C1524062', 'C4505222', 'C0237753', 'C1441672']","['Observed', 'Count of entities', 'Sleep', 'wake ups', 'Changing', 'Increase', 'Additional', 'And', 'Changed status', 'Numbers', 'Sleep Latency', 'Change -- procedure', 'Morning', 'Time', 'Reduced', 'Total', 'Duration', 'Night time', 'Delta (difference)', 'Duration (temporal concept)']","['idcn', 'topp', 'ftcn', 'fndg', 'tmco', 'orch', 'qlco', ' phsu', 'orgf', 'qnco']"
918,PMC3489506,S89,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical considerations,"we used the “intention to treat” principle throughout and undertook analyses with sas (version 9.1.3, cary, nc).","['C1426104', 'C0333052', 'C1515981', 'C0605290', 'C1823519']","['NANS gene', 'And', 'TSPAN31 gene', 'Version', 'SAS']","['inpr', 'gngm', 'orch', 'idcn']"
919,PMC3489506,S90,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical considerations,results are presented with 95% confidence intervals.,['C0009667'],['Confidence Intervals'],['qnco']
920,PMC3489506,S91,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical considerations,"continuous outcomes are presented with means and standard deviations at baseline, at study completion (week 12), and for the change from baseline for each group.","['C0168634', 'C0392747', 'C1705428', 'C1519504', 'C2828392', 'C0441833', 'C1457900', 'C1704970', 'C0687744', 'C1257890', 'C0443172', 'C4319952', 'C1515981', 'C1442989', 'C1705429', 'C0549178', 'C1442488', 'C1705241', 'C2348557', 'C0439230']","['BaseLine dental cement', 'Baseline', 'Groups', 'Changing', 'week', 'Standard (document)', 'And', 'Changed status', 'Study Completed', 'Continuous', 'Population Group', 'User Group', 'Means', 'Change -- procedure', 'Stage Grouping', 'Group Object', 'Each (qualifier value)', 'Social group', 'Standard (qualifier)', 'Delta (difference)']","['inpr', 'bodm', 'idcn', 'topp', 'popg', 'ftcn', 'cnce', 'qlco', 'tmco', 'qnco']"
921,PMC3489506,S92,"['12a', '12b']","[0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical considerations,"we used analysis of covariance to adjust results for the dependent variables (total sleep time, sleep onset latency) measured at baseline and in exploratory analyses for treatment covariate interactions.","['C3887704', 'C1705169', 'C0439828', 'C0439810', 'C1524024', 'C0936012', 'C0851827', 'C1442488', 'C0039798', 'C3538994', 'C1701901', 'C0429964', 'C4321395', 'C0168634', 'C0040223', 'C0332162', 'C3244310', 'C0087111', 'C0429986', 'C0037313', 'C1522326', 'C1533734', 'C0206132']","['Age of Onset', 'dependent', 'Baseline', 'Biomaterial Treatment', 'Time', 'Therapeutic procedure', 'Dependent for dressing', 'Sleep', 'Administration procedure', 'Variable (uniformity)', 'Total', 'Dependent for bathing', 'BaseLine dental cement', 'Treatment Epoch', 'Dependent - ability', 'Conditional', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'analysis aspect', 'Onset of (contextual qualifier)', 'Dependent for Toilet Use', 'Treating', 'Analysis']","['inpr', 'bodm', 'topp', 'ftcn', 'cnce', 'fndg', 'tmco', 'qlco', 'resa', 'hlca', 'orgf', 'qnco']"
922,PMC3489506,S93,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical considerations,the trial was originally designed with two primary outcomes: total sleep time according to the sleep diary and sleep onset latency measured with actigraphy.,"['C1171301', 'C0040223', 'C0439810', 'C1515981', 'C0008976', 'C0205225', 'C0376660', 'C0037313', 'C0205448', 'C4505222']","['Sleep', 'Clinical Trials', 'And', 'Sleep Latency', 'Two', 'Diary', 'Actigraphy', 'Time', 'Total', 'Primary']","['inpr', 'idcn', 'fndg', 'tmco', 'qlco', 'resa', 'diap', 'orgf', 'qnco']"
923,PMC3489506,S94,['6b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0]",Statistical considerations,during trial recruitment we observed high rates of missing data (66%) for actigraphy so we re-designated sleep onset latency as a secondary outcome and removed the bonferroni multiplicity adjustment21 in a protocol amendment.,"['C1511726', 'C0205436', 'C4522209', 'C1299351', 'C0205250', 'C1515981', 'C0008976', 'C0027627', 'C3714741', 'C3889660', 'C1274040', 'C4321237', 'C3887512', 'C1507394', 'C1171301', 'C2949735', 'C0449822', 'C4321383', 'C4505222', 'C3245479', 'C3889961', 'C2700149', 'C0849355', 'C0175668']","['And', 'Data call receiving device', 'Abnormally high', 'Actigraphy', 'Secondary to', 'High Level', 'Removed', 'high - ActExposureLevelCode', 'Clinical Trials', 'Clinical trial protocol document', 'Sleep Latency', 'Clinical Trial Protocol Amendment Summary', 'Protocol Amendment', 'High Mitosis-Karyorrhexis Index', 'Value Above Reference Range', 'IPSS Risk Category High', 'Data', 'Recruitment', 'multiplicity', 'Neoplasm Metastasis', 'High', 'second (number)', 'Data (eukaryote)', 'Result']","['inpr', 'idcn', 'acty', 'neop', 'medd', 'ftcn', 'fndg', 'qlco', 'euka', 'resa', 'diap', 'qnco']"
924,PMC3489506,S95,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical considerations,the process adopted in protecting trial validity was that suggested by evans.22,"['C1519941', 'C1522240', 'C2349101', 'C3833701', 'C1184743', 'C0008976', 'C4521541']","['Human Cells, Tissues, and Cellular and Tissue-Based Products Processing', 'Validity (characteristic)', 'Clinical Trials', ""Evan's coding system"", 'Validation', 'bony process', 'Process']","['inpr', 'phpr', 'bpoc', 'resa', 'hlca', 'qnco']"
925,PMC3489506,S96,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical considerations,total sleep time was powered at 80% with a 5% significance level to detect a change from baseline of one hour between the melatonin and placebo group with a common standard deviation of 1.7.23 24,"['C0441833', 'C0687744', 'C0439810', 'C1515981', 'C4288557', 'C3891454', 'C0205214', 'C1696465', 'C0814896', 'C1705241', 'C0871420', 'C1442488', 'C0332287', 'C3245511', 'C1527137', 'C1705429', 'C4319952', 'C0443172', 'C0032042', 'C0025219', 'C0168634', 'C0392747', 'C1517320', 'C1706408', 'C1519504', 'C0040223', 'C1257890', 'C0037313', 'C0205103', 'C0442726', 'C1705428', 'C1522138']","['Melatonin', 'Baseline', 'significance level', 'And', 'Detected (finding)', 'From', 'Time', 'placebo', 'Stage Grouping', 'Standard deviation', 'Delta (difference)', 'Sleep', 'shared attribute', 'Changed status', 'Placebos', 'User Group', 'Common (qualifier value)', 'Total', 'Group Object', 'Social group', 'BaseLine dental cement', 'Intermediate', 'Common Specifications in HL7 V3 Publishing', 'Changing', 'Change -- procedure', 'Dosing Days to Detection', 'In addition to', 'Placebo Control', 'Groups', 'Population Group', 'Recombinant melatonin', 'One Activity Hour']","[' orch', 'inpr', 'idcn', 'qnco', 'topp', 'popg', 'ftcn', 'fndg', 'cnce', 'tmco', 'qlco', 'horm', 'spco', 'resa', ' phsu', 'orgf', 'bodm']"
926,PMC3489506,S97,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical considerations,"allowing for 20% missing data based on observed rates at the time of the amendment, we calculated we needed 57 participants in each group.","['C1511726', 'C0679646', 'C1519504', 'C3245479', 'C0441833', 'C0040223', 'C2346732', 'C1457900', 'C1257890', 'C0687744', 'C1705429', 'C1441672', 'C1705428', 'C3714741', 'C0680532']","['Observed', 'Stage Grouping', 'Groups', 'Amendment Regulatory Submission', 'Data call receiving device', 'User Group', 'Population Group', 'Time', 'Amendment', 'Data (eukaryote)', 'Data', 'Group Object', 'Each (qualifier value)', 'Social group', 'Participant']","['inpr', 'idcn', 'ocac', 'medd', 'popg', 'ftcn', 'cnce', 'tmco', 'euka', 'qnco']"
927,PMC3489506,S98,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical considerations,"we reassessed the estimate of the common standard deviation used in the sample size calculation after the first 20 participants as 1.2 (95% confidence interval 0.8 to 1.7), and the independent data safety monitoring committee recommended the trial continue without revision of the sample size calculation for the estimated standard deviation used.","['C0085862', 'C1511726', 'C0036043', 'C0679646', 'C0150369', 'C0332288', 'C1515981', 'C0008976', 'C4321252', 'C3714741', 'C0205214', 'C0034866', 'C0750572', 'C0009667', 'C0439617', 'C1522138', 'C0871420', 'C2699414', 'C1527075', 'C1299583', 'C3245511', 'C1283169', 'C1273517', 'C1290940', 'C0521125', 'C0558347', 'C3245479', 'C3897657', 'C1279901', 'C0549178', 'C0687676', 'C1705187', 'C0205435', 'C0231290']","['Preventive monitoring', 'Status post', 'Firstly', 'And', 'Data call receiving device', 'First (number)', 'Independent for Transfer', 'Preposition For', 'Safety', 'WWOX wt Allele', 'Standard deviation', 'Revision procedure', 'Monitoring - action', 'Without', 'Surgical revision', 'Sample Size Calculation', 'Clinical Trials', 'shared attribute', 'Confidence Intervals', 'Committee', 'Common (qualifier value)', 'Revision', 'Estimated', 'Independently able', 'Common Specifications in HL7 V3 Publishing', 'Data', 'Recommendation', 'Post', 'Safety Study', 'used by', 'Continuous', 'Independence', 'Data (eukaryote)', 'Participant']","['hcpp', 'grup', 'inpr', 'idcn', 'gngm', 'topp', 'medd', 'popg', 'ftcn', 'fndg', 'qlco', 'euka', 'tmco', 'resa', 'hlca', 'qnco']"
928,PMC3502035,S36,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Methods,the australian universal health insurance scheme (medicare) provides citizens with free access to public hospitals and reimbursed access (70% of services with no co-payment) to a widespread network of primary care or general practice clinics.,"['C1996904', 'C1882071', 'C1554204', 'C0444454', 'C0150775', 'C0020022', 'C0442592', 'C1513822', 'C0015607', 'C1705739', 'C0205391', 'C1519193', 'C0238711', 'C1880497', 'C0205219', 'C0033137', 'C0332296', 'C0220808', 'C0682134', 'C1546906', 'C0680264', 'C0086343', 'C0376640', 'C1547152', 'C1515981', 'C0018717', 'C0557854']","['Universal Health Insurance', 'Medicare', 'Clinic', 'Network', 'And', 'Free of (attribute)', 'Widespread', 'australian', 'citizen', 'Access', 'Primary Health Care', 'Free (available (qualifier))', 'Financial compensation', 'general practice (field)', 'Network Device', 'Medicare Coding system', 'Services', 'Role Class - access', 'Empty (qualifier)', 'Scheme', 'family medicine (field)', 'Hospitals, Public', 'Diffuse', 'Consortium or Network', 'payment', 'Medicare DRG Payor', 'Social Networks']","['gora', 'ocac', 'prog', ' hcro', 'idcn', 'hlca', 'inpr', 'hcro', 'qlco', 'qnco', 'bmod', 'spco', 'ftcn', 'mnob', 'popg']"
929,PMC3502035,S37,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Methods,"a parallel system, the pharmaceutical benefits scheme, provides subsidised drug treatment to all australians, with capped payments for those with a chronic illness; most prescriptions for drugs being generated by general practitioners managing people with chronic conditions such as hypertension.","['C2741652', 'C0008679', 'C0359589', 'C1135440', 'C0449913', 'C0017319', 'C0814225', 'C3469597', 'C3687832', 'C0027361', 'C1519193', 'C3888058', 'C0238711', 'C0020538', 'C0031336', 'C0444868', 'C4554418', 'C0013227', 'C0205191', 'C0680264', 'C0033080', 'C0205393', 'C2826345', 'C1963138', 'C2348042', 'C1553451', 'C0150270']","['System - kit', 'Hypertension, CTCAE', 'Device system', 'Drugs - dental services', 'Procedures involving the use of pharmaceuticals', 'Prescriptions:Finding:Point in time:^Patient:Narrative', 'australian', 'Prescription procedure', 'Persons', 'Medication Management', 'Administration of medication', 'chronic', 'Parallel Study', 'System', 'General Practitioners', 'benefit', 'All', 'Provide (product)', 'Chronic disease', 'Pharmacy (field)', 'Hypertensive disease', 'Pharmaceutical Preparations', 'Scheme', 'Parallel Lesion', 'Most', 'Parallel', 'payment']","['tmco', 'food', 'fndg', 'prog', 'hlca', 'topp', 'inpr', 'qnco', 'qlco', 'phsu', 'bmod', 'dsyn', 'resa', 'ftcn', 'mnob', 'popg', 'clna']"
930,PMC3502035,S39,['4b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,study participants were recruited by 260 general practitioners from 119 general practices distributed throughout every state and territory of australia except the sparsely populated northern territory.,"['C2603343', 'C0086343', 'C1948061', 'C0679646', 'C3148680', 'C0028416', 'C1515981', 'C0017319', 'C2983136', 'C0004340', 'C1301808', 'C1442792']","['Northern Territory', 'General Practitioners', 'Participant', 'Australia', 'Territory', 'Every (qualifier)', 'And', 'Study', 'US State', 'Geographic state', 'State', 'general practice (field)']","['prog', 'idcn', 'geoa', 'qlco', 'bmod', 'resa', 'ftcn', 'popg']"
931,PMC3502035,S40,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,"people routinely managed by these doctors were potentially eligible to participate if they were aged 18 or more, had a diagnosis of hypertension requiring active drug treatment according to guidelines, and consented to participate.","['C0220845', 'C0031831', 'C0011900', 'C1963138', 'C1704656', 'C1704338', 'C0020538', 'C1548635', 'C0282423', 'C1515981', 'C0150270', 'C0162791', 'C0205172', 'C3469597', 'C3853793', 'C0027361', 'C0205177', 'C0039828', 'C3888249']","['Diagnosis', 'Active License', 'Guidelines', 'Hypertension, CTCAE', 'guiding characteristics', 'Persons', 'Guideline [Publication Type]', 'diagnosis aspect', 'And', 'More', 'active (HL7 RoleLink)', 'Eligible', 'Diagnosis Study', 'Medication Management', 'Physicians', 'Hypertensive disease', 'Administration of medication', 'Active', 'Theses']","['fndg', 'prog', 'topp', 'idcn', 'hlca', 'inpr', 'qlco', 'qnco', 'dsyn', 'resa', 'diap', 'popg']"
932,PMC3502035,S41,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,"we excluded people who had a mean initial systolic blood pressure of 180 mm hg or more while sitting, were prescribed three or more antihypertensives; had moderate to severe renal disease (clinical diagnosis or estimated glomerular filtration rate <60 ml/min/1.73m2), or had contraindications to angiotensin receptor blockers, calcium channel blockers, or thiazide diuretics.","['C1561549', 'C0750519', 'C0205265', 'C0205449', 'C4050224', 'C1279901', 'C0277814', 'C0488055', 'C0006684', 'C0205082', 'C3272598', 'C1555582', 'C1306620', 'C0521942', 'C0012798', 'C4321335', 'C0205172', 'C2757014', 'C0027361', 'C4049706', 'C0815017', 'C4049705', 'C1881878', 'C0871470', 'C0017654', 'C2348143', 'C0003364', 'C0022658', 'C4050466', 'C1705685', 'C0444504', 'C0332140', 'C2584297', 'C1301624', 'C4085643', 'C0205081', 'C2347634', 'C0541746', 'C4050465']","['Angiotensin Receptor Antagonists', 'Borg Category-Ratio 10 Perceived Exertion Score 3', 'Kidney Diseases', 'Moderate Level', 'Borg Category-Ratio 10 Perceived Exertion Score 5', 'Sitting Function', 'Systolic blood pressure measurement', 'Moderate (severity modifier)', 'Firstly', 'Thiazides', 'Antihypertensive Agents', 'Sample Mean', 'Persons', 'while', 'Population Mean', 'Glomerular Filtration Rate', 'Moderate Extremity Pain', 'Diagnosis, clinical', 'Initially', 'Angiotensin II receptor antagonist', 'Moderation', 'Severe Extremity Pain', 'Medical contraindication', 'More', 'Initial (abbreviation)', 'Initial Usage', 'Statistical mean', 'Glomerular Filtration Rate, CTCAE', 'Calcium Channel Antagonists [MoA]', 'Ability to Sit question', 'Calcium Channel Blockers', 'Sitting position', 'Moderate Response', 'Severe (severity modifier)', 'WHO Temperature/Humidity Storage Condition', 'Three', 'Systolic Pressure', 'Diuretics', 'Intravascular systolic:Pressure:Point in time:Arterial system:Quantitative']","['tmco', 'clna', 'fndg', 'idcn', 'phsf', 'inpr', 'orch', 'qlco', 'qnco', 'dsyn', ' phsu', 'ftcn', 'diap', 'popg', 'moft', 'phsu']"
933,PMC3502035,S42,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,"recruitment took place from july 2009 to december 2010, with follow-up completed in july 2011.",,,
934,PMC3502035,S44,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"this was an open label, two arm, randomised trial comparing an intensive blood pressure management strategy with usual care (control).13","['C2587213', 'C1947933', 'C3274648', 'C1080058', 'C4553389', 'C0679199', 'C0558010', 'C0446516', 'C4553528', 'C0005823', 'C1271104', 'C1882979', 'C3715044', 'C1709323', 'C1272641', 'C0008976', 'C0205448', 'C0243148', 'C1550141', 'C3538928']","['Blood Pressure', 'Two', 'strategy', 'AKR1A1 wt Allele', 'control substance', 'Clinical Trials', 'control aspects', 'Sequence Arm', 'True Control Status', 'care activity', 'Usual', 'Upper arm', 'Control function', 'pressure area care', 'This (eukaryote)', 'Systemic arterial pressure', 'Blood pressure finding', 'Open Label Study', 'Study Control', 'Scientific Control']","['blor', 'fndg', 'resa', 'gngm', 'topp', 'inpr', 'qlco', 'qnco', 'sbst', 'orgf', 'euka', 'ftcn', 'acty', 'menp', 'cnce']"
935,PMC3502035,S45,"['8a', '8b']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0]",Study design,"randomisation was by computer generated, group assignment stratified according to nominated blood pressure target (three strata) and block randomisation (units of 12) per general practitioner.","['C2986546', 'C1516050', 'C0205449', 'C3853603', 'C1521840', 'C1272641', 'C1257890', 'C0441833', 'C0028778', 'C0005823', 'C0017319', 'C1706084', 'C1705428', 'C0439148', 'C1519504', 'C1705429', 'C0009622', 'C1271104', 'C1533157', 'C0687744', 'C1515981', 'C1519795', 'C2828370', 'C0332206']","['Group Object', 'Unit - NCI Thesaurus Property', 'Block (unit of measure)', 'And', 'Systemic arterial pressure', 'Blocking', 'Blood Pressure', 'Unit of Measure', 'Unit', 'Target', 'Computers', 'User Group', '(City) Block', 'Assignment - action', 'Block Specimens', 'Groups', 'Population Group', 'General Practitioners', 'Social group', 'Blood pressure finding', 'Obstruction', 'Three', 'Stage Grouping', 'Target Lesion Identification']","['fndg', 'patf', 'prog', 'idcn', 'diap', 'geoa', 'qnco', 'orgf', 'ftcn', 'mnob', 'popg', 'cnce', 'bdsu']"
936,PMC3502035,S46,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,an independent data management team at baker idi coordinated a standardised protocol for randomising participants over the telephone.,"['C0238749', 'C3715209', 'C4282383', 'C1705541', 'C1515258', 'C0679646', 'C1507394', 'C0596404', 'C0039457', 'C0085862', 'C0871489', 'C1522729', 'C2348563', 'C1290940', 'C3891561', 'C1299583', 'C2599718', 'C3476796', 'C0442711']","['Telephone', 'Protocols documentation', 'Telephone Device', 'baker', 'teams', 'Participant', 'REMS Protocol', 'Clinical trial protocol document', 'Library Protocol', 'IDI', 'Study Protocol', 'Independently able', 'Protocol - answer to question', 'Data Management Oversight Documentation', 'Independent for Transfer', 'Independence', 'Data Management', 'Clinical trial protocol', 'Telephone Number']","['fndg', 'prog', 'idcn', 'inpr', 'grup', 'resa', 'mnob', 'popg']"
937,PMC3502035,S47,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,participants were assigned to the groups using a prespecified ratio of 1:2 for usual care versus intervention (with a further ratio of 1:2 within the intervention arm to assign participants to a monotherapy strategy and to two possible combined treatment strategies).,"['C1516050', 'C0009429', 'C0679199', 'C0446516', 'C1704537', 'C0521125', 'C4321252', 'C0441833', 'C1947933', 'C0332149', 'C1705910', 'C3715044', 'C0205448', 'C0456603', 'C0332287', 'C0332285', 'C0679646', 'C1552839', 'C4553528', 'C1547037', 'C0886296', 'C0687744', 'C1515981', 'C1517331', 'C0184661', 'C3538928']","['In addition to', 'And', 'Nursing interventions', 'Further', 'Possible', 'Table Rules - groups', 'Participant', 'Within', 'Sequence Arm', 'Ratio', 'Upper arm', 'Osteopathic Combined Method', 'Combined Modality Therapy', 'Assignment - action', 'Groups', 'strategy', 'Two', 'AKR1A1 wt Allele', 'Social group', 'WWOX wt Allele', 'Possibly Related to Intervention', 'Preposition For', 'data type - ratio', 'care activity', 'Usual', 'Interventional procedure']","['blor', 'fndg', 'gngm', 'hlca', 'topp', 'idcn', 'inpr', 'qnco', 'qlco', 'spco', 'ftcn', 'popg', 'menp', 'acty']"
938,PMC3502035,S48,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,quality control of the sites and general practitioners was achieved by visits before randomisation and at study end.,"['C2603343', 'C0034378', 'C0205145', 'C2746065', 'C1561524', 'C1515981', 'C0017319', 'C1610034', 'C0444930', 'C0545082', 'C1512346']","['Quality Control Specimen', 'General Practitioners', 'Patient Visit', 'Stop (qualifier value)', 'And', 'quality control', 'End', 'Study', 'Site', 'Specimen Source Codes - Quality Control', 'Visit']","['tmco', 'prog', 'idcn', 'hlca', 'inpr', 'bhvr', 'spco', 'resa', 'ftcn']"
939,PMC3502035,S49,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"the study was independently monitored by routine visits, and case report forms were verified against clinical records for 20% of patients.","['C0348078', 'C0205547', 'C2603343', 'C1548330', 'C0085973', 'C0376315', 'C0030705', 'C3853626', 'C1515981', 'C0007320', 'C0545082', 'C0205210', 'C1512346', 'C1553414', 'C0034869']","['Case Reports Publication Type', 'Clinical', 'Patient Visit', 'Qualitative form', 'Records', 'Case Study', 'And', 'Case report:Find:Pt:{Setting}:Doc:{Author Type}', 'Patients', 'Query Quantity Unit - Records', 'Study', 'Quantity limited request - Records', 'Routine', 'Manufactured form', 'Visit']","['idcn', 'hlca', 'inpr', 'qlco', 'bhvr', 'resa', 'podg', 'mnob', 'clna']"
940,PMC3502035,S50,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,we used standardised operating procedures for data queries and management.,"['C2700391', 'C3245479', 'C0025664', 'C3538935', 'C1515981', 'C3273539', 'C1273870', 'C3714741', 'C0001554', 'C1511726', 'C0184661', 'C0376636']","['Data call receiving device', 'Procedure (set of actions)', 'Management Occupations', 'Procedure Domain', 'Data (eukaryote)', 'And', 'Data', 'Management procedure', 'Interventional procedure', 'Methods aspects', 'Disease Management', 'Administration occupational activities']","['ocac', 'medd', 'topp', 'idcn', 'hlca', 'inpr', 'ocdi', 'euka', 'ftcn']"
941,PMC3502035,S51,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,all queries were resolved by the time the study dataset was locked and no further changes were permitted.,"['C0443172', 'C2603343', 'C1517331', 'C0150098', 'C0040223', 'C1706233', 'C0392747', 'C0444868']","['Changing', 'All', 'Time', 'Changed status', 'Silo (dataset)', 'Study', 'Data Set', 'Further']","['tmco', 'inpr', 'qnco', 'spco', 'resa', 'ftcn']"
942,PMC3502035,S52,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,figure 1 provides a graphical representation of the study timelines.,"['C1882932', 'C2603343', 'C1514861', 'C0145943']","['TimeLine Fluoride Releasing Resin', 'Representation Component', 'Study', 'Representation (action)']","['orch', 'resa', 'acty', ' phsu', 'cnce']"
943,PMC3502035,S53,"['3a', '5']","[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,fig 1 summary of study timelines,"['C1706244', 'C2603343', 'C1552616', 'C0145943']","['Summary (document)', 'TimeLine Fluoride Releasing Resin', 'summary - ActRelationshipSubset', 'Study']","[' phsu', 'inpr', 'orch', 'resa']"
944,PMC3502035,S55,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study entry,"eligible participants underwent baseline assessment, including determination of absolute cardiovascular risk.5","['C3887460', 'C4684571', 'C0035647', 'C0679646', 'C1548635', 'C0205344', 'C0521095', 'C0007226', 'C1148554', 'C4552904']","['absolute', 'Cardiovascular', 'Participant', 'Subject Risk', 'Determined by', 'Eligible', 'Determination Aspects', 'Cardiovascular system', 'Risk', 'Baseline Assessment']","['blor', 'idcn', 'bdsy', 'hlca', 'qlco', 'lbpr', 'popg', 'cnce']"
945,PMC3502035,S56,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study entry,"on the basis of this assessment, we identified target risk factor measures (including blood pressure, lipid levels, exercise levels, smoking status, and body mass index) for each participant according to national guidelines.6","['C0220845', 'C2986546', 'C1305855', 'C1521840', 'C1272641', 'C0441889', 'C0162791', 'C3245503', 'C4554048', 'C1519386', 'C0079809', 'C1457900', 'C0005893', 'C0005823', 'C1516048', 'C0679646', 'C1527178', 'C1271104', 'C1522704', 'C1874451', 'C0332257', 'C1521761', 'C0023779', 'C2827422', 'C1080058', 'C0578022', 'C1515981', 'C1261322', 'C2698741', 'C0015259', 'C0282423']","['Smoking Status', 'Each (qualifier value)', 'Guideline [Publication Type]', 'And', 'Participant Object', 'Evaluation procedure', 'Including (qualifier)', 'Measures', 'Systemic arterial pressure', 'Lipids', 'National citizen', 'Blood Pressure', 'Study Participant', 'Participant', 'Exercise', 'Target', 'Assessed', 'Mathematical Factor', 'Basis', 'Basis - conceptual entity', 'Finding of body mass index', 'Exercise Pain Management', 'Body mass index', 'Blood pressure finding', 'Factor', 'Levels (qualifier value)', 'Body mass index procedure', 'Guidelines', 'guiding characteristics', 'This (eukaryote)', 'Target Lesion Identification']","['acty', 'fndg', 'topp', 'idcn', 'dora', 'hlca', 'inpr', 'orch', 'clas', 'qlco', 'qnco', 'phsu', 'orgf', 'euka', 'ftcn', 'diap', 'popg', 'cnce', 'clna']"
946,PMC3502035,S57,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study entry,a computer program developed by baker idi enabled clinical profiling in all participants and subsequent management in intervention patients (see appendix i in the supplementary file).,"['C0886296', 'C0016094', 'C0238749', 'C1522646', 'C0332282', 'C0184661', 'C0679646', 'C0180853', 'C0030705', 'C1515981', 'C3273539', 'C1273870', 'C0205210', 'C0001554', 'C0037585', 'C0444868', 'C3476796', 'C0376636']","['Clinical', 'All', 'Following', 'Management Occupations', 'Participant', 'Filed', 'Computer software', 'IDI', 'And', 'Nursing interventions', 'Patients', 'Management procedure', 'Interventional procedure', 'Disease Management', 'file device', 'baker', 'File (record)', 'Administration occupational activities']","['tmco', 'ocac', 'prog', 'medd', ' mnob', 'idcn', 'hlca', 'topp', 'inpr', 'ocdi', 'qnco', 'qlco', 'podg', 'ftcn', 'popg']"
947,PMC3502035,S58,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study entry,"eligible participants began a standard 28 day run-in period of treatment with open label, oral valsartan 80 mg daily, with a mandatory blood pressure check 14 days after the start of treatment to determine the need for immediate (rescue) randomisation if systolic blood pressure was ≥180 mm hg or clinically indicated.","['C1554132', 'C1442989', 'C3538994', 'C0488055', 'C1272641', 'C1533734', 'C2828392', 'C0087111', 'C1514873', 'C0332173', 'C3887704', 'C0686904', 'C1705169', 'C1306620', 'C0039798', 'C0005823', 'C0439659', 'C0521095', 'C0439228', 'C0205253', 'C0871470', 'C0332287', 'C0205548', 'C0679646', 'C0442027', 'C0991107', 'C1271104', 'C1548635', 'C1522326', 'C0027552', 'C1619643', 'C3274438', 'C1709323']","['Stat (do immediately)', 'In addition to', 'Systolic blood pressure measurement', 'Systemic arterial pressure', 'Standard (document)', 'Eligible', 'Blood Pressure', 'Immediate', 'Participant', 'Patient need for (contextual qualifier)', 'valsartan 80 MG', 'Treatment Epoch', 'Determined by', 'Biomaterial Treatment', 'Administration procedure', 'Mandatory - HL7ConformanceInclusion', 'Open Label Study', 'Needs', 'Beginning', 'Mandatory - HL7DefinedRoseProperty', 'Requirement', 'Daily', 'Blood pressure finding', 'Run-in Period', 'day', 'treatment - ActInformationManagementReason', 'Treating', 'therapeutic aspects', 'Systolic Pressure', 'Oral', 'Intravascular systolic:Pressure:Point in time:Arterial system:Quantitative', 'Standard (qualifier)', 'Therapeutic procedure']","['tmco', 'clna', 'clnd', 'fndg', 'topp', 'hlca', 'inpr', 'qlco', 'orgf', 'resa', 'spco', 'ftcn', 'diap', 'popg', 'cnce']"
948,PMC3502035,S59,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study entry,we then randomised into the study those who did not achieve their prespecified blood pressure target within this run-in period or were not specifically withdrawn or lost to follow-up (blinded allocation).,"['C0439531', 'C1706778', 'C3272598', 'C2603343', 'C1518422', 'C2986546', 'C1080058', 'C1704688', 'C0005823', 'C1271104', 'C0150108', 'C0600140', 'C1521840', 'C1883708', 'C1272641', 'C0035953', 'C1948053']","['Blood Pressure', 'Period (temporal qualifier)', 'Allocation', 'Does run (finding)', 'Target', 'WHO Temperature/Humidity Storage Condition', 'Run action', 'Running (physical activity)', 'Blinded', 'Study', 'Then', 'This (eukaryote)', 'Systemic arterial pressure', 'per period (qualifier value)', 'Blood pressure finding', 'Target Lesion Identification', 'Negation']","['tmco', 'fndg', 'dora', 'qlco', 'orgf', 'resa', 'euka', 'ftcn', 'diap', 'acty']"
949,PMC3502035,S61,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Blood pressure measurement,throughout the study we used a standardised protocol based on national guidelines to record blood pressure measurements.6,"['C3245503', 'C0220845', 'C3715209', 'C4282383', 'C2603343', 'C1507394', 'C0005823', 'C1271104', 'C1522729', 'C2348563', 'C0442711', 'C1272641', 'C0162791', 'C2599718', 'C0242485', 'C0282423']","['National citizen', 'Protocols documentation', 'Blood Pressure', 'Guidelines', 'guiding characteristics', 'REMS Protocol', 'Clinical trial protocol document', 'Library Protocol', 'Study Protocol', 'Guideline [Publication Type]', 'Protocol - answer to question', 'Measurement', 'Study', 'Systemic arterial pressure', 'Blood pressure finding', 'Clinical trial protocol']","['fndg', 'inpr', 'orgf', 'resa', 'ftcn', 'popg']"
950,PMC3502035,S62,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Blood pressure measurement,"after participants had rested for at least five minutes and while they were seated we obtained three blood pressure measurements separated by one minute intervals using an appropriate sized cuff and a calibrated, semiautomated oscillometric device approved by the therapeutic goods administration of australia.","['C0205447', 'C0205449', 'C1272641', 'C0004340', 'C1548787', 'C1533734', 'C0242485', 'C2347166', 'C1550244', 'C0087111', 'C0699733', 'C0302350', 'C0038848', 'C0205451', 'C0005823', 'C0025080', 'C0439232', 'C0679646', 'C1271104', 'C1272706', 'C0001554', 'C0700321', 'C1282918', 'C1515981', 'C0441107']","['Minute Unit of Plane Angle', 'Small', 'And', 'Minute of time', 'Manufactured Supplies', 'Measurement', 'Systemic arterial pressure', 'Blood Pressure', 'Participant', 'Minute (diminutive)', 'Medical Devices', 'Devices', 'Cuff - body part', 'Administration procedure', 'Appropriate', 'Therapeutic procedure', 'Blood pressure finding', 'One', 'Therapeutic', 'Australia', 'Five', 'Interval', 'Three', 'Cuffs device', 'Administration occupational activities']","['tmco', 'fndg', 'ocac', 'medd', 'idcn', 'topp', 'geoa', 'qnco', 'qlco', 'orgf', 'ftcn', 'mnob', 'popg', 'bpoc']"
951,PMC3502035,S63,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Blood pressure measurement,we defined aberrant measurements as those where the lowest reading was 10 mm hg or more for systolic blood pressure or 5 mm hg or more for diastolic blood pressure below the highest of the three seated readings.,"['C0034754', 'C0205449', 'C1565156', 'C0277814', 'C0521125', 'C0488055', 'C3840882', 'C0242485', 'C0443127', 'C4321252', 'C1283233', 'C1306620', 'C1708760', 'C1552829', 'C0542339', 'C4284139', 'C0205172', 'C1522410', 'C0871470', 'C1421478', 'C0043194', 'C1305849', 'C1705179', 'C0428883']","['Systolic blood pressure measurement', 'Measurement', 'Reading Ability question', 'Reading (datum presentation)', 'Diastolic blood pressure measurement', 'Diastolic blood pressure', 'Highest', 'Wiskott-Aldrich Syndrome', 'Inferior', 'More', 'WWOX wt Allele', 'WAS gene', '5 mm', 'Preposition For', 'Sitting position', 'Reading (activity)', 'WAS protein, human', 'Table Frame - below', 'aberrant', 'Three', 'Seating', 'Systolic Pressure', 'Intravascular systolic:Pressure:Point in time:Arterial system:Quantitative', 'Lowest']","['clna', 'mnob', 'fndg', 'gngm', 'idcn', 'dora', 'inpr', 'qnco', 'qlco', 'bacs', 'dsyn', 'spco', 'ftcn', 'diap', ' aapp', 'cnce']"
952,PMC3502035,S64,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Blood pressure measurement,"if this occurred, the participant was rested for three minutes and the procedure repeated.","['C0439232', 'C2700391', 'C1282918', 'C1080058', 'C0205449', 'C0679646', 'C1421478', 'C1565156', 'C0043194', 'C2698741', 'C0521125', 'C3274430', 'C1515981', 'C0035253', 'C3539779', 'C1709305', 'C0184661', 'C4554048', 'C0700321', 'C4321252']","['Study Participant', 'Procedure (set of actions)', 'Rest', 'Participant', 'WAS protein, human', 'WAS gene', 'CDISC SDTM Procedure Terminology', 'And', 'Minute (diminutive)', 'Occur (action)', 'Participant Object', 'Small', 'WWOX wt Allele', 'Three', 'Interventional procedure', 'Physical Medical Procedure', 'Minute of time', 'This (eukaryote)', 'Preposition For', 'Wiskott-Aldrich Syndrome']","['tmco', 'gngm', 'topp', 'hlca', 'idcn', 'clas', 'inpr', 'dora', 'qnco', 'qlco', 'bacs', 'dsyn', 'euka', 'ftcn', 'popg', ' aapp', 'acty']"
953,PMC3502035,S65,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Blood pressure measurement,"given the size and nature of the study, it was impractical to obtain independent, blinded blood pressure levels.","['C0456389', 'C2603343', 'C0349590', 'C1262865', 'C0441889', 'C0005823', 'C1271104', 'C0150108', 'C0085862', 'C1515981', 'C1290940', 'C1272641', 'C1299583']","['Blood Pressure', 'Nature', 'Levels (qualifier value)', 'Independence', 'And', 'Independently able', 'Independent for Transfer', 'Blinded', 'Study', 'size', 'Systemic arterial pressure', 'Blood pressure finding', 'Natures']","['fndg', 'idcn', 'qlco', 'orgf', 'resa', 'spco', 'ftcn']"
954,PMC3502035,S66,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Blood pressure measurement,"nominated study staff at each site (general practitioner or practice nurse) verified the blood pressure measurements by an independent audit of the clinical details in the case records, outputs from the blood pressure monitor, and the computer decision tool.","['C1515974', 'C1706256', 'C0205145', 'C2827396', 'C1272641', 'C0242485', 'C1947908', 'C1457900', 'C1706255', 'C0005823', 'C1522508', 'C0085862', 'C0017319', 'C0034869', 'C1704774', 'C0868928', 'C1704775', 'C1271104', 'C0009622', 'C0679006', 'C1553414', 'C1517320', 'C0851286', 'C2825164', 'C2603343', 'C1548330', 'C3853835', 'C1622509', 'C3889431', 'C0401999', 'C1515981', 'C1290940', 'C0205210', 'C1299583']","['Blood Pressure Monitor device', 'Details', 'Each (qualifier value)', 'And', 'Independent for Transfer', 'Staff', 'Audit', 'Anatomic Site', 'From', 'Study', 'Study Site', 'Systemic arterial pressure', 'Independence', 'Measurement', 'Scientific Equipment', 'Blood Pressure', 'Audit Object', 'Records', 'Packaging Case', 'Query Quantity Unit - Records', 'Quantity limited request - Records', 'Clinical Study Case', 'Computers', 'On Staff', 'Alcohol Use Disorder Identification Test Self-Report Version Questionnaire', 'General Practitioners', 'Decision', 'Audit (administrative)', 'Independently able', 'practice nurse', 'Site', 'Blood pressure finding', 'Clinical', 'Case (situation)']","['blor', 'fndg', 'resa', 'prog', 'medd', 'idcn', 'inpr', 'qlco', 'qnco', 'orgf', 'spco', 'ftcn', 'mnob', 'menp', 'cnce']"
955,PMC3502035,S68,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Usual care,"for those assigned to usual care, we asked general practitioners to follow their usual pattern of clinic visits and treatment strategies (no restriction on prescribed drugs) to achieve the individualised blood pressure target and other prevention targets identified during the run-in phase; the only mandatory study visits were at weeks 6 (a typically brief 10-15 minute consultation) and 26 (final comprehensive evaluation).","['C2986546', 'C1554132', 'C0199176', 'C0008952', 'C0679199', 'C3202967', 'C3538994', 'C1282927', 'C0439230', 'C1710475', 'C1521840', 'C1272641', 'C0205396', 'C1512346', 'C1533734', 'C0205171', 'C2347166', 'C1514873', 'C0087111', 'C0443288', 'C1706420', 'C0205088', 'C1947933', 'C3887704', 'C3166216', 'C1705169', 'C3853528', 'C0005823', 'C2700409', 'C1879313', 'C0039798', 'C0017319', 'C4050216', 'C0600140', 'C0545082', 'C1546485', 'C0009818', 'C0439232', 'C1550043', 'C0220825', 'C0205390', 'C1704688', 'C1271104', 'C0347984', 'C0449774', 'C0700321', 'C1880156', 'C1282918', 'C2603343', 'C1522326', 'C1619643', 'C1515981', 'C1261322', 'C0035953', 'C3538928']","['Patient Visit', 'Restricted', 'Singular', 'Minute Unit of Plane Angle', 'End-stage', 'Prophylactic treatment', 'Small', 'And', 'Prevention Study', 'Run action', 'prevention aspects', 'Evaluation procedure', 'Study', 'Clinic Visits', 'Minute of time', 'Systemic arterial pressure', 'Comprehensive', 'Visit', 'Diagnosis Type - Final', 'Blood Pressure', 'Prescribed medications', 'pattern', 'Container status - Identified', 'Target', 'Minute (diminutive)', 'Consultation', 'Treatment Epoch', 'Behavior Rating Inventory of Executive Function', 'Biomaterial Treatment', 'Brief', 'Shortened', 'Administration procedure', 'Mandatory - HL7ConformanceInclusion', 'General Practitioners', 'strategy', 'Prescribed medications:-:Point in time:^Patient:-', 'Identified', 'Requirement', 'Mandatory - HL7DefinedRoseProperty', 'Running (physical activity)', 'Trial Phase', 'During', 'Blood pressure finding', 'Phase', 'treatment - ActInformationManagementReason', 'Does run (finding)', 'Treating', 'care activity', 'therapeutic aspects', 'Usual', 'week', 'Evaluation', 'Target Lesion Identification', 'Final', 'Therapeutic procedure']","['topp', 'qnco', 'bhvr', 'menp', 'clna', 'fndg', 'idcn', 'hlca', 'clas', 'inpr', 'qlco', 'resa', 'ftcn', 'phsu', 'tmco', 'prog', 'spco', 'acty', 'cnce', 'dora', 'orgf', 'diap']"
956,PMC3502035,S69,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Usual care,we explicitly acknowledged that this was an enhanced form of usual care given that the participants had already been subject to clinical profiling and had an identified blood pressure target and their doctors potentially had knowledge of the intervention (with the inherent problem of contamination).,"['C2697811', 'C4255237', 'C2986546', 'C2349001', 'C0259846', 'C2349975', 'C1881659', 'C1521840', 'C1272641', 'C0205396', 'C3539897', 'C3854081', 'C1442162', 'C0031831', 'C1706203', 'C1947933', 'C0005823', 'C0376315', 'C1947971', 'C0033213', 'C1415458', 'C0348078', 'C1550043', 'C0332287', 'C0679646', 'C0681850', 'C1271104', 'C0062074', 'C1522492', 'C3244317', 'C2349974', 'C0886296', 'C1080058', 'C0376554', 'C1550718', 'C1515981', 'C0205210', 'C0184661', 'C3538928']","['In addition to', 'And', 'Problem:Find:Pt:^Patient:Nom', 'Problem', 'Enhance (action)', 'Entity Name Part Type - given', 'Nursing interventions', 'HAC protocol', 'Given name', 'Systemic arterial pressure', 'HADH gene', 'Blood Pressure', 'Formation', 'Participant', 'Container status - Identified', 'Contamination', 'Target', 'Subject - topic', 'Human Study Subject', 'Physicians', 'Knowledge', 'Investigative Subject', 'Study Subject', 'Identified', 'Form:Finding:Point in time:{Setting}:Document:{Role}', 'Blood pressure finding', 'Manufactured form', 'adulteration', 'Medical Device Contamination during Use', 'Clinical', 'GIVEN', 'Qualitative form', 'Give - dosing instruction imperative', 'Have', 'care activity', 'Usual', 'Interventional procedure', 'This (eukaryote)', 'Target Lesion Identification']","['acty', 'fndg', 'prog', 'gngm', 'topp', 'idcn', 'hlca', 'hcpp', 'inpr', 'qlco', 'grup', 'orgf', 'euka', 'ftcn', 'mnob', 'popg', 'diap', 'clna']"
957,PMC3502035,S71,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study intervention,"those allocated to the intervention arm followed an intensive stepped programme of management, with mandatory visits to their doctor at weeks 6, 10, 14, and 18 after randomisation to review their blood pressure and to adjust their treatment if needed according to prespecified algorithms (see appendix ii in the supplementary file).","['C0016094', 'C1554132', 'C0332283', 'C0446516', 'C0002045', 'C3538994', 'C0439230', 'C0687676', 'C0282443', 'C1272641', 'C1512346', 'C1533734', 'C0376636', 'C0003617', 'C1514873', 'C0087111', 'C0031831', 'C3887704', 'C0686904', 'C1705169', 'C0039798', 'C0005823', 'C2348314', 'C3715044', 'C1273870', 'C0545082', 'C0680240', 'C0042789', 'C1947903', 'C0332287', 'C4553528', 'C1271104', 'C0001554', 'C0180853', 'C1552617', 'C0886296', 'C0231290', 'C1522646', 'C1522326', 'C1619643', 'C1515981', 'C3273539', 'C0184661']","['Followed by', 'Patient Visit', 'In addition to', 'And', 'Nursing interventions', 'Systemic arterial pressure', 'Visit', 'Post', 'Blood Pressure', 'Patient need for (contextual qualifier)', 'Sequence Arm', 'Treatment Epoch', 'Upper arm', 'Physicians', 'Biomaterial Treatment', 'Administration procedure', 'Mandatory - HL7ConformanceInclusion', 'Management Occupations', 'AKR1A1 wt Allele', 'algorithm', 'Status post', 'Requirement', 'Mandatory - HL7DefinedRoseProperty', 'Therapeutic procedure', 'Blood pressure finding', 'Disease Management', 'Agreement', 'file device', 'File (record)', 'Appendix', 'treatment - ActInformationManagementReason', 'Doctor - Title', 'Treating', 'Filed', 'therapeutic aspects', 'Management procedure', 'week', 'Act Class - review', 'Interventional procedure', 'See', 'Review [Publication Type]', 'Vision', 'Administration occupational activities']","['tmco', 'blor', 'fndg', 'ocac', 'resa', 'prog', 'gngm', 'idcn', 'topp', 'hlca', 'medd', 'inpr', 'ocdi', 'bhvr', 'orgf', 'socb', 'ftcn', 'acty', 'bpoc', 'cnce']"
958,PMC3502035,S72,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study intervention,"typically, these consultations lasted 10-15 minutes (about 60 minutes in total) in addition to the time taken for clinical profiling at baseline.","['C0439232', 'C1282918', 'C0332287', 'C1442488', 'C0039828', 'C0040223', 'C1883712', 'C0168634', 'C0439810', 'C1442447', 'C0205210', 'C0332232', 'C0009818', 'C0700321']","['Clinical', 'BaseLine dental cement', 'In addition to', 'Total', 'Time', 'Consultation', 'Minute (diminutive)', 'Small', 'Add - instruction imperative', '15 Minutes', 'Minute of time', 'Baseline', 'approximately', 'Theses']","['tmco', 'hlca', 'inpr', 'qnco', 'qlco', 'ftcn', 'bodm']"
959,PMC3502035,S73,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study intervention,"reflecting contemporary treatment options for the management of hypertension, different drug pathways were mandated (initial monotherapy with valsartan 160 mg or combined with hydrochlorothiazide or amlodipine, as single combined pills).","['C0020261', 'C0205265', 'C1279901', 'C0205195', 'C1704259', 'C0205171', 'C0376636', 'C1555582', 'C0683525', 'C1273870', 'C0994475', 'C1254351', 'C1705987', 'C0051696', 'C0991106', 'C0020538', 'C0087136', 'C1705685', 'C0001554', 'C1705242', 'C0013227', 'C1963138', 'C3273539']","['Pathway (interactions)', 'treatment options', 'Hypertension, CTCAE', 'Singular', 'Amlodipine', 'Biochemical Pathway', 'Unmarried', 'Firstly', 'Hydrochlorothiazide', 'valsartan 160 MG', 'Pills', 'Pharmacologic Substance', 'Initially', 'Management Occupations', 'Initial (abbreviation)', 'Initial Usage', 'Disease Management', 'Hypertensive disease', 'Pharmaceutical Preparations', 'Different', 'Management procedure', 'Combined', 'Administration occupational activities']","['tmco', 'clnd', 'ocac', 'fndg', 'bodm', 'hlca', 'idcn', 'ocdi', 'orch', 'qlco', 'phsu', 'qnco', 'dsyn', 'ftcn', ' phsu', 'moft', 'cnce']"
960,PMC3502035,S74,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study intervention,scheduling of visits and up-titration of drug treatment was guided by the same computer program developed by baker idi to facilitate the initial risk profiling and management.,"['C0238749', 'C1555582', 'C0205265', 'C0035647', 'C1279901', 'C0445247', 'C1512346', 'C1515981', 'C1705685', 'C3273539', 'C1273870', 'C0150270', 'C0376636', 'C0001554', 'C3469597', 'C0037585', 'C0162621', 'C3476796', 'C0545082', 'C4552904']","['Same', 'Firstly', 'baker', 'Patient Visit', 'Initially', 'Management Occupations', 'IDI', 'Computer software', 'And', 'Subject Risk', 'Initial (abbreviation)', 'Initial Usage', 'Management procedure', 'Medication Management', 'Disease Management', 'Administration of medication', 'Visit', 'Titration Method', 'Risk', 'Administration occupational activities']","['tmco', 'ocac', 'prog', ' mnob', 'idcn', 'topp', 'hlca', 'inpr', 'ocdi', 'qlco', 'lbpr', 'bhvr', 'ftcn', 'cnce']"
961,PMC3502035,S75,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study intervention,a final clinic visit for clinical re-evaluation was scheduled at 26 weeks.,"['C0205088', 'C0220825', 'C0442592', 'C3853528', 'C0439230', 'C2826704', 'C0545082', 'C1261322', 'C0205210', 'C1546485', 'C0002424', 'C1512346']","['Clinical', 'Patient Visit', 'End-stage', 'Visit Name', 'Clinic', 'Visit', 'Evaluation procedure', 'week', 'Ambulatory Care Facilities', 'Evaluation', 'Final', 'Diagnosis Type - Final']","['tmco', ' hcro', 'idcn', 'hlca', 'inpr', 'qlco', 'bhvr', 'mnob']"
962,PMC3502035,S77,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study endpoints,the primary endpoint was the percentage of participants who achieved their individualised blood pressure target according to national guidelines6 during 26 weeks of follow-up (using last recorded blood pressure for intention to treat analyses).,"['C1517741', 'C2986546', 'C3272598', 'C0332283', 'C0679646', 'C4281991', 'C1283828', 'C0162425', 'C0005823', 'C1271104', 'C1549488', 'C2986535', 'C0439230', 'C1521840', 'C1272641', 'C3245503', 'C0439165', 'C1561533']","['National citizen', 'Blood Pressure', 'Followed by', 'Participant', 'Percent (qualifier value)', 'Intention - mental process', 'Last', 'Primary Endpoint', 'WHO Temperature/Humidity Storage Condition', 'Target', 'week', 'Follow', 'Money or percentage indicator - Percentage', 'Systemic arterial pressure', 'Blood pressure finding', 'Target Lesion Identification', 'Amount type - Percentage', 'intent']","['tmco', 'fndg', 'idcn', 'irda', 'qlco', 'qnco', 'orgf', 'ftcn', 'diap', 'popg', 'menp']"
963,PMC3502035,S78,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study endpoints,"these stringent blood pressure targets, which have been rarely examined for feasibility in a controlled trial, are ≤125/75 mm hg if a patient has proteinuria, ≤130/80 mm hg if end organ damage is present (including any form of cardiovascular disease, diabetes, or microalbuminuria), and the classic target of ≤140/90 mm hg for those without evidence of the other two criteria.","['C2986546', 'C4255237', 'C0522498', 'C0449450', 'C0332288', 'C0439658', 'C0011849', 'C0521125', 'C0243161', 'C1521840', 'C1962972', 'C1272641', 'C3539897', 'C0730345', 'C4321252', 'C0936233', 'C0005823', 'C0376315', 'C0030705', 'C0205448', 'C3887511', 'C0033687', 'C0348078', 'C0011847', 'C4554346', 'C1271104', 'C4321286', 'C1522492', 'C1552551', 'C0332257', 'C0439858', 'C0039828', 'C0150312', 'C3272371', 'C1551058', 'C0007222', 'C0743496', 'C1515981', 'C0009933']","['Proteinuria, CTCAE 3.0', 'Evidence', 'Diabetes', 'Cardiovascular Diseases', 'And', 'Classic Histology', 'Diabetes Mellitus', 'Including (qualifier)', 'Systemic arterial pressure', 'Theses', 'Blood Pressure', 'Formation', 'Presentation', 'classical example', 'Controlled Clinical Trials as Topic', 'Target', 'Any Data Type', 'Rare', 'are unit of measure', 'classic behavior', 'Two', 'WWOX wt Allele', 'Any', 'Proteinuria', 'Patients', 'Form:Finding:Point in time:{Setting}:Document:{Role}', 'Blood pressure finding', 'Manufactured form', 'Preposition For', 'Microalbuminuria', 'Proteinuria, CTCAE 5.0', 'Qualitative form', 'end organ damage', 'Have', 'criteria', 'Controlled Clinical Trial [Publication Type]', 'Target Lesion Identification', 'Present', 'Without']","['fndg', 'gngm', 'idcn', 'clas', 'inpr', 'qlco', 'qnco', 'dsyn', 'orgf', 'resa', 'podg', 'ftcn', 'mnob', 'diap', 'clna']"
964,PMC3502035,S79,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study endpoints,key secondary endpoints included change in mean sitting systolic and diastolic blood pressure and absolute risk for cardiovascular disease within five years based on the framingham risk score5 (where applicable).,"['C0027627', 'C0443172', 'C1519101', 'C1705241', 'C3166866', 'C0035647', 'C0007222', 'C0175668', 'C2349179', 'C1272460', 'C0205436', 'C0039155', 'C0439234', 'C0205451', 'C1515981', 'C0332257', 'C0392747', 'C4319952', 'C1706839', 'C4552904']","['year', 'Neoplasm Metastasis', 'Changing', 'Applicable', 'Secondary to', 'second (number)', 'Subject Risk', 'And', 'Cardiovascular Diseases', 'Framingham', 'Changed status', 'Change -- procedure', 'Including (qualifier)', 'Delta (difference)', 'Risk Estimate', 'Not Applicable', 'Five', 'End Point', 'Systole', 'Risk']","['tmco', 'idcn', 'topp', 'inpr', 'qnco', 'qlco', 'dsyn', 'ftcn', 'neop', 'cnce']"
965,PMC3502035,S80,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study endpoints,"secondary endpoints also included the type and rate of adverse events potentially attributable to antihypertensive treatment, and serious adverse events including all cause mortality and fatal and non-fatal cardiovascular events—for example, acute myocardial infarction, stroke, and heart failure.","['C4554158', 'C1521828', 'C3538994', 'C0018802', 'C1705413', 'C0871208', 'C1524003', 'C0205404', 'C1533734', 'C0332307', 'C0087111', 'C1705232', 'C3887704', 'C1705169', 'C1707959', 'C0039798', 'C0205436', 'C0015127', 'C3887460', 'C0596130', 'C0175668', 'C0026566', 'C0003364', 'C2349179', 'C0332257', 'C0026565', 'C0444868', 'C0007226', 'C0027627', 'C1522326', 'C1518422', 'C0018801', 'C3541950', 'C0155626', 'C1302234', 'C1515981', 'C4554100', 'C0877248', 'C0038454']","['Etiology aspects', 'Cerebrovascular accident', 'Acute myocardial infarction', 'Rate', 'And', 'Including (qualifier)', 'Science of Etiology', 'Serious', 'Rating (action)', 'Fatal', 'Congestive heart failure', 'Acute Myocardial Infarction by ECG Finding', 'Cardiovascular', 'Antihypertensive Agents', 'Type - attribute', 'Stroke, CTCAE', 'second (number)', 'Treatment Epoch', 'Biomaterial Treatment', 'Heart failure', 'Administration procedure', 'Mortality Vital Statistics', 'Heart Failure, CTCAE', 'Death Related to Adverse Event', 'Neoplasm Metastasis', 'All', 'Negation', 'Aspects of mortality statistics', 'treatment - ActInformationManagementReason', 'Example', 'Treating', 'Secondary to', 'attribution', 'therapeutic aspects', 'Adverse Event Domain', 'End Point', 'Cardiovascular system', 'Adverse event', 'Therapeutic procedure']","['blor', 'cnce', 'fndg', 'resa', 'idcn', 'topp', 'bdsy', 'hlca', 'inpr', 'qnco', 'qlco', 'dsyn', 'ftcn', 'neop', 'acty', 'menp', 'patf', 'phsu']"
966,PMC3502035,S81,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study endpoints,"several other secondary endpoints will be the subject of future or expanded reports, including changes in quality of life, depression, self care behaviours, and evidence of end organ damage (including electrocardiographic evidence of left ventricular hypertrophy and newly detected proteinuria).","['C2697811', 'C2349001', 'C0684224', 'C0332306', 'C0443302', 'C3484363', 'C1962972', 'C0392747', 'C0700287', 'C0442726', 'C0443172', 'C1706203', 'C0011570', 'C0149721', 'C0205436', 'C0376558', 'C0344315', 'C3887511', 'C0036592', 'C4084909', 'C0033687', 'C0011581', 'C0016884', 'C0750546', 'C0175668', 'C4554346', 'C3889645', 'C2349179', 'C4085311', 'C0681850', 'C0332257', 'C0677505', 'C0205229', 'C0027627', 'C4553827', 'C0439064', 'C1511790', 'C0743496', 'C1515981', 'C4049644']","['Depression Subordinate Domain', 'Proteinuria, CTCAE 3.0', 'with quality', 'Evidence', 'Reporting', 'And', 'Detected (finding)', 'Detection', 'Including (qualifier)', 'Future', 'Left ventricular hypertrophy:Finding:Point in time:^Patient:Ordinal', 'second (number)', 'Depression Scale (BASC-2)', 'Subject - topic', 'Changed status', 'Human Study Subject', 'Report (document)', 'Depression - recess', 'Depressive disorder', 'Investigative Subject', 'Depressed mood', 'Neoplasm Metastasis', 'Changing', 'Study Subject', 'expanding', 'Proteinuria', 'Left Ventricular Hypertrophy', 'Numerous', 'Mental Depression', 'Life', 'Proteinuria, CTCAE 5.0', 'Behaviors and observations relating to behavior', 'end organ damage', 'Secondary to', 'Several', 'Depression Visual Analogue Scale', 'Clinical Trial Final Report', 'End Point', 'Self-care interventions', 'newly']","['tmco', 'fndg', 'hlca', 'idcn', 'dora', 'topp', 'inpr', 'qlco', 'qnco', 'mobd', 'grup', 'dsyn', 'spco', 'ftcn', 'neop', 'popg', 'clna']"
967,PMC3502035,S83,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study power,we largely met the study targets for overall recruitment and number of participants entering the run-in phase.,"['C0282416', 'C1561607', 'C2603343', 'C0237753', 'C0679646', 'C0205390', 'C1704688', 'C0449788', 'C0521125', 'C1710475', 'C1515981', 'C0600140', 'C2949735', 'C0035953', 'C4321252']","['Overall', 'Participant', 'Does run (finding)', 'Recruitment', 'Count of entities', 'And', 'Run action', 'WWOX wt Allele', 'Running (physical activity)', 'Study', 'Trial Phase', 'Overall Publication Type', 'Preposition For', 'Phase', 'Numbers']","['tmco', 'fndg', 'gngm', 'idcn', 'clas', 'dora', 'inpr', 'qlco', 'qnco', 'resa', 'ftcn', 'popg', 'acty']"
968,PMC3502035,S84,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Study power,"based on the combination of a strong potential for interventional contamination, balanced against the need to establish clinically significant differences between the two groups, the study was initially powered to detect a minimum absolute difference of 7% between the groups for the primary endpoint.13","['C0521124', 'C0205265', 'C0259846', 'C1565156', 'C1881659', 'C0521125', 'C0750502', 'C0442726', 'C4321252', 'C0205415', 'C0205103', 'C0441833', 'C0686904', 'C1552614', 'C0205448', 'C0443211', 'C3274035', 'C0032863', 'C1552839', 'C1421478', 'C0043194', 'C2826545', 'C2986535', 'C0442821', 'C2349974', 'C3811910', 'C2603343', 'C0027552', 'C1524031', 'C0687744', 'C3891454', 'C1947911', 'C3245505', 'C1549031', 'C1546944', 'C0184661', 'C0237881']","['ActRelationshipSubset - minimum', 'Detected (finding)', 'Study', 'Table Rules - groups', 'combination of objects', 'Patient need for (contextual qualifier)', 'Contamination', 'strong', 'Dosing Days to Detection', 'against', 'Wiskott-Aldrich Syndrome', 'Groups', 'Needs', 'Two', 'Initially', 'Social group', 'Balanced - adjective', 'Minimum', 'WWOX wt Allele', 'Primary Endpoint', 'Statistical Significance', 'WAS gene', 'Absolute Change', 'Minimum Value Derivation Technique', 'combination - answer to question', 'Event Seriousness - Significant', 'Preposition For', 'Intermediate', 'adulteration', 'Medical Device Contamination during Use', 'Significant', 'Power (Psychology)', 'WAS protein, human', 'potential', 'Interventional procedure', 'Established', 'Interventional Study']","['tmco', 'fndg', 'gngm', 'idcn', 'topp', 'hcpp', 'irda', 'inpr', 'qlco', 'qnco', 'bacs', 'dsyn', 'spco', 'resa', 'ftcn', 'phob', 'popg', ' aapp']"
969,PMC3502035,S85,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Study power,"as proportionately more patients achieved blood pressure control during the study run-in and thus the number of randomised participants was reduced, we recalculated that a total randomised cohort of more than 1500 participants would still provide sufficient study power to detect a minimum 8% difference between groups with more than 85% study power (two sided α level of 0.05 and adjusting for 2:1 randomisation for study intervention versus usual care).13","['C1705241', 'C3274648', 'C0237753', 'C4553389', 'C0009247', 'C1999230', 'C1565156', 'C0521125', 'C0392756', 'C2946261', 'C1272641', 'C1547707', 'C0441889', 'C0442726', 'C1550141', 'C4321252', 'C2587213', 'C0205103', 'C0441833', 'C1947933', 'C1552614', 'C0449788', 'C0005823', 'C0030705', 'C0439810', 'C0205448', 'C0205172', 'C0032863', 'C0332287', 'C0679646', 'C1552839', 'C1421478', 'C0043194', 'C1271104', 'C3854080', 'C0347984', 'C2826545', 'C0599755', 'C1705242', 'C0886296', 'C2603343', 'C1524031', 'C0205410', 'C1882979', 'C3274438', 'C0687744', 'C1515981', 'C3891454', 'C0243148', 'C0184661', 'C3538928']","['Providing (action)', 'In addition to', 'control substance', 'ActRelationshipSubset - minimum', 'And', 'Power', 'Detected (finding)', 'Nursing interventions', 'Study', 'Systemic arterial pressure', 'Study Control', 'Floor - story of building', 'Table Rules - groups', 'Blood Pressure', 'Participant', 'Count of entities', 'Dosing Days to Detection', 'Wiskott-Aldrich Syndrome', 'Groups', 'Cohort Studies', 'Two', 'Reduced', 'Social group', 'Total', 'control aspects', 'More', 'WWOX wt Allele', 'Minimum', 'WAS gene', 'Control function', 'Patients', 'Minimum Value Derivation Technique', 'During', 'Level', 'Blood pressure finding', 'Preposition For', 'Intermediate', 'Levels (qualifier value)', 'Numbers', 'Different', 'Scientific Control', 'Run-in Period', 'Power (Psychology)', 'WAS protein, human', 'care activity', 'True Control Status', 'Cohort', 'Usual', 'Delta (difference)', 'Interventional procedure', 'Sufficient']","['topp', 'qnco', 'podg', ' aapp', 'fndg', 'idcn', 'hlca', 'inpr', 'qlco', 'bacs', 'sbst', 'hcpp', 'resa', 'ftcn', 'popg', 'tmco', 'spco', 'cnce', 'acty', 'gngm', 'geoa', 'inch', 'dsyn', 'orgf', ' phsu']"
970,PMC3502035,S87,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,the study statistician (on behalf of the clinical safety and efficacy committee) independently analysed the data according to a prospectively designed statistical analysis plan.,"['C2603343', 'C3889277', 'C3245479', 'C0036043', 'C0334957', 'C2699414', 'C1515981', 'C1707887', 'C0205210', 'C3714741', 'C1511726', 'C1705187', 'C1280519']","['statistician', 'Clinical', 'Data call receiving device', 'Effectiveness', 'Data (eukaryote)', 'And', 'Efficacy Study', 'Committee', 'Statistical Analysis Plan', 'Safety', 'Safety Study', 'Study', 'Data']","['prog', 'medd', 'idcn', 'hcpp', 'inpr', 'qlco', 'grup', 'euka', 'resa']"
971,PMC3502035,S88,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,"if blood pressure values were missing at 26 weeks, we carried forward the last recorded blood pressure measurement after randomisation for primary endpoint analysis.","['C1517741', 'C0439780', 'C0005823', 'C1271104', 'C0439230', 'C2986535', 'C1272641', 'C1524024', 'C0042295', 'C0242485', 'C0936012']","['Blood Pressure', 'Last', 'Analysis', 'Primary Endpoint', 'Measurement', 'analysis aspect', 'week', 'Forward', 'Systemic arterial pressure', 'Blood pressure finding', 'Values']","['tmco', 'fndg', 'resa', 'irda', 'qlco', 'spco', 'orgf', 'ftcn']"
972,PMC3502035,S89,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,baseline and outcome data were analysed using spss for windows version 19.0.,"['C0333052', 'C1442488', 'C3245479', 'C0168634', 'C1515981', 'C3714741', 'C1511726', 'C1274040']","['Data call receiving device', 'BaseLine dental cement', 'Version', 'Data (eukaryote)', 'And', 'Baseline', 'Result', 'Data']","['medd', 'idcn', 'inpr', 'qnco', 'euka', 'ftcn', 'bodm']"
973,PMC3502035,S90,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,continuous data are presented as means (standard deviations) or medians (interquartile ranges).,"['C0549183', 'C0549178', 'C3245479', 'C1442989', 'C3714741', 'C1511726', 'C2828392', 'C1704970']","['Data call receiving device', 'Continuous', 'Data (eukaryote)', 'Midline (qualifier value)', 'Standard (qualifier)', 'Standard (document)', 'Means', 'Data']","['medd', 'idcn', 'inpr', 'qlco', 'spco', 'euka', 'cnce']"
974,PMC3502035,S91,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,categorical data are presented as percentages.,['C4684582'],['Categorical Data'],['inpr']
975,PMC3502035,S92,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,"we carried out efficacy analyses on an intention to treat population, consisting of all participants randomised to the intervention arm or to the usual care arm and who had at least one recorded blood pressure measurement after randomisation.","['C0205447', 'C0446516', 'C1272641', 'C0242485', 'C1257890', 'C0032659', 'C3272598', 'C1947933', 'C0005823', 'C3715044', 'C1707887', 'C1280519', 'C0679646', 'C4553528', 'C0162425', 'C1271104', 'C1283828', 'C0444868', 'C0886296', 'C1515981', 'C0184661', 'C3538928']","['And', 'Nursing interventions', 'Measurement', 'Systemic arterial pressure', 'geographic population', 'intent', 'Blood Pressure', 'Effectiveness', 'Participant', 'Intention - mental process', 'Sequence Arm', 'Upper arm', 'Population Group', 'All', 'AKR1A1 wt Allele', 'Blood pressure finding', 'One', 'care activity', 'WHO Temperature/Humidity Storage Condition', 'Efficacy Study', 'Usual', 'Interventional procedure']","['blor', 'fndg', 'gngm', 'idcn', 'topp', 'hlca', 'inpr', 'qlco', 'qnco', 'orgf', 'resa', 'ftcn', 'popg', 'menp', 'acty']"
976,PMC3502035,S93,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,analyses were based on the treatment group to which the participant was randomised.,"['C1257890', 'C0087111', 'C0441833', 'C1522326', 'C1519504', 'C0679646', 'C3887704', 'C1705169', 'C0039798', 'C3538994', 'C1705429', 'C0687744', 'C2698741', 'C4554048', 'C1705428', 'C1533734']","['Groups', 'Population Group', 'Group Object', 'Study Participant', 'Participant', 'treatment - ActInformationManagementReason', 'Social group', 'Treating', 'Treatment Epoch', 'therapeutic aspects', 'Participant Object', 'Stage Grouping', 'Biomaterial Treatment', 'Administration procedure', 'User Group', 'Therapeutic procedure']","['clas', 'topp', 'idcn', 'hlca', 'resa', 'ftcn', 'popg', 'cnce']"
977,PMC3502035,S94,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,we compared the primary endpoint measure (blood pressure control at week 26) between the study groups using a log binomial generalised linear model with stratification status at randomisation as a covariate.,"['C3274659', 'C3274648', 'C4553389', 'C0205246', 'C0439230', 'C0205132', 'C2986775', 'C1272641', 'C0242485', 'C1550141', 'C2587213', 'C0205103', 'C0441833', 'C0079809', 'C0005823', 'C3714583', 'C1708728', 'C0332287', 'C1552839', 'C1271104', 'C2986535', 'C1514983', 'C2603343', 'C3853906', 'C1882979', 'C0449438', 'C3161035', 'C0687744', 'C0243148']","['Logarithm', 'In addition to', 'control substance', 'Status', 'Study', 'Measures', 'Linear', 'Systemic arterial pressure', 'Measurement', 'Study Control', 'Table Rules - groups', 'Blood Pressure', 'Model Number', 'Digital Model Attachment', 'Generalized', 'Model - style/design', 'Groups', 'Event Log', 'Model', 'Social group', 'control aspects', 'Primary Endpoint', 'Control function', 'Blood pressure finding', 'Stratification', 'Intermediate', 'Scientific Control', 'True Control Status', 'week']","['tmco', 'fndg', 'resa', 'idcn', 'irda', 'inpr', 'qnco', 'qlco', 'sbst', 'orgf', 'spco', 'ftcn', 'popg', 'cnce']"
978,PMC3502035,S95,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,"stratification status was fit as a categorical variable with the three blood pressure target groups (≤125/75 mm hg, ≤130/80 mm hg, and ≤140/90 mm hg) based on the participant’s clinical profile.","['C2986546', 'C2003903', 'C1705938', 'C0441833', 'C0205449', 'C1552839', 'C1527178', 'C0005823', 'C1271104', 'C0687744', 'C0449438', 'C1515981', 'C4553760', 'C1521840', 'C0439828', 'C1272641', 'C0205210', 'C1979963', 'C1514983']","['Clinical', 'Blood Pressure', 'Base - General Qualifier', 'Basis - conceptual entity', 'Groups', 'Profile (lab procedure)', 'Stratification', 'Social group', 'Variable (uniformity)', 'Target', 'Status', 'And', 'Three', 'Profiling (action)', 'Study Variable', 'Systemic arterial pressure', 'Blood pressure finding', 'Target Lesion Identification', 'Table Rules - groups']","['fndg', 'idcn', 'inpr', 'qlco', 'qnco', 'lbpr', 'orgf', 'resa', 'ftcn', 'diap', 'popg']"
979,PMC3502035,S96,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,"change in systolic and diastolic blood pressure from baseline to 26 weeks were each analysed by analysis of covariance, with treatment group and stratification status as factors and mean baseline blood pressure as a covariate.","['C1705241', 'C0168634', 'C3538994', 'C0439230', 'C0392747', 'C1272641', 'C1533734', 'C0936012', 'C0443172', 'C1257890', 'C0087111', 'C0441833', 'C3887704', 'C1705169', 'C1457900', 'C0039798', 'C0005823', 'C0039155', 'C1705428', 'C2348143', 'C1519504', 'C1705429', 'C1271104', 'C4319952', 'C0444504', 'C1514983', 'C1305849', 'C1522326', 'C1442488', 'C0449438', 'C0687744', 'C1515981', 'C2347634', 'C1524024', 'C0428883']","['Group Object', 'Each (qualifier value)', 'Status', 'And', 'Systemic arterial pressure', 'Blood Pressure', 'Sample Mean', 'Population Mean', 'Treatment Epoch', 'Diastolic blood pressure measurement', 'analysis aspect', 'Changed status', 'Biomaterial Treatment', 'Baseline', 'Diastolic blood pressure', 'Administration procedure', 'User Group', 'Groups', 'Population Group', 'Changing', 'Social group', 'Statistical mean', 'Change -- procedure', 'Blood pressure finding', 'Stratification', 'BaseLine dental cement', 'treatment - ActInformationManagementReason', 'Treating', 'Analysis', 'Systole', 'therapeutic aspects', 'week', 'Stage Grouping', 'Delta (difference)', 'Therapeutic procedure']","['clna', 'tmco', 'fndg', 'bodm', 'idcn', 'topp', 'hlca', 'qnco', 'qlco', 'orgf', 'resa', 'ftcn', 'diap', 'popg', 'cnce']"
980,PMC3502035,S97,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,we also describe the proportion and rate of adverse events (per participant).,"['C1709707', 'C0679646', 'C1521828', 'C1515981', 'C1705413', 'C2698741', 'C0871208', 'C0877248', 'C4554048']","['Study Participant', 'Participant', 'Rate', 'And', 'Adverse Event Domain', 'Participant Object', 'Rating (action)', 'Adverse event', 'Proportion']","['idcn', 'clas', 'inpr', 'qnco', 'popg', 'patf', 'acty']"
981,PMC3551223,S157,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Supplementary Material,web appendix,"['C0282111', 'C0003617']","['Appendix', 'Internet']","['mnob', 'bpoc']"
982,PMC3551223,S41,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"this report covers the planned analysis of the first 24 weeks (including the primary endpoint) of an on-going 2-year double-blind placebo controlled parallel-group clinical trial (nct00810199, eudract no 2008-001847-20).","['C0684224', 'C1705764', 'C0441833', 'C0687744', 'C4255046', 'C0008976', 'C2911690', 'C4554418', 'C1524024', 'C1080058', 'C0525065', 'C3273238', 'C1696465', 'C1705765', 'C0936012', 'C0439230', 'C0456909', 'C1301732', 'C2986535', 'C0205173', 'C1705429', 'C2348042', 'C2826345', 'C0332257', 'C0700287', 'C0439234', 'C0032042', 'C1519504', 'C1706408', 'C1257890', 'C1279901', 'C0150108', 'C1096775', 'C1705428', 'C0205435', 'C4329800', 'C2587213']","['Firstly', 'This (eukaryote)', 'Reporting', 'First (number)', 'Blinded', 'placebo', 'Stage Grouping', 'Visually Impaired Persons', 'Regulatory Report', 'Doubling', 'Duplicate', 'Primary Endpoint', 'Clinical Trials', 'User Group', 'Placebos', 'Blindness', 'Group Object', 'Social group', 'Parallel Study', 'Planned', 'week', 'Disease Controlled', 'Control function', 'year', 'European Union Drug Regulating Authorities Clinical Trials Database', 'analysis aspect', 'Placebo Control', 'Parallel', 'Report (document)', 'Groups', 'Including (qualifier)', 'Population Group', 'Analysis', 'Clinical Trial [Publication Type]', 'Double Value Type', 'Report:Finding:Point in time:{Setting}:Document:{Role}', 'Parallel Lesion']","['inpr', 'clna', 'idcn', 'bodm', 'acty', 'topp', 'popg', 'ftcn', 'fndg', 'cnce', 'qlco', 'euka', 'podg', 'resa', 'tmco', 'hlca', 'irda', 'qnco']"
983,PMC3551223,S42,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"the treatment allocation of individual patients remained blinded for patients, site personnel and the data analysis/interpretation team, except for the separate subgroup technically preparing the data.","['C1511726', 'C0030705', 'C3887704', 'C1705169', 'C0871489', 'C1515021', 'C1515981', 'C0700103', 'C1079230', 'C4321252', 'C3714741', 'C0443299', 'C0332300', 'C1521827', 'C1527117', 'C0010992', 'C0027361', 'C3173575', 'C0039798', 'C1515974', 'C3538994', 'C0205145', 'C2825164', 'C0521125', 'C1706778', 'C3245479', 'C0237401', 'C0087111', 'C0150108', 'C0459471', 'C1522326', 'C1533734']","['Interpretation:Impression/interpretation of study:Point in time:^Patient:Nominal', 'except for', 'teams', 'Biomaterial Treatment', 'Anatomic Site', 'And', 'Data call receiving device', 'Patients', 'Site', 'Blinded', 'Persons', 'Preposition For', 'WWOX wt Allele', 'Therapeutic procedure', 'Personnel', 'Human Resources', 'Administration procedure', 'Separate', 'Treatment Epoch', 'Preparation', 'Subgroup', 'Allocation', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Individual', 'Data', 'Data Analysis', 'Interpretation Process', 'Treating', 'Subgroup A Nepoviruses', 'Data (eukaryote)', 'Study Site']","['clna', 'topp', 'medd', 'qlco', 'virs', 'hlca', 'inpr', 'idcn', 'gngm', 'clas', 'resa', 'ocac', 'popg', 'ftcn', 'blor', 'podg', 'grup', 'acty', 'cnce', 'spco', 'euka', 'qnco']"
984,PMC3551223,S43,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,the study was approved by the appropriate institutional review boards/ethics committees with written informed consent obtained from each patient before study participation.,"['C1301820', 'C0972401', 'C1517320', 'C0021430', 'C0030705', 'C1548787', 'C0085546', 'C1457900', 'C0282443', 'C0679823', 'C2603343', 'C1565156', 'C0205540', 'C1421478', 'C0043194', 'C0332287', 'C0332152', 'C1552617']","['Review [Publication Type]', 'WAS protein, human', 'Appropriate', 'Ethics Committees', 'Approved', 'WAS gene', 'Wiskott-Aldrich Syndrome', 'Patients', 'Study', 'Informed Consent', 'Act Class - review', 'From', 'Before', 'Boards (medical device)', 'participation', 'Each (qualifier value)', 'In addition to', 'Obtain']","['bacs', 'inpr', 'rnlw', 'idcn', 'gngm', 'prog', 'medd', 'ftcn', 'podg', 'qlco', 'tmco', 'resa', 'dsyn', ' aapp', 'qnco']"
985,PMC3551223,S44,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"the study was conducted in full accordance with international conference on harmonisation/good clinical practice and the principles, laws and regulations of the countries in which the research was conducted.","['C0242481', 'C1512888', 'C0023150', 'C0454664', 'C0220905', 'C0086047', 'C0443225', 'C1515981', 'C2986419', 'C2603343', 'C0220866', 'C0035168', 'C0728724', 'C0851285']","['full', 'Regulation', 'Legal system', 'Rules of conduct', 'And', 'Country', 'Research Activities', 'Study', 'International', 'regulatory', 'Good Clinical Practice', 'Conferences', 'research', 'aspects of laws']","['hcpp', 'inpr', 'rnlw', 'idcn', 'geoa', 'qlco', 'resa', 'gora']"
986,PMC3551223,S46,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"eligible patients had confirmed ra according to the 1987 american college of rheumatology (acr) criteria with active disease defined as disease activity score based on 28 joints–erythrocyte sedimentation rate (das28–esr) greater than 4.4 at baseline and 4.0 or more at screening, and had been receiving methotrexate for at least 12 weeks, with a stable dose of at least 15 mg/week for 6 weeks or longer before starting study treatment.","['C1292728', 'C0030705', 'C3853793', 'C4050231', 'C1515981', 'C0012634', 'C4321252', 'C0035452', 'C1548635', 'C1704788', 'C0439230', 'C0205177', 'C1442488', 'C0332287', 'C1514756', 'C1710477', 'C1547311', 'C3888249', 'C0205172', 'C2348164', 'C0178602', 'C0205360', 'C0557806', 'C0243161', 'C1710031', 'C0062074', 'C0521125', 'C1710032', 'C0220908', 'C0449820', 'C0596070', 'C1521826', 'C0025677', 'C0168634', 'C3539897', 'C1412134', 'C1704243', 'C1698960', 'C0220909', 'C1176468', 'C1415458', 'C1515941']","['Active License', 'Baseline', 'research subject screening', 'active (HL7 RoleLink)', 'And', 'Patients', 'Preposition For', 'Have', 'Receive', 'WWOX wt Allele', 'Disease activity', 'HADH gene', 'Patient Condition Code - Stable', 'Aspects of disease screening', 'Screening procedure', 'Stable status', 'college', 'criteria', 'Trial Screening', 'Dosage', 'Americas Ethnicity', 'Methotrexate', 'Active', 'American College of Radiology', 'BaseLine dental cement', 'Rheumatology specialty', 'Erythrocyte sedimentation rate measurement', 'ACR gene', 'week', 'Screening', 'Score', 'In addition to', 'Disease Screening', 'Eligible', 'More', 'Screening Study', 'Definition', 'HAC protocol', 'Disease', 'ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated', 'Greater', 'Protocol Agent']","['clna', 'topp', 'mnob', 'qlco', ' phsu', 'hlca', 'diap', 'bmod', 'inpr', 'pros', 'idcn', 'lbpr', 'gngm', 'resa', 'bodm', 'popg', 'ftcn', 'orch', 'tmco', 'podg', 'dsyn', 'qnco']"
987,PMC3551223,S47,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"for inclusion, patients were also required to have bone damage with radiographic evidence of at least one joint with definite erosion attributable to ra as determined by a central reader.","['C0030705', 'C3887511', 'C3887524', 'C0010957', 'C0205099', 'C0444708', 'C0333307', 'C0205447', 'C1514743', 'C0596130', 'C0392905', 'C0262950', 'C1706461', 'C1704787', 'C1959609', 'C1706309', 'C0022417', 'C1883709', 'C1880549', 'C1512693', 'C0007637', 'C0439544']","['Reader Device Component', 'Reader of medical images', 'Superficial ulcer', 'Patients', 'Joints', 'Definite', 'Skin Erosion', 'Skeletal bone', 'Definitely Related to Intervention', 'Central', 'Articular system', 'Inclusion Bodies', 'Evidence', 'Tissue damage', 'Inclusion', 'One', 'attribution', 'Damage', 'Joint Device', 'Erosion of Medical Device Material', 'Erosion lesion', 'radiographic']","['bsoj', 'bpoc', 'idcn', 'prog', 'inpo', 'ftcn', 'mnob', 'spco', 'podg', 'qlco', 'patf', 'fndg', 'bdsy', 'celc', 'acab', 'menp', 'npop', 'qnco', 'dsyn']"
988,PMC3551223,S48,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"major exclusion criteria included severe comorbidities, any previous use of biological agents as well as any conventional disease-modifying antirheumatic drug treatment other than methotrexate during the month (3 months for leflunomide) preceding the baseline visit (see supplementary data, available online only, for full inclusion and exclusion criteria).","['C1511726', 'C0063041', 'C0003191', 'C0439231', 'C0012634', 'C0470187', 'C3714741', 'C4050466', 'C0680251', 'C4050465', 'C3272371', 'C2826704', 'C3469597', 'C0443225', 'C1442488', 'C0205082', 'C0439858', 'C3146287', 'C0009488', 'C1552551', 'C0205164', 'C0150270', 'C0005515', 'C0545082', 'C0205156', 'C0025677', 'C0168634', 'C3245479', 'C0205171', 'C1512346', 'C1442461', 'C0332177', 'C4318856', 'C1552607', 'C0457083', 'C0205170', 'C0680252', 'C4283957', 'C0042153']","['Baseline', 'Major', 'Borg Category-Ratio 10 Perceived Exertion Score 5', 'Visit', 'Data call receiving device', 'Exclusion Criteria', 'month', 'Act Relationship Subset - previous', 'Well', 'Usage', 'Any Data Type', 'Visit Name', 'Severe (severity modifier)', 'inclusion and exclusion', 'Biological Factors', 'Methotrexate', 'classical example', 'Any', 'BaseLine dental cement', 'full', 'availability of', 'Patient Visit', 'Singular', 'Good', 'Major <insect>', 'Comorbidity', 'Monthly (qualifier value)', 'Data', 'Administration of medication', 'Medication Management', '3 Months', 'Microplate Well', 'Antirheumatic Agents', 'leflunomide', 'utilization qualifier', 'Severe Extremity Pain', 'Previous', 'Disease', 'Data (eukaryote)']","['bacs', 'inpr', 'idcn', 'qnco', 'topp', 'medd', 'ftcn', 'fndg', 'spco', 'orch', 'qlco', 'tmco', 'euka', 'bhvr', ' phsu', 'hlca', 'mnob', 'bodm', 'phsu', 'dsyn']"
989,PMC3551223,S50,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study treatment,"patients were randomly assigned either to the add-on or the switch strategy group (see supplementary data, available online only, for study design schematic).","['C1511726', 'C2983265', 'C0679199', 'C1519504', 'C0030705', 'C3245479', 'C0205171', 'C0441833', 'C2986888', 'C0687744', 'C1257890', 'C1705429', 'C3844638', 'C0035171', 'C0470187', 'C1705428', 'C1707719', 'C3714741', 'C1883712']","['Stage Grouping', 'strategy', 'Groups', 'availability of', 'Research Design', 'Data call receiving device', 'User Group', 'Patients', 'Add - instruction imperative', 'Population Group', 'Singular', 'Switch Device', 'Data (eukaryote)', 'Data', 'Group Object', 'Social group', 'CDISC SEND Study Design Terminology', 'Nonclinical Study Design', 'Either']","['inpr', 'idcn', 'medd', 'popg', 'ftcn', 'fndg', 'cnce', 'podg', 'euka', 'mnob', 'resa', 'menp', 'qnco']"
990,PMC3551223,S51,['8b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0]",Study treatment,randomisation was stratified by study site and baseline das28–esr (≤ or >5.5) using a minimisation algorithm.,"['C0168634', 'C2347790', 'C1553907', 'C1515981', 'C0002045', 'C1442488', 'C2825164']","['BaseLine dental cement', 'Baseline', 'Clinical Study Site', 'algorithm', 'And', 'Observation Method - algorithm', 'Study Site']","['inpr', 'bodm', 'idcn', 'ftcn', 'spco', 'hcro', 'qnco']"
991,PMC3551223,S52,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study treatment,all patients received open-label tocilizumab 8 mg/kg intravenously every 4 weeks.,"['C0175566', 'C0030705', 'C2827499', 'C1275555', 'C0444868', 'C4551445', 'C0439272', 'C1609165', 'C4522130', 'C0181496']","['Labels (device)', 'Open', 'Human Cells, Tissues, and Cellular and Tissue-Based Products Labeling', 'Every Four Weeks', 'All', 'Patients', 'Labeling Activity', 'mg/kg', 'tocilizumab', 'Label (document)']","['inpr', 'acty', 'mnob', 'spco', 'podg', 'imft', 'tmco', 'resa', ' phsu', ' aapp', 'qnco']"
992,PMC3551223,S53,"['11b', '5']","[0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study treatment,"treatment with methotrexate/placebo was double-blind: all patients received identical capsules of either placebo (switch strategy arm) or methotrexate 2.5 mg (add-on strategy arm), with the number of capsules at study entry being consistent with prestudy dosage.","['C3715044', 'C1705764', 'C0030705', 'C0205280', 'C0006935', 'C1705169', 'C3887704', 'C2986497', 'C0332290', 'C0525065', 'C0237753', 'C1696465', 'C1705765', 'C0456909', 'C2603343', 'C1883712', 'C1123321', 'C0039798', 'C3538994', 'C0679199', 'C0178602', 'C0205173', 'C3844638', 'C0449788', 'C1707719', 'C0032042', 'C0025677', 'C1706408', 'C1705654', 'C0446516', 'C0087111', 'C4553528', 'C0150108', 'C1522326', 'C1533734', 'C0444868']","['identical', 'Upper arm', 'Biomaterial Treatment', 'Patients', 'Blinded', 'Methotrexate 2.5 MG', 'placebo', 'Therapeutic procedure', 'Visually Impaired Persons', 'Either', 'Entry (data)', 'Doubling', 'Duplicate', 'Placebos', 'Blindness', 'Administration procedure', 'Cumulative Dose', 'Dosage', 'Methotrexate', 'strategy', 'Treatment Epoch', 'All', 'Numbers', 'Study', 'capsule (pharmacologic)', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Placebo Control', 'Consistent with', 'Count of entities', 'AKR1A1 wt Allele', 'Treating', 'Switch Device', 'Sequence Arm', 'Double Value Type', 'Add - instruction imperative']","['inpr', 'idcn', 'qnco', 'gngm', 'acty', 'topp', 'ftcn', 'blor', 'cnce', 'orch', 'podg', 'fndg', 'resa', 'qlco', ' phsu', 'menp', 'mnob', 'hlca', 'clnd', 'bodm']"
993,PMC3551223,S54,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study treatment,"tocilizumab and/or disease-modifying antirheumatic drug treatment was reduced or temporarily interrupted in patients with alanine aminotransferase or aspartate transaminase values greater than one to three times the upper limit of normal (uln), and was discontinued for persistent increases greater than three times uln.","['C0003191', 'C1444662', 'C0004002', 'C0030705', 'C1515981', 'C0012634', 'C4321252', 'C1565156', 'C1415274', 'C0205217', 'C3469597', 'C0205447', 'C1706528', 'C0043194', 'C1609165', 'C0150270', 'C0205449', 'C0042295', 'C3887708', 'C0332996', 'C1519815', 'C0001899', 'C0242192', 'C0521125', 'C1704243', 'C0040223', 'C1632851', 'C1421478', 'C0205322', 'C0442805']","['Discontinued', 'Increased', 'Alanine Transaminase', 'And', 'Persistent', 'Patients', 'Time', 'Preposition For', 'WWOX wt Allele', 'Times', 'Alanine Aminotransferase 1, human', 'Persistent embryonic structure', 'WAS protein, human', 'Upper Limit of Normal', 'WAS gene', 'GPT gene', 'Increase', 'One', 'Administration of medication', 'Medication Management', 'And/Or', 'Antirheumatic Agents', 'Three', 'Wiskott-Aldrich Syndrome', 'Values', 'Aspartate Transaminase', 'Disease', 'Greater', 'tocilizumab', 'SGOT - Glutamate oxaloacetate transaminase']","['bacs', 'idcn', 'gngm', 'enzy', 'topp', 'ftcn', 'fndg', 'cnce', 'tmco', 'imft', 'podg', 'qlco', 'cgab', ' phsu', 'hlca', ' aapp', 'qnco', 'phsu', 'dsyn']"
994,PMC3551223,S56,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Concomitant RA treatments,oral corticosteroids (≤10 mg/day prednisone or equivalent) and non-steroidal anti-inflammatory drugs were permitted as long as doses had been stable for at least 25 of 28 days before the start of study treatment.,"['C0032952', 'C0333348', 'C1515981', 'C0439659', 'C3687832', 'C0205166', 'C0001617', 'C1518422', 'C3540727', 'C1706317', 'C3540726', 'C3539185', 'C1547311', 'C0178602', 'C0205360', 'C3540725', 'C0332173', 'C0439228', 'C0013227', 'C0205163', 'C0442027', 'C0439185', 'C1521826']","['Equivalent Weight', 'day', 'And', 'Equal', 'Drugs - dental services', 'Corticosteroid ophthalmologic and otologic preparations', 'Patient Condition Code - Stable', 'Long', 'Prednisone', 'Stable status', 'Corticosteroid otologicals', 'Dosage', 'Long Variable', 'Negation', 'Adrenal Cortex Hormones', 'Oral', 'Corticosteroid nasal preparations for topical use', 'Daily', 'Beginning', 'inflammatory', 'Pharmaceutical Preparations', 'Protocol Agent', 'Corticosteroids, topical for treatment of hemorrhoids and anal fissures']","[' orch', 'inpr', 'idcn', 'topp', 'ftcn', 'spco', 'orch', 'tmco', 'horm', 'qlco', ' phsu', 'qnco', 'phsu']"
995,PMC3551223,S57,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Concomitant RA treatments,"alterations in the non-steroidal anti-inflammatory drug dose were not recommended during the study, particularly during the first 24 weeks.","['C0678766', 'C0034866', 'C0439230', 'C1279901', 'C2603343', 'C0347984', 'C0205435', 'C1518422', 'C3536840']","['Recommendation', 'Firstly', 'week', 'First (number)', 'Study', 'Nonsteroidal Anti-inflammatory Drug [EPC]', 'drug dose', 'Negation', 'During']","['idcn', 'ftcn', 'tmco', 'qlco', 'resa', 'qnco', 'phsu']"
996,PMC3551223,S58,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Concomitant RA treatments,the corticosteroid dose could not be changed during the first 24 weeks of the study.,"['C0178602', 'C0439230', 'C1518422', 'C1279901', 'C3536709', 'C2603343', 'C0205435', 'C0001617']","['Adrenal Cortex Hormones', 'Negation', 'Firstly', 'week', 'First (number)', 'Study', 'Dosage', 'Corticosteroid [EPC]']","[' orch', 'ftcn', 'qlco', 'tmco', 'horm', 'resa', ' phsu', 'qnco', 'phsu']"
997,PMC3551223,S60,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Collected patient data and assessments,data collected at baseline included demographics and disease characteristics such as ra disease duration.,"['C1511726', 'C1521970', 'C0168634', 'C3245479', 'C0872146', 'C1515981', 'C0012634', 'C1442488', 'C3714741', 'C1704791', 'C0011298']","['BaseLine dental cement', 'Baseline', 'And', 'Data call receiving device', 'Demographics Domain', 'disease length', 'Disease', 'Characteristics', 'Data (eukaryote)', 'Data', 'Demography']","['idcn', 'qnco', 'ocdi', 'medd', 'qlco', 'euka', 'tmco', 'dsyn', 'bodm']"
998,PMC3551223,S61,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Collected patient data and assessments,"at baseline and every 4 weeks thereafter the following parameters were assessed: tender joint count, swollen joint count, health assessment questionnaire–disability index (haq–di), patient's global assessment, physician's global assessment, c-reactive protein (crp), esr.","['C4554549', 'C0240094', 'C1705566', 'C1515981', 'C1275555', 'C3890735', 'C4048285', 'C4554794', 'C1442488', 'C0031831', 'C1552854', 'C2986546', 'C0918012', 'C0152031', 'C1413716', 'C0332282', 'C3811131', 'C0006560', 'C0804815', 'C0168634', 'C0281858', 'C4054229', 'C0600653', 'C0750480', 'C0175637']","['Baseline', 'Index', 'C-reactive protein', 'Joint tenderness', 'And', 'Tender joint:Anatomy:Point in time:^Patient:Nominal', 'Patient Assessment of Overall Well-Being', 'Complete Response with Incomplete Platelet Recovery', 'Estrogen Receptor Measurement', 'Every Four Weeks', 'CRP gene', 'Joint swelling', 'Following', 'Html Link Type - index', 'Count Dosing Unit', 'BaseLine dental cement', 'C-Reactive Protein, human', 'Count', 'Health evaluation', 'Target Lesion Identification', 'Physician:Identifier:Point in time:^Patient:Nominal', 'Indexes', 'global assessment', 'Physicians', 'Swollen joint:Anatomy:Point in time:^Patient:Nominal']","['sosy', 'clna', 'inpr', 'idcn', 'bodm', 'lbpr', 'gngm', 'prog', 'fndg', 'tmco', 'imft', 'resa', 'hlca', ' aapp', 'diap', 'qnco']"
999,PMC3551223,S62,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Collected patient data and assessments,"quality of life was assessed at baseline and at weeks 4, 8, 12 and 24 using the rheumatoid arthritis quality of life questionnaire (raqol).","['C0168634', 'C0332306', 'C0003873', 'C0034380', 'C0034394', 'C0376558', 'C0439230', 'C1515981', 'C0518214', 'C0043194', 'C1442488', 'C1421478', 'C1565156', 'C1516048']","['BaseLine dental cement', 'Life', 'Baseline', 'Perceived quality of life', 'WAS protein, human', 'week', 'WAS gene', 'And', 'Questionnaires', 'with quality', 'Wiskott-Aldrich Syndrome', 'Rheumatoid Arthritis', 'Quality of life', 'Assessed']","['sosy', 'bacs', 'inpr', 'idcn', 'acty', 'qnco', 'gngm', 'qlco', 'tmco', 'dsyn', ' aapp', 'bodm']"
1000,PMC3551223,S63,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Collected patient data and assessments,"at each visit, patients were monitored for adverse events, vital signs and laboratory tests (eg, blood counts, transaminases, cholesterol).","['C0022885', 'C0008377', 'C0030705', 'C0877248', 'C0005767', 'C2826704', 'C1457900', 'C1512346', 'C0229664', 'C0919834', 'C0545082', 'C0518766', 'C0002594', 'C1705413', 'C1515981', 'C0005768', 'C0439157']","['In Blood', 'Blood', 'Adverse Event Domain', 'Laboratory Procedures', 'And', 'Transaminase Assay', 'Transaminases', 'Patients', 'Adverse event', 'Patient Visit', 'Visit', 'Visit Name', 'counts', 'Vital signs', 'Each (qualifier value)', 'Cholesterol', 'peripheral blood']","['bacs', ' orch', 'clna', 'inpr', 'idcn', 'lbpr', 'enzy', 'patf', 'bdsu', 'podg', 'bhvr', 'hlca', ' aapp', 'qnco']"
1001,PMC3551223,S64,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Collected patient data and assessments,radiographs of the hands/wrists and feet were obtained at baseline and week 24.,"['C0018563', 'C0168634', 'C1306645', 'C0016504', 'C0439230', 'C1515981', 'C1442488', 'C0347981', 'C0043262']","['BaseLine dental cement', 'Wrist', 'Baseline', 'Feet, unit of measurement', 'week', 'Hand', 'And', 'Plain x-ray', 'Foot']","['bpoc', 'idcn', 'qnco', 'blor', 'tmco', 'diap', 'bodm']"
1002,PMC3551223,S65,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Collected patient data and assessments,"each radiograph was assessed applying the genant-modified sharp scoring system (gss) by two independent readers (perceptive informatics medical imaging services, berlin, germany) who were blinded to treatment assignment, chronological order of radiographs and patient's clinical status.","['C0085862', 'C1306645', 'C2347435', 'C0030705', 'C3888058', 'C1552081', 'C0017480', 'C1705169', 'C3887704', 'C1515981', 'C1516050', 'C0870065', 'C0449913', 'C1705175', 'C1705178', 'C0205210', 'C1705177', 'C3890003', 'C1299583', 'C1444775', 'C0039798', 'C3538994', 'C1539835', 'C0449438', 'C0005125', 'C1553451', 'C1457900', 'C0017495', 'C1290940', 'C3889737', 'C3889825', 'C0205448', 'C0449820', 'C0392747', 'C0087111', 'C1548003', 'C0150108', 'C1705176', 'C0599807', 'C1533734', 'C1522326', 'C1882348', 'C3272598', 'C1415327']","['Order (document)', 'Biomaterial Treatment', 'And', 'SPEN wt Allele', 'Patients', 'Blinded', 'Independent for Transfer', 'Germany', 'System', 'Therapeutic procedure', 'Permutation', 'Order (taxonomic)', 'Informatics (discipline)', 'PRNP wt Allele', 'Administration procedure', 'SPEN gene', 'Gerstmann-Straussler-Scheinker Disease', 'Each (qualifier value)', 'Data Change Date', 'Clinical', 'Independently able', 'Order (action)', 'Sequence of Planned Assessment Schedule', 'Treatment Epoch', 'Changing', 'WHO Temperature/Humidity Storage Condition', 'Assignment - action', 'Device system', 'Two', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'scoring - solid dosage form', 'Order (arrangement)', 'GSS gene', 'Diagnostic Service Section ID - Radiograph', 'City of Berlin', 'System - kit', 'Diagnostic Imaging Services', 'Treating', 'Plain x-ray', 'Independence', 'Sharp sensation quality', 'Score', 'Status']","['inpr', 'geoa', 'idcn', 'acty', 'gngm', 'ocdi', 'clas', 'topp', 'ftcn', 'cnce', 'mnob', 'qlco', 'podg', 'tmco', 'resa', 'fndg', 'hlca', 'diap', 'qnco', 'dsyn']"
1003,PMC3551223,S66,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Collected patient data and assessments,"the smallest detectable change (sdc) for gss was computed based on the observed sd of difference between the x-ray readers,14 whereas three readers in total participated in the campaign.","['C1306645', 'C2347435', 'C3891450', 'C1419891', 'C0439810', 'C3830527', 'C0043309', 'C0034571', 'C1441672', 'C1705242', 'C0043299', 'C2700395', 'C0205449', 'C0017495', 'C4319952', 'C0443172', 'C1962945', 'C0392747', 'C3273112', 'C0205103', 'C1705241', 'C1415327']","['Smallest', 'Delta (difference)', 'PRNP wt Allele', 'Radiography Study File', 'Changed status', 'roentgenographic', 'Gerstmann-Straussler-Scheinker Disease', 'Total', 'Observed', 'Diagnostic radiologic examination', 'Detectable', 'Intermediate', 'Changing', 'SDC1 wt Allele', 'SDC1 gene', 'Change -- procedure', 'Roentgen Rays', 'GSS gene', 'Three', 'Plain x-ray', 'Radiographic imaging procedure', 'Different']","['inpr', 'clna', 'gngm', 'topp', 'ftcn', 'spco', 'qlco', 'dsyn', 'diap', 'npop', 'qnco']"
1004,PMC3551223,S67,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Collected patient data and assessments,the sdc is the smallest change that can be attributed to something more than observed variability of reader differences.,"['C1706461', 'C0392747', 'C2700395', 'C3273112', 'C0443172', 'C4319952', 'C1514743', 'C1419891', 'C2827666', 'C1441672', 'C1705241']","['Observed', 'Smallest', 'Changing', 'Reader Device Component', 'SDC1 gene', 'SDC1 wt Allele', 'Changed status', 'Reader of medical images', 'Variability', 'Change -- procedure', 'Delta (difference)']","['gngm', 'prog', 'topp', 'ftcn', 'mnob', 'cnce', 'qnco']"
1005,PMC3551223,S69,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,the clinical superiority of the tocilizumab plus methotrexate combination treatment in the phase ii charisma study13 had an important influence on the statistical parts of the design.,"['C3887704', 'C1705169', 'C1709471', 'C0876955', 'C2983265', 'C0038215', 'C4054723', 'C0205210', 'C1609165', 'C4084912', 'C0680218', 'C3538994', 'C0039798', 'C0248593', 'C1707689', 'C3898777', 'C3811910', 'C0441767', 'C0062074', 'C0025677', 'C3539897', 'C1947911', 'C0087111', 'C1415458', 'C0449719', 'C1522326', 'C1533734']","['Influence', 'Biomaterial Treatment', 'Have', 'Part Dosing Unit', 'Therapeutic procedure', 'HADH gene', 'combination - answer to question', 'Administration procedure', 'Methotrexate', 'Clinical', 'Stage level 2', 'Treatment Epoch', 'Importance Rating Score 0', 'CDISC SEND Study Design Terminology', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Design', 'combination of objects', 'Important', '[ TRD] Charisma composite resin', 'Science of Statistics', 'Treating', 'HAC protocol', 'superiority', 'tocilizumab', 'Part', 'Charismatic Personality Trait']","['topp', 'fndg', 'qlco', 'socb', ' phsu', 'hlca', 'inpr', 'gngm', 'imft', 'resa', ' aapp', 'bodm', 'phob', 'ftcn', 'orch', 'menp', 'acty', 'ocdi', 'cnce', 'spco', 'qnco']"
1006,PMC3551223,S70,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical analysis,"to assess the working hypothesis that the add-on strategy (ie, initiation of tocilizumab plus continuation of methotrexate) would be superior to the switch strategy (ie, initiation of tocilizumab and discontinuation of methotrexate), the primary outcome measure of the study was defined as the percentage of patients in remission according to das28–esr (das28 <2.6) at week 24.","['C0457454', 'C1561533', 'C1444662', 'C0030705', 'C1158830', 'C1515981', 'C1565156', 'C1704788', 'C3274433', 'C1282910', 'C0439230', 'C0544452', 'C1704686', 'C2603343', 'C0043194', 'C0043227', 'C1883712', 'C1609165', 'C0679199', 'C1707719', 'C0589507', 'C4552847', 'C0025677', 'C1549488', 'C0439165', 'C0687702', 'C1512571', 'C1421478']","['Discontinued', 'And', 'Patients', 'Discontinuation (procedure)', 'Work', 'Money or percentage indicator - Percentage', 'Primary Outcome Measure', 'Cognitive function: initiation', 'WAS protein, human', 'WAS gene', 'Cancer Remission', 'Methotrexate', 'strategy', 'week', 'Hypothesis', 'Disease remission', 'Study', 'Amount type - Percentage', 'Upper', 'Percent (qualifier value)', 'Clinical Trial Discontinuation', 'Wiskott-Aldrich Syndrome', 'Definition', 'Switch Device', 'tocilizumab', 'Initiation', 'Add - instruction imperative', 'Transcription Initiation']","['bacs', 'neop', 'fndg', 'mnob', 'qlco', ' phsu', 'inpr', 'idcn', 'genf', 'gngm', 'imft', 'resa', ' aapp', 'ocac', 'ftcn', 'orch', 'podg', 'tmco', 'dsyn', 'menp', 'spco', 'qnco']"
1007,PMC3551223,S71,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,a two-sided statistical test of no difference between the two treatment arms at the 5% significance level was used.,"['C3842396', 'C3887704', 'C1705169', 'C0446516', 'C0087111', 'C0206655', 'C2681631', 'C0814896', 'C1522326', 'C1533734', 'C0205448', 'C0237913', 'C0039798', 'C3538994']","['No difference', 'Treatment Epoch', 'significance level', 'Upper arm', 'Biomaterial Treatment', 'Treating', 'Administration procedure', 'Two', 'Alveolar rhabdomyosarcoma', 'KIDINS220 gene', 'Statistical Test', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Therapeutic procedure']","['inpr', 'gngm', 'topp', 'neop', 'ftcn', 'blor', 'cnce', 'fndg', 'resa', 'hlca', 'qnco']"
1008,PMC3551223,S72,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"specifically for the primary endpoint, as well as for similar endpoints, a logistic regression model was employed including the stratification factors used at randomisation (site and baseline das28 ≤ or >5.5) with a supportive cochran–mantel–haenszel test stratified for the same parameters.","['C0205363', 'C3853906', 'C1515981', 'C4321252', 'C1521721', 'C1565156', 'C2349179', 'C4318744', 'C3161035', 'C0557351', 'C3274659', 'C0043194', 'C0206031', 'C1442488', 'C3146287', 'C0332287', 'C2986535', 'C0039593', 'C1515974', 'C1515976', 'C1273517', 'C0205145', 'C2825164', 'C3831328', 'C0521125', 'C0332257', 'C0022885', 'C0168634', 'C2348205', 'C0445247', 'C1514984', 'C0456984', 'C1421478', 'C0205170', 'C0392366', 'C3714583', 'C0014003', 'C4283957']","['Model Number', 'Baseline', 'Laboratory Procedures', 'Anatomic Site', 'And', 'Model', 'stratified', 'Site', 'Preposition For', 'WWOX wt Allele', 'Test - temporal region', 'Well', 'Primary Endpoint', 'WAS protein, human', 'Tests (qualifier value)', 'WAS gene', 'Testing', 'Supportive assistance', 'Test Result', 'BaseLine dental cement', 'End Point', 'Logistic Regression', 'Anatomic Structure, System, or Substance', 'Good', 'Same', 'Employment', 'Blood Products Laboratory Testing', 'In addition to', 'Microplate Well', 'Including (qualifier)', 'Wiskott-Aldrich Syndrome', 'Employed', 'Similarity', 'Model - style/design', 'Digital Model Attachment', 'used by', 'Stratification Factors', 'Study Site']","['bacs', 'inpr', 'idcn', ' aapp', 'qnco', 'gngm', 'clas', 'lbpr', 'lbtr', 'ftcn', 'blor', 'fndg', 'qlco', 'spco', 'cnce', 'resa', 'mnob', 'dsyn', 'irda', 'bodm']"
1009,PMC3551223,S73,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,analysis of covariance models were used to compare continuous outcome measures.,"['C0936012', 'C1524024', 'C0549178', 'C0086749', 'C3161035']","['Outcome Measures', 'Model', 'Continuous', 'Analysis', 'analysis aspect']","['inpr', 'idcn', 'ftcn', 'resa', 'qnco']"
1010,PMC3551223,S74,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"efficacy analyses were conducted in the intention-to-treat population (all randomly assigned and treated patients analysed in the arm they were randomly assigned to) with non-responder imputation for categorical variables (eg, das28 remission, acr response), last observation carried forward until patient withdrawal for missing joint counts and no additional imputation of missing values.","['C1704632', 'C3715044', 'C1710677', 'C3812880', 'C0030705', 'C1292734', 'C1706817', 'C1515981', 'C0439828', 'C1516050', 'C1518422', 'C0032659', 'C0162425', 'C3889687', 'C0544452', 'C0302523', 'C2911692', 'C0392905', 'C1280519', 'C1283828', 'C1964257', 'C1551393', 'C1705492', 'C0042295', 'C0439780', 'C0700325', 'C1706309', 'C1707887', 'C0022417', 'C0439157', 'C3272743', 'C1412134', 'C0687702', 'C1517741', 'C0446516', 'C1257890', 'C2699638', 'C1552601', 'C4553528', 'C0087111', 'C2349954', 'C2825032', 'C1522326', 'C0444868', 'C1515941', 'C4049634', 'C1524062', 'C0871261']","['Observation in research', 'Effectiveness', 'Withdrawal - birth control', 'Upper arm', 'And', 'geographic population', 'Patients', 'Observation - diagnostic procedure', 'Joints', 'Patient observation', 'Missing Study Animal', 'Therapeutic procedure', 'Last', 'PersonNameUse - assigned', 'Efficacy Study', 'Forward', 'Clinical Observation', 'Withdrawal Scale (BASC-2)', 'Additional', 'Response (communication)', 'Cancer Remission', 'Withdrawal (dysfunction)', 'Withdrawal by Subject', 'Variable (uniformity)', 'Articular system', 'Treatment intent', 'Negation', 'Intention - mental process', 'Statistical Imputation', 'American College of Radiology', 'Missing', 'intent', 'ACR gene', 'All', 'Disease Response', 'Assignment - action', 'Container status - Missing', 'Disease remission', 'counts', 'Response (statement)', 'Response process', 'Joint Device', 'AKR1A1 wt Allele', 'Withdraw (activity)', 'Treating', 'Population Group', 'Sequence Arm', 'Values']","['topp', 'neop', 'mnob', 'fndg', 'qlco', 'bdsy', 'hlca', 'diap', 'inpr', 'pros', 'idcn', 'gngm', 'resa', 'popg', 'ftcn', 'blor', 'podg', 'menp', 'bsoj', 'acty', 'spco', 'mobd', 'qnco', 'orga']"
1011,PMC3551223,S75,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analysis,the target sample size (235 patients per arm) was computed to provide 80% power to detect a 12.5% treatment effect difference between an expected 42.5% das28 remission rate at week 24 in the add-on strategy arm versus 30% in the switch strategy arm.12,"['C3715044', 'C0030705', 'C0032863', 'C1517001', 'C0439230', 'C0544452', 'C1883712', 'C1705242', 'C0679199', 'C0620347', 'C1518681', 'C1707719', 'C4528313', 'C0871208', 'C0687702', 'C0446516', 'C4553528', 'C3854080', 'C0205103', 'C1705241', 'C1521828']","['Target Sample Size', 'Rating (action)', 'Upper arm', 'Patients', 'Power', 'Delta (difference)', 'Outcome of Therapy', 'Cancer Remission', 'strategy', 'Intermediate', 'week', 'Disease remission', 'compound A 12', 'Expected', 'Rate', 'AKR1A1 wt Allele', 'Power (Psychology)', 'Switch Device', 'Sequence Arm', 'Different', 'Add - instruction imperative']","['hcpp', 'inpr', 'acty', 'gngm', 'neop', 'ftcn', 'blor', 'fndg', 'podg', 'qlco', 'spco', 'mnob', 'tmco', 'orch', 'menp', ' phsu', 'qnco']"
1012,PMC3551223,S76,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"this difference (12.5%) was deemed to be clinically relevant by the study's steering committee (see supplementary data, available online only).","['C1511726', 'C3245479', 'C0205171', 'C2347946', 'C0470187', 'C2603343', 'C2699414', 'C1705241', 'C1080058', 'C3714741', 'C1705242']","['availability of', 'Committee', 'Relevance', 'Data call receiving device', 'Singular', 'Study', 'Data (eukaryote)', 'Data', 'Different', 'Delta (difference)', 'This (eukaryote)']","['grup', 'idcn', 'medd', 'ftcn', 'qlco', 'euka', 'resa', 'qnco']"
1013,PMC3551223,S77,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,the following additional endpoints were analysed in accordance with the european league against rheumatism (eular)/acr collaborative recommendations for reporting ra disease activity in clinical trials:11,"['C1292728', 'C1535514', 'C0332282', 'C0034866', 'C0035435', 'C0521124', 'C1412134', 'C0008976', 'C0282116', 'C1096775', 'C1515941', 'C2349179', 'C1524062', 'C0239307', 'C0009326']","['Recommendation', 'American College of Radiology', 'End Point', 'against', 'collaboration', 'ACR gene', 'Additional', 'Clinical Trials', 'Clinical Trial [Publication Type]', 'ethnic european', 'European race', 'Following', 'Rheumatism', 'Disease activity', 'Collagen Diseases']","['inpr', 'pros', 'idcn', 'gngm', 'popg', 'ftcn', 'qlco', 'tmco', 'resa', 'socb', 'dsyn']"
1014,PMC3551223,S78,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical analysis,"other outcome measures at week 24 included mean changes in das28–esr and in selected variables (eg, swollen joint count, tender joint count, esr, crp, haq–di, raqol); percentage of patients who improved during the 24 weeks of the study according to acr20/50/70/90, eular response and the percentage of patients with das28 <3.2 (low disease activity state).","['C1292728', 'C1704632', 'C4554549', 'C1561533', 'C0240094', 'C0030705', 'C1301808', 'C1705566', 'C1706817', 'C1515981', 'C0439828', 'C3890211', 'C1550472', 'C4522223', 'C0444504', 'C0439230', 'C3890735', 'C4048285', 'C4554794', 'C2603343', 'C2347634', 'C2911692', 'C1707391', 'C3148680', 'C0443172', 'C0152031', 'C0086749', 'C4048187', 'C4321351', 'C3811131', 'C0392747', 'C1549488', 'C0439165', 'C2348143', 'C0205251', 'C0750480', 'C0680240', 'C3272598', 'C1442792', 'C0871261']","['Joint tenderness', 'And', 'Tender joint:Anatomy:Point in time:^Patient:Nominal', 'Geographic state', 'Patients', 'Complete Response with Incomplete Platelet Recovery', 'Disease activity', 'IPSS Risk Category Low', 'Estrogen Receptor Measurement', 'Sample Mean', 'Money or percentage indicator - Percentage', 'Low Mitosis-Karyorrhexis Index', 'Response (communication)', 'Changed status', 'low confidentiality', 'Choose (action)', 'Variable (uniformity)', 'Population Mean', 'Joint swelling', 'Count Dosing Unit', 'Outcome Measures', 'low', 'Disease Response', 'Changing', 'C-Reactive Protein, human', 'WHO Temperature/Humidity Storage Condition', 'week', 'Agreement', 'Count', 'Study', 'low exposure', 'Response (statement)', 'US State', 'Amount type - Percentage', 'Response process', 'State', 'Statistical mean', 'Low Level', 'Percent (qualifier value)', 'Swollen joint:Anatomy:Point in time:^Patient:Nominal']","['sosy', 'inpr', 'clna', 'idcn', 'geoa', 'acty', 'lbpr', 'ftcn', 'fndg', 'podg', 'qlco', 'tmco', 'imft', 'socb', 'resa', 'menp', ' aapp', 'qnco', 'orga']"
1015,PMC3551223,S79,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical analysis,"remission as defined by the 2010 acr–eular criteria (boolean definition),15 simplified disease activity index ≤3.3 and clinical disease activity index ≤2.8 were analysed post hoc.","['C1552854', 'C1292728', 'C1552663', 'C2986546', 'C0918012', 'C0687702', 'C3869583', 'C1704788', 'C1704687', 'C0544452', 'C3469826', 'C0243161', 'C0600653', 'C3888054', 'C0687676', 'C1550452']","['Post', 'DEFINITION - NCI Thesaurus Property', 'Index', 'Post Device', 'Cancer Remission', 'Definition', 'Boolean', 'Indexes', 'Disease remission', 'Clinical disease activity index', 'definition - ActMoodCompletionTrack', 'SLC35G1 gene', 'criteria', 'Target Lesion Identification', 'Html Link Type - index', 'Disease activity']","['inpr', 'idcn', 'gngm', 'neop', 'ftcn', 'cnce', 'fndg', 'tmco', 'mnob', 'diap']"
1016,PMC3551223,S80,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical analysis,"to approach the concepts of onset of action and sustainability, changes over time of selected variables such as joint counts, crp, pain and haq–di were evaluated.","['C4554132', 'C0030193', 'C0439828', 'C1515981', 'C0178566', 'C4085210', 'C3890735', 'C4048285', 'C4085211', 'C0392905', 'C1707391', 'C4553004', 'C0443172', 'C1706309', 'C0022417', 'C0439157', 'C2984058', 'C0392747', 'C3266814', 'C0518090', 'C0040223', 'C0332162', 'C0441472', 'C4085212', 'C0206132']","['Age of Onset', 'And', 'Usual Severity Pain', 'Joints', 'Time', 'Complete Response with Incomplete Platelet Recovery', 'Changed status', 'Choose (action)', 'Variable (uniformity)', 'Articular system', 'Feel Pain', 'How Much Distress Pain', 'concept', 'Have Pain', 'Changing', 'C-Reactive Protein, human', 'counts', 'Pain Distress Question', 'Clinical action', 'Pain', 'Frequency of Pain Question', 'Pain, CTCAE', 'Onset of (contextual qualifier)', 'Joint Device', 'Action']","['sosy', 'bsoj', 'inpr', 'idcn', 'acty', 'ftcn', 'fndg', 'mnob', 'tmco', 'imft', 'qlco', 'bdsy', ' aapp', 'qnco']"
1017,PMC3551223,S81,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical analysis,the domain fatigue was evaluated using question 21 of the raqol questionnaire.,"['C1522634', 'C0034394', 'C0015672', 'C4050243', 'C1883221', 'C3463815', 'C4554645', 'C1880389']","['Feel Fatigue', 'Fatigue, CTCAE 5.0', 'Domain (area of knowledge)', 'Superkingdom (taxonomic category)', 'Questionnaires', 'Question (inquiry)', 'Fatigue Subordinate Domain', 'Fatigue']","['sosy', 'inpr', 'ftcn', 'fndg', 'cnce']"
1018,PMC3551223,S82,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical analysis,"radiographic endpoints included changes from baseline in total gss, erosion and joint space narrowing scores and the proportion of patients with no radiographic progression (progression defined as change in gss >sdc or >0).","['C2347435', 'C0030705', 'C3887524', 'C0439810', 'C1515981', 'C1709707', 'C1859695', 'C2349179', 'C1704788', 'C0444708', 'C0333307', 'C1442488', 'C0332287', 'C0017495', 'C0443172', 'C4319952', 'C1959609', 'C0449820', 'C0392747', 'C0168634', 'C1880549', 'C0449258', 'C1705241', 'C0242656', 'C1415327']","['Baseline', 'And', 'Superficial ulcer', 'Patients', 'Skin Erosion', 'Proportion', 'Delta (difference)', 'PRNP wt Allele', 'Disease Progression', 'Changed status', 'Gerstmann-Straussler-Scheinker Disease', 'Total', 'Joint space narrowing', 'BaseLine dental cement', 'End Point', 'Progression', 'Changing', 'Change -- procedure', 'In addition to', 'GSS gene', 'Erosion of Medical Device Material', 'Erosion lesion', 'Definition', 'radiographic', 'Score']","['inpr', 'idcn', 'bodm', 'gngm', 'topp', 'ftcn', 'fndg', 'patf', 'podg', 'qlco', 'acab', 'dsyn', 'npop', 'qnco']"
1019,PMC3551223,S83,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical analysis,"safety endpoints included the incidence of adverse events (ae), serious ae, serious infections and specific laboratory abnormalities, which were analysed in the safety population (all treated patients with at least one post-dose assessment of safety, analysed according to the treatment received).","['C0687676', 'C0036043', 'C1853129', 'C1261322', 'C0030705', 'C3887704', 'C1705169', 'C3469826', 'C1704687', 'C1515981', 'C2349179', 'C0032659', 'C0877248', 'C0205447', 'C0332287', 'C1514756', 'C0205404', 'C1552740', 'C0039798', 'C3538994', 'C0178602', 'C0205369', 'C1705413', 'C0021149', 'C1257890', 'C0087111', 'C1522326', 'C1533734', 'C3714514', 'C0680240', 'C0444868', 'C1705187', 'C0220856', 'C1516048']","['Post Device', 'Specific qualifier value', 'Biomaterial Treatment', 'geographic population', 'And', 'Evaluation procedure', 'Patients', 'Safety', 'Receive', 'Therapeutic procedure', 'Incidence', 'Administration procedure', 'Adverse event', 'SLC35G1 gene', 'Dosage', 'End Point', 'Treatment Epoch', 'Entity Determiner - specific', 'Adverse Event Domain', 'All', 'Agreement', 'LABORATORY ABNORMALITIES', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'One', 'In addition to', 'incidence of cases', 'Post', 'Safety Study', 'Treating', 'Population Group', 'Infection', 'Assessed', 'Serious']","['hcpp', 'inpr', 'idcn', 'acty', 'gngm', 'topp', 'popg', 'lbtr', 'ftcn', 'cnce', 'patf', 'qlco', 'podg', 'tmco', 'resa', 'socb', 'hlca', 'mnob', 'qnco']"
1020,PMC3590447,S41,"['3a', '4b']","[0, 0, 0, 0, 0, 0, 1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Trial design and participants,"in this randomised controlled trial, patients were recruited from 37 of 45 renal units in acute hospitals throughout the uk that obtained local ethical approval.","['C1301820', 'C0019994', 'C0030705', 'C0026531', 'C3853603', 'C0439148', 'C0205276', 'C0022646', 'C0205178', 'C1519795', 'C0205540', 'C0936233', 'C0009933', 'C1080058', 'C2346845', 'C2697909']","['Morality', 'This (eukaryote)', 'Controlled Clinical Trial [Publication Type]', 'Unit - NCI Thesaurus Property', 'Local', 'Approved', 'Unit', 'Patients', 'acute', 'Kidney', 'Controlled Clinical Trials as Topic', 'Unit of Measure', 'Approval (document)', 'Letter of Authorization', 'Hospitals', 'Obtain']","['inpr', 'bpoc', 'rnlw', 'idcn', 'ftcn', 'mnob', 'spco', 'qlco', 'podg', 'euka', 'resa', 'tmco', ' hcro', 'qnco']"
1021,PMC3590447,S42,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Trial design and participants,"inclusion criteria were: age 18–75 years; biopsy-proven diagnosis of membranous nephropathy (we did not impose a limit on the time since biopsy), regarded as idiopathic with no evidence of an underlying cause (such as drugs, infections, or tumours); and serum or plasma creatinine concentration of less than 300 μmol/l together with a 20% or greater decline in excretory renal function (measured by creatinine clearance or estimated with the cockcroft-gault calculation, and later by the modification of diet in renal disease [mdrd] formula13) that was based on at least three measurements over a period of 3 months or longer within the 2 years before study entry.","['C0086045', 'C0812399', 'C0205087', 'C1948053', 'C0242485', 'C0220797', 'C1515981', 'C3687832', 'C0332125', 'C0232804', 'C1565156', 'C0332285', 'C1707660', 'C0347984', 'C0015127', 'C1518422', 'C1704656', 'C0012155', 'C2349209', 'C1441506', 'C0750572', 'C0439531', 'C1446561', 'C3827302', 'C0022658', 'C1524003', 'C0017665', 'C2603343', 'C0012159', 'C1705938', 'C1527178', 'C0439801', 'C1883357', 'C0332287', 'C0043194', 'C0444706', 'C1704338', 'C3541902', 'C0205449', 'C0205136', 'C1549649', 'C3840684', 'C0011900', 'C0005558', 'C3889737', 'C0456369', 'C0013227', 'C1711239', 'C0439234', 'C4067746', 'C2828361', 'C0392747', 'C1554963', 'C1704243', 'C0332240', 'C0040223', 'C1705654', 'C1442461', 'C2983588', 'C1519433', 'C1278055', 'C1512693', 'C1421478', 'C3714514', 'C0439092', 'C0001779']","['Measured Tumor Identification', 'biopsy characteristics', 'And', 'Cause of death.underlying', 'Drugs - dental services', 'Unknown (origin) (qualifier value)', 'Time', 'Creatinine clearance', 'Late', 'Entry (data)', 'Concentration measurement', 'Together', 'Bound (value)', 'WAS protein, human', 'WAS gene', 'Diagnosis', 'Diet', 'Age', 'Renal function', 'Within', 'ResponseLevel - modification', 'Special Diet Therapy', 'Diagnosis Study', 'Measurement', 'Negation', 'Data Change Date', 'Estimated', 'Since', 'Calculation', 'Changing', 'Inclusion', 'Do (activity)', 'Less Than', 'Mental concentration', 'diagnosis aspect', 'Etiology aspects', 'Proven findings', 'Study', 'per period (qualifier value)', 'Period (temporal qualifier)', 'Limit - Amount class', 'plasma creatinine measurement', 'year', 'Base - General Qualifier', 'Diet therapy', 'In addition to', 'During', '3 Months', 'Membranous glomerulonephritis', 'Basis - conceptual entity', 'Measured', 'Pharmaceutical Preparations', 'Modification', 'No evidence of', 'Limited (extensiveness)', 'Wiskott-Aldrich Syndrome', 'Three', 'Biopsy', 'Science of Etiology', 'Deidentification', 'Basal Diet', 'Greater', 'Kidney Diseases', 'Able to Concentrate Question', 'Infection', 'Over (spatial)']","['ortf', 'bacs', 'biof', 'topp', 'fndg', 'qlco', 'food', 'hlca', 'diap', 'phsu', 'inpr', 'idcn', 'lbpr', 'gngm', 'patf', 'resa', ' aapp', 'mcha', 'ftcn', 'tmco', 'dsyn', 'menp', 'acty', 'cnce', 'spco', 'qnco', 'orga']"
1022,PMC3590447,S43,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Trial design and participants,we excluded patients whose membranous nephropathy was a result of secondary causes (defined according to usual clinical practice).,"['C1274040', 'C1546471', 'C0205436', 'C3245512', 'C0030705', 'C3538928', 'C1314792', 'C2825142', 'C0205210', 'C0017665', 'C0027627', 'C0015127', 'C0175668', 'C0237607']","['Membranous glomerulonephritis', 'Clinical', 'Neoplasm Metastasis', 'What subject filter - Result', 'Usual', 'second (number)', 'Etiology aspects', 'HL7PublishingSubSection <practice>', 'Patients', 'Etiology', 'Secondary to', 'Result', 'Practice Experience', 'Experimental Result']","['inpr', 'idcn', 'neop', 'ftcn', 'fndg', 'qlco', 'podg', 'dsyn', 'menp', 'qnco']"
1023,PMC3590447,S44,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Trial design and participants,"other exclusion criteria were: known infection with hepatitis b or c virus or hiv; known malignant disease; positive antibodies to double-stranded dna; current treatment with gold, penicillamine, non-steroidal anti-inflammatory drugs, cytotoxic drugs, or ciclosporin; more than 3 months' treatment with corticosteroids in the preceding 2 years; pregnancy or unreliable contraception; or a previous adverse reaction to prednisolone, methylprednisolone, chlorambucil or ciclosporin.","['C3812269', 'C1304897', 'C2827774', 'C3887704', 'C0008163', 'C1705169', 'C0333348', 'C0032961', 'C3687832', 'C0442867', 'C0749770', 'C0001617', 'C1518422', 'C0680251', 'C3540727', 'C0012854', 'C0003241', 'C0304497', 'C3540726', 'C4521340', 'C3539185', 'C0019163', 'C0700589', 'C0039798', 'C3538994', 'C0205172', 'C0018026', 'C0032950', 'C3540725', 'C0013227', 'C0205156', 'C0332152', 'C0439234', 'C1514241', 'C0019682', 'C0205309', 'C2825490', 'C1442461', 'C0010592', 'C1446409', 'C0087111', 'C1552607', 'C1522326', 'C1533734', 'C3714514', 'C0559546']","['DNA', 'Positive', 'prednisolone', 'Cytotoxic agent (product)', 'Deoxyribonucleic Acid Measurement', 'HIV', 'unreliable', 'Biomaterial Treatment', 'Exclusion Criteria', 'Act Relationship Subset - previous', 'Gold color', 'Drugs - dental services', 'Contraceptive methods', 'Chlorambucil', 'Hepatitis B', 'Therapeutic procedure', 'Corticosteroid ophthalmologic and otologic preparations', 'Positive Charge', 'Administration procedure', 'Pregnancy', 'Before', 'Current Therapy', 'Positive Number', 'Corticosteroid otologicals', 'Negation', 'Adrenal Cortex Hormones', 'Treatment Epoch', 'Positive Finding', 'Corticosteroid nasal preparations for topical use', 'Known', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'inflammatory', 'Gold', 'year', '3 Months', 'malignant disease', 'Pharmaceutical Preparations', 'Cyclosporine', 'More', 'Previous', 'Treating', 'Antibodies', 'Adverse reactions', 'Infection', 'Corticosteroids, topical for treatment of hemorrhoids and anal fissures']","['bacs', ' orch', 'topp', 'fndg', 'qlco', 'virs', ' phsu', 'hlca', 'phsu', 'idcn', 'lbpr', 'patf', 'imft', 'horm', 'resa', ' aapp', 'orgf', 'elii', ' nnon', 'ftcn', 'orch', 'tmco', 'dsyn', 'cnce', 'aapp', 'qnco']"
1024,PMC3590447,S45,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Trial design and participants,ethics approval was obtained from the south west multicentre research ethics committee (reference mrec/97/6/12).,"['C1527243', 'C0015000', 'C1514811', 'C1706462', 'C1705493', 'C0205540', 'C0086911', 'C2346845', 'C2697909', 'C1710133']","['Reference Object', 'Approval (document)', 'Approved', 'West (direction)', 'Ethics', 'South', 'Bibliographic Reference', 'Ethics Committees, Research', 'Letter of Authorization', 'ethics qualifier']","['inpr', 'rnlw', 'idcn', 'prog', 'ftcn', 'cnce', 'spco', 'qlco']"
1025,PMC3590447,S46,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Trial design and participants,each participating centre also obtained local ethical approval.,"['C2346845', 'C0026531', 'C1457900', 'C0205276', 'C0679823', 'C0205540', 'C0205099', 'C2697909']","['Morality', 'Local', 'Approved', 'participation', 'Central', 'Approval (document)', 'Each (qualifier value)', 'Letter of Authorization']","['inpr', 'rnlw', 'idcn', 'ftcn', 'spco', 'qlco', 'qnco']"
1026,PMC3590447,S47,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Trial design and participants,all patients gave written informed consent.,"['C0444868', 'C0021430', 'C0030705']","['All', 'Informed Consent', 'Patients']","['podg', 'qnco', 'rnlw']"
1027,PMC3590447,S49,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation,"eligible patients were randomly assigned by a member of staff in the clinical trials office at the glasgow royal infirmary, glasgow, uk, who was not otherwise involved in the trial.","['C0680022', 'C0030705', 'C2698041', 'C0442603', 'C0008976', 'C0851286', 'C0043194', 'C1096775', 'C1548635', 'C1947908', 'C1314939', 'C1421478', 'C1565156', 'C0221502', 'C3272598', 'C1518422']","['Eligible', 'Involvement with', 'Member Organization', 'WAS protein, human', 'Office', 'WHO Temperature/Humidity Storage Condition', 'Clinical Trials', 'WAS gene', 'Wiskott-Aldrich Syndrome', 'member', 'Patients', 'infirmaries', 'Clinical Trial [Publication Type]', 'Staff', 'On Staff', 'Negation']","['bacs', 'inpr', 'gngm', 'prog', 'popg', 'ftcn', 'mnob', 'podg', 'qlco', 'resa', 'dsyn', 'hcro', ' aapp']"
1028,PMC3590447,S50,"['8a', '5', '8b']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 1, 0]",Randomisation,"a random numbers table had been prepared to allocate patients to one of three groups: supportive therapy alone, supportive therapy plus 6 months of prednisolone and chlorambucil, or supportive therapy plus 12 months of ciclosporin.","['C0439605', 'C0439231', 'C0030705', 'C0039224', 'C0441833', 'C0008163', 'C0687744', 'C1515981', 'C0237753', 'C0439044', 'C0034656', 'C0205447', 'C1706074', 'C0679994', 'C0344211', 'C1552839', 'C0205449', 'C0032950', 'C0449788', 'C0205171', 'C0010592']","['Randomization', 'prednisolone', 'Data Table', 'Random', 'And', 'Patients', 'month', 'alone - group size', 'Chlorambucil', 'Table - furniture', 'Social group', 'Numbers', 'Singular', 'One', 'Living Alone', 'Count of entities', 'Cyclosporine', 'Groups', 'Three', 'Table Rules - groups', 'Supportive care']","['inpr', 'grpa', 'idcn', 'topp', 'popg', 'mnob', 'fndg', 'orch', 'tmco', 'podg', 'qlco', 'resa', ' phsu', 'aapp', 'qnco']"
1029,PMC3590447,S51,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation,treatment allocation was communicated by fax to the clinician entering the patient into the trial.,"['C1706778', 'C0030705', 'C1880669', 'C0085205', 'C4552758', 'C1705169', 'C3887704', 'C0087111', 'C0008976', 'C0332286', 'C0039798', 'C0871685', 'C1522326', 'C1533734', 'C1549619', 'C3538994']","['Treatment Epoch', 'Telefacsimile', 'Clinical Trials', 'Biomaterial Treatment', 'Clinician', 'Treating', 'Patients', 'Administration procedure', 'into', 'Facsimile Machine', 'Allocation', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Therapeutic procedure', 'Fax Number', 'Fax (organism)']","['inpr', 'acty', 'prog', 'topp', 'ftcn', 'mnob', 'cnce', 'podg', 'euka', 'resa', 'hlca']"
1030,PMC3590447,S52,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation,we did not attempt to mask patients or investigators.,"['C0035173', 'C1518422', 'C0030705']","['Research Personnel', 'Negation', 'Patients']","['ftcn', 'prog', 'podg']"
1031,PMC3590447,S54,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,"we recorded baseline data for the supportive treatment alone group at randomisation, because these patients were effectively continuing their existing management.","['C1511726', 'C0039828', 'C0030705', 'C0441833', 'C1705169', 'C0687744', 'C3887704', 'C1521721', 'C3273539', 'C3714741', 'C0439044', 'C1442488', 'C0679994', 'C0039798', 'C3538994', 'C1273870', 'C1705429', 'C0376636', 'C0168634', 'C1519504', 'C3245479', 'C0205171', 'C1257890', 'C0087111', 'C1522326', 'C1533734', 'C1705428', 'C0001554']","['Theses', 'Baseline', 'Biomaterial Treatment', 'Data call receiving device', 'Patients', 'alone - group size', 'Stage Grouping', 'Therapeutic procedure', 'Disease Management', 'Administration occupational activities', 'User Group', 'Administration procedure', 'Management procedure', 'Group Object', 'Social group', 'BaseLine dental cement', 'Treatment Epoch', 'Singular', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Data', 'Management Occupations', 'Living Alone', 'Groups', 'Treating', 'Population Group', 'Data (eukaryote)', 'Supportive assistance']","['inpr', 'grpa', 'bodm', 'idcn', 'ocdi', 'ocac', 'topp', 'medd', 'popg', 'ftcn', 'cnce', 'fndg', 'podg', 'euka', 'resa', 'hlca', 'qnco']"
1032,PMC3590447,S55,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,"in the two groups receiving immunosuppressive treatment in addition to supportive therapy, baseline data were recorded when the new treatment began.","['C1511726', 'C0441833', 'C1705169', 'C0687744', 'C3887704', 'C3714741', 'C0021081', 'C1442488', 'C0332287', 'C1514756', 'C0344211', 'C1883712', 'C0039798', 'C3538994', 'C1552839', 'C0205448', 'C0168634', 'C3245479', 'C0087111', 'C1522326', 'C1533734']","['Baseline', 'Biomaterial Treatment', 'Data call receiving device', 'Receive', 'Therapeutic procedure', 'Administration procedure', 'Immunosuppressive Agents', 'Social group', 'BaseLine dental cement', 'Treatment Epoch', 'Two', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Data', 'In addition to', 'Groups', 'Table Rules - groups', 'Treating', 'Supportive care', 'Data (eukaryote)', 'Add - instruction imperative']","['inpr', 'bodm', 'idcn', 'topp', 'medd', 'popg', 'ftcn', 'cnce', 'qlco', 'euka', 'imft', 'resa', ' phsu', 'hlca', 'qnco']"
1033,PMC3590447,S56,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,we could not always start immunosuppressive treatment immediately after randomisation because the new treatments had to be prescribed and delivered.,"['C0205548', 'C0021081', 'C2003902', 'C0205314', 'C1705169', 'C3887704', 'C0087111', 'C3812891', 'C1522326', 'C1533734', 'C1518422', 'C0039798', 'C3538994']","['New', 'Treatment Epoch', 'Biomaterial Treatment', 'Immunosuppressive Agents', 'Treating', 'Administration procedure', 'All of the Time', 'Always (frequency)', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Stat (do immediately)', 'Therapeutic procedure', 'Negation']","['topp', 'ftcn', 'fndg', 'cnce', 'tmco', 'imft', 'qlco', 'resa', ' phsu', 'hlca']"
1034,PMC3590447,S57,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,the treatment schedules were based on best available evidence at the time.,"['C0086960', 'C3887511', 'C3887704', 'C0040223', 'C1705169', 'C0087111', 'C0470187', 'C1522326', 'C1533734', 'C1522427', 'C1554217', 'C0039798', 'C3538994']","['Evidence', 'Schedule (document type)', 'Act Relationship Type - schedules', 'Treatment Epoch', 'availability of', 'Biomaterial Treatment', 'Treating', 'Administration procedure', 'best (quality)', 'therapeutic aspects', 'Time', 'treatment - ActInformationManagementReason', 'Therapeutic procedure']","['inpr', 'idcn', 'topp', 'ftcn', 'cnce', 'tmco', 'qlco', 'resa', 'hlca']"
1035,PMC3590447,S58,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Procedures,"all patients received supportive therapy, including renin-angiotensin blockade, statins, and anticoagulants as indicated.","['C0003018', 'C0003280', 'C0030705', 'C0332206', 'C4521302', 'C1515981', 'C0360714', 'C0035094', 'C1419338', 'C0444868', 'C0344211', 'C3540676']","['REN gene', 'All', 'And', 'Patients', 'Anticoagulants', 'Angiotensin-1, human', 'Blocking', 'Supportive care', 'Blockade', 'Angiotensins', 'Renin', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors']","['bacs', 'idcn', 'gngm', 'elii', 'enzy', 'topp', 'ftcn', 'orch', 'podg', ' phsu', ' aapp', 'qnco', 'phsu']"
1036,PMC3590447,S59,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Procedures,"those assigned to supportive therapy plus 6 months' prednisolone and chorambucil11 received intravenous methyl prednisolone 1 g per day for 3 consecutive days then oral prednisolone 0·5 mg/kg per day for 28 days during months 1, 3, and 5.","['C0358513', 'C0439231', 'C1707491', 'C1883708', 'C0439505', 'C0032950', 'C1515981', 'C0344211', 'C4321252', 'C0439228', 'C0439272', 'C0347984', 'C0521125', 'C0348016']","['day', 'prednisolone', 'And', 'Intravenous', 'per day', 'month', 'Consecutive', 'Supportive care', 'Preposition For', 'Then', 'WWOX wt Allele', 'mg/kg', 'prednisolone Oral Product', 'During']","['idcn', 'gngm', 'topp', 'spco', 'orch', 'qlco', 'tmco', 'clnd', ' phsu', 'qnco']"
1037,PMC3590447,S60,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Procedures,intravenous prednisolone was administered in hospital.,"['C0019994', 'C0032950', 'C0348016']","['Hospitals', 'Intravenous', 'prednisolone']","['mnob', 'spco', 'orch', ' phsu', ' hcro']"
1038,PMC3590447,S61,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Procedures,"during months 2, 4, and 6, patients received oral chlorambucil at a starting dose of 0·15 mg/kg per day.","['C0178602', 'C0030705', 'C0439231', 'C0008163', 'C0439505', 'C1515981', 'C0442027']","['Oral', 'And', 'Patients', 'month', 'per day', 'Chlorambucil', 'Dosage']","['idcn', 'spco', 'orch', 'podg', 'tmco', ' phsu', 'qnco']"
1039,PMC3590447,S62,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Procedures,we gave this reduced dose because the parent drug and its metabolites are renally excreted and our preliminary work14 had shown that a dose of 0·2 mg/kg per day was poorly tolerated in patients with impaired excretory renal function.,"['C0221099', 'C0178602', 'C0030705', 'C1254351', 'C1515981', 'C0332173', 'C0205169', 'C0013227', 'C0392756', 'C0232804', 'C0870883', 'C0439228', 'C0439611', 'C1080058', 'C0030551', 'C2699423', 'C2698672']","['Metabolite', 'Bad', 'Pharmaceutical Preparations', 'day', 'Pharmacologic Substance', 'And', 'Daily', 'Renal function', 'Patients', 'Conceptual Parent', 'Other Toxicity Studies: Metabolites', 'preliminary', 'Impaired', 'Reduced', 'parent', 'Dosage', 'This (eukaryote)']","['bacs', 'ortf', 'rnlw', 'idcn', 'famg', 'ftcn', 'cnce', 'podg', 'qlco', 'tmco', 'euka', 'qnco', 'phsu']"
1040,PMC3590447,S63,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Procedures,we reduced the dose further if the patient developed leucopenia (weekly full blood counts were advised) and interrupted it if leucopenia was severe.,"['C4050465', 'C0178602', 'C0030705', 'C0023530', 'C0005767', 'C0229664', 'C0443225', 'C1515981', 'C1517331', 'C0205082', 'C0005768', 'C0332174', 'C4050466', 'C0439157']","['Further', 'full', 'In Blood', 'Blood', 'Borg Category-Ratio 10 Perceived Exertion Score 5', 'Leukopenia', 'And', 'Severe Extremity Pain', 'Severe (severity modifier)', 'Patients', 'counts', 'Weekly', 'Dosage', 'peripheral blood']","['inpr', 'idcn', 'spco', 'fndg', 'bdsu', 'podg', 'tmco', 'qlco', 'dsyn', 'qnco']"
1041,PMC3590447,S64,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Procedures,"those assigned to supportive therapy plus 12 months' of ciclosporin received a starting dose of 5 mg/kg per day,12 adjusted according to trough blood concentrations of the drug to achieve a concentration of 100–200 μg/l.","['C0086045', 'C0178602', 'C1254351', 'C0439231', 'C1313904', 'C0699870', 'C0010592', 'C0439505', 'C1446561', 'C0439272', 'C3827302', 'C0444506', 'C0680240', 'C0456081', 'C0013227', 'C0344211', 'C0427728']","['Concentration measurement', 'Adjustment Action', 'Pharmaceutical Preparations', 'Blood drug concentration', 'Cyclosporine', 'Pharmacologic Substance', 'Mental concentration', 'Blood concentration results', 'Agreement', 'month', 'per day', 'Supportive care', 'mg/kg', 'Able to Concentrate Question', 'Dosage', 'trough', 'Blood concentration test']","['inpr', 'lbpr', 'topp', 'lbtr', 'ftcn', 'tmco', 'qlco', 'socb', ' phsu', 'aapp', 'menp', 'qnco', 'phsu']"
1042,PMC3590447,S65,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Procedures,we reduced the dose if toxicity was evident.,"['C0040539', 'C0178602', 'C0600688']","['Toxicity aspects', 'Dosage', 'Toxic effect']","['inpo', 'qlco', 'qnco']"
1043,PMC3590447,S66,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"we followed up patients until they met the primary endpoint, or for a minimum of 3 years if they did not do so.","['C1524031', 'C0030705', 'C1552614', 'C2986535', 'C1518422', 'C2826545', 'C0439234']","['Minimum', 'Primary Endpoint', 'Minimum Value Derivation Technique', 'ActRelationshipSubset - minimum', 'Patients', 'year', 'Negation']","['idcn', 'ftcn', 'podg', 'qlco', 'tmco', 'irda', 'qnco']"
1044,PMC3590447,S67,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,the trial was not formally analysed until 3 years after all patients had begun treatment.,"['C0439234', 'C0030705', 'C3887704', 'C1705169', 'C0087111', 'C0008976', 'C1522326', 'C1533734', 'C0444868', 'C1518422', 'C0039798', 'C3538994']","['Treatment Epoch', 'All', 'Biomaterial Treatment', 'Clinical Trials', 'Treating', 'Administration procedure', 'Patients', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Therapeutic procedure', 'year', 'Negation']","['topp', 'ftcn', 'cnce', 'podg', 'tmco', 'resa', 'hlca', 'qnco']"
1045,PMC3590447,S68,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,all surviving trial patients remain under routine follow-up at their renal units.,"['C0030705', 'C3853603', 'C0439148', 'C0022646', 'C0008976', 'C0332283', 'C0444868', 'C1519795', 'C4281991', 'C0205547']","['Follow', 'Followed by', 'Routine', 'Unit - NCI Thesaurus Property', 'All', 'Clinical Trials', 'Unit', 'Patients', 'Kidney', 'Unit of Measure']","['bpoc', 'ftcn', 'podg', 'tmco', 'qlco', 'resa', 'qnco']"
1046,PMC3590447,S69,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"the primary endpoint was a further 20% decline in excretory renal function from baseline readings, calculated in all patients with the cockcroft-gault equation (standard methodology at the start of the trial).","['C0168634', 'C0030705', 'C2828392', 'C0552449', 'C3266812', 'C0439659', 'C0008976', 'C0969625', 'C1517331', 'C0232804', 'C1442488', 'C1442989', 'C0444868', 'C2986535']","['BaseLine dental cement', 'Further', 'Baseline', 'Primary Endpoint', 'equation', 'Methodology', 'All', 'Clinical Trials', 'Standard (document)', 'Renal function', 'Patients', 'Beginning', 'Methodology aspects', 'Standard (qualifier)']","['ortf', 'inpr', 'bodm', 'idcn', 'spco', 'cnce', 'podg', 'tmco', 'qlco', 'resa', 'irda', 'qnco']"
1047,PMC3590447,S70,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,secondary endpoints were proteinuria (measured with 24-h urinary collections or estimated from protein–creatinine ratios by multiplying the ratio [in mg/mmol] by 10) and severe adverse events.,"['C4050465', 'C1547037', 'C0205436', 'C2348885', 'C0877248', 'C1705413', 'C0456603', 'C1515981', 'C0027627', 'C1524119', 'C0205082', 'C2349179', 'C4050466', 'C0175668']","['End Point', 'Neoplasm Metastasis', 'Gram per Mole (g/mol)', 'second (number)', 'Adverse Event Domain', 'Borg Category-Ratio 10 Perceived Exertion Score 5', 'Severe Extremity Pain', 'And', 'Ratio', 'Severe (severity modifier)', 'Adverse event', 'urinary', 'Secondary to', 'data type - ratio']","['inpr', 'idcn', 'neop', 'fndg', 'patf', 'qlco', 'qnco']"
1048,PMC3590447,S71,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,the primary investigator (pwm) identified which adverse events were serious and categorised them according to the most affected body system.,"['C0877248', 'C1705413', 'C1521895', 'C0460002', 'C0032350', 'C0392760', 'C2981608', 'C0205404', 'C0205393']","['Principal Investigator', 'Affecting', 'CDISC SEND Body System Terminology', 'Most', 'Adverse Event Domain', 'body system', 'Adverse event', 'Pokeweed Mitogens', 'Serious']","['inpr', 'prog', 'ftcn', 'patf', 'qlco', 'imft', 'bdsy', ' aapp', 'qnco']"
1049,PMC3590447,S72,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,"we report all serious adverse events as defined by the medicines and healthcare products regulatory agency (mhra) guidance15—(ie, any adverse event, adverse reaction, or unexpected adverse reaction that results in death, is life-threatening, results in admission to hospital or extends the length of an existing hospital stay, results in persistent or serious disability or incapacity, or consists of a congenital anomaly or birth defect).","['C1704788', 'C1444754', 'C1706316', 'C0231170', 'C0877248', 'C0439792', 'C0376558', 'C3272371', 'C4684712', 'C0000768', 'C0205404', 'C1552551', 'C1705413', 'C0332996', 'C0184666', 'C1306577', 'C0011065', 'C3489408', 'C0205322', 'C0444868', 'C0559546', 'C4055646']","['Persistent', 'Persistent embryonic structure', 'Congenital Abnormality', 'Any Data Type', 'Hospital Stay', 'Death (finding)', 'Adverse event', 'Any', 'Life', 'Cessation of life', 'Hospital admission', 'Adverse Event Domain', 'All', 'Length', 'Medicines And Healthcare Products Regulatory Agency', 'Extent', 'Definition', 'disability', 'Adverse reactions', 'Unexpected', 'Length of Trial', 'Serious']","['inpr', 'idcn', 'prog', 'fndg', 'patf', 'tmco', 'qlco', 'spco', 'resa', 'cgab', 'hlca', 'orgf', 'qnco']"
1050,PMC3590447,S73,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,we also regarded as serious other important medical events that might have jeopardised the patient or needed intervention to prevent one of these outcomes.,"['C3541888', 'C0886296', 'C0184661', 'C3898777', 'C0030705', 'C0039828', 'C0441471', 'C0199168', 'C0205447', 'C0205404', 'C4084912', 'C0205476']","['Theses', 'CDISC Events Class', 'Importance Rating Score 0', 'Serious', 'Nursing interventions', 'Patients', 'Medical service', 'Medical', 'Important', 'Interventional procedure', 'One', 'Event']","['inpr', 'clas', 'topp', 'ftcn', 'podg', 'qlco', 'hlca', 'qnco', 'evnt']"
1051,PMC3590447,S74,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,we recorded information about deaths and development of end-stage renal disease.,"['C0205390', 'C1527148', 'C1306673', 'C1515981', 'C0022658', 'C1533716', 'C0243107', 'C1300072', 'C2746065', 'C0678723', 'C0444930', 'C0011065']","['Stop (qualifier value)', 'Stage', 'Kidney Diseases', 'Cessation of life', 'development aspects', 'And', 'Phase', 'End', 'Tumor stage', 'Development', 'Information', 'Biologic Development']","['clna', 'idcn', 'phsf', 'ftcn', 'spco', 'tmco', 'dsyn', 'orgf']"
1052,PMC3590447,S75,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,"in accordance with the medical research council's guidelines for good clinical practice, a trial steering committee and a data monitoring committee were established to receive yearly reports for primary endpoints, adverse events, and deaths.","['C2349179', 'C0220845', 'C0877248', 'C2348534', 'C0079816', 'C1705413', 'C1515981', 'C0008976', 'C2986419', 'C0162791', 'C0205225', 'C1551807', 'C0282423', 'C0011065', 'C0936091']","['Council Eskimos', 'End Point', 'Guideline [Publication Type]', 'Medical Research activity', 'Cessation of life', 'Adverse Event Domain', 'Clinical Trials', 'And', 'Steering Committee', 'Adverse event', 'Annual Reports', 'Good Clinical Practice', 'Guidelines', 'guiding characteristics', 'Primary']","['inpr', 'idcn', ' mnob', 'popg', 'patf', 'qlco', 'resa', 'orgf']"
1053,PMC3590447,S77,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analysis,"to have 90% power to detect a reduction in frequency of the primary endpoint from 80% in the supportive treatment group to 40% in the immunosuppression groups with p<0·05, we calculated that 35 patients would be needed in each group (105 in total).","['C0030705', 'C0441833', 'C1373218', 'C0687744', 'C0032863', 'C1705169', 'C0439810', 'C3887704', 'C0301630', 'C1521721', 'C0376249', 'C0871396', 'C4048329', 'C0021080', 'C2986535', 'C1293152', 'C0039798', 'C3538994', 'C4551656', 'C3898838', 'C1552839', 'C1457900', 'C1705502', 'C1705429', 'C4321352', 'C0392756', 'C0439603', 'C1517320', 'C0021079', 'C1519504', 'C1257890', 'C0087111', 'C3854080', 'C1522326', 'C1533734', 'C1705428', 'C1561548']","['Immunosuppression', 'Biomaterial Treatment', 'Patients', 'Power', 'From', 'Reduced', 'Surgical reduction', 'Stage Grouping', 'Therapeutic procedure', 'Reduction (chemical)', 'Primary Endpoint', 'User Group', 'Administration procedure', 'Frequencies (time pattern)', 'Kind of quantity - Frequency', 'Total', 'Group Object', 'Each (qualifier value)', 'Social group', 'Therapeutic immunosuppression', 'Treatment Epoch', 'Decreased Immunologic Activity [PE]', 'Statistical Frequency', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Frequency', 'Groups', 'Spatial Frequency', 'Power (Psychology)', 'Reduction procedure', 'Natural immunosuppression', 'Population Group', 'Table Rules - groups', 'Treating', 'With frequency', 'How Often', 'Supportive assistance']","['hcpp', 'inpr', 'idcn', 'topp', 'popg', 'ftcn', 'cnce', 'patf', 'podg', 'tmco', 'qlco', 'npop', 'resa', 'dsyn', 'hlca', 'irda', 'orgf', 'qnco']"
1054,PMC3590447,S78,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analysis,"after allowing for an estimated dropout rate of 10%, we concluded that we needed to recruit 116 patients.","['C0750572', 'C0030705', 'C0871208', 'C4554109', 'C1521828', 'C0013135']","['Estimated', 'Rate', 'Rating (action)', 'Clinical Trial Dropout', 'Patients', 'Dropouts']","['acty', 'podg', 'qnco', 'popg']"
1055,PMC3590447,S79,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"primary analysis followed the principles of intention to treat, and secondary analysis assessed all patients who received at least one dose of treatment.","['C1283828', 'C0205436', 'C0030705', 'C0178602', 'C0162425', 'C3887704', 'C0936012', 'C1705169', 'C0205447', 'C0087111', 'C0205225', 'C0027627', 'C1524024', 'C1522326', 'C1533734', 'C0444868', 'C3272598', 'C0175668', 'C0039798', 'C3538994']","['Neoplasm Metastasis', 'Therapeutic procedure', 'Treatment Epoch', 'intent', 'second (number)', 'WHO Temperature/Humidity Storage Condition', 'All', 'Biomaterial Treatment', 'Treating', 'Patients', 'Administration procedure', 'Analysis', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Secondary to', 'analysis aspect', 'Dosage', 'One', 'Primary', 'Intention - mental process']","['topp', 'neop', 'ftcn', 'cnce', 'qlco', 'podg', 'resa', 'hlca', 'menp', 'qnco']"
1056,PMC3590447,S80,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"unless otherwise stated, p values and estimates of treatment effects are based on two-way comparisons.","['C0750572', 'C3887704', 'C1705169', 'C0087111', 'C0042295', 'C1515981', 'C1280500', 'C1522326', 'C1533734', 'C0205448', 'C0039798', 'C3538994']","['Estimated', 'Effect', 'Treatment Epoch', 'Biomaterial Treatment', 'And', 'Treating', 'Administration procedure', 'Two', 'Values', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Therapeutic procedure']","['idcn', 'topp', 'ftcn', 'cnce', 'qlco', 'resa', 'hlca', 'qnco']"
1057,PMC3590447,S81,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,we did not make adjustments for multiple comparisons.,"['C2945673', 'C0439064', 'C1518422', 'C0376209']","['Numerous', 'Individual Adjustment', 'Negation', 'Clinical adjustment']","['ftcn', 'qnco', 'topp', 'inbe']"
1058,PMC3590447,S82,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,we analysed time to further 20% decline in renal function by the log-rank test and calculated hazard ratios [hrs] with cox proportional hazards regression.,"['C1515981', 'C0456603', 'C0684320', 'C0232804', 'C1836830', 'C0699794', 'C4318744', 'C0205351', 'C0684321', 'C1517331', 'C1565830', 'C0598697', 'C1515976', 'C0667477', 'C3831328', 'C1568891', 'C0022885', 'C0040223', 'C2986775', 'C0456984', 'C0392366', 'C0039593', 'C1708728']","['TNFRSF11A protein, human', 'HGS protein, human', 'Laboratory Procedures', 'Event Log', 'And', 'Time', 'Test - temporal region', 'PTGS1 protein, human', 'Tests (qualifier value)', 'Testing', 'Ratio', 'Renal function', 'Rank', 'Logarithm', 'Test Result', 'Developmental regression', 'Anatomic Structure, System, or Substance', 'Disease regression', 'Regression - mental defense mechanism', 'Blood Products Laboratory Testing', 'Further', 'hazard', 'proportional']","['bacs', 'inpr', 'ortf', 'idcn', 'lbpr', 'clas', 'enzy', 'lbtr', 'ftcn', 'spco', 'patf', 'qlco', 'tmco', 'blor', 'dsyn', 'menp', ' aapp', 'qnco']"
1059,PMC3590447,S83,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"we used the log-rank test for other survival endpoints, and repeated measures analysis of variance fowr continuous longitudinal data (eg, proteinuria).","['C1511726', 'C0079809', 'C1515981', 'C1524024', 'C0038952', 'C2349179', 'C0699794', 'C0205127', 'C3714741', 'C4318744', 'C0220921', 'C1962972', 'C0936012', 'C2348152', 'C4554346', 'C1515976', 'C0667477', 'C3831328', 'C1711260', 'C0022885', 'C3245479', 'C2986775', 'C0456984', 'C0549178', 'C0392366', 'C0039593', 'C1708728', 'C0033687']","['TNFRSF11A protein, human', 'Laboratory Procedures', 'Event Log', 'And', 'Data call receiving device', 'Continuance of life', 'Test - temporal region', 'Tests (qualifier value)', 'Testing', 'Rank', 'Logarithm', 'Test Result', 'End Point', 'survival aspects', 'Proteinuria, CTCAE 5.0', 'Variance', 'Anatomic Structure, System, or Substance', 'Data', 'Blood Products Laboratory Testing', 'Sample Variance', 'Longitudinal', 'analysis aspect', 'Continuous', 'Analysis', 'Measures', 'Data (eukaryote)', 'Proteinuria, CTCAE 3.0', 'Proteinuria']","['bacs', 'inpr', 'idcn', 'acty', 'lbpr', 'clas', 'medd', 'lbtr', 'ftcn', 'fndg', 'spco', 'qlco', 'euka', 'blor', 'resa', ' aapp', 'qnco']"
1060,PMC3590447,S84,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,we analysed serious adverse event data with the log-rank test on the basis of time to first serious adverse event.,"['C1519255', 'C1511726', 'C0022885', 'C0699794', 'C1515976', 'C3245479', 'C4318744', 'C0040223', 'C2986775', 'C0667477', 'C1279901', 'C0392366', 'C0456984', 'C1527178', 'C3714741', 'C1874451', 'C3831328', 'C1708728', 'C0205435', 'C0039593']","['Basis - conceptual entity', 'Test Result', 'Serious Adverse Event', 'TNFRSF11A protein, human', 'Firstly', 'Laboratory Procedures', 'Event Log', 'Logarithm', 'Tests (qualifier value)', 'Data call receiving device', 'First (number)', 'Testing', 'Anatomic Structure, System, or Substance', 'Rank', 'Time', 'Test - temporal region', 'Data (eukaryote)', 'Data', 'Blood Products Laboratory Testing', 'Basis']","['bacs', 'inpr', 'idcn', 'lbpr', 'clas', 'medd', 'lbtr', 'ftcn', 'fndg', 'blor', 'tmco', 'euka', 'qlco', ' aapp', 'qnco', 'phsu']"
1061,PMC3590447,S85,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,we did statistical analyses using sas software (version 9.2).,"['C0038215', 'C1426104', 'C0333052', 'C0037585', 'C0605290', 'C1823519']","['NANS gene', 'Science of Statistics', 'Computer software', 'TSPAN31 gene', 'Version', 'SAS']","['inpr', ' mnob', 'gngm', 'ocdi', 'orch']"
1062,PMC3590447,S86,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"in 2003, the trial was shown to comply with the requirements of the eu clinical trials directive, and in 2004, a clinical trial authorisation (cta) was obtained from the medicines and healthcare products regulatory authority (cta number 18524/0001/001).","['C1301820', 'C0086388', 'C1517320', 'C1514468', 'C3540513', 'C1515981', 'C3813556', 'C0008976', 'C3871158', 'C0043194', 'C1096775', 'C1421478', 'C1565156', 'C0449788', 'C0013227', 'C0332287', 'C0237753', 'C4554671', 'C2981655']","['CERNA3 gene', 'Health Care', 'Count of entities', 'Pharmaceutical Preparations', 'Cancer/Testis Antigen', 'PCYT1A wt Allele', 'WAS protein, human', 'Clinical Trials', 'WAS gene', 'And', 'Wiskott-Aldrich Syndrome', 'Directive', 'Numbers', 'Regulatory Authority', 'Clinical Trial [Publication Type]', 'From', 'In addition to', 'product', 'Obtain']","['bacs', 'inpr', 'idcn', 'gngm', 'enty', 'ftcn', 'qlco', 'resa', 'hlca', 'aapp', ' aapp', 'gora', 'qnco', 'phsu', 'dsyn']"
1063,PMC3590447,S87,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"in 2008, the trial was adopted onto the national institute for health research portfolio and assigned the uk clinical research network identification number 2579.","['C1272753', 'C0008972', 'C0018684', 'C1705739', 'C1300638', 'C1515981', 'C0008976', 'C1516050', 'C4321252', 'C1565156', 'C0021622', 'C3245503', 'C0425382', 'C0043194', 'C1513822', 'C1882071', 'C0035168', 'C0150775', 'C0521125', 'C0242481', 'C1552601', 'C1421478']","['identification number', 'And', 'Network', 'Preposition For', 'National citizen', 'WWOX wt Allele', 'PersonNameUse - assigned', 'WAS protein, human', 'Clinical Trials', 'WAS gene', 'Personal status - Adopted', 'Social Networks', 'Consortium or Network', 'Institutes', 'Assignment - action', 'research', 'Network Device', 'Clinical Research', 'Wiskott-Aldrich Syndrome', 'Research Activities', 'Institution (social concept)', 'Health']","['bacs', 'inpr', 'idcn', 'gngm', 'prog', 'popg', 'ftcn', 'mnob', 'fndg', 'qlco', 'resa', 'dsyn', ' aapp', 'orgt']"
1064,PMC3590447,S88,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"the trial is registered as an international standard randomised controlled trial, number 99959692.",,,
1065,PMC3590447,S90,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Role of the funding source,"the sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.","['C1511726', 'C0010995', 'C0684224', 'C0043266', 'C2584304', 'C4255046', 'C3714741', 'C3273238', 'C2983265', 'C2986888', 'C0010992', 'C2603343', 'C4283917', 'C3173575', 'C3887707', 'C0035171', 'C4050126', 'C0062074', 'C1705810', 'C0700287', 'C0035820', 'C3539897', 'C3245479', 'C1415458', 'C0459471', 'C3871154']","['Writing (function)', 'Reporting', 'Interpretation:Impression/interpretation of study:Point in time:^Patient:Nominal', 'Role', 'Data call receiving device', 'Ability to Write question', 'Have', 'Research Design', 'Writing Ability', 'Regulatory Report', 'HADH gene', 'Nonclinical Study Design', 'Data Collection', 'Data Collection Methods', 'Social Role', 'Study', 'Data', 'Data Analysis', 'Report (document)', 'Report:Finding:Point in time:{Setting}:Document:{Role}', 'Interpretation Process', 'HAC protocol', 'Generic Role', 'Data (eukaryote)', 'CDISC SEND Study Design Terminology', 'Writing (occupation or discipline)']","['inpr', 'clna', 'idcn', 'gngm', 'ocdi', 'ocac', 'topp', 'medd', 'qlco', 'euka', 'resa', 'socb', 'hlca', 'menp', 'qnco']"
1066,PMC3590447,S91,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Role of the funding source,the corresponding author had full access to all the data in the study and had final responsibility to submit for publication.,"['C1511726', 'C0034037', 'C3812881', 'C3245479', 'C0034036', 'C0678341', 'C0443225', 'C1515981', 'C1554204', 'C2603343', 'C1546485', 'C3853528', 'C0444868', 'C0444454', 'C1704324', 'C3714741', 'C0205088']","['author', 'Role Class - access', 'Scientific Publication', 'full', 'Final', 'responsibility', 'Diagnosis Type - Final', 'All', 'And', 'Data call receiving device', 'Study', 'Publishing', 'Publications', 'Data', 'End-stage', 'Access', 'Data (eukaryote)']","['inpr', 'inbe', 'idcn', ' mnob', 'prog', 'ocac', 'medd', 'ftcn', 'spco', 'qlco', 'euka', 'tmco', 'resa', 'qnco']"
1067,PMC3623038,S114,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Supplementary Material,web supplement,"['C0282111', 'C0242295', 'C2348609', 'C1947943']","['Supplement (document)', 'Internet', 'Dietary Supplements', 'Supplement']","['food', 'mnob', 'inpr', 'ftcn']"
1068,PMC3623038,S116,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Supplementary Material,web figure,['C0282111'],['Internet'],['mnob']
1069,PMC3623038,S118,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Supplementary Material,web table,"['C0282111', 'C1706074', 'C0039224']","['Table - furniture', 'Internet', 'Data Table']","['mnob', 'inpr']"
1070,PMC3623038,S28,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients and methods,the present randomised trial complied with the consort 2010 guidelines and was registered at clinicaltrials.gov (identifier: nct01108029).,,,
1071,PMC3623038,S30,"['4a', '4b']","[0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"consecutive patients (diagnosed according to gibb's criteria9 and monitored at lille university hospital's pd clinic) were invited to participate in the study by cm, ad, ld and dd until the required number of participants was obtained.","['C0020028', 'C1514873', 'C2603343', 'C0237753', 'C0679646', 'C0442592', 'C0449788', 'C0030705', 'C1515981', 'C1720302', 'C0002424', 'C1707491']","['Participant', 'Consecutive', 'Clinic', 'Requirement', 'Count of entities', 'And', 'Hospitals, University', 'Patients', 'Study', 'Ambulatory Care Facilities', 'Until', 'Numbers']","[' hcro', 'idcn', 'inpr', 'qlco', 'qnco', 'resa', 'podg', 'ftcn', 'mnob', 'popg']"
1072,PMC3623038,S31,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"patients were enrolled between may 2010 and november 2010, following their provision of written, informed consent to participation.",,,
1073,PMC3623038,S32,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,the research protocol was approved by the local independent ethics committee (protocol id: 2008-008210-38).,"['C3715209', 'C4282383', 'C0035168', 'C0205276', 'C1507394', 'C4554082', 'C0242481', 'C1522729', 'C2348563', 'C2599718', 'C0086911', 'C0442711']","['Protocols documentation', 'Research Activities', 'REMS Protocol', 'Clinical trial protocol document', 'Library Protocol', 'research', 'Study Protocol', 'Ethics Committees, Research', 'Protocol - answer to question', 'Independent Ethics Committee', 'Clinical trial protocol', 'Local']","['fndg', 'prog', 'inpr', 'spco', 'resa']"
1074,PMC3623038,S33,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"the main inclusion criterion was the presence of a severe gait disorder (defined as a score ≥2 for updrs part iii item 29) and an abnormal, forward-leaning stance (a score ≥2 for item 28) despite optimal l-dopa treatment.","['C2699333', 'C1512693', 'C0205225', 'C3538994', 'C0243161', 'C1533734', 'C0205082', 'C0575081', 'C0087111', 'C0205161', 'C1705160', 'C2698651', 'C3887704', 'C1705169', 'C0449820', 'C0039798', 'C1542147', 'C4554251', 'C0439070', 'C1709471', 'C4050231', 'C1704788', 'C0449719', 'C0439780', 'C0007637', 'C1551338', 'C4050466', 'C0150312', 'C0013023', 'C1522326', 'C0392148', 'C1515981', 'C4050465']","['Dopa', 'Part Dosing Unit', 'Borg Category-Ratio 10 Perceived Exertion Score 5', 'And', 'Clinical Item', 'Gait abnormality', 'Definition', 'Forward', 'Main', 'Score', 'Treatment Epoch', 'Entity', 'Inclusion Bodies', 'Biomaterial Treatment', 'Administration procedure', 'Abnormal Reference Range', 'Severe Extremity Pain', 'Roman Numeral III', 'Part', 'Inclusion', 'Optimum', 'Abnormal', 'III (suffix)', 'Primary', 'Severe (severity modifier)', 'treatment - ActInformationManagementReason', 'Treating', 'criteria', 'ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated', 'Providing presence (regime/therapy)', 'therapeutic aspects', 'Present', 'Therapeutic procedure']","['fndg', 'resa', 'topp', 'idcn', 'hlca', 'inpr', 'celc', 'qlco', 'bacs', 'qnco', 'enty', 'spco', 'ftcn', ' aapp', ' phsu', 'cnce', 'clna']"
1075,PMC3623038,S34,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,the main exclusion criterion was the presence of axial disorders related to insufficient doses of l-dopa or off-periods of motor fluctuation or those induced by stn stimulation.,"['C0205412', 'C0439856', 'C0013023', 'C1948023', 'C0205225', 'C2828389', 'C0012634', 'C0231180', 'C0178602', 'C1542147', 'C0392148', 'C0205131', 'C0243161', 'C1292856', 'C0680251', 'C1868976', 'C0150312']","['Dopa', 'Axial', 'Main', 'Primary', 'Unsatisfactory', 'Exclusion Criteria', 'criteria', 'Exclusion', 'Providing presence (regime/therapy)', 'Disease', 'Dosage', 'Insufficient (qualifier)', 'Motor fluctuation', 'Inadequate (qualifier)', 'Present', 'Stimulation procedure', 'Stimulation (motivation)']","['fndg', 'npop', 'topp', 'idcn', 'qnco', 'bacs', 'qlco', 'dsyn', 'spco', 'ftcn', ' aapp', ' phsu', 'acty']"
1076,PMC3623038,S35,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,patients receiving stn stimulation had to have shown an improvement of at least 50% in motor symptoms during the first year of this treatment (without a worsening in gait and posture).,"['C1279901', 'C3538994', 'C1546960', 'C0332271', 'C1533734', 'C0087111', 'C0205435', 'C1948023', 'C1262869', 'C1705169', 'C2986411', 'C0039798', 'C3887704', 'C0030705', 'C0439234', 'C1705994', 'C1522326', 'C1080058', 'C0683368', 'C1513492', 'C1457887', 'C1292856']","['year', 'Symptoms', 'Worsening pattern', 'Firstly', 'First (number)', 'Treatment Epoch', 'Biomaterial Treatment', 'Device Motor', 'Administration procedure', 'Stimulation procedure', 'Symptoms aspect', 'Patients', 'Improvement', 'Stimulation (motivation)', 'Patient Outcome - Worsening', 'treatment - ActInformationManagementReason', 'Treating', 'motor movement', 'therapeutic aspects', 'Body position', 'This (eukaryote)', 'Therapeutic procedure']","['tmco', 'fndg', 'npop', 'topp', 'idcn', 'hlca', 'sosy', 'qnco', 'qlco', 'euka', 'resa', 'podg', 'ftcn', 'mnob', 'cnce']"
1077,PMC3623038,S36,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,the appearance of axial signs immediately after the initiation of stn stimulation was also an exclusion criterion.,"['C1158830', 'C0205548', 'C1948023', 'C0700364', 'C2828389', 'C0220912', 'C1704686', 'C0243161', 'C0680251', 'C0205131', 'C0220913', 'C1292856', 'C4084721', 'C0589507', 'C0233426', 'C0311392']","['Appearance', 'Physical findings', 'Stat (do immediately)', 'Axial', 'Aspects of signs', 'Personal appearance', 'Exclusion Criteria', 'Transcription Initiation', 'Appearance Distress Question', 'criteria', 'Exclusion', 'Stimulation procedure', 'Manufactured sign', 'Cognitive function: initiation', 'Stimulation (motivation)', 'Initiation']","['tmco', 'fndg', 'npop', 'topp', 'idcn', 'inpr', 'genf', 'qlco', 'orga', 'spco', 'ftcn', 'mnob', 'menp', 'acty']"
1078,PMC3623038,S37,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"other notable exclusion criteria included (i) inability to walk unaided while on dopaminergic treatment, (ii) dementia (diagnosed according to the dsm-iv-r criteria and with a mattis dementia rating scale score <130) and (iii) the ongoing administration of an nmda antagonist other than memantine.","['C0750519', 'C0011265', 'C0560046', 'C4288581', 'C3538994', 'C0243161', 'C0680251', 'C1533734', 'C0220952', 'C0087111', 'C1705160', 'C0231491', 'C3887704', 'C1705169', 'C0039798', 'C0439070', 'C0439846', 'C0332287', 'C0451074', 'C0079883', 'C0497327', 'C0001554', 'C0549178', 'C0282151', 'C1522326', 'C1515981', 'C4049715', 'C0025242']","['DSM-IV', 'In addition to', 'Dementia', 'And', 'while', 'Presenile dementia', 'N-Methylaspartate', 'Treatment Epoch', 'Notable', 'Biomaterial Treatment', 'Administration procedure', 'Dopamine Hydrochloride', 'Continuous', 'Exclusion Criteria', 'Roman Numeral III', 'Therapeutic procedure', 'Memantine', 'PedsQL-4 Scale Score', 'III (suffix)', 'Antagonist muscle action', 'Clinical dementia rating scale', 'treatment - ActInformationManagementReason', 'Treating', 'criteria', 'therapeutic aspects', 'unaided', 'Inability to walk', 'Administration occupational activities']","['ocac', 'ortf', 'fndg', 'resa', ' orch', 'topp', 'idcn', 'hlca', 'inpr', 'orch', 'qlco', 'bacs', 'mobd', 'ftcn', ' aapp', ' phsu', 'cnce']"
1079,PMC3623038,S39,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Experimental design,"we performed a 90-day, double-blind, placebo-controlled pilot study.","['C2587213', 'C0332173', 'C2911690', 'C0031928', 'C0439228']","['day', 'Disease Controlled', 'Control function', 'Pilot Projects', 'Daily']","['tmco', 'ftcn', 'fndg', 'resa']"
1080,PMC3623038,S41,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,subjects were randomly assigned to memantine or placebo.,,,
1081,PMC3623038,S42,"['8a', '10']","[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0]",Randomisation and masking,the 1 : 1 assignment sequence (based on a computer random-number generator) was produced by our department of biostatistics.,"['C0439605', 'C0162326', 'C1516050', 'C2717898', 'C1704729', 'C0237753', 'C3853789', 'C0449788', 'C0004793', 'C0237638', 'C0009622', 'C0034656', 'C1519249', 'C2718322', 'C0162327', 'C0005544']","['Assignment - action', 'DNA Sequence', 'Sequence - TransmissionRelationshipTypeCode', 'Biometry and Biostatistics (occupation or discipline)', 'Sequence', 'Count of entities', 'Biometry', 'RNA Sequence', 'Department', 'Random', 'Generators (Apparatus)', 'Biostatistics', 'Computers', 'Randomization', 'Base Sequence', 'Numbers']","['nusq', 'orgt', 'ocdi', 'inpr', 'qnco', 'qlco', 'resa', 'ftcn', 'mnob']"
1082,PMC3623038,S43,"['11b', '10']","[0, 1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,"the randomisation list was sent to an independent contract research organisation (lc2, lentilly, france) for preparation and distribution of identical capsules of memantine and placebo.","['C3272378', 'C0205280', 'C0242481', 'C0035168', 'C1704711', 'C1521827', 'C0085862', 'C1706408', 'C3812761', 'C0332522', 'C1705564', 'C0016674', 'C0745732', 'C0032042', 'C0006935', 'C1515981', 'C1696465', 'C1290940', 'C0520511', 'C1299583', 'C0025242']","['placebo', 'And', 'Independent for Transfer', 'Independence', 'Distributing', 'List', 'Prepared Material', 'Preparation', 'Placebos', 'identical', 'Placebo Control', 'capsule (pharmacologic)', 'Independently able', 'Contract agreement', 'Memantine', 'Sequence Data Type', 'Research Activities', 'research', 'France', 'Routine Contract', 'Distribution']","['fndg', 'idcn', 'topp', 'inpr', 'geoa', 'orch', 'qnco', 'qlco', 'ftcn', 'resa', 'bodm', 'acty', ' phsu', 'cnce']"
1083,PMC3623038,S45,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Intervention,"patients, study staff and investigators were blinded to the assignment.","['C0851286', 'C1947908', 'C2603343', 'C1516050', 'C1515981', 'C0035173']","['Assignment - action', 'Research Personnel', 'And', 'Staff', 'Study', 'On Staff']","['idcn', 'resa', 'prog', 'ftcn']"
1084,PMC3623038,S46,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Intervention,"after a 30-day dose titration phase (with an increase of 5 mg of memantine per week or a placebo), the patients received a daily dose (at 7:00) of 20 mg of memantine (ie, the usual recommended dose) or placebo for a further 60 days.","['C0178602', 'C0521125', 'C1710475', 'C0025242', 'C0162621', 'C4321252', 'C0034866', 'C0332173', 'C0030705', 'C1706408', 'C2348070', 'C1514756', 'C0439228', 'C0442805', 'C0332287', 'C0205390', 'C0332174', 'C0032042', 'C1696465', 'C1517331', 'C3538928']","['placebo', 'In addition to', 'Further', 'Daily Dose', 'Placebos', 'Increase', 'Placebo Control', 'WWOX wt Allele', 'Dosage', 'Patients', 'Memantine', 'Daily', 'Trial Phase', 'Preposition For', 'Titration Method', 'Phase', 'Receive', 'Recommendation', 'day', 'Usual', 'Weekly']","['tmco', 'gngm', 'topp', 'idcn', 'clas', 'orch', 'qnco', 'qlco', 'lbpr', 'spco', 'resa', 'podg', 'bodm', 'ftcn', ' phsu']"
1085,PMC3623038,S47,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Intervention,all patients undergoing stn stimulation were assessed under ‘on-stim’ conditions.,"['C0444868', 'C1948023', 'C1292856', 'C0030705']","['Patients', 'Stimulation (motivation)', 'Stimulation procedure', 'All']","['podg', 'qnco', 'topp', 'npop']"
1086,PMC3623038,S48,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Intervention,patients were not allowed to change their medication regimen or stn stimulation settings in the 3 months prior to the study or during the study itself.,"['C2603343', 'C1518422', 'C1948023', 'C4284232', 'C4533435', 'C0030705', 'C3244316', 'C2945654', 'C0332152', 'C0013227', 'C0040808', 'C1292856']","['Settings', 'Treatment Protocols', 'Medications', 'Regimen - CHV concept', 'Patients', 'Stimulation procedure', 'Before', 'Study', 'Pharmaceutical Preparations', 'Negation', 'Stimulation (motivation)', 'medication - HL7 publishing domain']","['tmco', 'npop', 'topp', 'inpr', 'qlco', 'resa', 'podg', 'ftcn', 'phsu']"
1087,PMC3623038,S50,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Efficacy criteria,the primary efficacy criterion was the change in stride length (m) under ‘on-l-dopa’ conditions.,"['C0443172', 'C1705241', 'C0205225', 'C1706316', 'C0243161', 'C0392747', 'C4319952', 'C1444754', 'C1707887', 'C1280519']","['Effectiveness', 'Changing', 'Primary', 'criteria', 'Efficacy Study', 'Length of Trial', 'Changed status', 'Change -- procedure', 'Delta (difference)', 'Length']","['topp', 'idcn', 'qnco', 'qlco', 'resa', 'ftcn']"
1088,PMC3623038,S51,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Efficacy criteria,"stride length was assessed in an optoelectronic analysis with a 6-camera vicon video system from oxford metrics (oxford, uk) (sampling rate: 50 hz).","['C3888058', 'C0179533', 'C0449913', 'C1521828', 'C1654607', 'C0441621', 'C1553451', 'C3463807', 'C0042655', 'C1444754', 'C0699680', 'C1706316', 'C0871208', 'C1524024', 'C0870078', 'C0936012']","['Length', 'Sampling', 'System - kit', 'System', 'Device system', 'Analysis', 'Rate', 'analysis aspect', 'Length of Trial', 'Camera <invertebrate>', 'Rating (action)', 'videocassette', 'Video Media', 'Sampling - Surgical action', 'Camera, device', 'Metric']","['idcn', 'inpr', 'orch', 'qnco', 'euka', 'resa', 'ftcn', 'mnob', ' phsu', 'diap', 'acty']"
1089,PMC3623038,S52,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Efficacy criteria,"secondary efficacy criteria included (i) gait velocity (m/s) and cadence (steps/min); (ii) motor handicap, assessed as the overall updrs motor score and its axial subscore (the sum of items 18 (speech), 19 (facial expression), 22 (neck rigidity), 27 (arising from a chair), 28 (posture), 29 (gait) and 30 (postural stability)); (iii) lid, assessed as the overall dyskinesia rating scale score and its axial subscore; (iv) hypertonia of axial flexors and extensors, assessed as the mean work (in joules) performed during 10 passive trunk movements at 30°/s on a con-trex isokinetic dynamometer (cmv ag, dübendorf, switzerland)10; (v) trunk flexor and extensor strength, measured as the mean work (in joules) performed over three repetitions at 30°/s in active flexion and extension mode on the isokinetic dynamometer.10","['C1561607', 'C2348146', 'C0205449', 'C0013384', 'C0243161', 'C4049715', 'C1524106', 'C1513371', 'C0231452', 'C0205136', 'C0439830', 'C0205177', 'C0037817', 'C3888249', 'C1879367', 'C1705160', 'C0282416', 'C0460005', 'C1523842', 'C0439493', 'C1262869', 'C0439256', 'C0449820', 'C0205436', 'C0231172', 'C0439070', 'C0205131', 'C1525443', 'C0151315', 'C0179847', 'C0026649', 'C1707887', 'C0039021', 'C0233651', 'C0180572', 'C1280519', 'C4050231', 'C0237897', 'C0205341', 'C1880641', 'C3639721', 'C2348143', 'C0231448', 'C0175668', 'C2700369', 'C1705994', 'C0347984', 'C4019053', 'C0884358', 'C0026826', 'C0016928', 'C1705922', 'C0681889', 'C0205278', 'C4318616', 'C0444504', 'C0808080', 'C0332284', 'C1517320', 'C1705738', 'C0027627', 'C2347637', 'C2347098', 'C1184148', 'C1515051', 'C0205360', 'C1515981', 'C1513492', 'C0043227', 'C0015457', 'C2347634', 'C3853793']","['Active License', 'Usually Need Help from Another Person for Arising', 'Overall', 'Flexion, function', 'Movement', 'Population Mode', 'Performed', 'And', 'active (HL7 RoleLink)', 'From', 'Switzerland', 'Sum', 'Trunk structure', 'Medical Product Stability', 'Extensor', 'Stable status', 'rating scale', 'Effectiveness', 'Sample Mean', 'Physical Strength', 'Sample Mode', 'Arising in', 'Chairs', 'Mode', 'STRENGTH (attribute)', 'Score', 'second (number)', 'Population Mean', 'Muscle Hypertonia', 'Chairperson', 'W flexion', 'Device Motor', 'Speech', 'Active', 'Repeat', 'Axial', 'Neoplasm Metastasis', 'dynamometers', 'Trunk of plant', 'Pharmaceutical Strength', 'handicapping condition', 'Perseveration', 'Roman Numeral III', 'Joule, Unit of energy', 'Statistical mean', 'During', 'Overall Publication Type', 'Dyskinetic syndrome', 'Arising', 'PedsQL-4 Scale Score', 'Flexor (Anatomical coordinate)', 'Work', 'III (suffix)', 'Velocity', 'postural', 'Facial Expression', 'Neck stiffness', 'Meter per Second', 'dendritic shaft', 'Secondary to', 'motor movement', 'ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated', 'Over (spatial)', 'Efficacy Study', 'Gait', 'criteria', 'Body position', 'Three', 'Telephone Extension Number', ""Unified Parkinson's Disease Rating Scale"", 'Extension', 'Statistical Mode']","['celc', 'qnco', 'clna', ' qnco', 'blor', 'fndg', 'ortf', 'idcn', 'inpr', 'sosy', 'qlco', 'resa', 'ftcn', 'mnob', 'tmco', 'ocac', 'prog', 'plnt', 'mobd', 'spco', 'neop', 'cnce', 'medd', 'dora', 'geoa', 'dsyn', 'orgf']"
1090,PMC3623038,S53,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Efficacy criteria,"all measurements were recorded in a double-blind manner in our hospital's gait laboratory by cm, ad and vt.","['C0205173', 'C0456909', 'C0019994', 'C1705765', 'C3244292', 'C0150108', 'C1515981', 'C4283904', 'C0016928', 'C0022877', 'C0525065', 'C0444868', 'C1705764', 'C0242485']","['Duplicate', 'Laboratory', 'Laboratory domain', 'All', 'Visually Impaired Persons', 'And', 'Double Value Type', 'Gait', 'Hospitals', 'Blinded', 'Doubling', 'Measurement', 'Blindness', 'Laboratory observation']","['fndg', 'lbtr', ' hcro', 'idcn', 'qnco', 'qlco', 'resa', 'podg', 'ftcn', 'mnob', 'acty']"
1091,PMC3623038,S55,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Standardised assessment,"efficacy criteria were assessed at 8:30 in the morning under ‘off-l-dopa’ conditions, that is, at least 8 h after the withdrawal of dopaminergic medications.","['C0231290', 'C2349954', 'C0013036', 'C3812880', 'C0332170', 'C0687676', 'C0243161', 'C0542339', 'C1710677', 'C1707887', 'C2825032', 'C4049634', 'C1280519']","['Withdrawal (dysfunction)', 'Effectiveness', 'Inferior', 'Status post', 'Morning', 'Withdrawal - birth control', 'Withdrawal Scale (BASC-2)', 'Dopaminergic Agents', 'Withdrawal by Subject', 'criteria', 'Efficacy Study', 'Withdraw (activity)', 'Post']","['tmco', 'topp', 'idcn', 'inpr', 'qlco', 'mobd', 'spco', 'resa', 'acty', 'phsu']"
1092,PMC3623038,S56,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Standardised assessment,"after acute administration of l-dopa at 9:00, the ‘best on’ condition was assessed at between 9:30 and 10:00 on the same morning.","['C3864998', 'C1516048', 'C0205103', 'C0013023', 'C0205178', 'C0348080', 'C0445247', 'C1421478', 'C1565156', 'C0012634', 'C1705253', 'C0332170', 'C0043194', 'C1515981', 'C0001554', 'C1533734']","['Same', 'Dopa', 'Condition:Find:Pt:^Patient:Nom', 'Logical Condition', 'WAS protein, human', 'Morning', 'WAS gene', 'And', 'Disease', 'Assessed', 'Condition', 'acute', 'Administration procedure', 'Intermediate', 'Wiskott-Aldrich Syndrome', 'Administration occupational activities']","['clna', 'tmco', 'ocac', 'gngm', 'topp', 'idcn', 'qlco', 'bacs', 'dsyn', 'spco', ' aapp', ' phsu', 'cnce', 'acty']"
1093,PMC3623038,S57,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Standardised assessment,all assessments were performed once before the 90-day course of study medication and once afterwards.,"['C2603343', 'C0332173', 'C4284232', 'C1948045', 'C1515981', 'C3244316', 'C1261322', 'C0750729', 'C0444868', 'C0439228', 'C0013227']","['Once (schedule frequency)', 'Course', 'Medications', 'All', 'day', 'And', 'Evaluation procedure', 'Study', 'Daily', 'Pharmaceutical Preparations', 'medication - HL7 publishing domain']","['tmco', 'idcn', 'hlca', 'inpr', 'qnco', 'resa', 'phsu']"
1094,PMC3623038,S58,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Standardised assessment,"the l-dopa dose used in the assessment was 150% of the usual, first morning dose taken by patients to relieve their symptoms (table 1).","['C0013023', 'C0205435', 'C1279901', 'C1421478', 'C0683368', 'C0039224', 'C0030705', 'C0178602', 'C0332170', 'C1565156', 'C1706074', 'C0043194', 'C1261322', 'C1457887', 'C1516048', 'C3538928']","['Dopa', 'Firstly', 'Symptoms aspect', 'Data Table', 'First (number)', 'WAS protein, human', 'Morning', 'WAS gene', 'Symptoms', 'Usual', 'Dosage', 'Patients', 'Assessed', 'Evaluation procedure', 'Table - furniture', 'Wiskott-Aldrich Syndrome']","['tmco', 'gngm', 'hlca', 'inpr', 'sosy', 'qnco', 'bacs', 'qlco', 'dsyn', 'ftcn', 'podg', ' aapp', 'mnob', ' phsu', 'acty']"
1095,PMC3623038,S59,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Standardised assessment,table 1 characteristics of the study population,,,
1096,PMC3623038,S61,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Safety criteria,"adverse events, arterial blood pressure values, an electrocardiogram and a standard blood biochemistry profile were recorded monthly.","['C0005477', 'C2003903', 'C0005767', 'C0005768', 'C1442989', 'C0013798', 'C0229664', 'C0332177', 'C1515981', 'C1272641', 'C1705413', 'C1979963', 'C0877248', 'C0042295', 'C2828392', 'C1623258']","['Electrocardiography', 'Profile (lab procedure)', 'peripheral blood', 'Electrocardiogram', 'And', 'Adverse Event Domain', 'Monthly (qualifier value)', 'In Blood', 'Profiling (action)', 'Biochemistry', 'Standard (qualifier)', 'Systemic arterial pressure', 'Blood', 'Standard (document)', 'Adverse event', 'Values']","['tmco', 'fndg', 'idcn', 'inpr', 'ocdi', 'qlco', 'lbpr', 'ftcn', 'diap', 'patf', 'bdsu']"
1097,PMC3623038,S62,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Safety criteria,"in view of a possible antagonistic effect of memantine on nicotinic acetylcholine receptors,5 drowsiness was assessed on the epworth sleepiness scale.","['C4553332', 'C0013144', 'C2348382', 'C0332149', 'C1705910', 'C0449911', 'C1518681', 'C1280500', 'C0034830', 'C2830004', 'C3541276', 'C0025242']","['Effect, Appearance', 'Drowsiness Visual Analogue Scale', 'Outcome of Therapy', 'Possibly Related to Intervention', 'Nicotinic Receptors', 'Effect', 'view', 'Memantine', 'Epworth Sleepiness Scale Questionnaire', 'Drowsiness', 'Possible', 'Somnolence']","['fndg', 'inpr', 'orch', 'qlco', 'mobd', 'spco', 'rcpt', ' aapp', ' phsu']"
1098,PMC3623038,S63,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Safety criteria,the study's data and safety monitoring board examined adverse event reports periodically but the blinding code was not broken.,"['C2603343', 'C1511726', 'C3245479', 'C1518422', 'C0684224', 'C0805701', 'C3889645', 'C0150108', 'C1515981', 'C0949757', 'C0009219', 'C0332182', 'C3714741', 'C0700287', 'C0877248', 'C3889831']","['Coding', 'Data call receiving device', 'Periodic', 'eTMF Content Model Code', 'Data (eukaryote)', 'Reporting', 'And', 'Clinical Trial Final Report', 'Blinded', 'Study', 'Report (document)', 'Code', 'Clinical Trials Data Monitoring Committees', 'Negation', 'Adverse event', 'Data']","['tmco', 'ocac', 'prog', 'medd', 'hlca', 'idcn', 'inpr', 'euka', 'resa', 'ftcn', 'patf']"
1099,PMC3623038,S64,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Safety criteria,"in order to estimate the final plasma concentration of memantine, a blood sample was taken from all patients (ie, both groups, to maintain blinding) before the morning administration of study medication at 7:00 on the last day of treatment.","['C4284232', 'C1565156', 'C3538994', 'C0332170', 'C1706086', 'C0332152', 'C1533734', 'C1705176', 'C1883727', 'C0087111', 'C0683150', 'C0441833', 'C0205088', 'C0332173', 'C3887704', 'C1705169', 'C3853528', 'C0039798', 'C0030705', 'C0150108', 'C0178913', 'C3244316', 'C1546485', 'C0439228', 'C0024501', 'C1882348', 'C1552839', 'C1421478', 'C0043194', 'C0001554', 'C0444868', 'C1705177', 'C1517320', 'C0013227', 'C1517741', 'C1705175', 'C3889825', 'C1705178', 'C2603343', 'C1522326', 'C0687744', 'C0025242']","['Order (arrangement)', 'End-stage', 'From', 'Study', 'Diagnosis Type - Final', 'Table Rules - groups', 'Permutation', 'Morning', 'Treatment Epoch', 'plasma concentration', 'Before', 'Biomaterial Treatment', 'Administration procedure', 'Taken', 'Wiskott-Aldrich Syndrome', 'Groups', 'All', 'Order (action)', 'Social group', 'Maintenance', 'WAS gene', 'Patients', 'Blinded', 'Therapeutic procedure', 'Memantine', 'Daily', 'Order (document)', 'Pharmaceutical Preparations', 'Order (taxonomic)', 'Blood specimen', 'medication - HL7 publishing domain', 'Medications', 'day', 'treatment - ActInformationManagementReason', 'Last', 'Treating', 'WAS protein, human', 'therapeutic aspects', 'Both', 'Sequence of Planned Assessment Schedule', 'Final', 'Administration occupational activities']","['topp', 'qnco', 'podg', ' aapp', 'idcn', 'clas', 'hlca', 'inpr', 'qlco', 'bacs', 'resa', 'ftcn', 'popg', 'bdsu', 'tmco', 'phsu', 'ocac', 'orch', 'acty', 'cnce', 'gngm', 'dsyn', ' phsu']"
1100,PMC3623038,S66,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size calculation,"in a previous study of 17 patients on methylphenidate, we had observed a stride length increase (relative to baseline) of 0.4 m (sd: 0.4) in the stand-walk-sit test after 3 months of treatment.11","['C1515976', 'C0022885', 'C4318744', 'C0205156', 'C0168634', 'C3538994', 'C3539897', 'C1533734', 'C0087111', 'C3887704', 'C1705169', 'C0039798', 'C0030705', 'C0392366', 'C0442805', 'C1415458', 'C0596013', 'C0456984', 'C0025810', 'C0062074', 'C1444754', 'C1704644', 'C1441672', 'C2603343', 'C1522326', 'C1442488', 'C0039593', 'C1552607', 'C0205345', 'C3831328', 'C1706316', 'C0080103']","['Methylphenidate', 'Relative', 'Test - temporal region', 'HAC protocol', 'Study', 'HADH gene', 'Observed', 'Does stand', 'Treatment Epoch', 'Tests (qualifier value)', 'Biomaterial Treatment', 'Baseline', 'Laboratory Procedures', 'Administration procedure', 'Stand Device', 'Increase', 'Test Result', 'Testing', 'Relative (related person)', 'Patients', 'Act Relationship Subset - previous', 'BaseLine dental cement', 'treatment - ActInformationManagementReason', 'Anatomic Structure, System, or Substance', 'Treating', 'Have', 'therapeutic aspects', 'Blood Products Laboratory Testing', 'Length of Trial', 'Previous', 'Length', 'Therapeutic procedure']","['topp', 'qnco', 'podg', 'bodm', 'blor', 'fndg', 'clas', 'hlca', 'inpr', 'qlco', 'lbpr', 'resa', 'ftcn', 'mnob', 'tmco', 'lbtr', 'orch', 'cnce', 'gngm', 'famg', ' phsu']"
1101,PMC3623038,S67,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size calculation,"despite our use of a more sensitive optoelectronic analysis in the present study, we adopted the same anticipated stride length difference, that is, 0.4 m (sd: 0.4).","['C2603343', 'C0449450', 'C0936012', 'C0020517', 'C1522640', 'C0042153', 'C0205172', 'C1524024', 'C0332324', 'C0457083', 'C0150312']","['Presentation', 'Analysis', 'More', 'Usage', 'analysis aspect', 'Study', 'stimulus sensitivity', 'utilization qualifier', 'Hypersensitivity', 'Present', 'Sensitive']","['fndg', 'idcn', 'qnco', 'qlco', 'resa', 'ftcn', 'patf']"
1102,PMC3623038,S68,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size calculation,"with a power of 80% and a type i error of 5%, the total sample size was found to be 17 patients per group.","['C1257890', 'C0332307', 'C0032863', 'C0441833', 'C1519504', 'C0743559', 'C1608199', 'C1705429', 'C0030705', 'C3854080', 'C0687744', 'C1515981', 'C0439810', 'C0242618', 'C1705428']","['Groups', 'Population Group', 'Group Object', 'error', 'Sample Size', 'Power (Psychology)', 'Social group', 'Type - attribute', 'Total', 'And', 'Power', 'Patients', 'Stage Grouping', 'Act Reason - Error', 'User Group']","['idcn', 'qnco', 'qlco', 'hcpp', 'podg', 'ftcn', 'popg', 'cnce']"
1103,PMC3623038,S69,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size calculation,"next, on the basis of (i) a coefficient of 0.4 for the correlation between the baseline measurement and the end-of-study measurement in a covariance analysis, (ii) a very low dropout rate and (iii) the replacement of dropouts, we calculated the required sample size to be 14 patients per group.","['C0332282', 'C0444686', 'C0168634', 'C1521828', 'C0521125', 'C0559956', 'C4553149', 'C0205117', 'C1883708', 'C0871208', 'C0242485', 'C0936012', 'C1257890', 'C1514873', 'C0205103', 'C4321252', 'C0441833', 'C1705160', 'C0030705', 'C0439070', 'C1705428', 'C0242618', 'C0013135', 'C1441506', 'C1519504', 'C1527178', 'C1705429', 'C1707429', 'C1707520', 'C1874451', 'C4554109', 'C0444930', 'C1555302', 'C0442811', 'C2603343', 'C1442488', 'C2746065', 'C0687744', 'C1515981', 'C1524024', 'C0035139']","['Coefficient', 'Group Object', 'Replacement', 'Rate', 'And', 'Replacement - supply', 'Study', 'Measurement', 'Rating (action)', 'Dropouts', 'Following', 'analysis aspect', 'Calculation', 'Basis', 'Baseline', 'Trial Subject Replacement', 'Adjacent', 'User Group', 'Groups', 'Population Group', 'Basis - conceptual entity', 'very low', 'Correlation', 'Social group', 'Calculated', 'Roman Numeral III', 'Requirement', 'WWOX wt Allele', 'End', 'Patients', 'Preposition For', 'Intermediate', 'III (suffix)', 'BaseLine dental cement', 'Sample Size', 'Surgical Replantation', 'Analysis', 'Clinical Trial Dropout', 'Stop (qualifier value)', 'Then', 'Stage Grouping']","['tmco', 'fndg', 'bodm', 'gngm', 'idcn', 'hlca', 'topp', 'inpr', 'qnco', 'qlco', 'spco', 'resa', 'podg', 'ftcn', 'acty', 'popg', 'cnce', 'phsu']"
1104,PMC3623038,S71,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,descriptive analyses and the shapiro-wilk test were used to check whether data were normally distributed.,"['C1515976', 'C3245479', 'C0678257', 'C0022885', 'C4318744', 'C0039593', 'C0456984', 'C1515981', 'C0392366', 'C3714741', 'C3831328', 'C1511726']","['Data call receiving device', 'Anatomic Structure, System, or Substance', 'Test Result', 'Data (eukaryote)', 'Description', 'And', 'Testing', 'Blood Products Laboratory Testing', 'Tests (qualifier value)', 'Test - temporal region', 'Laboratory Procedures', 'Data']","['blor', 'lbtr', 'medd', 'clas', 'idcn', 'inpr', 'lbpr', 'euka', 'ftcn']"
1105,PMC3623038,S72,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,non-normally distributed data were log-transformed.,"['C1511726', 'C3245479', 'C1704711', 'C3714741']","['Data call receiving device', 'Data (eukaryote)', 'Distribution', 'Data']","['medd', 'idcn', 'euka', 'ftcn']"
1106,PMC3623038,S73,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,the primary criterion was tested in a covariance analysis (with adjustment for baseline) for all patients with data recorded in the final assessment.,"['C0456081', 'C1511726', 'C1442488', 'C3245479', 'C0205088', 'C0205225', 'C3853528', 'C0376209', 'C0030705', 'C0683269', 'C0168634', 'C1546485', 'C0243161', 'C1261322', 'C3714741', 'C0444868', 'C1524024', 'C1516048', 'C0936012']","['Data call receiving device', 'BaseLine dental cement', 'Adjustment Action', 'All', 'Primary', 'Baseline', 'Analysis', 'End-stage', 'Data (eukaryote)', 'criteria', 'Psychological adjustment', 'analysis aspect', 'Patients', 'Assessed', 'Diagnosis Type - Final', 'Evaluation procedure', 'Individual Adjustment', 'Final', 'Data']","['tmco', 'bodm', 'medd', 'inbe', 'idcn', 'hlca', 'qnco', 'qlco', 'euka', 'resa', 'podg', 'ftcn', 'acty']"
1107,PMC3623038,S74,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,the effect size was also computed.,['C0814843'],['effect size'],['qnco']
1108,PMC3623038,S75,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"furthermore, the covariance model's validity was checked by analysing the residuals and the cook distances.","['C3274659', 'C2349101', 'C3853906', 'C0012751', 'C0335326', 'C1421478', 'C1565156', 'C0043194', 'C1609982', 'C1515981', 'C1519941', 'C1283174', 'C3161035', 'C3714583', 'C1306756']","['Cook (occupation)', 'Residual', 'Model Number', 'Digital Model Attachment', 'Cooking (activity)', 'Model', 'WAS protein, human', 'Checking (action)', 'WAS gene', 'Distance', 'And', 'Validity (characteristic)', 'Validation', 'Model - style/design', 'Wiskott-Aldrich Syndrome']","['prog', 'gngm', 'idcn', 'dora', 'inpr', 'qnco', 'qlco', 'bacs', 'dsyn', 'resa', ' aapp', 'cnce', 'acty']"
1109,PMC3623038,S76,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,numerical safety data for all randomised patients were assessed in an analysis of variance.,"['C1511726', 'C3245479', 'C0237753', 'C0036043', 'C1711260', 'C0030705', 'C2348152', 'C3714741', 'C0444868', 'C1524024', 'C1705187', 'C0936012']","['Data call receiving device', 'All', 'Variance', 'Analysis', 'Data (eukaryote)', 'Sample Variance', 'analysis aspect', 'Patients', 'Numbers', 'Safety', 'Safety Study', 'Data']","['medd', 'hcpp', 'idcn', 'qnco', 'qlco', 'euka', 'resa', 'podg', 'ftcn']"
1110,PMC3623038,S77,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,the threshold for statistical significance was set to p=0.05 in all cases.,"['C1709380', 'C0449864', 'C0868928', 'C0444868', 'C0237881']","['Case (situation)', 'P-Value', 'threshold', 'All', 'Statistical Significance']","['qnco', 'ftcn', 'qlco']"
1111,PMC3623038,S78,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"all statistical tests were two-tailed and performed with sas software (v.9.2, sas institute inc., cary, north carolina, usa).","['C0041703', 'C0028407', 'C1823519', 'C0605290', 'C0205448', 'C1426104', 'C0444868', 'C0037585', 'C0237913']","['Two', 'All', 'TSPAN31 gene', 'Statistical Test', 'North Carolina', 'Computer software', 'United States', 'SAS', 'NANS gene']","['gngm', ' mnob', 'inpr', 'orch', 'geoa', 'qnco']"
1112,PMC3641608,S44,"['3a', '4a', '4b']","[0, 0, 0, 0, 0, 0, 1, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Trial design,"arrow was an open-label randomised parallel-group trial in untreated (except for art to prevent mother-to-child-transmission) children or adolescents (aged 3 months to 17 years) with hiv who met who 2006 criteria for art initiation15 from three centres in uganda (joint clinical research centre, kampala; baylor-uganda, mulago; mrc/uvri uganda research unit on aids, entebbe), and one in zimbabwe (university of zimbabwe, harare).","['C0008972', 'C0336721', 'C0205447', 'C0205449', 'C0242481', 'C0040722', 'C0439453', 'C0181496', 'C0521125', 'C3853603', 'C0243161', 'C0026591', 'C0019682', 'C0043476', 'C1257890', 'C4321252', 'C1550543', 'C3272598', 'C0035168', 'C0441833', 'C0220786', 'C1540289', 'C0439234', 'C0001779', 'C0003826', 'C1705428', 'C4522130', 'C4317104', 'C0439148', 'C2698590', 'C0242781', 'C2827499', 'C0332287', 'C0680063', 'C1519504', 'C4551445', 'C1705429', 'C0041573', 'C0309872', 'C0428210', 'C1880519', 'C4554418', 'C1517320', 'C1442461', 'C3890191', 'C1521797', 'C0001792', 'C0022417', 'C1706309', 'C0205099', 'C0175566', 'C0008059', 'C2826345', 'C0205653', 'C2348042', 'C0001175', 'C0687744', 'C1515981', 'C1509845', 'C1519795', 'C0332155', 'C0392905', 'C0008976', 'C0041740', 'C1704753', 'C1999167']","['Joints', 'Age', 'Group Object', 'year', 'HIV', 'In addition to', 'Articular system', 'Clinical Trials', 'Unit - NCI Thesaurus Property', 'CD200 gene', 'And', 'Offspring', 'From', '3 Months', 'Label (document)', 'Human Cells, Tissues, and Cellular and Tissue-Based Products Labeling', 'Uganda', 'transmission process', 'International Unit', 'disease transmission', 'Unit', 'Unit of Measure', 'Adolescent (age group)', 'Old age', 'Metabolic Equivalent of Task Unit', 'PREVENT (product)', 'Enzyme Unit', 'Universities', 'Zimbabwe', 'disease transmission qualifier', 'Clinical Research', 'User Group', 'Arts', 'Parallel Study', 'Groups', 'Population Group', 'Open', 'Products of the Arts', 'Social group', 'Labels (device)', 'WWOX wt Allele', 'Central', 'Storage Unit', 'Labeling Activity', 'One', 'Preposition For', 'arrow', 'Mother (person)', 'Fulfill', 'AGRP wt Allele', 'Did not receive therapy or drug for', 'Research Activities', 'Child', 'Parallel Lesion', 'Elderly (population group)', 'research', 'criteria', 'WHO Temperature/Humidity Storage Condition', 'CD200 wt Allele', 'Methionine measurement', 'Joint Device', 'Acquired Immunodeficiency Syndrome', 'Three', 'Stage Grouping', 'Parallel', 'Unit device']","['virs', 'qnco', 'phpr', 'patf', 'fndg', 'npop', 'idcn', 'inpr', 'qlco', 'lbpr', 'resa', 'ftcn', 'mnob', 'popg', 'phsu', 'tmco', ' mnob', 'bdsy', 'ocdi', 'spco', 'bsoj', 'cnce', 'acty', 'gngm', 'medd', 'orgt', 'geoa', 'famg', 'orga', 'dsyn', 'aggp']"
1113,PMC3641608,S45,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Trial design,"children with acute infections, on drugs contraindicated with art, unlikely to adhere or to attend regularly, with laboratory abnormalities contraindicating art, pregnant or breastfeeding, or perinatally exposed to art (if <6 months old) were excluded.","['C0275518', 'C0008059', 'C0680063', 'C0220786', 'C1999232', 'C0332287', 'C1853129', 'C0439231', 'C0006147', 'C1710571', 'C3714578', 'C0580836', 'C0013227', 'C0600457', 'C0003826', 'C0549206', 'C3687832', 'C0750558', 'C3890191']","['LABORATORY ABNORMALITIES', 'Products of the Arts', 'AGRP wt Allele', 'Child', 'Drugs - dental services', 'Fix', 'In addition to', 'Old', 'Patient currently pregnant', 'Unlikely', 'Offspring', 'Unlikely Related to Intervention', 'Gravidity', 'acute infection', 'Attending (action)', 'Pharmaceutical Preparations', 'month', 'Arts', 'Breast Feeding']","['tmco', 'fndg', 'lbtr', 'gngm', 'topp', 'ocdi', 'famg', 'qlco', 'phpr', 'dsyn', 'orgf', 'ftcn', 'mnob', 'aggp', 'phsu']"
1114,PMC3641608,S46,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Trial design,participants were randomly assigned (1:1) to clinically driven monitoring versus routine laboratory plus clinical monitoring for toxicity (haematology and biochemistry) and efficacy (cd4).,"['C1283169', 'C0005477', 'C0205547', 'C0679646', 'C3244292', 'C0150369', 'C1515981', 'C4283904', 'C0600688', 'C4048280', 'C0022877', 'C3541261', 'C0205210', 'C1707887', 'C0040539', 'C1280519']","['Monitoring - action', 'Laboratory', 'Preventive monitoring', 'Clinical', 'Effectiveness', 'Laboratory domain', 'Participant', 'Toxic effect', 'And', 'Efficacy Study', 'T-Cell Surface Glycoprotein CD4, human', 'Biochemistry', 'Toxicity aspects', 'CD4 Expressing Cell Count', 'Routine', 'Laboratory observation']","['lbtr', ' hcro', 'idcn', 'hlca', 'ocdi', 'qlco', 'bacs', 'inpo', 'lbpr', 'resa', 'ftcn', 'mnob', 'popg', ' aapp']"
1115,PMC3641608,S47,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Trial design,"children were also randomly assigned (1:1:1) in a factorial design to three approaches for first-line art: open-label lamivudine, abacavir, plus nnrti continuously (group a, control); induction-maintenance with four-drug lamivudine, abacavir, nnrti, plus zidovudine for 36 weeks, then lamivudine, abacavir, plus nnrti (group b); or induction-maintenance with lamivudine, abacavir, nnrti, plus zidovudine for 36 weeks, then lamivudine, abacavir, plus zidovudine (group c).","['C3274648', 'C0205449', 'C4553389', 'C1279901', 'C0439230', 'C0205132', 'C0521125', 'C0181496', 'C1883708', 'C1550141', 'C4321252', 'C1257890', 'C2587213', 'C0441833', 'C0205435', 'C0220786', 'C0700221', 'C3537104', 'C0209738', 'C0003826', 'C1254351', 'C1705428', 'C4522130', 'C0681865', 'C0024501', 'C2827499', 'C0043474', 'C0680063', 'C1519504', 'C1552960', 'C0663655', 'C4551445', 'C1705429', 'C0449445', 'C3890191', 'C0013227', 'C0008059', 'C1882979', 'C0687744', 'C0205450', 'C0243148', 'C4522078', 'C1550648']","['Group Object', 'Non-nucleoside Reverse Transcriptase Inhibitor', 'control substance', 'Offspring', 'Line Unit of Length', 'Linear', 'Study Control', 'factorial design', 'Label (document)', 'Firstly', 'Human Cells, Tissues, and Cellular and Tissue-Based Products Labeling', 'First (number)', 'Zidovudine', 'User Group', 'Pharmacologic Substance', 'Arts', 'Groups', 'Population Group', 'Products of the Arts', 'Social group', 'Maintenance', 'Four', 'control aspects', 'Labels (device)', 'WWOX wt Allele', 'Line Specimen', 'Control function', 'Lamivudine', 'Labeling Activity', 'Preposition For', 'Pharmaceutical Preparations', 'AGRP wt Allele', 'Scientific Control', 'Child', 'True Control Status', 'Group B', 'Three', 'Then', 'week', 'Stage Grouping', 'abacavir', 'Intravascular line', 'Approach']","['qnco', 'nnon', 'idcn', 'clas', 'inpr', 'qlco', 'sbst', 'resa', 'ftcn', 'mnob', 'popg', 'phsu', 'tmco', 'ocdi', 'orch', 'spco', 'cnce', 'acty', 'gngm', 'medd', 'famg', ' phsu', 'aggp']"
1116,PMC3641608,S48,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Trial design,hla testing was not done.,"['C1518422', 'C0242318']","['Negation', 'HLA Typing']","['ftcn', 'lbpr']"
1117,PMC3641608,S49,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Trial design,hiv viral loads were done retrospectively on stored samples.,"['C0019682', 'C0521026', 'C1698986']","['Viral', 'Storage', 'HIV']","['ftcn', 'virs']"
1118,PMC3641608,S50,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Trial design,the hypothesis was that clinically driven monitoring would result in similar outcomes to routine laboratory monitoring (non-inferiority) and that four-drug induction-maintenance would have greater efficacy than would standard three-drug art.,"['C1283169', 'C0205547', 'C0205449', 'C1442989', 'C2825142', 'C3539897', 'C2828392', 'C0678975', 'C3154893', 'C0220786', 'C1546471', 'C3244292', 'C4283904', 'C0003826', 'C1707887', 'C1254351', 'C1280519', 'C0024501', 'C4683688', 'C1704243', 'C0022877', 'C0013227', 'C3890191', 'C2348205', 'C1518422', 'C1512571', 'C0150369', 'C1515981', 'C0205263', 'C0857127', 'C0205450', 'C1274040']","['Monitoring - action', 'Laboratory', 'inferiority', 'And', 'Standard (document)', 'What subject filter - Result', 'Similarity', 'Laboratory observation', 'Effectiveness', 'Induction procedure', 'Induce (action)', 'Routine', 'Result', 'Pharmacologic Substance', 'Arts', 'Hypothesis', 'Possess', 'Products of the Arts', 'Maintenance', 'Four', 'Experimental Result', 'Driven', 'Pharmaceutical Preparations', 'Negation', 'AGRP wt Allele', 'Preventive monitoring', 'Laboratory domain', 'Have', 'Efficacy Study', 'Three', 'Standard (qualifier)', 'Greater']","['fndg', 'lbtr', ' hcro', 'hlca', 'gngm', 'idcn', 'topp', 'ocdi', 'inpr', 'qlco', 'qnco', 'phsu', 'socb', 'resa', 'ftcn', 'mnob', 'acty']"
1119,PMC3641608,S51,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Trial design,the nnrti (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.,"['C0871685', 'C0205276', 'C0132326', 'C0470187', 'C0674428', 'C1515981', 'C3537104', 'C0001779']","['availability of', 'Age', 'Non-nucleoside Reverse Transcriptase Inhibitor', 'And', 'Clinician', 'Nevirapine', 'efavirenz', 'Local']","['prog', 'idcn', 'orch', 'orga', 'spco', 'ftcn', ' phsu', 'phsu']"
1120,PMC3641608,S52,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Trial design,caregivers gave written informed consent; older children (8–17 years) aware of their hiv status also gave assent or consent following national guidelines.,"['C3245503', 'C1511481', 'C0220845', 'C0332282', 'C0008059', 'C0680063', 'C2923685', 'C0004448', 'C0439234', 'C0021430', 'C0458074', 'C0162791', 'C1554192', 'C0085537', 'C2709249', 'C0282423']","['National citizen', 'Consent:Finding:Point in time:{Setting}:Document:Patient', 'Caregiver', 'Guidelines', 'guiding characteristics', 'year', 'Following', 'Child', 'Guideline [Publication Type]', 'Human immunodeficiency virus (HIV) status', 'Awareness', 'Offspring', 'Consent', 'Informed Consent', 'ActClass - consent', 'human immunodeficiency virus status:History:Point in time:^Patient:Nominal']","['tmco', 'fndg', 'prog', 'rnlw', 'idcn', 'inpr', 'famg', 'menp', 'ftcn', 'popg', 'aggp', 'clna']"
1121,PMC3641608,S53,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Trial design,"the trial was approved by research ethics committees in uganda, zimbabwe, and the uk.","['C0041573', 'C1515981', 'C0008976', 'C0086911', 'C0043476']","['Uganda', 'Clinical Trials', 'And', 'Ethics Committees, Research', 'Zimbabwe']","['geoa', 'idcn', 'prog', 'resa']"
1122,PMC3641608,S55,['8b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0]",Randomisation and masking,"both factorial randomisations were stratified by centre and age (<7, 7–12, ≥13 years).","['C0001779', 'C2826344', 'C0439234', 'C1706086']","['Age', 'Both', 'Factorial Study', 'year']","['qlco', 'orga', 'tmco', 'resa']"
1123,PMC3641608,S56,"['9', '8a']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 1]",Randomisation and masking,"the computer-generated sequentially numbered randomisation list (with variable block sizes) containing both allocations was pre-prepared by the trial statistician and incorporated within the secure database at each trial centre, connected to but not located within each clinical centre, allowing trial managers to access the next number, but not the whole list.","['C0332282', 'C3272378', 'C0237753', 'C0439828', 'C3146231', 'C4553760', 'C1554204', 'C0444454', 'C0205117', 'C1883708', 'C1706086', 'C0993637', 'C1519222', 'C0028778', 'C1457900', 'C0449788', 'C1706084', 'C0332285', 'C0009622', 'C0745732', 'C1533157', 'C0205099', 'C1518422', 'C0335141', 'C0444667', 'C0683607', 'C0242356', 'C0659450', 'C4684804', 'C1515981', 'C0233535', 'C0008976', 'C0205210', 'C2828370', 'C0332206']","['Clinical Trials', 'Published Database', 'Each (qualifier value)', 'Block (unit of measure)', 'And', 'Secure - resin cement', 'Whole', 'List', 'Blocking', 'Trial Statistician', 'Following', 'Within', 'Variable (uniformity)', 'Count of entities', 'Databases', 'allowing', 'Access', 'Computers', 'manager', 'Adjacent', '(City) Block', 'butting', 'Block Specimens', 'Security - service', 'Role Class - access', 'Central', 'Study Variable', 'Secure feeling', 'Sequence Data Type', 'Negation', 'Numbers', 'Clinical', 'Obstruction', 'Then', 'Both']","['tmco', 'cnce', 'bodm', 'prog', 'idcn', 'inpr', 'geoa', 'qnco', 'qlco', 'mobd', 'spco', 'resa', 'socb', 'ftcn', 'mnob', 'menp', 'patf', 'bdsu']"
1124,PMC3641608,S57,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,randomisation was undertaken by clinicians phoning the local trials centre.,"['C0205276', 'C0871685', 'C0205099']","['Clinician', 'Local', 'Central']","['prog', 'spco']"
1125,PMC3641608,S58,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,"once randomised, allocation was open—ie, physicians and carers were aware of group assignment.","['C1257890', 'C1706778', 'C0031831', 'C0441833', 'C1516050', 'C1519504', 'C1305660', 'C0004448', 'C1948045', 'C1421478', 'C1705429', 'C1565156', 'C0687744', 'C0043194', 'C1515981', 'C0085537', 'C1705428']","['Assignment - action', 'Groups', 'Caregiver', 'Once (schedule frequency)', 'Group Object', 'Population Group', 'Social group', 'WAS protein, human', 'WAS gene', 'And', 'Awareness', 'Carer (occupation)', 'Physicians', 'Stage Grouping', 'Allocation', 'User Group', 'Wiskott-Aldrich Syndrome']","['tmco', 'prog', 'gngm', 'idcn', ' aapp', 'bacs', 'dsyn', 'ftcn', 'popg', 'menp', 'cnce', 'acty']"
1126,PMC3641608,S60,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"all participants were examined by a doctor and had routine full blood count with white cell differential, lymphocyte subsets (cd4, cd8), biochemistry tests (bilirubin, urea, creatinine, aspartate aminotransferase, alanine aminotransferase) at screening, randomisation (lymphocytes only), weeks 4, 8, and 12, then every 12 weeks.","['C0205547', 'C0005767', 'C0005437', 'C0022885', 'C0023516', 'C1710032', 'C0439230', 'C3540595', 'C4554467', 'C1883708', 'C0205171', 'C1561535', 'C0031831', 'C2348164', 'C2348314', 'C1698960', 'C0392366', 'C4048280', 'C3541261', 'C3538720', 'C0005477', 'C0005768', 'C0679646', 'C0220908', 'C0041942', 'C0444868', 'C1705242', 'C1710031', 'C0443199', 'C0010294', 'C0443225', 'C0004002', 'C1415274', 'C0001899', 'C0220909', 'C1948061', 'C0024264', 'C0229664', 'C1515981', 'C1710477', 'C3887708']","['Aspects of disease screening', 'Screening procedure', 'Bilirubin', 'Leukocytes', 'Singular', 'Alanine Aminotransferase 1, human', 'And', 'Alanine Transaminase', 'In Blood', 'Blood', 'full', 'Aspartate Transaminase', 'Trial Screening', 'Participant', 'Creatinine, CTCAE', 'peripheral blood', 'Every (qualifier)', 'Differential - view', 'Tests (qualifier value)', 'Urea', 'Screening', 'Physicians', 'Laboratory Procedures', 'Routine', 'Differential quality', 'CD8A wt Allele', 'Screening Study', 'All', 'Disease Screening', 'Biochemistry', 'CD4 Expressing Cell Count', 'Different', 'research subject screening', 'Creatinine', 'CD8 Expressing Cell Count', 'Lymphocyte', 'Doctor - Title', 'week', 'T-Cell Surface Glycoprotein CD4, human', 'Then', 'GPT gene']","['qnco', 'cell', ' aapp', 'fndg', ' orch', 'hlca', 'idcn', 'inpr', 'qlco', 'bacs', 'lbpr', 'resa', 'ftcn', 'popg', 'bdsu', 'tmco', 'prog', 'enzy', 'ocdi', 'spco', 'cnce', 'gngm', 'diap', ' phsu']"
1127,PMC3641608,S61,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,screening results were used to assess eligibility.,"['C0220909', 'C1710032', 'C0220908', 'C2348164', 'C1698960', 'C0013893', 'C1710477', 'C1548635', 'C1710031']","['Eligibility Determination', 'Screening Study', 'research subject screening', 'Aspects of disease screening', 'Screening procedure', 'Trial Screening', 'Disease Screening', 'Screening', 'Eligible']","['hlca', 'qlco', 'resa', 'ftcn', 'diap']"
1128,PMC3641608,S62,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,"all subsequent results for participants assigned to routine laboratory monitoring were returned to clinicians, whereas results at and after randomisation for participants allocated clinically driven monitoring were only returned if requested for clinical management (authorised by centre project leaders); haemoglobin results at week 8 were automatically returned on the basis of early anaemia in dart,16 as were grade 4 laboratory toxicities (protocol safety criteria; grades defined17 apart from neutrophils18).","['C1283169', 'C0205547', 'C0332282', 'C4284297', 'C0439230', 'C2983657', 'C2348563', 'C0243161', 'C4553732', 'C1705187', 'C3715209', 'C0871685', 'C4282383', 'C3244292', 'C0002871', 'C1522729', 'C4283904', 'C2599718', 'C3842331', 'C0547054', 'C3537125', 'C4683688', 'C4284296', 'C0036043', 'C0679646', 'C1527178', 'C1874451', 'C0022877', 'C0444868', 'C0336707', 'C0442711', 'C1709701', 'C1279919', 'C1507394', 'C1516615', 'C3889293', 'C0150369', 'C0019046', 'C0600688', 'C0441800', 'C0684258', 'C4284298']","['Monitoring - action', 'Laboratory', 'Toxic effect', 'Bayer Visual Acuity Changes Grade 4', 'Clinical Management', 'Safety', 'Clinician', 'Clinical trial protocol', 'Hemoglobin', 'Laboratory observation', 'Bayer Corneal Epitheliopathy Grade 4', 'Protocols documentation', 'Simpson Grade 4', 'Following', 'Participant', 'REMS Protocol', 'Reproductive and Developmental Toxicology', 'Anemia', 'Basis', 'Safety Study', 'Routine', 'Dart, device (physical object)', 'Distress Assessment and Response Tool', 'Basis - conceptual entity', 'Life Threatening or Disabling Adverse Event', 'All', 'Library Protocol', 'Early', 'Project', 'Driven', 'Fourth grade in elementary school', 'West Haven Hepatic Encephalopathy Grade 4', 'Preventive monitoring', 'Grade', 'Grade four rank', 'Laboratory domain', 'Automatically', 'Clinical trial protocol document', 'Study Protocol', 'criteria', 'week', 'Protocol - answer to question']","[' hcro', 'qnco', ' aapp', 'fndg', 'hlca', 'clas', 'idcn', 'inpr', 'qlco', 'bacs', 'resa', 'hcpp', 'ftcn', 'mnob', 'popg', 'phsu', 'tmco', 'prog', 'lbtr', 'acty', 'cnce', 'bmod', 'inpo', 'dsyn']"
1129,PMC3641608,S63,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,"total lymphocytes and cd4 tests were never returned for participants on clinically driven monitoring, but for all children other investigations could be requested and concomitant drugs prescribed, as clinically indicated.","['C1283169', 'C0521115', 'C4683688', 'C0008059', 'C0680063', 'C0022885', 'C2003901', 'C0024264', 'C0679646', 'C0150369', 'C1515981', 'C0439810', 'C0392366', 'C4048280', 'C0233535', 'C3541261', 'C0444868', 'C3687832', 'C0013227']","['Monitoring - action', 'Never (frequency)', 'Preventive monitoring', 'All', 'Lymphocyte', 'Child', 'Drugs - dental services', 'Driven', 'Participant', 'Total', 'And', 'Offspring', 'Tests (qualifier value)', 'T-Cell Surface Glycoprotein CD4, human', 'Laboratory Procedures', 'CD4 Expressing Cell Count', 'Pharmaceutical Preparations', 'butting', 'Simultaneous']","['tmco', 'idcn', 'topp', 'hlca', 'inpr', 'famg', 'qnco', 'phsu', 'bacs', 'qlco', 'cell', 'lbpr', 'mobd', ' aapp', 'popg', 'aggp', 'acty']"
1130,PMC3641608,S64,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Procedures,all children received art as syrups or tablets dosed according to who weight-band tables.19–21,"['C0439645', 'C0458173', 'C3272598', 'C0008059', 'C0680063', 'C0220786', 'C0991550', 'C0175723', 'C0005910', 'C0039224', 'C1705104', 'C1305866', 'C0043100', 'C1706074', 'C0039225', 'C0003826', 'C0444868', 'C3890191', 'C1521913']","['Body Weight', 'Syrup - Food', 'Products of the Arts', 'Tablet Dosage Form', 'Child', 'Data Table', 'All', 'Bands', 'Chromosome band', 'Weighing patient', 'WHO Temperature/Humidity Storage Condition', 'Importance Weight', 'Offspring', 'Band form', 'Syrup Drug Form', 'Weight', 'Arts', 'Table - furniture', 'AGRP wt Allele']","['food', 'gngm', 'medd', 'hlca', 'ocdi', 'famg', 'inpr', 'qlco', 'qnco', 'celc', 'orga', 'spco', 'bodm', 'mnob', 'aggp']"
1131,PMC3641608,S65,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Procedures,children were reviewed every 4–6 weeks by a nurse using a standard symptom checklist.,"['C0028661', 'C0008059', 'C1948061', 'C0680063', 'C1442989', 'C0451524', 'C0439230', 'C2828392']","['Child', 'Every (qualifier)', 'symptom checklist', 'Offspring', 'week', 'Standard (qualifier)', 'Nurses', 'Standard (document)']","['tmco', 'prog', 'inpr', 'famg', 'qlco', 'aggp']"
1132,PMC3641608,S66,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Procedures,"antiretroviral drugs could be substituted, preferably within class, after adverse events.","['C0456387', 'C1705413', 'C1705943', 'C1518526', 'C0877248', 'C3687832', 'C0013227']","['Class', 'Drugs - dental services', 'Adverse Event Domain', 'Class (taxonomic)', 'Object Class', 'Pharmaceutical Preparations', 'Adverse event']","['clas', 'topp', 'inpr', 'phsu', 'patf', 'cnce']"
1133,PMC3641608,S67,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Procedures,"during four-drug induction, a drug could be dropped because of toxicity or drug interactions with antituberculosis treatment.","['C1705648', 'C0687133', 'C0087111', 'C1522326', 'C3887704', 'C1705169', 'C0039798', 'C3538994', 'C0600688', 'C0205450', 'C0205263', 'C0003448', 'C0857127', 'C1254351', 'C0040539', 'C1533734', 'C0013227']","['treatment - ActInformationManagementReason', 'Induction procedure', 'Toxic effect', 'Drug Interactions', 'Induce (action)', 'Antitubercular Agents', 'Treating', 'Treatment Epoch', 'therapeutic aspects', 'Four', 'Dropping', 'Toxicity aspects', 'Biomaterial Treatment', 'Administration procedure', 'Pharmaceutical Preparations', 'Pharmacologic Substance', 'Therapeutic procedure']","['cnce', 'topp', 'hlca', 'qlco', 'qnco', 'inpo', 'resa', 'ftcn', 'acty', 'patf', 'phsu']"
1134,PMC3641608,S68,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Procedures,"switching to second-line art (including a ritonavir-boosted protease inhibitor) was based on clinical criteria in all participants (new or recurrent who stage 4 event;15 or who stage 3 event or events at clinician discretion, particularly if recurrent or persistent), or on laboratory criteria for routine laboratory monitoring (confirmed on-art cd4 of <15% at age 1–2 years, <10% at 3–4 years, <100 cells/ml at ≥5 years).","['C1283169', 'C0205547', 'C1561503', 'C0292818', 'C1306673', 'C0205132', 'C0243161', 'C3541888', 'C3272598', 'C0871685', 'C0700221', 'C0220786', 'C0033607', 'C3244292', 'C0439234', 'C0205436', 'C2945760', 'C4283904', 'C4048280', 'C0457385', 'C3541261', 'C0003826', 'C0205314', 'C1705190', 'C1552960', 'C0679646', 'C0205390', 'C1455761', 'C2699156', 'C0022877', 'C0332996', 'C0444868', 'C3890191', 'C0441471', 'C1441340', 'C0441771', 'C1300072', 'C1550648', 'C0205322', 'C0150369', 'C0205210', 'C0001779', 'C4019010', 'C3536890']","['Monitoring - action', 'Laboratory', 'Protease Inhibitors', 'year', 'National reporting jurisdiction:Loc:Pt:^Event:Nom', 'Age', 'Cells per Milliliter', 'Line Unit of Length', 'Event', 'Clinician', 'Linear', 'Stage level 3', 'Episodic', 'Laboratory observation', 'Participant', 'Recurrent', 'second (number)', 'Routine', 'Ritonavir', 'Precision - second', 'Arts', 'Products of the Arts', 'All', '100 cells', 'CDISC Events Class', 'Stage', 'Line Specimen', 'Protease Inhibitor [EPC]', 'Persistent embryonic structure', 'CD4 Expressing Cell Count', 'Second Suffix', 'Phase', 'AGRP wt Allele', 'Clinical', 'Preventive monitoring', 'seconds', 'Laboratory domain', 'Persistent', 'criteria', 'WHO Temperature/Humidity Storage Condition', 'New', 'Tumor stage', 'T-Cell Surface Glycoprotein CD4, human', 'Intravascular line']","[' hcro', 'qnco', 'cell', ' aapp', 'clna', 'cgab', 'idcn', 'clas', 'hlca', 'inpr', 'qlco', 'sbst', 'bacs', 'lbpr', 'ftcn', 'mnob', 'popg', 'phsu', 'tmco', 'prog', 'lbtr', 'ocdi', 'orch', 'spco', 'gngm', 'medd', 'orga', ' phsu', 'evnt']"
1135,PMC3641608,S69,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,see appendix for further details.,"['C1517331', 'C1522508', 'C0003617']","['Further', 'Details', 'Appendix']","['qlco', 'spco', 'bpoc']"
1136,PMC3641608,S70,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"co-primary endpoints for the monitoring randomisation were progression to new who stage 4 event or death (efficacy), and grade 3 or 4 adverse events not solely related to hiv (safety).","['C1283169', 'C0449258', 'C3889290', 'C0011065', 'C0205225', 'C1306577', 'C1705413', 'C0019682', 'C1705187', 'C0441772', 'C4283820', 'C3272598', 'C1707887', 'C0205314', 'C1280519', 'C0036043', 'C0242656', 'C2349179', 'C4283822', 'C4283821', 'C0441471', 'C0687697', 'C1518422', 'C0450094', 'C0150369', 'C1515981', 'C0475271', 'C0877248', 'C4019010']","['Monitoring - action', 'National reporting jurisdiction:Loc:Pt:^Event:Nom', 'HIV', 'Stage level 4', 'And', 'Event', 'Safety', 'Grade three rank', 'Progression', 'Tumor grade G3', 'Bayer Corneal Epitheliopathy Grade 3', 'Third grade in elementary school', 'Effectiveness', 'Simpson Grade 3', 'Safety Study', 'Cessation of life', 'Bayer Visual Acuity Changes Grade 3', 'Disease Progression', 'Negation', 'Death (finding)', 'Preventive monitoring', 'Primary', 'WHO Temperature/Humidity Storage Condition', 'New', 'Adverse Event Domain', 'Efficacy Study', 'West Haven Hepatic Encephalopathy Grade 3', 'End Point', 'Adverse event']","['fndg', 'resa', 'virs', 'idcn', 'hlca', 'clas', 'inpr', 'qlco', 'dsyn', 'orgf', 'hcpp', 'ftcn', 'evnt', 'patf', 'clna']"
1137,PMC3641608,S71,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,co-primary endpoints for the art-strategy randomisation were change in cd4 percentage from randomisation to 72 and 144 weeks (efficacy) and grade 3 or 4 adverse events (safety).,"['C1705241', 'C0679199', 'C3889290', 'C0205225', 'C0439230', 'C0392747', 'C1705413', 'C0439165', 'C1705187', 'C4283820', 'C0443172', 'C0220786', 'C1549488', 'C0003826', 'C1707887', 'C1561533', 'C1280519', 'C0036043', 'C2349179', 'C4283822', 'C4319952', 'C4283821', 'C3890191', 'C0687697', 'C0450094', 'C1515981', 'C0475271', 'C0877248']","['And', 'Safety', 'Money or percentage indicator - Percentage', 'Grade three rank', 'Tumor grade G3', 'Bayer Corneal Epitheliopathy Grade 3', 'Third grade in elementary school', 'Effectiveness', 'Simpson Grade 3', 'Changed status', 'Safety Study', 'Amount type - Percentage', 'Arts', 'Changing', 'Products of the Arts', 'strategy', 'Percent (qualifier value)', 'Change -- procedure', 'Bayer Visual Acuity Changes Grade 3', 'AGRP wt Allele', 'Primary', 'Adverse Event Domain', 'Efficacy Study', 'week', 'West Haven Hepatic Encephalopathy Grade 3', 'Delta (difference)', 'End Point', 'Adverse event']","['tmco', 'fndg', 'gngm', 'idcn', 'hcpp', 'topp', 'clas', 'ocdi', 'inpr', 'qnco', 'qlco', 'dsyn', 'resa', 'ftcn', 'mnob', 'menp', 'patf']"
1138,PMC3641608,S72,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"secondary endpoints for both randomisations (if not co-primary) were: mortality; new (or new or recurrent) who stage 4 event or death; new (or new or recurrent) who stage 3 or 4 event or death; grade 3 or 4 adverse events definitely, probably, or uncertainly art-related; serious adverse events22 not solely hiv-related; art-modifying adverse events; admissions to hospital; height, weight, and body-mass index for age; cd4; number and class of antiretrovirals received; switch to second-line regimen; adherence; viral load and resistance (done retrospectively; see appendix).","['C0376705', 'C2986546', 'C1561503', 'C0237753', 'C0011065', 'C3899394', 'C0205225', 'C3889290', 'C1514892', 'C1306577', 'C1705104', 'C0205132', 'C1261478', 'C1305866', 'C2945654', 'C1705413', 'C1706086', 'C0205404', 'C0441772', 'C0184666', 'C4283820', 'C0003617', 'C0489786', 'C0456387', 'C3272598', 'C0600653', 'C0700221', 'C0220786', 'C0019994', 'C0449788', 'C0205436', 'C2945760', 'C1514756', 'C4048280', 'C0457385', 'C3541261', 'C0003826', 'C0205314', 'C1510802', 'C1705190', 'C1306372', 'C0577573', 'C1552960', 'C0175668', 'C0026566', 'C1455761', 'C0005910', 'C2349179', 'C0460148', 'C0577559', 'C4283822', 'C0026565', 'C1705943', 'C1518526', 'C0439849', 'C4283821', 'C0043100', 'C3890191', 'C0441471', 'C0027627', 'C0687697', 'C0441771', 'C4283905', 'C1518422', 'C1550648', 'C0242821', 'C4281815', 'C0750492', 'C0450094', 'C0237834', 'C1515981', 'C1268086', 'C0040808', 'C0475271', 'C1552854', 'C4082212', 'C0001779', 'C0877248', 'C4019010', 'C3152252', 'C0918012']","['Age', 'National reporting jurisdiction:Loc:Pt:^Event:Nom', 'Mass of body structure', 'Regimen - CHV concept', 'Html Link Type - index', 'Weighing patient', 'And', 'Adult human body', 'Stage level 4', 'Class (taxonomic)', 'Event', 'Line Unit of Length', 'Linear', 'Serious', 'Grade three rank', 'Episodic', 'Stage level 3', 'Tumor grade G3', 'Bayer Corneal Epitheliopathy Grade 3', 'Third grade in elementary school', 'Class', 'Body Weight', 'Molecular Mass', 'Resistance', 'Simpson Grade 3', 'Index', 'Recurrent', 'second (number)', 'Count of entities', 'Hospitals', 'Weight', 'Resistance (Psychotherapeutic)', 'Mass of body region', 'Object Class', 'Precision - second', 'Cessation of life', 'Arts', 'Mortality Vital Statistics', 'Definitely', 'Human body', 'Neoplasm Metastasis', 'Products of the Arts', 'Relationships', 'Treatment Protocols', 'Adverse event', 'Line Specimen', 'Resistance Process', 'Adherence (attribute)', 'Probably', 'CD4 Expressing Cell Count', 'Bayer Visual Acuity Changes Grade 3', 'Viral Load result', 'Second Suffix', 'Appendix', 'Negation', 'AGRP wt Allele', 'Morphology, Attenuation, Size, and Structure Criteria', 'Death (finding)', 'Human body structure', 'Aspects of mortality statistics', 'Numbers', 'Receive', 'Intravascular line', 'Primary', 'seconds', 'Mass, a measure of quantity of matter', 'Secondary to', 'WHO Temperature/Humidity Storage Condition', 'New', 'Indexes', 'Adverse Event Domain', 'Body structure', 'Importance Weight', 'T-Cell Surface Glycoprotein CD4, human', 'Hospital admission', 'End Point', 'West Haven Hepatic Encephalopathy Grade 3', 'Height', 'Target Lesion Identification', 'Both', 'Viral load measurement']","[' hcro', 'topp', 'qnco', ' aapp', 'menp', 'patf', 'clna', 'fndg', 'clas', 'idcn', 'hlca', 'anst', 'inpr', 'phsf', 'sosy', 'qlco', 'bacs', 'sbst', 'lbpr', 'ftcn', 'mnob', 'humn', 'bpoc', 'tmco', 'ocdi', 'spco', 'neop', 'cnce', 'gngm', 'medd', 'orga', 'dsyn', 'orgf', 'diap', 'evnt']"
1139,PMC3641608,S73,"['6a', '11a']","[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"all who stage 3 or 4 events, deaths, and serious adverse events were reviewed against prespecified criteria by an endpoint review committee with an independent chair and members, masked to randomised allocations.","['C2826544', 'C3272598', 'C0680022', 'C0332287', 'C0011065', 'C2349179', 'C3541888', 'C0085862', 'C0243161', 'C1515981', 'C0205404', 'C1524106', 'C1290940', 'C1705413', 'C0179847', 'C0444868', 'C1299583', 'C0877248', 'C0949759', 'C0441471']","['Endpoint Value Derivation Technique', 'All', 'In addition to', 'Chairs', 'CDISC Events Class', 'Independence', 'WHO Temperature/Humidity Storage Condition', 'And', 'Independently able', 'Adverse Event Domain', 'Independent for Transfer', 'criteria', 'Event', 'Chairperson', 'Review Committees', 'End Point', 'Serious', 'Cessation of life', 'Adverse event', 'member']","['gora', 'fndg', 'prog', 'idcn', 'clas', 'inpr', 'qlco', 'qnco', 'orgf', 'ftcn', 'mnob', 'popg', 'evnt', 'patf']"
1140,PMC3641608,S75,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analysis,"1200 children followed up for 3·5–5·0 years with less than 10% loss to follow-up provided 90% power to establish that clinically driven monitoring was not inferior to routine laboratory monitoring on the primary efficacy outcome, defined as the upper 95% confidence limit for the difference (clinically driven minus routine laboratory monitoring) in rate of first new who stage 4 event or deaths per 100 child-years being no greater than 1·6 per 100 child-years (assumed rate for routine laboratory monitoring of 2·5 per 100 child-years).","['C1283169', 'C0205547', 'C0332288', 'C0011065', 'C0205225', 'C1279901', 'C1565156', 'C1521828', 'C0521125', 'C0871208', 'C3242379', 'C0678975', 'C0441772', 'C4321252', 'C3272598', 'C0205435', 'C4281991', 'C3244292', 'C0439234', 'C4019010', 'C4283904', 'C0542339', 'C1274040', 'C1707887', 'C0205314', 'C1280519', 'C0032863', 'C4683688', 'C0680063', 'C1704788', 'C0237530', 'C1421478', 'C0043194', 'C3854080', 'C1704243', 'C0022877', 'C2987476', 'C0441471', 'C0008059', 'C1518422', 'C1517945', 'C1282910', 'C0150369', 'C0439092', 'C0025320', 'C3887962']","['Monitoring - action', 'Laboratory', 'year', 'Confidence Limit', 'National reporting jurisdiction:Loc:Pt:^Event:Nom', 'inferiority', 'Per (qualifier)', 'Rate', 'Stage level 4', 'Power', 'Offspring', 'Event', 'Rating (action)', 'Definition', 'Loss', 'Exist', 'Laboratory observation', 'Firstly', 'Effectiveness', 'First (number)', 'Follow', 'Routine', 'Result', 'Cessation of life', 'Wiskott-Aldrich Syndrome', 'Inferior', 'Menopause', 'WAS gene', 'WWOX wt Allele', 'Driven', 'Preposition For', 'Negation', 'Preventive monitoring', 'Less Than', 'Laboratory domain', 'Child', 'Power (Psychology)', 'Primary', 'WAS protein, human', 'Assumed', 'WHO Temperature/Humidity Storage Condition', 'New', 'Upper', 'Efficacy Study', 'Greater', 'Without']","[' hcro', 'aggp', 'qnco', ' aapp', 'clna', 'hlca', 'phsf', 'inpr', 'qlco', 'bacs', 'socb', 'resa', 'hcpp', 'ftcn', 'mnob', 'tmco', 'lbtr', 'spco', 'cnce', 'acty', 'gngm', 'famg', 'dsyn', 'orgf', 'evnt']"
1141,PMC3641608,S76,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analysis,"for the art-strategy randomisation, 1200 children provided 80% power to detect differences in change in cd4 percentage of more than 2·5% across the three groups (f test, two-sided α=0·05) assuming 20% missing data (loss to follow-up, missed visit or test) and standard deviation 10%.23","['C1705241', 'C0870536', 'C1515976', 'C0022885', 'C0679199', 'C4318744', 'C0205449', 'C3274571', 'C1705492', 'C0392747', 'C0439165', 'C1512346', 'C0443172', 'C0589120', 'C0441833', 'C0220786', 'C1549488', 'C0545082', 'C0392366', 'C0205448', 'C0205172', 'C0003826', 'C1561533', 'C4684714', 'C0032863', 'C0680063', 'C1552839', 'C0456984', 'C3854080', 'C2826704', 'C4319952', 'C1522577', 'C3890191', 'C2828360', 'C0008059', 'C1704685', 'C0039593', 'C1517945', 'C0687744', 'C1515981', 'C3831328', 'C0871420']","['Patient Visit', 'Missing Data', 'And', 'Power', 'Offspring', 'Test - temporal region', 'Money or percentage indicator - Percentage', 'Loss', 'Visit', 'Follow-up status', 'Table Rules - groups', 'Tests (qualifier value)', 'Changed status', 'Laboratory Procedures', 'Traverse', 'Amount type - Percentage', 'Arts', 'Missing', 'Groups', 'Clinical Study Follow-up', 'Changing', 'Products of the Arts', 'Two', 'Percent (qualifier value)', 'Social group', 'Visit Name', 'Test Result', 'strategy', 'More', 'Testing', 'Change -- procedure', 'AGRP wt Allele', 'follow-up', 'Child', 'Power (Psychology)', 'Anatomic Structure, System, or Substance', 'Follow-Up Report', 'Blood Products Laboratory Testing', 'Three', 'f test', 'Delta (difference)', 'Standard deviation']","['topp', 'qnco', 'bhvr', 'menp', 'blor', 'fndg', 'idcn', 'clas', 'hlca', 'inpr', 'qlco', 'lbpr', 'hcpp', 'ftcn', 'mnob', 'popg', 'lbtr', 'ocdi', 'cnce', 'gngm', 'famg', 'aggp']"
1142,PMC3641608,S77,['7b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0]",Statistical analysis,interim data were reviewed annually by an independent data monitoring committee (four meetings) using the haybittle-peto criterion (p<0·001).,"['C0332181', 'C3245479', 'C2699414', 'C0085862', 'C2827738', 'C0243161', 'C0556656', 'C1290940', 'C0205450', 'C3714741', 'C1299583', 'C1511726']","['Data call receiving device', 'Four', 'Data (eukaryote)', 'criteria', 'Interim', 'Independently able', 'Independent for Transfer', 'Committee', 'Annual', 'meeting', 'Independence', 'Data']","['tmco', 'fndg', 'medd', 'idcn', 'qnco', 'grup', 'euka', 'acty']"
1143,PMC3641608,S78,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"randomised groups were compared with kaplan-meier plots, log-rank tests, and proportional hazards models, stratified by randomisation stratification factors (including the other factorial) for time-to-event disease progression, art, and adverse event outcomes, censoring at the earlier of trial closure or last follow-up.","['C0667477', 'C0332283', 'C2826344', 'C0022885', 'C0521125', 'C4321252', 'C0699794', 'C0441833', 'C4552808', 'C0220786', 'C4281991', 'C0392366', 'C0003826', 'C1335499', 'C0033489', 'C1521802', 'C0242656', 'C1552839', 'C0332257', 'C0441471', 'C3890191', 'C1517741', 'C3889990', 'C0205363', 'C1279919', 'C1514984', 'C0040223', 'C3889994', 'C0687744', 'C1515981', 'C0008976', 'C0877248', 'C4019010']","['TNFRSF11A protein, human', 'Followed by', 'National reporting jurisdiction:Loc:Pt:^Event:Nom', 'Disease Progression, CTCAE', 'Rank', 'Clinical Trials', 'Censor', 'Factorial Study', 'And', 'Event', 'Clinical Trial Censoring', 'Including (qualifier)', 'Closure', 'Table Rules - groups', 'Stratification Factors', 'stratified', 'Time', 'Tests (qualifier value)', 'Follow', 'Laboratory Procedures', 'Arts', 'Groups', 'Products of the Arts', 'Social group', 'Early', 'WWOX wt Allele', 'Preposition For', 'Disease Progression', 'AGRP wt Allele', 'Proportional Hazards Models', 'Last', 'Progressive Disease', 'Adverse event']","['tmco', 'clna', 'fndg', 'gngm', 'idcn', 'ocdi', 'inpr', ' aapp', 'qnco', 'qlco', 'bacs', 'lbpr', 'dsyn', 'resa', 'ftcn', 'mnob', 'popg', 'evnt', 'patf', 'acty']"
1144,PMC3641608,S79,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,categorical variables were compared with χ2 or exact (if indicated) tests.,"['C2828393', 'C0022885', 'C0439828', 'C4050514', 'C0392366']","['Variable (uniformity)', 'Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome Questionnaire', 'Tests (qualifier value)', 'Laboratory Procedures', 'Exact (qualifier)']","['qlco', 'lbpr', 'inpr']"
1145,PMC3641608,S80,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,change in cd4 percentage was compared with normal linear regression adjusted for randomisation stratification factors.,"['C0443172', 'C0231683', 'C1705241', 'C1514984', 'C2346679', 'C4553972', 'C0023733', 'C1549488', 'C0205307', 'C0392747', 'C4319952', 'C3541261', 'C4048280', 'C0439165', 'C1561533']","['Gait normal', 'Normal', 'Changing', 'Percent (qualifier value)', 'Stratification Factors', 'How Often Felt Normal question', 'Changed status', 'Linear Regression Body Surface Area Formula for Infants and Children', 'Change -- procedure', 'Delta (difference)', 'Money or percentage indicator - Percentage', 'CD4 Expressing Cell Count', 'Linear Regression', 'T-Cell Surface Glycoprotein CD4, human', 'Amount type - Percentage']","['fndg', 'topp', 'idcn', 'inpr', 'qnco', 'qlco', 'bacs', 'lbpr', 'ftcn', ' aapp']"
1146,PMC3641608,S81,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,laboratory measurements and adherence were compared across randomised groups over time with generalised estimating equations (independent correlation; closest measurement to each scheduled visit within equally spaced windows).,"['C1522666', 'C0086960', 'C0552449', 'C1512346', 'C0242485', 'C0441833', 'C1457900', 'C0085862', 'C0545082', 'C1510802', 'C0681902', 'C1552839', 'C0557702', 'C2826704', 'C1707520', 'C0205539', 'C0040223', 'C0687744', 'C1515981', 'C1290940', 'C1299583']","['Patient Visit', 'Each (qualifier value)', 'And', 'Independent for Transfer', 'Schedule (document type)', 'Measurement', 'Independence', 'Visit', 'Table Rules - groups', 'Window (physical object)', 'equation', 'Time', 'Closest', 'Groups', 'Correlation', 'Scheduled - procedure status', 'Social group', 'Visit Name', 'Independently able', 'Adherence (attribute)', 'laboratory measurement']","['tmco', 'fndg', 'idcn', 'hlca', 'inpr', 'qlco', 'qnco', 'bhvr', 'spco', 'resa', 'ftcn', 'mnob', 'popg', 'cnce']"
1147,PMC3641608,S82,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,all comparisons were as randomised (intention-to-treat).,"['C0087111', 'C1292734', 'C1522326', 'C1283828', 'C0162425', 'C0444868']","['All', 'Intention - mental process', 'Treating', 'Treatment intent', 'intent', 'Therapeutic procedure']","['topp', 'qlco', 'qnco', 'ftcn', 'menp']"
1148,PMC3641608,S83,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"subgroups specified in the analysis plan were the factorial randomisations, time on art, sex, age, centre, cd4, weight for age, randomisation year, and previous art for prevention of mother-to-child transmission.","['C0036864', 'C2826344', 'C0199176', 'C0205156', 'C0009253', 'C1705104', 'C0270724', 'C0040722', 'C1524024', 'C0521125', 'C1305866', 'C0026591', 'C0936012', 'C0599880', 'C4321252', 'C1706420', 'C0220786', 'C1522384', 'C1301732', 'C0439234', 'C2700409', 'C4048280', 'C3541261', 'C0804628', 'C0003826', 'C0242781', 'C0680063', 'C0005910', 'C1079230', 'C0043100', 'C1521797', 'C3890191', 'C0205099', 'C0079399', 'C0008059', 'C0040223', 'C1552607', 'C1515981', 'C0001779']","['Age', 'year', 'Treatment Plan', 'Prophylactic treatment', 'Factorial Study', 'Weighing patient', 'And', 'Prevention Study', 'Offspring', 'prevention aspects', 'Gender:Type:Point in time:^Patient:Nominal', 'sex', 'Body Weight', 'transmission process', 'disease transmission', 'Sex Behavior', 'Time', 'analysis aspect', 'Weight', 'Planned', 'disease transmission qualifier', 'Arts', 'Coitus', 'Products of the Arts', 'WWOX wt Allele', 'Infantile Neuroaxonal Dystrophy', 'Central', 'CD4 Expressing Cell Count', 'Preposition For', 'Act Relationship Subset - previous', 'Mother (person)', 'AGRP wt Allele', 'Gender', 'Child', 'Analysis', 'Importance Weight', 'Subgroup A Nepoviruses', 'T-Cell Surface Glycoprotein CD4, human', 'Previous']","['virs', 'topp', 'qnco', 'bhvr', ' aapp', 'patf', 'clna', 'npop', 'idcn', 'hlca', 'inpr', 'qlco', 'bacs', 'lbpr', 'resa', 'ftcn', 'mnob', 'tmco', 'ocdi', 'spco', 'gngm', 'famg', 'orga', 'dsyn', 'orgf', 'aggp']"
1149,PMC3641608,S84,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,baseline values were those nearest to but before and within 42 days of randomisation.,"['C0205107', 'C1442488', 'C0168634', 'C0233535', 'C0439228', 'C0332152', 'C0042295']","['BaseLine dental cement', 'day', 'Proximal', 'Before', 'Baseline', 'butting', 'Values']","['tmco', 'qnco', 'qlco', 'mobd', 'spco', 'bodm']"
1150,PMC3641608,S85,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,z scores were determined with the british reference because it covers the full age range of arrow children.24,"['C0443225', 'C0336721', 'C1514811', 'C0008059', 'C0680063', 'C0596227', 'C1514721', 'C2348147', 'C1706462', 'C0871421', 'C0180153', 'C0001779']","['Range', 'Age', 'british', 'Child', 'Covers (device)', 'Offspring', 'Bibliographic Reference', 'Reference Object', 'arrow', 'full', 'z-score', 'Sample Range']","['inpr', 'famg', 'qnco', 'qlco', 'orga', 'mnob', 'popg', 'aggp', 'cnce']"
1151,PMC3641608,S86,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,all analyses were done with stata 12.1.,['C0444868'],['All'],['qnco']
1152,PMC3641608,S87,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,all p values are two-sided.,"['C0444868', 'C0042295', 'C0205448']","['Two', 'All', 'Values']","['qnco', 'qlco']"
1153,PMC3641608,S88,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"this trial is registered, isrctn24791884.",,,
1154,PMC3641608,S90,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Role of the funding sources,"the sponsor (uk medical research council), other funders (uk department for international development), and viiv healthcare/glaxosmithkline (donated drugs; funded viral load assays) had no direct role in study design, data collection, analysis, interpretation, report writing, or the decision to submit for publication.",,,
1155,PMC3641608,S91,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Role of the funding sources,the corresponding author had full access to all data and responsibility for submission for publication.,"['C0034037', 'C1515022', 'C0443225', 'C3245479', 'C2347939', 'C1515023', 'C1704324', 'C1515981', 'C0444454', 'C1554204', 'C3812881', 'C3714741', 'C0444868', 'C1511726', 'C0678341', 'C0034036']","['Submitted', 'Data call receiving device', 'All', 'Publishing', 'Regulatory Submission', 'Scientific Publication', 'Data (eukaryote)', 'And', 'author', 'Role Class - access', 'Access', 'Submission', 'full', 'responsibility', 'Publications', 'Data']","['ocac', 'prog', 'medd', ' mnob', 'idcn', 'inbe', 'inpr', 'qnco', 'qlco', 'spco', 'euka', 'ftcn']"
1156,PMC3668094,S34,"['3a', '5']","[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design and sites,"this was a prospective, multicentre, double blinded, randomised trial of standard dose oseltamivir (75 mg twice a day or paediatric equivalent) versus double dose (150 mg twice a day or paediatric equivalent) for treating severe influenza.","['C0205173', 'C0023981', 'C1080058', 'C0021403', 'C0030755', 'C0439185', 'C1442989', 'C1705765', 'C0021400', 'C0150108', 'C0178602', 'C4050466', 'C0205163', 'C0874161', 'C0008976', 'C0585361', 'C1705764', 'C4050465', 'C2828392', 'C0205082']","['Duplicate', 'Longitudinal Studies', 'Equal', 'Severe (severity modifier)', 'Pediatrics', 'Oseltamivir', 'Clinical Trials', 'Borg Category-Ratio 10 Perceived Exertion Score 5', 'Severe Extremity Pain', 'Influenza', 'Double Value Type', 'Dosage', 'Blinded', 'Doubling', 'Equivalent Weight', 'This (eukaryote)', 'Standard (qualifier)', 'Twice a day', 'Standard (document)', 'Influenza virus vaccine']","['tmco', 'imft', 'fndg', 'inpr', 'orch', 'qnco', 'qlco', 'bmod', 'dsyn', 'euka', 'resa', 'ftcn', ' phsu', 'acty']"
1157,PMC3668094,S35,['4b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and sites,"the study took place between april 2007 and february 2010 in 13 hospitals in indonesia, singapore, thailand, and vietnam.","['C0042658', 'C3811652', 'C3715024', 'C2603343', 'C0039725', 'C0037173', 'C2987743', 'C0019994', 'C3715025', 'C1533810', 'C0442504', 'C1515981', 'C1706374', 'C1882509', 'C3154892', 'C0021247', 'C3830166']","['February', 'Indonesia', 'put - instruction imperative', 'Singapore', 'Place', 'Tumor Necrosis Factor Ligand Superfamily Member 13', 'Placement action', 'Thailand', 'And', 'Vietnam', 'Hospitals', 'A Proliferation-Inducing Ligand Measurement', 'Study', 'TNFSF13 wt Allele', 'Singapore Zebrafish', 'Indonesia Zebrafish', 'April']","['tmco', ' hcro', 'idcn', 'hlca', 'gngm', 'geoa', 'qlco', 'bacs', 'lbpr', 'spco', 'resa', ' aapp', 'mnob', 'fish', 'acty']"
1158,PMC3668094,S37,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,"the inclusion criteria were age ≥1 year, respiratory illness with duration of symptoms ≤10 days, laboratory confirmed influenza, and either evidence of severe influenza (defined below) or positive result of a diagnostic test for h5n1.","['C0521093', 'C1512693', 'C2825142', 'C3812269', 'C0430022', 'C2825490', 'C0205082', 'C3844638', 'C0221423', 'C1546471', 'C3244292', 'C0021400', 'C0439234', 'C1547061', 'C4283904', 'C3887511', 'C0449238', 'C0016627', 'C1514241', 'C1446409', 'C0750484', 'C4050466', 'C1546767', 'C0022877', 'C0021403', 'C0086143', 'C1457887', 'C0683368', 'C1515981', 'C0521346', 'C2926735', 'C0001779', 'C4050465', 'C1274040']","['Laboratory', 'Positive Finding', 'Age', 'year', 'Evidence', 'diagnostic procedure', 'Borg Category-Ratio 10 Perceived Exertion Score 5', 'Confirmation', 'Symptoms', 'And', 'Positive Charge', 'Influenza in Birds', 'Positive', 'Diagnostic tests', 'What subject filter - Result', 'Laboratory observation', 'Influenza virus vaccine', 'Confirmed by', 'Illness (finding)', 'Influenza', 'Result', 'Duration', 'Duration (temporal concept)', 'Symptoms aspect', 'Severe Extremity Pain', 'Inclusion', '10 days', 'Experimental Result', 'Positive Number', 'Laboratory domain', 'Either', 'Severe (severity modifier)', 'respiratory', 'Specimen Source Codes - Respiratory']","['tmco', 'imft', 'fndg', 'lbtr', ' hcro', 'idcn', 'inpr', 'orch', 'sosy', 'qlco', 'orga', 'dsyn', 'ftcn', 'mnob', ' phsu', 'diap', 'cnce']"
1159,PMC3668094,S38,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,"severe influenza was defined as admission to hospital and one of the following: new infiltrate on chest x ray; tachypnoea (respiratory rate ≥30 for ages ≥12, ≥40 for ages 6-11, ≥45 for ages 3-5, ≥50 for ages 1-2); dyspnoea; or hypoxia (arterial oxygen saturation ≤92% on room air).","['C0851346', 'C0332282', 'C0205447', 'C3846005', 'C0086894', 'C0013404', 'C1521828', 'C0521125', 'C1963140', 'C0162574', 'C0817096', 'C1692321', 'C0871208', 'C0184666', 'C4321252', 'C0205082', 'C0019994', 'C0242184', 'C0021400', 'C0003130', 'C1546677', 'C0205314', 'C0428175', 'C1527391', 'C4050466', 'C1549537', 'C1546767', 'C1304794', 'C2314876', 'C0809949', 'C0021403', 'C1515981', 'C0521346', 'C4050465', 'C0332448']","['Glycation End Products, Advanced', 'Borg Category-Ratio 10 Perceived Exertion Score 5', 'Rate', 'Anterior thoracic region', 'And', 'Arterial oxygen saturation finding', 'Administration Method - Infiltrate', 'Rating (action)', 'Dipturus trachyderma', 'Room air', 'Influenza virus vaccine', 'Following', 'Chest', 'Influenza', 'Infiltration', 'Hospitals', 'Radiation', 'Admission activity', 'Severe Extremity Pain', 'WWOX wt Allele', 'Specimen Source Codes - Infiltrate', 'Rajiformes', 'Anoxia', 'One', 'Preposition For', 'Arterial oxygen saturation measurement', 'Hypoxia', 'Dyspnea', 'Severe (severity modifier)', 'Hypoxia, CTCAE', 'New', 'Cellular infiltrate', 'Hospital admission', 'respiratory', 'Specimen Source Codes - Respiratory']","[' hcro', 'qnco', 'patf', 'blor', 'fndg', 'npop', ' orch', 'hlca', 'idcn', 'inpr', 'sosy', 'qlco', 'bacs', 'lbpr', 'ftcn', 'mnob', 'tmco', 'lbtr', 'fish', 'acty', 'imft', 'gngm', 'dsyn', ' phsu']"
1160,PMC3668094,S39,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,"exclusion criteria were pregnancy or positive for chorionic gonadotrophin (hcg) in urine, women who were actively breast feeding, a delay of more than 72 hours before treatment with oseltamivir, and severe renal impairment defined by creatinine clearance <10 ml/min (cockcroft-gault equation).","['C0042036', 'C1382187', 'C0449297', 'C0032961', 'C3812269', 'C0680251', 'C2825073', 'C1514463', 'C0552449', 'C2825490', 'C0205082', 'C4554548', 'C3272598', 'C0043210', 'C0205421', 'C0006147', 'C0018062', 'C0205172', 'C1141639', 'C0332287', 'C0042037', 'C1446409', 'C1514241', 'C4050466', 'C1565489', 'C2963137', 'C1292423', 'C0439445', 'C1515981', 'C0874161', 'C4050465', 'C4321295']","['Chorionic Gonadotropin', 'Positive Finding', 'Portion of urine', 'In addition to', 'Oseltamivir', 'Borg Category-Ratio 10 Perceived Exertion Score 5', 'And', 'Positive Charge', 'Positive', 'Prior Therapy', 'Pregnancy', 'equation', 'Urine', 'Milliliter per Minute', 'Woman', 'Renal Insufficiency', '72 Hours', 'Clearance procedure', 'Human Chorionic Gonadotropin', 'Severe Extremity Pain', 'Exclusion Criteria', 'Clearance of substance', 'More', 'CGA wt Allele', 'Deferred', 'Clearance', 'Positive Number', 'Clearance [PK]', 'Severe (severity modifier)', 'In Urine', 'WHO Temperature/Humidity Storage Condition', 'Breast Feeding']","['clna', 'tmco', 'cnce', 'fndg', 'popg', 'npop', 'gngm', 'idcn', 'topp', 'inpr', 'orch', 'qlco', 'horm', 'qnco', 'dsyn', 'orgf', 'ftcn', ' phsu', ' aapp', 'bdsu']"
1161,PMC3668094,S41,"['8a', '8b', '5']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 1, 0]",Treatment,patients were randomised to receive double or standard dose oseltamivir based on a computer generated list that was stratified by site and age group.,"['C2825164', 'C1515974', 'C0205173', 'C2348001', 'C3272378', 'C0205145', 'C1442989', 'C3146294', 'C1705765', 'C0030705', 'C0009622', 'C0178602', 'C1515981', 'C0874161', 'C1705764', 'C0745732', 'C2828392', 'C0027362']","['Duplicate', 'Age Cohort', 'Oseltamivir', 'Human Age Group', 'And', 'Double Value Type', 'Dosage', 'Patients', 'Anatomic Site', 'Doubling', 'Generation (action)', 'Site', 'Standard (document)', 'Computers', 'List', 'Standard (qualifier)', 'Sequence Data Type', 'Study Site']","['blor', 'popg', 'idcn', 'inpr', 'orch', 'qnco', 'qlco', 'spco', 'podg', 'ftcn', 'mnob', ' phsu', 'aggp', 'acty']"
1162,PMC3668094,S42,['8b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0]",Treatment,patients with h5n1 influenza were stratified separately.,"['C0016627', 'C0021400', 'C0030705', 'C0021403']","['Patients', 'Influenza in Birds', 'Influenza', 'Influenza virus vaccine']","['podg', 'imft', ' phsu', 'dsyn']"
1163,PMC3668094,S43,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Treatment,"oseltamivir capsules, paediatric oseltamivir suspensions, and placebo suspensions were provided by roche (basel, switzerland).","['C0038960', 'C0032042', 'C0331779', 'C0030755', 'C0006935', 'C1706408', 'C1515981', 'C1696465', 'C0874161', 'C0331965', 'C0039021']","['placebo', 'Placebo Control', 'Pediatrics', 'Oseltamivir', 'roche', 'capsule (pharmacologic)', 'And', 'Placebos', 'Switzerland', 'Suspensions', 'basel']","['idcn', 'topp', 'geoa', 'orch', 'hcro', 'bmod', 'resa', 'bodm', ' phsu']"
1164,PMC3668094,S44,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Treatment,"placebo capsules were manufactured by the pharmaceutical development section at the national institutes of health clinical center (bethesda, md, us).","['C3245503', 'C0021622', 'C0032042', 'C0006935', 'C1705191', 'C0700320', 'C0872152', 'C1706408', 'C1696465', 'C3714523', 'C1522472', 'C2347782', 'C1552923', 'C0018684']","['National citizen', 'placebo', 'Placebo Control', 'NIH Clinical Center', 'capsule (pharmacologic)', 'Institutes', 'Section - Geographic Area', 'Placebos', 'Section (object)', 'Drug Development', 'Square Mile', 'Health', 'Sectioning technique', 'section sample']","['idcn', 'orgt', 'topp', 'geoa', 'qnco', 'sbst', 'bmod', 'lbpr', 'resa', 'bodm', 'phob', 'popg']"
1165,PMC3668094,S45,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Treatment,the doses were 75 mg or 150 mg twice daily in those aged ≥15 or weighing >40 kg; 60 mg or 120 mg twice daily in those weighing >23-40 kg; 45 mg or 90 mg twice daily in those weighing >15-23 kg; and 30 mg or 60 mg twice daily in those weighing ≤15 kg.,"['C0178602', 'C0001792', 'C0585361', 'C0001779', 'C1999167']","['Age', 'Elderly (population group)', 'Old age', 'Dosage', 'Twice a day']","['tmco', 'qnco', 'popg', 'orga']"
1166,PMC3668094,S46,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Treatment,these doses were halved for patients with a creatinine clearance ≥10 and <30 ml/min.17 19 20,"['C0439445', 'C0030705', 'C0178602', 'C1515981', 'C0812399', 'C0039828']","['Creatinine clearance', 'And', 'Milliliter per Minute', 'Dosage', 'Patients', 'Theses']","['biof', 'idcn', 'inpr', 'qnco', 'podg']"
1167,PMC3668094,S47,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Treatment,all drug treatments were supervised by the research team.,"['C0087111', 'C0035168', 'C0871489', 'C0242481', 'C0444868', 'C1254351', 'C0013227']","['Research Activities', 'teams', 'All', 'research', 'Pharmaceutical Preparations', 'Pharmacologic Substance', 'Therapeutic procedure']","['topp', 'qnco', 'grup', 'resa', 'phsu']"
1168,PMC3668094,S48,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Treatment,all patients received five days of oseltamivir.,"['C0205451', 'C0030705', 'C0874161', 'C0444868', 'C0439228']","['day', 'All', 'Oseltamivir', 'Five', 'Patients']","['tmco', 'orch', 'qnco', 'podg', ' phsu']"
1169,PMC3668094,S49,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Treatment,"those with persistent tachypnoea, dyspnoea, or hypoxia on day five of the study were defined as meeting the criteria for clinical failure and continued to take the randomised dose for an additional five days.","['C1515187', 'C0013404', 'C0178602', 'C0521125', 'C0243161', 'C1963140', 'C1524062', 'C4321252', 'C0332173', 'C0242184', 'C0205451', 'C0003130', 'C0439228', 'C1704788', 'C0332996', 'C2603343', 'C0549178', 'C0205322', 'C0556656', 'C1515981', 'C3640841']","['And', 'Study', 'Definition', 'Take', 'Continuous', 'WWOX wt Allele', 'meeting', 'Dosage', 'Anoxia', 'Persistent embryonic structure', 'Daily', 'Preposition For', 'Hypoxia', 'Dyspnea', 'day', 'Persistent', 'Hypoxia, CTCAE', 'Additional', 'criteria', 'Five', 'Clinical Failure']","['tmco', 'fndg', 'cgab', 'gngm', 'idcn', 'hlca', 'inpr', 'sosy', 'qnco', 'qlco', 'resa', 'ftcn', 'patf', 'acty']"
1170,PMC3668094,S51,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study evaluations,"patients with severe influenza-like illness were screened with the quickvue rapid test (quidel, san diego, ca, us) and/or reverse transcriptase polymerase chain reaction (rt-pcr) of throat and nose swabs.","['C2257077', 'C1706528', 'C0028429', 'C4050242', 'C0205082', 'C0221423', 'C0021400', 'C0030705', 'C0699835', 'C1261188', 'C0031354', 'C0040646', 'C0032520', 'C3665375', 'C1826357', 'C0086890', 'C4050466', 'C0021403', 'C0183753', 'C1515981', 'C4050465']","['Quick Test for Liver Function', 'Swab specimen', 'Borg Category-Ratio 10 Perceived Exertion Score 5', 'Nose', 'And', 'Influenza virus vaccine', 'Quick Test of Performance Intelligence', 'NAA50 gene', 'Illness (finding)', 'And/Or', 'Influenza', 'Transcriptase activity', 'Transcriptase', 'Severe Extremity Pain', 'Pharyngeal structure', 'Patients', 'Throat', 'Polymerase Chain Reaction', 'Severe (severity modifier)', 'Swab', 'Pathologic Complete Response']","['mbrt', 'imft', 'fndg', 'cnce', 'gngm', 'idcn', 'medd', 'enzy', 'inpr', 'genf', 'sosy', 'sbst', 'lbpr', 'dsyn', 'podg', ' aapp', ' phsu', 'bpoc', ' diap']"
1171,PMC3668094,S52,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study evaluations,patients with positive results for influenza virus who met the inclusion criteria were randomised.,"['C3272598', 'C1512693', 'C1514241', 'C1446409', 'C0319157', 'C0030705', 'C3812269', 'C0042776', 'C2825490']","['Positive Finding', 'Virus', 'Inclusion', 'WHO Temperature/Humidity Storage Condition', 'Patients', 'Positive Charge', 'Positive', 'AS virus', 'Positive Number']","['fndg', 'virs', 'qlco', 'podg', 'cnce']"
1172,PMC3668094,S53,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study evaluations,swabs were obtained for virus detection in the nose and throat on days 0 to 10 and day 14.,"['C0332173', 'C0183753', 'C3665375', 'C1515981', 'C1294356', 'C0031354', 'C1261188', 'C0028429', 'C0439228']","['Throat', 'day', 'Swab specimen', 'Pharyngeal structure', 'And', 'Nose', 'Detection of virus procedure', 'Daily', 'Swab']","['tmco', 'medd', 'idcn', 'sbst', 'lbpr', 'bpoc']"
1173,PMC3668094,S54,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study evaluations,"study swabs were collected and eluted in m4 media (remel, lenexa, ks, us) before storage at −70 °c.","['C2603343', 'C0009458', 'C0183753', 'C1254021', 'C0337174', 'C1261188', 'C1753314', 'C1698986']","['Media layer', 'Swab specimen', 'Communications Media', 'cellular entity storage', 'Study', 'Storage area', 'Storage', 'Swab']","['medd', 'inpr', 'celc', 'tisu', 'sbst', 'spco', 'resa', 'ftcn']"
1174,PMC3668094,S56,"['6a', '11a']","[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Virology,"testing of the combined nasal and throat swab specimens on day five, which was the primary virological study endpoint, was done under blinded conditions in the seaicrn reference laboratories in vietnam and indonesia.","['C1514811', 'C0205225', 'C1565156', 'C0205195', 'C0028429', 'C2987743', 'C0332173', 'C1706462', 'C0205451', 'C0150108', 'C0542339', 'C0439056', 'C0439228', 'C2826544', 'C1272695', 'C2349179', 'C1421478', 'C0043194', 'C0022877', 'C0021247', 'C2603343', 'C1515981', 'C0042658']","['Laboratory', 'And', 'Nose', 'Study', 'Reference Object', 'Bibliographic Reference', 'Wiskott-Aldrich Syndrome', 'Indonesia', 'Endpoint Value Derivation Technique', 'Inferior', 'WAS gene', 'Vietnam', 'Blinded', 'Daily', 'Indonesia Zebrafish', 'Throat swab sample', 'day', 'Primary', 'WAS protein, human', 'Five', 'Combined', 'Done (qualifier value)', 'End Point']","['tmco', ' hcro', 'idcn', 'gngm', 'inpr', 'geoa', 'bdsu', 'qlco', 'bacs', 'qnco', 'dsyn', 'spco', 'resa', 'bpoc', ' aapp', 'mnob', 'fish', 'cnce']"
1175,PMC3668094,S57,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Virology,qualitative rt-pcr for detection of influenza a and b viruses and for subtyping of influenza a viruses was done according to who/us cdc protocols.21 22,"['C3272598', 'C0021403', 'C0007670', 'C1511790', 'C0205556', 'C0021400', 'C0019378', 'C1515981', 'C4084772', 'C0442711', 'C0599161', 'C4085194']","['Conventional Dendritic Cell', 'Protocols documentation', 'Reverse Transcriptase Polymerase Chain Reaction', 'qualitative', 'Influenza', 'WHO Temperature/Humidity Storage Condition', 'And', 'Herpesvirus 1, Cercopithecine', 'Detection', 'Centers for Disease Control and Prevention (U.S.)', 'Complement dependent cytotoxicity', 'Influenza virus vaccine']","['mbrt', 'imft', 'virs', 'idcn', 'topp', 'inpr', 'hcro', 'qlco', 'cell', 'lbpr', 'dsyn', ' phsu']"
1176,PMC3668094,S58,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Virology,"quantitative rt-pcr for influenza virus a and b, with a lower limit of quantification of 103 copies of cdna per ml, was performed as described previously.23","['C4316910', 'C0029341', 'C0006556', 'C1709793', 'C1549649', 'C2003888', 'C1548802', 'C1552738', 'C1948062', 'C0439801', 'C1515981', 'C2349209', 'C0392762', 'C0599161', 'C0441994']","['Reverse Transcriptase Polymerase Chain Reaction', 'Limit - Amount class', 'Limited (extensiveness)', 'Quantitation', 'Copy (object)', 'DNA, Complementary', 'Lower - spatial qualifier', 'quantitative', 'And', 'Lower (action)', 'Influenza virus', 'described', 'Orthomyxoviridae', 'Body Site Modifier - Lower', 'Bound (value)']","['blor', 'acty', 'mbrt', 'virs', 'idcn', 'qnco', 'nnon', 'spco', 'ftcn', 'mnob', 'cnce']"
1177,PMC3668094,S59,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Virology,virus culture and genotypic screening for oseltamivir resistance mutations were performed as described previously on day 0 samples for all enrolled patients and on day five samples for patients with positive results on rt-pcr.24 25,"['C0026882', 'C1710032', 'C4684790', 'C1514892', 'C0200955', 'C3812269', 'C2825490', 'C4050242', 'C0332173', 'C2348164', 'C0030705', 'C1698960', 'C0439228', 'C1552738', 'C1514241', 'C0032520', 'C1446409', 'C0220908', 'C0444868', 'C1710031', 'C0017431', 'C0220909', 'C4281815', 'C0237834', 'C1515981', 'C1710477']","['Positive Finding', 'Aspects of disease screening', 'Screening procedure', 'And', 'Positive Charge', 'Positive', 'Mutation', 'Resistance', 'Trial Screening', 'Screening', 'Genotype', 'Viral culture procedure', 'Screening Study', 'All', 'Disease Screening', 'Resistance Process', 'Patients', 'Daily', 'Positive Number', 'described', 'Study Subject Enrolled', 'research subject screening', 'Polymerase Chain Reaction', 'day', 'Resistance (Psychotherapeutic)', 'Pathologic Complete Response']","['tmco', 'mbrt', 'fndg', 'hlca', 'idcn', 'phsf', 'genf', 'qnco', 'qlco', 'orga', 'lbpr', 'resa', 'podg', 'ftcn', 'diap', 'menp', 'cnce']"
1178,PMC3668094,S62,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Data analysis,the primary efficacy endpoint was the proportion of all patients with no detectable viral rna by rt-pcr in a combined nasal and throat swab sample on day five.,"['C0439228', 'C2826544', 'C1709707', 'C0332173', 'C0205225', 'C2349179', 'C0205451', 'C0030705', 'C1515981', 'C0439056', 'C0205195', 'C0035736', 'C1707887', 'C0444868', 'C3830527', 'C0028429', 'C0599161', 'C1280519']","['Reverse Transcriptase Polymerase Chain Reaction', 'Endpoint Value Derivation Technique', 'Effectiveness', 'Throat swab sample', 'day', 'All', 'Primary', 'RNA, Viral', 'Proportion', 'And', 'Nose', 'Efficacy Study', 'Five', 'Patients', 'Combined', 'Daily', 'End Point', 'Detectable']","['tmco', 'mbrt', 'idcn', 'bdsu', 'qnco', 'qlco', 'nnon', 'resa', 'podg', 'bpoc', 'clna']"
1179,PMC3668094,S63,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Data analysis,"we also examined numerous secondary clinical endpoints (such as mortality, mechanical ventilation, admission to intensive care, symptoms, resumption of activity) and virological endpoints.","['C0027627', 'C0199470', 'C0809949', 'C0175668', 'C0026566', 'C0085559', 'C0205436', 'C2349179', 'C0683368', 'C4049938', 'C1515981', 'C0026565', 'C0441655', 'C0205210', 'C1548354', 'C0439064', 'C1457887', 'C4049939', 'C0184666', 'C0205177']","['Mortality Vital Statistics', 'Mechanical ventilation', 'Aspects of mortality statistics', 'Clinical', 'Neoplasm Metastasis', 'Physical Activity Measurement', 'Symptoms aspect', 'Specialty Type - Intensive care', 'Activities', 'Secondary to', 'second (number)', 'And', 'Symptoms', 'intensive care', 'Hospital admission', 'FDA Establishment Activity Terminology', 'Admission activity', 'End Point', 'Active', 'Numerous']","['topp', 'hlca', 'idcn', 'inpr', 'sosy', 'qnco', 'qlco', 'bmod', 'lbpr', 'ftcn', 'neop', 'acty']"
1180,PMC3668094,S64,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Data analysis,we chose the proportion of patients with viral rna shedding at day five after the start of treatment as the primary endpoint as this represents the duration of one standard course of oseltamivir and clinical failure is generally evaluated after five days of treatment.,"['C0205447', 'C1442989', 'C3538994', 'C0687676', 'C0035736', 'C1533734', 'C2828392', 'C0087111', 'C0332173', 'C3887704', 'C1705169', 'C0039798', 'C0205451', 'C0030705', 'C0439659', 'C0439228', 'C0449238', 'C1709707', 'C0220825', 'C0332287', 'C2986535', 'C0750729', 'C0231290', 'C1522326', 'C1080058', 'C1515981', 'C0874161', 'C2926735', 'C3640841']","['In addition to', 'Oseltamivir', 'And', 'Standard (document)', 'Post', 'RNA, Viral', 'Proportion', 'Treatment Epoch', 'Biomaterial Treatment', 'Administration procedure', 'Duration', 'Duration (temporal concept)', 'Status post', 'Beginning', 'Primary Endpoint', 'Patients', 'Daily', 'One', 'Course', 'day', 'treatment - ActInformationManagementReason', 'Treating', 'therapeutic aspects', 'Five', 'This (eukaryote)', 'Evaluation', 'Standard (qualifier)', 'Clinical Failure', 'Therapeutic procedure']","['tmco', 'fndg', 'topp', 'hlca', 'idcn', 'irda', 'inpr', 'orch', 'qnco', 'qlco', 'nnon', 'euka', 'resa', 'podg', 'ftcn', ' phsu', 'cnce']"
1181,PMC3668094,S65,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data analysis,this is also consistent with the 2010 position paper by ison and colleagues on the choice of efficacy endpoints in severe influenza studies.26,"['C1707391', 'C4019252', 'C0332290', 'C1080058', 'C0021403', 'C0947630', 'C0733755', 'C2349179', 'C0021400', 'C0008300', 'C1515981', 'C4050466', 'C1547566', 'C0205082', 'C1707887', 'C0030351', 'C4050465', 'C1280519']","['Paper', 'Paper Authorization', 'Effectiveness', 'Severe (severity modifier)', 'Severe Extremity Pain', 'Borg Category-Ratio 10 Perceived Exertion Score 5', 'Influenza', 'And', 'Choice Behavior', 'Efficacy Study', 'Positioning Attribute', 'Position of phenotypic abnormality', 'Scientific Study', 'This (eukaryote)', 'Consistent with', 'End Point', 'Choose (action)', 'Influenza virus vaccine']","['imft', 'fndg', 'idcn', 'inbe', 'inpr', 'qlco', 'lbpr', 'dsyn', 'euka', 'resa', 'spco', 'mnob', ' phsu', 'acty']"
1182,PMC3668094,S67,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Data analysis,"based on previous studies, we assumed that children and adults admitted to hospital with influenza would have detectable virus for an average of 6.3 days (plus or minus 1.5 days) and 4 days after onset of treatment, respectively.26 27 28.","['C0332288', 'C2825518', 'C0205156', 'C3538994', 'C1442765', 'C3830527', 'C1533734', 'C0087111', 'C0019994', 'C3887704', 'C0206132', 'C1705169', 'C0021400', 'C0039798', 'C1442459', 'C0680063', 'C0319157', 'C1510992', 'C0001675', 'C1522326', 'C0008059', 'C0021403', 'C1552607', 'C1515981', 'C1442466', 'C0042776', 'C0332162', 'C0947630']","['And', 'Offspring', 'Influenza virus vaccine', 'Onset of (contextual qualifier)', 'Detectable', 'Age of Onset', 'Influenza', 'Adult', 'Treatment Epoch', 'Hospitals', 'Biomaterial Treatment', 'AS virus', 'Administration procedure', '5 Days', '4 Days', 'Without', 'Average', 'Scientific Study', 'Act Relationship Subset - previous', 'Virus', 'treatment - ActInformationManagementReason', 'Child', 'Treating', 'therapeutic aspects', '3 Days', 'Average of Value Derivation Technique', 'Previous', 'Therapeutic procedure']","['tmco', 'clna', 'imft', 'virs', ' hcro', 'idcn', 'topp', 'hlca', 'famg', 'qnco', 'qlco', 'lbpr', 'dsyn', 'resa', 'ftcn', 'mnob', ' phsu', 'aggp', 'cnce']"
1183,PMC3668094,S68,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Data analysis,"if we assume that 30% of children and 55% of adults treated with standard dose oseltamivir would test negative for virus on day five, a sample size of 242 patients would be required to show a 20% absolute improvement in cessation of viral shedding with 85% power and a two sided α of 0.05.","['C1515976', 'C1160693', 'C0022885', 'C1547282', 'C1442989', 'C4318744', 'C0178602', 'C0521125', 'C1880019', 'C2828392', 'C2825415', 'C4321252', 'C1514873', 'C0332173', 'C2986411', 'C0205451', 'C0030705', 'C0392366', 'C0205448', 'C0439228', 'C0242618', 'C0032863', 'C0332287', 'C0680063', 'C0319157', 'C0456984', 'C3854080', 'C0001675', 'C2825491', 'C0205160', 'C0162633', 'C0008059', 'C1522326', 'C0039593', 'C3853545', 'C1513916', 'C1515981', 'C0042776', 'C0205344', 'C0874161', 'C3831328']","['absolute', 'Negative Charge', 'In addition to', 'Oseltamivir', 'Cessation', 'And', 'Power', 'Offspring', 'Test - temporal region', 'Standard (document)', 'Viral Shedding', 'Adult', 'Tests (qualifier value)', 'Laboratory Procedures', 'AS virus', 'Negative Finding', 'Two', 'Test Result', 'Requirement', 'WWOX wt Allele', 'Negative', 'viral release from host cell', 'Dosage', 'Patients', 'Show', 'Testing', 'Improvement', 'Daily', 'Preposition For', 'Negative - answer', 'Virus', 'day', 'Sample Size', 'Power (Psychology)', 'Child', 'Anatomic Structure, System, or Substance', 'Treating', 'Blood Products Laboratory Testing', 'Five', 'Negative Number', 'Standard (qualifier)']","['celf', 'virs', 'qnco', 'podg', 'patf', 'blor', 'fndg', 'idcn', 'clas', 'inpr', 'qlco', 'lbpr', 'hcpp', 'ftcn', 'tmco', 'lbtr', 'anim', 'orch', 'cnce', 'acty', 'gngm', 'famg', ' phsu', 'aggp']"
1184,PMC3668094,S69,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Data analysis,"to allow for study withdrawals, our target sample size was 300 patients.","['C4528313', 'C2603343', 'C0030705']","['Patients', 'Target Sample Size', 'Study']","['podg', 'qnco', 'resa']"
1185,PMC3668094,S71,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data analysis,"data were analysed with stata v10 (stata corporation, washington dc).","['C3245479', 'C0507132', 'C0043038', 'C3714741', 'C1511726', 'C0683758']","['Data call receiving device', 'Posterior basal segmental vein', 'Data (eukaryote)', 'corporation', 'Washington state', 'Data']","['medd', 'idcn', 'orgt', 'geoa', 'euka', 'bpoc']"
1186,PMC3668094,S72,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data analysis,"the intention to treat population included all patients randomised, whether or not they received study drug.",,,
1187,PMC3668094,S73,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data analysis,"for the virological endpoints, we included only patients with rt-pcr proved influenza virus infection on screening (day 0).",,,
1188,PMC3668094,S74,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data analysis,patients who died before day five were assumed to be virus positive on day five unless the virus was cleared before death.,"['C3272598', 'C0332173', 'C0011065', 'C1446409', 'C1514241', 'C0319157', 'C0205451', 'C0030705', 'C1306577', 'C3812269', 'C0042776', 'C0439228', 'C2825490']","['Death (finding)', 'Positive Finding', 'Virus', 'day', 'WHO Temperature/Humidity Storage Condition', 'Five', 'Patients', 'Positive Charge', 'Positive', 'Daily', 'AS virus', 'Positive Number', 'Cessation of life']","['tmco', 'fndg', 'virs', 'qlco', 'qnco', 'orgf', 'podg', 'cnce']"
1189,PMC3668094,S75,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data analysis,"for patients with missing results on day five, we carried forward the last available results.","['C1517741', 'C3272743', 'C0332173', 'C0439780', 'C0205451', 'C0470187', 'C0030705', 'C1705492', 'C0439228', 'C1551393']","['availability of', 'Container status - Missing', 'day', 'Last', 'Missing Study Animal', 'Five', 'Patients', 'Daily', 'Forward', 'Missing']","['tmco', 'fndg', 'qlco', 'qnco', 'spco', 'podg', 'ftcn']"
1190,PMC3668094,S76,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data analysis,we used conditional univariate logistic regression to calculate and compare the odds ratios of viral clearance for categorical data between the treatment arms stratified by study site and the mantel-haenszel method when the numbers of patients were small.,"['C0237753', 'C1382187', 'C0446516', 'C0449297', 'C3538994', 'C0521125', 'C2825073', 'C1533734', 'C4321252', 'C4554548', 'C0205103', 'C0087111', 'C3887704', 'C0025663', 'C1705169', 'C0449788', 'C0871511', 'C0039798', 'C0206031', 'C0030705', 'C2681631', 'C1963686', 'C1948054', 'C0028873', 'C0206655', 'C4684582', 'C2347790', 'C0449851', 'C0700321', 'C2825164', 'C0205363', 'C1522326', 'C1515981', 'C1701901', 'C0521026']","['Logistic Regression', 'KIDINS220 gene', 'Categorical Data', 'Small', 'And', 'Study Site', 'Alveolar rhabdomyosarcoma', 'stratified', 'Count of entities', 'Techniques', 'Treatment Epoch', 'Upper arm', 'Biomaterial Treatment', 'Conditional', 'Administration procedure', 'Clinical Study Site', 'Viral', 'When (temporal qualifier)', 'Clearance procedure', 'Clearance of substance', 'Test Method', 'WWOX wt Allele', 'Patients', 'Clearance', 'Conditional (Substitution Condition)', 'Preposition For', 'Odds Ratio', 'Clearance [PK]', 'Intermediate', 'Numbers', 'Methods', 'treatment - ActInformationManagementReason', 'Treating', 'therapeutic aspects', 'Therapeutic procedure']","['clna', 'blor', 'tmco', 'npop', 'gngm', 'topp', 'idcn', 'hlca', 'inpr', 'hcro', 'qnco', 'qlco', 'lbpr', 'ftcn', 'resa', 'podg', 'neop', 'spco', 'cnce']"
1191,PMC3668094,S77,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data analysis,the breslow-day test was used to test the heterogeneity of the results between study sites.,"['C1511325', 'C2603343', 'C1515976', 'C0332173', 'C0022885', 'C0205145', 'C4318744', 'C0039593', 'C0456984', 'C0242960', 'C0392366', 'C3831328', 'C0019409', 'C0439228']","['day', 'Heterogeneity', 'Anatomic Structure, System, or Substance', 'Test Result', 'Testing', 'Blood Products Laboratory Testing', 'Genetic Heterogeneity', 'Test - temporal region', 'Tests (qualifier value)', 'Study', 'Daily', 'Breslow Thickness', 'Laboratory Procedures', 'Site']","['tmco', 'blor', 'lbtr', 'clas', 'inpr', 'qlco', 'orga', 'lbpr', 'spco', 'resa', 'ftcn', 'clna']"
1192,PMC3668094,S78,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data analysis,"because we found no heterogeneity, we used conditional multiple logistic regression to investigate independent predictors of viral rna clearance on day five, stratified by study sites.","['C4554548', 'C4319105', 'C0439064', 'C2603343', 'C0332173', 'C0205145', 'C1382187', 'C0035668', 'C0449297', 'C0085862', 'C0206031', 'C0205451', 'C0242960', 'C1290940', 'C1701901', 'C1963686', 'C1299583', 'C0019409', 'C2825073', 'C0439228']","['Logistic Regression', 'Clearance procedure', 'day', 'Ribonucleic Acid Measurement', 'RNA', 'Clearance of substance', 'Heterogeneity', 'Independence', 'Independently able', 'Genetic Heterogeneity', 'Independent for Transfer', 'Five', 'Study', 'Conditional', 'Clearance', 'Conditional (Substitution Condition)', 'Daily', 'Site', 'Clearance [PK]', 'Numerous']","['tmco', 'fndg', 'npop', 'topp', 'idcn', 'qlco', 'qnco', 'lbpr', 'nnon', 'orga', 'resa', 'spco', 'ftcn', 'clna']"
1193,PMC3668094,S79,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data analysis,"in these regression models, the quantifiable viral load data were used (that is, ≥103 cdna copies/ml) and data from samples positive by qualitative rt-pcr but not quantifiable were given a value of 103 cdna copies(c)/ml, the lower limit of detection of the quantitative rt-pcr.","['C0376705', 'C0205556', 'C1261478', 'C3812269', 'C0684321', 'C2825490', 'C1442162', 'C1947971', 'C1836830', 'C3245479', 'C1514241', 'C1446409', 'C1522609', 'C3244317', 'C0392762', 'C1517320', 'C0039828', 'C0006556', 'C1518422', 'C2718050', 'C1948062', 'C1550718', 'C3161035', 'C1515981', 'C0684320', 'C0233535', 'C3714741', 'C1273517', 'C1511726', 'C1531853', 'C0599161']","['Positive Finding', 'Copy (object)', 'Numerical value', 'Data (eukaryote)', 'And', 'Entity Name Part Type - given', 'From', 'Positive Charge', 'Positive', 'Given name', 'used by', 'Regression - mental defense mechanism', 'Theses', 'qualitative', 'Copies per Milliliter', 'Developmental regression', 'Disease regression', 'butting', 'quantitative', 'Reverse Transcriptase Polymerase Chain Reaction', 'Data call receiving device', 'DNA, Complementary', 'Limit of Detection', 'Model', 'Positive Number', 'Viral Load result', 'Negation', 'GIVEN', 'Give - dosing instruction imperative', 'Viral load measurement', 'Data']","['mbrt', 'fndg', 'medd', 'idcn', 'inpr', 'qlco', 'qnco', 'mobd', 'lbpr', 'nnon', 'dsyn', 'euka', 'ftcn', 'mnob', 'menp', 'patf', 'cnce']"
1194,PMC3668094,S80,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data analysis,this analysis was repeated by giving these samples the value of 0.,"['C1080058', 'C1522609', 'C1524024', 'C0039828', 'C0936012']","['Numerical value', 'Analysis', 'analysis aspect', 'This (eukaryote)', 'Theses']","['inpr', 'qnco', 'euka', 'resa', 'ftcn']"
1195,PMC3668094,S81,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data analysis,"for multiple regression we forced important variables such as age group, (sub)type of virus, and treatment arm in the model, while for other factors we used forward stepwise variable selection procedure with 5% significance.","['C3274659', 'C1264637', 'C0439828', 'C4553760', 'C0750502', 'C0027362', 'C0332307', 'C2700391', 'C3274430', 'C3539779', 'C3714583', 'C3898777', 'C0681923', 'C2348001', 'C0439780', 'C0319157', 'C1522541', 'C4084912', 'C1707391', 'C3853906', 'C3161035', 'C1515981', 'C0036576', 'C0042776', 'C0184661', 'C0237881']","['Important', 'And', 'Forward', 'Procedure (set of actions)', 'Importance Rating Score 0', 'Digital Model Attachment', 'Model Number', 'Type - attribute', 'Variable (uniformity)', 'Human Age Group', 'Physical Medical Procedure', 'AS virus', 'Genetic Selection', 'Model - style/design', 'Model', 'Statistical Significance', 'Study Variable', 'Protocol Treatment Arm', 'multiple regression', 'Choose (action)', 'Significant', 'Virus', 'Age Cohort', 'Substance amount', 'CDISC SDTM Procedure Terminology', 'Interventional procedure']","['virs', 'topp', 'hlca', 'idcn', 'inpr', 'genf', 'qlco', 'qnco', 'spco', 'resa', 'ftcn', 'popg', 'aggp', 'cnce', 'acty']"
1196,PMC3668094,S82,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data analysis,normally distributed continuous data were compared between the two arms with the unpaired t test; the mann-whitney u or kruskal-wallis tests were used for skewed data.,"['C0549178', 'C3245479', 'C1704711', 'C0332287', 'C0022885', 'C0446516', 'C2700112', 'C2681631', 'C0206655', 'C0392366', 'C3714741', 'C0205448', 'C1511726', 'C0871472']","['Data call receiving device', 'Alveolar rhabdomyosarcoma', 'KIDINS220 gene', 'Continuous', 'Two', 'In addition to', 't test', 'Data (eukaryote)', 'Unpaired', 'Tests (qualifier value)', 'Upper arm', 'Distribution', 'Laboratory Procedures', 'Data']","['blor', 'gngm', 'idcn', 'medd', 'inpr', 'qnco', 'qlco', 'lbpr', 'euka', 'ftcn', 'neop']"
1197,PMC3668094,S83,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data analysis,"for all comparative analyses, p<0.05 was considered significant.","['C0444868', 'C1546944', 'C0750502', 'C0237881']","['Event Seriousness - Significant', 'Statistical Significance', 'Significant', 'All']","['qnco', 'idcn', 'qlco']"
1198,PMC3668094,S84,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data analysis,all p values are two tailed.,"['C0444868', 'C0042295', 'C0039259', 'C0205448']","['Tail', 'Two', 'All', 'Values']","['qnco', 'qlco', 'bpoc']"
1199,PMC3668094,S85,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data analysis,confidence intervals for proportions and their differences were calculated with wilson’s method.,"['C0009667', 'C0025663', 'C0871511', 'C1515981', 'C0449851']","['Methods', 'Confidence Intervals', 'Test Method', 'And', 'Techniques']","['idcn', 'inpr', 'qnco', 'lbpr', 'ftcn']"
1200,PMC3686261,S35,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,data from patients enrolled in the premier trial9 were used for all analyses.,"['C1511726', 'C3245479', 'C0030705', 'C4684790', 'C0309847', 'C0444868', 'C3714741']","['premier', 'All', 'Data call receiving device', 'Study Subject Enrolled', 'Patients', 'Data (eukaryote)', 'Data']","['idcn', 'medd', 'fndg', 'podg', 'euka', 'imft', ' phsu', ' aapp', 'qnco']"
1201,PMC3686261,S36,"['3a', '5']","[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,"premier was a 2-year, active-controlled, double-blind study of methotrexate-naive patients with early, progressive ra, in which patients were randomly assigned to the following treatment groups: combination treatment with subcutaneous adalimumab (40 mg every other week) and oral methotrexate (titrated to 20 mg/week by week 8, as tolerated), adalimumab monotherapy, or methotrexate monotherapy.","['C0030705', 'C3853793', 'C3887704', 'C1705169', 'C1279919', 'C0441833', 'C0687744', 'C1515981', 'C2911690', 'C1516050', 'C0205329', 'C1122087', 'C0439230', 'C0013072', 'C0205177', 'C0332287', 'C0039798', 'C3538994', 'C3888249', 'C1552839', 'C3811910', 'C0309847', 'C0443315', 'C0442027', 'C0439234', 'C0332282', 'C0025677', 'C1948061', 'C1947911', 'C0087111', 'C1552601', 'C1522326', 'C1533734', 'C2587213']","['Active License', 'premier', 'Progressive', 'Double-Blind Method', 'active (HL7 RoleLink)', 'Biomaterial Treatment', 'And', 'Patients', 'Therapeutic procedure', 'Every (qualifier)', 'PersonNameUse - assigned', 'adalimumab', 'combination - answer to question', 'Administration procedure', 'Following', 'Social group', 'Methotrexate', 'Active', 'Oral', 'Treatment Epoch', 'week', 'Assignment - action', 'Early', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Control function', 'Disease Controlled', 'combination of objects', 'In addition to', 'year', 'subcutaneous', 'Groups', 'Treating', 'Table Rules - groups']","['inpr', 'idcn', 'phob', 'topp', 'popg', 'ftcn', 'cnce', 'fndg', 'orch', 'imft', 'podg', 'resa', 'tmco', ' phsu', 'hlca', ' aapp', 'qlco', 'spco']"
1202,PMC3686261,S37,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,employment outcomes were assessed in a large subset of patients who participated in the de032 companion study.19,"['C0031268', 'C0030705', 'C0549177', 'C1515021', 'C2603343', 'C0335343', 'C3272598', 'C0014003']","['WHO Temperature/Humidity Storage Condition', 'Patients', 'Study', 'Subgroup', 'Companions', 'Employment', 'Pet Animal', 'Large']","['clas', 'popg', 'anim', 'podg', 'qlco', 'resa', 'qnco']"
1203,PMC3686261,S38,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"all patients provided written, informed consent, and the study protocols and informed consent forms were approved by the local institutional review boards or independent ethics committees at participating sites.","['C0085862', 'C0009797', 'C0972401', 'C0021430', 'C0030705', 'C0085546', 'C0205276', 'C1515981', 'C0442711', 'C0282443', 'C1290940', 'C2603343', 'C0205540', 'C0444868', 'C0205145', 'C1299583', 'C1552617']","['Independently able', 'Review [Publication Type]', 'Local', 'Ethics Committees', 'All', 'And', 'Consent Forms', 'Approved', 'Patients', 'Site', 'Independence', 'Informed Consent', 'Act Class - review', 'Independent for Transfer', 'Protocols documentation', 'Study', 'Boards (medical device)']","['inpr', 'rnlw', 'idcn', 'prog', 'medd', 'fndg', 'spco', 'podg', 'qlco', 'resa', 'qnco']"
1204,PMC3686261,S39,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,the studies were conducted in accordance with the principles of the declaration of helsinki and good clinical practice.,"['C2986419', 'C0947630', 'C1515981']","['And', 'Good Clinical Practice', 'Scientific Study']","['lbpr', 'inpr', 'idcn']"
1205,PMC3686261,S41,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patient characteristics,"adults aged 18 years and older with an ra diagnosis, as defined by the 1987-revised american college of rheumatology criteria,20 were eligible for enrolment.","['C0596070', 'C1999167', 'C1704656', 'C0001675', 'C0557806', 'C0243161', 'C1515981', 'C0011900', 'C0035452', 'C1548635', 'C1527075', 'C0001779', 'C0001792', 'C1704338']","['Old age', 'Eligible', 'Americas Ethnicity', 'Diagnosis', 'diagnosis aspect', 'Age', 'Adult', 'And', 'Elderly (population group)', 'college', 'criteria', 'Revision procedure', 'Diagnosis Study', 'Rheumatology specialty']","['bmod', 'idcn', 'aggp', 'topp', 'popg', 'mnob', 'qlco', 'resa', 'diap', 'orga']"
1206,PMC3686261,S42,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patient characteristics,"patients must have satisfied the following inclusion criteria: disease duration less than 3 years, eight or more swollen joints (out of 66 assessed), 10 or more tender joints (out of 68 assessed), either an erythrocyte sedimentation rate greater than 28 mm/h or c-reactive protein (crp) concentration of 1.5 mg/dl or greater and either rheumatoid factor positivity or at least one je.","['C0086045', 'C0030705', 'C1515981', 'C0205454', 'C1446561', 'C0205447', 'C3827302', 'C3890735', 'C4048285', 'C0392905', 'C0547044', 'C0205172', 'C0872146', 'C0152031', 'C3844638', 'C0234234', 'C1413716', 'C0022417', 'C1619634', 'C0332282', 'C0006560', 'C1704243', 'C1176468', 'C1512693', 'C0035448', 'C0439092', 'C1516048']","['C-reactive protein', 'erythrocyte sedimentation rate result', 'And', 'Patients', 'Joints', 'Tender', 'Complete Response with Incomplete Platelet Recovery', 'Either', 'Eight', 'Concentration measurement', 'disease length', 'CRP gene', 'Joint swelling', 'Articular system', 'Following', 'Rheumatoid Factor', 'Smaller', 'Erythrocyte sedimentation rate measurement', 'Less Than', 'C-Reactive Protein, human', 'Inclusion', 'Mental concentration', 'One', 'More', 'Greater', 'Able to Concentrate Question', 'Assessed']","['bsoj', 'inpr', 'idcn', 'lbpr', 'gngm', 'acty', 'lbtr', 'fndg', 'podg', 'imft', 'tmco', 'qlco', 'bdsy', 'menp', ' aapp', 'qnco']"
1207,PMC3686261,S43,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patient characteristics,"patients were excluded if they had received previous treatment with methotrexate, cyclophosphamide, ciclosporin, azathioprine, more than two other disease-modifying antirheumatic drugs, or prednisone equivalent greater than 10 mg/day within 30 days of screening.","['C0032952', 'C0030705', 'C3887704', 'C1705169', 'C1710477', 'C0004482', 'C0039798', 'C3538994', 'C0205172', 'C2348164', 'C1710031', 'C0332173', 'C0205448', 'C0439228', 'C0205163', 'C0205156', 'C1710032', 'C0220908', 'C0439185', 'C0025677', 'C1704243', 'C1698960', 'C0010592', 'C0087111', 'C0220909', 'C1552607', 'C1522326', 'C1533734', 'C0242708']","['Azathioprine', 'Equivalent Weight', 'research subject screening', 'day', 'Biomaterial Treatment', 'Equal', 'Patients', 'Act Relationship Subset - previous', 'Therapeutic procedure', 'Prednisone', 'Aspects of disease screening', 'Administration procedure', 'Screening procedure', 'Trial Screening', 'Methotrexate', 'Treatment Epoch', 'Daily', 'Two', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Screening', 'Disease Screening', 'Cyclosporine', 'Antirheumatic Drugs, Disease-Modifying', 'More', 'Screening Study', 'Previous', 'Treating', 'Greater']","[' orch', 'topp', 'ftcn', 'hops', 'cnce', 'orch', 'podg', ' phsu', 'resa', 'horm', 'hlca', 'aapp', 'tmco', 'diap', 'qlco', 'qnco', 'phsu']"
1208,PMC3686261,S45,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]","Clinical, radiographic, functional and employment assessments","the 28-joint disease activity score with crp (das28(crp), range 0–10; hereafter referred to as das28) was used to monitor disease activity.21","['C1292728', 'C2348147', 'C0022408', 'C4050231', 'C3890735', 'C4048285', 'C1514721', 'C0449820']","['Arthropathy', 'Sample Range', 'C-Reactive Protein, human', 'ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated', 'Range', 'Score', 'Complete Response with Incomplete Platelet Recovery', 'Disease activity']","['clna', 'ftcn', 'fndg', 'imft', 'dsyn', ' aapp', 'qnco']"
1209,PMC3686261,S46,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]","Clinical, radiographic, functional and employment assessments",das28 was calculated at baseline and regular intervals to week 104.,"['C0168634', 'C0439230', 'C1515981', 'C1442488', 'C1272706', 'C0205272']","['BaseLine dental cement', 'Baseline', 'week', 'And', 'Interval', 'Regular']","['bodm', 'idcn', 'tmco', 'qlco', 'qnco']"
1210,PMC3686261,S47,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]","Clinical, radiographic, functional and employment assessments",a time-averaged das28 (ta-das28) was calculated in order to control for intergroup differences in speed of responses and longitudinal fluctuations in inflammation.,"['C1705175', 'C0040223', 'C1705178', 'C1515981', 'C1705177', 'C0231239', 'C1705176', 'C3889825', 'C0678536', 'C1882348', 'C0205127', 'C0021368', 'C0871261']","['Response process', 'Speed (motion)', 'Order (action)', 'Sequence of Planned Assessment Schedule', 'Order (document)', 'Inflammation', 'And', 'Fluctuation', 'Time', 'Order (taxonomic)', 'Order (arrangement)', 'Permutation', 'Longitudinal']","['sosy', 'inpr', 'idcn', 'acty', 'clas', 'spco', 'patf', 'tmco', 'qlco', 'qnco', 'orga']"
1211,PMC3686261,S48,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]","Clinical, radiographic, functional and employment assessments","to obtain ta-das28, areas under the curve were determined for all time intervals of available das28 values from baseline to 52 or 104 weeks for individual patients.","['C0168634', 'C0030705', 'C0205134', 'C0237401', 'C0040223', 'C0205146', 'C4319729', 'C0042295', 'C0470187', 'C1442488', 'C0444868', 'C1272706', 'C0027361']","['BaseLine dental cement', 'Baseline', 'Curved', 'availability of', 'All', 'Area', 'Areas <moth>', 'Patients', 'Interval', 'Persons', 'Values', 'Time', 'Individual']","['bodm', 'popg', 'ftcn', 'spco', 'podg', 'euka', 'tmco', 'qlco', 'qnco']"
1212,PMC3686261,S49,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]","Clinical, radiographic, functional and employment assessments",values were summed and divided by the total time interval.,"['C0872291', 'C0439810', 'C0042295']","['Values', 'Time Interval', 'Total']","['qlco', 'tmco']"
1213,PMC3686261,S50,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]","Clinical, radiographic, functional and employment assessments",the distribution of ta-das28 values for all patients was then divided into tertiles at each assessment point.,"['C1261322', 'C0030705', 'C1883708', 'C1704711', 'C1457900', 'C1552961', 'C3714763', 'C0042295', 'C0444868', 'C2347617', 'C1516048', 'C0520511']","['Each (qualifier value)', 'Point', 'Distribution', 'All', 'Evaluation procedure', 'Patients', 'Values', 'point - UnitsOfMeasure', 'Point Name', 'Then', 'Distributing', 'Assessed']","['idcn', 'acty', 'ftcn', 'spco', 'podg', 'tmco', 'qlco', 'hlca', 'qnco']"
1214,PMC3686261,S51,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]","Clinical, radiographic, functional and employment assessments",radiographs of the hands and feet were taken at baseline and weeks 52 and 104.,"['C1306645', 'C0168634', 'C0016504', 'C0439230', 'C1515981', 'C1442488', 'C0347981', 'C0018563']","['BaseLine dental cement', 'Baseline', 'Feet, unit of measurement', 'week', 'Hand', 'And', 'Plain x-ray', 'Foot']","['bpoc', 'idcn', 'qnco', 'tmco', 'diap', 'bodm']"
1215,PMC3686261,S52,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]","Clinical, radiographic, functional and employment assessments","two readers, blinded to patient and sequence, scored radiographs individually for bone erosion (je, range 0–230) and jsn (range 0–168) using a modified form of the sharp scoring method (modified total sharp score; mtss).6 22–24","['C1306645', 'C0030705', 'C4050231', 'C3853789', 'C0004793', 'C1515981', 'C0439810', 'C4321252', 'C0036449', 'C1519249', 'C3890003', 'C0348078', 'C0587240', 'C4255237', 'C2348147', 'C1444775', 'C1539835', 'C3889737', 'C0205448', 'C1514721', 'C0521125', 'C0376315', 'C0162326', 'C0449820', 'C0392747', 'C0150108', 'C0162327', 'C1522492']","['Base Sequence', 'And', 'SPEN wt Allele', 'Patients', 'RNA Sequence', 'Blinded', 'Preposition For', 'WWOX wt Allele', 'Sequence', 'Sequence - TransmissionRelationshipTypeCode', 'Sample Range', 'DNA Sequence', 'SPEN gene', 'Range', 'Total', 'Data Change Date', 'Changing', 'Scoring Methods', 'Formation', 'Two', 'Form:Finding:Point in time:{Setting}:Document:{Role}', 'Manufactured form', 'Plain x-ray', 'Qualitative form', 'ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated', 'Sharp sensation quality', 'Score', 'bone erosion']","['clna', 'inpr', 'nusq', 'idcn', 'gngm', 'ftcn', 'fndg', 'mnob', 'tmco', 'podg', 'qlco', 'resa', 'patf', 'diap', 'qnco']"
1216,PMC3686261,S53,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]","Clinical, radiographic, functional and employment assessments","physical function was evaluated using the haq-di at baseline, week 52 and week 104.25","['C0168634', 'C0439230', 'C3826998', 'C1515981', 'C1442488', 'C0516981', 'C4321476', 'C4049916']","['BaseLine dental cement', 'Baseline', 'Physical function', 'week', 'Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale Questionnaire', 'And', 'Physical Function Subordinate Domain', 'Health Assessment Questionnaire Disability Index']","['inpr', 'bodm', 'idcn', 'fndg', 'tmco', 'qnco']"
1217,PMC3686261,S54,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]","Clinical, radiographic, functional and employment assessments",employment status (either employed or unemployed) was collected at baseline and at weeks 52 and 104.,"['C0168634', 'C0439230', 'C1515981', 'C3844638', 'C0242271', 'C1442488']","['BaseLine dental cement', 'Baseline', 'week', 'And', 'Employment status', 'Either']","['bodm', 'idcn', 'fndg', 'tmco', 'qnco']"
1218,PMC3686261,S55,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]","Clinical, radiographic, functional and employment assessments","at each time point, a patient was asked if there was a change in employment status from the previous visit.","['C2348792', 'C0392747', 'C0030705', 'C2826704', 'C1457900', 'C1512346', 'C0545082', 'C4319952', 'C0242271', 'C0443172', 'C0043194', 'C1565156', 'C1421478', 'C1552607', 'C1705241', 'C0205156']","['Each (qualifier value)', 'WAS protein, human', 'Changing', 'Visit', 'WAS gene', 'Wiskott-Aldrich Syndrome', 'Changed status', 'Patient Visit', 'Patients', 'Previous', 'Timepoint', 'Act Relationship Subset - previous', 'Change -- procedure', 'Visit Name', 'Employment status', 'Delta (difference)']","['bacs', 'inpr', 'gngm', 'topp', 'ftcn', 'fndg', 'podg', 'tmco', 'bhvr', 'dsyn', 'hlca', ' aapp', 'qnco']"
1219,PMC3686261,S57,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"descriptive analyses of changes in disease activity included observed data from patients who completed 52 or 104 weeks of treatment, had one or more post-baseline das28 and underwent radiography at baseline and weeks 52 or 104.","['C1292728', 'C1511726', 'C0030705', 'C3887704', 'C1705169', 'C3469826', 'C1704687', 'C1515981', 'C3714741', 'C0678257', 'C0439230', 'C0034571', 'C0205447', 'C1442488', 'C1441672', 'C0039798', 'C3538994', 'C0043299', 'C0205172', 'C0443172', 'C1962945', 'C0168634', 'C0392747', 'C3245479', 'C0087111', 'C1522326', 'C1533734', 'C0687676', 'C3272598']","['Baseline', 'Post Device', 'Biomaterial Treatment', 'And', 'Data call receiving device', 'Patients', 'Therapeutic procedure', 'Disease activity', 'Changed status', 'Administration procedure', 'roentgenographic', 'SLC35G1 gene', 'Observed', 'Diagnostic radiologic examination', 'BaseLine dental cement', 'Treatment Epoch', 'Changing', 'WHO Temperature/Humidity Storage Condition', 'week', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Data', 'One', 'Description', 'Post', 'More', 'Treating', 'Radiographic imaging procedure', 'Data (eukaryote)']","['inpr', 'idcn', 'qnco', 'gngm', 'topp', 'medd', 'ftcn', 'cnce', 'mnob', 'qlco', 'podg', 'euka', 'tmco', 'resa', 'hlca', 'diap', 'bodm']"
1220,PMC3686261,S58,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"analyses of the relationships between haq-di and je or jsn included observed data from patients with available haq-di, radiographic data and das28 at baseline, week 52, or week 104.","['C0451208', 'C1511726', 'C0168634', 'C3245479', 'C0030705', 'C0439849', 'C0439230', 'C4321476', 'C3826998', 'C1515981', 'C0470187', 'C1442488', 'C3714741', 'C0444708', 'C0102923']","['ametantrone', 'BaseLine dental cement', 'Baseline', 'radiographic', 'availability of', 'week', 'Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale Questionnaire', 'And', 'Health assessment questionnaire', 'Data call receiving device', 'Patients', 'Data (eukaryote)', 'Data', 'Health Assessment Questionnaire Disability Index', 'Relationships']","['inpr', 'idcn', 'qnco', 'medd', 'ftcn', 'orch', 'euka', 'tmco', 'podg', 'qlco', ' phsu', 'npop', 'bodm']"
1221,PMC3686261,S59,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"analysis of the relationships between employment status and je or jsn included observed data from patients with available employment status, radiographic data and haq-di at baseline, week 52, or week 104.","['C1511726', 'C0168634', 'C3245479', 'C0030705', 'C0439849', 'C0439230', 'C0936012', 'C4321476', 'C3826998', 'C1515981', 'C0242271', 'C1524024', 'C1442488', 'C0470187', 'C3714741', 'C0444708']","['BaseLine dental cement', 'Relationships', 'Baseline', 'radiographic', 'availability of', 'week', 'Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale Questionnaire', 'And', 'Data call receiving device', 'Patients', 'Analysis', 'Data (eukaryote)', 'Data', 'Employment status', 'Health Assessment Questionnaire Disability Index', 'analysis aspect']","['inpr', 'idcn', 'qnco', 'medd', 'ftcn', 'fndg', 'tmco', 'euka', 'podg', 'resa', 'qlco', 'npop', 'bodm']"
1222,PMC3686261,S60,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,overall mean changes from baseline in das28 were calculated at weeks 52 and 104 for the analysis population by treatment group.,"['C1561607', 'C0441833', 'C1705169', 'C0687744', 'C3887704', 'C1515981', 'C1524024', 'C0032659', 'C0439230', 'C0936012', 'C1442488', 'C0039798', 'C3538994', 'C1705429', 'C0443172', 'C0282416', 'C0168634', 'C0392747', 'C1519504', 'C1257890', 'C0087111', 'C1522326', 'C1533734', 'C1705428']","['Baseline', 'Biomaterial Treatment', 'geographic population', 'And', 'Stage Grouping', 'Therapeutic procedure', 'Changed status', 'User Group', 'Administration procedure', 'Group Object', 'Social group', 'BaseLine dental cement', 'Treatment Epoch', 'Changing', 'week', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'analysis aspect', 'Overall', 'Groups', 'Treating', 'Population Group', 'Analysis', 'Overall Publication Type']","['inpr', 'idcn', 'bodm', 'topp', 'popg', 'ftcn', 'cnce', 'qlco', 'tmco', 'resa', 'hlca', 'qnco']"
1223,PMC3686261,S61,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"at weeks 52 and 104, the associations between ta-das28 tertiles and changes from baseline in je and jsn were compared for patients who received ada+mtx combination therapy, adalimumab monotherapy, or methotrexate monotherapy between and within treatment groups using an analysis of variance on the van der waerden normal scores.26","['C0030705', 'C0441833', 'C1705169', 'C0556895', 'C0687744', 'C3887704', 'C1515981', 'C4321252', 'C0332285', 'C3811629', 'C1122087', 'C0439230', 'C1442488', 'C1707455', 'C1514756', 'C0009429', 'C4553972', 'C0039798', 'C3538994', 'C1060325', 'C0205307', 'C1552839', 'C1417487', 'C0443172', 'C0002780', 'C0521125', 'C0449820', 'C0231683', 'C0025677', 'C0168634', 'C0392747', 'C1517320', 'C1511780', 'C0087111', 'C0205103', 'C1533734', 'C1522326', 'C0004083', 'C3272598']","['Analysis of Variance', 'Baseline', 'Biomaterial Treatment', 'And', 'Patients', 'Derivative Chromosome', 'From', 'Preposition For', 'Receive', 'Mental association', 'Therapeutic procedure', 'WWOX wt Allele', 'adalimumab', 'MTX1 gene', 'Anti-Drug Antibody', 'Changed status', 'Administration procedure', 'Comparison', 'Within', 'Social group', 'How Often Felt Normal question', 'Combined Modality Therapy', 'Methotrexate', 'BaseLine dental cement', 'Normal', 'Intermediate', 'Treatment Epoch', 'Changing', 'WHO Temperature/Humidity Storage Condition', 'week', 'Genus Ada', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Groups', 'Table Rules - groups', 'Treating', 'Combination electrotherapy', 'Score', 'Gait normal']","['plnt', 'topp', 'fndg', 'qlco', ' phsu', 'hlca', 'inpr', 'idcn', 'gngm', 'imft', 'resa', ' aapp', 'bodm', 'popg', 'comd', 'ftcn', 'orch', 'podg', 'tmco', 'menp', 'acty', 'spco', 'cnce', 'qnco']"
1224,PMC3686261,S62,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"the relationships between haq-di and je or jsn at baseline, week 52 and week 104 were evaluated using quantile (non-parametric) regression models.","['C0451208', 'C0168634', 'C0439849', 'C0439230', 'C0684321', 'C1515981', 'C0684320', 'C1442488', 'C1836830', 'C1709792', 'C1518422', 'C0102923', 'C3161035']","['ametantrone', 'BaseLine dental cement', 'Baseline', 'week', 'And', 'Health assessment questionnaire', 'Model', 'Disease regression', 'Quantile', 'Regression - mental defense mechanism', 'Developmental regression', 'Negation', 'Relationships']","['inpr', 'idcn', 'qnco', 'ftcn', 'patf', 'orch', 'tmco', ' phsu', 'qlco', 'dsyn', 'menp', 'bodm']"
1225,PMC3686261,S63,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"each model evaluated the relationships between haq-di and either concurrent je or jsn as independent variables after covariate adjustment for concurrent das28 and baseline disease duration, age and sex.","['C0085862', 'C0687676', 'C3853906', 'C0439849', 'C0439828', 'C0376209', 'C1515981', 'C0683269', 'C4321252', 'C0456081', 'C3161035', 'C0451208', 'C0205420', 'C3274659', 'C0009253', 'C0804628', 'C1442488', 'C1299583', 'C1457900', 'C0872146', 'C3844638', 'C1290940', 'C0079399', 'C0036864', 'C0521125', 'C0102923', 'C0168634', 'C1522384', 'C3714583', 'C0001779', 'C0231290']","['Adjustment Action', 'Model Number', 'Gender', 'Baseline', 'Status post', 'And', 'Health assessment questionnaire', 'Model', 'Independent for Transfer', 'Preposition For', 'WWOX wt Allele', 'Gender:Type:Point in time:^Patient:Nominal', 'Psychological adjustment', 'ametantrone', 'Either', 'Sex Behavior', 'Concurrent', 'Coitus', 'Age', 'disease length', 'Variable (uniformity)', 'sex', 'Individual Adjustment', 'Each (qualifier value)', 'Independently able', 'BaseLine dental cement', 'Relationships', 'Post', 'Model - style/design', 'Digital Model Attachment', 'Independence']","['inpr', 'clna', 'inbe', 'idcn', 'qnco', 'gngm', 'ftcn', 'fndg', 'cnce', 'orch', 'tmco', 'qlco', 'bhvr', ' phsu', 'orgf', 'bodm', 'orga']"
1226,PMC3686261,S64,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"the relationships between employment status and je or jsn at baseline, week 52 and week 104 were evaluated using logistic regression models with covariate adjustment for concurrent haq-di and baseline disease duration, age and sex.","['C0439849', 'C0376209', 'C1515981', 'C0683269', 'C4321252', 'C0456081', 'C3161035', 'C0205420', 'C0009253', 'C0804628', 'C0439230', 'C0242271', 'C0206031', 'C1442488', 'C0332287', 'C4321476', 'C0872146', 'C0220825', 'C0079399', 'C0036864', 'C0521125', 'C0168634', 'C3826998', 'C1522384', 'C0001779']","['Adjustment Action', 'Gender', 'Baseline', 'And', 'Evaluation', 'Model', 'Preposition For', 'WWOX wt Allele', 'Health Assessment Questionnaire Disability Index', 'Gender:Type:Point in time:^Patient:Nominal', 'Psychological adjustment', 'Sex Behavior', 'Concurrent', 'Coitus', 'Age', 'disease length', 'sex', 'Individual Adjustment', 'Employment status', 'BaseLine dental cement', 'Logistic Regression', 'week', 'Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale Questionnaire', 'In addition to', 'Relationships']","['clna', 'inpr', 'inbe', 'idcn', 'qnco', 'gngm', 'ftcn', 'fndg', 'tmco', 'qlco', 'resa', 'bhvr', 'hlca', 'orgf', 'bodm', 'orga']"
1227,PMC3686261,S65,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,the relationship between baseline je or jsn and baseline employment status was further evaluated by calculating tertiles of je or jsn and determining the percentages of patients in each tertile who were employed at baseline; differences across je or jsn tertiles were evaluated through χ2.,"['C0168634', 'C3540605', 'C0030705', 'C1706279', 'C0439849', 'C1457900', 'C0242271', 'C1515981', 'C1705630', 'C1517331', 'C1442488', 'C3272598']","['Each (qualifier value)', 'BaseLine dental cement', 'Further', 'Baseline', 'Concept Relationship', 'WHO Temperature/Humidity Storage Condition', 'And', 'Patients', 'CDISC Relationship Class', 'Object Relationship', 'Employment status', 'Relationships']","['inpr', 'bodm', 'idcn', 'fndg', 'spco', 'qlco', 'podg', 'qnco']"
1228,PMC3756454,S38,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Subjects,the study was performed with the approval of the local research ethics committee in accordance with the declaration of helsinki and with the written informed consent of all participants.,"['C2603343', 'C2697909', 'C0332287', 'C0205276', 'C0679646', 'C4281991', 'C0021430', 'C0205540', 'C2346845', 'C1515981', 'C0444868', 'C0086911', 'C0018898']","['Helsinki Declaration', 'All', 'In addition to', 'Approved', 'Participant', 'Approval (document)', 'And', 'Ethics Committees, Research', 'Informed Consent', 'Study', 'Follow', 'Local', 'Letter of Authorization']","['prog', 'rnlw', 'idcn', 'inpr', 'qnco', 'qlco', 'spco', 'resa', 'ftcn', 'popg']"
1229,PMC3756454,S39,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Subjects,inclusion criteria were a typical history of myocardial ischaemia lasting more than 20 min within 24 h of hospitalisation with ischaemic electrocardiographic changes and an elevated troponin-i concentration (>0.2 µg/l).,"['C1512693', 'C3827302', 'C0019664', 'C0041199', 'C3163633', 'C1446561', 'C0205172', 'C0262926', 'C0010054', 'C0019993', 'C0332285', 'C0151744', 'C0019665', 'C0855329', 'C2004062', 'C1705255', 'C0262512', 'C0086045', 'C1515981', 'C0205250', 'C3538928']","['And', 'Electrocardiographic changes', 'High', 'History', 'Concentration measurement', 'Medical History', 'Elevated', 'Within', 'History of previous events', 'Concept History', 'History of present illness', 'Inclusion', 'More', 'Mental concentration', 'Able to Concentrate Question', 'Troponin', 'Myocardial Ischemia', 'Hospitalization', 'Usual', 'Historical aspects qualifier', 'Coronary Arteriosclerosis']","['fndg', 'idcn', 'hlca', 'ocdi', 'inpr', 'qnco', 'bacs', 'qlco', 'dsyn', 'spco', 'ftcn', 'menp', ' aapp', 'cnce']"
1230,PMC3756454,S40,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Subjects,"patients were excluded in the event of significant comorbidity, including active systemic inflammatory disorders, insulin-dependent diabetes mellitus and the use of anti-inflammatory drugs other than aspirin.","['C0205373', 'C0750502', 'C0205177', 'C3888249', 'C0003209', 'C1515999', 'C0030705', 'C0042153', 'C1290884', 'C3687832', 'C0332257', 'C0009488', 'C0441471', 'C0457083', 'C0013227', 'C0011854', 'C1515981', 'C0004057', 'C1546944', 'C3853793', 'C4019010', 'C0237881']","['Active License', 'National reporting jurisdiction:Loc:Pt:^Event:Nom', 'Drugs - dental services', 'Systemic', 'And', 'active (HL7 RoleLink)', 'Event', 'Including (qualifier)', 'utilization qualifier', 'Aspirin', 'Comorbidity', 'Active', 'Diabetes Mellitus, Insulin-Dependent', 'Anti-Inflammatory Agents', 'Statistical Significance', 'Patients', 'inflammatory disease', 'Event Seriousness - Significant', 'Pharmaceutical Preparations', 'Significant', 'Usage', 'Anti-inflammatory effect']","['fndg', 'idcn', 'topp', 'orch', 'qlco', 'phsu', 'qnco', 'dsyn', 'podg', 'ftcn', ' phsu', 'evnt', 'clna']"
1231,PMC3756454,S41,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Subjects,"given the immunosuppressive effects of etanercept, exclusion criteria also included any history of recent or recurrent infection, tuberculosis or any opportunistic infection within the previous 6 months.","['C3272371', 'C0041296', 'C0717758', 'C0021081', 'C0332185', 'C0029118', 'C0019665', 'C0019664', 'C1552607', 'C1280500', 'C2004062', 'C1552551', 'C1705255', 'C0332257', 'C0205156', 'C0239998', 'C0680251', 'C0262512', 'C0332285', 'C0262926']","['Opportunistic Infections', 'Etanercept', 'Medical History', 'Tuberculosis', 'Immunosuppressive Agents', 'Previous', 'Exclusion Criteria', 'History of present illness', 'Recurrent infections', 'Within', 'Any', 'Any Data Type', 'Effect', 'History of previous events', 'Including (qualifier)', 'Recent', 'History', 'Act Relationship Subset - previous', 'Concept History', 'Historical aspects qualifier']","['tmco', 'imft', 'fndg', 'ocdi', 'inpr', 'qlco', 'dsyn', 'spco', 'aapp', 'ftcn', ' phsu', 'cnce']"
1232,PMC3756454,S43,"['3a', '5']","[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,"in a randomised, double-blind, parallel group design, patients were evaluated on two occasions: before and 24 h after intravenous administration of the tnf-α antagonist, etanercept (10 mg), or saline placebo.","['C0021440', 'C0687676', 'C0036082', 'C0332152', 'C1257890', 'C0441833', 'C0231491', 'C1448177', 'C0030705', 'C1706408', 'C2983265', 'C0205448', 'C1705428', 'C0220825', 'C1519504', 'C0717758', 'C1705429', 'C1707689', 'C4554418', 'C0231290', 'C0013125', 'C2826345', 'C0032042', 'C2348042', 'C0687744', 'C1515981', 'C1696465']","['Group Object', 'placebo', 'And', 'TNF protein, human', 'Post', 'Design', 'Placebos', 'Saline Solution', 'Before', 'User Group', 'Parallel Study', 'intravenous administration', 'Groups', 'Population Group', 'Two', 'Placebo Control', 'Social group', 'Status post', 'CDISC SEND Study Design Terminology', 'Patients', 'Antagonist muscle action', 'Intravenous infusion procedures', 'Parallel Lesion', 'Stage Grouping', 'Parallel', 'Evaluation', 'Etanercept']","['topp', 'qnco', 'podg', ' aapp', 'bodm', 'ortf', 'fndg', 'idcn', 'hlca', 'inpr', 'qlco', 'sbst', 'bacs', 'resa', 'aapp', 'ftcn', 'popg', 'tmco', 'spco', 'cnce', 'acty', ' phsu']"
1233,PMC3756454,S44,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,a single subcutaneous 25 mg dose of etanercept improves endothelium-dependent vasodilatation within 6 h of administration in patients with heart failure.12,"['C0018801', 'C0429986', 'C0087136', 'C0443315', 'C0030705', 'C4321395', 'C0178602', 'C0595862', 'C3244310', 'C0851827', 'C1701901', 'C0018802', 'C0001554', 'C0429964', 'C4554158', 'C1533734', 'C0042401', 'C0205171']","['Dependent - ability', 'Heart Failure, CTCAE', 'Dependent for bathing', 'Dependent for dressing', 'Singular', 'subcutaneous', 'dependent', 'Vasodilation', 'Dosage', 'Patients', 'Unmarried', 'Conditional', 'Vasodilation disorder', 'Heart failure', 'Administration procedure', 'Congestive heart failure', 'Dependent for Toilet Use', 'Administration occupational activities']","['ocac', 'ortf', 'fndg', 'topp', 'inpr', 'qlco', 'qnco', 'dsyn', 'spco', 'podg', 'ftcn', 'patf']"
1234,PMC3756454,S45,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,"in order to achieve a rapid onset of action, we elected to use the intravenous route, and single intravenous doses of up to 10 mg/m2 have been used safely in patients with heart failure.15","['C0178602', 'C0018802', 'C1838994', 'C0205171', 'C1705176', 'C0030705', 'C0449444', 'C0441472', 'C1882348', 'C0547043', 'C0087136', 'C3266814', 'C0013153', 'C1705177', 'C1879941', 'C1705175', 'C3889825', 'C1705178', 'C0018801', 'C1515981', 'C0348016', 'C4554158']","['CDISC SDTM Route of Administration Terminology', 'Intravenous', 'Singular', 'Clinical action', 'And', 'Action', 'Congestive heart failure', 'Unmarried', 'Heart failure', 'Rapid onset', 'Drug Administration Routes', 'Heart Failure, CTCAE', 'Up', 'Order (action)', 'Dosage', 'Patients', 'Order (document)', 'Order (taxonomic)', 'Route', 'Sequence of Planned Assessment Schedule', 'Permutation', 'Order (arrangement)']","['fndg', 'idcn', 'clas', 'inpr', 'qnco', 'qlco', 'dsyn', 'spco', 'podg', 'ftcn', 'acty']"
1235,PMC3756454,S46,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,subcutaneous etanercept has 23% bioavailability and achieves peak plasma concentrations of 0.43 µg/ml at 66 h.16,"['C0717758', 'C0005508', 'C0032105', 'C0086045', 'C0443315', 'C1515981', 'C1706947', 'C0444505', 'C4521445']","['Peak level', 'Biological Availability', 'subcutaneous', 'And', 'Mental concentration', 'Bioavailability Study', 'Plasma Product', 'Plasma', 'Etanercept']","['idcn', 'bdsu', 'qnco', 'qlco', 'spco', 'resa', 'aapp', ' phsu', 'menp', 'phsu']"
1236,PMC3756454,S47,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"in contrast, a single intravenous dose of 10 mg etanercept achieves a maximum concentration of 2.32 µg/ml at 50 min.16","['C0717758', 'C1979874', 'C0087136', 'C0178602', 'C0348016', 'C0009924', 'C2347813', 'C0205171']","['Intravenous', 'Singular', 'Contrast', 'Dosage', 'Unmarried', 'Cmax', 'Etanercept', 'Contrast Media']","['fndg', 'irda', 'qnco', 'qlco', 'spco', 'aapp', ' phsu']"
1237,PMC3756454,S48,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,"given a plasma half-life of approximately 70 h,16 we judged that 24 h would be an appropriate time point to capture any potential beneficial cardiovascular effects of intravenous etanercept.","['C3272371', 'C2348792', 'C3887460', 'C2825407', 'C0717758', 'C1280500', 'C0032105', 'C1552551', 'C0376558', 'C0348016', 'C3245505', 'C1548787', 'C0007226', 'C4521445', 'C0332232']","['Half', 'Life', 'Cardiovascular', 'Intravenous', 'potential', 'Timepoint', 'Appropriate', 'Any', 'Any Data Type', 'Effect', 'Cardiovascular system', 'approximately', 'Plasma Product', 'Plasma', 'Etanercept']","['tmco', 'blor', 'idcn', 'bdsy', 'bdsu', 'inpr', 'qlco', 'qnco', 'spco', 'aapp', ' phsu', 'phsu']"
1238,PMC3756454,S49,"['8a', '9', '8b']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1]",Study design,"randomisation was performed by a computer generated sequence to ensure concealment of treatment allocation and following minimisation for age, sex, time to randomisation, peak troponin, serum cholesterol and cardiovascular risk factors including diabetes mellitus, hypertension and smoking.17","['C1881674', 'C3538994', 'C0011849', 'C0041199', 'C1533734', 'C0087111', 'C1706778', 'C3887704', 'C1705169', 'C0004793', 'C0039798', 'C0587184', 'C0162326', 'C1553898', 'C3887460', 'C3853789', 'C0020538', 'C0009622', 'C0037369', 'C1519249', 'C0332257', 'C0007226', 'C0453996', 'C1522326', 'C1963138', 'C0040223', 'C0035648', 'C1515981', 'C0162327', 'C0001779', 'C0444505']","['Age', 'Hypertension, CTCAE', 'Peak level', 'Serum cholesterol measurement', 'And', 'RNA Sequence', 'risk factors - observation list', 'Diabetes Mellitus', 'Including (qualifier)', 'Base Sequence', 'Smoking', 'Cardiovascular', 'Sequence - TransmissionRelationshipTypeCode', 'Time', 'Treatment Epoch', 'Biomaterial Treatment', 'Computers', 'Administration procedure', 'risk factors', 'Sequence', 'Tobacco smoking behavior', 'DNA Sequence', 'Hypertensive disease', 'Troponin', 'Medical Device Emits Smoke', 'treatment - ActInformationManagementReason', 'Treating', 'therapeutic aspects', 'Allocation', 'Cardiovascular system', 'Therapeutic procedure']","['topp', ' aapp', 'blor', 'nusq', 'fndg', 'idcn', 'hlca', 'inpr', 'qlco', 'bacs', 'lbpr', 'resa', 'ftcn', 'mnob', 'tmco', 'inbe', 'bdsy', 'cnce', 'acty', 'orga', 'dsyn']"
1239,PMC3756454,S50,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,study procedures were all completed prior to invasive angiography or percutaneous coronary intervention.,"['C2700391', 'C0002978', 'C2603343', 'C0332152', 'C0205281', 'C2826257', 'C1532338', 'C0025664', 'C3538935', 'C1334278', 'C0184661']","['Procedure (set of actions)', 'Procedure Domain', 'Invasive', 'Prior Medication Usage', 'angiogram', 'Percutaneous Coronary Intervention', 'Study', 'Interventional procedure', 'Methods aspects', 'Before', 'Invasive Lesion']","['tmco', 'fndg', 'topp', 'inpr', 'qlco', 'resa', 'ftcn', 'diap', 'evnt']"
1240,PMC3756454,S52,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Venous sampling and cytokine analysis,"patients abstained from food and caffeine containing drinks for 4 h, and 24 h from ingestion of alcohol prior to phlebotomy.","['C0452428', 'C0006644', 'C0001962', 'C0190979', 'C0232478', 'C2826257', 'C0030705', 'C3540798', 'C1515981', 'C0001975', 'C0016452', 'C0332152', 'C0684257']","['Alcohols', 'Drink (dietary substance)', 'Ingestion', 'Ethanol', 'Prior Medication Usage', 'And', 'Venesection', 'Patients', 'Caffeine', 'Before', 'Food allergenic extracts', 'Venous blood sampling', 'Food']","['tmco', 'food', 'imft', 'biof', 'topp', 'idcn', 'orch', 'podg', 'diap', ' phsu', 'evnt']"
1241,PMC3756454,S53,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Venous sampling and cytokine analysis,"blood samples were obtained through a 17-gauge cannula with careful attention to ensure smooth extraction of blood to avoid artefactual platelet activation ex vivo, and anticoagulated with d-phenylalanyl-l-propyl-l-arginine chloromethyl-ketone (ppack).","['C0005767', 'C0005768', 'C1515655', 'C0003765', 'C0004268', 'C0229664', 'C0684295', 'C1515981', 'C0178913', 'C0185115', 'C4281780', 'C0070655', 'C0032173', 'C0456564', 'C0022634', 'C0050288', 'C0205357']","['Ketones', 'Platelet Activation', 'Arginine', 'A 17', 'Blood specimen', 'Gauges (qualifier value)', 'peripheral blood', 'in vivo', 'Smooth', 'And', 'Chemical extraction', 'In Blood', 'Extraction', 'Blood', 'Attention', 'phenylalanyl-prolyl-arginine-chloromethyl ketone', 'Attention G-code']","['ortf', 'idcn', 'topp', 'inpr', 'orch', 'qlco', 'bacs', 'lbpr', 'spco', 'aapp', ' aapp', ' phsu', 'menp', 'bdsu']"
1242,PMC3756454,S54,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Venous sampling and cytokine analysis,"during vasomotor assessments, venous blood was withdrawn simultaneously from each arm and collected into tubes containing acidified buffered citrate (for t-pa assays), trisodium citrate (for plasminogen activator inhibitor type 1 (pai-1) assays) and potassium edta (for cytokine assays).","['C0521115', 'C0446516', 'C0521125', 'C4321252', 'C0795671', 'C0032143', 'C1457900', 'C0079189', 'C3715044', 'C1550615', 'C0229667', 'C1547937', 'C2338243', 'C4553528', 'C1620101', 'C0032830', 'C0030190', 'C1515981', 'C1519957', 'C1261322', 'C0175730', 'C1705527']","['Portion of venous blood', 'Each (qualifier value)', 'And', 'Evaluation procedure', 'SERPINE1 protein, human', 'Specimen Type - Blood venous', 'Simultaneous', 'Specimen Source Codes - Tube', 'Plasminogen Activator Inhibitor 1', 'cytokine', 'Sequence Arm', 'Upper arm', 'AKR1A1 wt Allele', 'WWOX wt Allele', 'Preposition For', 'biomedical tube device', 'trisodium citrate', 'Venous blood substance', 'alteplase', 'SERPINE1 wt Allele', 'Vasomotor', 'Edetic Acid, Potassium Salt']","['tmco', 'blor', 'imft', 'gngm', 'irda', ' orch', 'idcn', 'hlca', 'inpr', 'orch', 'tisu', 'qnco', 'bacs', 'qlco', 'medd', 'enzy', 'ftcn', ' aapp', ' phsu', 'bdsu']"
1243,PMC3756454,S55,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Venous sampling and cytokine analysis,citrate and acidified buffered citrate samples were centrifuged at 2000 g for 30 min at 4°c and edta samples at 1000 g for 10 min at 20°c. platelet-free plasma was decanted and stored at -80°c before assay.,"['C0243073', 'C0008857', 'C1996904', 'C1510438', 'C0032105', 'C0005507', 'C1880497', 'C1515981', 'C1553427', 'C0332296', 'C0013618', 'C0376259', 'C4521445']","['Free of (attribute)', 'Buffered Citrate', 'Free (available (qualifier))', 'Assay', 'And', 'Citrates', 'Citrate', 'Empty (qualifier)', 'Plasma Product', 'Plasma', 'Biological Assay', 'Edetic Acid', 'assay qualifier']","['idcn', 'bdsu', 'orch', 'qlco', 'lbpr', 'ftcn', ' phsu', 'phsu']"
1244,PMC3756454,S56,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Venous sampling and cytokine analysis,"plasma tnf-α and il-6 concentrations were determined as described previously18 using elisa (quantikine human tnf and il-6 immunoassays, r&d systems; and dako a/s, respectively) and fibrinolytic activities using a photometric method (coatest t-pa and pai-1, chomogenix ab).","['C0020980', 'C0031752', 'C1552738', 'C1448177', 'C2983957', 'C0025663', 'C0521095', 'C0871511', 'C0032105', 'C0014441', 'C0086045', 'C0040044', 'C1515981', 'C0086418', 'C0441655', 'C0449851', 'C1698754', 'C4521445']","['Methods', 'IL6 protein, human', 'Enzyme-Linked Immunosorbent Assay', 'Activities', 'Test Method', 'Photometry', 'And', 'Immunoassay method', 'Techniques', 'Determined by', 'Mental concentration', 'Homo sapiens', 'TNF protein, human', 'Thrombolytic Therapy', 'Plasma Product', 'Plasma', 'described', 'Interleukin-6, human']","['imft', 'idcn', 'topp', 'inpr', 'qlco', 'bacs', 'phsu', 'lbpr', 'ftcn', ' aapp', 'acty', ' phsu', 'menp', 'humn', 'bdsu']"
1245,PMC3756454,S57,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Venous sampling and cytokine analysis,haematocrit and white cell count were determined using an automated coulter counter (beckman-coulter).,"['C1515981', 'C0023508', 'C0518014', 'C0205554', 'C0427512']","['Automated (qualifier value)', 'White Blood Cell Count procedure', 'Hematocrit level', 'And', 'White blood cell count laboratory result']","['fndg', 'lbtr', 'idcn', 'lbpr', 'ftcn']"
1246,PMC3756454,S59,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Vasomotor assessment,assessment of vasomotor function in response to intra-arterial vasodilators was performed as described previously.19,"['C1516048', 'C1706817', 'C1552738', 'C0542341', 'C1705273', 'C2911692', 'C0871261', 'C1704632', 'C1261322', 'C0003842', 'C0031843', 'C0347985', 'C0221464', 'C0042402']","['Mathematical Operator', 'Arteries', 'Vasodilator Agents', 'physiological aspects', 'Assessed', 'Evaluation procedure', 'Arterial', 'Response (communication)', 'Function (attribute)', 'Response (statement)', 'described', 'Response process', 'Disease Response', 'intra']","['tmco', 'fndg', 'hlca', 'idcn', 'phsf', 'inpr', 'phsu', 'orga', 'spco', 'ftcn', 'menp', 'bpoc', 'acty']"
1247,PMC3756454,S60,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Vasomotor assessment,"briefly, studies were performed in a quiet, temperature-controlled environment with the patient in the supine position throughout.","['C0005903', 'C0030705', 'C0014409', 'C0039476', 'C0439654', 'C0038846', 'C0947630']","['Temperature', 'Supine Position', 'Patients', 'Scientific Study', 'Body Temperature', 'quiet', 'Environment, Controlled']","['qnco', 'qlco', 'orga', 'lbpr', 'spco', 'hcpp', 'podg']"
1248,PMC3756454,S61,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Vasomotor assessment,venous 17-gauge cannulae were inserted into each forearm for blood sampling and a 27-standard wire gauge steel needle placed in the brachial artery of the non-dominant forearm for vasodilator infusions.,"['C1527180', 'C1442989', 'C0190979', 'C0348013', 'C0027551', 'C2828392', 'C0042402', 'C1882041', 'C1457900', 'C0574032', 'C0456564', 'C0520453', 'C0038239', 'C4522306', 'C0016536', 'C0006087', 'C0042449', 'C1518422', 'C1533810', 'C3537240', 'C1515981']","['Infusion procedures', 'Each (qualifier value)', 'And', 'Needle Shape', 'Standard (document)', 'Structure of brachial artery', 'Forearm', 'Gauges (qualifier value)', 'Vasodilator Agents', 'Vasodilator [EPC]', 'Dominant', 'Placement action', 'Needle device', 'Steel', 'Wire -- device', 'Cannula device', 'Venous blood sampling', 'Negation', 'Venous', 'Veins', 'Standard (qualifier)']","['mnob', 'medd', 'idcn', 'topp', 'hlca', 'inpr', 'qnco', 'qlco', 'phsu', 'spco', 'ftcn', 'bodm', 'diap', 'bpoc', ' inch']"
1249,PMC3756454,S62,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Vasomotor assessment,"a baseline 30 min intra-arterial infusion of saline was followed by intra-arterial infusion of substance p at 2, 4 and 8 pmol/min; then acetylcholine at 5, 10 and 20 µg/min; and finally sodium nitroprusside at 2, 4 and 8 μg/min, infused for 10 min at each dose with each agonist separated by a 20 min saline infusion.","['C0028193', 'C0332287', 'C1442488', 'C2987634', 'C3887812', 'C1457900', 'C1420563', 'C0574032', 'C0168634', 'C1827465', 'C1515981', 'C0178602', 'C1883708', 'C0038585', 'C0036082', 'C0003842', 'C0221464', 'C0560021', 'C0347985']","['Infusion procedures', 'BaseLine dental cement', 'Gram per Minute', 'In addition to', 'Arteries', 'Baseline', 'Infusion route', 'Each (qualifier value)', 'And', 'Agonist', 'Dosage', 'Substance P', 'Saline Solution', 'Arterial', 'Then', 'Substance P, human', 'TAC1 gene', 'Nitroprusside', 'intra']","['tmco', 'bodm', 'gngm', 'idcn', 'topp', 'inch', 'qnco', 'bacs', 'sbst', 'spco', 'ftcn', ' aapp', ' phsu', 'bpoc', 'phsu']"
1250,PMC3756454,S63,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Vasomotor assessment,forearm blood flow was measured in both arms by venous occlusion plethysmography with the use of mercury-in-silastic strain gauges.,"['C0080194', 'C2348272', 'C0456178', 'C1518614', 'C4281554', 'C0025424', 'C0074517', 'C0016536', 'C0948441', 'C2987481', 'C0032221', 'C0042153', 'C0428257', 'C0456564', 'C0232338', 'C0457083', 'C0230348']","['Forearm', 'Gauges (qualifier value)', 'Both upper arms', 'Muscle strain', 'Venous occlusion', 'Plethysmography', 'Mercury measurement', 'Emotional Strain', 'Microbiology subtype strains', 'Dietary Mercury', 'Silastic', 'Usage', 'Venoocclusive disease', 'Organism Strain', 'Blood flow', 'utilization qualifier', 'Mercury']","['orgm', 'elii', ' orch', 'topp', 'phsf', ' hops', 'qlco', 'inpo', 'lbpr', 'dsyn', 'spco', 'ftcn', 'bodm', 'diap', 'menp', 'bpoc']"
1251,PMC3756454,S64,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Vasomotor assessment,"heart rate and blood pressure in the non-infused arm were monitored at intervals throughout with the use of a semiautomated, non-invasive oscillometric sphygmomanometer.","['C0332287', 'C1518422', 'C0446516', 'C4553528', 'C0005823', 'C0018810', 'C1271104', 'C0205303', 'C3715044', 'C1515981', 'C0183427', 'C1272641', 'C0042153', 'C1272706', 'C0457083']","['Blood Pressure', 'In addition to', 'AKR1A1 wt Allele', 'non-invasive', 'Sequence Arm', 'Usage', 'And', 'Negation', 'Sphygmomanometers', 'Upper arm', 'Interval', 'utilization qualifier', 'Systemic arterial pressure', 'Blood pressure finding', 'heart rate']","['tmco', 'blor', 'fndg', 'gngm', 'medd', 'idcn', 'inpr', 'orgf', 'ftcn', 'clna']"
1252,PMC3756454,S66,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Immunostaining and flow cytometry,"all reagents were obtained from abd serotec (oxford, uk) unless otherwise stated.","['C0444868', 'C0000726', 'C3811055', 'C0034760']","['All', 'Absence of Biallelic TCRgamma Deletion', 'Reagents', 'Abdomen']","['qnco', 'irda', 'blor', 'comd']"
1253,PMC3756454,S67,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Immunostaining and flow cytometry,"the following antibodies were used: igg1-fitc, cd14-pe, cd42a-fitc, igg2a-pe, cd62p-pe, igg1-pe (ebioscience ltd. uk) and cd14-rpe and igg1-rpe (dakocytomation, denmark).","['C0020857', 'C0085216', 'C0035322', 'C0332282', 'C3853555', 'C3538991', 'C0020855', 'C4049928', 'C4050303', 'C4284289', 'C0032193', 'C1136140', 'C2742134', 'C1439350', 'C1515981', 'C4283743', 'C0003241', 'C1367477', 'C0011318', 'C1419621']","['Immunoglobulin IgG1', 'SELP protein, human', 'CD14 gene', 'Long-Term Synaptic Depression', 'Following', 'Structure of retinal pigment epithelium', 'GP9 gene', 'IgG2A', 'Fluorescein-5-isothiocyanate', 'Rating of Perceived Exertion', 'And', 'Antibodies', 'IgG2a location', 'Platelet Glycoprotein IX, human', 'Platelet Membrane Glycoprotein IX', 'GP9 wt Allele', 'Immunoglobulin G Subclass 1 Measurement', 'RPE gene', 'CD14 Expressing Cell Measurement', 'Denmark']","['tmco', 'imft', 'ortf', ' imft', ' orch', 'irda', 'gngm', 'idcn', 'inpr', 'celc', 'geoa', 'bacs', 'lbpr', 'rcpt', ' aapp', ' phsu', 'bpoc']"
1254,PMC3756454,S68,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Immunostaining and flow cytometry,all antibodies were diluted 1:20 with flow buffer.,"['C0003241', 'C0806140', 'C0444868', 'C0006353']","['Flow', 'Buffers', 'All', 'Antibodies']","['imft', 'npop', 'irda', 'qnco', ' aapp', ' phsu']"
1255,PMC3756454,S69,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Immunostaining and flow cytometry,"facs-lyse was obtained from becton-dickinson (cowley, uk).",['C0024348'],['Lysis'],['patf']
1256,PMC3756454,S70,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Immunostaining and flow cytometry,blood anticoagulated with ppack was labelled with the appropriate antibodies exactly 5 min from collection and incubated in the dark for 20 min at room temperature.,"['C0005767', 'C0005768', 'C1439852', 'C1516698', 'C1704814', 'C2348236', 'C0229664', 'C3167821', 'C1515981', 'C0070655', 'C0003241', 'C1548787', 'C1517320', 'C0600644']","['Collection (action)', 'Specimen at Room Temperature', 'peripheral blood', 'Collections (publication)', 'incubated', 'And', 'Antibodies', 'Item Collection', 'Appropriate', 'In Blood', 'From', 'Blood', 'phenylalanyl-prolyl-arginine-chloromethyl ketone', 'Temperature.ambient:Temperature:Point in time:Room:Quantitative']","['clna', 'imft', 'idcn', 'inpr', 'qlco', 'lbpr', 'ftcn', 'aapp', ' aapp', ' phsu', 'bdsu']"
1257,PMC3756454,S71,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Immunostaining and flow cytometry,immunolabelling was performed on whole blood to avoid artefactual platelet activation caused by purification procedures.,"['C2700391', 'C0025664', 'C0229664', 'C3538935', 'C1608383', 'C0370231', 'C0032173', 'C0184661']","['Platelet Activation', 'Procedure (set of actions)', 'Procedure Domain', 'peripheral blood', 'Interventional procedure', 'Methods aspects', 'whole blood', 'whole blood specimen']","['ortf', 'topp', 'inpr', 'ftcn', 'bdsu']"
1258,PMC3756454,S72,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Immunostaining and flow cytometry,samples were then fixed and run through a facscalibur (becton-dickinson) flow cytometer within 2 h of fixing using an established flow protocol.20,"['C0806140', 'C3715209', 'C1272684', 'C4282383', 'C1507394', 'C0180279', 'C1522729', 'C2348563', 'C0442711', 'C1883708', 'C2599718', 'C0443211']","['Protocols documentation', 'REMS Protocol', 'Clinical trial protocol document', 'Library Protocol', 'Established', 'Study Protocol', 'automated flow cytometers', 'Accepted', 'Flow', 'Then', 'Protocol - answer to question', 'Clinical trial protocol']","['tmco', 'fndg', 'npop', 'medd', 'inpr', 'qlco']"
1259,PMC3756454,S73,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Immunostaining and flow cytometry,for determination of pma a total of 3000 events were collected in the cd14 monocyte gate.,"['C0026473', 'C3538991', 'C0521095', 'C3541888', 'C0439810', 'C1367477', 'C1148554', 'C0441471']","['CD14 gene', 'CDISC Events Class', 'Total', 'Determined by', 'Event', 'Determination Aspects', 'Monocytes', 'CD14 Expressing Cell Measurement']","['gngm', 'clas', 'qlco', 'lbpr', 'cell', 'evnt']"
1260,PMC3756454,S74,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Immunostaining and flow cytometry,for platelet expression of p-selectin 7500 events were collected in the platelet gate.,"['C1335809', 'C3890352', 'C0005821', 'C3541888', 'C2742134', 'C0185117', 'C0134835', 'C0441471']","['SELP protein, human', 'Expression procedure', 'CDISC Events Class', 'SELP gene', 'P-Selectin Measurement', 'Event', 'Blood Platelets', 'P-Selectin']","['imft', 'gngm', 'clas', 'topp', 'bacs', 'lbpr', 'cell', ' aapp', 'evnt']"
1261,PMC3756454,S76,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data and statistical analysis,cytometric data analysis was performed with flowjo v.7.2.5 (flow cytometry analysis software).,"['C0016263', 'C0010992', 'C1524024', 'C0037585', 'C0936012']","['Flow Cytometry', 'Data Analysis', 'Analysis', 'Computer software', 'analysis aspect']","['ocac', ' mnob', 'inpr', 'lbpr', 'resa', 'ftcn']"
1262,PMC3756454,S77,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data and statistical analysis,"plethysmographic data and net t-pa release were determined as described previously,19 21 as the product of the infused forearm plasma ﬂow (based on the mean haematocrit and the infused fbf) and the concentration difference between the infused ([t-pa] inf) and non-infused ([t-pa] non-inf) arms: estimated net t-pa release=fbf×(1−hct)×([tpa]inf−[tpa]non-inf).","['C1705241', 'C3827302', 'C1283071', 'C0446516', 'C0032105', 'C1456447', 'C1446561', 'C0518014', 'C0721062', 'C0205103', 'C0032143', 'C0750572', 'C2681631', 'C0521095', 'C1705938', 'C1415066', 'C3853572', 'C3245479', 'C2348143', 'C1552738', 'C1527178', 'C0030685', 'C0016536', 'C0206655', 'C1705242', 'C0444504', 'C4521445', 'C1704444', 'C3887809', 'C1514468', 'C1518422', 'C1963578', 'C0680255', 'C0086045', 'C1515981', 'C3714741', 'C2347634', 'C1511726', 'C0391871', 'C3890893']","['KIDINS220 gene', 'Estimated', 'SLC6A2 wt Allele', 'Data (eukaryote)', 'And', 'Release (procedure)', 'Concentration measurement', 'product', 'Alveolar rhabdomyosarcoma', 'Forearm', 'InFed', 'Sample Mean', 'Patient Discharge', 'Released (action)', 'Population Mean', 'Determined by', 'Upper arm', 'Discharge (release)', 'Data call receiving device', 'Basis - conceptual entity', 'GIF gene', 'Release - action (qualifier value)', 'Statistical mean', 'Mental concentration', 'Ephrin Type-B Receptor 1, human', 'Multiplicative Product', 'Intermediate', 'Able to Concentrate Question', 'Negation', 'described', 'Different', 'Base - General Qualifier', 'alteplase', 'Hematocrit level', 'Net (qualifier)', 'Delta (difference)', 'Plasma Product', 'Plasma', 'SLC6A2 protein, human', 'Data']","['topp', 'qnco', ' aapp', 'menp', 'blor', 'fndg', 'idcn', 'hlca', 'inpr', 'qlco', 'bacs', 'ftcn', 'bpoc', 'bdsu', 'phsu', 'enzy', 'orch', 'euka', 'spco', 'enty', 'neop', 'gngm', 'medd', ' enzy', 'rcpt', ' phsu']"
1263,PMC3756454,S78,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data and statistical analysis,continuous variables are reported as means±sem.,"['C0439828', 'C0549178']","['Variable (uniformity)', 'Continuous']","['qlco', 'idcn']"
1264,PMC3756454,S79,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Data and statistical analysis,analysis of variance with repeated measures and a two-tailed student t test were performed as appropriate with the use of graphpad prism software.,"['C0814195', 'C1711260', 'C0039259', 'C0871881', 'C0871472', 'C1515981', 'C1548787', 'C2348152', 'C0205448', 'C0042153', 'C1524024', 'C0037585', 'C1418877', 'C0038492', 'C0457083', 'C0936012']","['Two', 'Psychiatric Res. Interview f. Substance and Mental Disorders', 't test', 'student', 'Variance', 'Analysis', 'Tail', 'Computer software', 'Usage', 'And', 'Appropriate', 'Sample Variance', 'analysis aspect', 'PRDM6 gene', 'utilization qualifier', 'repeated measures']","['gngm', ' mnob', 'idcn', 'inpr', 'qlco', 'qnco', 'resa', 'ftcn', 'popg', 'bpoc']"
1265,PMC3756454,S80,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Data and statistical analysis,the primary outcome measure was pma.,"['C3274433', 'C0048451', 'C0039654', 'C2825188']","['Tetradecanoylphorbol Acetate', 'Premarket Device Application', 'Primary Outcome Measure', '4-methoxyamphetamine']","[' orch', 'inpr', 'qlco', 'hops', ' phsu']"
1266,PMC3756454,S81,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Data and statistical analysis,on the basis of previous work examining the effect of clopidogrel on pma22 we estimated that a 5% absolute change in pma would be of clinical significance and that at least 12 paired samples would provide an 80% power to detect a 10% absolute difference in pma from baseline at a significance level of 5%.,"['C1709450', 'C0205156', 'C1999230', 'C0168634', 'C0442726', 'C2348382', 'C1518681', 'C1280500', 'C2826293', 'C0032863', 'C1527178', 'C3854080', 'C1874451', 'C0048451', 'C0070166', 'C1517320', 'C0814896', 'C1442488', 'C1552607', 'C0039654', 'C2825188', 'C0332128', 'C1515981', 'C3891454', 'C0043227', 'C1549031']","['Pair', 'Providing (action)', 'Effect, Appearance', 'And', 'Power', 'Detected (finding)', 'From', 'significance level', 'Examined', 'Basis', 'Dosing Days to Detection', 'Baseline', 'Premarket Device Application', 'Basis - conceptual entity', '4-methoxyamphetamine', 'Clinical Significance', 'Outcome of Therapy', 'Absolute Change', 'Tetradecanoylphorbol Acetate', 'Effect', 'Act Relationship Subset - previous', 'Work', 'BaseLine dental cement', 'Power (Psychology)', 'clopidogrel', 'Previous']","['tmco', 'ocac', 'fndg', 'resa', ' orch', 'idcn', 'inpr', 'orch', 'qnco', 'qlco', 'hops', 'ftcn', 'hcpp', 'bodm', 'acty', ' phsu', 'phsu']"
1267,PMC4066691,S166,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Supplementary Material,additional file 1: table s1,"['C0016094', 'C1522646', 'C0039224', 'C1706074', 'C1524062', 'C0180853']","['Data Table', 'Filed', 'Additional', 'Table - furniture', 'file device', 'File (record)']","['ocac', 'medd', 'inpr', 'ftcn', 'mnob']"
1268,PMC4066691,S167,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Supplementary Material,adjusted mean differences in lung function and acq-7 score between tiotropium respimat® and placebo respimat®.,"['C0456081', 'C4050231', 'C0032042', 'C2348143', 'C0449820', 'C0035245', 'C1706408', 'C1515981', 'C2919686', 'C1696465', 'C2347634', 'C0213771', 'C0444504']","['tiotropium', 'Adjustment Action', 'Placebo Control', 'Sample Mean', 'placebo', 'Score', 'ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated', 'Asthma Control Questionnaire', 'And', 'Placebos', 'Population Mean', 'Statistical mean', 'Respiratory physiology']","['bodm', 'idcn', 'topp', 'phsf', 'inpr', 'orch', 'qnco', 'resa', 'ftcn', ' phsu', 'clna']"
1269,PMC4066691,S168,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Supplementary Material,click here for file,"['C0016094', 'C0180853', 'C1522646']","['file device', 'Filed', 'File (record)']","['medd', 'ftcn', 'ocac']"
1270,PMC4066691,S42,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Methods,"this was a phase ii, randomised, double-blind, placebo-controlled, crossover study to investigate the efficacy and safety of three doses of once-daily tiotropium respimat®.","['C0205173', 'C0456909', 'C0205449', 'C1948045', 'C0178602', 'C1705187', 'C0332173', 'C1705765', 'C0150108', 'C1706408', 'C0525065', 'C1705764', 'C1707887', 'C1280519', 'C0441767', 'C0036043', 'C0150097', 'C1080058', 'C1515981', 'C1292732', 'C0213771']","['Duplicate', 'And', 'Safety', 'Effectiveness', 'Stage level 2', 'Double Value Type', 'Safety Study', 'Once (schedule frequency)', 'tiotropium', 'Placebo Control', 'Visually Impaired Persons', 'Dosage', 'Blinded', 'Doubling', 'Daily', 'Cross-Over Studies', 'Efficacy Study', 'Three', 'This (eukaryote)', 'Blindness', 'investigates']","['tmco', 'fndg', 'resa', 'idcn', 'inpr', 'orch', 'qnco', 'qlco', 'euka', 'hcpp', 'podg', 'ftcn', ' phsu', 'acty']"
1271,PMC4066691,S43,['4b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Methods,"the study was conducted in 19 sites in three european countries (germany, austria and ukraine; clinicaltrials.gov identifier nct01233284), and was carried out in accordance with the principles of the declaration of helsinki and the international conference on harmonisation good clinical practice guidelines.","['C1554159', 'C0600091', 'C1512888', 'C2603343', 'C4086204', 'C0205145', 'C0282451', 'C0205449', 'C4281991', 'C0004348', 'C1554104', 'C1515981', 'C2986419', 'C0239307', 'C0017480', 'C0041580', 'C1535514', 'C0086047', 'C0454664', 'C0018898']","['Conferences', 'Helsinki Declaration', 'MDF Attribute Type - Identifier', 'Good Clinical Practice', 'Country', 'European race', 'Ukraine', 'And', 'Identifier', 'Austria', 'ethnic european', 'Three', 'Study', 'Follow', 'Site', 'Clinical Practice Guideline', 'ClinicalTrials.gov', 'Germany', 'International', 'HL7 Defined Rose Property - Identifier']","['resa', 'rnlw', 'idcn', 'inpr', 'geoa', 'qnco', 'spco', 'hcpp', 'ftcn', 'popg']"
1272,PMC4066691,S44,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Methods,"all patients provided written, informed consent.","['C0444868', 'C0030705', 'C0021430']","['Informed Consent', 'Patients', 'All']","['rnlw', 'podg', 'qnco']"
1273,PMC4066691,S46,"['5', '3a']","[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,"after an initial screening visit and a 4-week run-in period, patients were randomised to one of four treatment sequences, during which they received each of the four treatments (tiotropium 5 μg, 2.5 μg or 1.25 μg or placebo, all delivered via the respimat® softmist™ inhaler) (figure  1).","['C0205265', 'C0205447', 'C1881212', 'C1710032', 'C1279901', 'C3538994', 'C0439230', 'C1512346', 'C1533734', 'C0087111', 'C1555582', 'C3887704', 'C1705169', 'C1457900', 'C0039798', 'C2348164', 'C0030705', 'C1698960', 'C1706408', 'C1550513', 'C1514756', 'C3812285', 'C0545082', 'C0021461', 'C0213771', 'C0439531', 'C0162326', 'C0220908', 'C2826704', 'C0347984', 'C1705685', 'C0444868', 'C1710031', 'C1522326', 'C0032042', 'C0220909', 'C1705822', 'C1515981', 'C1696465', 'C1710477', 'C0205450', 'C1948053']","['Transfer Technique', 'Aspects of disease screening', 'Screening procedure', 'Patient Visit', 'placebo', 'Each (qualifier value)', 'And', 'SEMA6A wt Allele', 'Visit', 'Inhaler Dosing Unit', 'Firstly', 'Period (temporal qualifier)', 'Trial Screening', 'Treatment Epoch', 'Placebos', 'Screening', 'Biomaterial Treatment', 'Administration procedure', 'Screening Study', 'tiotropium', 'All', 'Initially', 'Placebo Control', 'Four', 'Visit Name', 'Disease Screening', 'Initial (abbreviation)', 'Initial Usage', 'Patients', 'Inhaler', 'During', 'via', 'One', 'DNA Sequence', 'Receive', 'research subject screening', 'treatment - ActInformationManagementReason', 'Treating', 'therapeutic aspects', 'week', 'per period (qualifier value)', 'Therapeutic procedure']","['tmco', 'nusq', 'bodm', 'medd', 'hlca', 'topp', 'idcn', 'gngm', 'inpr', 'orch', 'qnco', 'qlco', 'bhvr', 'resa', 'podg', 'ftcn', 'diap', ' phsu', 'cnce']"
1274,PMC4066691,S47,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,"each treatment was administered for 4 weeks, and there was no washout between treatment periods as pharmacodynamic steady state with tiotropium is known to be achieved after 3 weeks in chronic obstructive pulmonary disease [13,14].","['C1521801', 'C1565156', 'C3538994', 'C0521125', 'C1533734', 'C4321252', 'C0087111', 'C0024117', 'C0205103', 'C4554474', 'C0678587', 'C3887704', 'C1705169', 'C1457900', 'C0039798', 'C2986829', 'C1421478', 'C0043194', 'C1522326', 'C1710661', 'C1515981', 'C0213771']","['Each (qualifier value)', 'And', 'Washout Period', 'steady state', 'Treatment Epoch', 'Biomaterial Treatment', 'Administration procedure', 'Wiskott-Aldrich Syndrome', 'tiotropium', 'Washout phase', 'Chronic Obstructive Airway Disease', 'Having administered', 'WAS gene', 'WWOX wt Allele', 'Preposition For', 'Tracer Clearance', 'Intermediate', 'treatment - ActInformationManagementReason', 'Treating', 'WAS protein, human', 'therapeutic aspects', 'Therapeutic procedure']","['tmco', 'npop', 'gngm', 'topp', 'hlca', 'idcn', 'orch', 'qnco', 'bacs', 'qlco', 'dsyn', 'spco', 'resa', 'ftcn', 'diap', ' phsu', ' aapp', 'cnce']"
1275,PMC4066691,S48,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,seven clinic visits were scheduled: at screening (visit 0); prior to the 4-week run-in (visit 1); at randomisation (after the 4-week run-in [visit 2]); every 4 weeks at the end of each treatment period (visits 3–6); and 21 days following the end of the final treatment period (visit 7).,"['C0008952', 'C1710032', 'C3538994', 'C0439230', 'C0205453', 'C1512346', 'C0332152', 'C1533734', 'C0087111', 'C0205088', 'C3887704', 'C1705169', 'C1457900', 'C0039798', 'C2348164', 'C3853528', 'C1698960', 'C0545082', 'C1546485', 'C0439531', 'C2826257', 'C0220908', 'C2826704', 'C0444930', 'C1710031', 'C1522326', 'C1948061', 'C0220909', 'C2746065', 'C1710477', 'C1948053']","['Aspects of disease screening', 'Screening procedure', 'Patient Visit', 'End-stage', 'Each (qualifier value)', 'Clinic Visits', 'Visit', 'Diagnosis Type - Final', 'Period (temporal qualifier)', 'Trial Screening', 'Every (qualifier)', 'Treatment Epoch', 'Screening', 'Before', 'Biomaterial Treatment', 'Seven', 'Administration procedure', 'Screening Study', 'Visit Name', 'Disease Screening', 'End', 'research subject screening', 'treatment - ActInformationManagementReason', 'Treating', 'Prior Medication Usage', 'Stop (qualifier value)', 'therapeutic aspects', 'week', 'per period (qualifier value)', 'Final', 'Therapeutic procedure']","['tmco', 'hlca', 'topp', 'idcn', 'inpr', 'qnco', 'qlco', 'bhvr', 'spco', 'resa', 'ftcn', 'diap', 'evnt', 'cnce']"
1276,PMC4066691,S49,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,figure 1 study design.,"['C2983265', 'C2986888', 'C0035171']","['CDISC SEND Study Design Terminology', 'Nonclinical Study Design', 'Research Design']","['inpr', 'resa']"
1277,PMC4066691,S50,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,tiotropium respimat® (two puffs) or placebo respimat® (two puffs) was administered once daily in the evening between 18:00 and 20:00.,"['C0556983', 'C0032042', 'C1706408', 'C1515981', 'C0587117', 'C1696465', 'C0205448', 'C0213771']","['tiotropium', 'Two', 'Placebo Control', 'placebo', 'And', 'Placebos', 'Evening', 'Once daily']","['tmco', 'idcn', 'topp', 'orch', 'qnco', 'resa', 'bodm', ' phsu']"
1278,PMC4066691,S51,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,all patients were required to continue maintenance treatment with stable medium-dose ics (400–800 μg budesonide or equivalent) for at least 4 weeks prior to visit 1 and until visit 7.,"['C1705217', 'C0815320', 'C0178602', 'C0439185', 'C1512346', 'C0332152', 'C0009458', 'C4085196', 'C0030705', 'C0439536', 'C4522283', 'C0545082', 'C4522282', 'C1547311', 'C2826257', 'C2826704', 'C0054201', 'C4551720', 'C0444868', 'C0205360', 'C1515981', 'C0205163', 'C1720302', 'C3244283', 'C0814469']","['Patient Visit', 'Medium', 'And', 'Communications Media', 'Primary Ciliary Dyskinesia', 'treatment and maintenance', 'Stable status', 'Visit', 'Patient Condition Code - Stable', 'Equal', 'Before', 'medium exposure', 'All', 'A Medium Amount of Time', 'Visit Name', 'Dosage', 'Patients', 'Equivalent Weight', 'Impaired Control Scale', 'A Medium Amount', 'Prior Medication Usage', 'Budesonide', 'Until', 'Medium Growth Rate', 'Medium (Substance)']","['tmco', 'fndg', 'hlca', 'idcn', 'topp', 'inpr', 'orch', 'qnco', 'qlco', 'sbst', 'bhvr', 'dsyn', 'podg', ' phsu', 'evnt', 'cnce']"
1279,PMC4066691,S52,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,"patients using ics plus short-acting β2-agonist or ics + laba fixed-dose combinations were switched to the same dose of ics mono-product at least 8 or 24 hours, respectively, prior to visit 1.","['C3539956', 'C3540721', 'C0815320', 'C0178602', 'C3540719', 'C3539975', 'C3539972', 'C1282927', 'C3539971', 'C1512346', 'C0332152', 'C3539967', 'C3539963', 'C3539976', 'C3539181', 'C3539959', 'C0453882', 'C3539979', 'C3539965', 'C0030705', 'C3539970', 'C0545082', 'C3540027', 'C3539977', 'C3539968', 'C1551969', 'C3540724', 'C3540031', 'C3539962', 'C3539961', 'C0443218', 'C0445247', 'C2826257', 'C2826704', 'C3540723', 'C4551720', 'C1551432', 'C3854036', 'C3539973', 'C3539978', 'C3539960', 'C3539966', 'C1704444', 'C3539954', 'C1514468', 'C2987634', 'C3540026', 'C2350002', 'C3539957', 'C3540740', 'C1806781', 'C3539182', 'C3539964', 'C3540028', 'C3714578', 'C3539969', 'C3539955', 'C3539974', 'C3540722', 'C2827483', 'C3540030', 'C3540720']","['Patient Visit', 'Combination solutions for parenteral nutrition', 'Insulins and analogs for injection, intermediate-acting combined with fast-acting- combinations', 'Short Value', 'Insulins and analogs for injection, fast-acting combinations', 'Intermediate-acting sulfonamide combinations', 'Salt solution combinations', 'other nasal preparation combinations in ATC', 'Primary Ciliary Dyskinesia', 'Adrenergic and dopaminergic agents combinations', 'Aluminium antacid compound combinations', 'Other irrigating solution combinations in ATC', 'Visit', 'product', 'Specific immunoglobulin combinations', 'topical antibiotic combinations', 'Same', 'other cough suppressant combinations in ATC', 'opium alkaloids and derivative combination cough suppressants', 'otologic analgesic and anesthetic combinations', 'Fixed Specimen', 'Hepatitis vaccine combinations', 'Fix', 'Long-acting sulfonamide combinations', 'Other antifungal combinations for topical use in ATC', 'Platelet aggregation inhibitor combinations excl. heparin', 'Before', 'lung surfactant combinations', 'Short-acting sulfonamide combinations', 'Mono Indians', 'Shortened', 'Other anti-dementia drug combinations in ATC', 'gonadotropin combinations', 'vitamin D and analog combinations', 'expectorant combinations, excl. combinations with cough suppressants', 'Short', 'Visit Name', 'Agonist', 'Dosage', 'Patients', 'Beta-lactamase sensitive penicillin combinations', 'Caries prophylactic agent combinations', 'Enema combinations', 'Magnesium antacid compound combinations', 'Other intestinal adsorbent combinations in ATC', 'Multiplicative Product', 'Penicillins with extended spectrum combinations', 'Combinations (Undergarment)', 'Local hemostatic combinations', 'Mono language', 'Impaired Control Scale', 'Calcium antacid compound combinations', 'local opthalmologic anesthetic combinations', 'expectorant combinations excluding combinations with cough suppressants', 'Fixed behavior', 'Prior Medication Usage', 'combination drugs used in erectile dysfunction', 'Insulins and analogs for injection, intermediate-acting combinations', 'Antiinfective irrigating solution combinations', 'insulins and analogs for injection combinations, long-acting', 'Potassium supplement combinations', 'Amide local anesthetic combinations']","['antb', 'qnco', 'phpr', 'bhvr', 'podg', ' aapp', 'horm', 'lang', ' orch', 'hlca', 'inpr', 'qlco', 'mnob', 'popg', 'bdsu', 'tmco', 'phsu', 'orch', 'enty', 'imft', 'dsyn', ' phsu', 'evnt']"
1280,PMC4066691,S53,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,study medication was to be taken immediately after ics inhalation if normal ics dosing was in the evening.,"['C0231683', 'C2603343', 'C1705211', 'C0205548', 'C4284232', 'C4553972', 'C0815320', 'C0587117', 'C4551720', 'C0205307', 'C0013227', 'C3244316', 'C0205535', 'C0004048']","['Inspiration function', 'Stat (do immediately)', 'Gait normal', 'Normal', 'Impaired Control Scale', 'Medications', 'How Often Felt Normal question', 'Primary Ciliary Dyskinesia', 'Inhalation Route of Drug Administration', 'Study', 'Inhalation Dosing Unit', 'Evening', 'Pharmaceutical Preparations', 'medication - HL7 publishing domain']","['tmco', 'fndg', 'inpr', 'qnco', 'qlco', 'dsyn', 'orgf', 'resa', 'ftcn', 'phsu']"
1281,PMC4066691,S54,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,concomitant use of the following was not permitted for maintenance treatment: systemic oral or depot corticosteroids; anticholinergics other than tiotropium; labas; ics plus short-acting β2-agonist or ics + laba fixed-dose combinations; leukotriene modifiers; anti-immunoglobulin e treatment; chromone; methylxanthines; and phosphodiesterase-4 inhibitors.,"['C0242896', 'C0521115', 'C3539956', 'C0332282', 'C0205373', 'C0021027', 'C0001617', 'C3540721', 'C3540711', 'C3540727', 'C0178602', 'C0815320', 'C3539975', 'C3539972', 'C3540719', 'C1282927', 'C3538994', 'C3539185', 'C3539971', 'C3539967', 'C1533734', 'C3539963', 'C3539976', 'C0087111', 'C3539181', 'C3830287', 'C0243077', 'C3539959', 'C0453882', 'C3887704', 'C1705169', 'C3539979', 'C3539965', 'C3539970', 'C0039798', 'C0042153', 'C3540027', 'C3539974', 'C3539977', 'C3539968', 'C3540724', 'C3540031', 'C3539962', 'C0008594', 'C3539961', 'C0023545', 'C0443218', 'C0442027', 'C1621846', 'C3540723', 'C4284280', 'C3539973', 'C4551720', 'C3854036', 'C3539978', 'C3539960', 'C0457083', 'C3539966', 'C3539954', 'C1518422', 'C1522326', 'C2987634', 'C3540026', 'C2350002', 'C3539957', 'C3540740', 'C0814469', 'C3540726', 'C3539182', 'C1806781', 'C3539964', 'C3540725', 'C3714578', 'C3540028', 'C3539969', 'C3539955', 'C0213771', 'C3540722', 'C2827483', 'C0066447', 'C3540030', 'C3540720', 'C3537307']","['Short Value', 'Combination solutions for parenteral nutrition', 'Insulins and analogs for injection, intermediate-acting combined with fast-acting- combinations', 'Modifiers', 'Systemic', 'Insulins and analogs for injection, fast-acting combinations', 'Intermediate-acting sulfonamide combinations', 'Salt solution combinations', 'other nasal preparation combinations in ATC', 'Primary Ciliary Dyskinesia', 'Adrenergic and dopaminergic agents combinations', 'Leukotrienes', 'treatment and maintenance', 'Aluminium antacid compound combinations', 'Other irrigating solution combinations in ATC', 'utilization qualifier', 'Chromones', 'Simultaneous', 'Anticholinergic mydriatics and cycloplegics', 'Immunoglobulins', 'Specific immunoglobulin combinations', 'topical antibiotic combinations', 'Corticosteroid otologicals', 'opium alkaloids and derivative combination cough suppressants', 'other cough suppressant combinations in ATC', 'Fixed Specimen', 'Following', 'Corticosteroids, topical for treatment of hemorrhoids and anal fissures', 'Fix', 'Hepatitis vaccine combinations', 'otologic analgesic and anesthetic combinations', 'Adrenal Cortex Hormones', 'Corticosteroid ophthalmologic and otologic preparations', 'Long-acting sulfonamide combinations', 'Treatment Epoch', 'Other antifungal combinations for topical use in ATC', 'Platelet aggregation inhibitor combinations excl. heparin', 'Biomaterial Treatment', 'Short-acting sulfonamide combinations', 'lung surfactant combinations', 'Shortened', 'Administration procedure', 'Other anti-dementia drug combinations in ATC', 'gonadotropin combinations', 'vitamin D and analog combinations', 'expectorant combinations, excl. combinations with cough suppressants', 'Short', 'tiotropium', 'Corticosteroid nasal preparations for topical use', 'Agonist', 'inhibitors', 'Dosage', 'Beta-lactamase sensitive penicillin combinations', 'Caries prophylactic agent combinations', 'Enema combinations', 'Magnesium antacid compound combinations', 'Other intestinal adsorbent combinations in ATC', 'Therapeutic procedure', 'Penicillins with extended spectrum combinations', 'Combinations (Undergarment)', 'Local hemostatic combinations', 'Negation', 'Anticholinergic Agents', 'Calcium antacid compound combinations', 'methylxanthine', 'Impaired Control Scale', 'expectorant combinations excluding combinations with cough suppressants', 'Fixed behavior', 'Treating', 'local opthalmologic anesthetic combinations', 'treatment - ActInformationManagementReason', 'Usage', 'combination drugs used in erectile dysfunction', 'Anticholinergics inhalants for obstructive airway diseases', 'Extended Release Depot Dosage Form', 'Insulins and analogs for injection, intermediate-acting combinations', 'therapeutic aspects', 'Antiinfective irrigating solution combinations', 'insulins and analogs for injection combinations, long-acting', 'Oral', 'Potassium supplement combinations', 'Amide local anesthetic combinations', 'immunoglobulin activity']","['antb', 'topp', 'qnco', 'phpr', 'bodm', ' aapp', 'horm', 'chvf', ' orch', 'hlca', 'inpr', 'qlco', 'bacs', 'resa', 'ftcn', 'mnob', 'moft', 'bdsu', 'tmco', 'phsu', 'orch', 'spco', 'cnce', 'imft', 'dsyn', ' phsu']"
1282,PMC4066691,S55,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,salbutamol hydrofluoroalkane metered-dose inhaler was provided by the sponsor as rescue medication for use as needed.,"['C1711305', 'C1881212', 'C0686904', 'C4284232', 'C2347796', 'C1721232', 'C0178602', 'C3244316', 'C0042153', 'C0021461', 'C0001927', 'C0457083', 'C0013227']","['Inhaler Dosing Unit', 'Medications', 'Patient need for (contextual qualifier)', 'Sponsor (person)', 'Usage', 'Dosage', 'Albuterol', 'Inhaler', 'utilization qualifier', 'Clinical Study Sponsor', 'HYDROFLUOROALKANE', 'Pharmaceutical Preparations', 'medication - HL7 publishing domain']","['popg', 'medd', 'orgt', 'inpr', 'orch', 'qnco', 'ftcn', ' phsu', 'phsu']"
1283,PMC4066691,S56,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,"permitted medication for the treatment of acute asthma exacerbations included salbutamol hydrofluoroalkane metered-dose inhaler, systemic corticosteroids and short-acting theophylline preparations.","['C0329040', 'C0205373', 'C1881212', 'C0001617', 'C4284232', 'C3540727', 'C1282927', 'C0178602', 'C3538994', 'C0582415', 'C3539185', 'C1533734', 'C0349790', 'C0087111', 'C3887704', 'C1705169', 'C0039798', 'C3244316', 'C0021461', 'C0013227', 'C1522326', 'C2350002', 'C3540726', 'C1806781', 'C3540725', 'C1515981', 'C0039771']","['Short Value', 'Systemic', 'And', 'Theophylline', 'Inhaler Dosing Unit', 'Corticosteroid otologicals', 'Corticosteroids, topical for treatment of hemorrhoids and anal fissures', 'Adrenal Cortex Hormones', 'Corticosteroid ophthalmologic and otologic preparations', 'Trachinotus falcatus', 'Treatment Epoch', 'Biomaterial Treatment', 'Shortened', 'Administration procedure', 'Short', 'Corticosteroid nasal preparations for topical use', 'acute asthma', 'Dosage', 'Inhaler', 'Pharmaceutical Preparations', 'Exacerbation of asthma', 'medication - HL7 publishing domain', 'Medications', 'treatment - ActInformationManagementReason', 'Treating', 'therapeutic aspects', 'Therapeutic procedure']","['fndg', 'resa', 'medd', ' orch', 'topp', 'idcn', 'hlca', 'inpr', 'orch', 'qnco', 'phsu', 'qlco', 'dsyn', ' phsu', 'ftcn', 'horm', 'fish', 'cnce']"
1284,PMC4066691,S58,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,each patient received all treatments.,"['C0444868', 'C0087111', 'C1457900', 'C0030705']","['Patients', 'Each (qualifier value)', 'All', 'Therapeutic procedure']","['podg', 'qnco', 'topp']"
1285,PMC4066691,S59,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,eligible patients were randomly allocated to one of the four treatment sequences at visit 2 (figure  1).,"['C0087111', 'C0162326', 'C0205447', 'C1522326', 'C3887704', 'C1705169', 'C0039798', 'C3538994', 'C0030705', 'C2826704', 'C0545082', 'C0205450', 'C1548635', 'C1512346', 'C1533734']","['DNA Sequence', 'Patient Visit', 'treatment - ActInformationManagementReason', 'Treating', 'Visit Name', 'Four', 'Treatment Epoch', 'therapeutic aspects', 'Patients', 'Biomaterial Treatment', 'One', 'Administration procedure', 'Visit', 'Eligible', 'Therapeutic procedure']","['nusq', 'topp', 'hlca', 'inpr', 'qlco', 'qnco', 'bhvr', 'resa', 'podg', 'ftcn', 'cnce']"
1286,PMC4066691,S60,['8a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0]",Study design,"the randomisation list was generated by boehringer ingelheim pharma gmbh & co. kg, biberach an der riss, germany, using a validated pseudo-random number generator and a supplied seed number.","['C0205237', 'C0439605', 'C3272378', 'C0237753', 'C0036563', 'C0449788', 'C1999230', 'C0237638', 'C0034656', 'C0331792', 'C1515981', 'C0017480', 'C1705192', 'C2346495', 'C0745732', 'C1511780']","['Providing (action)', 'Seeding', 'Count of entities', 'And', 'False', 'boehringer ingelheim', 'Seed entity', 'Random', 'Derivative Chromosome', 'Generators (Apparatus)', 'Randomization', 'List', 'Germany', 'Sequence Data Type', 'Plant seeds', 'Numbers']","['acty', 'idcn', 'plnt', 'inpr', 'geoa', 'hcro', 'qnco', 'comd', 'qlco', 'lbpr', 'resa', 'mnob', 'cnce']"
1287,PMC4066691,S61,['8b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0]",Study design,"a fixed block randomisation, with a block size of 4, was used to ensure balanced and equal assignment.","['C0456389', 'C0205415', 'C2828370', 'C1516050', 'C1549782', 'C0028778', 'C1515981', 'C0205163', 'C1706084', 'C1533157', 'C0332206']","['Block Specimens', 'Assignment - action', 'Equal', 'Balanced - adjective', 'Relational Operator - Equal', 'Obstruction', 'Block (unit of measure)', 'And', 'size', 'Blocking', '(City) Block']","['idcn', 'inpr', 'geoa', 'qnco', 'qlco', 'spco', 'ftcn', 'patf', 'bdsu']"
1288,PMC4066691,S63,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study patients,"male or female patients aged 18–75 years, with at least a 3-month history of asthma at the time of enrolment and an initial diagnosis of asthma made before the age of 40 years, were included in the study.","['C0205265', 'C0150905', 'C1279901', 'C0019664', 'C1706428', 'C0332152', 'C2984299', 'C1555582', 'C1704656', 'C0439234', 'C0332177', 'C0262926', 'C1704338', 'C0004096', 'C0019665', 'C2004062', 'C1705685', 'C1705255', 'C0332257', 'C1706180', 'C0262512', 'C2603343', 'C0011900', 'C0439231', 'C0040223', 'C0086582', 'C1515981', 'C0001779', 'C1706429']","['Age', 'Male Phenotype', 'year', 'diagnosis aspect', 'And', 'Including (qualifier)', 'Study', 'History', 'month', 'Male, Self-Reported', 'Diagnosis', 'Firstly', 'Medical History', 'Males', 'Time', 'History of previous events', 'Before', 'Concept History', 'Male Gender, Self Report', 'Initially', 'History of present illness', 'Asthma', 'Initial (abbreviation)', 'Initial Usage', 'Monthly (qualifier value)', 'Asthma Pathway', 'patient is female', 'Diagnosis Study', 'Historical aspects qualifier']","['tmco', 'fndg', 'idcn', 'ocdi', 'qlco', 'orga', 'dsyn', 'resa', 'ftcn', 'diap', 'cnce']"
1289,PMC4066691,S64,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study patients,"patients were required to have been on maintenance treatment with stable medium-dose ics (400–800 μg budesonide or equivalent), alone or in a fixed-dose combination with a laba or short-acting β2-agonist, for at least 4 weeks prior to visit 1.","['C1705217', 'C0815320', 'C0178602', 'C1282927', 'C0439185', 'C1512346', 'C0332152', 'C0205171', 'C0009458', 'C4085196', 'C0030705', 'C0439536', 'C4522283', 'C0545082', 'C0332287', 'C0443218', 'C4522282', 'C1547311', 'C2826257', 'C2826704', 'C0054201', 'C4551720', 'C0679994', 'C0439044', 'C3811910', 'C2987634', 'C2350002', 'C1806781', 'C0205360', 'C0205163', 'C3714578', 'C1947911', 'C3244283', 'C2827483', 'C0814469']","['Patient Visit', 'In addition to', 'Medium', 'Short Value', 'Singular', 'alone - group size', 'Communications Media', 'Primary Ciliary Dyskinesia', 'treatment and maintenance', 'Stable status', 'Visit', 'Patient Condition Code - Stable', 'Equal', 'Fixed Specimen', 'combination of objects', 'Fix', 'Before', 'medium exposure', 'Shortened', 'Living Alone', 'Short', 'A Medium Amount of Time', 'Visit Name', 'Agonist', 'Dosage', 'Patients', 'Equivalent Weight', 'combination - answer to question', 'Impaired Control Scale', 'A Medium Amount', 'Fixed behavior', 'Prior Medication Usage', 'Budesonide', 'Medium Growth Rate', 'Medium (Substance)']","['topp', 'qnco', 'phpr', 'bhvr', 'podg', 'phob', 'fndg', 'hlca', 'inpr', 'qlco', 'sbst', 'ftcn', 'bdsu', 'tmco', 'phsu', 'orch', 'grpa', 'cnce', 'dsyn', ' phsu', 'evnt']"
1290,PMC4066691,S65,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study patients,"a diagnosis of asthma confirmed at visit 1 was required, with bronchodilator reversibility (15–30 minutes after 400 μg salbutamol) of ≥12% and ≥200 ml.","['C0439232', 'C1282918', 'C2984299', 'C0011900', 'C0006280', 'C1704656', 'C1704338', 'C0004096', 'C2826704', 'C1515981', 'C0545082', 'C0449261', 'C1512346', 'C0001927', 'C0700321']","['Asthma Pathway', 'Diagnosis', 'Patient Visit', 'Visit Name', 'Asthma', 'diagnosis aspect', 'And', 'Minute (diminutive)', 'Small', 'Albuterol', 'Diagnosis Study', 'Bronchodilator Agents', 'Minute of time', 'reversibility', 'Visit']","['tmco', 'idcn', 'hlca', 'inpr', 'orch', 'qlco', 'phsu', 'qnco', 'bhvr', 'dsyn', 'resa', 'diap', ' phsu', 'cnce']"
1291,PMC4066691,S66,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study patients,"patients were required to have a seven-question asthma control questionnaire (acq-7) mean score of ≥1.5 at visits 1 and 2, to have a pre-bronchodilator fev1 of ≥60% and ≤90% of predicted normal fev1 at visit 1, and to demonstrate absolute fev1 variability within 30% between visits 1 and 2.","['C0231683', 'C0205103', 'C1522634', 'C2599602', 'C2827666', 'C0332285', 'C3533236', 'C4553972', 'C0205453', 'C0030705', 'C2826704', 'C1515981', 'C0545082', 'C2919686', 'C0205344', 'C0205307', 'C0681842', 'C1512346', 'C3539897', 'C3154893']","['absolute', 'pre bronchodilator', 'Gait normal', 'Normal', 'Patient Visit', 'Visit Name', 'Within', 'Mean score', 'Have', 'Asthma Control Questionnaire', 'And', 'How Often Felt Normal question', 'Question (inquiry)', 'Patients', 'Variability', 'prediction', 'Seven', 'Intermediate', 'Visit', 'Possess']","['tmco', 'fndg', 'idcn', 'hlca', 'inpr', 'qlco', 'qnco', 'bhvr', 'spco', 'podg', 'cnce']"
1292,PMC4066691,S67,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study patients,"patients were required never to have smoked, or to be ex-smokers who had stopped smoking at least 1 year prior to enrolment and had a smoking history of less than 10 pack-years.","['C1519384', 'C3272598', 'C2003901', 'C0439234', 'C2699910', 'C0030705', 'C0337664', 'C0332152', 'C0439092']","['Never (frequency)', 'year', 'Less Than', 'Ten Pack', 'Smoking History', 'WHO Temperature/Humidity Storage Condition', 'Smoker', 'Patients', 'Before']","['tmco', 'fndg', 'qlco', 'qnco', 'podg']"
1293,PMC4066691,S68,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study patients,patients were excluded for any of the following reasons: a diagnosis of chronic obstructive pulmonary disease or any respiratory disease other than asthma; myocardial infarction within the last 6 months; hospitalisation due to cardiac failure or unstable cardiac arrhythmia within the past year; treatment with anti-immunoglobulin e antibodies within 6 months prior to visit 1.,"['C0392360', 'C0332282', 'C0021027', 'C3538994', 'C0428953', 'C1883468', 'C0678226', 'C0018802', 'C1512346', 'C0332152', 'C1533734', 'C0024117', 'C2984299', 'C0087111', 'C0443343', 'C1704656', 'C3887704', 'C1705169', 'C0039798', 'C2926063', 'C0030705', 'C3146286', 'C0545082', 'C4552959', 'C0019993', 'C1704338', 'C0004096', 'C4086728', 'C1621846', 'C2826257', 'C2826704', 'C1552551', 'C0027051', 'C3272371', 'C1517741', 'C0011900', 'C1522326', 'C0003811', 'C0018801', 'C3810814', 'C0003241', 'C1560249']","['Patient Visit', 'Past Year', 'diagnosis aspect', 'Unstable status', 'Visit', 'Congestive heart failure', 'Immunoglobulins', 'Diagnosis', 'Following', 'Myocardial infarction:Finding:Point in time:^Patient:Ordinal', 'Due', 'Due to', 'Treatment Epoch', 'Electrocardiogram: myocardial infarction (finding)', 'Myocardial Infarction', 'Any Data Type', 'Indication of (contextual qualifier)', 'Before', 'Biomaterial Treatment', 'Heart failure', 'Administration procedure', 'Unstable Medical Device Problem', 'Adverse Event Associated with Cardiac Arrhythmia', 'Chronic Obstructive Airway Disease', 'Visit Name', 'Asthma', 'Myocardial Infarction, CTCAE', 'Any', 'Patients', 'Therapeutic procedure', 'Cardiac Arrhythmia', 'Myocardial Infarction ECG Assessment', 'Asthma Pathway', 'treatment - ActInformationManagementReason', 'Last', 'Treating', 'Prior Medication Usage', 'Antibodies', 'Hospitalization', 'therapeutic aspects', 'Diagnosis Study', 'immunoglobulin activity']","['topp', 'bhvr', 'podg', ' aapp', 'clna', 'fndg', 'idcn', 'hlca', 'inpr', 'qlco', 'resa', 'ftcn', 'moft', 'tmco', 'lbtr', 'cnce', 'imft', 'dsyn', 'diap', ' phsu', 'evnt']"
1294,PMC4066691,S70,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study end points,all end points were determined at the end of each 4-week treatment period (visits 3–6) and analysed as a response defined as change from study baseline (pre-treatment value measured at visit 2 in the evening).,"['C1705241', 'C1882141', 'C3538994', 'C0168634', 'C0871261', 'C0439230', 'C0392747', 'C1512346', 'C0332152', 'C1533734', 'C0443172', 'C0087111', 'C3887704', 'C1705169', 'C0039798', 'C0545082', 'C0439531', 'C1704788', 'C1522609', 'C2826704', 'C0740175', 'C0444930', 'C4319952', 'C0444868', 'C1517320', 'C2257086', 'C2603343', 'C1522326', 'C1442488', 'C1706817', 'C2746065', 'C3541902', 'C2911692', 'C1515981', 'C0587117', 'C1704632', 'C0444706', 'C1948053']","['Patient Visit', 'Numerical value', 'And', 'From', 'Measured Tumor Identification', 'Response (communication)', 'Study', 'Definition', 'Response process', 'photoreactivating enzyme activity', 'Visit', 'Disease Response', 'Measured', 'Period (temporal qualifier)', 'Treatment Epoch', 'Changed status', 'Before', 'Biomaterial Treatment', 'Baseline', 'Administration procedure', 'Changing', 'All', 'Visit Name', 'End', 'Change -- procedure', 'Response (statement)', 'BaseLine dental cement', 'treatment - ActInformationManagementReason', 'Treating', 'Stop (qualifier value)', 'Of Each', 'therapeutic aspects', 'Before values', 'week', 'per period (qualifier value)', 'Delta (difference)', 'Evening', 'Therapeutic procedure']","['tmco', 'fndg', 'bodm', 'topp', 'hlca', 'idcn', 'inpr', 'genf', 'qnco', 'qlco', 'bhvr', 'orga', 'spco', 'resa', 'ftcn', 'diap', 'menp', 'cnce']"
1295,PMC4066691,S71,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study end points,the primary efficacy end point was peak fev1 measured within the first 3 hours after dosing (peak fev1(0-3h)).,"['C0231290', 'C0205435', 'C0332285', 'C3541902', 'C0205225', 'C2349179', 'C1279901', 'C0687676', 'C0444706', 'C1707887', 'C0444505', 'C1280519']","['Firstly', 'Measured', 'Effectiveness', 'Peak level', 'Primary', 'First (number)', 'Status post', 'Within', 'Efficacy Study', 'Measured Tumor Identification', 'End Point', 'Post']","['tmco', 'qlco', 'qnco', 'spco', 'resa', 'diap']"
1296,PMC4066691,S72,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study end points,"the following secondary efficacy end points were investigated: trough fev1; peak forced vital capacity (fvc) within the first 3 hours after dosing (fvc)(0-3h); trough fvc; fev1 area under the curve (auc) within the first 3 hours after dosing (fev1 auc(0-3h)); fvc auc(0-3h); pre-dose pefam and pefpm using the asthma monitor2+ device (am2+®; ert, philadelphia, pennsylvania, usa) based on the mean of the final week of each treatment period.","['C3714541', 'C0332282', 'C0017446', 'C1279901', 'C3538994', 'C0439230', 'C0178602', 'C1533734', 'C0087111', 'C2984299', 'C0041703', 'C0699733', 'C0205435', 'C0430511', 'C0030853', 'C0205088', 'C3887704', 'C1705169', 'C1457900', 'C3853528', 'C0205436', 'C0039798', 'C0025080', 'C1546485', 'C1707887', 'C0444506', 'C1280519', 'C0439531', 'C0376690', 'C2348143', 'C0332285', 'C0004096', 'C0175668', 'C1442460', 'C0444930', 'C0444504', 'C0031525', 'C0027627', 'C0205134', 'C1522326', 'C2746065', 'C0205146', 'C1515981', 'C0042834', 'C2347634', 'C1428749', 'C0444505', 'C1948053']","['3 Hours', 'Peak level', 'End-stage', 'Each (qualifier value)', 'And', 'ADM2 gene', 'Vital capacity test', 'Pennsylvania', 'Diagnosis Type - Final', 'Firstly', 'Period (temporal qualifier)', 'Effectiveness', 'Sample Mean', 'Following', 'First (number)', 'Within', 'second (number)', 'Population Mean', 'Treatment Epoch', 'Medical Devices', 'Biomaterial Treatment', 'Devices', 'Administration procedure', 'Forced Vital Capacity', 'Neoplasm Metastasis', 'Asthma', 'trough', 'Curved', 'Dosage', 'End', 'Vital capacity', 'Statistical mean', 'Area Under Curve', 'Asthma Pathway', 'treatment - ActInformationManagementReason', 'Treating', 'Philadelphia', 'Area', 'Secondary to', 'Stop (qualifier value)', 'United States', 'therapeutic aspects', 'Efficacy Study', 'week', 'per period (qualifier value)', 'Geographic Locations', 'Final', 'Therapeutic procedure']","['mnob', 'tmco', 'lbtr', 'gngm', 'topp', 'idcn', 'medd', 'hlca', 'geoa', 'qnco', 'qlco', 'dsyn', 'spco', 'resa', 'ftcn', 'neop', 'diap', 'cnce', 'clna']"
1297,PMC4066691,S73,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study end points,"control of asthma, as assessed by acq-7 self-administered at the end of each 4-week treatment period, was an additional exploratory end point.","['C3274648', 'C4553389', 'C1519231', 'C1882141', 'C3538994', 'C0439230', 'C1524062', 'C1533734', 'C1550141', 'C2587213', 'C0087111', 'C2984299', 'C3887704', 'C1705169', 'C0039798', 'C0439531', 'C0004096', 'C2349179', 'C0444930', 'C1522326', 'C2746065', 'C1882979', 'C2919686', 'C0243148', 'C1948053']","['control substance', 'Study Control', 'Period (temporal qualifier)', 'Self-Administered', 'Treatment Epoch', 'Asthma Control Questionnaire', 'Biomaterial Treatment', 'Administration procedure', 'control aspects', 'Asthma', 'Control function', 'End', 'Scientific Control', 'Asthma Pathway', 'treatment - ActInformationManagementReason', 'Treating', 'Additional', 'True Control Status', 'Of Each', 'Stop (qualifier value)', 'therapeutic aspects', 'week', 'per period (qualifier value)', 'End Point', 'Therapeutic procedure']","['tmco', 'topp', 'hlca', 'inpr', 'qlco', 'sbst', 'dsyn', 'spco', 'resa', 'ftcn', 'cnce']"
1298,PMC4066691,S74,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study end points,"safety and tolerability were assessed based on the incidence and intensity of adverse events, and on changes in vital signs.","['C0443172', 'C3274448', 'C0036043', 'C0518766', 'C0220856', 'C1515981', 'C0392747', 'C1705413', 'C0522510', 'C0021149', 'C1705187', 'C0877248']","['With intensity', 'Changing', 'Vital signs', 'incidence of cases', 'Incidence', 'And', 'Adverse Event Domain', 'Changed status', 'Safety', 'Safety Study', 'Tolerability Study', 'Adverse event']","['hcpp', 'idcn', 'inpr', 'qnco', 'qlco', 'resa', 'ftcn', 'patf', 'clna']"
1299,PMC4066691,S76,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study assessments,spirometric lung function tests were conducted at all in-clinic visits (visits 1–6).,"['C0024119', 'C0008952', 'C0545082', 'C0444868', 'C1512346']","['Patient Visit', 'All', 'Clinic Visits', 'Visit', 'Pulmonary function tests']","['qnco', 'hlca', 'diap', 'bhvr']"
1300,PMC4066691,S77,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study assessments,pre-dose lung function tests were scheduled between 18:00 and 20:00.,"['C0178602', 'C0024119', 'C1515981']","['Dosage', 'And', 'Pulmonary function tests']","['qnco', 'idcn', 'diap']"
1301,PMC4066691,S78,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study assessments,"at visits 2–6, lung function tests were performed 10 minutes prior to and up to 3 hours after dosing of study treatment.","['C0024119', 'C1521826', 'C2826257', 'C0545082', 'C1512346', 'C0332152']","['Patient Visit', 'Prior Medication Usage', 'Protocol Agent', 'Before', 'Visit', 'Pulmonary function tests']","['tmco', 'hlca', 'inpr', 'bhvr', 'diap', 'evnt']"
1302,PMC4066691,S79,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study assessments,acq-7 was self-administered at visits 1–6 prior to lung function tests.,"['C0022885', 'C0036588', 'C2826257', 'C0035245', 'C2919686', 'C1551994', 'C0392366', 'C0545082', 'C1512346', 'C0332152']","['Patient Visit', 'Prior Medication Usage', 'Asthma Control Questionnaire', 'subscriber - self', 'Tests (qualifier value)', 'Before', 'Laboratory Procedures', 'Self', 'Respiratory physiology', 'Visit']","['tmco', 'idcn', 'hlca', 'phsf', 'inpr', 'lbpr', 'bhvr', 'evnt']"
1303,PMC4066691,S80,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study assessments,"measurement of pefam and pefpm was to be performed prior to ics and study treatment inhalation, at approximately the same time each day, from 06:00 to 08:00 for pefam and from 18:00 to 20:00 for pefpm.","['C1521826', 'C0332173', 'C1705211', 'C0332152', 'C0040223', 'C0242485', 'C0445247', 'C1421478', 'C1565156', 'C0815320', 'C0521125', 'C0043194', 'C1515981', 'C0884358', 'C4551720', 'C0205535', 'C0332232', 'C1517320', 'C0004048', 'C4321252']","['Inspiration function', 'Same', 'Impaired Control Scale', 'WAS protein, human', 'WAS gene', 'WWOX wt Allele', 'And', 'Time', 'Performed', 'Primary Ciliary Dyskinesia', 'Inhalation Route of Drug Administration', 'From', 'Protocol Agent', 'Inhalation Dosing Unit', 'Before', 'Measurement', 'Daily', 'Preposition For', 'approximately', 'Wiskott-Aldrich Syndrome']","['tmco', 'gngm', 'idcn', 'inpr', 'qnco', 'qlco', 'bacs', 'dsyn', 'orgf', 'ftcn', ' aapp']"
1304,PMC4066691,S81,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study assessments,adverse events and concomitant medications were recorded on the electronic case report form at each visit.,"['C0521115', 'C1457900', 'C4284232', 'C4551412', 'C2826704', 'C1515981', 'C0802604', 'C0013227', 'C0545082', 'C1705413', 'C1512346', 'C0877248', 'C2598133']","['Medications:-:Point in time:^Patient:-', 'Medications', 'Medications:Presence or Identity:Duration of the study:^Patient:Nominal', 'Patient Visit', 'Visit Name', 'Electronic Case Report Form', 'Each (qualifier value)', 'And', 'Adverse Event Domain', 'Pharmaceutical Preparations', 'Visit', 'Simultaneous', 'Adverse event']","['tmco', 'idcn', 'hlca', 'inpr', 'qnco', 'phsu', 'bhvr', 'patf', 'clna']"
1305,PMC4066691,S82,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study assessments,vital signs were measured and recorded in conjunction with lung function tests at visits 2–6.,"['C0024119', 'C0518766', 'C0545082', 'C2699427', 'C1512346']","['Conjunction', 'Patient Visit', 'Vital signs', 'Visit', 'Pulmonary function tests']","['idcn', 'hlca', 'bhvr', 'diap', 'clna']"
1306,PMC4066691,S84,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,"efficacy data are reported for the full analysis set, which was defined as all randomised patients who were treated with at least one dose of study medication, had baseline data and had at least one on-treatment efficacy measurement after 4 weeks of treatment within a period.","['C0205447', 'C4284232', 'C0168634', 'C3538994', 'C0178602', 'C1524024', 'C3539897', 'C1533734', 'C0242485', 'C0936012', 'C0087111', 'C3272598', 'C3887704', 'C1705169', 'C0039798', 'C0030705', 'C3244316', 'C1707887', 'C1415458', 'C1280519', 'C0439531', 'C3245479', 'C0062074', 'C0444868', 'C0013227', 'C0443225', 'C2603343', 'C1522326', 'C1442488', 'C1515981', 'C3714741', 'C1511726', 'C1948053']","['Data (eukaryote)', 'And', 'HAC protocol', 'Study', 'Measurement', 'full', 'HADH gene', 'Period (temporal qualifier)', 'Effectiveness', 'Treatment Epoch', 'analysis aspect', 'Biomaterial Treatment', 'Baseline', 'Administration procedure', 'Data call receiving device', 'All', 'Dosage', 'Patients', 'Therapeutic procedure', 'One', 'Pharmaceutical Preparations', 'medication - HL7 publishing domain', 'BaseLine dental cement', 'Medications', 'treatment - ActInformationManagementReason', 'Treating', 'Analysis', 'Have', 'WHO Temperature/Humidity Storage Condition', 'therapeutic aspects', 'Efficacy Study', 'per period (qualifier value)', 'Data']","['tmco', 'bodm', 'medd', 'idcn', 'topp', 'gngm', 'hlca', 'inpr', 'qlco', 'qnco', 'phsu', 'euka', 'resa', 'podg', 'ftcn', 'cnce']"
1307,PMC4066691,S85,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,"data are presented as adjusted mean change from baseline after 4 weeks of treatment (defined as response), unless noted otherwise.","['C1705241', 'C0168634', 'C0871261', 'C3538994', 'C0392747', 'C1533734', 'C0443172', 'C0087111', 'C3887704', 'C1705169', 'C0039798', 'C0456081', 'C3245479', 'C2348143', 'C4319952', 'C0444504', 'C1706817', 'C1442488', 'C1522326', 'C2911692', 'C1704632', 'C3714741', 'C2347634', 'C1511726']","['Data (eukaryote)', 'Data', 'Response (communication)', 'Response process', 'Disease Response', 'Sample Mean', 'Adjustment Action', 'Population Mean', 'Treatment Epoch', 'Changed status', 'Biomaterial Treatment', 'Baseline', 'Administration procedure', 'Data call receiving device', 'Changing', 'Statistical mean', 'Change -- procedure', 'Response (statement)', 'BaseLine dental cement', 'treatment - ActInformationManagementReason', 'Treating', 'therapeutic aspects', 'Delta (difference)', 'Therapeutic procedure']","['fndg', 'resa', 'medd', 'idcn', 'topp', 'hlca', 'inpr', 'qnco', 'orga', 'euka', 'ftcn', 'bodm', 'menp', 'cnce']"
1308,PMC4066691,S86,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,"evaluation of safety and tolerability was performed on the treated set, defined as all randomised patients who received at least one dose of study medication.","['C3272598', 'C2603343', 'C0220825', 'C1442518', 'C0205447', 'C3274448', 'C0036043', 'C1705195', 'C4284232', 'C1522326', 'C0036849', 'C0030705', 'C0178602', 'C1515981', 'C3244316', 'C1261322', 'C0444868', 'C1705187', 'C0013227']","['set (group)', 'Set (Psychology)', 'Medications', 'All', 'Treating', 'WHO Temperature/Humidity Storage Condition', 'And', 'Dosage', 'Patients', 'Evaluation procedure', 'Set scale', 'Safety', 'Safety Study', 'Study', 'One', 'Tolerability Study', 'Evaluation', 'Pharmaceutical Preparations', 'medication - HL7 publishing domain']","['hcpp', 'hlca', 'idcn', 'inpr', 'qlco', 'qnco', 'phsu', 'resa', 'podg', 'ftcn', 'menp', 'cnce']"
1309,PMC4066691,S87,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,analysis of adverse events and vital signs was descriptive in nature.,"['C0349590', 'C1262865', 'C0518766', 'C1515981', 'C1705413', 'C1524024', 'C0877248', 'C0936012']","['Nature', 'Vital signs', 'Analysis', 'And', 'Adverse Event Domain', 'analysis aspect', 'Natures', 'Adverse event']","['idcn', 'inpr', 'resa', 'ftcn', 'patf', 'clna']"
1310,PMC4066691,S88,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,"to control the probability of a type i error in the primary efficacy analysis, stepwise testing of the null hypothesis was used to test the efficacy of tiotropium respimat® 5 μg, then 2.5 μg and then 1.25 μg, each over placebo respimat®.","['C1280519', 'C0032042', 'C0039593', 'C0205225', 'C1457900', 'C0033204', 'C0205557', 'C1706408', 'C1515981', 'C1696465', 'C0392366', 'C1883708', 'C0213771', 'C1524024', 'C1707887', 'C4684719', 'C0936012']","['Effectiveness', 'tiotropium', 'placebo', 'Placebo Control', 'Null Hypothesis', 'Primary', 'Analysis', 'Each (qualifier value)', 'And', 'False Positive', 'Efficacy Study', 'analysis aspect', 'Then', 'Placebos', 'Testing', 'Probability', 'Tests (qualifier value)']","['tmco', 'fndg', 'bodm', 'idcn', 'topp', 'inpr', 'orch', 'qnco', 'qlco', 'resa', 'ftcn', ' phsu']"
1311,PMC4066691,S89,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,"if the previous step was not successful, analysis of the current step was to be considered descriptive.","['C1272703', 'C1704379', 'C1518422', 'C1552607', 'C0205156', 'C1705970', 'C0521116', 'C1261552', 'C2825408', 'C1524024', 'C1705117', 'C0597535', 'C0936012']","['Treatment Step', 'Stair (equipment)', 'Increment', 'Previous', 'Successful', 'Analysis', 'Current (present time)', 'Success', 'analysis aspect', 'Electrical Current', 'Step (specific stage)', 'Act Relationship Subset - previous', 'Negation']","['tmco', 'npop', 'qnco', 'qlco', 'socb', 'resa', 'ftcn', 'mnob', 'cnce']"
1312,PMC4066691,S90,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analyses,"to detect a treatment difference of 80 ml for peak fev1(0-3h) with 90% power, and assuming a standard deviation of 228 ml, it was calculated that 88 completed patients were required.","['C0087111', 'C1705241', 'C0032863', 'C0332287', 'C1522326', 'C3887704', 'C1705169', 'C0039798', 'C3538994', 'C0030705', 'C3854080', 'C0521125', 'C1515981', 'C0871420', 'C1705242', 'C0444505', 'C1533734', 'C4321252']","['Different', 'Peak level', 'In addition to', 'Power (Psychology)', 'treatment - ActInformationManagementReason', 'Treating', 'Treatment Epoch', 'And', 'Power', 'WWOX wt Allele', 'therapeutic aspects', 'Patients', 'Delta (difference)', 'Biomaterial Treatment', 'Standard deviation', 'Preposition For', 'Administration procedure', 'Therapeutic procedure']","['resa', 'gngm', 'idcn', 'topp', 'hlca', 'qnco', 'qlco', 'hcpp', 'podg', 'ftcn', 'cnce']"
1313,PMC4066691,S91,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,testing was performed with α = 0.025 (one-sided).,"['C0392366', 'C0205447', 'C0039593']","['One', 'Tests (qualifier value)', 'Testing']","['qnco', 'ftcn', 'inpr']"
1314,PMC4066691,S92,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,the pre-specified hypotheses were tested using a mixed effects model with repeated measures.,"['C3274659', 'C0205430', 'C3160715', 'C2257086', 'C3853906', 'C1280500', 'C3161035', 'C0740175', 'C3714583', 'C0332152', 'C0205369', 'C0871881']","['Model Number', 'Digital Model Attachment', 'Mixed Cell Morphology', 'Model', 'Before values', 'Effect', 'Mixed (qualifier value)', 'Before', 'photoreactivating enzyme activity', 'Specific qualifier value', 'repeated measures', 'Model - style/design']","['tmco', 'fndg', 'inpr', 'genf', 'qlco', 'resa', 'ftcn', 'cnce']"
1315,PMC4066691,S93,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,the statistical model included ‘treatment’ and ‘period’ as fixed effects and ‘patient’ as a random effect.,"['C2348382', 'C0439605', 'C0443218', 'C1518681', 'C1280500', 'C0034656', 'C1515981', 'C3714578', 'C2827483', 'C0026348']","['Effect, Appearance', 'Fixed Specimen', 'Fix', 'Models, Statistical', 'Fixed behavior', 'And', 'Outcome of Therapy', 'Effect', 'Random', 'Randomization']","[' qnco', 'fndg', 'idcn', 'inpr', 'qlco', 'phpr', 'resa', 'bdsu']"
1316,PMC4066691,S94,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,"study baseline, defined as pre-treatment values measured at visit 2 in the evening, was included as covariate.","['C0087111', 'C1522326', 'C1442488', 'C3887704', 'C1705169', 'C0039798', 'C0168634', 'C3538994', 'C2826704', 'C0587117', 'C0545082', 'C1512346', 'C0042295', 'C1533734']","['BaseLine dental cement', 'Patient Visit', 'treatment - ActInformationManagementReason', 'Treating', 'Visit Name', 'Treatment Epoch', 'Visit', 'therapeutic aspects', 'Biomaterial Treatment', 'Baseline', 'Values', 'Evening', 'Administration procedure', 'Therapeutic procedure']","['tmco', 'resa', 'topp', 'hlca', 'inpr', 'qnco', 'qlco', 'bhvr', 'ftcn', 'bodm', 'cnce']"
1317,PMC4085478,S100,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistics,"the sample size was increased from 30 to 36 patients per group to accommodate for nonresponse, loss to follow-up, and other deviations from planned study conditions.","['C1257890', 'C2603343', 'C0441833', 'C1519504', 'C1517945', 'C1301732', 'C1705429', 'C0030705', 'C0687744', 'C0242618', 'C1705428']","['Groups', 'Population Group', 'Group Object', 'Sample Size', 'Social group', 'Patients', 'Stage Grouping', 'Study', 'Planned', 'Loss', 'User Group']","['idcn', 'qnco', 'resa', 'podg', 'ftcn', 'popg', 'cnce']"
1318,PMC4085478,S101,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,"we also included dose groups of 0.8 and 1.6 g lt-02 to allow for dose-finding and dose-response analyses, as the drug lt-02 was new and had not been tested in studies.","['C0037088', 'C0441833', 'C1518422', 'C1706817', 'C2911692', 'C0947630', 'C1552839', 'C0243095', 'C0871261', 'C0178602', 'C0687744', 'C1515981', 'C1704632', 'C1254351', 'C0205314', 'C0013227', 'C2825141']","['Finding', 'Groups', 'Pharmacologic Substance', 'Social group', 'Experimental Finding', 'Signs and Symptoms', 'And', 'New', 'Dosage', 'Response (communication)', 'Scientific Study', 'Response (statement)', 'Response process', 'Pharmaceutical Preparations', 'Disease Response', 'Negation', 'Table Rules - groups']","['fndg', 'idcn', 'inpr', 'sosy', 'qnco', 'qlco', 'orga', 'lbpr', 'ftcn', 'popg', 'menp', 'phsu']"
1319,PMC4085478,S102,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,primary analysis was based on the full analysis set (intention to treat) that included all randomized patients.,"['C3815594', 'C0443225', 'C0205225', 'C1283828', 'C0162425', 'C0030705', 'C0034656', 'C0444868', 'C1524024', 'C0936012']","['All', 'Primary', 'Intention - mental process', 'Analysis', 'Subject is Randomized', 'analysis aspect', 'Patients', 'Randomization', 'full', 'intent']","['fndg', 'qlco', 'qnco', 'resa', 'podg', 'ftcn', 'menp']"
1320,PMC4085478,S103,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,"if a patient had a missing value at the final visit (v5), the latest available value was carried forward.","['C3272743', 'C0205088', 'C0439780', 'C3853528', 'C0470187', 'C0030705', 'C1522609', 'C0062074', 'C2826704', 'C0545082', 'C1705492', 'C1546485', 'C1512346', 'C3539897', 'C1551393', 'C1415458']","['availability of', 'Container status - Missing', 'Patient Visit', 'Numerical value', 'End-stage', 'Visit Name', 'Have', 'Missing', 'Missing Study Animal', 'Visit', 'Patients', 'HAC protocol', 'Forward', 'Final', 'HADH gene', 'Diagnosis Type - Final']","['tmco', 'fndg', 'gngm', 'idcn', 'topp', 'hlca', 'inpr', 'qnco', 'qlco', 'bhvr', 'spco', 'podg', 'ftcn']"
1321,PMC4085478,S104,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,"analysis of covariance was used to model the primary end point, including the following baseline covariates: (i) mean sccai in the past 7 days of the screening period; and (ii) disease extent.","['C0332282', 'C0205225', 'C1710032', 'C0012634', 'C0168634', 'C0439792', 'C2987125', 'C0936012', 'C2348164', 'C1698960', 'C0439531', 'C2348143', 'C2349179', 'C0220908', 'C0332257', 'C0444504', 'C1710031', 'C1444637', 'C1442488', 'C0220909', 'C2347634', 'C1710477', 'C1524024', 'C1948053']","['Aspects of disease screening', 'Screening procedure', 'Including (qualifier)', 'Period (temporal qualifier)', 'Sample Mean', 'Extent', 'Trial Screening', 'Following', 'Past Week', 'Population Mean', 'analysis aspect', 'Screening', 'Baseline', 'Screening Study', 'Disease Screening', 'Statistical mean', 'research subject screening', 'BaseLine dental cement', 'Primary', 'Analysis', 'Disease', 'per period (qualifier value)', 'In the past', 'End Point']","['tmco', 'bodm', 'hlca', 'qnco', 'qlco', 'dsyn', 'spco', 'resa', 'ftcn', 'diap']"
1322,PMC4085478,S105,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,the model including these two covariates and the treatment group effect was considered to be the core model.,"['C3274659', 'C1565156', 'C3538994', 'C1533734', 'C1257890', 'C0087111', 'C2348382', 'C0441833', 'C1518681', 'C3887704', 'C1705169', 'C1280500', 'C0039798', 'C0205448', 'C3714583', 'C1705428', 'C1519504', 'C1421478', 'C0444669', 'C1705429', 'C0043194', 'C1167518', 'C3274653', 'C0039828', 'C0750591', 'C1522326', 'C3853906', 'C3161035', 'C0687744', 'C1515981', 'C1706352', 'C1882467']","['Group Object', 'Effect, Appearance', 'viral nucleocapsid location', 'And', 'Core Specimen', 'Theses', 'Model Number', 'Digital Model Attachment', 'Treatment Epoch', 'Core', 'Biomaterial Treatment', 'Administration procedure', 'User Group', 'Model - style/design', 'Wiskott-Aldrich Syndrome', 'Groups', 'Population Group', 'Two', 'Model', 'Social group', 'WAS gene', 'Outcome of Therapy', 'consider', 'Core Device', 'Effect', 'Processor Core', 'treatment - ActInformationManagementReason', 'Treating', 'WAS protein, human', 'therapeutic aspects', 'Stage Grouping', 'Therapeutic procedure']","['fndg', 'medd', 'topp', 'idcn', 'gngm', 'hlca', 'inpr', 'bdsu', 'celc', 'qlco', 'qnco', 'bacs', 'dsyn', 'spco', 'resa', 'ftcn', 'mnob', 'popg', ' aapp', 'cnce']"
1323,PMC4085478,S106,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,"it was used to compare the effects of placebo and the individual dose groups in fixed sequence, starting with the highest dose group of 3.2 g lt-02 daily, followed by the lower dose groups in descending order.","['C0237401', 'C0178602', 'C1705176', 'C1257890', 'C0441833', 'C0332173', 'C1280500', 'C0004793', 'C1706408', 'C1547177', 'C1522410', 'C1705428', 'C0027361', 'C1882348', 'C0162326', 'C0332287', 'C0443218', 'C3853789', 'C1519504', 'C1552839', 'C1705429', 'C1519249', 'C1705177', 'C1705175', 'C3889825', 'C1705178', 'C0032042', 'C0205386', 'C0687744', 'C1515981', 'C3714578', 'C0162327', 'C1696465', 'C2827483']","['Group Object', 'placebo', 'In addition to', 'And', 'RNA Sequence', 'Base Sequence', 'Table Rules - groups', 'Fixed Specimen', 'Sequence - TransmissionRelationshipTypeCode', 'Fix', 'Persons', 'Placebos', 'Highest', 'User Group', 'Groups', 'Individual', 'Population Group', 'Order (action)', 'Placebo Control', 'Social group', 'Sequence', 'Dosage', 'Effect', 'Daily', 'DNA Sequence', 'Order (document)', 'Order (taxonomic)', 'Descending', 'Sequencing - Descending', 'Fixed behavior', 'Stage Grouping', 'Sequence of Planned Assessment Schedule', 'Permutation', 'Order (arrangement)']","['tmco', 'nusq', 'bodm', 'idcn', 'clas', 'topp', 'inpr', 'qnco', 'qlco', 'phpr', 'resa', 'ftcn', 'acty', 'popg', 'cnce', 'bdsu']"
1324,PMC4085478,S107,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,"the confirmatory testing procedure stopped at the first nonsignificant result; superiority was given if the one-sided p value was <0.025, equivalent to a two-sided α level of 0.05.","['C2825142', 'C1279901', 'C1565156', 'C0205092', 'C2946261', 'C1547707', 'C0441889', 'C0439185', 'C2700391', 'C0205435', 'C1546471', 'C3274430', 'C0392366', 'C0205448', 'C3539779', 'C0680218', 'C1421478', 'C0043194', 'C1522609', 'C0750484', 'C0039593', 'C0205163', 'C0184661', 'C1274040']","['Numerical value', 'Confirmation', 'superiority', 'Unilateral', 'What subject filter - Result', 'Floor - story of building', 'Firstly', 'Procedure (set of actions)', 'Equal', 'First (number)', 'Tests (qualifier value)', 'Physical Medical Procedure', 'Result', 'Wiskott-Aldrich Syndrome', 'Two', 'WAS gene', 'Testing', 'Equivalent Weight', 'Experimental Result', 'Level', 'Levels (qualifier value)', 'WAS protein, human', 'CDISC SDTM Procedure Terminology', 'Interventional procedure']","['fndg', 'gngm', 'topp', 'hlca', 'idcn', 'inpr', 'geoa', 'inch', 'qlco', 'qnco', 'bacs', 'dsyn', 'socb', 'spco', 'ftcn', ' phsu', ' aapp']"
1325,PMC4085478,S108,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,survival methods were used to analyze time-to-event variables; the log-rank test compared time with event curves between treatment groups.,"['C0038952', 'C0667477', 'C1515976', 'C0022885', 'C4318744', 'C0439828', 'C3538994', 'C2986775', 'C1707455', 'C1533734', 'C0087111', 'C0699794', 'C0441833', 'C3887704', 'C0025663', 'C1705169', 'C0039798', 'C0025664', 'C0392366', 'C1708728', 'C1552839', 'C0456984', 'C0220921', 'C0449851', 'C0441471', 'C1522326', 'C0039593', 'C0040223', 'C0687744', 'C3831328', 'C4019010']","['TNFRSF11A protein, human', 'Logarithm', 'National reporting jurisdiction:Loc:Pt:^Event:Nom', 'Rank', 'Test - temporal region', 'Event', 'Table Rules - groups', 'Variable (uniformity)', 'Comparison', 'Time', 'Techniques', 'Treatment Epoch', 'Tests (qualifier value)', 'Methods aspects', 'Continuance of life', 'Biomaterial Treatment', 'Laboratory Procedures', 'Administration procedure', 'Groups', 'Event Log', 'Social group', 'Test Result', 'Testing', 'Methods', 'treatment - ActInformationManagementReason', 'survival aspects', 'Anatomic Structure, System, or Substance', 'Treating', 'therapeutic aspects', 'Blood Products Laboratory Testing', 'Therapeutic procedure']","['tmco', 'blor', 'lbtr', 'topp', 'clas', 'idcn', 'hlca', 'inpr', ' aapp', 'qnco', 'bacs', 'qlco', 'lbpr', 'resa', 'ftcn', 'acty', 'popg', 'evnt', 'cnce', 'clna']"
1326,PMC4085478,S109,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,likelihood ratio χ2 tests based on nominal logistic regression were planned to compare the results of qualitative variables between treatment groups.,"['C0087111', 'C0441833', 'C1522326', 'C0022885', 'C1552839', 'C3887704', 'C1705169', 'C0205556', 'C0439828', 'C3538994', 'C0206031', 'C0687744', 'C0039798', 'C0392366', 'C0150102', 'C1533734']","['Groups', 'Logistic Regression', 'qualitative', 'treatment - ActInformationManagementReason', 'Social group', 'Treating', 'Variable (uniformity)', 'Treatment Epoch', 'therapeutic aspects', 'Tests (qualifier value)', 'Therapeutic procedure', 'Biomaterial Treatment', 'Laboratory Procedures', 'likelihood ratio', 'Administration procedure', 'Table Rules - groups']","['topp', 'idcn', 'hlca', 'inpr', 'qnco', 'qlco', 'lbpr', 'resa', 'ftcn', 'popg', 'cnce']"
1327,PMC4085478,S110,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,"the analysis plan did not specify how the groups should be compared: in order to increase the statistical power, we focused on the comparisons between placebo and the three active groups pooled.","['C0270724', 'C0205234', 'C1285542', 'C1707455', 'C0814897', 'C0936012', 'C1705176', 'C0599880', 'C0441833', 'C1301732', 'C1706408', 'C0442805', 'C1882348', 'C1552839', 'C1705177', 'C1705175', 'C3889825', 'C1705178', 'C1518422', 'C0032042', 'C0687744', 'C1515981', 'C1696465', 'C1524024']","['placebo', 'Treatment Plan', 'And', 'statistical power', 'Table Rules - groups', 'Comparison', 'Placebos', 'analysis aspect', 'Planned', 'Increase', 'Groups', 'Order (action)', 'Placebo Control', 'Social group', 'Infantile Neuroaxonal Dystrophy', 'Order (document)', 'Order (taxonomic)', 'Negation', 'Focal', 'Analysis', 'Sequence of Planned Assessment Schedule', 'Has focus', 'Permutation', 'Order (arrangement)']","['bodm', 'idcn', 'clas', 'topp', 'inpr', 'qlco', 'dsyn', 'spco', 'resa', 'ftcn', 'popg', 'acty']"
1328,PMC4085478,S111,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,the statistical power to detect treatment effects in categorical parameters in this small sample size is far below the usual 80–90%.,"['C0087111', 'C1522326', 'C1080058', 'C3887704', 'C1705169', 'C1280500', 'C0039798', 'C3538994', 'C0205108', 'C0242618', 'C1533734', 'C0814897', 'C0700321', 'C3538928']","['Sample Size', 'Distal (qualifier value)', 'treatment - ActInformationManagementReason', 'Treating', 'Small', 'Treatment Epoch', 'therapeutic aspects', 'Usual', 'Effect', 'Biomaterial Treatment', 'This (eukaryote)', 'Administration procedure', 'statistical power', 'Therapeutic procedure']","['resa', 'topp', 'hlca', 'qnco', 'qlco', 'spco', 'euka', 'ftcn', 'cnce']"
1329,PMC4085478,S112,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,"this is why we defined categorical variables such as rate of remission or mucosal healing a priori as secondary and exploratory, in order to discover trends in treatment effects to gather information for the sample-size calculation for future phase iii studies.","['C1521798', 'C0456389', 'C1533716', 'C1521828', 'C3538994', 'C0439828', 'C0871208', 'C1533734', 'C1705176', 'C0087111', 'C0687702', 'C3887704', 'C1705169', 'C1280500', 'C0039798', 'C0205436', 'C0026724', 'C0016884', 'C2347026', 'C1882348', 'C1441506', 'C0175668', 'C1705177', 'C0370003', 'C0027627', 'C1705175', 'C3889825', 'C1705178', 'C0441771', 'C1522326', 'C1080058', 'C0040833', 'C1515981', 'C0544452', 'C0947630']","['Mucous Membrane', 'Rate', 'And', 'Disease remission', 'size', 'Stage level 3', 'Rating (action)', 'Future', 'Variable (uniformity)', 'second (number)', 'Treatment Epoch', 'Calculation', 'trends qualifier', 'Biomaterial Treatment', 'trend', 'Administration procedure', 'Neoplasm Metastasis', 'Order (action)', 'Effect', 'Scientific Study', 'Therapeutic procedure', 'Order (document)', 'Order (taxonomic)', 'Information', 'treatment - ActInformationManagementReason', 'Treating', 'Cancer Remission', 'Secondary to', 'therapeutic aspects', 'Specimen', 'Biospecimen', 'This (eukaryote)', 'Sequence of Planned Assessment Schedule', 'Permutation', 'Order (arrangement)']","['tmco', 'fndg', 'resa', 'topp', 'idcn', 'clas', 'hlca', 'inpr', 'tisu', 'qlco', 'qnco', 'sbst', 'lbpr', 'euka', 'ftcn', 'spco', 'neop', 'acty', 'cnce']"
1330,PMC4085478,S113,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,linearity was checked for important continuous variables compared with log transformation.,"['C1708728', 'C0549178', 'C0439828', 'C2986775', 'C1705163', 'C1510411', 'C4084912', 'C0040682', 'C3898777']","['Logarithm', 'Continuous', 'Importance Rating Score 0', 'Event Log', 'Important', 'Data Transformation', 'Variable (uniformity)', 'cell transformation', 'metaplastic cell transformation']","['celf', 'idcn', 'inpr', 'qlco', 'qnco', 'resa', 'patf']"
1331,PMC4085478,S114,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,normality for continuous parameters was assumed if the absolute value of skewness was<1.,"['C0205344', 'C0549178', 'C1882114', 'C0949333']","['absolute', 'Continuous', 'Normality', 'Normality Unit']","['qlco', 'qnco', 'idcn']"
1332,PMC4085478,S115,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,"in addition, the shapiro–wilk goodness-of-fit tests were applied.","['C4553125', 'C0036572', 'C0332287', 'C0022885', 'C1883712', 'C0392366', 'C2349186']","['Fit (action)', 'In addition to', 'Prosthesis fit', 'Seizures', 'Tests (qualifier value)', 'Add - instruction imperative', 'Laboratory Procedures']","['fndg', 'inpr', 'sosy', 'lbpr', 'ftcn', 'acty']"
1333,PMC4085478,S116,['7b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0]",Statistics,"a planned interim analysis was conducted by an independent data monitoring committee after half of the patients had terminated the treatment period to adjust the sample size or to stop the trial for futility, if indicated.","['C3538994', 'C3539897', 'C1533734', 'C0087111', 'C0086322', 'C2825407', 'C3887704', 'C1705169', 'C1301732', 'C2699414', 'C0030705', 'C0085862', 'C0039798', 'C0242618', 'C1415458', 'C1553404', 'C0439531', 'C3245479', 'C0062074', 'C4684691', 'C2348570', 'C1522326', 'C1290940', 'C1947925', 'C0008976', 'C3714741', 'C1299583', 'C1511726', 'C1948053']","['Half', 'Clinical Trials', 'Data (eukaryote)', 'Independent for Transfer', 'HAC protocol', 'Independence', 'terminated - RoleStatus', 'HADH gene', 'Interim Analysis', 'Period (temporal qualifier)', 'Futility', 'Treatment Epoch', 'Committee', 'Biomaterial Treatment', 'Planned', 'Administration procedure', 'Data call receiving device', 'Independently able', 'Patients', 'Therapeutic procedure', 'Sample Size', 'Study Terminated', 'treatment - ActInformationManagementReason', 'Treating', 'Have', 'therapeutic aspects', 'per period (qualifier value)', 'Stop (Instruction Imperative)', 'Data']","['tmco', 'fndg', 'medd', 'topp', 'idcn', 'gngm', 'hlca', 'qnco', 'qlco', 'grup', 'euka', 'resa', 'podg', 'ftcn', 'acty', 'cnce']"
1334,PMC4085478,S117,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistics,"software for sample-size estimation included nquery advisor v5.0 (statistical solutions ltd, cork, ireland) and studysize v2.0 (creostat hb, v.frolunda, sweden).","['C0456389', 'C0022067', 'C2347026', 'C0304066', 'C0370003', 'C0038995', 'C0038215', 'C0681916', 'C1136140', 'C0750572', 'C1515981', 'C0037585', 'C0037633', 'C0680844']","['Long-Term Synaptic Depression', 'Estimated', 'Ireland', 'estimation <subjective>', 'Computer software', 'Solutions', 'And', 'Statistical Estimation', 'Specimen', 'Sweden', 'Biospecimen', 'Cork', 'size', 'Science of Statistics']","['ortf', ' mnob', 'idcn', 'inpr', 'geoa', 'orch', 'qnco', 'sbst', 'ocdi', 'spco', 'menp', 'cnce']"
1335,PMC4085478,S118,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistics,"statistical analyses were performed using sas jmp v9 and sas jmp v8 and higher (jmp, sas institute inc., cary, nc).","['C3811068', 'C0038215', 'C1823519', 'C1515981', 'C0205250', 'C0605290', 'C1426104']","['TSPAN31 gene', 'And', 'PSMB8 wt Allele', 'High', 'SAS', 'NANS gene', 'Science of Statistics']","['gngm', 'idcn', 'ocdi', 'orch', 'qlco']"
1336,PMC4085478,S45,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",METHODS,figure 1 study flowchart.,,,
1337,PMC4085478,S46,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",METHODS,"inclusion criteria were as follows: proven mesalazine-refractory ulcerative colitis (european consensus definition (16) with an inadequate response to mesalazine for 6 weeks at a dose of ≥3 g/day for over 4 weeks or documented intolerance to mesalazine (a documented intolerance required previous doctors' letters or medical notes that stated that an adverse event possibly related to mesalazine led to a discontinuation of its therapy); active disease with blood in stool for at least 6 weeks; sccai ≥5 and sccai subscore for “blood in stool” ≥2 at baseline visit (v2); comedication was allowed if on a stable dose for 4 weeks (e.g., 5-asa, systemic acting steroids (if taken for ≥8 weeks before the start of the study), azathioprine (2–2.5 mg/kg), 6-mercaptopurine (1–1.5 mg/kg), both if taken for ≥3 months); and a negative pregnancy test at v1 and v2 plus the use of adequate contraception, if applicable.","['C0205411', 'C0168634', 'C0205136', 'C0332152', 'C0205177', 'C3888249', 'C1883727', 'C0457454', 'C1708698', 'C0042153', 'C0332287', 'C0000618', 'C1317574', 'C0347984', 'C3470573', 'C3888054', 'C0127615', 'C0205412', 'C1442488', 'C0205410', 'C4552847', 'C0205360', 'C1550452', 'C0004482', 'C0038317', 'C0005767', 'C1512693', 'C0427780', 'C0015733', 'C0521125', 'C1301725', 'C1535514', 'C1512346', 'C0039798', 'C0205476', 'C1444662', 'C0439849', 'C2603343', 'C2911692', 'C0229664', 'C0205373', 'C0439230', 'C0871261', 'C0439856', 'C0031831', 'C0332173', 'C1442465', 'C0231199', 'C0199168', 'C0439659', 'C0700589', 'C1706839', 'C0005768', 'C2826704', 'C0239307', 'C0009324', 'C0457083', 'C1552607', 'C2355652', 'C1704632', 'C0877248', 'C3853793', 'C0205156', 'C0012634', 'C0178602', 'C1363945', 'C1706086', 'C4321252', 'C0087111', 'C1514873', 'C0545082', 'C0439228', 'C1442792', 'C1609436', 'C1704788', 'C0376298', 'C1272460', 'C1547311', 'C1744706', 'C1706817', 'C0439231', 'C0282413', 'C1515981', 'C0205269', 'C1301808']","['Active License', 'Patient Visit', 'Systemic', 'Contraceptive methods', 'Ulcerative Colitis', 'Response (communication)', 'Unsatisfactory', 'Response process', 'Visit', 'mesalamine', 'Physicians', 'Therapy Object (animal model)', 'Taken', 'Response (statement)', 'Not Applicable', 'Preposition For', 'Act Relationship Subset - previous', 'Steroids', 'BaseLine dental cement', 'Intolerance - biological effect of chemicals', 'Over (spatial)', 'ethnic european', 'Previous', 'In addition to', 'European race', 'And', 'definition - ActMoodCompletionTrack', 'Study', 'utilization qualifier', 'In Blood', 'month', 'Patient Condition Code - Stable', 'Unresponsive to Treatment', 'peripheral blood', 'Feces', 'Baseline', 'intolerance function', 'Visit Name', 'Beginning', 'During', 'Daily', 'day', 'therapeutic aspects', 'DEFINITION - NCI Thesaurus Property', 'week', 'Discontinued', 'Both', 'Correspondence as Topic', 'Adverse event', 'Therapeutic procedure', 'Medical', 'mercaptopurine', 'Stable status', 'Medical service', 'State', 'Disease Response', 'Geographic state', 'Azathioprine', 'Documented', 'Inclusion', 'WWOX wt Allele', 'Requirement', 'Document completion status - Documented', '4 Weeks', 'Disease', 'Sufficient', 'SMIM10L2A gene', 'Inadequate (qualifier)', 'Pregnancy test negative', 'active (HL7 RoleLink)', 'Definition', 'Blood', 'Clinical Trial Discontinuation', 'Consensus', 'Before', 'Light Emitting Diode Device', 'Adequate', 'Discontinuation (procedure)', 'Active', 'intolerance to substance', 'Relationships', 'Applicable', 'Dosage', 'Note (document)', 'Usage']","['topp', 'qnco', 'nnon', 'bhvr', 'bodm', 'menp', 'patf', 'fndg', ' orch', 'idcn', 'hlca', 'inpr', 'qlco', 'socb', 'resa', 'ftcn', 'mnob', 'popg', 'bdsu', 'tmco', 'prog', 'lbtr', 'orch', 'hops', 'spco', 'cnce', 'gngm', 'geoa', 'orga', 'dsyn', 'orgf', ' phsu']"
1338,PMC4085478,S47,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",METHODS,"exclusion criteria were as follows: toxic megacolon or fulminant courses; therapy with cyclosporine, tacrolimus, methotrexate, or tnf-α-antagonists within 3 months before study entry; current treatment with opiates or loperamide; current antibiotic treatment; rectal applications of aminosalicylates, steroids, or budesonide; oral application of topically acting steroids; ulcerative proctitis with a disease extent <10 cm; inflammatory or bleeding disorders of the gastrointestinal tract other than uc, or diseases that may cause diarrhea or gastrointestinal bleeding; condition after surgery of the colon; any other uncontrolled systemic diseases (e.g., cardiac, renal, pulmonary, hepatic) or severe chronic diseases (e.g., malignancies, hiv infection); and pregnant or nursing women.","['C3864998', 'C0038317', 'C0017181', 'C0010594', 'C4084802', 'C0185125', 'C0332283', 'C0442893', 'C0368663', 'C0012634', 'C1705253', 'C0205052', 'C4085317', 'C0008679', 'C0038894', 'C0439792', 'C1363945', 'C0680251', 'C0006826', 'C1458140', 'C0028677', 'C1524003', 'C4084784', 'C0205082', 'C0087111', 'C0543467', 'C0043210', 'C1963091', 'C0348080', 'C2347934', 'C1448177', 'C0025162', 'C0039798', 'C0022646', 'C0006147', 'C0521116', 'C0015127', 'C0199779', 'C3641756', 'C0005779', 'C3812381', 'C1947919', 'C0019693', 'C2937222', 'C0442027', 'C3888384', 'C0376196', 'C0054201', 'C1552551', 'C0038895', 'C4050466', 'C0333348', 'C0750729', 'C1442461', 'C1705654', 'C3272371', 'C0205054', 'C2603343', 'C0017189', 'C0025677', 'C0205318', 'C0028678', 'C0010592', 'C0549206', 'C2707265', 'C1705970', 'C0024109', 'C0243076', 'C0011991', 'C0221793', 'C4048755', 'C2827774', 'C0600457', 'C1274039', 'C4050465', 'C3539080', 'C2709248', 'C0023992', 'C0009368']","['Etiology aspects', 'How Often Diarrhea', 'Followed by', 'Pulmonary (qualifier value)', 'Gastrointestinal Hemorrhage', 'Megacolon, Toxic', 'Borg Category-Ratio 10 Perceived Exertion Score 5', 'Diarrhea, CTCAE', 'Patient currently pregnant', 'Pulmonary:-:Point in time:^Patient:-', 'Bleeding tendency', 'Cyclosporins', 'Electrical Current', 'Methotrexate', 'Month of May', 'Science of Etiology', 'Condition', 'Malignant Neoplasms', 'Study', 'Systemic disease', 'TNF protein, human', 'Application procedure', 'Application Dosing Unit', 'Lung', 'Operative Surgical Procedures', '3 Months', 'Usual Severity Diarrhea', 'Colon structure (body structure)', 'Opiate Alkaloids', 'Extent', 'How Much Distress Diarrhea', 'Chronic ulcerative proctitis', 'antagonists', 'Any Data Type', 'Woman', 'Application (Document)', 'Diarrhea', 'Apply', 'Therapy Object (animal model)', 'Hepatic', 'Condition:Find:Pt:^Patient:Nom', 'Have Diarrhea', 'HIV Infections', 'General surgery specialty', 'Discipline of Nursing', 'Kidney', 'Severe Extremity Pain', 'Exclusion Criteria', 'aminosalicylate', 'Current (present time)', 'Surgery specialty', 'Opiates', 'Loperamide', 'Chronic disease', 'Therapeutic procedure', 'Administration of antibiotic', 'Any', 'Current Therapy', 'Blood Coagulation Disorders', 'rectal', 'inflammatory', 'Colon <insect>', 'Gastrointestinal tract structure', 'Steroids', 'Course', 'nursing therapy', 'Entry (data)', 'Severe (severity modifier)', 'Logical Condition', 'uncontrolled', 'Regulatory Application', 'therapeutic aspects', 'Disease', 'Gravidity', 'Budesonide', 'Oral', 'Surgical aspects', 'Cyclosporine', 'Breast Feeding']","['topp', 'qnco', ' aapp', 'patf', 'clna', 'blor', 'fndg', 'chvf', 'npop', ' orch', 'hlca', 'inpr', 'sosy', 'qlco', 'bacs', 'resa', 'aapp', 'ftcn', 'popg', 'bpoc', 'tmco', 'bdsy', 'orch', 'hops', 'euka', 'spco', 'neop', 'cnce', 'imft', 'bmod', 'dsyn', 'orgf', ' phsu']"
1339,PMC4085478,S48,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",METHODS,"5-asa, 5-aminosalicylic acid; ae, adverse event; discont.","['C0004057', 'C0877248', 'C3853627', 'C0030125']","['aminosalicylic acid', 'Arylsulfatase A, human', 'Adverse event', 'Aspirin']","['enzy', 'orch', ' aapp', ' phsu', 'patf']"
1340,PMC4085478,S49,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",METHODS,"intervent., discontinued intervention; inr, international normalized ratio; sccai, simple clinical colitis activity index; tnf-α, tumor necrosis factor-α uc, ulcerative colitis.","['C0886296', 'C2986546', 'C0009319', 'C0600653', 'C1704538', 'C1444662', 'C0205352', 'C4049938', 'C0009324', 'C1963084', 'C1552854', 'C0441655', 'C0205210', 'C4049939', 'C0184661', 'C0205177', 'C0918012', 'C0525032']","['Clinical', 'Physical Activity Measurement', 'International Normalized Ratio', 'Active', 'Activities', 'Simple', 'Colitis, CTCAE', 'Index', 'Html Link Type - index', 'Ulcerative Colitis', 'Indexes', 'Nursing interventions', 'Discontinued', 'Interventional procedure', 'FDA Establishment Activity Terminology', 'Colitis', 'Target Lesion Identification', 'Integrated Neuromusculoskeletal Release']","['fndg', 'idcn', 'topp', 'hlca', 'inpr', 'qlco', 'lbpr', 'dsyn', 'diap', 'acty']"
1341,PMC4085478,S50,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",METHODS,we calculated 160 patients with mesalazine-refractory uc for the screening phase in order to randomize 144 patients.,"['C1705176', 'C0127615', 'C1705175', 'C1705178', 'C1882348', 'C3889825', 'C0205269', 'C0220909', 'C0205390', 'C1710032', 'C2348164', 'C0220908', 'C1698960', 'C0030705', 'C1710475', 'C1705177', 'C1710477', 'C1710031']","['Phase', 'Screening Study', 'research subject screening', 'Aspects of disease screening', 'Screening procedure', 'Trial Screening', 'Order (action)', 'Unresponsive to Treatment', 'Disease Screening', 'mesalamine', 'Patients', 'Screening', 'Trial Phase', 'Sequence of Planned Assessment Schedule', 'Order (document)', 'Permutation', 'Order (taxonomic)', 'Order (arrangement)']","['tmco', 'hlca', 'clas', 'inpr', 'orch', 'qlco', 'resa', 'podg', 'ftcn', 'diap', ' phsu', 'acty']"
1342,PMC4085478,S51,['7b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0]",METHODS,a planned interim analysis included the possibility of increasing the sample size if necessary.,"['C0442808', 'C0242618', 'C4684691', 'C1301732']","['Planned', 'increasing', 'Sample Size', 'Interim Analysis']","['qnco', 'ftcn']"
1343,PMC4085478,S52,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",METHODS,"the main inclusion criteria were as follows: an active disease with the simple clinical colitis activity index (sccai) of ≥5 and a subscore for “blood in stool” of ≥2 at baseline; a history of bloody diarrhea for at least 6 weeks before inclusion despite mesalazine treatment at a dose of ≥3 g/day; or a documented intolerance to mesalazine (for details of criteria, see legend of figure 1).","['C2986546', 'C3853793', 'C1512693', 'C0332283', 'C0205225', 'C0019664', 'C0012634', 'C0168634', 'C1301725', 'C0178602', 'C2729544', 'C4049938', 'C0441655', 'C0521125', 'C3538994', 'C0243161', 'C0332152', 'C1533734', 'C0205177', 'C3888249', 'C4321252', 'C0087111', 'C0009319', 'C0600653', 'C0332173', 'C3887704', 'C1705169', 'C0039798', 'C1522508', 'C1542147', 'C0231199', 'C1963084', 'C0439228', 'C0205352', 'C0262926', 'C1609436', 'C0019665', 'C0007637', 'C1744706', 'C2004062', 'C1705255', 'C0262512', 'C0127615', 'C0151594', 'C1442488', 'C1522326', 'C2355652', 'C1515981', 'C1552854', 'C0205210', 'C4049939', 'C0918012', 'C0439230']","['Active License', 'Physical Activity Measurement', 'Followed by', 'Details', 'Html Link Type - index', 'And', 'active (HL7 RoleLink)', 'History', 'Medical History', 'Main', 'Simple', 'Colitis, CTCAE', 'Index', 'Treatment Epoch', 'mesalamine', 'History of previous events', 'Before', 'Biomaterial Treatment', 'Baseline', 'FDA Establishment Activity Terminology', 'Inclusion Bodies', 'Administration procedure', 'Concept History', 'intolerance function', 'Active', 'Hemorrhagic diarrhea', 'Documented', 'intolerance to substance', 'History of present illness', 'Inclusion', 'WWOX wt Allele', 'Dosage', 'Document completion status - Documented', 'Legend', 'Daily', 'Preposition For', 'Clinical', 'BaseLine dental cement', 'day', 'Primary', 'Intolerance - biological effect of chemicals', 'Activities', 'Treating', 'treatment - ActInformationManagementReason', 'criteria', 'Indexes', 'Disease', 'therapeutic aspects', 'week', 'Colitis', 'Target Lesion Identification', 'Historical aspects qualifier', 'Therapeutic procedure']","['topp', 'celc', 'qnco', 'bodm', 'fndg', 'idcn', 'hlca', 'inpr', 'qlco', 'lbpr', 'resa', 'ftcn', 'tmco', 'ocdi', 'orch', 'acty', 'cnce', 'gngm', 'orga', 'dsyn', 'orgf', 'diap', ' phsu']"
1344,PMC4085478,S53,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",METHODS,patients were required to maintain a stable comedication throughout the study; steroid tapering was not allowed.,"['C2603343', 'C0038317', 'C1518422', 'C1547311', 'C0441640', 'C0030705', 'C0205360', 'C1548969']","['Steroids', 'Patient Condition Code - Stable', 'Tapering - action', 'Service Request Relationship - Tapering', 'Patients', 'Study', 'Stable status', 'Negation']","['idcn', 'hlca', 'inpr', 'orch', 'qlco', 'resa', 'podg', 'ftcn', ' phsu']"
1345,PMC4085478,S54,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",METHODS,uc was defined in accordance with the european consensus conference (21).,"['C0376298', 'C0239307', 'C0086047', 'C1535514']","['ethnic european', 'European race', 'Conferences', 'Consensus']","['popg', 'socb', 'hcpp']"
1346,PMC4085478,S55,['4b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",METHODS,"recruitment took place in 24 referral centers in germany, lithuania, and romania.","['C0034927', 'C0035826', 'C1533810', 'C0023879', 'C0442504', 'C1515981', 'C1882509', 'C2949735', 'C0017480', 'C0205099']","['Place', 'Placement action', 'Patient referral', 'Lithuania', 'And', 'Romania', 'Central', 'put - instruction imperative', 'Germany', 'Recruitment']","['hlca', 'idcn', 'geoa', 'spco', 'acty']"
1347,PMC4085478,S56,"['8a', '8b', '10']","[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0]",METHODS,the contract research organization (cro) produced computer-generated randomization lists for every study center with the allocation of 1:1:1:1 in blocks of 4.,"['C1706778', 'C2603343', 'C1948061', 'C0028778', 'C1707500', 'C0034656', 'C0009622', 'C3811660', 'C3810851', 'C1533157', 'C0332206', 'C0205099']","['Block Specimens', 'Block Unit of Distance', 'Contract Research Organization', 'Every (qualifier)', 'Obstruction', 'Center of town', 'Study', 'Randomization', 'Blocking', 'Computers', 'Central', 'Allocation']","['fndg', 'orgt', 'bdsu', 'qnco', 'qlco', 'spco', 'resa', 'ftcn', 'mnob', 'patf', 'acty']"
1348,PMC4085478,S57,"['9', '5']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 1]",METHODS,"the study interventions consisting of three different doses of lt-02 (0.8, 1.6, and 3.2 g) were tested against placebo and were provided in sequentially numbered containers.","['C0886296', 'C2603343', 'C0180098', 'C0032042', 'C0205449', 'C1273869', 'C3542921', 'C0449788', 'C2979881', 'C0178602', 'C1706408', 'C1515981', 'C1696465', 'C1705242']","['Different', 'placebo', 'Placebo Control', 'Interventions:Finding:Point in time:^Patient:Narrative', 'Count of entities', 'And', 'Placebos', 'Dosage', 'Nursing interventions', 'Three', 'CDISC Interventions Class', 'Study', 'Intervention regimes', 'Containers']","['idcn', 'clas', 'hlca', 'topp', 'qnco', 'qlco', 'resa', 'bodm', 'mnob', 'clna']"
1349,PMC4085478,S58,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",METHODS,"doses were selected based on the results of the previous studies (18,19,20).","['C0178602', 'C0205156', 'C1552607', 'C0947630']","['Dosage', 'Act Relationship Subset - previous', 'Scientific Study', 'Previous']","['qnco', 'lbpr', 'tmco']"
1350,PMC4085478,S59,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",METHODS,the study medication was provided in sachets with pellets taken orally four times daily.,"['C2603343', 'C0993610', 'C0332173', 'C0442027', 'C4284232', 'C0040223', 'C3244316', 'C1632851', 'C0205450', 'C0013227', 'C1319685']","['Sachet', 'Medications', 'Four', 'Time', 'Study', 'Daily', 'Oral', 'Times', 'Pharmaceutical Preparations', 'Oral Pellet', 'medication - HL7 publishing domain']","['tmco', 'inpr', 'qnco', 'spco', 'resa', 'bodm', 'mnob', 'phsu']"
1351,PMC4085478,S60,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",METHODS,"the study medication was produced, packed, and labeled according to good manufacturing practice and stored at 2–8 °c.","['C3245512', 'C2603343', 'C4284232', 'C1515981', 'C0237607', 'C0870840', 'C3244316', 'C0013227', 'C0205170']","['manufacture', 'Practice Experience', 'Medications', 'HL7PublishingSubSection <practice>', 'And', 'Good', 'Study', 'Pharmaceutical Preparations', 'medication - HL7 publishing domain']","['ocac', 'idcn', 'inpr', 'qlco', 'resa', 'menp', 'phsu']"
1352,PMC4085478,S61,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",METHODS,"patients were interviewed, examined, and screened for eligibility at the screening visit (v1, for inclusion and exclusion criteria see legend of figure 1).","['C0220909', 'C1710032', 'C0220908', 'C2348164', 'C1698960', 'C0030705', 'C0013893', 'C0680251', 'C2729544', 'C1512346', 'C0545082', 'C1710477', 'C2826704', 'C1548635', 'C1710031', 'C0680252']","['Eligibility Determination', 'Screening Study', 'research subject screening', 'Aspects of disease screening', 'Screening procedure', 'Trial Screening', 'Patient Visit', 'inclusion and exclusion', 'Exclusion Criteria', 'Visit Name', 'Disease Screening', 'Patients', 'Screening', 'Legend', 'Visit', 'Eligible']","['hlca', 'inpr', 'orch', 'qlco', 'bhvr', 'resa', 'podg', 'ftcn', 'diap', ' phsu']"
1353,PMC4085478,S62,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",METHODS,"patients to be included received detailed study information, gave written informed consent, and were instructed in completing the study diary (comprising sccai and other interview parameters).","['C2603343', 'C0935630', 'C1533716', 'C0376660', 'C0030705', 'C0021430', 'C1515981', 'C0021822']","['Interview', 'Diary', 'Information', 'Published Interview', 'And', 'Informed Consent', 'Patients', 'Study']","['rnlw', 'idcn', 'inpr', 'resa', 'podg', 'acty']"
1354,PMC4085478,S63,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",METHODS,stool samples were taken to exclude for infectious enterocolitis (including clostridium difficile and escherichia coli 0157:h7).,"['C0079134', 'C0015733', 'C1515981', 'C0332257', 'C0014834', 'C1142115']","['And', 'Feces', 'Including (qualifier)', 'Infectious Enterocolitis', 'Escherichia coli', 'Clostridium difficile (bacteria)']","['bact', 'idcn', 'dsyn', 'ftcn', 'bdsu']"
1355,PMC4085478,S64,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",METHODS,"if the patient was still eligible after 1 week of screening (v2=baseline), a safety lab was taken and a sigmoidoscopy/colonoscopy was performed.","['C1883727', 'C1442488', 'C1548837', 'C0009378', 'C0036043', 'C1442452', 'C1421478', 'C1565156', 'C0168634', 'C0037075', 'C0030705', 'C0043194', 'C1515981', 'C0022877', 'C1548917', 'C1548635', 'C1705187']","['Laboratory', 'BaseLine dental cement', 'Baseline', 'WAS protein, human', 'WAS gene', '1 Week', 'And', 'Patients', 'Taken', 'Sigmoidoscopy (procedure)', 'Safety', 'colonoscopy', 'Consent Type - Sigmoidoscopy', 'Safety Study', 'Consent Type - Colonoscopy', 'Eligible', 'Wiskott-Aldrich Syndrome']","['mnob', 'tmco', ' hcro', 'hlca', 'hcpp', 'idcn', 'gngm', 'qnco', 'qlco', 'bacs', 'dsyn', 'resa', 'podg', 'bodm', 'diap', ' aapp', 'cnce']"
1356,PMC4085478,S65,['7b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0]",METHODS,"at the interim visits 2 and 6 weeks after baseline (v3 and v4), possible disease exacerbation and changes in medication or adverse events (aes) were assessed.","['C0443172', 'C1442488', 'C0332149', 'C1705910', 'C2699274', 'C4284232', 'C0168634', 'C1512346', 'C0439230', 'C2827738', 'C1515981', 'C0235874', 'C0545082', 'C0392747', 'C1705413', 'C1412268', 'C3244316', 'C0877248', 'C0013227']","['BaseLine dental cement', 'Changing', 'Medications', 'Patient Visit', 'Scanning Auger Spectrometer (device)', 'AES gene', 'Visit', 'And', 'Interim', 'Adverse Event Domain', 'Possibly Related to Intervention', 'Changed status', 'week', 'Baseline', 'Disease Exacerbation', 'Pharmaceutical Preparations', 'Possible', 'Adverse event', 'medication - HL7 publishing domain']","['tmco', 'fndg', 'gngm', 'idcn', 'hlca', 'inpr', 'resd', 'qnco', 'qlco', 'bhvr', 'ftcn', 'bodm', 'patf', 'phsu']"
1357,PMC4085478,S66,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",METHODS,"the treatment period ended 12 weeks after baseline at v5 and involved an interview, a physical examination, a sigmoidoscopy, a safety lab, and the sccai assessment.","['C0168634', 'C3538994', 'C0439230', 'C1705187', 'C1533734', 'C0087111', 'C0935630', 'C3887704', 'C1705169', 'C0039798', 'C1548917', 'C1516048', 'C0439531', 'C0036043', 'C0037075', 'C0022877', 'C1744699', 'C1522326', 'C1442488', 'C1515981', 'C0021822', 'C1261322', 'C1948053', 'C0031809']","['Laboratory', 'Interview', 'Physical Examination', 'Published Interview', 'And', 'Evaluation procedure', 'Safety', 'Consent Type - Sigmoidoscopy', 'Period (temporal qualifier)', 'Treatment Epoch', 'Assessed', 'Safety Study', 'Baseline', 'Biomaterial Treatment', 'Administration procedure', 'Sigmoidoscopy (procedure)', 'Physical Exam Domain', 'BaseLine dental cement', 'treatment - ActInformationManagementReason', 'Treating', 'therapeutic aspects', 'week', 'per period (qualifier value)', 'Therapeutic procedure']","['mnob', 'tmco', 'resa', ' hcro', 'hlca', 'idcn', 'topp', 'inpr', 'qnco', 'ftcn', 'hcpp', 'bodm', 'diap', 'cnce', 'acty']"
1358,PMC4085478,S67,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",METHODS,the maximal duration of the study was 21 weeks per patient: a 1-week screening period plus 12 weeks of treatment period; patients reaching partial or complete remission (sccai <5 at end of treatment) underwent an additional 8-week follow-up without study medication (see appendix figure a1).,"['C0332283', 'C4553336', 'C1710032', 'C4284232', 'C0439230', 'C3538994', 'C1550516', 'C1524062', 'C4049713', 'C0205289', 'C1533734', 'C0728938', 'C0003617', 'C0087111', 'C4553337', 'C3887704', 'C1705169', 'C4281991', 'C0039798', 'C2348164', 'C0030705', 'C1698960', 'C3244316', 'C0677874', 'C0449238', 'C0439531', 'C0220908', 'C0444930', 'C0806909', 'C1710031', 'C0013227', 'C2603343', 'C1522326', 'C0220909', 'C2746065', 'C1710477', 'C2926735', 'C1948053']","['Followed by', 'Aspects of disease screening', 'Screening procedure', 'Partial', 'Study', 'Borg Category-Ratio 10 Perceived Exertion Score 10', 'Maximal (qualifier value)', 'Maximum', 'Period (temporal qualifier)', 'Trial Screening', 'Treatment Epoch', 'Screening', 'Follow', 'Biomaterial Treatment', 'Administration procedure', 'Duration', 'Screening Study', 'In complete remission', 'Lugano Lymphoma Response Classification Complete Remission by CT', 'Duration (temporal concept)', 'Disease Screening', 'End', 'Patients', 'Pharmaceutical Preparations', 'Appendix', 'Lugano Lymphoma Response Classification Complete Remission by PET', 'medication - HL7 publishing domain', 'research subject screening', 'Medications', 'treatment - ActInformationManagementReason', 'Treating', 'Additional', 'Stop (qualifier value)', 'therapeutic aspects', 'week', 'per period (qualifier value)', 'Target Awareness - partial', 'Therapeutic procedure']","['tmco', 'fndg', 'hlca', 'topp', 'idcn', 'inpr', 'orch', 'qlco', 'qnco', 'phsu', 'spco', 'resa', 'podg', 'ftcn', 'diap', ' phsu', 'bpoc', 'cnce']"
1359,PMC4085478,S68,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",METHODS,patients could discontinue the study at any time without reason.,"['C3272371', 'C0392360', 'C2603343', 'C0040223', 'C0030705', 'C1552551']","['Time', 'Any', 'Any Data Type', 'Patients', 'Indication of (contextual qualifier)', 'Study']","['tmco', 'idcn', 'inpr', 'qlco', 'resa', 'podg']"
1360,PMC4085478,S69,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",METHODS,the investigator could withdraw a patient in case of aes or disease exacerbation or if therapeutic intervention was required.,"['C0087111', 'C0868928', 'C1706256', 'C2699274', 'C1706255', 'C0030705', 'C1412268', 'C0808232', 'C0035173']","['Case (situation)', 'Scanning Auger Spectrometer (device)', 'AES gene', 'Packaging Case', 'Research Personnel', 'Patients', 'Clinical Study Case', 'Therapeutic Intervention', 'Therapeutic procedure']","['prog', 'gngm', 'medd', 'topp', 'resd', 'podg', 'ftcn', 'cnce']"
1361,PMC4085478,S70,['7b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0]",METHODS,"discontinuation criteria were the development of complications such as pseudomembranous colitis, an sccai increase of ≥7 over baseline, or fever >39 °c. discontinuation because of disease exacerbation was defined as an ae.","['C0009566', 'C1527148', 'C1257843', 'C1442488', 'C1444662', 'C0442805', 'C0457454', 'C4552847', 'C0168634', 'C0678723', 'C0243161', 'C0235874', 'C0243107', 'C4552740', 'C0424755', 'C0015967', 'C1171258']","['Discontinuation (procedure)', 'Development', 'Increase', 'BaseLine dental cement', 'Fever symptoms (finding)', 'Biologic Development', 'Fever', 'pseudomembranous colitis', 'criteria', 'Complication', 'Discontinued', 'development aspects', 'Complication Aspects', 'Baseline', 'Disease Exacerbation', 'Fever, CTCAE', 'Clinical Trial Discontinuation']","['fndg', 'bodm', 'idcn', 'phsf', 'sosy', 'qnco', 'dsyn', 'orgf', 'resa', 'ftcn', 'patf']"
1362,PMC4085478,S71,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",METHODS,patients who discontinued the study early qualified as “premature discontinuation” which resulted in a final study visit.,"['C2603343', 'C0205088', 'C1279919', 'C3853528', 'C0030705', 'C2826704', 'C0545082', 'C1546485', 'C1512346']","['Patient Visit', 'End-stage', 'Early', 'Visit Name', 'Visit', 'Patients', 'Study', 'Final', 'Diagnosis Type - Final']","['tmco', 'idcn', 'hlca', 'inpr', 'qlco', 'bhvr', 'resa', 'podg']"
1363,PMC4085478,S72,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",METHODS,dropouts were not replaced.,"['C0013135', 'C1518422']","['Dropouts', 'Negation']","['ftcn', 'popg']"
1364,PMC4085478,S73,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",METHODS,"patients' compliance was monitored by returned sachets, diary entries, and interviews.","['C0009563', 'C3244300', 'C3714905', 'C0376660', 'C0030705', 'C3714738', 'C1515981', 'C1321605', 'C0021822', 'C0332156', 'C1319685']","['Quantity Final Containers Returned', 'Interview', 'Compliance behavior', 'Diary', 'Sachet', 'Compliance', 'Return to (contextual qualifier) (qualifier value)', 'Biomechanical compliance', 'And', 'Patients', 'Operational Compliance']","['fndg', 'inbe', 'idcn', 'inpr', 'qnco', 'qlco', 'podg', 'mnob', 'acty']"
1365,PMC4085478,S74,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",METHODS,the central ethics committees approved the study protocol in all participating countries.,"['C0085546', 'C1507394', 'C2348563', 'C0679823', 'C0444868', 'C2599718', 'C0454664', 'C0205099']","['All', 'Clinical trial protocol document', 'Study Protocol', 'Ethics Committees', 'participation', 'Central', 'Country', 'Clinical trial protocol']","['prog', 'inpr', 'geoa', 'qnco', 'spco', 'ftcn']"
1366,PMC4085478,S75,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",METHODS,no changes to the study methods were made after study initiation.,"['C0443172', 'C0231290', 'C2603343', 'C1158830', 'C0025663', 'C1704686', 'C0025664', 'C0687676', 'C0392747', 'C0449851', 'C0589507']","['Methods', 'Changing', 'Status post', 'Transcription Initiation', 'Post', 'Techniques', 'Changed status', 'Study', 'Methods aspects', 'Cognitive function: initiation', 'Initiation']","['tmco', 'inpr', 'genf', 'qnco', 'resa', 'ftcn', 'menp']"
1367,PMC4085478,S77,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Precautions against bias,"to avoid selection bias, all patients who fulfilled all criteria were included into the study in the predefined, randomized order.","['C1705176', 'C1705175', 'C3889825', 'C1705178', 'C3272598', 'C1882348', 'C2603343', 'C3815594', 'C0036577', 'C0034656', 'C0030705', 'C0243161', 'C0444868', 'C1705177']","['Order (action)', 'All', 'Subject is Randomized', 'criteria', 'WHO Temperature/Humidity Storage Condition', 'Selection Bias', 'Patients', 'Study', 'Randomization', 'Sequence of Planned Assessment Schedule', 'Order (document)', 'Permutation', 'Order (taxonomic)', 'Order (arrangement)']","['fndg', 'clas', 'idcn', 'inpr', 'qnco', 'qlco', 'resa', 'podg', 'acty']"
1368,PMC4085478,S78,['11b'],"[0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Precautions against bias,"pellets, sachets, and containers were completely indistinguishable between treatment arms.","['C0087111', 'C0180098', 'C0993610', 'C1522326', 'C3887704', 'C0205197', 'C1705169', 'C0446516', 'C0039798', 'C3538994', 'C1515981', 'C2681631', 'C0206655', 'C4319731', 'C4319730', 'C1533734', 'C1319685']","['Alveolar rhabdomyosarcoma', 'KIDINS220 gene', 'Sachet', 'treatment - ActInformationManagementReason', 'Treating', 'Treatment Epoch', 'And', 'therapeutic aspects', 'Complete Agreement', 'Upper arm', 'Oral Pellet', 'Completely Able', 'Biomaterial Treatment', 'Administration procedure', 'Complete', 'Containers', 'Therapeutic procedure']","['blor', 'fndg', 'resa', 'bodm', 'gngm', 'idcn', 'topp', 'hlca', 'inpr', 'qlco', 'ftcn', 'neop', 'mnob', 'cnce']"
1369,PMC4085478,S79,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Precautions against bias,both patients and study personnel remained blinded and unaware of the allocation method throughout the study until database closure.,"['C1706778', 'C2603343', 'C0150114', 'C1521802', 'C0025663', 'C0871511', 'C0242356', 'C0030705', 'C0150108', 'C2985653', 'C1515981', 'C1706086', 'C0993637', 'C0449851']","['Methods', 'Study Personnel', 'Test Method', 'Published Database', 'Techniques', 'And', 'Databases', 'Patients', 'Blinded', 'Study', 'Allocation', 'Both', 'unaware', 'Closure']","['prog', 'idcn', 'inpr', 'qlco', 'lbpr', 'resa', 'podg', 'ftcn', 'acty']"
1370,PMC4085478,S80,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Precautions against bias,it was not possible for patients or investigators to guess the next allocated medication in order to avoid selection or allocation biases.,"['C0332282', 'C0005346', 'C4284232', 'C0242568', 'C0205117', 'C1883708', 'C1705176', 'C1706778', 'C0332149', 'C1705910', 'C0030705', 'C3244316', 'C1882348', 'C1705177', 'C0013227', 'C0035173', 'C1705175', 'C1707391', 'C3889825', 'C1705178', 'C1518422', 'C0036576']","['Possible', 'Following', 'Biases', 'Genetic Selection', 'Adjacent', 'Order (action)', 'Possibly Related to Intervention', 'Patients', 'Order (document)', 'Pharmaceutical Preparations', 'Order (taxonomic)', 'Negation', 'Choose (action)', 'medication - HL7 publishing domain', 'Medications', 'Bias (Epidemiology)', 'Research Personnel', 'Then', 'Sequence of Planned Assessment Schedule', 'Allocation', 'Permutation', 'Order (arrangement)']","['tmco', 'fndg', 'prog', 'idcn', 'clas', 'inpr', 'genf', 'qlco', 'phsu', 'spco', 'podg', 'ftcn', 'acty']"
1371,PMC4085478,S81,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Precautions against bias,"to avoid attrition bias, we handled incomplete data in a conservative manner: all patients with premature treatment termination were included in all final analyses with their last available data (last observation carried forward (locf)), so that a possible lt-02 treatment effect was rather reduced than increased.","['C4698491', 'C0005346', 'C0004277', 'C3538994', 'C0470187', 'C0242568', 'C0700325', 'C0205252', 'C1549081', 'C1533734', 'C0087111', 'C0205217', 'C0302523', 'C0205088', 'C0332149', 'C0699809', 'C2825507', 'C1518681', 'C1705910', 'C1705169', 'C3887704', 'C3853528', 'C0039798', 'C0030705', 'C1504315', 'C1546485', 'C0442805', 'C0332287', 'C3245479', 'C1692758', 'C0151526', 'C0439780', 'C0332257', 'C0444868', 'C1517741', 'C1522326', 'C0206243', 'C1964257', 'C3889687', 'C3714741', 'C1511726', 'C3242203', 'C4018905']","['Termination - Inactive Reason Code', 'In addition to', 'Tooth Attrition', 'incomplete data', 'Observation in research', 'End-stage', 'Data (eukaryote)', 'Bias genus', 'Including (qualifier)', 'Forward', 'termination - ActReason', 'Possible', 'Diagnosis Type - Final', 'Last Observation Carried Forward Imputation Technique', 'Treatment Epoch', 'Increased', 'Biases', 'Biomaterial Treatment', 'Clinical Observation', 'Administration procedure', 'Carrying', 'Increase', 'Data call receiving device', 'availability of', 'All', 'Does carry', 'Premature Birth', 'Outcome of Therapy', 'Possibly Related to Intervention', 'Patients', 'Patient observation', 'Therapeutic procedure', 'Rather', 'treatment - ActInformationManagementReason', 'Observation - diagnostic procedure', 'Too early', 'Last', 'Treating', 'Bias (Epidemiology)', 'therapeutic aspects', 'Immature', 'Final', 'Data']","['tmco', 'acty', 'fndg', 'medd', 'idcn', 'hlca', 'topp', 'inpr', 'qnco', 'qlco', 'acab', 'euka', 'resa', 'podg', 'ftcn', 'diap', 'bird', 'spco', 'patf', 'cnce']"
1372,PMC4085478,S82,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Precautions against bias,"more placebo patients may have stopped treatment owing to a lack of efficacy or for other reasons; it is unlikely that the results would have improved if treatment had been continued, and carrying forward the last value appeared to be conservative.","['C0392360', 'C3538994', 'C0332268', 'C1710571', 'C1533734', 'C0087111', 'C3887704', 'C1705169', 'C0039798', 'C0030705', 'C1706408', 'C0205172', 'C1707887', 'C0750558', 'C1280519', 'C0439780', 'C1522609', 'C1517741', 'C1522326', 'C0032042', 'C1696465']","['Unlikely', 'placebo', 'Numerical value', 'Forward', 'lack', 'Effectiveness', 'Treatment Epoch', 'Indication of (contextual qualifier)', 'Placebos', 'Biomaterial Treatment', 'Administration procedure', 'Placebo Control', 'More', 'Unlikely Related to Intervention', 'Patients', 'treatment - ActInformationManagementReason', 'Treating', 'Last', 'therapeutic aspects', 'Efficacy Study', 'Therapeutic procedure']","['fndg', 'bodm', 'topp', 'hlca', 'idcn', 'qlco', 'qnco', 'spco', 'resa', 'podg', 'ftcn', 'cnce']"
1373,PMC4085478,S83,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Precautions against bias,all dropouts and losses to follow-up are described in figure 1.,,,
1374,PMC4085478,S84,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Precautions against bias,individuals with possible conflict of interest were neither allowed to recruit patients nor were they involved in the conduct or analyses of the study.,"['C2603343', 'C0028609', 'C0009671', 'C0332149', 'C1705910', 'C1513854', 'C4284892', 'C0004927', 'C0045071', 'C0030705', 'C1705242', 'C0028423', 'C0543488', 'C3274651']","['Different', 'NOR Mouse', 'Possibly Related to Intervention', 'Patients', '19-norandrostenedione', 'Nucleolus Organizer Region', 'Behavior', 'Neither', 'Neither Case or Control Status', 'Conflict (Psychology)', 'Study', 'Possible', 'interest', 'Norway']","['fndg', 'inbe', 'orch', 'geoa', 'qlco', 'celc', 'mamm', 'bhvr', 'resa', 'podg', 'menp']"
1375,PMC4085478,S85,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Precautions against bias,there were no changes in the study methods or outcome parameters after study initiation.,"['C0443172', 'C0231290', 'C2603343', 'C1158830', 'C0025663', 'C1704686', 'C0025664', 'C0687676', 'C0392747', 'C0449851', 'C0589507', 'C1274040']","['Methods', 'Changing', 'Status post', 'Transcription Initiation', 'Post', 'Techniques', 'Changed status', 'Study', 'Methods aspects', 'Cognitive function: initiation', 'Result', 'Initiation']","['tmco', 'inpr', 'genf', 'qnco', 'resa', 'ftcn', 'menp']"
1376,PMC4085478,S86,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Precautions against bias,all authors had access to the study data and have reviewed and approved this manuscript.,"['C1080058', 'C0600659', 'C0681873', 'C1554204', 'C1515981', 'C0444454', 'C3812881', 'C0444868']","['All', 'And', 'author', 'Role Class - access', 'Access', 'Manuscripts', 'This (eukaryote)', 'research data']","['resa', 'prog', ' mnob', 'idcn', 'inpr', 'qnco', 'spco', 'euka', 'ftcn']"
1377,PMC4085478,S88,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Outcomes,"the disease activity was assessed using the sccai (22) that is validated and has been proven to correlate well with other indices comprising invasive methods (23,24,25,26).","['C1292728', 'C3146287', 'C0038895', 'C4283957', 'C4033634', 'C0205170']","['Microplate Well', 'Blood Indices', 'Disease activity', 'Good', 'Well', 'Surgical aspects']","['fndg', 'qlco', 'spco', 'ftcn', 'mnob']"
1378,PMC4085478,S89,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,the primary end point was changes in sccai from baseline (v2) to v5.,"['C0443172', 'C1442488', 'C0205225', 'C2349179', 'C0168634', 'C0392747']","['BaseLine dental cement', 'Changing', 'Primary', 'Changed status', 'Baseline', 'End Point']","['qnco', 'bodm', 'qlco', 'ftcn']"
1379,PMC4085478,S90,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Outcomes,"the sccai assesses stool frequency during the day and at night, defecation urgency, blood in stool, general well-being, abdominal pain, and extraintestinal manifestations.","['C4554323', 'C4321352', 'C1705502', 'C0205246', 'C1561548', 'C0015733', 'C0000737', 'C1321898', 'C3812897', 'C0240526', 'C0018684', 'C0376249', 'C0332173', 'C0205319', 'C0871396', 'C1280464', 'C0439228', 'C3891294', 'C0347984', 'C0439603', 'C0426636', 'C3898838', 'C3813622', 'C1515981']","['Frequencies (time pattern)', 'Frequency', 'Overall Well Being', 'Bowel urgency', 'Abdominal Pain', 'And', 'Spatial Frequency', 'Health', 'Safety Reporting Documentation', 'Abdominal Pain, CTCAE 5', 'Feces', 'Generalized', 'Blood in stool', 'Daily', 'During', 'Statistical Frequency', 'With frequency', 'General medical service', 'How Often', 'Manifest', 'day', 'Kind of quantity - Frequency', 'Manifestation of', 'Night time']","['tmco', 'fndg', 'idcn', 'hlca', 'inpr', 'sosy', 'qnco', 'qlco', 'spco', 'ftcn', 'bdsu']"
1380,PMC4085478,S91,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Outcomes,"the score ranges from 0 to 19 points—the lower the score, the lower the disease activity.","['C4050231', 'C1292728', 'C2003888', 'C1548802', 'C0449820', 'C0441994']","['Body Site Modifier - Lower', 'Score', 'ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated', 'Lower (action)', 'Disease activity', 'Lower - spatial qualifier']","['clna', 'blor', 'qnco', 'spco', 'ftcn', 'acty']"
1381,PMC4085478,S92,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"we assessed the following secondary and a priori defined end points in an exploratory sense: complete remission (<3 mean sccai (26) and “blood in stool” subscore of 0 (see european crohn's and colitis organization (ecco) definition of remission (21), locf); partial remission (sccai <5, locf); clinical response (sccai decrease ≥2 (26); mucosal healing (endoscopic mayo score (ems) ≤1); achievement of mucosal healing (ems ≤1 at v5 and improvement of ems ≥1 from v2 to v5); patients with complete remission; and a “bowel frequency” subscore of 0.","['C0547047', 'C0332282', 'C1521726', 'C4553336', 'C1300196', 'C0392756', 'C0029246', 'C1535514', 'C0043240', 'C4553337', 'C0009319', 'C0687702', 'C2825507', 'C2986411', 'C1552679', 'C0449820', 'C0205436', 'C0030705', 'C1963084', 'C0677874', 'C0026724', 'C0036658', 'C4050231', 'C0042789', 'C1704788', 'C1947903', 'C2348143', 'C0175668', 'C0442418', 'C0220885', 'C0001072', 'C0239307', 'C0444930', 'C3888054', 'C4055223', 'C0444504', 'C1517320', 'C4552914', 'C1522486', 'C0027627', 'C2746065', 'C0014245', 'C1077578', 'C1515981', 'C0544452', 'C2347634', 'C1550452', 'C4552913']","['European race', 'Mucous Membrane', 'And', 'Disease remission', 'definition - ActMoodCompletionTrack', 'From', 'Definition', 'Endoscopy (procedure)', 'Sample Mean', 'Following', 'Colitis, CTCAE', 'Decrease', 'Score', 'second (number)', 'Last Observation Carried Forward Imputation Technique', 'Population Mean', 'Organization Name', 'Wound Healing', 'Professional Organization or Group', 'Organized', 'In complete remission', 'Neoplasm Metastasis', 'Lugano Lymphoma Response Classification Complete Remission by CT', 'organizational', 'Lugano Lymphoma Response Classification Partial Remission by PET', 'Reduced', 'Clinical Response', 'Vision', 'Endoscopic approach - access', 'End', 'Patients', 'Statistical mean', 'Improvement', 'partial response', 'Lugano Lymphoma Response Classification Complete Remission by PET', 'Esthesia', 'Cancer Remission', 'Secondary to', 'ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated', 'Bikinia le-testui', 'Stop (qualifier value)', 'Achievement', 'Organization administrative structures', 'DEFINITION - NCI Thesaurus Property', 'ethnic european', 'See', 'Colitis', 'Lugano Lymphoma Response Classification Partial Remission by CT']","['qnco', 'bhvr', 'podg', 'clna', 'fndg', 'ortf', 'idcn', 'inpr', 'qlco', 'ftcn', 'popg', 'tmco', 'prog', 'plnt', 'tisu', 'spco', 'neop', 'cnce', 'acty', 'orgt', 'dsyn', 'orgf', 'diap']"
1382,PMC4085478,S93,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,all sccai-based end points refer to the patient's mean values of 1 week rounded to integer numbers.,"['C2348143', 'C0237753', 'C2746065', 'C1442452', 'C0449788', 'C0030705', 'C0444930', 'C2347634', 'C0444868', 'C0444504', 'C0042295']","['Sample Mean', 'All', 'Count of entities', 'Population Mean', 'Stop (qualifier value)', '1 Week', 'End', 'Patients', 'Statistical mean', 'Values', 'Numbers']","['tmco', 'qnco', 'qlco', 'spco', 'podg']"
1383,PMC4085478,S94,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,time to symptom resolution was defined as the first 3 days with ≤3 stools per day without visible blood (21).,"['C0205435', 'C0332173', 'C0040223', 'C1279901', 'C4553272', 'C2699488', 'C0015733', 'C3854129', 'C1706463', 'C0489144', 'C1514893', 'C3842349', 'C1457887', 'C0439228', 'C1442459']","['Firstly', 'Resolution Property', 'day', 'First (number)', 'Resolution', 'Macroscopic Blood Measurement', 'Time', 'Symptoms', '3 Days', 'Feces', 'Symptom:Find:Pt:^Patient:Nom', 'Daily', 'physiologic resolution', 'Visible blood', 'Stools:Appearance:Point in time:Lower GI tract:Nominal']","['tmco', 'clna', 'fndg', 'patf', 'sosy', 'qnco', 'qlco', 'lbpr', 'cnce', 'bdsu']"
1384,PMC4085478,S95,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"the ems is categorized as follows: 0, inactive; 1, mild disease (erythema, decreased vascular pattern, minimal granularity); 2, moderate disease (marked erythema, friability, granularity, absent vascular pattern, bleeding on minimal trauma, no ulcerations); and 3, severe disease (ulceration, spontaneous bleeding).","['C0332283', 'C0547040', 'C0012634', 'C3472234', 'C1801960', 'C1963256', 'C0392756', 'C4049136', 'C0332535', 'C0442797', 'C3834263', 'C0019080', 'C0205216', 'C0041834', 'C4285062', 'C4321335', 'C0005847', 'C3263723', 'C4049706', 'C1881878', 'C4049705', 'C0332197', 'C3887532', 'C1836348', 'C0522501', 'C0449774', 'C3280118', 'C1558950', 'C3890554', 'C1706089', 'C1510467', 'C4684680', 'C0041582', 'C1524031', 'C0043251', 'C4085643', 'C0205081', 'C1321132', 'C3714660']","['Followed by', 'Inactive - answer to question', 'Borg Category-Ratio 10 Perceived Exertion Score 3', 'Moderate Level', 'Trauma, nursing specialty', 'Massive', 'Decreased', 'Blood Vessel', 'Nontraumatic hemorrhage', 'Friability (finding)', 'Moderate (severity modifier)', 'Ulceration, CTCAE', 'trauma qualifier', 'pattern', 'Mild disorder', 'Marked', 'Granularity', 'Moderate Extremity Pain', 'Ulceration', 'Moderation', 'Adverse Event Associated with Vascular', 'Reduced', 'Traumatic injury', 'Minimum', 'Vascular', 'Physical Inactivity', 'Minimal', 'Wounds and Injuries', 'Severe disorder', 'Decreasing', 'Trauma', 'Absent', 'Pharyngeal Stripping Wave Absent', 'Moderate Response', 'Ulcer', 'Disease', 'Hemorrhage', 'Erythema', 'Spontaneous hemorrhage']","['tmco', 'fndg', 'patf', 'dora', 'inpr', 'qlco', 'qnco', 'bmod', 'inpo', 'dsyn', 'spco', 'ftcn', 'bpoc']"
1385,PMC4085478,S96,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"the histologic index (by riley) ranges from 1 representing remission to 4 representing severe colitis; a central pathologist, who was blinded to the groups, assessed the score.","['C2986546', 'C3272598', 'C0600653', 'C4050231', 'C0687702', 'C0441833', 'C0205462', 'C1859543', 'C1552839', 'C0449820', 'C0205099', 'C0687744', 'C0544452', 'C0334866', 'C1552854', 'C1516048', 'C0918012']","['Groups', 'Histologic', 'Social group', 'Cancer Remission', 'Index', 'Html Link Type - index', 'WHO Temperature/Humidity Storage Condition', 'Medical pathologist', 'Indexes', 'ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated', 'Assessed', 'Severe colitis', 'Disease remission', 'Score', 'Central', 'Target Lesion Identification', 'Table Rules - groups']","['acty', 'fndg', 'prog', 'idcn', 'inpr', 'qlco', 'qnco', 'spco', 'ftcn', 'neop', 'diap', 'popg', 'clna']"
1386,PMC4085478,S98,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistics,data from a dose-finding study (19) showed that a relative effect size for the sccai of ∼0.8 could be expected from the 3.2 g dose group compared with placebo.,"['C0178602', 'C0521125', 'C1517001', 'C4321252', 'C1257890', 'C0037088', 'C0441833', 'C1706408', 'C1705428', 'C2825141', 'C3245479', 'C1519504', 'C1705429', 'C0814843', 'C1517320', 'C2603343', 'C0032042', 'C0243095', 'C0687744', 'C1696465', 'C0205345', 'C3714741', 'C1511726', 'C0080103']","['Finding', 'Group Object', 'placebo', 'Experimental Finding', 'Data (eukaryote)', 'Relative', 'From', 'Study', 'Placebos', 'User Group', 'effect size', 'Data call receiving device', 'Groups', 'Population Group', 'Placebo Control', 'Social group', 'Signs and Symptoms', 'WWOX wt Allele', 'Relative (related person)', 'Dosage', 'Preposition For', 'Expected', 'Stage Grouping', 'Data']","['fndg', 'bodm', 'medd', 'idcn', 'topp', 'gngm', 'inpr', 'famg', 'sosy', 'qnco', 'qlco', 'euka', 'resa', 'ftcn', 'popg', 'cnce']"
1387,PMC4085478,S99,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistics,"under the parametric assumptions of the t-test, 30 patients per group were needed to detect a difference of a relative effect size of 0.8 between placebo and an active group with a power of 85% (α=0.025, one sided).","['C1705241', 'C0205447', 'C1515976', 'C0022885', 'C4318744', 'C0205177', 'C3888249', 'C1257890', 'C0205103', 'C0441833', 'C0030705', 'C1706408', 'C0392366', 'C1705428', 'C0032863', 'C0332287', 'C1519504', 'C0456984', 'C1705429', 'C3854080', 'C0814843', 'C1705242', 'C0032042', 'C0039593', 'C0687744', 'C1515981', 'C1696465', 'C0205345', 'C3831328', 'C3853793', 'C0080103']","['Active License', 'Group Object', 'placebo', 'In addition to', 'And', 'Power', 'Relative', 'active (HL7 RoleLink)', 'Test - temporal region', 'Placebos', 'Tests (qualifier value)', 'Laboratory Procedures', 'User Group', 'Active', 'effect size', 'Groups', 'Population Group', 'Placebo Control', 'Social group', 'Test Result', 'Testing', 'Relative (related person)', 'Patients', 'One', 'Intermediate', 'Different', 'Power (Psychology)', 'Anatomic Structure, System, or Substance', 'Blood Products Laboratory Testing', 'Stage Grouping', 'Delta (difference)']","['blor', 'resa', 'bodm', 'lbtr', 'idcn', 'clas', 'topp', 'inpr', 'famg', 'qnco', 'qlco', 'lbpr', 'spco', 'hcpp', 'podg', 'ftcn', 'popg', 'cnce']"
1388,PMC4145439,S196,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Supplementary Material,web supplement,"['C0282111', 'C0242295', 'C2348609', 'C1947943']","['Supplement (document)', 'Internet', 'Dietary Supplements', 'Supplement']","['food', 'mnob', 'inpr', 'ftcn']"
1389,PMC4145439,S40,"['3a', '4a']","[0, 0, 0, 0, 0, 0, 1, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"this was a 12-week, phase iib, dose-ranging, double-blind, placebo (pbo) and active-controlled, multicenter, randomised study (nct01242488), conducted between november 2010 and june 2012, to evaluate the efficacy and safety of subcutaneous okz in patients with moderately to severely active ra who had previously failed tnf inhibitor therapy.","['C0205173', 'C0456909', 'C0441769', 'C0620347', 'C0439230', 'C0178602', 'C1363945', 'C1705187', 'C0205177', 'C3888249', 'C2587213', 'C0087111', 'C0205103', 'C3272598', 'C0205082', 'C1448177', 'C1705765', 'C0039798', 'C0030705', 'C0150108', 'C1706408', 'C0525065', 'C1705764', 'C1707887', 'C1881878', 'C1280519', 'C0220825', 'C0036043', 'C0457160', 'C2911690', 'C4321491', 'C2603343', 'C1080058', 'C3828767', 'C0032042', 'C3829443', 'C1999216', 'C4085643', 'C0443315', 'C0031962', 'C1515981', 'C1696465', 'C3853793']","['Duplicate', 'Active License', 'Piperonyl Butoxide', 'placebo', 'subcutaneous', 'compound A 12', 'And', 'active (HL7 RoleLink)', 'Moderately Able', 'November', 'Study', 'Safety', 'TNF protein, human', 'June', 'Effectiveness', 'Disease Controlled', 'Double Value Type', 'Placebos', 'Safety Study', 'Therapy Object (animal model)', 'Active', 'Moderation', 'Placebo Control', 'Visually Impaired Persons', 'Control function', 'Patients', 'Blinded', 'Dosage', 'Doubling', 'Inhibitor', 'Intermediate', 'Moderate Response', 'Severe (severity modifier)', 'WHO Temperature/Humidity Storage Condition', 'therapeutic aspects', 'Efficacy Study', 'Stage 2 lower case b', 'week', 'Stage 2B', 'This (eukaryote)', 'Blindness', 'Evaluation', 'Therapeutic procedure']","['topp', 'qnco', 'podg', 'bodm', ' aapp', 'fndg', ' orch', 'idcn', 'hlca', 'clas', 'inpr', 'qlco', 'bacs', 'hcpp', 'resa', 'ftcn', 'tmco', 'orch', 'hops', 'euka', 'spco', 'acty', ' phsu']"
1390,PMC4145439,S41,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,the study protocol was approved by the institutional review board/independent ethics committee as defined in local regulations and performed according to the declaration of helsinki.,"['C0851285', 'C1704788', 'C0220905', 'C0205276', 'C1507394', 'C1515981', 'C0884358', 'C2348563', 'C2599718', 'C0680240', 'C0086911', 'C4554082']","['Clinical trial protocol document', 'Study Protocol', 'Performed', 'And', 'Ethics Committees, Research', 'Independent Ethics Committee', 'Definition', 'Regulation', 'Agreement', 'Clinical trial protocol', 'Local', 'regulatory']","['gora', 'prog', 'rnlw', 'idcn', 'inpr', 'socb', 'spco', 'ftcn']"
1391,PMC4145439,S42,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,all patients provided written consent.,"['C1511481', 'C2923685', 'C0030705', 'C1554192', 'C0444868']","['Consent:Finding:Point in time:{Setting}:Document:Patient', 'All', 'Consent', 'Patients', 'ActClass - consent']","['idcn', 'qnco', 'podg', 'ftcn', 'clna']"
1392,PMC4145439,S43,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study design,the primary objective of the study was to evaluate the efficacy of okz at different doses and administration frequencies compared with pbo.,"['C2603343', 'C0220825', 'C1421478', 'C1565156', 'C0043194', 'C0178602', 'C0031962', 'C1515981', 'C0439603', 'C2827976', 'C0001554', 'C1707887', 'C1705242', 'C1533734', 'C1280519']","['Different', 'Frequencies (time pattern)', 'Piperonyl Butoxide', 'Effectiveness', 'Evaluation', 'Trial Primary Objective', 'WAS protein, human', 'WAS gene', 'And', 'Efficacy Study', 'Dosage', 'Study', 'Administration procedure', 'Wiskott-Aldrich Syndrome', 'Administration occupational activities']","['tmco', 'ocac', ' orch', 'topp', 'idcn', 'hlca', 'gngm', 'qlco', 'qnco', 'bacs', 'hops', 'dsyn', 'resa', 'ftcn', ' phsu', ' aapp']"
1393,PMC4145439,S44,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study design,"secondary objectives were to evaluate the safety, pharmacokinetics (pk), pharmacodynamics (pd) and immunogenicity of repeated doses of okz, and to assess the dose-response and exposure-response relationship of okz with efficacy.","['C1705630', 'C0871261', 'C0178602', 'C0031327', 'C1705187', 'C3540605', 'C0205436', 'C1706279', 'C1707887', 'C1516048', 'C1280519', 'C0243145', 'C0205341', 'C0851347', 'C0036043', 'C0175668', 'C0018017', 'C0439849', 'C0031328', 'C0027627', 'C1706817', 'C4054739', 'C2911692', 'C4554585', 'C1515981', 'C0332157', 'C1704632']","['Object Relationship', 'Exposure to', 'And', 'Response (communication)', 'Safety', 'Response process', 'Disease Response', 'Drug Kinetics', 'Effectiveness', 'Pharmacodynamics', 'second (number)', 'Assessed', 'Immunogenicity (package insert)', 'Safety Study', 'Concept Relationship', 'Repeat', 'Neoplasm Metastasis', 'Relationships', 'Dosage', 'Response (statement)', 'objective (goal)', 'Pharmacokinetic aspects', 'pharmacodynamic aspects', 'Secondary to', 'Efficacy Study', 'CDISC Relationship Class', 'Immunogenicity Study']","['fndg', 'biof', 'idcn', 'hcpp', 'phsf', 'inpr', 'qlco', 'qnco', 'orga', 'resa', 'neop', 'ftcn', 'menp', 'acty']"
1394,PMC4145439,S45,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study design,an exploratory endpoint was to compare the efficacy and safety of okz with tcz.,"['C0036043', 'C2349179', 'C1515981', 'C1707887', 'C1705187', 'C2826544', 'C1280519']","['Endpoint Value Derivation Technique', 'Effectiveness', 'And', 'Efficacy Study', 'Safety', 'Safety Study', 'End Point']","['idcn', 'hcpp', 'qlco', 'qnco', 'resa']"
1395,PMC4145439,S46,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"of the 398 patients enrolled in the study, 221 were randomised to 1 of 9 treatment arms (figure 1).",,,
1396,PMC4145439,S47,"['10', '8a']","[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0]",Study design,randomisation was performed centrally using an interactive voice-response system.,"['C3888058', 'C4281800', 'C0042939', 'C1706817', 'C2911692', 'C0449913', 'C0871261', 'C1553451', 'C1704632', 'C1704675', 'C3244282']","['TelecommunicationCapabilities <voice>', 'System - kit', 'Voice G-code', 'System', 'Device system', 'Voice', 'Response (communication)', 'Response (statement)', 'Response process', 'Disease Response', 'Interaction']","['fndg', 'inpr', 'qlco', 'orga', 'orgf', 'ftcn', 'mnob', 'menp']"
1397,PMC4145439,S48,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,"patients received either pbo or okz (60, 120 or 240 mg) every 4 weeks (q4w) or every 2 weeks (q2w), or 8 mg/kg tcz q4w.","['C3844638', 'C0031962', 'C1948061', 'C0030705']","['Piperonyl Butoxide', 'Patients', 'Every (qualifier)', 'Either']","['fndg', ' orch', 'qlco', 'hops', 'podg', ' phsu']"
1398,PMC4145439,S49,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,"doses were selected in order to cover 35–75% of the maximal anticipated effect on das28(erythrocyte sedimentation rate, esr) at 12 weeks, or 45–85% of the maximal anticipated effect at 24 weeks, based on pk/pd analysis of previous study data.19 20","['C3811131', 'C0205156', 'C0178602', 'C4049713', 'C0205289', 'C0936012', 'C1705176', 'C3840775', 'C2348382', 'C1518681', 'C1280500', 'C0681873', 'C1882348', 'C0806909', 'C1705177', 'C1705175', 'C3889825', 'C1705178', 'C1176468', 'C1552607', 'C1619634', 'C1524024']","['Effect, Appearance', 'Borg Category-Ratio 10 Perceived Exertion Score 10', 'Maximal (qualifier value)', 'Maximum', 'Erythrocyte sedimentation rate measurement', 'analysis aspect', 'Order (action)', 'erythrocyte sedimentation rate result', 'Outcome of Therapy', 'Dosage', 'Effect', 'Anticipated', 'Order (document)', 'Act Relationship Subset - previous', 'Order (taxonomic)', 'research data', 'Analysis', 'Estrogen Receptor Measurement', 'Sequence of Planned Assessment Schedule', 'Previous', 'Permutation', 'Order (arrangement)']","['tmco', 'fndg', 'lbtr', 'clas', 'inpr', 'qnco', 'qlco', 'lbpr', 'resa', 'ftcn', 'acty']"
1399,PMC4145439,S50,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,figure 1 patient disposition.,,,
1400,PMC4145439,S51,['8b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0]",Study design,randomisation was stratified according to the number of prior failed tnf inhibitors (1 vs 2 or more).,"['C0243077', 'C0237753', 'C1448177', 'C0449788', 'C2826257', 'C0205172', 'C0332152', 'C0231175']","['Prior Medication Usage', 'More', 'Count of entities', 'inhibitors', 'TNF protein, human', 'Before', 'failed', 'Numbers']","['tmco', 'chvf', 'qnco', 'bacs', 'ftcn', ' aapp', 'evnt']"
1401,PMC4145439,S52,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,two safety follow-up visits were undertaken 6 and 12 weeks after the last study dose.,"['C1517741', 'C2603343', 'C0036043', 'C0178602', 'C1515981', 'C0545082', 'C0205448', 'C1512346', 'C1705187']","['Two', 'Patient Visit', 'Last', 'And', 'Dosage', 'Study', 'Safety', 'Safety Study', 'Visit']","['idcn', 'hcpp', 'hlca', 'qnco', 'qlco', 'bhvr', 'resa']"
1402,PMC4145439,S53,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"to maintain blinding of the treatment, all patients received an intravenous infusion q4w and two 1.2 ml subcutaneous injections q2w.","['C0021440', 'C0087111', 'C1522326', 'C1272892', 'C3887704', 'C1705169', 'C0039798', 'C3538994', 'C0030705', 'C0021499', 'C0150108', 'C1515981', 'C1621368', 'C0205448', 'C0444868', 'C1533734']","['Intravenous Drip Route of Administration', 'Intravenous infusion procedures', 'Two', 'All', 'treatment - ActInformationManagementReason', 'Subcutaneous Injections', 'Treating', 'Treatment Epoch', 'And', 'therapeutic aspects', 'Patients', 'Intravenous infusion (product)', 'Blinded', 'Biomaterial Treatment', 'Administration procedure', 'Therapeutic procedure']","['bodm', 'topp', 'idcn', 'hlca', 'qnco', 'resa', 'podg', 'ftcn', 'cnce']"
1403,PMC4145439,S54,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"tcz dose is the approved dose in europe by the ema,21 and the highest dose approved by the us food and drug administration (fda).18","['C4318614', 'C4553329', 'C0015176', 'C0205540', 'C0178602', 'C1515981', 'C1612111', 'C0041714', 'C1522410']","['United States Food and Drug Administration', 'Approved', 'And', 'Dosage', 'human MUC1 protein', 'Europe', 'European Medicines Agency', 'ETFA wt Allele', 'Highest']","['imft', 'gngm', 'idcn', 'orgt', ' irda', 'geoa', 'hcro', 'qnco', 'qlco', ' aapp']"
1404,PMC4145439,S55,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,patients who completed the study were eligible to receive okz in an open-label extension study (nct01296711).,"['C2827499', 'C3272598', 'C2603343', 'C0175566', 'C1880641', 'C0231448', 'C4551445', 'C0030705', 'C0181496', 'C1548635', 'C4522130']","['Label (document)', 'Human Cells, Tissues, and Cellular and Tissue-Based Products Labeling', 'Open', 'Labels (device)', 'WHO Temperature/Humidity Storage Condition', 'Patients', 'Study', 'Telephone Extension Number', 'Labeling Activity', 'Extension', 'Eligible']","['inpr', 'qlco', 'spco', 'resa', 'podg', 'ftcn', 'mnob', 'cnce', 'acty']"
1405,PMC4145439,S57,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"this study population were individuals with active ra and an inadequate response to mtx, and at least one previous anti-tnf therapy.","['C1417487', 'C0205447', 'C0205156', 'C0871261', 'C1363945', 'C0205177', 'C3888249', 'C0087111', 'C0439856', 'C1448177', 'C0039798', 'C0205412', 'C1706817', 'C0025677', 'C1080058', 'C2911692', 'C1552607', 'C1515981', 'C1704632', 'C2348561', 'C3853793']","['Active License', 'MTX1 gene', 'And', 'active (HL7 RoleLink)', 'Response (communication)', 'Methotrexate', 'TNF protein, human', 'Unsatisfactory', 'Response process', 'Disease Response', 'Therapy Object (animal model)', 'Study Population (group)', 'Active', 'Response (statement)', 'One', 'Act Relationship Subset - previous', 'therapeutic aspects', 'This (eukaryote)', 'Previous', 'Inadequate (qualifier)', 'Therapeutic procedure']","['tmco', 'fndg', 'popg', 'gngm', 'topp', 'idcn', 'inpr', 'orch', 'qlco', 'qnco', 'bacs', 'orga', 'euka', 'ftcn', ' phsu', 'menp', ' aapp']"
1406,PMC4145439,S58,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"patients were ≥18 years old, with adult-onset ra of at least 6 months duration (1987 american college of rheumatology (acr) classification criteria22) or a score of ≥6 by the acr/european league against rheumatism (eular) classification and diagnostic criteria for ra.23","['C0521124', 'C0678229', 'C0521125', 'C1535514', 'C4321252', 'C0009326', 'C1515941', 'C0206132', 'C0596070', 'C0449820', 'C0030705', 'C0008902', 'C0035435', 'C1412134', 'C0449238', 'C4050231', 'C0035452', 'C0008903', 'C0001675', 'C0239307', 'C0557806', 'C0679228', 'C1706450', 'C1515981', 'C0580836', 'C2926735', 'C0332162']","['European race', 'And', 'Classification of information', 'American College of Radiology', 'Onset of (contextual qualifier)', 'Age of Onset', 'Score', 'Adult', 'Rheumatology specialty', 'Rheumatism', 'Americas Ethnicity', 'against', 'Duration', 'college', 'Collagen Diseases', 'Duration (temporal concept)', 'Old', 'WWOX wt Allele', 'Patients', 'diagnostic criteria', 'Preposition For', 'Taxonomic', 'ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated', 'Legal Adult', 'ethnic european', 'ACR gene', 'Classification']","['tmco', 'ocac', 'gngm', 'clas', 'idcn', 'pros', 'inpr', 'orch', 'qnco', 'qlco', 'bmod', 'dsyn', ' phsu', 'podg', 'ftcn', 'mnob', 'popg', 'aggp', 'clna']"
1407,PMC4145439,S59,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"eligible patients had tender joint count ≥6 (tjc; assessment of 68 joints) and swollen joint count ≥6 (sjc; assessment of 66 joints) and crp ≥1.2 times the upper limit of normal (uln), or esr >28 mm/h.","['C3811131', 'C3890735', 'C4553972', 'C0205307', 'C0231683', 'C0152031', 'C0030705', 'C4554549', 'C4554794', 'C1519815', 'C1516048', 'C0750480', 'C0439801', 'C2349209', 'C1548635', 'C1705566', 'C0240094', 'C4048285', 'C0022417', 'C1549649', 'C1282910', 'C1515981', 'C1261322', 'C0392905']","['Joints', 'C-Reactive Protein, human', 'Count Dosing Unit', 'Articular system', 'And', 'Evaluation procedure', 'Eligible', 'Tender joint:Anatomy:Point in time:^Patient:Nominal', 'Gait normal', 'Normal', 'Complete Response with Incomplete Platelet Recovery', 'Assessed', 'Count', 'Bound (value)', 'Limit - Amount class', 'Limited (extensiveness)', 'Joint tenderness', 'Patients', 'Joint swelling', 'Swollen joint:Anatomy:Point in time:^Patient:Nominal', 'Estrogen Receptor Measurement', 'How Often Felt Normal question', 'Upper', 'Upper Limit of Normal']","['clna', 'imft', 'fndg', 'idcn', 'bdsy', 'hlca', 'inpr', 'sosy', 'qnco', 'qlco', 'lbpr', 'bsoj', 'ftcn', 'podg', ' aapp', 'spco', 'cnce', 'acty']"
1408,PMC4145439,S60,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,patients were required to be on a stable dose of mtx and continued current steroids and nsaids.,"['C1417487', 'C0038317', 'C0025677', 'C1547311', 'C0030705', 'C0521116', 'C0178602', 'C1515981', 'C1705970', 'C0205360', 'C0003211']","['Steroids', 'Patient Condition Code - Stable', 'MTX1 gene', 'Anti-Inflammatory Agents, Non-Steroidal', 'Current (present time)', 'And', 'Dosage', 'Patients', 'Electrical Current', 'Methotrexate', 'Stable status']","['tmco', 'npop', 'gngm', 'idcn', 'inpr', 'orch', 'qnco', 'qlco', 'podg', ' phsu', 'phsu']"
1409,PMC4145439,S61,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"major exclusion criteria included diagnoses of other inflammatory arthritis or a non-inflammatory type of arthritis that interfered with efficacy evaluations, functional capacity steinbrocker class iv,24 and prior exposure to il-6 inhibitors.","['C0332307', 'C0521102', 'C0220825', 'C0243077', 'C1998319', 'C1518422', 'C2698970', 'C0441888', 'C0003864', 'C2826257', 'C1515981', 'C0332157', 'C0333348', 'C4318856', 'C0680251', 'C1707887', 'C0332152', 'C0205164', 'C1280519']","['Effectiveness', 'Arthritis', 'Type - attribute', 'Exposure to', 'Exclusion Criteria', 'Prior Medication Usage', 'interferes with', 'And', 'Efficacy Study', 'inhibitors', 'Major <insect>', 'Before', 'Functional capacity', 'Canadian Cardiovascular Society Grading Scale Class IV', 'Class 4', 'Evaluation', 'inflammatory', 'Negation', 'Major']","['tmco', 'fndg', 'chvf', 'idcn', 'clas', 'hlca', 'inpr', 'qlco', 'dsyn', 'euka', 'resa', 'ftcn', 'evnt']"
1410,PMC4145439,S62,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,patients were not permitted to use dmards other than mtx within 12 weeks prior to screening (unless undertaking appropriate washout).,"['C1417487', 'C4554474', 'C1518422', 'C0025677', 'C0220909', 'C1710661', 'C1710032', 'C2826257', 'C0220908', 'C2348164', 'C1698960', 'C0030705', 'C1710477', 'C1548787', 'C1710031', 'C0332152', 'C2986829']","['Screening Study', 'research subject screening', 'Aspects of disease screening', 'Screening procedure', 'Trial Screening', 'MTX1 gene', 'Washout phase', 'Prior Medication Usage', 'Disease Screening', 'Appropriate', 'Patients', 'Screening', 'Methotrexate', 'Before', 'Tracer Clearance', 'Washout Period', 'Negation']","['tmco', 'gngm', 'hlca', 'orch', 'qlco', 'resa', 'podg', 'ftcn', 'diap', ' phsu', 'evnt']"
1411,PMC4145439,S63,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"patients with a known risk of severe or major infections, or elevated levels at screening of creatinine, alanine aminotransferase (alt) or aspartate aminotransferase (ast), or reduced platelets, white blood cell count or neutrophil count were excluded.","['C1710032', 'C0205250', 'C3891303', 'C0441889', 'C3163633', 'C0205082', 'C1561535', 'C2348164', 'C0030705', 'C1698960', 'C0200633', 'C0023508', 'C0205309', 'C4050465', 'C4553172', 'C0427512', 'C1266129', 'C0220908', 'C4050466', 'C0392386', 'C1710031', 'C0010294', 'C0004002', 'C1415274', 'C0001899', 'C0220909', 'C0035647', 'C1415181', 'C1710477', 'C3887708', 'C4552904']","['Aspects of disease screening', 'Screening procedure', 'Borg Category-Ratio 10 Perceived Exertion Score 5', 'Alanine Aminotransferase 1, human', 'Alanine Transaminase', 'Atypical Lipoma', 'High', 'Aspartate Transaminase', 'Atlantic Standard Time', 'Trial Screening', 'White Blood Cell Count procedure', 'Creatinine, CTCAE', 'Elevated', 'Screening', 'Screening Study', 'Neutrophil count (procedure)', 'Severe Extremity Pain', 'GOT1 gene', 'Disease Screening', 'Patients', 'Antibiotic Lock Therapy', 'Levels (qualifier value)', 'Risk', 'White blood cell count laboratory result', 'research subject screening', 'Creatinine', 'Known', 'Severe (severity modifier)', 'Subject Risk', 'Decreased platelet count', 'GPT gene']","['tmco', 'fndg', 'lbtr', 'gngm', 'hlca', 'idcn', ' orch', 'enzy', 'topp', 'neop', 'inpr', 'qlco', 'bacs', 'lbpr', 'resa', 'podg', 'ftcn', 'diap', ' aapp', 'cnce']"
1412,PMC4145439,S65,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Efficacy analyses,"efficacy outcomes were assessed in the full analysis set (fas), consisting of all randomised patients who received at least one dose of study medication and had at least one post-baseline efficacy measurement.","['C0205447', 'C4284232', 'C0036849', 'C0168634', 'C0178602', 'C0687676', 'C3539897', 'C0242485', 'C0936012', 'C3272598', 'C0030705', 'C3244316', 'C1707887', 'C1415458', 'C1280519', 'C1705195', 'C0062074', 'C3469826', 'C0444868', 'C0013227', 'C0443225', 'C2603343', 'C1442488', 'C1515981', 'C1704687', 'C1524024', 'C1442518']","['set (group)', 'Set (Psychology)', 'And', 'HAC protocol', 'Study', 'Measurement', 'full', 'HADH gene', 'Post', 'Effectiveness', 'SLC35G1 gene', 'analysis aspect', 'Baseline', 'All', 'Dosage', 'Patients', 'One', 'Pharmaceutical Preparations', 'medication - HL7 publishing domain', 'BaseLine dental cement', 'Post Device', 'Medications', 'Analysis', 'Have', 'WHO Temperature/Humidity Storage Condition', 'Efficacy Study', 'Set scale']","['tmco', 'bodm', 'gngm', 'idcn', 'topp', 'inpr', 'qlco', 'qnco', 'phsu', 'resa', 'podg', 'ftcn', 'mnob', 'menp', 'cnce']"
1413,PMC4145439,S66,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Efficacy analyses,the primary efficacy endpoint was the change from baseline in das28(crp) at week 12.,"['C0443172', 'C3890735', 'C1705241', 'C1442488', 'C0205225', 'C2349179', 'C0168634', 'C0439230', 'C0392747', 'C4319952', 'C1707887', 'C2826544', 'C4048285', 'C1280519']","['C-Reactive Protein, human', 'BaseLine dental cement', 'Changing', 'Effectiveness', 'Endpoint Value Derivation Technique', 'Primary', 'Complete Response with Incomplete Platelet Recovery', 'Efficacy Study', 'Changed status', 'Change -- procedure', 'week', 'Delta (difference)', 'Baseline', 'End Point']","['tmco', 'imft', 'fndg', 'resa', 'topp', 'qnco', 'qlco', 'ftcn', 'bodm', ' aapp']"
1414,PMC4145439,S67,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Efficacy analyses,"secondary efficacy endpoints were acr20, acr50 and acr70 at week 12 for okz and pbo.","['C0027627', 'C0175668', 'C2349179', 'C0205436', 'C0439230', 'C0031962', 'C1515981', 'C1707887', 'C1280519']","['Piperonyl Butoxide', 'Effectiveness', 'Neoplasm Metastasis', 'Secondary to', 'second (number)', 'And', 'Efficacy Study', 'week', 'End Point']","['tmco', ' orch', 'idcn', 'qlco', 'qnco', 'hops', 'resa', 'neop', ' phsu']"
1415,PMC4145439,S68,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Efficacy analyses,"major exploratory analyses included: acr20/50/70 response rates (at weeks 1, 2, 4, 6, 8, 10 and 12), % of patients with das28(crp) <2.6 at weeks 2, 4, 8 and 12), tjc, sjc, clinical disease activity index (cdai) and the health assessment questionnaire-disability index (haq-di).","['C3890735', 'C0683448', 'C0332287', 'C1413248', 'C3273706', 'C3869583', 'C0451208', 'C2911692', 'C1706817', 'C0439230', 'C0030705', 'C0871261', 'C1515981', 'C0231170', 'C1704632', 'C4318856', 'C4048285', 'C0205164']","['C-Reactive Protein, human', 'disability', 'CDAN1 gene', 'In addition to', 'CDAN1 wt Allele', 'Complete Response with Incomplete Platelet Recovery', 'Health assessment questionnaire', 'And', 'week', 'Patients', 'Codependency Assessment Inventory', 'Disease Response', 'Response (communication)', 'Response (statement)', 'Response process', 'Major <insect>', 'Clinical disease activity index', 'Major']","['tmco', 'imft', 'fndg', 'gngm', 'idcn', 'inpr', 'qlco', 'orga', 'euka', 'ftcn', 'podg', ' aapp', 'menp']"
1416,PMC4145439,S70,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Safety,safety assessments included measurement of vital signs and laboratory parameters as well as recording of treatment-emergent adverse events (teaes) and serious teaes.,"['C3538994', 'C1705413', 'C0205404', 'C1705187', 'C1533734', 'C0242485', 'C0205170', 'C0087111', 'C3887704', 'C0518766', 'C1705169', 'C3244292', 'C0039798', 'C3146287', 'C4283904', 'C4283957', 'C0036043', 'C0022877', 'C0750573', 'C1522326', 'C1515981', 'C1261322', 'C0877248']","['Laboratory', 'And', 'Evaluation procedure', 'Safety', 'Serious', 'Measurement', 'Laboratory observation', 'Microplate Well', 'Treatment Epoch', 'Well', 'Safety Study', 'Biomaterial Treatment', 'Administration procedure', 'emergent', 'Vital signs', 'Laboratory domain', 'treatment - ActInformationManagementReason', 'Treating', 'therapeutic aspects', 'Adverse Event Domain', 'Good', 'Adverse event', 'Therapeutic procedure']","['cnce', 'resa', 'lbtr', ' hcro', 'idcn', 'topp', 'hlca', 'inpr', 'qlco', 'spco', 'hcpp', 'ftcn', 'mnob', 'patf', 'clna']"
1417,PMC4145439,S71,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Safety,"safety variables were analysed using the safety set (ss) (all patients who received at least 1 dose, or partial dose, of study medication).","['C3272598', 'C2603343', 'C1442518', 'C0036043', 'C1705195', 'C4284232', 'C0036849', 'C1550516', 'C0030705', 'C0178602', 'C0439828', 'C3244316', 'C0444868', 'C1705187', 'C0728938', 'C0013227']","['set (group)', 'Set (Psychology)', 'Medications', 'All', 'Variable (uniformity)', 'WHO Temperature/Humidity Storage Condition', 'Partial', 'Dosage', 'Patients', 'Set scale', 'Safety', 'Safety Study', 'Study', 'Target Awareness - partial', 'Pharmaceutical Preparations', 'medication - HL7 publishing domain']","['hcpp', 'idcn', 'inpr', 'qlco', 'qnco', 'phsu', 'resa', 'podg', 'ftcn', 'menp', 'cnce']"
1418,PMC4145439,S73,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,"unless specifically stated, fas was used for all analyses.",['C0444868'],['All'],['qnco']
1419,PMC4145439,S74,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,das28(crp) was analysed using a mixed effects model for repeated measures (mmrm).,"['C3274659', 'C3890735', 'C0205430', 'C3160715', 'C3853906', 'C1280500', 'C1421478', 'C1565156', 'C0043194', 'C3161035', 'C0521125', 'C0871881', 'C3714583', 'C4048285', 'C4321252']","['C-Reactive Protein, human', 'Model Number', 'Digital Model Attachment', 'Mixed Cell Morphology', 'Model', 'WAS protein, human', 'Complete Response with Incomplete Platelet Recovery', 'WAS gene', 'WWOX wt Allele', 'Effect', 'Mixed (qualifier value)', 'Preposition For', 'repeated measures', 'Model - style/design', 'Wiskott-Aldrich Syndrome']","['imft', 'fndg', 'resa', 'gngm', 'inpr', 'qlco', 'bacs', 'dsyn', 'ftcn', ' aapp', 'cnce']"
1420,PMC4145439,S75,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,acr20/50/70 responder rates were estimated using generalised estimating equation (gee) methodology with multiple imputation (mi).,"['C0205246', 'C0750572', 'C2699638', 'C0439064', 'C0552449', 'C3266812', 'C0969625']","['Estimated', 'equation', 'Methodology', 'Statistical Imputation', 'Methodology aspects', 'Generalized', 'Numerous']","['idcn', 'inpr', 'qnco', 'spco', 'ftcn', 'cnce']"
1421,PMC4145439,S76,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,missing data for sjc/tjc/haq-di/cdai change from baseline were imputed using last observation carried forward (locf).,"['C4321476', 'C1705241', 'C0168634', 'C0700325', 'C3826998', 'C0392747', 'C0443172', 'C0302523', 'C1413248', 'C2825507', 'C0683448', 'C3273706', 'C3245479', 'C0439780', 'C4319952', 'C1517741', 'C1442488', 'C1964257', 'C3889687', 'C3714741', 'C1511726']","['Observation in research', 'Data (eukaryote)', 'Health Assessment Questionnaire Disability Index With Pain Visual Analog Scale Questionnaire', 'Codependency Assessment Inventory', 'Forward', 'CDAN1 gene', 'Health Assessment Questionnaire Disability Index', 'Last Observation Carried Forward Imputation Technique', 'Changed status', 'Baseline', 'Clinical Observation', 'Data call receiving device', 'Changing', 'CDAN1 wt Allele', 'Patient observation', 'Change -- procedure', 'BaseLine dental cement', 'Observation - diagnostic procedure', 'Last', 'Delta (difference)', 'Data']","['gngm', 'hlca', 'topp', 'idcn', 'medd', 'inpr', 'qnco', 'qlco', 'ftcn', 'resa', 'euka', 'bodm', 'diap', 'spco']"
1422,PMC4145439,S77,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,non-responder imputation was used for analysis of % patients with das28(crp) <2.6 to control for missing values.,"['C3890735', 'C3272743', 'C1551393', 'C0030705', 'C2699638', 'C1705492', 'C1524024', 'C0042295', 'C4048285', 'C0936012']","['C-Reactive Protein, human', 'Container status - Missing', 'Analysis', 'Complete Response with Incomplete Platelet Recovery', 'Missing Study Animal', 'analysis aspect', 'Patients', 'Statistical Imputation', 'Values', 'Missing']","['imft', 'fndg', 'qlco', 'resa', 'podg', 'ftcn', ' aapp']"
1423,PMC4145439,S78,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,the number of prior failed tnf inhibitors was included as a categorical covariate in all statistical analyses.,"['C0243077', 'C0237753', 'C0038215', 'C1448177', 'C0449788', 'C2826257', 'C0444868', 'C0332152']","['All', 'Prior Medication Usage', 'Count of entities', 'inhibitors', 'TNF protein, human', 'Before', 'Science of Statistics', 'Numbers']","['tmco', 'chvf', 'ocdi', 'qnco', 'bacs', ' aapp', 'evnt']"
1424,PMC4145439,S79,"['12a', '12b']","[0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,"unless otherwise stated, all statistical tests were two-sided.","['C0444868', 'C0237913', 'C0205448']","['Statistical Test', 'Two', 'All']","['qnco', 'inpr']"
1425,PMC4145439,S80,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analyses,"power and sample size calculations were based upon simulations for change from baseline in das28 at all assessed postbaseline visits, using the mmrm method specified for the primary efficacy analysis.","['C1705241', 'C0205225', 'C0168634', 'C0521125', 'C0392747', 'C1512346', 'C0936012', 'C0443172', 'C4321252', 'C0025663', 'C0871511', 'C0545082', 'C1707887', 'C0242618', 'C1516048', 'C1280519', 'C0032863', 'C3854080', 'C4319952', 'C0444868', 'C0449851', 'C0679083', 'C1442488', 'C1515981', 'C1524024', 'C0205369']","['Patient Visit', 'And', 'Power', 'Specific qualifier value', 'Visit', 'Effectiveness', 'Techniques', 'analysis aspect', 'Assessed', 'Changed status', 'Baseline', 'Changing', 'All', 'Test Method', 'WWOX wt Allele', 'Change -- procedure', 'Preposition For', 'Methods', 'BaseLine dental cement', 'Sample Size', 'Power (Psychology)', 'Primary', 'Analysis', 'Efficacy Study', 'Delta (difference)', 'simulation']","['bodm', 'gngm', 'hcpp', 'idcn', 'topp', 'hlca', 'inpr', 'qnco', 'qlco', 'lbpr', 'bhvr', 'resa', 'ftcn', 'acty']"
1426,PMC4145439,S82,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Pharmacokinetic/pharmacodynamic analyses,"blood samples for determination of plasma okz, tcz and anti-okz antibodies were collected at baseline and at each subsequent visit.","['C0332282', 'C1442488', 'C1457900', 'C0032105', 'C0168634', 'C2826704', 'C1515981', 'C0178913', 'C0545082', 'C0003241', 'C0521095', 'C1512346', 'C1148554', 'C4521445']","['BaseLine dental cement', 'Patient Visit', 'Following', 'Baseline', 'Visit Name', 'Each (qualifier value)', 'And', 'Antibodies', 'Determined by', 'Determination Aspects', 'Plasma Product', 'Plasma', 'Visit', 'Blood specimen']","['tmco', 'imft', 'bodm', 'idcn', 'hlca', 'bdsu', 'inpr', 'qnco', 'qlco', 'lbpr', 'bhvr', ' aapp', ' phsu', 'phsu']"
1427,PMC4145439,S83,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Pharmacokinetic/pharmacodynamic analyses,non-linear mixed modelling was employed for the analysis of the okz pk data.,"['C0205430', 'C3160715', 'C1511726', 'C3245479', 'C3714741', 'C1524024', 'C0936012']","['Data call receiving device', 'Mixed Cell Morphology', 'Analysis', 'Data (eukaryote)', 'analysis aspect', 'Mixed (qualifier value)', 'Data']","['fndg', 'medd', 'idcn', 'euka', 'resa', 'ftcn']"
1428,PMC4145439,S84,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Pharmacokinetic/pharmacodynamic analyses,the final population pk model was used to derive individual concentration or exposure measures for use in the pk/pd analyses which involved describing the relationship between pk measures and multiple efficacy and safety endpoints via mixed effects methodology.,"['C3274659', 'C0237401', 'C0205430', 'C1705630', 'C3827302', 'C1565156', 'C0521125', 'C1314939', 'C1705187', 'C1446561', 'C3540605', 'C3266812', 'C4321252', 'C1257890', 'C0032659', 'C0205103', 'C0205088', 'C0079809', 'C1280500', 'C3853528', 'C0042153', 'C1546485', 'C1706279', 'C1707887', 'C3714583', 'C0027361', 'C1280519', 'C3160715', 'C0036043', 'C2349179', 'C1421478', 'C0043194', 'C0439849', 'C0457083', 'C0969625', 'C3853906', 'C0086045', 'C3161035', 'C1515981', 'C0332157', 'C1273517', 'C0439064']","['Object Relationship', 'Exposure to', 'End-stage', 'And', 'Measures', 'Safety', 'geographic population', 'used by', 'utilization qualifier', 'Concentration measurement', 'Diagnosis Type - Final', 'Effectiveness', 'Model Number', 'Digital Model Attachment', 'Persons', 'Methodology', 'Safety Study', 'Model - style/design', 'Wiskott-Aldrich Syndrome', 'Concept Relationship', 'Population Group', 'Individual', 'Relationships', 'Mixed Cell Morphology', 'Model', 'WAS gene', 'WWOX wt Allele', 'Methodology aspects', 'Mental concentration', 'Effect', 'Mixed (qualifier value)', 'Preposition For', 'Intermediate', 'Able to Concentrate Question', 'Numerous', 'WAS protein, human', 'Usage', 'Efficacy Study', 'Involvement with', 'End Point', 'CDISC Relationship Class', 'Final']","['tmco', 'fndg', 'gngm', 'hcpp', 'idcn', 'inpr', 'qnco', 'qlco', 'bacs', 'dsyn', 'spco', 'resa', 'ftcn', 'popg', 'menp', ' aapp', 'cnce']"
1429,PMC4145444,S40,"['4a', '4b']","[0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Subjects,children with active rickets were identified using radiographs of the wrists and the knees from among children who presented with leg deformities to the primary care setting of the family medicine department of the jos university teaching hospital in the geographic centre of nigeria (10° north latitude).,"['C1306645', 'C3853793', 'C1704729', 'C1709269', 'C0023216', 'C1515981', 'C0035579', 'C0041740', 'C1527361', 'C1627936', 'C0205099', 'C0028075', 'C0000872', 'C0205177', 'C0680063', 'C1632984', 'C1538301', 'C1140621', 'C4034203', 'C0000768', 'C0332287', 'C3888249', 'C0022742', 'C0020027', 'C1517526', 'C0449450', 'C0043262', 'C0033137', 'C0008059', 'C0015607', 'C1517320', 'C3272598']","['Active License', 'Academic Medical Centers', 'active (HL7 RoleLink)', 'And', 'deformities qualifier', 'From', 'Congenital Abnormality', 'Primary Health Care', 'Wrist', 'Geographic', 'Leg', 'Care setting', 'Central', 'Offspring', 'Teaching Hospitals', 'Active', 'Latitude', 'Knee', 'WHO Temperature/Humidity Storage Condition', 'Department', 'Nigeria', 'Rickets', 'Lower Extremity', 'ATXN3 gene', 'In addition to', 'Universities', 'Child', 'Latitude:Angle:Point in time:Cancer.To be specified in another part of the message:Quantitative', 'Presentation', 'Plain x-ray', 'North', 'family medicine (field)']","['clna', 'famg', 'mnob', 'qlco', 'hlca', 'diap', ' hcro', 'bmod', 'bpoc', 'geoa', ' mnob', 'aggp', 'gngm', 'idcn', 'cgab', 'ftcn', 'blor', 'dsyn', 'spco', 'qnco', 'orgt']"
1430,PMC4145444,S41,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Subjects,children were eligible for enrolment if they had a radiographic score of at least 2.5 on a validated 10-point scoring method that assessed the severity of rickets in the growth plates of the distal radius and ulna and around the knee.5,"['C0022742', 'C0008059', 'C0439793', 'C0036449', 'C0444708', 'C4050231', 'C0750503', 'C1552961', 'C3714763', 'C1515981', 'C0035579', 'C0018283', 'C0680063', 'C0022745', 'C1548635', 'C2347617', 'C0588207', 'C0700296', 'C0522510', 'C0449820']","['Epiphysial cartilage', 'distal radius', 'Eligible', 'Point', 'radius and ulna', 'Severities', 'radiographic', 'Scoring Methods', 'Knee joint', 'Knee', 'And', 'With intensity', 'around', 'Rickets', 'point - UnitsOfMeasure', 'ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated', 'Point Name', 'Offspring', 'Score', 'Child']","['bsoj', 'bpoc', 'clna', 'idcn', 'aggp', 'famg', 'spco', 'blor', 'qlco', 'resa', 'dsyn', 'npop', 'qnco']"
1431,PMC4145444,S42,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Subjects,"approval for the study was obtained from the ethical committee of the jos university teaching hospital and the institutional review board of mayo clinic, and written informed consent was obtained from a parent of each enrolled child.","['C1515981', 'C0041740', 'C4684790', 'C1565156', 'C2699423', 'C1301820', 'C0021430', 'C0000872', 'C0026531', 'C2603343', 'C0043194', 'C0680063', 'C2699414', 'C1538301', 'C2697909', 'C0002424', 'C0020027', 'C0442592', 'C1457900', 'C0086911', 'C0008059', 'C1517320', 'C0205540', 'C1421478', 'C1077578', 'C0030551', 'C2346845']","['Academic Medical Centers', 'Approved', 'And', 'From', 'Approval (document)', 'Ethics Committees, Research', 'Bikinia le-testui', 'Morality', 'Clinic', 'WAS protein, human', 'WAS gene', 'Study Subject Enrolled', 'Informed Consent', 'Committee', 'Offspring', 'parent', 'Each (qualifier value)', 'Letter of Authorization', 'Teaching Hospitals', 'Conceptual Parent', 'Study', 'ATXN3 gene', 'Ambulatory Care Facilities', 'Universities', 'Child', 'Wiskott-Aldrich Syndrome', 'Obtain']","['bacs', 'famg', 'plnt', 'mnob', 'fndg', 'qlco', ' hcro', 'inpr', 'idcn', ' mnob', 'aggp', 'gngm', 'prog', 'resa', ' aapp', 'rnlw', 'ftcn', 'dsyn', 'grup', 'cnce', 'qnco', 'orgt']"
1432,PMC4145444,S43,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Subjects,"data were collected regarding symptoms of rickets, the frequency and quantity of dairy product intake, and usual sunlight exposure.","['C1511726', 'C0683368', 'C1554108', 'C1515981', 'C0035579', 'C0559267', 'C3714741', 'C0376249', 'C0871396', 'C0332157', 'C3538928', 'C1265611', 'C3898838', 'C1705502', 'C4321352', 'C1457887', 'C0439603', 'C3245479', 'C1561573', 'C0038817', 'C1561548']","['Usual', 'And', 'Data call receiving device', 'Dairy Product intake', 'Frequencies (time pattern)', 'Kind of quantity - Frequency', 'Data Type - Quantity', 'MDF Attribute Type - Quantity', 'Symptoms', 'Statistical Frequency', 'Rickets', 'Symptoms aspect', 'Frequency', 'Data', 'Exposure to', 'Sunlight', 'Quantity', 'Spatial Frequency', 'With frequency', 'Data (eukaryote)', 'How Often']","['sosy', 'inpr', 'idcn', 'medd', 'ftcn', 'fndg', 'qlco', 'euka', 'tmco', 'dsyn', 'npop', 'qnco']"
1433,PMC4145444,S44,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Subjects,the percentage of unclothed skin at enrolment was estimated with a lund and browder age-related burn chart.,"['C0444099', 'C1561533', 'C1123023', 'C0001779', 'C1549488', 'C0439165', 'C0007963', 'C0684240', 'C1515981', 'C4520765']","['Money or percentage indicator - Percentage', 'Charts (publication)', 'Skin', 'Charts (device)', 'Percent (qualifier value)', 'And', 'Age', 'Amount type - Percentage', 'Skin Specimen', 'Skin, Human']","['inpr', 'idcn', 'medd', 'bdsu', 'bdsy', 'qnco', 'orga']"
1434,PMC4145444,S45,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Subjects,standing height was measured with a wall-mounted stadiometer.,"['C0677535', 'C0424645']","['Walls of a building', 'standing height']","['mnob', 'orga']"
1435,PMC4145444,S46,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Subjects,"two 24-h dietary recalls were obtained on separate days to determine energy, phosphorus and calcium intake.","['C0443299', 'C3540037', 'C0031705', 'C0012155', 'C0006726', 'C1442080', 'C0424589', 'C1512806', 'C2936886', 'C1515981', 'C0006675', 'C4330907', 'C0080014', 'C0205448', 'C0439228', 'C3714611', 'C3714498', 'C2699635', 'C0542479']","['Overall Energy Level', 'Energy, Physics', 'Dietary Route of Administration', 'day', 'Phosphorus Drug Class', 'Calcium [EPC]', 'And', 'Diet', 'Dietary Phosphorus', 'Phosphorus', 'Two', 'Intake', 'Vitality', 'Energy', 'CALCIUM SUPPLEMENTS', 'Calcium', 'Calcium Drug Class', 'Separate', 'Calcium, Dietary']","['bacs', 'inpr', 'idcn', 'inch', ' elii', 'elii', 'ftcn', 'fndg', 'qlco', 'vita', 'food', 'tmco', ' phsu', 'npop', 'qnco', 'phsu']"
1436,PMC4145444,S47,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Subjects,energy and mineral intakes were calculated using food composition tables for african foods.6–8,"['C0424589', 'C0027567', 'C1442080', 'C0039224', 'C0486616', 'C0026162', 'C0016452', 'C1515981', 'C1555710', 'C3540798', 'C1706074', 'C0006660', 'C4330907', 'C0542479']","['Overall Energy Level', 'Data Table', 'African race', 'Food', 'And', 'Composition', 'Minerals', 'Act Class - Attestable unit', 'Physiologic calcification', 'Food allergenic extracts', 'Vitality', 'Energy', 'Table - furniture', 'Energy, Physics']","['ortf', 'inpr', 'idcn', 'inch', 'popg', 'mnob', 'fndg', 'qlco', 'imft', 'food', ' phsu', 'npop', 'qnco']"
1437,PMC4145444,S48,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Subjects,weight was measured with a hanging weighing scale.,"['C1305866', 'C0043100', 'C1947916', 'C0175659', 'C1705104', 'C0349674', 'C0005910', 'C0544691']","['Scaling', 'Body Weight', 'Intellectual scale', 'Weight', 'Hanging', 'Weighing patient', 'Importance Weight', 'Weight measurement scales']","['inpr', 'acty', 'inpo', 'medd', 'qlco', 'hlca', 'qnco', 'orga']"
1438,PMC4145444,S49,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Subjects,"anthropometric z-scores were calculated with epi info 3.2.2 (cdc, atlanta, georgia, usa).","['C0162734', 'C0017452', 'C4084772', 'C4085194', 'C4281721', 'C1533716', 'C0007670', 'C2993063', 'C0449820']","['Tissue Factor Pathway Inhibitor, human', 'Information', 'Complement dependent cytotoxicity', 'Georgia, USA', 'Conventional Dendritic Cell', 'Centers for Disease Control and Prevention (U.S.)', 'Echo-Planar Imaging', 'Score', 'Atlanta']","['bacs', 'geoa', ' aapp', 'lbpr', 'idcn', 'euka', 'hcro', 'cell', 'diap', 'qnco']"
1439,PMC4145444,S50,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Subjects,all children were examined for clinical signs of rickets.,"['C0008059', 'C3540840', 'C0035579', 'C0680063', 'C0444868']","['All', 'Rickets', 'Sign or Symptom', 'Offspring', 'Child']","['aggp', 'famg', 'fndg', 'dsyn', 'qnco']"
1440,PMC4145444,S51,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Subjects,"dual energy x-ray absorptiometry of the left distal and proximal 1/3 forearm was performed by a single investigator (tdt) with a portable densitometer (norland pdexa, model 476a110).","['C1306645', 'C3853906', 'C3891450', 'C1515981', 'C0043309', 'C1554184', 'C4330907', 'C3161035', 'C3274659', 'C0034571', 'C0332287', 'C0035173', 'C4264326', 'C0443246', 'C0043299', 'C4522154', 'C0424589', 'C1442080', 'C0205173', 'C3714583', 'C0542479', 'C0180321', 'C0016536', 'C1552822', 'C1962945', 'C4299032', 'C0205108', 'C0205171', 'C0087136', 'C3887634', 'C1706216', 'C0205091']","['Model Number', 'Densitometer', 'Distal Resection Margin', 'And', 'Model', 'Research Personnel', 'Vitality', 'Unmarried', 'Proximal 1/3', 'Overall Energy Level', 'Duplicate', 'Radiography Study File', 'Dual', 'roentgenographic', 'Portable', 'Energy, Physics', 'Diagnostic radiologic examination', 'Left sided', 'Singular', 'Left', 'Table Cell Horizontal Align - left', 'In addition to', 'Energy', 'Roentgen Rays', 'Distal (qualifier value)', 'DNA Nucleotidylexotransferase, human', 'Plain x-ray', 'Model - style/design', 'Digital Model Attachment', 'Radiographic imaging procedure', 'Forearm', 'Densitometer Device']","['inpr', 'bpoc', 'clna', 'idcn', 'prog', 'enzy', 'medd', 'ftcn', 'mnob', 'spco', 'cnce', 'fndg', 'blor', ' aapp', 'diap', 'npop', 'qnco']"
1441,PMC4145444,S52,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Subjects,"the densitometer had a short-term in vivo precision of 6.4% for areal bone density at the distal radius and ulna, and 7.2% at the proximal 1/3 radius and ulna, and a long-term in vitro precision of 1.1%.","['C1515981', 'C0443252', 'C4321252', 'C1547902', 'C0700296', 'C0021135', 'C0005938', 'C0588207', 'C2350002', 'C1705313', 'C4264326', 'C2827718', 'C2826302', 'C1282927', 'C1806781', 'C0233324', 'C0180321', 'C1533691', 'C1515273', 'C0521125', 'C0177804', 'C1706245', 'C1706216']","['Bone Mineral Density Test', 'Densitometer', 'And', 'Term (temporal)', 'in vitro', 'Preposition For', 'WWOX wt Allele', 'Term (lexical)', 'Proximal 1/3', 'In Vitro Route of Administration', 'Short', 'radius and ulna', 'Shortened', 'Long-term', 'Term Birth', 'distal radius', 'Precision - characteristic', 'Short Value', 'In Vitro [Publication Type]', 'Reported Term', 'Precision - temporal', 'Bone Density', 'Densitometer Device']","['clna', 'inpr', 'bpoc', 'idcn', 'gngm', 'medd', 'ftcn', 'blor', 'mnob', 'qlco', 'tmco', 'diap', 'orgf', 'qnco']"
1442,PMC4145444,S54,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Intervention,all children were treated with calcium carbonate as powdered limestone.,"['C0008059', 'C3715099', 'C0007026', 'C0680063', 'C0444868', 'C0205688']","['carbonate ion', 'Carbonates', 'Limestone', 'All', 'Offspring', 'Child']","['inch', 'aggp', 'famg', 'elii', 'orch', ' phsu', 'qnco']"
1443,PMC4145444,S55,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Intervention,powdered limestone was locally available at a much lower cost than calcium tablets.,"['C1548802', 'C3540037', 'C1517927', 'C0039225', 'C0006726', 'C2936886', 'C2003888', 'C4281574', 'C4050363', 'C0006675', 'C0470187', 'C0010186', 'C0220812', 'C3714611', 'C0205688', 'C0441994']","['Lower - spatial qualifier', 'Locally', 'Lower (action)', 'Limestone', 'availability of', 'Calcium [EPC]', 'Much', 'Cost aspects', 'Comprehensive Score for Financial Toxicity', 'Tablet Dosage Form', 'CALCIUM SUPPLEMENTS', 'Body Site Modifier - Lower', 'Calcium', 'Financial cost', 'Calcium Drug Class', 'Calcium, Dietary']","['bacs', 'inpr', 'bodm', 'inch', ' elii', 'acty', 'ftcn', 'blor', 'spco', 'fndg', 'vita', ' phsu', 'qnco', 'phsu']"
1444,PMC4145444,S56,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Intervention,"the content of elemental calcium in 1.0 g of limestone was 268 mg (courtesy of michael gruzak, usda/ars children's nutrition research center, houston, texas, usa).","['C0039711', 'C0008059', 'C0041703', 'C0456205', 'C0683939', 'C0006675', 'C0423896', 'C0680063', 'C4085595', 'C0085410', 'C0205688', 'C1521729']","['Limestone', 'Texas', 'Calcium', 'research center', 'Contents', 'Feeling content', 'United States', 'Offspring', 'Nutritional Study', 'United States Department of Agriculture', 'AL-RAQAD SYNDROME', 'Child']","['bacs', 'geoa', 'inch', 'aggp', ' elii', 'famg', ' mnob', 'cnce', ' phsu', 'resa', 'dsyn', 'menp', 'orgt']"
1445,PMC4145444,S57,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Intervention,samples of limestone had no toxic concentrations of heavy metals.,"['C0086045', 'C0205688', 'C0857329', 'C0347988']","['No Toxicity', 'Mental concentration', 'Metals, Heavy', 'Limestone']","['inch', 'menp', 'elii', 'sosy']"
1446,PMC4145444,S58,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Intervention,one level teaspoon of powdered limestone (approximately 3.5 g=938 mg of elemental calcium) was mixed with the child's food or porridge twice daily.,"['C0008059', 'C2946261', 'C1547707', 'C0441889', 'C1704619', 'C0205447', 'C0016452', 'C0006675', 'C0585361', 'C0332232', 'C0680063', 'C3540798', 'C0205688']","['Twice a day', 'approximately', 'Limestone', 'Food', 'Level', 'Floor - story of building', 'Levels (qualifier value)', 'Offspring', 'Food allergenic extracts', 'Teaspoon Dosing Unit', 'One', 'Calcium', 'Child']","['bacs', 'geoa', 'inch', 'aggp', ' elii', 'famg', 'qlco', 'imft', 'food', 'tmco', ' phsu', 'qnco']"
1447,PMC4145444,S59,"['8b', '10']","[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0]",Intervention,"enrolled children were randomised by coin toss (performed by tdt) to receive under direct observation either oral vitamin d2 as 50 000 iu (ergocalciferol; pliva, inc., east hanover, new jersey) once every 4 weeks (ca+d group) or placebo, which was a single vitamin b complex tablet, once every 4 weeks (ca group) for 24 weeks.","['C1550369', 'C2700257', 'C0039225', 'C0441833', 'C0687744', 'C1705223', 'C4684790', 'C1565156', 'C1948045', 'C1696465', 'C0043194', 'C0680063', 'C4699984', 'C1514756', 'C0027971', 'C3714696', 'C1705429', 'C3844638', 'C0524669', 'C1416599', 'C0442027', 'C0008059', 'C0032042', 'C1519504', 'C1948061', 'C1706408', 'C0205171', 'C0087136', 'C0016410', 'C1257890', 'C0042849', 'C3887634', 'C1421478', 'C1705428', 'C1707877', 'C0014695', 'C0542339']","['Direct observation', 'Inferior', 'Ergocalciferol Drug Product', 'placebo', 'Receive', 'Stage Grouping', 'Every (qualifier)', 'East', 'Unmarried', 'Either', 'Coins', 'WAS protein, human', 'WAS gene', 'User Group', 'Placebos', 'Study Subject Enrolled', 'Offspring', 'Group Object', 'Once (schedule frequency)', 'Social group', 'KCNK6 gene', 'Oral', 'Vitamin D2 Measurement', 'Folic Acid', 'Singular', 'Tablet Dosing Unit', 'Ergocalciferol', 'Child', 'Placebo Control', 'DNA Nucleotidylexotransferase, human', 'Groups', 'Wiskott-Aldrich Syndrome', 'Population Group', 'Vitamin B Complex', 'Performed By', 'Tablet Dosage Form', 'New Jersey']","['bacs', ' orch', 'famg', 'enzy', 'topp', 'mnob', 'fndg', 'qlco', ' phsu', 'diap', 'geoa', 'idcn', 'lbpr', 'aggp', 'gngm', 'vita', 'resa', ' aapp', 'bodm', 'popg', 'ftcn', 'tmco', 'dsyn', 'spco', 'cnce', 'qnco']"
1448,PMC4145444,S60,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Intervention,subjects returned every 4 weeks for their supplements and assessment of adverse events.,"['C1261322', 'C0877248', 'C1948061', 'C1515981', 'C1705413', 'C1516048']","['Adverse Event Domain', 'Evaluation procedure', 'And', 'Adverse event', 'Every (qualifier)', 'Assessed']","['inpr', 'idcn', 'acty', 'patf', 'qlco', 'hlca']"
1449,PMC4145444,S61,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Intervention,the weight of limestone remaining at each visit was recorded to assess adherence.,"['C1305866', 'C1527428', 'C0043100', 'C2826704', 'C1457900', 'C1512346', 'C0545082', 'C1510802', 'C1705104', 'C0005910', 'C0205688']","['Remaining', 'Body Weight', 'Limestone', 'Visit', 'Patient Visit', 'Visit Name', 'Weight', 'Weighing patient', 'Adherence (attribute)', 'Each (qualifier value)', 'Importance Weight']","['inpr', 'inch', 'ftcn', 'qlco', 'bhvr', 'hlca', 'qnco', 'orga']"
1450,PMC4145444,S62,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Intervention,"height, weight, venous blood, wrist and knee radiographs, and forearm bone density measurements were obtained at baseline and at 12 and 24 weeks after enrolment.","['C1322271', 'C0168634', 'C0177804', 'C0005910', 'C1305866', 'C0043100', 'C0229667', 'C0242485', 'C0489786', 'C1515981', 'C0005938', 'C1550615', 'C1705104', 'C1442488', 'C0016536', 'C2338243', 'C0043262', 'C0203273']","['Bone Mineral Density Test', 'BaseLine dental cement', 'Wrist', 'Baseline', 'Body Weight', 'Importance Weight', 'Specimen Type - Blood venous', 'Wrist joint', 'Height', 'And', 'Weight', 'Radiologic examination of knee', 'Venous blood substance', 'Portion of venous blood', 'Measurement', 'Weighing patient', 'Bone Density', 'Forearm']","['bsoj', 'bpoc', 'clna', 'idcn', 'qnco', 'ftcn', 'blor', 'tisu', 'qlco', 'bdsu', 'hlca', 'diap', 'bodm', 'orga']"
1451,PMC4145444,S63,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Intervention,serum samples were stored at −20°c until transported frozen to the mayo clinic for analysis.,"['C0442592', 'C0936012', 'C0229671', 'C1546774', 'C1524024', 'C1077578', 'C1550100', 'C0002424']","['Ambulatory Care Facilities', 'Clinic', 'Specimen Type - Serum', 'Analysis', 'Serum', 'Bikinia le-testui', 'Specimen Source Codes - Serum', 'analysis aspect']","['inpr', 'plnt', 'ftcn', 'mnob', 'bdsu', 'resa', ' hcro']"
1452,PMC4145444,S64,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Intervention,"serum calcium, phosphorus, alkaline phosphatase and albumin were measured with standard methods.","['C0002059', 'C0449851', 'C0728876', 'C2828392', 'C1515981', 'C1442989', 'C0025664', 'C0001924', 'C0025663', 'C0036785']","['Serum Calcium Level', 'Alkaline Phosphatase', 'Standard (document)', 'Methods', 'Techniques', 'And', 'Standard (qualifier)', 'Methods aspects', 'Albumins', 'Serum calcium measurement']","['bacs', 'inpr', 'clna', 'idcn', 'lbpr', 'enzy', 'ftcn', 'qlco', ' aapp']"
1453,PMC4145444,S65,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Intervention,serum 25(oh)d was measured by isotope-dilution liquid chromatography–tandem mass spectrometry (lc-ms/ms).9,"['C0079240', 'C1304698', 'C0302908', 'C1948037', 'C0037813', 'C4281604', 'C0229671', 'C1546774', 'C0301571', 'C0599748', 'C1550100']","['Liquid (finding)', 'Liquid diet', 'Mass Spectrometry', 'Specimen Type - Serum', 'Dilution technique', 'Dilute (action)', 'Tandem Mass Spectrometry', 'dilution', 'Serum', 'Liquid substance', 'Specimen Source Codes - Serum']","['inpr', 'lbpr', 'topp', 'ftcn', 'fndg', 'mbrt', 'bdsu', 'sbst', 'irda']"
1454,PMC4145444,S66,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Intervention,"unless otherwise indicated by subscript notation for individual metabolites, 25(oh)d refers to the total concentrations of 25(oh)d2 and 25(oh)d3.","['C0086045', 'C0237401', 'C0868996', 'C0439810', 'C1515981', 'C2825229', 'C0870883', 'C0205543', 'C0027361', 'C2698672', 'C0006657']","['Metabolite', 'Referring', 'Mental concentration', 'And', 'Other Toxicity Studies: Metabolites', 'Persons', 'Calcifediol', 'Subscript', 'Individual', 'Total', 'notation']","['bacs', 'inpr', 'rnlw', 'idcn', 'popg', 'ftcn', 'qlco', 'vita', ' phsu', 'menp']"
1455,PMC4145444,S67,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Intervention,concentrations of 25(oh)d below the limit of detection (5 nmol/l for 25(oh)d3 and 10 nmol/l for 25(oh)d2) were designated as zero for the data analysis.,"['C4284144', 'C0086045', 'C0919414', 'C1552829', 'C0010992', 'C1515981', 'C4522323', 'C4321252', 'C1524084', 'C0521125', 'C2718050', 'C0006657', 'C0542339']","['Designated', 'Inferior', 'Zero Activity Time', 'Mental concentration', 'And', 'Designated Blood Product Donation', 'Limit of Detection', 'Arabic numeral 0', 'Table Frame - below', 'Calcifediol', 'Preposition For', 'WWOX wt Allele', 'Data Analysis']","['idcn', 'gngm', 'ocac', 'ftcn', 'spco', 'fndg', 'qlco', 'vita', ' phsu', 'menp', 'qnco', 'phsu']"
1456,PMC4145444,S69,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical analysis,the primary outcome was the combined attainment of a radiographic score of 1.5 or less and a serum alkaline phosphatase concentration of 350 u/l or less.,"['C0086045', 'C1274040', 'C4050231', 'C1446561', 'C3827302', 'C1515981', 'C0205225', 'C0036776', 'C0439092', 'C0444708', 'C0547044', 'C0205195', 'C0449820']","['Concentration measurement', 'Smaller', 'Less Than', 'Mental concentration', 'And', 'Combined', 'Serum alkaline phosphatase measurement', 'ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated', 'radiographic', 'Result', 'Score', 'Able to Concentrate Question', 'Primary']","['clna', 'inpr', 'idcn', 'lbpr', 'ftcn', 'qlco', 'menp', 'npop', 'qnco']"
1457,PMC4145444,S70,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical analysis,all radiographs were scored independently by two of the authors (tdt and prf) and the mean score was used for analysis.,"['C1306645', 'C3812881', 'C0936012', 'C1515981', 'C1524024', 'C3887634', 'C0444868', 'C3533236', 'C0205448']","['author', 'DNA Nucleotidylexotransferase, human', 'Mean score', 'All', 'And', 'Plain x-ray', 'Analysis', 'Two', 'analysis aspect']","['idcn', 'prog', 'enzy', 'ftcn', 'fndg', 'resa', ' aapp', 'diap', 'qnco']"
1458,PMC4145444,S71,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analysis,"based on the primary outcome measures of radiographic score and serum alkaline phosphatase values and sds based on previous studies (1.6 for radiographic score and 150 u/l in alkaline phosphatase), 40 subjects in each treatment group would provide 80% power and 95% ci to detect a difference between groups of 1.0 in final radiographic score and 100 u/l in alkaline phosphatase.","['C1705428', 'C0441833', 'C4050231', 'C0687744', 'C0032863', 'C1705169', 'C3887704', 'C1515981', 'C4321252', 'C3891454', 'C0444708', 'C3853528', 'C0002059', 'C1546485', 'C1705938', 'C1527178', 'C1999230', 'C1705242', 'C0039798', 'C3813719', 'C3538994', 'C1552839', 'C1457900', 'C1705429', 'C0042295', 'C0036776', 'C4084760', 'C0205225', 'C0086749', 'C0205156', 'C0521125', 'C0449820', 'C1519504', 'C1257890', 'C0087111', 'C3854080', 'C1552607', 'C0947630', 'C0205103', 'C1533734', 'C1705241', 'C0442726', 'C1522326', 'C0205088']","['Biomaterial Treatment', 'And', 'Detected (finding)', 'Providing (action)', 'Act Relationship Subset - previous', 'Power', 'Preposition For', 'Stage Grouping', 'WWOX wt Allele', 'Therapeutic procedure', 'Delta (difference)', 'Sheehan Disability Scale Questionnaire', 'Final', 'Diagnosis Type - Final', 'User Group', 'Administration procedure', 'Serum alkaline phosphatase measurement', 'Group Object', 'Each (qualifier value)', 'Social group', 'Outcome Measures', 'Intermediate', 'Treatment Epoch', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Dosing Days to Detection', 'End-stage', 'Base - General Qualifier', 'Basis - conceptual entity', 'Groups', 'Alkaline Phosphatase', 'Power (Psychology)', 'Previous', 'Table Rules - groups', 'Population Group', 'Treating', 'Values', 'ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated', 'Scientific Study', 'radiographic', 'Score', 'Different', 'Symptom Distress Scale', 'Primary']","['hcpp', 'clna', 'enzy', 'topp', 'fndg', 'qlco', 'hlca', 'inpr', 'idcn', 'lbpr', 'gngm', 'resa', ' aapp', 'npop', 'popg', 'ftcn', 'tmco', 'acty', 'cnce', 'spco', 'qnco']"
1459,PMC4145444,S72,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"data analysis was performed with excel 2003 (microsoft corp., redmond, washington, usa) and jmp v.9.0.1 (sas institute inc., cary, north carolina, usa).","['C3811068', 'C0041703', 'C1272753', 'C1426104', 'C2740529', 'C0010992', 'C1515981', 'C0043038', 'C0028407', 'C0605290', 'C0021622', 'C1823519']","['NANS gene', 'North Carolina', 'Institutes', 'And', 'TSPAN31 gene', 'Institution (social concept)', 'United States', 'Washington state', 'PSMB8 wt Allele', 'SAS', 'Data Analysis', 'Excel']","['idcn', 'geoa', 'gngm', 'ocac', 'orch', ' phsu', 'orgt']"
1460,PMC4145444,S73,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"unless otherwise noted, means and sds are reported for continuous variables with normal distributions, and medians are reported for non-normally distributed variables.","['C1704970', 'C1704711', 'C0549183', 'C4288581', 'C0439828', 'C1515981', 'C4084760', 'C0028377', 'C0549178', 'C1518422', 'C3813719']","['Sheehan Disability Scale Questionnaire', 'Distribution', 'And', 'Continuous', 'Midline (qualifier value)', 'Variable (uniformity)', 'Means', 'Notable', 'Normal Statistical Distribution', 'Symptom Distress Scale', 'Negation']","['inpr', 'idcn', 'ftcn', 'cnce', 'spco', 'qlco', 'qnco']"
1461,PMC4145444,S74,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"a paired t-test was used to compare values of continuous normally distributed variables with baseline values, and an unpaired t-test was used to compare values of continuous variables between groups.","['C0022885', 'C0168634', 'C2700112', 'C1515976', 'C1552839', 'C0441833', 'C1704711', 'C0687744', 'C0042295', 'C1515981', 'C0439828', 'C1709450', 'C0549178', 'C1442488', 'C0456984', 'C0392366', 'C3831328', 'C4318744', 'C0039593']","['BaseLine dental cement', 'Test Result', 'Baseline', 'Pair', 'Groups', 'Distribution', 'Laboratory Procedures', 'Tests (qualifier value)', 'And', 'Testing', 'Table Rules - groups', 'Anatomic Structure, System, or Substance', 'Continuous', 'Variable (uniformity)', 'Values', 'Unpaired', 'Test - temporal region', 'Blood Products Laboratory Testing', 'Social group']","['inpr', 'idcn', 'qnco', 'lbpr', 'clas', 'popg', 'lbtr', 'ftcn', 'blor', 'qlco', 'bodm']"
1462,PMC4145444,S75,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,the wilcoxon test was used to compare non-normally distributed variables.,"['C0871608', 'C1704711', 'C1518422', 'C0439828']","['Distribution', 'Variable (uniformity)', 'Negation', 'Wilcoxon Signed Rank Test']","['ftcn', 'inpr', 'qlco']"
1463,PMC4145444,S76,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,logistic regression was used to assess the effect of treatment group on the primary outcome while controlling for baseline group differences and to test for interactions between variables.,"['C0441833', 'C0687744', 'C1705169', 'C3887704', 'C0439828', 'C1515981', 'C1274040', 'C0206031', 'C1442488', 'C0039798', 'C3538994', 'C1705429', 'C1280500', 'C0205225', 'C1518681', 'C0168634', 'C1519504', 'C1257890', 'C0087111', 'C1522326', 'C1533734', 'C1705428', 'C2348382']","['Baseline', 'Biomaterial Treatment', 'And', 'Effect, Appearance', 'Stage Grouping', 'Therapeutic procedure', 'Outcome of Therapy', 'User Group', 'Administration procedure', 'Variable (uniformity)', 'Group Object', 'Social group', 'BaseLine dental cement', 'Treatment Epoch', 'Logistic Regression', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Effect', 'Groups', 'Treating', 'Population Group', 'Result', 'Primary']","['idcn', 'qnco', 'topp', 'popg', 'ftcn', 'cnce', 'fndg', 'qlco', 'resa', 'hlca', 'bodm']"
1464,PMC4145444,S77,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,p values less than 0.05 were considered significant.,"['C0237881', 'C0042295', 'C1546944', 'C0439092', 'C0750502']","['Event Seriousness - Significant', 'Less Than', 'Statistical Significance', 'Significant', 'Values']","['qlco', 'qnco', 'idcn']"
1465,PMC4213545,S37,"['3a', '4b']","[0, 0, 0, 0, 0, 0, 1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"this phase 3, randomized, double-blind study in patients with moderate to severe copd was conducted in 222 centers throughout north america, australia, and new zealand (nct01437397) in accordance with the international conference on harmonization/good clinical practice guidelines and the declaration of helsinki.","['C0324547', 'C0439561', 'C1705764', 'C0030705', 'C1412502', 'C1515981', 'C0004340', 'C4085643', 'C1080058', 'C4050466', 'C0027978', 'C0205099', 'C4049705', 'C4050465', 'C1705765', 'C4049706', 'C2347038', 'C3826813', 'C0205081', 'C0205082', 'C0205173', 'C1881878', 'C4321335', 'C0282461', 'C2986419', 'C0028405', 'C0282451']","['Borg Category-Ratio 10 Perceived Exertion Score 5', 'And', 'International Conference on Harmonization', 'Patients', 'Moderate Level', 'Doubling', 'Duplicate', 'Moderate (severity modifier)', 'North America', 'Severe (severity modifier)', 'ARCN1 gene', 'Central', 'Phase 3 Clinical Trials', 'Moderate Extremity Pain', 'New Zealand Rabbits', 'Good Clinical Practice', 'Borg Category-Ratio 10 Perceived Exertion Score 3', 'Phase 3', 'Blinded Clinical Study', 'Australia', 'Moderation', 'Clinical Practice Guideline', 'Severe Extremity Pain', 'New Zealand', 'Moderate Response', 'Double Value Type', 'This (eukaryote)']","['inpr', 'idcn', 'geoa', 'acty', 'gngm', 'ftcn', 'spco', 'fndg', 'podg', 'qlco', 'euka', 'resa', 'tmco', 'mamm']"
1466,PMC4213545,S38,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"the protocol was approved by the institutional review board at each study center, and all patients gave written informed consent before participating in any study procedures.","['C0030705', 'C4282383', 'C1515981', 'C2700391', 'C0205099', 'C3810851', 'C3715209', 'C0021430', 'C3272371', 'C0442711', 'C2599718', 'C1522729', 'C2603343', 'C1507394', 'C1552551', 'C3538935', 'C0184661', 'C1457900', 'C0086911', 'C0025664', 'C0444868', 'C2348563']","['REMS Protocol', 'And', 'Patients', 'Methods aspects', 'Center of town', 'Study Protocol', 'Ethics Committees, Research', 'Procedure Domain', 'Any Data Type', 'Protocol - answer to question', 'Clinical trial protocol', 'Clinical trial protocol document', 'Informed Consent', 'Protocols documentation', 'Central', 'Each (qualifier value)', 'Any', 'All', 'Study', 'Procedure (set of actions)', 'Library Protocol', 'Interventional procedure']","['inpr', 'rnlw', 'idcn', 'prog', 'topp', 'ftcn', 'fndg', 'spco', 'podg', 'qlco', 'resa', 'qnco']"
1467,PMC4213545,S39,"['11a', '3a']","[0, 0, 1, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,the study comprised a 2- to 3-week run-in period prior to a 24-week double-blind treatment period (figure 1).,"['C1705764', 'C0439230', 'C1705169', 'C1705765', 'C0205173', 'C0456909', 'C1948053', 'C0087111', 'C0439531', 'C0150108', 'C3887704', 'C2603343', 'C1522326', 'C1533734', 'C0525065', 'C3274438', 'C0332152', 'C0039798', 'C3538994']","['Doubling', 'Duplicate', 'Treatment Epoch', 'Run-in Period', 'week', 'Biomaterial Treatment', 'Blindness', 'Administration procedure', 'Study', 'Blinded', 'Treating', 'per period (qualifier value)', 'therapeutic aspects', 'Before', 'Period (temporal qualifier)', 'Therapeutic procedure', 'treatment - ActInformationManagementReason', 'Double Value Type', 'Visually Impaired Persons']","['acty', 'topp', 'ftcn', 'cnce', 'fndg', 'tmco', 'qlco', 'podg', 'resa', 'hlca']"
1468,PMC4213545,S40,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,"patients were equally randomized to twice-daily aclidinium/formoterol fdc 400/12 μg, aclidinium/formoterol fdc 400/6 μg, aclidinium 400 μg, formoterol 12 μg, or placebo, administered via a multidose, dry-powder inhaler (genuair®/pressair®)*.","['C0032042', 'C1512080', 'C3812285', 'C3539652', 'C0030705', 'C1706408', 'C1521801', 'C2699757', 'C1948050', 'C0011682', 'C1696465', 'C1550513', 'C0332173', 'C3853847', 'C0205222', 'C0340427', 'C1413520', 'C0060657']","['Placebo Control', 'formoterol', 'Dryness (characteristic)', 'Dry Powder Inhaler', 'Daily', 'LAG3 wt Allele', 'Placebos', 'Patients', 'aclidinium', 'Familial dilated cardiomyopathy', 'CMD1B gene', 'SEMA6A wt Allele', 'Desiccation', 'placebo', 'Dry', 'Twice (Numerical Qualifier)', 'Having administered', 'via']","['idcn', 'qnco', 'gngm', 'topp', 'ftcn', 'orch', 'podg', 'tmco', 'qlco', 'resa', ' phsu', 'npop', 'bodm', 'dsyn']"
1469,PMC4213545,S41,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,"the first patient/first visit was october 4, 2011 and the last patient completed february 6, 2013.",,,
1470,PMC4213545,S42,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design,figure 1 study design.,"['C0035171', 'C2986888', 'C2983265']","['Research Design', 'CDISC SEND Study Design Terminology', 'Nonclinical Study Design']","['inpr', 'resa']"
1471,PMC4213545,S43,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design,"acl400/for12 fdc, fixed-dose combination of aclidinium 400 μg and formoterol 12 μg; acl400/for6 fdc, fixed-dose combination of aclidinium 400 μg and formoterol 6 μg; d, day; wk, week.","['C0178602', 'C3539652', 'C3811910', 'C1947911', 'C2699757', 'C0439230', 'C1515981', 'C0332173', 'C0439228', 'C0340427', 'C1413520', 'C0060657']","['day', 'formoterol', 'week', 'And', 'LAG3 wt Allele', 'combination - answer to question', 'Daily', 'CMD1B gene', 'Familial dilated cardiomyopathy', 'aclidinium', 'combination of objects', 'Dosage']","['idcn', 'gngm', 'phob', 'fndg', 'orch', 'tmco', ' phsu', 'qnco', 'dsyn']"
1472,PMC4213545,S45,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"patients aged ≥40 years were eligible if they were current or former smokers (≥10 pack-years) and diagnosed with stable, moderate to severe expiratory airflow obstruction according to gold guidelines (postbronchodilator forced expiratory volume in 1 second [fev1]/forced vital capacity [fvc] <70% and fev1 ≥30% and <80% predicted) [1].","['C1304897', 'C2828395', 'C0205436', 'C0030705', 'C1515981', 'C1705190', 'C4085643', 'C1548635', 'C0430511', 'C0521116', 'C4050466', 'C0457385', 'C4049705', 'C1999167', 'C0337671', 'C4050465', 'C1306036', 'C4049706', 'C0162791', 'C0205081', 'C1882136', 'C0205082', 'C1968515', 'C1547311', 'C2713474', 'C0220845', 'C1561503', 'C0205360', 'C0018026', 'C1881878', 'C0011900', 'C4321335', 'C0681842', 'C0282423', 'C0439234', 'C1705970', 'C2825051', 'C0016529', 'C3714541', 'C0028778', 'C0042834', 'C0001779', 'C0001792']","['Old age', 'Electrical Current', 'Forced expiratory volume procedure', 'Former smoker', 'Borg Category-Ratio 10 Perceived Exertion Score 5', 'And', 'Patients', 'Elderly (population group)', 'Gold color', 'Forced expiratory volume function', 'Expiratory Airflow', 'Moderate Level', 'Forced Vital Capacity', 'Patient Condition Code - Stable', 'Moderate (severity modifier)', 'Diagnosis', 'Age', 'Severe (severity modifier)', 'Current (present time)', 'Packing (action)', 'Stable status', 'Obstruction within Medical Device', 'guiding characteristics', 'Moderate Extremity Pain', 'Second Suffix', 'Pack unit', 'Borg Category-Ratio 10 Perceived Exertion Score 3', 'Vital capacity test', 'Gold', 'year', 'seconds', 'Moderation', 'Vital capacity', 'Pack (physical object)', 'Eligible', 'Guideline [Publication Type]', 'Obstruction', 'Precision - second', 'second (number)', 'Severe Extremity Pain', 'prediction', 'Guidelines', 'Moderate Response']","['ortf', 'clna', 'inpr', 'idcn', 'acty', 'elii', 'drdd', 'popg', 'lbtr', 'medd', 'fndg', 'patf', 'qlco', 'podg', 'tmco', ' phsu', 'diap', 'npop', 'qnco', 'orga']"
1473,PMC4213545,S46,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"main exclusion criteria were: copd exacerbation or respiratory tract infection ≤6 weeks (≤3 months if hospitalized for exacerbation) before screening; clinically significant respiratory conditions (including asthma); clinically significant cardiovascular (cv) conditions including myocardial infarction (mi) within the previous 6 months; unstable angina; and, unstable arrhythmia that required changes in pharmacological therapy or other intervention within the previous 6 months.","['C0439231', 'C1542147', 'C0443343', 'C4321252', 'C0680251', 'C0237881', 'C0886296', 'C0007226', 'C0439230', 'C0004096', 'C0701159', 'C1883468', 'C0031330', 'C1710477', 'C3810814', 'C0039798', 'C1546767', 'C4552959', 'C3887460', 'C0027051', 'C2348164', 'C0003811', 'C0184661', 'C1710031', 'C1546944', 'C0443172', 'C0205225', 'C0205156', 'C0521125', 'C0521346', 'C1710032', 'C0220908', 'C0750502', 'C0002965', 'C0332257', 'C2984299', 'C0392747', 'C0205464', 'C2926063', 'C1698960', 'C0087111', 'C1363945', 'C0220909', 'C1552607', 'C3714514', 'C0428953', 'C4086268', 'C1185740']","['respiratory', 'Myocardial Infarction ECG Assessment', 'Myocardial Infarction', 'research subject screening', 'Asthma', 'Statistical Significance', 'Specimen Source Codes - Respiratory', 'Exclusion Criteria', 'Electrocardiogram: myocardial infarction (finding)', 'month', 'Act Relationship Subset - previous', 'hospitalized', 'Preposition For', 'WWOX wt Allele', 'Therapeutic procedure', 'Main', 'Tract', 'Unstable Medical Device Problem', 'Cardiac Arrhythmia', 'Aspects of disease screening', 'Cardiovascular system', 'Changed status', 'Cardiovascular', 'Significant', 'Nursing interventions', 'Screening procedure', 'Myocardial infarction:Finding:Point in time:^Patient:Ordinal', 'Asthma Pathway', 'Myocardial Infarction, CTCAE', 'Trial Screening', 'Event Seriousness - Significant', 'Changing', 'Unstable status', 'week', 'therapeutic aspects', 'Screening', 'pharmacological', 'Disease Screening', 'Pharmacology', 'Angina, Unstable', 'Screening Study', 'Previous', 'Including (qualifier)', 'Exacerbation', 'Therapy Object (animal model)', 'Interventional procedure', 'Infection', 'Primary']","['clna', 'topp', 'fndg', 'qlco', 'bdsy', 'hlca', 'diap', 'bmod', 'inpr', 'bpoc', 'idcn', 'gngm', 'lbtr', 'patf', 'resa', 'ftcn', 'blor', 'tmco', 'dsyn', 'cnce', 'qnco']"
1474,PMC4213545,S47,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Patients,use of long-acting bronchodilators other than investigative treatment was not permitted.,"['C0006280', 'C1706317', 'C3887704', 'C1705169', 'C0087111', 'C0042153', 'C0457083', 'C1522326', 'C1533734', 'C0205166', 'C1518422', 'C0039798', 'C3538994']","['Long', 'Negation', 'Treatment Epoch', 'utilization qualifier', 'Biomaterial Treatment', 'Treating', 'Administration procedure', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Bronchodilator Agents', 'Therapeutic procedure', 'Long Variable', 'Usage']","['topp', 'ftcn', 'cnce', 'qlco', 'resa', 'hlca', 'phsu']"
1475,PMC4213545,S48,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Patients,"other copd medications, such as theophylline, inhaled corticosteroids (ics), oral or parenteral corticosteroids (≤10 mg/day or 20 mg every other day of prednisone) were allowed if treatment was stable ≥4 weeks prior to screening.","['C0032952', 'C3887704', 'C1705169', 'C1412502', 'C0558287', 'C0001617', 'C3540727', 'C4284232', 'C0439230', 'C2598133', 'C0039771', 'C3540726', 'C0802604', 'C3539185', 'C0004048', 'C1710477', 'C1547311', 'C3538994', 'C0039798', 'C2348164', 'C0205360', 'C1710031', 'C3540725', 'C0332173', 'C0439228', 'C0013227', 'C0442027', 'C0332152', 'C1710032', 'C0220908', 'C1698960', 'C0087111', 'C0220909', 'C0030547', 'C1522326', 'C1533734', 'C2826257', 'C0815320', 'C4551720']","['research subject screening', 'day', 'Biomaterial Treatment', 'Therapeutic procedure', 'Corticosteroid ophthalmologic and otologic preparations', 'Parenteral Nutrition', 'Patient Condition Code - Stable', 'Medications', 'Prednisone', 'Aspects of disease screening', 'Administration procedure', 'ARCN1 gene', 'Screening procedure', 'Before', 'Medications:-:Point in time:^Patient:-', 'Stable status', 'Corticosteroid otologicals', 'Trial Screening', 'Primary Ciliary Dyskinesia', 'Prior Medication Usage', 'Adrenal Cortex Hormones', 'Oral', 'Treatment Epoch', 'week', 'Corticosteroid nasal preparations for topical use', 'Daily', 'Medications:Presence or Identity:Duration of the study:^Patient:Nominal', 'every other day', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Inspiration function', 'Screening', 'Impaired Control Scale', 'Disease Screening', 'Pharmaceutical Preparations', 'Theophylline', 'Screening Study', 'Treating', 'Corticosteroids, topical for treatment of hemorrhoids and anal fissures']","[' orch', 'inpr', 'clna', 'gngm', 'topp', 'ftcn', 'cnce', 'spco', 'orch', 'tmco', ' phsu', 'resa', 'horm', 'hlca', 'evnt', 'qlco', 'diap', 'orgf', 'phsu', 'dsyn']"
1476,PMC4213545,S49,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Patients,use of albuterol/salbutamol as rescue medication was permitted.,"['C3244316', 'C4284232', 'C0001927', 'C0457083', 'C0013227', 'C0042153']","['Albuterol', 'Pharmaceutical Preparations', 'medication - HL7 publishing domain', 'Medications', 'utilization qualifier', 'Usage']","['inpr', 'ftcn', 'orch', ' phsu', 'phsu']"
1477,PMC4213545,S51,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes and assessments,"coprimary efficacy parameters, assessed by standardized spirometric measurements of lung function [14], were change from baseline to week 24 in 1-hour morning postdose fev1 (each fdc versus aclidinium, contribution of formoterol) and change from baseline to week 24 in morning predose (trough) fev1 (each fdc versus formoterol, contribution of aclidinium).","['C0242485', 'C1515981', 'C0444506', 'C1413520', 'C0060657', 'C0035245', 'C3539652', 'C0439230', 'C1442488', 'C0332170', 'C1280519', 'C1457900', 'C4319952', 'C0443172', 'C1707887', 'C0340427', 'C0168634', 'C0392747', 'C1517320', 'C2699757', 'C1880177', 'C1705241', 'C0439227']","['Baseline', 'Effectiveness', 'Hour', 'And', 'CMD1B gene', 'Familial dilated cardiomyopathy', 'From', 'Delta (difference)', 'Efficacy Study', 'formoterol', 'Contribution', 'Changed status', 'LAG3 wt Allele', 'Each (qualifier value)', 'Measurement', 'BaseLine dental cement', 'Changing', 'week', 'Change -- procedure', 'trough', 'Respiratory physiology', 'aclidinium', 'Morning']","['bodm', 'idcn', 'acty', 'gngm', 'phsf', 'topp', 'ftcn', 'orch', 'qlco', 'tmco', 'resa', ' phsu', 'qnco', 'dsyn']"
1478,PMC4213545,S52,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes and assessments,secondary efficacy parameters were change from baseline in st. george’s respiratory questionnaire (sgrq) total score at week 24 (each fdc versus placebo) and improvement in transition dyspnea index (tdi) focal score at week 24 (each fdc versus placebo).,"['C0205436', 'C4050231', 'C1515981', 'C0027627', 'C1413520', 'C3539652', 'C1696465', 'C0439230', 'C0205234', 'C0013404', 'C1442488', 'C0599156', 'C1546767', 'C1552854', 'C1280519', 'C2964552', 'C2986546', 'C0034394', 'C1457900', 'C0918012', 'C4319952', 'C0443172', 'C0340427', 'C1707887', 'C0521346', 'C1963100', 'C0449820', 'C0032042', 'C2700061', 'C0168634', 'C0392747', 'C2674784', 'C1706408', 'C0205976', 'C2986411', 'C0600653', 'C1705241', 'C3714807', 'C0175668']","['respiratory', 'Baseline', 'Effectiveness', 'Index', 'Specimen Source Codes - Respiratory', 'And', 'Questionnaires', 'CMD1B gene', 'Familial dilated cardiomyopathy', 'placebo', 'Secondary to', 'TLX1NB gene', 'Delta (difference)', 'Efficacy Study', 'Improvement', 'Changed status', 'LAG3 wt Allele', 'Placebos', 'Tolylene Diisocyanate', 'Each (qualifier value)', 'Dyspnea, CTCAE', 'Html Link Type - index', 'Transition (action)', 'BaseLine dental cement', 'Changing', 'week', 'Total score', 'Change -- procedure', 'Transition Mutation', 'Dyspnea', 'Focal', 'Target Lesion Identification', 'Placebo Control', 'Neoplasm Metastasis', 'second (number)', 'Indexes', 'ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated', 'Score', 'Transition Dyspnea Index Questionnaire']","['clna', ' orch', 'topp', 'neop', 'fndg', 'qlco', 'diap', 'inpr', 'idcn', 'gngm', 'resa', 'bodm', 'sosy', 'comd', 'ftcn', 'hops', 'tmco', 'dsyn', 'acty', 'spco', 'cnce', 'qnco']"
1479,PMC4213545,S53,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes and assessments,additional treatment comparisons for each coprimary parameter included: each aclidinium/formoterol fdc dose versus each monotherapy; each active treatment versus placebo; and aclidinium/formoterol fdc 400/12 μg versus aclidinium/formoterol fdc 400/6 μg.,"['C3887704', 'C1705169', 'C1704532', 'C1413520', 'C0060657', 'C3539652', 'C1696465', 'C0549193', 'C0039798', 'C3538994', 'C0178602', 'C1704769', 'C1457900', 'C2350001', 'C0340427', 'C0332257', 'C0032042', 'C1706408', 'C2699757', 'C0087111', 'C1522326', 'C1533734', 'C1524062']","['Biomaterial Treatment', 'CMD1B gene', 'Familial dilated cardiomyopathy', 'placebo', 'Therapeutic procedure', 'Population Parameter', 'Active Method', 'formoterol', 'Additional', 'LAG3 wt Allele', 'Placebos', 'Administration procedure', 'Each (qualifier value)', 'Dosage', 'Treatment Epoch', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Placebo Control', 'Including (qualifier)', 'Parameter Value', 'Treating', 'aclidinium', 'Programming Parameter']","['bodm', 'gngm', 'topp', 'ftcn', 'cnce', 'orch', 'resa', ' phsu', 'hlca', 'qnco', 'dsyn']"
1480,PMC4213545,S54,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes and assessments,"additional efficacy parameters included: change from baseline in peak fev1 at all visits; 12-hour spirometry measurements (in a subset of the intention-to-treat [itt] population) based on change from baseline in fev1 at all study visits; sgrq and baseline/transition dyspnea index (bdi/tdi) at all study visits except week 24; rescue medication use; onset of action of bronchodilation; and, daily copd symptoms assessed by the exacerbations of chronic pulmonary disease tool (exact)-respiratory symptoms (e-rs) questionnaire [15].","['C2827396', 'C0683368', 'C3537072', 'C1292734', 'C0242485', 'C1412502', 'C1515981', 'C1515021', 'C3889415', 'C0032659', 'C1371299', 'C0162425', 'C0439230', 'C0013404', 'C0240320', 'C2603343', 'C1442488', 'C0599156', 'C3714938', 'C2828393', 'C1552854', 'C1280519', 'C1283828', 'C0006448', 'C2986546', 'C0034394', 'C0545082', 'C0918012', 'C4050514', 'C4319952', 'C0443172', 'C0332173', 'C1457887', 'C3714807', 'C1707887', 'C1963100', 'C0746102', 'C0444505', 'C2700061', 'C0168634', 'C0392747', 'C2674784', 'C0037090', 'C3266814', 'C1512346', 'C0037981', 'C0332162', 'C1257890', 'C0087111', 'C0205976', 'C0600653', 'C0441472', 'C1522326', 'C0444868', 'C1705241', 'C0451022', 'C1524062', 'C0206132', 'C0439227']","['Age of Onset', 'Baseline', 'Effectiveness', 'Index', 'Visit', 'Hour', 'geographic population', 'Questionnaires', 'And', 'Peak level', 'TLX1NB gene', 'Therapeutic procedure', 'Delta (difference)', 'Burundi', 'Biodynamic Imaging', 'Efficacy Study', 'Spirometry', 'Chronic lung disease', 'medication use', 'Bronchodilation [PE]', 'Additional', 'Changed status', 'Beck depression inventory', 'ARCN1 gene', 'Bronchodilation', 'Tolylene Diisocyanate', 'Treatment intent', 'Dyspnea, CTCAE', 'Html Link Type - index', 'Signs and Symptoms, Respiratory', 'Measurement', 'Symptoms', 'Intention - mental process', 'Transition (action)', 'BaseLine dental cement', 'intent', 'Changing', 'All', 'Patient Visit', 'Daily', 'week', 'Subgroup', 'Study', 'Change -- procedure', 'Symptoms aspect', 'Transition Mutation', 'Dyspnea', 'Target Lesion Identification', 'Clinical action', 'Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome Questionnaire', 'Onset of (contextual qualifier)', 'Action', 'Baseline Dyspnea Index Questionnaire', 'Treating', 'Population Group', 'Indexes', 'Exact (qualifier)', 'Scientific Equipment', 'Transition Dyspnea Index Questionnaire']","['ortf', ' orch', 'topp', 'fndg', 'mnob', 'qlco', 'hlca', 'diap', 'inpr', 'idcn', 'geoa', 'gngm', 'clas', 'resa', 'bodm', 'sosy', 'popg', 'comd', 'ftcn', 'hops', 'tmco', 'dsyn', 'menp', 'acty', 'bhvr', 'qnco']"
1481,PMC4213545,S55,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes and assessments,"a nighttime symptoms of copd instrument (nisci) [16,17] and an early morning symptoms of copd instrument (emsci) [18]—newly developed patient reported outcome measures undergoing empirical testing—were completed twice daily by patients using the electronic diary.","['C0683368', 'C0030705', 'C0013850', 'C1279919', 'C0348000', 'C4281784', 'C1412502', 'C1515981', 'C0585361', 'C0376660', 'C1457887', 'C1547561', 'C4277735', 'C0332170', 'C4554108']","['Twice a day', 'And', 'Patient-Reported Survey Instrument', 'Electronic', 'Authorization Mode - Electronic', 'ARCN1 gene', 'Patients', 'Diary', 'Early', 'Patient Reported Outcome Measures', 'Symptoms aspect', 'Instrument - device', 'Morning', 'Electronics discipline', 'Symptoms']","['sosy', 'inpr', 'idcn', 'gngm', 'ocdi', 'ftcn', 'mnob', 'podg', 'tmco', 'hlca']"
1482,PMC4213545,S56,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes and assessments,"safety was assessed through reporting of adverse events (aes), clinical laboratory tests, vital signs, electrocardiograms (ecgs), and 24-hour 12-lead holter monitoring.","['C0023175', 'C0036043', 'C0877248', 'C0181586', 'C1442948', 'C1412268', 'C0013798', 'C3275067', 'C0518766', 'C1705413', 'C1515981', 'C2699274', 'C1522538', 'C1705187', 'C0013801', 'C0700287', 'C2348269', 'C0439227']","['Electrocardiogram', 'Safety', 'Lead', 'Adverse Event Domain', 'Reporting', 'Safety Study', 'Hour', 'And', 'AES gene', 'Plumbum metallicum, homeopathic preparation', 'Leading', 'Adverse event', 'Scanning Auger Spectrometer (device)', 'Holter Electrocardiography', 'Leads (device)', 'Vital signs', 'Cardiac Lead Procedure', 'Dietary Lead']","['hcpp', 'clna', 'inpr', 'idcn', ' hops', 'inch', 'gngm', 'elii', 'topp', 'ftcn', 'mnob', 'patf', 'tmco', 'resd', 'resa', ' phsu', 'hlca', 'diap']"
1483,PMC4213545,S57,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes and assessments,"major adverse cardiovascular events (mace) were defined as the composite of cv deaths, nonfatal mis, and nonfatal strokes.","['C1547335', 'C0205164', 'C1320716', 'C1333208', 'C3538735', 'C1412384', 'C0038454', 'C0949745', 'C1515981', 'C4318856', 'C0349381', 'C1445339', 'C0205199', 'C0687670', 'C0011065']","['Mace extract', 'Mace Spice', 'Major', 'Cessation of life', 'Cerebrovascular accident', 'Composite', 'And', 'Data types- Composite', 'AMH gene', 'DHX16 gene', 'Major <insect>', 'AMH wt Allele', 'cardiovascular event', 'Myristica fragrans', 'Mullerian duct inhibiting substance']","[' orch', 'idcn', 'gngm', 'plnt', 'fndg', 'qlco', 'imft', 'food', ' phsu', 'euka', 'dsyn', 'horm', ' aapp', 'orgf']"
1484,PMC4213545,S58,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes and assessments,mace were evaluated and classified by an adjudication committee of independent cardiologists who were not participating in the study and were blinded to treatment.,"['C0085862', 'C1299583', 'C2700368', 'C3887704', 'C0949745', 'C1705169', 'C0087111', 'C0175906', 'C1515981', 'C1290940', 'C2603343', 'C0349381', 'C1445339', 'C1533734', 'C1522326', 'C3272598', 'C1518422', 'C0039798', 'C3538994']","['Cardiologists', 'Mace extract', 'Independently able', 'Mace Spice', 'Treatment Epoch', 'WHO Temperature/Humidity Storage Condition', 'Adjudication Committee', 'And', 'Biomaterial Treatment', 'Treating', 'Administration procedure', 'Study', 'Independence', 'Independent for Transfer', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Therapeutic procedure', 'Myristica fragrans', 'Negation']","[' orch', 'idcn', 'prog', 'plnt', 'topp', 'ftcn', 'cnce', 'fndg', 'qlco', 'imft', 'food', 'resa', ' phsu', 'hlca']"
1485,PMC4213545,S59,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes and assessments,"to identify all mace, a list of all aes that were reported in randomized patients based on standard medical dictionary for regulatory activities (meddra) queries of cardiac disorders and cerebrovascular disorders was used.","['C0030705', 'C1515981', 'C0745732', 'C0220905', 'C1412268', 'C0034656', 'C0007820', 'C0441655', 'C1442989', 'C0349381', 'C0012113', 'C1704735', 'C2828392', 'C0949745', 'C1140263', 'C2699274', 'C0018799', 'C3272378', 'C1445339', 'C0444868', 'C3815594']","['Randomization', 'Standard (document)', 'And', 'Patients', 'Cerebrovascular Disorders', 'Sequence Data Type', 'Regulator', 'Standard (qualifier)', 'Myristica fragrans', 'Mace Spice', 'Dictionary, Medical', 'All', 'Scanning Auger Spectrometer (device)', 'List', 'regulatory', 'Heart Diseases', 'Mace extract', 'Subject is Randomized', 'Medical Dictionary for Regulatory Activities Terminology (MedDRA)', 'AES gene', 'Activities']","['fndg', ' orch', 'inpr', 'rnlw', 'idcn', 'acty', 'gngm', 'plnt', 'mnob', 'cnce', 'podg', 'imft', 'food', ' phsu', 'resa', 'dsyn', 'resd', 'qlco', 'qnco']"
1486,PMC4213545,S60,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes and assessments,assessments for all efficacy and safety outcomes occurred at various timepoints throughout the study (additional file 1: table s1).,"['C3540769', 'C0036043', 'C1261322', 'C0016094', 'C0039224', 'C1515981', 'C3540765', 'C3540766', 'C2603343', 'C3540763', 'C1706074', 'C1280519', 'C3540762', 'C1707887', 'C3540761', 'C3540008', 'C0180853', 'C1522646', 'C0444868', 'C1705187', 'C1524062']","['Effectiveness', 'Data Table', 'various antiseptic throat preparations', 'Evaluation procedure', 'And', 'various allergen extracts', 'Safety', 'Table - furniture', 'Efficacy Study', 'Additional', 'various antiinfectives and antiseptics for local oral treatment', 'various other agents for local oral treatment in ATC', 'file device', 'VARIOUS DRUG CLASSES IN ATC', 'All', 'Study', 'File (record)', 'various other nasal preparations in ATC', 'Safety Study', 'Filed', 'various other intestinal adsorbents in ATC']","['hcpp', 'inpr', 'idcn', 'ocac', 'medd', 'ftcn', 'mnob', 'qlco', 'imft', ' phsu', 'resa', 'hlca', 'qnco', 'phsu']"
1487,PMC4213545,S62,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,statistical analyses were performed using sas® version 9.2.,"['C0333052', 'C0038215']","['Science of Statistics', 'Version']","['inpr', 'ocdi']"
1488,PMC4213545,S63,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"all efficacy analyses with the exception of e-rs were based on the itt population, defined as all randomized patients who took ≥1 dose of study medication and had a baseline and at least one postbaseline fev1 assessment.","['C1261322', 'C0030705', 'C1515981', 'C0032659', 'C4284232', 'C0034656', 'C0205447', 'C2603343', 'C1442488', 'C1705938', 'C1527178', 'C1280519', 'C0178602', 'C3244316', 'C0013227', 'C1707887', 'C1705847', 'C0168634', 'C1554961', 'C1257890', 'C0444868', 'C3272598', 'C1516048', 'C3815594']","['Baseline', 'Effectiveness', 'Randomization', 'medication - HL7 publishing domain', 'Evaluation procedure', 'geographic population', 'And', 'Patients', 'exception - ResponseLevel', 'Efficacy Study', 'Medications', 'Dosage', 'BaseLine dental cement', 'Exception - Property or Attribute', 'All', 'WHO Temperature/Humidity Storage Condition', 'Study', 'One', 'Base - General Qualifier', 'Basis - conceptual entity', 'Pharmaceutical Preparations', 'Subject is Randomized', 'Population Group', 'Assessed']","['inpr', 'idcn', 'bodm', 'acty', 'popg', 'ftcn', 'cnce', 'fndg', 'qlco', 'podg', 'resa', 'hlca', 'qnco', 'phsu']"
1489,PMC4213545,S64,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"e-rs data were analyzed for the itt-exacerbation population, which included all patients in the randomized population who took at least 1 dose of double-blind investigational product.","['C4688482', 'C1511726', 'C1705764', 'C0032659', 'C0030705', 'C3245479', 'C0178602', 'C1705765', 'C0205173', 'C0034656', 'C1257890', 'C0456909', 'C3815594', 'C0150108', 'C0444868', 'C0525065', 'C3714741', 'C4086268', 'C3272598', 'C0332257']","['Doubling', 'Duplicate', 'Randomization', 'Subject is Randomized', 'All', 'WHO Temperature/Humidity Storage Condition', 'geographic population', 'Data call receiving device', 'Blindness', 'Patients', 'Population Group', 'Blinded', 'Exacerbation', 'Including (qualifier)', 'Investigational Product', 'Visually Impaired Persons', 'Data (eukaryote)', 'Data', 'Double Value Type', 'Dosage']","['idcn', 'acty', 'popg', 'medd', 'ftcn', 'fndg', 'cnce', 'podg', 'qlco', 'euka', 'resa', 'qnco']"
1490,PMC4213545,S65,"['12a', '12b']","[0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"change from baseline in bronchodilation outcomes were analyzed by mixed model for repeated measures (mmrm) with treatment group, sex, smoking status, visit, and treatment-group-by-visit interaction as fixed-effect factors and corresponding baseline values and age as covariates, and pre- and postbronchodilator fev1 as a covariate for fev1 outcomes.","['C3853906', 'C3537072', 'C0441833', 'C1705169', 'C0687744', 'C3887704', 'C1515981', 'C4321252', 'C0205430', 'C3161035', 'C0740175', 'C3274659', 'C1371299', 'C0009253', 'C0804628', 'C2826704', 'C1705241', 'C1442488', 'C3714578', 'C3160715', 'C0039798', 'C3538994', 'C0545082', 'C1705429', 'C4319952', 'C0443172', 'C0042295', 'C1280500', 'C2257086', 'C0079399', 'C1518681', 'C0443218', 'C0036864', 'C1519386', 'C0521125', 'C0332152', 'C1704675', 'C2827483', 'C0168634', 'C0392747', 'C1519504', 'C0871881', 'C1512346', 'C1257890', 'C0087111', 'C1522384', 'C1522326', 'C1533734', 'C1705428', 'C3714583', 'C0001779', 'C2348382']","['Model Number', 'Gender', 'Baseline', 'Visit', 'Biomaterial Treatment', 'And', 'Fixed Specimen', 'Model', 'Effect, Appearance', 'Preposition For', 'Stage Grouping', 'WWOX wt Allele', 'Therapeutic procedure', 'Smoking Status', 'Delta (difference)', 'Gender:Type:Point in time:^Patient:Nominal', 'Outcome of Therapy', 'Sex Behavior', 'Bronchodilation [PE]', 'User Group', 'Visit Name', 'Coitus', 'Administration procedure', 'Age', 'Changed status', 'sex', 'Bronchodilation', 'Interaction', 'Before', 'Before values', 'Group Object', 'Social group', 'Fixed behavior', 'BaseLine dental cement', 'Treatment Epoch', 'Changing', 'Patient Visit', 'repeated measures', 'Mixed Cell Morphology', 'Change -- procedure', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Effect', 'Groups', 'photoreactivating enzyme activity', 'Treating', 'Population Group', 'Fix', 'Digital Model Attachment', 'Model - style/design', 'Values', 'Mixed (qualifier value)']","['ortf', 'clna', 'topp', 'fndg', 'qlco', 'bdsu', 'hlca', 'inpr', 'phpr', 'idcn', 'genf', 'gngm', 'resa', 'orgf', 'bodm', 'popg', 'ftcn', 'tmco', 'cnce', 'bhvr', 'qnco', 'orga']"
1491,PMC4213545,S66,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analysis,"a sample size of 1550 (310 per randomized group) was estimated to provide at least 90% power to detect a statistically significant treatment difference of 100 ml (standard deviation of 280 ml) between each fdc dose versus aclidinium monotherapy in change from baseline at 1-hour morning postdose fev1 at week 24, and 65 ml (standard deviation of 240 ml) between each fdc dose versus formoterol monotherapy in the change from baseline in morning predose (trough) fev1 at week 24.","['C1705428', 'C0441833', 'C1705169', 'C0687744', 'C0032863', 'C3887704', 'C1515981', 'C1565156', 'C0444506', 'C1413520', 'C0242618', 'C0060657', 'C3891454', 'C0237881', 'C3539652', 'C0750572', 'C0439230', 'C0034656', 'C0871420', 'C0043194', 'C1442488', 'C1999230', 'C0332170', 'C1705242', 'C0039798', 'C3538994', 'C0178602', 'C1457900', 'C1705429', 'C4319952', 'C0443172', 'C0340427', 'C4281991', 'C0168634', 'C0392747', 'C1517320', 'C1519504', 'C2699757', 'C3887962', 'C1257890', 'C0087111', 'C3854080', 'C0205103', 'C1533734', 'C1705241', 'C0442726', 'C1522326', 'C1421478', 'C3815594', 'C0439227']","['Baseline', 'Randomization', 'Statistical Significance', 'Biomaterial Treatment', 'Sample Size', 'And', 'Detected (finding)', 'Hour', 'CMD1B gene', 'Familial dilated cardiomyopathy', 'Providing (action)', 'Power', 'From', 'Stage Grouping', 'Standard deviation', 'Therapeutic procedure', 'Delta (difference)', 'formoterol', 'WAS protein, human', 'WAS gene', 'Changed status', 'LAG3 wt Allele', 'User Group', 'Administration procedure', 'Per (qualifier)', 'Group Object', 'Each (qualifier value)', 'Social group', 'Dosage', 'Estimated', 'BaseLine dental cement', 'Intermediate', 'Treatment Epoch', 'Changing', 'week', 'Change -- procedure', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Dosing Days to Detection', 'trough', 'Follow', 'Groups', 'Subject is Randomized', 'Power (Psychology)', 'Wiskott-Aldrich Syndrome', 'Treating', 'Population Group', 'aclidinium', 'Morning', 'Different']","['hcpp', 'bacs', 'topp', 'fndg', 'qlco', ' phsu', 'hlca', 'idcn', 'gngm', 'resa', ' aapp', 'bodm', 'popg', 'ftcn', 'orch', 'tmco', 'dsyn', 'acty', 'spco', 'cnce', 'qnco']"
1492,PMC4213545,S67,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"to control for family-wise type 1 error rate at the 2-sided 5% significance level for the primary and secondary efficacy endpoints, a prespecified multiple comparison strategy was conducted.","['C4321265', 'C0205436', 'C0743559', 'C0439064', 'C0441729', 'C1515981', 'C0027627', 'C4321252', 'C2349179', 'C1704727', 'C1608199', 'C0814896', 'C1707455', 'C0015576', 'C1280519', 'C0679199', 'C1427738', 'C0205225', 'C1707887', 'C0871208', 'C0521125', 'C4085651', 'C1521828', 'C0175668']","['Effectiveness', 'SOSTDC1 wt Allele', 'significance level', 'Rating (action)', 'And', 'Preposition For', 'Secondary to', 'WWOX wt Allele', 'Type 1', 'Family (taxonomic)', 'Act Reason - Error', 'Efficacy Study', 'Comparison', 'error', 'Family', 'strategy', 'End Point', 'Numerous', 'SOSTDC1 gene', 'Neoplasm Metastasis', 'second (number)', 'Rate', 'Bristol Stool Type 1', 'Primary']","['idcn', 'acty', 'gngm', 'famg', 'clas', 'neop', 'ftcn', 'cnce', 'fndg', 'qlco', 'resa', 'menp', 'qnco']"
1493,PMC4213545,S68,"['12a', '12b']","[0, 0, 0, 0, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"the onset of action of bronchodilation in fev1 (an additional endpoint defined as a >15% increase from baseline in fev1) from 5-minutes to 3-hours postdose on day 1 was evaluated using a logistic regression model with treatment groups, sex, and smoking status as fixed-effect factors and pre- and postbronchodilator fev1 at screening, age, and baseline fev1 as covariates.","['C3853906', 'C3537072', 'C0441833', 'C1705169', 'C0687744', 'C3887704', 'C1515981', 'C0700321', 'C1565156', 'C1704788', 'C2349179', 'C3161035', 'C0740175', 'C3274659', 'C1371299', 'C0009253', 'C0804628', 'C2826544', 'C0043194', 'C0206031', 'C1442488', 'C3714578', 'C0332287', 'C1710477', 'C1442449', 'C0039798', 'C3538994', 'C2348164', 'C1552839', 'C1710031', 'C3714583', 'C2257086', 'C1280500', 'C0220825', 'C0079399', 'C1518681', 'C0443218', 'C0036864', 'C0439227', 'C1519386', 'C0220908', 'C1710032', 'C0332152', 'C2827483', 'C0168634', 'C1517320', 'C1698960', 'C3266814', 'C0332162', 'C0087111', 'C0220909', 'C0439232', 'C1522384', 'C0441472', 'C1533734', 'C1282918', 'C1522326', 'C0442805', 'C1421478', 'C1524062', 'C0001779', 'C0206132', 'C2348382']","['Age of Onset', 'Model Number', 'Gender', 'Baseline', 'research subject screening', 'Biomaterial Treatment', 'And', 'Evaluation', 'Fixed Specimen', 'Hour', 'Model', 'Effect, Appearance', 'From', 'Smoking Status', 'Therapeutic procedure', 'Gender:Type:Point in time:^Patient:Nominal', 'Outcome of Therapy', 'Small', 'Sex Behavior', 'WAS protein, human', 'Additional', 'Bronchodilation [PE]', 'Aspects of disease screening', 'WAS gene', 'Coitus', 'Administration procedure', 'Age', 'Screening procedure', 'sex', 'Bronchodilation', 'Before', 'Before values', 'Minute (diminutive)', 'Trial Screening', 'Minute of time', 'Social group', 'Fixed behavior', 'BaseLine dental cement', 'End Point', 'Treatment Epoch', 'Logistic Regression', 'Increase', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Screening', 'Clinical action', 'In addition to', '1 Day', 'Disease Screening', 'Effect', 'Groups', 'Onset of (contextual qualifier)', 'Endpoint Value Derivation Technique', 'Action', 'photoreactivating enzyme activity', 'Screening Study', 'Wiskott-Aldrich Syndrome', 'Definition', 'Fix', 'Table Rules - groups', 'Model - style/design', 'Digital Model Attachment', 'Treating']","['ortf', 'clna', 'bacs', 'topp', 'fndg', 'qlco', 'bdsu', 'hlca', 'diap', 'inpr', 'phpr', 'idcn', 'genf', 'gngm', 'resa', ' aapp', 'orgf', 'bodm', 'popg', 'ftcn', 'tmco', 'dsyn', 'acty', 'cnce', 'bhvr', 'qnco', 'orga']"
1494,PMC4213545,S69,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,odds ratios were estimated for each treatment group versus placebo.,"['C0028873', 'C0032042', 'C1519504', 'C1706408', 'C1696465', 'C0441833', 'C1705169', 'C1457900', 'C0687744', 'C1257890', 'C0087111', 'C1705429', 'C3887704', 'C1522326', 'C1533734', 'C1705428', 'C0039798', 'C3538994']","['Placebo Control', 'Stage Grouping', 'Treatment Epoch', 'Groups', 'Biomaterial Treatment', 'User Group', 'Placebos', 'Treating', 'Administration procedure', 'Population Group', 'placebo', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Therapeutic procedure', 'Odds Ratio', 'Group Object', 'Each (qualifier value)', 'Social group']","['idcn', 'bodm', 'topp', 'popg', 'ftcn', 'cnce', 'resa', 'hlca', 'qnco']"
1495,PMC4213545,S70,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,change from baseline in tdi and sgrq were analyzed using a mmrm as described for bronchodilation outcomes.,"['C0168634', 'C0392747', 'C2674784', 'C3537072', 'C1371299', 'C0205976', 'C4319952', 'C1515981', 'C0443172', 'C1442488', 'C1705241', 'C3714807']","['BaseLine dental cement', 'Baseline', 'Changing', 'Bronchodilation [PE]', 'And', 'Changed status', 'Tolylene Diisocyanate', 'Bronchodilation', 'Change -- procedure', 'TLX1NB gene', 'Transition Dyspnea Index Questionnaire', 'Delta (difference)']","['ortf', ' orch', 'inpr', 'idcn', 'qnco', 'gngm', 'topp', 'ftcn', 'hops', 'bodm']"
1496,PMC4213545,S71,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,a logistic random-effect model was used to analyze the number and percentage of patients who achieved a clinically meaningful improvement from baseline in sgrq total score (decrease of ≥4 units) [19] or in tdi focal score (increase of ≥1 unit).,"['C3853906', 'C1561533', 'C0439605', 'C0030705', 'C4050231', 'C1515981', 'C0547047', 'C0237753', 'C3161035', 'C3274659', 'C3853603', 'C0439148', 'C0205234', 'C0034656', 'C1509845', 'C1442488', 'C1704753', 'C2964552', 'C3714583', 'C1280500', 'C0392756', 'C0449788', 'C1518681', 'C1519795', 'C0449820', 'C0168634', 'C1549488', 'C0439165', 'C1880519', 'C0439453', 'C2986411', 'C0242415', 'C0442805', 'C3272598', 'C2348382']","['Model Number', 'Baseline', 'Randomization', 'Random', 'Unit', 'And', 'Model', 'Patients', 'Effect, Appearance', 'Unit of Measure', 'Reduced', 'Enzyme Unit', 'Outcome of Therapy', 'Money or percentage indicator - Percentage', 'Improvement', 'Logistics', 'Decrease', 'BaseLine dental cement', 'Increase', 'WHO Temperature/Humidity Storage Condition', 'Numbers', 'Total score', 'Focal', 'International Unit', 'Amount type - Percentage', 'Effect', 'Count of entities', 'Unit - NCI Thesaurus Property', 'Percent (qualifier value)', 'Unit device', 'Model - style/design', 'Digital Model Attachment', 'ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated', 'Score', 'Storage Unit']","['clna', 'inpr', 'idcn', 'bodm', 'ocac', 'medd', 'ftcn', 'spco', 'cnce', 'qlco', 'podg', 'fndg', 'resa', 'mnob', 'qnco']"
1497,PMC4213545,S72,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,use of rescue medication was analyzed using averages of the daily diary values over the time periods between visits and were based on the change from baseline values.,"['C1948053', 'C1515981', 'C0347984', 'C4284232', 'C1442488', 'C1705938', 'C1527178', 'C3244316', 'C0205136', 'C0545082', 'C0042295', 'C4319952', 'C0443172', 'C0332173', 'C0376660', 'C0013227', 'C0168634', 'C0392747', 'C1512346', 'C0457083', 'C0205103', 'C1705241', 'C0042153']","['Baseline', 'medication - HL7 publishing domain', 'Visit', 'And', 'Delta (difference)', 'Usage', 'Medications', 'Changed status', 'Diary', 'BaseLine dental cement', 'Intermediate', 'Changing', 'Patient Visit', 'Daily', 'Change -- procedure', 'Period (temporal qualifier)', 'Base - General Qualifier', 'During', 'Basis - conceptual entity', 'Pharmaceutical Preparations', 'utilization qualifier', 'Values', 'Over (spatial)']","['inpr', 'idcn', 'qnco', 'topp', 'ftcn', 'spco', 'qlco', 'tmco', 'bhvr', 'hlca', 'bodm', 'phsu']"
1498,PMC4213545,S73,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"daily copd symptoms were analyzed by means of an mmrm adjusted for baseline, treatment, visit, sex, age, smoking status, and treatment-by-visit interaction.","['C0683368', 'C3887704', 'C1705169', 'C1412502', 'C1515981', 'C0009253', 'C0804628', 'C2826704', 'C1442488', 'C0039798', 'C3538994', 'C1704970', 'C0545082', 'C0332173', 'C0079399', 'C1457887', 'C0036864', 'C1519386', 'C1704675', 'C0168634', 'C1512346', 'C0087111', 'C1522384', 'C1522326', 'C1533734', 'C0001779']","['Gender', 'Baseline', 'Visit', 'Biomaterial Treatment', 'And', 'Therapeutic procedure', 'Smoking Status', 'Gender:Type:Point in time:^Patient:Nominal', 'Sex Behavior', 'Visit Name', 'Coitus', 'Administration procedure', 'Age', 'ARCN1 gene', 'sex', 'Interaction', 'Symptoms', 'BaseLine dental cement', 'Treatment Epoch', 'Patient Visit', 'Daily', 'Means', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Symptoms aspect', 'Treating']","['sosy', 'clna', 'inpr', 'idcn', 'qnco', 'gngm', 'topp', 'ftcn', 'cnce', 'tmco', 'bhvr', 'resa', 'hlca', 'orgf', 'bodm', 'orga']"
1499,PMC4213545,S74,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"safety results, summarized descriptively, were based on the safety population, defined as all randomized patients who took ≥1 dose of study medication.","['C0036043', 'C0032659', 'C0030705', 'C0178602', 'C4284232', 'C3244316', 'C0034656', 'C1257890', 'C2603343', 'C0444868', 'C0013227', 'C1705187', 'C3272598', 'C3815594']","['Pharmaceutical Preparations', 'Medications', 'Randomization', 'medication - HL7 publishing domain', 'Subject is Randomized', 'WHO Temperature/Humidity Storage Condition', 'Safety Study', 'geographic population', 'All', 'Patients', 'Population Group', 'Study', 'Safety', 'Dosage']","['hcpp', 'inpr', 'popg', 'fndg', 'podg', 'qlco', 'resa', 'qnco', 'phsu']"
1500,PMC4215282,S100,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,"briefly, linear, linear in log-dose, emax, sigmoid emax, logistic and exponential models were evaluated using multiple comparisons, and the data were fitted using the model with either the smallest akaike information criteria for normally distributed data or maxt for count data.","['C0242415', 'C3274659', 'C1533716', 'C0178602', 'C0205132', 'C2986775', 'C0243161', 'C3844638', 'C1704711', 'C1552645', 'C3714583', 'C0220825', 'C3245479', 'C1708728', 'C0332287', 'C0750480', 'C0227391', 'C2700395', 'C1705566', 'C1883663', 'C0036572', 'C3853906', 'C3161035', 'C1515981', 'C3714741', 'C0439064', 'C1511726']","['Logarithm', 'Count Dosing Unit', 'In addition to', 'Data (eukaryote)', 'And', 'Linear', 'Model Number', 'Digital Model Attachment', 'Seizures', 'Count', 'maxT', 'Model - style/design', 'Smallest', 'Data call receiving device', 'Sigmoid colon', 'exponential', 'Event Log', 'Model', 'Dosage', 'Numerous', 'Information', 'Either', 'criteria', 'Distribution', 'Evaluation', 'Logistics', 'Data']","['fndg', 'ocac', 'medd', 'idcn', 'hlca', 'inpr', 'sosy', 'qnco', 'euka', 'spco', 'ftcn', 'bpoc', 'cnce']"
1501,PMC4215282,S101,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,"to assess the precision of the model fitting, a bootstrap simulation was performed using 1000 iterations.","['C3274659', 'C0441548', 'C3853906', 'C1547902', 'C3161035', 'C1706245', 'C0679083', 'C1854293', 'C3714583']","['Model Number', 'Digital Model Attachment', 'Precision - characteristic', 'Fitting - action', 'Model', 'Precision - temporal', 'Iterations', 'Model - style/design', 'simulation']","['tmco', 'fndg', 'hlca', 'inpr', 'qlco', 'resa', 'cnce']"
1502,PMC4215282,S102,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,the cumulative number of new or enlarging non-enhancing t2 lesions at weeks 12–24 and the cumulative number of cuals at weeks 12 to 24 were analysed using the same statistical model and in the same patient analysis set as for the primary endpoint.,"['C0442800', 'C1518422', 'C1442518', 'C0237753', 'C1705195', 'C4321252', 'C0445247', 'C0449788', 'C0036849', 'C0439230', 'C0030705', 'C0521125', 'C1511559', 'C1515981', 'C2986535', 'C1524024', 'C0026348', 'C0205314', 'C0221198', 'C0936012']","['Same', 'set (group)', 'Set (Psychology)', 'Models, Statistical', 'Analysis', 'Cumulative', 'Primary Endpoint', 'Count of entities', 'And', 'Enlarged', 'Lesion', 'analysis aspect', 'week', 'Patients', 'Set scale', 'New', 'WWOX wt Allele', 'Preposition For', 'Negation', 'Numbers']","[' qnco', 'tmco', 'fndg', 'gngm', 'idcn', 'irda', 'inpr', 'qnco', 'qlco', 'resa', 'podg', 'ftcn', 'menp', 'cnce']"
1503,PMC4215282,S103,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,the time to first confirmed relapse was analysed using the kaplan–meier method.,"['C0205336', 'C0521093', 'C0205435', 'C0035020', 'C0025663', 'C0040223', 'C1279901', 'C0871511', 'C0750484', 'C0277556', 'C0449851']","['Methods', 'Firstly', 'Confirmed by', 'First (number)', 'Test Method', 'Confirmation', 'Time', 'Techniques', 'Relapse', 'Relapsing course', 'Recurrent disease']","['tmco', 'fndg', 'inpr', 'qlco', 'phpr', 'qnco', 'lbpr', 'dsyn', 'ftcn']"
1504,PMC4215282,S104,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,the treatment effect versus placebo was described by hrs and the 95% cis derived from a proportional hazards model.,"['C1504308', 'C1742862', 'C0033489', 'C0032042', 'C1518681', 'C1706408', 'C1696465']","['Proportional Hazards Models', 'Genus Cis', 'placebo', 'Placebo Control', 'Outcome of Therapy', 'Placebos', 'CISH protein, human']","['fndg', 'bodm', 'topp', 'qnco', 'bacs', 'euka', 'resa', ' aapp']"
1505,PMC4215282,S105,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,total lymphocyte counts were summarised for the all-treated analysis set (all randomised patients who received at least one dose of study drug); the absolute values and changes from baseline to scheduled visits and to eot (last available value) were summarised by descriptive statistics.,"['C0205447', 'C0038215', 'C0168634', 'C0470187', 'C0178602', 'C0600673', 'C0392747', 'C0086960', 'C1512346', 'C0936012', 'C0443172', 'C3272598', 'C0678257', 'C0030705', 'C0545082', 'C0042295', 'C0200635', 'C1522609', 'C0444868', 'C0013175', 'C0205539', 'C1517741', 'C1442488', 'C1515981', 'C0205344', 'C1524024']","['absolute', 'Patient Visit', 'Numerical value', 'And', 'Schedule (document type)', 'Visit', 'Description', 'analysis aspect', 'Changed status', 'Baseline', 'Statistics (publications)', 'Values', 'availability of', 'Changing', 'All', 'Scheduled - procedure status', 'Dosage', 'Patients', 'Lymphocyte Count measurement', 'One', 'Drug Evaluation', 'Science of Statistics', 'BaseLine dental cement', 'Last', 'Analysis', 'WHO Temperature/Humidity Storage Condition']","['bodm', 'idcn', 'hlca', 'ocdi', 'inpr', 'qlco', 'qnco', 'lbpr', 'bhvr', 'resa', 'podg', 'ftcn']"
1506,PMC4215282,S106,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,aes and saes were reported and summarised throughout the treatment and safety follow-up periods for the all-treated analysis set.,"['C0087111', 'C0332283', 'C1522326', 'C2699274', 'C0036043', 'C3887704', 'C1705169', 'C4281991', 'C0039798', 'C3538994', 'C1515981', 'C1412268', 'C1524024', 'C1705187', 'C1533734', 'C0936012']","['Followed by', 'treatment - ActInformationManagementReason', 'Scanning Auger Spectrometer (device)', 'Treating', 'Analysis', 'AES gene', 'Treatment Epoch', 'And', 'therapeutic aspects', 'analysis aspect', 'Safety', 'Safety Study', 'Biomaterial Treatment', 'Follow', 'Administration procedure', 'Therapeutic procedure']","['tmco', 'gngm', 'idcn', 'hcpp', 'topp', 'hlca', 'resd', 'resa', 'ftcn', 'cnce']"
1507,PMC4215282,S107,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analyses,the underlying assumption for the sample size calculation was a 50% decrease in the mean cumulative number of new gd+ lesions from weeks 12 to 24 in at least one ponesimod treatment group compared with placebo and assuming a mean of eight lesions under placebo; the anticipated sample size of 90 evaluable patients per group had a 90% power to detect a significant difference between ponesimod groups and placebo.,"['C0547047', 'C1705241', 'C0205447', 'C0237753', 'C2986511', 'C1565156', 'C3538994', 'C0439230', 'C1511559', 'C0750502', 'C0392756', 'C2934701', 'C1533734', 'C0442726', 'C1257890', 'C0087111', 'C3840775', 'C0205454', 'C0441833', 'C3887704', 'C1705169', 'C0449788', 'C0039798', 'C1706408', 'C4067746', 'C0242618', 'C1705428', 'C0205314', 'C0032863', 'C1519504', 'C2348143', 'C1552839', 'C1421478', 'C0043194', 'C1705429', 'C3854080', 'C1705242', 'C3897657', 'C0444504', 'C1522326', 'C0032042', 'C0687744', 'C1515981', 'C1696465', 'C3891454', 'C2347634', 'C1546944', 'C0221198', 'C0237881']","['Group Object', 'placebo', 'Lesion', 'Power', 'And', 'Detected (finding)', 'Eight', 'Evaluable Patient', 'Table Rules - groups', 'Sample Mean', 'Cause of death.underlying', 'Cumulative', 'Decrease', 'Count of entities', 'Population Mean', 'Treatment Epoch', 'Placebos', 'Dosing Days to Detection', 'Biomaterial Treatment', 'Administration procedure', 'User Group', 'Wiskott-Aldrich Syndrome', 'Groups', 'Population Group', 'Placebo Control', 'Reduced', 'Social group', 'WAS gene', 'Statistical Significance', 'ponesimod', 'Statistical mean', 'Anticipated', 'One', 'Event Seriousness - Significant', 'Numbers', 'Different', 'Significant', 'Sample Size Calculation', 'Sample Size', 'Power (Psychology)', 'treatment - ActInformationManagementReason', 'Treating', 'WAS protein, human', 'New', 'therapeutic aspects', 'week', 'Stage Grouping', 'Delta (difference)', 'Therapeutic procedure']","['topp', 'qnco', 'podg', 'bodm', ' aapp', 'fndg', 'idcn', 'hlca', 'inpr', 'qlco', 'bacs', 'resa', 'hcpp', 'ftcn', 'popg', 'tmco', 'orch', 'cnce', 'gngm', 'dsyn', ' phsu']"
1508,PMC4215282,S41,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"eligible patients were men and women aged 18–55 years with rrms (as defined by the revised 2005 macdonald criteria15) and an expanded disability status scale (edss) score of 0–5.5, with at least one of the following characteristics: ≥1 documented relapse(s) within the 12 months before screening; ≥2 documented relapses within the 24 months before screening or at least one t1-weighted gadolinium-enhanced (gd+) lesion detected on brain mri at screening.","['C0025266', 'C0332282', 'C0205447', 'C0035020', 'C2349975', 'C1710032', 'C0016911', 'C1305866', 'C1301725', 'C0332152', 'C0442726', 'C0043210', 'C0449820', 'C3887783', 'C2348164', 'C0030705', 'C1698960', 'C0277556', 'C1521970', 'C0412675', 'C1527075', 'C1609436', 'C4050231', 'C0205336', 'C0332285', 'C0005910', 'C0220908', 'C1548635', 'C1710031', 'C0043100', 'C1546698', 'C0220909', 'C1511790', 'C0451246', 'C1515981', 'C1710477', 'C0221198']","['Aspects of disease screening', 'Screening procedure', 'Weighing patient', 'And', 'Detected (finding)', 'Lesion', 'Detection', 'Enhance (action)', 'Characteristics', 'Eligible', 'Body Weight', 'Trial Screening', 'Following', 'Within', 'Score', 'Relapse', 'Weight', 'Woman', 'Screening', 'Relapsing course', 'Before', 'Male population group', 'Screening Study', 'Documented', 'Disease Screening', 'Patients', 'Document completion status - Documented', 'One', 'Gadolinium', 'research subject screening', 'MRI brain procedure', 'Kurtzke multiple sclerosis rating scale', 'ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated', 'Specimen Source Codes - Lesion', 'Revision procedure', 'Recurrent disease', 'Kurtzke Expanded Disability Status Scale Questionnaire']","['topp', 'qnco', 'phpr', 'podg', 'clna', 'fndg', 'hlca', 'idcn', 'inpr', 'qlco', 'resa', 'ftcn', 'popg', 'tmco', 'spco', 'acty', 'irda', 'orga', 'dsyn', 'diap', ' elii']"
1509,PMC4215282,S42,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"study exclusion criteria were use of systemic corticosteroids within 30 days of randomisation; use of immunomodulators (interferon β, glatiramer acetate) and some immunosuppressants (cyclosporine, sirolimus and mycophenolic acid) within 3 months of randomisation; use of other immunosuppressants (azathioprine, methotrexate and natalizumab) and non-lymphocyte-depleting biologic agents (eg, daclizumab) within 6 months prior to randomisation.","['C0205373', 'C0663182', 'C0010594', 'C0001617', 'C0021081', 'C1527392', 'C3540727', 'C3652465', 'C3539185', 'C0005525', 'C0332152', 'C0680251', 'C1172734', 'C0026933', 'C0042153', 'C2826257', 'C0457083', 'C0021747', 'C2603343', 'C1518422', 'C0025677', 'C0733470', 'C0072980', 'C0010592', 'C3540726', 'C0289884', 'C0205392', 'C1515981', 'C3540725', 'C0005515', 'C0001551', 'C0004482']","['Systemic', 'And', 'human leukocyte interferon', 'Cyclosporins', 'Methotrexate', 'utilization qualifier', 'Study', 'Daclizumab', 'Corticosteroid otologicals', 'natalizumab', 'Immunomodulators', 'Corticosteroids, topical for treatment of hemorrhoids and anal fissures', 'Corticosteroid ophthalmologic and otologic preparations', 'Immunologic Adjuvants', 'Interferons', 'Mycophenolic Acid', 'Adrenal Cortex Hormones', 'Biological Response Modifiers', 'Before', 'Interferon', 'Biological Factors', 'Azathioprine', 'Immunosuppressive Agents', 'Corticosteroid nasal preparations for topical use', 'Exclusion Criteria', 'Some (qualifier value)', 'Negation', 'Sirolimus', 'Prior Medication Usage', 'Usage', 'glatiramer acetate', 'Cyclosporine']","['tmco', 'imft', 'antb', 'resa', ' orch', 'idcn', 'orch', 'horm', 'bacs', 'qnco', 'hops', 'ftcn', 'aapp', ' aapp', ' phsu', 'evnt']"
1510,PMC4215282,S43,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"patients treated at any time with certain immunosuppressive (cyclophosphamide, mitoxantrone and cladribine) or lymphocyte-depleting biological agents (alemtuzumab and rituximab) were excluded from the study.","['C3272371', 'C0092801', 'C1704787', 'C2603343', 'C0383429', 'C0005515', 'C0026259', 'C0040223', 'C0021081', 'C0010583', 'C0030705', 'C1552551', 'C1515981', 'C0205423', 'C0393022']","['Immunosuppressive Agents', 'Cladribine', 'rituximab', 'Mitoxantrone', 'And', 'Time', 'Any', 'Any Data Type', 'Patients', 'Cyclophosphamide', 'Certain (qualifier value)', 'Study', 'Biological Factors', 'Definitely Related to Intervention', 'alemtuzumab']","['tmco', 'imft', 'idcn', 'inpr', 'orch', 'qlco', 'bacs', 'nnon', 'resa', 'podg', ' aapp', ' phsu']"
1511,PMC4215282,S45,"['3a', '4b']","[0, 0, 0, 0, 0, 0, 1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and procedures,"this was a prospective, multicentre and multinational (94 centres in 23 countries, including europe, australia, canada and usa), randomised, double-blind, placebo-controlled, four-arm, parallel-group, dose-finding phase iib study, conducted in accordance with the declaration of helsinki16 and adhering to the international conference on harmonisation guidelines for good clinical practice.17","['C0205173', 'C0023981', 'C0456909', 'C0220845', 'C0441769', 'C0015176', 'C0446516', 'C0178602', 'C2986419', 'C0162791', 'C0004340', 'C0454664', 'C1257890', 'C0037088', 'C0441833', 'C0041703', 'C0006823', 'C1705765', 'C4281991', 'C0150108', 'C1706408', 'C3715044', 'C0525065', 'C1705764', 'C1705428', 'C2825141', 'C1519504', 'C0457160', 'C4553528', 'C1705429', 'C0332257', 'C0086047', 'C4554418', 'C0205099', 'C2603343', 'C1512888', 'C2826345', 'C1080058', 'C2348042', 'C0243095', 'C0687744', 'C1515981', 'C0205450', 'C0282423']","['Duplicate', 'Finding', 'Group Object', 'Experimental Finding', 'Guideline [Publication Type]', 'And', 'Including (qualifier)', 'Study', 'International', 'Conferences', 'Sequence Arm', 'Double Value Type', 'Upper arm', 'Follow', 'User Group', 'Parallel Study', 'Groups', 'Population Group', 'Placebo Control', 'AKR1A1 wt Allele', 'Social group', 'Four', 'Signs and Symptoms', 'Visually Impaired Persons', 'Dosage', 'Blinded', 'Doubling', 'Central', 'Guidelines', 'guiding characteristics', 'Blindness', 'Longitudinal Studies', 'Australia', 'Canada', 'Good Clinical Practice', 'Parallel Lesion', 'United States', 'Stage 2 lower case b', 'Stage 2B', 'Stage Grouping', 'Europe', 'This (eukaryote)', 'Parallel', 'Country']","['blor', 'fndg', 'gngm', 'idcn', 'hcpp', 'clas', 'inpr', 'geoa', 'sosy', 'qnco', 'qlco', 'euka', 'resa', 'spco', 'ftcn', 'popg', 'podg', 'cnce', 'acty']"
1512,PMC4215282,S46,"['8b', '5']","[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 1, 0]",Study design and procedures,"within each investigation site, patients were randomised in a 1:1:1:1 ratio to once-daily treatment with placebo or ponesimod 10, 20 or 40 mg for 24 weeks.","['C2825164', 'C1515974', 'C0087111', 'C0220825', 'C1522326', 'C0332173', 'C0205145', 'C3887704', 'C1705169', 'C1457900', 'C1948045', 'C3538994', 'C0030705', 'C1547037', 'C0039798', 'C1261322', 'C0456603', 'C1552578', 'C1533734']","['data type - ratio', 'Once (schedule frequency)', 'Act Class - investigation', 'Evaluation', 'treatment - ActInformationManagementReason', 'Treating', 'Each (qualifier value)', 'Ratio', 'Treatment Epoch', 'therapeutic aspects', 'Patients', 'Anatomic Site', 'Evaluation procedure', 'Biomaterial Treatment', 'Daily', 'Site', 'Study Site', 'Administration procedure', 'Therapeutic procedure']","['tmco', 'blor', 'topp', 'hlca', 'inpr', 'qnco', 'spco', 'resa', 'podg', 'ftcn', 'cnce']"
1513,PMC4215282,S47,"['8a', '10']","[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0]",Study design and procedures,"patients were randomised by assignment of a unique randomisation number using an interactive voice or web response system, supplied by an independent service provider (icon clinical, research, usa).","['C3245478', 'C1516050', 'C0237753', 'C1999230', 'C0871261', 'C0242481', 'C0557854', 'C0035168', 'C0041703', 'C0042939', 'C0449913', 'C0449788', 'C0085862', 'C0030705', 'C1138603', 'C3888058', 'C4281800', 'C0282111', 'C1555587', 'C1710548', 'C1706817', 'C2911692', 'C2825316', 'C1553451', 'C1704632', 'C0243020', 'C0205210', 'C1290940', 'C1299583', 'C1704675', 'C3244282']","['System - kit', 'Providing (action)', 'Device system', 'Internet', 'Independent for Transfer', 'Voice', 'Response (communication)', 'ActInformationPrivacyReason <service>', 'Independence', 'Response process', 'Disease Response', 'Software Service', 'Unique', 'Provider', 'Count of entities', 'Interaction', 'Assignment - action', 'System', 'Independently able', 'Patients', 'Services', 'Response (statement)', 'Numbers', 'TelecommunicationCapabilities <voice>', 'Clinical', 'Research Activities', 'Voice G-code', 'research', 'United States', 'Transaction counts and value totals - provider', 'Immunoconjugates']","['imft', 'fndg', 'ocac', 'idcn', 'inpr', 'geoa', 'qlco', 'qnco', 'orga', 'orgf', 'resa', 'podg', 'ftcn', 'mnob', ' phsu', 'menp', 'acty']"
1514,PMC4215282,S48,['8b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0]",Study design and procedures,patient randomisation was stratified by centre using a block size of four for the first two blocks and eight thereafter.,"['C0456389', 'C0205454', 'C2828370', 'C0205435', 'C0028778', 'C1279901', 'C0030705', 'C3811660', 'C1515981', 'C0205448', 'C1706084', 'C0205450', 'C1533157', 'C0332206']","['Block Specimens', 'Firstly', 'Two', 'First (number)', 'Four', 'Obstruction', 'Block (unit of measure)', 'And', 'Eight', 'Patients', 'size', 'Block Unit of Distance', 'Blocking', '(City) Block']","['idcn', 'geoa', 'qnco', 'qlco', 'spco', 'podg', 'ftcn', 'patf', 'bdsu']"
1515,PMC4215282,S49,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and procedures,"the primary investigator/treating neurologist, independent evaluating neurologist, physician evaluating cardiac safety assessments, care providers, patients and sponsor were blinded to the treatment.","['C1522601', 'C0237426', 'C3538994', 'C1705187', 'C1533734', 'C0804815', 'C0087111', 'C0031831', 'C1711305', 'C1947933', 'C3887704', 'C1705169', 'C1521895', 'C0085862', 'C0030705', 'C0039798', 'C1138603', 'C0036043', 'C2347796', 'C1522326', 'C1515981', 'C1290940', 'C1261322', 'C1299583', 'C0018787']","['Neurologists', 'And', 'Independent for Transfer', 'Evaluation procedure', 'Safety', 'Independence', 'Heart', 'Provider', 'Treatment Epoch', 'Cardiac - anatomy qualifier', 'Physicians', 'Safety Study', 'Biomaterial Treatment', 'Clinical Study Sponsor', 'Administration procedure', 'Physician:Identifier:Point in time:^Patient:Nominal', 'Principal Investigator', 'Independently able', 'Patients', 'treatment - ActInformationManagementReason', 'Treating', 'Sponsor (person)', 'care activity', 'therapeutic aspects', 'Therapeutic procedure']","['fndg', 'resa', 'prog', 'topp', 'idcn', 'orgt', 'hlca', 'bpoc', 'qlco', 'hcpp', 'podg', 'ftcn', 'acty', 'popg', 'cnce', 'clna']"
1516,PMC4215282,S50,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and procedures,"the investigators and sponsor were blinded to the lymphocyte count results and first-dose effects of ponesimod, unless alerted for safety reasons.","['C0392360', 'C1711305', 'C0205435', 'C0036043', 'C1279901', 'C2347796', 'C1280500', 'C0178602', 'C1515981', 'C2934701', 'C1705187', 'C0200635', 'C0035173']","['Firstly', 'First (number)', 'Sponsor (person)', 'Research Personnel', 'And', 'ponesimod', 'Dosage', 'Indication of (contextual qualifier)', 'Effect', 'Lymphocyte Count measurement', 'Safety', 'Safety Study', 'Clinical Study Sponsor']","['popg', 'prog', 'hcpp', 'idcn', 'orgt', 'orch', 'qnco', 'qlco', 'lbpr', 'resa', ' phsu']"
1517,PMC4215282,S51,['11b'],"[0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and procedures,all ponesimod doses and matching placebo were indistinguishable and identically packaged.,"['C0032042', 'C1708943', 'C0178602', 'C1706408', 'C1515981', 'C0150103', 'C1696465', 'C2934701', 'C0444868']","['placebo', 'All', 'Placebo Control', 'And', 'Match', 'ponesimod', 'Dosage', 'Placebos', 'MATCHING']","['idcn', 'topp', 'orch', 'qnco', 'qlco', 'resa', 'bodm', ' phsu']"
1518,PMC4215282,S52,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and procedures,the dose range selected for this study was based on phase i data.12 13,"['C2603343', 'C3245479', 'C1080058', 'C0205390', 'C1514721', 'C2348147', 'C0178602', 'C1710475', 'C3714741', 'C1511726']","['Data call receiving device', 'Range', 'Data (eukaryote)', 'Dosage', 'Study', 'Trial Phase', 'This (eukaryote)', 'Phase', 'Sample Range', 'Data']","['tmco', 'medd', 'idcn', 'clas', 'qnco', 'euka', 'resa']"
1519,PMC4215282,S53,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and procedures,"ponesimod 10 mg was selected as the lowest dose as it was associated with an approximate 50% reduction in peripheral lymphocyte counts,13 which was considered as the minimum reduction required for an immunomodulatory effect.","['C1565156', 'C0332281', 'C0178602', 'C0521125', 'C0392756', 'C2934701', 'C4321252', 'C1514873', 'C1293152', 'C2348382', 'C1518681', 'C1552614', 'C1280500', 'C1708760', 'C1518997', 'C0332232', 'C1421478', 'C0043194', 'C4551656', 'C2826545', 'C0301630', 'C0750591', 'C0439157', 'C1524031']","['Effect, Appearance', 'ActRelationshipSubset - minimum', 'Surgical reduction', 'Reduction (chemical)', 'approximately', 'Wiskott-Aldrich Syndrome', 'Peripheral Blood Lymphocyte', 'Reduced', 'counts', 'Reduction procedure', 'WAS gene', 'Minimum', 'Outcome of Therapy', 'Requirement', 'ponesimod', 'Dosage', 'Minimum Value Derivation Technique', 'Effect', 'WWOX wt Allele', 'consider', 'Preposition For', 'Associated with', 'WAS protein, human', 'Lowest']","['fndg', 'npop', 'gngm', 'topp', 'idcn', 'orch', 'qlco', 'bacs', 'qnco', 'cell', 'dsyn', 'ftcn', ' aapp', ' phsu']"
1520,PMC4215282,S54,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and procedures,ponesimod 40 mg was selected as the highest dose as it was associated with an approximate 70% reduction in peripheral lymphocyte counts13; this degree of reduction has previously been shown to be associated with a significant therapeutic effect in patients with ms treated with fingolimod.18,"['C0301630', 'C1293152', 'C1699926', 'C1080058', 'C0441889', 'C4551656', 'C0030705', 'C0178602', 'C0750502', 'C0392756', 'C1518997', 'C0237881', 'C1527144', 'C2934701', 'C0332232', 'C1546944', 'C1522410', 'C0449286', 'C0542560', 'C2348088']","['fingolimod', 'Degree Unit of Plane Angle', 'Peripheral Blood Lymphocyte', 'Significant', 'Therapeutic Effect', 'Reduced', 'Reduction procedure', 'Reduction (chemical)', 'Surgical reduction', 'Academic degree', 'Statistical Significance', 'ponesimod', 'Dosage', 'Patients', 'Degree or extent', 'This (eukaryote)', 'approximately', 'Event Seriousness - Significant', 'Levels (qualifier value)', 'Highest']","['imft', 'npop', ' orch', 'topp', 'idcn', 'inpr', 'orch', 'qlco', 'qnco', 'cell', 'euka', 'podg', ' phsu', 'clna']"
1521,PMC4215282,S55,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and procedures,"furthermore, phase i studies demonstrated that through the use of an up-titration dosing regimen, the first-dose effects of ponesimod 20 and 40 mg on heart rate and conductivity were reduced, and the safety and tolerability of this higher dose were considered acceptable.","['C1879533', 'C3274448', 'C1279901', 'C0178602', 'C0392756', 'C2945654', 'C2934701', 'C1705187', 'C0162621', 'C0205435', 'C1280500', 'C0042153', 'C0036043', 'C0018810', 'C0457083', 'C0441766', 'C1080058', 'C1515981', 'C0205250', 'C0013777', 'C0947630', 'C0040808']","['Electric Conductivity', 'Regimen - CHV concept', 'And', 'Safety', 'High', 'utilization qualifier', 'Firstly', 'First (number)', 'Stage level 1', 'Safety Study', 'Tolerability Study', 'Treatment Protocols', 'Reduced', 'ponesimod', 'Dosage', 'Effect', 'Scientific Study', 'Titration Method', 'Acceptable', 'Usage', 'This (eukaryote)', 'heart rate']","['resa', 'npop', 'idcn', 'clas', 'topp', 'inpr', 'orch', 'qnco', 'qlco', 'lbpr', 'euka', 'hcpp', 'ftcn', ' phsu', 'clna']"
1522,PMC4215282,S56,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and procedures,study design is summarised in figure 1.,"['C2983265', 'C2986888', 'C0035171']","['CDISC SEND Study Design Terminology', 'Nonclinical Study Design', 'Research Design']","['inpr', 'resa']"
1523,PMC4215282,S57,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design and procedures,all patients randomised to ponesimod initially received ponesimod 10 mg (days 1–7).,"['C0444868', 'C0439228', 'C0205265', 'C0030705']","['day', 'Patients', 'Initially', 'All']","['podg', 'qnco', 'tmco']"
1524,PMC4215282,S58,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design and procedures,"on day 8, patients randomised to receive ponesimod 20 or 40 mg were up-titrated to the 20 mg dose and patients randomised to the 10 mg dose were mock up-titrated.","['C0332173', 'C0562577', 'C0030705', 'C0178602', 'C1515981', 'C2934701', 'C0439228']","['day', 'And', 'ponesimod', 'Dosage', 'Patients', 'mocking', 'Daily']","['tmco', 'fndg', 'idcn', 'orch', 'qnco', 'podg', ' phsu']"
1525,PMC4215282,S59,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design and procedures,"on day 15, patients randomised to receive ponesimod 40 mg were up-titrated to the 40 mg dose; patients randomised to ponesimod 10 or 20 mg were mock up-titrated.","['C0332173', 'C0030705', 'C0178602', 'C2934701', 'C0439228']","['day', 'ponesimod', 'Dosage', 'Patients', 'Daily']","['tmco', 'orch', 'qnco', 'podg', ' phsu']"
1526,PMC4215282,S60,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design and procedures,patients randomised to placebo were mock up-titrated on days 8 and 15 (figure 1).,"['C0032042', 'C0562577', 'C0030705', 'C1706408', 'C1515981', 'C1696465', 'C0439228']","['day', 'Placebo Control', 'placebo', 'And', 'Placebos', 'Patients', 'mocking']","['tmco', 'fndg', 'idcn', 'topp', 'resa', 'podg', 'bodm']"
1527,PMC4215282,S61,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and procedures,figure 1 study design.,"['C2983265', 'C2986888', 'C0035171']","['CDISC SEND Study Design Terminology', 'Nonclinical Study Design', 'Research Design']","['inpr', 'resa']"
1528,PMC4215282,S62,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design and procedures,all patients randomised to ponesimod initially received ponesimod 10 mg (days 1–7).,"['C0444868', 'C0439228', 'C0205265', 'C0030705']","['day', 'Patients', 'Initially', 'All']","['podg', 'qnco', 'tmco']"
1529,PMC4215282,S63,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design and procedures,"on day 8, patients randomised to receive ponesimod 20 or 40 mg were up-titrated to the 20 mg dose and patients randomised to the 10 mg dose were mock up-titrated.","['C0332173', 'C0562577', 'C0030705', 'C0178602', 'C1515981', 'C2934701', 'C0439228']","['day', 'And', 'ponesimod', 'Dosage', 'Patients', 'mocking', 'Daily']","['tmco', 'fndg', 'idcn', 'orch', 'qnco', 'podg', ' phsu']"
1530,PMC4215282,S64,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design and procedures,"on day 15, patients randomised to receive ponesimod 40 mg were up-titrated to the 40 mg dose; patients randomised to ponesimod 10 or 20 mg were mock up-titrated.","['C0332173', 'C0030705', 'C0178602', 'C2934701', 'C0439228']","['day', 'ponesimod', 'Dosage', 'Patients', 'Daily']","['tmco', 'orch', 'qnco', 'podg', ' phsu']"
1531,PMC4215282,S65,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design and procedures,patients randomised to placebo were mock up-titrated on days 8 and 15.,"['C0032042', 'C0562577', 'C0030705', 'C1706408', 'C1515981', 'C1696465', 'C0439228']","['day', 'Placebo Control', 'placebo', 'And', 'Placebos', 'Patients', 'mocking']","['tmco', 'fndg', 'idcn', 'topp', 'resa', 'podg', 'bodm']"
1532,PMC4215282,S66,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and procedures,patient numbers are for the all-treated population.,"['C1257890', 'C0032659', 'C0237753', 'C0449788', 'C0030705', 'C0444868']","['Population Group', 'All', 'Count of entities', 'Patients', 'geographic population', 'Numbers']","['podg', 'qnco', 'popg']"
1533,PMC4215282,S67,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and procedures,"fu, follow-up.",,,
1534,PMC4215282,S68,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design and procedures,"study visits took place at screening, baseline, on day 1 (randomisation), days 8 and 15 (up-titration), at week 4 and then every 4 weeks until the end of the 24-week treatment period or study drug discontinuation.","['C1710032', 'C0168634', 'C3538994', 'C0439230', 'C1883708', 'C1512346', 'C0162621', 'C1533734', 'C0087111', 'C3887704', 'C1705169', 'C0457454', 'C0039798', 'C2348164', 'C1698960', 'C0442504', 'C0545082', 'C0439228', 'C0439531', 'C1444662', 'C0220908', 'C1882509', 'C0444930', 'C0013175', 'C1710031', 'C2603343', 'C1522326', 'C1442488', 'C0220909', 'C1948061', 'C2746065', 'C1533810', 'C4552847', 'C1442449', 'C1515981', 'C1710477', 'C1948053']","['Aspects of disease screening', 'Screening procedure', 'Patient Visit', 'And', 'Study', 'put - instruction imperative', 'Visit', 'Clinical Trial Discontinuation', 'Period (temporal qualifier)', 'Place', 'Trial Screening', 'Every (qualifier)', 'Treatment Epoch', 'Screening', 'Biomaterial Treatment', 'Baseline', 'Discontinuation (procedure)', 'Administration procedure', 'Screening Study', '1 Day', 'Placement action', 'Disease Screening', 'End', 'Drug Evaluation', 'Titration Method', 'research subject screening', 'BaseLine dental cement', 'day', 'treatment - ActInformationManagementReason', 'Treating', 'Stop (qualifier value)', 'therapeutic aspects', 'Then', 'Discontinued', 'per period (qualifier value)', 'week', 'Therapeutic procedure']","['tmco', 'acty', 'fndg', 'bodm', 'hlca', 'idcn', 'topp', 'qnco', 'qlco', 'lbpr', 'bhvr', 'spco', 'resa', 'ftcn', 'diap', 'cnce']"
1535,PMC4215282,S69,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and procedures,"patients who completed treatment at week 24 were offered enrolment into an ongoing, long-term, dose-blinded extension study where all patients would receive ponesimod (clinicaltrials.gov identifier: nct01093326).","['C1554159', 'C1515273', 'C3538994', 'C0439230', 'C0178602', 'C2826302', 'C1533734', 'C0087111', 'C4086204', 'C3272598', 'C3887704', 'C1705169', 'C0039798', 'C0030705', 'C1554104', 'C1706317', 'C0600091', 'C1880641', 'C0205166', 'C0231448', 'C0444868', 'C0233324', 'C2603343', 'C0549178', 'C1522326', 'C1705313']","['MDF Attribute Type - Identifier', 'Reported Term', 'Study', 'Term (lexical)', 'HL7 Defined Rose Property - Identifier', 'Treatment Epoch', 'Biomaterial Treatment', 'ClinicalTrials.gov', 'Administration procedure', 'Continuous', 'All', 'Identifier', 'Dosage', 'Patients', 'treatment - ActInformationManagementReason', 'Long', 'Treating', 'WHO Temperature/Humidity Storage Condition', 'Term (temporal)', 'therapeutic aspects', 'week', 'Telephone Extension Number', 'Term Birth', 'Extension', 'Long Variable', 'Therapeutic procedure']","['tmco', 'topp', 'idcn', 'hlca', 'inpr', 'qlco', 'qnco', 'orgf', 'resa', 'podg', 'ftcn', 'cnce']"
1536,PMC4215282,S70,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study design and procedures,"for those patients who prematurely discontinued study treatment or who completed 24 weeks of treatment but chose not to enter the extension study, two safety follow-up visits were performed 7 and 30 days after the last dose of study drug (figure 1).","['C3854010', 'C1522196', 'C1521826', 'C3274571', 'C3538994', 'C0178602', 'C0687676', 'C1512346', 'C1705187', 'C1533734', 'C0087111', 'C3272598', 'C0589120', 'C3887704', 'C1705169', 'C0039798', 'C0030705', 'C0545082', 'C0205448', 'C1880641', 'C1444662', 'C0036043', 'C0231448', 'C0884358', 'C1522577', 'C0013175', 'C1517741', 'C1707391', 'C0231290', 'C2603343', 'C1518422', 'C1522326', 'C1704685', 'C0205197', 'C1515981', 'C0233535']","['Patient Visit', 'Performed', 'And', 'Study', 'Safety', 'Enteral Route of Drug Administration', 'Visit', 'Post', 'Follow-up status', 'Treatment Epoch', 'Safety Study', 'Biomaterial Treatment', 'Administration procedure', 'butting', 'completed - RoleLinkStatus', 'Clinical Study Follow-up', 'Two', 'Status post', 'Dosage', 'Patients', 'Drug Evaluation', 'Negation', 'Choose (action)', 'follow-up', 'treatment - ActInformationManagementReason', 'Follow-Up Report', 'Last', 'Treating', 'WHO Temperature/Humidity Storage Condition', 'Protocol Agent', 'therapeutic aspects', 'Discontinued', 'Telephone Extension Number', 'Extension', 'Complete', 'Therapeutic procedure']","['tmco', 'fndg', 'topp', 'hcpp', 'idcn', 'hlca', 'inpr', 'qlco', 'qnco', 'mobd', 'bhvr', 'resa', 'podg', 'ftcn', 'acty', 'cnce']"
1537,PMC4215282,S71,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study design and procedures,"mri scans were performed at baseline, every 4 weeks from week 4 to 24 (end of treatment (eot)) and at the second safety follow-up visit for patients not entering the extension study.","['C1561503', 'C0168634', 'C3538994', 'C0521125', 'C0439230', 'C0589121', 'C1705187', 'C1533734', 'C4321252', 'C0087111', 'C3887704', 'C1705169', 'C0039798', 'C0205436', 'C0030705', 'C0457385', 'C1705190', 'C1880641', 'C0231448', 'C0036043', 'C0444930', 'C2603343', 'C1518422', 'C1442488', 'C1948061', 'C2746065', 'C1522326', 'C0917711']","['Study', 'Safety', 'Every (qualifier)', 'Treatment Epoch', 'second (number)', 'Safety Study', 'Baseline', 'Biomaterial Treatment', 'Precision - second', 'Administration procedure', 'WWOX wt Allele', 'End', 'Patients', 'Preposition For', 'Second Suffix', 'Negation', 'follow-up visit', 'BaseLine dental cement', 'seconds', 'treatment - ActInformationManagementReason', 'Treating', 'MRI Scans', 'Stop (qualifier value)', 'therapeutic aspects', 'week', 'Telephone Extension Number', 'Extension', 'Therapeutic procedure']","['tmco', 'gngm', 'topp', 'hcpp', 'idcn', 'hlca', 'qnco', 'qlco', 'spco', 'resa', 'podg', 'bodm', 'diap', 'ftcn', 'cnce']"
1538,PMC4215282,S72,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and procedures,"mri scans were centrally evaluated in a fully blinded manner (medical image analysis centre, basel, switzerland).","['C0331779', 'C0150108', 'C0200765', 'C0917711', 'C0039021', 'C0205099']","['MRI Scans', 'Blinded', 'Switzerland', 'Central', 'Image Analysis', 'basel']","['geoa', 'hcro', 'lbpr', 'spco', 'resa', 'diap']"
1539,PMC4215282,S73,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study design and procedures,"edss assessments were performed at screening, baseline, week 24, at follow-up visit 2 and at unscheduled visits in case of ms relapse by an independent neurologist not otherwise involved in patient care.","['C1699701', 'C0332283', 'C1706256', 'C0035020', 'C0237426', 'C1710032', 'C0168634', 'C0439230', 'C1512346', 'C3853617', 'C1554098', 'C1706255', 'C4281991', 'C3887783', 'C2348164', 'C0085862', 'C1698960', 'C0277556', 'C0545082', 'C0017313', 'C0205336', 'C0868928', 'C0220908', 'C2826704', 'C1710031', 'C1518422', 'C1442488', 'C0220909', 'C0451246', 'C1515981', 'C1290940', 'C1261322', 'C1299583', 'C1710477', 'C3854240']","['Neurologists', 'Followed by', 'Aspects of disease screening', 'Screening procedure', 'Patient Visit', 'And', 'Independent for Transfer', 'Evaluation procedure', 'Independence', 'Visit', 'HL7 Committee ID In RIM - Patient Care', 'Trial Screening', 'Packaging Case', 'Relapse', 'Screening', 'Relapsing course', 'Follow', 'Baseline', 'Clinical Study Case', 'Screening Study', 'Visit Name', 'Disease Screening', 'Independently able', 'Unscheduled', 'Negation', 'Patient care - patient profile query reason', 'research subject screening', 'BaseLine dental cement', 'Case (situation)', 'Kurtzke multiple sclerosis rating scale', 'patient care', 'week', 'unscheduled - ClinicalResearchEventReason', 'Recurrent disease', 'Kurtzke Expanded Disability Status Scale Questionnaire']","['tmco', 'fndg', 'prog', 'bodm', 'medd', 'hlca', 'idcn', 'inpr', 'qnco', 'phpr', 'qlco', 'bhvr', 'dsyn', 'resa', 'ftcn', 'diap', 'cnce']"
1540,PMC4215282,S74,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study design and procedures,"the main pharmacodynamic variable was total lymphocyte count, which was centrally analysed at screening, baseline, on days 8 and 15, every 4 weeks thereafter until eot and at the two safety follow-up visits.","['C0205225', 'C1710032', 'C0439828', 'C0168634', 'C4553760', 'C1705187', 'C1512346', 'C2348164', 'C1542147', 'C1698960', 'C0545082', 'C0205448', 'C1709518', 'C0439228', 'C0200635', 'C0851347', 'C0036043', 'C0220908', 'C1710031', 'C1442488', 'C0220909', 'C1948061', 'C1515981', 'C1710477']","['Aspects of disease screening', 'Screening procedure', 'Patient Visit', 'Pharmacodynamic Study', 'And', 'Safety', 'Visit', 'Main', 'Trial Screening', 'Variable (uniformity)', 'Every (qualifier)', 'Pharmacodynamics', 'Screening', 'Safety Study', 'Baseline', 'Screening Study', 'Two', 'Disease Screening', 'Lymphocyte Count measurement', 'Study Variable', 'research subject screening', 'BaseLine dental cement', 'day', 'Primary']","['tmco', 'biof', 'bodm', 'hlca', 'hcpp', 'idcn', 'inpr', 'qnco', 'qlco', 'lbpr', 'bhvr', 'resa', 'ftcn', 'diap']"
1541,PMC4215282,S75,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study design and procedures,"on treatment initiation and dose up-titration days, cardiac monitoring was performed by an independent cardiologist.","['C0439228', 'C0087111', 'C1522326', 'C1158830', 'C0175906', 'C3887704', 'C1705169', 'C0039798', 'C0085862', 'C0150496', 'C0178602', 'C1704686', 'C1515981', 'C3538994', 'C1290940', 'C1299583', 'C0589507', 'C0162621', 'C1533734']","['day', 'treatment - ActInformationManagementReason', 'Transcription Initiation', 'Treating', 'Independence', 'Titration Method', 'And', 'Independently able', 'Independent for Transfer', 'Dosage', 'Treatment Epoch', 'therapeutic aspects', 'Cardiac monitoring', 'Biomaterial Treatment', 'Cognitive function: initiation', 'Cardiologists', 'Administration procedure', 'Initiation', 'Therapeutic procedure']","['tmco', 'fndg', 'prog', 'topp', 'idcn', 'hlca', 'genf', 'qnco', 'lbpr', 'resa', 'ftcn', 'diap', 'menp', 'cnce']"
1542,PMC4215282,S76,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study design and procedures,"this included 12-lead ecg, blood pressure measurements over 6 h and holter ecg monitoring over 24 h (subset of patients).","['C1515021', 'C1080058', 'C0181586', 'C0242485', 'C0005823', 'C1271104', 'C0030705', 'C1515981', 'C1442948', 'C3275067', 'C1272641', 'C0180580', 'C0023175', 'C1522538', 'C2348269']","['Blood Pressure', 'Electrocardiographic monitoring', 'Cardiac Lead Procedure', 'Leads (device)', 'Dietary Lead', 'Plumbum metallicum, homeopathic preparation', 'Systemic arterial pressure', 'Leading', 'And', 'Measurement', 'Patients', 'This (eukaryote)', 'Blood pressure finding', 'Lead', 'Subgroup']","['fndg', 'elii', 'topp', 'idcn', 'clas', ' hops', 'inch', 'orgf', 'euka', 'podg', 'ftcn', 'mnob', ' phsu', 'diap']"
1543,PMC4215282,S77,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study design and procedures,all ecg and holter measurements were centrally read in a blinded manner.,"['C0444868', 'C1515981', 'C0242485', 'C0150108']","['Blinded', 'And', 'All', 'Measurement']","['qnco', 'ftcn', 'idcn', 'resa']"
1544,PMC4215282,S78,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study design and procedures,pulmonary function tests (pfts) were performed at all study visits except day 1 (randomisation).,"['C0439228', 'C0024119', 'C0332173', 'C0545082', 'C0444868', 'C1512346', 'C2598152']","['Patient Visit', 'All', 'day', 'Daily', 'Pulmonary Function Tests:-:Point in time:^Patient:-', 'Visit', 'Pulmonary function tests']","['tmco', 'hlca', 'qnco', 'bhvr', 'diap', 'clna']"
1545,PMC4215282,S79,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study design and procedures,unscheduled pfts were performed in the event of respiratory symptoms or decreased pft parameters during treatment.,"['C0087111', 'C1699701', 'C1522326', 'C0037090', 'C3887704', 'C1705169', 'C0039798', 'C3538994', 'C4019010', 'C3854240', 'C1533734', 'C0441471']","['National reporting jurisdiction:Loc:Pt:^Event:Nom', 'treatment - ActInformationManagementReason', 'Signs and Symptoms, Respiratory', 'Treating', 'Treatment Epoch', 'therapeutic aspects', 'Event', 'Biomaterial Treatment', 'unscheduled - ClinicalResearchEventReason', 'Administration procedure', 'Unscheduled', 'Therapeutic procedure']","['tmco', 'topp', 'hlca', 'sosy', 'qlco', 'resa', 'ftcn', 'evnt', 'cnce', 'clna']"
1546,PMC4215282,S80,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study design and procedures,adverse events (aes) and serious aes (saes) were collected at each visit.,"['C2699274', 'C1457900', 'C1512346', 'C2826704', 'C1515981', 'C0545082', 'C1705413', 'C1412268', 'C0205404', 'C0877248']","['Patient Visit', 'Scanning Auger Spectrometer (device)', 'Visit Name', 'AES gene', 'Each (qualifier value)', 'And', 'Adverse Event Domain', 'Serious', 'Visit', 'Adverse event']","['gngm', 'idcn', 'hlca', 'inpr', 'resd', 'qnco', 'qlco', 'bhvr', 'patf']"
1547,PMC4215282,S81,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study design and procedures,laboratory assessments were performed at each visit except day 1 (randomisation).,"['C0439228', 'C0332173', 'C1457900', 'C3244292', 'C2826704', 'C4283904', 'C0545082', 'C1261322', 'C0022877', 'C1512346']","['Laboratory', 'Patient Visit', 'Laboratory domain', 'day', 'Visit Name', 'Each (qualifier value)', 'Evaluation procedure', 'Daily', 'Visit', 'Laboratory observation']","['tmco', 'lbtr', ' hcro', 'hlca', 'inpr', 'qnco', 'bhvr', 'ftcn', 'mnob']"
1548,PMC4215282,S82,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study design and procedures,aes of special interest were defined on the basis of preclinical and previous clinical safety findings for ponesimod.,"['C2607943', 'C2699274', 'C0036043', 'C0205555', 'C2926606', 'C1552607', 'C1527178', 'C3539655', 'C0205156', 'C1515981', 'C1874451', 'C1412268', 'C2934701', 'C0205210', 'C1705187', 'C0543488', 'C1709630']","['Clinical', 'Basis - conceptual entity', 'Previous', 'Scanning Auger Spectrometer (device)', 'AES gene', 'Special', 'And', 'ponesimod', 'CDISC Findings Class', 'Procedure findings:Finding:Point in time:^Patient:Narrative', 'Safety', 'Safety Study', 'Basis', 'findings aspects', 'Act Relationship Subset - previous', 'Preclinical', 'interest']","['tmco', 'clna', 'gngm', 'hcpp', 'idcn', 'inpr', 'orch', 'resd', 'qlco', 'resa', 'ftcn', ' phsu', 'menp', 'phsu']"
1549,PMC4215282,S83,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study design and procedures,"they were reported during the treatment and follow-up periods and grouped as follows: cardiovascular aes, infection-related aes, pulmonary aes, hepatobiliary disorders/liver toxicity and macular oedema.","['C0332283', 'C3538994', 'C1533734', 'C2346688', 'C0087111', 'C3887704', 'C1705169', 'C0039798', 'C3887460', 'C2699274', 'C0439849', 'C3714514', 'C0007226', 'C3486713', 'C0267792', 'C1522326', 'C2707265', 'C0023884', 'C0024109', 'C1515981', 'C0600688', 'C1412268', 'C0271051', 'C0040539', 'C2709248']","['Followed by', 'Pulmonary (qualifier value)', 'Toxic effect', 'And', 'Pulmonary:-:Point in time:^Patient:-', 'Lung', 'Cardiovascular', 'Infection', 'Treatment Epoch', 'Biomaterial Treatment', 'Administration procedure', 'Relationships', 'Liver Flavor', 'Toxicity aspects', 'hepatobiliary disease', 'treatment - ActInformationManagementReason', 'Scanning Auger Spectrometer (device)', 'Treating', 'AES gene', 'Liver', 'therapeutic aspects', 'Mammal liver preparation', 'Cardiovascular system', 'Macular retinal edema', 'Therapeutic procedure']","['tmco', 'food', 'blor', 'clna', 'gngm', 'idcn', 'topp', 'bdsy', 'hlca', 'aapp', 'resd', 'qlco', 'inpo', 'dsyn', 'resa', 'bpoc', 'ftcn', ' phsu', 'patf', 'cnce']"
1550,PMC4215282,S85,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study endpoints,the primary efficacy endpoint was the cumulative number of new gd+ lesions per patient detected on t1-weighted mri scans from weeks 12 to 24.,"['C0237753', 'C0205225', 'C2349179', 'C0005910', 'C0449788', 'C0439230', 'C0030705', 'C1305866', 'C1511559', 'C0917711', 'C0043100', 'C1707887', 'C0205314', 'C2826544', 'C0221198', 'C1280519']","['Body Weight', 'Endpoint Value Derivation Technique', 'Effectiveness', 'Primary', 'Cumulative', 'Weighing patient', 'MRI Scans', 'Count of entities', 'Lesion', 'Efficacy Study', 'New', 'Patients', 'Weight', 'week', 'End Point', 'Numbers']","['tmco', 'fndg', 'hlca', 'qnco', 'qlco', 'orga', 'resa', 'podg', 'diap']"
1551,PMC4215282,S86,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study endpoints,mri scans from weeks 4 and 8 were excluded from analysis of the primary endpoint due to the delayed anti-inflammatory effects evident with the s1p modulator fingolimod.18,"['C3272602', 'C1699926', 'C0332287', 'C1709060', 'C0074992', 'C0205421', 'C1280500', 'C1423502', 'C0439230', 'C0003209', 'C1515999', 'C2986535', 'C1515981', 'C0917711', 'C0678226', 'C1524024', 'C1545665', 'C0936012']","['fingolimod', 'MBTPS1 gene', 'In addition to', 'Views delayed', 'Modulator Device', 'Analysis', 'Delayed Testing', 'Primary Endpoint', 'MRI Scans', 'And', 'Due to', 'Deferred', 'analysis aspect', 'sphingosine 1-phosphate', 'Effect', 'week', 'Anti-inflammatory effect', 'Anti-Inflammatory Agents']","['tmco', 'mnob', 'imft', ' orch', 'idcn', 'gngm', 'irda', 'orch', 'qlco', 'phsu', 'resa', 'ftcn', 'diap', ' phsu', 'clna']"
1552,PMC4215282,S87,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study endpoints,"in addition, the primary endpoint was aligned with that of another agent (dimethyl fumarate) with delayed onset of anti-inflammatory effects in patients with rrms.19","['C1521826', 'C0332287', 'C0058218', 'C0205421', 'C0206132', 'C1280500', 'C1883712', 'C0450442', 'C0030705', 'C0332162', 'C2986535', 'C1545665', 'C0333348', 'C3272602', 'C1254351']","['Onset of (contextual qualifier)', 'Age of Onset', 'Agent', 'In addition to', 'Pharmacologic Substance', 'Views delayed', 'Delayed Testing', 'Primary Endpoint', 'Protocol Agent', 'Deferred', 'Add - instruction imperative', 'Patients', 'Effect', 'inflammatory', 'dimethyl fumarate']","['tmco', 'clna', 'imft', 'chvf', ' orch', 'irda', 'inpr', 'qnco', 'qlco', 'podg', 'ftcn', ' phsu', 'phsu']"
1553,PMC4215282,S88,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study endpoints,secondary efficacy endpoints were the annualised confirmed relapse rate (arr) and time to first confirmed relapse within 24 weeks of ponesimod initiation.,"['C0521093', 'C0035020', 'C1279901', 'C1521828', 'C0871208', 'C4084934', 'C0205435', 'C1158830', 'C0205436', 'C1704686', 'C0277556', 'C1707887', 'C1280519', 'C0205336', 'C0175668', 'C2349179', 'C0750484', 'C0589507', 'C0027627', 'C0040223', 'C2170357', 'C1515981']","['Confirmation', 'Rate', 'And', 'Rating (action)', 'Firstly', 'Effectiveness', 'Confirmed by', 'First (number)', 'second (number)', 'Time', 'Relapse', 'Relapsing course', 'Cognitive function: initiation', 'Neoplasm Metastasis', 'Transcription Initiation', 'age-related resistance', 'Aldosterone to Renin Activity Ratio Measurement', 'Secondary to', 'Efficacy Study', 'Recurrent disease', 'End Point', 'Initiation']","['tmco', 'fndg', 'biof', 'idcn', 'genf', 'qlco', 'phpr', 'qnco', 'lbpr', 'dsyn', 'ftcn', 'resa', 'neop', 'menp', 'acty']"
1554,PMC4215282,S89,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study endpoints,"relapse was defined as the occurrence of an acute episode of one or more new symptoms or a worsening of existing symptoms of ms, not associated with fever or infection, and lasting for at least 24 h after a stable period of at least 30 days.","['C0205447', 'C0035020', 'C0332281', 'C0521125', 'C2745955', 'C0687676', 'C1546960', 'C0332271', 'C4321252', 'C0277556', 'C4552740', 'C0439531', 'C0205178', 'C0205336', 'C1547311', 'C1554210', 'C3714514', 'C0332189', 'C0231290', 'C1518422', 'C0243132', 'C0683368', 'C0205360', 'C1515981', 'C1457887', 'C0424755', 'C0015967', 'C1948053']","['Symptoms', 'And', 'Stable status', 'acute', 'Post', 'Worsening pattern', 'Period (temporal qualifier)', 'Patient Condition Code - Stable', 'Infection', 'Fever', 'Relapse', 'occurrence characteristics', 'Relapsing course', 'Occurrence', 'Symptoms aspect', 'Status post', 'Episode of', 'WWOX wt Allele', 'One', 'Preposition For', 'Fever, CTCAE', 'Negation', 'Patient Outcome - Worsening', 'Fever symptoms (finding)', 'Associated with', 'Act Relationship Type - occurrence', 'per period (qualifier value)', 'Recurrent disease']","['tmco', 'fndg', 'gngm', 'idcn', 'inpr', 'sosy', 'qlco', 'phpr', 'qnco', 'dsyn', 'ftcn', 'patf']"
1555,PMC4215282,S90,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study endpoints,"a confirmed relapse was defined as a relapse with an increase of ≥0.5 points from baseline in the edss score or an increase of one point in at least one functional system score (excluding bowel, bladder and mental functional systems) assessed within 7 days of onset by the independent neurologist.","['C0521093', 'C0205447', 'C0035020', 'C0237426', 'C0168634', 'C2347617', 'C0229992', 'C1552961', 'C4319531', 'C0542341', 'C0206132', 'C0449820', 'C2700217', 'C0005682', 'C0085862', 'C3887783', 'C0277556', 'C1516048', 'C0442805', 'C3714763', 'C4050231', 'C0205336', 'C0332285', 'C0205245', 'C0750484', 'C1180473', 'C1442488', 'C0021853', 'C0451246', 'C1515981', 'C1290940', 'C1299583', 'C0332162', 'C4083257']","['Neurologists', 'Confirmation', 'Psyche structure', 'And', 'Functional system', 'Independent for Transfer', 'Function (attribute)', 'Independence', 'Urinary Bladder', 'Functional', 'Pattern of Bowel Movements Question', 'point - UnitsOfMeasure', 'Onset of (contextual qualifier)', 'Confirmed by', 'Age of Onset', 'Within', 'Score', 'Relapse', 'Assessed', 'Relapsing course', 'Baseline', 'Increase', 'Point Name', 'Bladder Continence Question', 'Functional Relationship', 'Independently able', 'One', 'BaseLine dental cement', 'Point', 'Kurtzke multiple sclerosis rating scale', 'ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated', 'Intestines', 'Recurrent disease', 'Kurtzke Expanded Disability Status Scale Questionnaire']","['tmco', 'cnce', 'fndg', 'prog', 'bodm', 'idcn', 'bdsy', 'inpr', 'qnco', 'phpr', 'qlco', 'dsyn', 'spco', 'ftcn', 'acty', 'menp', 'bpoc', 'clna']"
1556,PMC4215282,S91,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Study endpoints,"exploratory efficacy mri endpoints included cumulative number of new or enlarging non-enhancing t2 lesions at weeks 12, 16, 20 and 24; cumulative number of combined unique active lesions (cuals; sum of all new t1 gd+ lesions and new or enlarging t2 lesions since previous mri scan) at weeks 12, 16, 20 and 24; and percentage change from baseline to week 24 in brain volume as measured by mri using the structural image evaluation using normalisation of atrophy (siena) program.20","['C1705241', 'C3853793', 'C0237753', 'C0205156', 'C0439230', 'C0168634', 'C1511559', 'C0392747', 'C0205195', 'C0439165', 'C0205177', 'C1709697', 'C3888249', 'C0443172', 'C1704922', 'C3890166', 'C0449788', 'C1549488', 'C0678594', 'C1824234', 'C0205314', 'C1707887', 'C1561533', 'C1280519', 'C0442800', 'C0220825', 'C2349179', 'C4319952', 'C1113695', 'C0444868', 'C0333641', 'C1710548', 'C0376691', 'C2728259', 'C3484370', 'C1518422', 'C1442488', 'C1552607', 'C1515051', 'C0917711', 'C1515981', 'C1704254', 'C1261322', 'C0221198', 'C0024485']","['brain volume', 'Active License', 'Lesion', 'And', 'active (HL7 RoleLink)', 'Evaluation procedure', 'structure', 'Money or percentage indicator - Percentage', 'Sum', 'Magnetic Resonance Imaging', 'Effectiveness', 'Unique', 'Cumulative', 'Count of entities', 'Programs - Publication Format', 'Changed status', 'Baseline', 'Program', 'Medical Image', 'Active', 'Amount type - Percentage', 'CYREN gene', 'Programs', 'All', 'Changing', 'Percent (qualifier value)', 'Magnetic Resonance Imaging Study File', 'Enlarged', 'Change -- procedure', 'Atrophic', 'Act Relationship Subset - previous', 'Negation', 'Numbers', 'BaseLine dental cement', 'Program - framework of goals', 'MRI Scans', 'New', 'Efficacy Study', 'week', 'Combined', 'Delta (difference)', 'Image', 'Previous', 'Evaluation', 'End Point']","['tmco', 'fndg', 'bodm', 'gngm', 'idcn', 'topp', 'hlca', 'inpr', 'orch', 'qnco', 'qlco', 'spco', 'resa', 'ftcn', 'diap', ' phsu', 'patf', 'cnce']"
1557,PMC4215282,S93,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,the global null hypothesis was that none of the three ponesimod groups differed from the placebo group in the mean cumulative number of new t1 gd+ lesions at weeks 12 to 24.,"['C0205449', 'C0237753', 'C0205246', 'C4050155', 'C0439230', 'C1511559', 'C2934701', 'C1257890', 'C0441833', 'C4050154', 'C0449788', 'C1706408', 'C2348867', 'C0549184', 'C0205314', 'C1705428', 'C2348143', 'C1519504', 'C1552839', 'C1705429', 'C0444504', 'C1517320', 'C0456148', 'C0032042', 'C0687744', 'C1696465', 'C2347634', 'C0221198', 'C4684719']","['Global', 'Group Object', 'placebo', 'Lesion', 'From', 'None', 'Table Rules - groups', 'Sample Mean', 'No Hand Mobility', 'Null Hypothesis', 'Cumulative', 'Count of entities', 'Population Mean', 'Placebos', 'No Support Needed', 'Generalized', 'User Group', 'Groups', 'Population Group', 'Placebo Control', 'Social group', 'ponesimod', 'Statistical mean', 'Null Value', 'Numbers', 'New', 'Three', 'week', 'Stage Grouping']","['tmco', 'fndg', 'popg', 'bodm', 'idcn', 'topp', 'inpr', 'orch', 'qnco', 'qlco', 'spco', 'resa', 'ftcn', ' phsu', 'cnce']"
1558,PMC4215282,S94,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,the alternate hypothesis was that at least one of the ponesimod treatment groups differed from the placebo group.,"['C0205447', 'C3538994', 'C2934701', 'C1533734', 'C1523987', 'C1257890', 'C0087111', 'C0441833', 'C3887704', 'C1705169', 'C0039798', 'C1706408', 'C1705428', 'C1519504', 'C1552839', 'C1705429', 'C0332270', 'C1517320', 'C1522326', 'C0032042', 'C1512571', 'C0687744', 'C1696465']","['Group Object', 'placebo', 'From', 'Alternating', 'Table Rules - groups', 'Treatment Epoch', 'Placebos', 'Biomaterial Treatment', 'Administration procedure', 'User Group', 'Hypothesis', 'Groups', 'Population Group', 'Placebo Control', 'Social group', 'ponesimod', 'One', 'treatment - ActInformationManagementReason', 'Treating', 'therapeutic aspects', 'Stage Grouping', 'Alternative', 'Therapeutic procedure']","['popg', 'bodm', 'idcn', 'topp', 'hlca', 'inpr', 'orch', 'qlco', 'qnco', 'resa', 'ftcn', ' phsu', 'cnce']"
1559,PMC4215282,S95,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,the test of the null hypothesis was based on a negative binomial regression model with treatment group as a four-level nominal covariate for the per-protocol analysis set.,"['C3274659', 'C1515976', 'C0022885', 'C4318744', 'C1565156', 'C3538994', 'C2348563', 'C2946261', 'C0205450', 'C1547707', 'C0441889', 'C0684321', 'C1533734', 'C0936012', 'C2825415', 'C1257890', 'C3715209', 'C4282383', 'C0441833', 'C0087111', 'C3887704', 'C1705169', 'C0039798', 'C1522729', 'C0392366', 'C2599718', 'C3714583', 'C1705428', 'C1836830', 'C1705938', 'C0332287', 'C1519504', 'C1421478', 'C1527178', 'C0456984', 'C1705429', 'C0043194', 'C2825491', 'C0205160', 'C0442711', 'C1522326', 'C0039593', 'C3853545', 'C1513916', 'C1507394', 'C3853906', 'C3161035', 'C0687744', 'C0684320', 'C3831328', 'C1524024', 'C4684719']","['Group Object', 'Negative Charge', 'In addition to', 'Test - temporal region', 'Clinical trial protocol', 'Floor - story of building', 'Regression - mental defense mechanism', 'Protocols documentation', 'Model Number', 'Digital Model Attachment', 'Null Hypothesis', 'REMS Protocol', 'Treatment Epoch', 'Developmental regression', 'analysis aspect', 'Tests (qualifier value)', 'Biomaterial Treatment', 'Laboratory Procedures', 'Administration procedure', 'Disease regression', 'User Group', 'Model - style/design', 'Negative Finding', 'Wiskott-Aldrich Syndrome', 'Groups', 'Population Group', 'Basis - conceptual entity', 'Library Protocol', 'Model', 'Social group', 'Test Result', 'WAS gene', 'Four', 'Negative', 'Testing', 'Level', 'Negative - answer', 'Levels (qualifier value)', 'Base - General Qualifier', 'treatment - ActInformationManagementReason', 'Clinical trial protocol document', 'Anatomic Structure, System, or Substance', 'Analysis', 'Study Protocol', 'Treating', 'WAS protein, human', 'Protocol - answer to question', 'Blood Products Laboratory Testing', 'therapeutic aspects', 'Stage Grouping', 'Negative Number', 'Therapeutic procedure']","['topp', 'qnco', ' aapp', 'menp', 'patf', 'blor', 'fndg', 'clas', 'idcn', 'hlca', 'inpr', 'qlco', 'bacs', 'lbpr', 'resa', 'ftcn', 'popg', 'lbtr', 'cnce', 'gngm', 'geoa', 'inch', 'dsyn', ' phsu']"
1560,PMC4215282,S96,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,the null hypothesis was tested by a wald χ2 test with a two-sided significance level of 5%.,"['C0814896', 'C0332287', 'C0022885', 'C1515976', 'C0039593', 'C4318744', 'C0456984', 'C0392366', 'C3831328', 'C0205448', 'C4684719']","['Two', 'In addition to', 'Null Hypothesis', 'Anatomic Structure, System, or Substance', 'Test Result', 'significance level', 'Testing', 'Blood Products Laboratory Testing', 'Tests (qualifier value)', 'Test - temporal region', 'Laboratory Procedures']","['blor', 'lbtr', 'clas', 'inpr', 'qnco', 'lbpr', 'resa', 'ftcn']"
1561,PMC4215282,S97,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,no adjustment was applied for multiple comparisons.,"['C0456081', 'C0683269', 'C0439064', 'C0376209']","['Psychological adjustment', 'Adjustment Action', 'Numerous', 'Individual Adjustment']","['inbe', 'ftcn', 'qnco']"
1562,PMC4215282,S98,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,the per-protocol analysis set was defined as all randomised patients who received ≥80% of study drug from study drug initiation to the planned eot and had ≥2 valid post-baseline mris at weeks 12–24.,"['C0036849', 'C0168634', 'C0439230', 'C0687676', 'C2348563', 'C0936012', 'C3715209', 'C3272598', 'C4282383', 'C1158830', 'C4281991', 'C1301732', 'C0030705', 'C1704686', 'C1522729', 'C2599718', 'C1705195', 'C3469826', 'C0444868', 'C0013175', 'C0589507', 'C1517320', 'C0442711', 'C2349099', 'C1442488', 'C1507394', 'C1515981', 'C1704687', 'C1524024', 'C1442518', 'C3887962']","['set (group)', 'Set (Psychology)', 'Per (qualifier)', 'And', 'From', 'Clinical trial protocol', 'Post', 'Protocols documentation', 'REMS Protocol', 'SLC35G1 gene', 'analysis aspect', 'Follow', 'Cognitive function: initiation', 'Planned', 'Baseline', 'Valid', 'All', 'Library Protocol', 'Transcription Initiation', 'Patients', 'Drug Evaluation', 'BaseLine dental cement', 'Post Device', 'Clinical trial protocol document', 'Analysis', 'Study Protocol', 'WHO Temperature/Humidity Storage Condition', 'week', 'Set scale', 'Protocol - answer to question', 'Initiation']","['tmco', 'fndg', 'bodm', 'gngm', 'idcn', 'inpr', 'genf', 'qlco', 'qnco', 'resa', 'podg', 'ftcn', 'mnob', 'menp', 'cnce']"
1563,PMC4215282,S99,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analyses,"the dose–response relationship was explored for the primary endpoint and lymphocyte counts by means of multiple comparison procedures and modelling techniques, as previously described.21","['C2700391', 'C1706279', 'C0439157', 'C1705630', 'C0024264', 'C0449851', 'C0439849', 'C0025664', 'C2986535', 'C1515981', 'C3538935', 'C1707455', 'C0439064', 'C1704970', 'C0184661', 'C3540605']","['Concept Relationship', 'Object Relationship', 'Procedure (set of actions)', 'Relationships', 'Lymphocyte', 'counts', 'Procedure Domain', 'Comparison', 'Primary Endpoint', 'And', 'Techniques', 'Interventional procedure', 'Methods aspects', 'CDISC Relationship Class', 'Means', 'Numerous']","['idcn', 'topp', 'irda', 'inpr', 'qnco', 'qlco', 'cell', 'ftcn', 'cnce', 'acty']"
1564,PMC4392313,S176,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Supplementary Material,web supplement,"['C0282111', 'C1947943', 'C0242295', 'C2348609']","['Supplement (document)', 'Supplement', 'Dietary Supplements', 'Internet']","['ftcn', 'mnob', 'inpr', 'food']"
1565,PMC4392313,S177,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Supplementary Material,web table,"['C0282111', 'C0039224', 'C1706074']","['Data Table', 'Table - furniture', 'Internet']","['mnob', 'inpr']"
1566,PMC4392313,S46,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"this trial, conducted independently of the pivotal ra trials, was approved by an independent ethics committee or institutional review board, and all patients gave written informed consent for participation in the trial.","['C0021430', 'C0030705', 'C4554082', 'C0008976', 'C1515981', 'C0679823', 'C4321252', 'C1565156', 'C0205540', 'C0444868', 'C0086911', 'C1080058', 'C1421478', 'C0043194', 'C0521125']","['WAS protein, human', 'All', 'Clinical Trials', 'And', 'Approved', 'WAS gene', 'Patients', 'Wiskott-Aldrich Syndrome', 'Informed Consent', 'participation', 'Preposition For', 'WWOX wt Allele', 'Ethics Committees, Research', 'Independent Ethics Committee', 'This (eukaryote)']","['bacs', 'rnlw', 'idcn', 'gngm', 'prog', 'ftcn', 'podg', 'qlco', 'euka', 'resa', 'dsyn', ' aapp', 'qnco']"
1567,PMC4392313,S47,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,adult patients with moderately to severely active ra (diagnosed per american college of rheumatology (acr) criteria) of more than 6 months’ duration were recruited.,"['C0596070', 'C3888249', 'C0001675', 'C0205172', 'C1412134', 'C0030705', 'C3853793', 'C4321491', 'C0557806', 'C0205177', 'C1706450', 'C0449238', 'C1881878', 'C0011900', 'C4085643', 'C0035452', 'C1515941', 'C0205082', 'C2926735']","['Active', 'Active License', 'American College of Radiology', 'Legal Adult', 'Americas Ethnicity', 'ACR gene', 'More', 'active (HL7 RoleLink)', 'Diagnosis', 'Adult', 'Severe (severity modifier)', 'Patients', 'Moderate Response', 'college', 'Duration', 'Moderately Able', 'Moderation', 'Duration (temporal concept)', 'Rheumatology specialty']","['bmod', 'inpr', 'pros', 'idcn', 'aggp', 'gngm', 'popg', 'fndg', 'mnob', 'podg', 'qlco', 'orch', 'tmco', ' phsu', 'diap', 'qnco']"
1568,PMC4392313,S48,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"enrolment criteria included inadequate response to stable methotrexate (mtx) therapy, exemplified by a swollen joint count (sjc) ≥6 and a tender joint count (tjc) ≥6, together with c-reactive protein (crp) >10 mg/l or erythrocyte sedimentation rate (esr) >28 mm/h.","['C1704632', 'C1705566', 'C1706817', 'C1515981', 'C0439856', 'C3890735', 'C4048285', 'C4554794', 'C1883357', 'C2911692', 'C0039798', 'C1547311', 'C0205360', 'C1417487', 'C0243161', 'C0152031', 'C0871261', 'C0033684', 'C1619634', 'C3811131', 'C0025677', 'C0087111', 'C1363945', 'C1176468', 'C0205412', 'C0750480', 'C0205332']","['erythrocyte sedimentation rate result', 'And', 'Therapeutic procedure', 'Complete Response with Incomplete Platelet Recovery', 'Estrogen Receptor Measurement', 'Together', 'Patient Condition Code - Stable', 'MTX1 gene', 'Proteins', 'Response (communication)', 'Inadequate (qualifier)', 'Stable status', 'Joint swelling', 'criteria', 'Methotrexate', 'Count Dosing Unit', 'Erythrocyte sedimentation rate measurement', 'Disease Response', 'C-Reactive Protein, human', 'Count', 'therapeutic aspects', 'Unsatisfactory', 'Response (statement)', 'Response process', 'Reactive', 'Therapy Object (animal model)', 'Swollen joint:Anatomy:Point in time:^Patient:Nominal']","['bacs', 'inpr', 'clna', 'idcn', 'lbpr', 'gngm', 'topp', 'lbtr', 'ftcn', 'fndg', 'orch', 'imft', 'qlco', ' phsu', 'menp', ' aapp', 'qnco', 'orga']"
1569,PMC4392313,S49,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,patients with inadequate response to an antitumour necrosis factor-α (atnf) agent during the 6 months before baseline or to more than two previous atnf agents were ineligible.,"['C0450442', 'C1704632', 'C1512714', 'C1521761', 'C0030705', 'C1706817', 'C0439856', 'C1442488', 'C2911692', 'C0205172', 'C1334928', 'C0205448', 'C0205156', 'C1521826', 'C0168634', 'C1254351', 'C0027540', 'C2827422', 'C1552607', 'C0205412', 'C0871261']","['Mathematical Factor', 'Baseline', 'Necrosis', 'Patients', 'Act Relationship Subset - previous', 'Agent', 'Response (communication)', 'Inadequate (qualifier)', 'Necrotic changes (finding)', 'BaseLine dental cement', 'Disease Response', 'Factor', 'Two', 'Unsatisfactory', 'Response (statement)', 'Response process', 'More', 'Pharmacologic Substance', 'Previous', 'Protocol Agent', 'Ineligibility']","['ortf', 'inpr', 'qnco', 'orga', 'ftcn', 'fndg', 'cnce', 'podg', 'tmco', 'qlco', 'menp', 'chvf', 'bodm', 'phsu']"
1570,PMC4392313,S50,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Patients,mtx therapy was continued during the study.,"['C0025677', 'C1417487', 'C0087111', 'C1363945', 'C2603343', 'C0039798']","['Methotrexate', 'MTX1 gene', 'Study', 'therapeutic aspects', 'Therapy Object (animal model)', 'Therapeutic procedure']","['gngm', 'topp', 'ftcn', 'fndg', 'orch', 'resa', ' phsu']"
1571,PMC4392313,S51,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Patients,"initiation of lipid-lowering, oral antidiabetic or antihypertensive medications or change in dose within 12 weeks of baseline was prohibited, and glucocorticoid doses (≤10 mg) had to remain stable.","['C0935929', 'C0168634', 'C0392747', 'C0178602', 'C0205360', 'C1158830', 'C0003364', 'C0442027', 'C4319952', 'C1704686', 'C0443172', 'C1442488', 'C1705241', 'C0023779', 'C0017710', 'C0589507', 'C1547311']","['Patient Condition Code - Stable', 'BaseLine dental cement', 'Lipids', 'Baseline', 'Cognitive function: initiation', 'Oral', 'Antihypertensive Agents', 'Changing', 'Glucocorticoids', 'Changed status', 'Change -- procedure', 'Stable status', 'Initiation', 'Dosage', 'Delta (difference)', 'Antidiabetics', 'Transcription Initiation']","[' orch', 'inpr', 'bodm', 'genf', 'topp', 'ftcn', 'spco', 'orch', 'qlco', 'horm', 'menp', 'qnco', 'phsu']"
1572,PMC4392313,S52,['8b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0]",Patients,"patients were stratified at randomisation by age (<52 vs ≥52 years), mean arterial blood pressure (<93.3 vs ≥93.3 mm hg) and crp (<1.66 vs ≥1.66 mg/dl).","['C0030705', 'C0428886', 'C3890735', 'C4048285', 'C0488053', 'C0001779']","['C-Reactive Protein, human', 'Age', 'Patients', 'Mean blood pressure', 'Complete Response with Incomplete Platelet Recovery', 'Intravascular mean:Pressure:Point in time:Arterial system:Quantitative']","['clna', 'fndg', 'podg', 'imft', ' aapp', 'orga']"
1573,PMC4392313,S54,"['3a', '4b']","[0, 0, 0, 0, 0, 0, 1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,"this two-arm, randomised, multicentre, double-blind, placebo-controlled, parallel-group, phase iii study was conducted in the usa, canada and the uk (figure 1) at 34 sites (the measure study).","['C3715044', 'C0079809', 'C1705764', 'C0041703', 'C0441833', 'C0687744', 'C0242485', 'C1515981', 'C4554418', 'C1080058', 'C0525065', 'C1705765', 'C0456909', 'C0006823', 'C2603343', 'C0205173', 'C1705429', 'C0205448', 'C2348042', 'C0205145', 'C0282461', 'C2826345', 'C1519504', 'C1706408', 'C0446516', 'C1257890', 'C4553528', 'C0150108', 'C1705428']","['This (eukaryote)', 'Upper arm', 'And', 'Site', 'Blinded', 'Stage Grouping', 'Visually Impaired Persons', 'Doubling', 'Duplicate', 'User Group', 'Blindness', 'Group Object', 'Social group', 'Measurement', 'Parallel Study', 'Phase 3 Clinical Trials', 'Study', 'Two', 'Canada', 'Placebo Control', 'Parallel', 'Groups', 'AKR1A1 wt Allele', 'Population Group', 'Sequence Arm', 'Measures', 'United States', 'Double Value Type', 'Parallel Lesion']","['inpr', 'geoa', 'idcn', 'acty', 'gngm', 'popg', 'ftcn', 'blor', 'fndg', 'qlco', 'euka', 'cnce', 'resa', 'spco', 'podg', 'qnco']"
1574,PMC4392313,S55,"['11a', '5', '8a']","[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 1, 0, 0]",Procedures,"patients were randomly assigned using an interactive voice response system to blinded (patient and treating clinical team) intravenous treatment with tcz 8 mg/kg or placebo in a 1:1 ratio, both in combination with oral mtx, every 4 weeks for 6 months between november 2007 and june 2008.","['C1704632', 'C0030705', 'C3888058', 'C0871489', 'C3828767', 'C1515981', 'C0456603', 'C1706817', 'C0013125', 'C0449913', 'C1696465', 'C0042939', 'C0205210', 'C3829443', 'C3244282', 'C0021440', 'C2911692', 'C1547037', 'C3811910', 'C1553451', 'C1417487', 'C4281800', 'C0442027', 'C1704675', 'C0032042', 'C0025677', 'C1706086', 'C1948061', 'C1706408', 'C1947911', 'C0150108', 'C0871261']","['Voice G-code', 'teams', 'Both', 'And', 'Patients', 'Blinded', 'placebo', 'System', 'Intravenous infusion procedures', 'Every (qualifier)', 'MTX1 gene', 'TelecommunicationCapabilities <voice>', 'Response (communication)', 'Placebos', 'Ratio', 'combination - answer to question', 'Interaction', 'intravenous administration', 'November', 'Voice', 'data type - ratio', 'June', 'Methotrexate', 'Clinical', 'Oral', 'Disease Response', 'Device system', 'combination of objects', 'Response (statement)', 'Response process', 'Placebo Control', 'System - kit']","['topp', 'mnob', 'fndg', 'qlco', ' phsu', 'inpr', 'idcn', 'gngm', 'resa', 'orgf', 'bodm', 'phob', 'ftcn', 'podg', 'tmco', 'orch', 'menp', 'grup', 'spco', 'qnco', 'orga']"
1575,PMC4392313,S56,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Procedures,"patients who, despite scheduled infusions of double-blind study medication at weeks 8 and 12, did not achieve ≥20% improvement from baseline in sjc and tjc at week 16 were offered escape therapy with open-label tcz 8 mg/kg.","['C1705764', 'C0030705', 'C0086960', 'C1515981', 'C0574032', 'C1518422', 'C4284232', 'C2827499', 'C0439230', 'C1705765', 'C2347038', 'C1442488', 'C0175566', 'C0205539', 'C0181496', 'C0039798', 'C3244316', 'C0205173', 'C4551445', 'C0013227', 'C0168634', 'C0870509', 'C0087111', 'C1363945', 'C2986411', 'C4522130']","['Escape (mental process)', 'Labels (device)', 'Baseline', 'medication - HL7 publishing domain', 'And', 'Patients', 'Therapeutic procedure', 'Doubling', 'Duplicate', 'Improvement', 'Human Cells, Tissues, and Cellular and Tissue-Based Products Labeling', 'Medications', 'Infusion procedures', 'Negation', 'BaseLine dental cement', 'week', 'therapeutic aspects', 'Labeling Activity', 'Blinded Clinical Study', 'Scheduled - procedure status', 'Open', 'Pharmaceutical Preparations', 'Schedule (document type)', 'Therapy Object (animal model)', 'Double Value Type', 'Label (document)']","['inpr', 'idcn', 'qnco', 'acty', 'topp', 'ftcn', 'fndg', 'cnce', 'podg', 'tmco', 'qlco', 'resa', 'mnob', 'spco', 'menp', 'bodm', 'phsu']"
1576,PMC4392313,S57,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Procedures,"at completion of the 24-week randomised treatment period, all patients were offered open-label treatment with tcz 8 mg/kg plus mtx.","['C0030705', 'C3887704', 'C1705169', 'C1948053', 'C0205197', 'C1554962', 'C2827499', 'C0439230', 'C0439531', 'C0175566', 'C0039798', 'C0181496', 'C3538994', 'C1417487', 'C4551445', 'C0025677', 'C0087111', 'C1522326', 'C1533734', 'C0444868', 'C4522130']","['Labels (device)', 'Biomaterial Treatment', 'Patients', 'Therapeutic procedure', 'Human Cells, Tissues, and Cellular and Tissue-Based Products Labeling', 'MTX1 gene', 'Administration procedure', 'Methotrexate', 'Complete', 'Treatment Epoch', 'All', 'week', 'per period (qualifier value)', 'therapeutic aspects', 'Period (temporal qualifier)', 'Labeling Activity', 'completion - ResponseLevel', 'treatment - ActInformationManagementReason', 'Open', 'Treating', 'Label (document)']","['inpr', 'acty', 'gngm', 'topp', 'ftcn', 'cnce', 'mnob', 'podg', 'qlco', 'orch', 'resa', 'spco', ' phsu', 'tmco', 'hlca', 'qnco']"
1577,PMC4392313,S58,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"assessments during part 1 (randomised phase) of the study were performed at day 1 and at weeks 1, 2, 4, 8, 12, 16, 20 and 24.","['C0205390', 'C1261322', 'C0439230', 'C1709471', 'C1515981', 'C0449719', 'C2603343', 'C1710475', 'C1442449']","['Trial Phase', 'week', 'Evaluation procedure', 'Phase', 'And', 'Study', 'Part Dosing Unit', 'Part', '1 Day']","['idcn', 'clas', 'spco', 'tmco', 'resa', 'hlca', 'qnco']"
1578,PMC4392313,S59,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,open-label assessments were performed every 12 weeks to week 104 (clinicaltrials.gov number nct00535782).,"['C1261322', 'C0237753', 'C1948061', 'C2827499', 'C0439230', 'C4086204', 'C0449788', 'C4551445', 'C4522130', 'C0181496']","['Count of entities', 'Labels (device)', 'Human Cells, Tissues, and Cellular and Tissue-Based Products Labeling', 'week', 'Evaluation procedure', 'Numbers', 'Labeling Activity', 'Every (qualifier)', 'ClinicalTrials.gov', 'Label (document)']","['inpr', 'acty', 'mnob', 'qlco', 'tmco', 'resa', 'hlca', 'qnco']"
1579,PMC4392313,S60,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,"the study protocol (version c, 22 june 2009 (original protocol published 10 may 2007)) is available as online supplementary material.",,,
1580,PMC4392313,S61,"['3a', '5']","[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Procedures,figure 1 study design.,"['C0035171', 'C2986888', 'C2983265']","['Research Design', 'CDISC SEND Study Design Terminology', 'Nonclinical Study Design']","['inpr', 'resa']"
1581,PMC4392313,S62,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,"mtx, methotrexate; tcz, tocilizumab.","['C1609165', 'C1417487', 'C0025677']","['Methotrexate', 'tocilizumab', 'MTX1 gene']","['gngm', 'orch', 'imft', ' phsu', ' aapp']"
1582,PMC4392313,S63,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,(a) *patients who did not achieve ≥20% improvement from baseline in swollen and tender joint counts at week 16 were offered escape therapy with open-label tcz 8 mg/kg.,"['C4554549', 'C0240094', 'C0030705', 'C1515981', 'C0038999', 'C1518422', 'C2827499', 'C0439230', 'C1442488', 'C0175566', 'C0181496', 'C0039798', 'C4551445', 'C0439157', 'C0168634', 'C0870509', 'C0087111', 'C1363945', 'C2986411', 'C3272598', 'C4522130']","['Escape (mental process)', 'Labels (device)', 'Baseline', 'Joint tenderness', 'And', 'Patients', 'Therapeutic procedure', 'Improvement', 'Human Cells, Tissues, and Cellular and Tissue-Based Products Labeling', 'Swelling', 'Negation', 'BaseLine dental cement', 'WHO Temperature/Humidity Storage Condition', 'week', 'counts', 'therapeutic aspects', 'Labeling Activity', 'Open', 'Therapy Object (animal model)', 'Tender joint:Anatomy:Point in time:^Patient:Nominal', 'Label (document)']","['sosy', 'inpr', 'clna', 'idcn', 'qnco', 'acty', 'topp', 'ftcn', 'fndg', 'cnce', 'qlco', 'podg', 'mnob', 'resa', 'spco', 'tmco', 'menp', 'bodm']"
1583,PMC4392313,S64,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,†60 placebo+mtx and 65 tcz+mtx patients completed 12 weeks.,"['C0032042', 'C0025677', 'C0030705', 'C1706408', 'C1696465', 'C1417487', 'C1515981']","['Methotrexate', 'Placebo Control', 'MTX1 gene', 'And', 'Placebos', 'Patients', 'placebo']","['idcn', 'gngm', 'topp', 'orch', 'podg', 'resa', ' phsu', 'bodm']"
1584,PMC4392313,S65,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,‡59 placebo+mtx and 65 tcz+mtx patients completed 24 weeks.,"['C0032042', 'C0025677', 'C0030705', 'C1706408', 'C1696465', 'C1417487', 'C1515981']","['Methotrexate', 'Placebo Control', 'MTX1 gene', 'And', 'Placebos', 'Patients', 'placebo']","['idcn', 'gngm', 'topp', 'orch', 'podg', 'resa', ' phsu', 'bodm']"
1585,PMC4392313,S66,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,(b) *tcz 8 mg/kg every 4 weeks+background mtx (7.5–25 mg weekly).,"['C0025677', 'C1948061', 'C1417487', 'C1706907', 'C0332174']","['Methotrexate', 'MTX1 gene', 'Background', 'Weekly', 'Every (qualifier)']","['gngm', 'cnce', 'qlco', 'orch', 'tmco', ' phsu']"
1586,PMC4392313,S67,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,"†escape therapy, open-label tcz (8 mg/kg every 4 weeks+background mtx).","['C0025677', 'C0870509', 'C1948061', 'C2827499', 'C1417487', 'C0087111', 'C1363945', 'C1706907', 'C4551445', 'C0175566', 'C0181496', 'C4522130', 'C0039798']","['Escape (mental process)', 'Methotrexate', 'Labels (device)', 'Open', 'Human Cells, Tissues, and Cellular and Tissue-Based Products Labeling', 'MTX1 gene', 'Background', 'therapeutic aspects', 'Therapy Object (animal model)', 'Labeling Activity', 'Therapeutic procedure', 'Every (qualifier)', 'Label (document)']","['inpr', 'acty', 'gngm', 'topp', 'ftcn', 'fndg', 'cnce', 'qlco', 'mnob', 'orch', 'resa', 'spco', ' phsu', 'menp']"
1587,PMC4392313,S68,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,‡patients who received at least one dose of tcz (double-blind or open-label).,"['C1705764', 'C0178602', 'C0525065', 'C2827499', 'C1705765', 'C0205173', 'C0456909', 'C0205447', 'C0150108', 'C4551445', 'C0175566', 'C3272598', 'C4522130', 'C0181496']","['Doubling', 'Duplicate', 'Labels (device)', 'Open', 'Human Cells, Tissues, and Cellular and Tissue-Based Products Labeling', 'WHO Temperature/Humidity Storage Condition', 'Visually Impaired Persons', 'Blindness', 'Blinded', 'Labeling Activity', 'Double Value Type', 'Dosage', 'One', 'Label (document)']","['inpr', 'acty', 'ftcn', 'fndg', 'mnob', 'qlco', 'spco', 'podg', 'resa', 'qnco']"
1588,PMC4392313,S70,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Lipid and biomarker assays,"commercial assays were used to measure cholesterol, triglycerides, apolipoproteins a1 and b (apoa1 and apob), crp (by high-sensitivity assay) and esr (all assays conducted or facilitated by covance laboratories, greenfield, indiana, usa).","['C0041703', 'C0020517', 'C0008377', 'C2698168', 'C4522209', 'C1299351', 'C0205250', 'C1515981', 'C1511883', 'C2349185', 'C3889660', 'C0243073', 'C1412468', 'C0036667', 'C1677784', 'C3890735', 'C4048285', 'C4321237', 'C3887512', 'C0003591', 'C0022877', 'C0680536', 'C3272563', 'C3811131', 'C2346484', 'C0021206', 'C3252643', 'C1510438', 'C2700149', 'C0444868', 'C1522640', 'C0005507']","['Assay', 'Signal Sensitivity', 'assay qualifier', 'Commercial Lot', 'And', 'Abnormally high', 'High Level', 'Complete Response with Incomplete Platelet Recovery', 'Estrogen Receptor Measurement', 'high - ActExposureLevelCode', 'Laboratory', 'APOA1 protein, human', 'commercial', 'Hypersensitivity', 'High Mitosis-Karyorrhexis Index', 'Biological Assay', 'C-Reactive Protein, human', 'All', 'Apolipoproteins', 'Value Above Reference Range', 'Statistical sensitivity', 'IPSS Risk Category High', 'Apolipoprotein A1 Measurement', 'Cholesterol', 'Indiana', 'High', 'Diagnostic Sensitivity', 'APOB protein, human', 'Increased Sensitivy', 'United States', 'APOA1 gene', 'stimulus sensitivity']","['bacs', ' orch', 'phpr', 'inpr', 'geoa', 'idcn', 'lbpr', 'gngm', 'mnob', 'patf', 'qlco', 'imft', 'fndg', ' aapp', ' hcro', 'qnco']"
1589,PMC4392313,S71,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Lipid and biomarker assays,"serum lipid subclasses were characterised by nuclear magnetic resonance (nmr; liposcience, raleigh, north carolina, usa).","['C0028580', 'C0041703', 'C0024485', 'C0428462', 'C0028407', 'C1547989', 'C0445604']","['subclass', 'North Carolina', 'Nuclear Magnetic Resonance', 'Measurement of serum lipid level', 'United States', 'Magnetic Resonance Imaging', 'Diagnostic Service Section ID - Nuclear Magnetic Resonance']","['inpr', 'geoa', 'lbpr', 'clas', 'diap', 'npop']"
1590,PMC4392313,S72,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Lipid and biomarker assays,"assays for hdl-associated saa and serum paraoxonase, secretory phospholipase a2-iia (spla2-iia), oxidised ldl, d-dimer, fibrinogen, lp(a) and haptoglobin were performed at pacific biomarkers, inc. (seattle, washington, usa).","['C0041703', 'C0884358', 'C1327616', 'C0052451', 'C1515981', 'C0005516', 'C1550100', 'C1883018', 'C3715113', 'C1167394', 'C0018595', 'C0060323', 'C0332281', 'C0229671', 'C0031671', 'C1546774', 'C1419799', 'C2587184', 'C1418616', 'C0016006', 'C0002723', 'C0163401', 'C0043038', 'C1419798', 'C3540039', 'C1706169']","['Cell secretion', 'And', 'Serum', 'Fibrinogen', 'fibrinogen complex location', 'Phospholipase', 'HSD11B1 wt Allele', 'PLA2G2A wt Allele', 'aryldialkylphosphatase', 'Serum amyloid A protein', 'Specimen Type - Serum', 'Haptoglobins', 'SAA@ gene cluster', 'Washington state', 'PLA2G10 gene', 'Performed', 'Associated with', 'Biological Markers', 'Severe Aplastic Anemia', 'Arylesterase', 'Fibrinogen containing hemostatics', 'Fibrin fragment D', 'fibrinogen concentrate (human)', 'SAA1 gene', 'United States', 'Specimen Source Codes - Serum']","['bacs', 'inpr', 'clna', 'celf', 'geoa', 'idcn', 'gngm', 'enzy', 'ftcn', 'celc', 'bdsu', 'qlco', 'imft', ' phsu', 'aapp', ' aapp', 'dsyn']"
1591,PMC4392313,S73,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Lipid and biomarker assays,specific details are provided as online supplementary material.,"['C2936424', 'C1552740', 'C1522508', 'C0205369']","['Specific qualifier value', 'Electronic Supplementary Materials', 'Details', 'Entity Determiner - specific']","['inpr', 'qlco']"
1592,PMC4392313,S75,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Vascular physiology,"arterial stiffness was assessed by pwv according to the manufacturer's instructions using a pulse wave analysis apparatus (sphygmocor; atcor, san jose, california, usa).19","['C1442085', 'C0041703', 'C0243111', 'C0006754', 'C3494430', 'C0947322', 'C4019016', 'C0302828', 'C0599949', 'C1826357', 'C3494431', 'C3146274', 'C3263700', 'C1947951']","['Arterial Stiffness', 'Manufacturer Name', 'Anatomical Apparatus', 'California (plant)', 'NAA50 gene', 'manufactured apparatus', 'Pulse wave velocity:Vel:Pt:Arterial system:Qn', 'Instruction [Publication Type]', 'United States', 'California', 'Instructions', 'Instructions:Text:Point in time:^Patient:Narrative', 'Pulse Wave Analysis', 'Pulse Wave Velocity']","['inpr', 'clna', 'geoa', 'phsf', 'gngm', 'plnt', 'mnob', 'anst', 'diap', 'qnco']"
1593,PMC4392313,S76,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Vascular physiology,"blinded assessors from all centres underwent training with an expert assessor, and certification was provided by atcor.","['C0007836', 'C1707957', 'C2673163', 'C2646699', 'C1515981', 'C0220931', 'C0444868', 'C0205099', 'C0040607']","['All', 'And', 'Assessor (genus)', 'Training Programs', 'Central', 'Training', 'training aspects', 'Certification', 'Evaluator - personnel']","['fish', 'idcn', 'prog', 'spco', 'edac', 'qlco', 'gora', 'qnco']"
1594,PMC4392313,S77,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Vascular physiology,"all pwv scans were reviewed by atcor, and only those meeting predetermined quality control measures were accepted for analysis (details in online supplementary material).","['C0079809', 'C2936424', 'C4019016', 'C0205171', 'C0936012', 'C1515981', 'C0034378', 'C3494431', 'C1524024', 'C1522508', 'C0444868', 'C0556656', 'C0441633', 'C1610034', 'C1561524']","['Specimen Source Codes - Quality Control', 'Scanning', 'Pulse Wave Velocity', 'All', 'meeting', 'And', 'quality control', 'Singular', 'Analysis', 'Pulse wave velocity:Vel:Pt:Arterial system:Qn', 'Quality Control Specimen', 'Electronic Supplementary Materials', 'Measures', 'Details', 'analysis aspect']","['inpr', 'clna', 'idcn', 'acty', 'ftcn', 'qlco', 'resa', 'diap', 'qnco']"
1595,PMC4392313,S79,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical analysis,the primary objective was to investigate the effect of 12 weeks of treatment with tcz on pwv and on small ldl particle number assessed by nmr compared with placebo.,"['C0032042', 'C2612459', 'C4019016', 'C1706408', 'C1696465', 'C3538994', 'C1705169', 'C3887704', 'C0087111', 'C2827976', 'C1280500', 'C0449788', 'C1518681', 'C1533734', 'C0700321', 'C1522326', 'C3494431', 'C0237753', 'C0039798', 'C2348382']","['Placebo Control', 'Effect', 'Count of entities', 'Small', 'Treatment Epoch', 'low-density lipoprotein particle', 'Biomaterial Treatment', 'Numbers', 'Placebos', 'Administration procedure', 'Treating', 'Pulse wave velocity:Vel:Pt:Arterial system:Qn', 'Effect, Appearance', 'Trial Primary Objective', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'placebo', 'Therapeutic procedure', 'Pulse Wave Velocity', 'Outcome of Therapy']","['clna', 'bodm', 'topp', 'ftcn', 'cnce', 'fndg', 'qlco', 'celc', 'resa', 'hlca', 'qnco']"
1596,PMC4392313,S80,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical analysis,the secondary objective was to investigate the effect of tcz compared with placebo on these measurements at week 24.,"['C0032042', 'C0039828', 'C1706408', 'C1696465', 'C0439230', 'C0242485', 'C1280500', 'C2827977', 'C1518681', 'C2348382']","['Placebo Control', 'Effect', 'Theses', 'week', 'Placebos', 'Effect, Appearance', 'placebo', 'Measurement', 'Outcome of Therapy', 'Trial Secondary Objective']","['inpr', 'topp', 'ftcn', 'fndg', 'qlco', 'tmco', 'resa', 'bodm']"
1597,PMC4392313,S81,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"all other analyses, including lipid and lipoprotein parameters, were exploratory.","['C1515981', 'C0023820', 'C0444868', 'C0023779', 'C0332257']","['Lipids', 'All', 'Including (qualifier)', 'And', 'Lipoproteins']","['bacs', 'idcn', 'ftcn', 'orch', ' aapp', 'qnco']"
1598,PMC4392313,S82,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analysis,"a sample size of 120 patients (60 per arm), calculated based on previous results in patients with ra,5 18 was expected to provide sufficient power to detect a difference at week 12 in pwv (−1.14 m/s) and small ldl (−5.51 mg/dl (30% reduction)) in patients treated with tcz compared with placebo.","['C3715044', 'C0030705', 'C0032863', 'C0301630', 'C0700321', 'C0242618', 'C4019016', 'C1696465', 'C0439230', 'C0205410', 'C1293152', 'C1705242', 'C4551656', 'C0392756', 'C0205156', 'C3494431', 'C0032042', 'C1706408', 'C0446516', 'C3854080', 'C4553528', 'C1552607', 'C1705241']","['Upper arm', 'Sample Size', 'Patients', 'Act Relationship Subset - previous', 'Power', 'Reduced', 'Surgical reduction', 'placebo', 'Sufficient', 'Delta (difference)', 'Reduction (chemical)', 'Small', 'Placebos', 'week', 'Pulse wave velocity:Vel:Pt:Arterial system:Qn', 'Placebo Control', 'AKR1A1 wt Allele', 'Power (Psychology)', 'Previous', 'Reduction procedure', 'Sequence Arm', 'Different', 'Pulse Wave Velocity']","['hcpp', 'inpr', 'clna', 'bodm', 'gngm', 'topp', 'blor', 'podg', 'tmco', 'qlco', 'resa', 'npop', 'qnco']"
1599,PMC4392313,S83,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,the co-primary efficacy end points of change from baseline in pwv and small ldl particle number were analysed by parametric analysis of covariance.,"['C1280519', 'C0168634', 'C0392747', 'C4019016', 'C2612459', 'C2746065', 'C0936012', 'C4319952', 'C1515981', 'C0443172', 'C0205225', 'C1524024', 'C1442488', 'C0449788', 'C0700321', 'C1705241', 'C1707887', 'C3494431', 'C0444930', 'C0237753']","['Stop (qualifier value)', 'BaseLine dental cement', 'Count of entities', 'Baseline', 'Effectiveness', 'Efficacy Study', 'Pulse Wave Velocity', 'Changing', 'Small', 'low-density lipoprotein particle', 'And', 'Changed status', 'Numbers', 'Analysis', 'End', 'Change -- procedure', 'Pulse wave velocity:Vel:Pt:Arterial system:Qn', 'Delta (difference)', 'Primary', 'analysis aspect']","['clna', 'bodm', 'idcn', 'topp', 'ftcn', 'spco', 'celc', 'qlco', 'tmco', 'resa', 'qnco']"
1600,PMC4392313,S84,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,the 12-week and 24-week efficacy analyses of primary and secondary end points were performed on the intent-to-treat (itt) population using last-observation-carried-forward to impute missing data at the analysis time point.,"['C0884358', 'C0205436', 'C1292734', 'C1515981', 'C0027627', 'C1524024', 'C2348792', 'C0032659', 'C0162425', 'C3889687', 'C0936012', 'C0439230', 'C0302523', 'C0699809', 'C0444930', 'C1280519', 'C1283828', 'C1964257', 'C0439780', 'C0205225', 'C0700325', 'C0206243', 'C1707887', 'C1517741', 'C1257890', 'C0087111', 'C2699638', 'C1522326', 'C4684714', 'C1550453', 'C2746065', 'C0175668']","['Observation in research', 'Effectiveness', 'And', 'geographic population', 'Observation - diagnostic procedure', 'End', 'Act Mood - intent', 'Patient observation', 'Secondary to', 'Therapeutic procedure', 'Last', 'Efficacy Study', 'Forward', 'Clinical Observation', 'Missing Data', 'Treatment intent', 'Intention - mental process', 'Stop (qualifier value)', 'Statistical Imputation', 'intent', 'week', 'Does carry', 'Performed', 'analysis aspect', 'Neoplasm Metastasis', 'second (number)', 'Carrying', 'Treating', 'Population Group', 'Timepoint', 'Analysis', 'Primary']","['idcn', 'acty', 'topp', 'neop', 'popg', 'ftcn', 'fndg', 'spco', 'qlco', 'tmco', 'resa', 'hlca', 'menp', 'diap', 'qnco']"
1601,PMC4392313,S85,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,only measurements recorded before escape therapy were carried forward.,"['C0870509', 'C0205171', 'C0087111', 'C1363945', 'C0242485', 'C0439780', 'C0039798']","['Escape (mental process)', 'Forward', 'Singular', 'therapeutic aspects', 'Therapy Object (animal model)', 'Therapeutic procedure', 'Measurement']","['topp', 'ftcn', 'fndg', 'spco', 'menp', 'qnco']"
1602,PMC4392313,S86,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"all other exploratory end points were summarised for the itt population observed cases, without imputation of missing data and excluding escape data.","['C1511726', 'C0870509', 'C0032659', 'C3245479', 'C2746065', 'C1257890', 'C1515981', 'C2699638', 'C0444868', 'C3714741', 'C0868928', 'C0444930']","['Escape (mental process)', 'Stop (qualifier value)', 'Statistical Imputation', 'Case (situation)', 'All', 'geographic population', 'Data call receiving device', 'And', 'Population Group', 'End', 'Data (eukaryote)', 'Data']","['idcn', 'popg', 'medd', 'ftcn', 'spco', 'tmco', 'euka', 'menp', 'qnco']"
1603,PMC4392313,S87,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"all laboratory parameter values were converted to si units; for lipid parameters, only the latest fasted values within the time window were included.","['C4283904', 'C0205171', 'C1704769', 'C0872291', 'C3244292', 'C0023779', 'C0042295', 'C0021791', 'C0022877', 'C0444868', 'C0549193', 'C0332285', 'C2350001']","['Lipids', 'All', 'Parameter Value', 'Time Interval', 'Singular', 'Within', 'Values', 'Programming Parameter', 'International System of Units', 'Laboratory', 'Laboratory observation', 'Population Parameter', 'Laboratory domain']","['inpr', 'lbtr', 'ftcn', 'mnob', 'cnce', 'qlco', 'orch', 'tmco', 'spco', ' hcro', 'qnco']"
1604,PMC4392313,S88,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"assumptions of normality and homogeneity of the variance were assessed by inspecting normal probability plots, plots of standardised residual versus predicted values and plots of standardised residual versus continuous covariates.","['C0231683', 'C0205307', 'C0033204', 'C2348152', 'C1881065', 'C0042295', 'C1515981', 'C0549178', 'C1882114', 'C0681842', 'C1609982', 'C4553972', 'C0949333', 'C1711260']","['Residual', 'Normal', 'Sample Variance', 'Variance', 'Probability', 'And', 'Homogeneity', 'Continuous', 'Normality Unit', 'prediction', 'Values', 'Gait normal', 'Normality', 'How Often Felt Normal question']","['inpr', 'idcn', 'fndg', 'qlco', 'qnco']"
1605,PMC4392313,S89,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"primary end points in the study were analysed based on a normal distribution; however, because baseline values for several laboratory assessments in this study demonstrated non-normal distributions, values for exploratory serum analytes are presented as medians or median percentage changes from baseline.","['C1561533', 'C1261322', 'C2939193', 'C0439064', 'C4321252', 'C1550100', 'C1080058', 'C1518422', 'C4283904', 'C0443302', 'C2603343', 'C1442488', 'C0022877', 'C0444930', 'C0449450', 'C0443354', 'C2348144', 'C0042295', 'C0443172', 'C0229671', 'C0205225', 'C1546774', 'C0028377', 'C0521125', 'C0168634', 'C0392747', 'C1517320', 'C1549488', 'C0439165', 'C0549183', 'C3244292', 'C0876920', 'C1551058', 'C2746065', 'C2347635']","['Baseline', 'This (eukaryote)', 'Evaluation procedure', 'are unit of measure', 'End', 'Serum', 'From', 'Preposition For', 'WWOX wt Allele', 'Median Statistical Measurement', 'Laboratory domain', 'Money or percentage indicator - Percentage', 'Changed status', 'Several', 'Midline (qualifier value)', 'Population Median', 'Laboratory', 'Normal Statistical Distribution', 'Negation', 'Stop (qualifier value)', 'BaseLine dental cement', 'Changing', 'Specimen Type - Serum', 'Study', 'Numerous', 'analyte', 'Median (qualifier value)', 'Amount type - Percentage', 'Presentation', 'Percent (qualifier value)', 'Values', 'Sample Median', 'Laboratory observation', 'Specimen Source Codes - Serum', 'Primary']","['inpr', 'bodm', 'idcn', 'gngm', 'lbtr', 'ftcn', 'mnob', 'spco', 'bdsu', 'qlco', 'tmco', 'resa', 'euka', 'hlca', 'sbst', ' hcro', 'qnco']"
1606,PMC4392313,S90,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"exploratory analyses, based on observed cases, were performed using the non-parametric kruskal–wallis test.","['C0022885', 'C1515976', 'C0456984', 'C1441672', 'C0392366', 'C4318744', 'C3831328', 'C0868928', 'C1518422', 'C0039593']","['Observed', 'Test Result', 'Case (situation)', 'Laboratory Procedures', 'Tests (qualifier value)', 'Testing', 'Anatomic Structure, System, or Substance', 'Test - temporal region', 'Blood Products Laboratory Testing', 'Negation']","['inpr', 'lbpr', 'clas', 'lbtr', 'ftcn', 'blor']"
1607,PMC4392313,S91,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,hodges–lehmann estimates of location shift and 95% cis are presented.,"['C4284931', 'C0333051', 'C0750572', 'C4284930', 'C1515981', 'C0450429', 'C1504308', 'C2347509', 'C1742862', 'C1515974']","['Estimated', 'CISH protein, human', 'shift displacement', 'Anatomic Site', 'And', 'Location of Oral Residue Following Swallowing', 'Genus Cis', 'Location of Pharyngeal Residue Following Swallowing', 'Location', 'Physical Shift']","['bacs', 'phpr', 'idcn', 'ftcn', 'blor', 'spco', 'fndg', 'euka', ' aapp', 'qnco']"
1608,PMC4392313,S92,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,no adjustments for multiplicity were performed.,"['C2945673', 'C0449822', 'C0376209']","['multiplicity', 'Individual Adjustment', 'Clinical adjustment']","['qnco', 'topp', 'inbe']"
1609,PMC4431679,S40,"['3a', '4b']","[0, 0, 0, 0, 0, 0, 1, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Methods,"this was an open label, parallel, one to one randomised controlled trial, conducted in four acute care hospitals (rabin medical center, petah-tikva (192 patients); rambam health care campus (38 patients); holy family hospital nazareth (7 patients); wolfson medical center (6 patients)) in israel, between july 2007 and april 2014.","['C1706374', 'C0030705', 'C0259945', 'C1515981', 'C4554418', 'C3811652', 'C1080058', 'C0009933', 'C1709323', 'C0086388', 'C0205447', 'C1704727', 'C3829447', 'C0015576', 'C0019994', 'C0565990', 'C2348042', 'C3715025', 'C0936233', 'C0679878', 'C0205450', 'C2826345', 'C3715024', 'C0022271']","['Health Care', 'Israel', 'This (eukaryote)', 'And', 'Patients', 'hospital care', 'April', 'Family (taxonomic)', 'Four', 'Medical center', 'Controlled Clinical Trial [Publication Type]', 'Open Label Study', 'July', 'Family', 'Parallel Study', 'acute care', 'One', 'TNFSF13 wt Allele', 'Parallel', 'Tumor Necrosis Factor Ligand Superfamily Member 13', 'A Proliferation-Inducing Ligand Measurement', 'Controlled Clinical Trials as Topic', 'Hospitals', 'Parallel Lesion']","['bacs', 'inpr', 'geoa', 'idcn', 'lbpr', 'gngm', 'famg', 'cnce', 'mnob', 'podg', 'euka', 'tmco', 'resa', 'qlco', 'hlca', 'fndg', ' aapp', ' hcro', 'qnco']"
1610,PMC4431679,S41,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Methods,informed consent was obtained from all patients or their legal guardian.,"['C0023226', 'C0444868', 'C0021430', 'C0030705']","['Legal Guardians', 'All', 'Informed Consent', 'Patients']","['qnco', 'podg', 'popg', 'rnlw']"
1611,PMC4431679,S43,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population and procedures,"we included adult inpatients with severe infections caused by mrsa, including bacteraemia, and patients with highly probable mrsa infections.","['C0021562', 'C4050465', 'C0001675', 'C1546985', 'C0030705', 'C4521538', 'C1706450', 'C1515981', 'C0205082', 'C3714514', 'C4050466', 'C0004610', 'C1265292']","['Methicillin-resistant Staphylococcus aureus Measurement', 'Legal Adult', 'Borg Category-Ratio 10 Perceived Exertion Score 5', 'Severe Extremity Pain', 'And', 'Adult', 'Severe (severity modifier)', 'Patients', 'Methicillin-Resistant Staphylococcus aureus', 'Bacteremia', 'Highly probable', 'Infection', 'inpatient']","['inpr', 'idcn', 'aggp', 'popg', 'lbtr', 'fndg', 'patf', 'podg', 'bact', 'qlco', 'dsyn']"
1612,PMC4431679,S44,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population and procedures,"we defined bacteraemia as the isolation of mrsa in more than one blood culture bottle or isolated in a single bottle and accompanied by fever above 38°c, chills, or systolic blood pressure under 90 mm hg.","['C0179376', 'C0424755', 'C4521538', 'C1515981', 'C0085593', 'C0220862', 'C0204727', 'C0205447', 'C0871470', 'C0200949', 'C0015967', 'C0205409', 'C0205172', 'C1306620', 'C4553185', 'C0488055', 'C1633989', 'C1265292', 'C0205171', 'C0087136', 'C4552740']","['bottle - unit dose', 'And', 'Chills', 'isolation aspects', 'Unmarried', 'Fever, CTCAE', 'Blood culture', 'Fever symptoms (finding)', 'Bottle, device', 'Systolic Pressure', 'Systolic blood pressure measurement', 'Intravascular systolic:Pressure:Point in time:Arterial system:Quantitative', 'Chills, CTCAE', 'Singular', 'Methicillin-Resistant Staphylococcus aureus', 'Isolated', 'One', 'Isolation procedure', 'Methicillin-resistant Staphylococcus aureus Measurement', 'Fever', 'More']","['sosy', 'clna', 'idcn', 'lbpr', 'topp', 'lbtr', 'ftcn', 'fndg', 'mnob', 'bact', 'diap', 'qnco']"
1613,PMC4431679,S45,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population and procedures,"we defined other microbiologically documented mrsa infections by using predefined criteria adapted from surveillance definitions of healthcare associated infections,26 plus isolation of mrsa from a sterile sample from the source of infection.","['C0010356', 'C0205409', 'C0232920', 'C0220862', 'C4521538', 'C1609436', 'C1265292', 'C0204727', 'C1301725', 'C0243161', 'C0021359', 'C0733511', 'C1705919', 'C0220920', 'C3714514', 'C0449416', 'C0370003', 'C2347026']","['surveillance aspects', 'Isolation procedure', 'Term Source', 'Methicillin-resistant Staphylococcus aureus Measurement', 'Biospecimen', 'Medical Surveillance', 'Documented', 'criteria', 'Methicillin-Resistant Staphylococcus aureus', 'Document completion status - Documented', 'isolation aspects', 'Sterile (qualifier value)', 'Isolated', 'Specimen', 'Infertility', 'Source', 'Cross Infection', 'Infection']","['inpr', 'idcn', 'lbpr', 'topp', 'lbtr', 'ftcn', 'cnce', 'patf', 'fndg', 'bact', 'qlco', 'hlca', 'sbst']"
1614,PMC4431679,S46,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population and procedures,patients with skin and soft tissue infections could be included only if they fulfilled the sepsis inflammatory response syndrome criteria.27,"['C0444099', 'C0030705', 'C1090821', 'C1123023', 'C0205171', 'C0036690', 'C0243026', 'C4552837', 'C0039082', 'C1515981', 'C0243161', 'C1155266', 'C4520765', 'C0149778']","['Syndrome', 'Skin', 'Sepsis', 'Soft Tissue Infection', 'And', 'Septicemia', 'Patients', 'Sepsis, CTCAE', 'Singular', 'inflammatory response', 'criteria', 'Sepsis (Invertebrate)', 'Skin Specimen', 'Skin, Human']","['idcn', 'fndg', 'patf', 'podg', 'euka', 'bdsu', 'bdsy', 'dsyn', 'qnco']"
1615,PMC4431679,S47,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population and procedures,"patients with polymicrobial infections could be included, except those involving meticillin susceptible s aureus or mandating treatment with vancomycin or trimethoprim-sulfamethoxazole.","['C0030705', 'C2827758', 'C3887704', 'C1705169', 'C0038689', 'C0220898', 'C0025643', 'C0231204', 'C0087111', 'C1522326', 'C1533734', 'C0275524', 'C0039798', 'C3538994']","['Coinfection', 'Treatment Epoch', 'Methicillin', 'Biomaterial Treatment', 'Antimicrobial Susceptibility Result', 'Administration procedure', 'Patients', 'Treating', 'Predisposition -- attribute', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Sulfamethoxazole', 'Therapeutic procedure', 'Susceptible']","[' orch', 'topp', 'lbtr', 'ftcn', 'cnce', 'antb', 'podg', 'resa', 'dsyn', 'hlca', 'orga']"
1616,PMC4431679,S48,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population and procedures,"the highly probable group included patients with ventilator associated pneumonia and prior antibiotic treatment, central catheter related infections, and surgical site infections in the presence of a foreign body, all without microbiological documentation.28","['C0016542', 'C0175636', 'C0030705', 'C1547673', 'C0441833', 'C0687744', 'C1515981', 'C0205099', 'C0920316', 'C1546985', 'C0150312', 'C0199779', 'C0085590', 'C0332281', 'C3714514', 'C0392148', 'C1705429', 'C0332152', 'C0025953', 'C1519504', 'C1257890', 'C0032285', 'C0444868', 'C1705428', 'C2826257', 'C0038941']","['And', 'Present', 'Providing presence (regime/therapy)', 'Patients', 'Administration of antibiotic', 'Stage Grouping', 'Pneumonia', 'Document type', 'User Group', 'Before', 'Central', 'Group Object', 'Social group', 'Prior Medication Usage', 'All', 'Highly probable', 'Microbiological', 'Foreign Bodies', 'Surgical Wound Infection', 'Associated with', 'catheter device', 'Act of Documentation', 'Groups', 'Population Group', 'Documentation', 'Infection']","['inpr', 'idcn', 'inpo', 'topp', 'medd', 'popg', 'ftcn', 'spco', 'patf', 'podg', 'qlco', 'tmco', 'cnce', 'fndg', 'dsyn', 'hlca', 'qnco', 'evnt']"
1617,PMC4431679,S49,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population and procedures,"we excluded patients who had received trimethoprim-sulfamethoxazole or vancomycin for more than 48 hours; patients with mrsa resistant to trimethoprim-sulfamethoxazole or vancomycin; those with highly suspected or confirmed left sided endocarditis or meningitis; patients with chronic renal failure (creatinine clearance <15 ml/min) and chronic haemodialysis (those with severe acute renal failure, including acute haemodialysis, could be included); neutropenic patients with acute leukaemia or bone marrow transplantation; and patients with known allergy to either study drug, treatment with methotrexate, pregnancy or lactation, previous enrolment in this study, or concurrent participation in another trial.","['C0030705', 'C3845888', 'C0025289', 'C0812399', 'C1705169', 'C0038689', 'C4521538', 'C0205250', 'C3887704', 'C0022660', 'C0032961', 'C1561643', 'C1515981', 'C0008976', 'C1080058', 'C4050466', 'C0205191', 'C4050465', 'C0042313', 'C0205420', 'C0085669', 'C2827757', 'C0332325', 'C2603343', 'C0205082', 'C1550464', 'C0039798', 'C0443246', 'C3538994', 'C0205172', 'C0005953', 'C3844638', 'C4552844', 'C0013227', 'C0205156', 'C1514892', 'C1265292', 'C0040732', 'C0006147', 'C0750491', 'C0025677', 'C0022925', 'C0022661', 'C0014118', 'C1442464', 'C2316810', 'C1254351', 'C0087111', 'C0439445', 'C0019004', 'C0439586', 'C1552607', 'C0679823', 'C1522326', 'C1533734', 'C0040733', 'C3272598', 'C0205091']","['Borg Category-Ratio 10 Perceived Exertion Score 5', 'Biomaterial Treatment', 'And', 'Patients', 'Acute leukemia', 'Transplantation', 'Act Relationship Subset - previous', 'Milliliter per Minute', 'Creatinine clearance', 'Resistant (qualifier value)', 'Kidney Failure, Acute', 'Therapeutic procedure', 'Chronic Kidney Diseases', 'Either', 'Vancomycin', '48 hour time frame', 'Known allergy', '48 Hours', 'Clinical Trials', 'Concurrent', 'Severe (severity modifier)', 'Administration procedure', 'Pregnancy', 'Methotrexate', 'transplantation aspects', 'Treatment Epoch', 'Kidney Failure, Chronic', 'WHO Temperature/Humidity Storage Condition', 'Endocarditis', 'Left sided', 'Study', 'Methicillin-Resistant Staphylococcus aureus', 'Left', 'Resistance Process', 'chronic', 'Suspected qualifier', 'therapeutic aspects', 'resistant - Observation Interpretation Susceptibility', 'participation', 'treatment - ActInformationManagementReason', 'Hemodialysis', 'Bone Marrow', 'Methicillin-resistant Staphylococcus aureus Measurement', 'High', 'Pharmaceutical Preparations', 'More', 'Pharmacologic Substance', 'Severe Extremity Pain', 'Previous', 'Breast Feeding', 'Treating', 'Meningitis, CTCAE', 'Chronic kidney disease stage 5', 'Meningitis', 'Antimicrobial Resistance Result', 'Sulfamethoxazole', 'Lactation', 'This (eukaryote)']","['ortf', ' orch', 'biof', 'topp', 'neop', 'fndg', 'qlco', 'bact', ' phsu', 'hlca', 'phsu', 'inpr', 'idcn', 'lbtr', 'antb', 'resa', ' aapp', 'orgf', 'phsf', 'ftcn', 'tisu', 'podg', 'orch', 'tmco', 'dsyn', 'cnce', 'spco', 'euka', 'qnco']"
1618,PMC4431679,S50,['8a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0]",Study population and procedures,we used a central computer generated random number list to randomise patients to treatment with trimethoprim-sulfamethoxazole or vancomycin.,"['C0042313', 'C0009622', 'C0439605', 'C0030705', 'C3887704', 'C1705169', 'C0038689', 'C0034656', 'C0087111', 'C3272378', 'C0449788', 'C0745732', 'C1533734', 'C1522326', 'C0205099', 'C0237753', 'C0039798', 'C3538994']","['Vancomycin', 'Count of entities', 'Randomization', 'Treatment Epoch', 'Computers', 'Biomaterial Treatment', 'Random', 'Numbers', 'Treating', 'Administration procedure', 'Patients', 'Sequence Data Type', 'List', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Central', 'Sulfamethoxazole', 'Therapeutic procedure']","[' orch', 'inpr', 'topp', 'ftcn', 'mnob', 'cnce', 'antb', 'podg', 'spco', 'qlco', 'resa', 'hlca', ' aapp', 'qnco']"
1619,PMC4431679,S51,['9'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1]",Study population and procedures,"allocation was concealed in sealed, opaque numbered envelopes that were opened consecutively after informed consent was obtained.","['C1706778', 'C0021430', 'C1261286', 'C1882150', 'C0029053']","['Opaque', 'Informed Consent', 'Allocation', 'Decreased translucency', 'Opacification of Medical Device Material']","['acty', 'fndg', 'qlco', 'rnlw']"
1620,PMC4431679,S52,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study population and procedures,trimethoprim-sulfamethoxazole was started intravenously at a dose of 320 mg trimethoprim/1600 mg sulfamethoxazole twice daily and could be switched to oral treatment using the same dose at the discretion of the treating physician.,"['C0445247', 'C0001563', 'C0178602', 'C1710470', 'C0038689', 'C0585361', 'C0041041']","['Twice a day', 'Trimethoprim', 'Treating Physician', 'Same', 'Administration, Oral', 'Sulfamethoxazole', 'Dosage']","[' orch', 'prog', 'topp', 'qlco', 'antb', 'tmco', 'qnco']"
1621,PMC4431679,S53,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population and procedures,dosing was based on a pharmacokinetic study showing that a lower dose resulted in inhibition but not killing of s aureus and on the dose used in a previous trial.23 29,"['C1548802', 'C0178602', 'C3463820', 'C1273517', 'C2003888', 'C1515981', 'C0008976', 'C0021467', 'C0162388', 'C1552607', 'C0201734', 'C0233535', 'C0205156', 'C1518422', 'C0441994']","['Lower - spatial qualifier', 'Lower (action)', 'Inhibition', 'Killing', 'Clinical Trials', 'And', 'Pharmacokinetic study', 'Previous', 'used by', 'Act Relationship Subset - previous', 'butting', 'Psychological inhibition', 'Body Site Modifier - Lower', 'Dosage', 'Negation']","['idcn', 'acty', 'ftcn', 'blor', 'spco', 'tmco', 'fndg', 'resa', 'socb', 'menp', 'mobd', 'qnco']"
1622,PMC4431679,S54,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study population and procedures,the vancomycin starting dose was 1 g twice daily.,"['C0585361', 'C0042313', 'C0178602']","['Twice a day', 'Vancomycin', 'Dosage']","[' aapp', 'antb', 'qnco', 'tmco']"
1623,PMC4431679,S55,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study population and procedures,"in both arms, treatment was adjusted to renal function; in the vancomycin arm, it was directed by serum concentrations to obtain drug trough concentrations between 10 and 20 mg/dl.","['C0086045', 'C3715044', 'C3887704', 'C1705169', 'C1515981', 'C0444506', 'C1550100', 'C0042313', 'C0230348', 'C1705273', 'C0039798', 'C3538994', 'C0229671', 'C1546774', 'C0542341', 'C0013227', 'C1254351', 'C0446516', 'C0087111', 'C4553528', 'C0031843', 'C1522326', 'C1533734']","['Upper arm', 'And', 'Biomaterial Treatment', 'Serum', 'Therapeutic procedure', 'Both upper arms', 'Vancomycin', 'Function (attribute)', 'physiological aspects', 'Administration procedure', 'Mathematical Operator', 'Treatment Epoch', 'Mental concentration', 'Specimen Type - Serum', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'trough', 'Pharmaceutical Preparations', 'Pharmacologic Substance', 'AKR1A1 wt Allele', 'Treating', 'Sequence Arm', 'Specimen Source Codes - Serum']","['inpr', 'bpoc', 'idcn', 'phsf', 'gngm', 'topp', 'ftcn', 'blor', 'cnce', 'bdsu', 'antb', 'qlco', 'resa', 'hlca', 'menp', ' aapp', 'phsu']"
1624,PMC4431679,S56,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population and procedures,the complete study protocol is available on request.,,,
1625,PMC4431679,S57,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study population and procedures,"treatment had to be administered for a minimum of seven days, following which the duration depended on the indication.","['C1524031', 'C0392360', 'C3887704', 'C1705169', 'C0205453', 'C3146298', 'C0087111', 'C1552614', 'C0449238', 'C0039798', 'C1522326', 'C1533734', 'C0439228', 'C2926735', 'C2826545', 'C3538994']","['Minimum', 'Indication', 'Treatment Epoch', 'day', 'Minimum Value Derivation Technique', 'Biomaterial Treatment', 'Duration', 'ActRelationshipSubset - minimum', 'Treating', 'Administration procedure', 'Indication of (contextual qualifier)', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Seven', 'Therapeutic procedure', 'Duration (temporal concept)']","['idcn', 'topp', 'ftcn', 'cnce', 'orch', 'tmco', 'qlco', 'resa', ' phsu', 'hlca', 'qnco']"
1626,PMC4431679,S58,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study population and procedures,"concomitant antibiotics, other than the combination of vancomycin and co-trimoxazole, could be administered.","['C0042313', 'C3540705', 'C3540704', 'C0003237', 'C3811910', 'C1947911', 'C0521115', 'C1515981', 'C3540707', 'C3540706', 'C3540710', 'C3540709', 'C3540708', 'C0003232']","['Antibiotics, Gynecological', 'Vancomycin', 'Antifungal Antibiotics, Topical', 'Antibiotics', 'Antibiotics, Antitubercular', 'antibiotics, intestinal', 'And', 'Simultaneous', 'combination - answer to question', 'Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE', 'Antibiotics, ophthalmologic', 'Antibiotics for systemic use', 'combination of objects', 'Antibiotic throat preparations']","['idcn', 'phob', 'fndg', 'antb', 'tmco', ' aapp']"
1627,PMC4431679,S59,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study population and procedures,"after randomisation, no blinding was performed, but outcomes were adjudicated blinded to allocation.","['C0150108', 'C1706778']","['Blinded', 'Allocation']","['acty', 'resa']"
1628,PMC4431679,S61,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"the primary efficacy outcome was clinical treatment failure at seven days and was a composite of death, persistence of fever (<38°c for two consecutive days and no increase above 38° after resolution was required to rule out persistence), persistence of hypotension (<90 mm hg systolic or need for vasopressor support), non-improving sequential organ failure assessment (sofa) score (for baseline sofa ≥3, a decrease of at least 30% was required; and for baseline sofa <3, a stable or decreased sofa score was required to rule out failure), or persistent bacteraemia on day 7.","['C0039155', 'C0687676', 'C1261322', 'C0424755', 'C1548958', 'C0439787', 'C3842672', 'C4050231', 'C1552828', 'C1516635', 'C1515981', 'C0162643', 'C4321252', 'C1565156', 'C1521721', 'C0042397', 'C0349410', 'C0547047', 'C1518422', 'C1274040', 'C0522637', 'C0870077', 'C1707491', 'C0231174', 'C1282910', 'C1514893', 'C0205453', 'C0205216', 'C0442797', 'C0043194', 'C1442488', 'C3163620', 'C0015967', 'C0004610', 'C1547311', 'C1280519', 'C1705294', 'C0205360', 'C2699488', 'C0205448', 'C0686904', 'C0205225', 'C0392756', 'C0020649', 'C0332996', 'C0439228', 'C0546816', 'C1514873', 'C1707887', 'C1306577', 'C0521125', 'C0205322', 'C1706463', 'C0011065', 'C0449820', 'C0205199', 'C1547335', 'C0805874', 'C0168634', 'C4553402', 'C1547544', 'C0680095', 'C4552740', 'C0235828', 'C1421478', 'C1272745', 'C0027552', 'C0442805', 'C0849355', 'C1446409', 'C1516048', 'C0231290']","['Hypotension, CTCAE', 'Resolution Property', 'Status post', 'Baseline', 'day', 'Effectiveness', 'Positive', 'Sequential', 'Day 7', 'Out (direction)', 'Composite', 'And', 'Evaluation procedure', 'Persistent', 'Vasoconstrictor Agents', 'physiologic resolution', 'Lack of Efficacy', 'Reduced', 'treatment failure', 'Preposition For', 'WWOX wt Allele', 'Persistent embryonic structure', 'Removed', 'Fever, CTCAE', 'persistence', 'Group Sequential Design', 'Decreased', 'Patient Condition Code - Stable', 'Efficacy Study', 'Fever symptoms (finding)', 'Systole', 'WAS protein, human', 'WAS gene', 'Requirement', 'Death (finding)', 'Consecutive', 'Table Frame - above', 'Improving (qualifier value)', 'Supportive assistance', 'Stable status', 'Personal failure', 'Decrease', 'Negation', 'Charge Type Reason - Treatment Failure', 'BaseLine dental cement', 'organ failure', 'Cessation of life', 'Decreasing', 'Resolution', 'Increase', 'Hypotension', 'Needs', 'Two', 'derivation calculation', 'Seven', 'Rule (guideline)', 'Upper', 'Clinical Treatment', 'Failure (biologic function)', 'Post', 'Fever', 'Wiskott-Aldrich Syndrome', 'Data types- Composite', 'Bacteremia', 'ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated', 'Sequential - Sequence/Results Flag', 'Result', 'Score', 'Measuring ruler, device', 'Assessed', 'Primary', 'Patient need for (contextual qualifier)']","['bacs', 'clna', 'inbe', 'topp', 'fndg', 'mnob', 'qlco', 'hlca', 'phsu', 'inpr', 'idcn', 'gngm', 'patf', 'resa', 'cgab', ' aapp', 'orgf', 'bodm', 'sosy', 'ftcn', 'tmco', 'dsyn', 'menp', 'acty', 'spco', 'cnce', 'qnco']"
1629,PMC4431679,S62,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"blood cultures were repeated on day 2 for all patients with bacteraemia and daily thereafter for patients with persistent fever, persistent bacteraemia, or other signs of infection.","['C0476474', 'C0311392', 'C0220913', 'C0030705', 'C3842676', 'C3714514', 'C0332173', 'C0332996', 'C0444868', 'C0200949', 'C0205322', 'C0220912', 'C0004610']","['Blood culture', 'Day 2', 'Physical findings', 'persistent fever', 'Aspects of signs', 'All', 'Daily', 'Manufactured sign', 'Persistent', 'Patients', 'Bacteremia', 'Persistent embryonic structure', 'Infection']","['lbpr', 'ftcn', 'mnob', 'patf', 'podg', 'tmco', 'fndg', 'cgab', 'dsyn', 'qnco']"
1630,PMC4431679,S63,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,we also defined a primary safety outcome of all cause mortality at 30 days.,"['C1274040', 'C0036043', 'C0026565', 'C0026566', 'C4028326', 'C1524003', 'C0205225', 'C0444868', 'C1705187', 'C0015127']","['Aspects of mortality statistics', 'Safety Study', 'All', 'Etiology aspects', '30 days', 'Science of Etiology', 'Safety', 'Result', 'Mortality Vital Statistics', 'Primary']","['hcpp', 'ftcn', 'cnce', 'qlco', 'tmco', 'resa', 'qnco']"
1631,PMC4431679,S64,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"secondary outcomes included failure or modification of treatment, comprising treatment failure (as defined) or antibiotic treatment modification; bacteriological failure, defined as growth of mrsa on day 7 cultures; persistence of bacteraemia at 48 hours; length of hospital admission; duration of fever, summing all days with at least one measurement of temperature 38°c or above until day 30; and development of resistance defined as acquisition of trimethoprim-sulfamethoxazole or vancomycin resistant s aureus or vancomycin resistant enterococci.","['C0220844', 'C0205436', 'C0424755', 'C3842672', 'C3887704', 'C1705169', 'C0038689', 'C4521538', 'C0242485', 'C0162643', 'C0027627', 'C0005903', 'C0041041', 'C1704788', 'C1444754', 'C0010453', 'C1706316', 'C0175668', 'C0042313', 'C0199779', 'C0231174', 'C2827757', 'C0332325', 'C0205447', 'C4281815', 'C0015967', 'C0243107', 'C0004610', 'C1550464', 'C3640836', 'C3538994', 'C0039798', 'C1527148', 'C3840684', 'C0332173', 'C3889737', 'C0439228', 'C0546816', 'C1514892', 'C0184666', 'C0332257', 'C1265292', 'C1554963', 'C0392747', 'C2911660', 'C1442464', 'C0237834', 'C1547544', 'C1265175', 'C0087111', 'C0449238', 'C0680095', 'C4552740', 'C0018270', 'C0439586', 'C0235828', 'C1706701', 'C1533734', 'C0039476', 'C0444868', 'C2926735', 'C0678723', 'C1621966', 'C1522326']","['Vancomycin-Resistant Enterococci', 'day', 'Body Temperature', 'Day 7', 'Anthropological Culture', 'Biomaterial Treatment', 'growth aspects', 'Administration of antibiotic', 'Lack of Efficacy', 'treatment failure', 'Secondary to', 'Resistant (qualifier value)', 'Duration', 'Therapeutic procedure', 'Fever, CTCAE', 'persistence', 'Vancomycin', '48 hour time frame', 'Fever symptoms (finding)', 'development aspects', '48 Hours', 'Resistance', 'Tissue Growth', 'Administration procedure', 'ResponseLevel - modification', 'Personal failure', 'Measurement', 'Duration (temporal concept)', 'Charge Type Reason - Treatment Failure', 'Data Change Date', 'Hospital admission', 'Treatment Epoch', 'Changing', 'All', 'Daily', 'Length', 'Methicillin-Resistant Staphylococcus aureus', 'Resistance Process', 'Growth', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Development', 'resistant - Observation Interpretation Susceptibility', 'One', 'Biologic Development', 'Growth action', 'Trimethoprim', 'Failure (biologic function)', 'Methicillin-resistant Staphylococcus aureus Measurement', 'Fever', 'Neoplasm Metastasis', 'Modification', 'Bacteriological Failure', 'second (number)', 'Including (qualifier)', 'Definition', 'Resistance (Psychotherapeutic)', 'Treating', 'Temperature', 'Bacteremia', 'Antimicrobial Resistance Result', 'Sulfamethoxazole', 'Length of Trial', 'Acquisition (action)']","['ortf', ' orch', 'inbe', 'topp', 'neop', 'fndg', 'qlco', 'bact', ' phsu', 'hlca', 'inpr', 'phpr', 'idcn', 'lbtr', 'antb', 'resa', ' aapp', 'orgf', 'sosy', 'phsf', 'ftcn', 'tmco', 'orch', 'dsyn', 'menp', 'acty', 'cnce', 'qnco', 'orga']"
1632,PMC4431679,S65,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"adverse events included renal failure defined using rifle criteria,30 rash, leucopoenia, any diarrhoea and clostridium difficile associated diarrhoea, and other adverse events.","['C1963154', 'C0035611', 'C0877248', 'C3272371', 'C0332281', 'C0243161', 'C1705413', 'C1515981', 'C0015230', 'C0079134', 'C1552551', 'C0011991', 'C0035078']","['Any', 'Clostridium difficile (bacteria)', 'Any Data Type', 'Exanthema', 'Adverse Event Domain', 'And', 'Rifle (physical object)', 'criteria', 'Adverse event', 'Diarrhea', 'Associated with', 'Kidney Failure', 'Renal Failure, CTCAE']","['sosy', 'inpr', 'idcn', 'fndg', 'patf', 'qlco', 'bact', 'mnob', 'dsyn']"
1633,PMC4431679,S67,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size and analysis,"to establish non-inferiority, we allowed a difference of up to 15% in the primary outcome.","['C1274040', 'C0678975', 'C0547043', 'C0205225', 'C1705241', 'C1705242']","['Up', 'inferiority', 'Result', 'Different', 'Delta (difference)', 'Primary']","['ftcn', 'spco', 'qlco', 'socb', 'qnco']"
1634,PMC4431679,S68,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size and analysis,"assuming a 30% treatment failure rate for both treatment groups, we needed a sample of 128 patients per arm for a one sided test to rule out the pre-specified difference in the 95% confidence interval of the difference between groups, allowing for 10% non-evaluable patients (α=0.05, β=0.8).","['C3715044', 'C0030705', 'C0441833', 'C1705169', 'C0687744', 'C3887704', 'C0162643', 'C4321252', 'C4318744', 'C1518422', 'C0009667', 'C0205447', 'C0392366', 'C1705242', 'C0039798', 'C3538994', 'C1515976', 'C1552839', 'C2826245', 'C0686904', 'C2986511', 'C3831328', 'C0521125', 'C0871208', 'C4281991', 'C0022885', 'C1706086', 'C1547544', 'C0446516', 'C3887962', 'C0087111', 'C4553528', 'C0456984', 'C0235828', 'C1533734', 'C1705241', 'C1522326', 'C0039593', 'C1521828', 'C0370003', 'C2347026']","['Biospecimen', 'Laboratory Procedures', 'Both', 'Upper arm', 'Biomaterial Treatment', 'Rating (action)', 'Patients', 'Lack of Efficacy', 'treatment failure', 'Preposition For', 'WWOX wt Allele', 'Test - temporal region', 'Therapeutic procedure', 'Delta (difference)', 'Tests (qualifier value)', 'Testing', 'Administration procedure', 'Confidence Intervals', 'Per (qualifier)', 'Test Result', 'Social group', 'Negation', 'Charge Type Reason - Treatment Failure', 'Treatment Epoch', 'Anatomic Structure, System, or Substance', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Blood Products Laboratory Testing', 'One', 'Specimen', 'Follow', 'Evaluable Patient', 'Groups', 'Rate', 'AKR1A1 wt Allele', 'Table Rules - groups', 'Treating', 'Sequence Arm', 'Pre-specified', 'Different', 'Patient need for (contextual qualifier)']","['inpr', 'idcn', 'lbpr', 'gngm', 'clas', 'acty', 'topp', 'popg', 'lbtr', 'ftcn', 'fndg', 'blor', 'qlco', 'podg', 'cnce', 'resa', 'hlca', 'sbst', 'qnco']"
1635,PMC4431679,S69,['7b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0]",Sample size and analysis,"we did interim analyses of the primary safety outcome after recruitment of one third and two thirds of patients, with stopping boundaries (two sided α level, p<0.01).","['C1274040', 'C0036043', 'C2946261', 'C1547707', 'C0030705', 'C0441889', 'C2949735', 'C0205437', 'C0205447', 'C1515981', 'C0205225', 'C2827738', 'C0205448', 'C0723457', 'C1705187']","['Stop brand of fluoride', 'Recruitment', 'Safety Study', 'Level', 'And', 'Floor - story of building', 'Levels (qualifier value)', 'Patients', 'Two', 'Safety', 'Result', 'Interim', 'One', 'Third', 'Primary']","['hcpp', 'geoa', 'idcn', 'inch', 'acty', 'ftcn', 'podg', 'tmco', 'qlco', 'resa', ' phsu', 'qnco']"
1636,PMC4431679,S70,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and analysis,we did the primary analysis by intention to treat.,"['C1283828', 'C0162425', 'C0936012', 'C0205225', 'C1524024']","['intent', 'Analysis', 'Intention - mental process', 'Primary', 'analysis aspect']","['ftcn', 'menp', 'qlco', 'resa']"
1637,PMC4431679,S71,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and analysis,we did per protocol analysis for patients without exclusion criteria after randomisation who received allocated treatment for a minimum of seven days.,"['C0030705', 'C3887704', 'C1705169', 'C4282383', 'C1552614', 'C1524024', 'C2826545', 'C0680251', 'C1524031', 'C3715209', 'C0936012', 'C0442711', 'C2599718', 'C1522729', 'C1507394', 'C0039798', 'C3538994', 'C0439228', 'C0087111', 'C1522326', 'C1533734', 'C0205453', 'C2348563', 'C3272598']","['day', 'REMS Protocol', 'Biomaterial Treatment', 'Patients', 'Exclusion Criteria', 'Study Protocol', 'Therapeutic procedure', 'Protocol - answer to question', 'Clinical trial protocol', 'Minimum Value Derivation Technique', 'Clinical trial protocol document', 'ActRelationshipSubset - minimum', 'Administration procedure', 'Protocols documentation', 'Minimum', 'Treatment Epoch', 'WHO Temperature/Humidity Storage Condition', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Seven', 'analysis aspect', 'Treating', 'Analysis', 'Library Protocol']","['inpr', 'idcn', 'topp', 'ftcn', 'cnce', 'fndg', 'podg', 'qlco', 'tmco', 'resa', 'hlca', 'qnco']"
1638,PMC4431679,S72,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and analysis,we did subgroup analysis for patients with mrsa bacteraemia.,"['C0030705', 'C0936012', 'C4521538', 'C1524024', 'C0004610', 'C1265292']","['Methicillin-resistant Staphylococcus aureus Measurement', 'Patients', 'Methicillin-Resistant Staphylococcus aureus', 'Analysis', 'Bacteremia', 'analysis aspect']","['lbtr', 'ftcn', 'podg', 'bact', 'resa', 'dsyn']"
1639,PMC4431679,S73,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and analysis,we used χ2 or fisher’s exact tests to compare categorical outcomes.,"['C2828393', 'C0022885', 'C4050514', 'C0392366']","['Laboratory Procedures', 'Tests (qualifier value)', 'Exact (qualifier)', 'Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome Questionnaire']","['lbpr', 'inpr', 'qlco']"
1640,PMC4431679,S74,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and analysis,"continuous outcomes were skewed, so we described them as medians and compared them by using a median difference, all with 95% confidence intervals.31","['C2939193', 'C0009667', 'C0549183', 'C2348144', 'C1515981', 'C0876920', 'C0549178', 'C0444868', 'C1705241', 'C1705242', 'C2347635']","['All', 'And', 'Continuous', 'Midline (qualifier value)', 'Population Median', 'Confidence Intervals', 'Median Statistical Measurement', 'Sample Median', 'Median (qualifier value)', 'Different', 'Delta (difference)']","['spco', 'qlco', 'qnco', 'idcn']"
1641,PMC4431679,S75,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and analysis,"we did multivariable analyses for the primary efficacy outcome, including the treatment arm as an independent variable.","['C0085862', 'C1280519', 'C1522541', 'C1274040', 'C0439828', 'C1290940', 'C0205225', 'C4553760', 'C1707887', 'C1299583', 'C0332257']","['Independently able', 'Protocol Treatment Arm', 'Efficacy Study', 'Effectiveness', 'Including (qualifier)', 'Independence', 'Variable (uniformity)', 'Independent for Transfer', 'Study Variable', 'Result', 'Primary']","['inpr', 'idcn', 'ftcn', 'fndg', 'qlco', 'resa']"
1642,PMC4431679,S76,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and analysis,we entered all variables significantly associated with the outcome on univariate analysis (p<0.05) and not correlated (spearman correlation >0.5) into a logistic regression analysis.,"['C1274040', 'C0683962', 'C0439828', 'C1515981', 'C1707520', 'C0681925', 'C0444868', 'C1518422', 'C1710141']","['logistic regression analysis', 'univariate statistics', 'Spearman Correlation Test', 'All', 'And', 'Variable (uniformity)', 'Correlation', 'Result', 'Negation']","['inpr', 'idcn', 'ftcn', 'qlco', 'resa', 'qnco']"
1643,PMC4431679,S77,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size and analysis,we present risk ratios or odds ratios with 95% confidence intervals.,"['C0009667', 'C0028873']","['Odds Ratio', 'Confidence Intervals']",['qnco']
1644,PMC4469977,S100,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size,"we chose a difference of 0.5 standard deviations as being a clinically meaningful between group difference, as observational data suggested that ciclosporin was potentially more effective, but at higher cost, than prednisolone.19 20 21","['C1705241', 'C1442989', 'C2828392', 'C1257890', 'C0441833', 'C0220812', 'C1704419', 'C4050363', 'C1705428', 'C1280519', 'C3245479', 'C1519504', 'C1518527', 'C1705429', 'C0032950', 'C1705242', 'C2987476', 'C1964257', 'C0010186', 'C0687744', 'C3714741', 'C0205250', 'C1511726', 'C0010592']","['Group Object', 'prednisolone', 'Data (eukaryote)', 'High', 'Exist', 'Standard (document)', 'Standard (qualifier)', 'Effectiveness', 'User Group', 'Data call receiving device', 'Groups', 'Population Group', 'Social group', 'Observational Study', 'Different', 'Observation - diagnostic procedure', 'Financial cost', 'Cost aspects', 'Delta (difference)', 'Stage Grouping', 'Comprehensive Score for Financial Toxicity', 'Effective', 'Cyclosporine', 'Data']","['popg', 'medd', 'idcn', 'inpr', 'orch', 'qnco', 'qlco', 'euka', 'resa', 'aapp', 'ftcn', 'diap', ' phsu', 'cnce']"
1645,PMC4469977,S101,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size,"as a result, we felt that a substantial treatment effect was necessary to justify a change in clinical practice.","['C0443172', 'C3245512', 'C1705241', 'C1518681', 'C2825142', 'C1546471', 'C1421478', 'C1565156', 'C0043194', 'C1552821', 'C0237607', 'C0392747', 'C4319952', 'C0205210', 'C1274040']","['Clinical', 'justify', 'Practice Experience', 'Changing', 'WAS protein, human', 'HL7PublishingSubSection <practice>', 'WAS gene', 'Outcome of Therapy', 'Changed status', 'Change -- procedure', 'Delta (difference)', 'Experimental Result', 'Result', 'What subject filter - Result', 'Wiskott-Aldrich Syndrome']","['fndg', 'gngm', 'topp', 'idcn', 'inpr', 'qnco', 'qlco', 'bacs', 'dsyn', 'ftcn', 'menp', ' aapp']"
1646,PMC4469977,S103,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,we prespecified all analyses in a statistical analysis plan.,"['C0444868', 'C3889277']","['Statistical Analysis Plan', 'All']","['qnco', 'inpr']"
1647,PMC4469977,S104,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"analysis was conducted using intention to treat principles; defined as all randomised participants, excluding those with a later diagnosis determined to be something other than pyoderma gangrenosum.","['C0011900', 'C0205087', 'C1704656', 'C0679646', 'C1704338', 'C1283828', 'C0162425', 'C0444868', 'C1524024', 'C0936012']","['Diagnosis', 'Late', 'All', 'Participant', 'Intention - mental process', 'Analysis', 'diagnosis aspect', 'analysis aspect', 'Diagnosis Study', 'intent']","['tmco', 'qlco', 'qnco', 'resa', 'ftcn', 'diap', 'popg', 'menp']"
1648,PMC4469977,S105,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,we included all participants with available data at both the baseline and the six week visit in the primary analysis.,"['C1511726', 'C1442488', 'C3245479', 'C0679646', 'C0205225', 'C0205452', 'C0168634', 'C2826704', 'C0470187', 'C0439230', 'C1515981', 'C0545082', 'C1706086', 'C3714741', 'C0444868', 'C1524024', 'C1512346', 'C0936012']","['Data call receiving device', 'availability of', 'BaseLine dental cement', 'Patient Visit', 'All', 'Participant', 'Primary', 'Visit Name', 'Analysis', 'Data (eukaryote)', 'Visit', 'And', 'analysis aspect', 'week', 'Baseline', 'Six', 'Both', 'Data']","['tmco', 'bodm', 'medd', 'idcn', 'hlca', 'inpr', 'qnco', 'qlco', 'bhvr', 'euka', 'resa', 'ftcn', 'popg']"
1649,PMC4469977,S106,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,the impact of missing values was explored in sensitivity analysis.,"['C1511883', 'C3272743', 'C0036667', 'C1551393', 'C0020517', 'C1522640', 'C1825598', 'C1705492', 'C1524024', 'C2349185', 'C0042295', 'C2346484', 'C4049986', 'C0936012']","['Container status - Missing', 'Analysis', 'Diagnostic Sensitivity', 'Missing Study Animal', 'Statistical sensitivity', 'analysis aspect', 'Impact', 'Signal Sensitivity', 'stimulus sensitivity', 'Increased Sensitivy', 'Hypersensitivity', 'Values', 'IMPACT gene', 'Missing']","['fndg', 'gngm', 'qnco', 'phpr', 'qlco', 'resa', 'ftcn', 'patf']"
1650,PMC4469977,S107,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"a linear regression model was used to analyse differences between treatment groups for the primary outcome at six weeks, adjusting for the stratification variables.","['C3274659', 'C2346679', 'C0205225', 'C0439828', 'C0023733', 'C3538994', 'C0521125', 'C0439230', 'C1533734', 'C4321252', 'C0087111', 'C0441833', 'C3887704', 'C1705169', 'C0039798', 'C3714583', 'C1552839', 'C0205452', 'C1514983', 'C1522326', 'C3853906', 'C3161035', 'C0687744', 'C1274040']","['Table Rules - groups', 'Model Number', 'Digital Model Attachment', 'Variable (uniformity)', 'Treatment Epoch', 'Biomaterial Treatment', 'Administration procedure', 'Result', 'Model - style/design', 'Groups', 'Model', 'Social group', 'WWOX wt Allele', 'Linear Regression Body Surface Area Formula for Infants and Children', 'Stratification', 'Linear Regression', 'Preposition For', 'Six', 'Primary', 'treatment - ActInformationManagementReason', 'Treating', 'therapeutic aspects', 'week', 'Therapeutic procedure']","['tmco', 'gngm', 'topp', 'idcn', 'hlca', 'inpr', 'qnco', 'qlco', 'resa', 'ftcn', 'popg', 'cnce']"
1651,PMC4469977,S108,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"secondary outcomes were analysed using cox regression models (for time to event outcomes); linear regression models for dermatology life quality index, eq-5d, and eq-vas (adjusted for baseline values), and for self reported pain (which were summarised using area under the curve); proportional odds models for ordered categorical outcomes; and logistic regression models for binary outcomes.","['C4085210', 'C0017446', 'C0042815', 'C2346679', 'C0023733', 'C0168634', 'C0684321', 'C4085212', 'C1705176', 'C0518090', 'C0205436', 'C0206031', 'C3536884', 'C1706942', 'C4554132', 'C0030193', 'C0042295', 'C1836830', 'C0175668', 'C0036588', 'C4553004', 'C2984058', 'C0441471', 'C0011627', 'C0027627', 'C0205134', 'C1705178', 'C0205351', 'C1442488', 'C3827561', 'C0040223', 'C0451498', 'C0205146', 'C3161035', 'C1565830', 'C1515981', 'C1551994', 'C0684320', 'C4085211', 'C4019010']","['Visual Analog Scale', 'Dermatology field', 'Usual Severity Pain', 'Logistic Regression', 'Have Pain', 'National reporting jurisdiction:Loc:Pt:^Event:Nom', 'And', 'Pain Distress Question', 'Event', 'Vibroacoustic Stimulation', 'Regression - mental defense mechanism', 'proportional', 'second (number)', 'Time', 'Developmental regression', 'PTGS1 protein, human', 'Baseline', 'quality of life index', 'Disease regression', 'Values', 'Feel Pain', 'Neoplasm Metastasis', 'Order (action)', 'Model', 'Binary', 'Curved', 'Linear Regression Body Surface Area Formula for Infants and Children', 'Self', 'Linear Regression', 'Pain', 'How Much Distress Pain', 'BaseLine dental cement', 'Frequency of Pain Question', 'Visual Analog Pain Scale', 'Area', 'Secondary to', 'subscriber - self', 'Pain, CTCAE', 'Geographic Locations', 'Order (arrangement)']","['topp', 'qnco', 'bodm', ' aapp', 'menp', 'patf', 'clna', 'fndg', 'idcn', 'inpr', 'sosy', 'qlco', 'resa', 'tmco', 'enzy', 'spco', 'neop', 'acty', 'geoa', 'bmod', 'dsyn', 'diap', 'evnt']"
1652,PMC4469977,S109,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,all analyses were adjusted for the stratification variables.,"['C0444868', 'C1514983', 'C0439828']","['Variable (uniformity)', 'All', 'Stratification']","['qnco', 'qlco', 'resa']"
1653,PMC4469977,S110,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"sensitivity analysis of the primary outcome and time to healing were further adjusted for additional baseline variables including age, sex, weight, size of recruiting centre and geographical region; missing data; and participants who switched randomised treatments or received the trial drugs in combination during the period of the trial.","['C0456389', 'C0017446', 'C0036864', 'C0205225', 'C0439828', 'C0009253', 'C0168634', 'C1705104', 'C1524024', 'C1305866', 'C1524062', 'C0936012', 'C0043240', 'C0087111', 'C3272598', 'C1522384', 'C0001779', 'C0804628', 'C1274040', 'C3687832', 'C2346484', 'C1511883', 'C0439531', 'C3245479', 'C0036667', 'C0679646', 'C0005910', 'C0347984', 'C0332257', 'C0205147', 'C2349185', 'C0043100', 'C0013227', 'C0205099', 'C3811910', 'C0079399', 'C1442488', 'C0020517', 'C0040223', 'C1522640', 'C1515981', 'C1947911', 'C0008976', 'C3714741', 'C1517331', 'C1511726', 'C1948053']","['Age', 'Drugs - dental services', 'Clinical Trials', 'Diagnostic Sensitivity', 'Data (eukaryote)', 'And', 'Weighing patient', 'Signal Sensitivity', 'Including (qualifier)', 'size', 'Gender:Type:Point in time:^Patient:Nominal', 'Further', 'sex', 'Body Weight', 'Period (temporal qualifier)', 'regional', 'Participant', 'combination of objects', 'Sex Behavior', 'Variable (uniformity)', 'Time', 'analysis aspect', 'Weight', 'Baseline', 'Hypersensitivity', 'Wound Healing', 'Result', 'Data call receiving device', 'Coitus', 'Therapeutic procedure', 'stimulus sensitivity', 'Central', 'During', 'combination - answer to question', 'Pharmaceutical Preparations', 'BaseLine dental cement', 'Gender', 'Increased Sensitivy', 'Primary', 'Analysis', 'Additional', 'WHO Temperature/Humidity Storage Condition', 'Statistical sensitivity', 'Importance Weight', 'per period (qualifier value)', 'Geographic Locations', 'Data']","['topp', 'qnco', 'phpr', 'bhvr', 'bodm', 'phob', 'patf', 'clna', 'fndg', 'idcn', 'hlca', 'qlco', 'resa', 'ftcn', 'popg', 'phsu', 'tmco', 'euka', 'spco', 'medd', 'geoa', 'orga', 'orgf']"
1654,PMC4469977,S111,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"we analysed adverse reactions that occurred during the trial according to the original randomised allocation, regardless of whether other drugs had been introduced before the adverse reaction.","['C2347409', 'C3641650', 'C0559546', 'C1706778', 'C3539897', 'C0205313', 'C0062074', 'C3687832', 'C0013227', 'C0008976', 'C0680240', 'C0332152', 'C1415458']","['Original', 'Original Regulatory Submission', 'Regardless', 'Allocation', 'Drugs - dental services', 'Clinical Trials', 'Have', 'HAC protocol', 'Before', 'Agreement', 'Pharmaceutical Preparations', 'HADH gene', 'Adverse reactions']","['tmco', 'ocac', 'gngm', 'topp', 'qlco', 'phsu', 'socb', 'resa', 'patf', 'acty']"
1655,PMC4469977,S112,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"all statistical analyses were conducted using sas software, version 9.2 and r version 2.10.1.","['C0333052', 'C0038215', 'C1823519', 'C1515981', 'C0605290', 'C1426104', 'C0444868', 'C0037585']","['All', 'Version', 'TSPAN31 gene', 'Computer software', 'And', 'SAS', 'NANS gene', 'Science of Statistics']","['gngm', ' mnob', 'idcn', 'inpr', 'orch', 'ocdi', 'qnco']"
1656,PMC4469977,S39,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Methods,the trial protocol has been published previously.11,,,
1657,PMC4469977,S41,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Trial design and oversight,"we carried out a multicentre, parallel group, observer blind randomised controlled trial to compare the efficacy and safety of ciclosporin with that of prednisolone.","['C1280519', 'C0456909', 'C0936233', 'C0036043', 'C0870992', 'C0032950', 'C0150108', 'C1515981', 'C1707887', 'C0525065', 'C1705187', 'C0010592', 'C0009933']","['Effectiveness', 'observers', 'prednisolone', 'Visually Impaired Persons', 'Controlled Clinical Trials as Topic', 'And', 'Efficacy Study', 'Blinded', 'Controlled Clinical Trial [Publication Type]', 'Safety', 'Safety Study', 'Blindness', 'Cyclosporine']","['fndg', 'hcpp', 'idcn', 'inpr', 'orch', 'qlco', 'grup', 'resa', 'aapp', 'podg', ' phsu']"
1658,PMC4469977,S42,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Trial design and oversight,participants gave written informed consent.,"['C0679646', 'C0021430']","['Informed Consent', 'Participant']","['rnlw', 'popg']"
1659,PMC4469977,S43,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Trial design and oversight,oversight of the trial included a trial management group and independent trial steering and data monitoring committees.,"['C1283169', 'C0376636', 'C1257890', 'C0441833', 'C0085862', 'C1273870', 'C1705428', 'C3245479', 'C1519504', 'C1705429', 'C0001554', 'C0687744', 'C0150369', 'C0553654', 'C1515981', 'C1290940', 'C3273539', 'C0008976', 'C3714741', 'C1299583', 'C1511726']","['Monitoring - action', 'Group Object', 'Clinical Trials', 'Data (eukaryote)', 'And', 'Data', 'Independent for Transfer', 'Independence', 'does steer', 'User Group', 'Data call receiving device', 'Groups', 'Population Group', 'Management Occupations', 'Social group', 'Independently able', 'Disease Management', 'Preventive monitoring', 'Management procedure', 'Stage Grouping', 'Administration occupational activities']","['ocac', 'fndg', 'medd', 'idcn', 'hlca', 'ocdi', 'euka', 'resa', 'ftcn', 'popg', 'cnce']"
1660,PMC4469977,S44,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Trial design and oversight,"patients suitable for topical treatment were entered into a parallel observational study, the results of which will be reported separately.","['C0001566', 'C3900053', 'C2826345', 'C2348042', 'C1518527', 'C0030705', 'C4554418']","['Parallel Study', 'Parallel Lesion', 'Patients', 'Parallel', 'Administration, Topical', 'Amenable', 'Observational Study']","['fndg', 'topp', 'qlco', 'resa', 'podg']"
1661,PMC4469977,S46,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patient involvement,patients were involved in the design and conduct of this research.,"['C0035168', 'C1080058', 'C0004927', 'C0030705', 'C0242481', 'C1515981', 'C2983265', 'C1707689']","['Research Activities', 'Design', 'research', 'And', 'CDISC SEND Study Design Terminology', 'Patients', 'Behavior', 'This (eukaryote)']","['idcn', 'inpr', 'bhvr', 'euka', 'resa', 'podg', 'acty']"
1662,PMC4469977,S47,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patient involvement,"during the feasibility stage, priority of the research question, choice of outcome measures, and methods of recruitment were informed by discussions with patients through a focus group session and two structured interviews.","['C1707391', 'C0699033', 'C0549179', 'C0557061', 'C1300072', 'C0086749', 'C0025663', 'C1883016', 'C0205390', 'C1306673', 'C0030705', 'C0025664', 'C0008300', 'C1515981', 'C1883017', 'C0021822', 'C2949735', 'C0205448', 'C0449851', 'C0016400']","['Methods', 'Phase', 'Interview', 'Outcome Measures', 'Priority', 'Two', 'Recruitment', 'Discussion (procedure)', 'Stage', 'Techniques', 'And', 'Choice Behavior', 'Personal priorities', 'Focus Groups', 'Patients', 'Activity Session', 'Tumor stage', 'Methods aspects', 'Session', 'Choose (action)']","['tmco', 'clna', 'idcn', 'inbe', 'topp', 'inpr', 'qnco', 'grup', 'menp', 'podg', 'ftcn', 'evnt', 'cnce', 'acty']"
1663,PMC4469977,S48,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patient involvement,"during the trial, a patient joined the independent trial steering committee.","['C0085862', 'C0030705', 'C2348534', 'C1290940', 'C1299583', 'C0008976']","['Steering Committee', 'Clinical Trials', 'Independently able', 'Independent for Transfer', 'Patients', 'Independence']","['fndg', 'idcn', 'resa', 'podg', 'popg']"
1664,PMC4469977,S49,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patient involvement,members of the uk dermatology clinical trials network also identified this research as being a priority area for clinicians treating patients with pyoderma gangrenosum.,"['C0011627', 'C0085652', 'C0035168', 'C0871685', 'C0017446', 'C0549179', 'C1080058', 'C0680022', 'C1882071', 'C1513822', 'C0030705', 'C0242481', 'C0205146', 'C1705739', 'C0008976', 'C0150775', 'C0699033', 'C1096775']","['Network Device', 'Dermatology field', 'Research Activities', 'Priority', 'Clinical Trials', 'research', 'Area', 'Network', 'Clinical Trial [Publication Type]', 'Personal priorities', 'Patients', 'Pyoderma Gangrenosum', 'Consortium or Network', 'Clinician', 'Geographic Locations', 'This (eukaryote)', 'member', 'Social Networks']","['tmco', 'prog', 'inpr', 'geoa', 'bmod', 'dsyn', 'spco', 'resa', 'podg', 'ftcn', 'mnob', 'popg', 'menp', 'euka']"
1665,PMC4469977,S50,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patient involvement,"once the trial has been published, participants will be informed of the results through a dedicated website (www.stopgaptrial.co.uk) and will be sent details of the results in a study newsletter suitable for a non-specialist audience.","['C1948045', 'C0521125', 'C1519246', 'C4524529', 'C3539897', 'C4321252', 'C0042950', 'C2349146', 'C1522508', 'C0034037', 'C0282111', 'C0679646', 'C1611835', 'C0681273', 'C1704324', 'C1522154', 'C0087009', 'C2603343', 'C1518422', 'C1515981', 'C2348234', 'C0008976', 'C0027988', 'C3900053']","['Publishing', 'Clinical Trials', 'Internet', 'Details', 'Scientific Publication', 'Volition', 'And', 'Study', 'audience', 'Informed', 'Specialist Physician', 'Send (transmission)', 'Newsletters', 'Participant', 'Web Site', 'Hospital specialist', 'Dedicated Blood Product Donation', 'Specialist', 'Once (schedule frequency)', 'WWOX wt Allele', 'Preposition For', 'Negation', 'Have', 'Amenable']","['tmco', 'ocac', 'prog', 'gngm', ' mnob', 'idcn', 'inpr', 'qlco', 'resa', 'ftcn', 'mnob', 'popg', 'menp', 'phsu']"
1666,PMC4469977,S52,['4b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,recruitment took place at 39 hospitals in the united kingdom.,"['C0041700', 'C0019994', 'C1533810', 'C0442504', 'C1882509', 'C2949735']","['Place', 'Placement action', 'Hospitals', 'put - instruction imperative', 'United Kingdom', 'Recruitment']","[' hcro', 'hlca', 'geoa', 'spco', 'mnob', 'acty']"
1667,PMC4469977,S53,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,"participants were aged 18 years or more, with a diagnosis of pyoderma gangrenosum made by a recruiting dermatologist.","['C0085652', 'C0011900', 'C1704656', 'C0679646', 'C1704338', 'C0259831', 'C0439234', 'C0205172']","['Diagnosis', 'year', 'Participant', 'More', 'diagnosis aspect', 'Dermatologist', 'Pyoderma Gangrenosum', 'Diagnosis Study']","['tmco', 'prog', 'qlco', 'qnco', 'dsyn', 'resa', 'diap', 'popg']"
1668,PMC4469977,S54,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,"histopathology is rarely pathognomonic for pyoderma gangrenosum, and many clinicians avoid biopsy because of the risk of an immunological reaction that results in ulcer extension at the biopsy site.","['C0005558', 'C0085652', 'C0677043', 'C0041582', 'C0871685', 'C0747726', 'C0231448', 'C0035647', 'C3887532', 'C0522498', 'C0220797', 'C1880641', 'C1515981', 'C0243140', 'C0439064', 'C1301128', 'C4552904', 'C0443286']","['POLY', 'Extension', 'Ulcer', 'Reaction', 'Subject Risk', 'And', 'Pyoderma Gangrenosum', 'Rare', 'Biopsy', 'Clinician', 'biopsy characteristics', 'Histopathological aspects', 'Numerous', 'Ulceration', 'Telephone Extension Number', 'biopsy site', 'Histopathology', 'Risk']","['clna', 'prog', 'idcn', 'qnco', 'qlco', 'bmod', 'dsyn', 'ftcn', 'diap', 'patf', 'cnce']"
1669,PMC4469977,S55,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,"if the clinical diagnosis was uncertain, a biopsy was performed to exclude other diagnoses such as malignancy, granulomatous pyoderma gangrenosum, and arteritis, and advice was sought from an expert panel as necessary.","['C0005558', 'C0085652', 'C0011900', 'C0441833', 'C4085655', 'C0087130', 'C0220797', 'C0439667', 'C1706365', 'C1515981', 'C4282132', 'C0006826', 'C0150600', 'C0003860', 'C1999270', 'C0332140']","['Diagnosis', 'Groups', 'Uncertain - Response', 'Arteritis', 'Device Panel', 'Uncertainty', 'Advice', 'And', 'granulomatous', 'Malignant Neoplasms', 'Laboratory Order Panels', 'Malignancy', 'Pyoderma Gangrenosum', 'Biopsy', 'biopsy characteristics', 'Diagnosis, clinical']","['mnob', 'fndg', 'idcn', 'hlca', 'inpr', 'qlco', 'lbpr', 'dsyn', 'neop', 'ftcn', 'diap', 'patf']"
1670,PMC4469977,S56,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,"we excluded patients with pustular or granulomatous variants of pyoderma gangrenosum (as they may respond differently to treatment, and measurement of a single ulcer was not possible); patients receiving oral prednisolone, ciclosporin, or intravenous immunoglobulin in the previous month; patients participating in another clinical trial; women who were pregnant, lactating, or at risk of pregnancy; patients with known hypersensitivity to either of the study treatments; patients with clinically important renal impairment or other pretreatment findings that would result in the investigator not using either of the study drugs; patients with malignant or premalignant disease; patients with a concurrent medical condition for which treatments might interfere with ongoing treatment or cause harm; and patients taking rosuvastatin or those who had received a live vaccine in the two weeks before randomisation.","['C3864998', 'C2926606', 'C0205156', 'C3538994', 'C0012634', 'C1705253', 'C0439230', 'C0032961', 'C0205419', 'C1524003', 'C1533734', 'C3845888', 'C0242485', 'C1550147', 'C3844638', 'C0087111', 'C0205171', 'C3272598', 'C0043210', 'C0333369', 'C0332149', 'C0348080', 'C1705910', 'C3887704', 'C1705169', 'C0039798', 'C0030705', 'C0332177', 'C0015127', 'C0199168', 'C0205448', 'C3687832', 'C3539075', 'C3898777', 'C0032927', 'C0085652', 'C0205420', 'C0205476', 'C2607943', 'C0965129', 'C3887532', 'C0442027', 'C0439667', 'C0087136', 'C4552904', 'C0032950', 'C0205282', 'C4084912', 'C2828358', 'C1565489', 'C0013227', 'C0035173', 'C2603343', 'C0041582', 'C1518422', 'C1522326', 'C0439231', 'C0035647', 'C0549178', 'C3539076', 'C1552607', 'C3539655', 'C1515981', 'C0008976', 'C0600457', 'C0042211', 'C0549206', 'C0085297', 'C0010592', 'C1096775']","['Etiology aspects', 'Pretreatment (substance)', 'prednisolone', 'Singular', 'Drugs - dental services', 'Clinical Trials', 'Important', 'Medical', 'Patient currently pregnant', 'And', 'Clinical Trial [Publication Type]', 'Pyoderma Gangrenosum', 'Study', 'Science of Etiology', 'CDISC Findings Class', 'Condition', 'Measurement', 'Medical service', 'Possible', 'month', 'Unmarried', 'Importance Rating Score 0', 'Previous', 'Pregnancy', 'Variant', 'Treatment Epoch', 'granulomatous', 'Woman', 'Renal Insufficiency', 'Pretreatment', 'Biomaterial Treatment', 'Administration procedure', 'Ulceration', 'Known allergy', 'Condition:Find:Pt:^Patient:Nom', 'Continuous', 'Two', 'rosuvastatin', 'Possibly Related to Intervention', 'Monthly (qualifier value)', 'Patients', 'Procedure findings:Finding:Point in time:^Patient:Narrative', 'Vaccines, Attenuated', 'findings aspects', 'Precancerous Conditions', 'Act Relationship Subset - previous', 'Oral', 'Lactating (finding)', 'Negation', 'Malignant - descriptor', 'Risk', 'Pharmaceutical Preparations', 'Pretreatment Period', 'treatment - ActInformationManagementReason', 'Ulcer', 'Either', 'Treating', 'Logical Condition', 'Research Personnel', 'WHO Temperature/Humidity Storage Condition', 'Subject Risk', 'therapeutic aspects', 'Concurrent', 'Disease', 'week', 'Gravidity', 'Immunoglobulins, Intravenous', 'pustular', 'Cyclosporine', 'Therapeutic procedure']","['topp', 'qnco', 'podg', ' aapp', 'patf', 'clna', 'fndg', 'idcn', 'hlca', 'inpr', 'qlco', 'sbst', 'resa', 'aapp', 'ftcn', 'popg', 'phsu', 'tmco', 'prog', 'orch', 'spco', 'neop', 'cnce', 'acty', 'imft', 'dsyn', 'orgf', ' phsu']"
1671,PMC4469977,S58,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Interventions,participants received oral prednisolone (brand chosen according to local practice) 0.75 mg/kg/day in a single dose or ciclosporin (neoral; novartis) 4 mg/kg/day in two divided doses.,"['C3245512', 'C0205276', 'C0332173', 'C0592503', 'C0679646', 'C0332849', 'C0087136', 'C0205171', 'C0178602', 'C0237607', 'C0699605', 'C0205448', 'C0358513', 'C0439228', 'C0010592']","['Practice Experience', 'Proprietary Name', 'day', 'Participant', 'Singular', 'Neoral', 'Two', 'divided', 'prednisolone Oral Product', 'HL7PublishingSubSection <practice>', 'Dosage', 'Daily', 'Cyclosporine', 'Local', 'Unmarried']","['tmco', 'clnd', 'fndg', 'popg', 'inpr', 'qnco', 'spco', 'aapp', 'ftcn', ' phsu', 'menp']"
1672,PMC4469977,S59,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Interventions,"as this was a pragmatic trial, the dose could be adjusted according to normal practice, to a maximum of 1 mg/kg/day for prednisolone and 5 mg/kg/day for ciclosporin.7 10","['C0456081', 'C3245512', 'C0231683', 'C3658215', 'C1080058', 'C0332173', 'C3658312', 'C1552615', 'C4553972', 'C4684737', 'C0032950', 'C0178602', 'C1515981', 'C0237607', 'C0205307', 'C0806909', 'C0680240', 'C0439228', 'C2826546', 'C0010592']","['Maximum', 'Gait normal', 'Practice Experience', 'Maximum Value Derivation Technique', 'Adjustment Action', 'prednisolone', 'Normal', 'Pragmatic Clinical Trials as Topic', 'Pragmatic Trial', 'day', 'HL7PublishingSubSection <practice>', 'And', 'How Often Felt Normal question', 'Pragmatic Clinical Trial', 'Dosage', 'Agreement', 'Daily', 'This (eukaryote)', 'Act Relationship Subset - maximum', 'Cyclosporine']","['tmco', 'fndg', 'idcn', 'inpr', 'orch', 'qnco', 'qlco', 'socb', 'resa', 'aapp', 'ftcn', 'euka', ' phsu', 'menp']"
1673,PMC4469977,S60,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Interventions,topical treatment was prohibited during the trial.,"['C0001566', 'C0008976']","['Clinical Trials', 'Administration, Topical']","['topp', 'resa']"
1674,PMC4469977,S61,['3b'],"[0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Interventions,a change to the protocol was made in august 2011 (after 82 participants had been enrolled) as bowel perforation was experienced by a participant receiving prednisolone 110 mg/day.,"['C0443172', 'C3715209', 'C1705241', 'C4282383', 'C0332173', 'C0021845', 'C0679646', 'C1507394', 'C2698741', 'C1522729', 'C2348563', 'C0392747', 'C4319952', 'C3831448', 'C2599718', 'C0439228', 'C4554048', 'C0442711']","['August', 'Protocols documentation', 'Study Participant', 'Changing', 'day', 'Participant', 'Intestinal Perforation', 'Clinical trial protocol document', 'Library Protocol', 'REMS Protocol', 'Study Protocol', 'Participant Object', 'Changed status', 'Change -- procedure', 'Delta (difference)', 'Daily', 'Protocol - answer to question', 'Clinical trial protocol']","['tmco', 'fndg', 'topp', 'clas', 'inpr', 'qlco', 'qnco', 'dsyn', 'ftcn', 'popg']"
1675,PMC4469977,S62,['3b'],"[0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Interventions,as a result we implemented ceiling doses of 75 mg/day for prednisolone and 400 mg/day for ciclosporin.,"['C1546471', 'C2825142', 'C0032950', 'C0178602', 'C1515981', 'C1274040', 'C0439422', 'C0010592']","['prednisolone', 'And', 'Dosage', 'What subject filter - Result', 'Experimental Result', 'milligram/day', 'Result', 'Cyclosporine']","['fndg', 'idcn', 'orch', 'qnco', 'aapp', 'ftcn', ' phsu']"
1676,PMC4469977,S64,"['8a', '8b', '10']","[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 0]",Randomisation and blinding,"participants were randomised (1:1) to treatment allocation using a web based randomisation system hosted by nottingham clinical trials unit, using a computer generated pseudorandom list, with permuted blocks of randomly varying size between two and six (ralloc add-on12 for stata, tx).","['C0456389', 'C3272378', 'C1883712', 'C3538994', 'C0521125', 'C3853603', 'C0439453', 'C1533734', 'C4321252', 'C0087111', 'C1706778', 'C0205103', 'C0449913', 'C0028778', 'C3887704', 'C1705169', 'C0039798', 'C3811660', 'C0205448', 'C0439148', 'C1705938', 'C3888058', 'C0332287', 'C0282111', 'C0679646', 'C1527178', 'C0009622', 'C1880519', 'C0745732', 'C0205452', 'C1533157', 'C1522326', 'C4484277', 'C1553451', 'C1515981', 'C1509845', 'C1519795', 'C0008976', 'C1704753', 'C0332206', 'C1096775']","['System - kit', 'In addition to', 'Device system', 'Clinical Trials', 'Internet', 'Unit - NCI Thesaurus Property', 'Nottingham', 'And', 'Clinical Trial [Publication Type]', 'size', 'List', 'Blocking', 'International Unit', 'Unit of Measure', 'Participant', 'Unit', 'Treatment Epoch', 'Biomaterial Treatment', 'Enzyme Unit', 'Computers', 'Administration procedure', 'Block Specimens', 'Basis - conceptual entity', 'System', 'Two', 'WWOX wt Allele', 'Storage Unit', 'Preposition For', 'Six', 'Intermediate', 'Sequence Data Type', 'Base - General Qualifier', 'treatment - ActInformationManagementReason', 'Treating', 'Obstruction', 'therapeutic aspects', 'Add - instruction imperative', 'Block Unit of Distance', 'Allocation', 'Unit device', 'Therapeutic procedure']","['patf', 'medd', 'idcn', 'topp', 'gngm', 'hlca', 'bdsu', 'inpr', 'qnco', 'qlco', 'lbpr', 'spco', 'resa', 'ftcn', 'mnob', 'popg', 'cnce', 'acty']"
1677,PMC4469977,S65,['8b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0]",Randomisation and blinding,randomisation was stratified by target lesion size (<20 cm2; ≥20 cm2) and presence or absence of underlying systemic disease.,"['C0456389', 'C0332197', 'C0439479', 'C2986546', 'C1546698', 'C0442893', 'C0392148', 'C1515981', 'C1521840', 'C0221198', 'C0555206', 'C0150312']","['Absent', 'Target', 'And', 'Lesion', 'Providing presence (regime/therapy)', 'sq. cm', 'Specimen Source Codes - Lesion', 'Systemic disease', 'size', 'Chiari malformation type II', 'Target Lesion Identification', 'Present']","['fndg', 'cgab', 'idcn', 'topp', 'inpr', 'qnco', 'dsyn', 'spco', 'ftcn', 'diap']"
1678,PMC4469977,S66,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and blinding,it was not possible to blind clinicians and participants to treatment allocation owing to resource limitations and the complexities of different dosing regimens and safety testing of the two drugs.,"['C0456909', 'C3538994', 'C2945654', 'C1705187', 'C1533734', 'C0087111', 'C1706778', 'C0871685', 'C0332149', 'C1705910', 'C3887704', 'C1705169', 'C0039798', 'C0150108', 'C0392366', 'C0205448', 'C0525065', 'C3687832', 'C0036043', 'C0449295', 'C0679646', 'C1705242', 'C0013227', 'C1518422', 'C1522326', 'C0039593', 'C1515981', 'C0035201']","['Drugs - dental services', 'Regimen - CHV concept', 'And', 'Safety', 'Clinician', 'Possible', 'Participant', 'Treatment Epoch', 'Tests (qualifier value)', 'Safety Study', 'Biomaterial Treatment', 'Administration procedure', 'Two', 'Visually Impaired Persons', 'Possibly Related to Intervention', 'Testing', 'Blinded', 'Resources', 'Pharmaceutical Preparations', 'Negation', 'Different', 'treatment - ActInformationManagementReason', 'Treating', 'Limitation', 'therapeutic aspects', 'Blindness', 'Allocation', 'Therapeutic procedure']","['fndg', 'prog', 'idcn', 'topp', 'hcpp', 'hlca', 'inpr', 'qlco', 'phsu', 'qnco', 'resa', 'podg', 'ftcn', 'popg', 'cnce', 'acty']"
1679,PMC4469977,S67,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and blinding,"as a result, clinicians and participants were informed of their treatment allocation once data had been irrevocably entered into the randomisation database.","['C0087111', 'C1706778', 'C0871685', 'C1522326', 'C3245479', 'C0679646', 'C2825142', 'C1705169', 'C1948045', 'C1546471', 'C0242356', 'C3538994', 'C0039798', 'C3887704', 'C1515981', 'C3714741', 'C0993637', 'C1511726', 'C1533734', 'C1274040']","['Data call receiving device', 'Once (schedule frequency)', 'Allocation', 'Participant', 'treatment - ActInformationManagementReason', 'Treating', 'Published Database', 'Data (eukaryote)', 'Treatment Epoch', 'And', 'therapeutic aspects', 'Databases', 'Therapeutic procedure', 'Biomaterial Treatment', 'Clinician', 'Experimental Result', 'Administration procedure', 'Result', 'What subject filter - Result', 'Data']","['tmco', 'fndg', 'prog', 'medd', 'topp', 'idcn', 'hlca', 'inpr', 'euka', 'resa', 'ftcn', 'acty', 'popg', 'cnce']"
1680,PMC4469977,S68,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and blinding,"treatment allocation was concealed from the statistician and blinded assessors of the digital images until interventions were all assigned and recruitment, data collection, data cleaning, and blind analysis were complete.","['C0456909', 'C0010995', 'C1516050', 'C3538994', 'C1524024', 'C2949735', 'C1533734', 'C0936012', 'C0087111', 'C1706778', 'C3887704', 'C1705169', 'C3542921', 'C2979881', 'C0039798', 'C0150108', 'C3887707', 'C0525065', 'C3245479', 'C1273869', 'C3853530', 'C1883674', 'C0444868', 'C0886296', 'C1522326', 'C0334957', 'C0205197', 'C4283785', 'C1515981', 'C1552601', 'C3714741', 'C1511726']","['Data (eukaryote)', 'And', 'Complete Pharyngeal Contraction', 'Nursing interventions', 'Digital', 'Recruitment', 'Data Collection Methods', 'Treatment Epoch', 'analysis aspect', 'Biomaterial Treatment', 'Administration procedure', 'Assignment - action', 'Data call receiving device', 'All', 'Interventions:Finding:Point in time:^Patient:Narrative', 'Visually Impaired Persons', 'Data Collection', 'Blinded', 'Therapeutic procedure', 'Intervention regimes', 'statistician', 'treatment - ActInformationManagementReason', 'Data operation - complete', 'Treating', 'Analysis', 'therapeutic aspects', 'CDISC Interventions Class', 'Blindness', 'Allocation', 'Complete', 'PersonNameUse - assigned', 'Data']","['clna', 'fndg', 'prog', 'medd', 'idcn', 'topp', 'clas', 'hlca', 'inpr', 'qnco', 'qlco', 'euka', 'resa', 'podg', 'ftcn', 'acty', 'cnce']"
1681,PMC4469977,S69,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Randomisation and blinding,assessors blind to the allocated treatment assessed the ulcer size and global treatment response from digital images of the target lesion.,"['C0456389', 'C2986546', 'C0456909', 'C0205246', 'C3538994', 'C0871261', 'C1521840', 'C1533734', 'C0087111', 'C3887704', 'C1705169', 'C0039798', 'C0150108', 'C2348867', 'C0525065', 'C1516048', 'C3887532', 'C1883674', 'C1517320', 'C0041582', 'C1522326', 'C1706817', 'C1546698', 'C2911692', 'C1515981', 'C1704632', 'C0221198']","['Global', 'And', 'Lesion', 'From', 'Response (communication)', 'size', 'Response process', 'Disease Response', 'Digital', 'Target', 'Treatment Epoch', 'Assessed', 'Biomaterial Treatment', 'Generalized', 'Ulceration', 'Administration procedure', 'Visually Impaired Persons', 'Blinded', 'Response (statement)', 'treatment - ActInformationManagementReason', 'Ulcer', 'Treating', 'therapeutic aspects', 'Specimen Source Codes - Lesion', 'Blindness', 'Target Lesion Identification', 'Therapeutic procedure']","['fndg', 'topp', 'hlca', 'idcn', 'diap', 'inpr', 'qlco', 'orga', 'spco', 'resa', 'podg', 'ftcn', 'acty', 'menp', 'patf', 'cnce']"
1682,PMC4469977,S70,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Randomisation and blinding,"if digital images were not available, the assessors used physical measurements of the lesion taken during clinic visits and global response by the treating clinician.","['C0008952', 'C0205246', 'C0871261', 'C0470187', 'C0242485', 'C1883727', 'C0871685', 'C2348867', 'C0205485', 'C1883674', 'C0347984', 'C1518422', 'C1706817', 'C1546698', 'C1522326', 'C2911692', 'C1515981', 'C1704632', 'C1509143', 'C1273517', 'C0221198', 'C0031809']","['Global', 'Physical Examination', 'And', 'Lesion', 'Response (communication)', 'Clinic Visits', 'Clinician', 'Measurement', 'Response process', 'used by', 'Disease Response', 'Digital', 'Physical assessment findings', 'Generalized', 'Taken', 'availability of', 'During', 'Response (statement)', 'Negation', 'Physical', 'Treating', 'Specimen Source Codes - Lesion']","['tmco', 'fndg', 'prog', 'hlca', 'idcn', 'inpr', 'qlco', 'orga', 'spco', 'ftcn', 'menp', 'cnce']"
1683,PMC4469977,S72,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,"clinic visits took place at baseline, week 2, and week 6 (primary outcome) and when the ulcer had healed (up to a maximum of six months).","['C0041582', 'C1442488', 'C0008952', 'C0439231', 'C3887532', 'C1552615', 'C1533810', 'C0168634', 'C0442504', 'C1515981', 'C1882509', 'C0806909', 'C4484139', 'C0205452', 'C2826546']","['Maximum', 'Maximum Value Derivation Technique', 'BaseLine dental cement', 'Place', 'Ulcer', 'Ulceration', 'Placement action', 'And', 'week 2', 'Clinic Visits', 'Baseline', 'put - instruction imperative', 'Act Relationship Subset - maximum', 'Six', 'month']","['tmco', 'hlca', 'idcn', 'qnco', 'spco', 'bodm', 'patf', 'acty']"
1684,PMC4469977,S73,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,patient reported outcomes were collected from daily diaries or postal questionnaires.,"['C1706422', 'C1514253', 'C0332173', 'C0034394', 'C0376660', 'C0030705']","['Diary', 'Questionnaires', 'Patients', 'Daily', 'Postal', 'Questionnaire Domain']","['podg', 'ftcn', 'inpr', 'tmco']"
1685,PMC4469977,S74,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Assessments,"for participants whose pyoderma gangrenosum had healed, we assessed recurrence and time to recurrence from medical notes.","['C0085652', 'C0205476', 'C0679646', 'C0040223', 'C1317574', 'C0199168']","['Participant', 'Medical', 'Time', 'Pyoderma Gangrenosum', 'Medical service', 'Note (document)']","['tmco', 'hlca', 'inpr', 'dsyn', 'ftcn', 'popg']"
1686,PMC4469977,S76,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Digital image assessments,a template was photographed alongside the target ulcer to calibrate the image in the image analysis software (see supplementary figure).,"['C1704922', 'C2986546', 'C0041582', 'C0728990', 'C3887532', 'C1705542', 'C0200765', 'C1704254', 'C1521840', 'C0037585', 'C1514575']","['Protocol Forms Template', 'Ulcer', 'Computer software', 'Target', 'Clinical Use Template', 'Image', 'Image Analysis', 'Ulceration', 'Target Lesion Identification', 'Template', 'Medical Image']","['medd', ' mnob', 'idcn', 'inpr', 'lbpr', 'ftcn', 'diap', 'patf']"
1687,PMC4469977,S77,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Digital image assessments,"two trained assessors mapped the circumference of the lesion using verg videometry vev md software (vista medical, winnipeg, canada).","['C1824302', 'C1546698', 'C0205476', 'C0006823', 'C0199168', 'C0332520', 'C0205448', 'C0037585', 'C0221198', 'C4049866']","['Two', 'Canada', 'Medical', 'Computer software', 'VSIR gene', 'Lesion', 'Circumference', 'Specimen Source Codes - Lesion', 'VSIR wt Allele', 'Medical service']","['fndg', 'gngm', ' mnob', 'hlca', 'inpr', 'geoa', 'qnco', 'ftcn']"
1688,PMC4469977,S78,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Digital image assessments,two dermatologists independently reviewed all images to ensure that the lesions were consistent with a diagnosis of pyoderma gangrenosum and that the measurements taken by the trained assessors were an accurate representation of the ulcer’s size.,"['C0456389', 'C1883727', 'C1882932', 'C0085652', 'C0011900', 'C0332290', 'C1514861', 'C1704656', 'C1704338', 'C0259831', 'C0443131', 'C1515981', 'C0205448', 'C0444868', 'C0221198', 'C0242485']","['Diagnosis', 'Two', 'Accurate (qualifier)', 'All', 'diagnosis aspect', 'And', 'Lesion', 'Dermatologist', 'Pyoderma Gangrenosum', 'Diagnosis Study', 'size', 'Measurement', 'Consistent with', 'Representation Component', 'Taken', 'Representation (action)']","['fndg', 'prog', 'idcn', 'qlco', 'qnco', 'dsyn', 'spco', 'resa', 'ftcn', 'diap', 'cnce', 'acty']"
1689,PMC4469977,S81,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"the main outcome measure was speed of healing over six weeks, captured for a single target lesion for each patient.","['C2986546', 'C1546698', 'C0086749', 'C0205225', 'C1457900', 'C0678536', 'C0087136', 'C0030705', 'C0347984', 'C1542147', 'C0439230', 'C0205452', 'C1521840', 'C0205136', 'C0221198', 'C0205171']","['Outcome Measures', 'Main', 'Primary', 'Singular', 'Over (spatial)', 'Each (qualifier value)', 'Target', 'Lesion', 'Specimen Source Codes - Lesion', 'Patients', 'week', 'During', 'Six', 'Target Lesion Identification', 'Speed (motion)', 'Unmarried']","['tmco', 'fndg', 'inpr', 'qnco', 'qlco', 'spco', 'podg', 'ftcn', 'diap']"
1690,PMC4469977,S82,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"if multiple lesions were present, we designated the largest lesion that could be photographed on a single plane as the target lesion.","['C0683901', 'C0443228', 'C2986546', 'C1546698', 'C0449450', 'C0087136', 'C0444660', 'C1521840', 'C0439064', 'C0221198', 'C0205171', 'C0150312']","['Airplanes', 'Anatomic Plane', 'Presentation', 'Singular', 'Largest', 'Target', 'Lesion', 'Specimen Source Codes - Lesion', 'Target Lesion Identification', 'Present', 'Unmarried', 'Numerous']","['fndg', 'idcn', 'inpr', 'qnco', 'spco', 'ftcn', 'mnob', 'diap']"
1691,PMC4469977,S83,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"we chose speed of healing for the primary outcome as previous studies have shown it to be a good predictor of healing in patients with leg ulcers,13 14 and because blinded outcome assessment was possible using digital images and independent assessors.","['C0043240', 'C0023223', 'C0332149', 'C0085565', 'C1705910', 'C0947630', 'C0205225', 'C1883674', 'C1552607', 'C2698872', 'C0085862', 'C0150108', 'C0030705', 'C0205156', 'C1515981', 'C0678536', 'C1290940', 'C1299583', 'C1274040', 'C0205170']","['Leg Ulcer', 'Outcome Assessment (Health Care)', 'Previous', 'Primary', 'Speed (motion)', 'And', 'Independently able', 'Independent for Transfer', 'Possibly Related to Intervention', 'Patients', 'Blinded', 'Good', 'Predictor', 'Scientific Study', 'Independence', 'Wound Healing', 'Act Relationship Subset - previous', 'Result', 'Possible', 'Digital']","['tmco', 'fndg', 'ocac', 'idcn', 'qlco', 'qnco', 'lbpr', 'dsyn', 'orgf', 'resa', 'podg', 'ftcn']"
1692,PMC4469977,S84,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Outcomes,assessing the primary outcome at six weeks also minimised loss to follow-up and the impact of participants switching to alternative treatments before primary outcome assessment.,"['C0087111', 'C0589120', 'C1704685', 'C0085565', 'C1517945', 'C0205225', 'C0679646', 'C3274571', 'C0439230', 'C1515981', 'C1522577', 'C1274040', 'C0205452', 'C0332152', 'C1523987', 'C4049986', 'C1825598']","['Clinical Study Follow-up', 'Primary', 'Outcome Assessment (Health Care)', 'Participant', 'Follow-Up Report', 'Follow-up status', 'follow-up', 'And', 'Impact', 'week', 'Before', 'Alternative', 'Loss', 'Result', 'Six', 'IMPACT gene', 'Therapeutic procedure']","['tmco', 'ocac', 'fndg', 'gngm', 'idcn', 'topp', 'hlca', 'inpr', 'qlco', 'qnco', 'ftcn', 'popg', 'cnce']"
1693,PMC4469977,S85,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Outcomes,"in cases where digital images were unavailable, or of poor quality, we used physical measurements of the ulcer taken by non-blinded clinicians at baseline and six weeks.","['C0871685', 'C0041582', 'C1442488', 'C0868928', 'C1518422', 'C3887532', 'C0205485', 'C1883674', 'C2700379', 'C0332306', 'C0168634', 'C0150108', 'C0439230', 'C1515981', 'C0032854', 'C1509143', 'C0205452', 'C0686905', 'C0242485', 'C0031809']","['BaseLine dental cement', 'Case (situation)', 'with quality', 'Physical Examination', 'Ulcer', 'unavailable', 'Physical', 'Poor - qualifier', 'Poverty', 'And', 'Negation', 'Measurement', 'week', 'Blinded', 'Clinician', 'Baseline', 'Physical assessment findings', 'Six', 'Ulceration', 'Digital']","['tmco', 'fndg', 'prog', 'idcn', 'hlca', 'qnco', 'qlco', 'grpa', 'ftcn', 'resa', 'bodm', 'patf']"
1694,PMC4469977,S87,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Secondary outcomes,time to healing—defined as the time at which sterile dressings were no longer required (reported by patients and confirmed by clinicians at subsequent clinic visits).,"['C0871685', 'C0332282', 'C0008952', 'C0232920', 'C0040223', 'C0030705', 'C1515981', 'C0013119', 'C0021359']","['Following', 'Infertility', 'Time', 'And', 'Patients', 'Sterile (qualifier value)', 'Clinic Visits', 'Clinician', 'Medical dressing']","['tmco', 'prog', 'medd', 'hlca', 'idcn', 'qlco', 'podg', 'patf']"
1695,PMC4469977,S88,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Secondary outcomes,we identified this outcome as the most important of the secondary outcomes.,"['C0027627', 'C0205393', 'C1080058', 'C0175668', 'C0205436', 'C4084912', 'C1274040', 'C3898777']","['Importance Rating Score 0', 'Neoplasm Metastasis', 'Important', 'Secondary to', 'second (number)', 'Most', 'This (eukaryote)', 'Result']","['inpr', 'qlco', 'qnco', 'euka', 'ftcn', 'neop']"
1696,PMC4469977,S89,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Secondary outcomes,pyoderma gangrenosum specific global treatment response—to assess treatment response we used a seven point likert scale ranging from completely clear through to worse (assessed by clinicians and participants and from digital images for blinded assessment).,"['C0205246', 'C1457868', 'C3538994', 'C0871261', 'C0205453', 'C4319731', 'C2347617', 'C0332271', 'C1533734', 'C4319730', 'C0087111', 'C0349674', 'C0871685', 'C1552961', 'C1709157', 'C3887704', 'C1705169', 'C0039798', 'C0150108', 'C2348867', 'C1516048', 'C3714763', 'C1552740', 'C0085652', 'C2963144', 'C1550549', 'C1883674', 'C0332273', 'C0175659', 'C1522326', 'C1706817', 'C2911692', 'C0205197', 'C1515981', 'C1704632', 'C1261322', 'C1947916', 'C0205369']","['Global', 'Through', 'And', 'Complete Agreement', 'Evaluation procedure', 'Pyoderma Gangrenosum', 'Completely Able', 'Response (communication)', 'Clinician', 'Response process', 'Specific qualifier value', 'Disease Response', 'Digital', 'Worsening pattern', 'point - UnitsOfMeasure', 'Scaling', 'Treatment Epoch', 'Assessed', 'Seven', 'Biomaterial Treatment', 'Intellectual scale', 'Administration procedure', 'Generalized', 'Point Name', 'Negative Surgical Margin', 'Blinded', 'Response (statement)', 'Point', 'Entity Determiner - specific', 'treatment - ActInformationManagementReason', 'Treating', 'therapeutic aspects', 'Act Relationship Checkpoint - through', 'Worse', 'Weight measurement scales', 'Complete', 'Clear', 'Therapeutic procedure']","['fndg', 'prog', 'medd', 'topp', 'hlca', 'idcn', 'inpr', 'qlco', 'qnco', 'orga', 'dsyn', 'spco', 'resa', 'ftcn', 'acty', 'menp', 'cnce']"
1697,PMC4469977,S90,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Secondary outcomes,resolution of inflammation—this was recorded by clinicians and participants using a scale reported by foss.15,"['C0175659', 'C0349674', 'C0871685', 'C0679646', 'C2699488', 'C1706463', 'C1515981', 'C1947916', 'C1514893']","['Resolution Property', 'Scaling', 'Participant', 'Resolution', 'And', 'Clinician', 'Weight measurement scales', 'Intellectual scale', 'physiologic resolution']","['prog', 'medd', 'idcn', 'inpr', 'qnco', 'acty', 'popg', 'patf', 'cnce']"
1698,PMC4469977,S91,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Secondary outcomes,"self reported pain—participants self reported the severity of pain daily using a score from 0 to 4 (none, mild, moderate, severe, or extreme).","['C4085210', 'C0439793', 'C4050155', 'C4085212', 'C0205082', 'C4050154', 'C0332173', 'C0518090', 'C0449820', 'C4554132', 'C0030193', 'C4321335', 'C0549184', 'C0522510', 'C4050465', 'C4049706', 'C1881878', 'C4049705', 'C4050231', 'C0036588', 'C4553004', 'C4050466', 'C2945599', 'C2984058', 'C0456148', 'C0205403', 'C4085555', 'C4085643', 'C0205081', 'C1551994', 'C4085211']","['Usual Severity Pain', 'With intensity', 'Have Pain', 'Borg Category-Ratio 10 Perceived Exertion Score 3', 'Moderate Level', 'Borg Category-Ratio 10 Perceived Exertion Score 5', 'Extreme', 'Pain Distress Question', 'None', 'Moderate (severity modifier)', 'No Hand Mobility', 'Score', 'Extreme Response', 'Severities', 'Moderate Extremity Pain', 'No Support Needed', 'Mild (qualifier value)', 'Feel Pain', 'Moderation', 'Severe Extremity Pain', 'Daily', 'Self', 'Null Value', 'Pain', 'How Much Distress Pain', 'Moderate Response', 'Severe (severity modifier)', 'Frequency of Pain Question', 'ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated', 'subscriber - self', 'Pain, CTCAE']","['tmco', 'fndg', 'idcn', 'inpr', 'sosy', 'qlco', 'qnco', 'clna']"
1699,PMC4469977,S92,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Secondary outcomes,"health related quality of life—assessed using the dermatology life quality index16 and european quality of life-5 dimensions, three levels (eq-5d-3l and eq vas).17 18","['C0011627', 'C0518214', 'C0034380', 'C3827561', 'C0205449', 'C0042815', 'C0332306', 'C0441889', 'C3536884', 'C1515981', 'C0239307', 'C1535514', 'C0439534', 'C0018684']","['Visual Analog Scale', 'Dermatology field', 'with quality', 'European race', 'Dimensions', 'Visual Analog Pain Scale', 'Vibroacoustic Stimulation', 'And', 'ethnic european', 'Three', 'Perceived quality of life', 'Quality of life', 'Health', 'Levels (qualifier value)']","['idcn', 'topp', 'inpr', 'sosy', 'qnco', 'qlco', 'bmod', 'diap', 'popg']"
1700,PMC4469977,S93,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Secondary outcomes,time to recurrence—defined as the interval between the target lesion healing and a further episode of pyoderma gangrenosum (at any site).,"['C3272371', 'C1515974', 'C0205103', 'C0085652', 'C1272706', 'C1546698', 'C2825164', 'C0205145', 'C1552654', 'C2986546', 'C0040223', 'C1552713', 'C1552551', 'C1515981', 'C0043240', 'C1521840', 'C1517331', 'C0221198', 'C0332189']","['Data Type Interval', 'Wound Healing', 'Target', 'Time', 'And', 'Episode of', 'Any', 'Any Data Type', 'Interval', 'Anatomic Site', 'Pyoderma Gangrenosum', 'Lesion', 'Parameterized Data Type - Interval', 'Site', 'Specimen Source Codes - Lesion', 'Study Site', 'Further', 'Intermediate', 'Target Lesion Identification']","['tmco', 'blor', 'fndg', 'idcn', 'inpr', 'qlco', 'dsyn', 'spco', 'orgf', 'ftcn', 'diap']"
1701,PMC4469977,S94,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Secondary outcomes,the period of follow-up available varied depending on the time at which participants were randomised into the trial.,"['C0439531', 'C0332283', 'C0679646', 'C0040223', 'C4281991', 'C0470187', 'C0008976', 'C0332286', 'C1948053']","['availability of', 'Period (temporal qualifier)', 'Followed by', 'into', 'Participant', 'Clinical Trials', 'Time', 'per period (qualifier value)', 'Follow']","['tmco', 'ftcn', 'popg', 'resa']"
1702,PMC4469977,S95,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Secondary outcomes,"number of treatment failures—defined as those who withdrew from their randomised treatment because of treatment intolerance, whose pyoderma gangrenosum worsened, or whose target lesion remained unhealed after six months of follow-up.","['C2986546', 'C0332283', 'C0237753', 'C1457868', 'C3538994', 'C1521840', 'C1533734', 'C0087111', 'C3272598', 'C3887704', 'C1705169', 'C0449788', 'C0039798', 'C4281991', 'C0231199', 'C4084902', 'C0085652', 'C1744706', 'C0205452', 'C1517320', 'C1522326', 'C1546698', 'C0439231', 'C2355652', 'C0221198']","['Followed by', 'Lesion', 'From', 'Pyoderma Gangrenosum', 'month', 'Target', 'Treatment Epoch', 'Count of entities', 'Got Worse', 'Follow', 'Biomaterial Treatment', 'Administration procedure', 'intolerance function', 'intolerance to substance', 'Six', 'Numbers', 'treatment - ActInformationManagementReason', 'Intolerance - biological effect of chemicals', 'Treating', 'WHO Temperature/Humidity Storage Condition', 'therapeutic aspects', 'Specimen Source Codes - Lesion', 'Worse', 'Target Lesion Identification', 'Therapeutic procedure']","['tmco', 'fndg', 'topp', 'hlca', 'inpr', 'qlco', 'qnco', 'orga', 'dsyn', 'orgf', 'resa', 'ftcn', 'diap', 'cnce']"
1703,PMC4469977,S96,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Secondary outcomes,"adverse reactions to study drugs—adverse events that were possibly, probably, or definitely related to the study drug.","['C0559546', 'C3899394', 'C0750492', 'C0013175', 'C3541888', 'C0441471']","['Definitely', 'CDISC Events Class', 'Event', 'Probably', 'Drug Evaluation', 'Adverse reactions']","['clas', 'idcn', 'inpr', 'resa', 'evnt', 'patf']"
1704,PMC4469977,S98,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Sample size,"this was a superiority trial, with prednisolone as the control intervention.","['C2587213', 'C0886296', 'C3274648', 'C1080058', 'C4553389', 'C1882979', 'C0032950', 'C0243148', 'C0184661', 'C4505129', 'C1550141']","['prednisolone', 'control substance', 'control aspects', 'True Control Status', 'Control function', 'Nursing interventions', 'Interventional procedure', 'This (eukaryote)', 'Superiority Trial', 'Study Control', 'Scientific Control']","['topp', 'hlca', 'orch', 'qlco', 'sbst', 'euka', 'resa', 'ftcn', ' phsu', 'cnce']"
1705,PMC4469977,S99,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size,"to provide 80% power (5% level of significance) to detect a difference in means of 0.5 standard deviations in the primary outcome of speed of healing over six weeks, the target sample size was 140 participants, assuming a loss to follow-up of 10%.","['C1705241', 'C1442989', 'C0205225', 'C1565156', 'C0439230', 'C0750502', 'C2946261', 'C1547707', 'C0441889', 'C0205136', 'C2828392', 'C0442726', 'C0043240', 'C0032863', 'C0679646', 'C1421478', 'C0043194', 'C3854080', 'C0347984', 'C1705242', 'C0205452', 'C4528313', 'C1517945', 'C0678536', 'C3891454', 'C1704970', 'C1274040', 'C0237881']","['Detected (finding)', 'Power', 'Loss', 'Standard (document)', 'Means', 'Floor - story of building', 'Participant', 'Dosing Days to Detection', 'Wound Healing', 'Result', 'Wiskott-Aldrich Syndrome', 'WAS gene', 'Statistical Significance', 'During', 'Level', 'Six', 'Levels (qualifier value)', 'Different', 'Significant', 'Primary', 'Power (Psychology)', 'WAS protein, human', 'Target Sample Size', 'Over (spatial)', 'week', 'Delta (difference)', 'Standard (qualifier)', 'Speed (motion)']","['tmco', 'fndg', 'popg', 'gngm', 'idcn', 'inpr', 'geoa', 'inch', 'qnco', 'qlco', 'bacs', 'dsyn', 'spco', 'hcpp', 'orgf', 'ftcn', ' phsu', ' aapp', 'cnce']"
1706,PMC4515982,S100,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,the kaplan-meier method was used to obtain survival curves with the corresponding log-rank test.,"['C0871511', 'C0022885', 'C0699794', 'C1515976', 'C0449851', 'C0039593', 'C2986775', 'C0667477', 'C0456984', 'C0038952', 'C0392366', 'C4318744', 'C3831328', 'C1708728', 'C0025663', 'C0220921']","['Test Result', 'TNFRSF11A protein, human', 'survival aspects', 'Laboratory Procedures', 'Event Log', 'Tests (qualifier value)', 'Techniques', 'Methods', 'Testing', 'Anatomic Structure, System, or Substance', 'Rank', 'Continuance of life', 'Logarithm', 'Test - temporal region', 'Blood Products Laboratory Testing', 'Test Method']","['bacs', 'inpr', 'acty', 'lbpr', 'clas', 'lbtr', 'ftcn', 'blor', ' aapp', 'qnco']"
1707,PMC4515982,S101,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"a cox model was applied to estimate the treatment effect in terms of hr with 95% ci, adjusted for sex, age, alsfrs-r score at baseline and disease duration.","['C1565830', 'C3853906', 'C0168634', 'C3274659', 'C0009253', 'C0804628', 'C4050231', 'C0872146', 'C1515981', 'C0079399', 'C1522384', 'C1442488', 'C1518681', 'C0036864', 'C0449820', 'C3714583', 'C0001779', 'C3161035']","['Model Number', 'BaseLine dental cement', 'Gender', 'Baseline', 'Sex Behavior', 'Outcome of Therapy', 'And', 'Coitus', 'Age', 'Model', 'Digital Model Attachment', 'sex', 'Model - style/design', 'disease length', 'ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated', 'Score', 'PTGS1 protein, human', 'Gender:Type:Point in time:^Patient:Nominal']","['inpr', 'clna', 'idcn', 'qnco', 'enzy', 'cnce', 'fndg', 'tmco', 'bhvr', ' aapp', 'orgf', 'bodm', 'orga']"
1708,PMC4515982,S102,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,the number of patients experiencing an ae causing withdrawal were reported and compared between the two groups by kaplan-meier curves of the time to withdrawal and the corresponding log-rank test.,"['C0684224', 'C1710677', 'C3812880', 'C0030705', 'C0678227', 'C0441833', 'C0687744', 'C4319718', 'C1515981', 'C0699794', 'C4318744', 'C0237753', 'C1515976', 'C1552839', 'C0667477', 'C0449788', 'C0205448', 'C3831328', 'C0700287', 'C0022885', 'C0040223', 'C2349954', 'C0456984', 'C2825032', 'C4049634', 'C0392366', 'C0039593']","['TNFRSF11A protein, human', 'Laboratory Procedures', 'Reporting', 'Withdrawal - birth control', 'And', 'Patients', 'Causing', 'Time', 'Test - temporal region', 'Reported', 'Withdrawal Scale (BASC-2)', 'Tests (qualifier value)', 'Testing', 'Withdrawal (dysfunction)', 'Withdrawal by Subject', 'Rank', 'Test Result', 'Social group', 'Numbers', 'Anatomic Structure, System, or Substance', 'Two', 'Blood Products Laboratory Testing', 'Count of entities', 'Report (document)', 'Groups', 'Withdraw (activity)', 'Table Rules - groups']","['bacs', 'inpr', 'mobd', 'idcn', 'lbpr', 'acty', 'clas', 'topp', 'popg', 'lbtr', 'ftcn', 'blor', 'podg', 'tmco', 'hlca', ' aapp', 'qnco']"
1709,PMC4515982,S103,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"change from baseline in svc, alsfrs-r and alsaq-40 was assayed by mixed effect models.","['C0168634', 'C0392747', 'C4319952', 'C1515981', 'C0443172', 'C1280500', 'C3161035', 'C1442488', 'C1518681', 'C0231957', 'C1705241', 'C0205430', 'C3160715', 'C2348382']","['BaseLine dental cement', 'Effect', 'Baseline', 'Changing', 'slow vital capacity (SVC)', 'And', 'Changed status', 'Model', 'Effect, Appearance', 'Change -- procedure', 'Mixed Cell Morphology', 'Mixed (qualifier value)', 'Delta (difference)', 'Outcome of Therapy']","['inpr', 'idcn', 'qnco', 'topp', 'ftcn', 'fndg', 'qlco', 'bodm']"
1710,PMC4515982,S104,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"all data were analysed using sas v.9.3 (sas institute inc. cary, north carolina, usa).","['C1511726', 'C0041703', 'C3245479', 'C1426104', 'C0028407', 'C0444868', 'C0605290', 'C3714741', 'C1823519']","['NANS gene', 'All', 'North Carolina', 'Data call receiving device', 'TSPAN31 gene', 'United States', 'Data (eukaryote)', 'Data', 'SAS']","['idcn', 'geoa', 'gngm', 'medd', 'orch', 'euka', 'qnco']"
1711,PMC4515982,S105,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"this study is registered with eudract, number 2009-016066-91 (epos trial).",,,
1712,PMC4515982,S40,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,the trial was coordinated by the als centre at the irccs foundation ‘carlo besta’ of milan.,"['C0008976', 'C0205099', 'C0016617']","['Clinical Trials', 'Foundations', 'Central']","['spco', 'resa', 'orgt']"
1713,PMC4515982,S41,['4b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,consecutive patients were screened for eligibility at all the 25 italian als centres.,"['C0030705', 'C1707491', 'C0013893', 'C0337810', 'C1548635', 'C0444868', 'C0022275', 'C0205099']","['Eligibility Determination', 'Eligible', 'All', 'Consecutive', 'Patients', 'Italian language', 'Central', 'Italians']","['popg', 'spco', 'podg', 'qlco', 'hlca', 'lang', 'qnco']"
1714,PMC4515982,S42,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"patients aged 18–75 years and diagnosed with probable laboratory-supported, probable or definite als according to el escorial revised criteria were eligible.","['C1999167', 'C0332148', 'C0033204', 'C4283904', 'C0030705', 'C3244292', 'C1704787', 'C0243161', 'C1515981', 'C0011900', 'C1521721', 'C1548635', 'C0022877', 'C0439544', 'C0001779', 'C0001792']","['Old age', 'Eligible', 'Probability', 'And', 'Definitely Related to Intervention', 'Age', 'Patients', 'Diagnosis', 'Elderly (population group)', 'criteria', 'Laboratory', 'Definite', 'Supportive assistance', 'Laboratory observation', 'Probable diagnosis', 'Laboratory domain']","['idcn', 'lbtr', 'popg', 'ftcn', 'mnob', 'fndg', 'podg', 'qlco', 'diap', 'cnce', ' hcro', 'qnco', 'orga']"
1715,PMC4515982,S43,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,inclusion criteria were onset of weakness ≤18 months and slow vital capacity (svc) ≥70% of predicted in seated position at screening visit.,"['C2348164', 'C0439231', 'C1698960', 'C1512346', 'C0545082', 'C2584297', 'C1710031', 'C2826704', 'C0220909', 'C1515981', 'C3714552', 'C1512693', 'C1710032', 'C0231957', 'C0681842', 'C1710477', 'C0220908']","['Sitting Function', 'research subject screening', 'Weakness', 'slow vital capacity (SVC)', 'Inclusion', 'Screening Study', 'Aspects of disease screening', 'And', 'Patient Visit', 'Visit', 'Visit Name', 'month', 'Screening procedure', 'prediction', 'Screening', 'Trial Screening', 'Disease Screening']","['sosy', 'inpr', 'idcn', 'phsf', 'ftcn', 'fndg', 'qlco', 'tmco', 'resa', 'bhvr', 'hlca', 'diap']"
1716,PMC4515982,S44,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"exclusion criteria were haematocrit >51% in men and >49% in women, haemoglobin value >17 g/dl; non-invasive ventilation (niv) >6 h daily; known familial als or first-degree relative with als; diagnosis of frontotemporal dementia; history and/or instrumental evidence of previous thrombotic vascular event or cardiac diseases; uncontrolled hypertension (systolic ≥160 mm hg and diastolic ≥95 mm hg irrespective of treatments at two consecutive evaluations); active solid or myeloproliferative malignancy; known hypercoagulable disorders.","['C0006826', 'C0262926', 'C3887511', 'C3853793', 'C0205318', 'C4330491', 'C1334278', 'C0205345', 'C1515981', 'C1801960', 'C0449286', 'C0005847', 'C0012634', 'C0019665', 'C0205281', 'C0751673', 'C1558950', 'C4019010', 'C0241888', 'C1518422', 'C0680251', 'C1704656', 'C0019046', 'C1707491', 'C0043210', 'C0441471', 'C0262512', 'C0035203', 'C0542560', 'C0205177', 'C0012000', 'C1706528', 'C0020538', 'C4282132', 'C1378566', 'C1704338', 'C0080103', 'C3888249', 'C0015576', 'C0441889', 'C1963138', 'C0598902', 'C0332173', 'C0019664', 'C0011900', 'C0236642', 'C2348088', 'C0025266', 'C0220825', 'C0205448', 'C0205156', 'C2004062', 'C1522609', 'C0205309', 'C1705255', 'C0087111', 'C0018799', 'C1279901', 'C1552607', 'C0398623', 'C0039155', 'C0205435', 'C0042491', 'C0205208', 'C0338451']","['Woman', 'Active License', 'Medical History', 'Malignant Neoplasms', 'Firstly', 'Instrumental Activities Domain', 'active (HL7 RoleLink)', 'And', 'Evaluation', 'First (number)', 'Exclusion Criteria', 'Relative', 'History', 'Act Relationship Subset - previous', 'Degree or extent', 'Nipah Virus', 'Degree Unit of Plane Angle', 'uncontrolled', 'Adverse Event Associated with Vascular', 'Therapeutic procedure', 'Pick Disease of the Brain', 'Systole', 'Environmental air flow', 'Diagnosis', 'Consecutive', 'Hypertensive disease', 'Family', 'Diagnosis Study', 'Solid', 'Event', 'Relative (related person)', 'Active', 'Negation', 'Evidence', 'Blood Vessel', 'Thrombophilia', 'Daily', 'diagnosis aspect', 'Academic degree', 'Solid Dose Form', 'Invasive Lesion', 'Familial', 'Known', 'Two', 'Concept History', 'Hypertension, CTCAE', 'Malignancy', 'History of present illness', 'Heart Diseases', 'Vascular', 'Male population group', 'Numerical value', 'Frontotemporal dementia', 'murine nodule inducing virus', 'Respiration', 'And/Or', 'Historical aspects qualifier', 'Invasive', 'Diastole', 'Levels (qualifier value)', 'Previous', 'Disease', 'National reporting jurisdiction:Loc:Pt:^Event:Nom', 'Hemoglobin', 'History of previous events']","['bacs', 'clna', 'famg', 'topp', 'neop', 'fndg', 'qlco', 'virs', 'hlca', 'diap', 'inpr', 'phpr', 'bpoc', 'idcn', 'resa', ' aapp', 'bodm', 'phsf', 'popg', 'ftcn', 'tmco', 'dsyn', 'ocdi', 'cnce', 'qnco', 'evnt']"
1717,PMC4515982,S45,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,all patients were asked to continue riluzole 100 mg daily or to be on a stable dose for at least 30 days prior to screening.,"['C2348164', 'C0030705', 'C0178602', 'C0332152', 'C1698960', 'C0205360', 'C1710031', 'C0220909', 'C0332173', 'C1710032', 'C0444868', 'C2826257', 'C1710477', 'C0220908', 'C1547311']","['Patient Condition Code - Stable', 'Prior Medication Usage', 'research subject screening', 'All', 'Screening Study', 'Aspects of disease screening', 'Daily', 'Patients', 'Screening procedure', 'Before', 'Stable status', 'Screening', 'Trial Screening', 'Dosage', 'Disease Screening']","['inpr', 'ftcn', 'podg', 'tmco', 'qlco', 'resa', 'hlca', 'diap', 'qnco', 'evnt']"
1718,PMC4515982,S46,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,"patients who did not take riluzole at the screening visit were considered eligible and could be randomized; in this case, they could not start riluzole during the entire study period.","['C0030705', 'C1948053', 'C1515981', 'C1548635', 'C1080058', 'C0073379', 'C1518422', 'C0439751', 'C2826704', 'C0439531', 'C1706255', 'C2603343', 'C0868928', 'C1710477', 'C2348164', 'C0545082', 'C1710031', 'C1706256', 'C1710032', 'C0220908', 'C0444667', 'C1698960', 'C1512346', 'C0220909', 'C3272598']","['research subject screening', 'Case (situation)', 'Visit', 'And', 'Riluzole', 'Patients', 'Whole', 'Aspects of disease screening', 'Visit Name', 'Screening procedure', 'Packaging Case', 'Trial Screening', 'Negation', 'WHO Temperature/Humidity Storage Condition', 'Patient Visit', 'Entire', 'Study', 'per period (qualifier value)', 'Period (temporal qualifier)', 'Screening', 'Disease Screening', 'Eligible', 'Screening Study', 'Clinical Study Case', 'This (eukaryote)']","['inpr', 'idcn', 'medd', 'ftcn', 'cnce', 'orch', 'qlco', ' phsu', 'resa', 'podg', 'hlca', 'tmco', 'euka', 'diap', 'bhvr', 'qnco']"
1719,PMC4515982,S47,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,the protocol was approved by the ethics committee at each site.,"['C3715209', 'C0085546', 'C1457900', 'C4282383', 'C0442711', 'C2599718', 'C1522729', 'C1507394', 'C0205145', 'C2825164', 'C2348563', 'C1515974']","['Library Protocol', 'Protocol - answer to question', 'REMS Protocol', 'Clinical trial protocol', 'Ethics Committees', 'Anatomic Site', 'Clinical trial protocol document', 'Site', 'Protocols documentation', 'Study Protocol', 'Study Site', 'Each (qualifier value)']","['inpr', 'prog', 'blor', 'fndg', 'spco', 'qnco']"
1720,PMC4515982,S48,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patients,all patients provided written informed consent before any study-related procedure.,"['C0184661', 'C0021430', 'C0030705', 'C0439849', 'C3272371', 'C2700391', 'C2603343', 'C0444868', 'C3274430', 'C1552551', 'C3539779']","['Procedure (set of actions)', 'Any', 'Any Data Type', 'All', 'Patients', 'Study', 'Informed Consent', 'CDISC SDTM Procedure Terminology', 'Interventional procedure', 'Physical Medical Procedure', 'Relationships']","['inpr', 'rnlw', 'topp', 'ftcn', 'podg', 'qlco', 'resa', 'hlca', 'qnco']"
1721,PMC4515982,S50,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Trial outcomes,"the primary outcome was one single composite outcome of time from randomisation to death, tracheotomy or >23 h niv daily for 14 consecutive days.","['C0040590', 'C1274040', 'C1547335', 'C0040591', 'C1707491', 'C0205171', 'C0040223', 'C0087136', 'C0205447', 'C0598902', 'C0332173', 'C0205225', 'C0205199', 'C0439228', 'C0751673', 'C1306577', 'C0011065']","['Cessation of life', 'day', 'Composite', 'Daily', 'Death (finding)', 'Data types- Composite', 'Consecutive', 'Singular', 'Nipah Virus', 'Tracheostomy procedure', 'Time', 'Primary', 'Result', 'murine nodule inducing virus', 'One', 'Unmarried', 'Tracheotomy procedure']","['idcn', 'topp', 'ftcn', 'fndg', 'tmco', 'qlco', 'virs', 'orgf', 'qnco']"
1722,PMC4515982,S51,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Trial outcomes,"secondary outcomes were changed from baseline in the alsfrs-r score, svc in the seated position and patients’ quality of life measured by the alsaq-40 questionnaire.","['C0168634', 'C0332306', 'C0205436', 'C4285307', 'C0034394', 'C0376558', 'C4050231', 'C2584297', 'C1515981', 'C0027627', 'C1442488', 'C0231957', 'C0175668', 'C0449820']","['Sitting Function', 'BaseLine dental cement', 'Life', 'Neoplasm Metastasis', 'Baseline', 'second (number)', 'slow vital capacity (SVC)', 'And', 'Questionnaires', 'with quality', 'ALSFRS-R', 'ADHD hyperactive symptoms mean score:Score:Pt:^Patient:Qn:Calculated', 'Secondary to', 'Score']","['inpr', 'clna', 'idcn', 'bodm', 'phsf', 'neop', 'fndg', 'qlco', 'qnco']"
1723,PMC4515982,S52,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Trial outcomes,tolerability was evaluated analysing adverse events (aes) causing withdrawal.,"['C1710677', 'C3812880', 'C0678227', 'C0877248', 'C1412268', 'C2699274', 'C2349954', 'C1705413', 'C2825032', 'C4049634', 'C3274448']","['Tolerability Study', 'Adverse Event Domain', 'Withdrawal Scale (BASC-2)', 'Withdraw (activity)', 'Withdrawal - birth control', 'AES gene', 'Withdrawal (dysfunction)', 'Causing', 'Adverse event', 'Scanning Auger Spectrometer (device)', 'Withdrawal by Subject']","['inpr', 'idcn', 'acty', 'gngm', 'topp', 'ftcn', 'patf', 'resd', 'resa', 'mobd']"
1724,PMC4515982,S54,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Randomisation,patients were randomly assigned to receive either intravenous rhepo 40 000 iu or matching placebo (1:1 ratio) fortnightly for 12 months.,"['C1547037', 'C0030705', 'C0456603', 'C3844638', 'C0348016']","['Intravenous', 'Ratio', 'Patients', 'data type - ratio', 'Either']","['inpr', 'fndg', 'spco', 'podg', 'qnco']"
1725,PMC4515982,S55,['8b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0]",Randomisation,"randomisation was stratified by centre, disease severity (alsfrs-r ≤33 vs >33) and onset (spinal or bulbar), with a block size of four within each centre.","['C1706084', 'C0521117', 'C4285307', 'C2828370', 'C1457900', 'C0332162', 'C0332206', 'C0521329', 'C0205450', 'C1515981', 'C0028778', 'C0456389', 'C1947952', 'C1533157', 'C0205099', 'C0206132']","['Age of Onset', 'Each (qualifier value)', 'Obstruction', 'Onset of (contextual qualifier)', 'And', 'Block (unit of measure)', 'Block Specimens', 'anatomical bulb', 'ALSFRS-R', 'Blocking', 'Central', 'size', 'Severity of illness', '(City) Block', 'spinal', 'Four']","['inpr', 'idcn', 'geoa', 'ftcn', 'spco', 'patf', 'bdsu', 'qlco', 'anst', 'qnco']"
1726,PMC4515982,S56,"['8a', '9', '10']","[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 1]",Randomisation,"the neuroepidemiology unit at the coordinating centre, independent of the study, generated the computer-based randomisation sequence known only to two staff persons and the drug dispenser.","['C0180463', 'C3853789', 'C0004793', 'C1515981', 'C0205099', 'C0700114', 'C0009622', 'C0427184', 'C3853603', 'C1519249', 'C0439148', 'C0851286', 'C1509845', 'C0332291', 'C2603343', 'C1705938', 'C1527178', 'C1947908', 'C0027361', 'C1704753', 'C0205448', 'C0013227', 'C1519795', 'C0162326', 'C1254351', 'C0205309', 'C0205171', 'C1880519', 'C0439453', 'C3146294', 'C0162327']","['dispensers', 'Base Sequence', 'Computers', 'And', 'Unit', 'RNA Sequence', 'Independent of', 'Persons', 'Unit of Measure', 'Sequence', 'Enzyme Unit', 'Sequence - TransmissionRelationshipTypeCode', 'DNA Sequence', 'Central', 'Singular', 'Known', 'Study', 'Two', 'Staff', 'International Unit', 'Base - General Qualifier', 'Basis - conceptual entity', 'Pharmaceutical Preparations', 'Unit - NCI Thesaurus Property', 'Pharmacologic Substance', 'Unit device', 'Generation (action)', 'Coordinated', 'No incoordination', 'On Staff', 'Storage Unit']","['inpr', 'nusq', 'idcn', 'acty', 'prog', 'popg', 'medd', 'ftcn', 'mnob', 'spco', 'qlco', 'fndg', 'resa', 'qnco', 'phsu']"
1727,PMC4515982,S57,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation,"treatment was allocated by a web-based randomisation system, available 24 h a day.","['C0282111', 'C3888058', 'C1553451', 'C3887704', 'C1705169', 'C0087111', 'C0332173', 'C0470187', 'C1522326', 'C1705938', 'C1533734', 'C1527178', 'C0449913', 'C0439228', 'C0039798', 'C3538994']","['Basis - conceptual entity', 'Treatment Epoch', 'day', 'availability of', 'System - kit', 'Biomaterial Treatment', 'Daily', 'Treating', 'Administration procedure', 'Device system', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Internet', 'Therapeutic procedure', 'System', 'Base - General Qualifier']","['idcn', 'topp', 'ftcn', 'cnce', 'mnob', 'tmco', 'resa', 'hlca']"
1728,PMC4515982,S58,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation,the procedure incorporated eligibility checks according to protocol and was performed on request from the centres.,"['C1522634', 'C3715209', 'C0184661', 'C1272683', 'C0013893', 'C4282383', 'C1515981', 'C0442711', 'C2599718', 'C2700391', 'C1522729', 'C1507394', 'C1548635', 'C3274430', 'C2348563', 'C0205099', 'C3539779']","['Procedure (set of actions)', 'Eligibility Determination', 'Eligible', 'Library Protocol', 'Protocol - answer to question', 'REMS Protocol', 'Clinical trial protocol', 'And', 'Clinical trial protocol document', 'Request - action', 'Question (inquiry)', 'Protocols documentation', 'Study Protocol', 'Central', 'CDISC SDTM Procedure Terminology', 'Interventional procedure', 'Physical Medical Procedure']","['inpr', 'idcn', 'acty', 'topp', 'ftcn', 'spco', 'fndg', 'qlco', 'hlca']"
1729,PMC4515982,S59,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation,the sequence was always available for emergency unmasking.,"['C4553913', 'C2003902', 'C0013956', 'C1519249', 'C3812891', 'C0004793', 'C3853789', 'C0470187', 'C0162327', 'C2745965', 'C0162326']","['Sequence - TransmissionRelationshipTypeCode', 'Sequence', 'Emergency Situation', 'Base Sequence', 'availability of', 'DNA Sequence', 'RNA Sequence', 'Always (frequency)', 'All of the Time', 'Unblinding', 'Emergencies [Disease/Finding]']","['inpr', 'phpr', 'nusq', 'ftcn', 'fndg', 'patf', 'tmco']"
1730,PMC4515982,S61,['11b'],"[0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Masking,"rhepo (eprex) was purchased from janssen-cilag spa (cologno monzese, italy) by the coordinating centre and directly shipped to the company (pierrel research imp srl, cantù, italy) in charge of preparing the investigational drug (rhepo or 1 cc of saline) in syringes of identical appearance, sealed in sequentially numbered identical containers according to the allocation sequence.","['C0007961', 'C1420002', 'C0036971', 'C0205280', 'C3853789', 'C0004793', 'C1515981', 'C1416425', 'C0036082', 'C0205099', 'C1420403', 'C0700114', 'C0427184', 'C1521827', 'C0376539', 'C1519249', 'C0331842', 'C1706211', 'C0683757', 'C0013230', 'C0233426', 'C0449788', 'C0700364', 'C0035168', 'C0162326', 'C0242481', 'C1706778', 'C0180098', 'C0039142', 'C0022277', 'C1524049', 'C0680240', 'C4084721', 'C0162327', 'C1947931']","['Base Sequence', 'IMPA1 gene', 'SFTPA1 gene', 'identical', 'And', 'RNA Sequence', 'Italy', 'janssen', 'Sequence', 'Sequence - TransmissionRelationshipTypeCode', 'Shipping', 'charge amounts', 'Charge (electrical)', 'DNA Sequence', 'Company (organization)', 'Central', 'Containers', 'Agreement', 'Eprex', 'Preparation', 'Appearance Distress Question', 'Saline Solution', 'Allocation', 'Personal appearance', 'SRL gene', 'research', 'Direct (qualifier)', 'Count of entities', 'Investigational New Drugs', 'Ships', 'Coordinated', 'Research Activities', 'Appearance', 'No incoordination', 'Syringes']","['nusq', 'medd', 'mnob', 'fndg', 'qlco', 'socb', ' phsu', 'sbst', 'phsu', 'inpr', 'geoa', 'idcn', ' mnob', 'gngm', 'resa', 'ocac', 'ftcn', 'hcro', 'acty', 'spco', 'aapp', 'qnco', 'orga', 'orgt']"
1731,PMC4515982,S62,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Masking,shipping was performed for each patient within 1 week after randomisation using a refrigerated express carrier.,"['C2347927', 'C0030705', 'C0036971', 'C1457900', 'C1524049', 'C3273162', 'C0007294', 'C1325398', 'C1706209']","['Shipping', 'Ships', 'Reprint Carrier', 'small-molecule carrier or transporter', 'Patients', 'Refrigerated Specimen', 'Each (qualifier value)', 'Carrier Device', 'Genetic Carriers']","['inpr', 'ocac', 'medd', 'fndg', 'mnob', 'podg', 'qlco', 'moft', 'qnco']"
1732,PMC4515982,S63,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Masking,each centre stored the investigational drug at −4°c.,"['C0013230', 'C1457900', 'C0205099']","['Each (qualifier value)', 'Investigational New Drugs', 'Central']","['spco', 'qnco', 'phsu']"
1733,PMC4515982,S64,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Masking,"patients, neurologists, laboratory biologists/technicians (two at each centre) and a statistician were masked to treatment allocation and did not have access to any data related to rhepo haematopoietic activity.","['C4049938', 'C1511726', 'C0030705', 'C3887704', 'C1705169', 'C1515981', 'C3714741', 'C0205099', 'C1518422', 'C4283904', 'C3272371', 'C0205177', 'C0022877', 'C1552551', 'C0039798', 'C3538994', 'C0441655', 'C1457900', 'C0334957', 'C0444454', 'C0205448', 'C4049939', 'C0334861', 'C1706778', 'C3245479', 'C0018957', 'C3244292', 'C0087111', 'C0237426', 'C1522326', 'C1533734', 'C1554204']","['Role Class - access', 'Biomaterial Treatment', 'And', 'Data call receiving device', 'Patients', 'statistician', 'Therapeutic procedure', 'Laboratory domain', 'Any Data Type', 'biologist', 'Administration procedure', 'Laboratory', 'Central', 'Physical Activity Measurement', 'Each (qualifier value)', 'Negation', 'Active', 'Any', 'Treatment Epoch', 'Hematopoietic System', 'FDA Establishment Activity Terminology', 'Two', 'Allocation', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Data', 'Neurologists', 'Treating', 'Activities', 'Data (eukaryote)', 'Laboratory observation', 'Access']","['inpr', 'idcn', 'acty', 'lbpr', 'prog', 'topp', 'lbtr', 'medd', 'ftcn', 'mnob', 'spco', 'podg', 'qlco', 'cnce', 'euka', 'bdsy', 'resa', 'hlca', ' hcro', 'qnco']"
1734,PMC4515982,S65,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Masking,"briefly, all participating centres generated a specific access code for the blood withdrawals of patients with als enrolled in the epos trial.","['C1552740', 'C3889831', 'C0030705', 'C0205369', 'C0005767', 'C0805701', 'C0009219', 'C0229664', 'C0008976', 'C1554204', 'C0014822', 'C4684790', 'C0679823', 'C0444454', 'C0005768', 'C0444868', 'C0332287', 'C0205099']","['Role Class - access', 'Entity Determiner - specific', 'Erythropoietin', 'In Blood', 'Blood', 'All', 'Clinical Trials', 'Specific qualifier value', 'Study Subject Enrolled', 'eTMF Content Model Code', 'Patients', 'Coding', 'participation', 'Central', 'Code', 'In addition to', 'Access', 'peripheral blood']","['inpr', 'ocac', 'ftcn', 'spco', 'fndg', 'bdsu', 'podg', 'horm', 'resa', 'qlco', ' phsu', ' aapp', 'qnco']"
1735,PMC4515982,S66,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Masking,"at each treatment visit, the local laboratory unit received the de-identified vial reporting the randomisation number before treatment administration.","['C0030677', 'C0237753', 'C4283904', 'C3853603', 'C1514463', 'C0439148', 'C2359836', 'C1509845', 'C0022877', 'C1514756', 'C1704753', 'C0184301', 'C1706497', 'C1457900', 'C0205276', 'C0449788', 'C1519795', 'C0700287', 'C1550043', 'C3244292', 'C1880519', 'C0439453', 'C0205396']","['Prior Therapy', 'Reporting', 'Unit', 'Unit of Measure', 'Receive', 'Laboratory domain', 'Enzyme Unit', 'Identified', 'Laboratory', 'Patient Care Management', 'Each (qualifier value)', 'Local', 'Numbers', 'International Unit', 'Parenteral Vial', 'Treatment encounter', 'Count of entities', 'Vial device', 'Container status - Identified', 'Unit - NCI Thesaurus Property', 'Unit device', 'Laboratory observation', 'Storage Unit']","['clna', 'lbtr', 'medd', 'ftcn', 'mnob', 'fndg', 'qlco', 'spco', 'hlca', ' hcro', 'qnco']"
1736,PMC4515982,S67,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Masking,blood parameters were emailed to the coordinating unit where a trained person readily alerted the treating neurologist on the decision to administer or delay the treatment based on safety protocol parameters (see below).,"['C0036043', 'C0205421', 'C3887704', 'C1705169', 'C4282383', 'C2347489', 'C0700114', 'C3715209', 'C0427184', 'C3853603', 'C0439148', 'C1509845', 'C0442711', 'C2599718', 'C1522729', 'C1507394', 'C0027361', 'C1704753', 'C0039798', 'C3538994', 'C0229664', 'C0679006', 'C1519795', 'C0718338', 'C0005767', 'C1621583', 'C0087111', 'C0237426', 'C1880519', 'C0439453', 'C1522326', 'C1533734', 'C0005768', 'C0239110', 'C2348563', 'C1705187']","['REMS Protocol', 'In Blood', 'Biomaterial Treatment', 'Unit', 'Persons', 'Unit of Measure', 'Study Protocol', 'Safety', 'Therapeutic procedure', 'Enzyme Unit', 'Protocol - answer to question', 'Administer - dosing instruction imperative', 'Clinical trial protocol', 'Consciousness clear', 'Blood', 'Clinical trial protocol document', 'Administration procedure', 'Protocols documentation', 'Person Observer', 'Treatment Epoch', 'Alert brand of caffeine', 'Storage Unit', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'International Unit', 'Deferred', 'Neurologists', 'Unit - NCI Thesaurus Property', 'Unit device', 'Safety Study', 'Coordinated', 'Treating', 'No incoordination', 'Decision', 'Library Protocol', 'peripheral blood']","['hcpp', 'inpr', 'grup', 'prog', 'topp', 'popg', 'medd', 'ftcn', 'cnce', 'fndg', 'bdsu', 'orch', 'tmco', 'resa', 'mnob', ' phsu', 'menp', 'hlca', 'qnco']"
1737,PMC4515982,S68,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Masking,"patients and treating neurologists did not have access to any data on blood parameters, whereas laboratory personnel did not have access to any data allowing the identification of the patient.","['C3178774', 'C1511726', 'C0030705', 'C3245479', 'C0005767', 'C3272371', 'C0229664', 'C1518422', 'C0237426', 'C0020792', 'C1515981', 'C1554204', 'C1522326', 'C0444454', 'C0005768', 'C0205396', 'C3714741', 'C1552551']","['Neurologists', 'Any', 'Role Class - access', 'Any Data Type', 'Identification (Psychology)', 'Identified', 'In Blood', 'Blood', 'And', 'Data call receiving device', 'Treating', 'Patients', 'Data', 'Data (eukaryote)', 'Laboratory Personnel', 'Access', 'peripheral blood', 'Negation']","['inpr', 'idcn', 'prog', 'medd', 'ftcn', 'spco', 'bdsu', 'qlco', 'podg', 'euka', 'menp']"
1738,PMC4515982,S69,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Masking,this procedure was elaborated to maintain the blindness of the study.,"['C0184661', 'C0456909', 'C2700391', 'C2603343', 'C3274430', 'C1080058', 'C3539779']","['Procedure (set of actions)', 'This (eukaryote)', 'Blindness', 'Study', 'CDISC SDTM Procedure Terminology', 'Interventional procedure', 'Physical Medical Procedure']","['inpr', 'topp', 'ftcn', 'fndg', 'euka', 'resa', 'hlca']"
1739,PMC4515982,S70,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Masking,"finally, when we designed the study, we reasoned that patients treated with rhepo could have had a higher risk of treatment delay as defined by the safety protocol.","['C0036043', 'C0030705', 'C4282383', 'C0205250', 'C3693346', 'C1704788', 'C3715209', 'C0442711', 'C2599718', 'C1522729', 'C2603343', 'C1507394', 'C0332287', 'C3154893', 'C0062074', 'C4552904', 'C3539897', 'C1415458', 'C0035647', 'C1522326', 'C2348563', 'C1705187']","['REMS Protocol', 'Patients', 'Delayed Treatment', 'Study Protocol', 'Have', 'Safety', 'HADH gene', 'Protocol - answer to question', 'Clinical trial protocol', 'Clinical trial protocol document', 'Protocols documentation', 'Subject Risk', 'Risk', 'Study', 'In addition to', 'High', 'Safety Study', 'Definition', 'Possess', 'Treating', 'HAC protocol', 'Library Protocol']","['hcpp', 'inpr', 'idcn', 'gngm', 'topp', 'ftcn', 'cnce', 'fndg', 'qlco', 'podg', 'resa']"
1740,PMC4515982,S71,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Masking,"therefore, the randomisation centre generated a list of placebo patients randomly assigned to 1 week treatment delay balanced with the number of patients allocated on rhepo treatment needing true delay at each centre.","['C0030705', 'C0205421', 'C3887704', 'C1705169', 'C3693346', 'C1516050', 'C0745732', 'C0205099', 'C0237753', 'C1696465', 'C0332287', 'C0039798', 'C3538994', 'C1457900', 'C0449788', 'C0032042', 'C1706408', 'C0205415', 'C0087111', 'C3272378', 'C1552601', 'C0205238', 'C3146294', 'C1533734', 'C1522326']","['Biomaterial Treatment', 'Patients', 'Delayed Treatment', 'placebo', 'Therapeutic procedure', 'PersonNameUse - assigned', 'Balanced - adjective', 'Placebos', 'TRUE', 'Administration procedure', 'Sequence Data Type', 'Central', 'Each (qualifier value)', 'Treatment Epoch', 'Numbers', 'Assignment - action', 'List', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'In addition to', 'Deferred', 'Placebo Control', 'Count of entities', 'Generation (action)', 'Treating']","['inpr', 'bodm', 'acty', 'topp', 'ftcn', 'fndg', 'spco', 'podg', 'cnce', 'tmco', 'resa', 'qlco', 'hlca', 'qnco']"
1741,PMC4515982,S72,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Masking,this procedure was elaborated to maintain the blindness of the study.,"['C0184661', 'C0456909', 'C2700391', 'C2603343', 'C3274430', 'C1080058', 'C3539779']","['Procedure (set of actions)', 'This (eukaryote)', 'Blindness', 'Study', 'CDISC SDTM Procedure Terminology', 'Interventional procedure', 'Physical Medical Procedure']","['inpr', 'topp', 'ftcn', 'fndg', 'euka', 'resa', 'hlca']"
1742,PMC4515982,S74,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"after giving informed written consent, eligible patients underwent haematological examinations (haemochromocytometry, renal and liver function, serum iron, ferritin, transferrin, reticulocyte count, coagulation tests), blood pressure and body mass index (bmi) measurement and svc, alsfr-r and alsq40 assessment.","['C2923685', 'C1261322', 'C0030705', 'C0242485', 'C1515981', 'C0441509', 'C1548635', 'C1318312', 'C0005778', 'C1305855', 'C1271104', 'C0040679', 'C0232741', 'C0231957', 'C4048587', 'C0206161', 'C0005823', 'C0031809', 'C0005893', 'C1511481', 'C1554192', 'C1328723', 'C0022885', 'C1272641', 'C0578022', 'C0015879', 'C0022646', 'C0392366', 'C1318442', 'C1516048', 'C1442762']","['TF gene', 'Laboratory Procedures', 'slow vital capacity (SVC)', 'Evaluation procedure', 'And', 'Consent:Finding:Point in time:{Setting}:Document:Patient', 'Patients', 'Blood Pressure', 'Coagulation procedure', 'Kidney', 'ActClass - consent', 'Systemic arterial pressure', 'Physical Examination', 'Reticulocyte count result', 'Tests (qualifier value)', 'Finding of body mass index', 'Blood coagulation', 'Reticulocyte count (procedure)', 'Body mass index', 'liver function', 'Coagulation process', 'Measurement', 'Serotransferrin, human', 'Ferritin', 'Blood pressure finding', 'Eligible', 'Body mass index procedure', 'Consent', 'Transferrin', 'Serum iron measurement', 'Assessed']","['bacs', 'clna', 'ortf', 'topp', 'fndg', 'qlco', ' phsu', 'hlca', 'diap', 'bpoc', 'inpr', 'idcn', 'lbpr', 'gngm', 'lbtr', ' aapp', 'orgf', 'phsf', 'ftcn', 'podg', 'acty']"
1743,PMC4515982,S75,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,randomisation was performed within 15 days after the screening visit.,"['C2348164', 'C1698960', 'C1512346', 'C0545082', 'C2826704', 'C1710031', 'C0220909', 'C1710032', 'C1710477', 'C0220908']","['research subject screening', 'Visit', 'Screening Study', 'Aspects of disease screening', 'Patient Visit', 'Visit Name', 'Screening procedure', 'Screening', 'Trial Screening', 'Disease Screening']","['inpr', 'ftcn', 'bhvr', 'resa', 'hlca', 'diap']"
1744,PMC4515982,S76,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"at each fortnightly treatment visit, safety parameters (haematocrit >51% in men and >49% in women or haemoglobin value >17 g/dl and value raised >1 g/dl at the end of the interval between two subsequent doses), blood pressure and bmi were assessed.","['C0036043', 'C1515981', 'C0442818', 'C0518014', 'C0019046', 'C0043210', 'C1271104', 'C2359836', 'C1552654', 'C0444930', 'C0005823', 'C0178602', 'C1457900', 'C1552713', 'C0025266', 'C1272706', 'C0205448', 'C1522609', 'C0332282', 'C1272641', 'C0578022', 'C2746065', 'C1705187']","['Woman', 'Parameterized Data Type - Interval', 'And', 'Blood Pressure', 'End', 'Hematocrit level', 'Systemic arterial pressure', 'Safety', 'Finding of body mass index', 'Following', 'Each (qualifier value)', 'Dosage', 'Stop (qualifier value)', 'Data Type Interval', 'Interval', 'Two', 'Blood pressure finding', 'Raised', 'Male population group', 'Numerical value', 'Treatment encounter', 'Safety Study', 'Hemoglobin']","['hcpp', 'bacs', 'inpr', 'idcn', 'popg', 'fndg', 'spco', 'tmco', 'qlco', 'resa', ' aapp', 'orgf', 'qnco']"
1745,PMC4515982,S77,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"symptoms of nocturnal hypoventilation (nocturnal arousals, morning headache, excessive daytime sleepiness, vivid dreams), medications and ae were actively monitored and recorded.","['C0344320', 'C0683368', 'C4284232', 'C0003808', 'C4551761', 'C2598133', 'C1515981', 'C1457887', 'C0802604', 'C0240526', 'C0013227', 'C0581880', 'C1843643']","['morning headache', 'Pharmaceutical Preparations', 'Medications', 'vivid dreams', 'And', 'Arousal', 'Medications:Presence or Identity:Duration of the study:^Patient:Nominal', 'Medications:-:Point in time:^Patient:-', 'Symptoms aspect', 'Excessive daytime sleepiness', 'Symptoms', 'Night time', 'Nocturnal hypoventilation']","['sosy', 'inpr', 'clna', 'idcn', 'ftcn', 'fndg', 'tmco', 'menp', 'phsu']"
1746,PMC4515982,S78,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,alsfr-r and svc were assessed monthly.,"['C0332177', 'C0231957', 'C1515981']","['slow vital capacity (SVC)', 'And', 'Monthly (qualifier value)']","['fndg', 'tmco', 'idcn']"
1747,PMC4515982,S79,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"at the 6-month and study end or dropout visit, the patient also underwent complete haematological examinations and alsaq-40 assessment.","['C0444930', 'C1261322', 'C0031809', 'C0030705', 'C0439231', 'C2826704', 'C1512346', 'C0545082', 'C0205197', 'C0332177', 'C1515981', 'C3853530', 'C2603343', 'C4554109', 'C2746065', 'C0013135', 'C1516048', 'C4283785']","['Stop (qualifier value)', 'Complete', 'Visit', 'Evaluation procedure', 'Clinical Trial Dropout', 'And', 'Complete Pharyngeal Contraction', 'Patients', 'Patient Visit', 'Study', 'End', 'Visit Name', 'month', 'Monthly (qualifier value)', 'Physical Examination', 'Data operation - complete', 'Dropouts', 'Assessed']","['inpr', 'idcn', 'acty', 'popg', 'ftcn', 'fndg', 'spco', 'podg', 'qlco', 'tmco', 'resa', 'bhvr', 'hlca']"
1748,PMC4515982,S80,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Procedures,"at each treatment visit, treatment administration was allowed or delayed for 1 week by the trial coordinating office after assessment of safety parameters.","['C0036043', 'C1261322', 'C0427184', 'C0030677', 'C1457900', 'C0442603', 'C0008976', 'C2359836', 'C1705187', 'C1516048', 'C0700114']","['Treatment encounter', 'Office', 'Safety Study', 'Clinical Trials', 'Evaluation procedure', 'Coordinated', 'No incoordination', 'Safety', 'Patient Care Management', 'Each (qualifier value)', 'Assessed']","['hcpp', 'acty', 'ftcn', 'fndg', 'mnob', 'resa', 'hlca', 'qnco']"
1749,PMC4515982,S81,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Procedures,"if treatment was delayed, the following week safety parameters were repeated before drug administration.","['C0332282', 'C0036043', 'C3887704', 'C1705169', 'C0439230', 'C3469597', 'C0087111', 'C1522326', 'C1533734', 'C1705187', 'C0039798', 'C3538994']","['Treatment Epoch', 'Safety Study', 'Biomaterial Treatment', 'week', 'Treating', 'Administration procedure', 'therapeutic aspects', 'treatment - ActInformationManagementReason', 'Safety', 'Following', 'Therapeutic procedure', 'Administration of medication']","['hcpp', 'topp', 'ftcn', 'cnce', 'tmco', 'resa', 'hlca']"
1750,PMC4515982,S82,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,the delay of treatment administration for more than two times caused the dropout of the patient.,"['C0205172', 'C0030705', 'C0205421', 'C0030677', 'C1948050', 'C4554109', 'C0013135']","['More', 'Clinical Trial Dropout', 'Patients', 'Dropouts', 'Patient Care Management', 'Twice (Numerical Qualifier)', 'Deferred']","['popg', 'podg', 'tmco', 'hlca', 'qnco']"
1751,PMC4515982,S83,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"after the study end at month 12, patients underwent monthly follow-up visits for a further 6 months to record primary outcome events.","['C3541888', 'C1274040', 'C0439231', 'C0030705', 'C0441471', 'C1512346', 'C0332177', 'C0545082', 'C0205225', 'C1517331', 'C2603343', 'C2746065', 'C0444930']","['Stop (qualifier value)', 'Further', 'CDISC Events Class', 'Visit', 'Patient Visit', 'Patients', 'Study', 'month', 'End', 'Monthly (qualifier value)', 'Result', 'Primary', 'Event']","['clas', 'ftcn', 'spco', 'tmco', 'podg', 'qlco', 'resa', 'bhvr', 'hlca', 'evnt']"
1752,PMC4515982,S84,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"all centres were provided with a spirometer (spirobank g multifunction, medisan srl, milano, italy) and disposable tubes for svc assessment, and trained in its use.","['C1261322', 'C1516048', 'C1420403', 'C0022277', 'C1515981', 'C0183441', 'C0725865', 'C0457083', 'C0175730', 'C0231957', 'C0444868', 'C0042153', 'C0205099', 'C1547937']","['biomedical tube device', 'disposable', 'Spirometer (device)', 'slow vital capacity (SVC)', 'All', 'Evaluation procedure', 'And', 'utilization qualifier', 'Italy', 'Specimen Source Codes - Tube', 'Central', 'SRL gene', 'Assessed', 'Usage']","['inpr', 'idcn', 'geoa', 'acty', 'gngm', 'medd', 'ftcn', 'spco', 'fndg', 'hlca', 'qnco']"
1753,PMC4515982,S85,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,"all data were recorded by an electronic case record form specifically developed (nubilaria srl, novara, italy).","['C1511726', 'C3245479', 'C0013850', 'C0022277', 'C1516308', 'C4281784', 'C0444868', 'C1547561', 'C3714741', 'C1420403']","['Case Report Form', 'All', 'Data call receiving device', 'Electronic', 'Authorization Mode - Electronic', 'Italy', 'Data (eukaryote)', 'Data', 'Electronics discipline', 'SRL gene']","['inpr', 'geoa', 'idcn', 'gngm', 'ocdi', 'medd', 'euka', 'qnco']"
1754,PMC4515982,S86,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,"trial monitoring was performed by an independent contract research organisation (crom srl, verona, italy) that assured consistency in measuring outcomes across centres by scheduled site visits.","['C0085862', 'C0086960', 'C1705564', 'C3272447', 'C1420403', 'C0205099', 'C1824670', 'C1299583', 'C0205539', 'C1515974', 'C0545082', 'C1547017', 'C1290940', 'C0035168', 'C0205145', 'C2825164', 'C1292305', 'C0242481', 'C1516647', 'C0022277', 'C1512346', 'C0332529', 'C0332522']","['Kind of quantity - Consistency', 'Visit', 'Anatomic Site', 'CD55 gene', 'Consistency', 'Site', 'Independent for Transfer', 'Italy', 'Central', 'Clinical Trials, Monitoring', 'Cromer blood group system', 'Independently able', 'Routine Contract', 'Patient Visit', 'CD55 wt Allele', 'SRL gene', 'research', 'Scheduled - procedure status', 'Schedule (document type)', 'Research Activities', 'Independence', 'Contract agreement', 'Study Site']","['inpr', 'geoa', 'idcn', 'gngm', 'cnce', 'blor', 'spco', 'qlco', 'fndg', 'resa', 'bdsy', 'hlca', 'bhvr', 'qnco']"
1755,PMC4515982,S88,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Co-treatments,nutritional status and ventilation could affect survival and thus the primary outcome of the trial.,"['C1274040', 'C0035203', 'C1515981', 'C0008976', 'C0205225', 'C0038952', 'C0392209', 'C0042491', 'C0220921']","['survival aspects', 'Respiration', 'Environmental air flow', 'Clinical Trials', 'And', 'Continuance of life', 'Result', 'Nutritional status', 'Primary']","['phpr', 'idcn', 'acty', 'phsf', 'ftcn', 'fndg', 'qlco', 'resa']"
1756,PMC4515982,S89,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Co-treatments,"during the first investigator meeting held in milan on 6 june 2010, all participating centres agreed on the approach to cotreatments, sharing the opinion that the ultimate decision would be personal to each patient.","['C0871010', 'C0675390', 'C0030705', 'C0449445', 'C1519021', 'C1457900', 'C0679006', 'C1279901', 'C3829443', 'C0679823', 'C2985160', 'C0444868', 'C0556656', 'C0035173', 'C1948036', 'C0205435', 'C0205099', 'C0237876']","['Sharing (Social Behavior)', 'ARID1A wt Allele', 'Firstly', 'Approach', 'Held - activity status', 'All', 'meeting', 'First (number)', 'Patients', 'Personal Attribute', 'Research Personnel', 'participation', 'Central', 'Opinions', 'ARID1A protein, human', 'Decision', 'Each (qualifier value)', 'June']","['bacs', 'idcn', 'acty', 'gngm', 'prog', 'ftcn', 'spco', 'podg', 'qlco', 'tmco', 'socb', 'menp', ' aapp', 'qnco', 'orga']"
1757,PMC4515982,S90,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Co-treatments,"we agreed that percutaneous endoscopic gastrostomy or an equivalent device should be proposed to all patients in the case of score 1 or 2 at item 3 of the alsfrs-r, unintentional loss of body weight >10% in the past 3 months or choking during food, liquids or medication ingestion.","['C0302908', 'C0030705', 'C4285307', 'C4319783', 'C4319779', 'C4319781', 'C0008301', 'C1551338', 'C3540798', 'C0005910', 'C0347984', 'C4284232', 'C1706255', 'C0232478', 'C0176751', 'C4319780', 'C1517945', 'C0868928', 'C0699733', 'C3244316', 'C0016452', 'C1444637', 'C1706256', 'C0205163', 'C0013227', 'C4553398', 'C0439185', 'C1305866', 'C4319782', 'C4319784', 'C0025080', 'C0444868', 'C1283932', 'C4554251']","['Equivalent Weight', 'medication - HL7 publishing domain', 'Choking', 'Case (situation)', 'In the past', 'Equal', 'Patients', 'Food allergenic extracts', 'Clinical Study Case', 'Medications', 'ALSFRS-R', 'Packaging Case', 'Not Normal but Fairly Active', 'Entity', 'Loss', 'All', 'Food', 'Devices', 'GvHD Lung Symptom Score 1', 'GvHD Final Lung Score 1', 'Lung Obstructive Function Score 1', 'During', 'Percutaneous endoscopic gastrostomy', 'Pharmaceutical Preparations', 'Body Weight', 'Unintentional', 'Clinical Item', 'BSA Involvement Score 1', 'Ingestion', 'GvHD Final Skin Score 1', 'Medical Devices', 'Weighing patient', 'Score 1', 'Liquid substance']","['biof', 'topp', 'medd', 'fndg', 'mnob', 'qlco', 'food', ' phsu', 'sbst', 'hlca', 'phsu', 'inpr', 'patf', 'imft', 'ftcn', 'podg', 'tmco', 'enty', 'cnce', 'qnco', 'orga']"
1758,PMC4515982,S91,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Co-treatments,"niv should be proposed to all patients in the case of score 0 or 1 at item 10 or 11 of the alsfrs-r, svc<50% or abnormal nocturnal oximetry (sao2 <90% for 4% of the overnight recorded time).","['C0030705', 'C0523807', 'C4285307', 'C1551338', 'C4321252', 'C4321346', 'C0751673', 'C1706255', 'C0439583', 'C0240526', 'C0231957', 'C0868928', 'C4321348', 'C4553162', 'C0598902', 'C1706256', 'C0205161', 'C4321349', 'C0521125', 'C2699333', 'C0040223', 'C4321350', 'C0444868', 'C4321347', 'C4321345', 'C4554251']","['Case (situation)', 'slow vital capacity (SVC)', 'Patients', 'GvHD Final Skin Score 0', 'Nipah Virus', 'Time', 'Preposition For', 'BSA Involvement Score 0', 'WWOX wt Allele', 'Lung Obstructive Function Score 0', 'ALSFRS-R', 'Packaging Case', 'Night time', 'Entity', 'GvHD Lung Symptom Score 0', 'All', 'GvHD Final Lung Score 0', 'Oxygen saturation measurement', 'Skin Features Score 0', 'Normal Activity with No Limitations', 'Abnormal', 'murine nodule inducing virus', 'Abnormal Reference Range', 'overnight', 'Clinical Item', 'Clinical Study Case']","['inpr', 'lbpr', 'gngm', 'medd', 'ftcn', 'fndg', 'cnce', 'podg', 'virs', 'tmco', 'qlco', 'enty', 'qnco']"
1759,PMC4515982,S93,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Sample size estimation,"on the basis of the results of our pilot study (ie, observed rates of 0.56 for death and 0.33 for tracheotomy at 18 months in the placebo group),13 we estimated that we would need a sample size of 203 patients followed up for 12 months to give 97% power to detect a significant difference between rhepo and placebo corresponding to a 67% relative reduction of risk of death and 74% power to detect a 70% relative reduction of risk of respiratory events (tracheotomy or >23 h niv), with a two-sided type 1 error of 5% and given an anticipated dropout rate of 10%.","['C1705428', 'C0743559', 'C0030705', 'C0441833', 'C0687744', 'C0441729', 'C0032863', 'C0205345', 'C1515981', 'C0301630', 'C4321252', 'C4554109', 'C0751673', 'C0242618', 'C3891454', 'C0013135', 'C0237881', 'C0040591', 'C3840775', 'C1696465', 'C0441471', 'C1608199', 'C0332283', 'C1527178', 'C1441672', 'C1874451', 'C0332287', 'C1293152', 'C1705242', 'C1546767', 'C0080103', 'C0040590', 'C3541888', 'C4551656', 'C1705429', 'C1546944', 'C0598902', 'C0031928', 'C0392756', 'C0205448', 'C4552904', 'C1306577', 'C0521125', 'C0871208', 'C0521346', 'C0011065', 'C0750502', 'C0032042', 'C1519504', 'C1706408', 'C1257890', 'C3854080', 'C1947971', 'C0035647', 'C0205103', 'C0442726', 'C1705241', 'C4085651', 'C1521828']","['respiratory', 'Anticipated', 'CDISC Events Class', 'Followed by', 'Statistical Significance', 'Pilot Projects', 'Rating (action)', 'Specimen Source Codes - Respiratory', 'Sample Size', 'And', 'Detected (finding)', 'Relative', 'Patients', 'Clinical Trial Dropout', 'Nipah Virus', 'Tracheostomy procedure', 'Power', 'Reduced', 'Preposition For', 'Surgical reduction', 'WWOX wt Allele', 'placebo', 'Stage Grouping', 'Type 1', 'Delta (difference)', 'Tracheotomy procedure', 'Reduction (chemical)', 'Give - dosing instruction imperative', 'Act Reason - Error', 'User Group', 'Death (finding)', 'Placebos', 'Significant', 'Different', 'error', 'Group Object', 'Social group', 'Dropouts', 'Event', 'Observed', 'Bristol Stool Type 1', 'Subject Risk', 'Event Seriousness - Significant', 'Cessation of life', 'Intermediate', 'Risk', 'Two', 'Dosing Days to Detection', 'In addition to', 'murine nodule inducing virus', 'Placebo Control', 'Basis - conceptual entity', 'Groups', 'Rate', 'Power (Psychology)', 'Reduction procedure', 'Population Group', 'Basis', 'Relative (related person)']","['hcpp', 'famg', 'topp', 'fndg', 'qlco', 'virs', 'phsu', 'inpr', 'idcn', 'gngm', 'clas', 'resa', 'npop', 'bodm', 'orgf', 'popg', 'ftcn', 'tmco', 'podg', 'acty', 'cnce', 'spco', 'qnco', 'evnt']"
1760,PMC4515982,S95,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,the main analysis of primary and secondary outcomes included all randomised patients who took at least one dose of the investigational drug in their original assigned groups.,"['C0205436', 'C0030705', 'C0441833', 'C0687744', 'C1542147', 'C1515981', 'C2347409', 'C1516050', 'C0027627', 'C1524024', 'C0936012', 'C0205447', 'C0013230', 'C0178602', 'C1552839', 'C0205225', 'C0205313', 'C1552601', 'C0444868', 'C3272598', 'C0175668']","['And', 'Patients', 'Secondary to', 'PersonNameUse - assigned', 'Main', 'Social group', 'Original', 'Original Regulatory Submission', 'Dosage', 'WHO Temperature/Humidity Storage Condition', 'All', 'Assignment - action', 'One', 'analysis aspect', 'Neoplasm Metastasis', 'Investigational New Drugs', 'Groups', 'second (number)', 'Table Rules - groups', 'Analysis', 'Primary']","['inpr', 'idcn', 'ocac', 'neop', 'popg', 'ftcn', 'qlco', 'podg', 'resa', 'qnco', 'phsu']"
1761,PMC4515982,S96,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,all analyses were performed both for the entire population and for the subgroups of patients with alsfrs-r ≥33 or <3314 and with spinal or bulbar onset at randomisation.,"['C0444667', 'C0032659', 'C0030705', 'C1706086', 'C0439751', 'C0332162', 'C0521329', 'C1257890', 'C1515981', 'C4321252', 'C1079230', 'C0444868', 'C1947952', 'C0521125', 'C0206132']","['Age of Onset', 'Onset of (contextual qualifier)', 'All', 'Both', 'geographic population', 'And', 'Entire', 'Population Group', 'Patients', 'anatomical bulb', 'Whole', 'Preposition For', 'Subgroup A Nepoviruses', 'WWOX wt Allele', 'spinal']","['idcn', 'gngm', 'popg', 'spco', 'podg', 'qlco', 'virs', 'anst', 'qnco']"
1762,PMC4515982,S97,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,a per-protocol analysis was carried out excluding non-compliers (patients who took <80% therapy).,"['C3715209', 'C4281991', 'C0030705', 'C0439787', 'C0936012', 'C4282383', 'C0087111', 'C1363945', 'C3887962', 'C0442711', 'C2599718', 'C1522729', 'C1524024', 'C1507394', 'C2348563', 'C0849355', 'C3272598', 'C1518422', 'C0039798']","['Follow', 'Library Protocol', 'Protocol - answer to question', 'REMS Protocol', 'Clinical trial protocol', 'WHO Temperature/Humidity Storage Condition', 'Out (direction)', 'Clinical trial protocol document', 'Patients', 'Analysis', 'therapeutic aspects', 'Therapy Object (animal model)', 'Protocols documentation', 'Per (qualifier)', 'Study Protocol', 'Therapeutic procedure', 'Removed', 'Negation', 'analysis aspect']","['inpr', 'topp', 'ftcn', 'fndg', 'spco', 'qlco', 'podg', 'resa']"
1763,PMC4515982,S98,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"demographic characteristics and clinical features of randomised patients at baseline were reported by treatment arm and compared using χ2 test, student t test, wilcoxon rank-sum test or fisher’s exact test as appropriate.","['C0030705', 'C1548787', 'C1515981', 'C0699794', 'C0683970', 'C4318744', 'C0038492', 'C1522541', 'C0871472', 'C0205210', 'C1442488', 'C2828393', 'C1515976', 'C0667477', 'C4050514', 'C3831328', 'C0022885', 'C0168634', 'C0456984', 'C0392366', 'C0039593', 'C1515051']","['Baseline', 'TNFRSF11A protein, human', 'Laboratory Procedures', 'Appropriate', 'And', 'Patients', 'Sum', 'Test - temporal region', 'Protocol Treatment Arm', 't test', 'Tests (qualifier value)', 'Testing', 'Rank', 'Test Result', 'student', 'Clinical', 'BaseLine dental cement', 'demographic characteristics', 'Anatomic Structure, System, or Substance', 'Blood Products Laboratory Testing', 'Exacerbations of Chronic Pulmonary Disease Tool Patient-Reported Outcome Questionnaire', 'Exact (qualifier)']","['bacs', 'inpr', 'grpa', 'idcn', 'lbpr', 'qnco', 'clas', 'lbtr', 'popg', 'ftcn', 'blor', 'podg', 'qlco', 'resa', ' aapp', 'bodm']"
1764,PMC4515982,S99,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"time from randomisation to death, tracheotomy or >23 h niv daily for 14 consecutive days was analysed in terms of the annualised rate with the corresponding 95% ci, and p value using a χ2 test with one degree of freedom for rate comparison (based on poisson regression).","['C1515981', 'C0449286', 'C0684320', 'C4321252', 'C1836830', 'C0751673', 'C4318744', 'C0040591', 'C1707491', 'C0684321', 'C0205447', 'C0542560', 'C1707455', 'C0332287', 'C0040590', 'C1515976', 'C0441889', 'C0598902', 'C0332173', 'C2348088', 'C0439228', 'C3831328', 'C1306577', 'C0871208', 'C0521125', 'C0011065', 'C1522609', 'C0022885', 'C0040223', 'C0016694', 'C0456984', 'C0392366', 'C0039593', 'C1521828']","['day', 'Laboratory Procedures', 'Rating (action)', 'And', 'Degree or extent', 'Nipah Virus', 'Tracheostomy procedure', 'Time', 'Degree Unit of Plane Angle', 'Preposition For', 'Test - temporal region', 'WWOX wt Allele', 'Tracheotomy procedure', 'Tests (qualifier value)', 'Death (finding)', 'Testing', 'Comparison', 'Consecutive', 'Test Result', 'Developmental regression', 'Cessation of life', 'Daily', 'Academic degree', 'Anatomic Structure, System, or Substance', 'Disease regression', 'Freedom', 'Regression - mental defense mechanism', 'Blood Products Laboratory Testing', 'In addition to', 'One', 'murine nodule inducing virus', 'Numerical value', 'Rate', 'Levels (qualifier value)']","['inpr', 'idcn', 'acty', 'lbpr', 'clas', 'gngm', 'topp', 'lbtr', 'ftcn', 'fndg', 'patf', 'tmco', 'qlco', 'virs', 'blor', 'dsyn', 'menp', 'orgf', 'qnco']"
1765,PMC4621368,S39,['4b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Trial population,"between june 2011 and september 2013, consecutive patients referred for elective cabg surgery were recruited from two clinics at edinburgh heart centre.","['C0206058', 'C0543467', 'C3829443', 'C0442592', 'C3828193', 'C0030705', 'C0010055', 'C0038894', 'C0038895', 'C1515981', 'C0205448', 'C0018787', 'C0439608', 'C1274039', 'C0205099', 'C1707491']","['General surgery specialty', 'Two', 'September', 'Heart', 'Consecutive', 'elective', 'Clinic', 'And', 'Surgery specialty', 'Coronary Artery Bypass Surgery', 'Patients', 'Central', 'June', 'Elective Surgical Procedures', 'Surgical aspects', 'Operative Surgical Procedures']","['tmco', ' hcro', 'topp', 'idcn', 'qlco', 'qnco', 'bmod', 'spco', 'podg', 'ftcn', 'mnob', 'bpoc']"
1766,PMC4621368,S40,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Trial population,"patients were 18 years or older, and were referred for isolated cabg surgery requiring two or more grafts.","['C0543467', 'C0030705', 'C0332835', 'C1527362', 'C0010055', 'C0038894', 'C0038895', 'C0205409', 'C0205448', 'C0205172', 'C1274039', 'C1548221']","['grafting qualifier', 'General surgery specialty', 'Two', 'More', 'Transplanted tissue', 'Surgery specialty', 'Isolated', 'Coronary Artery Bypass Surgery', 'Patients', 'Bed Status - Isolated', 'Surgical aspects', 'Operative Surgical Procedures']","['topp', 'idcn', 'tisu', 'qlco', 'qnco', 'bmod', 'podg', 'ftcn']"
1767,PMC4621368,S41,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Trial population,"exclusion criteria included patients with recent myocardial infarction (within 1 month of surgery), emergency or concomitant valve surgery, significant renal impairment (estimated glomerular filtration rate<40 ml/min), severe respiratory disease (maintenance corticosteroid therapy or forced expiratory volume in 1 s <50% predicted), severe lv impairment (ef <40%), contraindication to magnetic resonance scanning, treatment for chronic inflammatory disease, women of childbearing potential and inability to provide consent.","['C1511481', 'C0521115', 'C3714732', 'C3538994', 'C0522473', 'C0428953', 'C0521125', 'C0038894', 'C0221099', 'C0441633', 'C0750502', 'C1554192', 'C0680251', 'C1533734', 'C0184252', 'C0205082', 'C4321252', 'C0035242', 'C0543467', 'C0087111', 'C0043210', 'C0684336', 'C1546944', 'C3887704', 'C1705169', 'C0039798', 'C2926063', 'C0030705', 'C0035204', 'C3831118', 'C4552959', 'C1306036', 'C0024501', 'C2745965', 'C2923685', 'C0038895', 'C0016529', 'C4050466', 'C0681842', 'C0027051', 'C1551403', 'C1565489', 'C1290886', 'C1522326', 'C0917874', 'C0332185', 'C0028580', 'C1301624', 'C3811844', 'C1704414', 'C1186983', 'C0013956', 'C3810814', 'C1515981', 'C0034606', 'C1274039', 'C4050465', 'C0149783', 'C0237881']","['Borg Category-Ratio 10 Perceived Exertion Score 5', 'Emergency Situation', 'And', 'Respiratory Tract Diseases', 'Consent', 'Steroid therapy', 'Emergencies [Disease/Finding]', 'Magnetic Resonance', 'prediction', 'Simultaneous', 'Operative Surgical Procedures', 'Consent:Finding:Point in time:{Setting}:Document:Patient', 'Estimated Glomerular Filtration Rate', 'Nuclear Magnetic Resonance', 'Forced expiratory volume procedure', 'Myocardial infarction:Finding:Point in time:^Patient:Ordinal', 'Treatment Epoch', 'Valve Device', 'Electrocardiogram: myocardial infarction (finding)', 'Myocardial Infarction', 'Woman', 'Contraindication:Find:Pt:^Patient:Nom', 'Renal Insufficiency', 'Biomaterial Treatment', 'Administration procedure', 'Observation Method - Magnetic resonance', 'Forced expiratory volume function', 'General surgery specialty', 'Severe Extremity Pain', 'Maintenance', 'Exclusion Criteria', 'Medical contraindication', 'Radionuclide Imaging', 'Myocardial Infarction, CTCAE', 'Statistical Significance', 'Surgery specialty', 'WWOX wt Allele', 'Patients', 'Recent', 'Event Seriousness - Significant', 'Preposition For', 'Medical Valves', 'anatomic valve', 'Myocardial Infarction ECG Assessment', 'Impaired', 'Significant', 'Impaired health', 'Severe (severity modifier)', 'treatment - ActInformationManagementReason', 'Treating', 'Childbearing Potential', 'chronic inflammatory disease', 'Contraindication', 'therapeutic aspects', 'Scanning', 'ActClass - consent', 'Respiration Disorders', 'Surgical aspects', 'Therapeutic procedure']","['topp', 'qnco', 'phpr', 'podg', 'patf', 'clna', 'ortf', 'fndg', 'npop', 'idcn', 'hlca', 'inpr', 'qlco', 'lbpr', 'resa', 'ftcn', 'popg', 'bpoc', 'tmco', 'lbtr', 'acty', 'cnce', 'medd', 'gngm', 'bmod', 'dsyn', 'diap']"
1768,PMC4621368,S43,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study drug and randomisation,"intravenous recombinant human elafin (proteo biotech ag, germany) 200 mg or saline placebo was prepared and infused as aqueous solution of 250 ml 0.9% saline.","['C1514798', 'C0032042', 'C1579194', 'C0142580', 'C1706408', 'C1696465', 'C0017480', 'C1418549', 'C0036082', 'C0348016', 'C0086418', 'C0037633', 'C0599956', 'C0525069']","['PI3 protein, human', 'Intravenous', 'placebo', 'Placebo Control', 'PI3 gene', 'aqueous', 'Solutions', 'Pharmaceutical Solutions', 'Placebos', 'Recombinants', 'Saline Solution', 'Homo sapiens', 'Germany', 'Elafin']","['orgm', 'bodm', 'gngm', 'topp', 'geoa', 'qlco', 'bacs', 'sbst', 'spco', 'resa', ' aapp', 'humn']"
1769,PMC4621368,S44,"['8b', '10', '9']","[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1]",Study drug and randomisation,patients were randomised (1:1) to receive elafin or matched placebo by edinburgh clinical trials unit to ensure allocation concealment.,"['C1706778', 'C0032042', 'C1708943', 'C0030705', 'C0142580', 'C1579194', 'C0439453', 'C0150103', 'C1706408', 'C3853603', 'C1418549', 'C0008976', 'C1509845', 'C1519795', 'C1696465', 'C1704753', 'C0439148', 'C1880519', 'C1096775']","['PI3 protein, human', 'International Unit', 'Unit of Measure', 'Placebo Control', 'placebo', 'Unit', 'PI3 gene', 'Clinical Trials', 'Unit - NCI Thesaurus Property', 'Match', 'Clinical Trial [Publication Type]', 'Placebos', 'Patients', 'Enzyme Unit', 'MATCHING', 'Storage Unit', 'Allocation', 'Elafin', 'Unit device']","['bodm', 'gngm', 'topp', 'medd', 'inpr', 'qnco', 'bacs', 'qlco', 'resa', 'podg', ' aapp', 'mnob', 'acty']"
1770,PMC4621368,S45,"['11a', '8b']","[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0]",Study drug and randomisation,"randomisation incorporated minimisation for age, presence of diabetes mellitus, extent of coronary artery disease, renal function and surgeon a or b. to ensure blinding, study drugs were prepared by staff independent of the study investigators or clinical team responsible for the patient’s care.","['C0871489', 'C0011849', 'C0521125', 'C0439792', 'C1956346', 'C0582175', 'C4321252', 'C1947908', 'C1947933', 'C0085862', 'C0150108', 'C1273518', 'C3687832', 'C0218063', 'C0010054', 'C0232804', 'C0013227', 'C0035173', 'C0150312', 'C0851286', 'C2603343', 'C0392148', 'C1515981', 'C1290940', 'C0205210', 'C1299583', 'C0001779']","['Age', 'responsible', 'teams', 'Drugs - dental services', 'Renal function', 'And', 'Independent for Transfer', 'Staff', 'Study', 'Diabetes Mellitus', 'Independence', 'Ensure (product)', 'Extent', 'On Staff', 'WWOX wt Allele', 'Independently able', 'Surgeon', 'Blinded', 'Preposition For', 'Pharmaceutical Preparations', 'Clinical', 'Research Personnel', 'care activity', 'Providing presence (regime/therapy)', 'Present', 'Coronary Artery Disease', 'Coronary Arteriosclerosis']","['food', 'fndg', 'ortf', 'prog', 'gngm', 'idcn', 'topp', 'qlco', 'grup', 'orga', 'dsyn', 'spco', 'resa', 'acty', 'phsu']"
1771,PMC4621368,S46,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Study drug and randomisation,intravenous elafin 200 mg causes complete inhibition of plasma elastase activity for 2 h and >50% inhibition for 6 h.,"['C3463820', 'C3853530', 'C0205197', 'C4283785', 'C0032105', 'C1579194', 'C0142580', 'C0348016', 'C1418549', 'C0021467', 'C4521445', 'C1323717']","['PI3 protein, human', 'Intravenous', 'Data operation - complete', 'PI3 gene', 'Psychological inhibition', 'Complete Pharyngeal Contraction', 'Plasma Product', 'Plasma', 'elastase activity', 'Inhibition', 'Elafin', 'Complete']","['fndg', 'gngm', 'bdsu', 'qlco', 'bacs', 'spco', 'ftcn', ' aapp', 'acty', 'menp', 'moft', 'phsu']"
1772,PMC4621368,S47,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study drug and randomisation,this dosage regimen was selected to cover the increased elastase release following cabg surgery that peaks at the time of weaning from cardiopulmonary bypass and has returned to baseline by 6–7 h.,"['C0332282', 'C1283071', 'C0168634', 'C0038894', 'C0543467', 'C0205217', 'C0442805', 'C0030306', 'C0030685', 'C0010055', 'C0038895', 'C0007202', 'C1442488', 'C1080058', 'C0040223', 'C1963578', 'C0699918', 'C0680255', 'C1515981', 'C4684645', 'C1274039', 'C0444505', 'C0391871']","['Peak level', 'Pancreatic Elastase', 'And', 'Release (procedure)', 'Operative Surgical Procedures', 'Dosage Regimen', 'Elastases', 'Following', 'Patient Discharge', 'Released (action)', 'Time', 'Cardiopulmonary Bypass', 'Baseline', 'Discharge (release)', 'Increase', 'General surgery specialty', 'Release - action (qualifier value)', 'Surgery specialty', 'Coronary Artery Bypass Surgery', 'BaseLine dental cement', 'This (eukaryote)', 'Surgical aspects', 'Increased']","['tmco', 'bodm', 'topp', 'idcn', 'hlca', 'enzy', 'qnco', 'qlco', 'bmod', 'euka', 'ftcn', ' aapp']"
1773,PMC4621368,S48,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Study drug and randomisation,the study drug was administered to the patient through a central venous cannula over a period of 30 min. the intravenous infusion was started at first skin incision and completed at least 20 min before cardiopulmonary bypass commenced.,"['C3854010', 'C0021440', 'C0444466', 'C1279901', 'C0191279', 'C0205136', 'C0456693', 'C0205435', 'C1442458', 'C0030705', 'C0439531', 'C0520453', 'C0347984', 'C0013175', 'C0007202', 'C1272892', 'C3463845', 'C0205197', 'C1515981', 'C1621368', 'C1948053']","['Intravenous Drip Route of Administration', 'And', 'central venous', 'Firstly', 'Period (temporal qualifier)', 'First (number)', 'per 30 minutes', 'Cannula <eukaryote>', 'Cardiopulmonary Bypass', 'completed - RoleLinkStatus', 'Patients', 'Intravenous infusion (product)', 'During', 'Drug Evaluation', 'Intravenous infusion procedures', '30 Minutes', 'Over (spatial)', 'Incision of skin', 'per period (qualifier value)', 'Cannula device', 'Complete']","['tmco', 'bodm', 'medd', 'topp', 'idcn', 'qlco', 'qnco', 'euka', 'resa', 'podg', 'ftcn', 'spco']"
1774,PMC4621368,S50,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Anaesthesia and coronary artery bypass surgery,general anaesthesia was maintained with isoflurane and propofol infusion during bypass.,"['C0741847', 'C1827465', 'C0574032', 'C0002915']","['Infusion procedures', 'Infusion route', 'General Anesthesia', 'bypass']","['topp', 'ftcn']"
1775,PMC4621368,S51,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Anaesthesia and coronary artery bypass surgery,surgical approach was via a median sternotomy and cardiopulmonary bypass was started after heparin administration with a non-pulsatile flow and a membrane oxygenator.,"['C0804726', 'C0231290', 'C1272689', 'C0007202', 'C0030068', 'C0332287', 'C1518422', 'C0449446', 'C1282959', 'C1421478', 'C0019134', 'C1565156', 'C0043194', 'C0687676', 'C1515981', 'C0001554', 'C1533734', 'C0770546', 'C0034106']","['Surgical approach', 'In addition to', 'Started', 'Status post', 'Surgical approach:Type:Point in time:Surgical procedure:Nominal', 'Pulsatile Flow', 'WAS gene', 'WAS protein, human', 'Cardiopulmonary Bypass', 'And', 'Negation', 'Oxygenators, Membrane', 'Median Sternotomy', 'heparin', 'Wiskott-Aldrich Syndrome', 'heparin, porcine', 'Administration procedure', 'Post', 'Administration occupational activities']","['tmco', 'ocac', ' orch', 'topp', 'medd', 'idcn', 'gngm', 'qlco', 'phpr', 'bacs', 'dsyn', 'ftcn', ' phsu', ' aapp', 'clna']"
1776,PMC4621368,S52,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Anaesthesia and coronary artery bypass surgery,"cardioprotection was provided by cold blood cardioplegia (1:4), which was administered antegradely, after cross-clamping the aorta, into the coronary arteries or by cross-clamp fibrillation.","['C2828360', 'C3810601', 'C0005767', 'C0005768', 'C0003483', 'C0205042', 'C0175721', 'C0018791', 'C0229664', 'C0234192', 'C0009443', 'C1883710', 'C0232197', 'C0332286', 'C0009264', 'C0041912']","['into', 'Clamping Activity', 'PDZK1 wt Allele', 'Cold Temperature', 'Upper Respiratory Infections', 'peripheral blood', 'Coronary artery', 'Aorta', 'Fibrillations', 'In Blood', 'Common Cold', 'Heart Arrest, Induced', 'Clamp (device)', 'Blood', 'Cold Sensation', 'Traverse']","['cnce', 'npop', 'gngm', 'topp', 'phsf', 'dsyn', 'ftcn', 'mnob', 'bpoc', 'bdsu']"
1777,PMC4621368,S54,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Blood samples,"blood samples were taken at baseline (time 0, skin incision) and at 2, 6, 24 and 48 h postoperatively.","['C1442488', 'C0040223', 'C0168634', 'C0191279', 'C1515981', 'C0178913']","['BaseLine dental cement', 'Time', 'And', 'Incision of skin', 'Baseline', 'Blood specimen']","['tmco', 'idcn', 'topp', 'qnco', 'bodm', 'bdsu']"
1778,PMC4621368,S55,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Blood samples,"plasma cardiac troponin i (ctni) concentrations were measured with the architectstat troponin i assay and architectstat high-sensitive troponin i assay (abbott laboratories, abbott park, illinois, usa) validated in our institution.16 17","['C1522601', 'C0032105', 'C0041199', 'C3889660', 'C0332324', 'C2700149', 'C0041703', 'C1552881', 'C1510438', 'C3538828', 'C3160718', 'C0020898', 'C4522209', 'C0883409', 'C0243073', 'C0332287', 'C3887512', 'C4321237', 'C1299351', 'C0005507', 'C0562547', 'C4521445', 'C1305957', 'C0077401', 'C0018787', 'C3541902', 'C0020517', 'C0018704', 'C1522640', 'C0086045', 'C0331761', 'C1515981', 'C0444706', 'C0205250', 'C2607850', 'C1272753']","['Health care facility', 'In addition to', 'High Level', 'Troponin I', 'And', 'TNNI3 wt Allele', 'Cardiac troponin I measurement', 'abbott', 'high - ActExposureLevelCode', 'High Mitosis-Karyorrhexis Index', 'Measured Tumor Identification', 'Cardiac troponin I', 'High', 'Park (environment)', 'Institution (social concept)', 'Measured', 'Heart', 'Assay', 'Value Above Reference Range', 'Cardiac - anatomy qualifier', 'Institution', 'Hypersensitivity', 'Biological Assay', 'Sensitive', 'Abbott Laboratories', 'Abnormally high', 'Mental concentration', 'stimulus sensitivity', 'Troponin', 'Illinois (geographic location)', 'United States', 'PARKINSON DISEASE, LATE-ONSET', 'Plasma Product', 'Plasma', 'assay qualifier', 'IPSS Risk Category High']","[' hcro', 'qnco', ' aapp', 'menp', 'patf', 'fndg', 'idcn', 'inpr', 'hcro', 'qlco', 'bacs', 'lbpr', 'ftcn', 'mnob', 'bpoc', 'bdsu', 'phsu', 'gngm', 'geoa', 'dsyn', 'diap']"
1779,PMC4621368,S56,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Blood samples,"plasma concentrations of high-sensitive c reactive protein, il-6, il-8, myeloperoxidase and elastase were quantified using elisas (r&d systems, uk; elastase elisa, cambridge biosciences, uk).","['C0032105', 'C3889660', 'C1698754', 'C0332324', 'C2700149', 'C0014441', 'C4522209', 'C1698756', 'C0030306', 'C0027021', 'C3887512', 'C4321237', 'C2983957', 'C1299351', 'C0440053', 'C4521445', 'C0006560', 'C0020517', 'C1522640', 'C0699918', 'C0086045', 'C1515981', 'C0205250']","['Enzyme-Linked Immunosorbent Assay', 'High Level', 'Pancreatic Elastase', 'And', 'high - ActExposureLevelCode', 'High Mitosis-Karyorrhexis Index', 'High', 'IL6 protein, human', 'Elastases', 'Value Above Reference Range', 'Hypersensitivity', 'Interleukin-6, human', 'Sensitive', 'CXCL8 protein, human', 'Abnormally high', 'Mental concentration', 'stimulus sensitivity', 'Peroxidase', 'C-reactive protein', 'Myeloperoxidase stain', 'Plasma Product', 'Plasma', 'IPSS Risk Category High']","['imft', 'fndg', 'irda', 'idcn', 'enzy', 'inpr', 'qlco', 'bacs', 'phsu', 'qnco', 'lbpr', 'ftcn', ' aapp', ' phsu', 'menp', 'patf', 'bdsu']"
1780,PMC4621368,S57,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Blood samples,"plasma elastase activity and serum elafin concentrations were measured by the department of dermatology, university of kiel, germany.","['C0011627', 'C1550100', 'C1704729', 'C0229671', 'C0032105', 'C1579194', 'C0142580', 'C1546774', 'C0086045', 'C1515981', 'C0017480', 'C1418549', 'C0041740', 'C4521445', 'C1323717']","['Dermatology field', 'PI3 protein, human', 'Specimen Type - Serum', 'elastase activity', 'PI3 gene', 'And', 'Specimen Source Codes - Serum', 'Mental concentration', 'Department', 'Plasma Product', 'Plasma', 'Universities', 'Germany', 'Elafin', 'Serum']","['gngm', ' mnob', 'orgt', 'idcn', 'bdsu', 'inpr', 'geoa', 'bacs', 'bmod', ' aapp', 'menp', 'moft', 'phsu']"
1781,PMC4621368,S59,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Cardiac MRI and analysis,each patient underwent cardiac mri twice: within 6 weeks before surgery and from 5 days after surgery.,"['C0543467', 'C0412692', 'C0241311', 'C1948050', 'C1457900', 'C0030705', 'C0038895', 'C0038894', 'C1515981', 'C1274039', 'C1517320']","['General surgery specialty', 'post operative (finding)', 'Each (qualifier value)', 'Magnetic Resonance Imaging (MRI) of Heart', 'And', 'Surgery specialty', 'Patients', 'From', 'Twice (Numerical Qualifier)', 'Surgical aspects', 'Operative Surgical Procedures']","['fndg', 'topp', 'idcn', 'qnco', 'qlco', 'bmod', 'podg', 'ftcn', 'diap']"
1782,PMC4621368,S60,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Cardiac MRI and analysis,"patients were scanned using a research-dedicated 3t siemens verio scanner (siemens medical, germany).","['C0035168', 'C0205476', 'C0030705', 'C0242481', 'C0199168', 'C0017480', 'C0183115', 'C1551054', 'C1710020']","['Research Activities', 'Scanner Device', 'Units Of Measure - Siemens', 'research', 'Medical', 'Scanning Systems', 'Patients', 'Medical service', 'Germany']","['medd', 'hlca', 'geoa', 'qnco', 'resa', 'podg', 'ftcn', 'mnob']"
1783,PMC4621368,S61,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Cardiac MRI and analysis,"quantification of lv mass, ef and late gadolinium enhancement infarct size were determined using established protocols and dedicated cardiac analysis software by two trained independent blinded observers.","['C0456389', 'C1522601', 'C2349975', 'C0016911', 'C0870992', 'C0037585', 'C0936012', 'C2985765', 'C0150108', 'C0085862', 'C0205448', 'C0443211', 'C0205087', 'C0021308', 'C0455825', 'C0442711', 'C1272684', 'C1709793', 'C1515981', 'C1290940', 'C1299583', 'C0018787', 'C1524024']","['observers', 'Computer software', 'And', 'Independent for Transfer', 'Enhance (action)', 'size', 'Independence', 'Protocols documentation', 'Heart', 'analysis aspect', 'Cardiac - anatomy qualifier', 'Late', 'Two', 'Independently able', 'left ventricular mass', 'Blinded', 'Gadolinium', 'Quantitation', 'Analysis', 'Accepted', 'Enhancement Description', 'Established', 'Infarction']","['tmco', 'fndg', 'irda', ' mnob', 'idcn', 'inpr', 'qnco', 'qlco', 'grup', 'spco', 'resa', 'bpoc', 'ftcn', ' elii', 'patf', 'acty']"
1784,PMC4621368,S63,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical analysis,the primary outcome variable was the 48 h area under the curve (auc) for plasma ctni concentration.,"['C0376690', 'C3827302', 'C0205225', 'C0439828', 'C0032105', 'C0086045', 'C4553760', 'C3538828', 'C0883409', 'C1274040', 'C1446561', 'C4521445', 'C1305957']","['Primary', 'Variable (uniformity)', 'TNNI3 wt Allele', 'Cardiac troponin I measurement', 'Mental concentration', 'Cardiac troponin I', 'Plasma Product', 'Plasma', 'Area Under Curve', 'Concentration measurement', 'Result', 'Able to Concentrate Question', 'Study Variable']","['gngm', 'inpr', 'bdsu', 'qnco', 'bacs', 'qlco', 'lbpr', 'ftcn', ' aapp', 'menp', 'phsu']"
1785,PMC4621368,S64,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"it was analysed using a generalised linear model, including terms for the treatment allocation and the variables on which the randomisation was minimised.","['C3274659', 'C1706778', 'C0087111', 'C1522326', 'C3887704', 'C0205246', 'C1705169', 'C3853906', 'C0439828', 'C3538994', 'C0039798', 'C0205132', 'C3161035', 'C1515981', 'C3714583', 'C1533734']","['Generalized', 'Model Number', 'Digital Model Attachment', 'Allocation', 'Model', 'Treating', 'Variable (uniformity)', 'treatment - ActInformationManagementReason', 'Treatment Epoch', 'And', 'therapeutic aspects', 'Biomaterial Treatment', 'Linear', 'Administration procedure', 'Model - style/design', 'Therapeutic procedure']","['topp', 'idcn', 'hlca', 'inpr', 'qlco', 'spco', 'resa', 'ftcn', 'acty', 'cnce']"
1786,PMC4621368,S65,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"log transformations were applied as the data were skewed, and the results have been unlogged and presented as geometric means.","['C1708728', 'C3245479', 'C2986775', 'C1515981', 'C3714741', 'C0040682', 'C1511726', 'C1704970']","['Data call receiving device', 'Logarithm', 'Event Log', 'Data (eukaryote)', 'cell transformation', 'And', 'Means', 'Data']","['celf', 'medd', 'idcn', 'inpr', 'qnco', 'euka', 'cnce']"
1787,PMC4621368,S66,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical analysis,"secondary outcome measures involving the auc (hs-crp, il-6, il-8, myeloperoxidase and elastase) were analysed similarly, taking log transformation if the data were skewed.","['C3890735', 'C0086749', 'C2986775', 'C1698754', 'C0205436', 'C1698756', 'C0376690', 'C0030306', 'C0027021', 'C3245479', 'C1708728', 'C2983957', 'C0175668', 'C0440053', 'C1705163', 'C1510411', 'C0040682', 'C4048285', 'C0027627', 'C0699918', 'C1515981', 'C3714741', 'C1511726']","['C-Reactive Protein, human', 'Logarithm', 'Pancreatic Elastase', 'Data Transformation', 'Data (eukaryote)', 'cell transformation', 'And', 'IL6 protein, human', 'Elastases', 'Complete Response with Incomplete Platelet Recovery', 'second (number)', 'Interleukin-6, human', 'Data call receiving device', 'CXCL8 protein, human', 'Outcome Measures', 'Neoplasm Metastasis', 'Event Log', 'Area Under Curve', 'metaplastic cell transformation', 'Peroxidase', 'Secondary to', 'Myeloperoxidase stain', 'Data']","['imft', 'fndg', 'celf', 'medd', 'irda', 'idcn', 'enzy', 'inpr', 'qnco', 'bacs', 'qlco', 'euka', 'resa', 'neop', ' aapp', ' phsu', 'patf']"
1788,PMC4621368,S67,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"lvef and mass were analysed using qmass software (medis medical imaging systems, the netherlands).","['C3152252', 'C0027778', 'C1306372', 'C4283905', 'C0577573', 'C0011923', 'C0577559', 'C0079595', 'C1515981', 'C0591764', 'C0428772', 'C0037585', 'C0025086']","['Netherlands', 'Imaging Techniques', 'Mass of body structure', 'Computer software', 'Medical Imaging', 'And', 'Mass, a measure of quantity of matter', 'Diagnostic Imaging', 'medised', 'Mass of body region', 'Left ventricular ejection fraction', 'Molecular Mass', 'Morphology, Attenuation, Size, and Structure Criteria']","['fndg', ' mnob', 'idcn', 'inpr', 'geoa', 'sosy', 'qnco', 'orch', 'diap', ' phsu', 'clna']"
1789,PMC4621368,S68,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"the change in volume of infarction from preoperative and first postoperative magnetic resonance scans was categorised as increased, no change or reduced according to detection threshold based on interobserver variability.","['C0021713', 'C1705241', 'C0442739', 'C1279901', 'C0441633', 'C0392747', 'C0443172', 'C0205217', 'C0449864', 'C0205435', 'C2700258', 'C1705102', 'C0445204', 'C0442805', 'C1548568', 'C0032790', 'C4319952', 'C0021308', 'C1551403', 'C0917874', 'C0028580', 'C1511790', 'C0449468', 'C1515981']","['Postoperative Period', 'threshold', 'Volume', 'And', 'Detection', 'Magnetic Resonance', 'Volume (publication)', 'Firstly', 'Action Code - No change', 'First (number)', 'Nuclear Magnetic Resonance', 'No status change', 'Preoperative', 'Volume Measurement', 'Changed status', 'Observation Method - Magnetic resonance', 'Increase', 'Changing', 'Change -- procedure', 'Scanning', 'Delta (difference)', 'Interobserver Variation', 'Infarction', 'Increased']","['tmco', 'fndg', 'npop', 'idcn', 'topp', 'inpr', 'qnco', 'qlco', 'lbpr', 'ftcn', 'diap', 'patf']"
1790,PMC4621368,S69,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,post hoc analyses of individual time points used wilcoxon tests.,"['C0237401', 'C0022885', 'C0040223', 'C3469826', 'C0687676', 'C0392366', 'C1704687', 'C0027361']","['Individual', 'Post Device', 'Persons', 'Time', 'SLC35G1 gene', 'Tests (qualifier value)', 'Laboratory Procedures', 'Post']","['tmco', 'gngm', 'inpr', 'lbpr', 'mnob', 'popg']"
1791,PMC4621368,S70,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,the primary analysis included all randomised patients on an intention-to-treat basis regardless of compliance with allocated treatment and post-randomisation events.,"['C0205225', 'C3538994', 'C0687676', 'C1321605', 'C3541888', 'C1533734', 'C0936012', 'C0087111', 'C3887704', 'C1705169', 'C0039798', 'C0030705', 'C0009563', 'C1283828', 'C0162425', 'C1527178', 'C3469826', 'C3714738', 'C1874451', 'C0444868', 'C0441471', 'C3641650', 'C3244300', 'C1292734', 'C1522326', 'C1515981', 'C1704687', 'C1524024']","['Compliance behavior', 'And', 'Event', 'Post', 'intent', 'Intention - mental process', 'Treatment Epoch', 'SLC35G1 gene', 'analysis aspect', 'Treatment intent', 'Basis', 'Biomaterial Treatment', 'Administration procedure', 'Basis - conceptual entity', 'Regardless', 'All', 'CDISC Events Class', 'Patients', 'Post Device', 'Compliance', 'Primary', 'treatment - ActInformationManagementReason', 'Treating', 'Analysis', 'Biomechanical compliance', 'therapeutic aspects', 'Operational Compliance', 'Therapeutic procedure']","['evnt', 'tmco', 'fndg', 'gngm', 'inbe', 'idcn', 'topp', 'clas', 'hlca', 'qlco', 'qnco', 'resa', 'podg', 'ftcn', 'mnob', 'menp', 'cnce', 'phsu']"
1792,PMC4621368,S71,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical analysis,"a secondary pre-specified exploratory analysis of auc ctni release excluded patients who had myocardial infarction or a cardiac arrest, resulting in loss of cardiac output for >1 min. type v myocardial infarction was defined according to the third universal definition.18","['C0018790', 'C0175671', 'C0428953', 'C0678226', 'C0332152', 'C0936012', 'C0332307', 'C3272598', 'C4553105', 'C2926063', 'C0007165', 'C0205436', 'C0030705', 'C3538828', 'C0883409', 'C4552959', 'C0376690', 'C1704788', 'C0175668', 'C0740175', 'C3888054', 'C0027051', 'C2257086', 'C1305957', 'C0027627', 'C1517945', 'C4316796', 'C0205437', 'C3810814', 'C1550452', 'C1552870', 'C1524024']","['TNNI3 wt Allele', 'Cardiac troponin I measurement', 'definition - ActMoodCompletionTrack', 'Cardiac troponin I', 'Definition', 'Loss', 'photoreactivating enzyme activity', 'Type - attribute', 'Myocardial infarction:Finding:Point in time:^Patient:Ordinal', 'Cardiac Arrest', 'second (number)', 'Due to', 'Electrocardiogram: myocardial infarction (finding)', 'Myocardial Infarction', 'analysis aspect', 'Before', 'Neoplasm Metastasis', 'Universal', 'Myocardial Infarction, CTCAE', 'Patients', 'Area Under Curve', 'Universal - VocabularyDomainQualifier', 'Myocardial Infarction ECG Assessment', 'Cardiac Output', 'Cardiac Arrest, CTCAE 5', 'Analysis', 'Third', 'Secondary to', 'WHO Temperature/Humidity Storage Condition', 'Before values', 'DEFINITION - NCI Thesaurus Property', 'Universal HL7CMETAttribution']","['tmco', 'cnce', 'fndg', 'lbtr', 'gngm', 'idcn', 'inpr', 'genf', 'qnco', 'qlco', 'bacs', 'lbpr', 'dsyn', 'resa', 'neop', 'ftcn', 'diap', 'podg', ' aapp', 'clna']"
1793,PMC4621368,S72,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Statistical analysis,"finally, post hoc, we examined treatment effect for each time point using the high-sensitive ctni assay.","['C0687676', 'C0205250', 'C3889660', 'C2348792', 'C0332324', 'C2700149', 'C1518681', 'C1510438', 'C1457900', 'C3538828', 'C4522209', 'C0883409', 'C0243073', 'C3887512', 'C4321237', 'C1299351', 'C0005507', 'C3469826', 'C1305957', 'C0020517', 'C1522640', 'C1704687']","['High Level', 'Each (qualifier value)', 'TNNI3 wt Allele', 'Cardiac troponin I measurement', 'high - ActExposureLevelCode', 'High Mitosis-Karyorrhexis Index', 'Cardiac troponin I', 'High', 'Post', 'Assay', 'Value Above Reference Range', 'Timepoint', 'SLC35G1 gene', 'Hypersensitivity', 'Biological Assay', 'Sensitive', 'Outcome of Therapy', 'Abnormally high', 'stimulus sensitivity', 'Post Device', 'assay qualifier', 'IPSS Risk Category High']","['tmco', 'fndg', 'gngm', 'idcn', 'inpr', 'qlco', 'bacs', 'qnco', 'lbpr', 'ftcn', ' aapp', 'mnob', 'patf']"
1794,PMC4621368,S73,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analysis,power calculations were based on a recent study of patients undergoing remote ischaemic preconditioning before coronary artery bypass surgery.5,"['C0871117', 'C0475224', 'C2603343', 'C0032863', 'C0332185', 'C0205157', 'C0030705', 'C3854080', 'C1550013', 'C0010055', 'C0443203']","['Remote', 'Ischemic', 'Power (Psychology)', 'Preconditioning', 'Distant', 'Power', 'Coronary Artery Bypass Surgery', 'Patients', 'Recent', 'Study', 'location - remote']","['tmco', 'resa', 'topp', 'qnco', 'spco', 'hcpp', 'podg', 'ftcn', 'menp']"
1795,PMC4621368,S74,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analysis,"mean cardiac troponin t release quantified as auc was 36.12 µg/l (sd 26.08) and 20.58 µg/l (sd 9.58) in the control and treated patients, respectively.","['C2587213', 'C0376690', 'C1522326', 'C3538889', 'C2348143', 'C4553389', 'C3274648', 'C1283071', 'C1963578', 'C1882979', 'C0680255', 'C0030705', 'C0030685', 'C1515981', 'C2347634', 'C0444504', 'C0243148', 'C0391871', 'C1550141']","['Troponin T, Cardiac Muscle', 'Sample Mean', 'Patient Discharge', 'control substance', 'Treating', 'Released (action)', 'Release - action (qualifier value)', 'Population Mean', 'And', 'True Control Status', 'control aspects', 'Control function', 'Patients', 'Release (procedure)', 'Statistical mean', 'Area Under Curve', 'Discharge (release)', 'Study Control', 'Scientific Control']","['idcn', 'hlca', 'topp', 'qnco', 'bacs', 'qlco', 'sbst', 'podg', 'ftcn', ' aapp', 'cnce']"
1796,PMC4621368,S75,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analysis,"no contemporary auc data were available for ctni release in this patient group, but the measurements are equivalent in terms of quantifying myocardial injury.","['C1283071', 'C0470187', 'C0439185', 'C0242485', 'C1257890', 'C0441833', 'C0030705', 'C1705428', 'C0376690', 'C3245479', 'C1519504', 'C0746730', 'C0030685', 'C1705429', 'C1080058', 'C1963578', 'C0680255', 'C0687744', 'C0205163', 'C0233535', 'C3714741', 'C1511726', 'C0391871']","['Group Object', 'Data (eukaryote)', 'Release (procedure)', 'Measurement', 'Equal', 'Patient Discharge', 'Released (action)', 'Discharge (release)', 'User Group', 'butting', 'Data call receiving device', 'Groups', 'Population Group', 'availability of', 'Social group', 'Release - action (qualifier value)', 'myocardial injury', 'Patients', 'Equivalent Weight', 'Area Under Curve', 'Stage Grouping', 'This (eukaryote)', 'Data']","['medd', 'idcn', 'hlca', 'topp', 'qnco', 'qlco', 'mobd', 'inpo', 'euka', 'podg', 'ftcn', 'popg', 'cnce']"
1797,PMC4621368,S76,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analysis,"with a sample size of 80 patients, we had 90% power to detect this 40% difference in auc ctni with a significance level of 5%, using a t test with unequal variances and allowing for four dropouts in each arm.","['C1705241', 'C0446516', 'C3539897', 'C0442726', 'C1457900', 'C0030705', 'C3538828', 'C3715044', 'C0883409', 'C0242618', 'C1415458', 'C0376690', 'C0032863', 'C0013135', 'C0332287', 'C4553528', 'C3854080', 'C0062074', 'C1705242', 'C1305957', 'C0814896', 'C1080058', 'C0193959', 'C0242503', 'C1515981', 'C3891454', 'C0205450', 'C0871472']","['In addition to', 'Each (qualifier value)', 'And', 'Power', 'Cardiac troponin I measurement', 'Detected (finding)', 'TNNI3 wt Allele', 'HAC protocol', 'Cardiac troponin I', 'adenotonsillectomy', 'HADH gene', 'Dropouts', 't test', 'significance level', 'Sequence Arm', 'Upper arm', 'Dosing Days to Detection', 'Inequalities', 'AKR1A1 wt Allele', 'Four', 'Patients', 'Area Under Curve', 'Different', 'Sample Size', 'Power (Psychology)', 'Have', 'Delta (difference)', 'This (eukaryote)']","['tmco', 'blor', 'fndg', 'resa', 'gngm', 'idcn', 'topp', 'inpr', 'qnco', 'bacs', 'qlco', 'lbpr', 'ftcn', 'hcpp', 'podg', ' aapp', 'euka', 'popg']"
1798,PMC4770816,S36,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,the methods used in past-bp have been reported in detail elsewhere.14,"['C0025663', 'C1522508', 'C0025664', 'C0449851', 'C1561567']","['Methods', 'detail - Response Level', 'Details', 'Techniques', 'Methods aspects']","['qlco', 'ftcn', 'inpr']"
1799,PMC4770816,S37,['3a'],"[0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,past-bp was an individually randomised trial in which participants were allocated to either an intensive blood pressure target (<130 mm hg or a 10 mm hg reduction if baseline pressure was <140 mm hg) or a standard target (<140 mm hg).,"['C2986546', 'C1442989', 'C1565156', 'C0168634', 'C0392756', 'C1521840', 'C1272641', 'C2828392', 'C0460139', 'C3844638', 'C1293152', 'C0033095', 'C0005823', 'C0679646', 'C1421478', 'C0043194', 'C1271104', 'C4551656', 'C0301630', 'C1442488', 'C0008976']","['Clinical Trials', 'Surgical reduction', 'Systemic arterial pressure', 'Standard (document)', 'Blood Pressure', 'Participant', 'Pressure- physical agent', 'Reduction (chemical)', 'Target', 'Target Lesion Identification', 'Baseline', 'Wiskott-Aldrich Syndrome', 'Reduced', 'Reduction procedure', 'WAS gene', 'Blood pressure finding', 'Pressure (finding)', 'BaseLine dental cement', 'Either', 'WAS protein, human', 'Standard (qualifier)']","['fndg', 'bodm', 'npop', 'gngm', 'topp', 'inpr', 'qnco', 'phpr', 'qlco', 'bacs', 'dsyn', 'orgf', 'resa', 'ftcn', 'diap', 'popg', ' aapp']"
1800,PMC4770816,S38,['4b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,patients were recruited from 106 general practices (of which 99 contributed at least one patient) in england during 2009-11.,"['C0014282', 'C0086343', 'C0205447', 'C0030705']","['One', 'Patients', 'England', 'general practice (field)']","['podg', 'qnco', 'bmod', 'geoa']"
1801,PMC4770816,S39,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,patients were considered for inclusion if they were on the practice’s tia/stroke register.,"['C1512693', 'C0007637', 'C0030705', 'C1054154', 'C4554100', 'C0917805', 'C0007787', 'C0038454']","['Transient Ischemic Attack', 'Tacca leontopetaloides', 'Cerebrovascular accident', 'Stroke, CTCAE', 'Inclusion', 'Transient Cerebral Ischemia', 'Patients', 'Inclusion Bodies']","['fndg', 'plnt', 'celc', 'qlco', 'dsyn', 'podg']"
1802,PMC4770816,S40,['4a'],"[0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,"they were excluded if their baseline systolic blood pressure was less than 125 mm hg, they were already taking three or more antihypertensive agents, they had a greater than 20 mm hg postural change in systolic blood pressure on standing, they were already being treated to a 130 mm hg systolic blood pressure target, they were unable to provide informed consent, or there was insufficient corroborative evidence that they had had a stroke or tia.","['C2986546', 'C4048706', 'C0205449', 'C1565156', 'C1999230', 'C0168634', 'C0488055', 'C1054154', 'C1521840', 'C3484017', 'C3539897', 'C3484018', 'C0439856', 'C1306620', 'C0231180', 'C0021430', 'C0231472', 'C0205172', 'C3887511', 'C1415458', 'C0871470', 'C1421478', 'C0003364', 'C0043194', 'C0062074', 'C1704243', 'C0917805', 'C0007787', 'C2987476', 'C0205278', 'C4321405', 'C0205412', 'C1299582', 'C0566415', 'C1522326', 'C1442488', 'C4554100', 'C0439092', 'C0038454']","['Providing (action)', 'Transient Ischemic Attack', 'Evidence', 'Cerebrovascular accident', 'Systolic blood pressure measurement', 'HAC protocol', 'Unable', 'Unsatisfactory', 'Unable to feed self', 'Exist', 'HADH gene', 'Antihypertensive Agents', 'Stroke, CTCAE', 'Target', 'Target Lesion Identification', 'Insufficient (qualifier)', 'Baseline', 'Wiskott-Aldrich Syndrome', 'Standing position', 'More', 'Unable to Do', 'Transient Cerebral Ischemia', 'Unable to Use Stairs', 'WAS gene', 'Informed Consent', 'postural', 'BaseLine dental cement', 'Less Than', 'Change in systolic blood pressure', 'Tacca leontopetaloides', 'Treating', 'WAS protein, human', 'Have', 'Change in systolic blood pressure:Pressure Difference:Point in time:^Patient:Quantitative', 'Three', 'Systolic Pressure', 'Intravascular systolic:Pressure:Point in time:Arterial system:Quantitative', 'Inadequate (qualifier)', 'Greater']","['clna', 'acty', 'fndg', 'rnlw', 'topp', 'gngm', 'idcn', 'plnt', 'inpr', ' aapp', 'qlco', 'qnco', 'bacs', 'dsyn', 'spco', 'ftcn', 'bodm', 'diap', 'cnce', 'phsu']"
1803,PMC4770816,S41,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,potentially eligible participants were identified using a search of the general practice’s clinical computer system.,"['C0009612', 'C0679646', 'C0205246', 'C1552603', 'C0205210', 'C3812897', 'C1548635', 'C1706202', 'C3891294']","['General medical service', 'Clinical', 'Safety Reporting Documentation', 'Search - action', 'Participant', 'Computer Systems', 'search - EntityNameUse', 'Generalized', 'Eligible']","[' mnob', 'hlca', 'inpr', 'qlco', 'spco', 'popg', 'acty']"
1804,PMC4770816,S42,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,a general practitioner reviewed this list to exclude patients for whom a study invitation would be inappropriate.,"['C2603343', 'C3537135', 'C1548788', 'C3272378', 'C1080058', 'C0030705', 'C0017319', 'C2826348', 'C0745732']","['Invitation', 'General Practitioners', 'Inappropriate Specimen', 'Patients', 'Study', 'Inappropriate', 'This (eukaryote)', 'List', 'Sequence Data Type']","['prog', 'inpr', 'qlco', 'euka', 'resa', 'podg']"
1805,PMC4770816,S43,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Participants,"the remainder were sent a letter inviting them to attend a study clinic appointment held at their general practice by a research nurse, where written informed consent was obtained.","['C2985160', 'C0086343', 'C2603343', 'C1999232', 'C0442592', 'C0675390', 'C1948036', 'C0021430', 'C1096774', 'C0015607', 'C0003629', 'C0002424', 'C0687693', 'C2360551']","['Letter [Publication Type]', 'Held - activity status', 'Clinic', 'ARID1A protein, human', 'Informed Consent', 'research nurse', 'ARID1A wt Allele', 'Letter:Finding:Point in time:{Setting}:Document:{Provider}', 'Ambulatory Care Facilities', 'Appointments', 'Study', 'Attending (action)', 'general practice (field)', 'family medicine (field)']","['tmco', 'resa', 'prog', 'rnlw', 'gngm', ' hcro', 'idcn', 'inpr', 'bacs', 'bmod', 'ftcn', ' aapp', 'mnob', 'clna']"
1806,PMC4770816,S45,"['10', '8b']","[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0]",Randomisation and masking,"the central study team at the university of birmingham randomised patients, with minimisation based on age, sex, diabetes mellitus, atrial fibrillation, baseline systolic blood pressure, and general practice.","['C0036864', 'C0004238', 'C0009253', 'C0011849', 'C0168634', 'C0488055', 'C0871489', 'C1522384', 'C1306620', 'C0030705', 'C0344434', 'C0015607', 'C0804628', 'C0871470', 'C1963067', 'C0205099', 'C2603343', 'C0079399', 'C0086343', 'C1442488', 'C0041740', 'C1515981', 'C0001779']","['Age', 'teams', 'And', 'Systolic blood pressure measurement', 'Diabetes Mellitus', 'Study', 'Gender:Type:Point in time:^Patient:Nominal', 'sex', 'Atrial Fibrillation, CTCAE', 'Atrial Fibrillation by ECG Finding', 'Sex Behavior', 'Atrial Fibrillation', 'Baseline', 'Universities', 'general practice (field)', 'Coitus', 'Patients', 'Central', 'family medicine (field)', 'BaseLine dental cement', 'Gender', 'Systolic Pressure', 'Intravascular systolic:Pressure:Point in time:Arterial system:Quantitative']","['fndg', 'resa', 'lbtr', ' mnob', 'orgt', 'idcn', 'qnco', 'bmod', 'grup', 'orga', 'dsyn', 'orgf', 'bhvr', 'podg', 'bodm', 'spco', 'diap', 'clna']"
1807,PMC4770816,S46,['10'],"[0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,the research nurse ascertained treatment allocation either by telephone or online.,"['C0087111', 'C1706778', 'C1705541', 'C1515258', 'C1522326', 'C3887704', 'C1705169', 'C0039798', 'C0039457', 'C3538994', 'C0687693', 'C1533734']","['Telephone', 'Telephone Device', 'Allocation', 'treatment - ActInformationManagementReason', 'Treating', 'Treatment Epoch', 'therapeutic aspects', 'research nurse', 'Biomaterial Treatment', 'Administration procedure', 'Telephone Number', 'Therapeutic procedure']","['acty', 'prog', 'topp', 'hlca', 'inpr', 'resa', 'ftcn', 'mnob', 'cnce']"
1808,PMC4770816,S47,['11a'],"[0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Randomisation and masking,neither participants nor clinicians were blinded to treatment allocation.,"['C0087111', 'C1706778', 'C0871685', 'C0028609', 'C1522326', 'C1513854', 'C0679646', 'C1705169', 'C3887704', 'C0039798', 'C3538994', 'C0045071', 'C0028423', 'C1533734']","['NOR Mouse', 'Allocation', 'Participant', 'treatment - ActInformationManagementReason', 'Treating', 'Treatment Epoch', 'therapeutic aspects', '19-norandrostenedione', 'Biomaterial Treatment', 'Clinician', 'Nucleolus Organizer Region', 'Administration procedure', 'Norway', 'Therapeutic procedure']","['prog', 'topp', 'hlca', 'orch', 'geoa', 'celc', 'mamm', 'resa', 'ftcn', 'acty', 'popg', 'cnce']"
1809,PMC4770816,S48,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Randomisation and masking,a research nurse who was not otherwise involved in the patient’s care obtained the primary outcome measure (blood pressure) by using an automated sphygmomanometer.,"['C3272598', 'C1301820', 'C1518422', 'C1947933', 'C0005823', 'C1271104', 'C0183427', 'C1272641', 'C3274433', 'C0687693', 'C0205554']","['Blood Pressure', 'Automated (qualifier value)', 'Primary Outcome Measure', 'care activity', 'WHO Temperature/Humidity Storage Condition', 'Sphygmomanometers', 'research nurse', 'Systemic arterial pressure', 'Obtain', 'Blood pressure finding', 'Negation']","['fndg', 'prog', 'medd', 'qlco', 'orgf', 'ftcn', 'acty']"
1810,PMC4770816,S50,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Procedures,patients randomised to the intensive arm were given a target systolic blood pressure of below 130 mm hg or a target reduction of 10 mm hg if their baseline blood pressure was between 125 and 140 mm hg.,"['C2986546', 'C0446516', 'C1565156', 'C0168634', 'C0488055', 'C0392756', 'C1521840', 'C1272641', 'C0205103', 'C1293152', 'C1306620', 'C0005823', 'C0030705', 'C1552829', 'C3715044', 'C0542339', 'C0871470', 'C1421478', 'C4553528', 'C0043194', 'C1271104', 'C4551656', 'C0301630', 'C1442488', 'C1515981']","['Surgical reduction', 'And', 'Systolic blood pressure measurement', 'Systemic arterial pressure', 'Blood Pressure', 'Reduction (chemical)', 'Sequence Arm', 'Target', 'Upper arm', 'Baseline', 'Wiskott-Aldrich Syndrome', 'Reduced', 'AKR1A1 wt Allele', 'Inferior', 'Reduction procedure', 'WAS gene', 'Patients', 'Blood pressure finding', 'Intermediate', 'BaseLine dental cement', 'WAS protein, human', 'Table Frame - below', 'Systolic Pressure', 'Intravascular systolic:Pressure:Point in time:Arterial system:Quantitative', 'Target Lesion Identification']","['blor', 'fndg', 'bodm', 'npop', 'gngm', 'idcn', 'topp', 'inpr', 'qnco', 'qlco', 'bacs', 'dsyn', 'orgf', 'spco', 'podg', 'ftcn', 'diap', ' aapp', 'clna']"
1811,PMC4770816,S51,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Procedures,"the target in the standard arm was less than 140 mm hg, irrespective of baseline blood pressure.","['C2986546', 'C1442488', 'C1442989', 'C0446516', 'C4553528', 'C0005823', 'C1271104', 'C0168634', 'C3715044', 'C1521840', 'C1272641', 'C0439092', 'C2828392']","['Blood Pressure', 'BaseLine dental cement', 'Less Than', 'AKR1A1 wt Allele', 'Baseline', 'Sequence Arm', 'Target', 'Upper arm', 'Target Lesion Identification', 'Standard (qualifier)', 'Systemic arterial pressure', 'Blood pressure finding', 'Standard (document)']","['blor', 'fndg', 'gngm', 'inpr', 'qnco', 'qlco', 'orgf', 'ftcn', 'bodm', 'diap']"
1812,PMC4770816,S52,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Procedures,"apart from the different blood pressure targets, the management of blood pressure was the same in both groups and was carried out by a practice nurse (to monitor blood pressure) and a general practitioner (responsible for modifying blood pressure treatment).","['C1565156', 'C3538994', 'C0521125', 'C0439787', 'C1272641', 'C1706086', 'C1533734', 'C0376636', 'C4321252', 'C0087111', 'C0441833', 'C0699809', 'C3887704', 'C1705169', 'C0039798', 'C0005823', 'C1273870', 'C0017319', 'C1273518', 'C0849355', 'C1552839', 'C0445247', 'C1421478', 'C0043194', 'C1271104', 'C0001554', 'C1705242', 'C1522326', 'C0026426', 'C0206243', 'C0401999', 'C0687744', 'C1515981', 'C3273539']","['responsible', 'Removed', 'And', 'Systemic arterial pressure', 'Table Rules - groups', 'Same', 'Blood Pressure', 'Treatment Epoch', 'Out (direction)', 'Biomaterial Treatment', 'Administration procedure', 'Carrying', 'Wiskott-Aldrich Syndrome', 'Groups', 'General Practitioners', 'Does carry', 'Management Occupations', 'Social group', 'Blood pressure monitoring', 'WAS gene', 'WWOX wt Allele', 'practice nurse', 'Therapeutic procedure', 'Blood pressure finding', 'Disease Management', 'Preposition For', 'Different', 'treatment - ActInformationManagementReason', 'WAS protein, human', 'Treating', 'therapeutic aspects', 'Management procedure', 'Both', 'Administration occupational activities']","['fndg', 'ocac', 'resa', 'prog', 'gngm', 'idcn', 'topp', 'hlca', 'ocdi', 'inpr', 'qlco', 'bacs', 'dsyn', 'orgf', 'spco', 'ftcn', ' aapp', 'acty', 'popg', 'cnce']"
1813,PMC4770816,S53,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Procedures,patients whose systolic blood pressure at baseline was above target (everyone in the intensive arm and those patients in the standard arm whose blood pressure was ≥140 mm hg) had their antihypertensive treatment reviewed by their general practitioner.,"['C2986546', 'C0446516', 'C0168634', 'C3538994', 'C0488055', 'C0282443', 'C1521840', 'C1533734', 'C0087111', 'C3887704', 'C1306620', 'C1705169', 'C0039798', 'C0030705', 'C3715044', 'C0017319', 'C0871470', 'C4553528', 'C0003364', 'C1552828', 'C1522326', 'C1442488', 'C1282910', 'C1709940', 'C1515981']","['And', 'Systolic blood pressure measurement', 'Antihypertensive Agents', 'Sequence Arm', 'Target', 'Treatment Epoch', 'Upper arm', 'Biomaterial Treatment', 'Baseline', 'Administration procedure', 'General Practitioners', 'Reviewed', 'AKR1A1 wt Allele', 'Patients', 'BaseLine dental cement', 'treatment - ActInformationManagementReason', 'Table Frame - above', 'Treating', 'Upper', 'therapeutic aspects', 'Systolic Pressure', 'Intravascular systolic:Pressure:Point in time:Arterial system:Quantitative', 'Review [Publication Type]', 'Target Lesion Identification', 'Therapeutic procedure']","['clna', 'blor', 'resa', 'prog', 'gngm', 'topp', 'idcn', 'hlca', 'inpr', 'qnco', 'qlco', 'spco', 'ftcn', 'podg', 'bodm', 'diap', 'cnce', 'phsu']"
1814,PMC4770816,S54,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Procedures,a practice nurse would see all patients at three month intervals (if their blood pressure was below target when previously measured) or after one month (if previous blood pressure was above target) and refer to the general practitioner if the blood pressure was above target.,"['C2986546', 'C0205447', 'C0205449', 'C1565156', 'C0205156', 'C0205543', 'C0687676', 'C1521840', 'C1272641', 'C0005823', 'C0030705', 'C0332177', 'C0017319', 'C1948054', 'C1421478', 'C0043194', 'C1271104', 'C1552828', 'C1272706', 'C0444868', 'C0231290', 'C0439231', 'C3541902', 'C1282910', 'C1552607', 'C0401999', 'C1515981', 'C0444706']","['And', 'Measured Tumor Identification', 'Systemic arterial pressure', 'month', 'Post', 'Blood Pressure', 'Measured', 'Target', 'Wiskott-Aldrich Syndrome', 'When (temporal qualifier)', 'General Practitioners', 'All', 'Status post', 'Referring', 'WAS gene', 'practice nurse', 'Monthly (qualifier value)', 'Patients', 'Blood pressure finding', 'One', 'Act Relationship Subset - previous', 'Table Frame - above', 'WAS protein, human', 'Upper', 'Interval', 'Three', 'Previous', 'Target Lesion Identification']","['tmco', 'fndg', 'prog', 'gngm', 'idcn', 'qnco', 'bacs', 'qlco', 'dsyn', 'orgf', 'spco', 'podg', 'ftcn', 'diap', ' aapp']"
1815,PMC4770816,S55,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Procedures,"the protocol required no formal down-titration of treatment if blood pressure was below target, but general practitioners had discretion to change or reduce treatment in the light of symptoms attributable to blood pressure drugs.","['C2986546', 'C4050248', 'C1705241', 'C3842678', 'C0205104', 'C3538994', 'C1565156', 'C2348563', 'C1521840', 'C0392747', 'C1272641', 'C3539897', 'C1533734', 'C0162621', 'C0443172', 'C0087111', 'C3715209', 'C4282383', 'C3887704', 'C1881376', 'C1705169', 'C0039798', 'C0005823', 'C1522729', 'C1552829', 'C0017319', 'C0542339', 'C2599718', 'C1415458', 'C0596130', 'C1421478', 'C4521367', 'C0003364', 'C1271104', 'C0062074', 'C0043194', 'C4319952', 'C0442711', 'C1522326', 'C1570446', 'C1507394', 'C0683368', 'C0023693', 'C0233535', 'C1457887']","['Light', 'Symptoms', 'HAC protocol', 'Systemic arterial pressure', 'Light (qualifier)', 'Clinical trial protocol', 'HADH gene', 'Borg Scale Rating of Perceived Exertion Score 11', 'Blood Pressure', 'Protocols documentation', 'Antihypertensive Agents', 'REMS Protocol', 'TNFSF14 protein, human', 'Treatment Epoch', 'Target', 'Changed status', 'Biomaterial Treatment', 'Administration procedure', 'butting', 'Wiskott-Aldrich Syndrome', 'General Practitioners', 'Changing', 'Symptoms aspect', 'Inferior', 'Library Protocol', 'WAS gene', 'Light - subjective measurement', 'Change -- procedure', 'Blood pressure finding', 'Titration Method', 'treatment - ActInformationManagementReason', 'Downward', 'Clinical trial protocol document', 'Treating', 'WAS protein, human', 'Study Protocol', 'Have', 'Table Frame - below', 'TNFSF14 wt Allele', 'therapeutic aspects', 'attribution', 'Delta (difference)', 'Protocol - answer to question', 'Target Lesion Identification', 'Therapeutic procedure']","['topp', 'qnco', ' aapp', 'menp', 'fndg', 'npop', 'hlca', 'idcn', 'inpr', 'sosy', 'qlco', 'bacs', 'lbpr', 'resa', 'ftcn', 'phsu', 'prog', 'mobd', 'spco', 'cnce', 'gngm', 'dsyn', 'orgf', 'diap']"
1816,PMC4770816,S56,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Procedures,we provided general practitioners with treatment protocols that reflected the national guidelines for blood pressure lowering in operation at the time of the trial.15,"['C3245503', 'C0220845', 'C0543467', 'C3241922', 'C2003888', 'C4321252', 'C0040223', 'C0005823', 'C1271104', 'C0521125', 'C0017319', 'C1272641', 'C0008976', 'C0162791', 'C0441994', 'C0040808', 'C0282423']","['National citizen', 'Blood Pressure', 'Treatment Protocols', 'General Practitioners', 'Guidelines', 'guiding characteristics', 'Clinical Trials', 'Guideline [Publication Type]', 'Time', 'WWOX wt Allele', 'Lower (action)', 'Operation Activity', 'Systemic arterial pressure', 'Preposition For', 'Blood pressure finding', 'Lower - spatial qualifier', 'Operative Surgical Procedures']","['tmco', 'fndg', 'prog', 'gngm', 'topp', 'inpr', 'qlco', 'orgf', 'resa', 'spco', 'popg', 'acty']"
1817,PMC4770816,S57,['5'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0]",Procedures,"in both arms of the trial, the general practitioners had access to a computer based algorithm that actively suggested drugs and dosage if the participant was above target.","['C2986546', 'C0002045', 'C0178602', 'C1554204', 'C0444454', 'C1521840', 'C3539897', 'C4554048', 'C0230348', 'C0017319', 'C3687832', 'C1415458', 'C1705938', 'C0679646', 'C1527178', 'C0009622', 'C0062074', 'C1552828', 'C2986497', 'C0013227', 'C1553907', 'C1282910', 'C1515981', 'C0008976', 'C2698741']","['Observation Method - algorithm', 'Drugs - dental services', 'Clinical Trials', 'And', 'Participant Object', 'HAC protocol', 'HADH gene', 'Study Participant', 'Participant', 'Cumulative Dose', 'Target', 'Access', 'Computers', 'Basis - conceptual entity', 'General Practitioners', 'Both upper arms', 'algorithm', 'Dosage', 'Role Class - access', 'Pharmaceutical Preparations', 'Base - General Qualifier', 'Table Frame - above', 'Have', 'Upper', 'Target Lesion Identification']","['prog', 'gngm', 'idcn', 'topp', 'clas', 'diap', 'inpr', 'qnco', 'qlco', 'phsu', 'spco', 'resa', 'ftcn', 'mnob', 'popg', 'bpoc', 'cnce']"
1818,PMC4770816,S58,['7b'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0]",Procedures,follow-up ceased if the participant had a major cardiovascular event.,"['C0679646', 'C1320716', 'C4318856', 'C2698741', 'C4554048', 'C0205164']","['Study Participant', 'Participant', 'Participant Object', 'cardiovascular event', 'Major <insect>', 'Major']","['fndg', 'clas', 'qlco', 'euka', 'popg']"
1819,PMC4770816,S59,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,the primary outcome was change in systolic blood pressure between baseline and one year.,"['C0443172', 'C0871470', 'C1705241', 'C0205447', 'C1442488', 'C0205225', 'C1306620', 'C0439234', 'C0168634', 'C0488055', 'C1515981', 'C0392747', 'C4319952', 'C1274040']","['BaseLine dental cement', 'Changing', 'One', 'Primary', 'year', 'And', 'Systolic blood pressure measurement', 'Changed status', 'Change -- procedure', 'Delta (difference)', 'Systolic Pressure', 'Baseline', 'Intravascular systolic:Pressure:Point in time:Arterial system:Quantitative', 'Result']","['tmco', 'idcn', 'topp', 'qnco', 'qlco', 'ftcn', 'bodm', 'diap', 'clna']"
1820,PMC4770816,S60,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,participants had blood pressure measured by a research nurse (separate from the practice nurse’s measurements described above) at baseline and at six and 12 months.,"['C3245512', 'C1442488', 'C0439231', 'C0679646', 'C0005823', 'C1271104', 'C0168634', 'C0443299', 'C1515981', 'C0237607', 'C1272641', 'C0205452', 'C0687693', 'C0242485']","['Blood Pressure', 'Practice Experience', 'BaseLine dental cement', 'Separate', 'Participant', 'Baseline', 'HL7PublishingSubSection <practice>', 'And', 'Measurement', 'research nurse', 'Systemic arterial pressure', 'Six', 'Blood pressure finding', 'month']","['tmco', 'fndg', 'prog', 'idcn', 'inpr', 'qnco', 'qlco', 'orgf', 'ftcn', 'bodm', 'popg', 'menp']"
1821,PMC4770816,S61,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,blood pressure was measured using a british hypertension society validated automated electronic monitor supplied and validated for the study.16,"['C0037455', 'C2603343', 'C1963138', 'C0596227', 'C0020538', 'C0005823', 'C1271104', 'C1272641', 'C0336646']","['Blood Pressure', 'Hypertension, CTCAE', 'british', 'electronic monitor', 'Societies', 'Blood pressure finding', 'Study', 'Systemic arterial pressure', 'Hypertensive disease']","['fndg', 'medd', 'orgt', 'dsyn', 'orgf', 'resa', 'popg']"
1822,PMC4770816,S62,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"blood pressure was measured in a standardised way, with the patient seated for five minutes and then six measurements taken at one minute intervals.","['C0439232', 'C1282918', 'C0205447', 'C0205451', 'C0005823', 'C1271104', 'C0030705', 'C1515981', 'C1883708', 'C1272641', 'C1272706', 'C0205452', 'C0242485', 'C0700321', 'C2347166']","['Blood Pressure', 'Minute Unit of Plane Angle', 'Minute (diminutive)', 'Small', 'And', 'Measurement', 'Interval', 'Patients', 'Then', 'Five', 'Minute of time', 'Systemic arterial pressure', 'One', 'Six', 'Blood pressure finding']","['tmco', 'fndg', 'idcn', 'qnco', 'orgf', 'podg', 'ftcn']"
1823,PMC4770816,S63,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,the primary outcome was the average of the second and third measurements.,"['C1561503', 'C2825518', 'C0205225', 'C0205437', 'C1510992', 'C0205436', 'C1515981', 'C0457385', 'C1274040', 'C0242485', 'C1705190']","['Second Suffix', 'seconds', 'Primary', 'Third', 'Average', 'second (number)', 'And', 'Average of Value Derivation Technique', 'Measurement', 'Precision - second', 'Result']","['tmco', 'idcn', 'qnco', 'qlco', 'ftcn']"
1824,PMC4770816,S64,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"secondary measures of blood pressure included diastolic blood pressure at six and 12 months, systolic blood pressure at six months, and proportion achieving target blood pressures at 12 months.","['C0027627', 'C0871470', 'C1709707', 'C2986546', 'C0079809', 'C0439231', 'C1306620', 'C0175668', 'C0005823', 'C1271104', 'C0205436', 'C0488055', 'C1515981', 'C1521840', 'C1272641', 'C0205452']","['Blood Pressure', 'Neoplasm Metastasis', 'Systemic arterial pressure', 'Secondary to', 'second (number)', 'And', 'Systolic blood pressure measurement', 'Target', 'Measures', 'Systolic Pressure', 'Blood pressure finding', 'Intravascular systolic:Pressure:Point in time:Arterial system:Quantitative', 'Six', 'Target Lesion Identification', 'month', 'Proportion']","['tmco', 'fndg', 'idcn', 'qlco', 'qnco', 'orgf', 'ftcn', 'neop', 'diap', 'clna']"
1825,PMC4770816,S65,['6a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0]",Procedures,"for the systolic blood pressure, we also calculated the means of readings 2-6 and 5-6 to look for any differential effects with regard to habituation to blood pressure measurement.","['C0221711', 'C0444686', 'C0013170', 'C0488055', 'C0521125', 'C4554467', 'C1272641', 'C0242485', 'C4321252', 'C1306620', 'C1280500', 'C0005823', 'C0871470', 'C1441506', 'C0332287', 'C1271104', 'C1552551', 'C1705242', 'C0233426', 'C0443199', 'C3272371', 'C1515981', 'C1704970']","['Personal appearance', 'In addition to', 'And', 'Systolic blood pressure measurement', 'Measurement', 'Systemic arterial pressure', 'Drug habituation', 'Means', 'Blood Pressure', 'Differential - view', 'Any Data Type', 'Calculation', 'Differential quality', 'Calculated', 'WWOX wt Allele', 'Any', 'Psychological habituation', 'Effect', 'Blood pressure finding', 'Preposition For', 'Different', 'Systolic Pressure', 'Intravascular systolic:Pressure:Point in time:Arterial system:Quantitative']","['clna', 'fndg', 'gngm', 'inbe', 'idcn', 'inpr', 'qlco', 'qnco', 'mobd', 'orga', 'orgf', 'spco', 'ftcn', 'diap', 'cnce', 'acty']"
1826,PMC4770816,S66,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,we identified clinical events through review of the general practice record at 12 months.,"['C0086343', 'C0439231', 'C3853788', 'C0015607', 'C0282443', 'C2827664', 'C1552617', 'C0034869']","['Records', 'Record - QueryRequestLimit', 'Act Class - review', 'Clinical Events Domain', 'Review [Publication Type]', 'general practice (field)', 'month', 'family medicine (field)']","['tmco', 'idcn', 'inpr', 'qnco', 'bmod']"
1827,PMC4770816,S67,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,"these comprised major cardiovascular events (composite of fatal and non-fatal stroke, myocardial infarction, fatal coronary heart disease, or other cardiovascular death), emergency hospital admissions, and deaths.","['C0011065', 'C0010068', 'C1306577', 'C0428953', 'C1956346', 'C0184666', 'C0205164', 'C1705232', 'C0205199', 'C2926063', 'C1320716', 'C4318856', 'C4552959', 'C0010054', 'C2745965', 'C3887460', 'C0027051', 'C0007226', 'C0039828', 'C1547335', 'C1518422', 'C1302234', 'C0013956', 'C3810814', 'C4554100', 'C1515981', 'C0038454']","['Cerebrovascular accident', 'Emergency Situation', 'And', 'Emergencies [Disease/Finding]', 'Coronary heart disease', 'Fatal', 'Major <insect>', 'Theses', 'Cardiovascular', 'Stroke, CTCAE', 'Myocardial infarction:Finding:Point in time:^Patient:Ordinal', 'Electrocardiogram: myocardial infarction (finding)', 'Myocardial Infarction', 'Composite', 'Cessation of life', 'Death Related to Adverse Event', 'Coronary Artery Disease', 'Myocardial Infarction, CTCAE', 'Negation', 'Myocardial Infarction ECG Assessment', 'Death (finding)', 'Data types- Composite', 'Hospital admission', 'cardiovascular event', 'Cardiovascular system', 'Major', 'Coronary Arteriosclerosis']","['blor', 'fndg', 'lbtr', 'idcn', 'bdsy', 'hlca', 'inpr', 'qlco', 'phpr', 'dsyn', 'orgf', 'euka', 'ftcn', 'diap', 'patf', 'clna']"
1828,PMC4770816,S68,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,participants were flagged for mortality at the nhs central register.,"['C0679646', 'C0026566', 'C1417725', 'C0026565', 'C0796085', 'C0205099']","['Mortality Vital Statistics', 'Aspects of mortality statistics', 'Participant', 'Nance-Horan syndrome', 'NHS gene', 'Central']","['gngm', 'qnco', 'dsyn', 'spco', 'popg']"
1829,PMC4770816,S69,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Procedures,side effects were assessed through the use of standard questionnaires.14,"['C1706422', 'C0034394', 'C1442989', 'C0001688', 'C0042153', 'C0877248', 'C2828392', 'C0457083', 'C0879626']","['Questionnaires', 'Usage', 'Adverse effects', 'Standard (qualifier)', 'utilization qualifier', 'Questionnaire Domain', 'aspects of adverse effects', 'Standard (document)', 'Adverse event']","['qlco', 'ftcn', 'inpr', 'patf']"
1830,PMC4770816,S71,['7a'],"[0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 0, 0, 0, 0]",Statistical analysis,"we estimated that a sample size of 305 patients in each group would detect a 5 mm hg difference in systolic blood pressure between groups with 90% power at a significance level of 5% assuming a standard deviation of 17.5 mm hg, 10% loss to follow-up, 5% mortality, and 10% major vascular events.5 7","['C1705241', 'C3274571', 'C0488055', 'C1801960', 'C3840882', 'C0442726', 'C3541888', 'C0205164', 'C1257890', 'C0205103', 'C0589120', 'C0441833', 'C1306620', 'C1457900', 'C0030705', 'C4318856', 'C0005847', 'C1705428', 'C0242618', 'C0871470', 'C0032863', 'C0332287', 'C1519504', 'C1552839', 'C0026566', 'C1705429', 'C3854080', 'C0026565', 'C1522577', 'C1705242', 'C1558950', 'C0441471', 'C0814896', 'C1704685', 'C1517945', 'C0687744', 'C1515981', 'C3891454', 'C0871420']","['Group Object', 'In addition to', 'Each (qualifier value)', 'And', 'Power', 'Detected (finding)', 'Systolic blood pressure measurement', 'Event', 'Blood Vessel', 'Loss', 'Major <insect>', 'Follow-up status', 'Table Rules - groups', 'significance level', 'Dosing Days to Detection', 'User Group', 'Mortality Vital Statistics', 'Groups', 'Population Group', 'Clinical Study Follow-up', 'Adverse Event Associated with Vascular', 'Social group', 'CDISC Events Class', 'Vascular', 'Patients', '5 mm', 'Intermediate', 'follow-up', 'Different', 'Aspects of mortality statistics', 'Sample Size', 'Power (Psychology)', 'Follow-Up Report', 'Stage Grouping', 'Delta (difference)', 'Standard deviation', 'Systolic Pressure', 'Intravascular systolic:Pressure:Point in time:Arterial system:Quantitative', 'Major']","['tmco', 'clna', 'fndg', 'resa', 'idcn', 'clas', 'diap', 'hlca', 'inpr', 'qnco', 'qlco', 'spco', 'hcpp', 'podg', 'ftcn', 'euka', 'popg', 'evnt', 'bpoc', 'cnce']"
1831,PMC4770816,S72,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"we used mixed models for the primary analysis, adjusting for baseline blood pressure, age group (<80 years, ≥80 years), sex, diabetes mellitus, atrial fibrillation, and practice (as a random effect).","['C0205430', 'C0036864', 'C0205225', 'C0168634', 'C0004238', 'C0011849', 'C0009253', 'C1272641', 'C0027362', 'C0936012', 'C2348382', 'C0439605', 'C1518681', 'C1522384', 'C1280500', 'C0439234', 'C0005823', 'C0034656', 'C0344434', 'C0804628', 'C3245512', 'C3160715', 'C2348001', 'C1271104', 'C1963067', 'C0079399', 'C1442488', 'C3161035', 'C1515981', 'C0237607', 'C1524024']","['Practice Experience', 'year', 'Effect, Appearance', 'And', 'Diabetes Mellitus', 'Gender:Type:Point in time:^Patient:Nominal', 'Systemic arterial pressure', 'sex', 'Atrial Fibrillation, CTCAE', 'Atrial Fibrillation by ECG Finding', 'Blood Pressure', 'Sex Behavior', 'HL7PublishingSubSection <practice>', 'Atrial Fibrillation', 'Human Age Group', 'analysis aspect', 'Random', 'Baseline', 'Coitus', 'Mixed Cell Morphology', 'Model', 'Outcome of Therapy', 'Effect', 'Mixed (qualifier value)', 'Blood pressure finding', 'BaseLine dental cement', 'Gender', 'Age Cohort', 'Primary', 'Analysis', 'Randomization']","['tmco', 'fndg', 'bodm', 'lbtr', 'aggp', 'idcn', 'inpr', 'qnco', 'qlco', 'orga', 'dsyn', 'orgf', 'resa', 'bhvr', 'ftcn', 'popg', 'menp', 'clna']"
1832,PMC4770816,S73,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,the principal analysis was a complete case analysis.,"['C0868928', 'C1706256', 'C3853530', 'C0205197', 'C1706255', 'C4283785', 'C0205225', 'C0401925', 'C1524024', 'C0936012']","['Case (situation)', 'Primary', 'Data operation - complete', 'Analysis', 'Packaging Case', 'Complete Pharyngeal Contraction', 'analysis aspect', 'Clinical Study Case', 'Teaching principal', 'Complete']","['fndg', 'prog', 'medd', 'qlco', 'resa', 'ftcn', 'cnce']"
1833,PMC4770816,S74,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"we also explored the potential effects of missing values by the use of three approaches: multiple imputation, group mean, and last available value.","['C0205449', 'C0470187', 'C1705492', 'C1257890', 'C0441833', 'C1280500', 'C0042153', 'C0042295', 'C1705428', 'C1551393', 'C1519504', 'C1705429', 'C1522609', 'C2699638', 'C0457083', 'C0449445', 'C1517741', 'C3272743', 'C0687744', 'C3245505', 'C0439064']","['Group Object', 'Numerical value', 'Statistical Imputation', 'utilization qualifier', 'Missing Study Animal', 'User Group', 'Values', 'Missing', 'Groups', 'Population Group', 'availability of', 'Container status - Missing', 'Social group', 'Effect', 'Numerous', 'Last', 'potential', 'Usage', 'Three', 'Stage Grouping', 'Approach']","['fndg', 'idcn', 'qlco', 'qnco', 'spco', 'ftcn', 'popg', 'cnce']"
1834,PMC4770816,S75,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"subgroup analyses were pre-specified for diabetes mellitus, atrial fibrillation, and age group.","['C1515021', 'C2348001', 'C1079230', 'C0004238', 'C1963067', 'C0344434', 'C1515981', 'C0027362']","['Age Cohort', 'Atrial Fibrillation', 'Human Age Group', 'And', 'Subgroup A Nepoviruses', 'Atrial Fibrillation, CTCAE', 'Atrial Fibrillation by ECG Finding', 'Subgroup']","['fndg', 'lbtr', 'virs', 'idcn', 'clas', 'dsyn', 'popg', 'aggp']"
1835,PMC4770816,S76,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"in addition, we did a subgroup analysis by baseline systolic blood pressure (<140 mm hg, ≥140 mm hg).","['C0871470', 'C0332287', 'C1442488', 'C1306620', 'C1883712', 'C0168634', 'C0488055', 'C2986480']","['BaseLine dental cement', 'In addition to', 'Systolic blood pressure measurement', 'Add - instruction imperative', 'Systolic Pressure', 'Baseline', 'Intravascular systolic:Pressure:Point in time:Arterial system:Quantitative', 'Subset Analysis']","['bodm', 'qnco', 'resa', 'ftcn', 'diap', 'clna']"
1836,PMC4770816,S77,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"we compared the number of consultations, treatment changes, and side effects by using generalised mixed modelling, adjusting for the same variables as in the primary outcome.","['C0205430', 'C0237753', 'C0205246', 'C0205225', 'C0439828', 'C3538994', 'C0521125', 'C0392747', 'C1533734', 'C4321252', 'C0443172', 'C0087111', 'C3887704', 'C1705169', 'C0449788', 'C0039798', 'C0009818', 'C3160715', 'C0445247', 'C0879626', 'C1522326', 'C0001688', 'C1515981', 'C0877248', 'C1274040']","['And', 'Same', 'Variable (uniformity)', 'Count of entities', 'Consultation', 'Treatment Epoch', 'Changed status', 'Biomaterial Treatment', 'Generalized', 'Administration procedure', 'Result', 'Changing', 'Mixed Cell Morphology', 'WWOX wt Allele', 'Adverse effects', 'Mixed (qualifier value)', 'Preposition For', 'Numbers', 'Primary', 'treatment - ActInformationManagementReason', 'Treating', 'therapeutic aspects', 'aspects of adverse effects', 'Adverse event', 'Therapeutic procedure']","['fndg', 'gngm', 'hlca', 'idcn', 'topp', 'qnco', 'qlco', 'spco', 'resa', 'ftcn', 'patf', 'cnce']"
1837,PMC4770816,S78,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"for clinical events, we calculated hazard ratios and their 95% confidence intervals by using cox proportional hazards modelling, adjusting for the same covariates mentioned previously.","['C0205351', 'C0009667', 'C0445247', 'C1565830', 'C1515981', 'C2827664', 'C0456603', 'C0598697']","['Same', 'Confidence Intervals', 'Ratio', 'proportional', 'And', 'PTGS1 protein, human', 'hazard', 'Clinical Events Domain']","['idcn', 'enzy', 'inpr', 'qnco', 'qlco', ' aapp']"
1838,PMC4770816,S79,['12b'],"[0, 0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,we checked the proportional hazard assumption with schoenfeld residual plots and by including interaction terms in the model (for each term by time).,"['C0205351', 'C3274659', 'C1515273', 'C0332287', 'C0040223', 'C1457900', 'C3853906', 'C1705313', 'C3161035', 'C2826302', 'C1515981', 'C0332257', 'C1609982', 'C0233324', 'C1704675', 'C3714583', 'C0598697']","['Residual', 'Model Number', 'In addition to', 'Digital Model Attachment', 'Model', 'Reported Term', 'Each (qualifier value)', 'Time', 'And', 'Term (temporal)', 'proportional', 'Including (qualifier)', 'Term (lexical)', 'hazard', 'Term Birth', 'Model - style/design', 'Interaction']","['tmco', 'idcn', 'inpr', 'qnco', 'qlco', 'orgf', 'ftcn', 'cnce']"
1839,PMC4770816,S80,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"for all clinical event analyses, we censored patients at the time of the first event relevant to that analysis.","['C0205435', 'C0040223', 'C1279901', 'C2347946', 'C0030705', 'C0205210', 'C0444868', 'C1524024', 'C4019010', 'C0441471', 'C0936012']","['Clinical', 'Firstly', 'National reporting jurisdiction:Loc:Pt:^Event:Nom', 'All', 'First (number)', 'Relevance', 'Analysis', 'Time', 'analysis aspect', 'Patients', 'Event']","['tmco', 'qnco', 'qlco', 'resa', 'podg', 'ftcn', 'evnt', 'clna']"
1840,PMC4770816,S81,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,"thus, if a patient had more than one emergency hospital admission, only the first one would be counted.","['C0205447', 'C0205435', 'C2745965', 'C1279901', 'C0030705', 'C0013956', 'C0205172', 'C0184666', 'C0205171']","['Firstly', 'First (number)', 'Singular', 'More', 'Emergency Situation', 'Patients', 'Emergencies [Disease/Finding]', 'Hospital admission', 'One']","['hlca', 'qnco', 'phpr', 'qlco', 'podg', 'patf']"
1841,PMC4770816,S82,['12a'],"[0, 0, 0, 0, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Statistical analysis,we used sas 9.2 and stata 12 for analyses.,"['C1823519', 'C1515981', 'C0605290', 'C1426104']","['NANS gene', 'TSPAN31 gene', 'And', 'SAS']","['gngm', 'idcn', 'orch']"
1842,PMC4770816,S84,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patient involvement,the study was discussed by a stroke survivor group who agreed that it was an important research question and that blood pressure was an important outcome for them.,"['C1565156', 'C1272641', 'C1257890', 'C3272598', 'C0441833', 'C0681799', 'C0005823', 'C1705428', 'C3898777', 'C1519504', 'C1421478', 'C0043194', 'C1705429', 'C1271104', 'C0206194', 'C4084912', 'C2603343', 'C0687744', 'C1515981', 'C4554100', 'C1274040', 'C0038454']","['Group Object', 'Important', 'Cerebrovascular accident', 'And', 'Study', 'Systemic arterial pressure', 'Blood Pressure', 'Importance Rating Score 0', 'Stroke, CTCAE', 'research question', 'Result', 'User Group', 'Wiskott-Aldrich Syndrome', 'Groups', 'Population Group', 'Social group', 'WAS gene', 'Blood pressure finding', 'WAS protein, human', 'WHO Temperature/Humidity Storage Condition', 'Survivors', 'Stage Grouping']","['fndg', 'resa', 'gngm', 'idcn', 'inpr', 'qlco', 'bacs', 'dsyn', 'orgf', 'ftcn', 'podg', ' aapp', 'popg', 'cnce']"
1843,PMC4770816,S85,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patient involvement,patients were involved in developing plans for recruitment and design of the study through representation on the trial steering committee.,"['C1882932', 'C2603343', 'C1550549', 'C0030705', 'C1515981', 'C2983265', 'C1707689', 'C2949735', 'C0008976', 'C2348534', 'C0332273', 'C1514861']","['Design', 'Steering Committee', 'Clinical Trials', 'Through', 'And', 'Act Relationship Checkpoint - through', 'CDISC SEND Study Design Terminology', 'Patients', 'Study', 'Representation Component', 'Recruitment', 'Representation (action)']","['idcn', 'inpr', 'resa', 'podg', 'ftcn', 'popg', 'cnce', 'acty']"
1844,PMC4770816,S86,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patient involvement,no patients were asked to advise on interpretation or writing up of the results.,"['C0459471', 'C3173575', 'C0030705']","['Interpretation Process', 'Patients', 'Interpretation:Impression/interpretation of study:Point in time:^Patient:Nominal']","['podg', 'inpr', 'clna']"
1845,PMC4770816,S87,['0'],"[1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0]",Patient involvement,we plan to disseminate the results of the research to the relevant patient community through local and nationally organised stroke groups.,"['C0035168', 'C0441833', 'C0205276', 'C1552839', 'C2347946', 'C0030705', 'C0242481', 'C0687744', 'C1515981', 'C4554100', 'C0009462', 'C0038454']","['Groups', 'Research Activities', 'Relevance', 'Social group', 'Cerebrovascular accident', 'Stroke, CTCAE', 'research', 'And', 'Community', 'Patients', 'Local', 'Table Rules - groups']","['fndg', 'idcn', 'inpr', 'qlco', 'grup', 'dsyn', 'spco', 'resa', 'podg', 'popg']"
